Rank,Title,Status,Study Results,Conditions,Interventions,Sponsor/Collaborators,Name1,Name2,Name3,Name4,Name5,Name6,Name7,Phases,Funded Bys,Study Type,Start Date,Completion Date,URL
1,Real World Glycemic Effectiveness of Linagliptin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,,Industry,Observational,11/21/2017,2/2/2018,https://ClinicalTrials.gov/show/NCT03338803
2,Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir,Completed,Has Results,HIV Infections,Drug: Conventional dolutegravir 10 mg tablet|Drug: Conventional dolutegravir 50 mg tablet|Drug: Dispersible dolutegravir 5 mg tablet|Drug: Conventional dolutegravir 25 mg tablet,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 1,Industry,Interventional,5/3/2017,6/23/2017,https://ClinicalTrials.gov/show/NCT03095638
3,Study of SOR007 Ointment for Actinic Keratosis,Completed,Has Results,Actinic Keratosis,Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|Other: SOR007 Ointment Vehicle,"DFB Soria, LLC|US Biotest, Inc.","DFB Soria, LLC","US Biotest, Inc.",,,,,,Phase 2,Industry,Interventional,5/18/2017,3/12/2018,https://ClinicalTrials.gov/show/NCT03083470
4,Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: Dolutegravir|Drug: Lamivudine|Drug: Dolutegravir + Lamivudine FDC Formulation 1|Drug: Dolutegravir + Lamivudine FDC Formulation 2,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 1,Industry,Interventional,3/27/2017,8/18/2017,https://ClinicalTrials.gov/show/NCT03078556
5,A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin,Completed,Has Results,Healthy,Drug: Lanabecestat|Drug: Rosuvastatin,Eli Lilly and Company|AstraZeneca,Eli Lilly and Company,AstraZeneca,,,,,,Phase 1,Industry,Interventional,1/12/2017,5/22/2017,https://ClinicalTrials.gov/show/NCT03019549
6,A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: ORMD-0801 (qd)|Drug: ORMD-0801 (bid)|Drug: ORMD-0801 (tid)|Other: Placebo,"Oramed, Ltd.|Integrium","Oramed, Ltd.",Integrium,,,,,,Phase 2,Industry,Interventional,10/16/2019,3/15/2017,https://ClinicalTrials.gov/show/NCT02954601
7,Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines,Completed,Has Results,Cataract Surgery,Device: Alcon phacoemulsification equipment|Device: AMO phacoemulsification equipment,"Intuor Technologies, Inc.|Abbott Medical Optics","Intuor Technologies, Inc.",Abbott Medical Optics,,,,,,Not Applicable,Industry,Interventional,9/16/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02910362
8,Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea (OSA),Completed,Has Results,Obstructive Sleep Apnea,Device: BONGO DEVICE,InnoMed Healthscience Inc.|RVW Clinical Consulting,InnoMed Healthscience Inc.,RVW Clinical Consulting,,,,,,Not Applicable,Industry,Interventional,9/16/2019,11/30/2017,https://ClinicalTrials.gov/show/NCT02878590
9,"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution",Completed,Has Results,Healthy Subjects,Drug: AC-170 0.24%|Drug: AC-170 Vehicle,"Nicox Ophthalmics, Inc.|ORA, Inc.","Nicox Ophthalmics, Inc.","ORA, Inc.",,,,,,Phase 3,Industry,Interventional,4/16/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02756624
10,"A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: Lamivudine|Drug: Sorbitol,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,1/1/2016,3/11/2016,https://ClinicalTrials.gov/show/NCT02634073
11,THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC,Completed,Has Results,Healthy Subjects,Drug: Maraviroc (Part 1)|Drug: Maraviroc (Part 2)|Drug: Darunavir/cobicistat (Part 2),ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 1,Industry,Interventional,11/6/2015,3/26/2016,https://ClinicalTrials.gov/show/NCT02625207
12,Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap,Completed,Has Results,End Stage Renal Disease (ESRD),Device: ClearGuard HD end cap,"Pursuit Vascular, Inc.|Fresenius Medical Care North America","Pursuit Vascular, Inc.",Fresenius Medical Care North America,,,,,,Not Applicable,Industry,Interventional,12/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02604264
13,Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap,Completed,Has Results,End Stage Renal Disease (ESRD),Device: ClearGuard HD End Cap,"Pursuit Vascular, Inc.|Davita Clinical Research","Pursuit Vascular, Inc.",Davita Clinical Research,,,,,,Not Applicable,Industry,Interventional,11/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02593149
14,A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants,Completed,Has Results,Healthy,Drug: Lanabecestat|Drug: Dabigatran etexilate,Eli Lilly and Company|AstraZeneca,Eli Lilly and Company,AstraZeneca,,,,,,Phase 1,Industry,Interventional,10/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02568397
15,A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants,Completed,Has Results,Healthy,Drug: Lanabecestat|Drug: Warfarin,Eli Lilly and Company|AstraZeneca,Eli Lilly and Company,AstraZeneca,,,,,,Phase 1,Industry,Interventional,9/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02540668
16,"Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006",Completed,Has Results,Glabellar Frown Lines,"Biological: DWP-450 (Botulinum purified neurotoxin, Type A)","Evolus, Inc.|PPD","Evolus, Inc.",PPD,,,,,,Phase 2,Industry,Interventional,5/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02428608
17,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002,Completed,Has Results,Glabellar Frown Lines,"Biological: Botulinum toxin, Type A|Other: 0.9% sterile, unpreserved saline","Evolus, Inc.|PPD","Evolus, Inc.",PPD,,,,,,Phase 3,Industry,Interventional,1/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02334436
18,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001,Completed,Has Results,Glabellar Frown Lines,"Biological: Botulinum toxin, Type A|Other: 0.9% sterile, unpreserved saline","Evolus, Inc.|PPD","Evolus, Inc.",PPD,,,,,,Phase 3,Industry,Interventional,1/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02334423
19,An RCT Comparing Xenograft and Allograft for Ridge Preservation,Completed,Has Results,Tooth Loss,Device: allograft + x-link collagen membrane|Device: xenograft + non-x-link collagen,McGuire Institute|Geistlich Pharma AG,McGuire Institute,Geistlich Pharma AG,,,,,,Not Applicable,Industry,Interventional,4/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02330523
20,Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I),Completed,Has Results,"Osteoarthritis, Knee",Biological: APS,"Zimmer Biomet|Biomet Biologics, LLC",Zimmer Biomet,"Biomet Biologics, LLC",,,,,,Phase 1,Industry,Interventional,11/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02262364
21,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity,Completed,Has Results,Schizophrenia With Impulsivity,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,2/15/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02194933
22,Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,,Industry,Observational,5/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02140645
23,Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns,Completed,Has Results,"Diabetes Mellitus, Type 2",,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,,Industry,Observational,5/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02138097
24,Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA,Completed,Has Results,Osteoarthritis,Device: Supartz|Device: Euflexxa,Bioventus LLC|Seikagaku Corporation,Bioventus LLC,Seikagaku Corporation,,,,,,Phase 3,Industry,Interventional,3/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02110238
25,Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets,Completed,Has Results,Healthy,Drug: 1 tablet Empagliflozin/2 tablets Metformin XR|Drug: 10 mg Empagliflozin/1000 mg Metformin XR|Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 1,Industry,Interventional,4/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02106923
26,Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease,Completed,Has Results,Crohn's Disease,Biological: CT-P13|Biological: Remicade,Celltrion|Pfizer,Celltrion,Pfizer,,,,,,Phase 3,Industry,Interventional,9/19/2014,2/15/2017,https://ClinicalTrials.gov/show/NCT02096861
27,"A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics",Completed,Has Results,Diabetes Mellitus Type 1,Biological: ORMD-0801 Capsules|Other: Placebo,"Oramed, Ltd.|Integrium","Oramed, Ltd.",Integrium,,,,,,Phase 2,Industry,Interventional,3/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02094534
28,Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects,Completed,Has Results,CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction],Drug: Clarithromycin XL|Drug: 2% Diltiazem,"Ventrus Biosciences, Inc|TKL Research, Inc.","Ventrus Biosciences, Inc","TKL Research, Inc.",,,,,,Phase 1,Industry,Interventional,9/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT02080780
29,Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis,Completed,Has Results,Allergic Conjunctivitis,Drug: OTX-DP treatment|Device: Placebo Plug with no drug,"Ocular Therapeutix, Inc.|ORA, Inc.","Ocular Therapeutix, Inc.","ORA, Inc.",,,,,,Phase 2,Industry,Interventional,3/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02062905
30,Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects,Completed,Has Results,Healthy Subjects,Drug: Apixaban|Dietary Supplement: Boost Plus,Bristol-Myers Squibb|Pfizer,Bristol-Myers Squibb,Pfizer,,,,,,Phase 1,Industry,Interventional,10/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT02034591
31,Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects,Completed,Has Results,Healthy Volunteers,Drug: Apixaban,Bristol-Myers Squibb|Pfizer,Bristol-Myers Squibb,Pfizer,,,,,,Phase 1,Industry,Interventional,7/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT02034578
32,Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects,Completed,Has Results,Healthy Volunteers,Drug: Apixaban,Bristol-Myers Squibb|Pfizer,Bristol-Myers Squibb,Pfizer,,,,,,Phase 1,Industry,Interventional,2/10/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT02034565
33,A Pilot Study to Assess the DynaSense System,Completed,Has Results,Pressure Ulcers,Device: DynaSense sensor,"Leaf Healthcare, Inc.|Centauri Medical, Inc.","Leaf Healthcare, Inc.","Centauri Medical, Inc.",,,,,,Not Applicable,Industry,Interventional,12/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02005692
34,Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets,Completed,Has Results,Healthy,"Drug: Empagliflozin/Metformin XR, FDC|Drug: Empagliflozin/Metformin XR FDC|Drug: 25 mg Empagliflozin/1000 mg Metformin XR, FDC|Drug: 1 tablet Empagliflozin/2 tablets Metformin XR|Drug: 1 tablet Empagliflozin/3 tablets Metformin XR",Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 1,Industry,Interventional,10/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01975220
35,Aripiprazole Once-monthly in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole once-monthly,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,10/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01959035
36,"Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)",Completed,Has Results,Diabetes Mellitus Type 2,Drug: ORMD-0801 Dose # 1|Drug: ORMD-0801 Dose # 2|Drug: Placebo,"Oramed, Ltd.|Integrium","Oramed, Ltd.",Integrium,,,,,,Phase 2,Industry,Interventional,6/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01889667
37,Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls,Completed,Has Results,"Diabetes Mellitus, Type 2|Healthy",Drug: Empagliflozin|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 2,Industry,Interventional,6/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01867307
38,Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer,Completed,Has Results,Cervical Cancer,Device: Treatment with Electronic Brachytherapy,"Xoft, Inc.|Icad, Inc.","Xoft, Inc.","Icad, Inc.",,,,,,Not Applicable,Industry,Interventional,11/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01851772
39,Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets,Completed,Has Results,Healthy,Drug: 2x500 mg Metformin (Glumetza)|Drug: 5 mg Linagliptin/1000 mg Metformin FDC|Drug: 5 mg Linagliptin (Tradjenta)|Drug: 3x500 mg Metformin (Glumetza)|Drug: 2 x 500 mg Metformin (Glumetza)|Drug: 5 mg Linagliptin/1000mg Metformin FDC|Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 1,Industry,Interventional,5/13/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01845077
40,Brexpiprazole in Patients With Acute Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Placebo|Drug: Brexpiprazole|Drug: Quetiapine extended release,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,3/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01810380
41,Synera Venipuncture Pain,Completed,Has Results,Pain|Phlebotomy|Palliative Care,Drug: Synera (lidocaine 70mg/tetracaine 70mg),US Oncology Research|Nuvo Research Inc.,US Oncology Research,Nuvo Research Inc.,,,,,,Phase 2,Industry,Interventional,1/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01744197
42,"Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain",Completed,Has Results,Postoperative Pain|Acute Pain,Drug: Tapentadol,"Grünenthal GmbH|Janssen Research & Development, LLC",Grünenthal GmbH,"Janssen Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,11/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01729728
43,Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese,Completed,Has Results,Healthy,Drug: T89 Group A|Drug: Placebo Group A|Drug: Placebo Group B|Drug: T89 Group B|Drug: Placebo Group C|Drug: T89 Group C,"Tasly Pharmaceuticals, Inc.|Parexel","Tasly Pharmaceuticals, Inc.",Parexel,,,,,,Phase 1,Industry,Interventional,8/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01679028
44,A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients,Completed,Has Results,Metastatic Castration-Resistant Prostate Cancer,Drug: enzalutamide|Drug: abiraterone acetate|Drug: prednisone,"Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc","Astellas Pharma Global Development, Inc.","Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Astellas Pharma Inc,,,,,Phase 2,Industry,Interventional,7/9/2012,1/4/2018,https://ClinicalTrials.gov/show/NCT01650194
45,A Study of Prasugrel in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Prasugrel ODT1 - Tablet|Drug: Prasugrel ODT2 - Tablet|Drug: Prasugrel ODT2 - Suspension,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,Phase 1,Industry,Interventional,7/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01648790
46,A Study of LY3009104 in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: LY3009104|Drug: Placebo|Drug: moxifloxacin,Eli Lilly and Company|Incyte Corporation,Eli Lilly and Company,Incyte Corporation,,,,,,Phase 1,Industry,Interventional,2/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01536951
47,Encore Revelation Hip Stem,Completed,Has Results,"Osteoarthritis, Hip|Complications; Arthroplasty",Device: Revelation Hip Stem (Revelation),"Encore Medical, L.P.|DJO Incorporated","Encore Medical, L.P.",DJO Incorporated,,,,,,,Industry,Observational,2/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01514318
48,Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever,Completed,Has Results,"Rhinitis, Allergic, Seasonal",Device: C-1266-7|Device: C-1266-6 (placebo),"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Early Phase 1,Industry,Interventional,1/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01500629
49,Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis,Completed,Has Results,Blepharitis,Drug: Erythromycin|Drug: Besifloxocin,"John, George, M.D.|Bausch & Lomb Incorporated","John, George, M.D.",Bausch & Lomb Incorporated,,,,,,Phase 4,Industry,Interventional,8/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01478256
50,Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography,Completed,Has Results,Drug Safety,Drug: Iodixanol|Drug: Iopamidol,GE Healthcare|i3 Statprobe,GE Healthcare,i3 Statprobe,,,,,,Phase 4,Industry,Interventional,10/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01475097
51,Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis,Completed,Has Results,Patient Comfort and Safety,Drug: Iodixanol|Drug: Iopamidol,GE Healthcare|i3 Statprobe,GE Healthcare,i3 Statprobe,,,,,,Phase 4,Industry,Interventional,5/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01376089
52,HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis,Completed,Has Results,End Stage Renal Disease (ESRD),,"Merit Medical Systems, Inc.|CryoLife, Inc.","Merit Medical Systems, Inc.","CryoLife, Inc.",,,,,,,Industry,Observational,1/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01343251
53,Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin,Completed,Has Results,Healthy,Drug: ChloraPrep|Drug: DuraPrep,3M|Cyberderm Inc.,3M,Cyberderm Inc.,,,,,,Phase 4,Industry,Interventional,2/10/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01290978
54,"QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo",Completed,Has Results,Healthy,Drug: MAP0004|Drug: Inhaler Placebo|Drug: Moxifloxacin|Drug: Placebo Capsule,"Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Allergan,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",,,,,,Phase 1,Industry,Interventional,8/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01191723
55,BGS649 Monotherapy in Moderate to Severe Endometriosis Patients,Completed,Has Results,Endometriosis,Drug: BGS649|Drug: Placebo,Mereo BioPharma|Novartis,Mereo BioPharma,Novartis,,,,,,Phase 2,Industry,Interventional,7/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01190475
56,Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database,Completed,Has Results,Ileus,Drug: Alvimopan,Cubist Pharmaceuticals LLC|GlaxoSmithKline,Cubist Pharmaceuticals LLC,GlaxoSmithKline,,,,,,,Industry,Observational,4/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01150760
57,Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure,Completed,Has Results,Healthy,Drug: MAP0004|Drug: IV Placebo (Saline)|Drug: Placebo Inhaler|Drug: IV Dihydroergotamine Mesylate (DHE),"Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Allergan,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",,,,,,Phase 1,Industry,Interventional,3/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01089062
58,PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus,Completed,Has Results,Normal Pressure Hydrocephalus,Drug: [18F] Flutemetamol,GE Healthcare|i3 Statprobe,GE Healthcare,i3 Statprobe,,,,,,Phase 3,Industry,Interventional,12/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01053312
59,Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users,Completed,Has Results,Opioid Abuse,Drug: 40/0mg taken first|Drug: 80/0mg taken first|Drug: 40/240mg taken first|Drug: 80/480mg taken first|Drug: 0/0mg taken first,Acura Pharmaceuticals Inc.|King Pharmaceuticals is now a wholly owned subsidiary of Pfizer,Acura Pharmaceuticals Inc.,King Pharmaceuticals is now a wholly owned subsidiary of Pfizer,,,,,,Phase 2,Industry,Interventional,1/10/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01030406
60,Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications,Completed,Has Results,Acne Vulgaris,Drug: Clindamycin and BPO 5% gel|Drug: Clindamycin phosphate and benzoyl peroxide 2.5% gel.,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,8/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT01015638
61,"First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors",Completed,Has Results,"Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available",Drug: MSC2156119J,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 1,Industry,Interventional,11/30/2009,10/31/2015,https://ClinicalTrials.gov/show/NCT01014936
62,Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications,Completed,Has Results,Acne Vulgaris,Drug: clindamycin and benzoyl peroxide|Drug: Dapsone gel,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,7/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00964366
63,Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications,Completed,Has Results,Acne Vulgaris,Drug: Clindamycin and benzoyl peroxide|Drug: benzoyl peroxide 2.5% and adapalene 0.1% gel,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,5/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00926367
64,Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI),Completed,Has Results,Chronic Kidney Disease|Renal Insufficiency,Drug: Omniscan,GE Healthcare|i3 Statprobe,GE Healthcare,i3 Statprobe,,,,,,Phase 4,Industry,Interventional,5/9/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00908310
65,"A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Other: Placebo,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 1|Phase 2,Industry,Interventional,4/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00894322
66,Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.,Completed,Has Results,Heart Failure (HF),,"GE Healthcare|H2O Clinical LLC|Quintiles, Inc.",GE Healthcare,H2O Clinical LLC,"Quintiles, Inc.",,,,,,Industry,Observational,2/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02127307
67,Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).,Completed,Has Results,Pulmonary Hypertension,Drug: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|Drug: Dextrose,GE Healthcare|ICON Clinical Research,GE Healthcare,ICON Clinical Research,,,,,,Phase 4,Industry,Interventional,3/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00878878
68,Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem,Completed,Has Results,Cognitive Impairment,,GE Healthcare|Covance|H2O Clinical LLC,GE Healthcare,Covance,H2O Clinical LLC,,,,,,Industry,Observational,9/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02090855
69,A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis,Completed,Has Results,Plaque-Type Psoriasis,Drug: Olux-E Foam|Drug: Clobex lotion,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,3/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00852761
70,"Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects",Completed,Has Results,Viral Infection,Drug: UV-4B 3 mg|Drug: UV-4B 10 mg|Drug: UV-4B 30 mg|Drug: UV-4B 90 mg|Drug: UV-4B 180 mg|Drug: UV-4B 360 mg|Drug: UV-4B 720 mg|Drug: UV-4B 1000 mg|Drug: Placebo,"Unither Virology|Quintiles, Inc.|Emergent BioSolutions",Unither Virology,"Quintiles, Inc.",Emergent BioSolutions,,,,,Phase 1,Industry,Interventional,7/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02061358
71,"Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis",Completed,Has Results,Hand Dermatosis,Drug: clobetasol propionate,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,10/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00828464
72,Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily,Completed,Has Results,Renal Failure,Drug: LCP-Tacro|Drug: Prograf,Veloxis Pharmaceuticals|PPD,Veloxis Pharmaceuticals,PPD,,,,,,Phase 3,Industry,Interventional,12/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00817206
73,A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.,Completed,Has Results,Overweight|Obesity,Drug: VI-0521|Drug: Placebo|Other: Alcohol|Other: alcohol placebo,"VIVUS, Inc.|MDS Pharma Services","VIVUS, Inc.",MDS Pharma Services,,,,,,Phase 2,Industry,Interventional,12/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00806260
74,Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment,Completed,Has Results,Bacterial Conjunctivitis,Drug: Vigamox Ophthalmic Solution|Drug: BSS placebo,Alcon Research|Topical Solutions Ltd.,Alcon Research,Topical Solutions Ltd.,,,,,,Phase 4,Industry,Interventional,10/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00798577
75,Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET),Completed,Has Results,Essential Tremor|Parkinson's Disease,Other: DaTscan™ - Non-Caucasian Participants|Other: DaTscan™ - Caucasian Participants,"GE Healthcare|H2O Clinical LLC|Quintiles, Inc.",GE Healthcare,H2O Clinical LLC,"Quintiles, Inc.",,,,,,Industry,Observational,7/30/2013,5/16/2019,https://ClinicalTrials.gov/show/NCT01952678
76,"Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.",Completed,Has Results,"Heart Failure (HF)|Ventricular Dysfunction, Left",Drug: AdreView (Iobenguane I 123 Injection),"GE Healthcare|H2O Clinical LLC|Quintiles, Inc.",GE Healthcare,H2O Clinical LLC,"Quintiles, Inc.",,,,,Phase 4,Industry,Interventional,8/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01936649
77,Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: sitagliptin|Drug: placebo,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 4,Industry,Interventional,8/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00729326
78,DuraSeal Sealant Post Market Study,Completed,Has Results,Elective Cranial Procedures With Dural Incision,Device: DuraSeal Dural Sealant System|Other: Standard of Care,Integra LifeSciences Corporation|Medtronic - MITG,Integra LifeSciences Corporation,Medtronic - MITG,,,,,,Not Applicable,Industry,Interventional,9/5/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00704340
79,"A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers",Completed,Has Results,Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms,Drug: doxorubicin HCL liposome; bevacizumab; carboplatin,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Centocor Ortho Biotech Services, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Centocor Ortho Biotech Services, L.L.C.",,,,,,Phase 2,Industry,Interventional,8/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00698451
80,Study of MAP0010 in Asthmatic Children and Adolescents,Completed,Has Results,Asthma,Drug: MAP0010 low dose|Drug: MAP0010 high dose|Drug: Placebo,"Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Allergan,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",,,,,,Phase 2,Industry,Interventional,7/6/2019,12/6/2019,https://ClinicalTrials.gov/show/NCT00697801
81,A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects,Completed,Has Results,Healthy,Drug: Maraviroc|Drug: Raltegravir,ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 4,Industry,Interventional,2/8/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00666705
82,Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: pirfenidone,"Genentech, Inc.|Hoffmann-La Roche","Genentech, Inc.",Hoffmann-La Roche,,,,,,Phase 3,Industry,Interventional,8/8/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00662038
83,Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex),Completed,Has Results,Healthy,Drug: recombinant human hyaluronidase,Halozyme Therapeutics|Baxter Healthcare Corporation,Halozyme Therapeutics,Baxter Healthcare Corporation,,,,,,Phase 4,Industry,Interventional,12/7/2019,1/30/2008,https://ClinicalTrials.gov/show/NCT00656370
84,Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers,Completed,Has Results,Chronic Kidney Disease,Device: Polyflux 210H dialyzer|Device: Polyflux HD-C4,"Baxter Healthcare Corporation|Gambro Renal Products, Inc.",Baxter Healthcare Corporation,"Gambro Renal Products, Inc.",,,,,,Not Applicable,Industry,Interventional,2/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00636389
85,Phase 3 Study of MAP0004 in Adult Migraineurs,Completed,Has Results,Migraine Disorders,Drug: MAP0004|Drug: Placebo,"Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Allergan,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",,,,,,Phase 3,Industry,Interventional,7/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00623636
86,Staccato Prochlorperazine Single Dose PK Study,Completed,Has Results,Migraine,Drug: Prochlorperazine 0.5 mg IV over 5 sec|Drug: Inhaled prochlorperazine 0.625 mg|Drug: Inhaled prochlorperazine 1.25 mg|Drug: Inhaled prochlorperazine 2.5 mg|Drug: Inhaled prochlorperazine 5 mg|Drug: Inhaled prochlorperazine 10 mg|Drug: Inhaled placebo|Drug: Prochlorperazine 10 mg IV over 5 sec,"Alexza Pharmaceuticals, Inc.|PPD","Alexza Pharmaceuticals, Inc.",PPD,,,,,,Phase 1,Industry,Interventional,8/4/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00610727
87,Reinforcement of Surgical Staple Lines Using Peri-Strips Dry (PSD) With Veritas Collagen Matrix,Completed,Has Results,Obesity,Device: PSD Veritas Collagen Matrix|Procedure: Roux-en-Y gastric by-pass surgery with no buttress,Baxter Healthcare Corporation|Synovis Surgical Innovations,Baxter Healthcare Corporation,Synovis Surgical Innovations,,,,,,Not Applicable,Industry,Interventional,3/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00566943
88,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: 23 mg SR in Study 326|Drug: 10 mg IR in Study 326,Eisai Inc.|Eisai Limited,Eisai Inc.,Eisai Limited,,,,,,Phase 3,Industry,Interventional,12/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00566501
89,"Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation",Completed,Has Results,Premature Ejaculation,"Drug: PSD502, contains a mixture of lidocaine and prilocaine|Drug: Placebo",Plethora Solutions Ltd|Shionogi Inc.,Plethora Solutions Ltd,Shionogi Inc.,,,,,,Phase 2|Phase 3,Industry,Interventional,10/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00556478
90,A Study of 2 Doses of MAP0010 in Adult Asthmatics,Completed,Has Results,Asthma,Drug: MAP0010 low dose|Drug: MAP0010 high dose|Drug: Budesonide inhalation suspension 0.25mg|Drug: Budesonide inhalation suspension 0.5mg,"Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Allergan,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",,,,,,Phase 2,Industry,Interventional,11/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00554970
91,Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects,Completed,Has Results,Anesthesia,Drug: 400uL of Kovacaine Mist|Drug: 200uL of Kovacaine Mist|Drug: 120uL of Kovacaine Mist,"St. Renatus, LLC|Triligent International|Rho, Inc.","St. Renatus, LLC",Triligent International,"Rho, Inc.",,,,,Phase 2,Industry,Interventional,10/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01701505
92,"ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.",Completed,Has Results,Venous Reflux,Device: Seg. RF Ablation & ClosureFAST catheter|Device: Endovenous Laser,"Medtronic Endovascular|VNUS Medical Technologies, A Covidien Company",Medtronic Endovascular,"VNUS Medical Technologies, A Covidien Company",,,,,,Phase 4,Industry,Interventional,3/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00509392
93,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Completed,Has Results,Diabetic Neuropathy,Drug: Placebo|Drug: E2007 (2 mg)|Drug: E2007 (4 mg)|Drug: E2007 (6 mg)|Drug: E2007 (8 mg),Eisai Inc.|Eisai Limited,Eisai Inc.,Eisai Limited,,,,,,Phase 2|Phase 3,Industry,Interventional,6/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00505284
94,Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania,Completed,Has Results,Bipolar Disorder,Drug: Cariprazine (RGH-188)|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 2,Industry,Interventional,6/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00488618
95,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg),Eisai Inc.|Eisai Limited,Eisai Inc.,Eisai Limited,,,,,,Phase 3,Industry,Interventional,6/7/2019,,https://ClinicalTrials.gov/show/NCT00478205
96,Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.,Completed,Has Results,HIV,"Drug: TMC125, Darunavir; Ritonavir","Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","Tibotec, Inc","Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 3,Industry,Interventional,5/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00460746
97,Study to Evaluate Safety & Effectiveness of Spinal Sealant,Completed,Has Results,"Cerebrospinal Fluid Leakage, Subdural",Device: Spinal Sealant|Other: Standard of Care,Integra LifeSciences Corporation|Medtronic - MITG,Integra LifeSciences Corporation,Medtronic - MITG,,,,,,Not Applicable,Industry,Interventional,5/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00444067
98,RNF and Betaseron® Tolerability Study,Completed,Has Results,Relapsing Remitting Multiple Sclerosis (RRMS),Drug: New Formulation of rebif - human interferon beta-1a|Drug: Interferon beta -1b,EMD Serono|Pfizer,EMD Serono,Pfizer,,,,,,Phase 3,Industry,Interventional,12/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00428584
99,Open-Label Study of Efficacy and Recommended Dose of Kovacaine Mist for Anesthetizing Maxillary Teeth,Completed,Has Results,Anesthesia,Drug: Kovacaine Mist 0.1 mL x 4 sprays|Drug: Kovacaine Mist 0.2 mL x 2 sprays|Drug: Kovacaine Mist 0.2 mL x 1 spray,"St. Renatus, LLC|Rho, Inc.|Triligent International","St. Renatus, LLC","Rho, Inc.",Triligent International,,,,,Phase 2,Industry,Interventional,1/12/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01479517
100,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: tadalafil|Drug: placebo,Eli Lilly and Company|ICOS Corporation,Eli Lilly and Company,ICOS Corporation,,,,,,Phase 2|Phase 3,Industry,Interventional,8/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00384930
101,Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Docetaxel|Drug: Oxaliplatin|Drug: Bevacizumab,"Sanofi|Genentech, Inc.",Sanofi,"Genentech, Inc.",,,,,,Phase 2,Industry,Interventional,7/6/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00356122
102,Rebif® Pregnancy Registry,Completed,Has Results,Multiple Sclerosis,,EMD Serono|Pfizer,EMD Serono,Pfizer,,,,,,,Industry,Observational,12/2/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00338741
103,A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX,Completed,Has Results,Japanese Encephalitis,Biological: ChimeriVax™-JE vaccine|Biological: JE-VAX® vaccine,Sanofi|PRA Health Sciences,Sanofi,PRA Health Sciences,,,,,,Phase 2,Industry,Interventional,5/5/2019,9/6/2019,https://ClinicalTrials.gov/show/NCT00319592
104,Dose-Escalation Safety and Pharmacokinetic Study of K305,Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%,"St. Renatus, LLC|Ground Zero Pharmaceuticals|Rho, Inc.","St. Renatus, LLC",Ground Zero Pharmaceuticals,"Rho, Inc.",,,,,Phase 2,Industry,Interventional,9/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01304316
105,Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia,Completed,Has Results,Dental Anesthesia Efficacy,Drug: 3% tetracaine HCL with 0.05% oxymetazoline HCL|Drug: Lidocaine Injection,"St. Renatus, LLC|Ground Zero Pharmaceuticals|Rho, Inc.","St. Renatus, LLC",Ground Zero Pharmaceuticals,"Rho, Inc.",,,,,Phase 2,Industry,Interventional,12/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT01302483
106,Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects,Completed,Has Results,Healthy,Drug: [18F] Flutemetamol,"GE Healthcare|i3 Statprobe|Medpace, Inc.",GE Healthcare,i3 Statprobe,"Medpace, Inc.",,,,,Phase 3,Industry,Interventional,12/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01265394
107,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Completed,Has Results,Post-operative Pain,Drug: Ibuprofen/acetaminophen|Drug: Ibuprofen/acetaminophen (higher dose)|Drug: Nurofen Plus®|Drug: Panadeine® Extra|Drug: Placebo,Reckitt Benckiser LLC|Premier Research Group plc|Aptuit Inc.,Reckitt Benckiser LLC,Premier Research Group plc,Aptuit Inc.,,,,,Phase 3,Industry,Interventional,1/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT01229449
108,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Completed,Has Results,Macular Degeneration|Choroidal Neovascularization,Drug: Verteporfin photodynamic therapy|Drug: Pegaptanib|Drug: Triamcinolone acetonide,Novartis Pharmaceuticals|QLT Inc.|Novartis,Novartis Pharmaceuticals,QLT Inc.,Novartis,,,,,Phase 3,Industry,Interventional,9/5/2019,,https://ClinicalTrials.gov/show/NCT00242580
109,Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels,Completed,Has Results,Brain Fibrillarab Levels,Drug: [18F] Flutemetamol,GE Healthcare|i3 Statprobe|Covance,GE Healthcare,i3 Statprobe,Covance,,,,,Phase 3,Industry,Interventional,5/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01165554
110,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Biological: Interferon-beta-1a FBS-free/HSA-free,EMD Serono|Pfizer,EMD Serono,Pfizer,,,,,,Phase 3,Industry,Interventional,1/5/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00110396
111,Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide,Completed,Has Results,Metastatic Progressive Castration-resistant Prostate Cancer,Drug: Enzalutamide,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Pfizer,Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,Phase 2,Industry,Interventional,2/18/2010,8/31/2013,https://ClinicalTrials.gov/show/NCT01091103
112,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,Completed,Has Results,Coronary Arteriosclerosis|Acute Coronary Syndromes,Drug: Prasugrel|Drug: Clopidogrel,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,Phase 3,Industry,Interventional,11/4/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00097591
113,"Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)",Completed,Has Results,Healthy,Drug: GE-145 (AN113111) Injection|Drug: Visipaque (iodixanol) Injection,"GE Healthcare|Medpace, Inc.|i3 Statprobe",GE Healthcare,"Medpace, Inc.",i3 Statprobe,,,,,Phase 1|Phase 2,Industry,Interventional,10/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01004770
114,The Zeaxanthin and Visual Function Study,Completed,Has Results,Age Related Macular Degeneration|Cognition Disorders,Drug: 3R 3'R Zeaxanthin|Dietary Supplement: Lutein|Dietary Supplement: Lutein and Zeaxanthin,"Chrysantis, Inc.|Kowa Company, Ltd.|IMAGE TECHNOLOGIES INC.","Chrysantis, Inc.","Kowa Company, Ltd.",IMAGE TECHNOLOGIES INC.,,,,,Not Applicable,Industry,Interventional,11/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00564902
115,Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence,Completed,Has Results,Asthma,Drug: Dulera,Asthma Management Systems|Merck Sharp & Dohme Corp.|West Penn Allegheny Health System,Asthma Management Systems,Merck Sharp & Dohme Corp.,West Penn Allegheny Health System,,,,,Phase 4,Industry|Other,Interventional,3/4/2014,7/12/2017,https://ClinicalTrials.gov/show/NCT02045875
116,Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes,Completed,Has Results,Hypoglycemia,Drug: G-Pen Mini™ (glucagon injection),Xeris Pharmaceuticals|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Emissary International LLC,Xeris Pharmaceuticals,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Emissary International LLC,,,,,Phase 2,Industry|NIH,Interventional,3/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02081014
117,PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients,Completed,Has Results,Hypoglycemia,Drug: Novo Nordisk GlucaGen®|Drug: G-Pump™ (glucagon infusion),Xeris Pharmaceuticals|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Emissary International LLC,Xeris Pharmaceuticals,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Emissary International LLC,,,,,Phase 2,Industry|NIH,Interventional,3/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02081001
118,Inguinal Hernia Study Using Biodesign IHM,Completed,Has Results,Inguinal Hernia,Device: Biodesign IHM|Device: Polypropylene mesh,"Cook Group Incorporated|Cook Biotech Incorporated|MED Institute, Incorporated",Cook Group Incorporated,Cook Biotech Incorporated,"MED Institute, Incorporated",,,,,Not Applicable,Industry,Interventional,3/7/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00393887
119,"Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia",Completed,Has Results,Hypoglycemia,Drug: G-Pen(TM) 1 mg|Drug: Lilly Glucagon(TM) 1 mg|Drug: G-Pen(TM) 0.5 mg,Xeris Pharmaceuticals|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Emissary International LLC,Xeris Pharmaceuticals,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Emissary International LLC,,,,,Phase 2,Industry|NIH,Interventional,10/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01972152
120,Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma,Completed,Has Results,Allergic Asthma,Drug: Placebo|Drug: Omalizumab|Drug: Immunotherapy,"Novartis|Genentech, Inc.|Tanox",Novartis,"Genentech, Inc.",Tanox,,,,,Phase 4,Industry,Interventional,12/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00267202
121,Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season,Completed,Has Results,Influenza|Healthy,Biological: Monovalent Influenza Vaccine|Other: Placebo,MedImmune LLC|AstraZeneca,MedImmune LLC,AstraZeneca,,,,,,Phase 4,Industry,Interventional,5/30/2017,12/14/2017,https://ClinicalTrials.gov/show/NCT03158038
122,"Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers",Completed,Has Results,Healthy,Drug: Ioforminol 160 mgI/mL|Drug: Ioforminol 200 mgI/mL|Drug: Iopamidol 300 mgI/mL,"GE Healthcare|Physician Reference Laboratory|Quintiles, Inc.",GE Healthcare,Physician Reference Laboratory,"Quintiles, Inc.",,,,,Phase 1|Phase 2,Industry|Other,Interventional,7/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01672996
123,The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate,Completed,Has Results,Hypogonadism,Drug: Oral Testosterone Undecanoate,"Clarus Therapeutics, Inc.|Celerion","Clarus Therapeutics, Inc.",Celerion,,,,,,Phase 2,Industry,Interventional,10/16/2019,1/21/2017,https://ClinicalTrials.gov/show/NCT02921386
124,"An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)",Completed,Has Results,Multiple Sclerosis,Other: Withdrawal of dalfampridine-ER 10mg,"Acorda Therapeutics|Prometrika, LLC|BCS Consulting, Inc.",Acorda Therapeutics,"Prometrika, LLC","BCS Consulting, Inc.",,,,,,Industry|Other,Observational,1/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01535664
125,Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection),Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%,"St. Renatus, LLC|Triligent International|Rho, Inc.|Analytical Bio-Chemistry Laboratories, Inc.","St. Renatus, LLC",Triligent International,"Rho, Inc.|Analytical Bio-Chemistry Laboratories, Inc.","Rho, Inc.","Analytical Bio-Chemistry Laboratories, Inc.",,,Phase 2,Industry,Interventional,3/13/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01807624
126,"Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults",Completed,Has Results,Malaria,Biological: Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|Biological: GSK Biologicals' malaria vaccine 257049 (2 doses)|Biological: GSK Biologicals' malaria vaccine 257049 (3 doses)|Other: Sporozoite challenge,GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)|Crucell Holland BV,GlaxoSmithKline,The PATH Malaria Vaccine Initiative (MVI),Crucell Holland BV,,,,,Phase 2,Industry|Other,Interventional,8/10/2011,7/3/2012,https://ClinicalTrials.gov/show/NCT01366534
127,A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants,Completed,Has Results,Healthy,Drug: Lanabecestat|Drug: Simvastatin|Drug: Midazolam|Drug: Donepezil,Eli Lilly and Company|AstraZeneca,Eli Lilly and Company,AstraZeneca,,,,,,Phase 1,Industry,Interventional,4/15/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02406261
128,A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents,Completed,Has Results,Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)|Healthy Subjects (Treated With no Diabetes Therapies),Drug: exenatide|Drug: Other antidiabetic therapies|Other: No diabetes therapy,AstraZeneca|Eli Lilly and Company|i3 Drug Safety,AstraZeneca,Eli Lilly and Company,i3 Drug Safety,,,,,,Industry|Other,Observational,9/4/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT01077323
129,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Completed,Has Results,Iron Deficiency Anaemia,Drug: iron isomaltoside 1000 (Monofer®)|Drug: iron sucrose (Venofer®),"Pharmacosmos A/S|BioStata|ClinStar, LLC|LabCorp",Pharmacosmos A/S,BioStata,"ClinStar, LLC|LabCorp","ClinStar, LLC",LabCorp,,,Phase 3,Industry|Other,Interventional,5/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02130063
130,"A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions",Completed,Has Results,Chronic Interstitial Cystitis,Drug: LiRIS® 400 mg,"Allergan|TARIS Biomedical, Inc.",Allergan,"TARIS Biomedical, Inc.",,,,,,Phase 1,Industry,Interventional,7/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01879683
131,Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18|Drug: [11C]-PIB,Avid Radiopharmaceuticals|American College of Radiology Imaging Network|General Electric,Avid Radiopharmaceuticals,American College of Radiology Imaging Network,General Electric,,,,,Phase 2,Industry|Other,Interventional,3/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00855868
132,The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009),Completed,Has Results,Hepatic Insufficiency,Drug: Elbasvir,Merck Sharp & Dohme Corp.|Celerion,Merck Sharp & Dohme Corp.,Celerion,,,,,,Phase 1,Industry,Interventional,3/6/2013,8/20/2014,https://ClinicalTrials.gov/show/NCT01797536
133,Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole and aripiprazole once-monthly|Drug: Paliperidone and paliperidone palmitate,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,2/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01795547
134,Ibuprofen Extended-Release Dental Pain Study,Completed,Has Results,Pain|Post-Operative Pain|Third Molar Extraction,Drug: Ibuprofen 600 mg Extended-Release Tablets|Drug: Placebo,"SCOLR Pharma, Inc.|AAIPharma|Jean Brown Research","SCOLR Pharma, Inc.",AAIPharma,Jean Brown Research,,,,,Phase 3,Industry|Other,Interventional,6/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00707057
135,Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients,Completed,Has Results,Liver Failure,Drug: LCP -Tacro|Drug: Prograf,Veloxis Pharmaceuticals|CTI Clinical Trial and Consulting Services|Aptuit Inc.,Veloxis Pharmaceuticals,CTI Clinical Trial and Consulting Services,Aptuit Inc.,,,,,Phase 2,Industry|Other,Interventional,10/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00772148
136,Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients,Completed,Has Results,Kidney Failure|Renal Failure,Drug: Tacrolimus (Tacro™)|Drug: Prograf,Veloxis Pharmaceuticals|CTI Clinical Trial and Consulting Services|Aptuit Inc.,Veloxis Pharmaceuticals,CTI Clinical Trial and Consulting Services,Aptuit Inc.,,,,,Phase 2,Industry|Other,Interventional,9/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00765661
137,Comparative Effects Of Dialysate Flow Rate And Membrane Packing On The Performance Of Dialyzers Used For Hemodialysis,Completed,Has Results,Chronic Kidney Disease|Chronic Renal Disease,Device: Polyflux HD-C4 Big|Device: HD-C4 Small|Device: Optiflux 160NR|Device: Optiflux 200NR,"Baxter Healthcare Corporation|University of Louisville|Gambro Renal Products, Inc.",Baxter Healthcare Corporation,University of Louisville,"Gambro Renal Products, Inc.",,,,,Not Applicable,Industry|Other,Interventional,2/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00636077
138,Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support),Completed,Has Results,Major Depressive Disorder,Other: Deplin®,"Pamlab, Inc.|InfoMedics, Inc.","Pamlab, Inc.","InfoMedics, Inc.",,,,,,,Industry,Observational,11/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01369030
139,"Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients",Completed,Has Results,Schizophrenia,Drug: Iloperidone crystalline formulation|Drug: Iloperidone microparticle formulation|Drug: Oral iloperidone,Novartis Pharmaceuticals|Vanda Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Vanda Pharmaceuticals,Novartis,,,,,Phase 1|Phase 2,Industry,Interventional,4/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01348100
140,A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects,Completed,Has Results,Healthy Subjects,Drug: Exenatide|Drug: Moxifloxacin|Drug: Placebo comparator,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 1,Industry,Interventional,2/11/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01297062
141,Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients,Completed,Has Results,Renal Transplant,Drug: Generic Tacrolimus|Drug: Branded Tacrolimus,Novartis|Sandoz,Novartis,Sandoz,,,,,,Phase 4,Industry,Interventional,10/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01256294
142,The Evicel Post-Authorization Surveillance Study,Completed,Has Results,Peripheral Vascular Disease|Hemorrhage,Biological: EVICEL ™ Fibrin Sealant (Human),"Ethicon, Inc.|OMRIX Biopharmaceuticals","Ethicon, Inc.",OMRIX Biopharmaceuticals,,,,,,,Industry,Observational,6/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01158261
143,"A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension",Completed,Has Results,Type 2 Diabetes,Drug: exenatide once weekly|Drug: exenatide once monthly suspension,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 2,Industry,Interventional,5/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01104701
144,Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma,Completed,Has Results,Asthma,Drug: 84ug MAP0020|Drug: 42ug MAP0020|Drug: 21ug MAP0020,"Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Allergan,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",,,,,,Phase 2,Industry,Interventional,9/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00995904
145,A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne,Completed,Has Results,Acne Vulgaris,Drug: Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Drug: benzoyl peroxide and adapalene gel (EPIDUO™ Gel),"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,7/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00964223
146,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,Completed,Has Results,"Macular Edema, Cystoid|Retinal Vein Occlusion",Other: Standard Care|Drug: intravitreal triamcinolone injection,"The Emmes Company, LLC|National Eye Institute (NEI)|Allergan","The Emmes Company, LLC",National Eye Institute (NEI),Allergan,,,,,Phase 3,Industry|NIH,Interventional,10/4/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00105027
147,Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam,Completed,Has Results,Psoriasis,Drug: Clobetasol propionate foam|Drug: Vehicle foam,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,11/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00842153
148,Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne,Completed,Has Results,Acne,Drug: Duac|Drug: Ziana gel,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,8/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00841776
149,Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne,Completed,Has Results,Acne,Drug: Benzoyl peroxide with clindamycin|Drug: Benzoyl peroxide with clindamycin and doxycycline,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,8/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00837213
150,Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection,Completed,Has Results,Solid Tumors|High Grade Gliomas|Lung Cancer|Head and Neck Cancer|Sarcoma|Renal Cell Carcinoma|Breast Cancer,Drug: Fluciclatide Injection,"GE Healthcare|BIAFFIN GmbH & Co. KG (Biomolecular Interaction Analyses)|Quintiles, Inc.|i3 Statprobe",GE Healthcare,BIAFFIN GmbH & Co. KG (Biomolecular Interaction Analyses),"Quintiles, Inc.|i3 Statprobe","Quintiles, Inc.",i3 Statprobe,,,Phase 2,Industry|Other,Interventional,6/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00918281
151,Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase,Completed,Has Results,Dehydration,Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion,Baxter Healthcare Corporation|Halozyme Therapeutics,Baxter Healthcare Corporation,Halozyme Therapeutics,,,,,,Phase 4,Industry,Interventional,12/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00807885
152,The Complete® Self-Expanding Stent and Stent Delivery System Registry,Completed,Has Results,Peripheral Vascular Disease,Device: Complete SE Iliac Stent,Medtronic Endovascular|Medtronic,Medtronic Endovascular,Medtronic,,,,,,Not Applicable,Industry,Interventional,11/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00730730
153,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Drug: Placebo,"St. Renatus, LLC|Triligent International|Rho, Inc.","St. Renatus, LLC",Triligent International,"Rho, Inc.",,,,,Phase 3,Industry,Interventional,5/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01844830
154,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Completed,Has Results,Obesity,Drug: VI-0521|Drug: topiramate|Drug: phentermine,"VIVUS, Inc.|Medpace, Inc.","VIVUS, Inc.","Medpace, Inc.",,,,,,Phase 3,Industry,Interventional,12/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00563368
155,Peri-Strips Dry (PSD) Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery,Completed,Has Results,Colorectal Cancer,Device: Staple line reinforcement,Baxter Healthcare Corporation|Synovis Surgical Innovations,Baxter Healthcare Corporation,Synovis Surgical Innovations,,,,,,Not Applicable,Industry,Interventional,3/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00559013
156,Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients,Completed,Has Results,Multiple Myeloma,Drug: VELCADE (bortezomib)|Drug: dexamethasone|Drug: cyclophosphamide|Drug: Revlimid (lenalidomide),"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Millennium Pharmaceuticals, Inc.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 1|Phase 2,Industry,Interventional,8/7/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00507442
157,Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure,Completed,Has Results,Chronic Renal Insufficiency|Diabete Mellitus|Congestive Heart Failure,Drug: GE-145,"GE Healthcare|i3 Statprobe|Medpace, Inc.|Biomedical Systems|Rules-Based Medicine, Inc.",GE Healthcare,i3 Statprobe,"Medpace, Inc.|Biomedical Systems|Rules-Based Medicine, Inc.","Medpace, Inc.","Biomedical Systems|Rules-Based Medicine, Inc.",Biomedical Systems,"Rules-Based Medicine, Inc.",Phase 2,Industry,Interventional,11/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01252810
158,Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses,Completed,Has Results,Common Cold,Drug: 3804-250A|Drug: 3804-291,"The Dial Corporation|Hill Top Research|TKL Research, Inc.",The Dial Corporation,Hill Top Research,"TKL Research, Inc.",,,,,Phase 2,Industry,Interventional,8/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00762476
159,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Flutemetamol (18F) Injection,"GE Healthcare|Medpace, Inc.|i3 Statprobe|i3 Research|Quintiles, Inc.",GE Healthcare,"Medpace, Inc.","i3 Statprobe|i3 Research|Quintiles, Inc.",i3 Statprobe,"i3 Research|Quintiles, Inc.",i3 Research,"Quintiles, Inc.",Phase 3,Industry,Interventional,12/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01028053
160,RETeval Study for Diabetic Retinopathy,Completed,Has Results,Diabetic Retinopathy,Device: RETeval,"Inoveon Corporation|LKC Technologies, Inc.|National Eye Institute (NEI)",Inoveon Corporation,"LKC Technologies, Inc.",National Eye Institute (NEI),,,,,Not Applicable,Industry|NIH,Interventional,9/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01950663
161,Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery,Completed,Has Results,Hernia|Obesity,Device: Surgisis Gold Graft|Procedure: Control,"Cook Group Incorporated|Cook Biotech Incorporated|MED Institute, Incorporated",Cook Group Incorporated,Cook Biotech Incorporated,"MED Institute, Incorporated",,,,,Not Applicable,Industry,Interventional,8/5/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00274625
162,Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients,Completed,Has Results,Chronic Pain,Drug: Hydrocodone,"NEMA Research, Inc.|Medtronic - MITG|International Clinical Research Institute","NEMA Research, Inc.",Medtronic - MITG,International Clinical Research Institute,,,,,Phase 4,Industry|Other,Interventional,2/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01517295
163,Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer,Completed,Has Results,Chronic Kidney Failure,,"Baxter Healthcare Corporation|Advanced Dialysis Center of Potomac|Advanced Dialysis Center of Easton|Gambro Renal Products, Inc.",Baxter Healthcare Corporation,Advanced Dialysis Center of Potomac,"Advanced Dialysis Center of Easton|Gambro Renal Products, Inc.",Advanced Dialysis Center of Easton,"Gambro Renal Products, Inc.",,,,Industry,Observational,3/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00659724
164,Comparing the Efficacy of a Dual-Frequency LLLT Device With a Sham Device as a Therapy for Adipose Tissue Loss,Completed,Has Results,Obesity|Body Weight|Fat Burn|Cellulite|Abdominal Fat|Adipose Tissue Atrophy,Device: Care as Usual Group|Device: Sham Group,"IR Technology, LLC","IR Technology, LLC",,,,,,,Not Applicable,Industry,Interventional,1/21/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT03811093
165,Desaturation Validation of INVSENSOR00031,Completed,Has Results,Healthy,Device: INVSENSOR00031,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,12/11/2018,12/18/2018,https://ClinicalTrials.gov/show/NCT03783780
166,A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC),Completed,Has Results,Non-melanoma Skin Cancer,Radiation: SRT-100,Sensus Healthcare,Sensus Healthcare,,,,,,,,Industry,Observational,11/15/2018,3/16/2019,https://ClinicalTrials.gov/show/NCT03693937
167,Hemodilution Validation of INVSENSOR00026,Completed,Has Results,Healthy,Device: INVSENSOR00026,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,9/4/2018,2/4/2019,https://ClinicalTrials.gov/show/NCT03677375
168,A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20),Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Rapid Acting insulin with pre-treatment of rHuPH20|Device: Sham injection,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 4,Industry,Interventional,10/3/2013,2/27/2014,https://ClinicalTrials.gov/show/NCT03662334
169,SpO2 Accuracy Comparison of Smart Sock V. 2 SpO2 to Arterial Blood CO-Oximetry,Completed,Has Results,Hypoxia,Diagnostic Test: Pulse oximetry with Owlet BabySat v1.0 sensor,"Owlet Baby Care, Inc.|Clinimark, LLC","Owlet Baby Care, Inc.","Clinimark, LLC",,,,,,Not Applicable,Industry|Other,Interventional,12/13/2017,12/17/2017,https://ClinicalTrials.gov/show/NCT03630016
170,Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study,Completed,Has Results,Organ Transplant Rejection|Psoriasis,Drug: Sustained Release Injectable Tacrolimus,Auritec Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID),Auritec Pharmaceuticals,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,Early Phase 1,Industry|NIH,Interventional,10/16/2018,1/5/2019,https://ClinicalTrials.gov/show/NCT03626714
171,Vscan Access R2 Feasibility Evaluation,Completed,Has Results,Gather Feasibility Data and User Feedback on Use of a Device in Vivo on Pregnant Volunteers in Their 2nd and 3rd Trimester,Device: GE VScan Access R2 Ultrasound System|Device: GE Corometrics 170 Series Fetal Monitor,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,11/14/2017,2/26/2018,https://ClinicalTrials.gov/show/NCT03617419
172,"Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years",Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Amphetamine Extended Release Suspension [Dyanavel],"Tris Pharma, Inc.","Tris Pharma, Inc.",,,,,,,Phase 4,Industry,Interventional,5/7/2018,5/23/2018,https://ClinicalTrials.gov/show/NCT03610464
173,Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation of INVSENSOR00026,Completed,Has Results,Anemia,Device: INVSENSOR00026 (Pulse CO-Oximeter and sensor),Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,8/1/2018,8/16/2018,https://ClinicalTrials.gov/show/NCT03610269
174,PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: AEVI-001|Drug: Placebo,Aevi Genomic Medicine,Aevi Genomic Medicine,,,,,,,Phase 2,Industry,Interventional,8/17/2018,11/30/2018,https://ClinicalTrials.gov/show/NCT03609619
175,Evaluation of the Ulthera® System and Efficacy Correlation to Morphological Differences,Completed,Has Results,Facial and Neck Skin Laxity,Device: Microfocused ultrasound w/ visualization,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,8/20/2015,7/13/2016,https://ClinicalTrials.gov/show/NCT03599349
176,SpO2 Accuracy Comparison of Medline ReNewal Sensors to Arterial Blood CO-Oximetry,Completed,Has Results,Arterial Oxygen Saturation|Healthy,Device: MEDLINE RENEWAL PULSE OXIMETRY SENSORS|Device: CO-OXIMETRY SENSORS,"Medline Industries|Clinimark, LLC",Medline Industries,"Clinimark, LLC",,,,,,Not Applicable,Industry|Other,Interventional,5/9/2018,5/10/2018,https://ClinicalTrials.gov/show/NCT03565679
177,Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4),Completed,Has Results,Healthy Volunteers,Combination Product: PRT064445/Enoxaparin|Combination Product: Placebo/Enoxaparin|Drug: Placebo,Portola Pharmaceuticals,Portola Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT03551730
178,Use of the Leva Incontinence System in Treating Bladder Incontinence.,Completed,Has Results,Stress Urinary Incontinence,Device: Leva Incontinence System For Pelvic Floor Muscle strengthening,"Renovia, Inc.","Renovia, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/10/2017,10/20/2017,https://ClinicalTrials.gov/show/NCT03536923
179,Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements,Completed,Has Results,Cystic Fibrosis|Bronchiectasis,Device: International Biophysics AffloVest|Device: Hill-Rom The Vest|Device: Respirtech inCourage|Device: Electromed SmartVest,International Biophysics Corporation,International Biophysics Corporation,,,,,,,Not Applicable,Industry,Interventional,2/20/2018,3/16/2018,https://ClinicalTrials.gov/show/NCT03534986
180,NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test,Completed,Has Results,"Allergy Skin|Allergy|Dermatitis, Allergic Contact",Device: NeoMatriX Wound MatriX Collagen Dressing,"NeXtGen Biologics, Inc.|State University of New York at Buffalo","NeXtGen Biologics, Inc.",State University of New York at Buffalo,,,,,,Not Applicable,Industry|Other,Interventional,4/11/2018,4/28/2018,https://ClinicalTrials.gov/show/NCT03522675
181,Clinical Comparison of Two Daily Disposable Soft Contact Lenses,Completed,Has Results,Myopia|Refractive Errors,Device: verofilcon A contact lenses|Device: somofilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,5/23/2018,6/11/2018,https://ClinicalTrials.gov/show/NCT03518008
182,Oral and Dermal Tolerability Clinical Study of an Experimental Denture Wipe,Completed,Has Results,Denture Cleansers,Device: Experimental Denture Wipe|Other: Tap Water,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,10/10/2016,10/31/2016,https://ClinicalTrials.gov/show/NCT03478644
183,Human Repeated Insult Patch Test,Completed,Has Results,Dermatitis|Allergy|Contact Allergy,Device: NeoMatriX Collagen Dressing,"NeXtGen Biologics, Inc.","NeXtGen Biologics, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/26/2018,4/6/2018,https://ClinicalTrials.gov/show/NCT03474874
184,Clinical Evaluation of Two Monthly Contact Lenses,Completed,Has Results,Refractive Errors,Device: Comfilcon A with Digital Zone Optics™ contact lenses|Device: Comfilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,3/7/2018,3/26/2018,https://ClinicalTrials.gov/show/NCT03459131
185,Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow,Completed,Has Results,Breast Cancer,Device: Patient-Assisted Compression (PAC)|Device: Technologist-Controlled (TC) Compression,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,1/4/2018,1/9/2018,https://ClinicalTrials.gov/show/NCT03456427
186,Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100,Completed,Has Results,Allergic Sensitization,Device: Light Therapy Mask Cream,"Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,11/15/2017,12/22/2017,https://ClinicalTrials.gov/show/NCT03450070
187,INVSENSOR00013 Respiratory Rate Clinical Performance Study,Completed,Has Results,Healthy,Device: INVSENSOR00013,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,2/6/2018,2/14/2018,https://ClinicalTrials.gov/show/NCT03440619
188,Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style,Completed,Has Results,Visual Acuity,Device: JJVC Marketed Contact Lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/16/2018,2/14/2018,https://ClinicalTrials.gov/show/NCT03431441
189,To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers,Completed,Has Results,Common Cold,Drug: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Drug: Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,3/1/2018,3/29/2018,https://ClinicalTrials.gov/show/NCT03415243
190,A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain,Completed,Has Results,"Pain, Postoperative","Drug: Naproxen Sodium (Aleve, BAY117031)|Drug: Ibuprofen (Advil)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 4,Industry,Interventional,2/12/2018,7/10/2018,https://ClinicalTrials.gov/show/NCT03404206
191,A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Nemiralisib|Drug: Itraconazole,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,1/17/2018,3/12/2018,https://ClinicalTrials.gov/show/NCT03398421
192,Comparison of Two Silicone Hydrogel Toric Contact Lenses,Completed,Has Results,Astigmatism,Device: Lotrafilcon B toric contact lenses with HYDRAGLYDE|Device: Lotrafilcon B toric contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,1/4/2018,1/26/2018,https://ClinicalTrials.gov/show/NCT03392532
193,The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression,Completed,Has Results,Depression,Drug: Scopolamine and naltrexone|Drug: placebo arm,The Taub Group,The Taub Group,,,,,,,Phase 4,Industry,Interventional,1/1/2018,11/20/2018,https://ClinicalTrials.gov/show/NCT03386448
194,Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds,Completed,Has Results,Healthy Volunteers,Device: ADHESIVE BANDAGE #1|Device: ADHESIVE BANDAGE #2|Device: ADHESIVE BANDAGE #3|Device: Antibacterial Bandage with 0.8% BZK|Other: Intact and No Bandage|Other: Wounded and No Bandage,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer Inc. (J&JCI),Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,11/20/2017,2/12/2018,https://ClinicalTrials.gov/show/NCT03365934
195,Study of EB-001 in Facial Scar Reduction,Completed,Has Results,Mohs Surgery,Drug: EB-001|Drug: 0.9% Sodium Chloride Injection,"Bonti, Inc.","Bonti, Inc.",,,,,,,Phase 2,Industry,Interventional,2/6/2018,10/8/2018,https://ClinicalTrials.gov/show/NCT03346902
196,A Study to Investigate a Method to Measure Food Occlusion by Denture Adhesives in Denture Wearers,Completed,Has Results,Denture Retention,Device: Denture Adhesive Cream (Conventional Application)|Device: Denture Adhesive (Continuous Strip Application)|Other: No Adhesive,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,11/20/2017,12/15/2017,https://ClinicalTrials.gov/show/NCT03345108
197,"In Home Assessment of Three Anti-Snoring Devices, a Cross Over Study",Completed,Has Results,Snoring,Device: Nasal Dilator|Device: Mandibular Advancement|Device: Positional Therapy,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,10/9/2017,12/3/2017,https://ClinicalTrials.gov/show/NCT03333876
198,TheraBracelet Phase I,Completed,Has Results,Hand Function|Stroke|Upper Extremity|Hemiparesis|Cerebrovascular Accident|Stroke Rehabilitation,Device: Real Stimulation|Device: Sham Stimulation,"TheraBracelet, Inc.|Medical University of South Carolina","TheraBracelet, Inc.",Medical University of South Carolina,,,,,,Not Applicable,Industry|Other,Interventional,1/9/2018,11/28/2018,https://ClinicalTrials.gov/show/NCT03318341
199,Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles,Completed,Has Results,Skin Aging,Device: Active Mask|Device: Sham Mask,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer Inc. (J&JCI),Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,10/9/2017,4/6/2018,https://ClinicalTrials.gov/show/NCT03312543
200,TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions,Completed,Has Results,Peripheral Arterial Disease,Device: Laser Atherectomy,Spectranetics Corporation,Spectranetics Corporation,,,,,,,,Industry,Observational,10/3/2017,6/5/2018,https://ClinicalTrials.gov/show/NCT03306199
201,Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage,Completed,Has Results,Skin Care,Other: Retinol Complex 0.5|Other: Facial cleanser|Other: Moisturizing lotion|Other: Sunscreen|Device: Skin Imaging,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,9/18/2017,4/30/2018,https://ClinicalTrials.gov/show/NCT03302559
202,In Situ Erosion Study to Investigate the Effectiveness of an Experimental Toothpaste,Completed,Has Results,Tooth Erosion,Drug: 0.254% w/w sodium fluoride and 5% KNO3|Drug: 0.454% w/w stannous fluoride|Drug: 5% KNO3,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2|Phase 3,Industry,Interventional,11/13/2017,1/16/2018,https://ClinicalTrials.gov/show/NCT03296072
203,A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices,Completed,Has Results,Oral Hygiene,Drug: 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Drug: 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Drug: 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Drug: 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/25/2017,12/2/2017,https://ClinicalTrials.gov/show/NCT03267511
204,PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: AEVI-001|Drug: Placebo,Aevi Genomic Medicine,Aevi Genomic Medicine,,,,,,,Phase 2,Industry,Interventional,8/28/2017,10/1/2018,https://ClinicalTrials.gov/show/NCT03265119
205,"Evaluation of Performance, Usability, and Reliability of a Novel Device for Continuous Collection of Physiological Data",Completed,Has Results,Healthy Normals,Device: Physiological signal monitor|Device: Heart rate and heart rate variability comparison device|Device: Respiration rate comparison device|Other: Activity classification,MC10 Inc.,MC10 Inc.,,,,,,,Not Applicable,Industry,Interventional,7/31/2017,8/30/2017,https://ClinicalTrials.gov/show/NCT03257189
206,ITU Treatment for Chronic Epicondylitis Musculoskeletal Pain Reduction,Completed,Has Results,Tennis Elbow,Device: Intense Therapeutic Ultrasound Treatment,Guided Therapy Systems|More Foundation,Guided Therapy Systems,More Foundation,,,,,,Not Applicable,Industry|Other,Interventional,7/14/2015,3/13/2017,https://ClinicalTrials.gov/show/NCT03255733
207,Intense Therapeutic Ultrasound - Treatment for Chronic Plantar Fascia Musculoskeletal Pain Reduction,Completed,Has Results,Chronic Plantar Fasciitis,Device: Intense Therapeutic Ultrasound Treatment - ITU,Guided Therapy Systems|University of Arizona,Guided Therapy Systems,University of Arizona,,,,,,Not Applicable,Industry|Other,Interventional,10/22/2014,3/1/2016,https://ClinicalTrials.gov/show/NCT03255655
208,Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics,Completed,Has Results,Type2 Diabetes,Device: Continuous Glucose Monitor (CGM)|Device: Activity Tracker|Behavioral: Coaching,"Savvysherpa, Inc.","Savvysherpa, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/28/2017,2/25/2019,https://ClinicalTrials.gov/show/NCT03252964
209,A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentin Sensitivity,Device: Potassium oxalate|Drug: Sodium fluoride|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/7/2017,10/27/2017,https://ClinicalTrials.gov/show/NCT03238352
210,Evaluation of DCTclock™ as a Cognitive Assessment Aid,Completed,Has Results,Cognitive Function,Device: DCTclock,Digital Cognition Technologies,Digital Cognition Technologies,,,,,,,Not Applicable,Industry,Interventional,7/11/2017,11/21/2017,https://ClinicalTrials.gov/show/NCT03238001
211,"A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: GSK2838232 100 mg tablet|Drug: GSK2838232 50 mg capsule|Drug: Ritonavir 100 mg tablets|Drug: Placebo for GSK2838232 tablets,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,8/2/2017,11/10/2017,https://ClinicalTrials.gov/show/NCT03234036
212,Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX,Completed,Has Results,Influenza,Biological: NasoVAX,"Altimmune, Inc.","Altimmune, Inc.",,,,,,,Phase 2,Industry,Interventional,9/18/2017,6/15/2018,https://ClinicalTrials.gov/show/NCT03232567
213,Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers,Completed,Has Results,Visual Acuity,Device: senofilcon A|Device: Control,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Phase 4,Industry,Interventional,6/27/2017,8/4/2017,https://ClinicalTrials.gov/show/NCT03222037
214,Qualitative Analysis of Subject Experience of Nasal Polyps,Completed,Has Results,Nasal Polyps,Other: VAS questionnaire|Other: SNOT-22 questionnaire|Other: Data capture app,GlaxoSmithKline,GlaxoSmithKline,,,,,,,,Industry,Observational,7/31/2017,2/28/2018,https://ClinicalTrials.gov/show/NCT03221192
215,Abortive Treatment of Migraine With the Cefaly® Abortive Program Device,Completed,Has Results,Migraine,Device: Cefaly® Abortive Program device,Cefaly Technology,Cefaly Technology,,,,,,,Not Applicable,Industry,Interventional,8/10/2017,1/10/2018,https://ClinicalTrials.gov/show/NCT03217968
216,Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066,Completed,Has Results,Obesity,Drug: LIK066|Dietary Supplement: Carbohydrate 50%|Dietary Supplement: Carbohydrate 25%|Dietary Supplement: Carbohydrate 8%|Dietary Supplement: Carbohydrate 0%|Dietary Supplement: Psyllium|Dietary Supplement: Calcium carbonate,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/21/2017,9/4/2017,https://ClinicalTrials.gov/show/NCT03198767
217,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Completed,Has Results,Ophthalmic Solutions,Drug: F# 13418-148 Eye Drops|Drug: F#13418-158 Eye Drops|Drug: F# PF-004390 Eye Drops,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer Inc. (J&JCI),Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Phase 3,Industry,Interventional,6/28/2017,7/21/2017,https://ClinicalTrials.gov/show/NCT03198000
218,Patient-Assisted Compression - Impact on Image Quality and Workflow,Completed,Has Results,Breast Cancer,Device: Patient-Assisted (PA) Breast Compression|Device: Technologist-Controlled (TC) Breast Compression,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,6/19/2017,6/29/2017,https://ClinicalTrials.gov/show/NCT03196635
219,Study to Evaluate EB-001 in Reducing Musculoskeletal Pain,Completed,Has Results,Musculoskeletal Pain,Drug: Placebo|Drug: EB-001,"Bonti, Inc.","Bonti, Inc.",,,,,,,Phase 2,Industry,Interventional,8/29/2017,8/7/2018,https://ClinicalTrials.gov/show/NCT03193593
220,Zip Arthroplasty Patient Satisfaction Evaluation,Completed,Has Results,Knee Arthroplasty,Device: Knee Arthroplasty,ZipLine Medical Inc.,ZipLine Medical Inc.,,,,,,,,Industry,Observational,12/1/2017,5/1/2018,https://ClinicalTrials.gov/show/NCT03178266
221,A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants,Completed,Has Results,Healthy Participants,Drug: TAK-954|Drug: Itraconazole,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,5/31/2017,7/24/2017,https://ClinicalTrials.gov/show/NCT03173170
222,AMG 529 First in Human Study,Completed,Has Results,Cardiovascular,Drug: AMG 529|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,5/15/2017,11/17/2017,https://ClinicalTrials.gov/show/NCT03170193
223,Clinical Evaluation of Fitting Investigational Contact Lenses Phase 2,Completed,Has Results,Visual Acuity,Device: JJVC Fitting Guides,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/1/2017,5/4/2017,https://ClinicalTrials.gov/show/NCT03168542
224,Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System,Completed,Has Results,Diabetes Mellitus,Device: Onyx BG Meter / App System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,3/17/2017,5/12/2017,https://ClinicalTrials.gov/show/NCT03165110
225,Immune Response Following Seasonal Influenza Vaccination,Completed,Has Results,Influenza,Biological: Licensed seasonal influenza vaccine,"Altimmune, Inc.|Optimal Health Research","Altimmune, Inc.",Optimal Health Research,,,,,,Phase 4,Industry|Other,Interventional,5/8/2017,6/15/2018,https://ClinicalTrials.gov/show/NCT03163342
226,"Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults",Completed,Has Results,Malaria,"Biological: RTS,S/AS01E|Biological: RTS,S/AS01B|Procedure: Sporozoite-infected mosquitoes challenge.",GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI),GlaxoSmithKline,The PATH Malaria Vaccine Initiative (MVI),,,,,,Phase 2,Industry|Other,Interventional,5/24/2017,9/24/2018,https://ClinicalTrials.gov/show/NCT03162614
227,A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: TAK-906 Maleate|Drug: Itraconazole,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,6/5/2017,7/10/2017,https://ClinicalTrials.gov/show/NCT03161405
228,Rainbow DCI vs. R1-25 Sensor SpHb Sub-Range Performance Equivalence,Completed,Has Results,Healthy,Device: Rainbow DCI and R1-25 sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,6/19/2009,6/29/2009,https://ClinicalTrials.gov/show/NCT03157232
229,Clinical Evaluation of Fitting Investigational Contact Lenses,Completed,Has Results,Visual Acuity,Device: JJVC Fitting Guides,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/27/2017,3/31/2017,https://ClinicalTrials.gov/show/NCT03150485
230,Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects,Completed,Has Results,Hypoparathyroidism,Drug: rhPTH(1-84),Shire,Shire,,,,,,,Phase 1,Industry,Interventional,5/16/2017,6/26/2017,https://ClinicalTrials.gov/show/NCT03150108
231,Rainbow R2-25 vs. R1-25 SpHb Sub-Range Performance Equivalence,Completed,Has Results,Healthy,Device: R1-25 and R2-25 Pulse Oximeter Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,6/18/2009,7/2/2009,https://ClinicalTrials.gov/show/NCT03134326
232,Accuracy of Noninvasive Rainbow Adhesive R1 Pulse Oximeter Sensor,Completed,Has Results,Healthy,Device: Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,12/12/2008,6/19/2009,https://ClinicalTrials.gov/show/NCT03134313
233,Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants,Completed,Has Results,Healthy Volunteers,Drug: 30 mg dexlansoprazole capsules manufactured at TOB|Drug: 30 mg dexlansoprazole capsules manufactured at TPC|Drug: 60 mg dexlansoprazole capsules manufactured at TOB|Drug: 60 mg dexlansoprazole capsules manufactured at TPC,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,4/25/2017,7/31/2017,https://ClinicalTrials.gov/show/NCT03131895
234,"Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.",Completed,Has Results,Renal Impairment,Drug: LIK066,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,4/28/2017,1/16/2018,https://ClinicalTrials.gov/show/NCT03131479
235,A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Device: Acne Mask,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer Inc. (J&JCI),Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,4/30/2017,6/8/2017,https://ClinicalTrials.gov/show/NCT03128723
236,Validation of Next Generation Cerebral and Tissue Oximeter,Completed,Has Results,Oxygen Deficiency,Device: Desaturation,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,5/22/2017,7/19/2017,https://ClinicalTrials.gov/show/NCT03128372
237,OTC Mouthpiece for Snoring,Completed,Has Results,Snoring,Device: Zyppah Anti-snoring Appliance,"Zyppah, Inc.","Zyppah, Inc.",,,,,,,Phase 3,Industry,Interventional,4/7/2017,8/10/2017,https://ClinicalTrials.gov/show/NCT03128307
238,Comparison of Noninvasive Hemoglobin Disposable Sensors,Completed,Has Results,Healthy,Device: Rainbow adhesive adult/pediatric sensor|Device: Rainbow adhesive adult/neonatal sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,7/10/2014,7/25/2014,https://ClinicalTrials.gov/show/NCT03125031
239,Accuracy of SpO2 for Noninvasive Pulse Oximeter Sensor (LNCS ADTX),Completed,Has Results,Healthy,Device: LNCS ADTX Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,9/30/2014,10/9/2014,https://ClinicalTrials.gov/show/NCT03125018
240,Accuracy of Noninvasive Pulse Oximeter Sensor (LNCS DBI),Completed,Has Results,Healthy,Device: LNCS DBI Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,1/18/2012,4/10/2012,https://ClinicalTrials.gov/show/NCT03124979
241,Accuracy of Methemoglobin Measurement of Various Rainbow Pulse Oximeter Sensors,Completed,Has Results,Healthy,Device: Pulse Oximeter Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,11/18/2009,12/17/2009,https://ClinicalTrials.gov/show/NCT03124836
242,Accuracy of Noninvasive Pulse Oximeter Sensor (Rainbow DCI),Completed,Has Results,Healthy,Device: Rainbow DCI Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,8/28/2015,9/8/2015,https://ClinicalTrials.gov/show/NCT03124823
243,Accuracy of SpO2 for Noninvasive Pulse Oximeter Sensor (RD DCI),Completed,Has Results,Healthy,Device: RD DCI Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,3/2/2016,4/5/2016,https://ClinicalTrials.gov/show/NCT03124797
244,Accuracy of Oxygen Saturation (SpO2) Noninvasive Pulse Oximeter Sensor (RD Disposable) Under Motion Conditions,Completed,Has Results,Healthy,Device: RD Disposable Sensors,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,1/3/2017,1/20/2017,https://ClinicalTrials.gov/show/NCT03124784
245,Accuracy of Noninvasive Hemoglobin Pulse Oximeter (Rainbow Resposable Adhesive Sensors),Completed,Has Results,Healthy,Device: Rainbow Resposable Adhesive Sensors,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,12/27/2011,4/3/2012,https://ClinicalTrials.gov/show/NCT03124771
246,Accuracy of Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI),Completed,Has Results,Healthy,"Device: Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))",Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,4/20/2010,10/31/2011,https://ClinicalTrials.gov/show/NCT03124758
247,"Calibration and Validation of Masimo's O3 Regional Oximetry Device in Neonates, Infants and Children",Completed,Has Results,Surgery,Device: O3 regional oximeter sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,5/1/2015,3/13/2017,https://ClinicalTrials.gov/show/NCT03123354
248,Study of PM Modulation Therapy in Trial Phase,Completed,Has Results,Chronic Pain,Device: Control - Conventional SCS|Device: Test - Stimgenics SCS,Stimgenics LLC,Stimgenics LLC,,,,,,,Not Applicable,Industry,Interventional,5/5/2017,10/12/2017,https://ClinicalTrials.gov/show/NCT03110601
249,A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation,Completed,Has Results,Healthy Volunteers,Drug: TAK-831,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,4/4/2017,5/26/2017,https://ClinicalTrials.gov/show/NCT03101293
250,Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment,Completed,Has Results,Dry Eye|Dry Eye Syndromes,Device: TrueTear,"Oculeve, Inc.","Oculeve, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/31/2017,6/26/2017,https://ClinicalTrials.gov/show/NCT03097614
251,Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects,Completed,Has Results,Thrombosis,Drug: xisomab 3G3- Dose 1|Drug: xisomab 3G3-Dose 2|Drug: xisomab 3G3-Dose 3|Drug: xisomab 3G3- Dose 4|Other: Placebo,"Aronora, Inc.","Aronora, Inc.",,,,,,,Phase 1,Industry,Interventional,6/5/2017,1/16/2018,https://ClinicalTrials.gov/show/NCT03097341
252,Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002),Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Biological: MK-5160 16 nmol/kg|Biological: MK-5160 32 nmol/kg|Biological: MK-5160 64 nmol/kg|Biological: Glargine 0.4 U/kg|Biological: Placebo to Glargine|Biological: Placebo to MK-5160|Drug: Dextrose|Biological: Glargine 0.6 U/kg,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 1,Industry,Interventional,4/12/2017,1/30/2018,https://ClinicalTrials.gov/show/NCT03095651
253,Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD,Completed,Has Results,"Chronic Obstructive Pulmonary Disease, COPD|Low Peak Inspiratory Flow Rate (PIFR)",Drug: Revefenacin|Combination Product: Spiriva Handihaler®|Drug: Placebo for Revefenacin|Drug: Placebo for Spiriva Handihaler®,Theravance Biopharma,Theravance Biopharma,,,,,,,Phase 3,Industry,Interventional,3/27/2017,11/25/2017,https://ClinicalTrials.gov/show/NCT03095456
254,Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study,Completed,Has Results,Attention Deficit Hyperactivity Disorder,"Drug: amphetamine extended-release oral suspension, 2.5 mg/mL|Drug: Placebo extended-release oral suspension","Tris Pharma, Inc.","Tris Pharma, Inc.",,,,,,,Phase 3,Industry,Interventional,2/11/2017,10/30/2017,https://ClinicalTrials.gov/show/NCT03088267
255,A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: Esomeprazole Capsule|Drug: Esomeprazole Tablet,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,3/27/2017,5/13/2017,https://ClinicalTrials.gov/show/NCT03083639
256,CAMS-RAS: for Suicide Prevention,Completed,Has Results,Suicide,Device: CAMS-RAS,"Evidence-Based Practice Institute, Seattle, WA|The Catholic University of America|University of Florida","Evidence-Based Practice Institute, Seattle, WA",The Catholic University of America,University of Florida,,,,,Not Applicable,Industry|Other,Interventional,12/18/2015,12/17/2017,https://ClinicalTrials.gov/show/NCT03072875
257,Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies,Completed,Has Results,"Metabolic Syndrome|Diabetes Mellitus, Type 2|Pre Diabetes",Behavioral: Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome,"Bristlecone Behavioral Health, Inc.|University of Minnesota - Clinical and Translational Science Institute","Bristlecone Behavioral Health, Inc.",University of Minnesota - Clinical and Translational Science Institute,,,,,,Not Applicable,Industry|Other,Interventional,2/25/2016,11/30/2016,https://ClinicalTrials.gov/show/NCT03047447
258,Autologous Stem Cell Treatment for Chronic Lung Disease Study,Completed,Has Results,COPD|Interstitial Lung Disease,Procedure: Cell therapy,Lung Institute,Lung Institute,,,,,,,,Industry,Observational,4/1/2016,6/9/2017,https://ClinicalTrials.gov/show/NCT03044431
259,Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects,Completed,Has Results,Obesity,Drug: Liraglutide|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/20/2017,1/16/2018,https://ClinicalTrials.gov/show/NCT03041792
260,A Clinical Bite Force Study of Two Marketed Adhesives Against no Adhesive,Completed,Has Results,Denture Retention,Other: Test Product|Other: Positive Contol|Other: Negative Control,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,2/13/2017,5/4/2017,https://ClinicalTrials.gov/show/NCT03037307
261,Urology of Virginia Case Series,Completed,Has Results,Prostate Cancer|Cancer of the PROSTATE|Prostatic Neoplasm,Device: Ultrasound guided prostate exam using SOC ultrasound system|Device: mpMRI guided prostate examination using PI-RADS v2|Device: High-resolution micro-ultrasound guided prostate biopsy,Exact Imaging,Exact Imaging,,,,,,,Not Applicable,Industry,Interventional,12/16/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT03035487
262,"The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis",Completed,Has Results,Atrial Fibrillation,Drug: Dabigatran vs. Rivaroxaban|Drug: Dabigatran vs. Apixaban,"Boehringer Ingelheim|Health ResearchTx, LLC (HRTX)|inVentiv Health Clinical (iVH)|United States Department of Defense (DOD)",Boehringer Ingelheim,"Health ResearchTx, LLC (HRTX)",inVentiv Health Clinical (iVH)|United States Department of Defense (DOD),inVentiv Health Clinical (iVH),United States Department of Defense (DOD),,,,Industry|Other,Observational,12/29/2016,8/23/2017,https://ClinicalTrials.gov/show/NCT03026556
263,An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye,Completed,Has Results,Dry Eye,Drug: NGF|Other: Vehicle,Dompé Farmaceutici S.p.A,Dompé Farmaceutici S.p.A,,,,,,,Phase 2,Industry,Interventional,1/20/2017,8/31/2017,https://ClinicalTrials.gov/show/NCT03019627
264,Self-adherent Absorbent Silver Dressing in Adults After Hip or Knee Arthroplasty,Completed,Has Results,"Arthroplasties, Hip Replacement|Arthroplasties, Knee Replacement",Device: Mepilex Border Post-Op Ag,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,2/1/2017,4/7/2017,https://ClinicalTrials.gov/show/NCT03016078
265,A Feasibility Device Study to Prevent Female Urinary Stress Incontinence,Completed,Has Results,"Stress Incontinence, Female",Device: With Yoni.Fit|Device: Without Yoni.Fit,Watkins Conti Products. Inc.|University of Oklahoma,Watkins Conti Products. Inc.,University of Oklahoma,,,,,,Not Applicable,Industry|Other,Interventional,1/4/2017,5/3/2017,https://ClinicalTrials.gov/show/NCT03010800
266,Validation of Predictors of OAC Initiation Using EMR Data,Completed,Has Results,Atrial Fibrillation,Drug: Dabigatran etexilate|Drug: Warfarin,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,,Industry,Observational,2/28/2017,5/9/2017,https://ClinicalTrials.gov/show/NCT03006341
267,Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects,Completed,Has Results,Xerostomia,Other: Biotene mouthwash|Other: Bottled mineral water,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,8/31/2016,10/19/2016,https://ClinicalTrials.gov/show/NCT03005041
268,Smart Television and Exercise Promotion for Independent Living Facilities,Completed,Has Results,Aging|Physical Activity,Other: Usability Testing,"Klein Buendel, Inc.|National Institute on Aging (NIA)","Klein Buendel, Inc.",National Institute on Aging (NIA),,,,,,Not Applicable,Industry|NIH,Interventional,8/15/2014,6/30/2017,https://ClinicalTrials.gov/show/NCT03001778
269,A Clinical Trial Evaluating the Efficacy of Resultz Lice and Egg Elimination Kit on Pediatric and Adult Subjects,Completed,Has Results,Pediculus Capitis,Device: Apply Liquid Then Comb Out,"Piedmont Pharmaceuticals, LLC|Lice Solutions Resource Network (LSRN) Research","Piedmont Pharmaceuticals, LLC",Lice Solutions Resource Network (LSRN) Research,,,,,,Not Applicable,Industry|Other,Interventional,12/16/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02997904
270,Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF,Completed,Has Results,Nasolabial Fold Correction,Device: Revanesse Ultra+ (with lidocaine)|Device: Revanesse Ultra,Prollenium Medical Technologies Inc.,Prollenium Medical Technologies Inc.,,,,,,,Not Applicable,Industry,Interventional,8/16/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02991040
271,Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma,Completed,Has Results,Melasma,Other: Lytera 2.0|Drug: 4% Hydroquinone Topical Cream|Other: SkinMedica Facial Cleanser|Other: SkinMedica Rejuvenative Moisturizer|Other: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,12/13/2016,10/9/2017,https://ClinicalTrials.gov/show/NCT02977507
272,Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Completed,Has Results,Lambert-Eaton Myasthenic Syndrome,Drug: Amifampridine Phosphate|Drug: Placebo Oral Tablet,"Catalyst Pharmaceuticals, Inc.","Catalyst Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,11/16/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02970162
273,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Completed,Has Results,Hypothyroidism,Drug: Iodinated contrast agents,Bayer,Bayer,,,,,,,,Industry,Observational,10/15/2016,6/15/2017,https://ClinicalTrials.gov/show/NCT02959827
274,"A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines",Completed,Has Results,Human Rabies,Biological: SYN023|Biological: Imovax|Biological: RabAvert|Biological: HyperRAB ST (human rabies immune globulin),"Synermore Biologics Co., Ltd.|inVentiv Health Clinical","Synermore Biologics Co., Ltd.",inVentiv Health Clinical,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,8/16/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02956746
275,Radiological Evaluation of Radiesse Implantation in the Hands,Completed,Has Results,Volume Loss in the Dorsum of the Hand,Device: Radiesse injectable implant and 2% lidocaine HCL,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/1/2015,1/2/2018,https://ClinicalTrials.gov/show/NCT02949921
276,Data Collection for Next Generation Ultrasound Technology Development,Completed,Has Results,Endstage Renal Disease,Device: Ultrasound scan,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,10/26/2016,12/6/2016,https://ClinicalTrials.gov/show/NCT02946229
277,Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema,Completed,Has Results,Head and Neck Neoplasms|Head and Neck Lymphedema|Head and Neck Cancer,Device: Head and neck garments for pneumatic compression device|Drug: NIRFLI with ICG,Tactile Medical,Tactile Medical,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/16/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT02946021
278,Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks,Completed,Has Results,Refractive Error,Device: Delefilcon A Multifocal Contact Lenses with Molded Mark|Device: Delefilcon A Multifocal Contact Lenses,"Alcon, a Novartis Company|Alcon Research","Alcon, a Novartis Company",Alcon Research,,,,,,Not Applicable,Industry,Interventional,11/14/2016,12/2/2016,https://ClinicalTrials.gov/show/NCT02939170
279,A Bite Force Study Comparing Two New Test Adhesives With Currently Marketed Denture Adhesive,Completed,Has Results,Denture Retention,Device: Test Product 1|Device: Test Product 2|Device: Reference Product|Other: Negative Control,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,3/7/2017,4/5/2017,https://ClinicalTrials.gov/show/NCT02937870
280,To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH),Completed,Has Results,Dentin Sensitivity,Device: Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,11/21/2016,12/22/2016,https://ClinicalTrials.gov/show/NCT02937623
281,"Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study",Completed,Has Results,Onychomycosis,Drug: NVXT topical|Drug: Placebo (Vehicle) Topical,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,3/21/2016,6/21/2018,https://ClinicalTrials.gov/show/NCT02933879
282,Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis,Completed,Has Results,Scalp Psoriasis,Drug: DSXS topical|Drug: Vehicle topical,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 3,Industry,Interventional,3/11/2016,9/29/2017,https://ClinicalTrials.gov/show/NCT02933866
283,Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS,Completed,Has Results,Psoriasis,Drug: DSXS Topical product,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,7/11/2016,11/27/2017,https://ClinicalTrials.gov/show/NCT02933528
284,Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product,Completed,Has Results,Scalp Psoriasis,Drug: DSXS topical product,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,7/11/2016,1/2/2018,https://ClinicalTrials.gov/show/NCT02933502
285,"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.",Completed,Has Results,Atopic Dermatitis,Drug: DSXS topical,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,8/16/2019,12/12/2017,https://ClinicalTrials.gov/show/NCT02932891
286,"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression",Completed,Has Results,Plaque Psoriasis,Drug: DSXS topical,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,9/2/2016,10/16/2017,https://ClinicalTrials.gov/show/NCT02932878
287,Evaluation of a Experimental Denture Adhesive to Prevent Food Ingress,Completed,Has Results,Denture Retention,Device: Experimental Denture Adhesive|Device: Reference (Marketed) Denture Adhesive,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,7/25/2016,9/16/2016,https://ClinicalTrials.gov/show/NCT02928380
288,Clinical Evaluation Of MP26 Features in Adults,Completed,Has Results,Brain Imaging|Whole Body Imaging,Device: Zero Echo Time (ZTE) scan for head attenuation|Device: Q.Static (Q. MRAC) for respiratory motion correction,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,11/16/2019,9/20/2017,https://ClinicalTrials.gov/show/NCT02927327
289,A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain,Completed,Has Results,Post-surgical Pain Following Extraction of Molar Teeth,Drug: Ibuprofen 250 mg / Acetaminophen 500 mg|Drug: Ibuprofen 250 mg|Drug: Acetaminophen 650 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02912650
290,Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers,Completed,Has Results,Anesthesia,Combination Product: One spray CTY-5339-A|Drug: One spray CTY-5339-CB|Combination Product: Two sprays CTY-5339-A|Drug: One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo),Cetylite Industries,Cetylite Industries,,,,,,,Phase 2,Industry,Interventional,12/7/2016,6/7/2017,https://ClinicalTrials.gov/show/NCT02908620
291,A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: TAK-935 Tablets|Drug: TAK-935 Oral Solution,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,9/12/2016,11/9/2016,https://ClinicalTrials.gov/show/NCT02906813
292,A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants,Completed,Has Results,Healthy,Drug: Abemaciclib|Drug: Metformin|Drug: Iohexol|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,8/16/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02884089
293,Curved Soft-Picks on Plaque Accumulation on Patients With Gingivitis,Completed,Has Results,Gingivitis,Device: Soft-Picks Advanced|Device: Floss,Sunstar Americas,Sunstar Americas,,,,,,,Not Applicable,Industry,Interventional,12/16/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02883244
294,Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution,Completed,Has Results,Ocular Hypertension|Open Angle Glaucoma,Drug: Netarsudil ophthalmic solution 0.02%|Other: Netarsudil Ophthalmic Solution Vehicle,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/16/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02874846
295,Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction,Completed,Has Results,Abdominal Fat,Device: truSculpt rf device,Cutera Inc.,Cutera Inc.,,,,,,,Not Applicable,Industry,Interventional,3/16/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02873104
296,Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,Completed,Has Results,Breast Cancer|Neutropenia,Drug: F-627|Drug: Placebo,Generon (Shanghai) Corporation Ltd.,Generon (Shanghai) Corporation Ltd.,,,,,,,Phase 3,Industry,Interventional,8/16/2019,12/20/2017,https://ClinicalTrials.gov/show/NCT02872103
297,A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function,Completed,Has Results,Moderate Hepatic Impairment|Normal Hepatic Function,Drug: Rivipansel,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,9/16/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02871570
298,A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine,Completed,Has Results,Pain,Drug: Ibuprofen/Caffeine|Drug: Ibuprofen|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/24/2017,4/6/2018,https://ClinicalTrials.gov/show/NCT02863575
299,A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain,Completed,Has Results,Pain,Drug: FDC IBU/APAP 250 mg/500 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,8/31/2016,2/1/2017,https://ClinicalTrials.gov/show/NCT02837952
300,Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed Diet,Completed,Has Results,Overweight|Obesity,Other: Take Shape For Life Program|Other: Medifast Direct Program|Other: Self-directed Control,"Medifast, Inc.|BioFortis","Medifast, Inc.",BioFortis,,,,,,Not Applicable,Industry|Other,Interventional,7/16/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02835092
301,Safety and Effectiveness Evaluation of the Device in Achieving Submental Lift,Completed,Has Results,Skin Laxity,Device: Percutaneous Radiofrequency single treatment,"ThermiGen, LLC","ThermiGen, LLC",,,,,,,Not Applicable,Industry,Interventional,6/25/2016,4/8/2017,https://ClinicalTrials.gov/show/NCT02832674
302,Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentin Sensitivity,Drug: stannous fluoride|Drug: sodium monofluorophosphate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2016,5/12/2016,https://ClinicalTrials.gov/show/NCT02832375
303,Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG,Completed,Has Results,Primary Open-Angle Glaucoma (POAG)|Ocular Hypertension (OHT),Drug: trabodenoson 6.0% / latanoprost 0.005% QD|Drug: trabodenoson 3.0% / latanoprost 0.005% QD|Drug: trabodenoson 6.0% / latanoprost 0.0025% QD|Drug: latanoprost 0.005% QD|Drug: latanoprost 0.0025% QD,Inotek Pharmaceuticals Corporation,Inotek Pharmaceuticals Corporation,,,,,,,Phase 2,Industry,Interventional,8/19/2016,5/31/2017,https://ClinicalTrials.gov/show/NCT02829996
304,"Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas",Completed,Has Results,Basal Cell Carcinomas,Drug: Patidegib|Drug: Vehicle gel,"PellePharm, Inc.","PellePharm, Inc.",,,,,,,Phase 2,Industry,Interventional,11/11/2016,11/9/2017,https://ClinicalTrials.gov/show/NCT02828111
305,Evaluation of Heel Offloading Devices for Reducing Heel Contact Pressures in Healthy Volunteers,Completed,Has Results,Heel Pressure Ulceration Prevention Strategies,Other: Pillow Condition 1|Other: Pillow Condition 2|Device: Heel Foam Pillow|Device: Offloading Device A|Device: Offloading Device B|Device: Offloading Device C,"DeRoyal Industries, Inc.|Lincoln Memorial University","DeRoyal Industries, Inc.",Lincoln Memorial University,,,,,,Not Applicable,Industry|Other,Interventional,6/16/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02811965
306,Servo-Ventilation In-lab PSG Evaluation,Completed,Has Results,Sleep Apnea Syndromes,Device: Philips BiPAP AutoSV Advanced System One|Device: Modified Philips BiPAP ASV|Device: ResMed S7 VPAP Adapt|Device: ResMed S9 VPAP Adapt,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,11/9/2015,7/6/2017,https://ClinicalTrials.gov/show/NCT02808338
307,An Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies,Completed,Has Results,Excision of Kidney,Device: Surgeon's 'standard of care' stapler|Device: Ethicon Powered Vascular Stapler,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,7/5/2016,8/23/2017,https://ClinicalTrials.gov/show/NCT02807376
308,A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers,Completed,Has Results,Healthy,Drug: PF-06463922|Drug: rifampin,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/16/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02804399
309,Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers,Completed,Has Results,Healthy Volunteers,Drug: Lenvatinib,Eisai Inc.,Eisai Inc.,,,,,,,Phase 1,Industry,Interventional,8/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02792829
310,Image Quality Assessment for Screening and Diagnostic Mammography,Completed,Has Results,Breast Health,Device: Full Field Digital Mammography|Device: Digital Breast Tomosynthesis,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,2/16/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02786004
311,A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects,Completed,Has Results,Healthy,Drug: PF-04447943|Drug: Placebo|Drug: Moxifloxacin,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,6/29/2016,10/20/2016,https://ClinicalTrials.gov/show/NCT02785770
312,Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD,Completed,Has Results,Attention Deficit Disorder With Hyperactivity,Drug: NFC-1|Drug: Placebo,Aevi Genomic Medicine,Aevi Genomic Medicine,,,,,,,Phase 2|Phase 3,Industry,Interventional,6/16/2019,2/17/2017,https://ClinicalTrials.gov/show/NCT02777931
313,Study of SHP620 (Maribavir) in Healthy Adults,Completed,Has Results,Cytomegalovirus (CMV),Drug: Digoxin|Drug: Maribavir|Drug: Dextromethorphan,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,7/21/2016,9/12/2016,https://ClinicalTrials.gov/show/NCT02775240
314,Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers,Completed,Has Results,"Iron-refractory, Iron-deficiency Anemia (IRIDA)",Drug: Triferic|Drug: Fer-In-Sol|Drug: Shohl's solution,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 1,Industry,Interventional,4/16/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02767128
315,Optimizing the Ocular Surface Prior to Cataract Surgery,Completed,Has Results,"Corneal Dystrophy, Epithelial Basement Membrane",Device: cryopreserved amniotic membrane,Tissue Tech Inc.,Tissue Tech Inc.,,,,,,,Not Applicable,Industry,Interventional,3/16/2019,4/18/2019,https://ClinicalTrials.gov/show/NCT02766907
316,A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers,Completed,Has Results,Fever,Drug: Ibuprofen 250 mg / Acetaminophen 500 mg|Drug: Ibuprofen 250 mg|Drug: Acetaminophen 500 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/6/2016,12/6/2017,https://ClinicalTrials.gov/show/NCT02761980
317,A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.,Completed,Has Results,Dentin Sensitivity,Device: Experimental Oral Rinse 1|Device: Experimental Oral Rinse 2|Other: Placebo Oral Rinse|Drug: Fluoride toothpaste,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,9/8/2015,12/18/2015,https://ClinicalTrials.gov/show/NCT02753075
318,Efficacy of Three Toothpastes Using an in Situ Caries Model,Completed,Has Results,Dental Caries,"Drug: 0.425 % w/w phytate,1150ppm F|Drug: 0.85 % w/w phytate,1150ppm F|Drug: 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Other: 0 ppm F|Drug: 1150ppm F|Drug: 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,2/1/2016,8/11/2016,https://ClinicalTrials.gov/show/NCT02751320
319,Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease,Completed,Has Results,Gingivitis,Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,11/1/2015,3/4/2016,https://ClinicalTrials.gov/show/NCT02750943
320,ACUVUE® OASYS® 1-DAY vs DAILIES TOTAL1®,Completed,Has Results,Refractive Error,Device: Delefilcon A contact lenses|Device: Senofilcon A contact lenses,"Alcon, a Novartis Company|Alcon Research","Alcon, a Novartis Company",Alcon Research,,,,,,Not Applicable,Industry,Interventional,4/27/2016,8/17/2016,https://ClinicalTrials.gov/show/NCT02750813
321,Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients,Completed,Has Results,End Stage Renal Disease,Drug: Triferic,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 1,Industry,Interventional,4/16/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02739100
322,"A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects",Completed,Has Results,Erythema|Edema,"Device: Trojan ""Chameleon"" Personal Lubricant","Church & Dwight Company, Inc.","Church & Dwight Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/16/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02737852
323,Human Repeat Insult Patch Test to Evaluate Personal Lubricants,Completed,Has Results,Erythema|Edema,"Device: Trojan ""Chameleon"" Personal Lubricant","Church & Dwight Company, Inc.","Church & Dwight Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/16/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02737631
324,14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon,Completed,Has Results,Dermal Irritation,"Device: Trojan ""Chameleon"" Personal Lubricant","Church & Dwight Company, Inc.","Church & Dwight Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/16/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02737618
325,A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects,Completed,Has Results,Erythema|Edema,"Device: Trojan ""Simply Pleasure"" Personal Lubricant","Church & Dwight Company, Inc.","Church & Dwight Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/16/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02737592
326,Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients,Completed,Has Results,Hypoglycemia|Complications of Bariatric Procedures,Drug: G-Pump™ (glucagon infusion),Xeris Pharmaceuticals|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Xeris Pharmaceuticals,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,,,,,Phase 2,Industry|NIH,Interventional,3/16/2019,6/1/2017,https://ClinicalTrials.gov/show/NCT02733588
327,Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD),Completed,Has Results,IgG4-RD,Biological: XmAb5871,"Xencor, Inc.|Massachusetts General Hospital","Xencor, Inc.",Massachusetts General Hospital,,,,,,Phase 2,Industry|Other,Interventional,3/16/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02725476
328,Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers,Completed,Has Results,Healthy Volunteers,Drug: Lenvatinib 10 mg,Eisai Inc.,Eisai Inc.,,,,,,,Phase 1,Industry,Interventional,7/13/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT02723630
329,A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Completed,Has Results,Hypogonadism,Drug: Oral Testosterone Undecanoate|Drug: Axiron Testosterone Topical Solution,"Clarus Therapeutics, Inc.|Syneos Health","Clarus Therapeutics, Inc.",Syneos Health,,,,,,Phase 3,Industry|Other,Interventional,3/16/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02722278
330,BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes,Completed,Has Results,Acne Vulgaris,"Drug: BPX-01, 1% Topical Gel|Drug: BPX-01 Vehicle Gel","BioPharmX, Inc.","BioPharmX, Inc.",,,,,,,Phase 2,Industry,Interventional,4/16/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02709096
331,Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies,Completed,Has Results,Non Small Cell Lung Cancer,Device: Surgeon's 'standard of care' stapler|Device: Ethicon Powered Vascular Stapler,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,2/1/2016,3/31/2017,https://ClinicalTrials.gov/show/NCT02702921
332,A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution,Completed,Has Results,Contact Lens Wear,Device: Complete MPS|Device: NNR06,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/15/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02701556
333,Nociceptive Pain Fiber Response,Completed,Has Results,Painful Peripheral Diabetic Neuropathy,Device: Provant Therapy System,"Regenesis Biomedical, Inc.","Regenesis Biomedical, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02696070
334,Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline,Completed,Has Results,Acne,Drug: Minocycline,"BioPharmX, Inc.","BioPharmX, Inc.",,,,,,,Phase 4,Industry,Interventional,3/16/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02695446
335,Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection,Completed,Has Results,Tuberculosis,Device: CST001,"QIAGEN Gaithersburg, Inc","QIAGEN Gaithersburg, Inc",,,,,,,,Industry,Observational,10/27/2015,5/26/2016,https://ClinicalTrials.gov/show/NCT02687529
336,Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: PG324 Ophthalmic Solution 0.02%/0.005%|Drug: Netarsudil (AR-13324) ophthalmic solution 0.02%|Drug: Latanoprost ophthalmic solution 0.005%,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/16/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02674854
337,Phlebotomy Study of Testosterone Undecanoate,Completed,Has Results,Hypogonadism,Drug: Oral Testosterone Undecanoate,"Clarus Therapeutics, Inc.","Clarus Therapeutics, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,1/16/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02670343
338,A Study of A-101 Solution in Subjects With Common Warts.,Completed,Has Results,Common Warts,Drug: A-101 Solution 40|Drug: A-101 Solution 45|Drug: Vehicle Solution,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,12/21/2015,9/16/2016,https://ClinicalTrials.gov/show/NCT02669862
339,An Open-Label Safety Study of A-101 Solution,Completed,Has Results,Seborrheic Keratosis,Drug: A-101 Solution,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,1/16/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02667288
340,"A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis",Completed,Has Results,Seborrheic Keratosis,Drug: A-101 Solution|Other: Vehicle Solution,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,1/16/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02667275
341,A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.,Completed,Has Results,Seborrheic Keratosis,Drug: A-101 Solution|Other: Vehicle Solution,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,1/16/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02667236
342,"Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects",Completed,Has Results,Hereditary Angioedema (HAE),Drug: Recombinant human C1 esterase inhibitor|Drug: Placebo|Drug: SHP623,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,2/19/2016,12/5/2016,https://ClinicalTrials.gov/show/NCT02663687
343,Clinical Trial of Smoking Cessation Mobile Phone Program,Completed,Has Results,Nicotine Addiction|Drug Addiction|Drug Dependence|Substance Use Disorder|Tobacco Dependence,Device: Mobile Smoking Cessation Solution,"Click Therapeutics, Inc.","Click Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/16/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02656745
344,"A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris",Completed,Has Results,Acne Vulgaris,Drug: B244|Drug: Placebo,AOBiome LLC,AOBiome LLC,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/5/2015,7/15/2016,https://ClinicalTrials.gov/show/NCT02656485
345,"A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.",Completed,Has Results,Dentin Sensitivity,"Other: Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Other: Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Other: Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,1/4/2016,4/22/2016,https://ClinicalTrials.gov/show/NCT02651467
346,A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects,Completed,Has Results,Asthma|Chronic Obstructive Pulmonary Disease (COPD),Drug: AZD7594 Solution for infusion (150 μg intravenous formulation)|Drug: AZD7594 Oral suspension (1200 μg oral formulation)|Drug: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Drug: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Drug: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,1/12/2016,6/1/2016,https://ClinicalTrials.gov/show/NCT02648438
347,"A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men",Completed,Has Results,Asthma|Chronic Obstructive Pulmonary Disease COPD,Drug: AZD7594 inhalation powder (200 μg)|Drug: AZD7594 inhalation powder (400 μg)|Drug: AZD7594 pressurized inhalation suspension (200 μg)|Drug: AZD7594 placebo inhalation powder|Drug: AZD7594 placebo pressurized inhalation suspension,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,1/12/2016,4/17/2016,https://ClinicalTrials.gov/show/NCT02645253
348,User Acceptability of a Nicotine Lactate Delivery System (P3L),Completed,Has Results,Smoking,Other: P3L|Other: VUSE|Other: CC,Philip Morris Products S.A.,Philip Morris Products S.A.,,,,,,,Not Applicable,Industry,Interventional,11/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02643693
349,Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms,Completed,Has Results,Xerostomia,Other: Biotene mouthwash|Other: Mineral Water,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,3/9/2016,4/15/2016,https://ClinicalTrials.gov/show/NCT02641912
350,Self-Centering Guide Catheter Feasibility Study,Completed,Has Results,Aortic Stenosis,Device: Self-Centering Guide Catheter,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,5/12/2016,10/6/2016,https://ClinicalTrials.gov/show/NCT02639494
351,Interactive Web Program and Health Coaching for Prehypertensive Adults,Completed,Has Results,Weight|Blood Pressure,Behavioral: BlipHub mobile-web app|Behavioral: BlipHub mobile-web app + health coaching|Other: Usual care,"Oregon Center for Applied Science, Inc.|National Heart, Lung, and Blood Institute (NHLBI)","Oregon Center for Applied Science, Inc.","National Heart, Lung, and Blood Institute (NHLBI)",,,,,,Not Applicable,Industry|NIH,Interventional,11/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02637063
352,A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects,Completed,Has Results,Bioequivalence|Fixed Dose Combination Tablets|Healthy Male and Female Subjects,Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao),AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,12/21/2015,4/7/2016,https://ClinicalTrials.gov/show/NCT02637037
353,Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers,Completed,Has Results,End Stage Renal Disease,Drug: Triferic,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 1,Industry,Interventional,10/15/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02636049
354,A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal,Completed,Has Results,Pigmented Skin Lesion of Suspected Benign Nature,Device: Investigational Enlighten Device,Cutera Inc.,Cutera Inc.,,,,,,,Not Applicable,Industry,Interventional,9/15/2019,3/23/2016,https://ClinicalTrials.gov/show/NCT02635880
355,Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: DSXS|Drug: Placebo,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 3,Industry,Interventional,8/28/2015,8/25/2017,https://ClinicalTrials.gov/show/NCT02618759
356,"A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,Drug: SER-287|Drug: Placebo|Drug: Placebo Pre-Treat|Drug: Vancomycin Pre-Treat,"Seres Therapeutics, Inc.","Seres Therapeutics, Inc.",,,,,,,Phase 1,Industry,Interventional,1/13/2016,1/26/2018,https://ClinicalTrials.gov/show/NCT02618187
357,Computer Assisted Instrument Guidance (CAIG) for Orthopedic Peripheral Nerve Blocks,Completed,Has Results,Peripheral Nerve Blocks,Device: Peripheral Nerve Blocks with CAIG,Clear Guide Medical|The Cooper Health System,Clear Guide Medical,The Cooper Health System,,,,,,Not Applicable,Industry|Other,Interventional,10/26/2015,5/25/2016,https://ClinicalTrials.gov/show/NCT02614222
358,Evaluation of an Ascensia Lancing System,Completed,Has Results,Diabetes,Device: Styx Lancing Device,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02606838
359,A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects,Completed,Has Results,Safety|Pharmacokinetics|Healthy Subjects,Drug: Anifrolumab SC injection (300mg)|Drug: Anifrolumab IV infusion (300mg)|Drug: Anifrolumab SC infusion (600mg)|Drug: Anifrolumab placebo SC injection (300mg)|Drug: Anifrolumab placebo IV infusion (300mg)|Drug: Anifrolumab placebo SC infusion (600mg),AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,11/16/2015,5/25/2016,https://ClinicalTrials.gov/show/NCT02601625
360,Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: DSXS,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,9/4/2015,8/25/2017,https://ClinicalTrials.gov/show/NCT02601469
361,Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: DSXS|Drug: Placebo,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 3,Industry,Interventional,9/4/2015,8/29/2017,https://ClinicalTrials.gov/show/NCT02595073
362,Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic",Drug: DSXS,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,8/28/2015,8/25/2017,https://ClinicalTrials.gov/show/NCT02595008
363,OxyGenesys Dissolved Oxygen Dressing; Abdominoplasty at Northwestern University,Completed,Has Results,Wounds,Device: OxyGenesys Dissolved Oxygen Dressing,Halyard Health|Northwestern University,Halyard Health,Northwestern University,,,,,,Not Applicable,Industry|Other,Interventional,10/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02591537
364,Computer Assisted Instrument Guidance (CAIG) For Arterial Line Placement,Completed,Has Results,Arterial and Midline Catheterization,"Device: Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.",Clear Guide Medical|The Cooper Health System,Clear Guide Medical,The Cooper Health System,,,,,,Not Applicable,Industry|Other,Interventional,10/15/2019,12/9/2016,https://ClinicalTrials.gov/show/NCT02584673
365,Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution,Completed,Has Results,Catheter-Associated Infections|Catheter-Related Infections,Drug: Nitroglycerin-citrate-ethanol (NiCE),"Novel Anti-Infective Technologies, LLC|M.D. Anderson Cancer Center","Novel Anti-Infective Technologies, LLC",M.D. Anderson Cancer Center,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,11/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02577718
366,A Study of Galcanezumab in Healthy Participants,Completed,Has Results,Healthy,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/19/2015,1/8/2018,https://ClinicalTrials.gov/show/NCT02576951
367,Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne,Completed,Has Results,Acne Vulgaris,Drug: LEO43204|Drug: Placebo,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,6/16/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02575950
368,Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study,Completed,Has Results,Myopia|Hyperopia,Device: Femtosecond Laser System|Procedure: LASIK surgery,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,10/28/2015,4/9/2016,https://ClinicalTrials.gov/show/NCT02575911
369,Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine,Completed,Has Results,Rapidly Escalating Migraine,Drug: DFN-11,Dr. Reddy's Laboratories Limited,Dr. Reddy's Laboratories Limited,,,,,,,Phase 2,Industry,Interventional,9/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02571049
370,Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction & Laxity of the Flanks,Completed,Has Results,Adipose Tissue,"Device: multipolar RF, varipulse|Device: cryolipolysis",Venus Concept,Venus Concept,,,,,,,Not Applicable,Industry,Interventional,8/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02569112
371,Evaluation of an Ascensia Blood Glucose Meter and App System,Completed,Has Results,Diabetes Mellitus,Device: Onyx BG Meter / App System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,10/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02568384
372,A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C,Completed,Has Results,Renal Transplantation,Biological: Process E Belatacept|Biological: Process C Belatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,10/2/2015,1/27/2017,https://ClinicalTrials.gov/show/NCT02564497
373,Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: PG324 Ophthalmic Solution 0.02%/0.005%|Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Drug: Latanoprost Ophthalmic Solution 0.005%,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/18/2015,6/30/2017,https://ClinicalTrials.gov/show/NCT02558400
374,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: Timolol Maleate Ophthalmic Solution 0.5% BID|Other: Placebo,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02558374
375,Optical Detection of Intravenous Infiltration:A Pilot Study,Completed,Has Results,Infiltration of Peripheral IV Therapy,Device: ivWatch Model 400,"ivWatch, LLC","ivWatch, LLC",,,,,,,Not Applicable,Industry,Interventional,8/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02553421
376,Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204 gel|Drug: Vehicle gel,LEO Pharma,LEO Pharma,,,,,,,Phase 3,Industry,Interventional,11/13/2015,8/10/2017,https://ClinicalTrials.gov/show/NCT02549339
377,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204 gel|Drug: Vehicle gel,LEO Pharma,LEO Pharma,,,,,,,Phase 3,Industry,Interventional,11/15/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02547363
378,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204 gel|Drug: Vehicle gel,LEO Pharma,LEO Pharma,,,,,,,Phase 3,Industry,Interventional,11/15/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT02547233
379,Cefaly® Device in the Treatment of Patients With Fibromyalgia.,Completed,Has Results,Fibromyalgia,Device: Cefaly,Cefaly Technology,Cefaly Technology,,,,,,,Not Applicable,Industry,Interventional,12/3/2015,5/15/2018,https://ClinicalTrials.gov/show/NCT02546362
380,Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentin Sensitivity,Device: Experimental Oral Rinse 1|Device: Experimental Oral Rinse 2|Other: Placebo Oral Rinse|Drug: Standard fluoride toothpaste,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,9/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02542943
381,Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery,Completed,Has Results,"Pain, Post-operative",Drug: N1539|Drug: Intravenous Placebo,"Recro Pharma, Inc.","Recro Pharma, Inc.",,,,,,,Phase 2,Industry,Interventional,8/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02540265
382,Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT),Completed,Has Results,Otitis Media With Effusion in Children|Otitis Media Recurrent,"Drug: EXE844 Sterile Otic Suspension, 0.3%|Procedure: Tympanostomy Tube Insertion",Alcon Research,Alcon Research,,,,,,,Phase 1,Industry,Interventional,11/17/2015,6/24/2016,https://ClinicalTrials.gov/show/NCT02539654
383,TAK-935 Multiple Rising Dose Study in Healthy Participants,Completed,Has Results,Epilepsy,Drug: TAK-935|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,9/15/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02539134
384,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL/VOX|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,7/29/2015,6/28/2016,https://ClinicalTrials.gov/show/NCT02536313
385,Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome,Completed,Has Results,Carpal Tunnel Syndrome,Device: Carpal Tunnel Tissue Manipulation Device (CTMD),"Pressure Profile Systems, Inc.","Pressure Profile Systems, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02534493
386,Symphion® System In-Office Study,Completed,Has Results,Uterine Leiomyomas|Endometrial Polyps,Device: Symphion® Bipolar Hysteroscopic Tissue Resection System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,11/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02520414
387,A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: TD-4208|Drug: Tiotropium,Theravance Biopharma,Theravance Biopharma,,,,,,,Phase 3,Industry,Interventional,9/15/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02518139
388,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: TD-4208|Drug: Placebo,Theravance Biopharma,Theravance Biopharma,,,,,,,Phase 3,Industry,Interventional,9/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02512510
389,"Phase 1, Febuxostat XR Relative Bioavailability Study",Completed,Has Results,Healthy Volunteers,Drug: Febuxostat XR 80 mg Capsule F1|Drug: Febuxostat XR 80 mg Capsule F2|Drug: Febuxostat XR 80 mg Capsule F3|Drug: Febuxostat XR 80 mg Capsule F4,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,8/15/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02504320
390,"Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia",Completed,Has Results,Any Ear Nose or Throat Conditions|With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities,Drug: Cocaine HCl 4% Topical Solution|Drug: Cocaine HCl 10% Topical Solution|Drug: Placebo Topical Solution,"Lannett Company, Inc.","Lannett Company, Inc.",,,,,,,Phase 3,Industry,Interventional,9/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02500836
391,A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935,Completed,Has Results,"Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents",Drug: TAK-935|Drug: [18F]MNI-792 (tracer),Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,7/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02497235
392,A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Albiglutide 50 mg|Drug: Placebo|Drug: CCK (Kinevac),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,6/11/2015,10/13/2015,https://ClinicalTrials.gov/show/NCT02496221
393,A Study of the Effect of SYN-010 on Subjects With IBS-C,Completed,Has Results,Irritable Bowel Syndrome With Constipation (IBS-C),Drug: SYN-010 21 mg|Drug: SYN-010 42 mg|Drug: Placebo,Synthetic Biologics Inc.,Synthetic Biologics Inc.,,,,,,,Phase 2,Industry,Interventional,6/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02495623
394,CoverEdge Algorithm Programming Study,Completed,Has Results,Chronic Pain,Device: Precision Spectra™ SCS system programming features,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,7/20/2015,2/21/2017,https://ClinicalTrials.gov/show/NCT02492880
395,Training Attentional Awareness and Control in ADHD,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Behavioral: Sustained Attention Control (SAC) Method|Behavioral: Scrabble,Think Now Incorporated|National Institute of Mental Health (NIMH),Think Now Incorporated,National Institute of Mental Health (NIMH),,,,,,Not Applicable,Industry|NIH,Interventional,6/15/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02489279
396,Webnovela for Hispanic Dementia Family Caregivers,Completed,Has Results,Alzheimer's Disease|Dementia,Behavioral: Webnovela|Behavioral: Information,"Photozig, Inc.|National Institute on Aging (NIA)|Stanford University","Photozig, Inc.",National Institute on Aging (NIA),Stanford University,,,,,Not Applicable,Industry|NIH|Other,Interventional,6/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02489110
397,Efficacy and Tolerability of Topical LFX453 for External Genital Warts,Completed,Has Results,External Genital Warts,Drug: Investigational Treatment|Drug: Aldara,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/12/2015,5/31/2016,https://ClinicalTrials.gov/show/NCT02482428
398,Effects of an Oxalate Containing Product on Dentinal Hypersensitivity With Dental Prophylaxis,Completed,Has Results,Dentin Sensitivity,Device: Oxalate Salt Solution,Procter and Gamble,Procter and Gamble,,,,,,,Not Applicable,Industry,Interventional,6/15/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02481557
399,A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: TAK-648 Tablet|Drug: TAK-648 Oral Solution,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,6/15/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02480439
400,A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Gefapixant,"Afferent Pharmaceuticals, Inc.","Afferent Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,7/20/2015,8/21/2015,https://ClinicalTrials.gov/show/NCT02477709
401,Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes,Completed,Has Results,Vitreoretinal Disease,Device: CONSTELLATION® 27-gauge Combined Surgical Pak|Device: CONSTELLATION® 23-gauge Combined Surgical Pak|Procedure: Vitrectomy surgery,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,7/16/2015,8/31/2016,https://ClinicalTrials.gov/show/NCT02477605
402,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Completed,Has Results,Post Operative Dental Pain,Drug: Diclofenac potassium|Drug: Ibuprofen|Drug: Placebo to ibuprofen|Drug: Placebo to diclofenac potassium,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/15/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02476422
403,"Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",Completed,Has Results,Norovirus|Healthy Participants,Biological: NoV GI.1/GII.4 Bivalent VLP Vaccine,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,2/26/2015,9/9/2015,https://ClinicalTrials.gov/show/NCT02475278
404,Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index,Completed,Has Results,Elevated Body Mass Index,Drug: LIK066|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/5/2015,4/4/2016,https://ClinicalTrials.gov/show/NCT02470403
405,"Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study",Completed,Has Results,Healthy Volunteers,Drug: TAK-915 suspension|Drug: Midazolam|Drug: Placebo|Drug: TAK-915 tablet,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,5/12/2015,8/1/2016,https://ClinicalTrials.gov/show/NCT02461160
406,Zip® Surgical Skin Closure Device vs. Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty,Completed,Has Results,"Arthroplasty, Knee Replacement|Wound Healing",Device: Zip Surgical Skin Closure|Device: Steel Staples,ZipLine Medical Inc.,ZipLine Medical Inc.,,,,,,,Not Applicable,Industry,Interventional,5/15/2019,2/15/2017,https://ClinicalTrials.gov/show/NCT02460172
407,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: TD-4208|Drug: Placebo,Theravance Biopharma,Theravance Biopharma,,,,,,,Phase 3,Industry,Interventional,9/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02459080
408,A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief,Completed,Has Results,Dry Eye Syndromes,Drug: Carboxymethylcellulose Sodium Based Eye Drops|Drug: Systane® Gel Drops|Drug: Genteal® Lubricant Gel Drops,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,12/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02455050
409,TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy,Completed,Has Results,Menopause|Vulvovaginal Atrophy|Painful Intercourse|Dyspareunia,Drug: Estradiol|Drug: placebo,TherapeuticsMD,TherapeuticsMD,,,,,,,Phase 2,Industry,Interventional,7/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT02449902
410,"Prospective Feasibility Trial of AccuCath 2.25"" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department",Completed,Has Results,Vascular Access Complication,"Device: AccuCath 2.25"" BC Intravascular Catheter",C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,3/15/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02449798
411,RDEA3170 Tablet and Capsule Bioavailability Study,Completed,Has Results,Healthy,"Drug: RDEA3170,10 mg|Drug: RDEA3170, 2.5 mg|Drug: RDEA3170, 5 mg|Drug: RDEA3170, 10 mg","Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 1,Industry,Interventional,5/1/2015,1/29/2016,https://ClinicalTrials.gov/show/NCT02448368
412,TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro,Completed,Has Results,Subjects Presenting With Normal Eyes,Device: 3D OCT-1 Maestro,"Topcon Medical Systems, Inc.","Topcon Medical Systems, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/15/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02447133
413,"Safety, Tolerability and Pharmacokinetics of PF-05251749",Completed,Has Results,Healthy,Drug: PF-05251749,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,5/15/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02443740
414,The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury,Completed,Has Results,Traumatic Brain Injury|Alexithymia,Behavioral: Emotion Builder,EmotEd|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),EmotEd,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),,,,,,Not Applicable,Industry|NIH,Interventional,5/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02432300
415,Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women,Completed,Has Results,Human Immunodeficiency Virus (HIV) Prophylaxis,Drug: TDF IVR|Drug: TDF-FTC IVR|Drug: TDF-FTC-MVC IVR,"Auritec Pharmaceuticals|The University of Texas Medical Branch, Galveston|Oak Crest Institute of Science|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",Auritec Pharmaceuticals,"The University of Texas Medical Branch, Galveston",Oak Crest Institute of Science|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Oak Crest Institute of Science,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),,,Early Phase 1,Industry|Other|NIH,Interventional,6/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02431273
416,Non-invasive Quantification of Liver Iron With MRI,Completed,Has Results,Iron Overload,Device: GE Optima/Discovery® MRI data of the liver,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,4/15/2019,6/30/2016,https://ClinicalTrials.gov/show/NCT02425956
417,G-Pen™ for Hypoglycemia Rescue in T1D Patients,Completed,Has Results,Hypoglycemia,Drug: Glucagon,Xeris Pharmaceuticals,Xeris Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,4/15/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02423980
418,"Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD",Completed,Has Results,Alzheimer's Disease,Drug: VX-745,EIP Pharma Inc,EIP Pharma Inc,,,,,,,Phase 2,Industry,Interventional,4/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02423200
419,SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA),Completed,Has Results,Open-Angle Glaucoma|Ocular Hypertension,Drug: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|Drug: Brinz/brim vehicle|Drug: Prostaglandin analogue,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,8/7/2015,2/27/2018,https://ClinicalTrials.gov/show/NCT02419508
420,"A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines",Completed,Has Results,Immunologic Tests,Other: Serum samples,GlaxoSmithKline|Icahn School of Medicine at Mount Sinai,GlaxoSmithKline,Icahn School of Medicine at Mount Sinai,,,,,,,Industry|Other,Observational,10/26/2015,2/16/2018,https://ClinicalTrials.gov/show/NCT02415842
421,"A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects",Completed,Has Results,Healthy,Drug: VBP15|Drug: Placebo,"ReveraGen BioPharma, Inc.","ReveraGen BioPharma, Inc.",,,,,,,Phase 1,Industry,Interventional,1/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02415439
422,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers",Completed,Has Results,Healthy Volunteers,Drug: TAK-020|Drug: TAK-020 Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,3/18/2015,5/4/2017,https://ClinicalTrials.gov/show/NCT02413255
423,Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata,Completed,Has Results,Leiomyomata,Device: OCL 503 (uterine artery embolization),IMBiotechnologies Ltd.,IMBiotechnologies Ltd.,,,,,,,Not Applicable,Industry,Interventional,4/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02410018
424,Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia,Completed,Has Results,Iron Deficiency|Fibromyalgia,Drug: Injectafer|Drug: Placebo,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 2,Industry,Interventional,3/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02409459
425,Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1),Completed,Has Results,Device Latency,Device: MIND1 System,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 4,Industry,Interventional,2/15/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02404532
426,Evaluation of Oral Hygiene Products in an In Situ Caries Model,Completed,Has Results,Dental Caries,Drug: Fluoride free toothpaste|Drug: Fluoride toothpaste|Drug: Fluoride mouthwash,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,4/15/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02399163
427,A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV),Completed,Has Results,Idiopathic Polypoidal Choroidal Vasculopathy,Drug: Zimura,Ophthotech Corporation,Ophthotech Corporation,,,,,,,Phase 2,Industry,Interventional,3/15/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02397954
428,TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma,Completed,Has Results,Choriocarcinoma,Biological: TRC105|Biological: Bevacizumab,Tracon Pharmaceuticals Inc.,Tracon Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,1/15/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02396511
429,Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: TAK-385 T2 Formulation|Drug: TAK-385 T4 Formulation B|Drug: TAK-385 T4 Formulation C,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,3/15/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02396147
430,"Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants",Completed,Has Results,Healthy Volunteers,Drug: TAK-058|Drug: TAK-058 Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,2/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02389881
431,Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer,Completed,Has Results,Lung Cancer,Device: CyPath®,bioAffinity Technologies Inc.|Radiology Associates of Albuquerque,bioAffinity Technologies Inc.,Radiology Associates of Albuquerque,,,,,,Not Applicable,Industry|Other,Interventional,3/15/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02388074
432,A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis,Completed,Has Results,Psoriasis,Drug: Ixekizumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,4/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02387801
433,A Pilot Clinical Study to Evaluate the Safety and Efficacy of Marketed Oxalate Strips Compared to a Marketed Safety Pen,Completed,Has Results,Dentin Sensitivity,Device: Crest® Sensi-Stop™ Strips|Device: Colgate® Sensitivity Relief Pen,Procter and Gamble,Procter and Gamble,,,,,,,Not Applicable,Industry,Interventional,2/15/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02384044
434,Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors,Completed,Has Results,Healthy,Radiation: Radiation,"Carestream Health, Inc.","Carestream Health, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/15/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02383420
435,Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule,Completed,Has Results,Healthy Volunteers,Drug: Febuxostat XR|Drug: Maalox Advance Regular Strength liquid,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,3/15/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02382640
436,Pharmacogenetic Testing Among Home Health Patients,Completed,Has Results,"Adverse Drug Events|Adverse Drug Reactions|Drug Interaction Potentiation|Drug Metabolism, Poor, CYP2D6-RELATED|Drug Metabolism, Poor, CYP2C19-RELATED|Cytochrome P450 Enzyme Deficiency|Cytochrome P450 CYP2D6 Enzyme Deficiency|Cytochrome P450 CYP2C9 Enzyme Deficiency|Cytochrome P450 CYP2C19 Enzyme Deficiency|Cytochrome P450 CYP3A Enzyme Deficiency|Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant|Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant|Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant",Genetic: Pharmacogenetic testing,Genelex Corporation|Harding University,Genelex Corporation,Harding University,,,,,,Not Applicable,Industry|Other,Interventional,3/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02378220
437,Food Effect Study of Febuxostat XR in Healthy Participants,Completed,Has Results,Gout,Drug: Febuxostat XR,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,2/15/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02374164
438,Concussion Testing: A Novel Non-invasive Concussion Detection Device,Completed,Has Results,Concussion,Device: Nautilus NeuroWaveTM System|Behavioral: SCAT,"Jan Medical, Inc.","Jan Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT02370914
439,A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: AR-C165395XX|Other: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,3/15/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02367066
440,"Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)",Completed,Has Results,Dental Plaque|Gingivitis,Drug: Triclosan/fluoride toothpaste|Drug: stannous fluoride toothpaste|Drug: fluoride only toothpaste|Drug: Cetylpyridinium chloride mouthwash|Drug: Fluoride only mouthwash,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 4,Industry,Interventional,6/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02366689
441,A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants,Completed,Has Results,Healthy,Drug: Evacetrapib|Drug: Omeprazole,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,1/15/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02365558
442,Portable EMG-triggered Hand Robot for Individuals After Stroke,Completed,Has Results,Stroke,Device: Hand of Hope (HOH),Rehab-Robotics Company Limited|New York Presbyterian Hospital,Rehab-Robotics Company Limited,New York Presbyterian Hospital,,,,,,Not Applicable,Industry|Other,Interventional,3/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02364700
443,Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics,Completed,Has Results,Diabetes Mellitus,,"DexCom, Inc.","DexCom, Inc.",,,,,,,,Industry,Observational,9/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT02363907
444,"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest",Completed,Has Results,Actinic Keratosis,Drug: Ingenol Mebutate|Other: Vehicle,LEO Pharma,LEO Pharma,,,,,,,Phase 3,Industry,Interventional,4/15/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02361216
445,The Clinical Investigation of Toothpaste as Compared to Toothpaste and Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US,Completed,Has Results,Dental Plaque|Gingivitis,Drug: Triclosan/fluoride toothpaste|Drug: stannous fluoride toothpaste|Drug: fluoride toothpaste|Drug: Fluoride Mouthwash|Drug: cetylpyridinium chloride Mouthwash,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 4,Industry,Interventional,6/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02360995
446,Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions,Completed,Has Results,Relative Bioavailability|AUC|Cmax|Pharmacokinetics,Drug: D1400147|Drug: D14000136|Drug: D14000137|Drug: Epanova®,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,2/12/2015,7/27/2015,https://ClinicalTrials.gov/show/NCT02359045
447,LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration,Completed,Has Results,Exudative Age-Related Macular Degeneration,Drug: LHA510 ophthalmic suspension|Drug: LHA510 vehicle|Drug: Ranibizumab ophthalmic solution,"Alcon, a Novartis Company|Alcon Research","Alcon, a Novartis Company",Alcon Research,,,,,,Phase 2,Industry,Interventional,3/3/2015,10/18/2016,https://ClinicalTrials.gov/show/NCT02355028
448,"Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers",Completed,Has Results,Healthy,Drug: Silenor 6 mg|Drug: zolpidem 10 mg|Drug: Placebo,Pernix Theraputics LLC|Henry Ford Hospital,Pernix Theraputics LLC,Henry Ford Hospital,,,,,,Phase 4,Industry|Other,Interventional,1/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02353299
449,Protocol for the Evaluation of Dario™ BGMS Performance at Elevated Altitude,Completed,Has Results,Diabetes,Device: Dario Blood Glucose Monitoring System|Device: YSI Analyzer,LabStyle Innovations Ltd.,LabStyle Innovations Ltd.,,,,,,,Not Applicable,Industry,Interventional,2/15/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02352298
450,Open-trial on the Prevention of Chronic Migraines With the CEFALY Device,Completed,Has Results,Migraine,Device: CEFALY,Cefaly Technology,Cefaly Technology,,,,,,,Not Applicable,Industry,Interventional,2/2/2015,4/11/2017,https://ClinicalTrials.gov/show/NCT02342743
451,Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®,Completed,Has Results,Myopia,Device: stenfilcon A|Device: delefilcon A|Device: narafilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/15/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02341859
452,A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects,Completed,Has Results,Healthy,Drug: PF-04958242|Drug: Itraconazole,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/15/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02341482
453,Pharmacokinetic Comparison Of All FK-506 Formulations,Completed,Has Results,Renal Failure,Drug: Prograf vs Envarsus XR vs Astagraf XL|Drug: Prograf vs Astagraf XL vs Envarsus XR,Veloxis Pharmaceuticals,Veloxis Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,1/15/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02339246
454,A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts,Completed,Has Results,Plantar Warts,Drug: Nowarta110|Drug: Placebo,Nowarta Biopharma Inc,Nowarta Biopharma Inc,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02338336
455,Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors,Completed,Has Results,Healthy,Radiation: Radiation,"Carestream Health, Inc.","Carestream Health, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/15/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02337959
456,RDEA3170 Bioavailability Study,Completed,Has Results,Gout,Drug: RDEA3170 10 mg|Drug: RDEA3170 2.5 mg,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 1,Industry,Interventional,11/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02336594
457,Acid-Base Composition With Use of hemoDialysates,Completed,Has Results,End Stage Renal Disease,Device: Group 1: GranuFlo|Device: Group 2: NaturaLyte,Fresenius Medical Care North America,Fresenius Medical Care North America,,,,,,,Not Applicable,Industry,Interventional,11/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02334267
458,Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia,Completed,Has Results,Schizophrenia,Drug: PF-04958242|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,1/15/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02332798
459,Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery,Completed,Has Results,Inflammation|Pain|Cataract,Drug: RX-10045,A.T. Resolve SARL,A.T. Resolve SARL,,,,,,,Phase 2,Industry,Interventional,12/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02329743
460,Central Corneal Swelling With Silicone Hydrogel Materials,Completed,Has Results,Corneal Swelling,Device: etafilcon A|Device: lotrafilcon B|Device: comfilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02328937
461,Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes,Completed,Has Results,Child Behavior Disorders,Device: VillageWhere App,"Evidence-Based Practice Institute, Seattle, WA|National Institute of Mental Health (NIMH)|Medical University of South Carolina","Evidence-Based Practice Institute, Seattle, WA",National Institute of Mental Health (NIMH),Medical University of South Carolina,,,,,Not Applicable,Industry|NIH|Other,Interventional,4/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02320903
462,"A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects",Completed,Has Results,Erythema|Edema,Device: Miami w/o frag Personal lubricant,"Church & Dwight Company, Inc.","Church & Dwight Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02320227
463,"A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects",Completed,Has Results,Erythema|Edema,Device: Miami w/ frag Personal lubricant,"Church & Dwight Company, Inc.","Church & Dwight Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02320214
464,Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude,Completed,Has Results,Chronic Pain,Device: Precision or Precision Spectra Spinal Cord Stimulator System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,12/14/2019,8/18/2019,https://ClinicalTrials.gov/show/NCT02314000
465,Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction,Completed,Has Results,Intracranial Aneurysms,Device: PulseRider,Pulsar Vascular,Pulsar Vascular,,,,,,,Not Applicable,Industry,Interventional,10/31/2014,10/30/2016,https://ClinicalTrials.gov/show/NCT02312856
466,"A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation",Completed,Has Results,Plaque Psoriasis,Drug: PF-06700841 oral solution/suspension|Other: Placebo|Drug: PF-06700841 tablet,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,11/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02310750
467,14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin,Completed,Has Results,Cumulative Irritation,Device: Novel lubricant Miami w/ fragrance|Device: Novel lubricant Miami no fragrance|Device: KY Liquid lubricant|Device: Astroglide Gel lubricant|Device: Wet Platinum lubricant,"Church & Dwight Company, Inc.","Church & Dwight Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02309294
468,"Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively",Completed,Has Results,Actinic Keratosis,Drug: LEO 43204,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,3/15/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02305888
469,EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD),Completed,Has Results,Generalized Anxiety Disorder (GAD),Drug: Extended-release lorazepam|Drug: Placebo,"Edgemont Pharmaceuticals, LLC","Edgemont Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,1/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02305797
470,Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease,Completed,Has Results,Hepatitis C Virus Infection,Drug: LDV/SOF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,3/2/2015,4/18/2016,https://ClinicalTrials.gov/show/NCT02301936
471,Pro-Change Smoking Cessation Intervention,Completed,Has Results,Tobacco Smoking Cessation|Motivation,Behavioral: Behavioral economics incentives|Other: Minimal incentives,"VAL Health, LLC|National Institute on Aging (NIA)|Rhode Island Primary Care Physicians Corporation|Pro-Change Behavior Systems","VAL Health, LLC",National Institute on Aging (NIA),Rhode Island Primary Care Physicians Corporation|Pro-Change Behavior Systems,Rhode Island Primary Care Physicians Corporation,Pro-Change Behavior Systems,,,Not Applicable,Industry|NIH|Other,Interventional,1/1/2016,7/1/2016,https://ClinicalTrials.gov/show/NCT02299076
472,A Study to Evaluate the Safety and Efficacy of an Oxalate Strip on Adjacent Teeth With Dentinal Hypersensitivity,Completed,Has Results,Dentin Sensitivity,Device: Crest® Sensi-Stop™ Strips,Procter and Gamble,Procter and Gamble,,,,,,,Not Applicable,Industry,Interventional,11/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02293044
473,Safety and Tolerability Study of SHP626 in Overweight and Obese Adults,Completed,Has Results,Non-Alcoholic Steatohepatitis,Drug: SHP626|Drug: Placebo,"Mirum Pharmaceuticals, Inc.","Mirum Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,1/19/2015,6/19/2015,https://ClinicalTrials.gov/show/NCT02287779
474,NuVent™ Revision Study,Completed,Has Results,Chronic Rhinosinusitis,Device: Electromagnetic Sinus Dilation System (NuVent™),Medtronic Surgical Technologies,Medtronic Surgical Technologies,,,,,,,Not Applicable,Industry,Interventional,12/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02284347
475,Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization,Completed,Has Results,Epilepsy,Drug: BIA 2-093|Drug: Moxifloxacin|Drug: Placebo,Bial - Portela C S.A.,Bial - Portela C S.A.,,,,,,,Phase 1,Industry,Interventional,3/7/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT02283788
476,RDEA3170 and Allopurinol Combination Study in Gout Subjects,Completed,Has Results,Gout,Drug: RDEA3170 10 mg|Drug: allopurinol 300 mg,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 1,Industry,Interventional,11/1/2014,9/11/2015,https://ClinicalTrials.gov/show/NCT02279641
477,"Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality",Completed,Has Results,Corneal Endothelial Cell Loss,Device: Specular Microscope Nidek CEM-530|Device: Specular Microscope Konan CELLCHEK XL,Nidek Co. LTD.,Nidek Co. LTD.,,,,,,,,Industry,Observational,9/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02276638
478,Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab,Completed,Has Results,Hyperlipidemia|Mixed Dyslipidemia,Biological: Evolocumab,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,8/19/2014,12/19/2014,https://ClinicalTrials.gov/show/NCT02275156
479,A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness,Completed,Has Results,Muscle Soreness,Drug: Diclofenac sodium gel 1%|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,10/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02271854
480,Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time,Completed,Has Results,Malocclusion,Other: Fixed Orthodontic Appliance Treatment|Device: OrthoPulse™|Device: Non-Functional OrthoPulse™,Biolux Research Ltd.,Biolux Research Ltd.,,,,,,,Not Applicable,Industry,Interventional,5/13/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02267850
481,OrthoPulse™ and Its Effect on the Rate of Orthodontic Tooth Alignment: A Pilot Feasibility Study,Completed,Has Results,Malocclusion,Device: OrthoPulse™,Biolux Research Ltd.,Biolux Research Ltd.,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT02267837
482,The Effect of OrthoPulse™ on the Rate of Orthodontic Tooth Movement,Completed,Has Results,Malocclusion,Other: Orthodontic Treatment|Device: OrthoPulse™,Biolux Research Ltd.,Biolux Research Ltd.,,,,,,,Not Applicable,Industry,Interventional,10/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02267811
483,Sensor Off Study Using a Nellcor USB Pulse Oximetry Monitor Interface Cable,Completed,Has Results,Healthy Volunteers,Device: Nellcor USB Pulse Oximeter Monitor Interface Cable,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,9/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02265783
484,"An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease",Completed,Has Results,"Hepatitis C, Chronic",Drug: Simeprevir|Drug: Daclatasvir|Drug: Sofosbuvir,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,9/30/2014,4/25/2018,https://ClinicalTrials.gov/show/NCT02262728
485,Evaluation of Two Hand Hygiene Products in ICUs,Completed,Has Results,Hand Hygiene Effectiveness,Drug: hand antiseptic with CHG and alcohol|Drug: Alcohol hand sanitizer foam,3M,3M,,,,,,,Phase 4,Industry,Interventional,10/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02258412
486,Phase 1 Study of ACE-083 in Healthy Subjects,Completed,Has Results,Musculoskeletal Diseases,Drug: ACE-083,"Acceleron Pharma, Inc.","Acceleron Pharma, Inc.",,,,,,,Phase 1,Industry,Interventional,9/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02257489
487,A Study of LY2835219 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY2835219|Drug: Rifampin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02256267
488,Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults,Completed,Has Results,MEDI3902 for Prevention of P. Aeruginosa Pneumonia,Drug: MEDI3902 - Dose 1|Drug: MEDI3902 - Dose 2|Drug: MEDI3902 - Dose 3|Drug: MEDI3902 - Dose 4|Other: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,9/4/2014,4/20/2015,https://ClinicalTrials.gov/show/NCT02255760
489,Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Completed,Has Results,Keratoconjunctivitis Sicca|Dry Eye Disease,Drug: OTX-101 0.05%|Drug: OTX-101 0.09%|Drug: Vehicle,Sun Pharma Global FZE,Sun Pharma Global FZE,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02254265
490,Evaluation of the QuantiFERON-TB Test.,Completed,Has Results,Tuberculosis,Device: CST001,"QIAGEN Gaithersburg, Inc","QIAGEN Gaithersburg, Inc",,,,,,,,Industry,Observational,2/2/2015,4/26/2016,https://ClinicalTrials.gov/show/NCT02253537
491,A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Other: Cetaphil Acne Regimen","Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,8/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02249104
492,AZD8108 SAD/MAD in Healthy Volunteers,Completed,Has Results,Healthy Volunteers,Drug: AZD8108|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,11/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02248818
493,Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Glaucoma,Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: AR-13324 Ophthalmic Solution 0.02% BID|Drug: Timolol maleate Ophthalmic Solution 0.5% BID|Other: Placebo,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02246764
494,A Study of LY3079514 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY3079514|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02242903
495,Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09,Completed,Has Results,Hypophosphatasia|Bone Disease,Biological: Retrospective Case Only,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,,Industry,Observational,8/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02235493
496,Pharmacokinetic Study of Subcutaneous Testosterone Enanthate,Completed,Has Results,Hypogonadism,Combination Product: Testosterone enanthate auto-injector,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 1,Industry,Interventional,9/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02233751
497,Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon),Completed,Has Results,Lower Eyelid Steatoblepharon (Excess Eyelid Fat),Drug: XOPH5 Ointment|Drug: Placebo,"Topokine Therapeutics, Inc.","Topokine Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,9/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02230761
498,Adherence Risk Indicator Validation Study,Completed,Has Results,Obstructive Sleep Apnea,Other: Administration of the questionnaire and monitoring of CPAP adherence,Fisher and Paykel Healthcare,Fisher and Paykel Healthcare,,,,,,,,Industry,Observational,9/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02230085
499,Naproxen Sodium/ASA Platelet Study,Completed,Has Results,Hematology,"Drug: Naproxen Sodium (Aleve, BAY117031)|Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)",Bayer,Bayer,,,,,,,Phase 1,Industry,Interventional,2/15/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02229461
500,A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.,Completed,Has Results,Seizure Disorders,Dietary Supplement: FruitiVits,"Vitaflo International, Ltd|Children's Hospital of Philadelphia","Vitaflo International, Ltd",Children's Hospital of Philadelphia,,,,,,Not Applicable,Industry|Other,Interventional,9/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02229318
501,Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects,Completed,Has Results,Obesity,Drug: Qsymia|Drug: Placebo,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 4,Industry,Interventional,8/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02229214
502,"Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers",Completed,Has Results,Healthy,Drug: PF-04958242|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,9/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02228395
503,Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentin Sensitivity,Drug: Potassium nitrate and sodium fluoride|Drug: Standard fluoride dentifrice,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/2/2014,12/5/2014,https://ClinicalTrials.gov/show/NCT02226562
504,Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: LDV/SOF|Drug: VDV|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,7/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02226549
505,Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth,Completed,Has Results,Surgery,Drug: 2% CHG Cloth solution|Device: Vehicle Cloth|Drug: Active Comparator|Other: Saline|Other: SLS,Medline Industries,Medline Industries,,,,,,,Phase 3,Industry,Interventional,8/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02224625
506,A Comparative Evaluation of the Performance and Fit of Pediatric Face Masks,Completed,Has Results,Healthy,Device: Medline Pediatric Face Masks|Device: KC Childs Mask,Medline Industries,Medline Industries,,,,,,,Phase 4,Industry,Interventional,1/14/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT02224612
507,Evaluation of Skin Affix in the Emergency Room,Completed,Has Results,Wounds,Procedure: Skin Affix,Medline Industries,Medline Industries,,,,,,,Phase 4,Industry,Interventional,7/14/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02223689
508,Oral Testosterone for the Treatment of Hypogonadism in Males,Completed,Has Results,Hypogonadism,Drug: TSX-002,"TesoRx Pharma, LLC","TesoRx Pharma, LLC",,,,,,,Phase 2,Industry,Interventional,9/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02222558
509,Case Series of New Alloplastic Bone Graft Material,Completed,Has Results,Periodontology|Oral Surgery,Device: easy-graft (beta-Tricalcium Phosphate),Sunstar Americas,Sunstar Americas,,,,,,,Not Applicable,Industry,Interventional,3/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02221557
510,A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban,Completed,Has Results,Bleeding,Biological: Andexanet|Other: Placebo,Portola Pharmaceuticals,Portola Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02220725
511,Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: LDV/SOF|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,8/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02219685
512,A Study of LY2409021 in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: LY2409021,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,8/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02217618
513,A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine,Completed,Has Results,Pain,Drug: JNJ-10450232 / Not yet marketed|Drug: acetaminophen / Tylenol,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Phase 2,Industry,Interventional,8/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02209181
514,To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste,Completed,Has Results,Oral Hygiene,Drug: Sodium bicarbonate plus sodium fluoride|Drug: Sodium fluoride,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02207907
515,A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban,Completed,Has Results,Bleeding,Biological: Andexanet|Other: Placebo,Portola Pharmaceuticals,Portola Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02207725
516,Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Open-angle Glaucoma,Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: Timolol maleate Ophthalmic Solution 0.5% BID|Other: Placebo|Drug: AR-13324 Ophthalmic Solution 0.02% BID,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02207621
517,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Open-angle Glaucoma,Drug: Timolol maleate Ophthalmic Solution 0.5% BID|Drug: AR-13324 Ophthalmic Solution 0.02%|Other: Placebo,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02207491
518,To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms,Completed,Has Results,Oral Hygiene,Drug: Sodium bicarbonate and sodium fluoride|Drug: Sodium fluoride,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/25/2014,4/30/2015,https://ClinicalTrials.gov/show/NCT02207400
519,A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations,Completed,Has Results,Autosomal Dominant Hypocalcemia (ADH),Drug: NPSP795,Shire|National Institutes of Health (NIH),Shire,National Institutes of Health (NIH),,,,,,Phase 2,Industry|NIH,Interventional,7/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02204579
520,Patient Perception of Visual Distortions,Completed,Has Results,Cataract|Astigmatism,Other: Administration of patient self-assessment,Abbott Medical Optics,Abbott Medical Optics,,,,,,,,Industry,Observational,8/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02203747
521,Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT,Completed,Has Results,Kaposi's Sarcoma,Drug: Tc 99m tilmanocept,Navidea Biopharmaceuticals,Navidea Biopharmaceuticals,,,,,,,Phase 2,Industry,Interventional,9/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02201420
522,"Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935",Completed,Has Results,Healthy Volunteers,Drug: TAK-935|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,7/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02201056
523,Near-infrared Software Performance Study,Completed,Has Results,Vascular Access Complication,Device: VeinViewer,"Christie Medical Holdings, Inc.","Christie Medical Holdings, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02200458
524,21 Day Cumulative Skin Irritation of RUT058-60,Completed,Has Results,Irritation/Irritant,"Drug: Hypochlorous acid solution 106 mg/L|Drug: 0.1% (w/v) Sodium Lauryl Sulfate|Drug: 0.9% Physiological Saline, USP",Pulmatrix Inc.,Pulmatrix Inc.,,,,,,,Phase 1,Industry,Interventional,7/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02198963
525,Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia,Completed,Has Results,Presbyopia,Drug: AGN-199201|Drug: AGN-190584|Drug: AGN-199201 Vehicle,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,7/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02197806
526,A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Peglispro|Drug: Insulin Glargine|Drug: Insulin Lispro,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02197520
527,PK Study of PT003 and PT001 in Japanese Healthy Subjects,Completed,Has Results,COPD,Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Drug: Glycopyrronium (GP) Dose 1|Drug: Glycopyrronium (GP) Dose 2,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 1,Industry,Interventional,7/14/2019,,https://ClinicalTrials.gov/show/NCT02196714
528,The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ,Completed,Has Results,Oral Hygiene,Drug: Sodium fluoride (1426 ppm)|Drug: Sodium fluoride (1150 ppm)|Drug: Sodium fluoride (250 ppm)|Drug: Sodium fluoride (1426 ppm) + zinc base A|Drug: Sodium fluoride (1426 ppm) + zinc base B|Drug: Fluoride (0 ppm),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02195583
529,Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria,Completed,Has Results,Oral Bacteria Levels in the Mouth,Drug: Total Flavor option 1|Drug: Total Flavor option 2|Drug: Placebo toothpaste: Crest Cavity Protection toothpaste,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 4,Industry,Interventional,1/14/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT02194621
530,Evaluation of the Safety and Efficacy of an Oxalate Gel or Negative Control on Dentinal Hypersensitivity,Completed,Has Results,Dentin Sensitivity,Device: Potassium Oxalate|Other: Water,Procter and Gamble,Procter and Gamble,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02189382
531,A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia,Completed,Has Results,Anal Intraepithelial Neoplasia (AIN)|High-grade Squamous Intraepithelial Lesions (HSIL),Device: Radiofrequency Ablation (Barrx™),Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,7/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02189161
532,Efficacy and Safety Study of Interproximal Cleaning Modalities on Oral Health,Completed,Has Results,Gingivitis,Device: AirFloss + BreathRx|Device: AirFloss + Listerine|Device: Dental Floss|Device: Manual Toothbrush,Philips Oral Healthcare,Philips Oral Healthcare,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02187016
533,Clinical Validation of Biofinity Toric MTO (Made To Order) Lenses,Completed,Has Results,Myopia|Astigmatism,Device: comfilcon A MTO|Device: comfilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/14/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02185105
534,"Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines",Completed,Has Results,Glabellar Frown Lines,"Biological: Botulinum purified neurotoxin, Type A","Evolus, Inc.","Evolus, Inc.",,,,,,,Phase 2,Industry,Interventional,8/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02184988
535,Donor Human Milk in Neonatal Abstinence Syndrome,Completed,Has Results,Neonatal Abstinence Syndrome,Dietary Supplement: donor human milk,Neolac Inc dba Medolac Laboratories|University of Louisville,Neolac Inc dba Medolac Laboratories,University of Louisville,,,,,,,Industry|Other,Observational,6/14/2019,9/9/2017,https://ClinicalTrials.gov/show/NCT02182973
536,A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration,Completed,Has Results,Macular Degeneration,Drug: abicipar pegol|Drug: ranibizumab|Other: sham procedure,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,7/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02181517
537,"Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)",Completed,Has Results,Facial Rhytides|Crow's Feet Lines|Glabellar Lines|Nasolabial Fold,Biological: onabotulinumtoxinA|Drug: bimatoprost ophthalmic solution 0.03%|Device: JUVÉDERM® ULTRA XC|Device: JUVÉDERM® ULTRA PLUS XC|Device: JUVÉDERM® VOLUMA® XC,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,6/30/2014,5/3/2015,https://ClinicalTrials.gov/show/NCT02176356
538,"Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment",Completed,Has Results,Severe Hepatic Impairment,Drug: Vortioxetine,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,7/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02170220
539,Neo-Synalar Modified 48 Hour Patch Test,Completed,Has Results,Allergy,Drug: Neo-Synalar Cream|Other: Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Other: Saline,"Noah Rosenberg, MD|Medimetriks Pharmaceuticals, Inc","Noah Rosenberg, MD","Medimetriks Pharmaceuticals, Inc",,,,,,Phase 4,Industry,Interventional,6/14/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02168478
540,"Study of Over-The-Counter Use of Low Level Laser Light Therapy for Body Contouring of the Waist, Hips and Thighs",Completed,Has Results,Circumference Reduction,Device: Lay End Users|Device: Treatment Subject Group,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,7/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02167867
541,Asthma Data Innovation Demonstration Project,Completed,Has Results,"Asthma|Bronchial Diseases|Respiratory Tract Diseases|Lung Diseases, Obstructive|Lung Diseases|Respiratory Hypersensitivity|Hypersensitivity, Immediate|Hypersensitivity|Immune System Diseases",Device: Propeller Health intervention,David Van Sickle|Foundation for a Healthy Kentucky|Norton Healthcare Foundation|Owsley Brown Charitable Foundation|Reciprocal Labs,David Van Sickle,Foundation for a Healthy Kentucky,Norton Healthcare Foundation|Owsley Brown Charitable Foundation|Reciprocal Labs,Norton Healthcare Foundation,Owsley Brown Charitable Foundation|Reciprocal Labs,Owsley Brown Charitable Foundation,Reciprocal Labs,Not Applicable,Industry|Other,Interventional,6/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT02162576
542,Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Evacetrapib|Drug: Warfarin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02161731
543,A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence,Completed,Has Results,Stress Urinary Incontinence,Device: pessary|Device: Absorbent pad,Procter and Gamble,Procter and Gamble,,,,,,,Not Applicable,Industry,Interventional,5/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02160314
544,Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants,Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Darunavir|Drug: Ritonavir|Drug: Lopinavir/Ritonavir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,6/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02159352
545,A Study Comparing Use of Manual and Power Bone Marrow Aspiration and Biopsy Devices in Children,Completed,Has Results,Bone Marrow Aspiration and Biopsy Specimen Collection,Device: Manual bone marrow aspiration and biopsy device|Device: Powered bone marrow aspiration and biopsy device,Vidacare Corporation,Vidacare Corporation,,,,,,,Not Applicable,Industry,Interventional,4/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT02159118
546,"A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects",Completed,Has Results,Healthy Volunteers,Drug: AGN-223575 Formulation A|Drug: AGN-223575 Formulation B|Drug: AGN-223575 Formulation C|Drug: AGN-223575 Vehicle,Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,5/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02155543
547,The Efficacy of the Kyrobak for Chronic Low Back Pain (LBP-2),Completed,Has Results,Low Back Pain,Device: Continuous Passive Motion,Radiancy,Radiancy,,,,,,,Not Applicable,Industry,Interventional,10/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT02155283
548,"Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants",Completed,Has Results,Dose Finding Study,Drug: TAK-058 (ENV8058)|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,6/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02153099
549,Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC),Completed,Has Results,Pachyonychia Congenita,Drug: 1% sirolimus cream (TD201 1%),"TransDerm, Inc.|Pachyonychia Congenita Project","TransDerm, Inc.",Pachyonychia Congenita Project,,,,,,Phase 1,Industry|Other,Interventional,1/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02152007
550,A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal,Completed,Has Results,Tooth Stain,"Drug: Colgate® Regular Cavity Protection|Drug: Experimental Mouth Rinse|Other: Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint",Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02151058
551,Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion,Completed,Has Results,Otitis Media,Device: Acclarent Tympanostomy Tube Delivery System (TTDS).,Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,2/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT02150044
552,Patient Perception of Visual Quality and Function,Completed,Has Results,Cataract,Other: Administration of patient self-assessment,Abbott Medical Optics,Abbott Medical Optics,,,,,,,,Industry,Observational,5/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02146599
553,Evaluation of the QuantiFERON-TB Test.,Completed,Has Results,Tuberculosis,Device: CST001,"QIAGEN Gaithersburg, Inc","QIAGEN Gaithersburg, Inc",,,,,,,,Industry,Observational,5/27/2014,3/28/2016,https://ClinicalTrials.gov/show/NCT02142894
554,Low Intensity Ultrasound Therapy for Upper Back Pain Relief,Completed,Has Results,Muscle Spasm,Device: Active ultrasound therapy device|Device: Placebo ultrasound therapy device,"ZetrOZ, Inc.","ZetrOZ, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02135094
555,A Multi-Center Study Evaluating the Safety of AC-170 0.24%,Completed,Has Results,Atopic Disease (Including Allergic Conjunctivitis),Drug: Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.","Aciex Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02132169
556,Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: Oxymetazoline HCL Cream 1.0%|Drug: Vehicle to Oxymetazoline HCL Cream,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,6/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02132117
557,Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: AGN-199201|Drug: Vehicle to AGN-199201,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,5/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02131636
558,A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence (SUI),Completed,Has Results,Stress Urinary Incontinence (SUI),"Device: disposable, single-use pessary",Procter and Gamble,Procter and Gamble,,,,,,,Not Applicable,Industry,Interventional,4/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02131311
559,Taste Assessment Study of SHP429 in Healthy Adult Subjects,Completed,Has Results,Healthy,Drug: Mesalamine,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,6/14/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02125292
560,ivWatch Model 400: Device Validation for Infiltrated Tissues,Completed,Has Results,Infiltration of Peripheral IV Therapy,Device: The ivWatch Model 400,"ivWatch, LLC","ivWatch, LLC",,,,,,,Not Applicable,Industry,Interventional,2/14/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02123745
561,Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy,Completed,Has Results,Colonoscopy Preparation,Drug: 90 grams of Crystalline Lactulose|Drug: 135 grams of Crystalline Lactulose|Drug: 180 grams of Crystalline Lactulose,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,4/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02123017
562,Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1,Completed,Has Results,Spinal Muscular Atrophy 1,Biological: AVXS-101,"AveXis, Inc.","AveXis, Inc.",,,,,,,Phase 1,Industry,Interventional,5/5/2014,12/15/2017,https://ClinicalTrials.gov/show/NCT02122952
563,Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy,Completed,Has Results,Dry Eye Syndromes,Drug: cyclosporine 0.05% ophthalmic emulsion|Drug: carboxymethylcellulose-based lubricant eye drops,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,4/3/2014,9/23/2014,https://ClinicalTrials.gov/show/NCT02121847
564,A Study of LY3050258 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY3050258|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02121834
565,Technical Efficacy of a Direction Specific Radiofrequency Device in the Performance of Lumbar Medial Branch Neurotomies,Completed,Has Results,Low Back Pain,Device: Lumbar MB RFN,"Nimbus Concepts, LLC","Nimbus Concepts, LLC",,,,,,,,Industry,Observational,12/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02120625
566,ivWatch Model 400: Device Validation for Non-Infiltrated Tissues,Completed,Has Results,Infiltration of Peripheral IV Therapy,Device: ivWatch Model 400,"ivWatch, LLC","ivWatch, LLC",,,,,,,Not Applicable,Industry,Interventional,1/14/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT02120443
567,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis",Completed,Has Results,"Dermatitis, Atopic","Drug: AN2728 Topical Ointment, 2%|Drug: Matching vehicle control",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02118792
568,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis",Completed,Has Results,"Dermatitis, Atopic","Drug: AN2728 Topical Ointment, 2%|Drug: Matching vehicle control",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02118766
569,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults",Completed,Has Results,Respiratory Syncytial Virus Infections,Drug: MEDI8897 Intravenous|Drug: Placebo|Drug: MEDI8897 Intramuscular,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,4/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02114268
570,A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease|COPD,Drug: TD-4208|Drug: Placebo,Theravance Biopharma,Theravance Biopharma,,,,,,,Phase 2,Industry,Interventional,4/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02109172
571,A Study of LY2951742 in Healthy Japanese and Caucasian Participants,Completed,Has Results,Migraine Disorders,Drug: LY2951742|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02104765
572,Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204|Drug: Placebo,LEO Pharma,LEO Pharma,,,,,,,Phase 1|Phase 2,Industry,Interventional,5/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02100813
573,Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: bimatoprost 0.01%|Drug: travoprost 0.004%|Drug: timolol 0.5%|Drug: hypromellose 0.3%,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,5/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02097719
574,Clinical Evaluation of Daily Disposable Contact Lenses,Completed,Has Results,Myopia,Device: filcon II 3|Device: etafilcon A|Device: nelfilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Phase 4,Industry,Interventional,3/14/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT02097030
575,Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers,Completed,Has Results,Healthy,Drug: Catapres-TTS-1|Drug: Intervention 1: Catapres-TTS-3|Drug: Intervention 2: Catapres-TTS-3,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,3/14/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02096744
576,Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets,Completed,Has Results,Gastroesophageal Reflux Disease|Erosive Esophagitis|Heartburn,Drug: Dexlansoprazole,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,2/14/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02096458
577,A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: Oxymetazoline HCL Cream 1.0%,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,4/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02095158
578,Second Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery,Completed,Has Results,Post Ocular Surgical Inflammation and Pain,Drug: Dexamethasone|Device: Punctum Plug,"Ocular Therapeutix, Inc.","Ocular Therapeutix, Inc.",,,,,,,Phase 3,Industry,Interventional,4/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02089113
579,The Use of Clear Aligners With Movement Enhancement Techniques,Completed,Has Results,Malocclusion,Device: Movement Enhancement Technique|Device: Clear Aligner,"Align Technology, Inc.","Align Technology, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/14/2019,12/18/2019,https://ClinicalTrials.gov/show/NCT02087163
580,Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Risperidone ISM,Rovi Pharmaceuticals Laboratories,Rovi Pharmaceuticals Laboratories,,,,,,,Phase 2,Industry,Interventional,3/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02086786
581,Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial,Completed,Has Results,Knee Osteoarthritis,Device: Sam Ultrasonic Diathermy Device,"ZetrOZ, Inc.|National Institutes of Health (NIH)|National Institute on Minority Health and Health Disparities (NIMHD)","ZetrOZ, Inc.",National Institutes of Health (NIH),National Institute on Minority Health and Health Disparities (NIMHD),,,,,Not Applicable,Industry|NIH,Interventional,3/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02083861
582,Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects,Completed,Has Results,Healthy,Drug: lomitapide|Drug: EE/norgestimate,"Aegerion Pharmaceuticals, Inc.","Aegerion Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,2/19/2014,4/24/2014,https://ClinicalTrials.gov/show/NCT02080468
583,A Study Examining the Bioequivalence of 3 Alectinib (RO5424802) Test Formulations to a Reference Formulation of in Healthy Participants,Completed,Has Results,Healthy Volunteer,Drug: Part 1 (Fasted): Treatment A|Drug: Part 1 (Fasted): Treatment B|Drug: Part 1 (Fasted): Treatment C|Drug: Part 1 (Fasted): Treatment D|Drug: Part 2 (Fed): Treatment A|Drug: Part 2 (Fed): Treatment B|Drug: Part 2 (Fed): Treatment C|Drug: Part 2 (Fed): Treatment D,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,2/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02074553
584,Crossover Comparison of MultiHance and Dotarem,Completed,Has Results,Brain Disease,Drug: MultiHance 0.1 mmol/kg|Drug: Dotarem|Drug: MultiHance 0.05 mmol/kg,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 4,Industry,Interventional,2/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02070380
585,"Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants",Completed,Has Results,Bioavailability,Drug: Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Drug: Dexlansoprazole Delayed Release Capsules,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,2/14/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT02064907
586,"To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects",Completed,Has Results,Solid Tumors,Drug: Selumetinib 50mg|Drug: Selumetinib 25mg,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,3/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02063230
587,The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage,Completed,Has Results,Atrial Fibrillation,Drug: Observational,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,,Industry,Observational,10/28/2014,3/15/2016,https://ClinicalTrials.gov/show/NCT02061748
588,Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Primary Open Angle Glaucoma|Ocular Hypertension,Drug: T-2345|Drug: Xalatan,Nephron Pharmaceuticals Corporation,Nephron Pharmaceuticals Corporation,,,,,,,Phase 3,Industry,Interventional,1/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02059278
589,A Study of LY2835219 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY2835219,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02059148
590,"To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers",Completed,Has Results,Solid Tumours,Drug: Selumetinib|Drug: Moxifloxacin|Drug: selumetinib placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,3/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02056392
591,Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis,Completed,Has Results,Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis,Drug: [¹⁴C]Etelcalcetide,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,2/7/2014,8/15/2014,https://ClinicalTrials.gov/show/NCT02054572
592,A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions,Completed,Has Results,Skin Diseases,Drug: 3% Benzoyl Peroxide|Drug: 3% Benzoyl Peroxide Placebo|Drug: Neutrogena Rapid Clear®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,2/14/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT02052752
593,Evaluation of Reader Training Processes,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 4,Industry,Interventional,3/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02051790
594,CC100: Safety and Tolerability of Single Doses,Completed,Has Results,Healthy,Drug: CC100|Drug: Placebo,"Chemigen, LLC","Chemigen, LLC",,,,,,,Phase 1,Industry,Interventional,11/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02050334
595,Pilot Study for Automated Deep Brain Stimulation Programming,Completed,Has Results,Parkinson's Disease|Tremor|Bradykinesia,Device: Automated Programming,Great Lakes NeuroTechnologies Inc.|National Institute of Neurological Disorders and Stroke (NINDS)|University of Cincinnati,Great Lakes NeuroTechnologies Inc.,National Institute of Neurological Disorders and Stroke (NINDS),University of Cincinnati,,,,,Not Applicable,Industry|NIH|Other,Interventional,11/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02046863
596,"Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers",Completed,Has Results,Hereditary Angioedema (HAE),Drug: Icatibant (30 mg),Shire,Shire,,,,,,,Phase 1,Industry,Interventional,2/14/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02045264
597,Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder,Completed,Has Results,Opioid Use Disorder,Drug: Buprenorphine|Drug: buprenorphine and naloxone|Drug: hydromorphone|Drug: placebo,Indivior Inc.,Indivior Inc.,,,,,,,Phase 2,Industry,Interventional,11/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02044094
598,The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage,Completed,Has Results,Atrial Fibrillation,,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,,Industry,Observational,1/14/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT02043808
599,A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,COPD,Drug: TD-4208|Drug: Placebo,Theravance Biopharma,Theravance Biopharma,,,,,,,Phase 2,Industry,Interventional,5/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02040792
600,Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population,Completed,Has Results,Opioid Dependence,Drug: Suboxone Sublingual Film|Drug: Zubsolv sublingual tablets,Indivior Inc.,Indivior Inc.,,,,,,,Phase 4,Industry,Interventional,11/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT02038790
601,Safety Study Looking at the Effects of Stendra on Vision,Completed,Has Results,Vision,Drug: Stendra 200 mg|Drug: Placebo,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 4,Industry,Interventional,1/14/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT02033200
602,Validation of Safety and Efficacy for Night Shift Therapy,Completed,Has Results,Obstructive Sleep Apnea,Device: Deliver therapy when the supine position is detected,"Advanced Brain Monitoring, Inc.","Advanced Brain Monitoring, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02032706
603,A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Dapsone Gel,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02032407
604,A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.,Completed,Has Results,Healthy Volunteer,Drug: Alectinib|Drug: Esomeprazole|Other: High Fat and Calorie Meal|Other: Standard Meal,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,12/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT02023125
605,Virtual Path Planning for Image-guided Needle Interventions,Completed,Has Results,Gastrointestinal Diseases|Bone Diseases|Muscular Diseases|Spinal Diseases|Vascular Diseases,Radiation: XperGuide|Radiation: XperGuide with virtual path planning,Philips Healthcare,Philips Healthcare,,,,,,,,Industry,Observational,12/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02021071
606,Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults,Completed,Has Results,Malaria,Biological: Pfs25 VLP- FhCMB,"Fraunhofer, Center for Molecular Biotechnology","Fraunhofer, Center for Molecular Biotechnology",,,,,,,Phase 1,Industry,Interventional,10/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02013687
607,"MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects",Completed,Has Results,Healthy,Drug: N91115|Drug: Placebo|Drug: Placebo-Day 1 only,"Nivalis Therapeutics, Inc.","Nivalis Therapeutics, Inc.",,,,,,,Phase 1,Industry,Interventional,2/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02013388
608,A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer,Completed,Has Results,Oral Mucositis,Drug: SGX942|Drug: Placebo,Soligenix,Soligenix,,,,,,,Phase 2,Industry,Interventional,12/13/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02013050
609,Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105),Completed,Has Results,Renal Insufficiency|Renal Impairment,Drug: sugammadex,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 1,Industry,Interventional,12/11/2013,6/6/2014,https://ClinicalTrials.gov/show/NCT02011490
610,Patient Experience Study of Deoxycholic Acid Injection,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic Acid Injection|Drug: Placebo|Other: Cold Compress|Drug: Lidocaine / Epinephrine|Drug: Loratadine|Drug: Ibuprofen|Other: Compression Chin Strap,Kythera Biopharmaceuticals,Kythera Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02007434
611,The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery,Completed,Has Results,Inflammation|Cataracts,Drug: IBI-10090|Drug: Placebo,ICON Bioscience Inc,ICON Bioscience Inc,,,,,,,Phase 3,Industry,Interventional,1/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02006888
612,Study Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI),Completed,Has Results,Routine Endoscopy,Device: FICE Image Acquisition followed by NBI Image Acquisition,"Fujifilm Medical Systems USA, Inc.","Fujifilm Medical Systems USA, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT02005393
613,A Study of Axiron® in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Axiron,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT02004132
614,Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin,Completed,Has Results,Dermatologic Complications,Device: Control Abdominal Skin|Device: Peristomal Abdominal Skin,Hollister Incorporated|Loyola University,Hollister Incorporated,Loyola University,,,,,,,Industry|Other,Observational,11/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02003404
615,The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers,Completed,Has Results,ECG Effects,Drug: Buprenorphine transdermal patch|Drug: Naltrexone tablet|Drug: Placebos (for TDS and for naltrexone and for moxifloxacin)|Drug: Moxifloxacin tablet,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,3/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01999114
616,"Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis",Completed,Has Results,Actinic Keratosis,Drug: ingenol mebutate|Other: Placebo,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,1/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01998984
617,A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement,Completed,Has Results,Subjects Desiring Lip Augmentation,Device: JUVEDERM VOLBELLA® XC|Device: Restylane-L®,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,11/1/2013,5/29/2015,https://ClinicalTrials.gov/show/NCT01998581
618,Evaluation of Procedural Analgesia for Liposonix Treatment,Completed,Has Results,Body Contouring,Device: Liposonix System (Model 2)|Drug: Pre-treatment analgesia,Solta Medical|Valeant Pharmaceuticals,Solta Medical,Valeant Pharmaceuticals,,,,,,Not Applicable,Industry,Interventional,11/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01993238
619,Relative Bioavailability of Pimasertib in Cancer Patients,Completed,Has Results,Neoplasms,Drug: Pimasertib Capsule (Part A)|Drug: Pimasertib Tablet (Part A)|Drug: Pimasertib Capsule (Part B and trial extension phase),EMD Serono,EMD Serono,,,,,,,Phase 1,Industry,Interventional,11/30/2013,2/28/2015,https://ClinicalTrials.gov/show/NCT01992874
620,Photocil (Topical) for the Treatment of Vitiligo,Completed,Has Results,Vitiligo,Drug: Photocil for Vitiligo|Other: Placebo - Sunscreen (SPF 2),"Applied Biology, Inc.","Applied Biology, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01992185
621,Photocil (Topical) for the Treatment of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Photocil for Atopic Dermatitis|Other: Placebo - Sunscreen (SPF 2),"Applied Biology, Inc.","Applied Biology, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01992172
622,US Phase III Study of APD421 in PONV,Completed,Has Results,PONV,Drug: APD421- Amisulpride for IV injection|Drug: Placebo,Acacia Pharma Ltd,Acacia Pharma Ltd,,,,,,,Phase 3,Industry,Interventional,8/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01991860
623,Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects,Completed,Has Results,Healthy,Drug: Midazolam|Drug: SSP-004184SS,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,11/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01989169
624,"Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis",Completed,Has Results,Seborrheic Keratosis (SK),Drug: A-101 25%|Drug: A-101 32.5%|Drug: A-101 40%|Drug: A-101 Vehicle,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,10/22/2013,2/25/2014,https://ClinicalTrials.gov/show/NCT01986920
625,Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method,Completed,Has Results,Acute Pharyngitis|Sore Throat,Drug: flurbiprofen|Drug: placebo,Reckitt Benckiser LLC,Reckitt Benckiser LLC,,,,,,,Phase 3,Industry,Interventional,9/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01986361
626,Comparison of Two Formulations of Androxal,Completed,Has Results,Bioequivalence,Drug: 12.5 mg Androxal Formulation A|Drug: 12.5 mg Androxal Formulation B|Drug: 25 mg Androxal Formulation A|Drug: 25 mg Androxal Formulation B,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1,Industry,Interventional,12/31/2013,12/31/2013,https://ClinicalTrials.gov/show/NCT01984398
627,Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection,Completed,Has Results,Chronic HCV Infection,Drug: LDV/SOF|Drug: RBV|Drug: GS-9669,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,10/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01984294
628,A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers,Completed,Has Results,Healthy Volunteer,Drug: Alectinib|Drug: Posaconazole,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,12/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01984229
629,Cangrelor to Clopidogrel or Prasugrel Transition Study,Completed,Has Results,Coronary Artery Disease (CAD),Drug: Cangrelor|Drug: Clopidogrel|Drug: Prasugrel,The Medicines Company,The Medicines Company,,,,,,,Phase 2,Industry,Interventional,12/2/2013,1/20/2014,https://ClinicalTrials.gov/show/NCT01979445
630,Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects,Completed,Has Results,Healthy,Drug: Simvastatin|Drug: SSP-004184SS,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,11/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01979185
631,FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.,Completed,Has Results,Chronic Kidney Disease|Acute Kidney Injury,Device: 75 mg / 6 mL VFI™,FAST BioMedical|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),FAST BioMedical,National Institutes of Health (NIH),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,,,,Not Applicable,Industry|NIH,Interventional,8/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01978314
632,A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System,Completed,Has Results,HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions,Device: Radiofrequency Ablation (RFA) using the HALO Ablation System,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,3/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01970787
633,JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines,Completed,Has Results,Patients With Moderate to Severe Perioral Lines,Device: JUVEDERM® Ultra XC|Device: Belotero Balance®,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,10/21/2013,8/4/2014,https://ClinicalTrials.gov/show/NCT01970397
634,A Study of LY3127760 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY3127760|Drug: Celecoxib|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01968070
635,Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol),Completed,Has Results,Smoking,Other: mTHS 2.2|Other: mCC|Other: NNS,Philip Morris Products S.A.,Philip Morris Products S.A.,,,,,,,Not Applicable,Industry,Interventional,10/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01967719
636,Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses,Completed,Has Results,Myopia,Device: Pair 1 (ocufilcon D / ocufilcon D)|Device: Pair 2 (ocufilcon D / enfilcon A)|Device: Pair 3 (ocufilcon D / comfilcon A)|Device: Pair 4 (methafilcon A / methafilcon A)|Device: Pair 5 (methafilcon A / comfilcon A)|Device: Pair 6 (omafilcon A / comfilcon A),"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01966770
637,Study of Long-Acting Acetaminophen in Postoperative Dental Pain,Completed,Has Results,Dental Pain,Drug: Acetaminophen ER|Drug: Placebo,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Phase 2,Industry,Interventional,10/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01960114
638,"Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)",Completed,Has Results,Influenza,Biological: Flublok® Quadrivalent Influenza Virus Vaccine|Biological: Fluarix Quadrivalent® Influenza Virus Vaccine,Protein Sciences Corporation,Protein Sciences Corporation,,,,,,,Phase 3,Industry,Interventional,11/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01959945
639,CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study),Completed,Has Results,Breast Augmentation|Breast Reconstruction|Breast Revision,Device: The Contour Profile Gel (CPG) breast implants,"Mentor Worldwide, LLC","Mentor Worldwide, LLC",,,,,,,Phase 3,Industry,Interventional,8/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01959880
640,A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal,Completed,Has Results,Pharmacokinetics|Tolerability,Drug: Androxal|Drug: Placebo,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1,Industry,Interventional,10/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01959685
641,A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.,Completed,Has Results,Schizophrenia,Drug: NW-3509a,Newron Pharmaceuticals SPA,Newron Pharmaceuticals SPA,,,,,,,Phase 1,Industry,Interventional,6/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01955564
642,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Completed,Has Results,Otitis Media With Effusion,Drug: OTO-201|Drug: Sham,"Otonomy, Inc.","Otonomy, Inc.",,,,,,,Phase 3,Industry,Interventional,11/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01949155
643,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Completed,Has Results,Otitis Media With Effusion,Drug: OTO-201|Drug: Sham,"Otonomy, Inc.","Otonomy, Inc.",,,,,,,Phase 3,Industry,Interventional,11/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01949142
644,The Feasibility of Florbetapir Quantitation,Completed,Has Results,Alzheimers Disease,Drug: Florbetapir F18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 4,Industry,Interventional,8/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01946243
645,A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache,Completed,Has Results,Migraine Disorders|Headache,Other: No Intervention,Allergan,Allergan,,,,,,,,Industry,Observational,3/14/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01946126
646,Multi-Center Trial to Evaluate an Internal Joint Stabilizer - Elbow,Completed,Has Results,Trauma|Chronic Elbow Dislocation,Device: Internal Joint Stabilizer - Elbow (IJS-E),"Skeletal Dynamics, LLC","Skeletal Dynamics, LLC",,,,,,,Not Applicable,Industry,Interventional,8/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01944670
647,AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use,Completed,Has Results,Vascular Access Complication,Device: AccuCath IV Catheter Device|Device: Conventional IV Catheter Device,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,4/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01943474
648,A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802,Completed,Has Results,Healthy Volunteer,Drug: RO5424802|Drug: rifampin,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,10/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01940510
649,Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology,Completed,Has Results,Vascular Access Complications,Device: AccuCath IV Catheter System|Device: Conventional IV Catheter System,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,8/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01940354
650,Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal,Completed,Has Results,Peripheral Artery Disease|PAD|Claudication|Peripheral Vascular Disease|PVD,Device: Stealth 360°® OAS,Cardiovascular Systems Inc,Cardiovascular Systems Inc,,,,,,,Not Applicable,Industry,Interventional,1/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01938391
651,AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT),Completed,Has Results,Vascular Access Complication,Device: AccuCath Intravenous Catheter System,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,4/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01937195
652,A Pharmacokinetic Substudy of the TDE-PH-304 Protocol,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: UT-15C SR|Drug: treprostinil diethanolamine,United Therapeutics,United Therapeutics,,,,,,,Phase 3,Industry,Interventional,8/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01934582
653,AM-101 in the Treatment of Post-Acute Tinnitus 1,Completed,Has Results,Tinnitus,Drug: AM-101,"Auris Medical, Inc.","Auris Medical, Inc.",,,,,,,Phase 3,Industry,Interventional,6/14/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01934010
654,Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns,Completed,Has Results,Multiple Sclerosis|Urinary Bladder Diseases,Behavioral: Systematic Screening and Education Regimen,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,8/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01930799
655,The Effects of an Antioxidant Formulation on Ocular Blood Flow,Completed,Has Results,Primary Open Angle Glaucoma,Dietary Supplement: dietary supplement with antioxidants|Dietary Supplement: Placebo,ScienceBased Health,ScienceBased Health,,,,,,,Not Applicable,Industry,Interventional,8/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01930487
656,Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant,Completed,Has Results,Single Umbilical Cord Blood Transplantation|Non-myeloablative Conditioning|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Multiple Myeloma|Chronic Lymphocytic Leukemia,Drug: HSC835,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,10/7/2014,8/29/2016,https://ClinicalTrials.gov/show/NCT01930162
657,A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: Cobimetinib|Drug: Itraconazole,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,7/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01929876
658,"Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK2330672|Drug: Placebo|Drug: Metformin,GlaxoSmithKline|Elite Research Institute,GlaxoSmithKline,Elite Research Institute,,,,,,Phase 2,Industry|Other,Interventional,8/1/2013,11/21/2013,https://ClinicalTrials.gov/show/NCT01929863
659,A Study of LY3050258 in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: LY3050258|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,8/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01929707
660,Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain,Completed,Has Results,"Pain, Postoperative|Tooth Diseases",Drug: ibuprofen + caffeine|Drug: ibuprofen|Drug: caffeine|Drug: placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,8/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01929031
661,A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics,Completed,Has Results,Type 1 Diabetes Mellitus,Biological: LY2605541|Biological: Insulin Glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01925989
662,Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection,Completed,Has Results,Hepatitis C,Drug: LDV/SOF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,7/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01924949
663,A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.,Completed,Has Results,"Kidney Failure, Chronic Therapy; Hemodialysis",Drug: soluble ferric pyrophosphate|Drug: Placebo,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 1,Industry,Interventional,6/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01920854
664,Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation,Completed,Has Results,Myocardial Blood Flow Reserve,Drug: Regadenoson|Radiation: Rubidium-82,"Timothy M. Bateman, MD|Cardiovascular Imaging Technologies","Timothy M. Bateman, MD",Cardiovascular Imaging Technologies,,,,,,Phase 4,Industry,Interventional,7/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01919450
665,A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema,Completed,Has Results,Retinal Vein Occlusion|Macular Edema,Drug: Anti-VEGF,Allergan,Allergan,,,,,,,,Industry,Observational,8/2/2013,9/4/2014,https://ClinicalTrials.gov/show/NCT01918371
666,Photocil (Topical) for the Treatment of Psoriasis Vulgaris,Completed,Has Results,Psoriasis,Drug: Photocil for Psoriasis|Other: Placebo - Sunscreen (SPF 2),"Applied Biology, Inc.","Applied Biology, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01916629
667,Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LIK066|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,7/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01915849
668,Resolute Integrity US Extended Length Sub-Study(RI US XL),Completed,Has Results,Coronary Artery Disease,Device: Resolute Integrity Stent,Medtronic Vascular,Medtronic Vascular,,,,,,,Not Applicable,Industry,Interventional,7/13/2019,12/18/2019,https://ClinicalTrials.gov/show/NCT01913600
669,A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: [^14C]-LY2835219,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,8/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01913314
670,Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.,Completed,Has Results,Acne Prone Skin,Drug: Facial Cleanser and Moisturizer SPF 30,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,5/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01909713
671,Clinical Evaluation for General Electric (GE) CT System,Completed,Has Results,CT Scanners X Ray,Device: Revolution CT Scanner,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,5/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01909180
672,A Study of Evacetrapib and Rifampin in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Evacetrapib|Drug: Rifampin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01908582
673,The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects,Completed,Has Results,Healthy,Drug: SSP-004184SS,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,8/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01905553
674,A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt),Completed,Has Results,Healthy,Drug: SSP-004184AQ|Drug: SSP-004184SS,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,8/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01905540
675,A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA),Completed,Has Results,"Alopecia|Alopecia, Androgenetic|Baldness",Drug: Bimatoprost Solution 1|Drug: Bimatoprost Solution 2|Drug: Bimatoprost Vehicle,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,8/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01904721
676,A Study of Evacetrapib (LY2484595) in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Evacetrapib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01903434
677,EVARREST™ Fibrin Sealant Patch Post-Market Study,Completed,Has Results,Hemorrhage|Soft Tissue Bleeding,Biological: EVARREST™ Fibrin Sealant Patch|Other: Standard of Care,"Ethicon, Inc.","Ethicon, Inc.",,,,,,,Phase 4,Industry,Interventional,7/1/2013,9/1/2015,https://ClinicalTrials.gov/show/NCT01902459
678,Clinical Study of Peripheral Capillary Oxygen Saturation (SpO2): Vital Signs Patch (VSP),Completed,Has Results,Desaturation of Blood,Device: Vital Signs Patch (VSP),"LifeWatch Services, Inc.","LifeWatch Services, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/13/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01899911
679,A Study of Evacetrapib and Digoxin in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Evacetrapib|Drug: Digoxin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01897493
680,Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Latanoprostene bunod,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,7/5/2013,4/14/2015,https://ClinicalTrials.gov/show/NCT01895972
681,Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy,Completed,Has Results,Airway Obstruction|Apnea|Hypopnea,Device: Airway Management System (AMS),"5i Sciences, Inc.","5i Sciences, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,3/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01895062
682,Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients,Completed,Has Results,Kidney Failure,Drug: Soluble Ferric Pyrophosphate|Other: Placebo,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,7/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01894906
683,Safety and Performance of the Steroid-Releasing S8 Sinus Implant,Completed,Has Results,Chronic Sinusitis,"Drug: S8 Sinus Implant (mometasone furoate, 1350 mcg)",Intersect ENT,Intersect ENT,,,,,,,Phase 2,Industry,Interventional,6/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01894503
684,Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%,Completed,Has Results,Plaque Psoriasis,Drug: Clobex Spray,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,7/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01893567
685,Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test,Completed,Has Results,Skin Irritation,Drug: Facial Moisturizer with SPF 50+,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,3/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT01892657
686,Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults,Completed,Has Results,Ketamine-Induced Brain Activity Changes|Psychotic-like Symptoms,Drug: Ketamine|Drug: TAK-063|Drug: TAK-063 Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,8/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01892189
687,Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers,Completed,Has Results,Healthy Volunteers,Drug: Lisdexamfetamine Dimesylate,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,7/15/2013,8/22/2013,https://ClinicalTrials.gov/show/NCT01890785
688,User Study for Enhanced Meter Feature,Completed,Has Results,Diabetes Mellitus,Device: AgaMatrix Blood Glucose Monitor,"AgaMatrix, Inc.","AgaMatrix, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/14/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01889355
689,2 Regimens of Lactulose for Colonoscopy Preparation in Adults,Completed,Has Results,Colonoscopy Preparation,Drug: Full dose preparation|Drug: Split dose preparation,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01887470
690,Pharmacokinetic Study of Testosterone Enanthate,Completed,Has Results,Hypogonadism,Drug: QuickShot™ - 50 mg Treatment B|Drug: QuickShot™ - 100 mg Treatment A|Drug: Delatestryl 200 mg IM Treatment C,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01887418
691,Laser Removal of Age (Sun) Spots on Hands,Completed,Has Results,Solar Lentigines,Device: Picosecond QS Nd:YAG Laser,Cutera Inc.,Cutera Inc.,,,,,,,Not Applicable,Industry,Interventional,6/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01885871
692,Study of Low Level Laser Light Therapy to Improve Blood Circulation in People With Chronic Heel Pain,Completed,Has Results,Defective; Circulation,Device: Erchonia HP Scanner (HPS),Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,6/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01882725
693,"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.","Aciex Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,6/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01881113
694,"Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants",Completed,Has Results,Schizophrenia,Drug: TAK-063|Drug: TAK-063 Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,6/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01879722
695,A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers,Completed,Has Results,Epilepsy,Drug: Placebo|Drug: BIA 2-093 3000 mg once daily|Drug: BIA 2-093 3600 mg once daily,Bial - Portela C S.A.,Bial - Portela C S.A.,,,,,,,Phase 1,Industry,Interventional,12/6/2019,2/7/2019,https://ClinicalTrials.gov/show/NCT01879332
696,ADASUVE-Lorazepam Drug-Drug Interaction,Completed,Has Results,Healthy Volunteers,Drug: Lorazepam 1 mg IM|Drug: Inhaled loxapine 10 mg|Drug: Inhaled Placebo|Drug: Placebo IM,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 4,Industry,Interventional,6/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01877642
697,A Study of LY2605541 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY2605541,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01877265
698,Duchenne Muscular Dystrophy Clinical Trial,Completed,Has Results,Duchenne Muscular Dystrophy,Device: VECTTOR,"Alan Neuromedical Technologies, LLC","Alan Neuromedical Technologies, LLC",,,,,,,Not Applicable,Industry,Interventional,6/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01874275
699,A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens,Completed,Has Results,Myopia,Device: Silicone Hydrogel Contact Lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,4/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01873846
700,OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion,Completed,Has Results,Degenerative Changes|Stenosis|Spondylosis,Procedure: Posterolateral Fusion,"SeaSpine, Inc.","SeaSpine, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/12/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01873586
701,A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal,Completed,Has Results,Acute Pain,Drug: Placebo|Drug: LY3023703|Drug: Celecoxib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01872910
702,Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea,Completed,Has Results,Papulopustular Rosacea,Drug: Oracea,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,3/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01872715
703,Remote Device Interrogation In The Emergency Department,Completed,Has Results,"Heart Disease|Cardiovascular Disease|Heart Failure|Arrhythmias, Cardiac",Device: Unpaired remote monitoring transmitter,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,9/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01871090
704,Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose,Completed,Has Results,Healthy Volunteer,Biological: Denosumab,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,6/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01869686
705,Salvage Ovarian FANG™ Vaccine + Carboplatinum,Completed,Has Results,Stage III Ovarian Cancer|Stage IV Ovarian Cancer,Biological: Vigil™ Vaccine|Drug: Carboplatinum|Drug: Carboplatinum and Taxol,"Gradalis, Inc.","Gradalis, Inc.",,,,,,,Phase 2,Industry,Interventional,6/13/2019,4/8/2016,https://ClinicalTrials.gov/show/NCT01867086
706,LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris,Completed,Has Results,Psoriasis Vulgaris|Plaque Psoriasis,Drug: LEO 90100|Drug: Vehicle,LEO Pharma,LEO Pharma,,,,,,,Phase 3,Industry,Interventional,6/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01866163
707,A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Fixed-Combination Bimatoprost/Brimonidine|Drug: Bimatoprost Ophthalmic Solution 0.01%|Drug: Vehicle Ophthalmic Solution|Drug: Brimonidine Tartrate Ophthalmic Solution 0.2%,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01863953
708,Post-market Study to Capture Information Regarding Performance of Lyric2,Completed,Has Results,Hearing Loss,Device: Lyric|Device: Lyric2,"Phonak AG, Switzerland","Phonak AG, Switzerland",,,,,,,Not Applicable,Industry,Interventional,4/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01861704
709,Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects,Completed,Has Results,Prolonged QTc Interval,Drug: Deferiprone|Drug: deferiprone matching placebo tablets|Drug: moxifloxacin|Drug: placebo,ApoPharma,ApoPharma,,,,,,,Phase 4,Industry,Interventional,11/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01860703
710,"Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults",Completed,Has Results,Malaria,Biological: GSK257049 Dosage 1|Biological: GSK257049 Dosage 2|Procedure: Sporozoite-infected mosquitoes challenge,GlaxoSmithKline|Walter Reed Army Institute of Research (WRAIR)|The PATH Malaria Vaccine Initiative (MVI),GlaxoSmithKline,Walter Reed Army Institute of Research (WRAIR),The PATH Malaria Vaccine Initiative (MVI),,,,,Phase 2,Industry|U.S. Fed|Other,Interventional,5/20/2013,12/16/2014,https://ClinicalTrials.gov/show/NCT01857869
711,Toric Eye Strain and Stability Study,Completed,Has Results,Astigmatism,Device: etafilcon A|Device: etafilcon A for Astigmatism,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01857102
712,PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Brexpiprazole 1mg to 4mg,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 1,Industry,Interventional,9/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01854944
713,Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum,Completed,Has Results,Intraosseous Vascular Access,Device: T.A.L.O.N. Intraosseous System,Vidacare Corporation,Vidacare Corporation,,,,,,,Not Applicable,Industry,Interventional,4/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01853215
714,Cangrelor Prasugrel Transition Study,Completed,Has Results,Coronary Artery Disease,Drug: Cangrelor|Drug: Prasugrel,The Medicines Company,The Medicines Company,,,,,,,Phase 2,Industry,Interventional,6/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01852019
715,A Multiple Dose Study of LY3023703 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Placebo|Drug: LY3023703|Drug: Celecoxib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,5/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01849055
716,Anticoagulant Utilization Pattern,Completed,Has Results,Atrial Fibrillation,,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,,Industry,Observational,4/17/2013,11/1/2017,https://ClinicalTrials.gov/show/NCT01847560
717,A Study to Compare a New Eye Drop Formulation With Refresh Contacts®,Completed,Has Results,Contact Lens Lubrication,Drug: carboxymethylcellulose based eye drop formula|Drug: carboxymethylcellulose sodium based eye drop solution,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,5/29/2013,12/2/2013,https://ClinicalTrials.gov/show/NCT01844388
718,Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids,Completed,Has Results,"Hemorrhoids, Internal",Device: HET Bipolar System,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,4/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01841970
719,"A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial",Completed,Has Results,Spasticity,Drug: Tizanidine|Drug: Placebo|Drug: Moxifloxacin,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 2,Industry,Interventional,4/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01839279
720,Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat,Completed,Has Results,Human Immunodeficiency Virus Type 1 (HIV-1),Drug: Atazanavir|Drug: Cobicistat|Drug: Atazanavir/Cobicistat FDC,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,4/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01837719
721,Respiration Rate V2.0 in a Hospital Setting,Completed,Has Results,Respiratory Rate,,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,3/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01837537
722,"The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream",Completed,Has Results,Healthy Volunteers,Drug: LY2409021|Drug: Gemfibrozil|Drug: Ketoconazole|Drug: Clarithromycin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,5/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01836198
723,Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®),Completed,Has Results,Chronic Migraine,Biological: OnabotulinumtoxinA|Drug: Normal saline (placebo),Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,4/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01833130
724,Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity,Completed,Has Results,Dentinal Hypersensitivity,Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Drug: 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Drug: Sodium monofluorophosphate dentifrice|Drug: Sodium Fluoride dentifrice,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,1/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01831817
725,ROBODOC® Clinical Trials: Long-Term Follow-Up,Completed,Has Results,Osteoarthritis,,Curexo Technology Corporation,Curexo Technology Corporation,,,,,,,,Industry,Observational,4/13/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01831219
726,Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women,Completed,Has Results,Postmenopausal Symptoms,Drug: Brisdelle (paroxetine mesylate),Noven Therapeutics,Noven Therapeutics,,,,,,,Phase 1,Industry,Interventional,7/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01829919
727,Myopia Progression After Ceasing Myopia Control Contact Lens Wear,Completed,Has Results,Myopia,Device: 1 Day Acuvue Moist,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01829230
728,Controlling Myopia Progression With Soft Contact Lenses (Contact Lens Control),Completed,Has Results,Myopia,Device: Soft Contact Test Lens A|Device: Soft Contact Test Lens C,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/1/2008,5/1/2010,https://ClinicalTrials.gov/show/NCT01829191
729,"A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: PF-02545920|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,3/6/2013,10/17/2013,https://ClinicalTrials.gov/show/NCT01829048
730,Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: Stannous fluoride|Drug: Sodium monofluorophosphate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01827670
731,A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Evacetrapib|Drug: Warfarin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,4/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01825876
732,Pilairo Lab Market Research,Completed,Has Results,Obstructive Sleep Apnea,Device: CPAP mask ( Pilairo)|Procedure: Other CPAP mask,Fisher and Paykel Healthcare,Fisher and Paykel Healthcare,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01824979
733,"AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184",Completed,Has Results,Healthy,"Drug: Radiolabeled SPD602 (FBS0701, SSP-004184)",Shire,Shire,,,,,,,Phase 1,Industry,Interventional,4/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01824446
734,Performance of an Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: Ninja 3 PLUS Investigational BG Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,3/13/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01824355
735,Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics,Completed,Has Results,Gastrointestinal Mucosal Damage,Drug: Ibuprofen|Drug: Paracetamol|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,2/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01822665
736,Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification,Completed,Has Results,Healthy Volunteers,Other: No Intervention,Allergan,Allergan,,,,,,,,Industry,Observational,3/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01821534
737,Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters,Completed,Has Results,Healthy,Drug: PF-05175157|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01819922
738,Contact Lens Comfort Relative to Meibomian Gland Status,Completed,Has Results,Meibomian Gland Dysfunction,Device: senofilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/13/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01819194
739,A Study of LY2605541 in Healthy Participants and in the Elderly,Completed,Has Results,Healthy Volunteers,Drug: LY2605541,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,3/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01818245
740,Assessment of Fluticasone Propionate on Ocular Allergy Symptoms,Completed,Has Results,Allergic Rhinitis|Seasonal Allergic Rhinitis,Drug: Fluticasone propionate|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01817790
741,A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis,Completed,Has Results,Gingivitis,Other: Probiotics,Sunstar Americas,Sunstar Americas,,,,,,,Not Applicable,Industry,Interventional,3/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01811316
742,Study of Food on Evacetrapib (LY2484595) in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Evacetrapib|Other: High-fat Meal,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,3/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01810432
743,Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3,Completed,Has Results,Hepatitis C,Drug: SOF|Drug: PEG|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,2/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01808248
744,GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs,Completed,Has Results,Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder|Pervasive Developmental Disorder|Asperger's Disorder,Device: Groundskeeper,"CogCubed, Corp|Ohio University","CogCubed, Corp",Ohio University,,,,,,Not Applicable,Industry|Other,Interventional,1/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01808066
745,A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease,Completed,Has Results,Alzheimer Disease|Healthy Volunteers,Drug: LY2886721|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,3/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01807026
746,"Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers",Completed,Has Results,Healthy,Drug: Radiolabeled Prucalopride Succinate,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,3/13/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01807000
747,Single Dose Bronchodilatory Study in Asthma,Completed,Has Results,Asthma,Drug: Zileuton extended release,Cornerstone Therapeutics Inc.,Cornerstone Therapeutics Inc.,,,,,,,Phase 4,Industry,Interventional,3/13/2019,,https://ClinicalTrials.gov/show/NCT01805687
748,Respiration Rate V2.0 in Healthy Volunteers,Completed,Has Results,Focus of the Study is Measuring Respiratory Rate,,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,2/13/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01804062
749,AM-101 in the Treatment of Acute Tinnitus 2,Completed,Has Results,Tinnitus,Drug: AM-101|Drug: Placebo,"Auris Medical, Inc.","Auris Medical, Inc.",,,,,,,Phase 3,Industry,Interventional,2/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01803646
750,EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair,Completed,Has Results,Hernia,Drug: EXPAREL,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 4,Industry,Interventional,4/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01801124
751,"Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)",Completed,Has Results,Pseudobulbar Affect (PBA)|Stroke|Dementia|Traumatic Brain Injury (TBI),Drug: Nuedexta (DM 20 mg/Q 10 mg),Avanir Pharmaceuticals,Avanir Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,2/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01799941
752,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Completed,Has Results,Thyroid Eye Disease,Device: SENSIMED Triggerfish,"Sensimed AG|University of California, San Diego",Sensimed AG,"University of California, San Diego",,,,,,Not Applicable,Industry|Other,Interventional,2/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01798966
753,Revised Algorithm for Next Generation DeVilbiss Healthcare AutoAdjust Continuous Positive Airway Pressure (CPAP),Completed,Has Results,Obstructive Sleep Apnea,Device: DeVilbiss AutoAdjust CPAP with revised algorithm,DeVilbiss Healthcare LLC,DeVilbiss Healthcare LLC,,,,,,,Not Applicable,Industry,Interventional,1/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01797705
754,A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery,Completed,Has Results,Acute Pain,Drug: CR845|Drug: Placebo,"Cara Therapeutics, Inc.","Cara Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,5/13/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01789476
755,"Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers",Completed,Has Results,Healthy Volunteers,Drug: Radiolabeled SPD557,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,3/7/2013,4/12/2013,https://ClinicalTrials.gov/show/NCT01786876
756,Thermage CPT for Treatment of Facial and Neck Laxity,Completed,Has Results,Skin Aging,Device: Thermage CPT,Valeant Pharmaceuticals,Valeant Pharmaceuticals,,,,,,,Not Applicable,Industry,Interventional,1/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01783496
757,A Study of Two Dosage Forms of LY2886721 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY2886721 in a Capsule|Drug: LY2886721 in an orally disintegrating tablet (ODT),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01775904
758,"Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris",Completed,Has Results,Acne Vulgaris,Drug: Dapsone Formulation A|Drug: Dapsone Formulation B|Drug: Dapsone Formulation C|Drug: Dapsone 5% Gel,Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,1/21/2013,5/5/2013,https://ClinicalTrials.gov/show/NCT01773122
759,Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans,Completed,Has Results,Contrast Enhanced Computed Tomography,Device: 20GA BD Nexiva Diffusics|Device: 18GA Conventional Catheter,"Becton, Dickinson and Company","Becton, Dickinson and Company",,,,,,,Not Applicable,Industry,Interventional,1/13/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01772550
760,A Test of Different Kinds of Bandages on Healing of Wounds,Completed,Has Results,Wound Healing,Device: 6660|Device: 4314|Device: 8336|Device: 4840,"Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,1/13/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01770860
761,Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.,Completed,Has Results,Medication Adherence,Behavioral: Experimental,"Inflexxion, Inc.","Inflexxion, Inc.",,,,,,,Phase 2,Industry,Interventional,9/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01770314
762,"Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age",Completed,Has Results,"Meningitis, Meningococcal, Serogroup B",Biological: rLP2086,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,2/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01768117
763,Cangrelor Ticagrelor Transition Study,Completed,Has Results,Coronary Artery Disease,Drug: cangrelor|Drug: Ticagrelor,The Medicines Company,The Medicines Company,,,,,,,Phase 2,Industry,Interventional,1/13/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01766466
764,Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers,Completed,Has Results,Transplant Rejection,Drug: Caffeine|Drug: Losartan|Drug: Omeprazole|Drug: Dextromethorphan|Drug: Midazolam|Biological: Belatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 4,Industry,Interventional,1/13/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01766050
765,The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina,Completed,Has Results,Coronary Artery Disease,Drug: Febuxostat|Drug: Febuxostat placebo,Takeda,Takeda,,,,,,,Phase 4,Industry,Interventional,5/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01763996
766,Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS),Completed,Has Results,Hyperglycemia,,Medtronic Diabetes,Medtronic Diabetes,,,,,,,,Industry,Observational,3/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01763567
767,A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence,Completed,Has Results,Stress Urinary Incontinence,Device: pessary (disposable intra-vaginal device),Procter and Gamble,Procter and Gamble,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01762345
768,Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab,Completed,Has Results,Plasma Concentrations,Drug: Single dose of SUF NT 15 mcg|Drug: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,1/13/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01761565
769,Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users,Completed,Has Results,Opioid-Related Disorders,Drug: Placebo taken first|Drug: Generic H/A taken first|Drug: Vycavert taken first|Drug: Generic H/A plus i taken first|Drug: Generic H/A plus p taken first,Acura Pharmaceuticals Inc.,Acura Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,2/13/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01759446
770,Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4),Completed,Has Results,Healthy Volunteers,Combination Product: PRT064445/Apixaban|Combination Product: Placebo/Apixaban|Drug: Placebo,Portola Pharmaceuticals,Portola Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01758432
771,Clinical Evaluation of the OrthoPAT Advance System,Completed,Has Results,"Transmission, Blood, Recipient/Donor",Device: OrthoPat Advance,Haemonetics Corporation,Haemonetics Corporation,,,,,,,,Industry,Observational,12/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01756976
772,Evaluation of Blood Glucose Monitoring Systems With Blood Samples From Neonates,Completed,Has Results,Diabetes,Device: Contour® NEXT BGMS|Device: Contour® PLUS BGMS|Device: Contour® Next EZ BGMS,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01756274
773,Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open-Angle Glaucoma|Ocular Hypertension,Drug: BOL-303259-X|Drug: Timolol,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,1/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01749930
774,Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open-Angle Glaucoma|Ocular Hypertension,Drug: BOL-303259-X|Drug: Timolol,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,1/31/2013,9/30/2015,https://ClinicalTrials.gov/show/NCT01749904
775,A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines,Completed,Has Results,"Chronic Migraine, Headaches",Biological: onabotulinumtoxinA,Allergan,Allergan,,,,,,,,Industry,Observational,5/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01749410
776,Users Study Of The Caverject Delivery System,Completed,Has Results,Healthy,Other: dual-chamber syringe,Pfizer,Pfizer,,,,,,,Early Phase 1,Industry,Interventional,3/13/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01747928
777,A Study of LY2940680 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: [^14C]-LY2940680,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,1/13/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01746745
778,A Study of Evacetrapib in Healthy Female Participants,Completed,Has Results,Healthy Volunteers,Drug: Ortho-Cyclen|Drug: Evacetrapib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01746732
779,Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance,Completed,Has Results,Ageing,Device: BMR Face,"Bio-Medical Research, Ltd.","Bio-Medical Research, Ltd.",,,,,,,Phase 4,Industry,Interventional,11/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01740440
780,Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects,Completed,Has Results,Opioid Related Disorder,Drug: RBP-6000|Drug: Subutex,Indivior Inc.,Indivior Inc.,,,,,,,Phase 2,Industry,Interventional,10/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01738503
781,Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration,Completed,Has Results,Rheumatoid Arthritis,Drug: Methotrexate (MTX),Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01737944
782,Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis,Completed,Has Results,Psoriasis|Immunomodulation,Drug: tofacitinib,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,11/2/2019,4/4/2019,https://ClinicalTrials.gov/show/NCT01736696
783,Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation,Completed,Has Results,Pharmacokinetics,Drug: LE Gel,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 1,Industry,Interventional,1/13/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01736527
784,A Study of Evacetrapib in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: Evacetrapib|Drug: Gemfibrozil,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01736254
785,Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH,Completed,Has Results,Endocrine Disease|Adrenal Insufficiency|Congenital Adrenal Hyperplasia,Drug: Hydrocortisone Modified Release Capsules,Diurnal Limited|National Institutes of Health (NIH),Diurnal Limited,National Institutes of Health (NIH),,,,,,Phase 2,Industry|NIH,Interventional,12/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01735617
786,AGN-199201 for the Treatment of Erythema With Rosacea,Completed,Has Results,Rosacea|Erythema,Drug: AGN-199201 Dose A|Drug: AGN-199201 Dose B|Drug: AGN-199201 Dose C|Drug: AGN-199201 Vehicle,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,12/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01735201
787,A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis,Completed,Has Results,"Conjunctivitis, Allergic",Drug: Alcaftadine 0.25%|Drug: Olopatadine 0.2%|Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,11/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01732757
788,Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model,Completed,Has Results,Chronic Allergic Conjunctivitis,Drug: Prednisolone Sodium Phosphate Ophthalmic Solution 1%|Drug: Tears Naturale II Ophthalmic Solution,"ORA, Inc.","ORA, Inc.",,,,,,,Phase 4,Industry,Interventional,11/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01730872
789,Study to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age,Completed,Has Results,Asthma,Device: NIOX MINO® Instrument (09-1100),Aerocrine AB,Aerocrine AB,,,,,,,,Industry,Observational,10/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01729247
790,Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity,Completed,Has Results,Dengue Fever,Biological: TDV,Takeda|Walter Reed Army Institute of Research (WRAIR),Takeda,Walter Reed Army Institute of Research (WRAIR),,,,,,Phase 1,Industry|U.S. Fed,Interventional,1/22/2013,11/21/2013,https://ClinicalTrials.gov/show/NCT01728792
791,A Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity,Completed,Has Results,Dentin Sensitivity,Device: Mouth Rinse|Drug: Fluoride Toothpaste|Drug: Potassium Nitrate Toothpaste,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01727258
792,Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects,Completed,Has Results,Chronic Hepatitis C Virus,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,10/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01726517
793,Magnetic Resonance Imaging Using Innovative Pulse Sequences,Completed,Has Results,Clinical Indication for a Head MRI,Device: pulse sequences,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01724216
794,Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics,Completed,Has Results,Pharmacokinetics,"Drug: Sufentanil NanoTab (SUF NT) 15 mcg|Drug: Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg","AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,11/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01721070
795,Oral Testosterone for the Treatment of Hypogonadism,Completed,Has Results,Hypogonadism,Drug: TSX-002,"TesoRx Pharma, LLC","TesoRx Pharma, LLC",,,,,,,Phase 2,Industry,Interventional,10/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01717768
796,"Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib",Completed,Has Results,Advanced Solid Tumors|Lymphoma,Drug: [^14C]-alisertib|Drug: alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,1/24/2013,6/14/2013,https://ClinicalTrials.gov/show/NCT01714947
797,Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion,Completed,Has Results,Stenosis|Spondylosis|Degenerative Changes,Device: Accell Evo3 Prospective Use,"SeaSpine, Inc.","SeaSpine, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/12/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01714804
798,Evaluation of Blood Glucose Meter Systems,Completed,Has Results,Diabetes,Device: Contour® PLUS BGMS|Device: OneTouch® SelectSimple™ BGMS|Device: Accu-Chek® Performa BGMS|Device: Accu-Chek® Active BGMS|Device: Freestyle Freedom® BGMS,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01714232
799,Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use,Completed,Has Results,Asthma,Device: Pressurized Metered-Dose Inhaler,Philips Respironics,Philips Respironics,,,,,,,,Industry,Observational,12/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01714063
800,Treatment of the Face and Neck With Lower Ulthera System Energy Settings,Completed,Has Results,Skin Laxity,Device: Ulthera System Treatment,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,9/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01713998
801,Evaluation of the Ulthera® System for Treatment of the Brachia,Completed,Has Results,Brachial Ptosis,Device: Ulthera® System,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,6/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01713933
802,Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection,Completed,Has Results,Hepatitis C Virus,Drug: SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,10/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01713283
803,Feasibility Study: Heavy Water Tissue Labeling Protocol,Completed,Has Results,Skin Laxity,Device: Ulthera® System Treatment|Other: Heavy Water,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,8/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01708525
804,BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Open Angle Glaucoma,Drug: BOL-303259-X|Drug: Timolol maleate,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 2,Industry,Interventional,11/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01707381
805,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,Completed,Has Results,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Drug: CTAP101 30 μg capsules|Other: Sugar pill to CTAP101 30 μg capsules,"OPKO IP Holdings II, Inc.|OPKO Health, Inc.","OPKO IP Holdings II, Inc.","OPKO Health, Inc.",,,,,,Phase 3,Industry,Interventional,11/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01704079
806,A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers,Completed,Has Results,Smoking,Drug: nicotine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,3/12/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01702519
807,Evaluation of Blood Glucose Monitoring Systems,Completed,Has Results,Diabetes,Device: Contour® NEXT LINK BGMS|Device: OneTouch® UltraLink® BGMS|Device: Nova Max Link® BGMS,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01699763
808,Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems,Completed,Has Results,Myopia|Astigmatism|Refractive Error,Device: Lotrafilcon B contact lenses|Device: Senofilcon A contact lenses|Device: OPTI-FREE® PUREMOIST® MPDS|Device: BIOTRUE®|Device: Balafilcon A contact lenses|Device: ReNu® Multiplus®,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01699750
809,Pharmacokinetic and Pharmacodynamic Study of Cyclofem,Completed,Has Results,Contraception,Drug: Injection Cyclofem,Sun Pharmaceutical Industries Limited,Sun Pharmaceutical Industries Limited,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01699022
810,Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients,Completed,Has Results,Allergic Conjunctivitis,"Drug: Olopatadine hydrochloride ophthalmic solution, 0.2%",Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,9/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01697969
811,Evaluation of Comfilcon A and Senofilcon A Lenses,Completed,Has Results,Myopia,Device: Senofilcon A; Comfilcon A|Device: Comfilcon A; Senofilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Phase 4,Industry,Interventional,8/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01695369
812,Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Drug: 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Drug: Sodium monofluorophosphate dentifrice|Drug: Sodium fluoride dentifrice,GlaxoSmithKline|BioSci Research,GlaxoSmithKline,BioSci Research,,,,,,Phase 2,Industry|Other,Interventional,8/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01691560
813,Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children,Completed,Has Results,Meningitis|Meningococcal Infection,Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,,Industry,Observational,6/11/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01689155
814,Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo-matched-to-ivacaftor tablet,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 2,Industry,Interventional,9/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01685801
815,"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.","Aciex Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,9/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01685242
816,Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator,Completed,Has Results,Lung Disease,Device: Pulse Dose (Sleep Mode)|Device: Continuous Dose,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,9/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01679301
817,"Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100""",Completed,Has Results,Dietary Carcinogenesis,Drug: ACCS100|Drug: Placebo,Texas Enterosorbents Incorporated|Texas A&M University|University of Georgia|The University of Texas at San Antonio,Texas Enterosorbents Incorporated,Texas A&M University,University of Georgia|The University of Texas at San Antonio,University of Georgia,The University of Texas at San Antonio,,,Phase 2,Industry|Other,Interventional,9/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01677195
818,A Study of LY3015014 in Healthy Participants With High Cholesterol,Completed,Has Results,Healthy Volunteers|Hypercholesterolemia,Drug: LY3015014|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,8/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01671085
819,NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study,Completed,Has Results,Tooth Hypersensitivity,Device: Group C|Device: Group A|Device: Group B,Dentsply International,Dentsply International,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01669785
820,Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Orteronel|Drug: Orteronel Placebo|Drug: Prednisone,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1|Phase 2,Industry,Interventional,8/20/2012,9/1/2016,https://ClinicalTrials.gov/show/NCT01666314
821,Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery,Completed,Has Results,Ocular Inflammation and Pain,Drug: OTX-DP (Dexamethasone punctum plug)|Drug: Placebo Vehicle Punctum Plug,"Ocular Therapeutix, Inc.","Ocular Therapeutix, Inc.",,,,,,,Phase 2,Industry,Interventional,10/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01666210
822,Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors,Completed,Has Results,Myopia,Device: LASIK correction of myopic refractive errors,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Phase 3,Industry,Interventional,8/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01663363
823,Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Saxagliptin|Drug: Dapagliflozin,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,8/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01662999
824,Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery,Completed,Has Results,Post Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: Placebo Sufentanil NanoTab PCA System,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,8/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01660763
825,Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion,Completed,Has Results,Dental Erosion|Acid Wear,Drug: Sodium Fluoride|Drug: Potassium nitrate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,11/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01657903
826,Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice,Completed,Has Results,Caries,Drug: Calcium sodium phosphosilicate|Drug: Sodium monoflurophosphate|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01657877
827,Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial,Completed,Has Results,Acute Ischemic Stroke,Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Device: Solitaire revascularization device,Medtronic Neurovascular Clinical Affairs,Medtronic Neurovascular Clinical Affairs,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01657461
828,A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE),Completed,Has Results,Fecal Incontinence,Device: vaginal bowel control system (LivSure),"Pelvalon, Inc.","Pelvalon, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01655498
829,A Study of LY2605541 Versus Insulin Glargine on Blood Sugar,Completed,Has Results,"Healthy Volunteers|Diabetes Mellitus, Type 1",Drug: LY2605541|Other: Insulin glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01654380
830,GLASSIA Infusion Rate Study,Completed,Has Results,Alpha1-antitrypsin Deficiency|Healthy Volunteers,Biological: Alpha1-proteinase inhibitor|Biological: Placebo: Human albumin 2.5%,Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 4,Industry,Interventional,7/31/2012,1/16/2013,https://ClinicalTrials.gov/show/NCT01651351
831,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,Completed,Has Results,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Drug: CTAP101 30 μg capsules|Other: Sugar pill to CTAP101 30 μg capsules,"OPKO IP Holdings II, Inc.|OPKO Health, Inc.","OPKO IP Holdings II, Inc.","OPKO Health, Inc.",,,,,,Phase 3,Industry,Interventional,9/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01651000
832,Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection,Completed,Has Results,Suspicion of Being Infected With H.Pylori,Device: Modified BreathID,Exalenz Bioscience LTD.,Exalenz Bioscience LTD.,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01650831
833,A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery,Completed,Has Results,Arthroscopic Knee Surgery,Drug: IV ibuprofen|Drug: IV ketorolac,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,9/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01650519
834,Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,Completed,Has Results,Breast Cancer|Neutropenia,Drug: F-627|Drug: Neulasta® (pegfilgrastim),Generon (Shanghai) Corporation Ltd.,Generon (Shanghai) Corporation Ltd.,,,,,,,Phase 2,Industry,Interventional,6/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01648322
835,Demodex Blepharitis Treatment Study,Completed,Has Results,Chronic Blepharitis,Drug: Terpinen-4-ol|Other: Placebo,Tissue Tech Inc.|National Eye Institute (NEI),Tissue Tech Inc.,National Eye Institute (NEI),,,,,,Phase 1,Industry|NIH,Interventional,2/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01647217
836,Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe,Completed,Has Results,Influenza Prophylaxis,Device: Stratis Jet Injector|Device: Needle and Syringe|Biological: 2011-2012 Fluzone trivalent inactivated influenza vaccine,"PharmaJet, Inc.","PharmaJet, Inc.",,,,,,,Phase 4,Industry,Interventional,1/12/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01644149
837,Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector,Completed,Has Results,Chronic Pain,Device: Non Boston Scientific SCS Trial Therapy|Device: BSC approved SCS Trial Therapy w/ OMG,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,7/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01643213
838,Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions,Completed,Has Results,Enamel Erosion,Drug: sodium fluoride|Drug: no added fluoride in a silica base,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01641237
839,Effect of Delivery Route on PK of Sufentanil NanoTab,Completed,Has Results,Pharmacokinetics,Drug: Treatment A: Sufentanil IV|Drug: Treatment B: Sufentanil NanoTab Sublingual|Drug: Treatment C: Sufentanil NanoTab Buccal|Drug: Treatment D: Sufentanil NanoTab Oral,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,7/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01639729
840,An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System,Completed,Has Results,Coronary Artery Disease,Device: Resolute Integrity Stent,Medtronic Vascular,Medtronic Vascular,,,,,,,Not Applicable,Industry,Interventional,7/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01638507
841,Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale,Completed,Has Results,Erythema|Rosacea,Drug: No Intervention,Allergan,Allergan,,,,,,,,Industry,Observational,5/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01636765
842,Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter,Completed,Has Results,Coronary Artery Disease,Device: Emerge™ 1.20 mm PTCA Dilatation Catheter,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,7/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01635881
843,Sensory Effects of Rapidly-Changing Magnetic Fields,Completed,Has Results,Sensory Disorders,Device: High pulsed magnetic fields,"Weinberg Medical Physics LLC|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Neurological Disorders and Stroke (NINDS)",Weinberg Medical Physics LLC,"National Heart, Lung, and Blood Institute (NHLBI)",National Institute of Neurological Disorders and Stroke (NINDS),,,,,Not Applicable,Industry|NIH,Interventional,8/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01632800
844,A Single Dose Study of LY3023703 in Healthy Participants,Completed,Has Results,Healthy Volunteers,Drug: LY3023703|Drug: Placebo|Drug: Celecoxib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01632579
845,Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm,Completed,Has Results,Depression|Anxiety,,Assurex Health Inc.,Assurex Health Inc.,,,,,,,,Industry,Observational,1/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01632267
846,PillCam® Platform With the PillCam Crohn's Disease Capsule,Completed,Has Results,Crohn's Disease,Other: Pillcam colon capsule and PillCam™ Prep Procedure|Device: Ileocolonoscopy,Given Imaging Ltd.,Given Imaging Ltd.,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01631435
847,High Rate Spinal Cord Stimulation (SCS) for Chronic Pain,Completed,Has Results,Chronic Pain,Device: Low Rate Stimulation|Device: High Rate Stimulation,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,6/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01624740
848,An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes,Completed,Has Results,Eyelash Hypotrichosis,Drug: bimatoprost 0.03%,Allergan,Allergan,,,,,,,,Industry,Observational,11/19/2010,9/1/2011,https://ClinicalTrials.gov/show/NCT01623479
849,Investigation of AVACEN Thermal Exchange System for Fibromyalgia Pain,Completed,Has Results,Fibromyalgia,Device: AVACEN Thermal Exchange System,"Avacen, Inc.|University of California, San Diego|San Diego Veterans Healthcare System","Avacen, Inc.","University of California, San Diego",San Diego Veterans Healthcare System,,,,,Phase 2,Industry|Other|U.S. Fed,Interventional,6/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01619579
850,Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device,Completed,Has Results,Rheumatoid Arthritis (RA),Drug: MTX,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 2,Industry,Interventional,5/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01618968
851,Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device,Completed,Has Results,Rheumatoid Arthritis (RA),Device: VIBEX MTX,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 2,Industry,Interventional,5/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01618955
852,Comparison Evaluation of Blood Glucose Meter Systems in a Clinical Setting,Completed,Has Results,Diabetes,Device: Bayer G3 / Tatsu System|Device: Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Device: Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Device: OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Device: One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Device: Truetrack® Meter/Truetrack® Test Strips,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01614613
853,Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain,Completed,Has Results,Brain Disease,Drug: gadoteridol|Drug: gadobutrol,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 4,Industry,Interventional,8/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01613417
854,SpO2 System Accuracy Testing With Different Sensors,Completed,Has Results,Pulse Oximetry,Device: Pulse oximetry,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,6/19/2012,2/15/2013,https://ClinicalTrials.gov/show/NCT01613222
855,Air Barrier System for the Prevention of Surgical Site Infection,Completed,Has Results,Surgical Site Infection,Device: Air Barrier System,"Nimbic Systems, LLC|National Institute of General Medical Sciences (NIGMS)|Baylor College of Medicine","Nimbic Systems, LLC",National Institute of General Medical Sciences (NIGMS),Baylor College of Medicine,,,,,Not Applicable,Industry|NIH|Other,Interventional,1/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01610271
856,NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r)Sensitivity Relief Study,Completed,Has Results,Tooth Hypersensitivity,Device: NUPRO Classic Prophy Paste|Device: NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Device: NUPRO Sensodyne Prophy Paste with Novamin without fluoride.,Dentsply International,Dentsply International,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01610167
857,A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model,Completed,Has Results,Dental Caries,Drug: Fluoride|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01607411
858,"Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers",Completed,Has Results,Healthy,Drug: BI 207127 NA,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,5/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01605461
859,Drug Interaction Study of Colchicine and Theophylline,Completed,Has Results,Healthy,Drug: theophylline|Drug: colchicine,Takeda,Takeda,,,,,,,Phase 4,Industry,Interventional,5/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01601132
860,Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease,Completed,Has Results,Heart Failure,Drug: CLP|Drug: Spironolactone,Sorbent Therapeutics,Sorbent Therapeutics,,,,,,,Phase 1,Industry,Interventional,6/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01598740
861,The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01592864
862,Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01592851
863,Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel,Completed,Has Results,Periodontal Disease,Drug: lidocaine and prilocaine,Dentsply International,Dentsply International,,,,,,,Phase 4,Industry,Interventional,4/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01591616
864,The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity,Completed,Has Results,Dentinal Hypersensitivity|Dental Pain,Drug: Potassium Nitrate|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,2/9/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT01587950
865,Multiple Areas of Pain (MAP),Completed,Has Results,Chronic Pain,,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,,Industry,Observational,6/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01583894
866,Study of EXPAREL in Patients Undergoing Breast Augmentation,Completed,Has Results,Mammoplasty|Postoperative Pain,Drug: Instillation - EXPAREL|Drug: Infiltration - EXPAREL,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 4,Industry,Interventional,4/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01582490
867,TAP-patients With Robotic Assisted Lap Prostatectomy,Completed,Has Results,Postsurgical Pain|Analgesia|Prostatectomy,Drug: EXPAREL 20 mL|Drug: EXPAREL 40 mL,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 4,Industry,Interventional,3/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01582477
868,Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea,Completed,Has Results,Rosacea|Erythema,Drug: AGN-199201 Formulation A|Drug: AGN-199201 Formulation B|Drug: AGN-199201 Formulation C|Drug: AGN-199201 Vehicle,Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,4/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01579084
869,Observational Study of Complications Related to Use of Peripherally Inserted Central Catheters,Completed,Has Results,Adult Patients With Peripherally Inserted Central Catheters,,Teleflex,Teleflex,,,,,,,,Industry,Observational,8/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01578993
870,Hair2Go Label Comprehension and Usability Study,Completed,Has Results,Hair Removal,Device: Hair2Go,Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01578187
871,Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C,Completed,Has Results,Advanced Gastrointestinal Malignancies,Drug: MLN0264,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,6/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01577758
872,Performance Evaluation of Blood Glucose Monitoring System Using ISO Study Design,Completed,Has Results,Diabetes,Device: Contour TS Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,4/12/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01575080
873,A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,4/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01569841
874,Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate,Completed,Has Results,Healthy,Drug: BG00012 (dimethyl fumarate)|Drug: BG00012 placebo|Drug: ASA|Drug: ASA placebo,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,4/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01568112
875,A Study of 18F-AV-45 in Healthy Volunteers,Completed,Has Results,Alzheimer Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 1,Industry,Interventional,10/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT01564706
876,Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride,Completed,Has Results,Dental Caries,"Drug: Sodium fluoride / silica and carbopol, 0.5g|Drug: Sodium fluoride / silica and carbopol, 1.5g|Other: Fluoride free dentifrice",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,1/1/2009,6/1/2009,https://ClinicalTrials.gov/show/NCT01563172
877,Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses,Completed,Has Results,Myopia,Device: Delefilcon A contact lenses|Device: Narafilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01561560
878,IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure,Completed,Has Results,"Sleep Apnea, Obstructive|Primary Open-angle Glaucoma",Device: SENSIMED Triggerfish®,Sensimed AG,Sensimed AG,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01560975
879,Air Barrier System Device to Reduce Contamination in Posterior Spine Surgery,Completed,Has Results,Surgery,Device: Air Barrier System device,"Nimbic Systems, LLC","Nimbic Systems, LLC",,,,,,,Not Applicable,Industry,Interventional,11/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01559506
880,"Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor",Completed,Has Results,Homozygous Familial Hypercholesterolemia,Drug: Lomitapide,"Aegerion Pharmaceuticals, Inc.|University of Pennsylvania|Doris Duke Charitable Foundation","Aegerion Pharmaceuticals, Inc.",University of Pennsylvania,Doris Duke Charitable Foundation,,,,,Phase 2,Industry|Other,Interventional,6/3/2019,2/4/2019,https://ClinicalTrials.gov/show/NCT01556906
881,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia",Completed,Has Results,Schizophrenia|Schizoaffective Disorder|Central Nervous System Diseases,Drug: EVP-6124 (0.3 mg/day)|Drug: EVP-6124 (1.0 mg/day)|Drug: Placebo|Drug: Antipsychotic therapy,FORUM Pharmaceuticals Inc,FORUM Pharmaceuticals Inc,,,,,,,Phase 1,Industry,Interventional,4/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT01556763
882,Study Will Test the Theory That Training With the Facial-Flex Exercise Device Will Improve Snoring in Patients,Completed,Has Results,Primary Snoring|Sleep Apnea,Device: Facial-Flex,"Facial Concepts, Inc.","Facial Concepts, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01554904
883,"Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Aclidinium/formoterol 400/12μg|Drug: Formoterol,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,1/12/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01551888
884,Salvage Ovarian FANG™ Vaccine + Bevacizumab,Completed,Has Results,Stage III Ovarian Cancer|Stage IV Ovarian Cancer,Biological: Vigil™ Vaccine|Drug: Bevacizumab,"Gradalis, Inc.","Gradalis, Inc.",,,,,,,Phase 2,Industry,Interventional,3/12/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01551745
885,A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC),Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.","Aciex Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,3/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01551056
886,Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Orteronel+Prednisone,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,5/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01549951
887,Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers,Completed,Has Results,Venous Insufficiency|Venous Reflux|Lower Extremity Ulcer,Device: MIST Therapy,"Celleration, Inc.","Celleration, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01549860
888,Comparison Evaluation of Blood Glucose Meter Systems,Completed,Has Results,Diabetes,Device: CONTOUR® NEXT EZ BGMS|Device: FreeStyle Freedom Lite® BGMS|Device: ACCU-CHEK® Aviva BGMS|Device: TRUEtrack® BGMS|Device: OneTouch® Ultra®2 BGMS,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01548885
889,Controlled Study of Kneehab XP for Patients Undergoing Total Knee Replacement,Completed,Has Results,Total Knee Replacement,Device: Kneehab XP|Device: Quadriceps TENS,Theragen Inc.,Theragen Inc.,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01548040
890,B40 Non-Invasive Blood Pressure Equivalency Study,Completed,Has Results,Blood Pressure,Device: Blood Pressure Readings on B40 Patient Monitor,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01546285
891,Anesthetic Effect Duration Assessment,Completed,Has Results,Healthy Volunteers,Drug: Lidocaine 7% + Tetracaine 7% cream,Galderma,Galderma,,,,,,,Phase 4,Industry,Interventional,5/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01545765
892,A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers,Completed,Has Results,Healthy Subjects,"Other: Placebo|Biological: MEDI7814, 1 MG/KG|Biological: MEDI7814, 3 MG/KG|Biological: MEDI7814, 10 MG/KG|Biological: MEDI7814, 20 MG/KG",MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,1/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01544361
893,Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT),Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension",Other: No Treatment,Allergan,Allergan,,,,,,,,Industry,Observational,2/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01540370
894,The Influence of Endotracheal Tube Design on Fluid Leakage Into the Lungs During Surgery,Completed,Has Results,Respiratory Aspiration,Drug: Methylene Blue,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,4/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01539135
895,Nicotine Lozenge Bioequivalence Study,Completed,Has Results,Smoking Cessation,Drug: Nicotine (2 mg)|Drug: Nicotine (4 mg),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,7/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01536704
896,Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus,Completed,Has Results,Onychomycosis,Device: Erchonia FX-405™ Laser,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,4/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01534689
897,Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model,Completed,Has Results,Allergic Conjunctivitis,Drug: Prednisolone Sodium Phosphate Ophthalmic Solution 1%|Drug: Tears Naturale II Ophthalmic Solution,"ORA, Inc.","ORA, Inc.",,,,,,,Phase 4,Industry,Interventional,1/12/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01534195
898,Proclear 1-D Multifocal Nondispensing Study,Completed,Has Results,Presbyopia,Device: omafilcon A / PC 1-D MF|Device: lotrafilcon B / Air Optix MF,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01526902
899,"Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase",Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Sham Injection|Drug: Recombinant human hyaluronidase PH20|Drug: Insulin aspart|Drug: Insulin lispro,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 4,Industry,Interventional,12/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01526733
900,Randomized Evaluation of Maxillary Antrostomy Versus Ostial Dilation Efficacy Through Long-Term Follow-Up,Completed,Has Results,Chronic Sinusitis,Device: Balloon Sinus Dilation|Procedure: Functional Endoscopic Sinus Surgery,"Entellus Medical, Inc.","Entellus Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01525849
901,A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: 0.1% brimonidine tartrate ophthalmic solution|Drug: 0.01% bimatoprost ophthalmic solution|Drug: 0.2% hypromellose lubricant eye drops|Drug: latanoprost 0.005% ophthalmic solution,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,1/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01525173
902,A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: Dulaglutide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,3/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01524770
903,Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel,Completed,Has Results,Acne Vulgaris,Drug: Epiduo Gel|Drug: Retin-A Micro Microsphere 0.1%,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,4/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01522456
904,Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects,Completed,Has Results,Parkinson Disease,Drug: BIA 9-1067|Drug: Placebo,Bial - Portela C S.A.,Bial - Portela C S.A.,,,,,,,Phase 1,Industry,Interventional,5/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01520987
905,A Retrospective Study to Evaluate the Effectiveness of the Ulthera System,Completed,Has Results,Skin Laxity|Wrinkles,,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,,Industry,Observational,10/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01519934
906,Lifting and Tightening of the Face and Neck Following an Increased Density Treatment,Completed,Has Results,Skin Laxity,Device: Ulthera System Treatment,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,8/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01519206
907,Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women,Completed,Has Results,Health,Other: No treatment,Allergan,Allergan,,,,,,,,Industry,Observational,12/1/2011,12/16/2011,https://ClinicalTrials.gov/show/NCT01518270
908,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PL2200 Aspirin Capsules|Drug: Immediate-Release Aspirin Tablets|Drug: Enteric-coated aspirin caplets,PLx Pharma,PLx Pharma,,,,,,,Phase 3,Industry,Interventional,1/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01515657
909,Skin Incision Adhesive in Pediatrics,Completed,Has Results,Wounds,Device: Surgiseal,Medline Industries,Medline Industries,,,,,,,Not Applicable,Industry,Interventional,2/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01514396
910,Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System,Completed,Has Results,Asthma,Device: Propeller Health System (formerly Asthmapolis System),Reciprocal Labs|California HealthCare Foundation,Reciprocal Labs,California HealthCare Foundation,,,,,,Not Applicable,Industry|Other,Interventional,4/12/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01509183
911,Adult Patients Undergoing Open Colectomy MA402S23B303,Completed,Has Results,Bowel Obstruction,Drug: IV morphine sulfate|Drug: EXPAREL (bupivacaine liposome injectable suspension),"Pacira Pharmaceuticals, Inc|Registrat-Mapi","Pacira Pharmaceuticals, Inc",Registrat-Mapi,,,,,,Phase 4,Industry|Other,Interventional,12/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01507246
912,An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay,Completed,Has Results,Treatment Resistant Depression|Generalized Anxiety Disorder,Device: Genecept Assay,"Genomind, LLC","Genomind, LLC",,,,,,,Not Applicable,Industry,Interventional,4/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01507155
913,Provoked Craving Assessment,Completed,Has Results,Smoking Dependence|Smoking,Drug: oral nicotine|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01506908
914,Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy,Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: Rolapitant|Drug: Granisetron|Drug: Dexamethasone|Drug: Placebo,"Tesaro, Inc.","Tesaro, Inc.",,,,,,,Phase 3,Industry,Interventional,2/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01500226
915,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: Rolapitant|Drug: Granisetron|Drug: Dexamethasone|Drug: Placebo,"Tesaro, Inc.","Tesaro, Inc.",,,,,,,Phase 3,Industry,Interventional,2/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01500213
916,Fluoride Varnish for Treatment of White Spot Lesions,Completed,Has Results,White Spot Lesions,Device: Vanish Varnish|Device: Pediagel,3M|University of Tennessee Health Science Center,3M,University of Tennessee Health Science Center,,,,,,Not Applicable,Industry|Other,Interventional,2/12/2019,3/31/2014,https://ClinicalTrials.gov/show/NCT01500187
917,Mobility Training Using a Bionic Knee Orthosis in Patients Chronic Post-Stroke: A Case Series,Completed,Has Results,Stroke,Device: Tibion Bionic Leg,"Tibion Bionics, Inc.|University of California, San Francisco","Tibion Bionics, Inc.","University of California, San Francisco",,,,,,Phase 4,Industry|Other,Interventional,6/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01499862
918,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: Rolapitant|Drug: Granisetron|Drug: dexamethasone|Drug: Placebo,"Tesaro, Inc.","Tesaro, Inc.",,,,,,,Phase 3,Industry,Interventional,2/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01499849
919,Long Term Safety Protocol for the AcrySof CACHET Phakic Lens,Completed,Has Results,Myopia,Device: ACRYSOF CACHET Phakic Lens (L-series),Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,11/21/2011,6/15/2018,https://ClinicalTrials.gov/show/NCT01497067
920,Tympanostomy Tube Placement in Children in the Office (Inova Study),Completed,Has Results,Otitis Media,Device: Tube Delivery System (TDS),Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,12/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01496287
921,Tecemotide (L-BLP25) in Prostate Cancer,Completed,Has Results,Prostate Cancer,Radiation: Radiation therapy|Drug: Goserelin|Drug: Cyclophosphamide|Drug: Tecemotide (L-BLP25),EMD Serono|National Cancer Institute (NCI),EMD Serono,National Cancer Institute (NCI),,,,,,Phase 2,Industry|NIH,Interventional,10/24/2011,11/25/2016,https://ClinicalTrials.gov/show/NCT01496131
922,Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentinal Sensitivity|Hypersensitivity,Drug: Test Toothpaste|Drug: Negative Control Toothpaste,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01494649
923,Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate),Completed,Has Results,COPD,"Drug: Perforomist-Placebo|Drug: Perforomist, nebulization, COPD",Dey,Dey,,,,,,,Phase 4,Industry,Interventional,3/12/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01488019
924,"Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia",Completed,Has Results,Primary Erythromelalgia|Inherited Erythromelalgia,Drug: XPF-002|Drug: Placebo,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,,,,,,,Phase 1|Phase 2,Industry,Interventional,12/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01486446
925,Accuracy Study of a Non-Invasive Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood Pressure,Completed,Has Results,Blood Pressure,Device: BP monitoring using two methods,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,12/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01485120
926,AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure,Completed,Has Results,Glaucoma,Drug: Brinzolamide 1% and timolol 0.5% fixed combination eye drops,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,5/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01484951
927,Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers,Completed,Has Results,Refractive Error,Device: OPTI-FREE PureMoist,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,2/11/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01484938
928,Lens Wearing Experience and Biocompatibility of a Multi-Purpose Disinfecting Solution (MPDS),Completed,Has Results,Healthy,Device: OPTI-FREE PureMoist multipurpose disinfecting solution,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,6/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01476722
929,Provoked Craving Relief Study by NRT,Completed,Has Results,Smoking Cessation,Drug: nicotine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01476202
930,Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Biological: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01475734
931,Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.,Completed,Has Results,Cataract,Drug: Loteprednol etabonate|Drug: Prednisolones acetate,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,6/13/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT01475643
932,Safety and Tolerability of HSC835 in Patients With Hematological Malignancies,Completed,Has Results,Acute Myelocytic Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Chronic Lymphocytic Leukemia|Marginal Zone Lymphoma|Follicular Lymphomas|Large-cell Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|High Grade Lymphomas|Mantle-cell Lymphoma|Lymphoplasmacytic Lymphoma,Biological: HSC835,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,1/9/2012,10/3/2016,https://ClinicalTrials.gov/show/NCT01474681
933,"Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2|Healthy",Drug: liraglutide-depot|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 1,Industry,Interventional,10/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01473953
934,A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz,Completed,Has Results,Healthy,Drug: efavirenz|Drug: fenofibric acid 105 mg,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,11/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01472380
935,A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis,Completed,Has Results,"Conjunctivitis, Allergic",Drug: alcaftadine 0.25% ophthalmic solution|Drug: olopatadine 0.2% ophthalmic solution|Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,10/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01470118
936,Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine,Completed,Has Results,Healthy,Drug: sulfamethoxazole + MMX placebo|Drug: Sulfamethoxazole + MMX Mesalazine/mesalamine,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,11/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01469637
937,Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving,Completed,Has Results,Smoking|Smoking Cessation,Drug: Nicotine lower dose|Drug: Nicotine higher dose|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01466361
938,Study of an Investigational Glucose Meter System,Completed,Has Results,Diabetes,Device: Apollo Evolution Investigational BG Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01466075
939,A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator,Completed,Has Results,Hypogonadal Males,Drug: Testosterone Gel (FE 999303),Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01464879
940,Comparative Study of Two Marketed 1-day Soft Contact Lenses,Completed,Has Results,Myopia,Device: ocufilcon D|Device: ocufilcon B,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01464255
941,Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use,Completed,Has Results,Obstructive Sleep Apnea|Central Sleep Apnea (Diagnosis)|Chronic Opioid Use,Device: Adaptive servo-ventilation (ASV)|Device: Bi-Level PAP,ResMed,ResMed,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01462084
942,TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides,Completed,Has Results,Wrinkles|Rhytides,Device: TriActive+ RF,"Deka Medical, Inc.","Deka Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01460927
943,A Study to Evaluate the Effect of Clarithromycin on LY2216684,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684|Drug: Clarithromycin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01460407
944,A Study to Evaluate the Effect of Genotype on LY2216684,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684|Drug: Quinidine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01460381
945,A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2409021|Drug: Placebo|Drug: Moxifloxacin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01460368
946,"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",Completed,Has Results,Dry Eye Syndromes,Drug: Carboxymethylcellulose Based Eye Drop Formulation A|Drug: Carboxymethylcellulose Based Eye Drop Formulation B|Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Drug: Carboxymethylcellulose Based Lubricant Eye Drops,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,10/1/2011,2/15/2012,https://ClinicalTrials.gov/show/NCT01459588
947,"A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease",Completed,Has Results,Multiple Myeloma|Non-hodgkin's Lymphoma|Hodgkin's Disease,Drug: TG-0054,"TaiGen Biotechnology Co., Ltd.","TaiGen Biotechnology Co., Ltd.",,,,,,,Phase 2,Industry,Interventional,10/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01458288
948,A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Ortho-Cyclen|Biological: Dulaglutide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01458210
949,Safety and Efficacy of AL-53817 Nasal Spray Solution,Completed,Has Results,Nasal Allergies|Allergies,Drug: AL-53817 nasal spray solution|Other: Vehicle nasal spray,Alcon Research,Alcon Research,,,,,,,Phase 1,Industry,Interventional,10/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01454505
950,Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma,Completed,Has Results,Nonhematologic Malignancies|Lymphoma,Drug: Ixazomib 2.5 mg|Drug: Ixazomib 4 mg Capsule A|Drug: Ixazomib 4 mg Capsule B|Drug: Ketoconazole|Drug: Rifampin|Drug: Clarithromycin,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,11/10/2011,6/16/2016,https://ClinicalTrials.gov/show/NCT01454076
951,A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration,Completed,Has Results,Opioid Dependence,Drug: VIVITROL 380mg,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 4,Industry,Interventional,1/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01453374
952,"Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study",Completed,Has Results,Asthma,Drug: Fluticasone Furoate|Drug: Fluticasone Furoate/Vilanterol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01453023
953,The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy,Completed,Has Results,Anesthesia|Neuromuscular Blockade,Drug: Saline 0.06 ml/kg|Drug: Rocuronium 0.2 mg/kg|Drug: Rocuronium 0.4 mg/kg|Drug: Rocuronium 0.6 mg/kg,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01450813
954,The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions,Completed,Has Results,Post-operative Complications|Surgical Site Infection|Surgical Wound Infection,Device: Prevena™ Incision Management System (PIMS)|Device: Standard-of-care Dressing,"KCI USA, Inc.","KCI USA, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01450631
955,A Study of LY2484595 in Healthy Subjects,Completed,Has Results,Healthy Volunteers,Drug: LY2484595 Reference Formulation (RF)|Drug: LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01450098
956,A Study of LY3031207 in Healthy Subjects,Completed,Has Results,Healthy Volunteers,Drug: LY3031207|Drug: Placebo|Drug: Celecoxib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/24/2011,4/2/2012,https://ClinicalTrials.gov/show/NCT01449630
957,Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence,Completed,Has Results,Hypotrichosis,Drug: bimatoprost ophthalmic solution 0.03%|Drug: bimatoprost vehicle solution,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,10/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01448525
958,User Study of an Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: Tatsu/Tradewind Investigational BG Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01447121
959,Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy,Completed,Has Results,Carotid Artery Disease|Stroke|Amaurosis Fugax|Transient Ischemic Attack (TIA),Device: RX Acculink Carotid Stent System (RX Acculink),Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,10/11/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01445613
960,inVENT-visIOn Study,Completed,Has Results,Otitis Media,Device: Tympanostomy tube placement (Acclarent iontophoresis device),Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,10/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01444391
961,Absolute Pro® MOMENTUM™,Completed,Has Results,Peripheral Artery Disease|Peripheral Vascular Disease,Device: Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,10/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01444378
962,Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine,Completed,Has Results,Healthy,Drug: Amoxicillin + MMX placebo|Drug: Amoxicillin + MMX mesalazine/mesalamine,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,10/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01442688
963,Clinical Utility of a New Silver Gel for Use on Chronic Wounds,Completed,Has Results,Chronic Wounds,Device: Normlgel Ag,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01442103
964,IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer,Completed,Has Results,Merkel Cell Carcinoma,Biological: Tavokinogene Telseplasmid (tavo)|Device: OncoSec Medical System (OMS),OncoSec Medical Incorporated|National Cancer Institute (NCI),OncoSec Medical Incorporated,National Cancer Institute (NCI),,,,,,Phase 2,Industry|NIH,Interventional,1/3/2012,4/10/2015,https://ClinicalTrials.gov/show/NCT01440816
965,"Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb",Completed,Has Results,Rheumatoid Arthritis,Biological: Abatacept (BMS-188667),Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,10/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01439204
966,A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Digoxin|Biological: Dulaglutide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,9/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01436201
967,Intravenous Tapentadol in Post-Bunionectomy Pain,Completed,Has Results,Bunion|Pain,Drug: Tapentadol|Drug: Matching Placebo,Grünenthal GmbH,Grünenthal GmbH,,,,,,,Phase 2,Industry,Interventional,9/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01435577
968,"EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions",Completed,Has Results,Coronary Artery Disease (CAD)|Chronic Total Occlusion (CTO),Device: CTO Treatment Device,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT01435031
969,A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: dulaglutide|Drug: Warfarin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,9/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01432938
970,Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion,Completed,Has Results,Stenosis|Spondylosis|Degenerative Changes,Device: Demineralized Bone Matrix|Device: rh-BMP2,"SeaSpine, Inc.","SeaSpine, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/11/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01430299
971,Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,9/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01430169
972,Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE),Completed,Has Results,Hypertrophic,Device: embrace device,"Neodyne Biosciences, Inc.","Neodyne Biosciences, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01430130
973,A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet,Completed,Has Results,Sickle Cell Disease,Drug: Prasugrel (clinical formulation)|Drug: Prasugrel (Orally Disintegrating Tablet [ODT]),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,9/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01430091
974,Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression,Completed,Has Results,Ocular Comfort,Device: Lotrafilcon A test contact lens|Device: Lotrafilcon A control contact lens|Device: Ultra-High Resolution Optical Coherence Tomographer (OCT),CIBA VISION|Bascom Palmer Eye Institute|Alcon Research,CIBA VISION,Bascom Palmer Eye Institute,Alcon Research,,,,,Not Applicable,Industry|Other,Interventional,8/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01423773
975,Ultherapy™ Treatment Following Sculptra® Treatment,Completed,Has Results,Skin Laxity,Device: Ulthera® System|Drug: Sculptra®|Other: Sculptra® treatment followed by Ultherapy™ treatment,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,5/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01422538
976,Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin,Completed,Has Results,Healthy,Drug: Pitavastatin (NK-104)|Drug: Diltiazem (Cardizem LA) 240 mg QD,"Kowa Research Institute, Inc.","Kowa Research Institute, Inc.",,,,,,,Phase 4,Industry,Interventional,5/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01422382
977,Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin,Completed,Has Results,Healthy,Drug: Pitavastatin (NK-104)|Drug: Darunavir/Ritonavir (Prezista),"Kowa Research Institute, Inc.","Kowa Research Institute, Inc.",,,,,,,Phase 4,Industry,Interventional,4/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01422369
978,Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy,Completed,Has Results,Obstructive Sleep Apnea,Device: S9 Elite with Acclimate|Device: S9 Elite,ResMed,ResMed,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01421654
979,Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine,Completed,Has Results,Healthy,Drug: Metronidazole + MMX Mesalazine/mesalamine placebo|Drug: Metronidazole + MMX Mesalazine/mesalamine,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,8/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01418365
980,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults,Completed,Has Results,Influenza,"Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/12/2011,9/28/2012,https://ClinicalTrials.gov/show/NCT01416571
981,A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens,Completed,Has Results,Myopia,Device: PureVision2 HD contact lenses|Device: Spectacles,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,7/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01416142
982,A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens,Completed,Has Results,Myopia,Device: Bausch & Lomb Test lens|Device: Ciba Vision soft contact lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,8/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01412983
983,Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale,Completed,Has Results,Healthy Volunteers,Drug: No Intervention,Allergan,Allergan,,,,,,,,Industry,Observational,8/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01412086
984,Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO),Completed,Has Results,Retinal Vein Occlusion|Macular Edema,Drug: dexamethasone intravitreal implant 0.7 mg,Allergan,Allergan,,,,,,,,Industry,Observational,7/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01411696
985,User Performance Evaluation of an Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: Ninja 2 Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,7/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01410773
986,Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects,Completed,Has Results,HIV,"Drug: Atazanavir (current formulation)|Drug: Atazanavir, powder for oral use 1 (POU1)|Drug: Atazanavir (POU2)",Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,8/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01404572
987,Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine,Completed,Has Results,Healthy,Drug: Ciprofloxacin XR + MMX Placebo|Drug: MMX Mesalazine/mesalamine + Ciprofloxacin XR,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,7/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01402947
988,VISIBILITY™ Iliac Study,Completed,Has Results,Peripheral Arterial Disease|Claudication,Device: Visi-Pro™ Balloon Expandable Stent System,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,7/11/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01402700
989,A Bioavailability Study of LY2452473 and Tadalafil,Completed,Has Results,Erectile Dysfunction,Drug: LY2452473|Drug: Tadalafil|Drug: LY900010,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01401543
990,DURABILITY™ Iliac Study,Completed,Has Results,Peripheral Arterial Disease|Claudication,"Device: Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.",Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,7/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01400919
991,Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability,Completed,Has Results,Pregnancy,,"Convergent Engineering, Inc.","Convergent Engineering, Inc.",,,,,,,,Industry,Observational,7/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01400880
992,Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery,Completed,Has Results,Peripheral Vascular Disease,Device: Omnilink Elite™ Peripheral Balloon-Expandable Stent System,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 3,Industry,Interventional,3/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01396525
993,Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients,Completed,Has Results,Duchenne Muscular Dystrophy,Drug: AVI-4658 (Eteplirsen)|Other: Placebo,"Sarepta Therapeutics, Inc.","Sarepta Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,7/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01396239
994,Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations,Completed,Has Results,Pharmacokinetic Study in Healthy Participants,Drug: Dasatinib as tablets|Drug: Dasatinib as liquid|Drug: Dasatinib as dispersed tablets,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,7/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01392703
995,Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines,Completed,Has Results,Glabellar Frown Lines,Biological: botulinum toxin Type A|Drug: normal saline (placebo),Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,6/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01391312
996,Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor,Completed,Has Results,Primary Open Angle Glaucoma|Healthy Subjects,Device: SENSIMED Triggerfish,Sensimed AG,Sensimed AG,,,,,,,Not Applicable,Industry,Interventional,7/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01390779
997,A Study to Evaluate the Effect of Food on LY2216684,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01389765
998,A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684|Drug: Activated Charcoal,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01389752
999,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,Completed,Has Results,"Pain, Postoperative","Drug: Naproxen Sodium ER (BAYH6689)|Drug: Naproxen Sodium IR (Aleve, BAYH6689)|Drug: Naproxen Sodium ER Placebo|Drug: Naproxen Sodium IR Placebo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,6/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01389284
1000,Does the Aid of MelaFind Affect Clinical Management Decisions,Completed,Has Results,Melanoma,,"MELA Sciences, Inc.","MELA Sciences, Inc.",,,,,,,,Industry,Observational,10/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01387581
1001,A Study of LY2216684 in Healthy Participants,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo-matching LY2216684|Drug: Placebo-matching alcoholic beverage|Drug: Alcoholic beverage,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01380691
1002,Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users,Completed,Has Results,"Nondependent Opioid Abuse, Episodic","Drug: Placebo|Drug: MS Contin (morphine sulfate, controlled release)|Drug: EMBEDA (morphine sulfate / naltrexone hydrochloride)",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/11/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01380093
1003,Endurant Stent Graft System Post Approval Study (ENGAGE PAS),Completed,Has Results,"Aortic Aneurysm, Abdominal",Device: Endurant Stent Graft System,Medtronic Endovascular|Duke Clinical Research Institute,Medtronic Endovascular,Duke Clinical Research Institute,,,,,,Not Applicable,Industry|Other,Interventional,8/11/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT01379222
1004,Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months,Completed,Has Results,Sedation|Pain,Drug: Dexmedetomidine,"Hospira, now a wholly owned subsidiary of Pfizer","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,,Phase 2,Industry,Interventional,6/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01378988
1005,Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome,Completed,Has Results,Leukemia,Drug: Decitabine (Dacogen),Eisai Inc.,Eisai Inc.,,,,,,,Phase 1,Industry,Interventional,4/5/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT01378416
1006,iCare Stress Management e-Training for Dementia Family Caregivers,Completed,Has Results,Alzheimer's Disease|Dementia,Behavioral: CBT-based program for dementia caregivers|Behavioral: Educational/Resources program,"Photozig, Inc.|Stanford University|National Institute on Aging (NIA)","Photozig, Inc.",Stanford University,National Institute on Aging (NIA),,,,,Phase 2,Industry|Other|NIH,Interventional,5/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01378195
1007,Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers,Completed,Has Results,Healthy,Drug: AG200-15,Agile Therapeutics,Agile Therapeutics,,,,,,,Phase 1,Industry,Interventional,5/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01375946
1008,"3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease",Completed,Has Results,Alzheimer's Disease,Drug: MSDC-0160|Drug: Placebo,Metabolic Solutions Development Company,Metabolic Solutions Development Company,,,,,,,Phase 2,Industry,Interventional,7/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01374438
1009,A Study of LY2216684 in Healthy Females,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684|Drug: Ortho Cyclen|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01373931
1010,Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging,Completed,Has Results,Breast Cancer,Device: SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM,Siemens Medical Solutions USA - CSG,Siemens Medical Solutions USA - CSG,,,,,,,Not Applicable,Industry,Interventional,5/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01373671
1011,Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Device: NIOV - Room Air|Device: NIOV - Oxygen|Device: Nasal Cannula Oxygen,"Breathe Technologies, Inc.","Breathe Technologies, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01372462
1012,"Efficacy, Pharmacokinetics and Safety of Testosterone",Completed,Has Results,Testicular Hypogonadism,Drug: Testosterone gel (FE 99903),Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01370369
1013,MyoSure Hysteroscopic Tissue Removal System Registry Study,Completed,Has Results,Uterine Fibroids|Polyps,Device: MyoSure Tissue Removal System,"Hologic, Inc.","Hologic, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01369758
1014,A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Prednisolone|Drug: dipyridamole|Drug: Prednisone|Drug: Z102|Other: placebo,Zalicus,Zalicus,,,,,,,Phase 2,Industry,Interventional,6/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01369745
1015,Clinical Study on a New Flowable Composite as a Restorative in Adult Teeth,Completed,Has Results,Dental Caries,Device: Flowable composite|Device: Conventional composite restorative,3M,3M,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01369108
1016,Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Completed,Has Results,Pain|Inflammation|Cataract,Drug: Bromfenac Ophthalmic Solution|Drug: Placebo,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,5/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01367249
1017,Analysis of ROM Plus to Detect Rupture of Membranes,Completed,Has Results,Rupture of Amniotic Membranes,Procedure: Sterile speculum exam|Procedure: ROM Plus Exam|Procedure: Chart Reveiw,"Clinical Innovations, LLC|Midwestern University|The Reading Hospital and Medical Center|University of Utah","Clinical Innovations, LLC",Midwestern University,The Reading Hospital and Medical Center|University of Utah,The Reading Hospital and Medical Center,University of Utah,,,,Industry|Other,Observational,9/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01366443
1018,Topical Antimicrobial Effectiveness Testing,Completed,Has Results,Antimicrobial Effectiveness,Drug: ChloraPrep One-Step|Drug: 70% isopropyl alcohol,CareFusion,CareFusion,,,,,,,Phase 4,Industry,Interventional,5/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01366417
1019,Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone|Drug: Placebo,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,6/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01366209
1020,Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects,Completed,Has Results,Healthy Subjects,Drug: Ketorolac tromethamine,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 1,Industry,Interventional,2/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT01365624
1021,Safety and Efficacy of a Contact Lens for Daily Disposable Use,Completed,Has Results,Myopia,"Device: Test, daily disposable contact lens|Device: SofLens daily disposable contact lens",Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,6/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01365039
1022,Safety Study of MotifMESH (cPTFE) in Abdominal Surgery,Completed,Has Results,Hernia,Device: MotifMESH,Medline Industries,Medline Industries,,,,,,,Not Applicable,Industry,Interventional,5/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01364233
1023,The Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years,Completed,Has Results,Postoperative Pain,Drug: Ketorolac Tromethamine,Egalet Ltd,Egalet Ltd,,,,,,,Phase 1,Industry,Interventional,6/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT01363076
1024,Ibuprofen Sodium Tension Headache Study,Completed,Has Results,Pain,Drug: Ibuprofen Sodium|Drug: Standard Ibuprofen|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01362491
1025,Treatment of Lower Extremity Spider Veins With Excel V,Completed,Has Results,Telangiectasis|Spider Veins,"Device: 532 nm KTP Excel V Laser, manufactured by Cutera, Inc.",Cutera Inc.,Cutera Inc.,,,,,,,Phase 4,Industry,Interventional,5/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01362192
1026,Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients,Completed,Has Results,Non-melanoma Skin Cancer,Biological: HP802-247|Biological: Bacitracin Ointment,Healthpoint,Healthpoint,,,,,,,Phase 2,Industry,Interventional,5/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01359735
1027,A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine,Completed,Has Results,Cancer,Drug: LY2603618|Drug: Desipramine|Drug: Pemetrexed|Drug: Gemcitabine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01358968
1028,Adhesive Tape Trauma Evaluation of Two Gentle Tapes,Completed,Has Results,Adhesive Tape Trauma,Device: Skin Trauma,3M,3M,,,,,,,Not Applicable,Industry,Interventional,5/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01354106
1029,Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy,Completed,Has Results,Allergy,Biological: Short Ragweed Pollen Allergenic Extract|Biological: Placebo,Greer Laboratories,Greer Laboratories,,,,,,,Phase 3,Industry,Interventional,4/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01353079
1030,Safety for Frequent Use Conditions of Hair Removal Device,Completed,Has Results,Hair Removal,Device: Hair2Go (Mē),Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,3/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01348789
1031,In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive|Airflow Obstruction, Chronic|Chronic Obstructive Airway Disease|Chronic Obstructive Lung Disease",Device: NIOV System|Device: Standard Oxygen Cannula,"Breathe Technologies, Inc.","Breathe Technologies, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01347931
1032,A Study of the Relief of Tooth Sensitivity of an Experimental Mouthrinse Device,Completed,Has Results,Dentin Sensitivity,Device: Mouthwash|Drug: Potassium nitrate toothpaste|Drug: Sodium fluoride toothpaste,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,4/11/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01345292
1033,Supporting Decision Making for Musculoskeletal Preference-Sensitive Care,Completed,Has Results,Knee Pain Chronic|Arthritis (Hip)|Arthritis (Knee)|Back Pain,Behavioral: Provision of condition specific shared decision making (SDM) aids only|Behavioral: Telephonic outreach and support by Health Coach,"Health Dialog|Foundation for Informed Medical Decision Making|University of Massachusetts, Boston",Health Dialog,Foundation for Informed Medical Decision Making,"University of Massachusetts, Boston",,,,,Not Applicable,Industry|Other,Interventional,1/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01345123
1034,Reducing Preterm Births in Underserved Pregnant Women,Completed,Has Results,Preterm Birth|Low Birth Weight <2500 Grams|Verylow Birthweight <1500 Grams,Behavioral: lifestyle support,PHCC LP,PHCC LP,,,,,,,Phase 2,Industry,Interventional,8/10/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01344616
1035,Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions,Completed,Has Results,Healthy,Drug: Norethindrone/Ethinyl Estradiol|Drug: FEMCON® Fe,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,8/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT01344369
1036,Effect of FID 114675A on Lens Wettability,Completed,Has Results,Contact Lens Wettability,Device: FID 114675A multi-purpose disinfecting solution (MPDS)|Device: Soft contact lens|Device: Blister pack solution,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01342107
1037,Effect of an Investigational Multi-Purpose Solution on Lens Moisture,Completed,Has Results,Contact Lens Moisture,Device: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Device: ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Device: Silicone Hydrogel Contact Lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT01341990
1038,Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution,Completed,Has Results,Healthy Contact Lens Wearers,Device: Alcon MPDS|Device: ReNu Fresh MPS,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01341977
1039,A Study of LY2495655 in Healthy Subjects,Completed,Has Results,Healthy Volunteer,Drug: LY2495655|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,5/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01341470
1040,Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,,Rocky Mountain Diabetes and Osteoporosis Center,Rocky Mountain Diabetes and Osteoporosis Center,,,,,,,,Industry,Observational,4/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01341067
1041,Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions,Completed,Has Results,Bioequivalence,Drug: Norethindrone/Ethinyl Estradiol|Drug: Ovcon® 35 Fe,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,12/6/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT01340625
1042,Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis,Completed,Has Results,End Stage Renal Disease,Drug: Apixaban,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,6/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01340586
1043,Drug Drug Interaction of BI 201335 and Tenofovir,Completed,Has Results,HIV Infections,Drug: tenofovir/BI 201335,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,4/11/2019,,https://ClinicalTrials.gov/show/NCT01340196
1044,A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects,Completed,Has Results,Healthy,Drug: 5 mg/N6022|Drug: Placebo|Drug: 10mg/N6022|Drug: 20mg/N6022,"Nivalis Therapeutics, Inc.","Nivalis Therapeutics, Inc.",,,,,,,Phase 1,Industry,Interventional,4/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01339897
1045,ESBA105 in Patients With Severe Dry Eye,Completed,Has Results,Eyes Dry Chronic,Biological: ESBA105 ophthalmic solution|Other: ESBA105 vehicle,Alcon Research,Alcon Research,,,,,,,Phase 2,Industry,Interventional,6/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01338610
1046,Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy,Completed,Has Results,Hearing Loss,Device: cochlear implant,Cochlear,Cochlear,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01337076
1047,Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol,Completed,Has Results,Glaucoma,Drug: Travoprost 0.004%/timolol maleate 0.5% fixed combination,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,2/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01336569
1048,A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand,Completed,Has Results,Corneal Staining,Other: Multipurpose Solution #1|Other: Multipurpose Solution #2|Other: Mutlipurpose Solution #3|Other: Multipurpose Solution #4,"Jennifer Streza|Coopervision, Inc.",Jennifer Streza,"Coopervision, Inc.",,,,,,Phase 4,Industry,Interventional,8/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01335750
1049,Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001),Completed,Has Results,HIV Infections,Biological: TUTI-16 (1.0 mg)|Other: Placebo,"Thymon, LLC","Thymon, LLC",,,,,,,Phase 1|Phase 2,Industry,Interventional,6/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01335191
1050,Simulated Driving Study in Restless Legs Syndrome,Completed,Has Results,Restless Legs Syndrome,Drug: XP13512|Drug: Diphenhydramine|Drug: Placebo,"XenoPort, Inc.","XenoPort, Inc.",,,,,,,Phase 2,Industry,Interventional,4/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT01332318
1051,Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome,Completed,Has Results,Restless Legs Syndrome,Drug: GEn (XP13512/GSK1838262)|Drug: Placebo,"XenoPort, Inc.","XenoPort, Inc.",,,,,,,Phase 2,Industry,Interventional,1/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT01332305
1052,Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model,Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.05%|Drug: AC-170 0.1%|Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.","Aciex Therapeutics, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,4/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01332188
1053,Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial,Completed,Has Results,Diabetes,Device: Contour Link Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01328717
1054,"Hemodynamic Effects of Standard Cardiopulmonary Resuscitation (CPR), Active Compression Decompression CPR With an Inspiratory Impedance Device, and Standard CPR With an Intrathoracic Pressure Regulator During Out-of-hospital Cardiac Arrest",Completed,Has Results,Cardiac Arrest|Sudden Cardiac Death,Device: ACD-CPR|Device: ITPR|Procedure: S-CPR|Device: Impedance Threshold Device (ITD),"Advanced Circulatory Systems|National Heart, Lung, and Blood Institute (NHLBI)",Advanced Circulatory Systems,"National Heart, Lung, and Blood Institute (NHLBI)",,,,,,Not Applicable,Industry|NIH,Interventional,3/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01325870
1055,inVENT-In-Office Study,Completed,Has Results,Otitis Media,Device: Acclarent Tympanostomy Tube Delivery system (TTDS),Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01324271
1056,Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis,Completed,Has Results,Allergic Conjunctivitis,Drug: SPARC1102 I|Drug: SPARC1102 II|Drug: SPARC1102 III|Drug: Vehicle,Sun Pharma Advanced Research Company Limited,Sun Pharma Advanced Research Company Limited,,,,,,,Phase 2,Industry,Interventional,6/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01320553
1057,Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye,Completed,Has Results,Dry Eye Syndromes,Drug: cyclosporine ophthalmic emulsion Formulation A|Drug: cyclosporine ophthalmic emulsion Formulation B|Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|Drug: cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B,Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,11/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01319773
1058,SENSIMED Triggerfish Safety and Tolerability,Completed,Has Results,Glaucoma,Device: SENSIMED Triggerfish,Sensimed AG,Sensimed AG,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01319617
1059,Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy,Completed,Has Results,Vitrectomy,Procedure: Pars Plana Vitrectomy,Allergan,Allergan,,,,,,,,Industry,Observational,3/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01319318
1060,Nepafenac 0.3% Two Study,Completed,Has Results,Cataract,"Drug: Nepafenac Ophthalmic Suspension, 0.3%|Drug: Nepafenac Ophthalmic Suspension, 0.1%|Other: Nepafenac Vehicle 0.3%",Alcon Research,Alcon Research,,,,,,,Phase 2,Industry,Interventional,3/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01318499
1061,Topical Antimicrobial Effectiveness Testing,Completed,Has Results,Antimicrobial Effectiveness,Drug: ChloraPrep One-Step|Drug: 70% isopropyl alcohol,CareFusion,CareFusion,,,,,,,Phase 4,Industry,Interventional,3/11/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01314703
1062,A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products,Completed,Has Results,Acne Vulgaris,Drug: Dapsone plus Tretinoin Gel|Drug: Tretinoin Gel,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 4,Industry,Interventional,12/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01313728
1063,Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin,Completed,Has Results,Surgical Site Infection,"Drug: mupirocin calcium ointment, 2%|Drug: Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation",3M|New York University,3M,New York University,,,,,,Phase 4,Industry|Other,Interventional,3/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01313182
1064,A Study to Evaluate a New Silicone Hydrogel Contact Lens,Completed,Has Results,Myopia,Device: Investigational Lens|Device: Air Optix Aqua lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01309893
1065,Evaluation of a New Silicone Hydrogel Contact Lens,Completed,Has Results,Myopia,Device: Test lens|Device: Air Optix Aqua,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01309880
1066,Product Feasibility of a New Silicone Hydrogel Contact Lens,Completed,Has Results,Myopia,Device: Investigational Lens|Device: Acuvue Oasys Lens|Device: Air Optix Aqua Lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,11/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01309100
1067,Adult Normative Performance of the Quotient ADHD System,Completed,Has Results,ADHD,,BioBehavioral Diagnostics Company,BioBehavioral Diagnostics Company,,,,,,,,Industry,Observational,3/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01308450
1068,Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids,Completed,Has Results,Hemorrhoids,Device: EEA Hemorrhoid and Prolapse Stapling Set|Device: Endosurgery Proximate PPH03 Stapling Set,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01306877
1069,Safety of SonoVue on Pulmonary Hemodynamics,Completed,Has Results,Pulmonary Hypertension,Drug: SonoVue|Drug: Placebo,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 2,Industry,Interventional,4/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01306292
1070,A Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite,Completed,Has Results,Hernia,,C. R. Bard,C. R. Bard,,,,,,,,Industry,Observational,8/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01305473
1071,Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study,Completed,Has Results,Diabetic Macular Edema,Drug: Fluocinolone Acetonide,Alimera Sciences,Alimera Sciences,,,,,,,Phase 3,Industry,Interventional,4/11/2019,,https://ClinicalTrials.gov/show/NCT01304706
1072,Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers,Completed,Has Results,Healthy,Drug: Aggrenox alone|Drug: Aggrenox and omeprazole|Drug: Omeprazole alone,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,3/11/2019,,https://ClinicalTrials.gov/show/NCT01303445
1073,A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.,Completed,Has Results,"Diabetes Mellitus, Type II",Biological: LY2189265,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01301092
1074,Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults,Completed,Has Results,Healthy,Drug: Vortioxetine|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,3/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01299805
1075,Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects,Completed,Has Results,Healthy Volunteers,Drug: LY3009104,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/11/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01299285
1076,Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial Wrinkles,Completed,Has Results,Appearance of Facial Wrinkles,Device: Pelleve Wrinkle Treatment System,Ellman International,Ellman International,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01299103
1077,Prospective Pellevé™ Neck Wrinkle Study,Completed,Has Results,Facial and Neck Rhytides,Device: Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator,Ellman International,Ellman International,,,,,,,Not Applicable,Industry,Interventional,11/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01299090
1078,Novel Non-Invasive Monitoring Parameter in Healthy Volunteers,Completed,Has Results,No Conditions|Focus is Respiratory Rate,,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,2/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01294514
1079,Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry,Completed,Has Results,Heart Failure,Device: MADIT-CRT ICD|Device: MADIT-CRT CRT-D,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,,Industry,Observational,3/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01294449
1080,Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: AGN-210669|Drug: bimatoprost|Drug: bimatoprost vehicle,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,4/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01291108
1081,Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women,Completed,Has Results,Iron Deficiency Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Iron Sucrose / Iron Dextran,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 2,Industry,Interventional,8/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01290315
1082,This Is A Study Of Bioavailability And Food Effect For Fesoterodine.,Completed,Has Results,"Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency",Drug: fesoterodine,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,12/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01286454
1083,Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study),Completed,Has Results,Cervical Ripening|Induction of Labor,Drug: MVI 200,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01283022
1084,Hair Count Reduction Verification Study With the LightSheer Duet HS Handpiece,Completed,Has Results,Hair Removal,Device: LightSheer Duet,Lumenis Ltd.,Lumenis Ltd.,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01282866
1085,Assessment of Alcon's Ocular Image Quantification System,Completed,Has Results,Allergic Conjunctivitis,"Drug: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|Other: Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)",Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,12/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01282138
1086,TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation,Completed,Has Results,Paroxysmal Atrial Fibrillation,Device: Catheter ablation to treat paroxysmal atrial fibrillation,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01278953
1087,Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates,Completed,Has Results,Heart Failure,Procedure: 3D echo-guided LV lead placement,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,8/10/2019,,https://ClinicalTrials.gov/show/NCT01278030
1088,Study of the Use of Low Level Laser Therapy to Reduce Acne,Completed,Has Results,Acne,Device: Erchonia MLS + Erchonia THL,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,3/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01276535
1089,Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients,Completed,Has Results,Dry Eye Disease,Drug: Difluprednate 0.05% ophthalmic emulsion|Other: Difluprednate vehicle,Alcon Research,Alcon Research,,,,,,,Phase 2,Industry,Interventional,2/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01276223
1090,"Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)",Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin aspart|Drug: Recombinant human hyaluronidase PH20 (rHuPH20),Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 1,Industry,Interventional,1/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01275131
1091,Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements,Completed,Has Results,Edematous|Synovitis|Foreign Body Reaction|Osteolysis,Drug: Placebo|Drug: Apatone®B,IC-MedTech Corporation|Summa Health System|Crystal Clinic Orthopaedic Center LLC,IC-MedTech Corporation,Summa Health System,Crystal Clinic Orthopaedic Center LLC,,,,,Phase 2,Industry|Other,Interventional,10/10/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01272830
1092,Safety Study of a Sensitive Sensual Touch and Personal Lubricant,Completed,Has Results,Inadequate Lubrication,Device: Formula PD-F-7716,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,12/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01271036
1093,Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke,Completed,Has Results,Ischemic Stroke,Device: Mechanical Thrombectomy,Stryker Neurovascular,Stryker Neurovascular,,,,,,,Not Applicable,Industry,Interventional,2/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01270867
1094,Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting,Completed,Has Results,Diabetes,Device: Ninja 2 Investigational Blood Glucose Meter,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01268488
1095,Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting,Completed,Has Results,Diabetes,Device: Ninja 2 Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01268267
1096,A Study of LY2216684 and Digoxin in Healthy Subjects,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Digoxin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01266590
1097,Secretin Infusion for Pain Due to Chronic Pancreatitis,Completed,Has Results,Chronic Pancreatitis,Drug: Human Secretin,"ChiRhoClin, Inc.|Dartmouth-Hitchcock Medical Center","ChiRhoClin, Inc.",Dartmouth-Hitchcock Medical Center,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,12/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01265875
1098,Performance of a New Glucose Meter System,Completed,Has Results,Diabetes,Device: Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01264016
1099,A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: albuterol|Drug: propranolol|Drug: placebo for LY2216684|Drug: placebo for albuterol|Drug: placebo for propranolol,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01263197
1100,A Study of LY2216684 and Warfarin in Healthy Subjects,Completed,Has Results,Major Depressive Disorder,Drug: Warfarin|Drug: LY2216684,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01263119
1101,A Study of LY2216684 and Theophylline in Healthy Subjects,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Theophylline,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01263106
1102,A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel,Completed,Has Results,Major Depressive Disorder,Drug: Clopidogrel|Drug: LY2216684,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01263093
1103,Device to Reduce Surgery Site Contamination - Spine,Completed,Has Results,Surgery,Device: Air Barrier System Device,"Nimbic Systems, LLC","Nimbic Systems, LLC",,,,,,,Not Applicable,Industry,Interventional,11/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01262105
1104,10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Donepezil Hydrochloride|Drug: Aricept®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,4/6/2019,5/6/2019,https://ClinicalTrials.gov/show/NCT01260948
1105,10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.,Completed,Has Results,Healthy,Drug: Donepezil Hydrochloride|Drug: Aricept®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,4/6/2019,5/6/2019,https://ClinicalTrials.gov/show/NCT01260922
1106,A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion,Completed,Has Results,Anesthesia,"Drug: Fospropofol disodium, propofol",Eisai Inc.,Eisai Inc.,,,,,,,Phase 4,Industry,Interventional,11/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01260142
1107,Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole,Completed,Has Results,Healthy,Drug: Buprenorphine transdermal patch|Drug: Ketoconazole tablet|Drug: Placebo to match ketoconazole tablet,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,10/2/2019,6/3/2019,https://ClinicalTrials.gov/show/NCT01259115
1108,Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods,Completed,Has Results,Healthy,Drug: Buprenorphine transdermal patch,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,11/1/2000,3/1/2019,https://ClinicalTrials.gov/show/NCT01259102
1109,The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery,Completed,Has Results,Breast Reconstruction,Device: SERI® Surgical Scaffold,"Sofregen Medical, Inc.","Sofregen Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01256502
1110,U.S. Study of Fibrocaps in Surgical Hemostasis,Completed,Has Results,Postoperative Hemorrhage,Device: Fibrocaps (fibrin sealant)|Device: Gelfoam,Mallinckrodt,Mallinckrodt,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01256164
1111,Study to Determine if Fibrin Affects the Ability of a Wound to Heal,Completed,Has Results,Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray,Biological: Fibrin|Other: White Petrolatum,Healthpoint,Healthpoint,,,,,,,Phase 1,Industry,Interventional,1/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01253135
1112,A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Sertraline,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01250873
1113,Evaluating the Effect of Tooth Cleaning Devices on Oral Health,Completed,Has Results,Dental Plaque,Device: Manual Toothbrush|Device: Interproximal Cleaning Device,Philips Oral Healthcare,Philips Oral Healthcare,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01250769
1114,The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients,Completed,Has Results,Dry Eye,Biological: Secukinumab 10 mg/kg|Biological: Canakinumab 10 mg/kg|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,11/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01250171
1115,"XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study",Completed,Has Results,Angioplasty|Chronic Coronary Occlusion|Stent Thrombosis|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis,Device: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS),Abbott Medical Devices,Abbott Medical Devices,,,,,,,,Industry,Observational,11/10/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01249027
1116,A Study of LY3009104(Baricitinib) for Healthy Subjects,Completed,Has Results,Healthy Volunteer,Drug: LY3009104|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01247350
1117,90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Fluoxetine Hydrochloride|Drug: PROZAC WEEKLY®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,5/1/2019,7/1/2019,https://ClinicalTrials.gov/show/NCT01247285
1118,90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Fluoxetine Hydrochloride|Drug: PROZAC WEEKLY®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,5/1/2019,7/1/2019,https://ClinicalTrials.gov/show/NCT01247272
1119,A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Fluoxetine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01243957
1120,AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol,Completed,Has Results,Healthy,Drug: Ortho-Cyclen|Drug: AG200-15,Agile Therapeutics,Agile Therapeutics,,,,,,,Phase 1,Industry,Interventional,8/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT01243580
1121,"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo",Completed,Has Results,Acne,Drug: Tretinoin|Drug: placebo,Spear Pharmaceuticals,Spear Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01243450
1122,Vasculaire Compression System Increases Flow Velocity in the Femoral Vein,Completed,Has Results,Venous Thrombosis,Device: Pneumatic Compression therapy,"Venous Health Systems, Inc.","Venous Health Systems, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01240330
1123,Short-Term Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions,Completed,Has Results,Corneal Staining,Device: Biotrue MPS|Device: Investigational MPS,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Not Applicable,Industry,Interventional,8/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01240122
1124,Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers,Completed,Has Results,Healthy,Drug: LDX + Venlafaxine XR|Drug: Venlafaxine XR + LDX,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,11/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01235338
1125,A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne,Completed,Has Results,Acne Vulgaris,Drug: Dapsone plus Adapalene|Drug: Clindamycin/benzoyl peroxide plus Adapalene,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,8/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01231334
1126,One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction,Completed,Has Results,Aphakia|Cataract,Device: enVista,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,10/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01230060
1127,ARemind: A Personalized System to Remind for Adherence,Completed,Has Results,Medication Adherence,Device: Beeper|Device: ARemind,Dimagi Inc.|Boston University|Boston Medical Center|Harvard Medical School|National Institute of Mental Health (NIMH),Dimagi Inc.,Boston University,Boston Medical Center|Harvard Medical School|National Institute of Mental Health (NIMH),Boston Medical Center,Harvard Medical School|National Institute of Mental Health (NIMH),Harvard Medical School,National Institute of Mental Health (NIMH),Not Applicable,Industry|Other|NIH,Interventional,10/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01229722
1128,Study of Naproxen Capsules to Treat Dental Pain,Completed,Has Results,Dental Pain,Drug: Naproxen Test|Drug: Naprosyn|Drug: Placebo,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 2,Industry,Interventional,10/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01229228
1129,Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza,Completed,Has Results,Influenza,Drug: Nitazoxanide|Drug: Placebo,Romark Laboratories L.C.,Romark Laboratories L.C.,,,,,,,Phase 2|Phase 3,Industry,Interventional,12/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01227421
1130,A Safety Study of LY2886721 Multiple Doses in Healthy Subjects,Completed,Has Results,Alzheimer's Disease,Drug: LY2886721|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01227252
1131,Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Glargine,Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,10/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01226043
1132,Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension,Completed,Has Results,Intraocular Pressure,Drug: BOL-303259-X|Drug: Latanoprost,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 2,Industry,Interventional,12/13/2010,6/22/2012,https://ClinicalTrials.gov/show/NCT01223378
1133,Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Completed,Has Results,Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,Drug: Cohort 1 CTAP101 Capsules- 60µg|Drug: Cohort 1 CTAP101 Capsules - 90µg|Drug: Cohort 1 Matching Sugar Capsule|Drug: Cohort 2 CTAP101 Capsules - 30µg|Drug: Cohort 2 Matching Sugar Capsule,"OPKO Health, Inc.","OPKO Health, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,10/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01219855
1134,Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL,Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Prolymphocyctic Leukemia|Richter's Transformation,Drug: PCI-32765|Drug: ofatumumab,Pharmacyclics LLC.|Ohio State University,Pharmacyclics LLC.,Ohio State University,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,12/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01217749
1135,Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain,Completed,Has Results,Pain,Drug: Novel Ibuprofen|Drug: Acetaminophen|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01216163
1136,A Phase 1 Study in Patients With Solid Tumors,Completed,Has Results,Solid Tumors,Drug: LY573636|Drug: Pemetrexed,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01215916
1137,Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma,Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|Drug: timolol ophthalmic solution 0.5%|Drug: AGN-207281 vehicle ophthalmic solution (Placebo),Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,10/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01215786
1138,Split Thickness Donor Site Healing With MIST Study,Completed,Has Results,Burns|Trauma|Venous Ulcers,Device: MIST Therapy|Other: Standard of care,"Celleration, Inc.","Celleration, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01214980
1139,A Retrospective Study Evaluating the Use of Permacol Surgical Implant in the Repair of Abdominal Wall Defects,Completed,Has Results,Abdominal Wall Defects,Device: Permacol Surgical Implant,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,10/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01214252
1140,High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Device: Bilevel positive airway pressure (BiPAP),Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,8/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01214200
1141,Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars,Completed,Has Results,Acne Scars,Drug: Adapalene,Galderma,Galderma,,,,,,,Phase 2,Industry,Interventional,3/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01213199
1142,Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers,Completed,Has Results,Myopia|Astigmatism|Refractive Error,Device: OPTI-FREE RepleniSH multipurpose solution|Device: ReNu Biotrue multipurpose solution|Device: Silicone hydrogel contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,9/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01211535
1143,Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Adapalene 0.1% and Benzoyl Peroxide 2.5% gel,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,10/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01209949
1144,"Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation",Completed,Has Results,Severe Hypertriglyceridemia,Drug: Epanova (4 g) and Lovaza (4 g)|Drug: Lovaza (4 g) and Epanova (4 g),AstraZeneca|Radiant Research,AstraZeneca,Radiant Research,,,,,,Phase 2,Industry|Other,Interventional,9/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01208961
1145,Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: Desoximetasone Spray 0.25%|Drug: placebo,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 3,Industry,Interventional,8/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01206660
1146,Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty,Completed,Has Results,Postoperative Pain,Drug: SKY0402 + bupivacaine HCl|Drug: Mid-dose SKY0402 + bupivacaine HCl,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 2,Industry,Interventional,3/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT01206608
1147,Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis,Completed,Has Results,Endogenous Anterior Uveitis,Drug: Difluprednate 0.05% ophthalmic emulsion|Drug: Prednisolone acetate 1.0% ophthalmic suspension,Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,10/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01201798
1148,A Study in Participants With End-Stage Renal Disease,Completed,Has Results,"Kidney Failure, Chronic",Drug: LY2127399,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01200290
1149,TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study,Completed,Has Results,Lumbar Degenerative Disc Disease,Device: TRIUMPH® Lumbar Artificial Disc,Globus Medical Inc,Globus Medical Inc,,,,,,,Not Applicable,Industry,Interventional,9/10/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01198470
1150,Wound Edge Changes Following Treatment With Santyl,Completed,Has Results,Diabetic Foot Ulcers|Diabetic Foot Wounds,Biological: Collagenase Santyl Ointment|Other: Placebo Comparator,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,12/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01197898
1151,Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation,Completed,Has Results,Lip Augmentation,Device: hyaluronic acid gel,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,8/1/2010,6/15/2015,https://ClinicalTrials.gov/show/NCT01197495
1152,"A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters",Completed,Has Results,Anemia|Diabetes|Heart Disease|High Blood Pressure|Hypotension|Metabolic Diseases|Respiratory Diseases,Device: Non invasive peripheral blood monitoring,Cnoga Medical Ltd.,Cnoga Medical Ltd.,,,,,,,Not Applicable,Industry,Interventional,8/10/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01196533
1153,"Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR",Completed,Has Results,Diabetes Mellitus,Drug: saxagliptin|Drug: Glucophage XR|Drug: saxagliptin + metformin XR (FDC tablet),AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,11/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT01192152
1154,"Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)",Completed,Has Results,Diabetes Mellitus,Drug: saxagliptin|Drug: metformin XR|Drug: saxagliptin + metformin XR (FDC tablet),AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,11/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT01192139
1155,A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens,Completed,Has Results,Myopia|Contact Lenses,Device: Bausch & Lomb new daily disposable|Device: Johnson & Johnson Acuvue Moist,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,8/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01192126
1156,Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds,Completed,Has Results,Normal Female Volunteers,Biological: HP802-247,Healthpoint,Healthpoint,,,,,,,Phase 1,Industry,Interventional,9/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01190865
1157,Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding,Completed,Has Results,Menorrhagia,Drug: tranexamic acid,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,8/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01190150
1158,Safety Study for an All-in-One Body and Personal Lubricant,Completed,Has Results,Lubricating Agents,Device: Formula PD-F-7619,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,6/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01189617
1159,Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia,Completed,Has Results,"Alopecia|Alopecia, Androgenetic|Baldness",Drug: bimatoprost Formulation A|Drug: bimatoprost Formulation B|Drug: bimatoprost Formulation C,Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,10/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01189279
1160,"Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics",Completed,Has Results,Asthma|Bronchospasm|Wheezing|Shortness of Breath,"Drug: Epinephrine Inhalation Aerosol, HFA|Drug: Epinephrine Inhalation Aerosol","Amphastar Pharmaceuticals, Inc.","Amphastar Pharmaceuticals, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,8/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01188577
1161,Alcon Multi-Purpose Disinfecting Solution Versus Renu Fresh Multi-Purpose Solution in Symptomatic Contact Lens Wearers,Completed,Has Results,Symptomatic Contact Lens Wearers,Device: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Device: renu fresh Multi-Purpose Solution (MPS)|Device: Contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,7/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01187355
1162,"Determination of the Lowest, Safe and Effective Dose of Proellex",Completed,Has Results,Amenorrhea,Drug: Proellex,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01187043
1163,Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)|Drug: YAZ®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,7/6/2019,8/6/2019,https://ClinicalTrials.gov/show/NCT01182207
1164,Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.,Completed,Has Results,Healthy,Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)|Drug: YAZ®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/6/2019,8/6/2019,https://ClinicalTrials.gov/show/NCT01182194
1165,Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers,Completed,Has Results,Healthy,Drug: Warfarin|Drug: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Drug: Warfarin 5 mg + Pitavastatin 4mg once daily (QD),"Kowa Research Institute, Inc.","Kowa Research Institute, Inc.",,,,,,,Phase 4,Industry,Interventional,7/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01178853
1166,Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial,Completed,Has Results,Overactive Bladder,Drug: trospium chloride|Drug: oxybutynin IR|Drug: oxybutynin IR placebo,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,8/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01178827
1167,Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle,Completed,Has Results,Bacterial Conjunctivitis,Drug: Besivance|Drug: Vehicle,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,6/10/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01175590
1168,A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers,Completed,Has Results,Healthy Volunteer,Drug: oseltamivir [Tamiflu]|Drug: rimantadine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,8/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01172847
1169,Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|Drug: bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01170884
1170,Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure,Completed,Has Results,Hemorrhoid,Device: Hemorrhoidopexy,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,7/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01169311
1171,Cryo-Touch II for the Treatment of Wrinkles,Completed,Has Results,Facial Wrinkles,Device: Cryo-Touch II,"MyoScience, Inc","MyoScience, Inc",,,,,,,Phase 2|Phase 3,Industry,Interventional,7/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01167140
1172,Study to Characterize the Effect of Heparin on Palifermin Activity,Completed,Has Results,Oral Mucositis,Drug: Palifermin|Drug: Heparin,Swedish Orphan Biovitrum,Swedish Orphan Biovitrum,,,,,,,Phase 1,Industry,Interventional,7/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01163097
1173,Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye,Completed,Has Results,Dry Eye,Procedure: Cataract Surgery and Limbal relaxing incision,Allergan,Allergan,,,,,,,,Industry,Observational,5/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01161771
1174,Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation,Completed,Has Results,Cystic Fibrosis,Drug: VX-770|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 2,Industry|Other,Interventional,10/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01161537
1175,Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients,Completed,Has Results,Acne Vulgaris,Drug: Area cleaned with saline water and occluded with Tegaderm|Drug: Area cleaned with saline water|Drug: Area cleaned with Ethyl alcohol solution|Drug: Visonac left on the skin for 24 hours in facial area one|Drug: Visonac wiped off after one hour|Drug: Visonac left on the skin 24 hours in facial area two,Photocure,Photocure,,,,,,,Phase 2,Industry,Interventional,8/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01160848
1176,VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV,Completed,Has Results,Smallpox Vaccine Adverse Reaction,Biological: ACAM2000,Cangene Corporation|Centers for Disease Control and Prevention,Cangene Corporation,Centers for Disease Control and Prevention,,,,,,Phase 3,Industry|U.S. Fed,Interventional,9/13/2010,2/14/2012,https://ClinicalTrials.gov/show/NCT01158157
1177,Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Buprenorphine,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,8/7/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT01157169
1178,Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration,Completed,Has Results,Exudative Age-Related Macular Degeneration,Drug: AL-78898A|Drug: Ranibizumab,Alcon Research,Alcon Research,,,,,,,Phase 2,Industry,Interventional,6/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01157065
1179,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),Completed,Has Results,Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome,Drug: cangrelor P2Y12 (platelet) inhibitor|Drug: Clopidogrel - 300 or 600 mg (study arm)|Drug: Clopidogrel 600 mg post cangrelor,The Medicines Company,The Medicines Company,,,,,,,Phase 3,Industry,Interventional,9/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01156571
1180,Oral Irritation Study of Two Experimental Mouthrinses,Completed,Has Results,Oral Manifestations,Device: Potassium Oxalate without Fluoride|Device: Potassium Oxalate with Fluoride|Device: Active Comparator PO-116-A,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01156376
1181,Clinical Evaluation of Direct Manufactured Prosthetic Sockets,Completed,Has Results,Amputation,Device: Traditional fabricated prosthetic socket|Device: Direct manufactured (DM) prosthetic socket,Ohio Willow Wood|United States Department of Defense,Ohio Willow Wood,United States Department of Defense,,,,,,Phase 2,Industry|U.S. Fed,Interventional,9/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01155024
1182,Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers,Completed,Has Results,Healthy,Drug: crizotinib|Drug: ketoconazole,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01149785
1183,Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Losartan potassium/Hydrochlorothiazide|Drug: Hyzaar®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/4/2019,2/4/2019,https://ClinicalTrials.gov/show/NCT01149486
1184,Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Losartan potassium/Hydrochlorothiazide,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,3/4/2019,4/4/2019,https://ClinicalTrials.gov/show/NCT01149473
1185,Iron Indices and Intravenous Ferumoxytol: Time to Steady State,Completed,Has Results,Iron Deficiency Anemia,Drug: ferumoxytol,"Dialysis Clinic, Inc.","Dialysis Clinic, Inc.",,,,,,,Phase 4,Industry,Interventional,3/10/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01148745
1186,The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers,Completed,Has Results,Healthy Volunteers,Drug: Buprenorphine transdermal patch|Drug: Matching placebo transdermal patch|Drug: Avelox (moxifloxacin hydrochloride) tablet,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,7/4/2019,12/4/2019,https://ClinicalTrials.gov/show/NCT01148537
1187,Safety and Tolerability Study of N6022 in Healthy Subjects,Completed,Has Results,Healthy,Drug: N6022|Drug: Placebo,"Nivalis Therapeutics, Inc.","Nivalis Therapeutics, Inc.",,,,,,,Phase 1,Industry,Interventional,8/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01147406
1188,Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers,Completed,Has Results,Healthy,Drug: crizotinib|Drug: rifampin,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01147055
1189,Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects,Completed,Has Results,HIV Infections,Biological: TUTI-16 (0.2mg)|Biological: TUTI-16 (1.0 mg),"Thymon, LLC","Thymon, LLC",,,,,,,Phase 1|Phase 2,Industry,Interventional,9/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01144026
1190,Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcers,Drug: Santyl|Drug: Tegaderm Hydrogel,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,7/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01143727
1191,Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia,Completed,Has Results,Keratoconus|Post-Refractive Ectasia,Drug: Riboflavin|Device: UVX light,Price Vision Group,Price Vision Group,,,,,,,Phase 2,Industry,Interventional,5/10/2019,8/30/2017,https://ClinicalTrials.gov/show/NCT01143389
1192,Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers,Completed,Has Results,Asthma,Drug: epinephrine inhalation aerosol,"Amphastar Pharmaceuticals, Inc.","Amphastar Pharmaceuticals, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,1/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01143051
1193,Toric Intraocular Lens Following Cataract Surgery,Completed,Has Results,Cataract|Astigmatism,Device: Toric Accommodating Lens|Device: Accommodating Lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01140477
1194,P400 for Stage II-IV Pressure Ulcers in Home and Extended Care,Completed,Has Results,Pressure Ulcers,Device: P400 mattress,Hill-Rom,Hill-Rom,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01139879
1195,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: 0417|Drug: Vehicle of 0417 test product|Drug: Tacrolimus Ointment 0.03%,Fougera Pharmaceuticals Inc.,Fougera Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,1/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT01139450
1196,Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin,Completed,Has Results,Skin Manifestations,Drug: metronidazole 1% gel|Drug: azelaic acid 15% gel,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,6/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01139047
1197,Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin,Completed,Has Results,Skin Manifestations,Drug: metronidazole 1% gel|Drug: azelaic acid 15% gel,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,6/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01139008
1198,Kidney Damage in Patients With Normal eGFR,Completed,Has Results,Coronary Artery Stenosis,Drug: Non ionic contrast media comparator,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 4,Industry,Interventional,12/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01137786
1199,"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo",Completed,Has Results,Acne,Drug: Tretinoin microsphere 0.1%|Drug: Brand Retin-A Micro tretinoin microsphere gel 0.1%|Drug: placebo microsphere gel,Spear Pharmaceuticals,Spear Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01135069
1200,Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model,Completed,Has Results,Allergic Conjunctivitis,Drug: AC-150 Combo|Drug: AC-150A 0.1%|Drug: AC-150B 0.005%|Drug: Vehicle,"Aciex Therapeutics, Inc.","Aciex Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,5/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01134328
1201,Tooth Sensitivity Relief by Two Mouthrinses,Completed,Has Results,Dentin Sensitivity,Device: 12027-019|Device: 12027-020|Device: 12027-021,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,5/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01133379
1202,Feasibility of a New Silicone Hydrogel Lens,Completed,Has Results,Myopia,Device: Investigational contact lens|Device: Acuvue Oasys Contact Lens|Device: Air Optix Aqua,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,5/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01131130
1203,A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens,Completed,Has Results,Myopia,Device: Bausch & Lomb contact lens|Device: Marketed daily disposable contact lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01130974
1204,Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce,Completed,Has Results,Healthy,Drug: Colchicine 0.6 mg tablet,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,5/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01130051
1205,Home Usability of a Nasal Lavage System in Children,Completed,Has Results,Nasal Congestion|Respiratory Tract Infection|Sinusitis|Allergic Rhinitis,Device: Use of an automatic nasal irrigator/aspirator,Aardvark Medical Company,Aardvark Medical Company,,,,,,,,Industry,Observational,7/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT01129765
1206,Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion,Completed,Has Results,Tooth Erosion,Drug: Sodium fluoride|Drug: Sodium monoflurophosphate|Drug: Sterile water,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT01128972
1207,Enamel Remineralization Potential of Dentifrices in Situ,Completed,Has Results,Dental Caries,Drug: NaF|Drug: SnF|Drug: NaMFP,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,11/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01128946
1208,Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers,Completed,Has Results,Pneumococcal Disease,Other: No Intervention,Pfizer|Kaiser Permanente,Pfizer,Kaiser Permanente,,,,,,,Industry|Other,Observational,6/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01128426
1209,Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery,Completed,Has Results,Cataracts|Inflammation,"Drug: Difluprednate ophthalmic emulsion, 0.05%|Drug: Prednisolone acetate ophthalmic suspension, 1.0%",Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,8/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01124045
1210,Bioavailability Study of Colcrys® in Apple Juice,Completed,Has Results,Healthy,Drug: colchicine 0.6 mg tablet,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,5/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01123395
1211,Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth,Completed,Has Results,Healthy Subjects,Drug: 0.12% chlorhexidine mouthrinse|Other: Cosmetic mouthrinse|Other: Sterile water,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/10/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01122862
1212,Evaluation of 3 Intraocular Lenses Following Lens Extraction,Completed,Has Results,Cataract,Device: Crystalens AO|Device: ReSTOR|Device: Tecnis Multifocal IOL,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 4,Industry,Interventional,6/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01122576
1213,Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain,Completed,Has Results,Opioid Induced Bowel Dysfunction,Drug: Naldemedine|Drug: Placebo,Shionogi|Shionogi Inc.,Shionogi,Shionogi Inc.,,,,,,Phase 2,Industry,Interventional,5/19/2010,3/22/2011,https://ClinicalTrials.gov/show/NCT01122030
1214,XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort),Completed,Has Results,Chronic Coronary Occlusion|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis,Device: XIENCE V® EECSS,Abbott Medical Devices,Abbott Medical Devices,,,,,,,,Industry,Observational,7/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01120379
1215,Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis,Completed,Has Results,Allergic Conjunctivitis,"Drug: Dexamethasone 0.1% ophthalmic suspension|Drug: Olopatadine hydrochloride 0.1% ophthalmic solution|Other: Inactive ingredients, used as placebo",Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,3/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01119287
1216,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine,Completed,Has Results,Sleep,Drug: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Drug: Naproxen Sodium 440 mg (BAYH6689)|Drug: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|Drug: Naproxen Sodium 220 mg (BAYH6689)|Drug: DPH 50mg|Drug: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg,Bayer,Bayer,,,,,,,Phase 4,Industry,Interventional,1/8/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT01118273
1217,To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery,Completed,Has Results,Pain,Drug: Acetaminophen|Drug: Placebo Control,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Phase 3,Industry,Interventional,6/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01115673
1218,Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis,Completed,Has Results,Inborn Errors of Bile Acid Synthesis,Drug: Cholic acid,"Retrophin, Inc.","Retrophin, Inc.",,,,,,,Phase 3,Industry,Interventional,4/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01115582
1219,Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: 5% Potassium nitrate|Drug: 2.5% Potassium nitrate|Other: Sterile water,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT01115452
1220,Travoprost Five Day Posology Study,Completed,Has Results,Open-angle Glaucoma (OAG)|Ocular Hypertension,"Drug: Travoprost 0.004%|Drug: Travoprost Vehicle|Drug: Travoprost (Groups A, B and C)",Alcon Research,Alcon Research,,,,,,,Phase 2,Industry,Interventional,4/10/2019,,https://ClinicalTrials.gov/show/NCT01114893
1221,Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection,Completed,Has Results,Acute Respiratory Infection,Drug: Mucinex|Drug: Placebo,Reckitt Benckiser LLC,Reckitt Benckiser LLC,,,,,,,Phase 2,Industry,Interventional,4/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01114581
1222,Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Primary Open-Angle Glaucoma,Drug: AGN-210961 Formulation 1|Drug: AGN-210961 Formulation 2|Drug: AGN-210961 Formulation 3|Drug: AGN-210961 Formulation 4|Drug: AGN-210961 Formulation 5|Drug: AGN-210961 Formulation 6|Drug: AGN-210961 Formulation 7|Drug: bimatoprost ophthalmic solution 0.03%,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01110499
1223,Confirmatory Study Nepafenac 0.3%,Completed,Has Results,Cataract,"Drug: Nepafenac Ophthalmic Suspension, 0.3%|Drug: Nepafenac Ophthalmic Suspension, 0.1%|Other: Nepafenac Ophthalmic Suspension 0.3% Vehicle|Other: NEVANAC Vehicle",Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,6/10/2019,,https://ClinicalTrials.gov/show/NCT01109173
1224,Long Term Safety of the Sonitus SoundBite System,Completed,Has Results,Hearing Loss|Unilateral Hearing Loss|Total Unilateral Deafness,Device: Sonitus SoundBite System|Device: SoundBite Hearing System,Sonitus Medical Inc,Sonitus Medical Inc,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01108406
1225,Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge,Completed,Has Results,Allergic Conjunctivitis,Drug: Loteprednol etabonate base (QD)|Drug: Loteprednol etabonate base (BID)|Drug: Loteprednol etabonate base (QID)|Drug: Loteprednol etabonate suspension|Drug: Vehicle of loteprednol etabonate,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 2,Industry,Interventional,4/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01107405
1226,Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions,Completed,Has Results,Depression,Drug: Imipramine Pamoate,Roxane Laboratories|West-Ward Pharmaceutical,Roxane Laboratories,West-Ward Pharmaceutical,,,,,,Not Applicable,Industry,Interventional,8/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT01107353
1227,To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities,Completed,Has Results,Healthy,Drug: Reformulated OXY (Totowa) (oxycodone HCl)|Drug: Reformulated OXY (Wilson) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,6/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT01101321
1228,A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities,Completed,Has Results,Healthy,Drug: Reformulated OXY (Totowa) (oxycodone HCl)|Drug: Reformulated OXY (Wilson) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,7/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT01101308
1229,A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,Completed,Has Results,Healthy,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,8/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT01101191
1230,To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,Completed,Has Results,Healthy,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,8/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT01101178
1231,To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,Completed,Has Results,Healthy,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,2/7/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT01101165
1232,A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,Completed,Has Results,Healthy Volunteers,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,1/7/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT01100320
1233,A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,Completed,Has Results,Healthy Volunteers,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,1/7/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT01100086
1234,Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution|Drug: Bimatoprost 0.03% Ophthalmic Solution,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,5/1/2010,4/29/2011,https://ClinicalTrials.gov/show/NCT01099774
1235,A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,Completed,Has Results,Healthy Volunteers,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,1/7/2019,8/7/2019,https://ClinicalTrials.gov/show/NCT01099709
1236,Oxygen Saturation Monitoring During Surgery,Completed,Has Results,"Sleep Apnea, Obstructive",,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,7/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT01098851
1237,Clinical Evaluation of a 1-Piece Intraocular Lens,Completed,Has Results,Cataract,Device: Tecnis ZCB00 IOL (control)|Device: Toric Intraocular lens,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Phase 3,Industry,Interventional,3/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01098812
1238,Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss,Completed,Has Results,Sleep Deprivation,Drug: SPD489 20 mg|Drug: SPD489 50 mg|Drug: SPD489 70 mg|Drug: Armodafinil|Drug: Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,4/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01096680
1239,Assessment of Daily Disposable Silicone Hydrogel Lens Wear,Completed,Has Results,Myopia,Device: Narafilcon B Contact Lens|Device: Spectacles,"Johnson & Johnson Vision Care, Inc.|Ohio State University","Johnson & Johnson Vision Care, Inc.",Ohio State University,,,,,,Not Applicable,Industry|Other,Interventional,1/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01093625
1240,Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily,Completed,Has Results,Overactive Bladder,Drug: trospium chloride|Drug: placebo,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,3/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01089751
1241,A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration,Completed,Has Results,Age-Related Macular Degeneration,Drug: E10030 plus Lucentis|Drug: Lucentis,Ophthotech Corporation,Ophthotech Corporation,,,,,,,Phase 2,Industry,Interventional,3/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01089517
1242,Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Abiraterone Acetate|Drug: Prednisone|Drug: LHRHa,"Cougar Biotechnology, Inc.","Cougar Biotechnology, Inc.",,,,,,,Phase 2,Industry,Interventional,12/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01088529
1243,A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers,Completed,Has Results,Pancreatic Disease,Drug: ChiRhoStim|Drug: Placebo,"ChiRhoClin, Inc.","ChiRhoClin, Inc.",,,,,,,Phase 3,Industry,Interventional,10/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT01087801
1244,Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial,Completed,Has Results,Multiple Sclerosis,Drug: Rebif,EMD Serono,EMD Serono,,,,,,,Phase 4,Industry,Interventional,6/30/2010,3/31/2012,https://ClinicalTrials.gov/show/NCT01085318
1245,"Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)",Completed,Has Results,Pharmacokinetics,Drug: Colchicine,Takeda,Takeda,,,,,,,Phase 4,Industry,Interventional,5/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01084278
1246,"Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers",Completed,Has Results,Healthy Volunteer,Drug: PF-02341066,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,3/10/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01082380
1247,Study of FORTEO Use in Subjects in the Community Setting,Completed,Has Results,Osteoporosis,Drug: FORTEO,Eli Lilly and Company,Eli Lilly and Company,,,,,,,,Industry,Observational,8/3/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01078805
1248,A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System,Completed,Has Results,Left Ventricular Dysfunction|Right Ventricular Dysfunction|Pulmonary Hypertension|Heart Valve Diseases,,GE Healthcare|Oregon Health and Science University,GE Healthcare,Oregon Health and Science University,,,,,,,Industry|Other,Observational,2/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01076296
1249,Dose Response of a Tubule Occlusion Agent,Completed,Has Results,Dentine Hypersensitivity|Dental Pain,Device: 5% calcium sodium phosphosilicate toothpaste|Device: 7.5% calcium sodium phosphosilicate toothpaste|Device: Placebo toothpaste,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,12/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT01075256
1250,Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy,Completed,Has Results,Post-surgical Dental Pain,Drug: Paracetamol 1000 mg|Drug: Paracetamol 650 mg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,11/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01075243
1251,Isovue in Peripheral Digital Subtraction Angiography (DSA),Completed,Has Results,Peripheral Arterial Occlusive Disease,Drug: iopamidol|Drug: iodixanol,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 4,Industry,Interventional,4/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01075217
1252,Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Pramipexole Dihydrochloride,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/5/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT01074463
1253,Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Pramipexole Dihydrochloride,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/5/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT01074450
1254,Clinical Evaluation of the Nucleus 5 Cochlear Implant (CI) System,Completed,Has Results,Hearing Loss,Device: Nucleus 5 Cochlear implant|Device: Cochlear implantation,Cochlear,Cochlear,,,,,,,Not Applicable,Industry,Interventional,3/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01072409
1255,Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste,Completed,Has Results,Hypersensitivity,Device: Arginine/Calcium Carbonate|Device: Nupro - Fluoride Free,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,7/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT01072188
1256,"EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events",Completed,Has Results,Coronary Artery Disease,Drug: Placebo Arm|Drug: Thienopyridine Therapy|Device: Surveillance Arm,Medtronic Vascular,Medtronic Vascular,,,,,,,Phase 4,Industry,Interventional,4/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01069003
1257,Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: saxagliptin|Drug: metformin|Drug: saxagliptin + metformin (FDC tablet),AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,2/10/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01068743
1258,Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: metformin (Diabex)|Drug: metformin (Glucophage™),AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,2/10/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01068730
1259,Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants,Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)",AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,3/10/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01068717
1260,Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence,Completed,Has Results,Eyelash Hypotrichosis,Drug: bimatoprost ophthalmic solution 0.005%|Drug: bimatoprost ophthalmic solution 0.015%|Drug: bimatoprost ophthalmic solution 0.03%,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,3/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01064882
1261,LapBand Adjustment to Improve Early Weight Loss,Completed,Has Results,Obesity,Device: EndoFLIP device (FDA Device Listing Number : D091203),Crospon,Crospon,,,,,,,Phase 2|Phase 3,Industry,Interventional,10/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01060592
1262,Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Completed,Has Results,Inflammation|Pain,Drug: Loteprednol etabonate|Drug: Vehicle of Loteprednol Etabonate,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,2/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01060072
1263,Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin,Completed,Has Results,Healthy Volunteers,Drug: Pitavastatin (NK-104)|Drug: Lopinavir/ritonavir,"Kowa Research Institute, Inc.","Kowa Research Institute, Inc.",,,,,,,Phase 4,Industry,Interventional,1/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01057433
1264,Study of 0416 Ointment in the Treatment of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: 0416|Drug: Vehicle of 0416 test product|Drug: tacrolimus ointment 0.1%,Fougera Pharmaceuticals Inc.,Fougera Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,1/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT01053247
1265,Trial of Versajet Compared With Conventional Treatment in Acute and Chronic Wounds,Completed,Has Results,Surgical Wound Dehiscence,Device: VERSAJET|Procedure: Scalpel or blade,"Smith & Nephew, Inc.","Smith & Nephew, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/7/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01050673
1266,A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis,Completed,Has Results,Pharyngitis,Drug: Placebo|Drug: Flurbiprofen,Reckitt Benckiser LLC,Reckitt Benckiser LLC,,,,,,,Phase 3,Industry,Interventional,11/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01049334
1267,A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis,Completed,Has Results,Pharyngitis,Drug: placebo|Drug: flurbiprofen|Drug: acetaminophen 650mg,Reckitt Benckiser LLC,Reckitt Benckiser LLC,,,,,,,Phase 3,Industry,Interventional,11/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01048866
1268,A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA),Completed,Has Results,Sanfilippo Syndrome Type A,Other: assessment,Shire,Shire,,,,,,,,Industry,Observational,2/10/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01047306
1269,Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin,Completed,Has Results,Skin Manifestations,Drug: adapalene cream 0.1%|Drug: adapalene lotion 0.1%,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 1,Industry,Interventional,1/10/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01046565
1270,Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin,Completed,Has Results,Skin Manifestations,Drug: adapalene cream 0.1% and adapalene lotion 0.1%|Drug: adapalene lotion 0.1%,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 1,Industry,Interventional,1/10/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01046396
1271,Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study,Completed,Has Results,Healthy,Drug: Lansoprazole|Drug: Prevacid®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/4/2019,1/4/2019,https://ClinicalTrials.gov/show/NCT01046253
1272,Mucinex Exploratory Cold Study,Completed,Has Results,Common Cold,Drug: guaifenesin (Mucinex)|Drug: placebo,Reckitt Benckiser LLC,Reckitt Benckiser LLC,,,,,,,Phase 2,Industry,Interventional,12/9/2019,,https://ClinicalTrials.gov/show/NCT01046136
1273,Lansoprazole 30 mg DR Capsule Replicate Food Study,Completed,Has Results,Healthy,Drug: Lansoprazole|Drug: Prevacid®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,8/3/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT01046084
1274,A Study To Evaluate Methods To Evaluate Back Pain,Completed,Has Results,Pain,Device: Heat Device|Device: Sham Device|Drug: marketed analgesic|Drug: Placebo,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Not Applicable,Industry,Interventional,2/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01045993
1275,Lansoprazole 30 mg DR Capsule Fasting Study,Completed,Has Results,Healthy,Drug: Lansoprazole|Drug: Prevacid®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,5/4/2019,7/4/2019,https://ClinicalTrials.gov/show/NCT01045967
1276,"A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience",Completed,Has Results,Gastroesophageal Reflux Disease,Drug: AZD3355|Drug: placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01043185
1277,"Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers",Completed,Has Results,Severe Renal Impairment,Drug: Pitavastatin 4mg,"Kowa Research Institute, Inc.","Kowa Research Institute, Inc.",,,,,,,Phase 4,Industry,Interventional,12/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01043094
1278,A Pharmacokinetic Study of Colchicine With an Oral Contraceptive,Completed,Has Results,Pharmacokinetics,Drug: Norethindrone/Ethinyl Estradiol|Drug: Colchicine|Drug: Placebo (for Colchicine),"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,8/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT01040845
1279,Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction,Completed,Has Results,Hypersensitivity,Device: Arginine/Calcium Carbonate|Device: Mint Prophy paste - Fluoride free,Colgate Palmolive,Colgate Palmolive,,,,,,,Not Applicable,Industry,Interventional,5/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT01040169
1280,"A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations",Completed,Has Results,Vulvovaginal Candidiasis,Drug: Butoconazole Nitrate Vaginal Cream|Drug: Placebo|Drug: Gynazole 1 vaginal cream,Perrigo Company,Perrigo Company,,,,,,,Not Applicable,Industry,Interventional,2/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT01039584
1281,Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn,Completed,Has Results,Heartburn,Drug: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Drug: Lansoprazole|Drug: Calcium carbonate/magnesium hydroxide|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,12/9/2019,,https://ClinicalTrials.gov/show/NCT01037452
1282,"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study",Completed,Has Results,Multiple Sclerosis,Device: RebiSmart™,EMD Serono,EMD Serono,,,,,,,Phase 3,Industry,Interventional,1/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01036165
1283,The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial,Completed,Has Results,Relapsing Multiple Sclerosis,Other: Blood sampling,EMD Serono,EMD Serono,,,,,,,Phase 4,Industry,Interventional,2/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01034579
1284,Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure (CPAP),Completed,Has Results,"Sleep Apnea, Obstructive",Device: Paced Breathing,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,10/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01031914
1285,Tri Staple Technology Stapler Used in Gastric Bypass,Completed,Has Results,Sleep Apnea|Hypertension|Hyperlipidemia|Coronary Artery Disease|Gastroesophageal Reflux Disease|Osteoarthritis|Diabetes,Device: Tri Staple Technology stapler,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,1/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01026103
1286,Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions,Completed,Has Results,Myopia|Hyperopia|Astigmatism,Device: RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control),Abbott Medical Optics,Abbott Medical Optics,,,,,,,Phase 1|Phase 2,Industry,Interventional,4/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT01024855
1287,A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution,Completed,Has Results,Ocular Discomfort,Device: Bausch & Lomb Multi-Purpose Solution|Device: Ciba's Multi-Purpose Solution,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01024751
1288,Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse,Completed,Has Results,Dental Plaque,"Drug: Fluoride|Drug: Triclosan, fluoride|Drug: Chlorhexidine Gluconate",Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,3/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT01024738
1289,Bioequivalence Study of Colchicine Tablets,Completed,Has Results,Healthy,Drug: Colchicine|Drug: Colchicine/Probenecid,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,9/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT01021020
1290,Clinical Research Study Efficacy of a Prototype Oral Rinse,Completed,Has Results,Dental Plaque,Drug: Iodine|Other: water,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,10/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT01021007
1291,Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects,Completed,Has Results,Healthy,Drug: Metronidazole,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,11/1/2019,1/2/2019,https://ClinicalTrials.gov/show/NCT01020877
1292,Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study,Completed,Has Results,Pharmacokinetics,Drug: Colchicine|Drug: Moxifloxacin,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,11/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT01018420
1293,Pharmacokinetic Study of an Acute Gout Regimen,Completed,Has Results,Pharmacokinetics,Drug: colchicine tablets,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,9/7/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT01017042
1294,Pharmacokinetic Study With Colchicine in Healthy Volunteers,Completed,Has Results,Pharmacokinetics,Drug: colchicine tablets,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,9/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT01017003
1295,Evaluating Commercial Anti-Plaque Products and Oral Rinse,Completed,Has Results,Dental Plaque,"Drug: Fluoride|Drug: Chlorhexidine digluconate|Drug: Fluoride, triclosan",Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 2,Industry,Interventional,8/7/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT01014143
1296,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Completed,Has Results,Cerebral Arterial Diseases,Drug: Dotarem|Other: TOF MRA,Guerbet,Guerbet,,,,,,,Phase 3,Industry,Interventional,10/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01012674
1297,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Completed,Has Results,Cerebral Arterial Diseases,Drug: Dotarem|Other: TOF MRA,Guerbet,Guerbet,,,,,,,Phase 3,Industry,Interventional,10/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01010932
1298,Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention-Deficit Hyperactivity Disorder,Drug: Lisdexamfetamine Dimesylate (LDX)|Drug: Immediate Release Mixed Amphetamine Salts (MAS-IR)|Drug: LDX Placebo + MAS-IR Placebo,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,1/10/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01010750
1299,Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Completed,Has Results,Inflammation|Pain,Drug: Vehicle of Loteprednol Etabonate|Drug: Loteprednol Etabonate,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,11/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01010633
1300,Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects,Completed,Has Results,Dry Eye Syndrome,"Drug: Glycerin and Polysorbate 80 based artificial tear|Drug: Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|Drug: Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear",Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01010282
1301,Oral Tissue Tolerance of a Mouthrinse,Completed,Has Results,Dental Health,Device: Potassium Oxylate Mouthwash|Drug: Sodium Fluoride Dentifrice,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,10/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT01009554
1302,InterStim Therapy Programming Study,Completed,Has Results,Urgency Frequency|Urinary Urge Incontinence,Device: InterStim Therapy at rate 5.2 Hz|Device: InterStim Therapy at rate 14 Hz|Device: InterStim Therapy,MedtronicNeuro,MedtronicNeuro,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01009333
1303,Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI,Completed,Has Results,Gastroesophageal Reflux Disease|Heartburn|Regurgitation,Drug: lesogaberan (AZD3355)|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,10/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01005251
1304,Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis,Completed,Has Results,Major Depressive Disorder,Drug: L-methylfolate|Drug: Selective serotonin reuptake inhibitor (SSRI)|Drug: Serotonin and norepinephrine reuptake inhibitor (SNRI),"Pamlab, Inc.|Red Oak Psychiatry Associates, PA|Baylor Health Care System","Pamlab, Inc.","Red Oak Psychiatry Associates, PA",Baylor Health Care System,,,,,,Industry|Other,Observational,8/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01001559
1305,Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution,Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension","Drug: AGN-210669 ophthalmic solution, 0.1%|Drug: AGN-210669 ophthalmic solution, 0.075%|Drug: AGN-210669 ophthalmic solution, 0.05%|Drug: bimatoprost ophthalmic solution 0.03%",Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,11/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01001195
1306,Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge,Completed,Has Results,Hypoglycemia|Obesity,,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,9/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00998374
1307,Trial of Yellow Fever Inactivated Vaccine,Completed,Has Results,Yellow Fever,Biological: XRX-001 Inactivated yellow fever vaccine|Biological: Placebo,GE Healthcare,GE Healthcare,,,,,,,Phase 1,Industry,Interventional,1/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00995865
1308,Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers,Completed,Has Results,Aspirin-Associated Gastric Ulcers,Drug: PA32540,POZEN,POZEN,,,,,,,Phase 3,Industry,Interventional,10/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00995410
1309,Study of Cyclosporine in Post-LASIK Patients,Completed,Has Results,Laser In Situ Keratomileusis,Drug: Cyclosporine 0.010% eye drops|Drug: Cyclosporine 0.005% eye drops|Drug: Placebo (Vehicle for Cyclosporine),Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,10/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00991458
1310,Clinical Evaluation of Two Daily Disposable Lenses in Neophytes,Completed,Has Results,Myopia,Device: nelfilcon A contact lens|Device: narafilcon A contact lens,CIBA VISION|Alcon Research,CIBA VISION,Alcon Research,,,,,,Not Applicable,Industry,Interventional,8/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00987623
1311,This is a Study to Determine the Antidepressant Effects of AZD6765,Completed,Has Results,Treatment Resistant Major Depressive Disorder,Drug: AZD6765|Drug: Placebo to AZD6765,AstraZeneca|National Institute of Mental Health (NIMH),AstraZeneca,National Institute of Mental Health (NIMH),,,,,,Phase 2,Industry|NIH,Interventional,12/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00986479
1312,Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects,Completed,Has Results,Healthy,Drug: Trospium Chloride (Sanctura XR®)|Drug: Metformin hydrochloride (Glucophage®),Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,10/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00986401
1313,Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy,Completed,Has Results,Vitrectomy,Drug: Ocriplasmin|Drug: Placebo,ThromboGenics,ThromboGenics,,,,,,,Phase 2,Industry,Interventional,2/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00986362
1314,Study of Diclofenac Capsules to Treat Dental Pain,Completed,Has Results,Dental Pain,Drug: Diclofenac Test (lower dose)|Drug: Diclofenac Test (upper dose)|Drug: Celecoxib 400 mg|Drug: Placebo,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 2,Industry,Interventional,9/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00985439
1315,Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers,Completed,Has Results,Vision Disorders,Device: PureVision Multi-Focal contact lenses|Device: SofLens59 contact lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00985231
1316,Drug-Drug Interaction Study of Colchicine and Clarithromycin,Completed,Has Results,Pharmacokinetics,Drug: colchicine|Drug: clarithromycin,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,11/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00984061
1317,A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice,Completed,Has Results,Pharmacokinetics,Drug: Colchicine|Other: Grapefruit Juice,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,9/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00984009
1318,Drug-Drug Interaction Study Between Colchicine and Cyclosporine,Completed,Has Results,Pharmacokinetics|Healthy,Drug: Colchicine|Drug: Cyclosporine,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,8/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00983931
1319,Drug-Drug Interaction Study of Colchicine and Theophylline,Completed,Has Results,Pharmacokinetics,Drug: Theophylline|Drug: Colchicine,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,8/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00983905
1320,Drug-Drug Interaction Between Colchicine and Ritonavir,Completed,Has Results,Pharmacokinetics,Drug: Colchicine|Drug: Ritonavir,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,7/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00983515
1321,Drug-Drug Interaction Study Between Colchicine and Diltiazem ER,Completed,Has Results,Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein,Drug: Colchicine|Drug: Diltiazem ER,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,8/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00983372
1322,Drug-Drug Interaction Between Colchicine and Verapamil ER,Completed,Has Results,Pharmacokinetics,Drug: Colchicine|Drug: Verapamil HCl ER,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,9/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00983242
1323,Drug-Drug Interaction Study Between Colchicine and Ketoconazole,Completed,Has Results,Pharmacokinetics,Drug: Colchicine|Drug: Ketoconazole,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,7/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00983216
1324,Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA),Completed,Has Results,Iron Deficiency Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate Tablets|Drug: IV Iron (standard of care),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,9/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00982007
1325,Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function,Completed,Has Results,Iron Deficiency Anemia|Impaired Renal Function,Drug: Ferric Carboxymaltose (FCM)|Drug: Iron Sucrose (Venofer),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,8/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00981045
1326,A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone,Completed,Has Results,Healthy,Drug: Recombinant human hyaluronidase PH20 (rHuPH20)|Drug: Insulin lispro|Drug: Insulin glulisine|Drug: Insulin aspart,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 1,Industry,Interventional,9/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00979875
1327,Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis,Completed,Has Results,Vasomotor Rhinitis,"Drug: Olopatadine HCL (Patanase) Nasal Spray, 0.6%|Drug: Azelastine HCl (Astelin) Nasal Spray, 137 mcg",Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,9/9/2019,,https://ClinicalTrials.gov/show/NCT00979615
1328,Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System,Completed,Has Results,Venous Thromboembolism,Other: vMetrics protocol,"ZIN Technologies, Inc.|The Cleveland Clinic","ZIN Technologies, Inc.",The Cleveland Clinic,,,,,,Not Applicable,Industry|Other,Interventional,9/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00978445
1329,Comparison of StentOptimizer With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography,Completed,Has Results,Coronary Artery Disease,,Paieon Inc.,Paieon Inc.,,,,,,,,Industry,Observational,9/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00973921
1330,Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis,Completed,Has Results,Bacterial Conjunctivitis,Drug: Besifloxacin|Drug: Vehicle (Placebo),Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 2|Phase 3,Industry,Interventional,10/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00972777
1331,Clinical Evaluation of a New Viscoelastic for Cataract Surgery,Completed,Has Results,Cataract,Device: Vitrax II|Device: Viscoat,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00972621
1332,Device to Reduce Surgery Site Contamination,Completed,Has Results,Surgery,Device: Air Barrier System Device|Device: Sham Air Barrier System device,"Nimbic Systems, LLC","Nimbic Systems, LLC",,,,,,,Not Applicable,Industry,Interventional,5/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00972153
1333,ACRYSOF® Toric NATURAL T9 Intraocular Lens (IOL),Completed,Has Results,Bilateral Cataract,Device: ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,8/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00967473
1334,Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.,Completed,Has Results,Gingival Diseases,Drug: Fluoride|Drug: Triclosan/Fluoride toothpaste|Other: antibacterial plant extract,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,10/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00966953
1335,Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults,Completed,Has Results,Healthy Volunteers,Drug: Naproxen|Drug: PL 3100,PLx Pharma|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),PLx Pharma,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),,,,,,Phase 1|Phase 2,Industry|NIH,Interventional,8/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00966641
1336,A Study of Tomato Products and Disease Risk,Completed,Has Results,Inflammation,Other: Tomato|Other: Non-tomato,"Institute for Food Safety and Health, United States|Tomato Products Wellness Council","Institute for Food Safety and Health, United States",Tomato Products Wellness Council,,,,,,Not Applicable,Industry|Other,Interventional,8/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00966550
1337,Phase 2 Study of Indomethacin Capsules to Treat Dental Pain,Completed,Has Results,Dental Pain,Drug: Celecoxib 400 mg|Drug: Placebo|Drug: Indomethacin Test (lower dose)|Drug: Indomethacin Test (upper dose),"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 2,Industry,Interventional,8/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00964431
1338,Presbyopia-Correcting Intraocular Lenses (IOLs),Completed,Has Results,Cataract,Device: ReSTOR +3|Device: Crystalens HD|Device: Crystalens AO,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,8/9/2019,,https://ClinicalTrials.gov/show/NCT00963560
1339,Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance,Completed,Has Results,Abdominal Adhesions,Device: Transgastric diagnostic peritoneoscopy with laparoscopic assistance,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00962650
1340,Study of MLN8237 in Participants With Advanced Solid Tumors,Completed,Has Results,Advanced Solid Tumors,Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,9/25/2009,7/1/2014,https://ClinicalTrials.gov/show/NCT00962091
1341,Study of LX4211 in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LX4211 Low Dose|Drug: LX4211 High Dose|Drug: Placebo,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,8/9/2019,,https://ClinicalTrials.gov/show/NCT00962065
1342,A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Completed,Has Results,Gastric Ulcer,Drug: PA32540|Drug: EC Aspirin 325,POZEN,POZEN,,,,,,,Phase 3,Industry,Interventional,10/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00961350
1343,Sprinter Legend Balloon Catheter,Completed,Has Results,Coronary Artery Disease,Procedure: Percutaneous Coronary Intervention|Device: Sprinter Legend 1.25mm Balloon Catheter,Medtronic Vascular,Medtronic Vascular,,,,,,,Not Applicable,Industry,Interventional,8/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00961311
1344,Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate),Completed,Has Results,Healthy,Drug: Fenofibric Acid (Fibricor™) 105 mg Tablet|Drug: Fenofibrate (Tricor®) 145 mg Tablet,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,10/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00961116
1345,Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Completed,Has Results,Gastric Ulcer,Drug: PA32540|Drug: EC-Aspirin 325 mg,POZEN,POZEN,,,,,,,Phase 3,Industry,Interventional,10/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00960869
1346,Four Arm Food Effect Study of Fenofibric Acid Tablets,Completed,Has Results,Healthy,Drug: Fenofibric Acid 105 mg Tablet,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,11/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00960856
1347,Drug-Drug Interaction Study Between Colchicine and Atorvastatin,Completed,Has Results,Healthy,Drug: Colchicine|Drug: Atorvastatin,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,2/9/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00960323
1348,Drug-Food Interaction Study of Seville Orange Juice and Colchicine,Completed,Has Results,Healthy,Drug: Colchicine|Other: Seville Orange Juice,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,2/9/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00960193
1349,Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis,Completed,Has Results,Hypotrichosis,Drug: bimatoprost ophthalmic 0.03% solution|Drug: vehicle sterile solution (placebo),Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,11/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00958035
1350,"The Multicenter, Open-label, Single-use Autoinjector Convenience Study",Completed,Has Results,Multiple Sclerosis,Device: Rebidose®,EMD Serono,EMD Serono,,,,,,,Phase 3,Industry,Interventional,10/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00958009
1351,Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis,Completed,Has Results,"Mucositis|Pain|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Fentanyl sublingual spray,INSYS Therapeutics Inc,INSYS Therapeutics Inc,,,,,,,Phase 3,Industry,Interventional,10/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00956254
1352,Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction,Completed,Has Results,Dental Pain,Drug: XPF-001|Drug: placebo,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,9/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00954356
1353,Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained Release|Drug: Midazolam,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,6/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00952653
1354,Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face,Completed,Has Results,Acne Vulgaris,Drug: Tretinoin Facial Gel|Drug: Adapalene/Benzoyl Peroxide Facial Gel,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 4,Industry,Interventional,7/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00952523
1355,Safety and Efficacy Study of Duet TRS,Completed,Has Results,Roux En Y Gastric Bypass,Device: Duet TRS,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00950872
1356,Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open Angle Glaucoma|Ocular Hypertension,Drug: SPARC0912|Drug: Reference0912,Sun Pharma Advanced Research Company Limited,Sun Pharma Advanced Research Company Limited,,,,,,,Phase 3,Industry,Interventional,7/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00947661
1357,Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy,Completed,Has Results,Primary Prevention of Sudden Cardiac Arrest,Device: Standard ICD programming|Device: High rate cutoff|Device: Long delay,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00947310
1358,Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open Angle Glaucoma|Ocular Hypertension,Drug: SPARC0913,Sun Pharma Advanced Research Company Limited,Sun Pharma Advanced Research Company Limited,,,,,,,Phase 3,Industry,Interventional,11/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00945958
1359,PEAK PlasmaBlade™ vs. Traditional Electrosurgery in Abdominoplasty,Completed,Has Results,Elastosis,Device: PEAK PlasmaBlade|Procedure: Standard of Care (SOC),Medtronic Surgical Technologies,Medtronic Surgical Technologies,,,,,,,Not Applicable,Industry,Interventional,12/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00943150
1360,"A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.",Completed,Has Results,Healthy,Drug: Clopidogrel|Drug: Clopidogrel and Lansoprazole|Drug: Clopidogrel and Dexlansoprazole|Drug: Clopidogrel and Omeprazole|Drug: Clopidogrel and Esomeprazole,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,12/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00942175
1361,Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to External Auditory Apparatus,Completed,Has Results,Acute Otitis Media|Chronic Otitis Media|Recurrent Acute Otitis Media,Device: Iontophoresis System (Acclarent),Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,4/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00941993
1362,Evaluate Inflammation Caused by Gingivitis in Adults,Completed,Has Results,Gingivitis,Drug: Triclosan/Copolymer/fluoride toothpaste|Drug: sodium monofluorophosphate toothpaste,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 4,Industry,Interventional,1/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00941668
1363,SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients,Completed,Has Results,Tachyarrhythmias|Sudden Cardiac Death|Heart Failure,Device: SJ4 connector and RV high voltage SJ4 lead,Abbott Medical Devices,Abbott Medical Devices,,,,,,,,Industry,Observational,6/9/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00940888
1364,A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects,Completed,Has Results,Aspergillosis|Candidemia,Drug: anidulafungin and voriconazole,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,9/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00940017
1365,Relative Drug Exposures Of Two Formulations of PF-02341066,Completed,Has Results,Healthy,Drug: PF-02341066,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00939731
1366,Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions,Completed,Has Results,Healthy,Drug: topiramate,Torrent Pharmaceuticals Limited,Torrent Pharmaceuticals Limited,,,,,,,Phase 1,Industry,Interventional,,,https://ClinicalTrials.gov/show/NCT00939705
1367,Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions,Completed,Has Results,Healthy,Drug: Topiramate,Torrent Pharmaceuticals Limited,Torrent Pharmaceuticals Limited,,,,,,,Phase 1,Industry,Interventional,1/7/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00939692
1368,Safety and Efficacy of Balloon Sinuplasty in Pediatric Sinusitis,Completed,Has Results,Chronic Sinusitis,Device: Relieva™ Balloon Sinuplasty™ System,Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,4/1/2007,5/1/2010,https://ClinicalTrials.gov/show/NCT00939471
1369,Balloon Sinus Dilation In Office or OR,Completed,Has Results,Chronic Sinusitis,Device: FESS instruments with or without balloon treatment|Device: Balloon Sinuplasty,Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,4/1/2008,7/1/2010,https://ClinicalTrials.gov/show/NCT00939393
1370,Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Ondansetron|Drug: Zofran®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/3/2019,2/3/2019,https://ClinicalTrials.gov/show/NCT00934921
1371,Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL,Completed,Has Results,Cataract,Device: AcrySof® ReSTOR® Aspheric IOL,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,11/7/2019,,https://ClinicalTrials.gov/show/NCT00934622
1372,Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Ondansetron|Drug: Zofran®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,12/2/2019,12/2/2019,https://ClinicalTrials.gov/show/NCT00934180
1373,Safety and Tolerability of Artificial Tears in Dry Eye Subjects,Completed,Has Results,Dry Eye Syndrome,"Drug: Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|Drug: Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|Drug: Glycerin and Polysorbate 80 based artificial tear",Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,8/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00932477
1374,Trospium Chloride XR in Obese Female Patients With Overactive Bladder,Completed,Has Results,Obesity|Overactive Bladder|Incontinence,"Drug: Trospium Chloride, Extended Release (XR)|Other: placebo",Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,7/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00932022
1375,Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension,Completed,Has Results,Stage 2 Systolic Hypertension,"Drug: valsartan, amlodipine, HCTZ|Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ",Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,7/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00931710
1376,Compare the Clinical Efficacy of Prototype Toothpastes,Completed,Has Results,Dental Plaque,"Drug: Fluoride|Drug: Triclosan, fluoride|Other: Metal salt",Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,1/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00926029
1377,A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation,Completed,Has Results,Multiple Myeloma,Drug: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Drug: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free),"Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",,,,,,,Phase 2,Industry,Interventional,1/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00925782
1378,The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers,Completed,Has Results,Healthy,Drug: Calcitriol|Drug: Lanthanum carbonate + Calcitriol|Drug: Sevelamer carbonate + Calcitriol,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,6/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00925704
1379,"Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes",Completed,Has Results,Diabetes Mellitus Type 2,Drug: EGT0001474|Drug: Placebo,Theracos,Theracos,,,,,,,Phase 1,Industry,Interventional,6/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00924053
1380,Evaluation of DIDGET TM World Reports,Completed,Has Results,Diabetes,Device: DIDGET World Web Community Reports,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00923975
1381,Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults,Completed,Has Results,Influenza,Biological: VAX102,VaxInnate Corporation,VaxInnate Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00921947
1382,A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers,Completed,Has Results,Healthy,Drug: SPD503|Drug: VYVANSE|Drug: SPD503 and VYVANSE,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,7/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00919867
1383,Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C,Completed,Has Results,Hepatitis C,"Drug: interferon alfa-2b|Drug: peginterferon alfa-2b|Drug: ribavirin, USP|Device: external drug infusion pump",Medtronic Corporate Technologies and New Ventures,Medtronic Corporate Technologies and New Ventures,,,,,,,Phase 2,Industry,Interventional,6/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00919633
1384,Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face,Completed,Has Results,Acne Vulgaris,Drug: Tretinoin gel|Drug: Adapalene and Benzoyl peroxide,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 4,Industry,Interventional,4/9/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00919191
1385,Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects,Completed,Has Results,Prostate Cancer,Device: balloon implant|Procedure: Balloon implantation,BioProtect,BioProtect,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00918229
1386,Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Genetic: Atorvastatin,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,7/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00917644
1387,Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,7/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00917579
1388,"Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Humalog|Drug: Humulin-R|Drug: Recombinant human hyaluronidase PH20 (rHuPH20),Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 2,Industry,Interventional,7/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00916357
1389,Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures,Completed,Has Results,Thrombocytopenia Related to Chronic Liver Disease,Drug: Avatrombopag|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,5/9/2019,12/21/2011,https://ClinicalTrials.gov/show/NCT00914927
1390,Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain,Completed,Has Results,Pain,Drug: ibuprofen|Drug: naproxen|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,5/7/2009,8/5/2009,https://ClinicalTrials.gov/show/NCT00913627
1391,Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis,Completed,Has Results,Chronic Sinusitis,Device: Steroid-Eluting Sinexus Intranasal Splint,Intersect ENT,Intersect ENT,,,,,,,Not Applicable,Industry,Interventional,3/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00912405
1392,Laparoscopic Sleeve Gastrectomy With Endoscopic Visualization,Completed,Has Results,Morbid Obesity,Device: NOTES toolbox,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,7/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00911989
1393,Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Mycophenolate Mofetil|Drug: CellCept®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/6/2019,11/6/2019,https://ClinicalTrials.gov/show/NCT00911274
1394,A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes,Completed,Has Results,Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS),Drug: Lenalidomide|Drug: Recombinant human erythropoietin,Celgene Corporation|Celgene,Celgene Corporation,Celgene,,,,,,Phase 1|Phase 2,Industry,Interventional,1/5/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00910858
1395,Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions,Completed,Has Results,Healthy,Drug: Mycophenolate Mofetil|Drug: CellCept®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/6/2019,11/6/2019,https://ClinicalTrials.gov/show/NCT00910663
1396,Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes,Completed,Has Results,P Acnes Colonization,Drug: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel),"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,6/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00907101
1397,Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression,Completed,Has Results,Healthy,Drug: Prilosec OTC (omeprazole-magnesium)|Drug: Prevacid,Procter and Gamble,Procter and Gamble,,,,,,,Phase 4,Industry,Interventional,4/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00903448
1398,One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens,Completed,Has Results,Myopia,Device: SofLens Daily Disposable|Device: Marketed 1 Day Contact Lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,10/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00902850
1399,A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers,Completed,Has Results,Healthy,Drug: SPD503|Drug: Concerta|Drug: SPD503 + Concerta,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,5/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00901576
1400,Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A),Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Co-administration of Saxagliptin and Metformin IR, Fasted|Drug: Saxagliptin/Metformin, Fasting|Drug: Co-administration of Saxagliptin and Metformin IR, Fed|Drug: Saxagliptin/Metformin, Fed",AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,6/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00899470
1401,Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Saxagliptin|Drug: Metformin IR (glucophage)|Drug: Saxagliptin + Metformin IR (FDC),AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,6/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00897390
1402,"A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure",Completed,Has Results,Sedation|Anxiety|Pain,Drug: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Drug: Placebo NanoTab™,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,6/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00894699
1403,A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia,Completed,Has Results,Benign Prostatic Hyperplasia,Biological: Botulinum Toxin Type A|Drug: Placebo (saline),Allergan,Allergan,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/9/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00894517
1404,ORCA - Oracea® for Rosacea: A Community-based Assessment,Completed,Has Results,Rosacea,Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy|Drug: doxycycline (Oracea®) 40 mg modified release as add-on therapy,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,4/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00892281
1405,Evaluation of GLUCOFACTS® Deluxe Diabetes Management System,Completed,Has Results,Diabetes Mellitus,Device: GLUCOFACTS® Deluxe,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,4/9/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00892151
1406,Study of Postoperative Analgesia in Bunionectomy,Completed,Has Results,Bunion|Hallux Valgus,Drug: SKY0402|Drug: Placebo,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,4/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00890682
1407,A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance,Completed,Has Results,Gallbladder Disease,Device: NOTES GEN 1 Toolbox,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,4/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00889928
1408,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Completed,Has Results,Allergic Conjunctivitis,Device: contact lens with ketotifen|Device: contact lens,Vistakon Pharmaceuticals,Vistakon Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/9/2019,,https://ClinicalTrials.gov/show/NCT00889252
1409,Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis,Completed,Has Results,Allergic Conjunctivitis,Drug: Lifitegrast|Other: Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,4/9/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00882687
1410,Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults,Completed,Has Results,End Stage Renal Disease,Drug: Lanthanum carbonate Granule Formulation|Drug: Lanthanum carbonate Chewable Tablets (Fosrenol),Shire,Shire,,,,,,,Phase 1,Industry,Interventional,4/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00880750
1411,Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults,Completed,Has Results,"Meningitis, Meningococcal",Biological: rLP2086 vaccine or control,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00879814
1412,Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States,Completed,Has Results,"Infections, Rotavirus",Other: Health Insurance Database,GlaxoSmithKline,GlaxoSmithKline,,,,,,,,Industry,Observational,4/20/2009,11/4/2016,https://ClinicalTrials.gov/show/NCT00875641
1413,A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women,Completed,Has Results,Hot Flashes,Drug: RAD1901|Drug: Placebo,"Radius Pharmaceuticals, Inc.","Radius Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00875420
1414,Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers,Completed,Has Results,"Kidney Failure, Chronic",Drug: Lanthanum Carbonate|Drug: Sevelamer,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,4/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00875017
1415,Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic,Completed,Has Results,Aneurysm,Device: GORE CTAG Device,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,1/6/2017,https://ClinicalTrials.gov/show/NCT00874250
1416,Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm,Completed,Has Results,Subarachnoid Hemorrhage,Drug: Sodium nitrite|Drug: Saline,Hope Pharmaceuticals|National Institute of Neurological Disorders and Stroke (NINDS),Hope Pharmaceuticals,National Institute of Neurological Disorders and Stroke (NINDS),,,,,,Phase 2,Industry|NIH,Interventional,4/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00873015
1417,"Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis",Completed,Has Results,Cystinosis,Drug: Cystagon®|Drug: RP103,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,5/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00872729
1418,Optimized Programming in Spinal Cord Stimulation (SCS) System,Completed,Has Results,Neuropathic Pain|Pain,Device: Precision Spinal Cord Stimulation (SCS),Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,3/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00871819
1419,Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery,Completed,Has Results,Cataract,Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,9/8/2019,,https://ClinicalTrials.gov/show/NCT00870103
1420,A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa,Completed,Has Results,Parkinson's Disease,Drug: IPX066|Drug: IR CD-LD,"Impax Laboratories, LLC","Impax Laboratories, LLC",,,,,,,Phase 2,Industry,Interventional,11/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00869791
1421,"A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,",Completed,Has Results,Snake Bite|Blood Coagulation Disorders,Biological: Anavip|Biological: CroFab,Instituto Bioclon S.A. de C.V.|University of Arizona,Instituto Bioclon S.A. de C.V.,University of Arizona,,,,,,Phase 2,Industry|Other,Interventional,1/5/2019,2/7/2019,https://ClinicalTrials.gov/show/NCT00868309
1422,Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial,Completed,Has Results,Elderly|Pharmacokinetics|Overactive Bladder,Drug: Trospium Chloride,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,4/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00863551
1423,Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis,Completed,Has Results,Epistaxis,Device: 2009-I-Epistaxis-1,"HemCon Medical Technologies, Inc","HemCon Medical Technologies, Inc",,,,,,,Not Applicable,Industry,Interventional,3/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00863356
1424,Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone,Completed,Has Results,Diabetes Mellitus,Drug: Insulin Lispro|Drug: Regular Human Insulin|Drug: rHuPH20,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 1,Industry,Interventional,3/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00862849
1425,Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants,Completed,Has Results,"Blood Loss, Surgical","Biological: rThrombin, 1000 IU/mL",ZymoGenetics,ZymoGenetics,,,,,,,Phase 4,Industry,Interventional,3/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00859547
1426,Levetiracetam 1000 mg Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Levetiracetam|Drug: Keppra®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/7/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00859521
1427,Levetiracetam 1000 mg Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Levetiracetam|Drug: Keppra®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/7/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00859430
1428,Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation,Completed,Has Results,Pediculus Humanus Capitis (Head Lice),"Drug: ivermectin treatment conditioner|Drug: Placebo, vehicle control",Topaz Pharmaceuticals Inc,Topaz Pharmaceuticals Inc,,,,,,,Phase 2,Industry,Interventional,3/9/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00857948
1429,Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients,Completed,Has Results,Parkinson's Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),Avid Radiopharmaceuticals,National Institutes of Health (NIH),National Institute of Neurological Disorders and Stroke (NINDS),,,,,Phase 2,Industry|NIH,Interventional,1/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00857532
1430,Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes,Completed,Has Results,Type II Diabetes,Drug: AZD1656|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00856908
1431,Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients,Completed,Has Results,Ovarian Cancer,Drug: ON 01910.Na,"Onconova Therapeutics, Inc.","Onconova Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,3/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00856791
1432,"Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers",Completed,Has Results,Safety and Tolerability of EGT0001474 in Healthy Volunteers,Drug: EGT0001474|Drug: Placebo,Theracos,Theracos,,,,,,,Phase 1,Industry,Interventional,2/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00854113
1433,Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Completed,Has Results,Pain|Inflammation,Drug: Bromfenac Ophthalmic Solution|Drug: Placebo Comparator,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,2/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00853970
1434,"MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma",Completed,Has Results,Ovarian Carcinoma,Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,3/23/2009,1/27/2011,https://ClinicalTrials.gov/show/NCT00853307
1435,"A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis",Completed,Has Results,Actinic Keratosis,"Drug: PEP005 (ingenol mebutate) Gel, 0.05%|Drug: Vehicle Gel",Peplin,Peplin,,,,,,,Phase 2,Industry,Interventional,3/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00852137
1436,Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®,Completed,Has Results,Meningococcal Infections|Meningitis,Biological: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/2/2019,11/4/2019,https://ClinicalTrials.gov/show/NCT00850603
1437,HALO Patient Registry: Ablation of Barrett's Esophagus,Completed,Has Results,Barrett Esophagus,Device: Radiofrequency Ablation (HALO Ablation Systems),Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,7/7/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00848237
1438,Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects,Completed,Has Results,HIV Infections,Other: Placebo|Biological: TUTI-16 (0.03mg)|Biological: TUTI-16 (0.1mg)|Biological: TUTI-16 (0.6mg),"Thymon, LLC","Thymon, LLC",,,,,,,Phase 1|Phase 2,Industry,Interventional,2/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00848211
1439,Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: LX3305|Drug: LX3305 Placebo|Drug: Methotrexate,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,2/9/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00847886
1440,Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Sumatriptan Succinate|Drug: Imitrex®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,8/4/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00846885
1441,PROTECT Continued Access Post Marketing Surveillance Trial,Completed,Has Results,"Coronary Artery Disease, Autosomal Dominant, 1",Device: Endeavor® Zotarolimus Eluting Coronary Stent System,Medtronic Vascular,Medtronic Vascular,,,,,,,Phase 4,Industry,Interventional,1/9/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00846846
1442,Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV),Completed,Has Results,Anthrax,Biological: AIGIV 3.5 mg/kg|Biological: Gamunex 90 mg/kg|Biological: AIGIV 7.0 mg/kg|Biological: Gamunex 180 mg/kg|Biological: AIGIV 14.0 mg/kg|Biological: Gamunex 360 mg/kg,Emergent BioSolutions|National Institutes of Health (NIH),Emergent BioSolutions,National Institutes of Health (NIH),,,,,,Phase 1|Phase 2,Industry|NIH,Interventional,2/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00845650
1443,Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid,Completed,Has Results,Seasonal Allergic Rhinitis,"Drug: Olopatadine HCl Nasal Spray, 0.6%|Drug: Azelastine HCl Nasal Spray, 0.1%",Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,3/9/2019,,https://ClinicalTrials.gov/show/NCT00845195
1444,Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.,Completed,Has Results,Peripheral Vascular Disease,Device: Absolute Pro™ Peripheral Self-Expanding Stent System,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 3,Industry,Interventional,3/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00844532
1445,Bioavailability Study for New Atorvastatin Formulation,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin suspension|Drug: Lipitor,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,2/8/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00844376
1446,"A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors",Completed,Has Results,Advanced Solid Tumors,Drug: JI-101,Jubilant Innovation Ltd.,Jubilant Innovation Ltd.,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00842335
1447,Assessment of Visual Performance in Patients With Low Levels of Astigmatism,Completed,Has Results,Cataract Extraction|Corneal Astigmatism,Other: Visual performance measures,Alcon Research,Alcon Research,,,,,,,,Industry,Observational,1/9/2019,,https://ClinicalTrials.gov/show/NCT00842231
1448,Cefprozil 500 mg Tablets Under Fed Conditions,Completed,Has Results,Healthy,Drug: cefprozil|Drug: Cefzil®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/3/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT00840866
1449,Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Clarithromycin ER 500 mg tablets|Drug: BIAXIN® XL 500 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/2/2019,10/2/2019,https://ClinicalTrials.gov/show/NCT00840411
1450,Cefprozil 500 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Cefzil® 500 mg tablets|Drug: Cefprozil 500 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/3/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT00840281
1451,Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.,Completed,Has Results,Healthy,Drug: Clarithromycin ER 500 mg tablets|Drug: BIAXIN® XL 500 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,8/2/2019,8/2/2019,https://ClinicalTrials.gov/show/NCT00840216
1452,Mesalamine 4 gm/60 mL Rectal Enema,Completed,Has Results,Healthy,Drug: Rowasa® 4 gm/60 mL Rectal Enema|Drug: Mesalamine 4 gm/60 mL Rectal Enema,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,5/3/2019,6/3/2019,https://ClinicalTrials.gov/show/NCT00840203
1453,Cilostazol 100 mg Tablet Formulations Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Cilostazol 100 mg tablets|Drug: Pletal® 100 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,11/3/2019,11/3/2019,https://ClinicalTrials.gov/show/NCT00838630
1454,Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures,Completed,Has Results,Iliac Crest Harvesting Procedure-Bone Void Filler,Device: Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures,"Osteotech, Inc|Medtronic Spinal and Biologics","Osteotech, Inc",Medtronic Spinal and Biologics,,,,,,Not Applicable,Industry,Interventional,1/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00837473
1455,Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®,Completed,Has Results,Influenza,Biological: Influenza virus vaccine (Pediatric formulation),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/3/2019,7/4/2019,https://ClinicalTrials.gov/show/NCT00836953
1456,Comparison of Breathing Event Detection by a Continuous Positive Airway Pressure Device to Clinical Polysomnography,Completed,Has Results,Sleep Apnea,Device: Analysis with AED and manual PSG scoring,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00836758
1457,Clarithromycin 500 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: clarithromycin|Drug: BIAXIN®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,7/2/2019,7/2/2019,https://ClinicalTrials.gov/show/NCT00836706
1458,CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy,Completed,Has Results,Cervical Dystonia,Other: No Intervention,Allergan,Allergan,,,,,,,,Industry,Observational,1/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00836017
1459,A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination,Completed,Has Results,Influenza,Biological: Influenza virus vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,7/3/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT00835926
1460,"Finasteride 5 mg Tablets, Non-fasting",Completed,Has Results,Healthy,Drug: Finasteride 5 mg tablets|Drug: PROSCAR® 5mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/2/2019,7/2/2019,https://ClinicalTrials.gov/show/NCT00835796
1461,Finasteride 5 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Finasteride 5 mg tablets|Drug: PROSCAR®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/2/2019,6/2/2019,https://ClinicalTrials.gov/show/NCT00835666
1462,Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Fexofenadine 180 mg tablets|Drug: ALLEGRA® 180 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/2/2019,1/2/2019,https://ClinicalTrials.gov/show/NCT00835640
1463,"15 mg Mirtazapine Orally Disintegrating Tablets, Fasting",Completed,Has Results,Healthy,Drug: Mirtazapine 15 mg (Orally Disintegrating) Tablets|Drug: REMERON SolTab® 15 mg Orally Disintegrating Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,7/3/2019,8/3/2019,https://ClinicalTrials.gov/show/NCT00835575
1464,Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Fexofenadine 180 mg tablets|Drug: ALLEGRA® 180 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,3/2/2019,3/2/2019,https://ClinicalTrials.gov/show/NCT00835276
1465,Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Dapsone; Tretinoin|Drug: Tretinoin,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00835198
1466,Glimepiride 4 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Glimepiride 4 mg Tablets|Drug: AMARYL® 4 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,3/3/2019,3/3/2019,https://ClinicalTrials.gov/show/NCT00835172
1467,Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: divalproex sodium|Drug: Depakote®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/3/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT00834990
1468,"Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects",Completed,Has Results,Healthy,Drug: Carvedilol 25 mg tablets|Drug: COREG® 25 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,12/1/2019,12/1/2019,https://ClinicalTrials.gov/show/NCT00834873
1469,"Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects",Completed,Has Results,Healthy,Drug: Carvedilol 25 mg tablets|Drug: COREG® 25 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,12/1/2019,12/1/2019,https://ClinicalTrials.gov/show/NCT00834795
1470,"Azithromycin 600 Mg Tablets, Fasting",Completed,Has Results,Healthy,Drug: Azithromycin 600 mg Tablet|Drug: Zithromax® 600 mg Tablet,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/2/2019,10/2/2019,https://ClinicalTrials.gov/show/NCT00834756
1471,Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: divalproex sodium|Drug: Depakote®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/3/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT00834639
1472,Leflunomide 20 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Leflunomide 20 mg Tablets|Drug: ARAVA™ 20 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/2/2019,7/2/2019,https://ClinicalTrials.gov/show/NCT00834418
1473,Glimepiride 4 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Glimepiride 4 mg Tablets|Drug: AMARYL® 4 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/3/2019,3/3/2019,https://ClinicalTrials.gov/show/NCT00834340
1474,Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Dapsone|Drug: Tazarotene,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00834210
1475,"15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting",Completed,Has Results,Healthy,Drug: Mirtazapine 15 mg (Orally Disintegrating) Tablets|Drug: REMERON SolTab® 15 mg Orally Disintegrating Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,7/3/2019,8/3/2019,https://ClinicalTrials.gov/show/NCT00834197
1476,A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin,Completed,Has Results,Ocular Hypertension,Drug: Loteprednol etabonate ophthalmic suspension 0.5%|Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).,Allergan,Allergan,,,,,,,,Industry,Observational,1/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00834171
1477,"Azithromycin 600 Mg Tablets, Fed",Completed,Has Results,Healthy,Drug: Azithromycin 600 mg Tablet|Drug: Zithromax® 600 mg Tablet,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,7/2/2019,8/2/2019,https://ClinicalTrials.gov/show/NCT00834132
1478,Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Terbinafine HCl 250mg tablets|Drug: Lamisil® 250 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/2/2019,1/2/2019,https://ClinicalTrials.gov/show/NCT00833664
1479,A Study in Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction,Drug: Placebo|Drug: Tadalafil,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,2/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00833638
1480,Terbinafine HCl 250 mg Tablet Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Terbinafine HCl 250mg tablets|Drug: Lamisil® 250 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/2/2019,1/2/2019,https://ClinicalTrials.gov/show/NCT00833586
1481,Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Zolpidem 10 mg tablets|Drug: AMBIEN® 10 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/2/2019,2/2/2019,https://ClinicalTrials.gov/show/NCT00833521
1482,Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine,Completed,Has Results,Influenza,Biological: Fluzone®: Influenza virus vaccine 2004-2005 formulation,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,8/4/2019,2/6/2019,https://ClinicalTrials.gov/show/NCT00831987
1483,Study of Safety and Immunogenicity of Fluzone® in Healthy Children,Completed,Has Results,Influenza,Biological: Influenza Vaccine 2004-2005 Paediatric Formulation,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/4/2019,4/6/2019,https://ClinicalTrials.gov/show/NCT00831675
1484,Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Closed Loop,Medtronic Diabetes|Juvenile Diabetes Research Foundation,Medtronic Diabetes,Juvenile Diabetes Research Foundation,,,,,,Not Applicable,Industry|Other,Interventional,1/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00831389
1485,Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement,Completed,Has Results,Malocclusion,Device: OrthoAccel Device|Device: Sham Device,OrthoAccel Technologies Inc.,OrthoAccel Technologies Inc.,,,,,,,Phase 3,Industry,Interventional,2/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00830947
1486,A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome,Completed,Has Results,Acute Myelogenous Leukemia|High-Grade Myelodysplastic Syndrome,Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,2/10/2009,7/4/2011,https://ClinicalTrials.gov/show/NCT00830518
1487,A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Azithromycin|Drug: Zithromax®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/5/2019,11/5/2019,https://ClinicalTrials.gov/show/NCT00830336
1488,The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions,Completed,Has Results,Healthy,Drug: Ropinirole HCl 0.25 mg Tablets|Drug: Requip® 0.25 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,11/4/2019,11/4/2019,https://ClinicalTrials.gov/show/NCT00830219
1489,A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions,Completed,Has Results,Healthy,Other: Azithromycin|Drug: Zithromax®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,1/6/2019,1/6/2019,https://ClinicalTrials.gov/show/NCT00830206
1490,Zaleplon 10mg Capsules Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Zaleplon 10 mg Capsules|Drug: Sonata® 10 mg Capsules,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/4/2019,2/4/2019,https://ClinicalTrials.gov/show/NCT00829998
1491,Zaleplon 10 mg Capsules Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Zaleplon 10 mg Capsules|Drug: SONATA® 10 mg capsules,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/4/2019,3/4/2019,https://ClinicalTrials.gov/show/NCT00829868
1492,Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions,Completed,Has Results,Healthy,Drug: Doxycycline Monohydrate,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/6/2019,10/6/2019,https://ClinicalTrials.gov/show/NCT00829790
1493,Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Doxycycline Monohydrate,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/6/2019,10/6/2019,https://ClinicalTrials.gov/show/NCT00829764
1494,Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Dexmethylphenidate Hydrochloride,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/4/2019,6/4/2019,https://ClinicalTrials.gov/show/NCT00829712
1495,Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Dexmethylphenidate Hydrochloride,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/4/2019,6/4/2019,https://ClinicalTrials.gov/show/NCT00829673
1496,Ropinirole 0.25 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Ropinirole HCl 0.25 mg Tablets|Drug: Requip® 0.25 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/4/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00829504
1497,SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization,Completed,Has Results,Liver Neoplasms,Drug: SonoVue®,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 3,Industry,Interventional,6/10/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00829413
1498,Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Pravastatin,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,3/5/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00829309
1499,Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%,Completed,Has Results,Dry Eye Disease,Drug: Cyclosporine Ophthalmic Emulsion 0.05%,Allergan,Allergan,,,,,,,,Industry,Observational,1/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00827255
1500,"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects",Completed,Has Results,Cataract Extraction,Drug: Besifloxacin hydrochloride|Drug: moxifloxacin hydrochloride|Drug: gatifloxacin,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 1,Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00824070
1501,A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: timolol hemihydrate|Drug: timolol maleate,Vistakon Pharmaceuticals,Vistakon Pharmaceuticals,,,,,,,,Industry,Observational,1/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00823043
1502,Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL,Completed,Has Results,Cataracts,Device: AcrySof ReSTOR Aspheric IOL,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,12/8/2019,,https://ClinicalTrials.gov/show/NCT00818116
1503,Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin,Completed,Has Results,Type 2 Diabetes,Drug: AZD1656|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,1/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00817778
1504,Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation,Completed,Has Results,Acute Wounds,Other: Procellera™ Antimicrobial Dressing|Other: Mepilex® Border Lite|Device: Adhesive Bandage,Vomaris Innovations,Vomaris Innovations,,,,,,,Phase 2,Industry,Interventional,3/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00816101
1505,Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis,Completed,Has Results,"Blood Loss, Surgical","Biological: rThrombin, 1000 IU/mL",ZymoGenetics,ZymoGenetics,,,,,,,Phase 4,Industry,Interventional,1/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00813904
1506,Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Biological: octagam 10%,Octapharma,Octapharma,,,,,,,Phase 2,Industry,Interventional,2/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00812565
1507,Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial,Completed,Has Results,Breast Augmentation|Breast Reconstruction|Breast Revision,Device: Mentor Siltex® Contour Profile Gel Mammary Prosthesis,"Mentor Worldwide, LLC","Mentor Worldwide, LLC",,,,,,,Phase 3,Industry,Interventional,2/2/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00812097
1508,Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow,Completed,Has Results,Glaucoma,Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|Drug: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00811850
1509,An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|Drug: latanoprost 0.005%,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00811564
1510,8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension,Completed,Has Results,Stage 2 Hypertension,Drug: Valsartan/aliskiren|Drug: Valsartan,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,1/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00809926
1511,Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma,Completed,Has Results,Ocular Hypertension|Glaucoma,"Drug: AGN-210669 ophthalmic solution, 0.075%|Drug: AGN-210669 ophthalmic solution, 0.05%|Drug: AGN-210669 ophthalmic solution, 0.025%|Drug: bimatoprost ophthalmic solution 0.03%|Drug: AGN-210669 vehicle ophthalmic solution",Allergan,Allergan,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/9/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00809848
1512,Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression,Completed,Has Results,Normal Healthy Subject Population,Drug: Zegerid®|Drug: Prilosec OTC®,Procter and Gamble,Procter and Gamble,,,,,,,Phase 4,Industry,Interventional,11/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00808769
1513,Comparison of Three Soft Bifocal Contact Lenses,Completed,Has Results,Presbyopia,Device: balafilcon A|Device: senofilcon A production|Device: senofilcon A test,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/1/2008,12/1/2008,https://ClinicalTrials.gov/show/NCT00808340
1514,Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma,Completed,Has Results,"Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma|T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma|Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component",Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,2/10/2009,2/13/2013,https://ClinicalTrials.gov/show/NCT00807495
1515,Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System,Completed,Has Results,Diabetes,Device: Apollo Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,12/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00804596
1516,A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women,Completed,Has Results,Phase 1 Pharmacodynamic Study,Drug: Oral rsCT tablet|Drug: Oral Placebo Tablet|Drug: Fortical (rsCT) nasal spray,"Tarsa Therapeutics, Inc.","Tarsa Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,12/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00803686
1517,Trial Assessing Cooled Radiofrequency Denervation as a Treatment for Sacroiliac Joint Pain Using the Sinergy System,Completed,Has Results,Other Acute Pain|Chronic Pain,Device: Sinergy|Device: Placebo sham,Baylis Medical Company,Baylis Medical Company,,,,,,,Not Applicable,Industry,Interventional,6/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00802997
1518,ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Placebo|Drug: TrIP-2D|Drug: TrIP-2SS|Drug: TrIP-2SS + Foradil,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 2,Industry,Interventional,2/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00801684
1519,Circadian Ocular Perfusion Pressure and Ocular Blood Flow,Completed,Has Results,Glaucoma,Drug: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Drug: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,2/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00800540
1520,Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients,Completed,Has Results,Conjunctival Staining,Device: Complete Easy Rub|Device: ReNu MultiPlus|Device: Clear Care|Device: Contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00799422
1521,Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood,Completed,Has Results,Diabetes Mellitus,Device: Apollo Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00797563
1522,Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension,Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Hydrochlorothiazide,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,11/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00797316
1523,A New Glucose Meter With Alternative Site Testing,Completed,Has Results,Diabetes Mellitus,Device: Apollo Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00797212
1524,Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents,Completed,Has Results,"Dermatitis, Contact",Biological: T.R.U.E. Test,Allerderm,Allerderm,,,,,,,Phase 4,Industry,Interventional,11/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00795951
1525,Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age,Completed,Has Results,Allergic Rhinitis,Drug: Olopatadine Hydrochloride Nasal Spray 0.6%|Drug: Olopatadine Hydrochloride Nasal Spray Vehicle,Alcon Research,Alcon Research,,,,,,,Phase 2,Industry,Interventional,10/8/2019,,https://ClinicalTrials.gov/show/NCT00794144
1526,Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation,Completed,Has Results,Wounds,Drug: GLYC-101 Gel (0.1%)|Drug: GLYC-101 Gel (1.0%)|Drug: GLYC-101 Placebo,"Glycotex, Inc.","Glycotex, Inc.",,,,,,,Phase 2,Industry,Interventional,10/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00792688
1527,Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide,Completed,Has Results,Sinusitis,Device: Stratus Microflow Ethmoid Spacer,Acclarent,Acclarent,,,,,,,Phase 3,Industry,Interventional,8/8/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00791934
1528,Study to Evaluate Potential Food Effects,Completed,Has Results,Healthy,Drug: PG-760564,Procter and Gamble,Procter and Gamble,,,,,,,Phase 1,Industry,Interventional,8/5/2019,1/6/2019,https://ClinicalTrials.gov/show/NCT00791817
1529,Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 Days,Completed,Has Results,Healthy,Drug: Placebo|Drug: PG-760564,Procter and Gamble,Procter and Gamble,,,,,,,Phase 1,Industry,Interventional,8/5/2019,1/6/2019,https://ClinicalTrials.gov/show/NCT00791388
1530,Efficacy of Ketorolac 0.4% in Prostaglandin Suppression,Completed,Has Results,Inflammation,Drug: Ketorolac 0.4%|Drug: Lubricating Eye Drop,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,11/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00791323
1531,Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis,"Drug: Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Other: Olopatadine nasal spray vehicle, pH 3.7|Other: Olopatadine nasal spray vehicle, pH 7.0",Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,11/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00789555
1532,Staccato Loxapine Pulmonary Safety in Healthy Volunteers,Completed,Has Results,Healthy,Drug: Inhaled Placebo|Drug: Inhaled Loxapine,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,11/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00789360
1533,SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization,Completed,Has Results,Liver Neoplasms,Drug: SonoVue-enhanced ultrasound|Other: Unenhanced ultrasound,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 3,Industry,Interventional,9/9/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00788697
1534,Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus,Completed,Has Results,Hypertension|Diabetes Mellitus,Drug: Amlodipine|Drug: Hydrochlorothiazide (HCTZ)|Drug: Aliskiren,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,11/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00787605
1535,"Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting",Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Intranasal granisetron,"Shin Nippon Biomedical Laboratories, Ltd.","Shin Nippon Biomedical Laboratories, Ltd.",,,,,,,Phase 2,Industry,Interventional,10/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00787566
1536,Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals,Completed,Has Results,Sensorineural Hearing Loss,Device: The Hearing Laser|Device: Placebo Laser,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,8/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00787189
1537,Drug-Drug Interaction Study of Qualaquin and Midazolam,Completed,Has Results,Healthy,Drug: Midazolam Alone|Drug: Qualaquin (quinine) alone steady state|Drug: Midazolam and Qualaquin at steady state,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,3/7/2019,3/7/2019,https://ClinicalTrials.gov/show/NCT00785486
1538,Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone,Completed,Has Results,Healthy,Drug: Rosiglitazone 4 mg Tablets|Drug: Quinine Sulfate 324 mg Capsules,"Mutual Pharmaceutical Company, Inc.|Cetero Research, San Antonio","Mutual Pharmaceutical Company, Inc.","Cetero Research, San Antonio",,,,,,Phase 1,Industry|Other,Interventional,9/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00785213
1539,Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event,Completed,Has Results,Congestive Heart Failure,Drug: I-123 mIBG,GE Healthcare,GE Healthcare,,,,,,,,Industry,Observational,5/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00785044
1540,Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis,Completed,Has Results,Chronic Allergic Rhinitis|Nonallergic Rhinitis,Drug: Astepro Nasal Spray (0.1% azelastine hydrochloride)|Drug: Astelin Nasal Spray (0.1% azelastine hydrochloride),Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/6/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00783432
1541,Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care,Completed,Has Results,Coronary Artery Disease (CAD),,GE Healthcare,GE Healthcare,,,,,,,,Industry,Observational,9/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00783302
1542,Success Rate of Immediately Loaded Implants With Platform Switched Design Placed in Anterior Part of Mandible and Restored With Fixed Prostheses,Completed,Has Results,Edentulism,Device: Ankylos Implants|Device: Biomet 3i Prevail Implants,Dentsply International,Dentsply International,,,,,,,Phase 4,Industry,Interventional,9/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00780273
1543,Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline,Completed,Has Results,Pharmacokinetics,Drug: Theophylline 300mg|Drug: Quinine 648 mg|Drug: Theophylline 300 mg,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,8/7/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00779259
1544,Study of Magnetic Fields for Treatment of Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Device: The Resonator|Device: The Resonator control,"pico-tesla Magnetic Therapies, LLC","pico-tesla Magnetic Therapies, LLC",,,,,,,Phase 2,Industry,Interventional,8/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00779155
1545,A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use Conditions,Completed,Has Results,Coitus,Device: PD-F-5254|Device: 10855-096,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,1/8/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00779025
1546,Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Humalog|Drug: Humulin-R|Drug: Recombinant human hyaluronidase PH20 (rHuPH20)|Other: Liquid meal,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 2,Industry,Interventional,10/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00774800
1547,A Multi‐Center Investigation of Patient Acceptability of OPTI‐FREE RepleniSH® Multi-Purpose Disinfecting Solution (MPDS),Completed,Has Results,Myopia,Device: Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|Device: Contact Lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,9/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00772707
1548,Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis,Completed,Has Results,Allergic Rhinitis,Drug: Olopatadine 0.6% / Azelastine 137 mcg,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,10/8/2019,,https://ClinicalTrials.gov/show/NCT00772304
1549,Pilot Study of Incidence and Change in Existing Pressure Ulcers: TC500 Bed Compared With Standard Beds,Completed,Has Results,Pressure Ulcers,Device: P500 Mattress,Hill-Rom,Hill-Rom,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00771238
1550,Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: Corticosteroid|Other: Placebo|Drug: LCD,"NeoStrata Company, Inc.","NeoStrata Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00769184
1551,Defining the Conjunctival Staining Method: Instillation Volume and Time Course to Assess Staining With Lissamine Green,Completed,Has Results,Conjunctival Staining,Other: 2.5/5.0/10.0 ÂµL lissamine green,Alcon Research,Alcon Research,,,,,,,,Industry,Observational,8/8/2019,,https://ClinicalTrials.gov/show/NCT00768898
1552,Contact Sensitization Potential of 828 Ointment,Completed,Has Results,Healthy Volunteers,Device: HP828-101,Healthpoint,Healthpoint,,,,,,,Phase 1,Industry,Interventional,10/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00767676
1553,Maintenance of Platelet Inhibition With Cangrelor,Completed,Has Results,Acute Coronary Syndrome (ACS),Drug: cangrelor|Other: Placebo,The Medicines Company,The Medicines Company,,,,,,,Phase 2,Industry,Interventional,10/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00767507
1554,Cumulative Irritation Potential of 828 Ointment,Completed,Has Results,Healthy Volunteers,Device: HP828-101,Healthpoint,Healthpoint,,,,,,,Phase 1,Industry,Interventional,10/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00767455
1555,Retrospective Encore Reverse Shoulder Prosthesis Study,Completed,Has Results,Rotator Cuff Deficiency|Glenohumeral Arthritis,Device: Encore Reverse Shoulder Prosthesis,"Encore Medical, L.P.","Encore Medical, L.P.",,,,,,,,Industry,Observational,8/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00765037
1556,The 3DKnee™ System: A Post-Market Study,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Post Traumatic Arthritis|Varus Deformity|Avascular Necrosis,Device: 3DKnee,"Encore Medical, L.P.","Encore Medical, L.P.",,,,,,,Phase 4,Industry,Interventional,10/6/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00764673
1557,Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers,Completed,Has Results,Diabetic Foot Ulcer,Drug: doxycycline|Drug: placebo gel,NanoSHIFT LLC,NanoSHIFT LLC,,,,,,,Phase 2,Industry,Interventional,1/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00764361
1558,To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.,Completed,Has Results,Cataract,Device: DisCoVisc®|Drug: Healon|Drug: Amvisc Plus,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,5/8/2019,,https://ClinicalTrials.gov/show/NCT00763360
1559,The Efficacy of a Toothpaste to Reduce Sensitivity,Completed,Has Results,Dentin Hypersensitivity,"Drug: Triclosan, Silicon dioxide, fluoride|Drug: Triclosan, fluoride",Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,9/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00763269
1560,Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma,Drug: Travoprost 0.004% Ophthalmic Solution (Travatan)|Drug: Timolol 0.5% Ophthalmic Solution (Timoptic),Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,5/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00763061
1561,Collection of Gingival Crevicular Fluid From Periodontitis Patients,Completed,Has Results,Gingival Diseases,"Drug: Fluoride|Drug: Fluoride, triclosan",Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,3/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00763048
1562,Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG),Completed,Has Results,Angle-Closure Glaucoma,Drug: Travoprost 0.004% (Travatan)|Drug: Pilocarpine 1%,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,2/7/2019,,https://ClinicalTrials.gov/show/NCT00762645
1563,Phaco Versus Small Incision Cataract Surgery (SICS) Health Economic Study,Completed,Has Results,Cataract,Procedure: Phacoemulsification cataract extraction surgery|Procedure: Small incision cataract surgery,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,9/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00762606
1564,Compare Anti-inflammatory Dentifrices,Completed,Has Results,Gingivitis,Drug: Triclosan/Copolymer/fluoride toothpaste|Drug: Sodium monofluorophosphate toothpaste,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 4,Industry,Interventional,2/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00762528
1565,Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes,Completed,Has Results,Dental Plaque,Drug: Fluoride|Drug: Triclosan,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,2/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00762515
1566,Rotational Stability of the AcrySof® Toric,Completed,Has Results,Cataract,Device: AcrySof® Toric intraocular lens,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,5/8/2019,,https://ClinicalTrials.gov/show/NCT00762216
1567,Investigate Oral Bacteria in Adult Population,Completed,Has Results,Oral Bacteria,"Drug: Fluoride|Drug: Fluoride, Triclosan|Drug: Stannous Fluoride",Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,5/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00762177
1568,Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens,Completed,Has Results,Cataract,Device: SN60AT|Device: SN60WF,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,12/6/2019,,https://ClinicalTrials.gov/show/NCT00762021
1569,Compare the Clinical Efficacy of Prototype Toothpastes.,Completed,Has Results,Gingival Diseases,Drug: Fluoride|Drug: Triclosan and fluoride|Drug: Herbal Ingredient and fluoride,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,3/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00761930
1570,Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens,Completed,Has Results,Cataract,Device: AcrySof Toric IOL,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,10/6/2019,,https://ClinicalTrials.gov/show/NCT00760487
1571,Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population,Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Hydrochlorothiazide,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,9/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00760266
1572,Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome,Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: Decitabine,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,7/5/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00760084
1573,Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce,Completed,Has Results,Healthy,Drug: morphine sulfate sustained-release capsules|Drug: KADIAN (morphine sulfate sustained-release) capsules,Actavis Inc.,Actavis Inc.,,,,,,,Phase 1,Industry,Interventional,9/4/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00759954
1574,A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin,Completed,Has Results,Glaucoma,Drug: Brinzolamide 1% ophthalmic solution (Azopt)|Drug: Placebo eye drops|Drug: Latanoprost 0.005% ophthalmic solution (Xalatan),Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,10/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00759941
1575,Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions,Completed,Has Results,Healthy,Drug: morphine sulfate extended-release capsules|Drug: KADIAN (morphine sulfate extended-release) capsules,Actavis Inc.,Actavis Inc.,,,,,,,Phase 1,Industry,Interventional,8/6/2019,10/6/2019,https://ClinicalTrials.gov/show/NCT00759915
1576,Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions,Completed,Has Results,Healthy,Drug: morphine sulfate extended-release capsules|Drug: KADIAN (morphine sulfate extended-release) capsules,Actavis Inc.,Actavis Inc.,,,,,,,Phase 1,Industry,Interventional,8/6/2019,10/6/2019,https://ClinicalTrials.gov/show/NCT00759902
1577,LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia,Completed,Has Results,Alzheimer's Disease|Dementia,Behavioral: Lifezig,"Photozig, Inc.","Photozig, Inc.",,,,,,,Phase 2,Industry,Interventional,8/6/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00759863
1578,Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions,Completed,Has Results,Healthy,Drug: morphine sulfate sustained-release capsules|Drug: KADIAN (morphine sulfate sustained-release) capsules,Actavis Inc.,Actavis Inc.,,,,,,,Phase 1,Industry,Interventional,9/4/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00759759
1579,"ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial",Completed,Has Results,Vascular Disease,Device: ArterX Surgical Sealant|Device: Gelfoam and Thrombin,"Tenaxis Medical, Inc.","Tenaxis Medical, Inc.",,,,,,,Phase 3,Industry,Interventional,9/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00759681
1580,Visual Function and Patient Satisfaction After Bilateral Implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT),Completed,Has Results,Cataract,Device: Acrysof Natural ReSTOR SN60D3|Device: Acrysof Natural Monofocal SN60AT,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,5/7/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00759668
1581,"Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)",Completed,Has Results,Anxious Major Depressive Disorder,Drug: AZD2327|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,1/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00759395
1582,Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions,Completed,Has Results,Healthy,Drug: morphine sulfate sustained-release capsules|Drug: KADIAN,Actavis Inc.,Actavis Inc.,,,,,,,Phase 1,Industry,Interventional,8/4/2019,9/4/2019,https://ClinicalTrials.gov/show/NCT00759356
1583,Evaluate Clinical Research From Commerical Oral Care Products,Completed,Has Results,Gingival Diseases,Drug: Fluoride|Drug: Triclosan/Fluoride|Drug: Chlorhexidine Gluconate,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,1/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00759187
1584,Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL,Completed,Has Results,Visual Acuity,Device: RESTOR IOL Model SA60D3,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,5/7/2019,,https://ClinicalTrials.gov/show/NCT00759096
1585,Investigation of Dental Plaque and Gingival Index,Completed,Has Results,Dental Plaque,Drug: Sodium Monofluorophosphate|Drug: Triclosan/Fluoride/Copolymer,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,2/8/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00759031
1586,The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo,Completed,Has Results,Secondarily Infected Traumatic Lesions (SITL)|Impetigo,Drug: 2% TD1414 Cream,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,12/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00758862
1587,Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).,Completed,Has Results,Cataract,Device: Model SN60WF|Device: Model MA60AC,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,1/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00758745
1588,Train New Examiners Via Modified Gingival Margin Plaque,Completed,Has Results,Dental Plaque,Drug: Fluoride|Drug: Triclosan/Fluoride,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,3/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00758563
1589,Visual Function After Bilateral Implantation of AcrySof® Toric,Completed,Has Results,Visual Function,Device: AcrySof® Toric IOL|Device: AcrySof Natural,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,4/7/2019,,https://ClinicalTrials.gov/show/NCT00758550
1590,Clinical Study to Compare Dental Plaque Control,Completed,Has Results,Dental Plaque,Drug: Fluoride|Drug: Triclosan/Fluoride,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,9/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00758394
1591,Clinical Study to Evaluate Dental Plaque,Completed,Has Results,Gingival Diseases,Drug: Triclosan/Fluoride|Drug: Fluoride/triclosan,Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,5/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00758290
1592,Efficacy and Acceptability of Two Lubricant Eye Drops,Completed,Has Results,Dry Eye Syndromes,Drug: Lubricant Eye Drops (Optive™)|Drug: Lubricating Eye Drops (blink® Tears),Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,9/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00756678
1593,Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops,Completed,Has Results,Dry Eye,Other: Systane Ultra Lubricant Eye Drops|Other: Optive Lubricant Eye Drops|Other: Blink Tears|Other: GenTeal Moderate Lubricant Eye Drops,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,9/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00756093
1594,Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®,Completed,Has Results,Influenza|Orthomyxoviridae Infections,Biological: Influenza Virus Vaccine No Preservative: Pediatric Dose,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00755274
1595,"Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.",Completed,Has Results,Barrett's Esophagus|Esophageal Cancer,Device: Cryo Spray Ablation,"CSA Medical, Inc.|University of Miami","CSA Medical, Inc.",University of Miami,,,,,,Phase 4,Industry|Other,Interventional,2/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00754468
1596,Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses,Completed,Has Results,Breast Reconstruction|Breast Augmentation|Breast Revision,"Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface","Mentor Worldwide, LLC","Mentor Worldwide, LLC",,,,,,,Phase 3,Industry,Interventional,9/1/2000,6/12/2019,https://ClinicalTrials.gov/show/NCT00753922
1597,Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS),Completed,Has Results,"Sleep Apnea, Obstructive",Device: SleepStyle 200 Auto Series CPAP Humidifier,Fisher and Paykel Healthcare,Fisher and Paykel Healthcare,,,,,,,Not Applicable,Industry,Interventional,5/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00750165
1598,Crossover Study of the Safety and PK Properties of Proellex®,Completed,Has Results,Pharmacokinetics,Drug: Proellex,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1,Industry,Interventional,8/11/2008,10/23/2008,https://ClinicalTrials.gov/show/NCT00749879
1599,Acute Comfort and Blur of Systane Ultra and Systane,Completed,Has Results,Dry Eye,Other: Systane Ultra Lubricant Eye Drops|Other: Systane Lubricant Eye Drops,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,7/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00748865
1600,Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC,Completed,Has Results,Healthy Volunteers,Drug: Lisdexamfetamine Dimesylate|Drug: Adderall XR (mixed salts amphetamine),Shire,Shire,,,,,,,Phase 1,Industry,Interventional,9/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00746733
1601,A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults,Completed,Has Results,Sleep Apnea,Drug: VI-0521|Drug: placebo,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,8/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00745251
1602,A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination,Completed,Has Results,Influenza,"Biological: Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,8/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00743275
1603,"Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects",Completed,Has Results,Drug Interactions,Drug: Proellex|Drug: CYP1A2 probe|Drug: CYP2C9 probe|Drug: CYP2C19 probe|Drug: CYP2D6 probe|Drug: CYP3A4 probe,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1,Industry,Interventional,7/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00741468
1604,Study Comparing the Efficacy of Two Ibuprofen Formulations,Completed,Has Results,Pain,Drug: placebo|Drug: ibuprofen Formulation 1|Drug: ibuprofen Formulation 2,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 4,Industry,Interventional,8/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00740857
1605,Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans,Completed,Has Results,Hypertension,Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Drug: Amlodipine: 8 weeks,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,7/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00739596
1606,Study Assessing High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations,Completed,Has Results,Cerebral Palsy,Device: Vest Treatment (high frequency chest wall oscillation),Hill-Rom,Hill-Rom,,,,,,,Not Applicable,Industry,Interventional,8/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00739310
1607,S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease,Completed,Has Results,Superficial Femoral Artery Disease,Device: S.M.A.R.T. ® Stent,Cordis Corporation,Cordis Corporation,,,,,,,Not Applicable,Industry,Interventional,8/8/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00739102
1608,A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events,Completed,Has Results,Postoperative Complications|Memory Disorders,Device: pulsatile saline lavage|Device: carbon dioxide lavage,Kinamed Incorporated|US Department of Veterans Affairs,Kinamed Incorporated,US Department of Veterans Affairs,,,,,,Not Applicable,Industry|U.S. Fed,Interventional,12/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00736125
1609,Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL),Completed,Has Results,Cataract,Device: ReSTOR,Alcon Research,Alcon Research,,,,,,,,Industry,Observational,6/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00733512
1610,Evaluation of Daily Disposable Lenses With Multi-Purpose Solution (MPS),Completed,Has Results,Myopia,Device: Nelfilcon A contact lens|Device: Etafilcon A contact lens|Device: FID 107027 solution,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,1/8/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00733291
1611,DisCoVisc Comparative Evaluation,Completed,Has Results,Cataracts,Device: DisCoVisc|Device: DuoVisc|Device: BioVisc|Device: Healon5|Device: Amvisc Plus,Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,5/7/2019,,https://ClinicalTrials.gov/show/NCT00732225
1612,Low Cylinder Toric,Completed,Has Results,Cataracts,Device: Toric IOL (SN60T3),Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,6/7/2019,,https://ClinicalTrials.gov/show/NCT00732030
1613,Contralateral ReSTOR / Monofocal or Phakic Eye,Completed,Has Results,Cataracts,Device: ReSTOR,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,6/7/2019,,https://ClinicalTrials.gov/show/NCT00731640
1614,A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.,Completed,Has Results,Echocardiography,"Drug: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)",GE Healthcare,GE Healthcare,,,,,,,Phase 4,Industry,Interventional,5/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00730964
1615,A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects,Completed,Has Results,Obesity,Device: BioEnterics® Intragastric Balloon|Other: Behavioral modification,"Apollo Endosurgery, Inc.","Apollo Endosurgery, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/8/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00730327
1616,Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma,Completed,Has Results,Renal Cell Carcinoma,Drug: IMO-2055,"Idera Pharmaceuticals, Inc.","Idera Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,6/4/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00729053
1617,A Study of Osseotite Certain Prevail Implants Used to Support Short Fixed Bridges With Immediate Occlusal Loading.,Completed,Has Results,Partial Edentulism|Tooth Disease,,Zimmer Biomet,Zimmer Biomet,,,,,,,,Industry,Observational,3/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00728962
1618,A Study of Certain Prevail Implants Used for the Preservation of Crestal Bone in Short Fixed Bridge Cases.,Completed,Has Results,Partial Edentulism|Tooth Disease,Device: Dental implant Osseotite Prevail|Device: Dental implant Osseotite,Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,3/5/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00728754
1619,Phase I Trial of an Investigational Small Pox Medication,Completed,Has Results,Orthopoxviral Disease|Smallpox|Monkey Pox,Drug: ST-246 Days 1 - 3|Drug: ST-246 Days 11 - 13,SIGA Technologies|National Institutes of Health (NIH),SIGA Technologies,National Institutes of Health (NIH),,,,,,Phase 1,Industry|NIH,Interventional,8/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00728689
1620,36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds,Completed,Has Results,Meningitis|Meningococcal Disease,Biological: None administered in this study,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,,Industry,Observational,7/5/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00728260
1621,A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions,Completed,Has Results,Healthy,Drug: Quinine Sulfate Capsules 324 mg|Drug: Quinine Sulphate Tablets 300 mg,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,2/4/2019,3/4/2019,https://ClinicalTrials.gov/show/NCT00727272
1622,Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects,Completed,Has Results,Healthy,Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: Venlafaxine Extended Release (VEN ER),Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 1,Industry,Interventional,6/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00727064
1623,The Medtronic RESOLUTE US Clinical Trial,Completed,Has Results,Coronary Artery Disease,Device: Resolute Zotarolimus-Eluting Coronary Stent,Medtronic Vascular,Medtronic Vascular,,,,,,,Not Applicable,Industry,Interventional,7/8/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT00726453
1624,A Prospective Study Evaluating the Performance of Nanotite Osseotite Implants When Placed by Graduate Student Programs,Completed,Has Results,Tooth Disease|Partial Edentulism,Device: Nanotite dental implant|Device: Osseotite dental implant,Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,4/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00726063
1625,Evaluation of Deposits on Contact Lenses Worn Extended Wear,Completed,Has Results,Myopia,Device: balafilcon A contact lens (PureVision)|Device: etafilcon A contact lens (Acuvue2),Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,3/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00725530
1626,Evaluation of Deposits on Contact Lenses Worn Daily Wear,Completed,Has Results,Refractive Error,Device: Balafilcon A contact lenses (PureVision)|Device: Etafilcon A contact lenses (Acuvue2),Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,3/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00725153
1627,Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA,Completed,Has Results,Cataract,Device: ReSTOR|Device: Tecnis|Device: Acri.LISA,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,7/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00721253
1628,Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates,Completed,Has Results,Obesity,Procedure: Reduction Gastroplasty,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,4/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00721227
1629,Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients,Completed,Has Results,Anemia,Drug: Venofer,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 2,Industry,Interventional,1/6/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00721188
1630,Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3,Completed,Has Results,Cataract,Device: ReSTOR,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,9/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00719732
1631,"A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery",Completed,Has Results,Major Upper or Lower Abdominal Surgery,Drug: Oral sufentanil|Drug: Placebo,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,8/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00718081
1632,Evaluation of High-Frequency Chest Wall Oscillation,Completed,Has Results,Airway Secretion Clearance,Device: Airway clearance Device,Hill-Rom,Hill-Rom,,,,,,,Not Applicable,Industry,Interventional,6/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00717873
1633,Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease,Completed,Has Results,Keratoconjunctivitis Sicca,"Drug: cyclosporine ophthalmic emulsion 0.05%, artificial tears",Allergan,Allergan,,,,,,,,Industry,Observational,9/4/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00717418
1634,"Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)",Completed,Has Results,Open-Angle Glaucoma|Ocular Hypertension,"Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%",Allergan,Allergan,,,,,,,,Industry,Observational,9/4/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00716742
1635,Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia,Completed,Has Results,Attention Deficit Hyperactivity Disorder|Dyslexia,Drug: Atomoxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,9/8/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT00716274
1636,Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.,Completed,Has Results,Acne Vulgaris,Drug: Adapalene Gel|Drug: Tretinoin Gel,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 4,Industry,Interventional,1/8/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00714714
1637,Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing,Completed,Has Results,Wounds,Drug: Xenaderm Vehicle|Other: Placebo comparator,Healthpoint,Healthpoint,,,,,,,Phase 2,Industry,Interventional,6/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00713349
1638,"DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus",Completed,Has Results,Cataract,Device: DisCoVisc|Device: DuoVisc|Device: Healon5|Device: Amvisc Plus,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,10/7/2019,,https://ClinicalTrials.gov/show/NCT00712244
1639,A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects,Completed,Has Results,Obesity,Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day|Drug: Placebo|Other: fMRI scan,"Orexigen Therapeutics, Inc","Orexigen Therapeutics, Inc",,,,,,,Phase 2,Industry,Interventional,9/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00711477
1640,Intraoperative Floppy Iris Syndrome,Completed,Has Results,Cataract|Floppy Iris Syndrome,Device: DisCoVisc|Device: Healon5,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,6/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00711347
1641,Blue Light Intraocular Lenses (IOLs) and Photostress,Completed,Has Results,Cataract,,Alcon Research,Alcon Research,,,,,,,,Industry,Observational,1/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00710996
1642,Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1,Completed,Has Results,Cataract,Device: AcrySof ReSTOR Aspheric IOL model SN6AD1,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,10/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00710931
1643,Evaluation of a Multi-Purpose Solution,Completed,Has Results,Contact Lens Solutions,Device: Bausch & Lomb Multi-Purpose Solution,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,7/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00710879
1644,NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study,Completed,Has Results,Plaque Psoriasis,Other: LCD Solution with NB-UVB Phototherapy|Device: NB-UVB Light Device (311-315 nm),"NeoStrata Company, Inc.","NeoStrata Company, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00708851
1645,Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes,Completed,Has Results,Dental Caries,Drug: Sodium Fluoride (NaF)|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00708305
1646,In Situ Caries Efficacy of Fluoride Toothpastes,Completed,Has Results,Caries,Drug: NaF|Drug: Placebo|Drug: NaMFP,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00708097
1647,Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors,Completed,Has Results,Cancer,Drug: PG-11047,Progen Pharmaceuticals,Progen Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,3/5/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00705653
1648,"Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20",Completed,Has Results,Diabetes Mellitus,Drug: Humalog|Drug: Humulin-R|Drug: Recombinant human hyaluronidase PH20 (rHuPH20),Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 1,Industry,Interventional,12/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00705536
1649,"Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis",Completed,Has Results,Conjunctivitis,Drug: loteprednol etabonate and tobramycin|Drug: loteprednol etabonate|Drug: Tobramycin|Drug: Vehicle of Zylet,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 4,Industry,Interventional,6/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00705159
1650,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Completed,Has Results,Cataract,Drug: Bromfenac|Drug: Placebo,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,6/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00704418
1651,Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,6/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00704353
1652,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Iron Dextran,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,6/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00704028
1653,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Standard Medical Care (SMC) for the treatment of IDA,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,7/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00703937
1654,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Completed,Has Results,Cataract,Drug: bromfenac ophthalmic solution|Drug: placebo,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,6/8/2019,,https://ClinicalTrials.gov/show/NCT00703781
1655,Evaluation of SYSTANE Ultra Lubricant Eye Drops,Completed,Has Results,Dry Eye,Other: SYSTANE Ultra|Other: Optive,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,6/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00702377
1656,A Comparison of Two Contact Lenses,Completed,Has Results,Refractive Error|Myopia,Device: senofilcon A|Device: balafilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00700752
1657,Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery,Completed,Has Results,Ocular Inflammation,Drug: Loteprednol Etabonate|Drug: Vehicle of Ophthalmic Loteprednol Etabonate,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,6/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00699153
1658,Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse,Completed,Has Results,Opioid Abuse,Drug: Acurox 5/30mg taken first|Drug: Oxycodone 5mg taken first,Acura Pharmaceuticals Inc.,Acura Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,3/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00699010
1659,Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%,Completed,Has Results,Erythematous Rosacea,Drug: 0.18% COL-118 facial gel (1.8 mg brimonidine)|Drug: 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|Drug: Advanced Eye Relief|Drug: COL-118 facial gel vehicle,Galderma,Galderma,,,,,,,Phase 2,Industry,Interventional,5/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00697541
1660,Tobramycin Tear Concentrations,Completed,Has Results,Dry Eye,Drug: TOBRADEX Ophthalmic Suspension|Drug: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Drug: TOBREX Ophthalmic Solution,Alcon Research,Alcon Research,,,,,,,Phase 1,Industry,Interventional,6/8/2019,,https://ClinicalTrials.gov/show/NCT00695435
1661,Evaluation of a Diabetes Data Management System,Completed,Has Results,Diabetes,,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,,Industry,Observational,7/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00694070
1662,Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial,Completed,Has Results,Seasonal Allergic Rhinitis,"Drug: Olopatadine HCL Nasal Spray, 0.6%|Drug: Fluticasone Propionate Nasal Spray, 50 mcg",Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,5/8/2019,,https://ClinicalTrials.gov/show/NCT00691665
1663,Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants,Completed,Has Results,Breast Reconstruction,Device: Natrelle(TM) Silicone-Filled Breast Implants,Allergan Medical|Allergan,Allergan Medical,Allergan,,,,,,Not Applicable,Industry,Interventional,12/1/1997,12/12/2019,https://ClinicalTrials.gov/show/NCT00691327
1664,Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear,Completed,Has Results,Ametropia,Device: Carboxymethylcellulose sodium and Glycerin|Device: Carboxymethylcellulose sodium,Allergan,Allergan,,,,,,,Phase 2|Phase 3,Industry,Interventional,3/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00691197
1665,Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study,Completed,Has Results,Breast Augmentation|Breast Reconstruction|Revision of Augmentation or Reconstruction,Device: Style 410 Silicone-Filled Breast Implants,Allergan Medical|Allergan,Allergan Medical,Allergan,,,,,,Not Applicable,Industry,Interventional,2/1/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00690339
1666,Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants,Completed,Has Results,Breast Augmentation|Breast Reconstruction|Revision of Augmentation or Reconstruction,Device: Natrelle(TM) Silicone-Filled Breast Implants,Allergan Medical|Allergan,Allergan Medical,Allergan,,,,,,Not Applicable,Industry,Interventional,1/1/1999,8/11/2019,https://ClinicalTrials.gov/show/NCT00689871
1667,Easypod United States User Trial,Completed,Has Results,Growth Hormone Deficiency,Device: easypod,EMD Serono,EMD Serono,,,,,,,Phase 4,Industry,Interventional,3/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00689260
1668,Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model,Completed,Has Results,Allergic Conjunctivitis,Drug: Prednisolone Acetate 1%|Drug: Prednisolone Acetate 0.12%|Drug: Loteprednol Etabonate 0.2%|Drug: Placebo,"ORA, Inc.","ORA, Inc.",,,,,,,Phase 4,Industry,Interventional,5/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00689078
1669,Fed Bioavailability Study of Zonisamide Capsules,Completed,Has Results,Healthy,Drug: Zonisamide 100 mg Capsule|Drug: Zonisamide (Zonegran®) 100 mg Capsule,"Mutual Pharmaceutical Company, Inc.","Mutual Pharmaceutical Company, Inc.",,,,,,,Phase 1,Industry,Interventional,1/5/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00687167
1670,Phase IIA Study in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: AZD2624|Drug: Olanzapine|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,5/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00686998
1671,AngioSculpt® Coronary Bifurcation Study,Completed,Has Results,Coronary Artery Disease|Myocardial Ischemia,Device: AngioSculpt® Scoring Balloon Catheter|Device: AngioSculpt Scoring Balloon Catheter,"AngioScore, Inc.","AngioScore, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00686647
1672,ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL),Completed,Has Results,Cataract,Device: ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Device: ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,6/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00684138
1673,Tear Film Break-up Time After Instillation of Artificial Tears,Completed,Has Results,Keratoconjunctivitis Sicca,Drug: glycerin|Drug: polyethylene glycol 400/propylene glycol,"Eyeon Therapeutics, Inc.","Eyeon Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00681265
1674,Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System,Completed,Has Results,Sensorineural Hearing Loss,Device: Nucleus Hybrid L24,Cochlear,Cochlear,,,,,,,Not Applicable,Industry,Interventional,4/8/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00678899
1675,Pivotal Study for the FLAIR Endovascular Stent Graft,Completed,Has Results,Stenoses,Device: FLAIR Endovascular Stent Graft|Procedure: PTA,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,1/1/2019,6/4/2019,https://ClinicalTrials.gov/show/NCT00678249
1676,Post-Approval Study for the FLAIR Endovascular Stent Graft,Completed,Has Results,"Stenosis of Vascular Prosthetic Devices, Implants and Grafts",Device: FLAIR Endovascular Stent Graft|Procedure: PTA,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,12/8/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00677235
1677,Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT),Completed,Has Results,Heart Failure,Device: AV Delay programming through cardiac resynchronization therapy,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,5/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00677014
1678,XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1),Completed,Has Results,Coronary Artery Disease,Device: XIENCE V® Everolimus Eluting Coronary Stent,Abbott Medical Devices,Abbott Medical Devices,,,,,,,,Industry,Observational,7/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00676520
1679,Acute Comfort of Lubricant Eye Drops FID 112903,Completed,Has Results,Dry Eye,Other: Lubricant Eye Drops FID 112903|Other: Optive Lubricant Eye Drops,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,5/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00673855
1680,The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance,Completed,Has Results,Dry Eye,Other: Systane Ultra Lubricant Eye Drops|Other: Optive Lubricant Eye Drops,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,5/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00673764
1681,Guanfacine Immediate-release Electrocardiogram Results (QTc) Study,Completed,Has Results,Healthy Volunteers,Drug: immediate release guanfacine hydrochloride|Drug: moxifloxacin|Drug: Placebo,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,4/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00672984
1682,Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386,Completed,Has Results,Pain,Drug: AZD1386|Drug: Naproxen|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,4/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00672646
1683,Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.,Completed,Has Results,"Hepatitis, Chronic|Hepatitis C Virus",Drug: Small Molecule Agent (PF-868554),Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00671671
1684,Oral Nadolol for the Treatment of Adults With Mild Asthma,Completed,Has Results,Asthma,Drug: nadolol,"Invion, Inc.|University of Houston|Sandler Program for Asthma Research|Baylor College of Medicine","Invion, Inc.",University of Houston,Sandler Program for Asthma Research|Baylor College of Medicine,Sandler Program for Asthma Research,Baylor College of Medicine,,,Phase 1|Phase 2,Industry|Other,Interventional,1/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00670267
1685,Long-term Safety of Minocycline in Patients With Gum Disease,Completed,Has Results,Periodontitis,Drug: Minocycline HCl microspheres,OraPharma,OraPharma,,,,,,,Phase 4,Industry,Interventional,12/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00668746
1686,"The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy",Completed,Has Results,Hypertension,Drug: valsartan and amlodipine,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,3/8/2019,,https://ClinicalTrials.gov/show/NCT00666536
1687,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Completed,Has Results,Osteoarthritis,Drug: PN 400 (VIMOVO)|Drug: celebrex|Other: Placebo|Drug: Rescue Antacid,POZEN,POZEN,,,,,,,Phase 3,Industry,Interventional,4/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00665431
1688,Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves,Completed,Has Results,Unilateral Carpal Tunnel Syndrome,Device: StimRouter System,Bioness Inc,Bioness Inc,,,,,,,Phase 1|Phase 2,Industry,Interventional,4/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00665132
1689,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Completed,Has Results,Osteoarthritis,Drug: PN 400 (VIMOVO)|Drug: celebrex|Drug: Placebo|Drug: Rescue Antacid,POZEN,POZEN,,,,,,,Phase 3,Industry,Interventional,4/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00664560
1690,Application of the Apsara Thermal Wand System,Completed,Has Results,Tightening of Skin Laxity,Device: Apsara Thermal Wand System,Apsara Medical Corporation,Apsara Medical Corporation,,,,,,,Early Phase 1,Industry,Interventional,4/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00662389
1691,Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism,Completed,Has Results,Aldehyde Dehydrogenase-2 (ALDH2) Deficiency,Drug: Antizol|Drug: Placebo|Other: Ethanol,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 2,Industry,Interventional,4/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00661141
1692,A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Aliskiren|Drug: Irbesartan|Drug: Captopril,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,4/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00660309
1693,Clinical Application of BioCleanse Meniscus,Completed,Has Results,Tear of Meniscus of Knee,Other: BioCleanse Meniscus,RTI Surgical,RTI Surgical,,,,,,,,Industry,Observational,4/8/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00659880
1694,Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a New Packaging Configuration,Completed,Has Results,Comfort,Device: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Device: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,3/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00659815
1695,Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940,Completed,Has Results,Pain,Drug: AZD1940|Drug: Naproxen|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,2/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00659490
1696,Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension,Completed,Has Results,Intradialytic Hypotension,Drug: Droxidopa|Drug: Placebo,Chelsea Therapeutics,Chelsea Therapeutics,,,,,,,Phase 2,Industry,Interventional,12/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00657046
1697,Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation,Completed,Has Results,Wounds,Drug: Placebo gel|Drug: GLYC-101 gel (1.0 %),"Glycotex, Inc.","Glycotex, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,3/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00656474
1698,Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency,Completed,Has Results,Interdental Papillary Insufficiency,Biological: Autologous Human Fibroblasts (azficel-T),"Fibrocell Technologies, Inc.","Fibrocell Technologies, Inc.",,,,,,,Phase 2,Industry,Interventional,1/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00655889
1699,The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects,Completed,Has Results,Healthy,Drug: Dasatinib + Omeprazole,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,4/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00655746
1700,Safety and Effectiveness of JUVÉDERM™ Injectable Gel With Lidocaine,Completed,Has Results,Nasolabial Folds,Device: JUVÉDERM™ Injectable Gel with Lidocaine|Device: JUVÉDERM™ Injectable Gel,Allergan Medical|Allergan,Allergan Medical,Allergan,,,,,,Not Applicable,Industry,Interventional,4/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00653861
1701,Effect of Collagenase on Healing and Scarring,Completed,Has Results,Scarring|Impaired Wound Healing,Drug: Collagenase Santyl|Drug: Collagenase Santyl Vehicle,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,4/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00651820
1702,A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Metoprolol ER (TM),Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,11/7/2019,,https://ClinicalTrials.gov/show/NCT00648895
1703,A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD),Completed,Has Results,Hyperphosphatemia|End-stage Renal Disease,Drug: ferric citrate,Keryx Biopharmaceuticals|Collaborative Study Group (CSG),Keryx Biopharmaceuticals,Collaborative Study Group (CSG),,,,,,Phase 2,Industry|Other,Interventional,3/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00648167
1704,Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage,Completed,Has Results,Photoaging,"Drug: adapalene gel, 0.3%|Drug: tretinoin 0.05% emollient cream","Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 3,Industry,Interventional,4/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00647556
1705,Drug Interaction Study,Completed,Has Results,Antivirals/HIV,Drug: Rifabutin|Drug: Rifabutin + Atazanavir + Ritonavir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,4/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00646776
1706,Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis,Completed,Has Results,Staphylococcal Sepsis,Drug: Placebo|Drug: Pagibaximab 50 mg/mL,Biosynexus Incorporated,Biosynexus Incorporated,,,,,,,Phase 2|Phase 3,Industry,Interventional,3/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00646399
1707,Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery,Completed,Has Results,Ocular Inflammation,Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment|Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,3/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00645671
1708,Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment,Completed,Has Results,Healthy,Other: Ointment Vehicle|Drug: Xenaderm,Healthpoint,Healthpoint,,,,,,,Phase 1,Industry,Interventional,3/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00645164
1709,Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection,Completed,Has Results,HIV -1 Infection|HIV Infections,Drug: PRO 140 (humanized monoclonal antibody to CCR5)|Drug: Placebo Comparator,"CytoDyn, Inc.","CytoDyn, Inc.",,,,,,,Phase 2,Industry,Interventional,3/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00642707
1710,"Comparative Performance of PureVision, Acuvue Oasys and O2Optix",Completed,Has Results,Myopia,Device: PureVision Contact Lens|Device: Acuvue Oasys Contact Lens|Device: O2Optix Contact lens,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 4,Industry,Interventional,2/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00640341
1711,A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354,Completed,Has Results,Asthma|Healthy,Biological: CAT-354 150 mg (intravenous)|Biological: CAT-354 150 mg (subcutaneous)|Biological: CAT-354 300 mg (subcutaneous),MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,4/11/2008,6/7/2008,https://ClinicalTrials.gov/show/NCT00638989
1712,Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone,Completed,Has Results,Opioid-related Disorders,Drug: Buprenorphine soluble film|Drug: Buprenorphine/naloxone film strip|Drug: Placebo,Indivior Inc.,Indivior Inc.,,,,,,,Phase 2,Industry,Interventional,3/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00637000
1713,Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution,Completed,Has Results,Contact Lens Solutions,Device: Bausch & Lomb Multipurpose Solution - Rub Care|Device: Bausch & Lomb Multipurpose Solution - No Rub Care|Device: Ciba Vision Aquify Multipurpose Solution,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Not Applicable,Industry,Interventional,3/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00636363
1714,Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid,Completed,Has Results,HIV Infections,,"Chembio Diagnostic Systems, Inc.|University of Maryland","Chembio Diagnostic Systems, Inc.",University of Maryland,,,,,,,Industry|Other,Observational,3/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00636220
1715,"Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen",Completed,Has Results,Cutaneous Leishmaniasis,Biological: Leishmania tropica Skin Test Antigen (LtSTA)|Biological: Leishmania tropica Skin Test Antigen Placebo (Placebo),"Nielsen BioSciences, Inc.|U.S. Army Medical Research and Development Command","Nielsen BioSciences, Inc.",U.S. Army Medical Research and Development Command,,,,,,Phase 2,Industry|U.S. Fed,Interventional,8/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00633009
1716,A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE),Completed,Has Results,Leiomyoma|Uterine Fibroids|Uterine Neoplasms|Menorrhagia|Leiomyomatosis,Procedure: Uterine Fibroid Embolization (UFE)|Device: Contour SE™ Microspheres|Device: Embosphere® Microspheres,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,1/6/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00628901
1717,Staccato Loxapine in Agitated Patients With Schizophrenia,Completed,Has Results,Patients With Schizophrenia and Acute Agitation,Drug: Inhaled loxapine 5 mg|Drug: Inhaled loxapine 10 mg|Drug: Inhaled placebo,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,2/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00628589
1718,Coloplast DialogueStudy,Completed,Has Results,Stoma,Device: SenSura,Coloplast A/S,Coloplast A/S,,,,,,,Phase 4,Industry,Interventional,2/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00626821
1719,A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children,Completed,Has Results,Asthma|Wheezing|Immunosuppression,Drug: No Intervention,MedImmune LLC|RTI International,MedImmune LLC,RTI International,,,,,,,Industry|Other,Observational,10/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00626808
1720,Surveillance of Ocular Surface Flora (SURFACE),Completed,Has Results,Cataract,,Allergan,Allergan,,,,,,,,Industry,Observational,12/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00621933
1721,"A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women",Completed,Has Results,Osteoporosis,Drug: Recombinant Salmon Calcitonin (rsCT)|Drug: Oral Tablet|Drug: Nasal Spray,"Tarsa Therapeutics, Inc.","Tarsa Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,2/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00620854
1722,Proellex® Pharmacokinetic Bridging Study II,Completed,Has Results,Healthy,Drug: Proellex 25 mg formulation A|Drug: Proellex 25 mg formulation B,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1,Industry,Interventional,2/29/2008,4/30/2008,https://ClinicalTrials.gov/show/NCT00620503
1723,The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo|Drug: glimepiride,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,2/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00620282
1724,A Safety and Pharmacokinetic Study of Proellex®,Completed,Has Results,Healthy,Drug: Proellex,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1,Industry,Interventional,2/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00619385
1725,Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms,Completed,Has Results,"Aortic Aneurysm, Abdominal",Device: 31 mm GORE EXCLUDER® AAA Endoprosthesis,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Phase 2,Industry,Interventional,5/6/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00615069
1726,FLAIR™ Delivery System Study,Completed,Has Results,"Constriction, Pathologic",Device: FLAIR™ Endovascular Stent Graft,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,12/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00614315
1727,PRO 140 by IV Administration in Adults With HIV-1 Infection,Completed,Has Results,HIV Infections,Drug: PRO 140|Drug: Placebo,"CytoDyn, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)","CytoDyn, Inc.",National Institute of Allergy and Infectious Diseases (NIAID),,,,,,Phase 2,Industry|NIH,Interventional,12/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00613379
1728,Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216),Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Chronic Low Back Pain|Chronic Regional Pain Syndrome|Chronic Soft Tissue Pain,Drug: HZT-501|Drug: Ibuprofen,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 3,Industry,Interventional,9/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00613106
1729,"A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement",Completed,Has Results,Post Operative Pain,Drug: Sufentanil NanoTab|Drug: Placebo NanoTab,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00612534
1730,Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients,Completed,Has Results,Dry Eye Syndromes,Drug: Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Drug: Artificial Tears REFRESH ENDURA®,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,12/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00611403
1731,Staccato Prochlorperazine in Migraine (in Clinic),Completed,Has Results,"Migraine Headache, With or Without Aura",Drug: Staccato Placebo|Drug: Staccato Prochlorperazine 5 mg|Drug: Staccato Prochlorperazine 10 mg,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/5/2019,10/5/2019,https://ClinicalTrials.gov/show/NCT00610428
1732,Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.,Completed,Has Results,Coronary Artery Disease,Device: Endeavor Zotarolimus-Eluting Coronary Stent,Medtronic Vascular,Medtronic Vascular,,,,,,,Not Applicable,Industry,Interventional,1/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00609947
1733,Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects,Completed,Has Results,Infection,Drug: omiganan 1% gel|Drug: chlorhexidine 2% solution,Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,5/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00608959
1734,GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta,Completed,Has Results,"Aortic Aneurysm, Thoracic",Device: GORE TAG® Thoracic Endoprosthesis,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Phase 2,Industry,Interventional,2/7/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00608829
1735,Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients,Completed,Has Results,Liver Failure,Drug: LCP Tacro|Drug: Prograf,Veloxis Pharmaceuticals|CTI Clinical Trial and Consulting Services,Veloxis Pharmaceuticals,CTI Clinical Trial and Consulting Services,,,,,,Phase 2,Industry|Other,Interventional,11/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00608244
1736,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,Completed,Has Results,Diabetic Retinopathy,Drug: ruboxistaurin|Drug: placebo,"Chromaderm, Inc.","Chromaderm, Inc.",,,,,,,Phase 3,Industry,Interventional,3/1/2019,6/5/2019,https://ClinicalTrials.gov/show/NCT00604383
1737,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg QD|Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo,Arena Pharmaceuticals,Arena Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,1/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00603902
1738,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg QD|Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo,Arena Pharmaceuticals,Arena Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00603291
1739,"Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor",Completed,Has Results,Essential Tremor,Drug: Sodium Oxybate|Other: Placebo,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00598078
1740,Study to Evaluate Safety and Effectiveness of Spinal Sealant,Completed,Has Results,Spinal Procedure Requiring Dura Incision,Device: Spinal Sealant System|Device: Standard of care,Integra LifeSciences Corporation,Integra LifeSciences Corporation,,,,,,,Not Applicable,Industry,Interventional,9/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00594035
1741,Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN),Completed,Has Results,Neuralgia,Drug: E2007,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2|Phase 3,Industry,Interventional,1/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00592904
1742,A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids,Completed,Has Results,Keloid,Device: Apligraf|Other: Standard dressing regimen,Organogenesis,Organogenesis,,,,,,,Phase 1|Phase 2,Industry,Interventional,12/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00587587
1743,Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis,Completed,Has Results,Allergic Conjunctivitis,Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%|Drug: placebo comparator|Drug: Bepotastine Besilate Ophthalmic Solution 1.0%,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 3,Industry,Interventional,10/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00586664
1744,Efficacy and Safety of Bromfenac Ophthalmic Solution,Completed,Has Results,Cataract Surgery,Drug: bromfenac ophthalmic solution,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 2,Industry,Interventional,10/7/2019,,https://ClinicalTrials.gov/show/NCT00585975
1745,An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters,Completed,Has Results,Colonoscopy|Bowel Preparation,Drug: BLI-800,Braintree Laboratories,Braintree Laboratories,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00583713
1746,Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding,Completed,Has Results,Hearing Impairment,Device: Hearing Aid,EarLens Corporation|National Institute on Deafness and Other Communication Disorders (NIDCD),EarLens Corporation,National Institute on Deafness and Other Communication Disorders (NIDCD),,,,,,Phase 1,Industry|NIH,Interventional,5/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00582946
1747,Long-term Safety Study of the GORE® HELEX® Septal Occluder,Completed,Has Results,"Septal Defect, Atrial",Device: GORE® HELEX® Septal Occluder,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,8/6/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00581308
1748,Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Olopatadine Hydrochloride Nasal Spray 0.6%|Drug: Vehicle,Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,9/7/2019,,https://ClinicalTrials.gov/show/NCT00578929
1749,Safety Study of Olopatadine Nasal Spray,Completed,Has Results,Perennial Allergic Rhinitis,Drug: Olopatadine 0.6% nasal spray|Drug: Placebo Nasal Spray,Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,12/6/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00578331
1750,TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension,Completed,Has Results,Ocular Inflammation Associated With Blepharaconjunctivitis,Drug: Tobramycin 0.3%/Dexamethasone 0.05%|Drug: TOBRADEX,Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,10/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00576251
1751,Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers,Completed,Has Results,Bacterial Infections|Eye Infections,Drug: AzaSite (azithromycin ophthalmic solution)|Drug: Vigamox (moxifloxacin hydrochloride ophthalmic solution),Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 4,Industry,Interventional,3/8/2019,,https://ClinicalTrials.gov/show/NCT00575367
1752,A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: GSK189075|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/31/2008,12/18/2008,https://ClinicalTrials.gov/show/NCT00575159
1753,Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2,Completed,Has Results,Obesity,Device: LAP-BAND System,"Apollo Endosurgery, Inc.","Apollo Endosurgery, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/7/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00570505
1754,Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Nitric Oxide for Inhalation|Drug: Nitrogen,Mallinckrodt,Mallinckrodt,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/4/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00570349
1755,Subcutaneous Pharmacokinetics of Belatacept,Completed,Has Results,Transplantation,Drug: belatacept|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,12/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00569803
1756,A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis,Completed,Has Results,High-grade Glioma|Lung Cancer|Head & Neck Cancer|Sarcoma|Melanoma,Drug: Fluciclatide Injection - (AH111585 (F18)),GE Healthcare,GE Healthcare,,,,,,,Phase 2,Industry,Interventional,11/7/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00565721
1757,Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins,Completed,Has Results,Venous Insufficiency,Device: Short Catheter Delivery,"Vascular Solutions, Inc","Vascular Solutions, Inc",,,,,,,Not Applicable,Industry,Interventional,10/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00565604
1758,Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males,Completed,Has Results,Fever,Drug: Intravenous acetaminophen plus oral placebo|Drug: Oral acetaminophen plus IV placebo|Biological: Reference standard endotoxin (RSE),Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,8/7/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00564629
1759,A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge,Completed,Has Results,Allergic Rhinitis,Drug: Placebo|Drug: Allegra|Drug: Allegra-D|Drug: PF-03654746,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00562120
1760,Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine,Completed,Has Results,Influenza,Biological: 2007-2008 Influenza Virus Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00561002
1761,Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute,Completed,Has Results,COPD,Device: Lung Flute|Device: Acapella,Medical Acoustics LLC,Medical Acoustics LLC,,,,,,,Not Applicable,Industry,Interventional,11/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00560105
1762,Coronary MDCTA With Iopamidol Injection 370,Completed,Has Results,Coronary Artery Disease,"Drug: Isovue 370, 70 mL|Drug: Isovue 370, 80 mL|Drug: Isovue 370, 90 mL","Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 2,Industry,Interventional,11/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00558792
1763,Evaluation of an Endoscopic Suturing System for Tissue Apposition in Colonic Polypectomy,Completed,Has Results,Polyps,Device: Tissue Apposition System (TAS) Device,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,11/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00553436
1764,Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,10/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00548860
1765,Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,10/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00548691
1766,Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery,Completed,Has Results,Dry Eye Syndrome,Drug: Carboxymethylcellulose and Glycerin based artificial tear|Drug: Carboxymethylcellulose,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,9/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00544713
1767,An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma,Completed,Has Results,Prostate Neoplasms,Drug: Abiraterone acetate|Drug: Prednisone,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,10/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00544440
1768,Staccato Prochlorperazine Thorough QT/QTc,Completed,Has Results,Cardiotoxicity,Drug: Inhaled placebo|Drug: Oral placebo|Drug: Inhaled prochlorperazine 5 mg|Drug: Inhaled prochlorperazine 10 mg|Drug: Oral moxifloxacin,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,10/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00543062
1769,Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis,Completed,Has Results,Osteoporosis,Drug: teriparatide|Drug: Placebo|Drug: BA058 20 µg|Drug: BA058 40 µg|Drug: BA058 80 µg,"Radius Health, Inc.","Radius Health, Inc.",,,,,,,Phase 2,Industry,Interventional,4/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00542425
1770,Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Glaucoma,Drug: bimatoprost 0.03% eye drops|Drug: latanoprost 0.005% eye drops,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00541242
1771,Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues,Completed,Has Results,Open Angle Glaucoma|Ocular Hypertension,Drug: Bimatoprost 0.03%|Drug: travoprost 0.004%|Drug: latanoprost 0.005% eye drops,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,9/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00539526
1772,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,Completed,Has Results,Cancer,Drug: Fentanyl sublingual spray|Drug: Placebo,INSYS Therapeutics Inc|National Cancer Institute (NCI),INSYS Therapeutics Inc,National Cancer Institute (NCI),,,,,,Phase 3,Industry|NIH,Interventional,10/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00538850
1773,A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: bimatoprost eye drops|Drug: placebo,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,11/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00538304
1774,Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer,Completed,Has Results,"Neoplasms, Colorectal",Drug: lapatinib|Drug: oxaliplatin|Drug: capecitabine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,9/26/2007,10/31/2008,https://ClinicalTrials.gov/show/NCT00536809
1775,Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis,Completed,Has Results,Allergic Conjunctivitis,Drug: Elestat|Drug: Pataday,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 4,Industry,Interventional,10/7/2019,,https://ClinicalTrials.gov/show/NCT00534794
1776,CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients,Completed,Has Results,"Heart Failure, Congestive",Device: HF Pressure Measurement System,CardioMEMS,CardioMEMS,,,,,,,Not Applicable,Industry,Interventional,9/7/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00531661
1777,"A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture",Completed,Has Results,Dupuytren's Contracture,Biological: collagenase clostridium histolyticum,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,9/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00528931
1778,"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",Completed,Has Results,Gastric Ulcer,Drug: PN400 (VIMOVO)|Drug: PN 400 (VIMOVO),POZEN,POZEN,,,,,,,Phase 3,Industry,Interventional,3/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00527904
1779,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen,Completed,Has Results,Gastric Ulcer,Drug: PN400 (VIMOVO)|Drug: Naproxen,POZEN,POZEN,,,,,,,Phase 3,Industry,Interventional,9/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00527787
1780,Trial to Describe the Safety and Immunogenicity of Fluzone®,Completed,Has Results,Influenza,"Biological: Inactivated, Split-Virion Influenza Virus","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,8/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00524940
1781,A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery,Completed,Has Results,Cataract Extraction|Pain|Inflammation,Drug: ketorolac,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,10/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00524264
1782,The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction,Completed,Has Results,Hypertension|Diastolic Dysfunction,Drug: valsartan|Drug: amlodipine,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,11/6/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00523549
1783,A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery,Completed,Has Results,Cataract Extraction,Drug: ketorolac eye drops,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,10/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00521456
1784,A Study of Pemetrexed in Children With Recurrent Cancer,Completed,Has Results,"Osteosarcoma|Medulloblastoma|Sarcoma, Ewing's|Neuroblastoma (Measurable Disease)|Neuroblastoma (Metaiodobenzylguanidine|Positive Evaluable)|Rhabdomyosarcoma|Ependymoma|Non-brainstem High-grade Glioma",Drug: pemetrexed,Eli Lilly and Company|Children's Oncology Group,Eli Lilly and Company,Children's Oncology Group,,,,,,Phase 2,Industry|Other,Interventional,9/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00520936
1785,Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia,Completed,Has Results,Congenital Adrenal Hyperplasia|21-Hydroxylase Deficiency|Adrenogenital Syndrome,Drug: Chronocort|Drug: Cortef,Diurnal Limited|National Institutes of Health Clinical Center (CC),Diurnal Limited,National Institutes of Health Clinical Center (CC),,,,,,Phase 1|Phase 2,Industry|NIH,Interventional,8/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00519818
1786,Transdermal Basal Insulin Patch Study in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Other: PassPort(R) Transdermal Insulin Delivery System,Altea Therapeutics,Altea Therapeutics,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00519623
1787,Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye,Completed,Has Results,Dry Eye Syndrome,Drug: Carboxymethylcellulose and Glycerin based artificial tear|Drug: Carboxymethylcellulose,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,10/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00514852
1788,"ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults",Completed,Has Results,Alcohol Dependence,Drug: VIVITROL 380 mg|Drug: Placebo,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 4,Industry,Interventional,7/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00511836
1789,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Completed,Has Results,Bacterial Conjunctivitis,Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,8/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00509873
1790,Lipid Infusion in Dialysis Patients With Endotoxemia,Completed,Has Results,Fatigue|End Stage Renal Disease (ESRD),Drug: Lipidose|Drug: Placebo,Sepsicure|The Rogosin Institute,Sepsicure,The Rogosin Institute,,,,,,Phase 2,Industry|Other,Interventional,8/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00506454
1791,Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART),Completed,Has Results,Infertility,Drug: AS900672-Enriched 50 microgram (mcg)|Drug: AS900672-Enriched 100 mcg|Drug: AS900672-Enriched 150 mcg|Drug: Follitropin alfa 150 international unit (IU)|Drug: Recombinant human chorionic gonadotropin (r-hCG),"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",,,,,,,Phase 2,Industry,Interventional,1/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00505752
1792,LAP-BAND AP Early Experience Trial (APEX),Completed,Has Results,"Obesity, Morbid",Device: LAP-BAND AP Adjustable Gastric Banding System,"Apollo Endosurgery, Inc.","Apollo Endosurgery, Inc.",,,,,,,,Industry,Observational,6/7/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00501085
1793,"A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors",Completed,Has Results,Advanced Malignancies,Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,5/15/2007,2/23/2011,https://ClinicalTrials.gov/show/NCT00500903
1794,Endoscopic Suturing System for Tissue Apposition,Completed,Has Results,Obesity,Procedure: Tissue plication|Device: Endoscopic Suturing System|Device: Tissue Plication,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Not Applicable,Industry,Interventional,2/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00495222
1795,"Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients",Completed,Has Results,"Lymphoma, Follicular","Drug: Ofatumumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone, Prednisone or equivalent",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00494780
1796,Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males,Completed,Has Results,Fever,Drug: IV Placebo|Drug: IV Acetaminophen|Biological: Reference Standard Endotoxin (RSE),Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,6/7/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00493311
1797,Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis,Completed,Has Results,Spinal Surgery|Vascular Surgery,Biological: rThrombin,ZymoGenetics,ZymoGenetics,,,,,,,Phase 3,Industry,Interventional,6/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00491608
1798,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",Completed,Has Results,Mixed Dyslipidemia,Drug: ABT-335|Drug: rosuvastatin calcium|Drug: simvastatin|Drug: atorvastatin calcium,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,6/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00491530
1799,The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis,Completed,Has Results,"Renal Artery Obstruction|Hypertension, Renal",Device: Herculink Elite Renal Stent System,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,8/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00490841
1800,Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Fluocinolone Acetonide,Alimera Sciences,Alimera Sciences,,,,,,,Phase 3,Industry,Interventional,8/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00490815
1801,Staccato Loxapine in Migraine (in Clinic),Completed,Has Results,Migraine,Drug: Staccato Loxapine|Drug: Staccato Placebo,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,6/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00489476
1802,"Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass",Completed,Has Results,Osteoporosis,Drug: Placebo|Drug: Acetaminophen|Drug: Fluvastatin,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,6/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00489424
1803,Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty,Completed,Has Results,Postoperative Pain,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 2,Industry,Interventional,6/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00485693
1804,Rebif New Formulation (RNF) Quality of Life (QOL) Study,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: Rebif New Formulation Non Titrated|Drug: Rebif New Formulation Titrated,EMD Serono,EMD Serono,,,,,,,Phase 3,Industry,Interventional,4/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00472797
1805,Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men,Completed,Has Results,Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism,Drug: Testosterone Undecanoate 750 mg|Drug: Testosterone Undecanoate 1000 mg,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/6/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00467870
1806,A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia,Completed,Has Results,Insomnia,Drug: zolpidem tartrate sublingual tablet|Drug: Placebo,Transcept Pharmaceuticals,Transcept Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00466193
1807,A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer,Completed,Has Results,Ovarian Cancer|Peritoneal Cancer,Drug: pemetrexed,Eli Lilly and Company|Gynecologic Oncology Group,Eli Lilly and Company,Gynecologic Oncology Group,,,,,,Phase 2,Industry|Other,Interventional,9/4/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00461786
1808,24-hour IOP-lowering Effect of Brimonidine 0.1%,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: brimonidine 0.1% (Alphagan® P),Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/6/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00457795
1809,Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Device: Gel-200,Seikagaku Corporation,Seikagaku Corporation,,,,,,,Phase 3,Industry,Interventional,3/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00450112
1810,Gel-200 Versus Placebo in Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Device: Gel-200|Device: Placebo,Seikagaku Corporation,Seikagaku Corporation,,,,,,,Phase 3,Industry,Interventional,9/6/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00449696
1811,"Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)",Completed,Has Results,"Rhinitis, Allergic, Perennial","Other: Placebo|Drug: TAA-AQ, Nasacort® AQ|Drug: Claritin®",Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,3/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00449072
1812,Overactive Bladder Innovative Therapy Trial (OrBIT),Completed,Has Results,Overactive Bladder,Device: Urgent PC Neuromodulation System|Drug: Tolterodine,"Uroplasty, Inc","Uroplasty, Inc",,,,,,,Phase 4,Industry,Interventional,6/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00448175
1813,Effectiveness and Safety Study of LAP-BAND Treatment for Obese Adolescents,Completed,Has Results,Morbid Obesity,Device: LAP-BAND System,"Apollo Endosurgery, Inc.","Apollo Endosurgery, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/7/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00447590
1814,Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV),Completed,Has Results,Chronic Hepatitis C,Drug: Taribavirin|Drug: Ribavirin,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 2,Industry,Interventional,3/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00446134
1815,Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Docetaxel|Drug: Doxorubicin|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Trastuzumab|Drug: Bevacizumab,Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,3/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00446030
1816,The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD),Completed,Has Results,Non-Hodgkin Lymphoma|Hodgkin Disease,Drug: G-CSF plus plerixafor|Biological: rituximab,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,2/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00444912
1817,Staccato Loxapine Single Dose PK,Completed,Has Results,Schizophrenia,Drug: inhaled Loxapine 0.625 mg|Drug: inhaled Loxapine 1.25 mg|Drug: inhaled Loxapine 2.5 mg|Drug: inhaled Loxapine 5 mg|Drug: inhaled Loxapine 10 mg|Drug: inhaled Placebo (0 mg),"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,9/5/2019,11/5/2019,https://ClinicalTrials.gov/show/NCT00444028
1818,Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: bimatoprost 0.03% eye drops|Drug: travoprost 0.004% eye drops,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,8/6/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00440011
1819,"Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers",Completed,Has Results,Healthy,Drug: ST-246|Drug: Placebo,SIGA Technologies|National Institute of Allergy and Infectious Diseases (NIAID),SIGA Technologies,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,Phase 1,Industry|NIH,Interventional,2/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00431951
1820,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b),Completed,Has Results,Inflammation,Drug: Difluprednate|Drug: Placebo,"Sirion Therapeutics, Inc.","Sirion Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,,,https://ClinicalTrials.gov/show/NCT00430092
1821,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a),Completed,Has Results,Inflammation,Drug: Difluprednate|Drug: Placebo,"Sirion Therapeutics, Inc.","Sirion Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,,,https://ClinicalTrials.gov/show/NCT00429923
1822,Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS),Completed,Has Results,Crohn's Disease,Biological: adalimumab,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,1/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00427921
1823,Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis,Completed,Has Results,"Conjunctivitis, Allergic",Drug: Bepreve|Drug: Placebo|Drug: Bepotastine Besilate,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 2|Phase 3,Industry,Interventional,2/7/2019,,https://ClinicalTrials.gov/show/NCT00424398
1824,A Study of Dental Implants Coated With Bone Morphogenetic Protein,Completed,Has Results,Alveolar Ridge Abnormality,Device: Nobel Replace Tapered Groovy,Nobel Biocare,Nobel Biocare,,,,,,,Not Applicable,Industry,Interventional,11/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00422279
1825,Pediatric Zylet Safety and Efficacy Study,Completed,Has Results,Chalazion|Hordeolum,Drug: loteprednol etabonate/tobramycin opthalmic suspension|Drug: vehicle,Bausch & Lomb Incorporated,Bausch & Lomb Incorporated,,,,,,,Phase 4,Industry,Interventional,11/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00420628
1826,Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy,Completed,Has Results,Colorectal Cancer,Drug: Everolimus (RAD001),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,12/6/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00419159
1827,Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome,Completed,Has Results,High Blood Pressure|Metabolic Syndrome|Insulin Resistance|Endothelial Dysfunction,Drug: Aliskiren|Drug: Amlodipine|Drug: Placebo Aliskiren|Drug: Placebo Amlodipine,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,10/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00417170
1828,Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer,Completed,Has Results,Cancer,Drug: IC83/LY2603618|Drug: pemetrexed,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,1/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00415636
1829,Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|Behavioral: Behavior Therapy,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,11/6/2019,,https://ClinicalTrials.gov/show/NCT00409708
1830,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia,Completed,Has Results,Cervical Dystonia,Drug: incobotulinumtoxinA (Xeomin) (240 Units)|Drug: incobotulinumtoxinA (Xeomin) (120 Units)|Drug: Placebo,Merz Pharmaceuticals GmbH,Merz Pharmaceuticals GmbH,,,,,,,Phase 3,Industry,Interventional,7/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00407030
1831,The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia,Drug: BMS-201038 (AEGR-733)|Drug: Ezetimibe,"Aegerion Pharmaceuticals, Inc.","Aegerion Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,5/6/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00405067
1832,Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat,Completed,Has Results,Pharyngitis,Drug: celecoxib|Drug: celecoxib followed by placebo|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00402987
1833,"A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients",Completed,Has Results,Bipolar I Disorder,Drug: olanzapine|Drug: placebo|Drug: divalproex,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,12/6/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00402324
1834,Effect of Pulse Width With Spinal Cord Stimulation,Completed,Has Results,Pain|Chronic Pain|Back Pain,Device: Precision,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,11/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00399516
1835,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia,Completed,Has Results,Anemia,Drug: Oral iron tablets|Drug: VIT-45,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,2/5/2019,2/6/2019,https://ClinicalTrials.gov/show/NCT00396292
1836,AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease,Completed,Has Results,Hodgkin's Disease,Drug: G-CSF Plus Plerixafor,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,11/4/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00396201
1837,COSMO Post Approval Registry: Corox OTW Steroid LV Lead Monitoring,Completed,Has Results,Congestive Heart Failure,Device: Corox OTW Steroid Left Ventricular Lead,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,Phase 4,Industry,Interventional,10/6/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00396136
1838,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate tablets,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,5/5/2019,6/6/2019,https://ClinicalTrials.gov/show/NCT00395993
1839,Multihance at 3 Tesla in Brain Tumors,Completed,Has Results,Brain Tumor,Drug: Multihance|Drug: Arm 2 - Magnevist,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 4,Industry,Interventional,11/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00395863
1840,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo BID,Arena Pharmaceuticals,Arena Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/6/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00395135
1841,Trial to Collect Safety Data and Sera for Immunogenicity Testing,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine (Fluzone®),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00389857
1842,Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/6/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00389532
1843,Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS Products,Completed,Has Results,Vaginal Prolapse,Device: AMS Prolapse Product,ASTORA Women's Health,ASTORA Women's Health,,,,,,,,Industry,Observational,9/6/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00388947
1844,TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine,Completed,Has Results,Migraine Disorders,Drug: Combination Product (sumatriptan succinate / naproxen sodium)|Drug: RELPAX(eletriptan) 40mg Tablet,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/13/2006,11/24/2006,https://ClinicalTrials.gov/show/NCT00385008
1845,"Insulin Glargine ""All to Target"" Trial",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Glulisine|Drug: Insulin Glargine|Drug: Premixed Insulin,Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,5/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00384085
1846,A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors,Completed,Has Results,Pancreatic Cancer,Drug: Romidepsin|Drug: Gemcitabine,Celgene Corporation|Celgene,Celgene Corporation,Celgene,,,,,,Phase 1,Industry,Interventional,7/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00379639
1847,A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee,Completed,Has Results,"Osteoarthritis, Knee",Device: EUFLEXXA™|Device: placebo,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Not Applicable,Industry,Interventional,10/6/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00379236
1848,A Trial for Patients With Advanced/Recurrent Endometrial Cancer,Completed,Has Results,"Neoplasms|Neoplasms by Site|Urogenital Neoplasms|Genital Neoplasms, Female|Uterine Neoplasms|Endometrial Neoplasms|Cancer of Endometrium|Endometrial Cancer|Cancer of the Endometrium|Endometrium Cancer|Neoplasms, Endometrial",Drug: pemetrexed,Eli Lilly and Company|Gynecologic Oncology Group,Eli Lilly and Company,Gynecologic Oncology Group,,,,,,Phase 2,Industry|Other,Interventional,9/6/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00377520
1849,"Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin",Completed,Has Results,Pulmonary Hypertension,Drug: treprostinil sodium,United Therapeutics,United Therapeutics,,,,,,,Phase 4,Industry,Interventional,9/6/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00373360
1850,Staccato Loxapine in Agitation (Proof of Concept),Completed,Has Results,Schizophrenia,Drug: Inhaled Placebo|Drug: Inhaled Loxapine 5 mg|Drug: Inhaled Loxapine 10 mg,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,8/6/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00369577
1851,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Ramipril|Drug: Hydrochlorothiazide|Drug: Amlodipine,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/6/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00368277
1852,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,Completed,Has Results,Breast Cancer,"Drug: Doxorubicin and cyclophosphamide (AC) + bevacizumab|Drug: Docetaxel (T) + bevacizumab|Drug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|Drug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|Drug: Bevacizumab and trastuzumab maintenance therapy|Drug: Bevacizumab maintenance therapy",Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,8/6/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00365365
1853,Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Bevacizumab|Drug: Docetaxel|Drug: Trastuzumab,Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,8/6/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00364611
1854,Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents,Completed,Has Results,Healthy,Drug: atorvastatin|Drug: simvastatin|Drug: ezetimibe|Drug: fenofibrate|Drug: dextromethorphan|Drug: Extended Release Niacin,"Aegerion Pharmaceuticals, Inc.","Aegerion Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00359281
1855,Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects,Completed,Has Results,Human Immunodeficiency Virus Infections,Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs),Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,8/6/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00358917
1856,Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA),Completed,Has Results,Obstructive Sleep Apnea,Device: ApneaLink Sleep Screener,ResMed,ResMed,,,,,,,,Industry,Observational,6/6/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00354614
1857,Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients,Completed,Has Results,Postpartum Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate tablets,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,5/6/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00354484
1858,Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: fluocinolone acetonide|Drug: Fluocinolone Acetonide|Procedure: Standard of care laser photocoagulation,Alimera Sciences,Alimera Sciences,,,,,,,Phase 3,Industry,Interventional,9/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00344968
1859,Study to Assess the Safety and Effectiveness of the Penumbra System,Completed,Has Results,Stroke,Device: Penumbra System,Penumbra Inc.,Penumbra Inc.,,,,,,,Phase 2,Industry,Interventional,6/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00334061
1860,VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease,Completed,Has Results,Anemia,Drug: Ferrous Sulfate tablets|Drug: Ferric Carboxymaltose (FCM),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,5/5/2019,8/7/2019,https://ClinicalTrials.gov/show/NCT00317239
1861,Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose (FCM),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,6/5/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00317226
1862,Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora,Completed,Has Results,Bacterial Conjunctivitis,Drug: VIGAMOX,Alcon Research|Tufts University,Alcon Research,Tufts University,,,,,,Phase 4,Industry|Other,Interventional,6/6/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT00312338
1863,OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration,Completed,Has Results,Geographic Atrophy|Age-Related Macular Degeneration|AMD,Drug: OT-551 antioxidant eye drop,Othera Pharmaceuticals|National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC),Othera Pharmaceuticals,National Eye Institute (NEI),National Institutes of Health Clinical Center (CC),,,,,Phase 2,Industry|NIH,Interventional,3/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00306488
1864,To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days,Completed,Has Results,"Infections, Fungal",Drug: voriconazole,"Pfizer|McLean Hospital. Belmont, MA.",Pfizer,"McLean Hospital. Belmont, MA.",,,,,,Phase 4,Industry|Other,Interventional,3/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00300677
1865,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335|Drug: Rosuvastatin Calcium|Drug: Placebo,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,3/6/2019,,https://ClinicalTrials.gov/show/NCT00300482
1866,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Completed,Has Results,Mixed Dyslipidemia|Coronary Heart Disease|Dyslipidemia,Drug: ABT-335|Drug: Atorvastatin|Drug: Placebo,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,3/6/2019,,https://ClinicalTrials.gov/show/NCT00300469
1867,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335|Drug: Simvastatin|Drug: Placebo,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,3/6/2019,,https://ClinicalTrials.gov/show/NCT00300456
1868,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335 and atorvastatin calcium|Drug: ABT-335 and simvastatin,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,9/6/2019,,https://ClinicalTrials.gov/show/NCT00300430
1869,Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency,Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: EUR-1008 (APT-1008)|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,5/6/2019,11/6/2019,https://ClinicalTrials.gov/show/NCT00297167
1870,"TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary",Completed,Has Results,Ovarian Cancer,Drug: Bevacizumab (Avastin®)|Drug: Docetaxel (Taxotere®)|Drug: Oxaliplatin (Eloxatin®),Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,3/6/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00296816
1871,Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy,Completed,Has Results,Pain|Cancer,Drug: BEMA Fentanyl,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 3,Industry,Interventional,2/6/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00293020
1872,Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone|Drug: Placebo,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,4/6/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00287729
1873,Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone|Drug: Placebo,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,7/14/2006,11/10/2008,https://ClinicalTrials.gov/show/NCT00287716
1874,Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa,Completed,Has Results,Retinitis Pigmentosa,Device: Argus 16 Retinal Stimulation System,Second Sight Medical Products,Second Sight Medical Products,,,,,,,Not Applicable,Industry,Interventional,2/27/2002,12/31/2014,https://ClinicalTrials.gov/show/NCT00279500
1875,Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder,Completed,Has Results,Generalized Anxiety Disorder|Panic Disorder,Drug: Niravam|Drug: SSRI/SNRI,UCB Pharma,UCB Pharma,,,,,,,Phase 4,Industry,Interventional,10/5/2019,6/6/2019,https://ClinicalTrials.gov/show/NCT00266409
1876,"Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients",Completed,Has Results,Multiple Sclerosis,,EMD Serono,EMD Serono,,,,,,,,Industry,Observational,10/1/2000,9/8/2019,https://ClinicalTrials.gov/show/NCT00262314
1877,Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE),Completed,Has Results,Hereditary Angioedema (HAE),"Drug: ecallantide|Drug: Phosphate Buffer Saline (PBS),",Shire,Shire,,,,,,,Phase 3,Industry,Interventional,12/5/2019,2/7/2019,https://ClinicalTrials.gov/show/NCT00262080
1878,Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children,Completed,Has Results,Prevention of Meningococcal Disease,Biological: MenACWY-CRM Vaccine|Biological: MenACWY-PS Vaccine,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 2,Industry,Interventional,4/5/2019,11/6/2019,https://ClinicalTrials.gov/show/NCT00262028
1879,Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine,Completed,Has Results,Influenza,Biological: Fluzone®: Influenza Virus Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/5/2019,3/7/2019,https://ClinicalTrials.gov/show/NCT00258830
1880,Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine (Fluzone®),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/5/2019,8/7/2019,https://ClinicalTrials.gov/show/NCT00258817
1881,Efficacy Study of a Facemask Device to Treat Hypotension,Completed,Has Results,Hypotension,Device: Impedance Threshold Device|Device: sham ITD,Advanced Circulatory Systems|United States Department of Defense,Advanced Circulatory Systems,United States Department of Defense,,,,,,Phase 2,Industry|U.S. Fed,Interventional,6/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00256724
1882,"Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine",Completed,Has Results,Meningitis|Meningococcal Disease,Biological: None administered in this study,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,,Industry,Observational,7/5/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00254995
1883,Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,Completed,Has Results,Kidney Transplantation|Graft Rejection,Drug: Everolimus|Drug: Mycophenolic Acid (MPA)|Drug: Cyclosporine A (CsA)|Drug: Basiliximab|Drug: Corticosteroids,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,10/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00251004
1884,Safety and Efficacy of Iron Sucrose in Children,Completed,Has Results,Anemia|Chronic Kidney Disease,Drug: Venofer (iron sucrose injection),"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 4,Industry,Interventional,7/5/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00239642
1885,A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults,Completed,Has Results,Dengue,Biological: Live attenuated tetravalent dengue vaccine|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/5/2006,6/19/2007,https://ClinicalTrials.gov/show/NCT00239577
1886,Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia,Completed,Has Results,Anemia,Drug: Venofer|Drug: Ferrous Sulfate,"American Regent, Inc.","American Regent, Inc.",,,,,,,Phase 3,Industry,Interventional,8/3/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00236977
1887,E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Completed,Has Results,Heartburn,Drug: rabeprazole sodium|Drug: placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,10/5/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00236197
1888,E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Completed,Has Results,Heartburn,Drug: rabeprazole sodium|Other: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,10/5/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00236184
1889,A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients,Completed,Has Results,Obesity,Drug: Sibutramine hydrochloride|Drug: Placebo,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,1/3/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00234832
1890,Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions,Completed,Has Results,Coronary Artery Disease,Device: CYPHER Sirolimus-eluting Coronary Stent,Cordis Corporation,Cordis Corporation,,,,,,,Phase 3,Industry,Interventional,9/3/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00232739
1891,NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions,Completed,Has Results,Coronary Artery Disease,Device: CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS),Cordis Corporation,Cordis Corporation,,,,,,,Phase 3,Industry,Interventional,4/4/2019,7/5/2019,https://ClinicalTrials.gov/show/NCT00231283
1892,A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Plitidepsin,PharmaMar,PharmaMar,,,,,,,Phase 2,Industry,Interventional,2/5/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00229203
1893,Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP,Completed,Has Results,"Purpura, Thrombocytopenic, Idiopathic","Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified",Grifols Therapeutics LLC,Grifols Therapeutics LLC,,,,,,,Phase 2,Industry,Interventional,7/3/2019,10/3/2019,https://ClinicalTrials.gov/show/NCT00220727
1894,Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction,Completed,Has Results,Anovulation,Drug: Anastrozole 1 mg|Drug: Anastrozole 5 mg|Drug: Anastrozole 10 mg|Drug: Clomiphene Citrate 50 mg|Drug: Clomiphene Citrate 100 mg,EMD Serono,EMD Serono,,,,,,,Phase 2,Industry,Interventional,3/10/2005,12/12/2007,https://ClinicalTrials.gov/show/NCT00213148
1895,Feasibility Study of a Percutaneous Mitral Valve Repair System.,Completed,Has Results,Mitral Valve Insufficiency|Mitral Valve Regurgitation|Mitral Valve Incompetence|Mitral Regurgitation|Mitral Insufficiency,Device: Percutaneous mitral valve repair (MitraClip Implant),Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/3/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00209339
1896,Pivotal Study of a Percutaneous Mitral Valve Repair System,Completed,Has Results,Mitral Valve Insufficiency|Mitral Valve Regurgitation|Mitral Valve Incompetence|Mitral Regurgitation|Mitral Insufficiency,Device: Percutaneous mitral valve repair using MitraClip implant|Procedure: Mitral valve repair or replacement surgery,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,8/5/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00209274
1897,Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer,Completed,Has Results,Advanced Solid Tumors|Neoplasms,Drug: ixabepilone|Drug: Rifampin,R-Pharm,R-Pharm,,,,,,,Phase 1,Industry,Interventional,9/5/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00207090
1898,Study Evaluating Pneumococcal Vaccine in Healthy Infants,Completed,Has Results,Healthy Subjects|Pneumococcal Infections,Biological: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|Biological: 7-Valent Pneumococcal Conjugate Vaccine (7vPnC),Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/4/2019,5/7/2019,https://ClinicalTrials.gov/show/NCT00205803
1899,Malignant Obstruction ZILVER Against Routine Therapy (MOZART I),Completed,Has Results,"Biliary Tract Neoplasms|Pancreatic Neoplasms|Jaundice, Obstructive",Device: 6 mm Nitinol Zilver Stent|Device: 10 mm Nitinol Zilver Stent|Device: 10 mm Stainless Steel Wallstent,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,9/3/2019,12/6/2019,https://ClinicalTrials.gov/show/NCT00196105
1900,Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Etanercept|Drug: Methotrexate|Drug: Placebo,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 4,Industry,Interventional,11/4/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00195494
1901,"Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers",Completed,Has Results,Asthma,Biological: MEDI-528 0.3 mg/kg|Biological: MEDI-528 1 mg/kg|Biological: MEDI-528 3 mg/kg|Biological: MEDI-528 9 mg/kg,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,8/4/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00192296
1902,A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Gemcitabine|Drug: Carboplatin|Drug: Herceptin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/4/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00191451
1903,A Trial for Patients With Advanced/Recurrent Cervical Cancer,Completed,Has Results,"Cervical Intraepithelial Neoplasia|Uterine Neoplasms|Genital Neoplasms, Female",Drug: Pemetrexed,Eli Lilly and Company|Gynecologic Oncology Group,Eli Lilly and Company,Gynecologic Oncology Group,,,,,,Phase 2,Industry|Other,Interventional,2/5/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00190983
1904,Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: olanzapine|Drug: risperidone,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,10/3/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00190749
1905,Response of Cardiac Resynchronization Therapy Optimization With Ventricle to Ventricle Timing in Heart Failure Patients,Completed,Has Results,Heart Failure,Device: Simultaneous VV Pacing|Device: Sequential VV Pacing,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 4,Industry,Interventional,1/5/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00187200
1906,MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy,Completed,Has Results,Tachycardia|Congestive Heart Failure,Device: Cardiac resynchronization therapy with defibrillation|Device: Implantable Cardioverter Defibrillator (ICD),Boston Scientific Corporation|University of Rochester,Boston Scientific Corporation,University of Rochester,,,,,,Not Applicable,Industry|Other,Interventional,12/4/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00180271
1907,Maintenance Intermittent Therapy for Symptomatic GERD Patients,Completed,Has Results,Gastroesophageal Reflux Disease,Drug: Rabeprazole 20 mg,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,10/4/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00165841
1908,The EASYTRAK EPI Clinical Investigation,Completed,Has Results,Bradycardia|Congestive Heart Failure,Device: EASYTRAK EPI lead,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,9/4/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00158925
1909,RIGHT: Rhythm ID Going Head-to-Head Trial,Completed,Has Results,Tachycardia,Device: VITALITY 2 Implantable Cardioverter Defibrillator|Device: Medtronic Implantable Cardioverter Defibrillator,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,7/5/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00148954
1910,Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Colesevelam|Drug: Colesevelam matching placebo|Drug: Insulin glargine (Lantus),"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 2,Industry,Interventional,6/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00147745
1911,PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy,Completed,Has Results,Heart Failure,Device: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,12/4/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00146848
1912,Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction,Completed,Has Results,Malignant Melanoma,Drug: Vincristine Sulfate Liposomes Injection,"Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",,,,,,,Phase 1,Industry,Interventional,2/5/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00145041
1913,"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older",Completed,Has Results,Osteopenia,Drug: Zoledronic Acid|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,7/4/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00132808
1914,Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids,Completed,Has Results,Leiomyoma,Device: ExAblate 2000,InSightec,InSightec,,,,,,,Not Applicable,Industry,Interventional,1/6/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00131365
1915,Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,Completed,Has Results,"Heart Failure, Congestive",Drug: 123I-mIBG (meta-iodobenzylguanidine),GE Healthcare,GE Healthcare,,,,,,,Phase 3,Industry,Interventional,7/5/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00126438
1916,Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,Completed,Has Results,"Heart Failure, Congestive",Drug: 123I-mIBG (meta-iodobenzylguanidine),GE Healthcare,GE Healthcare,,,,,,,Phase 3,Industry,Interventional,7/5/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00126425
1917,Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency,Completed,Has Results,Insulin-Like Growth Factor-1 Deficiency|Growth Disorders,Drug: rhIGF-1 (mecasermin) for a period of 86 weeks,Ipsen,Ipsen,,,,,,,Phase 2|Phase 3,Industry,Interventional,7/5/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00125190
1918,Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency,Completed,Has Results,Growth Disorders|Insulin-Like Growth Factor-1 Deficiency,"Drug: rhIGF-1 (mecasermin, Tercica, Inc.)",Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,3/4/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00125164
1919,Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project,Completed,Has Results,Pregnancy,Drug: Etanercept,Amgen,Amgen,,,,,,,,Industry,Observational,4/5/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00116272
1920,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Completed,Has Results,Colorectal Cancer,Biological: Bevacizumab|Drug: Capecitabine|Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin calcium|Drug: Oxaliplatin,Hoffmann-La Roche|National Cancer Institute (NCI),Hoffmann-La Roche,National Cancer Institute (NCI),,,,,,Phase 3,Industry|NIH,Interventional,12/4/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00112918
1921,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Completed,Has Results,Staphylococcal Skin Infection,Drug: Telavancin|Drug: Vancomycin,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/5/2019,5/6/2019,https://ClinicalTrials.gov/show/NCT00107978
1922,Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus,Completed,Has Results,Bacterial Pneumonia,Drug: Telavancin|Drug: Vancomycin,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/5/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00107952
1923,Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement,Completed,Has Results,"Arthroplasty, Replacement, Hip|Thrombosis",Drug: DU-176b,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 2,Industry,Interventional,1/5/2019,12/5/2019,https://ClinicalTrials.gov/show/NCT00107900
1924,Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer,Completed,Has Results,"Breast Cancer|Breast Neoplasms, Male|Carcinoma, Ductal",Drug: pemetrexed,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/5/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00106002
1925,Study of rhASB in Patients With Mucopolysaccharidosis VI,Completed,Has Results,Mucopolysaccharidosis VI,Drug: N-acetylgalactosamine 4-sulfatase|Drug: Placebo/rhASB,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 3,Industry,Interventional,2/4/2019,10/6/2019,https://ClinicalTrials.gov/show/NCT00104234
1926,Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema,Completed,Has Results,Angioedema,Drug: Icatibant|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,8/4/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00097695
1927,Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B,Completed,Has Results,Chronic Hepatitis B,Drug: Placebo (PLB)|Drug: Adefovir Dipivoxil (ADV)|Drug: Lamivudine,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,6/4/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00095121
1928,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Completed,Has Results,Staphylococcal Skin Infection,Drug: Telavancin|Drug: Vancomycin,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,1/5/2019,6/6/2019,https://ClinicalTrials.gov/show/NCT00091819
1929,A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer,Completed,Has Results,Breast Cancer,Drug: capecitabine [Xeloda]|Drug: Taxotere,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,8/2/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00089479
1930,Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI),Completed,Has Results,"Infections, Gram-positive Bacterial",Drug: Telavancin|Drug: vancomycin or antistaphylococcal penicillin,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,2/4/2019,9/4/2019,https://ClinicalTrials.gov/show/NCT00077675
1931,AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS),Completed,Has Results,Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome,Drug: AG-013736 (Axitinib),Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/3/2019,7/4/2019,https://ClinicalTrials.gov/show/NCT00071006
1932,Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI,Completed,Has Results,Mucopolysaccharidosis VI,Drug: Placebo|Drug: N-acetylgalactosamine 4-sulfatase,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 3,Industry,Interventional,9/3/2019,3/4/2019,https://ClinicalTrials.gov/show/NCT00067470
1933,Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia,Completed,Has Results,Gram-Positive Bacterial Infections,"Drug: Telavancin|Drug: Vancomycin, nafcillin, oxacillin, or cloxacillin",Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,8/3/2019,8/6/2019,https://ClinicalTrials.gov/show/NCT00062647
1934,Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI),Completed,Has Results,"Infections, Gram-Positive Bacterial|Abscess|Burns|Cellulitis|Ulcer|Wound Infections",Drug: Telavancin|Drug: Vancomycin or antistaphylococcal penicillin,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,6/3/2019,1/4/2019,https://ClinicalTrials.gov/show/NCT00061633
1935,A Long-term Safety Study of Once-daily Travatan,Completed,Has Results,"Glaucoma, Open-angle|Ocular Hypertension",Drug: Travatan,Alcon Research,Alcon Research,,,,,,,Phase 3,Industry,Interventional,1/6/2019,,https://ClinicalTrials.gov/show/NCT00051168
1936,Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors,Completed,Has Results,Neoplasms,Drug: rhuMAb 2C4,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,11/1/2019,8/3/2019,https://ClinicalTrials.gov/show/NCT00027027
1937,A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips),Completed,Has Results,"Congestion, Nasal",Device: Breathe Right Tan (small/medium) nasal strips|Other: Placebo nasal strip,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/4/2010,2/17/2011,https://ClinicalTrials.gov/show/NCT03549130
1938,A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan),Completed,Has Results,"Congestion, Nasal",Device: Breathe Right Tan (small/medium) nasal strips|Other: Placebo nasal strip,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/25/2010,1/14/2011,https://ClinicalTrials.gov/show/NCT03549117
1939,Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients,Completed,Has Results,COPD|Dyspnea,Device: Vitabreath Device|Other: Pursed Lip Breathing,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,11/6/2017,2/20/2018,https://ClinicalTrials.gov/show/NCT03349437
1940,SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.,Completed,Has Results,Transient Insomnia,Drug: SM-1|Drug: D+Z|Drug: D+L|Drug: Placebo,Sequential Medicine Ltd,Sequential Medicine Ltd,,,,,,,Phase 3,Industry,Interventional,10/9/2017,3/22/2018,https://ClinicalTrials.gov/show/NCT03331042
1941,"A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA",Completed,Has Results,Asymptomatic Hyperuricemia,Drug: Verinurad|Drug: Febuxostat|Drug: Dapagliflozin|Other: Dapagliflozin matched placebo,"AstraZeneca|Contract Research Organization: USA|PAREXEL Early Phase Clinical Unit Baltimore|PAREXEL Early Phase Clinical Unit-Los Angeles|Clinical Laboratory: USA|Harbor Hospital Laboratory|GenX Laboratories Inc.|Analytical Laboratory (Pharmacokinetic Sample Analysis): USA|Covance Bioanalytical Services, LLC",AstraZeneca,Contract Research Organization: USA,"PAREXEL Early Phase Clinical Unit Baltimore|PAREXEL Early Phase Clinical Unit-Los Angeles|Clinical Laboratory: USA|Harbor Hospital Laboratory|GenX Laboratories Inc.|Analytical Laboratory (Pharmacokinetic Sample Analysis): USA|Covance Bioanalytical Services, LLC",PAREXEL Early Phase Clinical Unit Baltimore,"PAREXEL Early Phase Clinical Unit-Los Angeles|Clinical Laboratory: USA|Harbor Hospital Laboratory|GenX Laboratories Inc.|Analytical Laboratory (Pharmacokinetic Sample Analysis): USA|Covance Bioanalytical Services, LLC",PAREXEL Early Phase Clinical Unit-Los Angeles,"Clinical Laboratory: USA|Harbor Hospital Laboratory|GenX Laboratories Inc.|Analytical Laboratory (Pharmacokinetic Sample Analysis): USA|Covance Bioanalytical Services, LLC",Phase 2,Industry|Other,Interventional,10/25/2017,7/19/2018,https://ClinicalTrials.gov/show/NCT03316131
1942,Pediatric Ease of Use ELLIPTA Items,Completed,Has Results,Asthma,Other: Interviewer administered version of ease of use items|Other: Self-administered version of ease of use items|Other: Caregiver version of ease of use items,GlaxoSmithKline|RTI Health Solutions(RTI HS),GlaxoSmithKline,RTI Health Solutions(RTI HS),,,,,,,Industry|Other,Observational,10/17/2017,12/1/2017,https://ClinicalTrials.gov/show/NCT03315572
1943,Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management,Completed,Has Results,Sickle Cell Disease,Other: Pinpoint App,"Klein Buendel, Inc.|Hilton Publishing Company|National Institute on Minority Health and Health Disparities (NIMHD)","Klein Buendel, Inc.",Hilton Publishing Company,National Institute on Minority Health and Health Disparities (NIMHD),,,,,Not Applicable,Industry|Other|NIH,Interventional,1/15/2017,9/30/2017,https://ClinicalTrials.gov/show/NCT03291613
1944,Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005),Completed,Has Results,Renal Impairment,Drug: MK-3866,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 1,Industry,Interventional,9/1/2017,2/9/2018,https://ClinicalTrials.gov/show/NCT03259087
1945,Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain,Completed,Has Results,"Pain, Postoperative",Drug: Buprenorphine Sublingual Spray|Drug: Morphine|Drug: Oxycodone Hydrochloride|Drug: Zofran,INSYS Therapeutics Inc,INSYS Therapeutics Inc,,,,,,,Phase 2,Industry,Interventional,9/12/2017,11/13/2017,https://ClinicalTrials.gov/show/NCT03254459
1946,Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT),Completed,Has Results,Primary Open Angle Glaucoma or Ocular Hypertension,Drug: Netarsudil Ophthalmic Solution 0.02%|Other: Placebo Comparator,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/20/2017,4/19/2018,https://ClinicalTrials.gov/show/NCT03233308
1947,Accuracy of Methemoglobin Measurement for Rainbow Universal Pulse Oximeter Sensor,Completed,Has Results,Healthy,Device: Rainbow Universal Pulse Oximeter Sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,4/12/2012,6/21/2012,https://ClinicalTrials.gov/show/NCT03125005
1948,Accuracy of Hemoglobin Measurement for Various Rainbow Pulse Oximeter Sensors,Completed,Has Results,Healthy,Device: Pulse Oximeter sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,12/9/2009,12/31/2009,https://ClinicalTrials.gov/show/NCT03124966
1949,Accuracy of Methemoglobin Measurement for Rainbow DCI Sensors,Completed,Has Results,Healthy,Device: DCI pulse oximeter sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,4/23/2008,8/8/2008,https://ClinicalTrials.gov/show/NCT03124927
1950,Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor,Completed,Has Results,Surgery|Healthy,Device: DCI pulse oximeter sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,9/30/2008,10/27/2008,https://ClinicalTrials.gov/show/NCT03124901
1951,A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne,Completed,Has Results,Acne Vulgaris,"Device: Cleanser, Acne Mask|Device: Cleanser, Gel-Cream, Acne Mask",Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer Inc. (J&JCI),Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,4/8/2017,9/6/2017,https://ClinicalTrials.gov/show/NCT03124381
1952,In Vivo Recovery and Survival Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution,Completed,Has Results,Healthy Volunteers,Device: Trima Accel system,Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,7/26/2017,11/24/2017,https://ClinicalTrials.gov/show/NCT03097289
1953,Profound Dermal and SubQ Cartridges for the Treatment of Cellulite,Completed,Has Results,Cellulite,Device: Profound,Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,9/13/2017,1/31/2019,https://ClinicalTrials.gov/show/NCT03078647
1954,Caminamos: A Smartphone App to Connect With Walking Partners,Completed,Has Results,Physical Activity,Other: Caminamos App,"Klein Buendel, Inc.|Stanford University|National Institute on Minority Health and Health Disparities (NIMHD)","Klein Buendel, Inc.",Stanford University,National Institute on Minority Health and Health Disparities (NIMHD),,,,,Not Applicable,Industry|Other|NIH,Interventional,8/4/2015,12/31/2016,https://ClinicalTrials.gov/show/NCT03059901
1955,A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: Kevetrin,"Innovation Pharmaceuticals, Inc.","Innovation Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,2/9/2017,11/10/2017,https://ClinicalTrials.gov/show/NCT03042702
1956,Pressure Injury Prevention in the ICU With Multi-Layer Foam Dressings,Completed,Has Results,Pressure Incidence Prevention,Device: Mepilex Border,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,9/9/2016,5/4/2017,https://ClinicalTrials.gov/show/NCT02962882
1957,Pressure Variability Study,Completed,Has Results,Heart Failure,"Other: Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.",Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,7/16/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02943941
1958,Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines,Completed,Has Results,Glabellar Frown Lines (GL),Drug: EB-001 injection|Drug: Placebo injection,"Bonti, Inc.","Bonti, Inc.",,,,,,,Phase 2,Industry,Interventional,12/16/2019,7/12/2017,https://ClinicalTrials.gov/show/NCT02939326
1959,Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain,Completed,Has Results,Pain,Drug: Fentanyl|Drug: Placebo,INSYS Therapeutics Inc,INSYS Therapeutics Inc,,,,,,,Phase 2,Industry,Interventional,12/16/2019,2/10/2017,https://ClinicalTrials.gov/show/NCT02915978
1960,"Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations",Completed,Has Results,Influenza,"Biological: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|Biological: Fluzone High-Dose, vaccine, 2016-2017 formulation","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/15/2016,12/9/2016,https://ClinicalTrials.gov/show/NCT02908269
1961,"To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.",Completed,Has Results,"Infections, Bacterial",Drug: Gepotidacin RC Tablet|Drug: Gepotidacin HSWG Tablet|Drug: Gepotidacin Capsule,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,8/4/2016,10/17/2017,https://ClinicalTrials.gov/show/NCT02853435
1962,A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy,Completed,Has Results,Painful Peripheral Diabetic Neuropathy,Device: Provant,"Regenesis Biomedical, Inc.","Regenesis Biomedical, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/16/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02809911
1963,Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator,Completed,Has Results,Dry Eye Syndrome|Keratoconjunctivitis Sicca,Device: Oculeve Intranasal Neurostimulator,"Oculeve, Inc.","Oculeve, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/16/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02798289
1964,Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium,Completed,Has Results,Esophageal Cancer,Device: CryoBalloon™ Full Ablation System|Device: CryoBalloon™ Swipe Ablation System,"C2 Therapeutics, Inc.","C2 Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/16/2019,10/30/2016,https://ClinicalTrials.gov/show/NCT02729753
1965,"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants",Completed,Has Results,Healthy Volunteer,Drug: Oseltamivir|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,12/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT02717754
1966,Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment,Completed,Has Results,Heartburn,Drug: Esomeprazole 20 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,1/16/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02708355
1967,"Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants",Completed,Has Results,Dose Finding Study,Drug: TAK-828|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,3/1/2016,6/17/2016,https://ClinicalTrials.gov/show/NCT02706834
1968,A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.,Completed,Has Results,Acne Vulgaris,Device: Acne Mask|Drug: 2.5% Benzoyl Peroxide Treatment,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,3/31/2016,8/31/2016,https://ClinicalTrials.gov/show/NCT02698436
1969,Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men,Completed,Has Results,Hypogonadism,Drug: Testosterone undecanoate|Drug: Testosterone enanthate,"Clarus Therapeutics, Inc.|Los Angeles Biomedical Research Institute","Clarus Therapeutics, Inc.",Los Angeles Biomedical Research Institute,,,,,,Phase 2,Industry|Other,Interventional,11/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT02697188
1970,Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee,Completed,Has Results,"Osteoarthritis, Knee",Device: Provant Therapy System,"Regenesis Biomedical, Inc.","Regenesis Biomedical, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/2/2016,9/23/2016,https://ClinicalTrials.gov/show/NCT02696083
1971,Multiple Dose Study Of PF-05251749 In Healthy Volunteers,Completed,Has Results,Healthy Adult Subjects|Healthy Elderly Subjects,Drug: PF-05251749|Drug: Melatonin,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,3/28/2016,1/12/2017,https://ClinicalTrials.gov/show/NCT02691702
1972,"Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema",Completed,Has Results,Atopic Dermatitis,Device: EpiCeram Skin Barrier Emulsion|Drug: Experimental Product 1% Colloidal Oatmeal Balm,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer Inc. (J&JCI),Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Phase 2,Industry,Interventional,2/16/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02691507
1973,Trima Accel® System Post Count Algorithm Study,Completed,Has Results,Healthy Volunteers,Device: Trima Accel System,Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,1/28/2016,5/28/2016,https://ClinicalTrials.gov/show/NCT02684630
1974,A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome,Completed,Has Results,Dry Eye Syndrome|Keratoconjunctivitis Sicca,Device: Oculeve Intranasal|Device: Sham|Device: Oculeve Extranasal,"Oculeve, Inc.","Oculeve, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/31/2016,3/31/2016,https://ClinicalTrials.gov/show/NCT02680158
1975,"To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration",Completed,Has Results,Cystic Fibrosis,Drug: AZD5634 for inhalation|Drug: AZD5634 for infusion|Other: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,2/11/2016,10/24/2016,https://ClinicalTrials.gov/show/NCT02679729
1976,A Study of Abemaciclib in Healthy Participants,Completed,Has Results,Healthy,Drug: Abemaciclib|Drug: Placebo|Drug: Loperamide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/16/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02677844
1977,A Study of Abemaciclib in Healthy Participants,Completed,Has Results,Healthy,Drug: Abemaciclib Capsules (Reference Formulation)|Drug: Abemaciclib Tablet (Test Formulation),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/16/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02672423
1978,"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain",Completed,Has Results,Acute Moderate-to-severe Pain,Drug: sufentanil sublingual tablet 30 mcg,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,3/16/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02662556
1979,Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2),Completed,Has Results,"Keratosis, Actinic",Drug: Aminolevulinic Acid (ALA)|Device: BLU-U,"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,2/16/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02628236
1980,Adipose-derived SVF for Treatment of Alopecia,Completed,Has Results,Androgenetic Alopecia,Device: GID SVF-2,The GID Group,The GID Group,,,,,,,Not Applicable,Industry,Interventional,7/20/2016,1/22/2017,https://ClinicalTrials.gov/show/NCT02626780
1981,Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement,Completed,Has Results,Osteoporosis,Other: Tetracycline|Other: Demeclocycline|Procedure: Total Hip Replacement,Amgen,Amgen,,,,,,,Phase 4,Industry,Interventional,12/22/2015,12/18/2017,https://ClinicalTrials.gov/show/NCT02576652
1982,LEO 124249 Ointment in the Treatment of Alopecia Areata,Completed,Has Results,Alopecia Areata,Drug: LEO 124249|Other: Vehicle,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,1/16/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02561585
1983,Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®,Completed,Has Results,Dry Eye Syndromes,Drug: Cyclosporine 0.05% Ophthalmic Emulsion,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,7/21/2015,3/24/2016,https://ClinicalTrials.gov/show/NCT02554981
1984,Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children,Completed,Has Results,Influenza,"Biological: Fluzone® Quadrivalent Influenza Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,8/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02539108
1985,Evaluation of 8.5 vs 9.0 Base Curve for 1-DAY ACUVUE(r) TruEye(r) Brand Contact Lenses,Completed,Has Results,Contact Lens Base Curve (BC) Fit and Comfort,Device: Contact Lenses with 8.5 BC|Device: Contact Lenses with 9.0 BC,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Phase 4,Industry,Interventional,7/1/2015,7/1/2015,https://ClinicalTrials.gov/show/NCT02537522
1986,First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979,Completed,Has Results,Healthy Subjects,Drug: PF-06751979 single ascending dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple dose|Drug: PF-06751979 multiple dose,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02509117
1987,"A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure",Completed,Has Results,Heart Failure,Drug: GSK2798745|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/13/2016,8/21/2017,https://ClinicalTrials.gov/show/NCT02497937
1988,A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food,Completed,Has Results,Healthy,Drug: Abemaciclib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/15/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02482935
1989,TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: TAK-648|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,4/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02430870
1990,Evaluation of a Ascensia ONYX NEXT Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: ONYX NEXT BGMS,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,3/15/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02390167
1991,Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study,Completed,Has Results,Arteriovenous Malformations,Device: Apollo™ Onyx™ Delivery Micro Catheter,Medtronic Neurovascular Clinical Affairs,Medtronic Neurovascular Clinical Affairs,,,,,,,Not Applicable,Industry,Interventional,5/18/2015,2/20/2018,https://ClinicalTrials.gov/show/NCT02378883
1992,Evaluation of an Ascensia Diabetes Care ONYX PLUS Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: ONYX PLUS Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,2/15/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02371876
1993,BradyXplore Phase II: Bradykinesia Feature Extraction System,Completed,Has Results,Parkinson's Disease,,Great Lakes NeuroTechnologies Inc.|University of Cincinnati|The Cleveland Clinic,Great Lakes NeuroTechnologies Inc.,University of Cincinnati,The Cleveland Clinic,,,,,,Industry|Other,Observational,2/15/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02358876
1994,Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema,Completed,Has Results,Atopic Dermatitis (AD),Drug: Experimental Product,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer Inc. (J&JCI),Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,1/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02357940
1995,A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib,Completed,Has Results,"Healthy, Hepatic Insufficiency",Drug: Palbociclib 75 mg Capsule,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,3/31/2015,10/9/2016,https://ClinicalTrials.gov/show/NCT02334800
1996,"Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa",Completed,Has Results,Retinitis Pigmentosa (RP),Biological: human retinal progenitor cells,"jCyte, Inc|California Institute for Regenerative Medicine (CIRM)","jCyte, Inc",California Institute for Regenerative Medicine (CIRM),,,,,,Phase 1|Phase 2,Industry|Other,Interventional,6/15/2019,7/19/2017,https://ClinicalTrials.gov/show/NCT02320812
1997,Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography,Completed,Has Results,"Breast Cancer|Tumors, Breast|Cancer Screening",Device: FFDM|Device: DBT,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,5/15/2019,7/7/2017,https://ClinicalTrials.gov/show/NCT02306265
1998,In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution,Completed,Has Results,Healthy Volunteers,Device: Platelets stored in InterSol|Device: Platelets stored in Plasma,Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,11/5/2015,5/12/2016,https://ClinicalTrials.gov/show/NCT02298842
1999,Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit,Completed,Has Results,Infertility,Procedure: Intrauterine Insemination|Drug: Clomiphene|Drug: Letrozole,Midwest Fertility Specialists,Midwest Fertility Specialists,,,,,,,Not Applicable,Industry,Interventional,10/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02294773
2000,Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds,Completed,Has Results,Migraine,Drug: Diclofenac Potassium for Oral Solution,Depomed,Depomed,,,,,,,Phase 4,Industry,Interventional,1/15/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02287376
2001,Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty,Completed,Has Results,Pain,Drug: Bupivacaine SNB|Drug: EXPAREL Infiltration,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 4,Industry,Interventional,12/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02284386
2002,Feasibility Study Evaluating the ParaPatch System,Completed,Has Results,Urinary Incontinence,Device: ParaPatch,"ParaPatch, Inc","ParaPatch, Inc",,,,,,,Not Applicable,Industry,Interventional,11/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02278146
2003,Clinical Study of the Optic Disc Parameters,Completed,Has Results,Normal Healthy Subjects With No Known Ocular Diseases|Glaucomatous Eyes|Eyes With Retinal Diseases,Device: Maestro|Device: iVue,"Topcon Medical Systems, Inc.","Topcon Medical Systems, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02277119
2004,An Evaluation of the Spectra Optia CMNC Collection Procedure,Completed,Has Results,Healthy Apheresis Donors|Mononuclear (MNC) Cell Donors,Device: Spectra Optia CMNC|Device: COBE Spectra MNC|Drug: Granulocyte-colony stimulating factor (G-CSF),Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,9/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02253160
2005,"Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis",Completed,Has Results,Sporadic Inclusion Body Myositis (sIBM),Drug: BYM338 (Bimagrumab),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2|Phase 3,Industry,Interventional,3/11/2014,8/23/2016,https://ClinicalTrials.gov/show/NCT02250443
2006,Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion,Completed,Has Results,Healthy|Hypoxia,Device: Arterial line|Device: Motion,Medtronic - MITG,Medtronic - MITG,,,,,,,Phase 3,Industry,Interventional,11/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02247765
2007,Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis,Completed,Has Results,Anaemia,Drug: GSK1278863,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,10/24/2014,5/10/2017,https://ClinicalTrials.gov/show/NCT02243306
2008,Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia,Completed,Has Results,Chronic Sinusitis,Device: Propel Nova Sinus Implant,Intersect ENT,Intersect ENT,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02228720
2009,Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo|Drug: M2951,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono","EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",EMD Serono,,,,,Phase 2,Industry,Interventional,7/31/2016,11/14/2017,https://ClinicalTrials.gov/show/NCT02784106
2010,Wound Management for Sacral Pressure Ulcers With Necrotic Tissue,Completed,Has Results,Pressure Ulcers,Device: TheraHoney HD|Device: SkinTegrity,Medline Industries,Medline Industries,,,,,,,Phase 4,Industry,Interventional,12/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02224638
2011,Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers,Completed,Has Results,Healthy Volunteer,Procedure: Pharmacokinetic sampling - AZD9291|Drug: AZD9291 tablet dosing|Drug: Omeprazole tablet dosing|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,9/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02224053
2012,Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry,Completed,Has Results,"Meningococcal Disease|Pregnancy|Infections, Meningococcal",Biological: Meningococcal quadrivalent CRM-197 conjugate vaccine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,,Industry,Observational,9/30/2014,12/8/2017,https://ClinicalTrials.gov/show/NCT02223637
2013,"Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine",Completed,Has Results,Influenza,"Biological: Fluzone® Quadrivalent Influenza Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,8/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02222870
2014,Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: PF-04937319 IR MST|Drug: PF-04937319 MR 1|Drug: PF-04937319 MR 2|Drug: PF-04937319 MR 3,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,9/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02206607
2015,Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy,Completed,Has Results,Pain,Drug: EXPAREL,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 4,Industry,Interventional,8/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02199574
2016,Evaluation of a Novel Electronic Urine Output Monitor (eUOM),Completed,Has Results,Oliguria|Polyuria,Device: Accuryn,Potrero Medical,Potrero Medical,,,,,,,,Industry,Observational,7/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02195713
2017,Multicenter Dispensing Study of Biofinity Toric Made-To-Order Lenses in Extended Power Ranges,Completed,Has Results,Myopia|Astigmatism,Device: comfilcon A Toric,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02193178
2018,Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System (ISO/FDA Study),Completed,Has Results,Diabetes,Device: Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Device: Subjects WITH Diabetes Use Karajishi Contour BGMS,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02150109
2019,Non-invasive Computer-Aided Phenotyping of Vasculopathy,Completed,Has Results,Carotid Atherosclerosis|Peripheral Arterial Disease,,Elucid Bioimaging Inc.,Elucid Bioimaging Inc.,,,,,,,,Industry,Observational,7/14/2019,6/30/2017,https://ClinicalTrials.gov/show/NCT02143102
2020,A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin,Completed,Has Results,Eczema,Device: EpiCeram® Skin Barrier Emulsion|Drug: Colloidal Oatmeal Cream,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Phase 3,Industry,Interventional,3/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02120833
2021,A Study of LY2835219 in Participants With Cancer,Completed,Has Results,Neoplasm|Neoplasm Metastasis,Drug: Abemaciclib|Drug: Clarithromycin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,4/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02117648
2022,Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity,Completed,Has Results,Dentin Sensitivity,Device: Experimental Mouth Rinse 12027-033|Other: Placebo Mouth Rinse,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,3/14/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT02113579
2023,Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria,Completed,Has Results,Hereditary Orotic Aciduria,Drug: uridine triacetate,Wellstat Therapeutics,Wellstat Therapeutics,,,,,,,Phase 3,Industry,Interventional,4/14/2019,9/8/2016,https://ClinicalTrials.gov/show/NCT02110147
2024,Study of Low Level Laser Light Therapy on Circumference Reduction,Completed,Has Results,Circumference Reduction,Device: Erchonia EZ6 Laser,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,10/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02109107
2025,A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants,Completed,Has Results,"Osteoporosis, Postmenopausal",Drug: Blosozumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,4/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02109042
2026,"PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",Completed,Has Results,Multiple Myeloma|Non-Hodgkin Lymphoma|Hodgkin Disease,Drug: TG-0054 combined with G-CSF,"TaiGen Biotechnology Co., Ltd.","TaiGen Biotechnology Co., Ltd.",,,,,,,Phase 2,Industry,Interventional,2/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02104427
2027,A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers,Completed,Has Results,Asthma|Healthy Subjects or Volunteers,Biological: Tralokinumab 300 mg,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,3/19/2014,7/10/2014,https://ClinicalTrials.gov/show/NCT02085473
2028,A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy,Completed,Has Results,Postoperative Pain,Drug: MDT-10013|Drug: Standard of care for pain,Medtronic Spinal and Biologics,Medtronic Spinal and Biologics,,,,,,,Phase 2,Industry,Interventional,2/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02077140
2029,Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product,Completed,Has Results,Healthy Volunteer,Drug: Denosumab CP4|Drug: Denosumab CP2,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,2/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02053753
2030,Utility of Presepsin in Distinguishing Between Sepsis and SIRS,Completed,Has Results,SIRS|Sepsis,,"Mochida Pharmaceutical Company, Ltd.","Mochida Pharmaceutical Company, Ltd.",,,,,,,,Industry,Observational,1/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02052895
2031,Evaluation of an Karajishi TS Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: Karajishi TS Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,1/14/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT02041377
2032,Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: Karajishi Contour Investigational BG Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,1/14/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT02041286
2033,Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2),Completed,Has Results,Chronic Graft-versus-host Disease,"Drug: R348 Ophthalmic Solution, 0.2%|Drug: R348 Ophthalmic Solution, 0.5%|Other: Placebo Ophthalmic Solution",Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/14/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02040623
2034,PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers,Completed,Has Results,Renal Impairment|Renal Insufficiency|Kidney Disease|Kidney Diseases,Drug: IDN-6556,Conatus Pharmaceuticals Inc.,Conatus Pharmaceuticals Inc.,,,,,,,Phase 1,Industry,Interventional,1/14/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT02039817
2035,"Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects",Completed,Has Results,"Kidney Failure, Chronic",Drug: ticagrelor,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,12/29/2013,5/9/2016,https://ClinicalTrials.gov/show/NCT02022748
2036,Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting,Completed,Has Results,Smoking,Other: THS 2.2 Menthol (mTHS 2.2)|Other: Menthol Conventional Cigarette (mCC)|Other: Smoking Abstinence (SA),Philip Morris Products S.A.,Philip Morris Products S.A.,,,,,,,Not Applicable,Industry,Interventional,12/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01989156
2037,Comparison of 18F FDG PET/CT TO PET MRI,Completed,Has Results,Any Condition With a Clinical Indication for PET/CT Exam,Device: PET/MRI system,GE Healthcare,GE Healthcare,,,,,,,Not Applicable,Industry,Interventional,1/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01986985
2038,Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute,Completed,Has Results,Pain,Drug: Zipsor®,Depomed,Depomed,,,,,,,Phase 4,Industry,Interventional,11/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01982539
2039,A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy,Completed,Has Results,Androgenetic Alopecia,Device: Handi-Dome Laser|Device: Incandescent red light source.,"Capillus, LLC","Capillus, LLC",,,,,,,Not Applicable,Industry,Interventional,3/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01967277
2040,InFlux System for Nasal Breathing Improvement,Completed,Has Results,Nasal Airway Obstruction,Device: Procedure: thermal coagulation of tissue in the nasal airway,Aerin Medical,Aerin Medical,,,,,,,Not Applicable,Industry,Interventional,9/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01960816
2041,Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine,Completed,Has Results,Influenza,"Biological: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01946425
2042,Cognitive ADHD Videogame Exploratory Study,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Device: Neuro-typical controls and ADHD will receive EVO game play.,"Akili Interactive Labs, Inc.","Akili Interactive Labs, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01943539
2043,EVEREST II Pivotal Study High Risk Registry (HRR),Completed,Has Results,Mitral Valve Insufficiency|Mitral Valve Regurgitation|Mitral Valve Incompetence|Mitral Regurgitation|Mitral Insufficiency,Device: Percutaneous mitral valve repair using MitraClip implant,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,2/7/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01940120
2044,Use of Radiofrequency Ablation for RGB Salvage,Completed,Has Results,Obesity,Device: RFA treatment,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,7/13/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01910688
2045,Inactivation of Whole Blood With Mirasol,Completed,Has Results,Focus of Study: Radiolabel Recovery and Survival of RBCs,Device: Mirasol System for Whole Blood,Terumo BCTbio|U.S. Army Medical Research and Development Command,Terumo BCTbio,U.S. Army Medical Research and Development Command,,,,,,Phase 1,Industry|U.S. Fed,Interventional,6/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01907906
2046,A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease,Completed,Has Results,Liver Diseases|Hepatic Insufficiency,Drug: Baricitinib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01870388
2047,Measuring Wounds Found on the Outside of the Body Surface,Completed,Has Results,External Wounds Measured for Length by Width Using a Ruler,"Device: ""gold standard"" LxW manual ruler measurement technique|Device: WMMS ImageReview software's LxW measurement technique|Device: WMMS ImageReview software's Visual External Wound Trace|Device: WMMS ImageReview software's External Wound Trace Overlay",Wound Vision,Wound Vision,,,,,,,Not Applicable,Industry,Interventional,5/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01869439
2048,TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides,Completed,Has Results,Wrinkles|Rhytides,Device: TriActive+ RF,El. En. SpA,El. En. SpA,,,,,,,Not Applicable,Industry,Interventional,5/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01859611
2049,Evaluation of an Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: NINJA 3 Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,4/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01859494
2050,Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method,Completed,Has Results,Subcutaneous Adipose Tissue,Device: Liposonix System (Model 2),Solta Medical|Valeant Pharmaceuticals,Solta Medical,Valeant Pharmaceuticals,,,,,,Not Applicable,Industry,Interventional,4/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01853397
2051,A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment,Completed,Has Results,Hepatic Insufficiency,Drug: Evacetrapib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,4/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01836185
2052,Study of Low Level Laser Therapy to Treat Low Back Pain,Completed,Has Results,Low Back Pain,Device: Erchonia MLS|Device: Placebo Laser,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,9/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01835756
2053,Study of Low Level Laser Therapy to Treat Chronic Heel Pain Arising From Plantar Fasciitis,Completed,Has Results,Plantar Fasciitis,Device: Erchonia HPS Laser|Device: Placebo Laser,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,2/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01835743
2054,Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment,Completed,Has Results,Hepatitis C,Drug: Daclatasvir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,9/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01830205
2055,A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Bimatoprost 0.01%|Drug: Bimatoprost 0.03%,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,7/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01830140
2056,Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals,Completed,Has Results,Obesity,Device: Erchonia Obesity Laser|Device: Placebo Laser,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,3/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01821352
2057,Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study,Completed,Has Results,Bipolar Disorder|Schizophrenia,Other: Digital Health Feedback System,"Proteus Digital Health, Inc.|Massachusetts General Hospital|The Zucker Hillside Hospital","Proteus Digital Health, Inc.",Massachusetts General Hospital,The Zucker Hillside Hospital,,,,,Not Applicable,Industry|Other,Interventional,5/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01804257
2058,"An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers",Completed,Has Results,Hepatic Impairment,Drug: Ferriprox®,ApoPharma,ApoPharma,,,,,,,Phase 4,Industry,Interventional,1/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01767103
2059,Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector,Completed,Has Results,Healthy Volunteers,Biological: TDV|Drug: Placebo,Takeda|National Institutes of Health (NIH),Takeda,National Institutes of Health (NIH),,,,,,Phase 1,Industry|NIH,Interventional,2/15/2013,6/26/2014,https://ClinicalTrials.gov/show/NCT01765426
2060,"Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study",Completed,Has Results,Parkinson's Disease,Device: Medtronic DBS system,MedtronicNeuro,MedtronicNeuro,,,,,,,,Industry,Observational,11/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01750242
2061,A Study of LY2541546 in Healthy Postmenopausal Women,Completed,Has Results,Healthy,Drug: LY2541546 - IV|Drug: LY2541546 - SC|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01742078
2062,An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.,Completed,Has Results,Wound Healing.,Device: Mepilex Transfer Ag,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01734317
2063,Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function,Completed,Has Results,Hepatic Impairment|Healthy,Drug: SSP-004184,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,12/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01732263
2064,A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: Testosterone|Other: Deodorant Spray|Other: Deodorant and Antiperspirant Combination Spray|Other: Deodorant and Antiperspirant Combination Stick,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01725451
2065,Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function,Completed,Has Results,Impaired Renal Function,Drug: SSP-004184,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,11/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01716455
2066,Corneal Incisions With the IntraLase iFS Femtosecond Laser System,Completed,Has Results,Cataract,Device: iFS Femtosecond Laser,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Not Applicable,Industry,Interventional,11/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01713660
2067,Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy,Completed,Has Results,Acute Pain,Drug: Sufentanil NanoTab 20 mcg|Drug: Sufentanil NanoTab 30 mcg|Drug: Placebo NanoTab,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,10/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01710345
2068,"Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease",Completed,Has Results,End-Stage Renal Disease|Hemodialysis,"Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/3/2019,6/3/2019,https://ClinicalTrials.gov/show/NCT01710020
2069,Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine,Completed,Has Results,Chronic Migraine,Drug: Marcaine|Drug: Saline,Tian Medical Inc.|Clinvest,Tian Medical Inc.,Clinvest,,,,,,Phase 4,Industry|Other,Interventional,9/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01709708
2070,Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season,Completed,Has Results,Influenza|Healthy,Biological: Monovalent Influenza Vaccine|Other: Placebo,MedImmune LLC|AstraZeneca,MedImmune LLC,AstraZeneca,,,,,,Phase 4,Industry,Interventional,5/2/2016,11/30/2016,https://ClinicalTrials.gov/show/NCT02743117
2071,Nicotine Mouth Film for Craving Relief.,Completed,Has Results,Smoking Cessation,Drug: Nicotine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01702532
2072,Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks.,Completed,Has Results,Cellulite,Device: Erchonia Scanner device (GLS)|Device: Placebo device,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,10/9/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01702259
2073,A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis,Completed,Has Results,Psoriasis|Plaque Psoriasis,Drug: 122-0551|Drug: Vehicle,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,5/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01700985
2074,"Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)",Completed,Has Results,Breast Cancer,Device: Optical coherence tomography,"Diagnostic Photonics, Inc.|Johns Hopkins University","Diagnostic Photonics, Inc.",Johns Hopkins University,,,,,,,Industry|Other,Observational,12/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01699867
2075,Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation),Completed,Has Results,Influenza,"Biological: Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|Biological: Fluzone®; Influenza Virus Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01691326
2076,"Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy",Completed,Has Results,Schizophrenia,Drug: Risperidone|Drug: RBP-7000,Indivior Inc.,Indivior Inc.,,,,,,,Phase 2,Industry,Interventional,8/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01677377
2077,Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: EFB0027 (metformin delayed release)|Drug: EFB0026 (metformin immediate-release),"Elcelyx Therapeutics, Inc.","Elcelyx Therapeutics, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,5/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01677299
2078,Wide Diameter Bone Anchored Implant Study,Completed,Has Results,"Conductive Hearing Loss|Conductive and Sensori-neural Hearing Loss in the Same Ear|Unilateral, Profound Sensori-neural Hearing Loss",Device: Wide diameter bone anchored implant,Oticon Medical,Oticon Medical,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01671176
2079,An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients,Completed,Has Results,Donor Site Complication,Device: Mepilex Transfer Ag,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,9/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01670201
2080,Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Roflumilast|Drug: Alogliptin|Drug: Exenatide|Drug: Placebo to roflumilast|Drug: Placebo to alogliptin,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,7/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01664624
2081,Abbott ESA Chagas Assay Post-Market Study,Completed,Has Results,Chagas Disease,Device: Testing Donor Specimens with ESA Chagas,Abbott Diagnostics Division,Abbott Diagnostics Division,,,,,,,Not Applicable,Industry,Interventional,7/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01662362
2082,Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation,Completed,Has Results,Pediculosis,Drug: spinosad,ParaPRO LLC,ParaPRO LLC,,,,,,,Phase 4,Industry,Interventional,9/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01660321
2083,"A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Dose escalation followed by treatment with MTD,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,7/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01647711
2084,Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Device: NIOX MINO® Instrument (09-1100),Aerocrine AB,Aerocrine AB,,,,,,,,Industry,Observational,6/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01634620
2085,A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol,Completed,Has Results,Healthy Volunteers,Drug: LY3015014|Other: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01618916
2086,Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea,Completed,Has Results,Rosacea|Wrinkles,Device: Luxe,Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01618864
2087,Efficacy and Safety of IBI-10090 in Ocular Surgery Patients,Completed,Has Results,Inflammation Associated With Cataract Surgery,Drug: IBI-10090,ICON Bioscience Inc,ICON Bioscience Inc,,,,,,,Phase 2,Industry,Interventional,4/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01606735
2088,Performance Evaluation of an Investigational Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: CONTOUR® PLUS Investigational BG Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01598610
2089,Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol,Completed,Has Results,Spinal Injuries,,"Carestream Health, Inc.","Carestream Health, Inc.",,,,,,,,Industry,Observational,4/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01592435
2090,Comparative Study of Two Marketed Spherical Soft Contact Lenses,Completed,Has Results,Refractive Error,Device: enfilcon A|Device: senofilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Phase 4,Industry,Interventional,4/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01582789
2091,Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients,Completed,Has Results,Crohn's Disease,Other: bowel prep regimen first boost 6 oz. and second boost 3 oz.|Other: bowel prep regimen first boost 3 oz. and second boost 6 oz.,Given Imaging Ltd.,Given Imaging Ltd.,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01576120
2092,"ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus",Completed,Has Results,Viral Infection,Biological: Multivirus-specific T cells Dose Level 1|Biological: Multivirus-specific T cells Dose Level 2|Biological: Multivirus-specific T cells Dose Level 3,"ViraCyte|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine",ViraCyte,Texas Children's Hospital,"The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine",The Methodist Hospital System,"Center for Cell and Gene Therapy, Baylor College of Medicine",,,Phase 1|Phase 2,Industry|Other,Interventional,9/12/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT01570283
2093,IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA),Completed,Has Results,Femoral Artery Stenosis|Popliteal Artery Stenosis|Femoral Artery Occlusion|Popliteal Artery Occlusion,Device: Drug-Coated Balloon (DCB)|Device: PTA Balloon: Balloon Angioplasty,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,3/12/2019,5/18/2019,https://ClinicalTrials.gov/show/NCT01566461
2094,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Completed,Has Results,Colonoscopy,Drug: Remimazolam|Drug: Midazolam|Drug: Placebo,Paion UK Ltd.|Premier Research Group plc,Paion UK Ltd.,Premier Research Group plc,,,,,,Phase 3,Industry,Interventional,11/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02532647
2095,A Study of LY2484595 on the Electrical Activity of the Heart,Completed,Has Results,Healthy Volunteers,Drug: LY2484595|Drug: Placebo|Drug: Moxifloxacin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,2/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01537887
2096,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Dapsone Gel|Drug: Dapsone Gel Vehicle,"Almirall, S.A.|Allergan","Almirall, S.A.",Allergan,,,,,,Phase 3,Industry,Interventional,11/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01974141
2097,Octylseal Surgical Adhesive in General Surgery,Completed,Has Results,Wounds,Device: Cyanoacrylate (Octylseal ),Medline Industries,Medline Industries,,,,,,,Phase 4,Industry,Interventional,1/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01514383
2098,A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501,Completed,Has Results,Retraction of Colostomy,Drug: Group 1 Standard of Care|Drug: Group 2 EXPAREL,"Pacira Pharmaceuticals, Inc|Registrat-Mapi","Pacira Pharmaceuticals, Inc",Registrat-Mapi,,,,,,Phase 4,Industry|Other,Interventional,3/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01509638
2099,Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,Completed,Has Results,"Pain, Postoperative",Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Drug: Naproxen Sodium 440 mg (BAYH6689)|Drug: DPH 50 mg,Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,12/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01495858
2100,Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season,Completed,Has Results,Influenza|Healthy,Biological: Trivalent Influenza Vaccine|Other: Placebo,MedImmune LLC|AstraZeneca,MedImmune LLC,AstraZeneca,,,,,,Phase 4,Industry,Interventional,6/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02473510
2101,Study of an Investigational Glucose Meter System,Completed,Has Results,Diabetes,Device: G3 Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01474317
2102,Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae,Completed,Has Results,End Stage Renal Disease|AV Fistula|Kidney Failure,Device: Venous Window Needle Guide,Vital Access Corp.,Vital Access Corp.,,,,,,,Phase 2|Phase 3,Industry,Interventional,12/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01471041
2103,A Study of LY3007113 in Participants With Advanced Cancer,Completed,Has Results,Metastatic Cancer,Drug: LY3007113,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01463631
2104,"Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,10/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01457339
2105,Navigator II Continuous Glucose Monitor Home Use Study,Completed,Has Results,Diabetes,Device: FreeStyle Navigator II Continuous Glucose Monitoring System,Abbott Diabetes Care,Abbott Diabetes Care,,,,,,,,Industry,Observational,10/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01455064
2106,Blood Glucose Testing and You,Completed,Has Results,Diabetes,Other: Blood Glucose meter,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,10/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01453413
2107,"Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids",Completed,Has Results,Uterine Fibroids,Drug: Proellex,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,2/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01451424
2108,A Study of LY2484595 on Pharmacokinetics in Healthy Participants,Completed,Has Results,Healthy Participants,Drug: LY2484595|Drug: Placebo|Drug: Ketoconazole,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01448824
2109,A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1),Completed,Has Results,Hypertension,Drug: MK-8457|Drug: Placebo for MK-8457,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 1,Industry,Interventional,10/25/2011,3/3/2012,https://ClinicalTrials.gov/show/NCT01446003
2110,Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females,Completed,Has Results,Healthy,Drug: AG200-15,Agile Therapeutics,Agile Therapeutics,,,,,,,Phase 1,Industry,Interventional,2/11/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01422135
2111,Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed,Completed,Has Results,"Infections, Bacterial",Biological: AVA|Biological: Raxibacumab|Drug: Diphenhydramine,Emergent BioSolutions|GlaxoSmithKline,Emergent BioSolutions,GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,2/24/2015,6/6/2017,https://ClinicalTrials.gov/show/NCT02339155
2112,The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone),Completed,Has Results,Secondary Hypogonadism,Drug: Androxal (enclomiphene citrate)|Drug: Testosterone,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,6/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01386606
2113,Lifting and Tightening of the Face in Subjects With Skin of Darker Color,Completed,Has Results,Facial Skin Laxity,Device: Ulthera® System treatment,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,3/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01368965
2114,Reducing Wrinkles Around the Eyes Using the Ulthera® System,Completed,Has Results,Periorbital Wrinkles,Device: Ulthera® System treatment,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,3/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01368900
2115,Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System,Completed,Has Results,Facial and Neck Skin Laxity,Device: Ulthera® System treatment,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,3/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01368874
2116,AVAPS-AE Efficacy Study,Completed,Has Results,Obesity Hypoventilation Syndrome,Device: AVAPS-AE Mode of Therapy|Device: Respironics OnmiLab BiPAP S mode|Device: Respironics OmniLab Advanced CPAP mode,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,9/12/2011,5/30/2013,https://ClinicalTrials.gov/show/NCT01368614
2117,Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501,Completed,Has Results,Thrombocytopenia,Drug: Avatrombopag|Drug: Placebo|Drug: Pegylated interferon (PEG-IFN)|Drug: Telaprevir|Drug: Ribavirin,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,11/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01355289
2118,An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation,Completed,Has Results,Pediculosis,Drug: Group A - Low-Dose Ha44 0.37% w/w|Drug: Group B - High Dose Ha44 Gel 0.74% w/w|Drug: Group C - Placebo,Hatchtech Pty Ltd,Hatchtech Pty Ltd,,,,,,,Phase 2,Industry,Interventional,4/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01336647
2119,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,Completed,Has Results,Her2normal,Drug: eribulin mesylate,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,2/25/2011,10/11/2017,https://ClinicalTrials.gov/show/NCT01328249
2120,Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema,Completed,Has Results,Atopic Dermatitis,Drug: Colloidal Oatmeal|Device: Topical Cream,"Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Not Applicable,Industry,Interventional,3/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01326910
2121,Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: TRC105|Drug: Capecitabine,Tracon Pharmaceuticals Inc.|Roswell Park Cancer Institute|United States Department of Defense,Tracon Pharmaceuticals Inc.,Roswell Park Cancer Institute,United States Department of Defense,,,,,Phase 1|Phase 2,Industry|Other|U.S. Fed,Interventional,6/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01326481
2122,"Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems",Completed,Has Results,Hypogonadism,Drug: testosterone matrix transdermal system,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,4/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01323140
2123,Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma,Completed,Has Results,Asthma,Drug: Active|Drug: Placebo,"Nivalis Therapeutics, Inc.","Nivalis Therapeutics, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,3/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01316315
2124,Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment,Completed,Has Results,Renal Insufficiency,Drug: Dalfampridine-ER,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 1,Industry,Interventional,1/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01316055
2125,Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors,Completed,Has Results,Head and Neck Cancer,Genetic: Ad/PNP and fludarabine monophosphate,"PNP Therapeutics, Inc.","PNP Therapeutics, Inc.",,,,,,,Phase 1,Industry,Interventional,2/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01310179
2126,"Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",Completed,Has Results,Indolent Non-Hodgkin's Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma,Drug: Idelalisib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01306643
2127,Novel Non-Invasive Monitoring Parameter in a Hospital Setting,Completed,Has Results,Respiratory Insufficiency|Respiratory Failure,,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,2/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01306201
2128,Study of the Effectiveness of Green Diode Laser Light on Body Shaping,Completed,Has Results,Body Contouring,Device: Erchonia GLS|Device: Placebo laser,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,2/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01292538
2129,Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects,Completed,Has Results,Schizophrenia|Psychiatric Disorders,Drug: OPC-34712,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 1,Industry,Interventional,1/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01289080
2130,A Study of LY2090314 in Patients With Advanced or Metastatic Cancer,Completed,Has Results,Advanced Cancer,Drug: LY2090314|Drug: pemetrexed|Drug: Carboplatin|Other: ranitidine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01287520
2131,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,Completed,Has Results,"Pain, Postoperative",Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 440 mg (BAYH6689)|Drug: DPH 50 mg,Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,10/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01280591
2132,Accuracy and Reliability of Fetal Heart Rate and Uterine Contraction Monitoring Method,Completed,Has Results,Pregnancy; Habitual Aborter|Weeks of Gestation 37 or More,Device: Monica AN24 (K101081)|Device: Philips 50XM,Monica Healthcare Ltd,Monica Healthcare Ltd,,,,,,,Not Applicable,Industry,Interventional,2/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01280357
2133,Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE),Completed,Has Results,Age Related Macular Degeneration|Geographic Atrophy,,"Carl Zeiss Meditec, Inc.","Carl Zeiss Meditec, Inc.",,,,,,,,Industry,Observational,1/11/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01272076
2134,Multiple Dose Dental Pain Study Of Ibuprofen Extended Release,Completed,Has Results,Pain,Drug: Ibuprofen 600 mg ER|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/22/2010,3/31/2011,https://ClinicalTrials.gov/show/NCT01266161
2135,A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01263223
2136,Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure,Completed,Has Results,Heart Failure,Drug: Glial growth factor 2/ Neuregulin 1β3|Other: Placebo,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 1,Industry,Interventional,12/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01258387
2137,A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022),Completed,Has Results,Psoriasis|Plaque Psoriasis,Drug: MK-0873 2% Cream|Drug: MK-0873 vehicle (placebo) Cream|Drug: Calcitriol Cream,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 1,Industry,Interventional,11/1/2010,4/1/2011,https://ClinicalTrials.gov/show/NCT01235728
2138,Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies,Completed,Has Results,Acute Lymphoblastic Leukemia (ALL)|Acute Myelogenous Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma|Hodgkin's Disease,Drug: NiCord®,Gamida Cell ltd,Gamida Cell ltd,,,,,,,Phase 1|Phase 2,Industry,Interventional,11/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01221857
2139,A Dose-Escalation Study for Patients With Advanced Cancer,Completed,Has Results,Advanced Cancer,Drug: pegfilgrastim|Drug: LY2523355,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,5/8/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01214642
2140,A Study for Participants With Advanced Cancer,Completed,Has Results,Advanced Cancer|Metastatic Cancer,Drug: LY2523355|Drug: pegfilgrastim,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/7/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01214629
2141,VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK,Completed,Has Results,Cancer,Drug: pazopanib,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,9/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01205230
2142,DeVilbiss AutoAdjust With SmartFlex Comparative Study,Completed,Has Results,Obstructive Sleep Apnea,Device: SmartFlex|Device: Standard,DeVilbiss Healthcare LLC,DeVilbiss Healthcare LLC,,,,,,,Not Applicable,Industry,Interventional,9/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01203956
2143,A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar,Completed,Has Results,Healthy Volunteer,Drug: aleglitazar,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,9/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01197911
2144,Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms,Completed,Has Results,Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Borderline Personality Disorder,Drug: Lithium Carbonate|Drug: Placebo|Drug: Citalopram,Columbia Northwest Pharmaceuticals,Columbia Northwest Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01189812
2145,Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects,Completed,Has Results,Pharmacokinetics,Drug: Tamoxifen|Drug: Tamoxifen and Desvenlafaxine Succinate Sustained Release,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,8/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01189500
2146,Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects,Completed,Has Results,"Pharmacokinetics|Cytochrome P-450 CYP2D6|CYP3A4 Protein, Human",Drug: Aripiprazole|Drug: Aripiprazole + desvenlafaxine succinate sustained release,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,8/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01188668
2147,A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects,Completed,Has Results,Healthy,Drug: 4mg fesoterodine|Drug: 8mg fesoterodine|Drug: alprazolam 1mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01161472
2148,WallFlex Biliary Post Liver Transplant IDE Pilot,Completed,Has Results,Anastomotic Biliary Stricture Post Orthotopic Liver Transplant,Device: WallFlex Biliary Fully Covered Stent,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,10/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01151280
2149,Rehabilitation of the Stroke Hand at Home,Completed,Has Results,Stroke,Device: Hand Mentor (TM) robotic stroke therapy device|Device: Home Therapy Program,Kinetic Muscles|The Cleveland Clinic|Emory University|National Institute of Neurological Disorders and Stroke (NINDS),Kinetic Muscles,The Cleveland Clinic,Emory University|National Institute of Neurological Disorders and Stroke (NINDS),Emory University,National Institute of Neurological Disorders and Stroke (NINDS),,,Phase 4,Industry|Other|NIH,Interventional,6/10/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01144715
2150,Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults,Completed,Has Results,Gastroduodenal Ulcerations|Erosion,Drug: PL3100|Drug: Naproxen,PLx Pharma|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),PLx Pharma,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),,,,,,Phase 2,Industry|NIH,Interventional,7/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01139190
2151,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma",Completed,Has Results,Malignant Melanoma,Biological: IMC-20D7S (Cohort 1A)|Biological: IMC-20D7S (Cohort 2A)|Biological: IMC-20D7S (Cohort 3A)|Biological: IMC-20D7S (Cohort 4A)|Biological: IMC-20D7S (Cohort 1B)|Biological: IMC-20D7S (Cohort 2B)|Biological: IMC-20D7S (Cohort 3B),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01137006
2152,Kidney Damage in Patients With Moderate Fall in eGFR,Completed,Has Results,Coronary Artery Stenosis,Drug: Iopamidol|Drug: Iodixanol-320,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",,,,,,,Phase 4,Industry,Interventional,11/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01136876
2153,"A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK1292263|Drug: GSK1292263 matching placebo|Drug: Sitagliptin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/23/2009,4/12/2010,https://ClinicalTrials.gov/show/NCT01128621
2154,Exploratory Subjective Sleep Study of a Prototype Nasal Dilator,Completed,Has Results,"Sleep Disorders|Congestion, Nasal",Device: Prototype Nasal Dilator|Device: Marketed Nasal Strip|Device: Placebo Nasal Strip,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/1/2009,2/1/2010,https://ClinicalTrials.gov/show/NCT01122849
2155,Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types,Completed,Has Results,Astigmatism,Device: etafilcon A toric contact lens with new wetting agent|Device: etafilcon A toric contact lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/1/2010,2/1/2010,https://ClinicalTrials.gov/show/NCT01120782
2156,Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery,Completed,Has Results,Cerebral Palsy|Multiple Sclerosis|Traumatic Brain Injury|Spinal Cord Injury,,MedtronicNeuro,MedtronicNeuro,,,,,,,,Industry,Observational,6/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01117090
2157,Dispensing Evaluation of a Prototype Contact Lens and a Marketed Contact Lens,Completed,Has Results,Myopia,Device: galyfilcon A prototype lens|Device: lotrafilcon B lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/1/2010,3/1/2010,https://ClinicalTrials.gov/show/NCT01094743
2158,Post-operative Dental Pain Study Comparing Analgesic Efficacy,Completed,Has Results,Post-surgical Dental Pain,Drug: Paracetamol 1000 mg|Drug: Paracetamol 500 mg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,10/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01082081
2159,Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease,Completed,Has Results,Lesch-Nyhan Disease,Drug: Ecopipam,Psyadon Pharma,Psyadon Pharma,,,,,,,Phase 1,Industry,Interventional,2/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01065558
2160,Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections,Completed,Has Results,Infection,Drug: Placebo|Drug: Guaifenesin|Other: Buckwheat Honey,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Not Applicable,Industry,Interventional,1/10/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01062256
2161,An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter,Completed,Has Results,Gastroesophageal Reflux Disease,"Device: Torax Medical, Inc. LINX Reflux Management System",Torax Medical Incorporated,Torax Medical Incorporated,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/7/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01058070
2162,SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study,Completed,Has Results,Ischemic Stroke,Device: SOLITAIRE™ Device|Device: MERCI® Device,Medtronic Neurovascular Clinical Affairs,Medtronic Neurovascular Clinical Affairs,,,,,,,Not Applicable,Industry,Interventional,1/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01054560
2163,Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery,Completed,Has Results,Scar Formation,Biological: GBT009|Biological: Placebo,"Garnet BioTherapeutics, Inc.","Garnet BioTherapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,1/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01053897
2164,"Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies",Completed,Has Results,Advanced Nonhematological Malignancies|Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Metastatic Breast Cancer|Head and Neck Squamous Cell Carcinoma|Gastroesophageal Adenocarcinoma,Drug: MLN8237 (Alisertib),"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,2/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01045421
2165,Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults,Completed,Has Results,Influenza|Healthy,Biological: Trivalent Influenza Vaccine|Other: Placebo,MedImmune LLC|AstraZeneca,MedImmune LLC,AstraZeneca,,,,,,Phase 4,Industry,Interventional,5/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01859143
2166,Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler,Completed,Has Results,Nasolabial Folds,Device: Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Device: Radiesse® Injectable Dermal Filler without Lidocaine,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 4,Industry,Interventional,9/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT01012661
2167,Caverject User Study,Completed,Has Results,Erectile Dysfunction,Other: delivery system,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/11/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01008605
2168,Performance of a New Glucose Meter System in Children and Young Adults,Completed,Has Results,Diabetes,Device: DIDGET (Investigational Blood Glucose Monitoring System),Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00985257
2169,Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles,Completed,Has Results,Peri-oral Wrinkles,Device: Restylane and Perlane,Medicis Global Service Corporation,Medicis Global Service Corporation,,,,,,,Phase 4,Industry,Interventional,9/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00977704
2170,Bone Conduction Auditory Performance Via the Tooth for Single-Sided Deafness,Completed,Has Results,Unilateral Hearing Loss,Device: The Sonitus Bone Conduction Hearing System|Device: SoundBite|Device: SoundBite Hearing System,Sonitus Medical Inc,Sonitus Medical Inc,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00977314
2171,A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia,Completed,Has Results,Down Syndrome,Drug: ELND005|Drug: Placebo,Transition Therapeutics Ireland Limited|Elan Pharmaceuticals,Transition Therapeutics Ireland Limited,Elan Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,9/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01791725
2172,A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen,Completed,Has Results,Dysmenorrhea,Device: Vipon|Drug: Ibuprofen,Another Way Products,Another Way Products,,,,,,,Not Applicable,Industry,Interventional,11/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00951561
2173,Treatment of Androgenetic Alopecia in Males,Completed,Has Results,Androgenetic Alopecia|Hair Loss|Male Pattern Baldness,"Device: HairMax LaserComb 2009, 7 Beam|Device: HairMax LaserComb","Lexington International, LLC","Lexington International, LLC",,,,,,,Not Applicable,Industry,Interventional,8/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00947505
2174,Clinical Study of the Tympanostomy Tube Delivery System,Completed,Has Results,Otitis Media With Effusion,Device: Acclarent Tympanostomy Tube Delivery System,Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,3/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00939796
2175,Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling,Completed,Has Results,Urinary Incontinence|Prostate Cancer,Procedure: Prostatectomy|Device: Surgisis Male Sling,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00937833
2176,Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.,Completed,Has Results,Down Syndrome|Amyloid Beta-protein,Drug: Florbetaben (BAY94-9172),Life Molecular Imaging SA,Life Molecular Imaging SA,,,,,,,Phase 2,Industry,Interventional,6/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00928304
2177,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Completed,Has Results,Pediculosis,Drug: Malathion gel 0.5%|Drug: Permethrin 1% rinse,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 3,Industry,Interventional,8/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00927472
2178,Computer-Assisted Versus Manual Hair Harvest Comparative Study,Completed,Has Results,Androgenetic Alopecia,Device: ARTAS™ System|Procedure: Manual Hair Harvest,"Restoration Robotics, Inc.","Restoration Robotics, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00926211
2179,Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy,Completed,Has Results,Cervical Priming,Drug: misoprostol|Drug: placebo,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00925938
2180,Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults,Completed,Has Results,Insomnia,Drug: Ramelteon,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,11/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00914862
2181,Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora,Completed,Has Results,Vaginal Microflora,Device: Experimental - Tampon with GML|Device: Sham Control - Tampons without GML,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,1/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00913523
2182,Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Quillivant Oral Suspension XR|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,4/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00904670
2183,Safety and Efficacy Study of a Eye Drop for Eye Allergy,Completed,Has Results,Allergic Conjunctivitis,Drug: alcaftadine|Drug: Placebo,Vistakon Pharmaceuticals,Vistakon Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/9/2019,,https://ClinicalTrials.gov/show/NCT00889330
2184,A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: CVX-096,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,10/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00886821
2185,To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children,Completed,Has Results,Atopic Dermatitis,Device: F# 11054-010|Device: F# 10495-053,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,4/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00886587
2186,Study to Evaluate Daptomycin Given During Dialysis and After Dialysis,Completed,Has Results,End-stage Renal Disease|Renal Failure Chronic Requiring Hemodialysis,Drug: daptomycin,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 1,Industry,Interventional,4/29/2009,7/17/2009,https://ClinicalTrials.gov/show/NCT00882557
2187,Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment,Completed,Has Results,Hepatic Insufficiency,Drug: BMS-790052,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,3/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00859053
2188,Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines,Completed,Has Results,Skin Aging,Biological: botulinum toxin Type A,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,3/9/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00856414
2189,Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck,Completed,Has Results,Head and Neck Cancer,Device: AuroLase Therapy,"Nanospectra Biosciences, Inc.","Nanospectra Biosciences, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/8/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00848042
2190,A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation,Completed,Has Results,Lung Cancer|Head and Neck Cancer,Drug: [F-18]FLT,Siemens Molecular Imaging,Siemens Molecular Imaging,,,,,,,Not Applicable,Industry,Interventional,2/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00847509
2191,Alice PDx User/Validation Extended Trial,Completed,Has Results,Sleep Apnea|Sleep-Disordered Breathing,Device: Alice PDx with only written instructions|Device: Alice PDx with written and verbal instructions,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,9/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00841906
2192,Cilostazol 50 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Cilostazol 50 mg Tablets|Drug: Pletal®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/4/2019,2/4/2019,https://ClinicalTrials.gov/show/NCT00839930
2193,Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids,Completed,Has Results,Uterine Fibroids|Uterine Leiomyomata,Device: Philips MR guided HIFU system,Philips Healthcare,Philips Healthcare,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00837161
2194,Clarithromycin 500 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Clarithromycin|Drug: Biaxin®,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/2/2019,9/2/2019,https://ClinicalTrials.gov/show/NCT00835692
2195,"Cefprozil for Oral Suspension 250 mg/5 mL, Fasting",Completed,Has Results,Healthy,Drug: Cefprozil for oral suspension 250 mg/5 mL|Drug: CEFZIL® for Oral Suspension 250 mg/5mL,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,4/4/2019,4/4/2019,https://ClinicalTrials.gov/show/NCT00835614
2196,Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Pantoprazole Sodium 40 mg delayed-release tablets|Drug: PROTONIX® 40 mg delayed-release tablets.,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,12/3/2019,12/3/2019,https://ClinicalTrials.gov/show/NCT00835588
2197,"Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting",Completed,Has Results,Healthy,Drug: Cefdinir for oral suspension 250 mg/5mL|Drug: OMNICEF® for oral suspension 250 mg/5mL,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,3/5/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00835549
2198,Ribavirin 200 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Ribavirin 200 mg tablets|Drug: COPEGUS™ 200 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/3/2019,10/3/2019,https://ClinicalTrials.gov/show/NCT00835536
2199,"5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting",Completed,Has Results,Healthy,Drug: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|Drug: 5 mg/500 mg METAGLIP™ Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/4/2019,6/4/2019,https://ClinicalTrials.gov/show/NCT00835497
2200,"Cefdinir Capsules 300 mg, Fasting",Completed,Has Results,Healthy,Drug: Cefdinir Capsules 300 mg|Drug: OMNICEF® 300 mg,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,7/5/2019,7/5/2019,https://ClinicalTrials.gov/show/NCT00835484
2201,"Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting",Completed,Has Results,Healthy,Drug: Cefprozil for oral suspension 250 mg/5 mL|Drug: CEFZIL® for Oral Suspension 250 mg/5mL,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,5/4/2019,5/4/2019,https://ClinicalTrials.gov/show/NCT00835354
2202,Ribavirin 200 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Ribavirin 200 mg tablets|Drug: COPEGUS™,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/3/2019,10/3/2019,https://ClinicalTrials.gov/show/NCT00835146
2203,Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|Drug: UNIRETIC® 15/25 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/3/2019,11/3/2019,https://ClinicalTrials.gov/show/NCT00835042
2204,"5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting",Completed,Has Results,Healthy,Drug: 5 mg/500 mg METAGLIP™ Tablets|Drug: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/4/2019,6/4/2019,https://ClinicalTrials.gov/show/NCT00834587
2205,"Cefdinir for Oral Suspension 250 mg/5mL, Fasting",Completed,Has Results,Healthy,Drug: Cefdinir for oral suspension 250 mg/5mL|Drug: OMNICEF® for oral suspension 250 mg/5mL,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,2/5/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00834574
2206,"Cefdinir Capsules 300 mg, Non-fasting",Completed,Has Results,Healthy,Drug: Cefdinir Capsules 300 mg|Drug: OMNICEF® Capsule 300 mg,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,7/5/2019,8/5/2019,https://ClinicalTrials.gov/show/NCT00834535
2207,"Leflunomide 20 mg Tablets, Non-Fasting",Completed,Has Results,Healthy,Drug: ARAVA® 20 mg tablets|Drug: Leflunomide 20 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,4/2/2019,5/2/2019,https://ClinicalTrials.gov/show/NCT00834405
2208,Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|Drug: UNIRETIC® 15/25 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,10/3/2019,11/3/2019,https://ClinicalTrials.gov/show/NCT00834067
2209,Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Zolpidem 10 mg tablets|Drug: AMBIEN® 10 mg tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,3/2/2019,3/2/2019,https://ClinicalTrials.gov/show/NCT00833937
2210,Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions,Completed,Has Results,Healthy,Drug: Alprazolam Extended-Release 3 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/5/2019,6/5/2019,https://ClinicalTrials.gov/show/NCT00830024
2211,Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Alprazolam Extended-Release 3 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/5/2019,6/5/2019,https://ClinicalTrials.gov/show/NCT00829426
2212,A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars,Completed,Has Results,Scar Prevention|Scar Reduction,Drug: AZX100 Drug Product|Drug: Placebo,Capstone Therapeutics,Capstone Therapeutics,,,,,,,Phase 2,Industry,Interventional,3/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00825916
2213,Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort,Completed,Has Results,Pneumococcal Conjugate Vaccine,Biological: 13-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,1/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00824850
2214,Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,"Glaucoma, Open Angle|Ocular Hypertension",Drug: Timolol Maleate in Sorbate|Drug: Timolol hemihydrate|Drug: Timolol maleate gel forming solution,Vistakon Pharmaceuticals,Vistakon Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,11/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00804648
2215,Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT),Completed,Has Results,Hypertension,Drug: clevidipine,The Medicines Company,The Medicines Company,,,,,,,Phase 2,Industry,Interventional,11/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00799604
2216,Lab School Day Study for CONCERTA of Older Children With ADHD,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Placebo/ CONCERTA (methylphenidate HCl)|Drug: CONCERTA (methylphenidate HCl) / Placebo,"Ortho-McNeil Janssen Scientific Affairs, LLC","Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,,Phase 4,Industry,Interventional,12/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00799409
2217,Evaluation of the A1CNow+ Test Kit,Completed,Has Results,Diabetes,Device: A1C Test Kit,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00798486
2218,A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults,Completed,Has Results,Influenza,Biological: Trivalent Influenza Virus Vaccine|Other: Placebo,MedImmune LLC|AstraZeneca,MedImmune LLC,AstraZeneca,,,,,,Phase 4,Industry,Interventional,5/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01579916
2219,An fMRI Study Of Brain Response In Patients With Fibromyalgia,Completed,Has Results,Fibromyalgia,"Drug: Pregabalin, then placebo|Drug: Placebo, then pregabalin",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,1/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00760474
2220,The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study,Completed,Has Results,Peripheral Vascular Disease,Device: Assurant® Cobalt Iliac Stent System,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,10/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00753337
2221,Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice,Completed,Has Results,Pediculosis,Drug: MALG (malathion) Treatment,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/8/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00752973
2222,Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty,Completed,Has Results,Lower Back Pain,Device: The Transdiscal Radiofrequency Annuloplasty,Baylis Medical Company,Baylis Medical Company,,,,,,,Phase 1,Industry,Interventional,9/7/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00750191
2223,Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis,Completed,Has Results,Leber Congenital Amaurosis,Biological: rAAV2-CB-hRPE65,"Applied Genetic Technologies Corp|Oregon Health and Science University|University of Massachusetts, Worcester",Applied Genetic Technologies Corp,Oregon Health and Science University,"University of Massachusetts, Worcester",,,,,Phase 1|Phase 2,Industry|Other,Interventional,6/17/2009,9/22/2017,https://ClinicalTrials.gov/show/NCT00749957
2224,"Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo",Completed,Has Results,Smoking Cessation,Drug: varenicline|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,9/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00749944
2225,AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair,Completed,Has Results,"Hernia, Inguinal|Hernia, Ventral",Device: AbsorbaTack|Device: ProTack,Medtronic - MITG,Medtronic - MITG,,,,,,,Phase 4,Industry,Interventional,10/8/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00749268
2226,Study to Evaluate Implant Survival Rate of Astra Tech Fixture ST in the Posterior Maxilla With One-stage Surgery and Early Loading,Completed,Has Results,"Jaw, Edentulous, Partially",Device: Astra Tech Fixture ST,Dentsply Sirona Implants,Dentsply Sirona Implants,,,,,,,Not Applicable,Industry,Interventional,9/1/2000,,https://ClinicalTrials.gov/show/NCT00748241
2227,Study to Compare Marginal Bone Loss Around Implants From Two Dental Implant Systems.,Completed,Has Results,"Jaw, Edentulous, Partially","Device: ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|Device: 3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm",Dentsply Sirona Implants,Dentsply Sirona Implants,,,,,,,Not Applicable,Industry,Interventional,12/2/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00746187
2228,Proximal Protection With The Mo.Ma Device During Carotid Stenting,Completed,Has Results,Carotid Artery Disease,Device: Mo.Ma cerebral protection device,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,9/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00744523
2229,Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults,Completed,Has Results,Impaired Liver Function,Drug: Proellex,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 1,Industry,Interventional,10/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00741273
2230,A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients,Completed,Has Results,Advanced Malignant Solid Tumors,Drug: PF-00299804,Pfizer|Roswell Park Cancer Institute|South Texas Accelerated Research Therapeutics (START),Pfizer,Roswell Park Cancer Institute,South Texas Accelerated Research Therapeutics (START),,,,,Phase 1,Industry|Other,Interventional,9/8/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00728468
2231,HFCWO in Hospitalized Asthmatic Children,Completed,Has Results,Bronchial Asthma|Asthma|Status Asthmaticus,Device: VEST,Hill-Rom,Hill-Rom,,,,,,,Not Applicable,Industry,Interventional,7/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00722020
2232,A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas,Completed,Has Results,Pancreatic Neoplasm,Biological: monoclonal antibody|Drug: chemotherapy,Hoffmann-La Roche|University of Pennsylvania,Hoffmann-La Roche,University of Pennsylvania,,,,,,Phase 1,Industry|Other,Interventional,6/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00711191
2233,"A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing",Completed,Has Results,Tooth Extractions,Device: Hemcon Dental Dressing|Device: Gauze with Pressure and/or Gelfoam,"HemCon Medical Technologies, Inc","HemCon Medical Technologies, Inc",,,,,,,Phase 3,Industry,Interventional,6/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00707486
2234,To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone,Completed,Has Results,Secondary Hypogonadism,Drug: 25 mg Androxal|Drug: Testim 1%,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,6/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00706719
2235,Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP),Completed,Has Results,"Purpura, Thrombocytopenic, Idiopathic",Drug: Fostamatinib Disodium / R935788,Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00706342
2236,An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease,Completed,Has Results,Pompe Disease|Glycogen Storage Disease Type II,Biological: Alglucosidase Alfa|Drug: Methotrexate|Drug: Rituximab,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00701129
2237,Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients,Completed,Has Results,Friedreich's Ataxia,Drug: Idebenone,Santhera Pharmaceuticals,Santhera Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00697073
2238,Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix,Completed,Has Results,Influenza,Biological: Trivalent influenza vaccine GSK 138842A|Biological: Fluarix,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,6/2/2008,3/26/2009,https://ClinicalTrials.gov/show/NCT00693706
2239,Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics,Completed,Has Results,Hepatic Insufficiency,Drug: AG-013736,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,5/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00692341
2240,Titration Pressures in Sleep Apnea Patients Using ThermoSmart® Versus Conventional Humidification,Completed,Has Results,"Sleep Apnea, Obstructive",Device: Heated breathing tube (CPAP with ThermoSmart)|Device: Non heated breathing tube (CPAP with conventional humidification),Fisher and Paykel Healthcare|Sleep Disorder Centers Institute for Clinical Research,Fisher and Paykel Healthcare,Sleep Disorder Centers Institute for Clinical Research,,,,,,Not Applicable,Industry|Other,Interventional,4/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00681083
2241,Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Methyl aminolevulinate (MAL) PDT,Photocure,Photocure,,,,,,,Phase 2,Industry,Interventional,5/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00673933
2242,A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro,Completed,Has Results,Diabetes Mellitus: Type 1,Drug: Technosphere® Insulin Inhalation Powder|Drug: Technosphere Insulin® Inhalation Powder|Drug: RAA Population,Mannkind Corporation,Mannkind Corporation,,,,,,,Phase 2,Industry,Interventional,4/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00662857
2243,"Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%",Completed,Has Results,Acne Vulgaris,Drug: Adapalene,Galderma,Galderma,,,,,,,Phase 4,Industry,Interventional,5/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00660985
2244,A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma,Completed,Has Results,Follicular Lymphoma,Drug: VELCADE|Drug: Bendamustine|Drug: Rituximab,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,2/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00636792
2245,Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer,Completed,Has Results,Pancreatic Adenocarcinoma,Drug: Pimasertib|Drug: Gemcitabine|Drug: Placebo,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 1|Phase 2,Industry,Interventional,11/30/2009,4/30/2015,https://ClinicalTrials.gov/show/NCT01016483
2246,'Effect of CRT on Defibrillation Threshold Estimates' Study,Completed,Has Results,Sudden Cardiac Death,Device: Cardiac Resynchronization Therapy - Defibrillator (CRT-D),Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 4,Industry,Interventional,1/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00626093
2247,Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults,Completed,Has Results,Influenza,Biological: Fluzone: Influenza virus vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,1/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00623181
2248,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,Completed,Has Results,Acute Myeloid Leukemia,Drug: LY2181308 sodium|Drug: cytarabine|Drug: idarubicin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,3/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00620321
2249,StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects,Completed,Has Results,Third Degree Burn|Burns|Wound Infection|Degloving Injury,Biological: StrataGraft Skin Tissue|Procedure: Cadaver allograft,"Stratatech, a Mallinckrodt Company|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","Stratatech, a Mallinckrodt Company",National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),,,,,,Phase 1|Phase 2,Industry|NIH,Interventional,7/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00618839
2250,Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td,Completed,Has Results,Diphtheria|Tetanus,Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,5/4/2019,7/5/2019,https://ClinicalTrials.gov/show/NCT00601835
2251,Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee,Completed,Has Results,"Osteoarthritis, Knee",Biological: TissueGene-C|Biological: Placebo,"Kolon TissueGene, Inc.","Kolon TissueGene, Inc.",,,,,,,Phase 1,Industry,Interventional,1/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00599248
2252,Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD),Completed,Has Results,Generalized Anxiety Disorder,Drug: SYN111|Drug: Placebo,Biotie Therapies Inc.|Syneos Health,Biotie Therapies Inc.,Syneos Health,,,,,,Phase 2,Industry|Other,Interventional,3/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00595231
2253,GORE Embolic Protection With Reverse Flow,Completed,Has Results,Carotid Artery Stenosis,Device: GORE Flow Reversal System (GFRS),W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Phase 3,Industry,Interventional,7/6/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00594100
2254,Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event,Completed,Has Results,Acute Coronary Syndrome,Drug: VIA-2291|Drug: Placebo,"Tallikut Pharmaceuticals, Inc.|Massachusetts General Hospital|Icahn School of Medicine at Mount Sinai|University of Massachusetts, Worcester|Winthrop University Hospital|Montreal Heart Institute","Tallikut Pharmaceuticals, Inc.",Massachusetts General Hospital,"Icahn School of Medicine at Mount Sinai|University of Massachusetts, Worcester|Winthrop University Hospital|Montreal Heart Institute",Icahn School of Medicine at Mount Sinai,"University of Massachusetts, Worcester|Winthrop University Hospital|Montreal Heart Institute","University of Massachusetts, Worcester",Winthrop University Hospital|Montreal Heart Institute,Phase 2,Industry|Other,Interventional,10/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00552188
2255,Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders,Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100|Drug: BUPHENYL®,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 2,Industry,Interventional,10/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00551200
2256,"Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia",Completed,Has Results,Friedreich's Ataxia,Drug: Idebenone|Drug: Placebo,Santhera Pharmaceuticals,Santhera Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00537680
2257,Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study,Completed,Has Results,Carotid Artery Disease,Device: PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,5/7/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00530504
2258,Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness,Completed,Has Results,Type 1 Diabetes,Device: MiniMed Paradigm REAL-Time System,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Phase 4,Industry,Interventional,2/6/2019,9/6/2019,https://ClinicalTrials.gov/show/NCT00530023
2259,(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol,Completed,Has Results,Hypercholesterolemia,Device: Secura then Futura|Device: Futura then Secura,B. Braun Medical Inc.,B. Braun Medical Inc.,,,,,,,Not Applicable,Industry,Interventional,8/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00526058
2260,Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis,Completed,Has Results,Myelofibrosis|Polycythemia Vera|Thrombocytosis,Drug: Ruxolitinib,Incyte Corporation,Incyte Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/7/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT00509899
2261,The Pivotal Study of the Aptus Endovascular AAA Repair System,Completed,Has Results,Abdominal Aortic Aneurysms (AAA),Device: Aptus Endovascular AAA Repair System,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,9/7/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00507559
2262,Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients,Completed,Has Results,Renal Failure,Drug: LCP Tacro (tacrolimus)|Drug: Prograf,Veloxis Pharmaceuticals|CTI Clinical Trial and Consulting Services,Veloxis Pharmaceuticals,CTI Clinical Trial and Consulting Services,,,,,,Phase 2,Industry|Other,Interventional,7/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00496483
2263,Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers,Completed,Has Results,Circadian Rhythm Sleep Disorders,Drug: VEC-162,Vanda Pharmaceuticals,Vanda Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/4/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00490945
2264,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status",Completed,Has Results,Glioblastoma,Drug: Cilengitide (2-times weekly)|Drug: cilengitide (5-times weekly)|Drug: Temozolomide|Radiation: Radiotherapy,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 2,Industry,Interventional,3/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00813943
2265,Evaluation of Pigmented Skin Lesions With MelaFind(R) System,Completed,Has Results,Melanoma,Device: MelaFind(R),"MELA Sciences, Inc.","MELA Sciences, Inc.",,,,,,,Phase 3,Industry,Interventional,1/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00434057
2266,A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma,Completed,Has Results,Fatigue|Multiple Myeloma,Drug: armodafinil|Drug: Placebo,Oncotherapeutics|Cephalon,Oncotherapeutics,Cephalon,,,,,,Phase 3,Industry,Interventional,6/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01160380
2267,A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer,Completed,Has Results,Cancer,"Drug: Ixabepilone, 5 mg/d|Drug: Ixabepilone, 10 mg/d|Drug: Ixabepilone, 15 mg/d|Drug: Ixabepilone, 20 mg/d|Drug: Ixabepilone, 25 mg/d|Drug: Ixabepilone, 30 mg/d|Drug: Ixabepilone, 25 mg, with famotidine|Drug: Ixabepilone, 25 mg, with food",R-Pharm,R-Pharm,,,,,,,Phase 1,Industry,Interventional,1/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00422097
2268,Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: GTS21/Placebo,CoMentis,CoMentis,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00419445
2269,FREEDOM - A Frequent Optimization Study Using the QuickOpt Method,Completed,Has Results,Cardiac Arrhythmias|Heart Failure,Device: Control|Device: QuickOpt,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,10/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00418314
2270,"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",Completed,Has Results,Respiratory Tract Diseases,Biological: DR-5001|Other: Placebo,Duramed Research|Teva Pharmaceutical Industries,Duramed Research,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,9/6/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00382408
2271,Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: NOV-002|Drug: Carboplatin,"Cellectar Biosciences, Inc.|Massachusetts General Hospital|Dana-Farber Cancer Institute","Cellectar Biosciences, Inc.",Massachusetts General Hospital,Dana-Farber Cancer Institute,,,,,Phase 2,Industry|Other,Interventional,7/6/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00345540
2272,A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY,Completed,Has Results,Meningococcal Disease|Meningococcal Meningitis,Biological: Novartis Meningococcal (MenACWY-CRM) vaccine,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 2,Industry,Interventional,1/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01018732
2273,Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II),Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo matched to atacicept|Drug: Atacicept: with loading dose|Drug: Atacicept|Biological: Adalimumab,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 2,Industry,Interventional,9/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00595413
2274,POWER (Pulse Width Optimized Waveform Evaluation Trial),Completed,Has Results,Sudden Cardiac Death,"Device: Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)",Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 4,Industry,Interventional,8/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00311181
2275,Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Post-traumatic Arthritis|Juvenile Rheumatoid Arthritis|Avascular Necrosis of Bone,Device: Total Knee Replacement|Device: Total knee replacement,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,3/1/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00289094
2276,"Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)",Completed,Has Results,Carcinoma,Drug: Sorafenib 100 mg (50-mg tablet)|Drug: Sorafenib 200 mg (50-mg tablet)|Drug: Sorafenib 400 mg (50-mg tablet)|Drug: Sorafenib 400 mg (200-mg tablet)|Drug: Sorafenib 400 mg (Expansion),Bayer|Amgen,Bayer,Amgen,,,,,,Phase 1,Industry,Interventional,7/2/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00941863
2277,Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock,Completed,Has Results,Sepsis|Septic Shock,Drug: drotrecogin alfa (activated),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,11/5/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00279214
2278,A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease,Completed,Has Results,"Chronic Kidney Disease, Stage 5|Secondary Hyperparathyroidism",Drug: Zemplar® injection|Drug: Hectorol® injection,Abbott,Abbott,,,,,,,Phase 4,Industry,Interventional,6/6/2019,,https://ClinicalTrials.gov/show/NCT00257920
2279,Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects,Completed,Has Results,Periodontal Diseases,Other: DFDBA|Device: Regenafil,RTI Surgical,RTI Surgical,,,,,,,Phase 2|Phase 3,Industry,Interventional,1/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00255970
2280,"Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers",Completed,Has Results,Clostridium Infections,Biological: Vaccine diluent buffer (Placebo)|Biological: C. difficile toxoid vaccine (2 µg)|Biological: C. difficile toxoid vaccine (10 µg)|Biological: C. difficile toxoid vaccine (50 µg),Sanofi,Sanofi,,,,,,,Phase 1,Industry,Interventional,11/5/2019,2/6/2019,https://ClinicalTrials.gov/show/NCT00214461
2281,28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study,Completed,Has Results,Joint Diseases,Device: 28 mm ceramic head on ceramic acetabular liner.|Device: 28 mm ceramic head on polyethylene liner,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,4/3/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00208507
2282,Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose,Completed,Has Results,Nasolabial Folds,Device: Perlane and Perlane-L,"Medicis Global Service Corporation|Q-Med Scandinavia, Inc.",Medicis Global Service Corporation,"Q-Med Scandinavia, Inc.",,,,,,Not Applicable,Industry,Interventional,1/9/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00823069
2283,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528",Completed,Has Results,Healthy,Biological: MEDI-528 0.3 mg/kg|Biological: MEDI-528 1 mg/kg|Biological: MEDI-528 3 mg/kg|Biological: MEDI-528 9 mg/kg,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,6/5/2019,7/6/2019,https://ClinicalTrials.gov/show/NCT00116168
2284,Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds,Completed,Has Results,Nasolabial Folds,Device: Restylane and Restylane-L,"Medicis Global Service Corporation|Q-Med Scandinavia, Inc.",Medicis Global Service Corporation,"Q-Med Scandinavia, Inc.",,,,,,Not Applicable,Industry,Interventional,11/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00797459
2285,A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I),Completed,Has Results,Rheumatoid Arthritis,Drug: Atacicept|Drug: Placebo matched to atacicept,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 2,Industry,Interventional,12/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00430495
2286,Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,Completed,Has Results,Advanced Solid Tumors,Drug: MM-121,Merrimack Pharmaceuticals|Sanofi,Merrimack Pharmaceuticals,Sanofi,,,,,,Phase 1,Industry,Interventional,7/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00734305
2287,Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung,Completed,Has Results,Osteosarcoma Metastatic,Drug: Cisplatin liposomal,Insmed Incorporated,Insmed Incorporated,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/12/2005,3/17/2008,https://ClinicalTrials.gov/show/NCT00102531
2288,A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms,Completed,Has Results,Parkinsonian Syndromes,Procedure: DaTSCAN SPECT imaging,GE Healthcare|i3 Statprobe,GE Healthcare,i3 Statprobe,,,,,,Phase 4,Industry,Interventional,10/6/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00382967
2289,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Drug: Placebo,"St. Renatus, LLC|Triligent International|Rho, Inc.","St. Renatus, LLC",Triligent International,"Rho, Inc.",,,,,Phase 3,Industry,Interventional,2/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01745380
2290,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Drug: Tetracaine HCl 3%|Drug: Placebo,"St. Renatus, LLC|Triligent International|Rho, Inc.","St. Renatus, LLC",Triligent International,"Rho, Inc.",,,,,Phase 3,Industry,Interventional,10/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01710787
2291,Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: MDV3100,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Pfizer,Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,Phase 1,Industry,Interventional,1/24/2012,2/26/2018,https://ClinicalTrials.gov/show/NCT01565928
2292,Study of E7389 in Patients With Advanced Solid Tumors,Completed,Has Results,Advanced Solid Tumors,Drug: E7389,Eisai Inc.,Eisai Inc.,,,,,,,Phase 1,Industry,Interventional,9/3/2019,7/5/2019,https://ClinicalTrials.gov/show/NCT00069264
2293,A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: Dolutegravir,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,1/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01499199
2294,BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC),Completed,Has Results,"Cancer|Carcinoma, Non-Small Cell Lung","Drug: Sorafenib (Nexavar, BAY43-9006)",Bayer|Amgen,Bayer,Amgen,,,,,,Phase 2,Industry,Interventional,4/4/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00101413
2295,"A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer",Completed,Has Results,"Prostatic Neoplasms|Metastases, Neoplasm",Drug: ZD4054 10 mg|Drug: ZD4054 15 mg|Drug: ZD4054 22.5 mg,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,6/3/2019,10/5/2019,https://ClinicalTrials.gov/show/NCT00055471
2296,Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL),Completed,Has Results,"Non-Hodgkin's Lymphoma|Lymphoma, B-cell|Lymphoma, Low-grade",Drug: ONTAK,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,5/1/2000,9/6/2019,https://ClinicalTrials.gov/show/NCT00051025
2297,Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents,Completed,Has Results,Prevention of Meningococcal Disease,"Biological: MenACWY-CRM conjugate vaccine, adjuvanted|Biological: MenACWY-CRM conjugate vaccine, unadjuvanted|Biological: MenACWY polysaccharide vaccine",Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 2,Industry,Interventional,10/4/2019,3/6/2019,https://ClinicalTrials.gov/show/NCT00262041
2298,Accommodative Relief for Uncomfortable Non-Presbyopes,Completed,Has Results,Asthenopia,Device: Multifocal Contact Lens|Device: Single Vision Contact Lens,Ohio State University|Bausch & Lomb Incorporated,Ohio State University,Bausch & Lomb Incorporated,,,,,,Not Applicable,Other|Industry,Interventional,2/2/2017,5/6/2018,https://ClinicalTrials.gov/show/NCT03544216
2299,"Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults",Completed,Has Results,Healthy Adult Immune Responses to Vaccine,Biological: VRC-EBOMAB092-00-AB (MAb114),"National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Institute of Allergy and Infectious Diseases (NIAID),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1,NIH|Industry,Interventional,5/16/2018,3/20/2019,https://ClinicalTrials.gov/show/NCT03478891
2300,Brexpiprazole for Bipolar Depression,Completed,Has Results,Bipolar Depression,Drug: Brexpiprazole,University of Texas Southwestern Medical Center|Otsuka America Pharmaceutical,University of Texas Southwestern Medical Center,Otsuka America Pharmaceutical,,,,,,Phase 4,Other|Industry,Interventional,3/1/2017,3/15/2018,https://ClinicalTrials.gov/show/NCT03427892
2301,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Completed,Has Results,Caries,"Drug: 0 ppm F (placebo, negative control)|Drug: 250 ppm F as NaF (dose-response control)|Drug: 500 ppm F as NaF (dose-response control)|Drug: 1100 ppm F as NaF (positive control)",Domenick Zero|GlaxoSmithKline|Indiana University,Domenick Zero,GlaxoSmithKline,Indiana University,,,,,Phase 3,Other|Industry,Interventional,12/19/2017,5/2/2018,https://ClinicalTrials.gov/show/NCT03383783
2302,Functional Effects of Botox on the Brain Using MRS and fMRI,Completed,Has Results,Healthy,Drug: onabotulinumtoxinA,"University of California, Irvine|Allergan","University of California, Irvine",Allergan,,,,,,Phase 4,Other|Industry,Interventional,9/30/2017,11/1/2017,https://ClinicalTrials.gov/show/NCT03373162
2303,Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder,Completed,Has Results,Body Dysmorphic Disorders,Behavioral: App-Based Cognitive Behavioral Therapy,Massachusetts General Hospital|Telefónica S.A.,Massachusetts General Hospital,Telefónica S.A.,,,,,,Not Applicable,Other|Industry,Interventional,7/24/2017,1/18/2019,https://ClinicalTrials.gov/show/NCT03221738
2304,3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization,Completed,Has Results,Enlarged Prostate,Device: cone-beam CT 3D Emboguide,"University of Miami|Siemens Corporation, Corporate Technology",University of Miami,"Siemens Corporation, Corporate Technology",,,,,,Not Applicable,Other|Industry,Interventional,4/17/2017,10/19/2018,https://ClinicalTrials.gov/show/NCT03164629
2305,Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract,Completed,Has Results,Metastatic Transitional Cell Cancer of the Urothelial Tract,Drug: Docetaxel|Drug: Oxaliplatin,Leonard Appleman|Sanofi-Synthelabo|University of Pittsburgh,Leonard Appleman,Sanofi-Synthelabo,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,12/17/2004,12/2/2009,https://ClinicalTrials.gov/show/NCT03159143
2306,Pilot Evaluation Comparing Regional Distribution of Ventilation During Lung Expansion Therapy,Completed,Has Results,Ventilation|Breathing|Atelectasis,Device: Volumetric Incentive Spirometry|Device: EzPAP® POSITIVE AIRWAY PRESSURE,"University of Virginia|Draeger Medical, Inc",University of Virginia,"Draeger Medical, Inc",,,,,,Not Applicable,Other|Industry,Interventional,3/6/2017,4/21/2017,https://ClinicalTrials.gov/show/NCT03083379
2307,"VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults",Completed,Has Results,HIV Prevention,Biological: VRC-HIVMAB075-00-AB,"National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Institute of Allergy and Infectious Diseases (NIAID),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1,NIH|Industry,Interventional,2/21/2017,7/10/2018,https://ClinicalTrials.gov/show/NCT03015181
2308,Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy,Completed,Has Results,Plaque Psoriasis,Drug: Apremilast,"Derm Research, PLLC|Celgene","Derm Research, PLLC",Celgene,,,,,,Phase 4,Other|Industry,Interventional,12/29/2016,4/25/2018,https://ClinicalTrials.gov/show/NCT03000309
2309,C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection,Completed,Has Results,Antibody Mediated Rejection of Kidney Transplant,Drug: C1-INH (Berinert),NYU Langone Health|CSL Behring,NYU Langone Health,CSL Behring,,,,,,Phase 2,Other|Industry,Interventional,10/16/2019,10/30/2018,https://ClinicalTrials.gov/show/NCT02936479
2310,Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE),Completed,Has Results,"Kidney Failure, Chronic",Drug: Patiromer 25.2 g,"Baylor College of Medicine|Relypsa, Inc.",Baylor College of Medicine,"Relypsa, Inc.",,,,,,Phase 4,Other|Industry,Interventional,8/16/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02933450
2311,"Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Cystoscopy",Completed,Has Results,Bacteriuria,Device: EndoSheath CST-5000 Scope|Device: Olympus Visera Elite OTV-S190 Scope,Wake Forest University Health Sciences|Cogenix Medical Corporation,Wake Forest University Health Sciences,Cogenix Medical Corporation,,,,,,Not Applicable,Other|Industry,Interventional,3/16/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02922868
2312,Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults,Completed,Has Results,Epilepsy,Drug: Eslicarbazepine|Drug: Carbamazepine,Stanford University|Sunovion,Stanford University,Sunovion,,,,,,Phase 4,Other|Industry,Interventional,7/16/2019,4/20/2018,https://ClinicalTrials.gov/show/NCT02912364
2313,Lifestyle Modification and Liraglutide,Completed,Has Results,Obesity,Behavioral: CMS-recommended lifestyle counseling|Drug: Liraglutide 3.0mg|Other: Portion-Controlled Diet|Drug: Placebo Oral Tablet|Drug: Phentermine 15 MG|Behavioral: Extension Study CMS-recommended lifestyle counseling,University of Pennsylvania|Novo Nordisk A/S,University of Pennsylvania,Novo Nordisk A/S,,,,,,Phase 4,Other|Industry,Interventional,9/16/2019,12/18/2019,https://ClinicalTrials.gov/show/NCT02911818
2314,Brain Morphometry in OA Patients Treated With Duloxetine,Completed,Has Results,Pain|Osteoarthritis,Drug: Duloxetine|Drug: Placebo Oral Tablet,Northwestern University|Eli Lilly and Company,Northwestern University,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,7/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT02903238
2315,Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications,Completed,Has Results,Adherence,Device: Portal-724 MEMs Cap,Saint Michael's Medical Center|Merck Sharp & Dohme Corp.,Saint Michael's Medical Center,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,9/9/2016,1/25/2018,https://ClinicalTrials.gov/show/NCT02858050
2316,Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study,Completed,Has Results,Contraception,Drug: Etonogestrel contraceptive implant,"University of California, Davis|Merck Sharp & Dohme Corp.","University of California, Davis",Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,9/15/2016,7/26/2017,https://ClinicalTrials.gov/show/NCT02852265
2317,Use of the Passy Muir Swallowing Self Trainer,Completed,Has Results,Stroke|Brain Injury|Head and Neck Cancer,Device: Dysphagia retraining with device,James Madison University|Passy Muir Inc.,James Madison University,Passy Muir Inc.,,,,,,,Other|Industry,Observational,8/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02848664
2318,A Volumetric Analysis of Soft and Hard Tissue Healing for Ridge Preservation and Socket Seal After Tooth Extraction,Completed,Has Results,Tooth Extraction,Device: Xenograft bone substitute|Device: Collagen dressing|Device: 3D-collagen matrix,"University of North Carolina, Chapel Hill|Geistlich Pharma AG","University of North Carolina, Chapel Hill",Geistlich Pharma AG,,,,,,Not Applicable,Other|Industry,Interventional,7/16/2019,2/28/2018,https://ClinicalTrials.gov/show/NCT02844569
2319,Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers,Completed,Has Results,"Kidney Failure, Chronic|Eye Diseases|Diabetic Retinopathy",Device: RetinaVue 100 camera,"University of North Carolina, Chapel Hill|Welch Allyn","University of North Carolina, Chapel Hill",Welch Allyn,,,,,,Not Applicable,Other|Industry,Interventional,7/16/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02823600
2320,Validation of Sleep Apnea Screening Device,Completed,Has Results,Obstructive Sleep Apnea,Device: Zansors® sleep screening device,University of Michigan|Zansors,University of Michigan,Zansors,,,,,,Not Applicable,Other|Industry,Interventional,9/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02814227
2321,Alpha-1 Carrier Genomics Study,Completed,Has Results,Alpha-1 Antitrypsin Deficiency|Emphysema|COPD|Smoking,Genetic: Genetic Sequencing,Medical University of South Carolina|CSL Behring,Medical University of South Carolina,CSL Behring,,,,,,,Other|Industry,Observational,2/15/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02810327
2322,Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients,Completed,Has Results,End-Stage Renal Disease|Hepatitis C,Drug: Zepatier|Drug: Ribavirin|Drug: Sofosbuvir,Johns Hopkins University|Merck Sharp & Dohme Corp.,Johns Hopkins University,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,7/20/2016,1/1/2018,https://ClinicalTrials.gov/show/NCT02781649
2323,"Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED",Completed,Has Results,"Catheters|Catheterization, Peripheral",Device: Terumo SurFlash Plus catheter|Device: BD Insyte Autoguard catheter,University of Maryland|Terumo Medical Corporation,University of Maryland,Terumo Medical Corporation,,,,,,Not Applicable,Other|Industry,Interventional,6/16/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02769442
2324,Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients,Completed,Has Results,Uveitis|Anterior Uveitis|Intermediate Uveitis|Posterior Uveitis|Scleritis|Clinically Significant Macular Edema,Drug: H.P. ACTHAR SUBCUTANEOUS GEL INJECTION,"Tampa Bay Uveitis Center, LLC|Mallinckrodt","Tampa Bay Uveitis Center, LLC",Mallinckrodt,,,,,,Phase 4,Other|Industry,Interventional,6/30/2016,12/20/2016,https://ClinicalTrials.gov/show/NCT02764697
2325,Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Diabetes Assistant (DiAs) with Closed-Loop,"University of Virginia|DexCom, Inc.",University of Virginia,"DexCom, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,5/16/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02750267
2326,Comparison of Oral Hygiene & Root Resorption During Orthodontic Treatment,Completed,Has Results,Orthodontic Pathological Resorption of External Root|Complication of Personal Oral Hygiene,Device: Appliance,"UConn Health|Align Technology, Inc.",UConn Health,"Align Technology, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,12/11/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02745626
2327,Surgical Conditions During Laparoscopic Bariatric Surgery,Completed,Has Results,Morbid Obesity,Drug: Rocuronium|Device: Insufflation pressure,University of Missouri-Columbia|Merck Sharp & Dohme Corp.,University of Missouri-Columbia,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,5/16/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02703909
2328,The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant,Completed,Has Results,"Chronic Sinusitis, Ethmoidal",Combination Product: Steroid-eluting sinus implant|Other: Post-op standard of care,Collin County Ear Nose & Throat|Intersect ENT,Collin County Ear Nose & Throat,Intersect ENT,,,,,,Phase 4,Other|Industry,Interventional,11/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02668302
2329,PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of FFR Measurements,Completed,Has Results,Ischemia|Angina,Device: St. Jude Medical Pressure Wire|Device: ACIST Navvus Microcatheter,Columbia University|Abbott Medical Devices,Columbia University,Abbott Medical Devices,,,,,,Not Applicable,Other|Industry,Interventional,12/15/2019,12/8/2016,https://ClinicalTrials.gov/show/NCT02648230
2330,Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores,Completed,Has Results,Oral Herpes Simplex,Drug: Matching Placebo|Drug: BTL-TML-HSV,"Beech Tree Labs, Inc.|Norwich Clinical Research Associates Ltd.|Hill Top Research","Beech Tree Labs, Inc.",Norwich Clinical Research Associates Ltd.,Hill Top Research,,,,,Phase 2,Industry|Other,Interventional,7/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01902303
2331,Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: Siltuximab,"Carla Greenbaum, MD|Janssen Research & Development, LLC|Benaroya Research Institute","Carla Greenbaum, MD","Janssen Research & Development, LLC",Benaroya Research Institute,,,,,Early Phase 1,Other|Industry,Interventional,3/8/2016,3/16/2017,https://ClinicalTrials.gov/show/NCT02641522
2332,Evaluating and Improving Functional Driving Vision of Patients With Astigmatism,Completed,Has Results,Astigmatism,Device: 1-DAY ACUVUE® MOIST contact lenses|Device: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|Other: No contact lenses,"University of Virginia|Johnson & Johnson Vision Care, Inc.",University of Virginia,"Johnson & Johnson Vision Care, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,9/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT02624791
2333,Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis,Completed,Has Results,Diabetes|Wound Infection|Healthy Volunteers,Drug: Tedizolid|Procedure: Microdialysis Catheter Insertion,Hartford Hospital|Merck Sharp & Dohme Corp.,Hartford Hospital,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,2/23/2016,3/1/2017,https://ClinicalTrials.gov/show/NCT02620787
2334,Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections,Completed,Has Results,Diabetes|Wound Infection|Healthy Volunteers,Drug: Ceftolozane/tazobactam|Procedure: Microdialysis Catheter Insertion,Hartford Hospital|Merck Sharp & Dohme Corp.,Hartford Hospital,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,2/19/2016,4/17/2019,https://ClinicalTrials.gov/show/NCT02620774
2335,Nutramax Joint Health Formulation Biochemical Response Study,Completed,Has Results,"Osteoarthritis, Knee",Dietary Supplement: Nutraceutical joint health formulation,"University of Missouri-Columbia|Nutramax Laboratories, Inc.",University of Missouri-Columbia,"Nutramax Laboratories, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02614274
2336,Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy,Completed,Has Results,Idiopathic Small Fiber Neuropathy,Drug: Pregabalin|Drug: Placebo,Johns Hopkins University|Pfizer,Johns Hopkins University,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,9/15/2019,7/18/2019,https://ClinicalTrials.gov/show/NCT02607254
2337,Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction,Completed,Has Results,Heart Transplant|Acute Graft Rejection|Chronic Graft Rejection,Drug: Regadenoson|Drug: Gadolinium|Procedure: Cardiac MRI,Paul Kim|Astellas Pharma Inc|Stanford University,Paul Kim,Astellas Pharma Inc,Stanford University,,,,,Phase 4,Other|Industry,Interventional,11/15/2019,6/30/2016,https://ClinicalTrials.gov/show/NCT02597543
2338,Secukinumab for Treatment of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Secukinumab|Drug: Placebo,Icahn School of Medicine at Mount Sinai|Novartis,Icahn School of Medicine at Mount Sinai,Novartis,,,,,,Phase 2,Other|Industry,Interventional,11/15/2019,1/30/2018,https://ClinicalTrials.gov/show/NCT02594098
2339,Milk Patch for Eosinophilic Esophagitis,Completed,Has Results,Eosinophilic Esophagitis|Milk Allergy,Drug: Viaskin Milk 500 mcg|Drug: Viaskin Placebo,Children's Hospital of Philadelphia|DBV Technologies,Children's Hospital of Philadelphia,DBV Technologies,,,,,,Phase 2,Other|Industry,Interventional,10/15/2019,11/20/2018,https://ClinicalTrials.gov/show/NCT02579876
2340,Sub-Q Versus IV Furosemide in Acute Heart Failure,Completed,Has Results,Congestive Heart Failure,"Drug: Furosemide Injection Solution (SCP-101)|Drug: Furosemide Injection Solution, USP","Johns Hopkins University|scPharmaceuticals, Inc.",Johns Hopkins University,"scPharmaceuticals, Inc.",,,,,,Phase 2|Phase 3,Other|Industry,Interventional,2/16/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT02579057
2341,Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints,Completed,Has Results,Minor Procedural Pain,Drug: Lazanda,Defense and Veterans Center for Integrative Pain Management|Depomed,Defense and Veterans Center for Integrative Pain Management,Depomed,,,,,,Phase 4,Other|Industry,Interventional,5/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02571634
2342,L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD,Completed,Has Results,Attention Deficit/Hyperactivity Disorder|ADHD,Drug: L-Threonic Acid Magnesium Salt (L-TAMS),"Massachusetts General Hospital|Neurocentria, Inc.",Massachusetts General Hospital,"Neurocentria, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/16/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02558790
2343,Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE),Completed,Has Results,Mild Cognitive Impairment|Dementia,Behavioral: neuropsychological testing,"Douglas Scharre|Brain Test, Inc.|Ohio State University",Douglas Scharre,"Brain Test, Inc.",Ohio State University,,,,,,Other|Industry,Observational,1/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02544074
2344,A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED),Completed,Has Results,Type 1 Diabetes,Drug: ORMD-0801 capsules- 2x8mg|Drug: ORMD-0801 capsules- 3x8mg|Drug: ORMD-0801 capsules- 1x16mg,"The University of Texas Health Science Center at San Antonio|Oramed, Ltd.",The University of Texas Health Science Center at San Antonio,"Oramed, Ltd.",,,,,,Phase 2,Other|Industry,Interventional,1/15/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02535715
2345,Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers,Completed,Has Results,Pressure Ulcer,Other: Optimal Turning|Other: Standard Care Practices|Other: Patient Sensor,"Stanford University|Leaf Healthcare, Inc.",Stanford University,"Leaf Healthcare, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,8/15/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02533726
2346,Ticagrelor Therapy for RefrACTORy Migraine Study,Completed,Has Results,Migraine|Headache|Migraine Headache,Drug: Ticagrelor 90 mg twice per day,Columbia University|AstraZeneca,Columbia University,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,10/15/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02518464
2347,Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide,Completed,Has Results,Breast Cancer|Breast Cancer Female,Drug: Standard of Care: Docetaxel|Drug: Standard of Care: Cyclophosphamide|Other: Function Assessment of Cancer Therapy (FACT) Surveys,"H. Lee Moffitt Cancer Center and Research Institute|Saladax Biomedical, Inc.",H. Lee Moffitt Cancer Center and Research Institute,"Saladax Biomedical, Inc.",,,,,,Phase 4,Other|Industry,Interventional,2/9/2016,1/31/2019,https://ClinicalTrials.gov/show/NCT02502864
2348,Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis,Completed,Has Results,"Cystitis, Interstitial",Biological: Certolizumab pegol|Drug: Placebo,"ICStudy, LLC|UCB Pharma","ICStudy, LLC",UCB Pharma,,,,,,Phase 3,Other|Industry,Interventional,12/15/2015,7/12/2017,https://ClinicalTrials.gov/show/NCT02497976
2349,Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL),Completed,Has Results,Breast Cancer|Upper Extremity Lymphedema,Drug: QBX258,Memorial Sloan Kettering Cancer Center|Novartis,Memorial Sloan Kettering Cancer Center,Novartis,,,,,,Not Applicable,Other|Industry,Interventional,7/15/2019,5/18/2019,https://ClinicalTrials.gov/show/NCT02494206
2350,The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction,Completed,Has Results,Crohn's Disease,Device: Ultrasound,"Icahn School of Medicine at Mount Sinai|Janssen Scientific Affairs, LLC",Icahn School of Medicine at Mount Sinai,"Janssen Scientific Affairs, LLC",,,,,,Not Applicable,Other|Industry,Interventional,4/16/2019,8/17/2017,https://ClinicalTrials.gov/show/NCT02488005
2351,Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access,Completed,Has Results,AV Fistula,Drug: Vorapaxar sulfate|Drug: Placebo,Ken Mahaffey|Merck Sharp & Dohme Corp.|Stanford University,Ken Mahaffey,Merck Sharp & Dohme Corp.,Stanford University,,,,,Phase 2,Other|Industry,Interventional,8/26/2015,10/23/2017,https://ClinicalTrials.gov/show/NCT02475837
2352,Single-shot TAP Block vs Continuous TAP Block,Completed,Has Results,Postoperative Pain,Device: TAP-C|Drug: TAP-S,Indiana University|Halyard Health,Indiana University,Halyard Health,,,,,,Phase 4,Other|Industry,Interventional,7/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02475031
2353,"Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults",Completed,Has Results,Human Immunodeficiency Virus (HIV),Biological: Quadrivalent Live Attenuated Influenza Vaccine,"University of Colorado, Denver|MedImmune LLC","University of Colorado, Denver",MedImmune LLC,,,,,,Phase 2,Other|Industry,Interventional,7/13/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02474901
2354,Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus,Completed,Has Results,Atrial Fibrillation|Atrial Flutter,Device: Amigo™ Robotic Catheter Manipulation|Device: Manual Catheter Manipulation,"University of California, San Diego|Catheter Robotics, Inc.","University of California, San Diego","Catheter Robotics, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,3/15/2019,3/30/2018,https://ClinicalTrials.gov/show/NCT02467179
2355,The Clinical Efficacy of Next Science Wound Gel (NXTSC) in the Healing of Chronic Wounds,Completed,Has Results,Wound Infection,Device: NXTSC wound gel|Device: NXTSC wound gel plus Standard of Care|Device: Standard of Care Group,Southwest Regional Wound Care Center|Next Science TM,Southwest Regional Wound Care Center,Next Science TM,,,,,,Not Applicable,Other|Industry,Interventional,7/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02465073
2356,Study of Clinical Efficacy and Safety of Tosedostat in MDS,Completed,Has Results,Myelodysplastic Syndrome,Drug: Tosedostat,Weill Medical College of Cornell University|CTI BioPharma,Weill Medical College of Cornell University,CTI BioPharma,,,,,,Phase 2,Other|Industry,Interventional,3/20/2015,10/25/2017,https://ClinicalTrials.gov/show/NCT02452346
2357,Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness,Completed,Has Results,Tooth Loss|Peri-implant Mucosa Defect,Drug: Acellular Dermal Matrix|Procedure: Autologous subepithelial connective tissue graft,"University of Iowa|BioHorizons, Inc.",University of Iowa,"BioHorizons, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02450383
2358,Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Tedizolid PO|Drug: Tedizolid IV,University of Southern California|Merck Sharp & Dohme Corp.,University of Southern California,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,7/15/2019,12/31/2017,https://ClinicalTrials.gov/show/NCT02444234
2359,A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients,Completed,Has Results,Kidney Transplantation,Drug: tacrolimus extended release,"University of Illinois at Chicago|Astellas Pharma US, Inc.",University of Illinois at Chicago,"Astellas Pharma US, Inc.",,,,,,Phase 4,Other|Industry,Interventional,5/15/2019,6/9/2017,https://ClinicalTrials.gov/show/NCT02444143
2360,Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding,Completed,Has Results,Melena|Gastrointestinal Hemorrhage,Device: Early Video Capsule Endoscopy,"University of Massachusetts, Worcester|Olympus Corporation","University of Massachusetts, Worcester",Olympus Corporation,,,,,,Not Applicable,Other|Industry,Interventional,4/19/2015,7/2/2017,https://ClinicalTrials.gov/show/NCT02442830
2361,Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index,Completed,Has Results,Osteoporosis|Bone Fracture,Drug: denosumab,HealthEast Care System|Amgen,HealthEast Care System,Amgen,,,,,,,Other|Industry,Observational,4/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02435147
2362,An Open-label Phase II Study of Lorvotuzumab Mertansine,Completed,Has Results,Leukemia,Drug: Lorvotuzumab Mertansine (IMGN901),"M.D. Anderson Cancer Center|ImmunoGen, Inc.",M.D. Anderson Cancer Center,"ImmunoGen, Inc.",,,,,,Phase 2,Other|Industry,Interventional,5/12/2015,6/6/2017,https://ClinicalTrials.gov/show/NCT02420873
2363,Effectiveness of Two Self Assessment Tools: KIOS-Bipolar or eMoods,Completed,Has Results,Bipolar Disorder,,The University of Texas Health Science Center at San Antonio|Biomedical Development Corporation,The University of Texas Health Science Center at San Antonio,Biomedical Development Corporation,,,,,,,Other|Industry,Observational,10/15/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02418910
2364,Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B,Completed,Has Results,Healthy,Drug: Celecoxib|Drug: Placebo,University of Pennsylvania|Eli Lilly and Company,University of Pennsylvania,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,3/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02413203
2365,Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: apremilast,Psoriasis Treatment Center of Central New Jersey|Celgene,Psoriasis Treatment Center of Central New Jersey,Celgene,,,,,,Phase 4,Other|Industry,Interventional,5/28/2015,7/16/2019,https://ClinicalTrials.gov/show/NCT02412644
2366,Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis,Completed,Has Results,Actinic Cheilitis,Drug: aminolevulinic acid hydrochloride|Procedure: Photodynamic therapy with blue light,"Dartmouth-Hitchcock Medical Center|DUSA Pharmaceuticals, Inc.",Dartmouth-Hitchcock Medical Center,"DUSA Pharmaceuticals, Inc.",,,,,,Phase 4,Other|Industry,Interventional,4/15/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT02409732
2367,Flunisolide HFA in Children With Small Airway Disease,Completed,Has Results,Childhood Asthma,Drug: Flunisolide HFA,University of Louisville|Meda Pharmaceuticals,University of Louisville,Meda Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,3/15/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02404103
2368,Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC),Completed,Has Results,Breast Cancer,Drug: Selinexor,H. Lee Moffitt Cancer Center and Research Institute|Karyopharm Therapeutics Inc,H. Lee Moffitt Cancer Center and Research Institute,Karyopharm Therapeutics Inc,,,,,,Phase 2,Other|Industry,Interventional,7/8/2015,6/6/2019,https://ClinicalTrials.gov/show/NCT02402764
2369,Hemosonics- VCU Cardiac Surgery Clinical Study,Completed,Has Results,Cardiopulmonary Bypass,Device: Coagulation function,Virginia Commonwealth University|HemoSonics LLC,Virginia Commonwealth University,HemoSonics LLC,,,,,,,Other|Industry,Observational,4/15/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02392247
2370,Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5,Completed,Has Results,End-Stage Renal Disease|Stage 5 Chronic Kidney Disease,Drug: Telavancin|Procedure: Pharmacokinetic Blood Sampling,University of Michigan|Theravance Biopharma,University of Michigan,Theravance Biopharma,,,,,,Phase 4,Other|Industry,Interventional,7/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02392208
2371,Lifestyle Modification and Lorcaserin for Weight Loss Maintenance,Completed,Has Results,Obesity,Drug: Lorcaserin|Drug: Placebo,University of Pennsylvania|Eisai Inc.,University of Pennsylvania,Eisai Inc.,,,,,,Not Applicable,Other|Industry,Interventional,1/15/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02388568
2372,Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?,Completed,Has Results,Physical Activity,Drug: Dapagliflozin|Drug: Placebo,Christopher Bell|AstraZeneca|Colorado State University,Christopher Bell,AstraZeneca,Colorado State University,,,,,Phase 2,Other|Industry,Interventional,6/15/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02371187
2373,"Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease",Completed,Has Results,Coronary Artery Disease,,Icahn School of Medicine at Mount Sinai|Boston Scientific Corporation,Icahn School of Medicine at Mount Sinai,Boston Scientific Corporation,,,,,,,Other|Industry,Observational,12/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02364778
2374,Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME,Completed,Has Results,Diabetic Macular Edema,Drug: Ranibizumab 0.3 mg|Drug: Aflibercept 2.0 mg,"Arshad Khanani|Genentech, Inc.|Sierra Eye Associates",Arshad Khanani,"Genentech, Inc.",Sierra Eye Associates,,,,,Phase 2,Other|Industry,Interventional,1/15/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02363621
2375,Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users,Completed,Has Results,Epilepsy|Contraception,Drug: levonorgestrel IUS,Columbia University|Bayer,Columbia University,Bayer,,,,,,Phase 4,Other|Industry,Interventional,8/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT02362373
2376,Mechanisms of Weight Loss With SGLT2 Inhibition,Completed,Has Results,Type 2 Diabetes|Overweight|Obesity,Drug: Canagliflozin|Drug: Placebo,"Beth Israel Deaconess Medical Center|Janssen Scientific Affairs, LLC",Beth Israel Deaconess Medical Center,"Janssen Scientific Affairs, LLC",,,,,,Phase 4,Other|Industry,Interventional,2/15/2019,8/18/2019,https://ClinicalTrials.gov/show/NCT02360774
2377,Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies,Completed,Has Results,Healthy,Dietary Supplement: Probiotic mixture|Dietary Supplement: Placebo,"University of Florida|Wakunaga Pharmaceutical Co., Ltd.",University of Florida,"Wakunaga Pharmaceutical Co., Ltd.",,,,,,Not Applicable,Other|Industry,Interventional,1/15/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02349711
2378,Remifentanil and Glycemic Response in Cardiac Surgery,Completed,Has Results,Heart Diseases|Hyperglycemia,Drug: Remifentanil|Drug: Fentanyl,Kathirvel Subramaniam|Mylan Inc.|University of Pittsburgh,Kathirvel Subramaniam,Mylan Inc.,University of Pittsburgh,,,,,Phase 4,Other|Industry,Interventional,1/16/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02349152
2379,A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices,Completed,Has Results,Total Hip Arthroplasty,Device: ActiveCare+SFT Supine|Device: VenaFlow Elite Supine|Device: ActiveCare+SFT Standing|Device: VenaFlow Elite Standing,"Hospital for Special Surgery, New York|DJO Incorporated","Hospital for Special Surgery, New York",DJO Incorporated,,,,,,Not Applicable,Other|Industry,Interventional,2/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02345642
2380,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Completed,Has Results,Diabetes Prevention in Women After GDM Who Are at High-risk,Drug: DAPA/MET XR|Drug: DAPA|Drug: MET XR,Woman's|AstraZeneca,Woman's,AstraZeneca,,,,,,Phase 3,Other|Industry,Interventional,9/22/2015,3/13/2019,https://ClinicalTrials.gov/show/NCT02338193
2381,Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Placebo and Insulin monotherapy via CL|Drug: Sitagliptin and insulin/novolog via CL,Albert Einstein College of Medicine|Medtronic,Albert Einstein College of Medicine,Medtronic,,,,,,Phase 1,Other|Industry,Interventional,9/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02328040
2382,Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Canagliflozin|Drug: Liraglutide,"The University of Texas Health Science Center at San Antonio|Janssen Scientific Affairs, LLC",The University of Texas Health Science Center at San Antonio,"Janssen Scientific Affairs, LLC",,,,,,Not Applicable,Other|Industry,Interventional,11/14/2019,3/31/2019,https://ClinicalTrials.gov/show/NCT02324842
2383,Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax,Completed,Has Results,Sjogren's Disease,Drug: Administration of Lotemax,University of Rochester|Bausch & Lomb Incorporated,University of Rochester,Bausch & Lomb Incorporated,,,,,,Not Applicable,Other|Industry,Interventional,4/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02322528
2384,Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients,Completed,Has Results,Breast Cancer,Drug: Perflutren Protein-Type A Microspheres Injectable Suspension|Device: Contrast-Enhanced Ultrasound (CEUS)|Procedure: Biopsy + Radioactive Seed Placement|Behavioral: Phone Call,M.D. Anderson Cancer Center|GE Healthcare,M.D. Anderson Cancer Center,GE Healthcare,,,,,,Not Applicable,Other|Industry,Interventional,7/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02321527
2385,Temperature Monitoring With InnerSense Esophageal Temperature Sensor/Feeding Tube After Birth Through Stabilization in VLBW Infants,Completed,Has Results,Body Temperature,Device: Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|Device: Standard of care feeding tube,Duke University|Philips Healthcare,Duke University,Philips Healthcare,,,,,,Not Applicable,Other|Industry,Interventional,11/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02311972
2386,Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Device: Beta amyloid imaging,Tufts Medical Center|GE Healthcare,Tufts Medical Center,GE Healthcare,,,,,,Not Applicable,Other|Industry,Interventional,9/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT02309723
2387,Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach,Completed,Has Results,Unilateral Acoustic Neuroma|Meniere's Disease,Device: Cochlear Implant,"University of North Carolina, Chapel Hill|Med-El Corporation","University of North Carolina, Chapel Hill",Med-El Corporation,,,,,,Not Applicable,Other|Industry,Interventional,11/14/2019,11/8/2017,https://ClinicalTrials.gov/show/NCT02309099
2388,To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study,Completed,Has Results,"Diabetes Mellitus, Non-Insulin-Dependent|Hypertensive Disease",Drug: Liraglutide or Placebo,Tulane University Health Sciences Center|Novo Nordisk A/S|Tulane University,Tulane University Health Sciences Center,Novo Nordisk A/S,Tulane University,,,,,Phase 4,Other|Industry,Interventional,10/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02299388
2389,Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy,Completed,Has Results,Type 2 Diabetes,Drug: Cycloset,The University of Texas Health Science Center at San Antonio|VeroScience,The University of Texas Health Science Center at San Antonio,VeroScience,,,,,,Phase 4,Other|Industry,Interventional,6/14/2019,4/30/2018,https://ClinicalTrials.gov/show/NCT02299050
2390,Intravesicular Onabotulinumtoxin A in Interstitial Cystitis,Completed,Has Results,Interstitial Cystitis,Drug: Onabotulinumtoxin A|Procedure: injections upper aspect of trigone of urinary bladder|Procedure: injections on posterior bladder wall excluding the trigone,Wake Forest University Health Sciences|Allergan,Wake Forest University Health Sciences,Allergan,,,,,,Phase 4,Other|Industry,Interventional,12/14/2019,1/10/2018,https://ClinicalTrials.gov/show/NCT02297100
2391,Negative Pressure Wound Therapy in Cesarean Section,Completed,Has Results,Postoperative Wound Complications,Device: Negative pressure wound therapy,"University of Texas Southwestern Medical Center|KCI USA, Inc.",University of Texas Southwestern Medical Center,"KCI USA, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,1/27/2015,10/21/2016,https://ClinicalTrials.gov/show/NCT02289157
2392,Adolescent Idiopathic Scoliosis (AIS) Patient Positioning in EOS System®,Completed,Has Results,Adolescent Idiopathic Scoliosis,Device: EOS® imaging system,Children's Hospital of Philadelphia|EOS imaging Inc.,Children's Hospital of Philadelphia,EOS imaging Inc.,,,,,,,Other|Industry,Observational,11/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02269657
2393,Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF),Completed,Has Results,Myeloproliferative Diseases,Drug: Ruxolitinib|Drug: Pracinostat|Behavioral: Questionnaire,M.D. Anderson Cancer Center|Helsinn Healthcare SA,M.D. Anderson Cancer Center,Helsinn Healthcare SA,,,,,,Phase 2,Other|Industry,Interventional,1/12/2015,6/1/2018,https://ClinicalTrials.gov/show/NCT02267278
2394,Ranolazine Among Unrevascularized Chronic Stable Angina Patients,Completed,Has Results,Angina,Drug: Ranolazine|Drug: Sugar pill,North Florida Foundation for Research and Education|Gilead Sciences,North Florida Foundation for Research and Education,Gilead Sciences,,,,,,Phase 2,Other|Industry,Interventional,9/14/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02265796
2395,Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System,Completed,Has Results,Pain,Device: Valveless recirculating insufflation (VTI)|Device: Conventional pressure,"Yale University|SurgiQuest, Inc.",Yale University,"SurgiQuest, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,8/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02262039
2396,"A Pilot Study: Snacking, Willpower and Glucose Availability",Completed,Has Results,Willpower,Dietary Supplement: Sequence 1|Dietary Supplement: Sequence 2|Dietary Supplement: Sequence 3|Dietary Supplement: Sequence 4,"University of Colorado, Denver|Johnson & Johnson","University of Colorado, Denver",Johnson & Johnson,,,,,,Not Applicable,Other|Industry,Interventional,10/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02258477
2397,Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study,Completed,Has Results,ADHD|Autism,Drug: Very Low Dose Quillivant XR|Drug: Low Dose Quillivant XR|Drug: Moderate Dose Quillivant XR,Seattle Children's Hospital|Pfizer,Seattle Children's Hospital,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,9/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02255565
2398,Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses,Completed,Has Results,Actinic Keratoses,Drug: Ingenol Mebutate|Procedure: Cryotherapy,Icahn School of Medicine at Mount Sinai|LEO Pharma,Icahn School of Medicine at Mount Sinai,LEO Pharma,,,,,,Phase 4,Other|Industry,Interventional,4/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02251652
2399,McGRATH MAC Video Laryngoscope,Completed,Has Results,Intubation; Difficult,Device: McGrath MAC enhanced direct laryngoscope,"The University of Texas Health Science Center, Houston|Medtronic - MITG","The University of Texas Health Science Center, Houston",Medtronic - MITG,,,,,,Not Applicable,Other|Industry,Interventional,8/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02250521
2400,Investigation of a Novel Sleep Surface for Treatment of Positional Sleep Apnea,Completed,Has Results,"Sleep Apnea, Obstructive",Other: Wave sleep surface,Ohio State University|Hill-Rom,Ohio State University,Hill-Rom,,,,,,Not Applicable,Other|Industry,Interventional,8/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02250417
2401,Promoting the Universal Medication Schedule Via Mobile and EHR Technologies,Completed,Has Results,Type 2 Diabetes,Other: UMS Strategy|Other: SMS Texting Reminders,Northwestern University|Merck Sharp & Dohme Corp.,Northwestern University,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,12/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02248857
2402,Arthritis Pilot for Preserving Muscle While Losing Weight,Completed,Has Results,Obesity|Osteoarthritis,Behavioral: Vest|Behavioral: Diet,"Wake Forest University Health Sciences|Medifast, Inc.",Wake Forest University Health Sciences,"Medifast, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,10/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02239939
2403,Biosignatures of Latuda for Bipolar Depression,Completed,Has Results,Bipolar Depression,Drug: Lurasidone (Latuda),New York State Psychiatric Institute|Sunovion,New York State Psychiatric Institute,Sunovion,,,,,,Not Applicable,Other|Industry,Interventional,1/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02239094
2404,MediHoney for Radiation Dermatitis,Completed,Has Results,Breast Cancer|Radiation Dermatitis,Biological: Hydrophor (Group A)|Biological: MediHoney (Group B),University of Maryland|Integra LifeSciences Corporation,University of Maryland,Integra LifeSciences Corporation,,,,,,Not Applicable,Other|Industry,Interventional,6/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02234479
2405,Vortioxetine for Menopausal Depression,Completed,Has Results,Depression|Menopause|Vasomotor Disturbance|Hot Flashes|Sleep,Drug: vortioxetine,"Massachusetts General Hospital|Takeda Pharmaceuticals North America, Inc.",Massachusetts General Hospital,"Takeda Pharmaceuticals North America, Inc.",,,,,,Phase 4,Other|Industry,Interventional,6/12/2015,9/29/2016,https://ClinicalTrials.gov/show/NCT02234362
2406,Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults,Completed,Has Results,Human Immunodeficiency Virus,Drug: Raltegravir|Drug: Dolutegravir|Procedure: Colonoscopy with biopsy,"University of North Carolina, Chapel Hill|Merck Sharp & Dohme Corp.","University of North Carolina, Chapel Hill",Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,10/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02218320
2407,Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography,Completed,Has Results,Atrial Fibrillation|Atrial Flutter,Device: Intracardiac Imaging,"Elad Anter|Biosense Webster, Inc.|Beth Israel Deaconess Medical Center",Elad Anter,"Biosense Webster, Inc.",Beth Israel Deaconess Medical Center,,,,,,Other|Industry,Observational,1/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT02213666
2408,ZIPS Study - Zip Incision aPproximation vs. Suture,Completed,Has Results,Wound|Cardiac Arrhythmia,Device: Zip Surgical Skin Closure Device|Device: Standard Suture Closure,"University of California, San Diego|ZipLine Medical Inc.","University of California, San Diego",ZipLine Medical Inc.,,,,,,Not Applicable,Other|Industry,Interventional,8/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02213510
2409,Reversing Ticagrelor's Effects With Fresh Platelets,Completed,Has Results,Coronary Artery Disease,Drug: Ticagrelor loading dose|Drug: Aspirin loading dose|Drug: Ticagrelor maintenance dose|Drug: Aspirin maintenance dose,Icahn School of Medicine at Mount Sinai|AstraZeneca,Icahn School of Medicine at Mount Sinai,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,7/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02201394
2410,Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis,Completed,Has Results,Fibrillary Glomerulonephritis,Drug: rituximab,"Mayo Clinic|Genentech, Inc.",Mayo Clinic,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,11/14/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02197767
2411,Computer-Assisted Navigation for Intramedullary Nail Fixation of Intertrochanteric Femur Fractures,Completed,Has Results,Intertrochanteric Femur Fractures,Device: Stryker ADAPT computer-assisted navigation|Device: Conventional technique,William Beaumont Hospitals|Stryker Orthopaedics,William Beaumont Hospitals,Stryker Orthopaedics,,,,,,Not Applicable,Other|Industry,Interventional,7/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02190435
2412,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,Completed,Has Results,"Diseases, Metabolic|Insulin Sensitivity",Drug: Intralipid|Drug: ClinOleic|Drug: Dextrose|Other: Saline (control),Emory University|Baxter Healthcare Corporation,Emory University,Baxter Healthcare Corporation,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,6/8/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT02185729
2413,Buprenorphine Used With Treatment Resistant Depression in Older Adults,Completed,Has Results,Major Depressive Disorder|Depression,Drug: venlafaxine XR|Drug: buprenorphine|Drug: Placebo,Washington University School of Medicine|Reckitt Benckiser LLC,Washington University School of Medicine,Reckitt Benckiser LLC,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/1/2016,4/30/2018,https://ClinicalTrials.gov/show/NCT02181231
2414,UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation,Completed,Has Results,Diabetes,,Beth Israel Deaconess Medical Center|Ornim Medical Ltd.,Beth Israel Deaconess Medical Center,Ornim Medical Ltd.,,,,,,,Other|Industry,Observational,4/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02178787
2415,Bone Remodeling After Immediate Implant Placement With and Without Bone Grafting,Completed,Has Results,Tooth Loss,Device: BioOss Collagen at the time of implant placement,Columbia University|Geistlich Pharma AG,Columbia University,Geistlich Pharma AG,,,,,,Not Applicable,Other|Industry,Interventional,1/14/2019,8/18/2019,https://ClinicalTrials.gov/show/NCT02174198
2416,Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions,Completed,Has Results,Cervical Lesions,Procedure: Self etch enamel etching|Procedure: selective etch protocol|Device: Adhese Universal,Indiana University|Ivoclar Vivadent AG,Indiana University,Ivoclar Vivadent AG,,,,,,Not Applicable,Other|Industry,Interventional,6/14/2019,5/18/2019,https://ClinicalTrials.gov/show/NCT02172664
2417,Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis,Completed,Has Results,Granulomatosis With Polyangiitis|Microscopic Polyangiitis,Drug: Glucocorticoids|Drug: Rituximab,"Massachusetts General Hospital|Genentech, Inc.",Massachusetts General Hospital,"Genentech, Inc.",,,,,,Phase 4,Other|Industry,Interventional,6/14/2019,11/1/2017,https://ClinicalTrials.gov/show/NCT02169219
2418,Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID),Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Combigan Two Times Daily (BID)|Drug: Simbrinza Three Times Daily (TID),"Cornerstone Health Care, PA|Allergan","Cornerstone Health Care, PA",Allergan,,,,,,Phase 4,Other|Industry,Interventional,8/14/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT02167035
2419,Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch),Completed,Has Results,Transverse Myelitis|Neuromyelitis Optica|Idiopathic Transverse Myelitis|Myelitis NOS,Drug: Dalfampridine|Drug: Placebo,Johns Hopkins University|Acorda Therapeutics,Johns Hopkins University,Acorda Therapeutics,,,,,,Phase 2,Other|Industry,Interventional,2/14/2019,1/8/2017,https://ClinicalTrials.gov/show/NCT02166346
2420,Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome,Completed,Has Results,Scleroderma|Raynaud's Syndrome,Drug: Onabotulinumtoxin A|Drug: sterile saline solution,Johns Hopkins University|Allergan,Johns Hopkins University,Allergan,,,,,,Phase 3,Other|Industry,Interventional,1/15/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02165111
2421,Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome,Completed,Has Results,Basal Cell Nevus Syndrome,Drug: Levulan|Other: Red Light Photodynamic Therapy|Other: Blue Light Photodynamic Therapy,"Edward Maytin, MD, PhD|DUSA Pharmaceuticals, Inc.|The Cleveland Clinic","Edward Maytin, MD, PhD","DUSA Pharmaceuticals, Inc.",The Cleveland Clinic,,,,,Not Applicable,Other|Industry,Interventional,2/1/2016,12/1/2016,https://ClinicalTrials.gov/show/NCT02157623
2422,Social Forces to Improve Statin Adherence (Study B),Completed,Has Results,Medication Adherence|High Blood Pressure|Diabetes,Behavioral: Comparison to peers|Behavioral: Adherence feedback|Device: Electronic pill bottle,University of Pennsylvania|Merck Sharp & Dohme Corp.,University of Pennsylvania,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,1/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02148523
2423,Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study,Completed,Has Results,Acne Rosacea,Drug: Azelaic acid 15%|Drug: Brimonidine 0.33%,"Derm Research, PLLC|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","Derm Research, PLLC","Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",,,,,,Phase 4,Other|Industry,Interventional,5/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02147691
2424,Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment,Completed,Has Results,External Genital Warts,Drug: Sinecatechins 15% Ointment|Drug: Cryotherapy alone,Icahn School of Medicine at Mount Sinai|Fougera Pharmaceuticals Inc.,Icahn School of Medicine at Mount Sinai,Fougera Pharmaceuticals Inc.,,,,,,Not Applicable,Other|Industry,Interventional,9/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT02147353
2425,Prevention of Seroma Formation and Wound Complications Using NPWT Devices,Completed,Has Results,Seroma|Wound Dehiscence|Wound Infection,Device: Renasys*GO Negative Pressure Wound Therapy System,"Yale University|Smith & Nephew, Inc.",Yale University,"Smith & Nephew, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,1/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02147288
2426,Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA),Completed,Has Results,Microvascular Angina,Drug: Ranolazine|Drug: Placebo,Emory University|Gilead Sciences,Emory University,Gilead Sciences,,,,,,Phase 2,Other|Industry,Interventional,9/14/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT02147067
2427,Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa,Completed,Has Results,Retinitis Pigmentosa,Drug: Minocycline,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1|Phase 2,NIH|Industry,Interventional,5/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02140164
2428,Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops,Completed,Has Results,Glaucoma,,"MDbackline, LLC|Allergan","MDbackline, LLC",Allergan,,,,,,,Other|Industry,Observational,10/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02138461
2429,Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction,Completed,Has Results,Pulmonary Hypertension|Diastolic Left Ventricular Dysfunction,Drug: Ranolazine,Boston University|Gilead Sciences,Boston University,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,7/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT02133352
2430,PROphylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population,Completed,Has Results,Wound Complication,Device: Closed incision wound vacuum (Prevena),"University of Pennsylvania|Kinetic Concepts, Inc.",University of Pennsylvania,"Kinetic Concepts, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,5/14/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02128997
2431,Evaluation of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Revision Arthroplasty.,Completed,Has Results,Prosthesis-related Infections|Wound Complications|Joint Diseases|Musculoskeletal Diseases,Device: Prevena,"The Cleveland Clinic|KCI USA, Inc.",The Cleveland Clinic,"KCI USA, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,5/14/2019,6/30/2017,https://ClinicalTrials.gov/show/NCT02127281
2432,Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme,Completed,Has Results,Glioblastoma Multiforme|Glioblastoma - Category,Drug: Bevacizumab|Procedure: Magnetic Resonance Spectroscopy (MRS)|Procedure: Border Zone Stereotactic Radiosurgery (BZ-SRS),"Ajay Niranjan|Genentech, Inc.|University of Pittsburgh",Ajay Niranjan,"Genentech, Inc.",University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,5/14/2019,3/31/2018,https://ClinicalTrials.gov/show/NCT02120287
2433,Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation,Completed,Has Results,Cardiomyopathy|Heart Failure|Cardiac Arrhythmia,Device: Standard Defibrillation Testing|Device: Upper Limit of Vulnerability Testing,"University of California, San Diego|Medtronic","University of California, San Diego",Medtronic,,,,,,Not Applicable,Other|Industry,Interventional,8/11/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02111993
2434,Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy,Completed,Has Results,Peripheral Pulmonary Nodules,Device: Navigation guided bronchoscopy,Johns Hopkins University|Veran Medical Technologies,Johns Hopkins University,Veran Medical Technologies,,,,,,Not Applicable,Other|Industry,Interventional,9/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02109458
2435,NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy,Completed,Has Results,Xerostomia,Drug: NeutraSal|Drug: Placebo Comparator,Medical University of South Carolina|Invado Pharmaceuticals LLC,Medical University of South Carolina,Invado Pharmaceuticals LLC,,,,,,Not Applicable,Other|Industry,Interventional,11/13/2019,7/3/2017,https://ClinicalTrials.gov/show/NCT02107300
2436,Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery,Completed,Has Results,ATIII Deficiency,Drug: Anti-thrombin III|Other: Placebo,"Duke University|Grifols Biologicals, LLC",Duke University,"Grifols Biologicals, LLC",,,,,,Phase 2,Other|Industry,Interventional,6/14/2019,7/1/2016,https://ClinicalTrials.gov/show/NCT02103114
2437,Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD,Completed,Has Results,COPD,Drug: Roflumilast Placebo|Drug: Roflumilast,University of Miami|Forest Laboratories,University of Miami,Forest Laboratories,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,2/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02097992
2438,Novartis Everolimus Transition,Completed,Has Results,Graft Dysfunction|Interstitial Fibrosis,Drug: Everolimus|Other: Standard of Care,Medical University of South Carolina|Novartis,Medical University of South Carolina,Novartis,,,,,,Phase 4,Other|Industry,Interventional,2/14/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02096107
2439,"An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS",Completed,Has Results,Pain|Delayed Onset Muscle Soreness,Drug: 1% diclofenac sodium gel|Drug: Placebo,"Lotus Clinical Research, LLC|Novartis Pharmaceuticals","Lotus Clinical Research, LLC",Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,3/14/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT02087748
2440,In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients,Completed,Has Results,Coronary Artery Disease,Drug: Ticagrelor 180mg|Drug: Ticagrelor 90mg,University of Florida|The Medicines Company,University of Florida,The Medicines Company,,,,,,Not Applicable,Other|Industry,Interventional,4/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02081443
2441,BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome,Completed,Has Results,Carpal Tunnel Syndrome,Drug: Botulinum Toxin Type A|Drug: Placebo,"Benjamin Sucher|Allergan|Arizona Arthritis & Rheumatology Research, PLLC.",Benjamin Sucher,Allergan,"Arizona Arthritis & Rheumatology Research, PLLC.",,,,,Phase 2,Other|Industry,Interventional,10/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02070302
2442,Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy,Completed,Has Results,Barrett's Esophagus,Device: EG Scan II (transnasal endoscopy)|Procedure: Standard Endoscopy,"Mayo Clinic|IntroMedic Co., Ltd.",Mayo Clinic,"IntroMedic Co., Ltd.",,,,,,Not Applicable,Other|Industry,Interventional,3/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02066233
2443,Study to Compare Negative Pressure Wound Therapy or Standard Dressings After Orthopedic Surgery,Completed,Has Results,Wound of Knee|Wound of Hip,Device: Single-Use Negative Pressure Wound Therapy|Device: Standard postsurgical dressings,"University of Missouri-Columbia|Smith & Nephew, Inc.",University of Missouri-Columbia,"Smith & Nephew, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,3/14/2019,9/7/2017,https://ClinicalTrials.gov/show/NCT02064270
2444,LASIK Flap Thickness and Visual Outcomes Using the WaveLight FS200 Femtosecond Laser,Completed,Has Results,Myopia,Device: FS200 femtosecond laser LASIK|Device: IntraLase femtosecond laser LASIK,The Cleveland Clinic|Alcon Research,The Cleveland Clinic,Alcon Research,,,,,,Not Applicable,Other|Industry,Interventional,8/12/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02060461
2445,Intraosseous Pressure Monitoring in Intensive Care Unit Patients,Completed,Has Results,Blood Pressure,Device: Intraosseous Device,HealthPartners Institute|Vidacare Corporation,HealthPartners Institute,Vidacare Corporation,,,,,,Not Applicable,Other|Industry,Interventional,12/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02059928
2446,Botulinum Toxin for the Management of Chronic Orchialgia,Completed,Has Results,Chronic Testicular Pain,Drug: Botox Injection|Procedure: Normal saline injection,Wake Forest University Health Sciences|Allergan,Wake Forest University Health Sciences,Allergan,,,,,,Phase 2,Other|Industry,Interventional,11/14/2019,10/18/2016,https://ClinicalTrials.gov/show/NCT02058836
2447,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,Completed,Has Results,Metastatic Biliary Tract Carcinoma,Drug: Regorafenib,"Nathan Bahary, MD|Bayer|University of Pittsburgh","Nathan Bahary, MD",Bayer,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,1/14/2019,5/14/2018,https://ClinicalTrials.gov/show/NCT02053376
2448,Study of Gralise to Treat Fibromyalgia Patients,Completed,Has Results,Fibromyalgia,Drug: Gabapentin ER,"The Center for Clinical Research, Winston-Salem, NC|Depomed","The Center for Clinical Research, Winston-Salem, NC",Depomed,,,,,,Not Applicable,Other|Industry,Interventional,7/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT02052414
2449,Ranolazine and Microvascular Angina by PET in the Emergency Department,Completed,Has Results,Microvascular Angina,Drug: Ranolazine|Drug: Placebo,Yale University|Gilead Sciences,Yale University,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,4/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02052011
2450,Study of the Effectiveness of Ozurdex for the Control of Uveitis,Completed,Has Results,"Uveitis, Intermediate|Uveitis, Posterior",Drug: Dexamethasone pellet,Johns Hopkins University|Allergan,Johns Hopkins University,Allergan,,,,,,Phase 4,Other|Industry,Interventional,1/14/2019,6/30/2018,https://ClinicalTrials.gov/show/NCT02049476
2451,Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder,Completed,Has Results,Intermittent Explosive Disorder|Childhood Aggression|Oppositional Defiant Disorder|Attention Deficit Disorder,Behavioral: Parent Management Training|Other: Placebo|Drug: Intuniv,New York State Psychiatric Institute|Shire,New York State Psychiatric Institute,Shire,,,,,,Phase 4,Other|Industry,Interventional,7/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02048241
2452,Post-bypass Prophylactic IVIG in Infants and Neonates,Completed,Has Results,Hypogammaglobulinemia|Congenital Heart Disease,Drug: IVIG|Other: Placebo,"University of Alabama at Birmingham|Grifols Biologicals, LLC",University of Alabama at Birmingham,"Grifols Biologicals, LLC",,,,,,Not Applicable,Other|Industry,Interventional,5/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02043379
2453,Zoledronic Acid Administration in Acute Spinal Cord Injury,Completed,Has Results,Disuse Osteoporosis,Drug: Zoledronic acid,James J. Peters Veterans Affairs Medical Center|Kessler Institute for Rehabilitation,James J. Peters Veterans Affairs Medical Center,Kessler Institute for Rehabilitation,,,,,,Phase 4,U.S. Fed|Industry,Interventional,5/6/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT02042872
2454,Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women,Completed,Has Results,Pregnancy,Drug: Intravaneous iron(low molecular weight iron dextran),Auerbach Hematology Oncology Associates P C|Pharmacosmos A/S,Auerbach Hematology Oncology Associates P C,Pharmacosmos A/S,,,,,,Phase 2,Other|Industry,Interventional,7/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02038023
2455,Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine,Completed,Has Results,Chronic Migraine,Drug: onabotulinumtoxinA,"Cady, Roger, M.D.|Allergan","Cady, Roger, M.D.",Allergan,,,,,,Phase 4,Other|Industry,Interventional,4/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02037425
2456,Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Ozurdex|Drug: Bevacizumab,"Raj K. Maturi, MD|Allergan|Maturi, Raj K., M.D., P.C.","Raj K. Maturi, MD",Allergan,"Maturi, Raj K., M.D., P.C.",,,,,Phase 4,Other|Industry,Interventional,1/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02036424
2457,Prevention of Lymphoceles After Robotic PLND,Completed,Has Results,Lymphoceles|Prostate Cancer,Device: Intuitive Vessel Sealer,OhioHealth|Intuitive Surgical,OhioHealth,Intuitive Surgical,,,,,,Not Applicable,Other|Industry,Interventional,8/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02035475
2458,Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines,Completed,Has Results,Chronic Idiopathic Urticaria,Drug: AZD1981|Drug: Placebo,Johns Hopkins University|AstraZeneca,Johns Hopkins University,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,1/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02031679
2459,Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD),Completed,Has Results,Cardiomyopathy,Device: Nominal T shock setting|Device: Educated T shock setting,James Merrill|Medtronic|Wellmont CVA Heart Institute,James Merrill,Medtronic,Wellmont CVA Heart Institute,,,,,Not Applicable,Other|Industry,Interventional,1/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT02027883
2460,Hemodynamic and Respiratory Variations During Laparoscopic Surgery With and Without Deep Neuromuscular Blockade.,Completed,Has Results,Intraoperative Complications|Postoperative Complications|Laparoscopy|Surgical Complications From General Anesthesia|Ventilator-Induced Lung Injury,Drug: Rocuronium,Massachusetts General Hospital|Merck Sharp & Dohme Corp.,Massachusetts General Hospital,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,1/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02025075
2461,Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,George Washington University|AstraZeneca,George Washington University,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,11/13/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02024477
2462,Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils,Completed,Has Results,Allergic Asthma,Drug: Omalizumab,Johns Hopkins University|Novartis Pharmaceuticals,Johns Hopkins University,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,2/13/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02023151
2463,Sodium Nitrite to Treat Arterial Aging,Completed,Has Results,Vascular Aging,Drug: Placebo|Drug: Sodium Nitrite,"University of Colorado, Boulder|TheraVasc Inc.","University of Colorado, Boulder",TheraVasc Inc.,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT02022670
2464,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Completed,Has Results,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Drug: Metformin XR|Drug: Saxagliptin|Drug: Saxagliptin-Metformin XR,Woman's|AstraZeneca,Woman's,AstraZeneca,,,,,,Phase 3,Other|Industry,Interventional,3/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02022007
2465,Regional Prophylactic Vancomycin in Revision Total Knee Replacement,Completed,Has Results,Arthropathy of Knee Joint,Drug: Vancomycin,Mayo Clinic|Vidacare Corporation,Mayo Clinic,Vidacare Corporation,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,12/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02020031
2466,Social Forces to Improve Statin Adherence (Study A),Completed,Has Results,Medication Adherence|High Blood Pressure|Diabetes,Behavioral: Medication Adherence Partner|Device: Electronic pill bottle,University of Pennsylvania|Merck Sharp & Dohme Corp.,University of Pennsylvania,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,1/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02018809
2467,An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata,Completed,Has Results,Alopecia Areata,Drug: Abatacept,Columbia University|Bristol-Myers Squibb,Columbia University,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,9/13/2019,7/31/2017,https://ClinicalTrials.gov/show/NCT02018042
2468,V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds,Completed,Has Results,Lower Extremity Wound Infected|Venous Stasis Ulcers,Device: VAC VeraFlo with Dakins Instillation|Device: VAC Ulta Therapy,"St. Luke's-Roosevelt Hospital Center|Kinetic Concepts, Inc.",St. Luke's-Roosevelt Hospital Center,"Kinetic Concepts, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02009501
2469,Study of PTSD in Military Veterans Who Have Suffered Traumatic Brain Injuries,Completed,Has Results,PTSD|TBI,Procedure: Functional Neurological Rehabilitation,Carrick Institute for Graduate Studies|Carrick Brain Centers,Carrick Institute for Graduate Studies,Carrick Brain Centers,,,,,,Not Applicable,Other|Industry,Interventional,3/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02003352
2470,Pressure Ulcer Healing With Microcyn,Completed,Has Results,Pressure Ulcer|Spinal Cord Injuries,Drug: Microcyn|Other: Sterile saline,"University of Alabama at Birmingham|Oculus Innovative Sciences, Inc.",University of Alabama at Birmingham,"Oculus Innovative Sciences, Inc.",,,,,,Phase 4,Other|Industry,Interventional,3/13/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02001558
2471,Vilazodone for Separation Anxiety Disorder,Completed,Has Results,Separation Anxiety Disorder,Drug: Vilazodone|Drug: Placebo,New York State Psychiatric Institute|Forest Laboratories,New York State Psychiatric Institute,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,12/13/2019,12/30/2017,https://ClinicalTrials.gov/show/NCT01999920
2472,Use of Prineo in Breast Reduction Surgery,Completed,Has Results,Efficiency of Surgical Incision Closure|Post-operative Scar,Device: Prineo,"Columbia University|Ethicon, Inc.",Columbia University,"Ethicon, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,8/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01996917
2473,Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1,Completed,Has Results,"Hepatitis C, Chronic",Drug: Telaprevir and Sofosbuvir,University of Florida|Vertex Pharmaceuticals Incorporated,University of Florida,Vertex Pharmaceuticals Incorporated,,,,,,Phase 2,Other|Industry,Interventional,12/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01994486
2474,Neural Signatures of Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Device: Activa PC+S,Stanford University|Medtronic,Stanford University,Medtronic,,,,,,Not Applicable,Other|Industry,Interventional,10/13/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT01990313
2475,Etanercept and Vascular Function in Psoriasis,Completed,Has Results,PSORIASIS,Drug: Etanercept|Drug: Placebo,Emory University|Amgen,Emory University,Amgen,,,,,,Phase 2,Other|Industry,Interventional,8/10/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01989689
2476,Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED,Completed,Has Results,Reproductive Tract Infections,Device: Roche AMPLICOR CT/NG|Device: Cepheid Xpert CT/NG Test,George Washington University|Cepheid,George Washington University,Cepheid,,,,,,Not Applicable,Other|Industry,Interventional,10/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01989130
2477,Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis,Completed,Has Results,Diverticulitis,Procedure: Colon resection,Stony Brook University|Merck Sharp & Dohme Corp.,Stony Brook University,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,10/11/2019,7/16/2016,https://ClinicalTrials.gov/show/NCT01986686
2478,Genistein in Treatment of Metastatic Colorectal Cancer,Completed,Has Results,Colon Cancer|Rectal Cancer|Colorectal Cancer,Drug: Genistein,"Sofya Pintova|DSM Nutritional Products, Inc.|Icahn School of Medicine at Mount Sinai",Sofya Pintova,"DSM Nutritional Products, Inc.",Icahn School of Medicine at Mount Sinai,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/13/2019,10/31/2018,https://ClinicalTrials.gov/show/NCT01985763
2479,Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy,Completed,Has Results,Myelodysplastic Syndrome,Drug: Vosaroxin,Weill Medical College of Cornell University|Sunesis Pharmaceuticals,Weill Medical College of Cornell University,Sunesis Pharmaceuticals,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/25/2013,1/19/2015,https://ClinicalTrials.gov/show/NCT01980056
2480,Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen,Completed,Has Results,HIV|HIV-associated Neurocognitive Disorder|Neurotoxicity,Drug: Raltegravir,Massachusetts General Hospital|Merck Sharp & Dohme Corp.,Massachusetts General Hospital,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,1/14/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01978743
2481,LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women,Completed,Has Results,Menopause|Brain Activity|Cognition,Drug: Lisdexamfetamine|Other: Placebo,University of Pennsylvania|Shire,University of Pennsylvania,Shire,,,,,,Phase 4,Other|Industry,Interventional,12/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01977625
2482,Switching From Oral Dopamine Agonists to Rotigotine,Completed,Has Results,Restless Legs Syndrome|Ekbom Syndrome|Willis-Ekbom Disease,Drug: Rotigotine,"John Winkelman, MD, PhD|UCB Pharma|Massachusetts General Hospital","John Winkelman, MD, PhD",UCB Pharma,Massachusetts General Hospital,,,,,Phase 4,Other|Industry,Interventional,8/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01976871
2483,Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism,Completed,Has Results,Atrial Fibrillation|Atrial Flutter,Drug: dabigatran etexilate mesylate,Vanderbilt University Medical Center|Boehringer Ingelheim,Vanderbilt University Medical Center,Boehringer Ingelheim,,,,,,Phase 4,Other|Industry,Interventional,10/13/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01976507
2484,Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease,Completed,Has Results,End Stage Renal Disease,Biological: 13-valent conjugate pneumococcal vaccine,Michigan State University|Pfizer,Michigan State University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,5/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01974817
2485,The Immunological Basis for Treatment Resistance to Anti-TNF Treatments,Completed,Has Results,Psoriasis,Drug: etanercept,University of Michigan|Amgen,University of Michigan,Amgen,,,,,,Phase 4,Other|Industry,Interventional,3/13/2014,11/1/2017,https://ClinicalTrials.gov/show/NCT01971346
2486,Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat,Completed,Has Results,Major Depressive Disorder|Generalized Anxiety Disorder,Drug: seroquel xr|Behavioral: CBT,Icahn School of Medicine at Mount Sinai|AstraZeneca,Icahn School of Medicine at Mount Sinai,AstraZeneca,,,,,,Not Applicable,Other|Industry,Interventional,9/9/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01971203
2487,Stress CT Perfusion in Patients With Chest Pain,Completed,Has Results,Coronary Artery Disease,Drug: Regadenoson,University of Chicago|Astellas Pharma Inc,University of Chicago,Astellas Pharma Inc,,,,,,Not Applicable,Other|Industry,Interventional,6/14/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT01969916
2488,Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction,Completed,Has Results,Ductal Carcinoma in Situ - Category|Breast Cancer|Prophylactic Mastectomy,Procedure: Inframammary Fold Incision or Lateral Radial Incision|Procedure: Lateral Radial Incision|Procedure: Inframammary Fold Incision|Device: Laser-assisted fluorescence angiography|Drug: Indocyanine Green,Washington University School of Medicine|LifeCell,Washington University School of Medicine,LifeCell,,,,,,Not Applicable,Other|Industry,Interventional,3/28/2013,4/17/2017,https://ClinicalTrials.gov/show/NCT01969448
2489,Effects of Intravenous Lidocaine on Endometriosis Pain,Completed,Has Results,Endometriosis,Drug: IV Lidocaine|Drug: IV diphenhydramine,Brigham and Women's Hospital|Pfizer,Brigham and Women's Hospital,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,12/10/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01968694
2490,3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery,Completed,Has Results,Hypomastia|Primary Breast Augmentation,Device: 3D Imaging,Washington University School of Medicine|Allergan,Washington University School of Medicine,Allergan,,,,,,Not Applicable,Other|Industry,Interventional,11/12/2019,5/16/2017,https://ClinicalTrials.gov/show/NCT01964105
2491,Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart,Completed,Has Results,Hypertension|Left Ventricular Diastolic Dysfunction,Drug: Nebivolol,Icahn School of Medicine at Mount Sinai|Forest Laboratories,Icahn School of Medicine at Mount Sinai,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,3/12/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01961323
2492,An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq),Completed,Has Results,Diarrhea|Gastroenteritis,Biological: RV5 (Pentavalent Rotavirus Vaccine),Dennis Clements|Merck Sharp & Dohme Corp.|Duke University,Dennis Clements,Merck Sharp & Dohme Corp.,Duke University,,,,,Phase 4,Other|Industry,Interventional,2/14/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01960725
2493,Metabolomics of Insomnia-Related Hyperarousal,Completed,Has Results,Primary Insomnia,,University of Pennsylvania|Merck Sharp & Dohme Corp.,University of Pennsylvania,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,10/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01957111
2494,Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes|Cardiovascular Disease,Drug: Sitagliptin|Drug: Glimepiride|Drug: Placebo,"University of Colorado, Denver|Merck Sharp & Dohme Corp.","University of Colorado, Denver",Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,10/13/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT01951339
2495,Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies,Completed,Has Results,Coronary Artery Disease|CAD,Drug: regadenoson|Drug: Optimark®|Device: Myocardial perfusion MRI,"Daniel S. Berman|Astellas Pharma US, Inc.|Cedars-Sinai Medical Center",Daniel S. Berman,"Astellas Pharma US, Inc.",Cedars-Sinai Medical Center,,,,,Not Applicable,Other|Industry,Interventional,5/16/2014,10/23/2017,https://ClinicalTrials.gov/show/NCT01949844
2496,Effects of Ranolazine and Exercise on Daily Physical Activity Trial,Completed,Has Results,Chronic Stable Angina,Drug: Ranolazine|Behavioral: Aerobic Exercise|Drug: Placebo,Duke University|Gilead Sciences,Duke University,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,12/13/2019,10/10/2016,https://ClinicalTrials.gov/show/NCT01948310
2497,Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination,Completed,Has Results,Splenomegaly|Pleural Effusion,Device: resident with GE vscan,Brigham and Women's Hospital|General Electric,Brigham and Women's Hospital,General Electric,,,,,,Not Applicable,Other|Industry,Interventional,9/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01948076
2498,Ubiquinol (Reduced COQ10) for Patients With Sepsis,Completed,Has Results,Sepsis,Drug: Ubiquinol|Dietary Supplement: Placebo,Beth Israel Deaconess Medical Center|Kaneka Pharma America LLC,Beth Israel Deaconess Medical Center,Kaneka Pharma America LLC,,,,,,Phase 2,Other|Industry,Interventional,10/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01948063
2499,Procellera and Negative Pressure Therapy for Acute Wounds,Completed,Has Results,Wound,Device: Procellera|Device: negative pressure therapy,Gayle Gordillo|Vomaris Innovations|Ohio State University,Gayle Gordillo,Vomaris Innovations,Ohio State University,,,,,Not Applicable,Other|Industry,Interventional,7/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01938066
2500,Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.,Completed,Has Results,Restless Leg Syndrome,Drug: incobotulinumtoxinA|Drug: Placebo,"Yale University|Merz North America, Inc.",Yale University,"Merz North America, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/12/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01931878
2501,DBS for Home Monitoring in Children With Kidney Transplantation,Completed,Has Results,Kidney Disease,,"Oregon Health and Science University|Astellas Pharma US, Inc.",Oregon Health and Science University,"Astellas Pharma US, Inc.",,,,,,,Other|Industry,Observational,7/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01931397
2502,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Completed,Has Results,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Drug: Topical Dapsone 5% Gel|Other: Moisturizer|Drug: oral antibiotics,Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb,Memorial Sloan Kettering Cancer Center,Bristol-Myers Squibb,,,,,,Phase 3,Other|Industry,Interventional,8/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01931150
2503,Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration,Completed,Has Results,Neovascular Age-Related Macular Degeneration,Drug: Ranibizumab 0.5mg|Drug: Aflibercept 2.0mg,"Arshad Khanani|Genentech, Inc.|Sierra Eye Associates",Arshad Khanani,"Genentech, Inc.",Sierra Eye Associates,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01926977
2504,Dysport for the Treatment of OMD,Completed,Has Results,Oral Dystonia|Tardive Dystonia,Drug: Low Dose - AbobotulinumtoxinA,Emory University|Ipsen,Emory University,Ipsen,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/13/2019,2/8/2017,https://ClinicalTrials.gov/show/NCT01921270
2505,Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo,Completed,Has Results,Healthy,Drug: olanzapine|Drug: iloperidone|Drug: Placebo,New York State Psychiatric Institute|Novartis Pharmaceuticals,New York State Psychiatric Institute,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,11/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01920802
2506,Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma,Completed,Has Results,Normal-Tension Glaucoma,Device: Sensimed Triggerfish|Device: Blood Pressure,"University of North Carolina, Chapel Hill|Sensimed AG","University of North Carolina, Chapel Hill",Sensimed AG,,,,,,Not Applicable,Other|Industry,Interventional,7/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01912599
2507,A Comparison of Bone Formation With Three Different Bone Graft Materials Following Sinus Graft,Completed,Has Results,Inadequate Bone Height in Maxillary Posterior Area,Procedure: Sinus augmentation|Drug: Equimatrix|Drug: OSSIF-i sem|Drug: Bio-oss,"Loma Linda University|American Regent, Inc.",Loma Linda University,"American Regent, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,12/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01911819
2508,Role of Everolimus in Highly Sensitized Patients,Completed,Has Results,Highly-sensitized Kidney Transplant Recipients,Drug: everolimus + low-dose tacrolimus,"Joseph Kahwaji, MD, MPH|Novartis|Cedars-Sinai Medical Center","Joseph Kahwaji, MD, MPH",Novartis,Cedars-Sinai Medical Center,,,,,Phase 2,Other|Industry,Interventional,6/13/2019,1/19/2016,https://ClinicalTrials.gov/show/NCT01911546
2509,Dose-Response of Salmeterol in Children,Completed,Has Results,Asthma,Drug: Advair Diskus100/50 µg|Drug: Flovent Diskus 100 µg|Drug: Methacholine Chloride|Drug: Albuterol,"University of Florida|Teva Branded Pharmaceutical Products, R&D Inc.",University of Florida,"Teva Branded Pharmaceutical Products, R&D Inc.",,,,,,Phase 4,Other|Industry,Interventional,8/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01907334
2510,Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation,Completed,Has Results,Leukemia,Drug: Bortezomib,"M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.",M.D. Anderson Cancer Center,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/7/2013,1/18/2017,https://ClinicalTrials.gov/show/NCT01891968
2511,New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C,Completed,Has Results,"Cirrhosis|Chronic Hepatitis C|Hepatitis C|Hepatitis C, Chronic",Drug: DUAL|Drug: QUAD,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Bristol-Myers Squibb|National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Bristol-Myers Squibb,National Institutes of Health Clinical Center (CC),,,,,Phase 2,NIH|Industry,Interventional,5/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01888900
2512,A Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps After Ventral Hernia Repair,Completed,Has Results,Ventral Hernia,Procedure: SPY - Unblinded use of SPY Elite|Procedure: Control - Blinded use of SPY Elite,"Atrium Health|Novadaq Technologies ULC, now a part of Stryker",Atrium Health,"Novadaq Technologies ULC, now a part of Stryker",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01886963
2513,Studying the Effects of Phentermine on Eating Behavior,Completed,Has Results,Obesity,Drug: Phentermine|Drug: placebo,New York State Psychiatric Institute|AstraZeneca,New York State Psychiatric Institute,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,7/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01886937
2514,UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma,Completed,Has Results,Asymptomatic Multiple Myeloma,Drug: ENK Cell Infusion,"University of Arkansas|Millennium Pharmaceuticals, Inc.",University of Arkansas,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,4/13/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01884688
2515,Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation,Completed,Has Results,Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency,Drug: Ravicti,"University of Pittsburgh|Horizon Pharma Ireland, Ltd., Dublin Ireland",University of Pittsburgh,"Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,Phase 1,Other|Industry,Interventional,6/13/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01881984
2516,Continuous Interscalene Block Results in Superior Recovery Throughout the First Postoperative Week,Completed,Has Results,Postoperative Pain|Adverse Effects,Procedure: ISB,St. Luke's-Roosevelt Hospital Center|Baxter Healthcare Corporation,St. Luke's-Roosevelt Hospital Center,Baxter Healthcare Corporation,,,,,,Early Phase 1,Other|Industry,Interventional,8/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01881776
2517,Safety and Efficacy of Eltrombopag at Escalated Doses,Completed,Has Results,Immune Thrombocytopenia|Platelet Disorder,Drug: Eltrombopag|Drug: Placebo,Weill Medical College of Cornell University|Novartis,Weill Medical College of Cornell University,Novartis,,,,,,Phase 2,Other|Industry,Interventional,2/13/2019,10/16/2017,https://ClinicalTrials.gov/show/NCT01880047
2518,Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance,Completed,Has Results,Hypoxia,Drug: Placebo|Drug: Aes-103,"Colorado State University|AesRx, LLC",Colorado State University,"AesRx, LLC",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01871142
2519,Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy,Completed,Has Results,Diabetes|Atherosclerosis,Drug: sitagliptin|Drug: Placebo,Medical College of Wisconsin|Merck Sharp & Dohme Corp.,Medical College of Wisconsin,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,6/13/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01859793
2520,Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans,Completed,Has Results,Hyperlipidemia,Dietary Supplement: Capros dietary supplement,"Chandan K Sen|Natreon, Inc.|Ohio State University",Chandan K Sen,"Natreon, Inc.",Ohio State University,,,,,Not Applicable,Other|Industry,Interventional,3/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01858376
2521,Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM,Completed,Has Results,Disorder of Glucose Regulation,Drug: Sitagliptin-Metformin|Drug: Metformin|Drug: Placebo pill,Woman's|Merck Sharp & Dohme Corp.,Woman's,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,9/28/2013,9/28/2017,https://ClinicalTrials.gov/show/NCT01856907
2522,Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease,Completed,Has Results,Inflammatory Bowel Disease|Glycogen Storage Disease Type Ia,Other: Glycogen Storage Disease type Ia patients,University of Florida|Prometheus Laboratories,University of Florida,Prometheus Laboratories,,,,,,,Other|Industry,Observational,11/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01854242
2523,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: L-methylfolate|Drug: OROS-Methylphenidate|Drug: Placebo,"Massachusetts General Hospital|Pamlab, Inc.",Massachusetts General Hospital,"Pamlab, Inc.",,,,,,Phase 2|Phase 3,Other|Industry,Interventional,5/14/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT01853280
2524,Duloxetine Treatment in Elderly With Dysthymia,Completed,Has Results,Depression|Dysthymic Disorder,Drug: Duloxetine,New York State Psychiatric Institute|Eli Lilly and Company,New York State Psychiatric Institute,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,1/6/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01852383
2525,Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis,Completed,Has Results,Breast Cancer,Radiation: Tomosynthesis Breast Scanning|Radiation: Breast CT Scanning,"University of California, Davis|Hologic, Inc.","University of California, Davis","Hologic, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/10/2019,3/4/2016,https://ClinicalTrials.gov/show/NCT01852032
2526,"Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography",Completed,Has Results,Coronary Artery Disease,Drug: Iodixanol|Drug: Ioxaglate|Drug: Bivalirudin,NYU Langone Health|Guerbet,NYU Langone Health,Guerbet,,,,,,Phase 4,Other|Industry,Interventional,2/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01848899
2527,"Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",Completed,Has Results,Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer,Drug: Alisertib|Drug: Abiraterone acetate|Drug: Prednisone,Sidney Kimmel Cancer Center at Thomas Jefferson University|Millennium: The Takeda Oncology Company|Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Millennium: The Takeda Oncology Company,Thomas Jefferson University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/14/2013,6/23/2016,https://ClinicalTrials.gov/show/NCT01848067
2528,Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery,Completed,Has Results,Cataract|Retinal Edema|Inflammation,Drug: Prolensa (bromfenac 0.07%)|Drug: Ilevro (nepafenac 0.3%),Melissa Toyos|Bausch & Lomb Incorporated|Toyos Clinic,Melissa Toyos,Bausch & Lomb Incorporated,Toyos Clinic,,,,,Not Applicable,Other|Industry,Interventional,4/1/2013,8/23/2018,https://ClinicalTrials.gov/show/NCT01847638
2529,Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions,Completed,Has Results,Lung Cancer,Procedure: Video-Assisted Thoracic Surgery (VATS) wedge resection,Brigham and Women's Hospital|Siemens Medical Solutions USA - CSG,Brigham and Women's Hospital,Siemens Medical Solutions USA - CSG,,,,,,Phase 2,Other|Industry,Interventional,4/13/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT01847209
2530,Gevokizumab for Active Scleritis,Completed,Has Results,Scleritis,Device: Gevokizumab,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1|Phase 2,NIH|Industry,Interventional,3/13/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01835132
2531,E-Stim and Achilles Tendon Repair Study,Completed,Has Results,Achilles Tendon Rupture,Device: Compex® muscle stimulator|Device: (inactive) muscle stimulator,"Orthopedic Foot and Ankle Center, Ohio|DonJoy Orthotics","Orthopedic Foot and Ankle Center, Ohio",DonJoy Orthotics,,,,,,Not Applicable,Other|Industry,Interventional,1/13/2019,9/22/2016,https://ClinicalTrials.gov/show/NCT01833936
2532,A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection,Completed,Has Results,Adenocarcinoma of the Prostate,Drug: Pazopanib|Other: Placebo,University of Utah|Novartis,University of Utah,Novartis,,,,,,Phase 2,Other|Industry,Interventional,8/13/2019,8/9/2018,https://ClinicalTrials.gov/show/NCT01832259
2533,Lactoferrin Treatment in HIV Patients,Completed,Has Results,HIV Infection,Drug: Recombinant Lactoferrin|Drug: Placebo,Jason Baker|Ventria Bioscience|Hennepin Healthcare Research Institute.,Jason Baker,Ventria Bioscience,Hennepin Healthcare Research Institute.,,,,,Phase 2,Other|Industry,Interventional,9/14/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT01830595
2534,"Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial",Completed,Has Results,Fibromyalgia|Neurocognition,Drug: Milnacipran|Drug: Placebo,Duke University|Forest Laboratories,Duke University,Forest Laboratories,,,,,,Phase 3,Other|Industry,Interventional,7/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01829243
2535,Vilazodone for Corticosteroid-Induced Memory Impairment,Completed,Has Results,Memory Impairment,Drug: Vilazodone|Drug: Placebo|Drug: Hydrocortisone,University of Texas Southwestern Medical Center|Forest Laboratories,University of Texas Southwestern Medical Center,Forest Laboratories,,,,,,Phase 2,Other|Industry,Interventional,12/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01828515
2536,Impairment of Reading Ability in Dry Eye Patients,Completed,Has Results,Dry Eye Syndromes,Other: 30 minutes sustained reading|Other: Dry eye exam,Johns Hopkins University|Allergan,Johns Hopkins University,Allergan,,,,,,,Other|Industry,Observational,4/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01826812
2537,Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients,Completed,Has Results,Type-2 Diabetes Mellitus|Coronary Artery Disease,Drug: Ticagrelor + Aspirin|Drug: Clopidogrel + Aspirin,Juan J Badimon|AstraZeneca|Icahn School of Medicine at Mount Sinai,Juan J Badimon,AstraZeneca,Icahn School of Medicine at Mount Sinai,,,,,Phase 4,Other|Industry,Interventional,7/13/2019,5/10/2016,https://ClinicalTrials.gov/show/NCT01823510
2538,Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS),Completed,Has Results,Myelodysplastic Syndromes,Drug: INCB024360,H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation,H. Lee Moffitt Cancer Center and Research Institute,Incyte Corporation,,,,,,Phase 2,Other|Industry,Interventional,7/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01822691
2539,A Study to Evaluate the Effectiveness of Laser-Ablated Implant-Abutments to Promote Tissue Healing,Completed,Has Results,"Jaw, Edentulous, Partially",Device: Dental implant-abutments,"University of Alabama at Birmingham|BioHorizons, Inc.",University of Alabama at Birmingham,"BioHorizons, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01822223
2540,Performance of MicroTextured Dental Implants,Completed,Has Results,Partially Edentulous Jaw,Device: Microtextured dental implant treatment|Device: Dental implant treatment,University of Alabama at Birmingham|Zimmer Dental,University of Alabama at Birmingham,Zimmer Dental,,,,,,Not Applicable,Other|Industry,Interventional,5/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01821417
2541,Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly,Completed,Has Results,Acromegaly,,Massachusetts General Hospital|Ipsen,Massachusetts General Hospital,Ipsen,,,,,,,Other|Industry,Observational,4/13/2019,3/30/2016,https://ClinicalTrials.gov/show/NCT01819883
2542,Plerixafor for Stem Cell Mobilization in Normal Donors,Completed,Has Results,Blood And Marrow Transplantation,Drug: Filgrastim|Drug: Plerixafor|Procedure: Apheresis Procedure,"M.D. Anderson Cancer Center|Proteonomix, Inc.",M.D. Anderson Cancer Center,"Proteonomix, Inc.",,,,,,Phase 2,Other|Industry,Interventional,10/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01818284
2543,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,Completed,Has Results,Clostridium Difficile Infection,Drug: Vancomycin|Drug: Fidaxomicin,Hartford Hospital|Optimer Pharmaceuticals LLC,Hartford Hospital,Optimer Pharmaceuticals LLC,,,,,,Phase 4,Other|Industry,Interventional,10/17/2012,12/15/2014,https://ClinicalTrials.gov/show/NCT01818141
2544,Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient,Completed,Has Results,Pectus Excavatum,Device: ON-Q soaker catheter system|Drug: Epidural (ropivicaine 0.25%),Mayo Clinic|Halyard Health,Mayo Clinic,Halyard Health,,,,,,Not Applicable,Other|Industry,Interventional,4/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01816477
2545,Sequencing Treatments for Mothers With ADHD and Their At - Risk Children,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Vyvanse (lisdexamphetamine)|Behavioral: Behavior Parent Training,Seattle Children's Hospital|Shire,Seattle Children's Hospital,Shire,,,,,,Phase 4,Other|Industry,Interventional,10/12/2019,5/1/2017,https://ClinicalTrials.gov/show/NCT01816074
2546,Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS,Completed,Has Results,Ovarian Hyperstimulation Syndrome,Drug: hCG,UConn Health|Merck Sharp & Dohme Corp.,UConn Health,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,3/13/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01815138
2547,Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation,Completed,Has Results,Inflammatory Responses,Drug: 4 g prescription omega-3 concentrate|Drug: Placebo,Penn State University|Pronova BioPharma,Penn State University,Pronova BioPharma,,,,,,Not Applicable,Other|Industry,Interventional,5/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01813110
2548,Dalfampridine and Gait in Spinocerebellar Ataxias,Completed,Has Results,Spinocerebellar Ataxias Type 1|Spinocerebellar Ataxias Type 2|Spinocerebellar Ataxias Type 3|Spinocerebellar Ataxias Type 6,Drug: Dalfampridine|Drug: Placebo,University of Florida|Acorda Therapeutics,University of Florida,Acorda Therapeutics,,,,,,Not Applicable,Other|Industry,Interventional,2/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01811706
2549,Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine,Completed,Has Results,Migraines,Drug: Ketorolac|Drug: Sumatriptan|Drug: Placebo,"Johns Hopkins University|American Regent, Inc.",Johns Hopkins University,"American Regent, Inc.",,,,,,Phase 4,Other|Industry,Interventional,2/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01807234
2550,Efficacy of Socket Grafting for Alveolar Ridge Preservation,Completed,Has Results,Atrophy of Edentulous Alveolar Ridge,Procedure: Tooth extraction and grafting with allograft|Procedure: Tooth extraction,University of Iowa|Osteogenics Biomedical,University of Iowa,Osteogenics Biomedical,,,,,,Not Applicable,Other|Industry,Interventional,3/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01794806
2551,Ozurdex for Retinal Vein Occlusion Study (ORVO Study),Completed,Has Results,Retinal Vein Occlusion,Drug: dexamethasone implant,Johns Hopkins University|Allergan,Johns Hopkins University,Allergan,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,2/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01790685
2552,Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting,Completed,Has Results,Community Acquired Pneumonia,Other: Focused Health Education,Carilion Clinic|Merck Sharp & Dohme Corp.,Carilion Clinic,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,1/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01787838
2553,Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin,Completed,Has Results,Metabolic Syndrome,Drug: Atorvastatin|Other: Placebo,University of Rochester|Pfizer,University of Rochester,Pfizer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/4/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01785615
2554,Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery,Completed,Has Results,Lung Tumor,Drug: IV Acetaminophen|Drug: Saline Placebo,Weill Medical College of Cornell University|Mallinckrodt,Weill Medical College of Cornell University,Mallinckrodt,,,,,,Phase 4,Other|Industry,Interventional,6/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01783236
2555,"The Beneficial Effects of Healthy Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People",Completed,Has Results,Obesity,Behavioral: High Protein|Behavioral: Low Protein,"University of Missouri-Columbia|Solae, LLC",University of Missouri-Columbia,"Solae, LLC",,,,,,Not Applicable,Other|Industry,Interventional,1/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01781286
2556,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,Completed,Has Results,Melanoma,Drug: Vemurafenib,"Yale University|Genentech, Inc.",Yale University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,4/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01781026
2557,Effect of a Single Dose of Cranberry Beverage on Inflammation and Oxidative Stress,Completed,Has Results,Inflammation,Other: Low Calorie Cranberry Juice Cocktail|Other: Cranberry Extract Beverage|Other: Non-Cranberry Beverage,"Washington State University|Ocean Spray Cranberries, Inc.",Washington State University,"Ocean Spray Cranberries, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01780922
2558,Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson,Completed,Has Results,Ischemic Heart Disease,Drug: Regadenoson,"Washington University School of Medicine|Astellas Pharma US, Inc.",Washington University School of Medicine,"Astellas Pharma US, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01779869
2559,Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib,Completed,Has Results,Relapse Multiple Myeloma|Refractory Multiple Myeloma,Drug: Carfilzomib,Ajai Chari|Amgen|Icahn School of Medicine at Mount Sinai,Ajai Chari,Amgen,Icahn School of Medicine at Mount Sinai,,,,,Phase 2,Other|Industry,Interventional,9/13/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01775553
2560,Effect of Azilsartan on Aldosterone in Postmenopausal Females,Completed,Has Results,Hypertension,Drug: Azilsartan medoximil|Drug: Placebo,University of Chicago|Takeda,University of Chicago,Takeda,,,,,,Not Applicable,Other|Industry,Interventional,1/13/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01774591
2561,The Passy Muir Swallowing Self Training Device,Completed,Has Results,Oropharyngeal Dysphagia,Device: Vibrotactile stimulation,James Madison University|Passy Muir Inc.,James Madison University,Passy Muir Inc.,,,,,,,Other|Industry,Observational,1/1/2013,2/22/2016,https://ClinicalTrials.gov/show/NCT01765673
2562,Nonin 4 Wavelength Cerebral Oximeter Study,Completed,Has Results,Healthy,Device: Reduction of inspired oxygen,"Duke University|Nonin Medical, Inc",Duke University,"Nonin Medical, Inc",,,,,,Not Applicable,Other|Industry,Interventional,9/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01762722
2563,A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy,Completed,Has Results,Psoriasis,Drug: Taclonex Topical Suspension,University of Pittsburgh|LEO Pharma,University of Pittsburgh,LEO Pharma,,,,,,Phase 4,Other|Industry,Interventional,1/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01761019
2564,Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone,Completed,Has Results,Heroin Dependence,Drug: Intranasal challenge drug,New York State Psychiatric Institute|Indivior Inc.,New York State Psychiatric Institute,Indivior Inc.,,,,,,Phase 3,Other|Industry,Interventional,5/9/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01760473
2565,C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation,Completed,Has Results,Neuromyelitis Optica,Drug: C1-esterase inhibitor (Cinryze),Michael Levy|ViroPharma|Johns Hopkins University,Michael Levy,ViroPharma,Johns Hopkins University,,,,,Phase 1,Other|Industry,Interventional,1/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01759602
2566,Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting,Completed,Has Results,Type 1 Diabetes,"Drug: Closed loop with sensor and Insulin|Drug: Closed loop with sensor, Insulin and Liraglutide",Albert Einstein College of Medicine|Medtronic,Albert Einstein College of Medicine,Medtronic,,,,,,Phase 2,Other|Industry,Interventional,1/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01755416
2567,Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression,Completed,Has Results,Major Depression|Irritable Bowel Syndrome,Drug: Duloxetine,New York State Psychiatric Institute|Eli Lilly and Company,New York State Psychiatric Institute,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,12/8/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01754493
2568,"A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury",Completed,Has Results,Neuropathic Pain Due to Spinal Cord Injury,Drug: V158866|Drug: Placebo,Brigham and Women's Hospital|Vernalis (R&D) Ltd,Brigham and Women's Hospital,Vernalis (R&D) Ltd,,,,,,Phase 2,Other|Industry,Interventional,6/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01748695
2569,Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: vehicle foam|Drug: calcipotriene|Drug: calcipotriene + clobetasol propionate,"Leon Kircik, M.D.|Stiefel, a GSK Company|Derm Research, PLLC","Leon Kircik, M.D.","Stiefel, a GSK Company","Derm Research, PLLC",,,,,Phase 4,Other|Industry,Interventional,1/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01745133
2570,A Pilot Study of Oxaloacetate in Subjects With Treated PD,Completed,Has Results,Parkinson's Disease,Drug: Oxaloacetate (OAA)|Drug: Placebo,University of Kansas Medical Center|Terra Biological LLC,University of Kansas Medical Center,Terra Biological LLC,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,12/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01741701
2571,Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Gardasil,Wayne State University|Merck Sharp & Dohme Corp.,Wayne State University,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,1/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01741012
2572,Acromegaly Treatment Quality of Life Study,Completed,Has Results,Acromegaly,,Massachusetts General Hospital|Pfizer,Massachusetts General Hospital,Pfizer,,,,,,,Other|Industry,Observational,1/13/2019,12/19/2016,https://ClinicalTrials.gov/show/NCT01732406
2573,Impact of Ticagrelor Re-load on Pharmacodynamic Profiles,Completed,Has Results,Coronary Artery Disease,Drug: Ticagrelor 180mg|Drug: Ticagrelor 90mg,University of Florida|AstraZeneca,University of Florida,AstraZeneca,,,,,,Not Applicable,Other|Industry,Interventional,1/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01731041
2574,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebo,Kaleida Health|Novo Nordisk A/S,Kaleida Health,Novo Nordisk A/S,,,,,,Phase 3,Other|Industry,Interventional,11/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01722266
2575,Ranolazine for the Treatment of Chest Pain in HCM Patients,Completed,Has Results,Hypertrophic Cardiomyopathy,Drug: Ranolazine,Duke University|Gilead Sciences,Duke University,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,11/12/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01721967
2576,Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment,Completed,Has Results,Malocclusion,Device: Micro-osteoperforation|Drug: Anesthestic|Other: Chlorhexidine,University of Florida|AlevoLogic LLC,University of Florida,AlevoLogic LLC,,,,,,Not Applicable,Other|Industry,Interventional,2/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01720797
2577,Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab,"University of California, Los Angeles|Genentech, Inc.","University of California, Los Angeles","Genentech, Inc.",,,,,,Phase 4,Other|Industry,Interventional,9/14/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT01717859
2578,Dental Implant Study Comparing Two Types of Metals Used for Dental Implants,Completed,Has Results,Tooth Replacement,Device: Zimmer Trabecular Metal Test Cylinder|Device: Zimmer Titanium Test Cylinder,"University of North Carolina, Chapel Hill|Zimmer Dental","University of North Carolina, Chapel Hill",Zimmer Dental,,,,,,Not Applicable,Other|Industry,Interventional,10/12/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01714024
2579,Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris,Completed,Has Results,Plaque Psoriasis,Drug: Taclonex,Wake Forest University|LEO Pharma|Wake Forest University Health Sciences,Wake Forest University,LEO Pharma,Wake Forest University Health Sciences,,,,,Phase 4,Other|Industry,Interventional,10/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01707043
2580,Accelerating Gastrointestinal Recovery,Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Alvimopan|Drug: Placebo,Jamie N. Bakkum-Gamez|Cubist Pharmaceuticals LLC|Mayo Clinic,Jamie N. Bakkum-Gamez,Cubist Pharmaceuticals LLC,Mayo Clinic,,,,,Phase 3,Other|Industry,Interventional,1/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01704651
2581,Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia,Completed,Has Results,Severe Aplastic Anemia|Very Severe Aplastic Anemia|Moderate Aplastic Anemia,Drug: Eltrombopag,University of Utah|Novartis,University of Utah,Novartis,,,,,,Phase 2,Other|Industry,Interventional,11/12/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01703169
2582,A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency,Completed,Has Results,Chronic Migraine,Drug: onabotulinumtoxinA|Drug: Topiramate|Drug: Placebo,"Cady, Roger, M.D.|Allergan","Cady, Roger, M.D.",Allergan,,,,,,Phase 4,Other|Industry,Interventional,10/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01700387
2583,Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes,Completed,Has Results,Basal Cell Carcinoma,Drug: vismodegib (150 mg PO daily),"Mayo Clinic|Genentech, Inc.",Mayo Clinic,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,1/14/2013,7/3/2018,https://ClinicalTrials.gov/show/NCT01700049
2584,"E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes",Completed,Has Results,Leukemia,Drug: E7070|Drug: Idarubicin|Drug: Cytarabine|Drug: Dexamethasone,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 2,Other|Industry,Interventional,2/1/2013,6/7/2017,https://ClinicalTrials.gov/show/NCT01692197
2585,Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence,Completed,Has Results,Opiate Dependence,Drug: very low dose naltrexone|Drug: extended release naltrexone|Drug: buprenorphine/naloxone,"Paolo Mannelli|Alkermes, Inc.|Duke University",Paolo Mannelli,"Alkermes, Inc.",Duke University,,,,,Phase 2,Other|Industry,Interventional,9/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01690546
2586,High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status,Completed,Has Results,Hypovitaminosis D,"Drug: 100,000 IU cholecalciferol|Drug: Placebo","Massachusetts General Hospital|Bio-Tech Pharmacal, Inc.",Massachusetts General Hospital,"Bio-Tech Pharmacal, Inc.",,,,,,Phase 3,Other|Industry,Interventional,1/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01689779
2587,The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease,Completed,Has Results,Breast Abnormalities,Device: molecular breast imaging (Discovery),University of Pittsburgh|GE Healthcare,University of Pittsburgh,GE Healthcare,,,,,,Not Applicable,Other|Industry,Interventional,9/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01687790
2588,Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects,Completed,Has Results,Polio Immunity,Drug: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose,Eastern Virginia Medical School|NanoPass Technologies Ltd,Eastern Virginia Medical School,NanoPass Technologies Ltd,,,,,,Phase 2,Other|Industry,Interventional,9/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01686503
2589,Vilazodone for Menopausal Hot Flashes,Completed,Has Results,Hot Flushes,Drug: vilazodone|Drug: placebo capsules,University of Pennsylvania|Forest Laboratories,University of Pennsylvania,Forest Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,11/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01680900
2590,Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,Completed,Has Results,Non-Small Cell Lung Cancer|Colorectal Cancer,Drug: Dovitinib,"University of California, Davis|Novartis","University of California, Davis",Novartis,,,,,,Phase 2,Other|Industry,Interventional,2/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01676714
2591,A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus,Completed,Has Results,Macular Edema|Diabetes Mellitus,Drug: Dexamethasone intravitreal implant|Drug: Steroid plus NSAID eye drop combination therapy,Retinal Consultants of Arizona|Allergan,Retinal Consultants of Arizona,Allergan,,,,,,Phase 2,Other|Industry,Interventional,11/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01673191
2592,Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®),Completed,Has Results,Healthy Adult Volunteers,Device: HFNC|Device: CPAP,"University of Maryland|Vapotherm, Inc.",University of Maryland,"Vapotherm, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01672242
2593,Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation,Completed,Has Results,Chronic Kidney Disease|Cardiovascular Disease,,Vanderbilt University Medical Center|Merck Sharp & Dohme Corp.,Vanderbilt University Medical Center,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,2/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01671605
2594,Dose Dense TC + Pegfilgrastim Support for Breast Cancer,Completed,Has Results,Female Breast Cancer,Drug: docetaxel + cyclophosphamide + pegfilgrastim,"University of Wisconsin, Madison|Amgen","University of Wisconsin, Madison",Amgen,,,,,,Phase 2,Other|Industry,Interventional,6/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01671319
2595,Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR),Completed,Has Results,Common Cold,Dietary Supplement: Bifidobacterium lactis Bl-04|Dietary Supplement: Placebo|Biological: Rhinovirus,University of Virginia|DuPont Nutrition and Health,University of Virginia,DuPont Nutrition and Health,,,,,,Not Applicable,Other|Industry,Interventional,8/12/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01669603
2596,Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.,Completed,Has Results,Alpha 1 Antitrypsin Deficiency,Drug: Alpha-1 Antitrypsin (human),"Michael Campos, MD|CSL Behring|University of Miami","Michael Campos, MD",CSL Behring,University of Miami,,,,,Phase 2,Other|Industry,Interventional,7/12/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01669421
2597,Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography,Completed,Has Results,Breast Cancer,Device: Tomosynthesis|Device: Conventional,"Massachusetts General Hospital|Hologic, Inc.",Massachusetts General Hospital,"Hologic, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/7/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01669148
2598,Comparison of Wound Bed Establishment in Facial Burns,Completed,Has Results,Burns,Drug: Enzymatic agent|Drug: Bacitracin,University of Louisville|Healthpoint,University of Louisville,Healthpoint,,,,,,Phase 4,Other|Industry,Interventional,2/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01668030
2599,Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease,Completed,Has Results,Microvascular Angina,Drug: Nebivolol,Massachusetts General Hospital|Forest Laboratories,Massachusetts General Hospital,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,4/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01665508
2600,Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin,Completed,Has Results,Intraoperative Complications|Thermal Injury|Electrocoagulation,Device: Covidien Triad monopolar generator,"University of Colorado, Denver|Medtronic - MITG","University of Colorado, Denver",Medtronic - MITG,,,,,,Phase 3,Other|Industry,Interventional,11/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01664806
2601,Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma,Completed,Has Results,Anaplastic Astrocytomas|Anaplastic Oligodendrogliomas|Glioblastomas (GBM),Drug: Etirinotecan pegol,Lawrence Recht|Nektar Therapeutics|Stanford University,Lawrence Recht,Nektar Therapeutics,Stanford University,,,,,Phase 2,Other|Industry,Interventional,7/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01663012
2602,AMBU AScope2 Fiberoptic Intubation Versus Fastrach Intubating LMA,Completed,Has Results,Supraglottic Airway,Device: AMBU Aura-I/aScope 2|Device: LMA Fastrach Single Use,"The University of Texas Health Science Center, Houston|Ambu A/S","The University of Texas Health Science Center, Houston",Ambu A/S,,,,,,Not Applicable,Other|Industry,Interventional,7/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01656967
2603,Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image,Completed,Has Results,"Catheters, With or Without Malposition|Image Interpretation, Computer Assisted",,Georgetown University|Riverain Technologies,Georgetown University,Riverain Technologies,,,,,,,Other|Industry,Observational,8/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01655329
2604,Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI,Completed,Has Results,Myocardial Ischemia,Drug: Regadenoson|Drug: gadofoveset trisodium,"Northwestern University|Astellas Pharma Global Development, Inc.",Northwestern University,"Astellas Pharma Global Development, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01655043
2605,Efficacy and Safety of Synera in Osteoarthritis Pain,Completed,Has Results,Knee Osteoarthritis,Drug: Synera|Drug: Inactive patch,Thomas J. Schnitzer|Nuvo Research Inc.|Northwestern University,Thomas J. Schnitzer,Nuvo Research Inc.,Northwestern University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01654302
2606,Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting,Completed,Has Results,Influenza,Biological: High Dose Inactivated Influenza Vaccine|Biological: Standard Dose Inactivated Influenza Vaccine,"University of Pittsburgh|Sanofi Pasteur, a Sanofi Company",University of Pittsburgh,"Sanofi Pasteur, a Sanofi Company",,,,,,Phase 4,Other|Industry,Interventional,11/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01654224
2607,Effect of Phytochemicals From Theobroma Cacao on Mental Energy,Completed,Has Results,Mental Fatigue,Other: Caffeinated cocoa|Other: Cocoa|Other: Caffeine|Other: Placebo,University of Georgia|The Hershey Company,University of Georgia,The Hershey Company,,,,,,Not Applicable,Other|Industry,Interventional,7/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01651793
2608,Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations,Completed,Has Results,Coronary Artery Disease,Behavioral: Motivational Interviewing (MINT)|Behavioral: Mailed DVD,"University of Miami|Humana, Inc",University of Miami,"Humana, Inc",,,,,,Not Applicable,Other|Industry,Interventional,1/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01651208
2609,"Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)",Completed,Has Results,Multiple Myeloma,Drug: Panobinostat|Drug: Lenalidomide|Drug: Dexamethasone,Ajai Chari|Novartis Pharmaceuticals|Icahn School of Medicine at Mount Sinai,Ajai Chari,Novartis Pharmaceuticals,Icahn School of Medicine at Mount Sinai,,,,,Phase 2,Other|Industry,Interventional,7/12/2019,12/21/2016,https://ClinicalTrials.gov/show/NCT01651039
2610,Impact of Expanded Peri Operative Warming,Completed,Has Results,Hypothermia|Complications,Device: Warming Gown|Other: Standard of care warming,Genesys Regional Medical Center|3M,Genesys Regional Medical Center,3M,,,,,,Not Applicable,Other|Industry,Interventional,8/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01649596
2611,Green Tea Lozenges for the Management of Dry Mouth,Completed,Has Results,Xerostomia|Sjogren Syndrome|Dry Mouth,Dietary Supplement: MighTeaFlow|Dietary Supplement: Xylitol,Augusta University|GlaxoSmithKline,Augusta University,GlaxoSmithKline,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01647737
2612,Bacterial Genomic Sequencing in Overactive Bladder,Completed,Has Results,Overactive Bladder,Drug: Solifenacin,"Loyola University|Astellas Pharma US, Inc.",Loyola University,"Astellas Pharma US, Inc.",,,,,,Phase 2,Other|Industry,Interventional,7/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01642277
2613,Antithrombotic Effects of Ticagrelor Versus Clopidogrel,Completed,Has Results,Acute Coronary Syndrome,Drug: Ticagrelor + ASA + Bivalirudin|Drug: Clopidogrel + ASA + Bivalirudin,Juan J Badimon|AstraZeneca|Icahn School of Medicine at Mount Sinai,Juan J Badimon,AstraZeneca,Icahn School of Medicine at Mount Sinai,,,,,Phase 4,Other|Industry,Interventional,7/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01642238
2614,Evaluation of Electrical Nerve Stimulation (TENS) Therapy for Pain Relief Following Total Knee Arthroplasty (TKA),Completed,Has Results,"Osteoarthritis, Knee|Arthritis|Pain",Device: EMPI Select TENS|Device: Placebo EMPI Select TENS,The Cleveland Clinic|DJO Incorporated,The Cleveland Clinic,DJO Incorporated,,,,,,Not Applicable,Other|Industry,Interventional,12/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01641471
2615,Assessing Tolerability of Avonex Intramuscular Injections,Completed,Has Results,Multiple Sclerosis,Drug: Avonex,Saint Francis Care|Biogen,Saint Francis Care,Biogen,,,,,,Not Applicable,Other|Industry,Interventional,5/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01641120
2616,Varenicline for Light Smokers,Completed,Has Results,Smoking,Drug: Varenicline|Drug: Placebo,Mayo Clinic|Pfizer,Mayo Clinic,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01639560
2617,Negative Pressure Wound Therapy After Cesarean Delivery,Completed,Has Results,"Major Puerperal Infection, Postpartum|Wound Complications|Wound Seroma|Caesarean Section Wound Separation|Wound Infection",Device: Prevena negative pressure wound system,"Abbey Hardy-Fairbanks|Kinetic Concepts, Inc.|University of Iowa",Abbey Hardy-Fairbanks,"Kinetic Concepts, Inc.",University of Iowa,,,,,Not Applicable,Other|Industry,Interventional,8/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01637870
2618,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Completed,Has Results,Glioblastoma,Drug: Cilengitide|Drug: Temozolomide|Radiation: Radiotherapy,"EMD Serono|European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA, Darmstadt, Germany",EMD Serono,European Organisation for Research and Treatment of Cancer - EORTC,"Merck KGaA, Darmstadt, Germany",,,,,Phase 3,Industry|Other,Interventional,9/8/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00689221
2619,Combination Gel and Vascular ND in Mild to Moderate Rosacea,Completed,Has Results,Rosacea,Drug: Azelaic acid|Device: Nd:Yag laser,Wake Forest University Health Sciences|Bayer,Wake Forest University Health Sciences,Bayer,,,,,,Not Applicable,Other|Industry,Interventional,7/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01631656
2620,Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma,Completed,Has Results,HIV,Drug: Etravirine pharmacokinetics in breast milk and plasma,"University of Southern California|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",University of Southern California,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Not Applicable,Other|Industry,Interventional,4/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01625169
2621,"Esthetic, Clinical and Radiographic Outcomes of Immediately Placed Implants (Type 1) and Early Placed Implants (Type 2)",Completed,Has Results,"Jaw, Edentulous, Partially|Acquired Absence of Single Tooth",Procedure: Placement of a dental implant,The University of Texas Health Science Center at San Antonio|Institut Straumann AG,The University of Texas Health Science Center at San Antonio,Institut Straumann AG,,,,,,Not Applicable,Other|Industry,Interventional,12/10/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01623739
2622,Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia,Completed,Has Results,Type 1 Diabetes,Drug: Apidra|Drug: Humalog|Drug: Novolog,University of Florida|Sanofi,University of Florida,Sanofi,,,,,,Not Applicable,Other|Industry,Interventional,6/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01621776
2623,Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects,Completed,Has Results,Healthy Subjects,Device: Hypertonic Saline,"University of North Carolina, Chapel Hill|Gilead Sciences","University of North Carolina, Chapel Hill",Gilead Sciences,,,,,,Not Applicable,Other|Industry,Interventional,6/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01617369
2624,Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept,Completed,Has Results,Exudative Macular Degeneration,Drug: Aflibercept,Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic,Rishi Singh,Regeneron Pharmaceuticals,The Cleveland Clinic,,,,,Phase 4,Other|Industry,Interventional,6/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01617148
2625,Effects of Kuvan on Melatonin Secretion,Completed,Has Results,Phenylketonuria (PKU),Drug: Kuvan|Dietary Supplement: Large Neutral Amino Acid Therapy,University of Southern California|BioMarin Pharmaceutical,University of Southern California,BioMarin Pharmaceutical,,,,,,Phase 4,Other|Industry,Interventional,5/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01617070
2626,Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study),Completed,Has Results,Diabetic Macular Edema|Epiretinal Membrane,Drug: Ozurdex,The Cleveland Clinic|Allergan,The Cleveland Clinic,Allergan,,,,,,Phase 4,Other|Industry,Interventional,7/12/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT01613716
2627,A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma,Completed,Has Results,Lipoma,Drug: Collagenase Clostridium Histolyticum,"Zachary Gerut|Advance Biofactures Corporation|Gerut, Zachary, M.D.",Zachary Gerut,Advance Biofactures Corporation,"Gerut, Zachary, M.D.",,,,,Phase 2,Other|Industry,Interventional,5/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01613313
2628,Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression,Completed,Has Results,Menopausal and Other Perimenopausal Disorders,Drug: Mirena|Drug: Estradiol|Drug: Placebo Gel,"University of Colorado, Denver|Bayer","University of Colorado, Denver",Bayer,,,,,,Not Applicable,Other|Industry,Interventional,4/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01613131
2629,Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting,Completed,Has Results,Depression,Other: Pharmacogenomic algorithm,Mayo Clinic|Assurex Health Home,Mayo Clinic,Assurex Health Home,,,,,,Not Applicable,Other|Industry,Interventional,1/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01610063
2630,Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery,Completed,Has Results,Chronic Sinusitis,Drug: IV Acetaminophen|Drug: Placebo,"The University of Texas Health Science Center, Houston|Mallinckrodt","The University of Texas Health Science Center, Houston",Mallinckrodt,,,,,,Not Applicable,Other|Industry,Interventional,7/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01608308
2631,Vilazodone for Treatment of Geriatric Depression,Completed,Has Results,Major Depressive Disorder,Drug: Vilazodone; Viibryd|Drug: Paroxetine; Paxil,"University of California, Los Angeles|Forest Laboratories","University of California, Los Angeles",Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,7/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01608295
2632,Intravenous Acetaminophen in Craniotomy,Completed,Has Results,Postoperative Pain,Drug: Acetaminophen|Drug: Placebo,"The University of Texas Health Science Center, Houston|Mallinckrodt","The University of Texas Health Science Center, Houston",Mallinckrodt,,,,,,Phase 4,Other|Industry,Interventional,5/2/2012,3/30/2016,https://ClinicalTrials.gov/show/NCT01598701
2633,Nebivolol and Endothelial Regulation of Fibrinolysis (NERF),Completed,Has Results,Prehypertension|Hypertension,Drug: Nebivolol|Drug: Metoprolol|Drug: Placebo|Other: Bradykinin|Other: Saline|Other: Vitamin C,"University of Colorado, Boulder|Forest Laboratories","University of Colorado, Boulder",Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,2/12/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT01595516
2634,Acute Effect of Exenatide on Brain Glucose Metabolism,Completed,Has Results,Impaired Glucose Tolerance (IGT)|Diabetes,Drug: Exenatide|Drug: Placebo,"The University of Texas Health Science Center at San Antonio|Amylin Pharmaceuticals, LLC.",The University of Texas Health Science Center at San Antonio,"Amylin Pharmaceuticals, LLC.",,,,,,Phase 4,Other|Industry,Interventional,7/10/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01588418
2635,"Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress",Completed,Has Results,Cardiovascular Disease,Drug: Efavirenz|Drug: Rilpivirine,"Indiana University|Janssen Services, LLC",Indiana University,"Janssen Services, LLC",,,,,,Phase 4,Other|Industry,Interventional,7/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01585038
2636,Resin Infiltration to Arrest Early Tooth Decay,Completed,Has Results,Dental Caries,Device: Resin infiltration|Device: Sham treatment,University of Michigan|DMG Dental Material Gesellschaft mbH,University of Michigan,DMG Dental Material Gesellschaft mbH,,,,,,Not Applicable,Other|Industry,Interventional,3/13/2019,12/31/2017,https://ClinicalTrials.gov/show/NCT01584024
2637,Herpes Simplex Type 1 Suppression in Hepatitis C,Completed,Has Results,Chronic Hepatitis C Infection,Drug: Valacyclovir|Drug: Placebo,VA Office of Research and Development|GlaxoSmithKline,VA Office of Research and Development,GlaxoSmithKline,,,,,,Phase 2,U.S. Fed|Industry,Interventional,4/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01580995
2638,Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer,Completed,Has Results,Head and Neck Cancer,Radiation: Intensity Modulated Radiation Therapy,Stanford University|Varian Medical Systems,Stanford University,Varian Medical Systems,,,,,,Not Applicable,Other|Industry,Interventional,8/11/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01576939
2639,Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema|Non-proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy,Drug: dexamethasone intravitreal implant|Drug: intravitreal bevacizumab,Retina Macula Institute|Allergan,Retina Macula Institute,Allergan,,,,,,Phase 2,Other|Industry,Interventional,4/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01571232
2640,PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors,Completed,Has Results,Bladder Cancer,Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors|Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors,Emory University|Olympus,Emory University,Olympus,,,,,,Not Applicable,Other|Industry,Interventional,9/12/2019,3/28/2017,https://ClinicalTrials.gov/show/NCT01567462
2641,Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects,Completed,Has Results,Obesity,Drug: Tigecycline,Manjunath Prakash Pai|Pfizer|University of Michigan,Manjunath Prakash Pai,Pfizer,University of Michigan,,,,,Phase 4,Other|Industry,Interventional,3/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01560143
2642,Duloxetine in Osteoarthritis (OA) Pain,Completed,Has Results,Osteoarthritis,Drug: Duloxetine|Drug: Sugar pill,Northwestern University|Eli Lilly and Company,Northwestern University,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,3/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01558700
2643,Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myeloid Leukemia With 11q23-abnormality in Relapse,Drug: Temozolomide|Drug: Vorinostat,Steven E. Coutre|Merck Sharp & Dohme Corp.|Stanford University,Steven E. Coutre,Merck Sharp & Dohme Corp.,Stanford University,,,,,Phase 2,Other|Industry,Interventional,5/1/2013,11/17/2014,https://ClinicalTrials.gov/show/NCT01550224
2644,Once-Daily Asenapine for Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Asenapine 10 mg daily in the evening|Drug: Asenapine 5 mg twice daily,Duke University|Merck Sharp & Dohme Corp.,Duke University,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,4/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01549041
2645,IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery,Completed,Has Results,Acute Pain|Hyperalgesia,Drug: IV acetaminophen|Drug: Placebo,University of Washington|Mallinckrodt,University of Washington,Mallinckrodt,,,,,,Phase 4,Other|Industry,Interventional,7/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01544062
2646,Study for Recalcitrant Age Related Macular Degeneration,Completed,Has Results,Age Related Macular Degeneration,Drug: aflibercept 2.0 mg,"David M. Brown, M.D.|Regeneron Pharmaceuticals|Greater Houston Retina Research","David M. Brown, M.D.",Regeneron Pharmaceuticals,Greater Houston Retina Research,,,,,Phase 4,Other|Industry,Interventional,2/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01543568
2647,A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans,Completed,Has Results,Intestinal FDG Uptake,Drug: Rifaximin,"Beth Israel Deaconess Medical Center|Bausch Health Americas, Inc.",Beth Israel Deaconess Medical Center,"Bausch Health Americas, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01542541
2648,"IL1-TRAP, Rilonacept, in Systemic Sclerosis",Completed,Has Results,Scleroderma|Systemic Sclerosis|Diffuse Scleroderma|Diffuse Systemic Sclerosis,Drug: Rilonacept|Other: Placebo,Boston University|Regeneron Pharmaceuticals,Boston University,Regeneron Pharmaceuticals,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/11/2019,8/11/2017,https://ClinicalTrials.gov/show/NCT01538719
2649,Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma,Completed,Has Results,Lymphoma,Drug: Y Zevalin|Drug: In Zevalin|Drug: Rituxan|Drug: BCNU|Drug: VP -16|Drug: Ara-C|Drug: Melphalan|Procedure: Stem Cell Infusion|Drug: G-CSF,M.D. Anderson Cancer Center|Biogen,M.D. Anderson Cancer Center,Biogen,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/3/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01538472
2650,Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma,Completed,Has Results,Acute Coagulopathy,Biological: Blood product transfusion based on conventional coagulation tests.|Biological: Blood product transfusion based on rapid thrombelastography (r-TEG) results.,Denver Health and Hospital Authority|Haemonetics Corporation,Denver Health and Hospital Authority,Haemonetics Corporation,,,,,,Not Applicable,Other|Industry,Interventional,9/10/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01536496
2651,Comparison of Contrast Agents During CT Angiography,Completed,Has Results,Contrast Enhancement on Cardiac CT,Diagnostic Test: contrast agent,Los Angeles Biomedical Research Institute|General Electric,Los Angeles Biomedical Research Institute,General Electric,,,,,,Not Applicable,Other|Industry,Interventional,1/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01534975
2652,Effect of Aged Garlic Extract on Atherosclerosis,Completed,Has Results,Metabolic Syndrome,Drug: aged garlic extract|Drug: placebo,"Los Angeles Biomedical Research Institute|Wakunaga Pharmaceutical Co., Ltd.",Los Angeles Biomedical Research Institute,"Wakunaga Pharmaceutical Co., Ltd.",,,,,,Phase 4,Other|Industry,Interventional,5/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01534910
2653,Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,Completed,Has Results,Papillary Thyroid Carcinoma,Drug: GSK2118436,Massachusetts General Hospital|GlaxoSmithKline,Massachusetts General Hospital,GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,7/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01534897
2654,Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM),Completed,Has Results,Myeloma,Drug: Lenalidomide|Drug: Bortezomib|Drug: Siltuximab|Drug: Dexamethasone|Behavioral: Questionnaires,"M.D. Anderson Cancer Center|Janssen Services, LLC",M.D. Anderson Cancer Center,"Janssen Services, LLC",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01531998
2655,Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors,Completed,Has Results,Basal Cell Carcinoma,Drug: LDE225,Anne Chang|Novartis|Stanford University,Anne Chang,Novartis,Stanford University,,,,,Not Applicable,Other|Industry,Interventional,2/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01529450
2656,Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy,Completed,Has Results,Smoking,Behavioral: Acceptance Therapy (ACT)|Other: Cognitive Behavioral Therapy (CBT),Fred Hutchinson Cancer Research Center|Alere Wellbeing,Fred Hutchinson Cancer Research Center,Alere Wellbeing,,,,,,Not Applicable,Other|Industry,Interventional,3/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01525420
2657,Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma,Completed,Has Results,Adenoid Cystic Carcinoma,Drug: Dovitinib (TKI258),University of Virginia|Novartis Pharmaceuticals,University of Virginia,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,3/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01524692
2658,Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia,Completed,Has Results,"Pneumonia, Bacterial|Community-acquired",Drug: Ceftaroline|Drug: Levofloxacin,"Gary E. Stein, Pharm.D.|Forest Laboratories|Michigan State University","Gary E. Stein, Pharm.D.",Forest Laboratories,Michigan State University,,,,,Phase 4,Other|Industry,Interventional,2/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01524302
2659,Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations,Completed,Has Results,Hepatitis C,,University of Cincinnati|Merck Sharp & Dohme Corp.,University of Cincinnati,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,1/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01517529
2660,Brain Imaging of Lidoderm for Chronic Back Pain,Completed,Has Results,Low Back Pain,Drug: lidocaine|Drug: placebo,Northwestern University|Endo Pharmaceuticals,Northwestern University,Endo Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,1/4/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01515540
2661,Treatment of Diabetes After Gastric Bypass With Sitagliptin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin phosphate|Other: Placebo,Blandine Laferrere|Merck Sharp & Dohme Corp.|Columbia University,Blandine Laferrere,Merck Sharp & Dohme Corp.,Columbia University,,,,,Not Applicable,Other|Industry,Interventional,7/12/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01512797
2662,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,Completed,Has Results,BRAF Mutant Metastatic Melanoma,Drug: BKM120 Combined with Vemurafenib (PLX4032),"University of California, San Francisco|Novartis","University of California, San Francisco",Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/9/2012,3/21/2017,https://ClinicalTrials.gov/show/NCT01512251
2663,Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection,Completed,Has Results,Cytomegalovirus Disease,Drug: Valganciclovir|Biological: CMV hyperimmune globulin,Medical University of South Carolina|CSL Behring,Medical University of South Carolina,CSL Behring,,,,,,Phase 4,Other|Industry,Interventional,11/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01509404
2664,Adding Liraglutide to High Dose Insulin: Breaking the Cycle,Completed,Has Results,Type 2 Diabetes Mellitus|Obesity,Drug: Liraglutide|Drug: Saline,Ildiko Lingvay|Novo Nordisk A/S|University of Texas Southwestern Medical Center,Ildiko Lingvay,Novo Nordisk A/S,University of Texas Southwestern Medical Center,,,,,Phase 4,Other|Industry,Interventional,1/12/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01505673
2665,Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients,Completed,Has Results,Alzheimer's Disease,Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Behavioral: NICE Cognitive Training,Beth Israel Deaconess Medical Center|Neuronix Ltd,Beth Israel Deaconess Medical Center,Neuronix Ltd,,,,,,Not Applicable,Other|Industry,Interventional,12/10/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01504958
2666,Effect of Samples on Acne Treatment With Epiduo® Gel,Completed,Has Results,Acne Vulgaris,Drug: Adapalene + benzoyl peroxide samples|Drug: Adapalene + benzoyl peroxide from standard tube,"Wake Forest University|Galderma Laboratories, L.P.|Wake Forest University Health Sciences",Wake Forest University,"Galderma Laboratories, L.P.",Wake Forest University Health Sciences,,,,,Phase 4,Other|Industry,Interventional,12/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01504204
2667,Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients,Completed,Has Results,Hypertension,Drug: Metoprolol succinate|Drug: Nebivolol|Procedure: Forearm blood flow|Procedure: Microneurography|Procedure: Rhythmic handgrip exercise|Procedure: Lower body negative pressure|Drug: Angiotensin II,University of Texas Southwestern Medical Center|Forest Laboratories,University of Texas Southwestern Medical Center,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,4/9/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01502787
2668,Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients,Completed,Has Results,Hypertension,Drug: Metoprolol succinate|Drug: Nebivolol|Procedure: Non-invasive measurement of Cardiac Output (CO)|Procedure: Endothelial cell collection|Procedure: Microvascular perfusion assessment using Definity,University of Texas Southwestern Medical Center|Forest Laboratories,University of Texas Southwestern Medical Center,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01501929
2669,Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure,Completed,Has Results,Peripheral Artery Disease|Hypertension,Drug: nebivolol|Drug: Metoprolol succinate,Thomas Jefferson University|Forest Laboratories,Thomas Jefferson University,Forest Laboratories,,,,,,Phase 3,Other|Industry,Interventional,8/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01499134
2670,Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars,Completed,Has Results,Irreversible Pulpitis,Drug: IANB Articaine|Drug: SUP Articaine|Drug: SUP Lidocaine,University of Michigan|Dentsply International,University of Michigan,Dentsply International,,,,,,Phase 4,Other|Industry,Interventional,9/11/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01496846
2671,Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma,Completed,Has Results,Melanoma,Drug: Sylatron|Drug: Yervoy,H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.,H. Lee Moffitt Cancer Center and Research Institute,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,2/17/2012,8/29/2016,https://ClinicalTrials.gov/show/NCT01496807
2672,Radiographic Progression of Infiltrated Caries Lesions In-vivo,Completed,Has Results,Dental Caries,Device: Resin infiltration|Behavioral: Caries management,University of Michigan|DMG Dental Material Gesellschaft mbH,University of Michigan,DMG Dental Material Gesellschaft mbH,,,,,,Not Applicable,Other|Industry,Interventional,5/10/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01496456
2673,"IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma",Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Bendamustine + Rituximab + Pixantrone|Drug: Pegfilgrastim,"Anne Beaven, MD|CTI BioPharma|Duke University","Anne Beaven, MD",CTI BioPharma,Duke University,,,,,Phase 1,Other|Industry,Interventional,11/1/2011,2/17/2017,https://ClinicalTrials.gov/show/NCT01491841
2674,A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease,Completed,Has Results,Parkinson's Disease,"Drug: Ampyra first, then Placebo|Drug: placebo first, then Ampyra",University of Miami|Acorda Therapeutics,University of Miami,Acorda Therapeutics,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01491022
2675,Medtronic Treat to Range (TTR) Closed-Loop Control,Completed,Has Results,Diabetes Mellitus|Type 1 Diabetes|Metabolic and Nutritional Disorders,Device: TTR controller (Medtronic),Stanford University|Medtronic,Stanford University,Medtronic,,,,,,Not Applicable,Other|Industry,Interventional,12/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01490151
2676,Fosaprepitant in Patients Receiving Ifosfamide-based Regimen,Completed,Has Results,Sarcoma|Chemotherapy-induced Nausea and Vomiting|Effects of Chemotherapy|Adverse Effects of Medical Drugs,Drug: Fosaprepitant|Drug: Dexamethasone|Drug: 5HT3 receptor antagonist|Drug: Ifosfamide-based chemotherapy (AI)|Drug: Doxorubicin|Drug: Mesna|Drug: Ifosfamide|Drug: Vincristine,M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.,M.D. Anderson Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,5/12/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01490060
2677,Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR),Completed,Has Results,Coronary Artery Disease,Drug: FFR Measurement with IV Adenoscan® then with Regadenoson,"Ochsner Health System|Astellas Pharma Global Development, Inc.",Ochsner Health System,"Astellas Pharma Global Development, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,3/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01482169
2678,A Five-Year Metal-on-Metal Retrospective Clinical Study,Completed,Has Results,Osteoarthritis,Device: Metal-on-metal primary total hip arthroplasty (DePuy ),Anderson Orthopaedic Research Institute|DePuy Orthopaedics,Anderson Orthopaedic Research Institute,DePuy Orthopaedics,,,,,,,Other|Industry,Observational,12/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01481896
2679,Simplified Insulin Protocol Using Lantus in Elderly,Completed,Has Results,Diabetes,Drug: Glargine,Joslin Diabetes Center|Sanofi,Joslin Diabetes Center,Sanofi,,,,,,Phase 4,Other|Industry,Interventional,6/11/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01480843
2680,Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota,Completed,Has Results,Healthy Volunteers,Dietary Supplement: Saccharomyces boulardii|Drug: Amoxicillin Clavulanate,Beth Israel Deaconess Medical Center|Biocodex,Beth Israel Deaconess Medical Center,Biocodex,,,,,,Not Applicable,Other|Industry,Interventional,4/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01473368
2681,Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease,Completed,Has Results,Wilson Disease,Drug: Once a day Trientine,"Yale University|Bausch Health Americas, Inc.",Yale University,"Bausch Health Americas, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,1/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01472874
2682,An Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain,Completed,Has Results,Other Acute Pain,Drug: intranasal ketorolac,"The Cleveland Clinic|American Regent, Inc.",The Cleveland Clinic,"American Regent, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01471639
2683,"Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia",Completed,Has Results,Waldenstrom's Macroglobulinemia,Drug: Dexamethasone|Drug: Carfilzomib|Drug: Rituximab,Dana-Farber Cancer Institute|Amgen,Dana-Farber Cancer Institute,Amgen,,,,,,Phase 2,Other|Industry,Interventional,10/11/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01470196
2684,Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation,Completed,Has Results,Chronic Idiopathic Constipation,Drug: Lubiprostone,"Texas Tech University Health Sciences Center, El Paso|Takeda Pharmaceuticals North America, Inc.","Texas Tech University Health Sciences Center, El Paso","Takeda Pharmaceuticals North America, Inc.",,,,,,Phase 2|Phase 3,Other|Industry,Interventional,6/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01469819
2685,Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Fluocinonide cream,Wake Forest University|Medicis Pharmaceutical Corporation|Wake Forest University Health Sciences,Wake Forest University,Medicis Pharmaceutical Corporation,Wake Forest University Health Sciences,,,,,Phase 2,Other|Industry,Interventional,2/1/2012,8/17/2013,https://ClinicalTrials.gov/show/NCT01469767
2686,Topical Interferon Gamma-1b for Central Serous Chorioretinopathy,Completed,Has Results,Retinal Disease|Macular Disease,Drug: Interferon gamma-1b,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1|Phase 2,NIH|Industry,Interventional,10/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01468337
2687,Fondaparinux in Critically Ill Patients With Renal Failure,Completed,Has Results,Venous Thromboembolism,Drug: Fondaparinux,Wayne State University|GlaxoSmithKline,Wayne State University,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,11/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01467583
2688,Improving the Understanding of the Response to Vitamin D Supplementation,Completed,Has Results,Vitamin D Deficiency,Dietary Supplement: cholecalciferol|Dietary Supplement: Placebo,"University of Wisconsin, Madison|Merck Sharp & Dohme Corp.","University of Wisconsin, Madison",Merck Sharp & Dohme Corp.,,,,,,Phase 3,Other|Industry,Interventional,12/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01465178
2689,Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability,Completed,Has Results,Major Depressive Disorder,Drug: Iloperidone|Drug: Placebo,"Maurizio Fava, MD|Novartis Pharmaceuticals|Massachusetts General Hospital","Maurizio Fava, MD",Novartis Pharmaceuticals,Massachusetts General Hospital,,,,,Phase 4,Other|Industry,Interventional,4/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01464229
2690,Recombinant Interferon Alfa-2b in Treating Patients With Melanoma,Completed,Has Results,Stage IA Skin Melanoma|Stage IB Skin Melanoma|Stage IIA Skin Melanoma|Stage IIB Skin Melanoma|Stage IIC Skin Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma,Biological: recombinant interferon alfa-2b|Other: laboratory biomarker analysis,William Carson|Schering-Plough|Ohio State University Comprehensive Cancer Center,William Carson,Schering-Plough,Ohio State University Comprehensive Cancer Center,,,,,Not Applicable,Other|Industry,Interventional,4/22/2008,1/5/2014,https://ClinicalTrials.gov/show/NCT01460875
2691,Effect of Nuvigil on Fatigue,Completed,Has Results,Menopause,Drug: Armodafinil,Massachusetts General Hospital|Teva Pharmaceuticals USA,Massachusetts General Hospital,Teva Pharmaceuticals USA,,,,,,Phase 4,Other|Industry,Interventional,10/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01460628
2692,Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation,Completed,Has Results,Chronic Idiopathic Constipation,Drug: lubiprostone,"Dartmouth-Hitchcock Medical Center|Takeda Pharmaceuticals North America, Inc.",Dartmouth-Hitchcock Medical Center,"Takeda Pharmaceuticals North America, Inc.",,,,,,Phase 4,Other|Industry,Interventional,9/7/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01460225
2693,Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms,Completed,Has Results,Lower Urinary Tract Symptoms,Drug: Tamsulosin|Drug: Solifenacin,"Timothy Boone, MD, PhD|Astellas Pharma US, Inc.|The Methodist Hospital System","Timothy Boone, MD, PhD","Astellas Pharma US, Inc.",The Methodist Hospital System,,,,,Phase 4,Other|Industry,Interventional,10/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01457573
2694,Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis,Completed,Has Results,Meibomian Gland Dysfunction|Posterior Blepharitis,Drug: Loteprednol/tobramycin|Drug: Loteprednol|Drug: B+L Advanced Eye Relief Lubricant Drop,Massachusetts Eye and Ear Infirmary|Bausch & Lomb Incorporated,Massachusetts Eye and Ear Infirmary,Bausch & Lomb Incorporated,,,,,,Phase 4,Other|Industry,Interventional,8/11/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT01456780
2695,True Functional Restoration and Analgesia in Non-Radicular Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Hydromorphone ER|Drug: Sugar pill,Shirley Ryan AbilityLab|Mallinckrodt,Shirley Ryan AbilityLab,Mallinckrodt,,,,,,Phase 4,Other|Industry,Interventional,10/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01455519
2696,Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate,Completed,Has Results,Multiple Sclerosis,Drug: diclofenac sodium topical gel|Other: Placebo,"Brown, Theodore R., M.D., MPH|Teva Neuroscience, Inc.","Brown, Theodore R., M.D., MPH","Teva Neuroscience, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01454791
2697,Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I),Completed,Has Results,Chronic Hepatitis C Infection,Drug: Valacyclovir|Drug: Placebo,VA Office of Research and Development|GlaxoSmithKline,VA Office of Research and Development,GlaxoSmithKline,,,,,,Phase 1,U.S. Fed|Industry,Interventional,11/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01453075
2698,Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease,Completed,Has Results,Huntington's Disease,,Ohio State University|Lundbeck LLC,Ohio State University,Lundbeck LLC,,,,,,,Other|Industry,Observational,4/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01451463
2699,Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide,Completed,Has Results,Nausea|Vomiting|Glioma,Drug: aprepitant|Drug: ondansetron,Katy Peters|Merck Sharp & Dohme Corp.|Duke University,Katy Peters,Merck Sharp & Dohme Corp.,Duke University,,,,,Phase 2,Other|Industry,Interventional,6/24/2014,4/21/2017,https://ClinicalTrials.gov/show/NCT01450826
2700,MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex,Completed,Has Results,Dupuytren's Disease,Biological: XIAFLEX,"Hospital for Special Surgery, New York|Auxilium Pharmaceuticals, Inc.","Hospital for Special Surgery, New York","Auxilium Pharmaceuticals, Inc.",,,,,,Phase 4,Other|Industry,Interventional,3/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01450397
2701,Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.,Completed,Has Results,Retinal Vein Occlusion|Macular Edema,Drug: Ozurdex,Retina Macula Institute|Allergan,Retina Macula Institute,Allergan,,,,,,Phase 3,Other|Industry,Interventional,10/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01449682
2702,Dalfampridine for Imbalance in Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis|Fatigue,Drug: Dalfampridine|Drug: Placebo,Oregon Health and Science University|Acorda Therapeutics,Oregon Health and Science University,Acorda Therapeutics,,,,,,Phase 2,Other|Industry,Interventional,9/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01444300
2703,Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis,Completed,Has Results,"Respiratory Tract Diseases|Lung Diseases|Lung Diseases, Interstitial|Pulmonary Fibrosis",Drug: Interferon alpha oral lozenge,"Texas Tech University Health Sciences Center|Amarillo Biosciences, Inc.",Texas Tech University Health Sciences Center,"Amarillo Biosciences, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/1/2000,5/7/2019,https://ClinicalTrials.gov/show/NCT01442779
2704,Dextromethorphan for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Dextromethorphan hydrobromide,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1|Phase 2,NIH|Industry,Interventional,8/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01441102
2705,Utility of Interface Pressure Mapping,Completed,Has Results,Ulcers|Bedsores,Device: Mapping System|Device: Non-Mapping System,Henry Ford Health System|Wellsense USA Inc.,Henry Ford Health System,Wellsense USA Inc.,,,,,,Not Applicable,Other|Industry,Interventional,8/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01439581
2706,Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients,Completed,Has Results,End-stage Renal Disease|Cardiovascular Disease,Drug: Ranolazine|Procedure: Pharmacokinetic Blood and Dialysate Sampling|Procedure: QT Interval,University of Michigan|Gilead Sciences,University of Michigan,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,10/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01435174
2707,Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG,Completed,Has Results,Stress Induced Cardiomyopathy,Drug: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging,University of Pittsburgh|GE Healthcare,University of Pittsburgh,GE Healthcare,,,,,,Not Applicable,Other|Industry,Interventional,9/11/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01432626
2708,Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™,Completed,Has Results,Cystinosis|Nephropathic Cystinosis,Drug: Cysteamine bitartrate,"University of California, San Diego|Raptor Pharmaceuticals Corp.","University of California, San Diego",Raptor Pharmaceuticals Corp.,,,,,,Not Applicable,Other|Industry,Interventional,9/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01432561
2709,Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting,Completed,Has Results,Ovarian Cancer|Uterine Cancer,Drug: fosaprepitant|Drug: aprepitant|Other: Oral Placebo|Other: IV placebo,Gynecologic Oncology Associates|Merck Sharp & Dohme Corp.,Gynecologic Oncology Associates,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,9/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01432015
2710,Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants,Completed,Has Results,Healthy,Drug: gadofosveset,Duke University|Lantheus Medical Imaging,Duke University,Lantheus Medical Imaging,,,,,,Not Applicable,Other|Industry,Interventional,8/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01431300
2711,Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children,Completed,Has Results,Congenital Nasolacrimal Duct Obstruction,Drug: Besivance Treatment Group|Drug: Polytrim Treatment Group,"Rutgers, The State University of New Jersey|Bausch & Lomb Incorporated","Rutgers, The State University of New Jersey",Bausch & Lomb Incorporated,,,,,,Phase 1,Other|Industry,Interventional,9/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01431170
2712,Implant Placement With Simultaneous Gum Grafting,Completed,Has Results,Edentulous,Procedure: connective tissue autograft|Procedure: connective tissue allograft,"University of Louisville|BioHorizons, Inc.",University of Louisville,"BioHorizons, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,9/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01431144
2713,Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI,Completed,Has Results,Melanoma,Biological: recMAGE-A3 + AS15 ASCI,"Craig L Slingluff, Jr|GlaxoSmithKline|University of Virginia","Craig L Slingluff, Jr",GlaxoSmithKline,University of Virginia,,,,,Early Phase 1,Other|Industry,Interventional,6/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01425749
2714,Study of Kuvan Treatment in Adults With GTPCH Deficiency,Completed,Has Results,GTP Cyclohydrolase Deficiency,Drug: Sapropterin,University of Utah|BioMarin Pharmaceutical,University of Utah,BioMarin Pharmaceutical,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01425528
2715,DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects,Completed,Has Results,HIV,Drug: Twice-daily Darunavir and ritonavir|Drug: Once-daily Darunavir and ritonavir,"Ruth M. Rothstein CORE Center|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Ruth M. Rothstein CORE Center,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 4,Other|Industry,Interventional,1/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01423812
2716,Study of Botulinum Toxin and Recovery of Hand Function After Stroke,Completed,Has Results,Stroke With Hemiparesis,Drug: Botulinum Toxin commonly known as BOTOX®|Drug: Placebo,NYU Langone Health|Allergan,NYU Langone Health,Allergan,,,,,,Phase 3,Other|Industry,Interventional,4/10/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01422161
2717,Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease,Completed,Has Results,Parkinson's Disease|Neurogenic Bladder|Urinary Incontinence|Clostridium Botulinum Toxin Adverse Reaction,Drug: Cystoscopic injection of Botox into the urinary bladder,Stanford University|Allergan,Stanford University,Allergan,,,,,,Phase 4,Other|Industry,Interventional,2/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01421719
2718,Growth Hormone Treatment on Phosphocreatine Recovery in Obesity,Completed,Has Results,Obese|Growth Hormone Secretion Abnormality,Drug: Growth hormone treatment,Massachusetts General Hospital|Pfizer,Massachusetts General Hospital,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,9/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01421589
2719,Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo,Completed,Has Results,Sickle Cell Disease|Vaso-occlusive Crisis,Drug: Placebo|Drug: Dalteparin,Duke University|Eisai Limited,Duke University,Eisai Limited,,,,,,Phase 2,Other|Industry,Interventional,5/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01419977
2720,A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing,Completed,Has Results,Fungal Infection,Drug: Prospective TDM Arm,Johns Hopkins University|Pfizer,Johns Hopkins University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01416025
2721,Varenicline In-Patient Study,Completed,Has Results,Smoking Cessation,Behavioral: Smoking cessation counseling|Drug: Placebo|Drug: Varenicline,Stanford University|Pfizer,Stanford University,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,8/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01413516
2722,Comparative Study Between Two Fecal Management Systems,Completed,Has Results,Anal Erosion,Device: Fecal management system,The Cleveland Clinic|Bard Ltd,The Cleveland Clinic,Bard Ltd,,,,,,Not Applicable,Other|Industry,Interventional,1/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01411488
2723,"Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease",Completed,Has Results,Lymphoma,Drug: Interferon-2A|Drug: Adriamycin|Drug: Bleomycin|Drug: Velban|Drug: Dacarbazine,M.D. Anderson Cancer Center|Schering-Plough,M.D. Anderson Cancer Center,Schering-Plough,,,,,,Phase 2,Other|Industry,Interventional,7/1/1996,12/11/2019,https://ClinicalTrials.gov/show/NCT01404936
2724,Brain Imaging and Treatment Studies of the Night Eating Syndrome,Completed,Has Results,Night Eating Syndrome,Drug: escitalopram oxalate,University of Pennsylvania|Forest Laboratories,University of Pennsylvania,Forest Laboratories,,,,,,Phase 3,Other|Industry,Interventional,12/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01401595
2725,Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol,Completed,Has Results,Complication of Injection|Pain,Drug: Fospropofol|Drug: Propofol/Lidocaine,NYU Langone Health|Eisai Inc.,NYU Langone Health,Eisai Inc.,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01401049
2726,Treating Acutely Agitated Patients With Asenapine Sublingual Tablets,Completed,Has Results,Agitation,Drug: Asenapine|Drug: Placebo,St. Joseph Hospital Health Center|Schering-Plough,St. Joseph Hospital Health Center,Schering-Plough,,,,,,Phase 4,Other|Industry,Interventional,4/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01400113
2727,Study of Tocilizumab to Treat Polymyalgia Rheumatica,Completed,Has Results,Polymyalgia Rheumatica (PMR),Drug: Tocilizumab,"Hospital for Special Surgery, New York|Genentech, Inc.","Hospital for Special Surgery, New York","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,4/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01396317
2728,Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level,Completed,Has Results,Non-Hodgkin Lymphoma (NHL)|Cutaneous Lymphoma|Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides|Sezary Syndrome,Drug: Brentuximab vedotin,"Youn Kim|Seattle Genetics, Inc.|Stanford University",Youn Kim,"Seattle Genetics, Inc.",Stanford University,,,,,Phase 2,Other|Industry,Interventional,5/11/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01396070
2729,"Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone",Completed,Has Results,Opioid Abuse,Drug: pioglitazone,New York State Psychiatric Institute|Omeros Corporation,New York State Psychiatric Institute,Omeros Corporation,,,,,,Phase 2,Other|Industry,Interventional,8/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01395784
2730,Nebivolol and the Endothelin (ET)-1 System,Completed,Has Results,Prehypertension|Hypertension,Drug: Nebivolol|Drug: Metoprolol|Drug: Placebo|Other: Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|Other: FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|Other: FBF response to Acetylcholine|Other: FBF response to Sodium Nitroprusside|Other: FBF response to BQ-123+BQ-788+ACh,"University of Colorado, Boulder|Forest Laboratories","University of Colorado, Boulder",Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,5/11/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01395329
2731,Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica,Completed,Has Results,Post-operative Pain,Drug: lyrica,University of Texas Southwestern Medical Center|Pfizer,University of Texas Southwestern Medical Center,Pfizer,,,,,,Phase 3,Other|Industry,Interventional,12/6/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01391858
2732,Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: arformoterol|Drug: salmeterol,Dartmouth-Hitchcock Medical Center|Sunovion,Dartmouth-Hitchcock Medical Center,Sunovion,,,,,,Not Applicable,Other|Industry,Interventional,7/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01391559
2733,Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Device: EMS 7500 Digital Muscle Stimulator,"University of California, Los Angeles|NeuroSigma, Inc.","University of California, Los Angeles","NeuroSigma, Inc.",,,,,,Early Phase 1,Other|Industry,Interventional,7/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01388530
2734,Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly,Completed,Has Results,Aging,Drug: N-acetylcysteine|Drug: Losartan|Drug: Placebo losartan|Drug: Placebo N-acetylcysteine,"The University of Texas Medical Branch, Galveston|Lantheus Medical Imaging","The University of Texas Medical Branch, Galveston",Lantheus Medical Imaging,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01384591
2735,The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis,Completed,Has Results,Knee Osteoarthritis,Drug: Diclofenac Gel,Brigham and Women's Hospital|Endo Pharmaceuticals,Brigham and Women's Hospital,Endo Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,6/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01383954
2736,Chlorhexidine Gluconate Oral Care for Adults Experiencing Trauma,Completed,Has Results,Ventilator Associated Pneumonia,Drug: Chlorhexidine gluconate|Other: Toothpaste,"St. Joseph's Hospital and Medical Center, Phoenix|3M","St. Joseph's Hospital and Medical Center, Phoenix",3M,,,,,,Not Applicable,Other|Industry,Interventional,7/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01382446
2737,Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants,Completed,Has Results,Atopic Dermatitis,Other: Cetaphil Restoraderm|Other: Standard of Care,Oregon Health and Science University|Galderma,Oregon Health and Science University,Galderma,,,,,,Not Applicable,Other|Industry,Interventional,6/11/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01375205
2738,Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia,Completed,Has Results,Iron Deficiency Anemia,Drug: ferumoxytol,"Auerbach Hematology Oncology Associates P C|AMAG Pharmaceuticals, Inc.",Auerbach Hematology Oncology Associates P C,"AMAG Pharmaceuticals, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,6/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01374919
2739,Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer,Completed,Has Results,Bladder Cancer,Drug: Bacille Calmette-Guerrin (BCG)|Drug: Lenalidomide,H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation,H. Lee Moffitt Cancer Center and Research Institute,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,11/30/2011,12/10/2018,https://ClinicalTrials.gov/show/NCT01373294
2740,Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress,Completed,Has Results,Coronary Artery Disease,Drug: Regadenoson|Drug: Adenosine|Drug: N-13 ammonia,Mayo Clinic|Astellas Pharma Inc,Mayo Clinic,Astellas Pharma Inc,,,,,,Not Applicable,Other|Industry,Interventional,2/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01370265
2741,Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions,Completed,Has Results,TBI|Major Depression|Other Psychiatric Disorders,Drug: Escitalopram|Drug: Placebo,Johns Hopkins University|Forest Laboratories,Johns Hopkins University,Forest Laboratories,,,,,,Phase 2,Other|Industry,Interventional,4/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01368432
2742,Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome,Completed,Has Results,Turner Syndrome,Drug: somatotropin,"Rebecca Knickmeyer Santelli, PhD|Pfizer|University of North Carolina, Chapel Hill","Rebecca Knickmeyer Santelli, PhD",Pfizer,"University of North Carolina, Chapel Hill",,,,,Not Applicable,Other|Industry,Interventional,5/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01367834
2743,Anal Human Papillomavirus in Inflammatory Bowel Disease Study,Completed,Has Results,Inflammatory Bowel Disease (IBD)|Ulcerative Colitis (UC)|Crohn's Disease (CD)|Anal Human Papillomavirus,"Procedure: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples",University of Pittsburgh|Merck Sharp & Dohme Corp.,University of Pittsburgh,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,6/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01364896
2744,A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers,Completed,Has Results,Epilepsy,Drug: Diazepam,"University of Minnesota - Clinical and Translational Science Institute|Neurelis, Inc.",University of Minnesota - Clinical and Translational Science Institute,"Neurelis, Inc.",,,,,,Phase 1,Other|Industry,Interventional,2/11/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01364558
2745,Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement,Completed,Has Results,Infections After Lung Transplant,Drug: SQ IVIG,University of Pittsburgh|CSL Behring,University of Pittsburgh,CSL Behring,,,,,,Not Applicable,Other|Industry,Interventional,1/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01361178
2746,Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis,Completed,Has Results,Trichomonas Vaginitis,Drug: oral metronidazole|Drug: neo penotran forte|Drug: neo penotran forte once a day,University of Alabama at Birmingham|Embil Pharmaceutical Co. Ltd,University of Alabama at Birmingham,Embil Pharmaceutical Co. Ltd,,,,,,Phase 2,Other|Industry,Interventional,12/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01361048
2747,Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism,Completed,Has Results,Polycystic Ovary Syndrome,Drug: 3 mg DRSP/20 μg EE,"Woman's|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Woman's,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",,,,,,Phase 4,Other|Industry,Interventional,8/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01360996
2748,A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: dalfampridine ER|Drug: placebo,"Brown, Theodore R., M.D., MPH|Acorda Therapeutics","Brown, Theodore R., M.D., MPH",Acorda Therapeutics,,,,,,Phase 4,Other|Industry,Interventional,11/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01356940
2749,Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Amrubicin|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Aspirin|Drug: Pegfilgrastim,Michaela Liedtke|Celgene Corporation|Stanford University,Michaela Liedtke,Celgene Corporation,Stanford University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/11/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT01355705
2750,Diabetes Remote Care Management System,Completed,Has Results,Diabetes,Device: DRMS,Tulane University School of Medicine|Eli Lilly and Company|Tulane University,Tulane University School of Medicine,Eli Lilly and Company,Tulane University,,,,,Not Applicable,Other|Industry,Interventional,5/11/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01354015
2751,Botox Injection for Treatment of Vaginismus,Completed,Has Results,Vaginismus,Biological: BOTOX,Plastic Surgery Professional Association|Allergan,Plastic Surgery Professional Association,Allergan,,,,,,Phase 1,Other|Industry,Interventional,8/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01352546
2752,Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib,Memorial Sloan Kettering Cancer Center|Amgen,Memorial Sloan Kettering Cancer Center,Amgen,,,,,,Phase 2,Other|Industry,Interventional,5/9/2011,1/26/2016,https://ClinicalTrials.gov/show/NCT01351623
2753,Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients,Completed,Has Results,Rheumatoid Arthritis,Biological: abatacept,Arthritis & Rheumatic Disease Specialties Research|Bristol-Myers Squibb,Arthritis & Rheumatic Disease Specialties Research,Bristol-Myers Squibb,,,,,,Phase 3,Other|Industry,Interventional,6/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01351480
2754,Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease,Completed,Has Results,Chronic Kidney Disease|Diabetes,Drug: Febuxostat|Drug: Placebo,University of Utah|Takeda,University of Utah,Takeda,,,,,,Not Applicable,Other|Industry,Interventional,5/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01350388
2755,Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission,Completed,Has Results,Multiple Myeloma,Drug: Lenalidomide|Biological: Allogeneic Myeloma Vaccine|Biological: Prevnar-13,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene Corporation,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,1/12/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01349569
2756,Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2,Completed,Has Results,Genital Herpes,Drug: valacyclovir|Drug: Valacyclovir,University of Washington|GlaxoSmithKline,University of Washington,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,11/8/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01346475
2757,Pilot Study of Using Copeptin to Predict Response to Tolvaptan,Completed,Has Results,Cardiovascular Diseases|Heart Diseases|Heart Failure,Drug: tolvaptan,"University of North Carolina, Chapel Hill|Otsuka America Pharmaceutical","University of North Carolina, Chapel Hill",Otsuka America Pharmaceutical,,,,,,Phase 4,Other|Industry,Interventional,4/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01346072
2758,Ranolazine in Ischemic Cardiomyopathy,Completed,Has Results,Cardiomyopathy|Chest Pain|Dyspnea,Drug: Ranexa|Drug: Placebo,Midwest Cardiovascular Research Foundation|Gilead Sciences,Midwest Cardiovascular Research Foundation,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,4/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01345188
2759,An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH),Completed,Has Results,Exercise-induced Pulmonary Arterial Hypertension,Drug: Ambrisentan,Brigham and Women's Hospital|Gilead Sciences,Brigham and Women's Hospital,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,9/8/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01338636
2760,Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients,Completed,Has Results,Kidney Transplant Recipients,Drug: mycophenolic acid,University of Cincinnati|Novartis Pharmaceuticals,University of Cincinnati,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,9/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01336296
2761,The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients,Completed,Has Results,"HIV|Hepatitis C, Chronic|HCV Coinfection",,University of Cincinnati|Merck Sharp & Dohme Corp.,University of Cincinnati,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,4/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01335230
2762,TPI 287 in Breast Cancer Metastatic to the Brain,Completed,Has Results,Breast Cancer,Drug: TPI 287|Drug: Dexamethasone|Drug: Benadryl|Drug: Ranitidine,"M.D. Anderson Cancer Center|Cortice Biosciences, Inc.",M.D. Anderson Cancer Center,"Cortice Biosciences, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/16/2011,4/14/2017,https://ClinicalTrials.gov/show/NCT01332630
2763,Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery,Completed,Has Results,Congenital Heart Defect|Surgery-Induced Tissue Adhesions|Hemorrhage,Device: CoSeal Surgical Spray Group,Loma Linda University|Baxter Healthcare Corporation,Loma Linda University,Baxter Healthcare Corporation,,,,,,Phase 2,Other|Industry,Interventional,8/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01330433
2764,Levels of Raltegravir in the Female Genital Tissue,Completed,Has Results,HIV,Drug: Raltegravir,University of Washington|Merck Sharp & Dohme Corp.,University of Washington,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,10/11/2019,,https://ClinicalTrials.gov/show/NCT01327482
2765,Attention & Memory Impairments in Menopausal Women,Completed,Has Results,Symptomatic Menopause|Cognitive Impairments,Drug: Lisdexamfetamine|Drug: Placebo,University of Pennsylvania|Shire,University of Pennsylvania,Shire,,,,,,Phase 4,Other|Industry,Interventional,5/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01324024
2766,Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,Completed,Has Results,Melanoma,"Drug: Ipilimumab, Melphalan and Dactinomycin",Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb,Memorial Sloan Kettering Cancer Center,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,2/11/2019,8/14/2017,https://ClinicalTrials.gov/show/NCT01323517
2767,Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.,Completed,Has Results,Psoriasis,Drug: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA],"University of North Carolina, Chapel Hill|AbbVie","University of North Carolina, Chapel Hill",AbbVie,,,,,,Not Applicable,Other|Industry,Interventional,3/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01320293
2768,Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Pomalidomide,Yale University|Celgene Corporation,Yale University,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,6/11/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01319422
2769,Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia,Completed,Has Results,Epilepsy,Drug: Levetiracetam,Drexel University College of Medicine|UCB Pharma|Drexel University,Drexel University College of Medicine,UCB Pharma,Drexel University,,,,,Phase 4,Other|Industry,Interventional,11/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT01318408
2770,12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder,Completed,Has Results,Social Anxiety Disorder,Drug: Pristiq|Drug: Placebo,The Medical Research Network|Pfizer,The Medical Research Network,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,4/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01316302
2771,Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females,Completed,Has Results,Ureteral Stent Occlusion|Exposure Laser|Ureterostomy; Functional Disturbance|Vaginal Diseases|Injury of Bladder|Excessive Repair|Calculi,Drug: Desflurane|Drug: Sevoflurane,Hahnemann University Hospital|Baxter Healthcare Corporation,Hahnemann University Hospital,Baxter Healthcare Corporation,,,,,,Phase 4,Other|Industry,Interventional,5/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01310582
2772,Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit,Completed,Has Results,Tobacco Use Disorder,Drug: Varenicline|Drug: Placebo pill,"Rutgers, The State University of New Jersey|Pfizer","Rutgers, The State University of New Jersey",Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,1/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01308736
2773,Savella in Treatment for Provoked Vestibulodynia,Completed,Has Results,Vestibulodynia|Vulvodynia,Drug: Milnacipran,University of Tennessee|Forest Laboratories,University of Tennessee,Forest Laboratories,,,,,,Phase 3,Other|Industry,Interventional,10/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01304589
2774,Spaeth/Richman Contrast Sensitivity Test,Completed,Has Results,Glaucoma,Diagnostic Test: Spaeth/Richman Contrast Sensitivity Test|Diagnostic Test: Pelli-Robson Contrast Sensitivity Chart,Wills Eye|Pfizer,Wills Eye,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,1/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01300949
2775,TissueLink Study During Multi-Level Spine Surgery,Completed,Has Results,Low Back Pain,Device: Tissuelink device,Duke University|Salient Surgical Technologies,Duke University,Salient Surgical Technologies,,,,,,Phase 4,Other|Industry,Interventional,4/6/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01300559
2776,Open Label Use Of RiaStap During Aortic Reconstruction,Completed,Has Results,Coagulopathic Bleeding,Drug: RiaSTAP,Duke University|CSL Behring,Duke University,CSL Behring,,,,,,Phase 4,Other|Industry,Interventional,12/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01300286
2777,Efficacy Study of Adalimumab to Treat Interstitial Cystitis,Completed,Has Results,Interstitial Cystitis,Drug: Adalimumab|Other: inactive drug,"ICStudy, LLC|Abbott","ICStudy, LLC",Abbott,,,,,,Phase 3,Other|Industry,Interventional,3/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01295814
2778,Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation,Completed,Has Results,Ventricular Tachycardia,Device: Circulatory Support System,Vivek Reddy|Abiomed Inc.|Icahn School of Medicine at Mount Sinai,Vivek Reddy,Abiomed Inc.,Icahn School of Medicine at Mount Sinai,,,,,Not Applicable,Other|Industry,Interventional,9/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01294267
2779,Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches,Completed,Has Results,Migraine Headache,Device: Deep Brain Stimulation of SPG for Migraine,"The Cleveland Clinic|Autonomic Technologies, Inc.",The Cleveland Clinic,"Autonomic Technologies, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,3/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01294046
2780,Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad),Completed,Has Results,Medication Adherence|Bipolar Disorder,Drug: ziprasidone,University Hospitals Cleveland Medical Center|Pfizer,University Hospitals Cleveland Medical Center,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01293825
2781,Tolvaptan for Ascites in Cirrhotic Patients,Completed,Has Results,Ascites|Cirrhosis,Drug: Tolvaptan,University of Florida|Otsuka America Pharmaceutical,University of Florida,Otsuka America Pharmaceutical,,,,,,Phase 4,Other|Industry,Interventional,3/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01292304
2782,"A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer",Completed,Has Results,Head and Neck Neoplasms|Cancer of the Head and Neck,Drug: Carboplatin|Drug: Cetuximab|Drug: RAD001,Emory University|Novartis,Emory University,Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/11/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01283334
2783,Abatacept in the Treatment of Uveitis,Completed,Has Results,Uveitis,Drug: Abatacept,Oregon Health and Science University|Bristol-Myers Squibb,Oregon Health and Science University,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,1/12/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT01279954
2784,Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic,Completed,Has Results,Colic|Inflammation,Dietary Supplement: Nutramigen with Enflora|Dietary Supplement: Nutramigen A+,"The University of Texas Health Science Center, Houston|Mead Johnson Nutrition","The University of Texas Health Science Center, Houston",Mead Johnson Nutrition,,,,,,Not Applicable,Other|Industry,Interventional,9/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01279265
2785,Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment,Completed,Has Results,Administration Site Reaction,Drug: Fentanyl,University of Texas Southwestern Medical Center|Baxter Healthcare Corporation,University of Texas Southwestern Medical Center,Baxter Healthcare Corporation,,,,,,Phase 4,Other|Industry,Interventional,1/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01277861
2786,Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas,Completed,Has Results,Neurofibromatosis|NF1|Neurofibromas,Drug: Tasigna,Indiana University|Novartis,Indiana University,Novartis,,,,,,Early Phase 1,Other|Industry,Interventional,1/11/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01275586
2787,Lenalidomide in HTLV-1 Adult T-Cell Leukemia,Completed,Has Results,Adult T Cell Leukemia/Lymphoma,Drug: Lenalidomide,Columbia University|Celgene Corporation,Columbia University,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,12/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01274533
2788,Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS),Completed,Has Results,Leukemia,Drug: Omacetaxine|Drug: Cytarabine,M.D. Anderson Cancer Center|Cephalon,M.D. Anderson Cancer Center,Cephalon,,,,,,Phase 2,Other|Industry,Interventional,7/11/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01272245
2789,Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder,Completed,Has Results,PTSD,Drug: Escitalopram,VA Nebraska Western Iowa Health Care System|Forest Laboratories,VA Nebraska Western Iowa Health Care System,Forest Laboratories,,,,,,Phase 4,U.S. Fed|Industry,Interventional,6/8/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01271244
2790,Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients,Completed,Has Results,HIV,Drug: Tenofovir/emtricitabine|Drug: Tenofovir/emtricitabine/efavirenz|Drug: Raltegravir,Indiana University|Merck Sharp & Dohme Corp.,Indiana University,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,4/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01270802
2791,Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement,Completed,Has Results,Obesity|Arthritis,Drug: propofol|Drug: Desflurane,Pedro Paulo Tanaka|Baxter Healthcare Corporation|Stanford University,Pedro Paulo Tanaka,Baxter Healthcare Corporation,Stanford University,,,,,Phase 4,Other|Industry,Interventional,12/10/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01270620
2792,Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses,Completed,Has Results,Keratitis,Device: B+L Biotrue MPS and B+L PureVision,"Epstein, Arthur B., OD, FAAO|Alcon Research","Epstein, Arthur B., OD, FAAO",Alcon Research,,,,,,Phase 4,Other|Industry,Interventional,10/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01268306
2793,The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain,Completed,Has Results,Pulmonary Hypertension|Pulmonary Arterial Hypertension,Drug: Qutenza (8% capsaicin),University of Rochester|United Therapeutics,University of Rochester,United Therapeutics,,,,,,Phase 2,Other|Industry,Interventional,11/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01260454
2794,Homeopathic Cold Remedy for Children Study,Completed,Has Results,Upper Respiratory Tract Infections,Drug: Hyland's Cold 'n Cough 4 kids|Drug: placebo,University of Washington|Standard Homeopathic Company,University of Washington,Standard Homeopathic Company,,,,,,Not Applicable,Other|Industry,Interventional,12/10/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01257503
2795,"Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer",Completed,Has Results,Adrenal Cortex Neoplasms,Drug: Axitinib,National Cancer Institute (NCI)|Pfizer|National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Pfizer,National Institutes of Health Clinical Center (CC),,,,,Phase 2,NIH|Industry,Interventional,9/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01255137
2796,Breast Cancer Risk Biomarkers in Postmenopausal Women,Completed,Has Results,Breast Cancer,Drug: Lovaza™,"Carol Fabian, MD|GlaxoSmithKline|University of Kansas Medical Center","Carol Fabian, MD",GlaxoSmithKline,University of Kansas Medical Center,,,,,Phase 2,Other|Industry,Interventional,11/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01252290
2797,RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma,Completed,Has Results,Uveal Melanoma,Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR,Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals,Memorial Sloan Kettering Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,11/10/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01252251
2798,Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2),Completed,Has Results,Choroidal Melanoma,Drug: Ranibizumab 2 mg|Drug: 0.5 mg Ranibizumab,"New England Retina Associates|Genentech, Inc.",New England Retina Associates,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,7/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01251978
2799,Preoperative Alignment of Total Knee Replacement,Completed,Has Results,Knee Arthritis,Procedure: trumatch group|Procedure: control group,VA Palo Alto Health Care System|DePuy Orthopaedics,VA Palo Alto Health Care System,DePuy Orthopaedics,,,,,,Phase 3,U.S. Fed|Industry,Interventional,11/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01242085
2800,Satisfaction of Treatment Among Elderly Patients With Insulin Therapy,Completed,Has Results,Diabetes Mellitus,Drug: Glargine|Device: glargine via insulin pen,Emory University|Sanofi,Emory University,Sanofi,,,,,,Phase 4,Other|Industry,Interventional,1/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01240200
2801,Comparing OTC Acne Treatment to Prescription Regimen,Completed,Has Results,Acne Vulgaris,Drug: BenzaClin|Drug: Effaclar,Milton S. Hershey Medical Center|Loreal USA,Milton S. Hershey Medical Center,Loreal USA,,,,,,Not Applicable,Other|Industry,Interventional,10/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01237821
2802,Lubiprostone in Patients With Multiple Sclerosis Associated Constipation,Completed,Has Results,Multiple Sclerosis|Constipation,Drug: Lubiprostone|Drug: Placebo,University of Rochester|Takeda,University of Rochester,Takeda,,,,,,Phase 4,Other|Industry,Interventional,11/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01236534
2803,"MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies",Completed,Has Results,Advanced Solid Tumors|Tumors|Cancer,Drug: MK-2206|Drug: Paclitaxel|Drug: Trastuzumab,"University of California, San Francisco|Merck Sharp & Dohme Corp.","University of California, San Francisco",Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,3/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01235897
2804,The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery,Completed,Has Results,Osteoarthritis,Drug: Evicel fibrin sealant,"Hospital for Special Surgery, New York|Ethicon, Inc.","Hospital for Special Surgery, New York","Ethicon, Inc.",,,,,,Phase 4,Other|Industry,Interventional,9/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01235715
2805,The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia,Completed,Has Results,Sleep Disorders|Fibromyalgia|Sleep,Drug: Milnacipran,Mansoor Ahmed M.D.|Forest Laboratories|Cleveland Sleep Research Center,Mansoor Ahmed M.D.,Forest Laboratories,Cleveland Sleep Research Center,,,,,Phase 4,Other|Industry,Interventional,11/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01234675
2806,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Completed,Has Results,Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation,Drug: Metformin XR plus placebo|Drug: Metformin XR plus liraglutide,Woman's|Novo Nordisk A/S,Woman's,Novo Nordisk A/S,,,,,,Phase 3,Other|Industry,Interventional,8/11/2011,6/14/2019,https://ClinicalTrials.gov/show/NCT01234649
2807,Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle,Completed,Has Results,Presbyopia,"Device: Standard, non-free-form, non-customized PAL spectacles|Device: Individually customized free-form surfaced PAL spectacles","University of California, Berkeley|Carl Zeiss Meditec, Inc.","University of California, Berkeley","Carl Zeiss Meditec, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,2/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT01234207
2808,AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: AMG 102 and erlotinib,Ahmad Tarhini|Amgen|University of Pittsburgh,Ahmad Tarhini,Amgen,University of Pittsburgh,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/11/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01233687
2809,Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Milnacipran,"University of California, Los Angeles|Forest Laboratories","University of California, Los Angeles",Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,11/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01225991
2810,Injectable Filler for Cheek Flattening,Completed,Has Results,Malar Deficiency,Drug: Calcium hydroxylapatite,DeNova Research|Merz Aesthetics Inc.,DeNova Research,Merz Aesthetics Inc.,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01225354
2811,Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab,Completed,Has Results,Fallopian Tubes Cancer|Ovarian Cancer|Peritoneal Cancer,Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821,"Memorial Sloan Kettering Cancer Center|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,"Genentech, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,10/10/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT01223235
2812,Processing Speed as an Objective Measure of Tinnitus,Completed,Has Results,Tinnitus,,Washington University School of Medicine|Posit Science Corporation,Washington University School of Medicine,Posit Science Corporation,,,,,,,Other|Industry,Observational,7/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01222507
2813,Tissue Expander Breast Reconstruction Study on Breast Volume and Shape Change,Completed,Has Results,Contour Irregularity of Reconstructed Breast,Device: Contour Profile Tissue Expander,"Northwestern University|Mentor Worldwide, LLC",Northwestern University,"Mentor Worldwide, LLC",,,,,,Not Applicable,Other|Industry,Interventional,11/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01222390
2814,Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery,Completed,Has Results,Cystoscopes|Baxter Anaesthesia Brand of Desflurane|Sevoflurane,Drug: Desflurane|Drug: Sevoflurane,Ohio State University|Baxter Healthcare Corporation,Ohio State University,Baxter Healthcare Corporation,,,,,,Phase 3,Other|Industry,Interventional,9/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01219881
2815,Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian,Completed,Has Results,Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer,Drug: carboplatin|Drug: Bevacizumab|Drug: Paclitaxel,"Ritu Salani|Genentech, Inc.|Ohio State University Comprehensive Cancer Center",Ritu Salani,"Genentech, Inc.",Ohio State University Comprehensive Cancer Center,,,,,Phase 1,Other|Industry,Interventional,9/10/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01219777
2816,Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide,Completed,Has Results,Asthma,Drug: Budesonide 360ug|Drug: Budesonide 720ug|Drug: Budesonide 1440ug|Drug: Budesonide720ug 4 times|Drug: Placebo,University of Miami|AstraZeneca,University of Miami,AstraZeneca,,,,,,Not Applicable,Other|Industry,Interventional,7/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01219738
2817,Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations,Completed,Has Results,Asthma,Drug: Symbicort,Stanford University|AstraZeneca,Stanford University,AstraZeneca,,,,,,Not Applicable,Other|Industry,Interventional,9/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01218399
2818,ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma,Completed,Has Results,Squamous Cell Carcinoma of the Head and Neck,Drug: Cetuximab|Procedure: Surgery|Radiation: Post-surgical radiation|Drug: Cisplatin or carboplatin,Robert Ferris|Bristol-Myers Squibb|University of Pittsburgh,Robert Ferris,Bristol-Myers Squibb,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,2/11/2019,2/14/2017,https://ClinicalTrials.gov/show/NCT01218048
2819,Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers,Completed,Has Results,Tobacco Abuse Smoke,Drug: Fluticasone|Drug: Placebo,University of Miami|GlaxoSmithKline,University of Miami,GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01216735
2820,Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II),Completed,Has Results,Urinary Incontinence,Drug: Vesicare,"University of California, Irvine|Astellas Pharma US, Inc.","University of California, Irvine","Astellas Pharma US, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,10/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01215721
2821,Telephone Based Management of Hyperlipidemia,Completed,Has Results,Hyperlipidemia,Device: Self Monitoring Lipid Analyzer,Temple University|Merck Sharp & Dohme Corp.,Temple University,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,11/10/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01212159
2822,Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma,Completed,Has Results,Asthma,Drug: placebo|Drug: mometasone 400 mcg|Drug: mometasone 200 mcg,University of Miami|Merck Sharp & Dohme Corp.,University of Miami,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,10/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01210170
2823,PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma,Completed,Has Results,Sarcoma|Liposarcoma,Drug: Palbociclib 200mg|Drug: Palbociclib 125mg,Memorial Sloan Kettering Cancer Center|Pfizer,Memorial Sloan Kettering Cancer Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,9/23/2010,10/25/2016,https://ClinicalTrials.gov/show/NCT01209598
2824,Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme,Completed,Has Results,Glioblastoma Multiforme,Drug: Bevacizumab|Drug: Temozolomide|Radiation: RT (Radiation Therapy),"University of Colorado, Denver|Genentech, Inc.","University of Colorado, Denver","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/16/2010,2/3/2017,https://ClinicalTrials.gov/show/NCT01209442
2825,Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access,Completed,Has Results,Heart Diseases,Device: Radiofrequency energy needle|Device: Mechanical Needle,"University of California, San Francisco|Baylis Medical Company","University of California, San Francisco",Baylis Medical Company,,,,,,Not Applicable,Other|Industry,Interventional,11/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01209260
2826,High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia,Completed,Has Results,Retinal Diseases|Telangiectasis,Drug: ranibizumab 2.0mg,"Eye Center of Northern Colorado, P.C.|Genentech, Inc.","Eye Center of Northern Colorado, P.C.","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,10/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01205035
2827,R5 Integrase Study in HIV-1 Naive Patients,Completed,Has Results,HIV Infections,Drug: Raltegravir and Maraviroc in combination,University of Maryland|Merck Sharp & Dohme Corp.,University of Maryland,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,9/10/2019,5/16/2014,https://ClinicalTrials.gov/show/NCT01204905
2828,Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901),Completed,Has Results,Mesothelioma,Drug: Zometa,University of Alabama at Birmingham|Novartis Pharmaceuticals,University of Alabama at Birmingham,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,6/9/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01204203
2829,Study of SB939 in Subjects With Myelofibrosis,Completed,Has Results,Myeloproliferative Disorders,Drug: SB939,M.D. Anderson Cancer Center|S*BIO,M.D. Anderson Cancer Center,S*BIO,,,,,,Phase 2,Other|Industry,Interventional,11/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01200498
2830,"Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome",Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: micafungin|Drug: posaconazole,"Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc.",Memorial Sloan Kettering Cancer Center,"Astellas Pharma US, Inc.",,,,,,Phase 4,Other|Industry,Interventional,9/9/2010,4/3/2018,https://ClinicalTrials.gov/show/NCT01200355
2831,Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis,Completed,Has Results,Uveitis,Drug: B27PD|Drug: Placebo,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1|Phase 2,NIH|Industry,Interventional,8/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01195948
2832,Veritas Laparoscopic Paraesophageal Hiatal Hernia (PEH) Repair Pilot Trial,Completed,Has Results,Hiatal Hernia,Device: Veritas® Collagen Matrix,University of Washington|Synovis Surgical Innovations,University of Washington,Synovis Surgical Innovations,,,,,,Not Applicable,Other|Industry,Interventional,5/10/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01195545
2833,Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: quetiapine SR|Drug: quetiapine sr placebo,The University of Texas Health Science Center at San Antonio|AstraZeneca,The University of Texas Health Science Center at San Antonio,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,4/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01195363
2834,"Building Recovery By Improving Goals, Habits, and Thoughts",Completed,Has Results,Depression|Substance Use,Behavioral: Group Cognitive Behavioral Therapy|Behavioral: Group CBT for Depression,"RAND|Behavioral Health Services, Inc.",RAND,"Behavioral Health Services, Inc.",,,,,,Phase 2|Phase 3,Other|Industry,Interventional,8/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01191788
2835,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Completed,Has Results,Hyperparathyroidism|Chronic Kidney Disease,Drug: sevelamer carbonate|Drug: placebo,"Kenneth R. Phelps, M.D.|Genzyme, a Sanofi Company|Phelps, Kenneth R., M.D.","Kenneth R. Phelps, M.D.","Genzyme, a Sanofi Company","Phelps, Kenneth R., M.D.",,,,,Phase 3,Other|Industry,Interventional,4/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01191762
2836,Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy,Completed,Has Results,Partial Epilepsy,Drug: Lacosamide|Drug: Placebo,The Cleveland Clinic|UCB Pharma,The Cleveland Clinic,UCB Pharma,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01190098
2837,Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer,Completed,Has Results,Renal Cell Cancer,Drug: sorafenib,University of Kansas Medical Center|Bayer,University of Kansas Medical Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,6/8/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01189370
2838,Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting,Completed,Has Results,Quadrivalent HPV Vaccine|Human Papillomavirus Vaccine,Biological: quadrivalent human papillomavirus vaccine,University of Pittsburgh|Merck Sharp & Dohme Corp.,University of Pittsburgh,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,10/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01184079
2839,Evaluation of the Trabecular Metal™ Revision Hip Cup Using Bone Mineral Density (DEXA),Completed,Has Results,"Revision, Joint",Device: Trabecular Metal Revision Cup|Device: Trabecular Metal Modular Cup,The Cleveland Clinic|Zimmer Biomet,The Cleveland Clinic,Zimmer Biomet,,,,,,Not Applicable,Other|Industry,Interventional,8/10/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01183260
2840,Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects,Completed,Has Results,Obesity,Drug: Oseltamivir,Manjunath Prakash Pai|Hoffmann-La Roche|University of Michigan,Manjunath Prakash Pai,Hoffmann-La Roche,University of Michigan,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01179919
2841,Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation,Completed,Has Results,End Stage Renal Disease,Biological: Rituxan,"Stanley Jordan, MD|Genentech, Inc.|Cedars-Sinai Medical Center","Stanley Jordan, MD","Genentech, Inc.",Cedars-Sinai Medical Center,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/13/2019,7/28/2017,https://ClinicalTrials.gov/show/NCT01178216
2842,Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Pomalidomide,University of Arkansas|Celgene,University of Arkansas,Celgene,,,,,,Phase 2,Other|Industry,Interventional,10/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01177735
2843,Assessing Arrhythmias After Ablation Using Implantable Recorders,Completed,Has Results,Atrial Fibrillation,Device: Reveal XT implantable loop recorder,University of Pennsylvania|Medtronic,University of Pennsylvania,Medtronic,,,,,,Not Applicable,Other|Industry,Interventional,6/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01176617
2844,20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD),Completed,Has Results,Age-Related Macular Degeneration|Choroidal Neovascularization,Drug: IBI-20089/Lucentis,University of Illinois at Chicago|ICON Bioscience Inc,University of Illinois at Chicago,ICON Bioscience Inc,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01175395
2845,Ranolazine and Pulmonary Hypertension,Completed,Has Results,Angina|Pulmonary Arterial Hypertension,Drug: Ranolazine,Northwestern University|Gilead Sciences,Northwestern University,Gilead Sciences,,,,,,Phase 3,Other|Industry,Interventional,6/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01174173
2846,Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia,Completed,Has Results,"Leukemia, Myelomonocytic, Acute",Drug: Erlotinib,Indiana University|OSI Pharmaceuticals,Indiana University,OSI Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,7/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01174043
2847,A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: milnacipran|Drug: Placebo,University of Michigan|Forest Laboratories,University of Michigan,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,6/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01173055
2848,Topical Treatment of Under Eye Dark Circles and Swelling,Completed,Has Results,Edema,Drug: Fexofenadine|Drug: Placebo,"The Connecticut Sinus Center, PC|TKL Research, Inc.","The Connecticut Sinus Center, PC","TKL Research, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01172522
2849,Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET),Completed,Has Results,PANCREAS|Neuroendocrine,Drug: MK-2206,Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.,Memorial Sloan Kettering Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Phase 2,Other|Industry,Interventional,7/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01169649
2850,Cerebral Perfusion Pressure Using Precedex and Other Sedatives,Completed,Has Results,Endotracheal Intubation|Continuous IV Sedation|ICP Monitoring,Drug: Standard-of-Care plus Dexmedetomidine|Other: Standard-of-Care,"Duke University|Hospira, now a wholly owned subsidiary of Pfizer",Duke University,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 3,Other|Industry,Interventional,10/9/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01169467
2851,Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls,Completed,Has Results,Obesity,Drug: recombinant human growth hormone (rhGH)|Drug: Placebo,"Massachusetts General Hospital|Genentech, Inc.",Massachusetts General Hospital,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01169103
2852,Evaluation of Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block After Ankle Surgery,Completed,Has Results,Orthopedic Surgery of Lower Extremity,Device: 0.2% ropivacaine|Drug: saline,Wake Forest University Health Sciences|I-Flow,Wake Forest University Health Sciences,I-Flow,,,,,,Not Applicable,Other|Industry,Interventional,7/10/2019,9/7/2017,https://ClinicalTrials.gov/show/NCT01167907
2853,ORAL T-8 Oral Testosterone for Male Hormonal Contraception,Completed,Has Results,Healthy,Drug: Oral Testosterone|Drug: Acyline,University of Washington|GlaxoSmithKline,University of Washington,GlaxoSmithKline,,,,,,Phase 1,Other|Industry,Interventional,7/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01167829
2854,Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D,Completed,Has Results,Breast Cancer,Drug: vitamin D3,"Carol Fabian, MD|BTR Group|University of Kansas Medical Center","Carol Fabian, MD",BTR Group,University of Kansas Medical Center,,,,,Not Applicable,Other|Industry,Interventional,5/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01166763
2855,The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes,Completed,Has Results,Diabetes Type 2,Drug: Placebo|Drug: Aliskiren,Beth Israel Deaconess Medical Center|Novartis Pharmaceuticals,Beth Israel Deaconess Medical Center,Novartis Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,11/9/2019,,https://ClinicalTrials.gov/show/NCT01165983
2856,Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia,Completed,Has Results,Menorrhagia,Drug: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Drug: Naproxen sodium pills|Device: NovaSure® Radiofrequency Endometrial Ablation,"Abimbola Famuyide|Hologic, Inc.|Mayo Clinic",Abimbola Famuyide,"Hologic, Inc.",Mayo Clinic,,,,,Phase 4,Other|Industry,Interventional,8/9/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01165307
2857,"The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate",Completed,Has Results,Chronic Kidney Disease,Drug: Paricalcitol,Indiana University|Abbott,Indiana University,Abbott,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01163162
2858,Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation,Completed,Has Results,Irritable Bowel Syndrome|Constipation,Drug: Lubiprostone|Drug: Placebo|Other: Smartpill wireless motility capsule,"University of Michigan|Takeda Pharmaceuticals North America, Inc.",University of Michigan,"Takeda Pharmaceuticals North America, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01162863
2859,"Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma",Completed,Has Results,Multiple Myeloma,Drug: dexamethasone|Drug: clarithromycin|Drug: Pomalidomide,Weill Medical College of Cornell University|Celgene,Weill Medical College of Cornell University,Celgene,,,,,,Phase 2,Other|Industry,Interventional,8/10/2019,5/5/2015,https://ClinicalTrials.gov/show/NCT01159574
2860,Alternative Sedation During Bronchoscopy,Completed,Has Results,Sedation,Drug: Dexmedetomidine load|Drug: Ketamine load|Drug: Midazolam load|Drug: Fentanyl load|Drug: Dexmedetomidine maintenance|Drug: Ketamine maintenance|Drug: Midazolam demand|Drug: Fentanyl demand|Drug: Benadryl demand,"University of Pennsylvania|Hospira, now a wholly owned subsidiary of Pfizer",University of Pennsylvania,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 4,Other|Industry,Interventional,6/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01158820
2861,Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity,Completed,Has Results,Asthma|Obesity,,University of Michigan|Merck Sharp & Dohme Corp.,University of Michigan,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,7/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01158573
2862,"Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients",Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Metoprolol,University of Florida|Forest Laboratories,University of Florida,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,7/10/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01157234
2863,Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: pioglitazone,"University of Miami|Takeda Pharmaceuticals North America, Inc.",University of Miami,"Takeda Pharmaceuticals North America, Inc.",,,,,,Phase 3,Other|Industry,Interventional,4/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01156597
2864,Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH,Completed,Has Results,Kidney Diseases,Drug: H.P. Acthar Gel,Stanford University|Mallinckrodt,Stanford University,Mallinckrodt,,,,,,Phase 4,Other|Industry,Interventional,9/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01155141
2865,PEMF: an Adjunct Therapy for Anterior Uveitis,Completed,Has Results,Anterior Uveitis|Iritis,Device: PEMF|Device: PEMF Placebo,Massachusetts Eye and Ear Infirmary|BioElectronics Corporation,Massachusetts Eye and Ear Infirmary,BioElectronics Corporation,,,,,,Not Applicable,Other|Industry,Interventional,8/9/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01154010
2866,Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue,Completed,Has Results,Metabolic Syndrome|Insulin Resistance,Drug: Rosiglitazone|Drug: Placebo,"University of Massachusetts, Worcester|GlaxoSmithKline","University of Massachusetts, Worcester",GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,11/6/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01150981
2867,Alteration in Timing of Plerixafor Administration,Completed,Has Results,Autologous Transplantation,Drug: Plerixafor,"Emory University|Genzyme, a Sanofi Company",Emory University,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,6/10/2019,,https://ClinicalTrials.gov/show/NCT01149863
2868,Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.,Completed,Has Results,Major Depressive Disorder,Drug: Lisdexamfetamine Dimesylate (Vyvanse)|Drug: Placebo,Mclean Hospital|Shire,Mclean Hospital,Shire,,,,,,Phase 4,Other|Industry,Interventional,9/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01148979
2869,Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion,Completed,Has Results,Healthy,Drug: ertapenem,Hartford Hospital|Merck Sharp & Dohme Corp.,Hartford Hospital,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01148771
2870,Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver,Completed,Has Results,Hepatitis B|Liver Transplantation,Drug: Adefovir dipivoxil and hepatitis B vaccination,Columbia University|Gilead Sciences,Columbia University,Gilead Sciences,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/6/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01146808
2871,Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial,Completed,Has Results,Hypertension,Other: Active Outreach to Patients and Providers,"University of Colorado, Denver|Novartis Pharmaceuticals","University of Colorado, Denver",Novartis Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,11/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01145391
2872,Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab,Completed,Has Results,Osteoarthritis of the Knee,Drug: Infliximab|Drug: Placebo|Drug: Standard of Care: Methylprednisolone acetate,"Herbert Lindsley, MD|Centocor, Inc.|University of Kansas Medical Center","Herbert Lindsley, MD","Centocor, Inc.",University of Kansas Medical Center,,,,,Phase 4,Other|Industry,Interventional,7/7/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01144143
2873,Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes,Completed,Has Results,Partially Edentulous Mandible|Type 2 Diabetes,Device: dental implant and modified dental implant,The University of Texas Health Science Center at San Antonio|Institut Straumann AG,The University of Texas Health Science Center at San Antonio,Institut Straumann AG,,,,,,Not Applicable,Other|Industry,Interventional,7/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01142297
2874,Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders,Completed,Has Results,Autism Spectrum Disorder,Drug: sapropterin dihydrochloride,"The University of Texas Health Science Center, Houston|BioMarin Pharmaceutical","The University of Texas Health Science Center, Houston",BioMarin Pharmaceutical,,,,,,Not Applicable,Other|Industry,Interventional,7/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01141595
2875,Functional Performance of the Journey Deuce Bicompartmental Versus the Genesis II Total Knee System,Completed,Has Results,Knee Arthroplasty,Device: Total Knee Replacement|Device: Deuce,"Anderson Orthopaedic Research Institute|Smith & Nephew, Inc.",Anderson Orthopaedic Research Institute,"Smith & Nephew, Inc.",,,,,,Phase 4,Other|Industry,Interventional,9/7/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01140815
2876,Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics,Completed,Has Results,Dehydration|Cardiac Output|Pediatrics,Drug: Hylenex,Vanderbilt University Medical Center|Baxter Healthcare Corporation,Vanderbilt University Medical Center,Baxter Healthcare Corporation,,,,,,Phase 4,Other|Industry,Interventional,2/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01139294
2877,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Completed,Has Results,Gastric Bypass|Parathyroid Hormone,Drug: Paricalcitol|Drug: Cholecalciferol|Drug: Placebo,"Kerstyn C. Zalesin, M.D.|Abbott|William Beaumont Hospitals","Kerstyn C. Zalesin, M.D.",Abbott,William Beaumont Hospitals,,,,,Phase 3,Other|Industry,Interventional,7/10/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01138475
2878,TVT-SECUR as an Office-based Procedure,Completed,Has Results,Urinary Incontinence|Stress Urinary Incontinence,Device: Gynecare TVT-SECUR system,"Michigan Institution of Women's Health PC|Ethicon, Inc.",Michigan Institution of Women's Health PC,"Ethicon, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,10/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01137539
2879,CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL),Completed,Has Results,Acute Lymphoblastic Leukemia,Drug: CMC-544 (Inotuzumab Ozogamycin)|Drug: Rituximab,M.D. Anderson Cancer Center|Wyeth is now a wholly owned subsidiary of Pfizer,M.D. Anderson Cancer Center,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 2,Other|Industry,Interventional,6/4/2010,4/18/2018,https://ClinicalTrials.gov/show/NCT01134575
2880,Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection,Completed,Has Results,Kidney Transplantation,Drug: C1 Esterase Inhibitor|Drug: Placebos,"Stanley Jordan, MD|CSL Behring|Cedars-Sinai Medical Center","Stanley Jordan, MD",CSL Behring,Cedars-Sinai Medical Center,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01134510
2881,Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts,Completed,Has Results,Gingival Recession,Biological: CelTx™|Procedure: Free Gingival Graft,University of Michigan|Organogenesis,University of Michigan,Organogenesis,,,,,,Not Applicable,Other|Industry,Interventional,1/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT01134081
2882,Cetuximab and Lenalidomide in Head and Neck,Completed,Has Results,Squamous Cell Carcinoma,Drug: Cetuximab and Lenalidomide,University of Chicago|Celgene Corporation,University of Chicago,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,2/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01133665
2883,Midvastus Versus Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty,Completed,Has Results,Osteoarthritis,Procedure: Total knee arthroplasty,Heekin Orthopedic Research Institute|Stryker Orthopaedics,Heekin Orthopedic Research Institute,Stryker Orthopaedics,,,,,,Not Applicable,Other|Industry,Interventional,1/6/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01132378
2884,Comparative Study of Sham Versus Mild® Procedure in Patients Diagnosed With Symptomatic Lumbar Central Canal Stenosis,Completed,Has Results,Lumbar Spine Stenosis Central Canal,Device: Percutaneous Lumbar Decompression|Device: Sham lumbar decompression,"Napa Pain Institute|Vertos Medical, Inc.",Napa Pain Institute,"Vertos Medical, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,4/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01129921
2885,Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness,Completed,Has Results,Post Traumatic Stiffness,Drug: Botulinum Toxin Type A|Drug: Saline,Columbia University|Allergan,Columbia University,Allergan,,,,,,Not Applicable,Other|Industry,Interventional,11/3/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01129583
2886,Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR),Completed,Has Results,Treatment Resistant Nephrotic Syndrome,Drug: ACTHAR gel,Columbia University|Mallinckrodt,Columbia University,Mallinckrodt,,,,,,Phase 4,Other|Industry,Interventional,12/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01129284
2887,Fat Perception in Humans (09-0873),Completed,Has Results,Obesity,,Washington University School of Medicine|GlaxoSmithKline,Washington University School of Medicine,GlaxoSmithKline,,,,,,,Other|Industry,Observational,5/10/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01128400
2888,"Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation",Completed,Has Results,Aqueous Deficient Dry Eye|Meibomium Gland Dysfunction,"Behavioral: Subjective Questionnaire|Procedure: Measurement with wavefront sensor (right eye, then left eye)|Drug: Instill Saline Drop",University of Rochester|Bausch & Lomb Incorporated,University of Rochester,Bausch & Lomb Incorporated,,,,,,Not Applicable,Other|Industry,Interventional,6/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01128049
2889,RAD001 Plus Carboplatin in Breast Cancer Patients,Completed,Has Results,Breast Cancer,Drug: RAD001|Drug: Carboplatin,NYU Langone Health|Novartis Pharmaceuticals,NYU Langone Health,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,6/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01127763
2890,Oxazyme in Patients With Hyperoxaluria,Completed,Has Results,Hyperoxaluria,Drug: Oxazyme,Mayo Clinic|OxThera,Mayo Clinic,OxThera,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01127087
2891,Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection,Completed,Has Results,Impetigo|Folliculitis|Secondarily Infected Eczema|Minor Soft Tissue Infections,Drug: Retapamulin (Altabax),"The University of Texas Health Science Center, Houston|GlaxoSmithKline","The University of Texas Health Science Center, Houston",GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,4/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01126268
2892,Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty,Completed,Has Results,Osteoarthritis|Arthritis|Joint Diseases|Musculoskeletal Diseases|Rheumatic Diseases,Device: Total Hip Replacement,Anderson Orthopaedic Research Institute|DePuy Orthopaedics,Anderson Orthopaedic Research Institute,DePuy Orthopaedics,,,,,,Not Applicable,Other|Industry,Interventional,12/1/1998,3/12/2019,https://ClinicalTrials.gov/show/NCT01121146
2893,A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Minocycline,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 1|Phase 2,NIH|Industry,Interventional,4/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01120899
2894,A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study),Completed,Has Results,Age Related Macular Degeneration,Drug: Ranibizumab,"Vitreous -Retina- Macula Consultants of New York|Genentech, Inc.",Vitreous -Retina- Macula Consultants of New York,"Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01115556
2895,"Functional Status, Morbidity and Mortality in Cemented Versus Press-Fit Hemiarthroplasty",Completed,Has Results,Femoral Neck Fracture,"Device: Cemented Hip Hemiarthroplasty|Device: VerSys Beaded FullCoat, Zimmer",Hartford Hospital|Zimmer Biomet,Hartford Hospital,Zimmer Biomet,,,,,,Not Applicable,Other|Industry,Interventional,3/5/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT01114646
2896,AMG 102 and Avastin for Recurrent Malignant Glioma,Completed,Has Results,Glioblastoma Multiforme|Gliosarcoma,Drug: AMG 102|Drug: Avastin,Katy Peters|Amgen|Duke University,Katy Peters,Amgen,Duke University,,,,,Phase 2,Other|Industry,Interventional,8/10/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01113398
2897,Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome,Completed,Has Results,Down Syndrome,Drug: Memantine|Drug: Placebo,"University of Colorado, Denver|Forest Laboratories","University of Colorado, Denver",Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,7/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01112683
2898,Clinical and Translational Study of STA-9090,Completed,Has Results,Colon Cancer|Rectal Cancer,Drug: STA-9090,Memorial Sloan Kettering Cancer Center|Synta Pharmaceuticals Corp.,Memorial Sloan Kettering Cancer Center,Synta Pharmaceuticals Corp.,,,,,,Phase 2,Other|Industry,Interventional,4/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01111838
2899,Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD),Completed,Has Results,Graft-Versus-Host Disease,Drug: Panobinostat (LBH589),H. Lee Moffitt Cancer Center and Research Institute|Novartis,H. Lee Moffitt Cancer Center and Research Institute,Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/10/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01111526
2900,Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function,Completed,Has Results,Cardiovascular Diseases,Drug: Estradiol+MPA|Drug: Estradiol+Drospirenone,Brigham and Women's Hospital|Bayer,Brigham and Women's Hospital,Bayer,,,,,,Phase 4,Other|Industry,Interventional,12/9/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01109979
2901,Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage,Completed,Has Results,Nasopharyngeal Carriage of S. Pneumoniae,,Boston Medical Center|Merck Sharp & Dohme Corp.,Boston Medical Center,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,4/10/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01109108
2902,Heart Function in HIV-Negative Children Exposed to HIV and HAART,Completed,Has Results,HIV Infections,,Washington University School of Medicine|GlaxoSmithKline,Washington University School of Medicine,GlaxoSmithKline,,,,,,,Other|Industry,Observational,5/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01107834
2903,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,Completed,Has Results,Stage III Melanoma|Stage IV Melanoma|Unresectable Melanoma,Drug: Pazopanib and Paclitaxel,"University of California, Irvine|GlaxoSmithKline","University of California, Irvine",GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,8/10/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT01107665
2904,Treatment of Hemorrhagic Radiation Proctitis Using the Halo System,Completed,Has Results,Pelvic Neoplasms,Device: HALO90 Ablation catheter,"University Hospitals Cleveland Medical Center|Covidien, GI Solutions",University Hospitals Cleveland Medical Center,"Covidien, GI Solutions",,,,,,Not Applicable,Other|Industry,Interventional,7/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT01103492
2905,Pilot Study Using a Wireless Motility Capsule,Completed,Has Results,Food Selection,Device: SmartPill,University of Minnesota - Clinical and Translational Science Institute|General Mills Inc.,University of Minnesota - Clinical and Translational Science Institute,General Mills Inc.,,,,,,Not Applicable,Other|Industry,Interventional,8/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01102894
2906,Prandial Insulin Dosing in Hospitalized Patients,Completed,Has Results,Diabetes|Admitting Hospital|Non-critically Ill,Drug: Aspart fixed dose|Drug: Aspart flexible dose,Kathleen Dungan|Novo Nordisk A/S|Ohio State University,Kathleen Dungan,Novo Nordisk A/S,Ohio State University,,,,,Phase 4,Other|Industry,Interventional,6/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01101867
2907,Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection,Completed,Has Results,Myeloma|Lymphoma,Drug: Plerixafor,"Emory University|Genzyme, a Sanofi Company",Emory University,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,3/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01095757
2908,Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis,Completed,Has Results,Systemic Sclerosis|Scleroderma,Drug: Ambrisentan,University of Pennsylvania|Gilead Sciences,University of Pennsylvania,Gilead Sciences,,,,,,Not Applicable,Other|Industry,Interventional,2/10/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01093885
2909,Pre-operative Preparation Using 2% Chlorhexidine Cloth For Shoulder Surgery,Completed,Has Results,Post-operative Surgical Site Infections,Drug: 2% Chlorhexidine cloth,"Northwestern University|Sage Products, Inc.",Northwestern University,"Sage Products, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,1/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01090479
2910,Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis,Completed,Has Results,Moderate to Severe Palmar Plantar Psoriasis,Drug: Ustekinumab,"Tufts Medical Center|Centocor, Inc.",Tufts Medical Center,"Centocor, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,2/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01090063
2911,Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS),Completed,Has Results,Constipation-predominant Irritable Bowel Syndrome,Drug: Lubiprostone|Drug: Placebo,"Cedars-Sinai Medical Center|Takeda Pharmaceuticals North America, Inc.",Cedars-Sinai Medical Center,"Takeda Pharmaceuticals North America, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,3/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01085643
2912,"Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,12/2/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01082939
2913,Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet,Completed,Has Results,Ischemia,Drug: ambrisentan,Soumya Chatterjee|Gilead Sciences|The Cleveland Clinic,Soumya Chatterjee,Gilead Sciences,The Cleveland Clinic,,,,,Not Applicable,Other|Industry,Interventional,2/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01072669
2914,Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Tysabri,University of Chicago|Biogen,University of Chicago,Biogen,,,,,,Not Applicable,Other|Industry,Interventional,4/10/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01071512
2915,Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome,Completed,Has Results,Chronic Fatigue Syndrome|Cognitive Impairments,"Drug: Lisdexamfetamine Dimesylate|Drug: Placebo ""30, 50 or 70 mg""",Rochester Center for Behavioral Medicine|Shire,Rochester Center for Behavioral Medicine,Shire,,,,,,Phase 4,Other|Industry,Interventional,11/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01071044
2916,Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: LDX Treatment,NYU Langone Health|Shire,NYU Langone Health,Shire,,,,,,Phase 4,Other|Industry,Interventional,2/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01070394
2917,Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Disorder With Hyperactivity,Drug: Guanfacine Extended Release|Drug: Placebo,The University of Texas Health Science Center at San Antonio|Shire,The University of Texas Health Science Center at San Antonio,Shire,,,,,,Phase 4,Other|Industry,Interventional,3/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01069523
2918,Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery,Completed,Has Results,Rubeosis Iridis|Proliferative Diabetic Retinopathy,Drug: Ranibizumab,"Bhagat, Neelakshi, M.D., M.P.H.|Genentech, Inc.","Bhagat, Neelakshi, M.D., M.P.H.","Genentech, Inc.",,,,,,Phase 1,Other|Industry,Interventional,7/7/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01069341
2919,Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain,Completed,Has Results,Chest Pain Syndrome,Radiation: Comprehensive Cardiothoracic CT arm,"Massachusetts General Hospital|Bracco Diagnostics, Inc",Massachusetts General Hospital,"Bracco Diagnostics, Inc",,,,,,Phase 4,Other|Industry,Interventional,5/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT01067456
2920,Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis,Completed,Has Results,Chronic Rhinosinusitis|Nasal Polyps,Drug: Xolair placebo|Drug: Xolair (omalizumab),"Massachusetts General Hospital|Genentech, Inc.",Massachusetts General Hospital,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01066104
2921,A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Hydrogel vehicle|Drug: Eucerin Lotion,"Derm Research, PLLC|Bayer","Derm Research, PLLC",Bayer,,,,,,Phase 4,Other|Industry,Interventional,2/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01065714
2922,Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis|Secondary Infection,Drug: Retapamulin 1%,"Derm Research, PLLC|GlaxoSmithKline","Derm Research, PLLC",GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,2/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01064947
2923,Topical Cyclosporine Suspension for the Treatment of Brittle Nails,Completed,Has Results,Brittle Nail Syndrome,Drug: topical cyclosporine ophthalmic suspension 0.05%|Drug: vehicle,"University of North Carolina, Chapel Hill|Allergan","University of North Carolina, Chapel Hill",Allergan,,,,,,Phase 2,Other|Industry,Interventional,2/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01064830
2924,Phase II Study of Tesetaxel in Metastatic Melanoma,Completed,Has Results,Advanced Melanoma|Cancer,Drug: Tesetaxel,M.D. Anderson Cancer Center|Genta Incorporated,M.D. Anderson Cancer Center,Genta Incorporated,,,,,,Phase 2,Other|Industry,Interventional,2/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01064713
2925,Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Osmotic Release Methylphenidate,Massachusetts General Hospital|ElMindA Ltd,Massachusetts General Hospital,ElMindA Ltd,,,,,,Phase 4,Other|Industry,Interventional,9/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01063153
2926,Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function,Completed,Has Results,Hypertension,Drug: Nebivolol,Mercy Research|Forest Laboratories,Mercy Research,Forest Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,11/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01056718
2927,Telemonitoring Versus Usual Care,Completed,Has Results,Health Care Quality|Health Care Access,Device: Intel Health Guide|Other: Usual Care,Mayo Clinic|GE Healthcare,Mayo Clinic,GE Healthcare,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,11/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01056640
2928,Effect of Methylnaltrexone on GI Transit in Healthy Volunteers,Completed,Has Results,Gastric Motility Disorder,Drug: Methylnaltrexone only|Drug: Codeine only|Drug: Methylnaltrexone + codeine|Drug: Placebo + placebo,Mayo Clinic|Wyeth is now a wholly owned subsidiary of Pfizer,Mayo Clinic,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 4,Other|Industry,Interventional,11/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01055704
2929,Can We Miss Pigmented Lesions in Psoriasis Patients?,Completed,Has Results,Psoriasis|Melanoma|Non-melanoma Skin Cancer,Drug: etanercept,University of Alabama at Birmingham|Amgen,University of Alabama at Birmingham,Amgen,,,,,,Phase 4,Other|Industry,Interventional,9/7/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01053819
2930,A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer,Completed,Has Results,Colorectal Cancer,Drug: Temozolomide|Drug: ABT-888,Georgetown University|Abbott,Georgetown University,Abbott,,,,,,Phase 2,Other|Industry,Interventional,9/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01051596
2931,The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma,Completed,Has Results,Venous Thromboembolism,Drug: Dalteparin sodium|Drug: Dalteparin sodium/aspirin,Denver Health and Hospital Authority|Eisai Inc.,Denver Health and Hospital Authority,Eisai Inc.,,,,,,Not Applicable,Other|Industry,Interventional,3/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01050153
2932,Contrastim Stroke Trial,Completed,Has Results,Stroke,Device: Repetititve transcranial magnetic stimulation,Shirley Ryan AbilityLab|Nexstim Ltd,Shirley Ryan AbilityLab,Nexstim Ltd,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/10/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01049802
2933,A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Fluocinonide Cream 0.1%,Wake Forest University Health Sciences|Medicis Pharmaceutical Corporation,Wake Forest University Health Sciences,Medicis Pharmaceutical Corporation,,,,,,Phase 4,Other|Industry,Interventional,3/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT01049243
2934,The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension,Completed,Has Results,High Blood Pressure,Drug: Nebivolol|Drug: Metoprolol XL,Emory University|Forest Laboratories,Emory University,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,12/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01049009
2935,Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD),Completed,Has Results,Critically Ill Renal Failure Requiring CVVHD and Oseltamivir|Critically Ill Requiring ECMO and Oseltamivir,Procedure: pharmacokinetic blood sampling|Procedure: pharmacokinetic blood and dialysate sampling,University of Michigan|Roche Pharma AG,University of Michigan,Roche Pharma AG,,,,,,Phase 4,Other|Industry,Interventional,10/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT01048879
2936,Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375),Completed,Has Results,Insomnia|Obstructive Sleep Apnea,Drug: rozerem|Drug: Placebo,University of Pennsylvania|Takeda,University of Pennsylvania,Takeda,,,,,,Phase 3,Other|Industry,Interventional,7/6/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT01048242
2937,Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: clindamycin phosphate 1.2% and tretinoin 0.025%|Drug: clindamycin 1% gel|Drug: tretinoin 0.025% cream,Wake Forest University|Medicis Pharmaceutical Corporation|Wake Forest University Health Sciences,Wake Forest University,Medicis Pharmaceutical Corporation,Wake Forest University Health Sciences,,,,,Phase 4,Other|Industry,Interventional,3/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT01047189
2938,Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults,Completed,Has Results,HIV|Endothelial Dysfunction|Inflammation|Insulin Resistance,Drug: Salsalate,University Hospitals Cleveland Medical Center|Bristol-Myers Squibb,University Hospitals Cleveland Medical Center,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,1/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT01046682
2939,Open Label Pilot Study of Apremilast in Treatment of Rosacea,Completed,Has Results,Erythematotelangiectatic Rosacea|Papulopustular Rosacea,Drug: Apremilast,Julian M. Mackay-Wiggan|Celgene Corporation|Columbia University,Julian M. Mackay-Wiggan,Celgene Corporation,Columbia University,,,,,Phase 2,Other|Industry,Interventional,6/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01045551
2940,Nebivolol in the Supine Hypertension of Autonomic Failure,Completed,Has Results,Hypertension|Pure Autonomic Failure|Multiple System Atrophy,Drug: Placebo|Drug: Nebivolol 5 mg|Drug: metoprolol tartrate 50 mg|Drug: Sildenafil25 mg,Vanderbilt University|Forest Laboratories,Vanderbilt University,Forest Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,1/10/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01044693
2941,Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study),Completed,Has Results,"Transplant; Failure, Kidney",Drug: Myfortic Escalation,East Carolina University|Novartis Pharmaceuticals,East Carolina University,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,1/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01044303
2942,Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Metoprolol succinate,Emory University|Forest Laboratories,Emory University,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,12/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01041287
2943,Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH),Completed,Has Results,Acne Vulgaris|Post Inflammatory Hyperpigmentation,Drug: Azelaic acid,"Derm Research, PLLC|Bayer","Derm Research, PLLC",Bayer,,,,,,Phase 4,Other|Industry,Interventional,12/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01038869
2944,5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML),Completed,Has Results,Leukemia,Drug: 5-Azacytidine|Drug: Lenalidomide,M.D. Anderson Cancer Center|Celgene,M.D. Anderson Cancer Center,Celgene,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/9/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01038635
2945,"Blood Flow, Muscle Regeneration and Sarcopenia",Completed,Has Results,Sarcopenia,,University of Florida|Merck Sharp & Dohme Corp.,University of Florida,Merck Sharp & Dohme Corp.,,,,,,,Other|Industry,Observational,6/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01035060
2946,Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia,Completed,Has Results,Hypertriglyceridemia,Drug: POM3|Drug: Placebo,Provident Clinical Research|GlaxoSmithKline,Provident Clinical Research,GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,3/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01034540
2947,Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease,Completed,Has Results,Inflammatory Bowel Disease|Uterine Cervical Dysplasia,Biological: Human Papillomavirus Vaccine,Mayo Clinic|Merck Sharp & Dohme Corp.,Mayo Clinic,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,2/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01034358
2948,Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting,Completed,Has Results,Acute Myelogenous Leukemia|Chemotherapy-induced Nausea and Vomiting,Drug: Ondansetron|Drug: Palonosetron,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT01031498
2949,Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain,Completed,Has Results,Breast Cancer,Drug: Duloxetine,University of Michigan Rogel Cancer Center|Eli Lilly and Company,University of Michigan Rogel Cancer Center,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,10/8/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01028352
2950,"Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters",Completed,Has Results,Urethral Sphincter Activity,Drug: Pseudoephedrine|Drug: Tamsulosin|Drug: Imipramine|Drug: Cyclobenzaprine|Drug: Lactose capsule|Drug: Solifenacin,University of Alabama at Birmingham|Astellas Pharma Inc,University of Alabama at Birmingham,Astellas Pharma Inc,,,,,,Not Applicable,Other|Industry,Interventional,4/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01028014
2951,Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients,Completed,Has Results,Sepsis,Drug: Doripenem,"Emory University|Ortho-McNeil Janssen Scientific Affairs, LLC",Emory University,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 4,Other|Industry,Interventional,4/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01027897
2952,Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty,Completed,Has Results,Arthritis,Device: Vitagel,The Cleveland Clinic|Orthovita d/b/a Stryker,The Cleveland Clinic,Orthovita d/b/a Stryker,,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01027286
2953,Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing,Completed,Has Results,Cardiac Function,Drug: regadenoson,"University of Maryland|Astellas Pharma US, Inc.",University of Maryland,"Astellas Pharma US, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,12/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01026012
2954,"Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction",Completed,Has Results,Acute Myeloid Leukemia,Drug: Clofarabine|Drug: Idarubicin|Drug: Cytarabine,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,1/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01025154
2955,Efficacy Study to Evaluate Laparoscopic Fascial Closure Device,Completed,Has Results,"Hernia, Abdominal",Device: Port Close,"Stanford University|SurgSolutions, LLC",Stanford University,"SurgSolutions, LLC",,,,,,Not Applicable,Other|Industry,Interventional,7/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01024296
2956,A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID),Completed,Has Results,Post Operative Anterior Chamber Inflammation (Flare),Drug: Ketorolac Tromethamine 0.45%|Drug: Bromfenac 0.09%,Bucci Laser Vision Institute|Allergan,Bucci Laser Vision Institute,Allergan,,,,,,Phase 4,Other|Industry,Interventional,12/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01023724
2957,Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging,Completed,Has Results,Coronary Artery Disease|Myocardial Ischemia,Drug: Regadenoson|Other: Symptom-limited exercise,Hartford Hospital|Astellas Pharma Inc,Hartford Hospital,Astellas Pharma Inc,,,,,,Not Applicable,Other|Industry,Interventional,1/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01021618
2958,Radiosurgery and Avastin for Recurrent Malignant Gliomas,Completed,Has Results,Malignant Glioma,Radiation: Stereotactic Radiosurgery (SRS)|Drug: Bevacizumab,"Duke University|Genentech, Inc.",Duke University,"Genentech, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,12/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01017250
2959,Azacitidine and Lenalidomide for Acute Myeloid Leukemia,Completed,Has Results,"Leukemia, Myeloid, Acute",Drug: Lenalidomide|Drug: Azacitidine,Washington University School of Medicine|Celgene Corporation,Washington University School of Medicine,Celgene Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01016600
2960,Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease,Completed,Has Results,Chronic Kidney Disease|Bacterial Infection,Drug: Daptomycin,University of Oklahoma|Cubist Pharmaceuticals LLC,University of Oklahoma,Cubist Pharmaceuticals LLC,,,,,,Not Applicable,Other|Industry,Interventional,11/9/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01012089
2961,Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age,Completed,Has Results,Chronic Lymphocytic Leukemia|Leukemia,Drug: lenalidomide,Memorial Sloan Kettering Cancer Center|Celgene Corporation,Memorial Sloan Kettering Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,11/6/2009,2/23/2016,https://ClinicalTrials.gov/show/NCT01011894
2962,"Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects",Completed,Has Results,Hypertriglyceridemia|HIV Infection,Dietary Supplement: Lovaza|Drug: fosamprenavir/ritonavir,"Felizarta, Franco, M.D.|GlaxoSmithKline","Felizarta, Franco, M.D.",GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,9/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01010399
2963,Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: PL nasal spray|Drug: fluticasone furoate (FF)|Drug: PL eye drops|Drug: olopatadine (OLO),University of Chicago|GlaxoSmithKline,University of Chicago,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,11/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01007253
2964,Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency,Completed,Has Results,Hypopituitarism,Drug: Human Growth Hormone (1-134)|Drug: Placebo,"Stanford University|Genentech, Inc.",Stanford University,"Genentech, Inc.",,,,,,Phase 3,Other|Industry,Interventional,11/1/2009,12/12/2012,https://ClinicalTrials.gov/show/NCT01007071
2965,Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease,Completed,Has Results,Nonalcoholic Fatty Liver Disease|Type 2 Diabetes Mellitus,Drug: Exenatide,"University of Florida|Amylin Pharmaceuticals, LLC.",University of Florida,"Amylin Pharmaceuticals, LLC.",,,,,,Phase 4,Other|Industry,Interventional,1/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01006889
2966,Sirolimus Conversions in African-American Renal Transplant Recipients,Completed,Has Results,Absence; Kidney,"Drug: rapamune, mycophenolate mofetil and steroid|Drug: tacrolimus, sirolimus and steroid",Medical University of South Carolina|Wyeth is now a wholly owned subsidiary of Pfizer,Medical University of South Carolina,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,8/9/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01005706
2967,Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma,Completed,Has Results,Diffuse Large B Cell Lymphoma,Biological: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: doxorubicin|Drug: prednisone|Drug: azacytidine,Weill Medical College of Cornell University|Celgene,Weill Medical College of Cornell University,Celgene,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/10/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01004991
2968,Metabolic Effects of Paricalcitol,Completed,Has Results,Chronic Kidney Disease,Drug: Paricalcitol|Drug: Placebo,University of Washington|Abbott,University of Washington,Abbott,,,,,,Phase 2,Other|Industry,Interventional,10/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01003275
2969,Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions,Completed,Has Results,Retinal Vein Occlusion,Drug: Ranibizumab 0.5mg (monthly)|Drug: Ranibizumab 2.0mg (monthly)|Drug: Pro re nata (prn) ranibizumab|Procedure: Pro re nata (prn) Laser photocoagulation,"Peter A Campochiaro, MD|Genentech, Inc.|Johns Hopkins University","Peter A Campochiaro, MD","Genentech, Inc.",Johns Hopkins University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/9/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01003106
2970,"A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification",Completed,Has Results,Cataracts,Drug: Ketorolac Tromethamine 0.45%|Drug: bromfenac 0.09%|Drug: nepafenac 0.1%,"Frank A. Bucci, Jr., M.D.|Allergan|Bucci Laser Vision Institute","Frank A. Bucci, Jr., M.D.",Allergan,Bucci Laser Vision Institute,,,,,Phase 4,Other|Industry,Interventional,10/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT01001806
2971,Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life,Completed,Has Results,Hypertension,Drug: Metoprolol|Drug: Nebivolol,Weill Medical College of Cornell University|Forest Laboratories,Weill Medical College of Cornell University,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,10/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00999102
2972,Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients,Completed,Has Results,Hepatitis B,Procedure: glucose monitoring before and after HepaGam B administration|Biological: HepaGam B (Hepatitis B Immune Globulin (HBIG)),Georgetown University|Cangene Corporation,Georgetown University,Cangene Corporation,,,,,,Phase 4,Other|Industry,Interventional,10/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00998426
2973,Patient Comfort With Vascular Closure,Completed,Has Results,Vascular Closure,Device: Mynx Vascular Closure Device|Device: AngioSeal Vascular Closure Device,"University of Florida|Access Pharmaceuticals, Inc.",University of Florida,"Access Pharmaceuticals, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,10/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00998023
2974,"Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)",Completed,Has Results,Metastatic Pancreatic Cancer,"Drug: Gemcitabine, Docetaxel, Capecitabine",Columbia University|Sanofi,Columbia University,Sanofi,,,,,,Phase 2,Other|Industry,Interventional,6/3/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00996333
2975,Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis,Completed,Has Results,Lumbar Spinal Stenosis,Device: MILD® (Minimally Invasive Lumbar Decompression)|Drug: Epidural Steroid Injection,"Coastal Orthopedics & Sports Medicine|Vertos Medical, Inc.",Coastal Orthopedics & Sports Medicine,"Vertos Medical, Inc.",,,,,,Phase 4,Other|Industry,Interventional,8/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00995371
2976,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",Completed,Has Results,Pancreatic Cancer,Drug: Pasireotide (SOM230)|Other: placebo,Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals,Memorial Sloan Kettering Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 3,Other|Industry,Interventional,10/9/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00994110
2977,Nebivolol Versus Metoprolol: Sodium Sensitivity,Completed,Has Results,Hypertension,Drug: nebivolol|Drug: Metoprolol,University of Miami|Forest Laboratories,University of Miami,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,12/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00992056
2978,Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment,Completed,Has Results,Esophageal Lesion,Diagnostic Test: PillCam ESO Capsule Endoscope,The Cleveland Clinic|Given Imaging Ltd.,The Cleveland Clinic,Given Imaging Ltd.,,,,,,Not Applicable,Other|Industry,Interventional,9/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00990782
2979,Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide,Completed,Has Results,Brain and Central Nervous System Tumors,Drug: Bortezomib|Drug: Temozolomide,"Northwestern University|Millennium Pharmaceuticals, Inc.",Northwestern University,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,5/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00990652
2980,The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery,Completed,Has Results,Blood Loss,Drug: Hemostatic Matrix,"Hospital for Special Surgery, New York|Baxter Healthcare Corporation","Hospital for Special Surgery, New York",Baxter Healthcare Corporation,,,,,,Phase 4,Other|Industry,Interventional,10/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00990288
2981,Endothelin Blockade in Patients With Single Ventricle Physiology,Completed,Has Results,Congenital Heart Disease,Drug: Bosentan,"University of California, Los Angeles|Actelion","University of California, Los Angeles",Actelion,,,,,,Not Applicable,Other|Industry,Interventional,5/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00989911
2982,Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,Completed,Has Results,Lymphoma,"Biological: milatuzumab|Biological: veltuzumab|Procedure: Correlative/Special Studies|Procedure: Quantitative T-, B-, and NK cell subsets|Procedure: Pharmacokinetics|Procedure: Human Anti-Human Antibodies|Biological: veltuzumab and milatuzumab","Beth Christian|Immunomedics, Inc.|Ohio State University Comprehensive Cancer Center",Beth Christian,"Immunomedics, Inc.",Ohio State University Comprehensive Cancer Center,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/9/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT00989586
2983,The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems,Completed,Has Results,Parkinsons Disease With Dementia|Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems,Drug: Rivastigmine Patch 9.5 cm2,"University of California, San Francisco|Novartis","University of California, San Francisco",Novartis,,,,,,Phase 4,Other|Industry,Interventional,4/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00988117
2984,Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels,Completed,Has Results,HIV Infections,Drug: maraviroc (Selzentry),University of Hawaii|Pfizer,University of Hawaii,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,1/10/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00987948
2985,Restasis for Treatment of Brittle Nails,Completed,Has Results,Brittle Nails,Drug: Restasis (cyclosporine ophthalmic emulsion) 0.05%|Drug: Refresh® Dry Eye therapy,Julian M. Mackay-Wiggan|Allergan|Columbia University,Julian M. Mackay-Wiggan,Allergan,Columbia University,,,,,Phase 2,Other|Industry,Interventional,7/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00986427
2986,Brain Imaging of Quetiapine Response in Anxious Depression,Completed,Has Results,Major Depression,Drug: quetiapine (Seroquel XR),Indiana University School of Medicine|AstraZeneca|Indiana University,Indiana University School of Medicine,AstraZeneca,Indiana University,,,,,Phase 4,Other|Industry,Interventional,3/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00982345
2987,Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction,Completed,Has Results,Heart Failure,Drug: aliskiren|Drug: placebo,Wake Forest University Health Sciences|Novartis Pharmaceuticals,Wake Forest University Health Sciences,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00982033
2988,Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme,Completed,Has Results,Glioblastoma Multiforme|Gliosarcoma,Drug: Avastin|Drug: Temozolomide|Drug: Irinotecan,"Katy Peters|Genentech, Inc.|Duke University",Katy Peters,"Genentech, Inc.",Duke University,,,,,Phase 2,Other|Industry,Interventional,11/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00979017
2989,Erlotinib Study for Myelodysplastic Syndrome (MDS),Completed,Has Results,Myelodysplastic Syndrome,Drug: Erlotinib,"H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc.",H. Lee Moffitt Cancer Center and Research Institute,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00977548
2990,Orthotic Use for Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Device: Shoe orthotic|Device: Shoe Orthotic Wait Group,"National University of Health Sciences|Foot Levelers, Inc.",National University of Health Sciences,"Foot Levelers, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,6/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00976664
2991,Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors,Completed,Has Results,Neurofibromatosis 2|Vestibular Schwannoma,Drug: Lapatinib,NYU Langone Health|GlaxoSmithKline,NYU Langone Health,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,9/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00973739
2992,Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant,Completed,Has Results,Liver Transplantation,Biological: Thymoglobulin 3mg total|Biological: Thymoglobulin 4.5mg total|Drug: Mycophenolate mofetil|Drug: tacrolimus 3-8|Drug: tacrolimus 8-12,"The Cleveland Clinic|Genzyme, a Sanofi Company",The Cleveland Clinic,"Genzyme, a Sanofi Company",,,,,,Not Applicable,Other|Industry,Interventional,8/9/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00970073
2993,Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA),Completed,Has Results,Osteoarthritis,Drug: EUFLEXXA,"Georgia Institute for Clinical Research, LLC|Ferring Pharmaceuticals","Georgia Institute for Clinical Research, LLC",Ferring Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,8/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00969501
2994,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,Completed,Has Results,Leukemia|Acute Lymphocytic Leukemia,Drug: Everolimus (RAD001)|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Mesna|Drug: Methotrexate|Drug: Ara-C (Cytarabine)|Drug: Methylprednisone|Drug: G-CSF,M.D. Anderson Cancer Center|Novartis,M.D. Anderson Cancer Center,Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/9/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00968253
2995,Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma,Completed,Has Results,Lymphoma,Drug: Panobinostat|Drug: Everolimus,M.D. Anderson Cancer Center|Novartis,M.D. Anderson Cancer Center,Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/9/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00967044
2996,Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients,Completed,Has Results,Pancreatic Cancer|Venous Thromboembolism,Drug: Dalteparin,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 4,Other|Industry,Interventional,4/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00966277
2997,Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Carvedilol,Virginia Commonwealth University|GlaxoSmithKline,Virginia Commonwealth University,GlaxoSmithKline,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00964678
2998,Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE),Completed,Has Results,Eosinophilic Esophagitis,Drug: inhaled/swallowed budesonide|Drug: viscous/swallowed budesonide,"University of North Carolina, Chapel Hill|AstraZeneca","University of North Carolina, Chapel Hill",AstraZeneca,,,,,,Not Applicable,Other|Industry,Interventional,10/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00961233
2999,Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects,Completed,Has Results,HIV,Drug: Truvada|Drug: Combivir|Drug: Trizivir,St. Luke's-Roosevelt Hospital Center|Gilead Sciences,St. Luke's-Roosevelt Hospital Center,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00960622
3000,Study of Bortezomib in Combination With Cyclophosphamide and Rituximab,Completed,Has Results,Mantle Cell Lymphoma|Lymphoma,Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Mesna|Drug: G-CSF,"M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.",M.D. Anderson Cancer Center,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/9/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00958256
3001,CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML),Completed,Has Results,Leukemia,Drug: CLAG Regimen|Drug: Gleevec®,H. Lee Moffitt Cancer Center and Research Institute|Novartis,H. Lee Moffitt Cancer Center and Research Institute,Novartis,,,,,,Phase 2,Other|Industry,Interventional,8/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00955916
3002,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,Completed,Has Results,Hematologic Diseases|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia,Drug: Ondansetron|Drug: Aprepitant,M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.,M.D. Anderson Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Phase 2,Other|Industry,Interventional,11/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00954941
3003,Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression,Completed,Has Results,Major Depressive Disorder,Drug: Escitalopram|Drug: Aripiprazole|Drug: Placebo Capsule|Drug: Placebo Tablet,Washington University School of Medicine|Bristol-Myers Squibb,Washington University School of Medicine,Bristol-Myers Squibb,,,,,,Not Applicable,Other|Industry,Interventional,5/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00953745
3004,A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion,Completed,Has Results,Central Retinal Vein Occlusion,"Device: fluocinolone acetonide (Retisert Implant, Bausch and Lomb)",Glenn Jaffe|Bausch & Lomb Incorporated|Duke University,Glenn Jaffe,Bausch & Lomb Incorporated,Duke University,,,,,Not Applicable,Other|Industry,Interventional,10/2/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00952614
3005,Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV,Completed,Has Results,PONV,Drug: Palonosetron only|Drug: Palonosetron with Dexamethasone,NYU Langone Health|Eisai Inc.,NYU Langone Health,Eisai Inc.,,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00952133
3006,A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients,Completed,Has Results,Hypertension|Brain Tumor|Epilepsy,Drug: Clevidipine,NYU Langone Health|The Medicines Company,NYU Langone Health,The Medicines Company,,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00952081
3007,Measuring Smoking Behaviors While Using Varenicline,Completed,Has Results,Nicotine Dependence,Drug: Varenicline,University of Pennsylvania|Pfizer,University of Pennsylvania,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00948155
3008,Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema,Completed,Has Results,Atopic Dermatitis,Drug: Pimecrolimus|Other: Vehicle cream,"University of California, San Diego|Novartis","University of California, San Diego",Novartis,,,,,,Not Applicable,Other|Industry,Interventional,10/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00946478
3009,Pomalidomide for Myelofibrosis Patients,Completed,Has Results,Polycythemia Vera|Thrombocythemia,Drug: CC-4047|Drug: Prednisone,M.D. Anderson Cancer Center|Celgene,M.D. Anderson Cancer Center,Celgene,,,,,,Phase 2,Other|Industry,Interventional,7/22/2009,5/22/2018,https://ClinicalTrials.gov/show/NCT00946270
3010,Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity,Completed,Has Results,Upper Limb Spasticity,"Drug: Botulinum toxin type A, BoNT-A|Other: Rehabilitation Therapy",JoAnn Harnar|Allergan|Biomedical Research Institute of New Mexico,JoAnn Harnar,Allergan,Biomedical Research Institute of New Mexico,,,,,Not Applicable,Other|Industry,Interventional,1/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00945295
3011,Relapse Prevention With Varenicline,Completed,Has Results,Recurrence|Smoking Cessation|Substance-Related Disorders,Drug: Varenicline|Drug: Placebo,Johns Hopkins University|Pfizer,Johns Hopkins University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,10/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00944554
3012,Open-Label Extension Study of Kuvan for Autism,Completed,Has Results,Autistic Disorder,Drug: Kuvan®,The Children's Health Council|BioMarin Pharmaceutical,The Children's Health Council,BioMarin Pharmaceutical,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,8/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00943579
3013,A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm,Completed,Has Results,Focal Dystonia,Drug: Acetyl-Hexapeptide Topical Treatment|Drug: placebo,National Institute of Neurological Disorders and Stroke (NINDS)|BCN Peptides|National Institutes of Health Clinical Center (CC),National Institute of Neurological Disorders and Stroke (NINDS),BCN Peptides,National Institutes of Health Clinical Center (CC),,,,,Phase 1|Phase 2,NIH|Industry,Interventional,7/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00942851
3014,"Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment",Completed,Has Results,Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer,Drug: fluorouracil|Drug: leucovorin calcium|Drug: vorinostat|Other: pharmacological study,Roswell Park Cancer Institute|Merck Sharp & Dohme Corp.,Roswell Park Cancer Institute,Merck Sharp & Dohme Corp.,,,,,,Phase 2,Other|Industry,Interventional,7/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00942266
3015,Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia,Completed,Has Results,Leukemia,Drug: GM-CSF (Sargramostim)|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,10/12/2004,1/5/2017,https://ClinicalTrials.gov/show/NCT00940342
3016,Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis,Completed,Has Results,Continuous Ambulatory Peritoneal Dialysis|End Stage Renal Disease,Drug: ertapenem,Albany College of Pharmacy and Health Sciences|Merck Sharp & Dohme Corp.,Albany College of Pharmacy and Health Sciences,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,6/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00939952
3017,Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA),Completed,Has Results,Multiple Sclerosis,Drug: Copaxone,"University at Buffalo|Teva Neuroscience, Inc.",University at Buffalo,"Teva Neuroscience, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,9/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00937157
3018,Daily Wear Corneal Infiltrative Event Study,Completed,Has Results,Myopia|Hyperopia|Corneal Infiltrative Events,Device: lotrafilcon A contact lenses|Device: Renu Multiplus|Device: Clear Care,University Hospitals Cleveland Medical Center|Alcon Research,University Hospitals Cleveland Medical Center,Alcon Research,,,,,,Phase 4,Other|Industry,Interventional,11/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00937105
3019,Antifungal Locks to Treat Fungal-related Central Line Infections,Completed,Has Results,Central Line Fungal Infections,Drug: amphotericin B liposomal (Ambisome),Bill McGhee|Astellas Pharma Inc|University of Pittsburgh,Bill McGhee,Astellas Pharma Inc,University of Pittsburgh,,,,,Phase 4,Other|Industry,Interventional,9/6/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00936910
3020,Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal,Completed,Has Results,Acute Alcohol Withdrawal,Drug: Dexmedetomidine|Other: Placebo,"University of Colorado, Denver|Hospira, now a wholly owned subsidiary of Pfizer","University of Colorado, Denver","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Not Applicable,Other|Industry,Interventional,9/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00936377
3021,Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia,Completed,Has Results,Leukemia|Fungal Infection,Drug: Posaconazole,M.D. Anderson Cancer Center|Schering-Plough,M.D. Anderson Cancer Center,Schering-Plough,,,,,,Phase 2,Other|Industry,Interventional,9/9/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00936117
3022,Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD),Completed,Has Results,Age-Related Macular Degeneration,Drug: Eculizumab|Drug: Saline,"Philip J. Rosenfeld, MD, PhD|Alexion Pharmaceuticals|University of Miami","Philip J. Rosenfeld, MD, PhD",Alexion Pharmaceuticals,University of Miami,,,,,Phase 2,Other|Industry,Interventional,7/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00935883
3023,Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: memantine|Drug: Placebo,NYU Langone Health|Forest Laboratories,NYU Langone Health,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00933608
3024,Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients,Completed,Has Results,"Arrhythmias, Cardiac","Device: continuous cardiac monitoring device (REVEAL, Medtronic)",Duke University|Medtronic,Duke University,Medtronic,,,,,,,Other|Industry,Observational,6/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00932659
3025,Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy,Completed,Has Results,Peanut Hypersensitivity,Drug: Peanut Oral Immunotherapy|Drug: Omalizumab,"University of North Carolina, Chapel Hill|Genentech, Inc.","University of North Carolina, Chapel Hill","Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/9/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00932282
3026,Lovaza® and Microvascular Function in Type 2 Diabetes,Completed,Has Results,Hypertriglyceridemia|Diabetic Neuropathy,Drug: omega-3-ethyl esters|Drug: Placebo,Eastern Virginia Medical School|GlaxoSmithKline,Eastern Virginia Medical School,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,10/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00931879
3027,Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD),Completed,Has Results,Age Related Macular Degeneration,Drug: ranibizumab (Lucentis(R)),"Lawrence S. Morse, MD|Genentech, Inc.|University of California, Davis","Lawrence S. Morse, MD","Genentech, Inc.","University of California, Davis",,,,,Phase 2,Other|Industry,Interventional,8/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00931489
3028,Study of Apremilast in Atopic or Contact Dermatitis,Completed,Has Results,Atopic Dermatitis|Allergic Contact Dermatitis,Drug: Apremilast,Tufts Medical Center|Celgene Corporation,Tufts Medical Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,6/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00931242
3029,Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer,Completed,Has Results,Ovarian Cancer|Primary Peritoneal Cancer,Drug: imatinib mesylate by mouth|Drug: Gemcitabine Intravenous,Henry M. Jackson Foundation for the Advancement of Military Medicine|Novartis,Henry M. Jackson Foundation for the Advancement of Military Medicine,Novartis,,,,,,Phase 2,Other|Industry,Interventional,6/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00928642
3030,Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery,Completed,Has Results,"Pain, Postoperative",Drug: Bupivacaine Block|Drug: Placebo,"Stanford University|Hospira, now a wholly owned subsidiary of Pfizer",Stanford University,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 4,Other|Industry,Interventional,8/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00927888
3031,Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance,Completed,Has Results,"Carcinoma, Hepatocellular",Device: C-arm CT + DSA as needed|Device: DSA only,Stanford University|Siemens Healthcare Diagnostics Inc,Stanford University,Siemens Healthcare Diagnostics Inc,,,,,,Not Applicable,Other|Industry,Interventional,4/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00926536
3032,"Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis",Completed,Has Results,Osteoporosis,Drug: denosumab|Drug: teriparatide,Massachusetts General Hospital|Amgen,Massachusetts General Hospital,Amgen,,,,,,Phase 2,Other|Industry,Interventional,6/9/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00926380
3033,Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy,Completed,Has Results,Extrahepatic Bile Duct Cancer|Gallbladder Cancer,Drug: Gemcitabine|Drug: Cisplatin|Drug: Sorafenib,Memorial Sloan Kettering Cancer Center|Bayer,Memorial Sloan Kettering Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,8/9/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00919061
3034,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,Completed,Has Results,Esophageal Cancer|Gastroesophageal Junction Cancer,"Drug: Sorafenib, administered orally|Procedure: CT/MRI",Memorial Sloan Kettering Cancer Center|Bayer,Memorial Sloan Kettering Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,6/9/2019,8/18/2019,https://ClinicalTrials.gov/show/NCT00917462
3035,Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone,Completed,Has Results,Hyperglycemia|Hyperlipidemia,Drug: Olanzapine|Drug: Ziprasidone,Washington University School of Medicine|Pfizer,Washington University School of Medicine,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,2/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00910988
3036,Validation of a Real-time Urodynamic Measure of Urinary Urgency,Completed,Has Results,Overactive Bladder Syndrome,Drug: Solifenacin Succinate,Loyola University|Astellas Pharma Inc,Loyola University,Astellas Pharma Inc,,,,,,Phase 4,Other|Industry,Interventional,1/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00909428
3037,Brain Imaging Techniques That Predict Antidepressant Responsiveness,Completed,Has Results,Major Depressive Disorder,Drug: Venlafaxine ERT|Drug: Fluoxetine,"University of Wisconsin, Madison|Wyeth is now a wholly owned subsidiary of Pfizer","University of Wisconsin, Madison",Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,7/2/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00909155
3038,Sirolimus as Therapeutic Approach to Uveitis,Completed,Has Results,Uveitis|Intermediate Uveitis|Posterior Uveitis|Panuveitis,Drug: Sirolimus (rapamycin),"Johns Hopkins University|MacuSight, Inc.",Johns Hopkins University,"MacuSight, Inc.",,,,,,Phase 1,Other|Industry,Interventional,7/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00908466
3039,Testing of Computer Aided Detection Software for Riverain Medical Group,Completed,Has Results,Lung Cancer,Behavioral: Software,Georgetown University|Riverain Technologies,Georgetown University,Riverain Technologies,,,,,,,Other|Industry,Observational,5/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00906789
3040,Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions,Completed,Has Results,Glaucoma,Drug: Cosopt (combination eyedrop of dorzolamide and timolol),University of Michigan|Merck Sharp & Dohme Corp.,University of Michigan,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,8/4/2009,7/18/2012,https://ClinicalTrials.gov/show/NCT00906087
3041,Optima: Optimizing Prograf Therapy in Maintenance Allografts II,Completed,Has Results,Kidney Transplantation,Drug: cyclosporine|Drug: Prograf (Tacrolimus),"East Carolina University|Astellas Pharma US, Inc.",East Carolina University,"Astellas Pharma US, Inc.",,,,,,Phase 4,Other|Industry,Interventional,8/3/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00905515
3042,"Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage",Completed,Has Results,"Leukemia, Lymphocytic, Acute",Drug: Methotrexate|Drug: Vincristine|Drug: PEG-l-asparaginase|Drug: Dexamethasone|Drug: Rituximab,"M.D. Anderson Cancer Center|Leadiant Biosciences, Inc.",M.D. Anderson Cancer Center,"Leadiant Biosciences, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/9/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT00905034
3043,Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis,Completed,Has Results,Leukemia|Fungal Infection,Drug: Voriconazole,M.D. Anderson Cancer Center|Pfizer,M.D. Anderson Cancer Center,Pfizer,,,,,,Phase 3,Other|Industry,Interventional,5/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00904995
3044,Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma,Completed,Has Results,Lymphoma,Drug: CT-011|Drug: Rituximab,M.D. Anderson Cancer Center|CureTech Ltd,M.D. Anderson Cancer Center,CureTech Ltd,,,,,,Phase 2,Other|Industry,Interventional,1/10/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT00904722
3045,Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS),Completed,Has Results,Myelodysplastic Syndrome,Drug: Decitabine|Drug: Clofarabine,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,1/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00903760
3046,Impact of Vitamin D Supplementation on Lactation Associated Bone Loss,Completed,Has Results,Osteoporosis,Drug: Vitamin D3|Dietary Supplement: Multivitamin,"Leigh Eck, MD|Bio-Tech Pharmacal, Inc.|University of Kansas Medical Center","Leigh Eck, MD","Bio-Tech Pharmacal, Inc.",University of Kansas Medical Center,,,,,Not Applicable,Other|Industry,Interventional,12/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00903344
3047,Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP),Completed,Has Results,Immune Thrombocytopenia,Drug: Eltrombopag|Drug: Romiplostim|Other: healthy controls,Weill Medical College of Cornell University|GlaxoSmithKline,Weill Medical College of Cornell University,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,1/9/2019,9/7/2015,https://ClinicalTrials.gov/show/NCT00902018
3048,Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant,Completed,Has Results,Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease,Drug: G-CSF plus Plerixafor,"Duke University|Genzyme, a Sanofi Company",Duke University,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,5/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00901225
3049,Comparison of Mobile-Bearing and Fixed-Bearing All-Polyethylene Tibia Total Knee Designs,Completed,Has Results,"Osteoarthritis, Knee",Procedure: TKA surgery with the rotating platform mobile-bearing knee design|Procedure: TKA surgery with the all-polyethylene tibia knee design,"Minneapolis Veterans Affairs Medical Center|Depuy, Inc.",Minneapolis Veterans Affairs Medical Center,"Depuy, Inc.",,,,,,Phase 4,U.S. Fed|Industry,Interventional,10/1/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00894361
3050,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Completed,Has Results,Smoking Cessation,"Drug: Nicotine Patches|Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|Drug: Nicotine patches, then varenicline (Pre-Quit)|Drug: Nicotine patches, then nicotine patches (Pre-Quit)|Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit)|Drug: Nicotine patches, then varenicline (Post-Quit)|Drug: Nicotine patches, then nicotine patches (Post-Quit)","Duke University|Philip Morris USA, Inc.",Duke University,"Philip Morris USA, Inc.",,,,,,Phase 3,Other|Industry,Interventional,5/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00894166
3051,Acupuncture for Chemo-Induced Peripheral Neuropathy,Completed,Has Results,Lymphoma|Myeloma|Peripheral Neuropathy,Other: Acupuncture,"M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.",M.D. Anderson Cancer Center,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,4/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00891618
3052,Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms,Completed,Has Results,Allergic Conjunctivitis to Tree Pollen or Grass Pollen,Drug: Fluticasone furoate nasal spray|Drug: Placebo nasal spray,Rush University Medical Center|GlaxoSmithKline,Rush University Medical Center,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,4/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00891436
3053,Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myeloid Leukemia (AML)|Adult Acute Myeloblastic Leukemia,Drug: Lenalidomide|Drug: Azacitidine,Stanford University|Celgene Corporation,Stanford University,Celgene Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00890929
3054,Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage,Completed,Has Results,Acute Lymphoblastic Leukemia,Drug: Cyclophosphamide (CTX)|Drug: Vincristine|Drug: Doxorubicin|Drug: Decadron|Drug: G-CSF|Drug: Methotrexate (MTX)|Drug: Ara-C|Drug: Pegaspargase,"M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.",M.D. Anderson Cancer Center,"Enzon Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/3/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00890656
3055,"A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis",Completed,Has Results,Leukemia|Amyloidosis,Drug: Lenalidomide|Drug: Melphalan|Drug: Dexamethasone,Stanford University|Celgene Corporation,Stanford University,Celgene Corporation,,,,,,Not Applicable,Other|Industry,Interventional,4/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00890552
3056,Eszopiclone Treatment & Cortisol Responsivity,Completed,Has Results,Insomnia,Drug: eszopiclone,Butler Hospital|Sunovion,Butler Hospital,Sunovion,,,,,,Phase 4,Other|Industry,Interventional,5/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00889200
3057,Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes,Completed,Has Results,Sarcoma|Leiomyosarcoma|Malignant Fibrous|Histiocytoma|Angiosarcoma,Drug: gemcitabine|Drug: docetaxel|Drug: bevacizumab,"Memorial Sloan Kettering Cancer Center|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,4/9/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00887809
3058,Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS,Completed,Has Results,Anxiety Disorders|HIV Infections,Drug: Escitalopram,Duke University|Forest Laboratories,Duke University,Forest Laboratories,,,,,,Phase 3,Other|Industry,Interventional,5/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00887679
3059,Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes,Completed,Has Results,MELAS Syndrome,Drug: Idebenone|Other: Placebo,Michio Hirano|Santhera Pharmaceuticals|Columbia University,Michio Hirano,Santhera Pharmaceuticals,Columbia University,,,,,Phase 2,Other|Industry,Interventional,5/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00887562
3060,Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy,Completed,Has Results,Urticaria,Drug: abatacept (Orencia ®),Johns Hopkins University|Bristol-Myers Squibb,Johns Hopkins University,Bristol-Myers Squibb,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00886795
3061,Management of Pruritus With Xyzal in Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis|Pruritus,Drug: Levocetirizine dihydrochloride (Xyzal)|Drug: placebo,"Derm Research, PLLC|UCB Pharma","Derm Research, PLLC",UCB Pharma,,,,,,Phase 4,Other|Industry,Interventional,2/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00884325
3062,Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS),Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: Decitabine|Drug: Gemtuzumab ozogamicin,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 2,Other|Industry,Interventional,4/9/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00882102
3063,Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis,Completed,Has Results,Suspected Eosinophilic Esophagitis,Procedure: Esophageal dilation|Drug: Steroid and Proton Pump Inhibitor Therapy,Vanderbilt University|Takeda|Vanderbilt University Medical Center,Vanderbilt University,Takeda,Vanderbilt University Medical Center,,,,,Not Applicable,Other|Industry,Interventional,8/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00880906
3064,A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas,Completed,Has Results,"Lymphoma, Non-Hodgkin|Lymphoma|Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell|Lymphomas: Non-Hodgkin",Drug: PF-3512676|Radiation: Local radiotherapy,Ronald Levy|Pfizer|Stanford University,Ronald Levy,Pfizer,Stanford University,,,,,Phase 2,Other|Industry,Interventional,1/9/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00880581
3065,Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer,Completed,Has Results,Arm Lymphedema|Truncal Lymphedema|Breast Cancer,Device: Flexitouch System,"Vanderbilt University|Tactile Systems Technology, Inc.",Vanderbilt University,"Tactile Systems Technology, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,5/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00880022
3066,"Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer",Completed,Has Results,Endometrial Carcinoma,"Drug: carboplatin, paclitaxel, and bevacizumab","The Cleveland Clinic|Genentech, Inc.",The Cleveland Clinic,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/7/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00879359
3067,LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed,Completed,Has Results,Hepatocellular Carcinoma,Drug: LC Bead loaded with doxorubicin,University of Pittsburgh|Biocompatibles UK Ltd,University of Pittsburgh,Biocompatibles UK Ltd,,,,,,Phase 2,Other|Industry,Interventional,11/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00877071
3068,Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study,Completed,Has Results,Endothelial Function|Lipids|Insulin Resistance|Inflammation|HIV Infections,Drug: Etravirine,"Indiana University|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Indiana University,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 1,Other|Industry,Interventional,4/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00871234
3069,Living Well With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Behavioral: IFS|Other: Education,Brigham and Women's Hospital|Bristol-Myers Squibb,Brigham and Women's Hospital,Bristol-Myers Squibb,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00869349
3070,Safety and Efficacy of CC-10004 for Prurigo Nodularis,Completed,Has Results,Prurigo Nodularis,Drug: CC-10004,University Hospitals Cleveland Medical Center|Celgene Corporation,University Hospitals Cleveland Medical Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,9/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00869089
3071,Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: Bendamustine HCL,University of Arizona|Cephalon,University of Arizona,Cephalon,,,,,,Phase 2,Other|Industry,Interventional,2/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00867503
3072,Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients,Completed,Has Results,Renal Transplant Rejection,"Drug: Sirolimus|Other: Demographic Data, Medical History, and Donor Data|Procedure: Blood Draws for Control Group|Procedure: Blood Draws for Experimental Group|Procedure: Donor Blood Draws|Other: Donor Information|Procedure: Kidney Biopsy",Northwestern University|Wyeth is now a wholly owned subsidiary of Pfizer,Northwestern University,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 4,Other|Industry,Interventional,6/7/2019,3/19/2019,https://ClinicalTrials.gov/show/NCT00866879
3073,Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall,Completed,Has Results,Soft Tissue Sarcoma,Drug: Sorafenib,"University of California, Davis|Bayer","University of California, Davis",Bayer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00864032
3074,The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers,Completed,Has Results,Healthy,"Drug: tenofovir, emtricitabine and efavirenz fixed dose tablet|Drug: tenofovir, emtricitabine and efavirenz tablet added to solution",University of Alabama at Birmingham|Bristol-Myers Squibb,University of Alabama at Birmingham,Bristol-Myers Squibb,,,,,,Phase 4,Other|Industry,Interventional,2/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00862823
3075,Self-Management of Cancer-Related Fatigue by Adolescents,Completed,Has Results,Neoplasms|Fatigue,Behavioral: 'Fatigue Facts & Fixes',Seattle Children's Hospital|Alex's Lemonade Stand Foundation,Seattle Children's Hospital,Alex's Lemonade Stand Foundation,,,,,,Not Applicable,Other|Industry,Interventional,4/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00862186
3076,Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL),Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Rituximab|Drug: Fludarabine|Drug: Lenalidomide,Georgetown University|Celgene Corporation,Georgetown University,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,2/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00860457
3077,Effects of Body Mass Index on the Hyperemic Response to Regadenoson,Completed,Has Results,Obesity|Endothelial Dysfunction|Decreased Vascular Flow,Drug: Adenosine|Drug: Regadenoson,University of Utah|Astellas Pharma Inc,University of Utah,Astellas Pharma Inc,,,,,,Not Applicable,Other|Industry,Interventional,2/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00859833
3078,Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists,Completed,Has Results,End Stage Renal Disease,Drug: Rabbit Antithymocyte globulin|Drug: Daclizumab,"Medical University of South Carolina|Genzyme, a Sanofi Company",Medical University of South Carolina,"Genzyme, a Sanofi Company",,,,,,Not Applicable,Other|Industry,Interventional,3/9/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00859131
3079,Homeopathic Cold Medicine for Children,Completed,Has Results,Upper Respiratory Tract Infection,Drug: Hyland's Cold 'n Cough 4 Kids,University of Washington|Standard Homeopathic Company,University of Washington,Standard Homeopathic Company,,,,,,Not Applicable,Other|Industry,Interventional,3/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00858494
3080,Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging,Completed,Has Results,Coronary Disease,Drug: regadenoson,University of Chicago|Astellas Pharma Inc,University of Chicago,Astellas Pharma Inc,,,,,,Not Applicable,Other|Industry,Interventional,3/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00857792
3081,Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?,Completed,Has Results,Glaucoma,Drug: Triesence|Drug: balanced salt solution BSS,Wills Eye|Alcon Research,Wills Eye,Alcon Research,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,2/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00853905
3082,Myocardial Stress Perfusion Imaging With Dual Source CT,Completed,Has Results,Coronary Artery Disease,Other: Adenosine Stress Dual-source CTP,Massachusetts General Hospital|Astellas Pharma Inc,Massachusetts General Hospital,Astellas Pharma Inc,,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00853671
3083,Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram,Completed,Has Results,Major Depressive Disorder,Drug: Creatine Monohydrate,"University of Utah|AlzChem, LLC",University of Utah,"AlzChem, LLC",,,,,,Phase 2,Other|Industry,Interventional,4/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00851006
3084,Sapropterin as a Treatment for Autistic Disorder,Completed,Has Results,Autistic Disorder,Drug: sapropterin|Drug: Placebo,The Children's Health Council|BioMarin Pharmaceutical,The Children's Health Council,BioMarin Pharmaceutical,,,,,,Phase 2,Other|Industry,Interventional,3/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00850070
3085,Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults,Completed,Has Results,Weight Gain,Drug: Exenatide|Drug: Placebo,University of Cincinnati|Eli Lilly and Company,University of Cincinnati,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,12/8/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00845507
3086,Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit,Completed,Has Results,Constipation,Drug: Lubiprostone,University of Louisville|Takeda,University of Louisville,Takeda,,,,,,Phase 4,Other|Industry,Interventional,5/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00844831
3087,Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy,Completed,Has Results,Endothelial Function|Rheumatoid Arthritis|Inflammation,Drug: Rituxan,"University of California, San Francisco|Genentech, Inc.","University of California, San Francisco","Genentech, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/9/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00844714
3088,Fruit and Vegetable Juice Concentrate Effects on RBP4 and Antioxidant Capacity in Lean and Overweight 6-10 Year Old Boys,Completed,Has Results,Obesity,Dietary Supplement: Fruit and Vegetable Juice Concentrate (FVJC)|Dietary Supplement: Placebo,"Nemours Children's Clinic|NSA, LLC",Nemours Children's Clinic,"NSA, LLC",,,,,,Not Applicable,Other|Industry,Interventional,7/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00842543
3089,Pramlintide in Adolescents With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: pramlintide,"University of Colorado, Denver|Amylin Pharmaceuticals, LLC.","University of Colorado, Denver","Amylin Pharmaceuticals, LLC.",,,,,,Not Applicable,Other|Industry,Interventional,12/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00842075
3090,Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins,Completed,Has Results,Candidemia,Drug: micafungin|Drug: Micafungin|Drug: Caspofungin,"Gary E. Stein, Pharm.D.|Astellas Pharma US, Inc.|Michigan State University","Gary E. Stein, Pharm.D.","Astellas Pharma US, Inc.",Michigan State University,,,,,Phase 4,Other|Industry,Interventional,12/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00839540
3091,Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy,Completed,Has Results,Polypoidal Choroidal Vasculopathy,Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc,"Southeast Retina Center, Georgia|Genentech, Inc.","Southeast Retina Center, Georgia","Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/6/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00837330
3092,Sorafenib and Dacarbazine in Soft Tissue Sarcoma,Completed,Has Results,Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor,Drug: Sorafenib and Dacarbazine,Memorial Sloan Kettering Cancer Center|Bayer,Memorial Sloan Kettering Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,2/9/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00837148
3093,Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer,Completed,Has Results,Skin Cancer|Basal Cell Carcinoma|Squamous Cell Carcinoma,,Massachusetts General Hospital|Nu Skin Enterprises,Massachusetts General Hospital,Nu Skin Enterprises,,,,,,,Other|Industry,Observational,2/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00836342
3094,Phase II Study of Irinotecan and Panitumumab,Completed,Has Results,Esophageal Cancer,Drug: Panitumumab|Drug: Irinotecan,"Weijing Sun, MD, FACP|Amgen|University of Pittsburgh","Weijing Sun, MD, FACP",Amgen,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,5/9/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00836277
3095,An Alternative Dosing Schedule of Varenicline for Smoking Cessation,Completed,Has Results,Smoking Cessation,Drug: varenicline|Drug: placebo,Roswell Park Cancer Institute|Pfizer,Roswell Park Cancer Institute,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,3/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00835900
3096,Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial,Completed,Has Results,Delirium|Postoperative Cognitive Dysfunction,Drug: Rivastigmine Patch|Other: Placebo Patch,NYU Langone Health|Novartis,NYU Langone Health,Novartis,,,,,,Phase 4,Other|Industry,Interventional,12/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00835159
3097,Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia,Completed,Has Results,High Triglycerides|Hypercholesterolemia|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder,Drug: Lovaza,Massachusetts General Hospital|GlaxoSmithKline,Massachusetts General Hospital,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00833976
3098,Escitalopram (Lexapro) for the Treatment of Postpartum Depression,Completed,Has Results,Postpartum Depression,Drug: Escitalopram,Massachusetts General Hospital|Forest Laboratories,Massachusetts General Hospital,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00833469
3099,Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Alefacept,"Rush University Medical Center|Astellas Pharma US, Inc.",Rush University Medical Center,"Astellas Pharma US, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00832585
3100,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Completed,Has Results,Pre-diabetes,Drug: Rosiglitazone|Drug: Placebo Rosiglitazone|Drug: Simvastatin,University of Chicago|GlaxoSmithKline,University of Chicago,GlaxoSmithKline,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,9/6/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00831129
3101,Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2),Completed,Has Results,"Fractures, Closed",Other: 75 mmHg suction|Other: 125 mmHg,University of Missouri-Columbia|Medtronic,University of Missouri-Columbia,Medtronic,,,,,,Not Applicable,Other|Industry,Interventional,12/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00829621
3102,Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries,Completed,Has Results,Hypertension|Diabetes,Drug: nebivolol|Drug: Metoprolol,University of Chicago|Forest Laboratories,University of Chicago,Forest Laboratories,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,1/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00829296
3103,Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma,Completed,Has Results,Allergic Asthma,Drug: RhuMab-E25,"Duke University|Genentech, Inc.",Duke University,"Genentech, Inc.",,,,,,Phase 3,Other|Industry,Interventional,10/2/2019,7/4/2019,https://ClinicalTrials.gov/show/NCT00829179
3104,The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia,Completed,Has Results,Depression|Anxiety|Insomnia,Drug: Eszopiclone|Drug: Placebo,"Steward St. Elizabeth's Medical Center of Boston, Inc.|Sunovion","Steward St. Elizabeth's Medical Center of Boston, Inc.",Sunovion,,,,,,Phase 4,Other|Industry,Interventional,8/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00826111
3105,Omega-3 for Peri- and Postmenopausal Depression,Completed,Has Results,Depression,Drug: Omega-3 Fatty Acids,Massachusetts General Hospital|GlaxoSmithKline,Massachusetts General Hospital,GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,11/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00825994
3106,Brain Effects of Escitalopram and Citalopram Using fMRI,Completed,Has Results,Antidepressant Activity in Healthy Volunteers,Drug: Escitalopram|Drug: Citalopram|Drug: Placebo,"Michael Henry, MD|Forest Laboratories|Steward St. Elizabeth's Medical Center of Boston, Inc.","Michael Henry, MD",Forest Laboratories,"Steward St. Elizabeth's Medical Center of Boston, Inc.",,,,,Phase 4,Other|Industry,Interventional,5/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00825825
3107,Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients,Completed,Has Results,Hematological Malignancies,Drug: Ibandronate|Drug: Vitamin Supplements,M.D. Anderson Cancer Center|Roche Pharma AG,M.D. Anderson Cancer Center,Roche Pharma AG,,,,,,Phase 3,Other|Industry,Interventional,12/9/2008,4/7/2017,https://ClinicalTrials.gov/show/NCT00824993
3108,"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin",Completed,Has Results,Stem Cell Transplantation|Leukemia,Drug: Plerixafor|Drug: Filgrastim|Drug: Fludarabine|Drug: Busulfan|Procedure: Allogeneic blood stem cell transplant|Drug: ATG (Thymoglobulin),"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00822770
3109,Tadalafil for the Treatment of Raynaud's,Completed,Has Results,Raynaud,Drug: Tadalafil,Northwestern University|Eli Lilly and Company,Northwestern University,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00822354
3110,Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer (NSCLC),Drug: Vorinostat|Radiation: Radiotherapy,Yale University|Merck Sharp & Dohme Corp.,Yale University,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,5/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00821951
3111,VANOS Cream and Skin Barrier Function,Completed,Has Results,Atopic Dermatitis,Drug: Fluocinonide,Oregon Health and Science University|Medicis Pharmaceutical Corporation,Oregon Health and Science University,Medicis Pharmaceutical Corporation,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,6/21/2010,https://ClinicalTrials.gov/show/NCT00819507
3112,Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease,Completed,Has Results,Chronic Graft Versus Host Disease,Drug: bortezomib|Drug: Prednisone,"Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.",Dana-Farber Cancer Institute,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/8/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00815919
3113,Validation of Brain Oxygenation Monitor,Completed,Has Results,Healthy,Device: Desaturation,"Duke University|Nonin Medical, Inc",Duke University,"Nonin Medical, Inc",,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00815490
3114,Study of Sorafenib/Cetuximab in Head and Neck Cancer,Completed,Has Results,Squamous Cell Cancer,Drug: Sorafenib|Drug: Cetuximab,Duke University|Bayer,Duke University,Bayer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/8/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00815295
3115,Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Bicalutamide|Drug: Everolimus,"University of California, Davis|Novartis","University of California, Davis",Novartis,,,,,,Phase 2,Other|Industry,Interventional,12/8/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT00814788
3116,CC-10004 For The Treatment Of Vulvodynia,Completed,Has Results,Vulvodynia,Drug: CC-10004,"Kenneth Peters, MD|Celgene Corporation|William Beaumont Hospitals","Kenneth Peters, MD",Celgene Corporation,William Beaumont Hospitals,,,,,Phase 2,Other|Industry,Interventional,12/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00814632
3117,Zolpidem CR and Hospitalized Patients With Dementia,Completed,Has Results,"Dementia|Alzheimer Disease|Dementia, Vascular|Sleep Disorders|Circadian Dysregulation",Drug: Zolpidem CR|Drug: Placebo,Massachusetts General Hospital|Sanofi,Massachusetts General Hospital,Sanofi,,,,,,Not Applicable,Other|Industry,Interventional,12/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00814502
3118,Varenicline in Bipolar Depressed Patients,Completed,Has Results,Smoking|Bipolar Disorder|Depression,Drug: Varenicline,Mark Frye|Pfizer|Mayo Clinic,Mark Frye,Pfizer,Mayo Clinic,,,,,Not Applicable,Other|Industry,Interventional,1/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00813800
3119,Sorafenib in Treating Patients With Advanced Malignant Solid Tumors,Completed,Has Results,"Unspecified Adult Solid Tumor, Protocol Specific",Drug: Sorafenib,"University of California, Davis|Bayer","University of California, Davis",Bayer,,,,,,Phase 2,Other|Industry,Interventional,12/8/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00810394
3120,Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome,Completed,Has Results,Myelodysplastic Syndrome|Aplastic Anemia,Drug: Thymoglobulin|Drug: Cyclosporine|Drug: Methylprednisolone|Drug: G-CSF,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,5/5/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00806598
3121,An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: emollient (Cetaphil cream),Oregon Health and Science University|Galderma,Oregon Health and Science University,Galderma,,,,,,Phase 2,Other|Industry,Interventional,11/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00806221
3122,The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers,Completed,Has Results,Muscle Damage|Muscle Inflammation,Drug: Lovaza (omega-3-acid ethyl esters)|Drug: Wheat Germ Oil,Western Michigan University|GlaxoSmithKline,Western Michigan University,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,3/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00805870
3123,Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure,Completed,Has Results,Normal Contact Lens Wear,Drug: Clear Care|Drug: ReNu|Drug: OPTI-FREE,Christine Sindt|Alcon Research|University of Iowa,Christine Sindt,Alcon Research,University of Iowa,,,,,Not Applicable,Other|Industry,Interventional,11/1/2008,3/1/2009,https://ClinicalTrials.gov/show/NCT00804999
3124,Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding,Completed,Has Results,HIV|HIV Infections,Drug: Valacyclovir|Drug: Placebo,University of Alabama at Birmingham|GlaxoSmithKline,University of Alabama at Birmingham,GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,1/9/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00803543
3125,An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects,Completed,Has Results,Healthy,Drug: Raltegravir|Drug: Fosamprenavir|Drug: Ritonavir,"Garden State Infectious Disease Associates, PA|GlaxoSmithKline","Garden State Infectious Disease Associates, PA",GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,12/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00802074
3126,Effect of Vyvanse on Driving in Young Adults With ADHD,Completed,Has Results,Attention Deficit/Hyperactivity Disorder(ADHD),Drug: Vyvanse|Drug: Placebo,Massachusetts General Hospital|Shire,Massachusetts General Hospital,Shire,,,,,,Phase 4,Other|Industry,Interventional,12/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00801229
3127,Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors,Completed,Has Results,Gynecologic Tumors,Drug: Oral Topotecan|Drug: Pazopanib,Vector Oncology|GlaxoSmithKline,Vector Oncology,GlaxoSmithKline,,,,,,Phase 1,Other|Industry,Interventional,4/9/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT00800345
3128,A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH),Completed,Has Results,Fatty Liver,Drug: Cysteamine,"Joel Lavine|Raptor Pharmaceuticals Corp.|University of California, San Diego",Joel Lavine,Raptor Pharmaceuticals Corp.,"University of California, San Diego",,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00799578
3129,How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?,Completed,Has Results,Glaucoma,Drug: Xalatan|Drug: Travatan Z,Wills Eye|Pfizer,Wills Eye,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,11/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00798694
3130,"Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer",Completed,Has Results,"Cancer of Head|Cancer of Head and Neck|Cancer of Neck|Cancer of the Head|Cancer of the Head and Neck|Cancer of the Neck|Head and Neck Cancer|Head Cancer|Head Neoplasms|Head, Neck Neoplasms|Neck Cancer|Neck Neoplasms|Neoplasms, Head|Neoplasms, Head and Neck|Neoplasms, Neck|Neoplasms, Upper Aerodigestive Tract|UADT Neoplasms|Upper Aerodigestive Tract Neoplasms",Drug: Panitumumab|Drug: Cisplatin|Radiation: Radiation Therapy,Robert Ferris|Amgen|University of Pittsburgh,Robert Ferris,Amgen,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,11/7/2019,11/9/2016,https://ClinicalTrials.gov/show/NCT00798655
3131,The Effect of an Azygos Vein Coil on Defibrillation Threshold,Completed,Has Results,Heart Failure,Device: Standard configuration vs. azygos coil,Washington University School of Medicine|Medtronic,Washington University School of Medicine,Medtronic,,,,,,Not Applicable,Other|Industry,Interventional,12/15/2008,11/18/2009,https://ClinicalTrials.gov/show/NCT00798174
3132,"Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Fludarabine Phosphate|Drug: Cyclophosphamide|Drug: Rituximab,"M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/3/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00794820
3133,Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen,Completed,Has Results,Allergic Rhinitis,Drug: fluticasone furoate|Drug: Placebo,University of Chicago|GlaxoSmithKline,University of Chicago,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,11/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00791973
3134,Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease,Completed,Has Results,Pyoderma Gangrenosum|Crohn's Disease|Ulcerative Colitis|Inflammatory Bowel Disease,Drug: Infliximab,"University Hospitals Cleveland Medical Center|Centocor, Inc.",University Hospitals Cleveland Medical Center,"Centocor, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,10/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00791557
3135,Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC),Completed,Has Results,Allergic Rhinitis,Drug: ASP-1001 nasal spray|Drug: Placebo for ASP-1001,University of Chicago|Asphelia Pharmaceuticals,University of Chicago,Asphelia Pharmaceuticals,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,1/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00791102
3136,Objective Testing of Tear Film Stability,Completed,Has Results,Contact Lens Solutions,Device: Opti-Free® RepleniSH® MPDS|Device: ReNu MultiPlus®,Manhattan Vision Associates|Alcon Research,Manhattan Vision Associates,Alcon Research,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00789529
3137,Determination of Absorption and Elimination of Lamotrigine-XR,Completed,Has Results,Epilepsy|Seizures|Bipolar Disorder|Bipolar Depression,Drug: Extended Release Lamotrigine,University of Minnesota - Clinical and Translational Science Institute|GlaxoSmithKline,University of Minnesota - Clinical and Translational Science Institute,GlaxoSmithKline,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00789113
3138,SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma,Completed,Has Results,Lymphoma,Drug: Zolinza (vorinostat)|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone,M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.,M.D. Anderson Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00787527
3139,Study of Gamma Interfereon in Metastatic Colorectal Carcinoma,Completed,Has Results,Colorectal Cancer,Drug: 5-Fluorouracil|Drug: Leucovorin (LV)|Drug: Gamma-Interferon-1b (IFN-γ)|Drug: Bevacizumab,Accelerated Community Oncology Research Network|InterMune,Accelerated Community Oncology Research Network,InterMune,,,,,,Phase 2,Other|Industry,Interventional,2/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00786643
3140,Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women,Completed,Has Results,Systemic Lupus Erythematosus,Biological: Gardasil,University of Chicago|Merck Sharp & Dohme Corp.,University of Chicago,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,11/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00786409
3141,Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation,Completed,Has Results,End Stage Renal Disease,Drug: CMVIG,Tampa General Hospital|CSL Behring,Tampa General Hospital,CSL Behring,,,,,,Phase 4,Other|Industry,Interventional,1/2/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00784979
3142,The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics,Completed,Has Results,Atopic Asthma,Drug: abatacept|Drug: Placebo,Washington University School of Medicine|Bristol-Myers Squibb,Washington University School of Medicine,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,10/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00784459
3143,N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients,Completed,Has Results,Radiocontrast Nephropathy,Drug: N-Acetylcysteine (NAC)|Drug: 0.9% Sodium-chloride,Beth Israel Deaconess Medical Center|Cumberland Pharmaceuticals,Beth Israel Deaconess Medical Center,Cumberland Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,10/16/2007,8/9/2010,https://ClinicalTrials.gov/show/NCT00780962
3144,Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD,Completed,Has Results,Adult Attention Deficit Hyperactivity Disorder (ADHD),Drug: Daytrana (methylphenidate patch),Medical University of South Carolina|Shire,Medical University of South Carolina,Shire,,,,,,Not Applicable,Other|Industry,Interventional,4/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00780208
3145,Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections,Completed,Has Results,Staphylococcal Infections,Other: Nasal swabs for MRSA culture|Drug: Chlorhexidine gluconate|Other: Contact isolation,"Christiana Care Health Services|Sage Products, Inc.",Christiana Care Health Services,"Sage Products, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00779246
3146,Neuroimaging of the Effects of Concerta in the Treatment of ADHD,Completed,Has Results,Attention Deficit Disorder With Hyperactivity,Drug: methylphenidate-OROS|Drug: Placebo,"The University of Texas Health Science Center at San Antonio|Ortho-McNeil Janssen Scientific Affairs, LLC",The University of Texas Health Science Center at San Antonio,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 4,Other|Industry,Interventional,11/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00778310
3147,Follow-Up Extension to the Family Study of Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Other: No intervention.,"Mclean Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC",Mclean Hospital,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,,Other|Industry,Observational,6/5/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00777634
3148,Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,COPD,Drug: Arformoterol (Brovana)|Drug: Placebo,Saint Francis Care|Sunovion,Saint Francis Care,Sunovion,,,,,,Phase 4,Other|Industry,Interventional,10/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00773786
3149,Botox for Cervical Dystonia Following EMG Mapping,Completed,Has Results,Cervical Dystonia,Drug: Botulinum toxin A,"University of California, San Francisco|Allergan","University of California, San Francisco",Allergan,,,,,,Phase 4,Other|Industry,Interventional,4/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00773253
3150,Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients,Completed,Has Results,Renal Transplant Rejection|Transplants and Implants,Drug: Thymoglobulin,"University of Cincinnati|Genzyme, a Sanofi Company",University of Cincinnati,"Genzyme, a Sanofi Company",,,,,,Phase 4,Other|Industry,Interventional,9/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00771745
3151,Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes,Completed,Has Results,Diabetes,Drug: Pioglitazone then Placebo|Drug: Placebo then Pioglitazone,"Medical University of South Carolina|Takeda Pharmaceuticals North America, Inc.",Medical University of South Carolina,"Takeda Pharmaceuticals North America, Inc.",,,,,,Phase 4,Other|Industry,Interventional,10/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00770367
3152,The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT),Completed,Has Results,"Stem Cell Transplantation|Ventricular Dysfunction, Left",Biological: Autologous human mesenchymal cells (hMSCs)|Biological: Autologous human bone marrow cells (hBMCs)|Biological: Placebo,"University of Miami|The Emmes Company, LLC",University of Miami,"The Emmes Company, LLC",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00768066
3153,Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas,Completed,Has Results,Malignant Glioma,Biological: Dendritic vaccine pulsed with multiple peptides|Biological: The first booster vaccine phase:|Biological: The second booster vaccine phase:,"Frank Lieberman|Oncovir, Inc.|University of Pittsburgh",Frank Lieberman,"Oncovir, Inc.",University of Pittsburgh,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/6/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT00766753
3154,An Interaction Study to Assess Drug Levels in Healthy Adult Subjects,Completed,Has Results,Healthy,Drug: Maraviroc|Drug: Fosamprenavir|Drug: Ritonavir,"Garden State Infectious Disease Associates, PA|GlaxoSmithKline","Garden State Infectious Disease Associates, PA",GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,10/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00764465
3155,Trial Of Double Umbilical Cord Blood Transplantation,Completed,Has Results,Hematological Malignancies,"Procedure: Full intensity, double umbilical cord, stem cell transplant|Drug: Flu/Bu4 conditioning regimen|Radiation: Total Lymphoid Irradiation (TLI)|Drug: Graft versus Host Disease prevention (GVHD prophylaxis)|Drug: Mycophenolate Mofetil","University of Michigan Rogel Cancer Center|Otsuka Pharmaceutical Development & Commercialization, Inc.",University of Michigan Rogel Cancer Center,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/8/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT00763490
3156,Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients,Completed,Has Results,HIV Infections,"Drug: Raltegravir and truvada|Drug: Atazanavir, Norvir and Truvada","The University of Texas Health Science Center, Houston|Merck Sharp & Dohme Corp.","The University of Texas Health Science Center, Houston",Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00762892
3157,Comparison of Liquid Kaletra and Low Dose Kaletra Tablets,Completed,Has Results,HIV Infections,Drug: Low dose Kaletra tablets,Phoenix Children's Hospital|Abbott,Phoenix Children's Hospital,Abbott,,,,,,Not Applicable,Other|Industry,Interventional,10/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00762320
3158,The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa,Completed,Has Results,Anorexia Nervosa|Osteoporosis,Drug: Placebo|Drug: Teriparatide,Massachusetts General Hospital|Eli Lilly and Company,Massachusetts General Hospital,Eli Lilly and Company,,,,,,Phase 2,Other|Industry,Interventional,9/8/2019,2/22/2016,https://ClinicalTrials.gov/show/NCT00759772
3159,Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia,Completed,Has Results,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Lenalidomide|Drug: Rituximab,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,9/8/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00759603
3160,Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents,Completed,Has Results,Cystic Fibrosis,,"University of California, San Francisco|Genentech, Inc.","University of California, San Francisco","Genentech, Inc.",,,,,,,Other|Industry,Observational,10/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00758771
3161,Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study,Completed,Has Results,Arrhythmia,Drug: Atorvastatin|Drug: Placebo,University of Alabama at Birmingham|Pfizer,University of Alabama at Birmingham,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00756886
3162,Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy,Completed,Has Results,Alveolar Bone Loss,Biological: Tissue Repair Cells (TRC)|Device: Control,University of Michigan|Vericel Corporation,University of Michigan,Vericel Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00755911
3163,Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Arformoterol tartrate|Drug: Placebo: Normal Saline|Other: Treadmill Exercise|Other: Cycle Exercise,Dartmouth-Hitchcock Medical Center|Sunovion,Dartmouth-Hitchcock Medical Center,Sunovion,,,,,,Phase 4,Other|Industry,Interventional,8/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00754546
3164,Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults,Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: Lisdexamfetamine,Massachusetts General Hospital|Shire,Massachusetts General Hospital,Shire,,,,,,Phase 4,Other|Industry,Interventional,4/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00753012
3165,Vitamin D and Coronary Calcification Study,Completed,Has Results,Chronic Kidney Disease|Vitamin D Deficiency|Coronary Calcification|Disorders of Calcium and Bone Metabolism,Drug: Calcitriol (Rocaltrol®)|Drug: Paricalcitol,Joslin Diabetes Center|Abbott,Joslin Diabetes Center,Abbott,,,,,,Phase 4,Other|Industry,Interventional,9/8/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00752102
3166,Temperature Control in Central Fever in the Neuro-ICU,Completed,Has Results,Fever|Brain Hemorrhage,Device: Gaymar Rapr-Round (external cooling blanket),"Northwestern University|Gaymar Industries, Inc.",Northwestern University,"Gaymar Industries, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00751634
3167,Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC),Completed,Has Results,Invasive Fungal Infections|Hematologic Malignancies,Drug: Posaconazole|Drug: ABLC,"M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.",M.D. Anderson Cancer Center,"Enzon Pharmaceuticals, Inc.",,,,,,Phase 3,Other|Industry,Interventional,6/8/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00750737
3168,Pilot Study for Patients With Poor Response to Deferasirox,Completed,Has Results,Transfusion-dependent Hemachromatosis|Thalassemia Major|Sickle Cell Disease,Drug: Deferoxamine|Drug: Deferasirox|Radiation: HIDA,Boston Children’s Hospital|Novartis,Boston Children’s Hospital,Novartis,,,,,,Phase 4,Other|Industry,Interventional,3/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00749515
3169,A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer,Completed,Has Results,Advanced or Metastatic Solid Tumors|Advanced or Metastatic Breast Cancer,Drug: Azacitidine (Vidaza)|Drug: Nab-paclitaxel (Abraxane),University of Utah|Celgene Corporation,University of Utah,Celgene Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/8/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT00748553
3170,Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement,Completed,Has Results,Tobacco Dependence,Drug: varenicline|Drug: placebo,H. Lee Moffitt Cancer Center and Research Institute|Pfizer,H. Lee Moffitt Cancer Center and Research Institute,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00747643
3171,"Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial",Completed,Has Results,Vasomotor Rhinitis,Drug: esomeprazole|Drug: placebo,University of Texas Southwestern Medical Center|AstraZeneca,University of Texas Southwestern Medical Center,AstraZeneca,,,,,,Not Applicable,Other|Industry,Interventional,6/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00745849
3172,Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women,Completed,Has Results,HIV Infections,Drug: Raltegravir,University of Rochester|Merck Sharp & Dohme Corp.,University of Rochester,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00745368
3173,Dexmedetomidine Versus Midazolam for Facilitating Extubation,Completed,Has Results,Critical Illness,Drug: Midazolam|Drug: Dexmedetomidine,"University of Colorado, Denver|Hospira, now a wholly owned subsidiary of Pfizer","University of Colorado, Denver","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Not Applicable,Other|Industry,Interventional,8/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00744380
3174,EASI Access II --- Follow-up Study to the EASI Access Trial,Completed,Has Results,Disaster Medicine|Difficult Intravenous Access|Dehydration,Drug: Human recombinant hyaluronidase (HRH)|Procedure: Enzymatically Augmented Subcutaneous Infusion (EASI) line placement,Massachusetts General Hospital|Baxter Healthcare Corporation,Massachusetts General Hospital,Baxter Healthcare Corporation,,,,,,Phase 1,Other|Industry,Interventional,2/9/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00740727
3175,Darusentan Effect on PET Uptake Heterogeneity,Completed,Has Results,Coronary Artery Disease|Endothelial Dysfunction,Drug: darusentan 100 mg,"K.Lance Gould|Gilead Sciences|The University of Texas Health Science Center, Houston",K.Lance Gould,Gilead Sciences,"The University of Texas Health Science Center, Houston",,,,,Phase 2,Other|Industry,Interventional,6/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00738049
3176,Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes|Hypertension,Drug: Rosiglitazone|Drug: Normal saline 0.9%|Drug: Intralipid 20%,Emory University|GlaxoSmithKline,Emory University,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,3/4/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00738023
3177,Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study,Completed,Has Results,Attention Deficit Hyperactivity Disorder|Nicotine Dependence,Drug: Transdermal Nicotine Patch|Drug: Lis-dexamphetamine (Vyvanse)|Drug: Placebo,Duke University|Shire,Duke University,Shire,,,,,,Not Applicable,Other|Industry,Interventional,12/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00736255
3178,Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients,Completed,Has Results,Hyperglycemia|Acute Coronary Syndromes|Myocardial Infarction,Drug: Exenatide,"Saint Luke's Health System|Amylin Pharmaceuticals, LLC.",Saint Luke's Health System,"Amylin Pharmaceuticals, LLC.",,,,,,Phase 4,Other|Industry,Interventional,8/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00736229
3179,A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis,Completed,Has Results,Pancreatitis,Drug: aprepitant|Drug: Placebo,Duke University|Merck Sharp & Dohme Corp.,Duke University,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,8/7/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00736073
3180,A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer,Completed,Has Results,Aerodigestive Tract Cancer|Lung Cancer|Esophageal Cancer|Head and Neck Cancer,Drug: Vorinostat,Dartmouth-Hitchcock Medical Center|Merck Sharp & Dohme Corp.,Dartmouth-Hitchcock Medical Center,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,3/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00735826
3181,"Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma",Completed,Has Results,Pancreatic Cancer,Drug: Avastin|Drug: Tarceva|Radiation: Radiation Therapy,"Duke University|Genentech, Inc.",Duke University,"Genentech, Inc.",,,,,,Phase 1,Other|Industry,Interventional,7/8/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00735306
3182,Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy,Completed,Has Results,Postoperative Nausea and Vomiting,Drug: Aprepitant + Dexamethasone|Drug: Ondansetron + Dexamethasone,Duke University|Merck Sharp & Dohme Corp.,Duke University,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,9/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00734929
3183,Combining Objective and Subjective Sedation Assessment Tools,Completed,Has Results,Critical Illness,Device: Bispectral Index (BIS) Monitor,Duke University|Medtronic - MITG,Duke University,Medtronic - MITG,,,,,,Not Applicable,Other|Industry,Interventional,5/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00734409
3184,Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection,Completed,Has Results,Acute HIV Infection,Drug: Raltegravir|Drug: Efavirenz|Drug: Emtricitibine|Drug: Tenofovir disoproxil once daily|Drug: Tenofovir disoproxil twice daily,University of Alabama at Birmingham|Merck Sharp & Dohme Corp.,University of Alabama at Birmingham,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,9/8/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00734344
3185,The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading,Completed,Has Results,Attention Deficit/Hyperactivity Disorder,Drug: Vyvanse,"Kimberley Lakes|Shire|University of California, Irvine",Kimberley Lakes,Shire,"University of California, Irvine",,,,,Phase 4,Other|Industry,Interventional,7/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00733356
3186,Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep,Completed,Has Results,COPD,Drug: Advair 250|Drug: Placebo- matched|Drug: Placebo|Drug: Advair 250 - matched,Milton S. Hershey Medical Center|GlaxoSmithKline,Milton S. Hershey Medical Center,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00731770
3187,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,Completed,Has Results,PAIN,Drug: Pregabalin|Drug: Placebo,Asokumar Buvanendran|Pfizer|Rush University Medical Center,Asokumar Buvanendran,Pfizer,Rush University Medical Center,,,,,Phase 3,Other|Industry,Interventional,8/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00729690
3188,The Differential Effects of 3 Different Immunosuppressive,Completed,Has Results,Immunosuppression|Kidney Transplantation,,"Northwestern University|Astellas Pharma US, Inc.",Northwestern University,"Astellas Pharma US, Inc.",,,,,,,Other|Industry,Observational,7/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00729248
3189,Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study,Completed,Has Results,Dyslipidemia,Drug: Atorvastatin|Drug: ABT335|Drug: ER Niacin,University of Pennsylvania|Abbott,University of Pennsylvania,Abbott,,,,,,Phase 2,Other|Industry,Interventional,6/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00728910
3190,The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis,Completed,Has Results,Eosinophilic Esophagitis|Gastroesophageal Reflux Disease|EE|GERD,Drug: Esomeprazole|Drug: Budesonide,Mayo Clinic|AstraZeneca,Mayo Clinic,AstraZeneca,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,5/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00728481
3191,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,Completed,Has Results,Human Immunodeficiency Virus Infections,Drug: Efavirenz 600mg|Drug: Boosted Lexiva,Georgetown University|GlaxoSmithKline,Georgetown University,GlaxoSmithKline,,,,,,Phase 3,Other|Industry,Interventional,7/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00727597
3192,Clofarabine Bone Marrow Cytoreduction,Completed,Has Results,Leukemia,Drug: Clofarabine,"University of Chicago|Genzyme, a Sanofi Company",University of Chicago,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,12/7/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00724009
3193,Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia,Completed,Has Results,Febrile Neutropenia,,"Brigham and Women's Hospital|Astellas Pharma US, Inc.",Brigham and Women's Hospital,"Astellas Pharma US, Inc.",,,,,,,Other|Industry,Observational,1/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00723073
3194,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,Completed,Has Results,Acne Vulgaris,Drug: drospirenone and ethinyl estradiol|Drug: Placebo tablet,Massachusetts General Hospital|Bayer,Massachusetts General Hospital,Bayer,,,,,,Phase 3,Other|Industry,Interventional,4/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00722761
3195,The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates,Completed,Has Results,Kidney Transplantation,Drug: Bortezomib,"Mayo Clinic|Millennium Pharmaceuticals, Inc.",Mayo Clinic,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/8/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00722722
3196,5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome,Completed,Has Results,Myelodysplastic Syndrome,Drug: 5-azacytidine,Virginia Commonwealth University|Celgene Corporation,Virginia Commonwealth University,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,7/8/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00721214
3197,Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir,Completed,Has Results,Diabetes Mellitus,Drug: Detemir,Ohio State University|Novo Nordisk A/S,Ohio State University,Novo Nordisk A/S,,,,,,Phase 4,Other|Industry,Interventional,7/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00717288
3198,Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting,Completed,Has Results,Nausea|Vomiting,Drug: Aprepitant|Drug: Scopolamine,Drexel University|Merck Sharp & Dohme Corp.,Drexel University,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,2/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00717054
3199,Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL),Completed,Has Results,Breast Cancer,Drug: Zometa,Milton S. Hershey Medical Center|Novartis,Milton S. Hershey Medical Center,Novartis,,,,,,Phase 3,Other|Industry,Interventional,9/5/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00712985
3200,Comparison of Intraoperative Warming Devices,Completed,Has Results,Total Knee Arthroplasty,Device: VH2|Device: Bair Hugger,Mayo Clinic|Dynatherm Medical Inc.,Mayo Clinic,Dynatherm Medical Inc.,,,,,,Phase 3,Other|Industry,Interventional,7/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00711867
3201,Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®,Completed,Has Results,Pharmacokinetics,Drug: NuvaRing,Columbia University|Organon,Columbia University,Organon,,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00710606
3202,Abuse Liability of Suboxone Versus Subutex,Completed,Has Results,Opioid-related Disorders,Drug: Heroin|Drug: Naloxone|Drug: Low Bup Dose|Drug: High Bup Dose|Drug: Low Bup/Nal Dose|Drug: High Bup/Nal Dose|Drug: Placebo (PCB),New York State Psychiatric Institute|Schering-Plough,New York State Psychiatric Institute,Schering-Plough,,,,,,Phase 3,Other|Industry,Interventional,9/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00710385
3203,Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors,Completed,Has Results,Skin Rash,Procedure: Skin Biopsy of Skin Rash Secondary to EGFRI Use,Northwestern University|GlaxoSmithKline,Northwestern University,GlaxoSmithKline,,,,,,,Other|Industry,Observational,4/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00709878
3204,Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT,Completed,Has Results,Non-Hodgkin's Lymphoma|Leukemia|Multiple Myeloma|Acute Myeloid Leukemia|Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome,Biological: Thymoglobulin|Radiation: Total-Body Irradiation|Procedure: Allogeneic PBSCT or BMT|Drug: Tacrolimus|Drug: Mycophenolate Mofetil,"Virginia Commonwealth University|Genzyme, a Sanofi Company",Virginia Commonwealth University,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,7/21/2008,6/28/2017,https://ClinicalTrials.gov/show/NCT00709592
3205,Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea,Completed,Has Results,Hypercapnia,Other: standard of care for phase one anesthesia care|Device: Quick Emergence Device,University of Utah|Anecare,University of Utah,Anecare,,,,,,Phase 2,Other|Industry,Interventional,3/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00708526
3206,Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis,Completed,Has Results,Constipation|Cystic Fibrosis,Drug: lubiprostone,"University of Arkansas|Takeda Pharmaceuticals North America, Inc.",University of Arkansas,"Takeda Pharmaceuticals North America, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00706004
3207,Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma,Completed,Has Results,Hodgkin's Disease|Lymphoma,Drug: bendamustine hcl,Memorial Sloan Kettering Cancer Center|Cephalon,Memorial Sloan Kettering Cancer Center,Cephalon,,,,,,Phase 2,Other|Industry,Interventional,6/8/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00705250
3208,Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care,Completed,Has Results,Management of Anticoagulation,Device: INRatio monitor by Hemosense|Other: Usual Care,Mayo Clinic|LivaNova,Mayo Clinic,LivaNova,,,,,,Not Applicable,Other|Industry,Interventional,3/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00703963
3209,Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer,Completed,Has Results,Esophageal Cancer,Drug: sunitinib malate,Tony Bekaii-Saab|Pfizer|Ohio State University Comprehensive Cancer Center,Tony Bekaii-Saab,Pfizer,Ohio State University Comprehensive Cancer Center,,,,,Phase 2,Other|Industry,Interventional,6/30/2008,12/30/2013,https://ClinicalTrials.gov/show/NCT00702884
3210,"Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia",Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Tamsulosin,"Siami, Paul F., M.D.|GlaxoSmithKline","Siami, Paul F., M.D.",GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,9/5/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00701779
3211,An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome,Completed,Has Results,Prostatitis|Chronic Prostatitis With Chronic Pelvic Pain Syndrome,Drug: CC-10004,"Kenneth Peters, MD|Celgene Corporation|William Beaumont Hospitals","Kenneth Peters, MD",Celgene Corporation,William Beaumont Hospitals,,,,,Phase 2,Other|Industry,Interventional,6/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00701311
3212,Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery,Completed,Has Results,Critical Illness,Device: Freestyle Navigator,Massachusetts General Hospital|Abbott Diabetes Care,Massachusetts General Hospital,Abbott Diabetes Care,,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT00694473
3213,Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon,Completed,Has Results,Type 1 Diabetes|Dawn Phenomenon,Drug: Lantus (glargine),Massachusetts General Hospital|Sanofi,Massachusetts General Hospital,Sanofi,,,,,,Phase 3,Other|Industry,Interventional,6/5/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00694122
3214,Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients,Completed,Has Results,Pruritis,Drug: Sarna|Drug: Cetaphil,"Wake Forest University|Stiefel, a GSK Company|Wake Forest University Health Sciences",Wake Forest University,"Stiefel, a GSK Company",Wake Forest University Health Sciences,,,,,Phase 4,Other|Industry,Interventional,11/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00693654
3215,Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study,Completed,Has Results,Erosive Esophagitis,Drug: Omeprazole/sodium bicarbonate,"Yvonne Romero|Bausch Health Americas, Inc.|Mayo Clinic",Yvonne Romero,"Bausch Health Americas, Inc.",Mayo Clinic,,,,,Phase 4,Other|Industry,Interventional,1/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00693225
3216,Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy,Completed,Has Results,Multiple Myeloma,Drug: Lenalidomide Induction|Drug: Sequential Maintenance Therapy,Cristina Gasparetto|Celgene Corporation|Duke University,Cristina Gasparetto,Celgene Corporation,Duke University,,,,,Phase 2,Other|Industry,Interventional,8/8/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00691704
3217,Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies,Completed,Has Results,Hodgkin's Disease|Non-Hodgkin's Lymphoma,Drug: Vorinostat|Drug: Niacinamide|Drug: Etoposide,Columbia University|Merck Sharp & Dohme Corp.,Columbia University,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,6/8/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00691210
3218,Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder|Diabetes|Weight Gain,Drug: Pramlintide|Drug: Placebo,"University of Texas Southwestern Medical Center|Amylin Pharmaceuticals, LLC.",University of Texas Southwestern Medical Center,"Amylin Pharmaceuticals, LLC.",,,,,,Phase 4,Other|Industry,Interventional,11/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00690235
3219,Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery,Completed,Has Results,Crohn's Disease,Drug: infliximab|Drug: placebo,"University of Pittsburgh|Centocor, Inc.",University of Pittsburgh,"Centocor, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/5/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00688636
3220,Mobius® Post-cesarean Pain Randomized Control Trial,Completed,Has Results,Complications; Cesarean Section|Pregnancy,Device: Mobius Retractor,Abbey Hardy-Fairbanks|Apple Medical Corporation|University of Iowa,Abbey Hardy-Fairbanks,Apple Medical Corporation,University of Iowa,,,,,Not Applicable,Other|Industry,Interventional,7/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00685932
3221,Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings,Completed,Has Results,Cystic Fibrosis,Device: HFCWC with higher pressure/variable-frequency settings|Device: HFCWC with lower pressure/mid-frequency settings,University of Minnesota - Clinical and Translational Science Institute|Hill-Rom,University of Minnesota - Clinical and Translational Science Institute,Hill-Rom,,,,,,Phase 4,Other|Industry,Interventional,5/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00685035
3222,A Pilot Study to Evaluate the BodyLogic TM System (Mentor) in Augmentation Mammaplasty,Completed,Has Results,Breast Augmentation|Breast Reconstruction,,"University of Minnesota - Clinical and Translational Science Institute|Mentor Worldwide, LLC",University of Minnesota - Clinical and Translational Science Institute,"Mentor Worldwide, LLC",,,,,,,Other|Industry,Observational,5/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00684749
3223,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Completed,Has Results,Major Depressive Disorder,Drug: Aripiprazole 5mg|Drug: Aripiprazole 2mg|Drug: Placebo,Massachusetts General Hospital|Bristol-Myers Squibb,Massachusetts General Hospital,Bristol-Myers Squibb,,,,,,Phase 3,Other|Industry,Interventional,9/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00683852
3224,Safety of Vitamin D Supplementation in Older Persons,Completed,Has Results,Vitamin D Deficiency,Dietary Supplement: cholecalciferol (vitamin D),University of Miami|Merck Sharp & Dohme Corp.,University of Miami,Merck Sharp & Dohme Corp.,,,,,,Phase 3,Other|Industry,Interventional,4/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00681590
3225,Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol,Completed,Has Results,End Stage Cardiac Failure|Pulmonary Failure|End Stage Liver Disease|Morbid Obesity|Recalcitrant Epilepsy Requiring Surgery|Healthy Subjects,"Dietary Supplement: To surgery patients, Tocopherol capsules.|Dietary Supplement: Tocotrienol to healthy subjects.|Dietary Supplement: To surgery patients, Tocotrienol capsules.",Chandan K Sen|Carotech Inc.|Ohio State University,Chandan K Sen,Carotech Inc.,Ohio State University,,,,,Early Phase 1,Other|Industry,Interventional,3/6/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00678834
3226,Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis,Completed,Has Results,Nephrogenic Systemic Fibrosis,Drug: Imatinib mesylate,Massachusetts General Hospital|Novartis Pharmaceuticals,Massachusetts General Hospital,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,12/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00677092
3227,Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC),Completed,Has Results,Lung Cancer,Drug: Cetuximab|Radiation: Conformal Thoracic Radiotherapy (CTRT),H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,H. Lee Moffitt Cancer Center and Research Institute,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,4/8/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00673738
3228,"Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies",Completed,Has Results,Hematologic Malignancy|Myelodysplastic Syndrome (MDS)|Aplastic Anemia,Biological: haplo/cord transplant,"Joanne Kurtzberg, MD|Miltenyi Biotec GmbH|Duke University","Joanne Kurtzberg, MD",Miltenyi Biotec GmbH,Duke University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/7/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00673114
3229,β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients,Completed,Has Results,Invasive Candidiasis,Drug: Preemptive Therapy with Anidulafungin|Drug: Empiric antifungal therapy based on physician discretion.,Duke University|Pfizer,Duke University,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00672841
3230,Heritability of Opioid Effects: A Twin Study,Completed,Has Results,Pain,Drug: Alfentanil|Other: Saline placebo infusion,Martin Angst|SRI International|Stanford University,Martin Angst,SRI International,Stanford University,,,,,Not Applicable,Other|Industry,Interventional,5/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00672438
3231,Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG),Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: Bevacizumab and Erlotinib,"Duke University|Genentech, Inc.",Duke University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,2/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00671970
3232,Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome,Completed,Has Results,"Depressive Disorder, Major|Metabolic Syndrome X",Drug: Pioglitazone,"Joseph Calabrese, MD|Takeda Pharmaceuticals North America, Inc.|University Hospitals Cleveland Medical Center","Joseph Calabrese, MD","Takeda Pharmaceuticals North America, Inc.",University Hospitals Cleveland Medical Center,,,,,Phase 2,Other|Industry,Interventional,4/8/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00671515
3233,Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant,Completed,Has Results,Kidney Transplant,Drug: Eculizumab,Mark Stegall|Alexion Pharmaceuticals|Mayo Clinic,Mark Stegall,Alexion Pharmaceuticals,Mayo Clinic,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/8/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT00670774
3234,T-wave Alternans and Intrathoracic Impedance Measurements,Completed,Has Results,Congestive Heart Failure|Arrhythmias,Other: Congestive heart failure,Columbia University|Medtronic,Columbia University,Medtronic,,,,,,,Other|Industry,Observational,8/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00669682
3235,Intracardiac T-wave Alternans and Ischemia,Completed,Has Results,Ischemia,Procedure: Percutaneous coronary intervention,Columbia University|Medtronic,Columbia University,Medtronic,,,,,,,Other|Industry,Observational,8/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00669552
3236,Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure,Completed,Has Results,Hypertension,Drug: Carvedilol CR|Drug: Atenolol,University of Florida|GlaxoSmithKline,University of Florida,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,4/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00669279
3237,Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole,Completed,Has Results,Healthy,Drug: [13C]Pantoprazole,Indiana University|Sponsor Name Pending,Indiana University,Sponsor Name Pending,,,,,,Not Applicable,Other|Industry,Interventional,3/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00668902
3238,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Completed,Has Results,Papillary Thyroid Cancer|Follicular Thyroid Cancer|Differentiated Thyroid Cancer,"Drug: SU011248, Sutent",Washington Hospital Center|Pfizer,Washington Hospital Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,4/8/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00668811
3239,Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms,Completed,Has Results,Leukemia,Biological: WT-1|Drug: Montanide|Drug: Sargramostim (GM-CSF),H. Lee Moffitt Cancer Center and Research Institute|Innovive Pharmaceuticals,H. Lee Moffitt Cancer Center and Research Institute,Innovive Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT00665002
3240,Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD),Completed,Has Results,Critically Ill|Hemodialysis,Drug: Daptomycin,University of Michigan|Cubist Pharmaceuticals LLC,University of Michigan,Cubist Pharmaceuticals LLC,,,,,,Phase 4,Other|Industry,Interventional,2/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00663403
3241,Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection,Completed,Has Results,HIV Infections|Hepatitis B,Drug: Entecavir with continued standard of care antiretroviral therapy|Drug: continued standard of care with tenofovir in addition to emtricitabine or lamivudine,"University of California, San Francisco|Bristol-Myers Squibb","University of California, San Francisco",Bristol-Myers Squibb,,,,,,Phase 4,Other|Industry,Interventional,4/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00662545
3242,Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation,Completed,Has Results,Constipation,Drug: Lubiprostone|Drug: Senna,"Shirley Ryan AbilityLab|Takeda Pharmaceuticals North America, Inc.",Shirley Ryan AbilityLab,"Takeda Pharmaceuticals North America, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00662363
3243,Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Alprazolam (Xanax)|Drug: Placebo,"University of California, San Diego|Hoffmann-La Roche","University of California, San Diego",Hoffmann-La Roche,,,,,,Phase 4,Other|Industry,Interventional,4/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00662259
3244,Use of Ranibizumab With Mitomycin C During Trabeculectomy,Completed,Has Results,Glaucoma,Drug: Ranibizumab|Drug: Ranibizumab and MMC|Drug: MMC,"University of Colorado, Denver|Genentech, Inc.","University of Colorado, Denver","Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/8/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00661583
3245,Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients,Completed,Has Results,Multiple Myeloma|Stem Cell Transplantation,Drug: Arsenic Trioxide|Drug: Melphalan|Drug: Ascorbic Acid,M.D. Anderson Cancer Center|CTI BioPharma,M.D. Anderson Cancer Center,CTI BioPharma,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/4/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT00661544
3246,Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity,Completed,Has Results,Post-stroke Shoulder Pain and Spasticity,Drug: Botulinum Toxin Type A - OnabotulinumtoxinA|Drug: Placebo (Saline),Shirley Ryan AbilityLab|Allergan,Shirley Ryan AbilityLab,Allergan,,,,,,Not Applicable,Other|Industry,Interventional,9/3/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00661089
3247,Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant,Completed,Has Results,Leukemia,Drug: 5-azacitidine|Procedure: Allogeneic Hematopoietic Cell Transplantation (HCT),H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation,H. Lee Moffitt Cancer Center and Research Institute,Celgene Corporation,,,,,,Not Applicable,Other|Industry,Interventional,3/8/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00660400
3248,Feasibility Study of a Novel Device for Chronic Wounds,Completed,Has Results,Ulcer|Wounds and Injuries,Device: SNaP Advanced Wound Care System|Other: SNaP,"Stanford University|KCI USA, Inc.",Stanford University,"KCI USA, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,3/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00660049
3249,Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery,Completed,Has Results,Postoperative Nausea and Vomiting,Drug: Aprepitant plus Ondansetron|Drug: Ondansetron plus placebo,University of Pittsburgh|Merck Sharp & Dohme Corp.,University of Pittsburgh,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,6/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00659945
3250,Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting,Completed,Has Results,Nausea|Vomiting,Drug: Aprepitant|Drug: Scopolamine,Drexel University College of Medicine|Merck Sharp & Dohme Corp.|Drexel University,Drexel University College of Medicine,Merck Sharp & Dohme Corp.,Drexel University,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00659737
3251,Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure,Completed,Has Results,"Heart Failure, Congestive",Drug: Sitagliptin,Stanford University|Merck Sharp & Dohme Corp.,Stanford University,Merck Sharp & Dohme Corp.,,,,,,Early Phase 1,Other|Industry,Interventional,4/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00657280
3252,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,Completed,Has Results,Breast Cancer,Drug: sunitinib alone|Drug: sunitinib plus paclitaxel|Drug: doxorubicin and cyclophosphamide,Indiana University|Pfizer,Indiana University,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00656669
3253,"Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",Completed,Has Results,Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS),Drug: Idarubicin|Drug: Cytarabine|Drug: Vorinostat,M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.,M.D. Anderson Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Phase 2,Other|Industry,Interventional,4/8/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00656617
3254,A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS,Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia,Drug: Procrit,"M.D. Anderson Cancer Center|Centocor, Inc.",M.D. Anderson Cancer Center,"Centocor, Inc.",,,,,,Phase 3,Other|Industry,Interventional,3/8/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00656448
3255,Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF),Completed,Has Results,Infertility,Drug: Crinone 8% Vaginal Gel|Drug: Intramuscular Progesterone,Brigham and Women's Hospital|EMD Serono,Brigham and Women's Hospital,EMD Serono,,,,,,Phase 4,Other|Industry,Interventional,7/3/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00656201
3256,Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Paclitaxel|Drug: Gemcitabine|Biological: Avastin,"University of Alabama at Birmingham|Genentech, Inc.",University of Alabama at Birmingham,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/8/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT00655850
3257,Fixation of Unstable Distal Radius Fractures,Completed,Has Results,Distal Radius Fractures,Device: Intramedullary Radius Fixation (Micronail)|Procedure: Volar Plate Fixation,Wake Forest University|Wright Medical Technology|Wake Forest University Health Sciences,Wake Forest University,Wright Medical Technology,Wake Forest University Health Sciences,,,,,Not Applicable,Other|Industry,Interventional,5/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00654615
3258,Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy,Completed,Has Results,Tonsillitis,Drug: Fentanyl|Drug: Dexmedetomidine,"Children's Research Institute|Hospira, now a wholly owned subsidiary of Pfizer",Children's Research Institute,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 4,Other|Industry,Interventional,1/5/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00654511
3259,Dexmedetomidine vs Fentanyl for BMT,Completed,Has Results,Otitis,Drug: Saline|Drug: Fentanyl|Drug: Dexmedetomidine,"Children's Research Institute|Hospira, now a wholly owned subsidiary of Pfizer",Children's Research Institute,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 4,Other|Industry,Interventional,8/5/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00654329
3260,Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®,Completed,Has Results,"Gastrointestinal Lesions|Signs and Symptoms, Digestive",Procedure: Small bowel capsule endoscopy (SBCE)|Drug: myfortic,"University of California, Los Angeles|Novartis","University of California, Los Angeles",Novartis,,,,,,Phase 4,Other|Industry,Interventional,4/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00652834
3261,Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients,Completed,Has Results,Lymphoma,Drug: Aprepitant|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab|Drug: Ondansetron,M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.,M.D. Anderson Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,3/8/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00651755
3262,Intraoperative Warming Comparison of Devices,Completed,Has Results,Hypothermia,"Device: Dynatherm Medical vitalHEAT Temperature Management System vH2|Device: Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)",University of South Florida|Dynatherm Medical Inc.,University of South Florida,Dynatherm Medical Inc.,,,,,,Not Applicable,Other|Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00650260
3263,"Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia",Completed,Has Results,Insomnia|Schizophrenia|Schizoaffective Disorder|Sleep Disorders,Drug: Eszopiclone|Drug: Placebo,Yale University|Sunovion,Yale University,Sunovion,,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00645944
3264,Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay,Completed,Has Results,Asthma,Drug: formoterol|Device: Dry Powder Inhaler (Twisthaler),"University of Florida|Teva Branded Pharmaceutical Products, R&D Inc.",University of Florida,"Teva Branded Pharmaceutical Products, R&D Inc.",,,,,,Not Applicable,Other|Industry,Interventional,3/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00643578
3265,Clinical Trial of Factor XIII (FXIII) Concentrate,Completed,Has Results,Hemophilia|Factor XIII Deficiency,Drug: Fibrogammin P,Children’s Hospital of Orange County|CSL Behring,Children’s Hospital of Orange County,CSL Behring,,,,,,Not Applicable,Other|Industry,Interventional,1/1/2000,12/11/2019,https://ClinicalTrials.gov/show/NCT00640289
3266,Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal,Completed,Has Results,Healthy,"Device: 1064 nm Nd:YAG laser|Drug: Imiquimod, 5% cream","University of Miami|Graceway Pharmaceuticals, LLC",University of Miami,"Graceway Pharmaceuticals, LLC",,,,,,Phase 1,Other|Industry,Interventional,2/8/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00638651
3267,ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management,Completed,Has Results,Postoperative Pain,Drug: Ketorolac|Drug: Ketorolac and Ropivacaine,Maimonides Medical Center|I-Flow,Maimonides Medical Center,I-Flow,,,,,,Phase 4,Other|Industry,Interventional,6/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00638508
3268,Lumbar Stenosis Outcomes Research (LUSTOR),Completed,Has Results,Lumbar Spinal Stenosis,Drug: Pregabalin|Drug: Diphenhydramine,University of Rochester|Pfizer,University of Rochester,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,3/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00638443
3269,Memantine for Spasticity in MS Patients,Completed,Has Results,Multiple Sclerosis,Drug: placebo|Drug: memantine,University of Rochester|Forest Laboratories,University of Rochester,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,7/6/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00638027
3270,A Phase I/II Trial of VR-CHOP in Lymphoma Patients,Completed,Has Results,"Lymphoma, B-Cell|Follicular Lymphoma",Drug: Bortezomib|Biological: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone,"Emory University|Millennium Pharmaceuticals, Inc.",Emory University,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,2/8/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT00634179
3271,The Oral Contraceptive Pill for Premenstrual Worsening of Depression,Completed,Has Results,Premenstrual Syndrome|Depression,Drug: Drospirenone and ethinyl estradiol|Drug: Placebo,Massachusetts General Hospital|Bayer,Massachusetts General Hospital,Bayer,,,,,,Not Applicable,Other|Industry,Interventional,2/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00633360
3272,LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients,Completed,Has Results,Breast Cancer,Drug: LBH589|Drug: Capecitabine|Drug: Lapatinib,"SCRI Development Innovations, LLC|Novartis","SCRI Development Innovations, LLC",Novartis,,,,,,Phase 1,Other|Industry,Interventional,5/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00632489
3273,Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin,Completed,Has Results,HIV Infections|Hyperlipidemia,Drug: Pravastatin|Drug: Darunavir|Drug: Ritonavir|Other: Washout,"University of Colorado, Denver|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","University of Colorado, Denver","Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 4,Other|Industry,Interventional,2/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00630734
3274,"RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer",Completed,Has Results,Hormone Refractory Prostate Cancer,Drug: RAD001,"Daniel George, MD|Novartis Pharmaceuticals|Duke University","Daniel George, MD",Novartis Pharmaceuticals,Duke University,,,,,Phase 2,Other|Industry,Interventional,8/5/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00629525
3275,Rasburicase in Patients at Risk for Tumor Lysis Syndrome,Completed,Has Results,Tumor Lysis Syndrome,Drug: As Needed Rasburicase|Drug: Fixed Dose Rasburicase,M.D. Anderson Cancer Center|Sanofi,M.D. Anderson Cancer Center,Sanofi,,,,,,Phase 2,Other|Industry,Interventional,1/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00628628
3276,Effects of Sternal Wall Pressure in Children,Completed,Has Results,"Respiration, Artificial",,Children's Hospital of Philadelphia|Laerdal Medical,Children's Hospital of Philadelphia,Laerdal Medical,,,,,,,Other|Industry,Observational,1/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00628407
3277,Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons,Completed,Has Results,Metastatic Breast Cancer,Drug: ixabepilone,Weill Medical College of Cornell University|Bristol-Myers Squibb,Weill Medical College of Cornell University,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,11/7/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00627978
3278,Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria,Completed,Has Results,Kidney Disease|Albuminuria,Drug: 6R BH4|Dietary Supplement: Vitamin C,University of Michigan|BioMarin Pharmaceutical,University of Michigan,BioMarin Pharmaceutical,,,,,,Phase 2,Other|Industry,Interventional,5/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00625820
3279,Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts,Completed,Has Results,Myelodysplastic Syndromes,Drug: Dasatinib,H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,H. Lee Moffitt Cancer Center and Research Institute,Bristol-Myers Squibb,,,,,,Not Applicable,Other|Industry,Interventional,2/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00624585
3280,Ear Drops for Children With Otitis Media,Completed,Has Results,Acute Otitis Media,Drug: Hyland's earache drops,University of Washington|Standard Homeopathic Company,University of Washington,Standard Homeopathic Company,,,,,,Not Applicable,Other|Industry,Interventional,2/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00622518
3281,Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia,Completed,Has Results,ADHD With Sleep Onset Insomnia,Drug: Ramelteon|Drug: Placebo,University of Alabama at Birmingham|Takeda,University of Alabama at Birmingham,Takeda,,,,,,Phase 4,Other|Industry,Interventional,2/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00622427
3282,Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder,Completed,Has Results,Severe Asthma|Moderate or Severe Major Depressive Disorder,Drug: Placebo|Drug: Escitalopram,University of Texas Southwestern Medical Center|Forest Laboratories,University of Texas Southwestern Medical Center,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,3/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00621946
3283,The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty,Completed,Has Results,Osteoarthritis,Other: Placebo saline injection|Drug: Ropivicaine 0.5%,Duke University|Pfizer,Duke University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,5/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00620828
3284,Extended-release Naltrexone for Alcohol Dependence in Primary Care,Completed,Has Results,Alcohol Dependence,Drug: Extended release injectable naltrexone (Vivitrol),"NYU Langone Health|Alkermes, Inc.",NYU Langone Health,"Alkermes, Inc.",,,,,,Phase 4,Other|Industry,Interventional,7/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00620750
3285,"A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients",Completed,Has Results,Panic Disorder,Drug: quetiapine XR|Drug: placebo,Indiana University|AstraZeneca,Indiana University,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,2/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00619892
3286,Study of Aripiprazole to Treat Children and Adolescents With Autism,Completed,Has Results,Autistic Disorder|Asperger Syndrome|Autism Spectrum Disorder,Drug: aripiprazole,"University of North Carolina, Chapel Hill|Bristol-Myers Squibb","University of North Carolina, Chapel Hill",Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,1/6/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00619190
3287,Intranasal CO2 for Allergic Rhinitis,Completed,Has Results,Allergic Rhinitis,"Device: Carbon dioxide, USP|Other: Placebo","University of Chicago|Capnia, Inc.",University of Chicago,"Capnia, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,2/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00618410
3288,Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: mometasone furoate nasal spray|Drug: placebo,University of Chicago|Schering-Plough,University of Chicago,Schering-Plough,,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00618332
3289,Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder,Completed,Has Results,Functional Bowel Disorders,Drug: Quetiapine (50 mg/day-100mg/day),"University of North Carolina, Chapel Hill|AstraZeneca","University of North Carolina, Chapel Hill",AstraZeneca,,,,,,Not Applicable,Other|Industry,Interventional,2/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00617396
3290,Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days,Completed,Has Results,Drug Induced Liver Injury,Drug: acetaminophen,"Kennon Heard|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|Denver Health and Hospital Authority",Kennon Heard,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Denver Health and Hospital Authority,,,,,Phase 4,Other|Industry,Interventional,8/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00616018
3291,Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG),Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: Imatinib Mesylate & Hydroxyurea,Duke University|Novartis Pharmaceuticals,Duke University,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,2/6/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00615927
3292,Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan,Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: Temo + Avastin|Drug: VP-16 + Avastin,"Duke University|Genentech, Inc.",Duke University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,4/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00613028
3293,Ph II Bevacizumab + Etoposide for Pts w Recurrent MG,Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: Bevacizumab and Etoposide,"Duke University|Genentech, Inc.",Duke University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/7/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00612430
3294,Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women,Completed,Has Results,Menopause|Cognitive Disturbances,Drug: atomoxetine|Drug: placebo,University of Pennsylvania|Eli Lilly and Company,University of Pennsylvania,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,5/4/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00611533
3295,Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy,Completed,Has Results,Bowel Preparation for Colonoscopy,Drug: lubiprostone|Drug: placebo,Brooke Army Medical Center|Takeda,Brooke Army Medical Center,Takeda,,,,,,Not Applicable,U.S. Fed|Industry,Interventional,10/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00611442
3296,Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia,Completed,Has Results,"Leukemia, Myeloid",Drug: Temozolomide,Bruno C. Medeiros|Schering-Plough|Stanford University,Bruno C. Medeiros,Schering-Plough,Stanford University,,,,,Phase 2,Other|Industry,Interventional,12/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00611247
3297,Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma,Completed,Has Results,Melanoma,Drug: Anti-CTLA4 monoclonal antibody and HDI,Ahmad Tarhini|Pfizer|University of Pittsburgh,Ahmad Tarhini,Pfizer,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,11/6/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00610857
3298,Photopheresis for the Treatment of Acute Graft Versus Host Disease,Completed,Has Results,Graft Versus Host Disease,Procedure: Photopheresis|Drug: Methylprednisolone,M.D. Anderson Cancer Center|Mallinckrodt,M.D. Anderson Cancer Center,Mallinckrodt,,,,,,Phase 2,Other|Industry,Interventional,1/8/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT00609609
3299,Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression,Completed,Has Results,Major Depressive Disorder,Drug: Aripiprazole,University of Texas Southwestern Medical Center|Bristol-Myers Squibb,University of Texas Southwestern Medical Center,Bristol-Myers Squibb,,,,,,Phase 4,Other|Industry,Interventional,10/5/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00608543
3300,Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression,Completed,Has Results,Binge Eating|Depression,Drug: Duloxetine|Drug: Placebo,University of Cincinnati|Eli Lilly and Company,University of Cincinnati,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,10/6/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00607789
3301,A Randomized Prospective Clinical Trial Comparing Single Tooth Implant 3 Loading Protocols,Completed,Has Results,Dental Implant,Device: dental implant,Clark Stanford|Dentsply Sirona Implants|University of Iowa,Clark Stanford,Dentsply Sirona Implants,University of Iowa,,,,,Not Applicable,Other|Industry,Interventional,12/7/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00607022
3302,Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging,Completed,Has Results,Proliferative Diabetic Retinopathy,Drug: ranibizumab|Procedure: Laser photocoagulation,"Rush University Medical Center|Genentech, Inc.",Rush University Medical Center,"Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00606138
3303,A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma,Completed,Has Results,Anaplastic Astrocytoma|Glioblastoma,Drug: Sunitinib Malate,H. Lee Moffitt Cancer Center and Research Institute|Pfizer,H. Lee Moffitt Cancer Center and Research Institute,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,3/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00606008
3304,An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia,Completed,Has Results,Bladder Outlet Obstruction,Drug: Toviaz (Fesoterodine),Weill Medical College of Cornell University|Pfizer,Weill Medical College of Cornell University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00605319
3305,ACY-7 Oral Administration of Acyline,Completed,Has Results,Healthy,Drug: Acyline,"University of Washington|Merrion Pharmaceuticals, LLC",University of Washington,"Merrion Pharmaceuticals, LLC",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/8/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00603187
3306,Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome,Completed,Has Results,Childhood Obstructive Sleep Apnea Syndrome (OSAS),Drug: fluticasone furoate,University of Chicago|GlaxoSmithKline,University of Chicago,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,1/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00603044
3307,Multi-day Doses in Prevention of Nausea and Emesis,Completed,Has Results,"Myeloma, Plasma-Cell|Lymphoma, Malignant",Drug: Palonosetron|Drug: Aprepitant|Drug: Dexamethasone,University of Kansas Medical Center|Eisai Inc.,University of Kansas Medical Center,Eisai Inc.,,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00600353
3308,Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda,Completed,Has Results,Porphyria Cutanea Tarda,Drug: Deferasirox,University of Texas Southwestern Medical Center|Novartis Pharmaceuticals,University of Texas Southwestern Medical Center,Novartis Pharmaceuticals,,,,,,Phase 3,Other|Industry,Interventional,1/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00599326
3309,GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients,Completed,Has Results,Corneal Epithelium Defect,Drug: 0.3% hypromellose,Augusta University|Novartis,Augusta University,Novartis,,,,,,Phase 4,Other|Industry,Interventional,10/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00598689
3310,"Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS",Completed,Has Results,Chronic Fatigue Syndrome,Drug: Sildenafil (Viagra)|Drug: Placebo,Charles Drew University of Medicine and Science|Pfizer,Charles Drew University of Medicine and Science,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,7/2/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00598585
3311,Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma,Completed,Has Results,Melanoma,Drug: ZK-EPO,H. Lee Moffitt Cancer Center and Research Institute|Bayer,H. Lee Moffitt Cancer Center and Research Institute,Bayer,,,,,,Phase 2,Other|Industry,Interventional,5/7/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00598507
3312,Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints,Completed,Has Results,Subjective Memory Loss in Older Persons,Other: Cerefolin NAC (a medical food)|Other: Cerefolin NAC placebo,"Rush University Medical Center|Pamlab, Inc.",Rush University Medical Center,"Pamlab, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,11/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00597376
3313,Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorders,Drug: Ramelteon|Drug: Placebo,Massachusetts General Hospital|Takeda,Massachusetts General Hospital,Takeda,,,,,,Phase 4,Other|Industry,Interventional,1/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00595504
3314,Study of the Mechanisms of Asthma,Completed,Has Results,Asthma,Drug: Pulmicort,"University of California, San Francisco|Genentech, Inc.","University of California, San Francisco","Genentech, Inc.",,,,,,Phase 1,Other|Industry,Interventional,4/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00595153
3315,HIV Non Occupational Post-Exposure Prophylaxis (PEP),Completed,Has Results,HIV Infections,Drug: TRUVADA + raltegravir,Fenway Community Health|Merck Sharp & Dohme Corp.,Fenway Community Health,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,2/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00594646
3316,Sodium Oxybate in Schizophrenia With Insomnia,Completed,Has Results,Schizophrenia|Insomnia Related to Schizophrenia (307.42),Drug: Sodium Oxybate,Nathan Kline Institute for Psychiatric Research|Jazz Pharmaceuticals,Nathan Kline Institute for Psychiatric Research,Jazz Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,5/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00594256
3317,The Safety Evaluation of Silver Alginate (Algidex™) Dressing in Very Low Birth Weight (VLBW) Infants,Completed,Has Results,Prematurity|Very Low Birth Weight,Device: Silver Alginate,"Baylor Research Institute|DeRoyal Industries, Inc.",Baylor Research Institute,"DeRoyal Industries, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,4/6/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00593684
3318,Intramedullary Nailing of the Femur:Trochanteric vs Piriformis Starting Portals,Completed,Has Results,Femur Fracture,Device: Antegrade Intramedullary Nail|Device: Trigen Trochanteric Femoral Nail,"University of Alabama at Birmingham|Smith & Nephew, Inc.",University of Alabama at Birmingham,"Smith & Nephew, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,6/3/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00593333
3319,An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants,Completed,Has Results,Anxiety,Drug: Acamprosate,State University of New York - Upstate Medical University|Forest Laboratories,State University of New York - Upstate Medical University,Forest Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,6/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00591565
3320,Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma,Completed,Has Results,Melanoma,Drug: Temozolomide (TMZ),Memorial Sloan Kettering Cancer Center|Schering-Plough,Memorial Sloan Kettering Cancer Center,Schering-Plough,,,,,,Phase 2,Other|Industry,Interventional,1/5/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00591370
3321,Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: insulins aspart and detemir,Rush University Medical Center|Novo Nordisk A/S,Rush University Medical Center,Novo Nordisk A/S,,,,,,Phase 4,Other|Industry,Interventional,5/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00591227
3322,GLP1R Polymorphisms and Response to GLP1,Completed,Has Results,Diabetes,Drug: GLP-1,Mayo Clinic|Merck Sharp & Dohme Corp.,Mayo Clinic,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,11/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00588380
3323,Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection,Completed,Has Results,Melanoma|Skin Cancer|Cancer,Drug: Temozolomide,Memorial Sloan Kettering Cancer Center|Schering-Plough,Memorial Sloan Kettering Cancer Center,Schering-Plough,,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00588341
3324,"Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",Completed,Has Results,Ovarian Cancer|Primary PERITONEUM|Fallopian Tube Cancer,"Drug: Paclitaxel,Cisplatin, Bevacizumab","Memorial Sloan Kettering Cancer Center|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/6/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00588237
3325,Vashe Wound Therapy Study,Completed,Has Results,Burns,Device: Vashe|Drug: Mafenide acetate,"Maricopa Integrated Health System|PuriCore, Inc.",Maricopa Integrated Health System,"PuriCore, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00586729
3326,Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD,Completed,Has Results,ADHD|Attention Deficit Hyperactivity Disorder,Drug: Atomoxetine and OROS Methylphenidate,"Massachusetts General Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC",Massachusetts General Hospital,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 4,Other|Industry,Interventional,1/4/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00585910
3327,"Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer",Completed,Has Results,Bladder Cancer,Drug: ABI-007|Drug: Carboplatin|Drug: Gemcitabine|Procedure: Radical Cystectomy,University of Michigan Rogel Cancer Center|Celgene Corporation,University of Michigan Rogel Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,12/7/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00585689
3328,"Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer",Completed,Has Results,Cancer,Drug: Bevacizumab and Erlotinib,"University of Utah|Genentech, Inc.",University of Utah,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/7/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00585377
3329,Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT,Completed,Has Results,Obesity|Venous Thrombosis|Anticoagulants,Drug: Enoxaparin 0.5 mg/kg once daily,University of Utah|Sanofi,University of Utah,Sanofi,,,,,,Phase 4,Other|Industry,Interventional,1/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00585182
3330,Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma,Completed,Has Results,Pancreatic Cancer,Drug: Capecitabine|Drug: Oxaliplatin,Beth Israel Deaconess Medical Center|Sanofi|Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Sanofi,Dana-Farber Cancer Institute,,,,,Phase 2,Other|Industry,Interventional,5/4/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00585078
3331,Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass,Completed,Has Results,Congenital Heart Disease,Drug: Nitric Oxide,Washington University School of Medicine|Mallinckrodt,Washington University School of Medicine,Mallinckrodt,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00585013
3332,Intranasal Steroids and Oxymetazoline in Allergic Rhinitis,Completed,Has Results,Allergic Rhinitis,Drug: Fluticasone furoate|Drug: Placebo Fluticasone furoate|Drug: Oxymetazoline|Drug: Placebo Oxymetazoline,University of Chicago|GlaxoSmithKline,University of Chicago,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,6/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00584987
3333,Celecoxib as a Post-tonsillectomy Pain Medication,Completed,Has Results,Tonsillitis,Drug: Celecoxib|Drug: Placebo,University of Iowa|Pfizer,University of Iowa,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT00583453
3334,Vacuum Assisted Closure as a Treatment for Soft Tissue Injuries,Completed,Has Results,"Fracture of Calcaneus, Pilon or Tibial Plateau",Procedure: Standard Wound Dressing|Device: Vacuum Assisted Closure Device,"University of Alabama at Birmingham|KCI USA, Inc.",University of Alabama at Birmingham,"KCI USA, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,6/1/2019,3/7/2019,https://ClinicalTrials.gov/show/NCT00582998
3335,Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy,Completed,Has Results,Prostate Cancer,Drug: Zometa|Drug: zometa,"University of Wisconsin, Madison|Novartis Pharmaceuticals","University of Wisconsin, Madison",Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,4/3/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00582556
3336,Compass Hinge Stabilization of Knee Dislocations: A Randomized Trial,Completed,Has Results,Knee Dislocation,Device: Compass Universal Hinge External Fixator|Procedure: Non-invasive External Knee Brace,"University of Alabama at Birmingham|Smith & Nephew, Inc.",University of Alabama at Birmingham,"Smith & Nephew, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,8/1/2000,12/8/2019,https://ClinicalTrials.gov/show/NCT00582517
3337,Vacuum Assisted Closure as a Treatment for Open Fractures,Completed,Has Results,Orthopaedic Traumatic Open Fractures,Procedure: Standard Wound Dressing|Device: VAC,"University of Alabama at Birmingham|KCI USA, Inc.",University of Alabama at Birmingham,"KCI USA, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,6/1/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00582361
3338,Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases,Completed,Has Results,Cancer|Brain Metastases,Drug: temozolomide,University of Alabama at Birmingham|Integrated Therapeutics Group,University of Alabama at Birmingham,Integrated Therapeutics Group,,,,,,Phase 2,Other|Industry,Interventional,7/2/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00582075
3339,CoolCap Followup Study-Coordination of Participating Centers,Completed,Has Results,Neonatal Encephalopathy,,University of Rochester|Olympic Medical,University of Rochester,Olympic Medical,,,,,,,Other|Industry,Observational,9/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00581581
3340,A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation),Completed,Has Results,Pain,Drug: Oxymorphone,Icahn School of Medicine at Mount Sinai|Endo Pharmaceuticals,Icahn School of Medicine at Mount Sinai,Endo Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,11/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00580294
3341,Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath,Completed,Has Results,Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors,Drug: Campath Purged Non-myeloablative ASCT|Procedure: Donor Apheresis,"David Rizzieri, MD|Miltenyi Biotec GmbH|Duke University","David Rizzieri, MD",Miltenyi Biotec GmbH,Duke University,,,,,Phase 2,Other|Industry,Interventional,2/3/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00580034
3342,The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Arrhythmia|Inflammation|Endothelial Dysfunction,Drug: Atorvastatin|Drug: Placebo,Mayo Clinic|Pfizer,Mayo Clinic,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,12/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00579098
3343,Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath,Completed,Has Results,Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors,Drug: Campath Purged Non-myeloablative ASCT,"David Rizzieri, MD|Miltenyi Biotec GmbH|Duke University","David Rizzieri, MD",Miltenyi Biotec GmbH,Duke University,,,,,Phase 2,Other|Industry,Interventional,5/5/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00578942
3344,"Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer",Completed,Has Results,Cancer of the Esophagus,Drug: Panitumumab|Drug: Capecitabine|Drug: Oxaliplatin|Radiation: Radiation Therapy (RT),Brian Czito|Amgen|Duke University,Brian Czito,Amgen,Duke University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/7/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00578071
3345,Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON),Completed,Has Results,Non Small Cell Lung Cancer|Lung Cancer,Drug: erlotinib|Drug: Pemetrexed|Drug: Cisplatin|Procedure: Resection,"Memorial Sloan Kettering Cancer Center|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,11/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00577707
3346,Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma,Completed,Has Results,"Lymphoma, B-Cell",Drug: cyclophosphamide|Drug: etoposide|Drug: rituximab|Drug: cytarabine|Drug: doxorubicin|Drug: tositumomab,Duke University|GlaxoSmithKline,Duke University,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,6/18/2005,11/3/2016,https://ClinicalTrials.gov/show/NCT00577629
3347,Evaluation of Atorvastatin on Atherosclerosis Composition,Completed,Has Results,Atherosclerosis,Drug: Atorvastatin,Emory University|Pfizer,Emory University,Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,7/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00576576
3348,Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection,Completed,Has Results,Infectious Mononucleosis,Drug: Valomaciclovir|Drug: placebo,University of Minnesota - Clinical and Translational Science Institute|Epiphany Biosciences,University of Minnesota - Clinical and Translational Science Institute,Epiphany Biosciences,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00575185
3349,Characteristics of Glargine in Type 2 Diabetics,Completed,Has Results,Type 2 Diabetes,Drug: Placebo|Drug: Insulin Glargine 0.5 u/kg body wt SC|Drug: Insulin Glargine 1.0 u/kg body wt SC|Drug: Insulin Glargine 1.5 u/kg body wt SC|Drug: Insulin Glargine 2.0 u/kg body wt SC,Vanderbilt University Medical Center|Sanofi,Vanderbilt University Medical Center,Sanofi,,,,,,Phase 1,Other|Industry,Interventional,3/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00574912
3350,Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma,Completed,Has Results,Metastatic Colorectal Cancer,Drug: lapatinib|Drug: Capecitabine,"University of Wisconsin, Madison|GlaxoSmithKline","University of Wisconsin, Madison",GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,9/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00574171
3351,A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy,Completed,Has Results,Diabetic Neuropathy,Drug: Pregabalin|Drug: Placebo,Duke University|Pfizer,Duke University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,3/6/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00573261
3352,Circadian Rhythms of Aqueous Humor Dynamics in Humans,Completed,Has Results,Glaucoma,Drug: Latanoprost|Drug: Dorzolamide|Drug: Timolol,University of Nebraska|Pfizer,University of Nebraska,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,11/5/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00572936
3353,Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting,Completed,Has Results,Human Papillomavirus Infection,Biological: Quadrivalent human papillomavirus vaccine on-time administration|Biological: Quadrivalent human papillomavirus vaccine delayed administration,University of Pittsburgh|Merck Sharp & Dohme Corp.,University of Pittsburgh,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,9/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00572832
3354,Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation,Completed,Has Results,Cancer of the Breast,"Device: AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)","University of Arkansas|Angiodynamics, Inc.",University of Arkansas,"Angiodynamics, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/4/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00571987
3355,Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir),Completed,Has Results,HIV Infections,Drug: Kaletra (lopinavir/ritonavir)|Drug: buprenorphine|Other: Clinical evaluations/Blood draws,Yale University|Abbott,Yale University,Abbott,,,,,,Not Applicable,Other|Industry,Interventional,1/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00571961
3356,A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction,Completed,Has Results,"Methamphetamine Dependence, Treatment Seeking",Drug: Acamprosate|Drug: placebo,NYU Langone Health|Forest Laboratories,NYU Langone Health,Forest Laboratories,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00571922
3357,Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?,Completed,Has Results,Bipolar Disorder,Drug: Risperdal (risperidone) Consta|Drug: Treatment as usual,"Vanderbilt University|Ortho-McNeil Janssen Scientific Affairs, LLC|Vanderbilt University Medical Center",Vanderbilt University,"Ortho-McNeil Janssen Scientific Affairs, LLC",Vanderbilt University Medical Center,,,,,Phase 4,Other|Industry,Interventional,11/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00571688
3358,Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant,Completed,Has Results,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes|Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease|Peripheral T-cell Lymphoma,Drug: Pentostatin|Radiation: Total-body irradiation (TBI)|Drug: Cyclosporine A (CsA)|Drug: Mycophenolate Mofetil (MMF)|Drug: G-CSF,University of Nebraska|Astex Pharmaceuticals,University of Nebraska,Astex Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,12/1/2000,12/8/2019,https://ClinicalTrials.gov/show/NCT00571662
3359,"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma",Completed,Has Results,Non-hodgkin's Lymphoma|Mantle Cell Lymphoma,"Drug: Bortezomib|Drug: BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)","University of Nebraska|Millennium Pharmaceuticals, Inc.",University of Nebraska,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/6/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00571493
3360,Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure,Completed,Has Results,Breast Cancer,Drug: Everolimus|Drug: Fulvestrant,Mara Chambers|Novartis|University of Kentucky,Mara Chambers,Novartis,University of Kentucky,,,,,Phase 2,Other|Industry,Interventional,4/8/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00570921
3361,Microvascular Coronary Disease In Women: Impact Of Ranolazine,Completed,Has Results,Myocardial Ischemia,Drug: Ranolazine|Drug: Placebo,Cedars-Sinai Medical Center|CV Therapeutics,Cedars-Sinai Medical Center,CV Therapeutics,,,,,,Phase 2,Other|Industry,Interventional,4/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00570089
3362,Ph II Study of Azacitidine in Myelofibrosis,Completed,Has Results,Myelofibrosis,Drug: Azacitidine,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00569660
3363,Study With Candida Antigen for Treatment of Warts,Completed,Has Results,Warts|HPV,Drug: Candida Antigen,"University of Arkansas|Allermed Laboratories, Inc.",University of Arkansas,"Allermed Laboratories, Inc.",,,,,,Phase 1,Other|Industry,Interventional,2/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00569231
3364,Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia,Drug: Azacitidine|Drug: Ara-C,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00569010
3365,The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning,Completed,Has Results,Major Depression|Bipolar Depression|Schizoaffective Disorder,Drug: Razadyne|Drug: Placebo,"Massachusetts General Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC",Massachusetts General Hospital,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 3,Other|Industry,Interventional,7/4/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00566735
3366,Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy,Completed,Has Results,Nonarteritic Anterior Ischemic Optic Neuropathy,Drug: ranibizumab,"University of Colorado, Denver|Genentech, Inc.","University of Colorado, Denver","Genentech, Inc.",,,,,,Phase 1,Other|Industry,Interventional,11/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00561834
3367,High Dose CVVHDF Compared to Standard Dose CVVHDF,Completed,Has Results,Acute Renal Failure,Device: Standard dose of dialysis|Device: High dose of dialysis,University of Alabama at Birmingham|Pfizer,University of Alabama at Birmingham,Pfizer,,,,,,Phase 3,Other|Industry,Interventional,7/3/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00561431
3368,Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma,Completed,Has Results,Lymphoma|Small Intestine Cancer,Drug: vorinostat|Other: Correlative studies,Ohio State University Comprehensive Cancer Center|Merck Sharp & Dohme Corp.,Ohio State University Comprehensive Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Other|Industry,Interventional,11/7/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00561418
3369,Improved Induction and Maintenance Immunosuppression in Kidney Transplantation,Completed,Has Results,End-stage Renal Disease,Drug: rabbit anti-thymocyte globulin|Drug: mycophenolate mofetil|Drug: sirolimus|Drug: tacrolimus,"R. Brian Stevens, MD|Genzyme, a Sanofi Company|University of Nebraska","R. Brian Stevens, MD","Genzyme, a Sanofi Company",University of Nebraska,,,,,Phase 4,Other|Industry,Interventional,4/4/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00556933
3370,Clinical Study of the U-Plate Fracture Repair System to Treat Rib Fractures,Completed,Has Results,Rib Fracture|Flail Chest,Device: U-plate fracture repair system,"Oregon Health and Science University|ACUTE Innovations, LLC",Oregon Health and Science University,"ACUTE Innovations, LLC",,,,,,Not Applicable,Other|Industry,Interventional,11/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00556543
3371,Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen,Completed,Has Results,Leukemia|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome,Drug: Clofarabine/Busulfan x 4|Procedure: Peripheral blood stem cell transplant|Radiation: Total Lymphoid Irradiation,"University of Michigan Rogel Cancer Center|Genzyme, a Sanofi Company",University of Michigan Rogel Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/7/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00556452
3372,The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression,Completed,Has Results,Psychotic Depression,Drug: Aripiprazole,Massachusetts General Hospital|Bristol-Myers Squibb,Massachusetts General Hospital,Bristol-Myers Squibb,,,,,,Phase 3,Other|Industry,Interventional,6/3/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00556140
3373,Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization,Completed,Has Results,Aspirin Sensitivity,Drug: Omalizumab|Drug: placebo,"David Lang|Genentech, Inc.|The Cleveland Clinic",David Lang,"Genentech, Inc.",The Cleveland Clinic,,,,,Phase 4,Other|Industry,Interventional,5/6/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00555971
3374,Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis,Completed,Has Results,Systemic Sclerosis,Drug: Imatinib Mesylate,"Hospital for Special Surgery, New York|Novartis Pharmaceuticals","Hospital for Special Surgery, New York",Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,8/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00555581
3375,Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease,Completed,Has Results,Pre-hypertension,Drug: carvedilol phosphate|Drug: lisinopril|Drug: carvedilol phosphate and lisinopril|Drug: placebo and placebo,University of Minnesota - Clinical and Translational Science Institute|GlaxoSmithKline,University of Minnesota - Clinical and Translational Science Institute,GlaxoSmithKline,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00553969
3376,Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: Ramelteon|Drug: Placebo,Lehigh Valley Hospital|Takeda,Lehigh Valley Hospital,Takeda,,,,,,Phase 4,Other|Industry,Interventional,11/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00552760
3377,Ultrasound Guided Octreotide LAR Injection in Acromegaly,Completed,Has Results,Acromegaly,Drug: Octreotide LAR 30 MG Injection,Cedars-Sinai Medical Center|Novartis Pharmaceuticals,Cedars-Sinai Medical Center,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,7/7/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00552071
3378,Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease,Completed,Has Results,Alzheimer Disease,Drug: memantine,Northwell Health|Forest Laboratories,Northwell Health,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,8/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00551161
3379,Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Dasatinib|Drug: Dasatinib Maximum Tolerated Dose,University of Nebraska|Bristol-Myers Squibb,University of Nebraska,Bristol-Myers Squibb,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/7/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT00550615
3380,Testing Methylphenidate for Smoking Abstinence,Completed,Has Results,Smoking,Drug: Methylphenidate|Drug: Placebo,"Mayo Clinic|Ortho-McNeil Janssen Scientific Affairs, LLC",Mayo Clinic,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 2,Other|Industry,Interventional,1/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00549640
3381,Study of Paliperidone ER in Adolescents and Young Adults With Autism,Completed,Has Results,Autism,Drug: Paliperidone ER,"Indiana University School of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC|Indiana University",Indiana University School of Medicine,"Ortho-McNeil Janssen Scientific Affairs, LLC",Indiana University,,,,,Phase 3,Other|Industry,Interventional,11/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00549562
3382,"Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",Completed,Has Results,Leukemia,Biological: GM-CSF|Biological: Interferon-α-2b,Emory University|Bayer,Emory University,Bayer,,,,,,Phase 2,Other|Industry,Interventional,1/7/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00548847
3383,Rapid HIV Testing Program in the Emergency Department,Completed,Has Results,HIV Infections,Other: HIV test by oral swab,Temple University|Gilead Sciences,Temple University,Gilead Sciences,,,,,,Not Applicable,Other|Industry,Interventional,4/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00548041
3384,Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment,Completed,Has Results,Uveitis,Drug: 0.59 mg Fluocinolone Acetonide implant,Duke University|Bausch & Lomb Incorporated,Duke University,Bausch & Lomb Incorporated,,,,,,Phase 4,Other|Industry,Interventional,3/4/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00543296
3385,"Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)",Completed,Has Results,AML|Acute Myeloid Leukemia|Myelodysplastic Disorders,Drug: Idarubicin|Drug: Sorafenib|Drug: Ara-C,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00542971
3386,Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women,Completed,Has Results,Skin Diseases,Drug: Dietary Supplement: LifePak Nano,Stanford University|Nu Skin Enterprises,Stanford University,Nu Skin Enterprises,,,,,,Not Applicable,Other|Industry,Interventional,10/7/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00541931
3387,"Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: lenalidomide (Revlimid®)|Drug: Cyclophosphamide|Drug: Prednisone,Attaya Suvannasankha|Celgene|Indiana University,Attaya Suvannasankha,Celgene,Indiana University,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00540644
3388,Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.,Completed,Has Results,Hepatocellular Carcinoma,Drug: gadobenate dimeglumine (MultiHance),"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bracco Diagnostics, Inc",Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"Bracco Diagnostics, Inc",,,,,,Not Applicable,Other|Industry,Interventional,9/7/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00539253
3389,Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion,Completed,Has Results,Brain Injury|Intracranial Pressure,Drug: Dexmedetomidine|Drug: Propofol,"Carmelo Graffagnino|Hospira, now a wholly owned subsidiary of Pfizer|Duke University",Carmelo Graffagnino,"Hospira, now a wholly owned subsidiary of Pfizer",Duke University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00538616
3390,Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders,Completed,Has Results,Alcohol Consumption,Drug: Vivitrol (Medication Therapy)|Other: Medication Management Therapy,Pacific Institute for Research and Evaluation|Cephalon,Pacific Institute for Research and Evaluation,Cephalon,,,,,,Phase 4,Other|Industry,Interventional,4/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00537745
3391,A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome,Completed,Has Results,Antiphospholipid Syndrome,Drug: Rituximab,"Hospital for Special Surgery, New York|Genentech, Inc.","Hospital for Special Surgery, New York","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/7/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00537290
3392,Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older,Completed,Has Results,Leukemia|CLL|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Lenalidomide,M.D. Anderson Cancer Center|Celgene,M.D. Anderson Cancer Center,Celgene,,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00535873
3393,Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients,Completed,Has Results,Type 1 Diabetes,Drug: Rapamycin|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Drug: Steroids,University of Miami|Astellas Pharma Inc,University of Miami,Astellas Pharma Inc,,,,,,Phase 2,Other|Industry,Interventional,9/1/2000,5/16/2019,https://ClinicalTrials.gov/show/NCT00533442
3394,Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine,Completed,Has Results,Major Depression,Drug: Duloxetine,Indiana University School of Medicine|Eli Lilly and Company|Indiana University,Indiana University School of Medicine,Eli Lilly and Company,Indiana University,,,,,Phase 4,Other|Industry,Interventional,9/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00532480
3395,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Completed,Has Results,Venous Thromboembolism,Drug: fondaparinux sodium|Device: sequential compression devices,"Mary Knudson, M.D.|GlaxoSmithKline|University of California, San Francisco","Mary Knudson, M.D.",GlaxoSmithKline,"University of California, San Francisco",,,,,Phase 2|Phase 3,Other|Industry,Interventional,12/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00531843
3396,Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Placebo|Drug: OROS-methylphenidate,"Children's Hospital of Philadelphia|Ortho-McNeil Janssen Scientific Affairs, LLC",Children's Hospital of Philadelphia,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 4,Other|Industry,Interventional,6/4/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00530257
3397,How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis,Completed,Has Results,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",Drug: doxercalciferol,"Duke University|Genzyme, a Sanofi Company",Duke University,"Genzyme, a Sanofi Company",,,,,,Phase 4,Other|Industry,Interventional,9/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00528788
3398,Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV,Completed,Has Results,Genital Herpes|HIV Infection,Drug: valacyclovir|Drug: acyclovir,University of Washington|GlaxoSmithKline,University of Washington,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,12/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00527618
3399,Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome,Completed,Has Results,Churg Strauss Syndrome,Biological: Mepolizumab,Brigham and Women's Hospital|GlaxoSmithKline,Brigham and Women's Hospital,GlaxoSmithKline,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00527566
3400,Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy,Completed,Has Results,Esophageal Diseases|Gastrointestinal Diseases|Disorder of the Genitourinary System|Gynecologic Diseases|Kidney Diseases|Liver Diseases|Pancreatic Diseases|Prostate Cancer|Spinal Disease,Device: Vigileo Monitor|Device: FloTrac Sensor,M.D. Anderson Cancer Center|Edwards Lifesciences,M.D. Anderson Cancer Center,Edwards Lifesciences,,,,,,Phase 4,Other|Industry,Interventional,8/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00526331
3401,"Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients",Completed,Has Results,Gastrointestinal Diseases,Drug: 5-Fluorouracil|Drug: Docetaxel|Drug: Oxaliplatin,M.D. Anderson Cancer Center|Sanofi-Synthelabo,M.D. Anderson Cancer Center,Sanofi-Synthelabo,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/4/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00526110
3402,Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma,Completed,Has Results,Esophageal Cancer|Gastroesophageal Cancer,Drug: 5-Fluorouracil|Drug: Oxaliplatin|Radiation: Radiation Therapy|Procedure: Surgery,M.D. Anderson Cancer Center|Sanofi,M.D. Anderson Cancer Center,Sanofi,,,,,,Phase 2,Other|Industry,Interventional,4/5/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00525915
3403,CFAR Study in Patients With Chronic Lymphocytic Leukemia,Completed,Has Results,Leukemia|Chronic Lymphocytic Leukemia,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Alemtuzumab|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00525603
3404,Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients,Completed,Has Results,Melanoma,Drug: Temozolomide (TMZ)|Drug: Pegylated Interferon Alpha-2b (PGI),M.D. Anderson Cancer Center|Schering-Plough,M.D. Anderson Cancer Center,Schering-Plough,,,,,,Phase 2,Other|Industry,Interventional,8/6/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT00525031
3405,Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents,Completed,Has Results,Anorexia Nervosa,Drug: RhIGF-1,Massachusetts General Hospital|Tercica,Massachusetts General Hospital,Tercica,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00516386
3406,A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis,Completed,Has Results,Alveolitis|Systemic Sclerosis,Drug: Imatinib,"University of California, Los Angeles|Novartis Pharmaceuticals","University of California, Los Angeles",Novartis Pharmaceuticals,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00512902
3407,Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer,Completed,Has Results,Advanced Ovarian Carcinoma|Primary Peritoneal Carcinoma|Ovarian Carcinosarcoma,Drug: Avastin|Drug: Paclitaxel|Drug: Cisplatin,"University of Oklahoma|Genentech, Inc.",University of Oklahoma,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,7/7/2019,8/3/2015,https://ClinicalTrials.gov/show/NCT00511992
3408,IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures,Completed,Has Results,Tonic-clonic Seizure,Drug: Keppra|Drug: Fosphenytoin|Drug: Dilantin,Emory University|UCB Pharma,Emory University,UCB Pharma,,,,,,Phase 4,Other|Industry,Interventional,7/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00510783
3409,Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients,Completed,Has Results,Obesity,Drug: pancreatic enzyme supplement,University of Pittsburgh|Solvay Pharmaceuticals,University of Pittsburgh,Solvay Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,8/7/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00510744
3410,Iressa Study in Patients With Salivary Gland Cancer,Completed,Has Results,Salivary Gland Cancer,Drug: Gefitinib,M.D. Anderson Cancer Center|AstraZeneca,M.D. Anderson Cancer Center,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,5/4/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT00509002
3411,Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer,Completed,Has Results,Lung Cancer,Drug: Alimta,M.D. Anderson Cancer Center|Eli Lilly and Company,M.D. Anderson Cancer Center,Eli Lilly and Company,,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00508144
3412,Dynasplint Therapy for Trismus in Head and Neck Cancer,Completed,Has Results,Trismus,Device: Dynasplint Trismus System|Other: Tongue Depressors,"University of Alabama at Birmingham|Dynasplint Systems, Inc.",University of Alabama at Birmingham,"Dynasplint Systems, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/7/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00507208
3413,Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT,Completed,Has Results,Leukemia|Lymphoma,Drug: Pentostatin|Drug: Tacrolimus|Drug: Methotrexate,M.D. Anderson Cancer Center|Astex Pharmaceuticals,M.D. Anderson Cancer Center,Astex Pharmaceuticals,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/1/2000,11/9/2019,https://ClinicalTrials.gov/show/NCT00506922
3414,Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Methylphenidate Transdermal System (MTS)|Other: placebo patch,University of Utah|Shire,University of Utah,Shire,,,,,,Phase 3,Other|Industry,Interventional,6/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00506285
3415,"Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer",Completed,Has Results,Bladder Cancer,Drug: Avastin|Drug: Cisplatin|Drug: Doxorubicin|Drug: Methotrexate|Drug: Vinblastine Sulfate,"M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/7/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00506155
3416,"Phase II Study of ""VIPER"" Chemotherapy in Rel/Ref DLBCL",Completed,Has Results,Non-Hodgkin's Lymphoma,"Drug: bortezomib, dexamethasone, ifosfamide|Drug: mesna, cisplatin, etoposide, rituximab","Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.",Weill Medical College of Cornell University,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,5/7/2019,2/17/2012,https://ClinicalTrials.gov/show/NCT00504751
3417,Rituximab and ABVD for Hodgkin's Patients,Completed,Has Results,Lymphoma,Drug: Rituximab|Drug: Adriamycin|Drug: Bleomycin|Drug: Vinblastine|Drug: Dacarbazine (DTIC),"M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/1/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00504504
3418,Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides,Completed,Has Results,Hypertriglyceridemia,"Drug: 4/day of 4g P-OM3 capsules|Drug: 4/day of 1g P-OM3 capsules|Drug: Corn Oil Placebo, 4 capsules/day for 8 weeks",Penn State University|Reliant Pharmaceuticals,Penn State University,Reliant Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,7/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00504309
3419,Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women,Completed,Has Results,Osteopenia|Osteoporosis,Drug: alendronate sodium|Other: placebo comparator,"University of California, San Francisco|Merck Sharp & Dohme Corp.","University of California, San Francisco",Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,2/6/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00504166
3420,HIV Testing Strategies in the Perinatal Setting,Completed,Has Results,HIV Infections|Pregnancy Related,Procedure: Abbreviated HIV test counseling,"University of California, San Francisco|Pfizer","University of California, San Francisco",Pfizer,,,,,,Not Applicable,Other|Industry,Interventional,10/6/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00503308
3421,Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder,Completed,Has Results,Seasonal Affective Disorder,Drug: Ramelteon|Drug: Placebo,"Lehigh Valley Hospital|Takeda Pharmaceuticals North America, Inc.",Lehigh Valley Hospital,"Takeda Pharmaceuticals North America, Inc.",,,,,,Phase 4,Other|Industry,Interventional,9/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00502320
3422,Intermittent Use of Aerosolized Ribavirin for Treatment of RSV,Completed,Has Results,Hematological Malignancies,Drug: Ribavirin,M.D. Anderson Cancer Center|ICN Pharmaceuticals,M.D. Anderson Cancer Center,ICN Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,2/3/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00500578
3423,"Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer",Completed,Has Results,Prostate Cancer,Drug: Docetaxel|Drug: Imatinib Mesylate|Drug: Leuprolide|Drug: Goserelin Acetate,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,M.D. Anderson Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,6/3/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00500110
3424,G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients,Completed,Has Results,Lymphoma,Drug: Etoposide|Drug: G-CSF|Drug: GM-CSF|Drug: Isophosphamide|Drug: Rituximab|Procedure: Apheresis,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,1/4/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00499343
3425,Lucentis for Inflammatory Macular Edema Trial,Completed,Has Results,Uveitis|Cytoid Macular Edema,Drug: Ranibizumab,"University of California, San Francisco|Genentech, Inc.","University of California, San Francisco","Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00498355
3426,"Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma",Completed,Has Results,Renal Cell Carcinoma|Kidney Cancer,Drug: Capecitabine|Drug: Gemcitabine|Drug: Bevacizumab,M.D. Anderson Cancer Center|Eli Lilly and Company,M.D. Anderson Cancer Center,Eli Lilly and Company,,,,,,Phase 2,Other|Industry,Interventional,7/7/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT00496587
3427,CEP-701 for PH-negative Myelofibrosis,Completed,Has Results,Leukemia|Myelofibrosis,Drug: CEP-701,M.D. Anderson Cancer Center|Cephalon,M.D. Anderson Cancer Center,Cephalon,,,,,,Phase 2,Other|Industry,Interventional,6/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00494585
3428,"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients",Completed,Has Results,Leukemia|Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia,Drug: Interleukin-11 (IL-11 or Neumega),M.D. Anderson Cancer Center|Wyeth is now a wholly owned subsidiary of Pfizer,M.D. Anderson Cancer Center,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 2,Other|Industry,Interventional,10/5/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00493181
3429,Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis,Completed,Has Results,Gastroparesis|Gastroesophageal Reflux Disease,Drug: Immediate-release omeprazole|Drug: Delayed-release omeprazole,"University of Louisville|Bausch Health Americas, Inc.",University of Louisville,"Bausch Health Americas, Inc.",,,,,,Phase 4,Other|Industry,Interventional,6/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00492622
3430,Zoledronate With Atorvastatin in Renal Cell Carcinoma,Completed,Has Results,Kidney Cancer|Renal Cell Carcinoma,Drug: Zoledronate|Drug: Atorvastatin,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,M.D. Anderson Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,10/6/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00490698
3431,Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC),Completed,Has Results,Advanced Non-small Cell Lung Cancer,"Drug: paclitaxel poliglumex, pemetrexed",Dartmouth-Hitchcock Medical Center|CTI BioPharma,Dartmouth-Hitchcock Medical Center,CTI BioPharma,,,,,,Phase 2,Other|Industry,Interventional,10/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00487669
3432,Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir,Completed,Has Results,HIV Infections,"Drug: Buprenorphine, Tipranavir and ritonavir",Yale University|Boehringer Ingelheim,Yale University,Boehringer Ingelheim,,,,,,Not Applicable,Other|Industry,Interventional,5/6/2019,5/7/2019,https://ClinicalTrials.gov/show/NCT00486330
3433,Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer,Completed,Has Results,Head and Neck Cancer|Squamous Cell Cancer,Drug: Imatinib Mesylate|Drug: Docetaxel,M.D. Anderson Cancer Center|Novartis,M.D. Anderson Cancer Center,Novartis,,,,,,Phase 2,Other|Industry,Interventional,1/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00485485
3434,Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma,Completed,Has Results,Hodgkin's Disease,Drug: I-131 Tositumomab therapeutic regimen,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|GlaxoSmithKline,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,GlaxoSmithKline,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/7/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT00484874
3435,Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK),Completed,Has Results,Respiratory Tract Infections,Other: Kefir|Other: Placebo,"Georgetown University|Lifeway Foods, Inc.",Georgetown University,"Lifeway Foods, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00481507
3436,Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT,Completed,Has Results,Healthy,Drug: Omnipaque|Drug: Gastroview,University of Alabama at Birmingham|GE Healthcare,University of Alabama at Birmingham,GE Healthcare,,,,,,Phase 4,Other|Industry,Interventional,8/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00478556
3437,Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: decitabine,Indiana University|Eisai Inc.,Indiana University,Eisai Inc.,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/7/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00477386
3438,Fulvestrant in Hormone Refractory Prostate Cancer,Completed,Has Results,Prostatic Neoplasms|Prostate Cancer,Drug: Fulvestrant,Stanford University|AstraZeneca,Stanford University,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,9/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00476645
3439,Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies,Completed,Has Results,Lymphoma|Leukemia,Drug: Thymoglobulin|Radiation: Total Lymphoid Irradiation|Procedure: Peripheral Blood Stem Cell Infusion|Drug: Rituximab,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Not Applicable,Other|Industry,Interventional,6/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00476229
3440,Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Memantine|Drug: Placebo,Florida Atlantic University|Forest Laboratories,Florida Atlantic University,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,7/7/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00476008
3441,Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration,Completed,Has Results,Age-Related Maculopathy|Choroidal Neovascularization,Drug: Ranibizumab|Drug: Verteporfin,Oklahoma State University Center for Health Sciences|Novartis,Oklahoma State University Center for Health Sciences,Novartis,,,,,,Phase 4,Other|Industry,Interventional,5/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00473642
3442,"Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias",Completed,Has Results,Richter's Transformation|Leukemia,Drug: Oxaliplatin|Drug: Fludarabine|Drug: Cytarabine|Drug: Rituximab|Drug: Pegfilgrastim,M.D. Anderson Cancer Center|Sanofi,M.D. Anderson Cancer Center,Sanofi,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/7/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00472849
3443,Geodon in Weight Loss Study for Bipolar Disorders,Completed,Has Results,Bipolar Disorder,Drug: Ziprasidone/Geodon,Stanford University|Pfizer,Stanford University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00472641
3444,Efficacy and Safety of Omalizumab in Bullous Pemphigoid,Completed,Has Results,Bullous Pemphigoid,Drug: Omalizumab|Drug: prednisone,"University of Iowa|Genentech, Inc.",University of Iowa,"Genentech, Inc.",,,,,,Phase 4,Other|Industry,Interventional,8/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00472030
3445,"Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients",Completed,Has Results,Myeloma,Drug: Trisenox (Arsenic Trioxide)|Drug: Velcade (Bortezomib)|Drug: Melphalan|Drug: Vitamin C (Ascorbic Acid),M.D. Anderson Cancer Center|Cephalon,M.D. Anderson Cancer Center,Cephalon,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00469209
3446,Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas,Completed,Has Results,Pleural Effusion Associated With Pulmonary Infection|Bacterial Pleural Effusion Other Than Tuberculosis,Drug: Alteplase|Drug: Placebo,"Midwest Pulmonary and Critical Care|Genentech, Inc.",Midwest Pulmonary and Critical Care,"Genentech, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,4/4/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00468104
3447,Acamprosate vs. Placebo in Bipolar Alcoholics,Completed,Has Results,Alcohol Dependence|Bipolar Disorder,Drug: Acamprosate|Drug: Placebo,Medical University of South Carolina|Forest Laboratories,Medical University of South Carolina,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,4/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00466661
3448,Metabolic Signatures and Biomarkers in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole|Drug: Risperidone|Other: Healthy volunteers,Duke University|Bristol-Myers Squibb,Duke University,Bristol-Myers Squibb,,,,,,Phase 1,Other|Industry,Interventional,2/7/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00466310
3449,Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer,Completed,Has Results,Renal Cell Cancer|Kidney Cancer,Drug: Sunitinib Malate,M.D. Anderson Cancer Center|Pfizer,M.D. Anderson Cancer Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,3/7/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00465179
3450,Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD),Completed,Has Results,Obsessive Compulsive Disorder,Drug: Duloxetine,Massachusetts General Hospital|Eli Lilly and Company,Massachusetts General Hospital,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,12/5/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00464698
3451,Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism,Completed,Has Results,Alcohol Dependence|Schizophrenia,Drug: Acamprosate|Drug: Placebo,Yale University|Forest Laboratories,Yale University,Forest Laboratories,,,,,,Phase 3,Other|Industry,Interventional,9/6/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00463346
3452,Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer,Completed,Has Results,Cancer,Drug: sunitinib malate (Sutent)|Procedure: radiotherapy,Icahn School of Medicine at Mount Sinai|Pfizer,Icahn School of Medicine at Mount Sinai,Pfizer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/7/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00463060
3453,Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity,Completed,Has Results,Upper Extremity Spasticity|Stroke|Acquired Brain Injury,Device: Functional Electrical Stimulation (FES) through the Ness H200,University of Pittsburgh|Allergan,University of Pittsburgh,Allergan,,,,,,Not Applicable,Other|Industry,Interventional,11/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00462449
3454,Centocor Microarray Study of Patients,Completed,Has Results,Rheumatoid Arthritis|Psoriatic Arthritis|Psoriasis|Crohn's Disease,Drug: Infliximab,"University of Rochester|Centocor, Inc.",University of Rochester,"Centocor, Inc.",,,,,,Phase 4,Other|Industry,Interventional,3/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00462072
3455,"Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma",Completed,Has Results,Bladder Cancer,Drug: Gemcitabine|Drug: Carboplatin|Drug: Sorafenib,Yale University|Bayer,Yale University,Bayer,,,,,,Phase 2,Other|Industry,Interventional,3/7/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00461851
3456,Therapeutic Approaches to HAART-Induced Lipodystrophy,Completed,Has Results,HIV Infections|Lipodystrophy,Drug: Leptin|Other: Placebo,"University of Texas Southwestern Medical Center|Amylin Pharmaceuticals, LLC.",University of Texas Southwestern Medical Center,"Amylin Pharmaceuticals, LLC.",,,,,,Phase 2,Other|Industry,Interventional,1/3/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00461552
3457,The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients,Completed,Has Results,Abdominal Obesity|Hypertension,Drug: Carvedilol CR + Lisinopril|Drug: Lisinopril + HCTZ,St. Paul Heart Clinic|GlaxoSmithKline,St. Paul Heart Clinic,GlaxoSmithKline,,,,,,Phase 3,Other|Industry,Interventional,4/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00459056
3458,Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA,Completed,Has Results,Obstructive Sleep Apnea,Device: Bi-Flex|Device: CPAP,Children's Hospital of Philadelphia|Philips Respironics,Children's Hospital of Philadelphia,Philips Respironics,,,,,,Not Applicable,Other|Industry,Interventional,5/7/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00458406
3459,A Study to Test the Use of Duloxetine for Pain in MS,Completed,Has Results,Multiple Sclerosis,Drug: Duloxetine|Drug: Placebo,"Brown, Theodore R., M.D., MPH|Eli Lilly and Company","Brown, Theodore R., M.D., MPH",Eli Lilly and Company,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,1/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00457730
3460,A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room,Completed,Has Results,Agitation,Drug: Quetiapine|Drug: Haloperidol|Drug: Lorazepam|Drug: Cogentin,University of Southern California|AstraZeneca,University of Southern California,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,5/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00457366
3461,Effect of Ranibizumab on Malignant Conjunctival Neoplasia,Completed,Has Results,Conjunctival Neoplasms,Drug: ranibizumab,"The New York Eye Cancer Center|Genentech, Inc.",The New York Eye Cancer Center,"Genentech, Inc.",,,,,,Phase 1,Other|Industry,Interventional,3/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00456495
3462,Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis,Completed,Has Results,Systemic Mastocytosis,Drug: RAD001 (Everolimus),M.D. Anderson Cancer Center|Novartis Pharmaceuticals,M.D. Anderson Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,4/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00449748
3463,FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL),Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Bevacizumab,"M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,2/7/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00448019
3464,Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery,Completed,Has Results,Atrial Fibrillation,Drug: Omega Three Polyunsaturated fatty acids,Chirag Sandesara|GlaxoSmithKline|University of Iowa,Chirag Sandesara,GlaxoSmithKline,University of Iowa,,,,,Phase 4,Other|Industry,Interventional,2/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00446966
3465,Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.,Completed,Has Results,"Kidney Failure, Chronic|Diabetic Nephropathies|Glomerulonephritis, IGA|Hypertension, Renal",Drug: mycophenolate mofetil (CellCept),University of Washington|Hoffmann-La Roche,University of Washington,Hoffmann-La Roche,,,,,,Phase 2,Other|Industry,Interventional,4/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00446459
3466,Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin|Drug: Pramlintide + Insulin,"Montefiore Medical Center|Amylin Pharmaceuticals, LLC.",Montefiore Medical Center,"Amylin Pharmaceuticals, LLC.",,,,,,Phase 4,Other|Industry,Interventional,2/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00442767
3467,A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma),Completed,Has Results,"Scleroderma, Diffuse|Scleroderma, Systemic",Drug: Abatacept|Drug: Placebo,Stanford University|Bristol-Myers Squibb,Stanford University,Bristol-Myers Squibb,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00442611
3468,"Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer",Completed,Has Results,Esophageal Cancer|Gastric Cancer,"Drug: Cetuximab,Paclitaxel, Carboplatin",Brown University|Bristol-Myers Squibb,Brown University,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,10/4/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00439608
3469,"A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema",Completed,Has Results,Metastatic Pancreatic Cancer,Drug: cohort 1|Drug: cohort 2|Drug: cohort 3|Drug: cohort 4,Brown University|GlaxoSmithKline,Brown University,GlaxoSmithKline,,,,,,Phase 1,Other|Industry,Interventional,7/6/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00439179
3470,The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder,Completed,Has Results,Panic Disorder,Drug: Duloxetine,Massachusetts General Hospital|Eli Lilly and Company,Massachusetts General Hospital,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00438971
3471,Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease,Completed,Has Results,Chronic Kidney Disease,Drug: Lanthanum Carbonate|Dietary Supplement: Low Phosphorus Diet|Dietary Supplement: Unrestricted Phosphorus Diet|Drug: Placebo,Massachusetts General Hospital|Shire,Massachusetts General Hospital,Shire,,,,,,Not Applicable,Other|Industry,Interventional,1/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00438932
3472,Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization,Completed,Has Results,Neuroendocrine Tumor|Islet Cell Tumor,Drug: Sunitinib malate|Procedure: Hepatic Artery Embolizations,H. Lee Moffitt Cancer Center and Research Institute|Pfizer,H. Lee Moffitt Cancer Center and Research Institute,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,11/6/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00434109
3473,Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis,Completed,Has Results,Gastroparesis,"Device: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.",University of Mississippi Medical Center|Medtronic,University of Mississippi Medical Center,Medtronic,,,,,,Phase 3,Other|Industry,Interventional,8/5/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00432835
3474,Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases,Completed,Has Results,Breast Cancer|Bone Metastases,Drug: 153 Sm-EDTMP|Behavioral: Questionnaire|Procedure: Stem Cell Transplant,M.D. Anderson Cancer Center|Cytogen Corporation,M.D. Anderson Cancer Center,Cytogen Corporation,,,,,,Phase 2,Other|Industry,Interventional,3/7/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00429507
3475,GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients,Completed,Has Results,Amenorrhea|Premature Ovarian Failure|Ovarian Function Insufficiency,Drug: Leuprolide Acetate|Behavioral: Questionnaire|Procedure: Hematopoietic Stem Cell Transplantation,M.D. Anderson Cancer Center|TAP Pharmaceutical Products Inc.,M.D. Anderson Cancer Center,TAP Pharmaceutical Products Inc.,,,,,,Phase 2,Other|Industry,Interventional,11/2/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00429494
3476,Herceptin and GM-CSF for Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Herceptin|Drug: GM-CSF,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,8/2/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00429104
3477,Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation,Completed,Has Results,Chronic Kidney Disease|Endothelial Dysfunction|Inflammation|Hypertension,Drug: paricalcitol|Drug: Placebo,Indiana University School of Medicine|Abbott|Indiana University,Indiana University School of Medicine,Abbott,Indiana University,,,,,Not Applicable,Other|Industry,Interventional,11/6/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00428246
3478,Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria,Completed,Has Results,Progeria|Hutchinson-Gilford Syndrome,Drug: Lonafarnib,Monica E. Kleinman|Schering-Plough|Boston Children’s Hospital,Monica E. Kleinman,Schering-Plough,Boston Children’s Hospital,,,,,Phase 2,Other|Industry,Interventional,5/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00425607
3479,PS-341 Followed by Removal of Prostate for Those With Prostate Cancer,Completed,Has Results,Prostate Neoplasms,Drug: PS-341 (bortezomib),"Baylor College of Medicine|Millennium Pharmaceuticals, Inc.",Baylor College of Medicine,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/1/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00425503
3480,Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia,Completed,Has Results,Waldenstrom's Macroglobulinemia,Drug: Bortezomib|Drug: Rituximab,"Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.",Dana-Farber Cancer Institute,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/30/2006,10/9/2015,https://ClinicalTrials.gov/show/NCT00422799
3481,2 Arm Study of Clofarabine IV in MDS Patients,Completed,Has Results,Myelodysplastic Syndrome|Leukemia,Drug: Clofarabine,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,1/6/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00422032
3482,Open-label Ziprasidone Study for Psychosis Treatment in Adolescents,Completed,Has Results,"Schizophreniform Disorder|Schizoaffective Disorder|Psychosis|Depressive Disorder, Major|Bipolar Disorder",Drug: Ziprasidone,New York State Psychiatric Institute|Pfizer,New York State Psychiatric Institute,Pfizer,,,,,,Phase 3,Other|Industry,Interventional,5/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00421954
3483,Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®),Completed,Has Results,Otitis Media,Drug: dornase alfa (Pulmozyme®),"University of Colorado, Denver|Genentech, Inc.","University of Colorado, Denver","Genentech, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00419380
3484,Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis,Completed,Has Results,Sinusitis|Cystic Fibrosis,Drug: Pulmozyme (dornase alfa)|Drug: Placebo,"University of Vermont|Genentech, Inc.",University of Vermont,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/6/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00416182
3485,Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation,Completed,Has Results,Scleritis|Orbital Disease,Drug: Rituximab,"Oregon Health and Science University|Genentech, Inc.",Oregon Health and Science University,"Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00415506
3486,Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML),Completed,Has Results,Myelodysplastic Syndrome|Acute Myelogenous Leukemia,Drug: Decitabine|Drug: Valproic Acid,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 2,Other|Industry,Interventional,12/6/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00414310
3487,Study of TNF-Antagonism in the Metabolic Syndrome (II),Completed,Has Results,Metabolic Syndrome,Drug: Etanercept|Drug: Placebo,Massachusetts General Hospital|Amgen,Massachusetts General Hospital,Amgen,,,,,,Not Applicable,Other|Industry,Interventional,12/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00413400
3488,Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism,Completed,Has Results,Deep Vein Thrombosis|Pulmonary Embolism,Drug: Enoxaparin,Brigham and Women's Hospital|Sanofi,Brigham and Women's Hospital,Sanofi,,,,,,Not Applicable,Other|Industry,Interventional,5/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00413374
3489,The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery,Completed,Has Results,Coronary Artery Disease,Drug: AndroGel 5 Grams|Drug: Placebo,Icahn School of Medicine at Mount Sinai|Abbott,Icahn School of Medicine at Mount Sinai,Abbott,,,,,,Phase 3,Other|Industry,Interventional,1/7/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00413244
3490,Metabolic Effects of Switching Kaletra to Boosted Reyataz,Completed,Has Results,HIV Infections,Drug: atazanavir/ritonavir|Drug: lopinavir/ritonavir,Massachusetts General Hospital|Bristol-Myers Squibb,Massachusetts General Hospital,Bristol-Myers Squibb,,,,,,Not Applicable,Other|Industry,Interventional,5/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00413153
3491,Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas,Completed,Has Results,Glioblastoma Multiforme|Glioma,Drug: Thalidomide|Drug: CPT-11|Procedure: MRI Scan|Procedure: Quantitative Sensory Tests (QST),M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,10/3/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00412542
3492,Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting,Completed,Has Results,Melanoma,Drug: Palonosetron,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00412425
3493,Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients,Completed,Has Results,Burkitt's Lymphoma|Lymphoblastic Lymphoma|Acute Lymphoblastic Leukemia,Drug: Clofarabine|Drug: Cyclophosphamide,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/6/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00412243
3494,Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex,Completed,Has Results,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Drug: Everolimus,"Children's Hospital Medical Center, Cincinnati|Novartis","Children's Hospital Medical Center, Cincinnati",Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/7/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00411619
3495,Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI),Completed,Has Results,Sarcoma|Nausea|Vomiting,Drug: Palonosetron - Single Dose|Drug: Palonosetron - Triple Dose|Drug: Adriamycin|Drug: Ifosfamide chemotherapy (AI)|Drug: Zinecard|Drug: Mesna|Drug: Vincristine|Drug: Dexamethasone,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Not Applicable,Other|Industry,Interventional,12/6/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00410488
3496,Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias,Completed,Has Results,Relapsed Acute Leukemia|Refractory Acute Leukemia,"Drug: Bortezomib with mitoxantrone, etoposide and cytarabine|Drug: Bortezomib 1.0mg/m^2|Drug: Bortezomib 1.3mg/m^2","Sidney Kimmel Cancer Center at Thomas Jefferson University|Millennium Pharmaceuticals, Inc.|Thomas Jefferson University",Sidney Kimmel Cancer Center at Thomas Jefferson University,"Millennium Pharmaceuticals, Inc.",Thomas Jefferson University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/6/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00410423
3497,Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions,Completed,Has Results,Macular Edema|Retinal Vein Occlusion,Drug: Intravitreal injection of ranibizumab .3 dose|Drug: Intravitreal injection of Ranibizumab .5 dose,"Peter A Campochiaro, MD|Genentech, Inc.|Johns Hopkins University","Peter A Campochiaro, MD","Genentech, Inc.",Johns Hopkins University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/6/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00407355
3498,An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome,Completed,Has Results,Irritable Bowel Syndrome,Drug: duloxetine,Mclean Hospital|Eli Lilly and Company,Mclean Hospital,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,11/6/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00401258
3499,Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma,Completed,Has Results,Liposarcoma|Leiomyosarcoma|Fibrosarcoma|Malignant Fibrous Histiocytoma,Drug: Sunitinib Malate (SU011248),H. Lee Moffitt Cancer Center and Research Institute|Pfizer,H. Lee Moffitt Cancer Center and Research Institute,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,11/6/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00400569
3500,Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myelogenous Leukemia,Drug: Decitabine,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,8/6/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00398983
3501,Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine,Completed,Has Results,Bipolar Disorder|Weight Gain,Drug: Topiramate|Drug: Placebo,University of Cincinnati|Eli Lilly and Company,University of Cincinnati,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,12/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00394095
3502,Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,Completed,Has Results,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: bortezomib|Drug: pemetrexed disodium|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: flow cytometry|Other: immunoenzyme technique|Other: immunohistochemistry staining method,"University of California, Davis|Eli Lilly and Company","University of California, Davis",Eli Lilly and Company,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/5/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT00389805
3503,Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma|Lymphoma,Drug: Rituximab|Drug: Zevalin,M.D. Anderson Cancer Center|Biogen,M.D. Anderson Cancer Center,Biogen,,,,,,Not Applicable,Other|Industry,Interventional,2/4/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00387023
3504,Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-small Cell Lung",Drug: Tarceva (Erlotinib),Weill Medical College of Cornell University|OSI Pharmaceuticals,Weill Medical College of Cornell University,OSI Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,10/6/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00385996
3505,"Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence",Completed,Has Results,Cocaine Dependence,Drug: Risperidone|Drug: Placebo,"Massachusetts General Hospital|Janssen, LP",Massachusetts General Hospital,"Janssen, LP",,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00385801
3506,Lucentis (Ranibizumab) for Eales' Disease,Completed,Has Results,Eales' Disease,Drug: Ranibizumab,"Oregon Health and Science University|Genentech, Inc.",Oregon Health and Science University,"Genentech, Inc.",,,,,,Phase 2|Phase 3,Other|Industry,Interventional,10/6/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00384449
3507,"Medication, Weight Gain and GI Hormones",Completed,Has Results,Bipolar Depression,Drug: orally-disintegrating olanzapine|Drug: regular olanzapine,Vanderbilt University|Eli Lilly and Company|Vanderbilt University Medical Center,Vanderbilt University,Eli Lilly and Company,Vanderbilt University Medical Center,,,,,Phase 4,Other|Industry,Interventional,1/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00384332
3508,Oral Topotecan to Treat Recurrent or Persistent Solid Tumors,Completed,Has Results,Tumors,Drug: Oral Topotecan,Accelerated Community Oncology Research Network|GlaxoSmithKline,Accelerated Community Oncology Research Network,GlaxoSmithKline,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/6/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00382733
3509,FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Sargramostim|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,9/6/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00381004
3510,The Effects of Thalidomide on Symptom Clusters,Completed,Has Results,Advanced Cancers,Drug: Thalidomide|Drug: Placebo,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,9/6/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00379353
3511,Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy,Completed,Has Results,Asthma|Rheumatic Disease,"Drug: Drug: Acetaminophen, Drug: Placebo","University of Texas Southwestern Medical Center|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",University of Texas Southwestern Medical Center,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",,,,,,Phase 4,Other|Industry,Interventional,11/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00377364
3512,Extracellular Matrix Marker of Arrhythmia Risk (EMMA),Completed,Has Results,"Myocardiopathies|Ischemia, Myocardial|Arrythmia|Death, Sudden, Cardiac",,Thomas Jefferson University|Medtronic,Thomas Jefferson University,Medtronic,,,,,,,Other|Industry,Observational,9/6/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00376532
3513,Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome,Completed,Has Results,"Fatigue Syndrome, Chronic",Drug: Duloxetine|Drug: Placebo,University of Cincinnati|Eli Lilly and Company,University of Cincinnati,Eli Lilly and Company,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,9/6/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00375973
3514,Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients,Completed,Has Results,Liver Transplantation,Drug: tacrolimus|Drug: mycophenolate mofetil|Drug: Prednisone,University of Cincinnati|Astellas Pharma Inc,University of Cincinnati,Astellas Pharma Inc,,,,,,Phase 4,Other|Industry,Interventional,10/2/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00374231
3515,Comparison of Keppra and Clonidine in the Treatment of Tics,Completed,Has Results,Tic Disorders|Tourette Syndrome,Drug: Levetiracetam|Drug: Clonidine,Harvey S. Singer|UCB Pharma|Johns Hopkins University,Harvey S. Singer,UCB Pharma,Johns Hopkins University,,,,,Phase 4,Other|Industry,Interventional,2/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00370838
3516,Atomoxetine and Huntington's Disease,Completed,Has Results,Huntington Disease|Chorea,Drug: atomoxetine|Drug: Matching Placebo,University of Iowa|Eli Lilly and Company,University of Iowa,Eli Lilly and Company,,,,,,Phase 2,Other|Industry,Interventional,11/5/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00368849
3517,Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy,Completed,Has Results,Psoriasis,Drug: Methotrexate|Drug: Raptiva,"University of California, Davis|Genentech, Inc.","University of California, Davis","Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00368654
3518,Study of the Insomnia in Patients With Low Back Pain,Completed,Has Results,Primary Insomnia,Drug: Eszopiclone|Drug: Placebo,Duke University|Sunovion,Duke University,Sunovion,,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00365976
3519,Initial Study of Rituximab to Treat Primary Biliary Cirrhosis,Completed,Has Results,Primary Biliary Cirrhosis,Drug: rituximab,"University of California, Davis|Genentech, Inc.","University of California, Davis","Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00364819
3520,Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825),Completed,Has Results,Leukemia|Lymphoma,Drug: Dasatinib (BMS-354825),M.D. Anderson Cancer Center|Bristol-Myers Squibb,M.D. Anderson Cancer Center,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,8/6/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00364286
3521,Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial,Completed,Has Results,Choroidal Neovascularization,Drug: Ranibizumab,"Johns Hopkins University|Genentech, Inc.",Johns Hopkins University,"Genentech, Inc.",,,,,,Phase 1,Other|Industry,Interventional,8/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00363168
3522,Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women,Completed,Has Results,Osteoporosis,Drug: zoledronic acid,The Cleveland Clinic|Novartis Pharmaceuticals,The Cleveland Clinic,Novartis Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,8/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00361595
3523,Duloxetine for Chronic Depression: a Double-blind Study,Completed,Has Results,Dysthymic Disorder|Depressive Disorder NOS,Drug: Duloxetine (Cymbalta),New York State Psychiatric Institute|Eli Lilly and Company,New York State Psychiatric Institute,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00360724
3524,Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome,Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: Revlimid,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,1/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00360672
3525,Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?,Completed,Has Results,Migraine,Drug: Rizatriptan|Other: Placebo,University of Pittsburgh|Merck Sharp & Dohme Corp.,University of Pittsburgh,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,8/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00360282
3526,Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater,Completed,Has Results,Gastrointestinal Cancer,Drug: Capecitabine|Drug: Oxaliplatin,M.D. Anderson Cancer Center|Sanofi-Synthelabo,M.D. Anderson Cancer Center,Sanofi-Synthelabo,,,,,,Phase 2,Other|Industry,Interventional,11/4/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00354887
3527,Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma,Completed,Has Results,Renal Cell Carcinoma,Drug: Erlotinib hydrochloride|Drug: Sirolimus,"University of Colorado, Denver|Genentech, Inc.","University of Colorado, Denver","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,7/6/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00353301
3528,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Completed,Has Results,Non-Hodgkin's Lymphoma|Lymphoma,Drug: Zoledronic Acid|Drug: Vitamin D|Drug: Calcium Carbonate,M.D. Anderson Cancer Center|Novartis,M.D. Anderson Cancer Center,Novartis,,,,,,Phase 3,Other|Industry,Interventional,1/6/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00352846
3529,Lenalidomide for Patients With Myelofibrosis (MF),Completed,Has Results,Myelofibrosis,Drug: Lenalidomide|Drug: Prednisone,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,7/7/2006,3/8/2018,https://ClinicalTrials.gov/show/NCT00352794
3530,"A Placebo-Controlled, Cross-Over Trial of Aripiprazole",Completed,Has Results,Schizophrenia,Drug: Aripiprazole|Drug: placebo,North Suffolk Mental Health Association|Eli Lilly and Company,North Suffolk Mental Health Association,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,12/5/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00351936
3531,Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus,Completed,Has Results,Schizophrenia,Drug: Ziprasidone,North Suffolk Mental Health Association|Pfizer,North Suffolk Mental Health Association,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/5/2019,3/7/2019,https://ClinicalTrials.gov/show/NCT00351000
3532,Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer,Completed,Has Results,Urologic Neoplasm,Drug: Cetuximab|Drug: Paclitaxel,Fox Chase Cancer Center|Bristol-Myers Squibb,Fox Chase Cancer Center,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,8/6/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00350025
3533,Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Revlimid,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene Corporation,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Celgene Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/20/2006,6/29/2016,https://ClinicalTrials.gov/show/NCT00348595
3534,Exercise and Testosterone Therapy in Elderly Men With Physical Frailty,Completed,Has Results,Physical Frailty|Hip Fracture|Elective Hip Replacement|Hypogonadism,Drug: Transdermal Testosterone gel (1%)|Behavioral: Supervised exercise training,Washington University School of Medicine|Solvay Pharmaceuticals,Washington University School of Medicine,Solvay Pharmaceuticals,,,,,,Phase 3,Other|Industry,Interventional,11/4/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00345969
3535,Memantine Augmentation of Antidepressants,Completed,Has Results,Depressive Disorder,Drug: memantine|Drug: Placebo,"University of Massachusetts, Worcester|Forest Laboratories","University of Massachusetts, Worcester",Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,6/6/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00344682
3536,"A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine",Completed,Has Results,HIV,"Drug: Nevirapine, FTC, and Tenofovir",University of Maryland|Boehringer Ingelheim,University of Maryland,Boehringer Ingelheim,,,,,,Phase 4,Other|Industry,Interventional,3/4/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00344461
3537,"Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)",Completed,Has Results,Cancer of Head and Neck,"Drug: Erbitux, Paclitaxel & Carboplatin|Radiation: Radiation",Department of Radiation Oncology|Bristol-Myers Squibb|University of Maryland,Department of Radiation Oncology,Bristol-Myers Squibb,University of Maryland,,,,,Phase 2,Other|Industry,Interventional,12/4/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00343083
3538,Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma,Completed,Has Results,Cancer of the Gallbladder|Cancer of the Biliary Tract,Drug: Capecitabine|Drug: Oxaliplatin,M.D. Anderson Cancer Center|Sanofi-Synthelabo,M.D. Anderson Cancer Center,Sanofi-Synthelabo,,,,,,Phase 2,Other|Industry,Interventional,8/3/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00338988
3539,Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin,Completed,Has Results,Hyperglycemia|Diabetes,Drug: insulin glargine,Northwestern University|Sanofi,Northwestern University,Sanofi,,,,,,Phase 4,Other|Industry,Interventional,7/4/2019,5/5/2019,https://ClinicalTrials.gov/show/NCT00338104
3540,"Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients",Completed,Has Results,Pancreatic Cancer,Drug: Cetuximab|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Capecitabine|Radiation: Radiotherapy,M.D. Anderson Cancer Center|Bristol-Myers Squibb,M.D. Anderson Cancer Center,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00338039
3541,A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma,Completed,Has Results,Peripheral T-Cell Lymphoma,"Drug: Ontak|Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy",Yale University|Eisai Inc.,Yale University,Eisai Inc.,,,,,,Phase 2,Other|Industry,Interventional,11/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00337987
3542,Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients,Completed,Has Results,Immunosuppression,Drug: Myfortic,University of Pittsburgh|Novartis Pharmaceuticals,University of Pittsburgh,Novartis Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,11/6/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00336895
3543,Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy,Completed,Has Results,Colon Cancer|Rectum Cancer,Drug: Cetuximab|Drug: Irinotecan,University of Pittsburgh|Bristol-Myers Squibb,University of Pittsburgh,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,6/6/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00336856
3544,A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients,Completed,Has Results,Immunosuppression,Drug: Myfortic|Drug: CellCept,University of Pittsburgh|Novartis Pharmaceuticals,University of Pittsburgh,Novartis Pharmaceuticals,,,,,,Not Applicable,Other|Industry,Interventional,11/6/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00336817
3545,Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients,Completed,Has Results,Lumbar Spine Surgery,Drug: DepoDur,"University of Rochester|EKR Therapeutics, Inc",University of Rochester,"EKR Therapeutics, Inc",,,,,,Not Applicable,Other|Industry,Interventional,6/6/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00335517
3546,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Completed,Has Results,Larynx Disease,Drug: Lansoprazole Tablet|Procedure: PH and impedence testing|Procedure: manometry|Drug: lansoprazole|Drug: placebo,Vanderbilt University|TAP Pharmaceutical Products Inc.,Vanderbilt University,TAP Pharmaceutical Products Inc.,,,,,,Phase 3,Other|Industry,Interventional,8/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00335283
3547,Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement,Completed,Has Results,"Scleroderma, Systemic",Drug: Mycophenolate mofetil,"University of California, San Francisco|Roche Pharma AG","University of California, San Francisco",Roche Pharma AG,,,,,,Not Applicable,Other|Industry,Interventional,5/6/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00333437
3548,Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Samarium-153|Drug: Total Androgen Suppression (TAS) with Bicalutamide|Drug: Total androgen suppression (TAS) with Goserelin Acetate|Device: Radiation Therapy,Sidney Kimmel Cancer Center at Thomas Jefferson University|Cytogen Corporation|Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Cytogen Corporation,Thomas Jefferson University,,,,,Phase 1,Other|Industry,Interventional,3/3/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00328614
3549,ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Carcinoma (NSCLC),Drug: ZD1839 (Iressa)|Radiation: Thoracic Radiotherapy,Sidney Kimmel Cancer Center at Thomas Jefferson University|AstraZeneca|Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,AstraZeneca,Thomas Jefferson University,,,,,Phase 1,Other|Industry,Interventional,12/3/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00328562
3550,Phase II 5-Azacytidine Plus VPA Plus ATRA,Completed,Has Results,Myelodysplastic Syndrome|Acute Myelogenous Leukemia,Drug: 5-Azacytidine (5-aza)|Drug: Valproic Acid|Drug: All-Trans Retinoic Acid (ATRA),M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,7/5/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00326170
3551,Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients,Completed,Has Results,Leukemia,Drug: Sargramostim (GM-CSF)|Biological: Pneumococcal Vaccine,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,6/4/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00323557
3552,"Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers",Completed,Has Results,Breast Cancer|Ovarian Cancer|Endometrial Cancer|Cervical Cancer,Drug: 852A,"Masonic Cancer Center, University of Minnesota|Pfizer","Masonic Cancer Center, University of Minnesota",Pfizer,,,,,,Phase 2,Other|Industry,Interventional,4/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00319748
3553,Tolerability and Efficacy of Depakote-extended Release in the Elderly,Completed,Has Results,Elderly|Epilepsy|Seizures,Drug: Divalproex Sodium Extended-Release Tablets,Virginia Commonwealth University|Abbott,Virginia Commonwealth University,Abbott,,,,,,Not Applicable,Other|Industry,Interventional,4/6/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00318929
3554,Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer,Completed,Has Results,Breast Cancer|Neoplasm Metastasis,Drug: Trastuzumab|Drug: RAD001,M.D. Anderson Cancer Center|Novartis,M.D. Anderson Cancer Center,Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/6/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00317720
3555,A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas,Completed,Has Results,Brain Neoplasms|Nausea|Vomiting,Drug: Dronabinol,Duke University|Solvay Pharmaceuticals,Duke University,Solvay Pharmaceuticals,,,,,,Phase 1,Other|Industry,Interventional,4/6/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00314808
3556,Effect of LY686017 on Alcohol Craving,Completed,Has Results,Alcohol Dependence|Alcoholism,Drug: LY686017|Drug: Placebo,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Eli Lilly and Company|National Institutes of Health Clinical Center (CC),National Institute on Alcohol Abuse and Alcoholism (NIAAA),Eli Lilly and Company,National Institutes of Health Clinical Center (CC),,,,,Phase 2,NIH|Industry,Interventional,3/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00310427
3557,An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders,Completed,Has Results,Autism|Asperger's Disorder|Pervasive Developmental Disorder,Drug: Aripiprazole,Cambridge Health Alliance|Bristol-Myers Squibb,Cambridge Health Alliance,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,2/6/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00308074
3558,Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC),Completed,Has Results,Prostate Cancer,Drug: Thalidomide|Drug: Doxil,"University of Pittsburgh|Ortho Biotech, Inc.",University of Pittsburgh,"Ortho Biotech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/6/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00307294
3559,Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants,Completed,Has Results,Multiple Myeloma|Plasma Cell Leukemia,Drug: Bortezomib|Drug: Melphalan|Procedure: PBSCT,"H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc.",H. Lee Moffitt Cancer Center and Research Institute,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00307086
3560,A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults,Completed,Has Results,Healthy,Drug: OROS-Methylphenidate|Drug: Immediate Release Methylphenidate|Drug: Placebo,"Massachusetts General Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC",Massachusetts General Hospital,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 4,Other|Industry,Interventional,1/6/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT00302458
3561,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Completed,Has Results,Depression|Heart Diseases,Behavioral: Supervised Aerobic Exercise|Drug: Sertraline|Drug: Placebo Pill.,Duke University|Pfizer,Duke University,Pfizer,,,,,,Phase 3,Other|Industry,Interventional,7/6/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00302068
3562,Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma,Completed,Has Results,Glioblastoma Multiforme|Anaplastic Astrocytoma,Drug: Erlotinib,"Northwell Health|Genentech, Inc.",Northwell Health,"Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/6/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00301418
3563,Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL,Completed,Has Results,Metabolic Syndrome,Drug: Pioglitazone|Other: Placebo|Drug: Niacin ER|Drug: Aspirin,University of Pennsylvania|Kos Pharmaceuticals,University of Pennsylvania,Kos Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,11/5/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00300365
3564,Oral Clofarabine Study in Patients With Myelodysplastic Syndrome,Completed,Has Results,Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia,Drug: Clofarabine,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,3/6/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00299156
3565,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Completed,Has Results,Heart Transplantation|Liver Transplantation|Bone Resorption,Drug: Zoledronic acid|Drug: Alendronate|Other: Placebo Zoledronic Acid|Other: Placebo Alendronate,Columbia University|Novartis Pharmaceuticals,Columbia University,Novartis Pharmaceuticals,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,11/5/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00297830
3566,Pimecrolimus Cream for Oral Lichen Planus,Completed,Has Results,Oral Lichen Planus,Drug: Pimecrolimus 1% cream,University of Utah|Novartis,University of Utah,Novartis,,,,,,Phase 2,Other|Industry,Interventional,8/5/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00297037
3567,Steroid Free Immunosuppression in Liver Transplantation,Completed,Has Results,Liver Cirrhosis|Liver Transplant Disorder,Drug: Steroids|Drug: Basiliximab|Drug: Tacrolimus|Drug: Enteric-coated Mycophenolic acid (EC-MPA),Thomas Jefferson University|Novartis Pharmaceuticals,Thomas Jefferson University,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,2/6/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00296244
3568,Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia,Completed,Has Results,Parkinson's Disease|Cognitive Impairment|Dementia,Drug: Memantine|Drug: Placebo Oral Tablet,Johns Hopkins University|Forest Laboratories,Johns Hopkins University,Forest Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,4/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00294554
3569,Protocol for Women at Increased Risk of Developing Breast Cancer,Completed,Has Results,Breast Cancer,Drug: letrozole,"Carol Fabian, MD|Novartis|University of Kansas Medical Center","Carol Fabian, MD",Novartis,University of Kansas Medical Center,,,,,Phase 2,Other|Industry,Interventional,1/3/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00291135
3570,The Utility of Nexium in Chronic Cough and Reflux Disease,Completed,Has Results,Cough|GERD,Drug: Esomeprazole|Drug: Placebo,"University of North Carolina, Chapel Hill|AstraZeneca","University of North Carolina, Chapel Hill",AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,9/5/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00287339
3571,"Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation",Completed,Has Results,Healthy,Drug: divalproex sodium,Pennington Biomedical Research Center|Abbott,Pennington Biomedical Research Center,Abbott,,,,,,Phase 4,Other|Industry,Interventional,2/6/2019,10/6/2019,https://ClinicalTrials.gov/show/NCT00287053
3572,Treatment of Executive Dysfunction in Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: Atomoxetine,Johns Hopkins University|Eli Lilly and Company,Johns Hopkins University,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,1/6/2005,6/30/2008,https://ClinicalTrials.gov/show/NCT00286949
3573,Rituximab in the Treatment of Patients With Bullous Pemphigoid,Completed,Has Results,Bullous Pemphigoid,Drug: Rituximab,"Duke University|Genentech, Inc.",Duke University,"Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/5/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00286325
3574,Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD),Completed,Has Results,Polycystic Kidney Diseases,Drug: Rapamune,The Cleveland Clinic|Wyeth is now a wholly owned subsidiary of Pfizer,The Cleveland Clinic,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/6/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00286156
3575,Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses,Completed,Has Results,Abdominal Abscess|Pelvic Abscess,Drug: Alteplase|Other: saline,"Kaiser Permanente|Genentech, Inc.",Kaiser Permanente,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,2/6/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00284739
3576,Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Exisulind|Drug: luteinizing hormone-releasing hormone (LHRH) agonist|Drug: Antiandrogen,University of Washington|OSI Pharmaceuticals,University of Washington,OSI Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,3/12/2002,10/11/2019,https://ClinicalTrials.gov/show/NCT00283803
3577,Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa,Completed,Has Results,Anorexia Nervosa|Osteopenia|Osteoporosis|Eating Disorders,Drug: Recombinant Human Growth Hormone|Drug: Placebo for Recombinant Human Growth Hormone,"Massachusetts General Hospital|Genentech, Inc.",Massachusetts General Hospital,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,1/6/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00283595
3578,Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC,Completed,Has Results,Lung Cancer,Drug: carboplatin|Drug: docetaxel,UNC Lineberger Comprehensive Cancer Center|Aventis Pharmaceuticals,UNC Lineberger Comprehensive Cancer Center,Aventis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,5/4/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00280735
3579,Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays,Completed,Has Results,"Otitis Media, Serous|Negative Middle Ear Pressure|Rhinitis|Otitis Media With Effusion|Otitis Media, Secretory",Drug: Triamcinolone acetonide nasal spray|Drug: Placebo nasal spray,Mayo Clinic|Aventis Pharmaceuticals,Mayo Clinic,Aventis Pharmaceuticals,,,,,,Phase 3,Other|Industry,Interventional,9/1/2005,3/9/2019,https://ClinicalTrials.gov/show/NCT00279916
3580,PET Imaging and Olanzapine Treatment in Borderline Personality Disorder,Completed,Has Results,Borderline Personality Disorder,Drug: olanzapine,University of Minnesota - Clinical and Translational Science Institute|Eli Lilly and Company,University of Minnesota - Clinical and Translational Science Institute,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,12/5/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00275301
3581,Pramipexole Conversion to Ropinirole Controlled Release (CR),Completed,Has Results,Parkinson Disease,Drug: Requip PR|Drug: Mirapex,"Rajesh Pahwa, MD|GlaxoSmithKline|University of Kansas Medical Center","Rajesh Pahwa, MD",GlaxoSmithKline,University of Kansas Medical Center,,,,,Phase 3,Other|Industry,Interventional,1/6/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00275275
3582,GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere,Completed,Has Results,Prostate Cancer,Drug: GM CSF,"Oncology Specialists, S.C.|Genzyme, a Sanofi Company","Oncology Specialists, S.C.","Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,1/6/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00274287
3583,Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome,Completed,Has Results,Cardiovascular Diseases|Metabolic Syndrome X|Atherosclerosis,Drug: Aspirin,Florida Atlantic University|Bayer,Florida Atlantic University,Bayer,,,,,,Phase 4,Other|Industry,Interventional,10/6/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00272311
3584,Infliximab (Remicade) for Patients With Acute Kawasaki Disease,Completed,Has Results,Kawasaki Disease,Drug: Infliximab (Remicade)|Biological: Intravenous immunoglobulin (IVIG),"University of California, San Diego|Centocor, Inc.","University of California, San Diego","Centocor, Inc.",,,,,,Phase 1,Other|Industry,Interventional,4/4/2019,10/6/2019,https://ClinicalTrials.gov/show/NCT00271570
3585,"EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)",Completed,Has Results,Head and Neck Cancer,Drug: Amifostine|Drug: Carboplatin|Drug: Taxol|Device: Radiotherapy,Mohan Suntharalingam|MedImmune LLC|University of Maryland,Mohan Suntharalingam,MedImmune LLC,University of Maryland,,,,,Phase 2,Other|Industry,Interventional,5/2/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00270790
3586,Research Study of Treatment for Winter Depression With Different Colors of Light,Completed,Has Results,Seasonal Affective Disorder,Device: Blue Light Box 467 nm|Device: Red Light Box 657 nm,Thomas Jefferson University|Apollo Health Systems,Thomas Jefferson University,Apollo Health Systems,,,,,,Phase 2,Other|Industry,Interventional,11/6/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00269633
3587,Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease,Completed,Has Results,Chronic Myeloid Leukemia|Minimal Residual Disease,Biological: Synthetic Tumor-Specific Breakpoint Peptide Vaccine,M.D. Anderson Cancer Center|BreakThrough Therapeutics,M.D. Anderson Cancer Center,BreakThrough Therapeutics,,,,,,Phase 2,Other|Industry,Interventional,12/5/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00267085
3588,Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL),Completed,Has Results,Chronic Lymphocytic Leukemia|Leukemia,Drug: Lenalidomide,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,12/5/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00267059
3589,Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder,Completed,Has Results,Body Dysmorphic Disorder,Drug: Levetiracetam,Butler Hospital|UCB Pharma,Butler Hospital,UCB Pharma,,,,,,Phase 4,Other|Industry,Interventional,12/4/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00265109
3590,Valganciclovir to Reduce T Cell Activation in HIV Infection,Completed,Has Results,HIV Infections|Cytomegalovirus Infections,Drug: Valganciclovir|Drug: Placebo,"University of California, San Francisco|Roche Pharma AG","University of California, San Francisco",Roche Pharma AG,,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00264290
3591,Prospective Survey of Menstrual Migraine & Prevention With Eletriptan,Completed,Has Results,Migraine,Drug: eletriptan,University of Pittsburgh|Pfizer,University of Pittsburgh,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,8/4/2019,,https://ClinicalTrials.gov/show/NCT00259649
3592,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,Completed,Has Results,Metastatic Melanoma,Drug: Vinorelbine|Drug: Docetaxel|Drug: Sargramostim,"John P. Fruehauf|Bayer|University of California, Irvine",John P. Fruehauf,Bayer,"University of California, Irvine",,,,,Phase 2,Other|Industry,Interventional,4/3/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00256282
3593,Dasatinib as Therapy for Myeloproliferative Disorders (MPDs),Completed,Has Results,"Acute Myeloid Leukemia|Myelodysplastic Syndromes|Agnogenic Myeloid Metaplasia|Myelofibrosis|Hypereosinophilic Syndrome|Polycythemia Vera|Mastocytosis|Leukemia, Myelomonocytic, Chronic",Drug: Dasatinib (BMS-354825),M.D. Anderson Cancer Center|Bristol-Myers Squibb,M.D. Anderson Cancer Center,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,11/15/2005,3/3/2017,https://ClinicalTrials.gov/show/NCT00255346
3594,A Study of Imatinib and Docetaxel in Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Gleevec|Drug: Docetaxel,Leonard Appleman|Novartis Pharmaceuticals|University of Pittsburgh,Leonard Appleman,Novartis Pharmaceuticals,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,8/5/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00251225
3595,Trial of Aripiprazole in the Treatment of CD in Adolescents,Completed,Has Results,Conduct Disorder,Drug: Aripiprazole,University of Iowa|Bristol-Myers Squibb,University of Iowa,Bristol-Myers Squibb,,,,,,Phase 4,Other|Industry,Interventional,11/17/2004,3/23/2009,https://ClinicalTrials.gov/show/NCT00250705
3596,Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,"Drug: Interferon beta 1a, oral doxycycline",Louisiana State University Health Sciences Center Shreveport|Biogen,Louisiana State University Health Sciences Center Shreveport,Biogen,,,,,,Phase 4,Other|Industry,Interventional,12/3/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00246324
3597,Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,Completed,Has Results,Lymphoma,Biological: rituximab|Drug: pegylated liposomal doxorubicin hydrochloride,"Roswell Park Cancer Institute|Ortho Biotech, Inc.",Roswell Park Cancer Institute,"Ortho Biotech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/5/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00244985
3598,Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI,Completed,Has Results,Facial Neuropathy,Drug: Lamotrigine|Drug: Placebo (for Lamotrigine),Pain and Analgesia Imaging and Neuroscience Group|GlaxoSmithKline,Pain and Analgesia Imaging and Neuroscience Group,GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,10/5/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00243152
3599,Treatment With Namenda in Women at Risk for Cognitive Decline,Completed,Has Results,Dementia,Drug: Namenda,Stanford University|Forest Laboratories,Stanford University,Forest Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,6/4/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00242632
3600,Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery,Completed,Has Results,Hepatocellular Carcinoma|Liver Cancer,Drug: Bevacizumab (Avastin)|Drug: Erlotinib,"M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,10/5/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00242502
3601,Nitric Oxide Administration for Acute Respiratory Distress Syndrome,Completed,Has Results,Acute Respiratory Distress Syndrome,Drug: Nitric Oxide|Other: No Intervention,Children's Hospital of Philadelphia|Mallinckrodt,Children's Hospital of Philadelphia,Mallinckrodt,,,,,,Phase 3,Other|Industry,Interventional,9/1/2000,9/8/2019,https://ClinicalTrials.gov/show/NCT00240487
3602,Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.,Completed,Has Results,Metastatic Breast Cancer,Drug: Avastin|Drug: Hormonal therapy,"University of Alabama at Birmingham|Genentech, Inc.",University of Alabama at Birmingham,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,10/5/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00240071
3603,Provision of Antioxidant Therapy in Hemodialysis (PATH) Study,Completed,Has Results,End-stage Renal Disease,"Drug: Alpha, gamma, beta, and delta (mixed) tocopherols|Drug: Alpha lipoic acid|Drug: Placebo",Vanderbilt University|Fresenius Medical Care North America,Vanderbilt University,Fresenius Medical Care North America,,,,,,Phase 2,Other|Industry,Interventional,4/6/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00237718
3604,"Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer",Completed,Has Results,Breast Cancer,"Drug: trastuzumab, docetaxel and carboplatin in dose dense regimen",University of Miami|Aventis Pharmaceuticals,University of Miami,Aventis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00232479
3605,Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: docetaxel (Taxotere®)|Drug: ZD1839,H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca,H. Lee Moffitt Cancer Center and Research Institute,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,7/3/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00231465
3606,"Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia",Completed,Has Results,Leukemia|B-cell Leukemia|Chronic Leukemia|Chronic Lymphocytic Leukemia (CLL),Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cytoxan,Steven E. Coutre|Bayer|Stanford University,Steven E. Coutre,Bayer,Stanford University,,,,,Phase 2,Other|Industry,Interventional,7/4/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00230282
3607,OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: erlotinib,"Ohio State University Comprehensive Cancer Center|Genentech, Inc.",Ohio State University Comprehensive Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,10/5/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00230126
3608,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Completed,Has Results,Cytomegalovirus Infections,Drug: valganciclovir|Other: Placebo,Scott Palmer|Roche Pharma AG|Duke University,Scott Palmer,Roche Pharma AG,Duke University,,,,,Phase 3,Other|Industry,Interventional,7/3/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00227370
3609,"Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer",Completed,Has Results,Cancer,Drug: Docetaxel|Drug: Cisplatin|Drug: Cetuximab|Procedure: Radiation Therapy,University of Pittsburgh|Bristol-Myers Squibb,University of Pittsburgh,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,10/5/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00226239
3610,Wellbutrin XL for Dysthymic Disorder,Completed,Has Results,Dysthymic Disorder,Drug: bupropion XL|Other: Placebo,St. Luke's-Roosevelt Hospital Center|GlaxoSmithKline,St. Luke's-Roosevelt Hospital Center,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,11/4/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00225251
3611,Effect of Age on Latanoprost 0.005% in Patients With Glaucoma,Completed,Has Results,Glaucoma,Drug: Latanoprost 0.005%,Yale University|Pfizer,Yale University,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,3/5/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00224289
3612,Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Flutamide|Drug: Leuprolide Acetate,University of Washington|Sanofi,University of Washington,Sanofi,,,,,,Phase 2,Other|Industry,Interventional,1/8/1997,9/6/2012,https://ClinicalTrials.gov/show/NCT00223665
3613,12- Week Open Label Treatment of Refractory Bipolar Depression,Completed,Has Results,Bipolar Disorder,Drug: Aripiprazole,The University of Texas Health Science Center at San Antonio|Bristol-Myers Squibb,The University of Texas Health Science Center at San Antonio,Bristol-Myers Squibb,,,,,,Phase 4,Other|Industry,Interventional,9/4/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00223496
3614,"Escitalopram in the Treatment of Dysthymic Disorder, Double Blind",Completed,Has Results,Dysthymic Disorder,Drug: Lexapro (escitalopram),St. Luke's-Roosevelt Hospital Center|Forest Laboratories,St. Luke's-Roosevelt Hospital Center,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,6/2/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00220701
3615,Abilify as an Adjunctive Treatment for Refractory Depression,Completed,Has Results,"Depressive Disorder, Major",Drug: Aripiprazole,St. Luke's-Roosevelt Hospital Center|Bristol-Myers Squibb,St. Luke's-Roosevelt Hospital Center,Bristol-Myers Squibb,,,,,,Phase 4,Other|Industry,Interventional,3/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00220636
3616,Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD),Completed,Has Results,Generalized Anxiety Disorder,Behavioral: Cognitive Behavioral Therapy|Drug: escitalopram,New York State Psychiatric Institute|Forest Laboratories,New York State Psychiatric Institute,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,1/5/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00219349
3617,Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder,Completed,Has Results,OCD,Drug: escitalopram|Drug: Placebo ( sugar pill),Duke University|Forest Laboratories,Duke University,Forest Laboratories,,,,,,Phase 2,Other|Industry,Interventional,10/4/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00215137
3618,The Effect of Salmeterol on Eosinophil (EOS) Function,Completed,Has Results,Allergic Asthma,Drug: salmeterol|Drug: Fluticasone|Drug: Placebo,"University of Wisconsin, Madison|GlaxoSmithKline","University of Wisconsin, Madison",GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,11/3/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00214019
3619,Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia,Completed,Has Results,Focal Dystonia,"Drug: Botulinum toxin, type B",Columbia University|Solstice Neurosciences,Columbia University,Solstice Neurosciences,,,,,,Phase 4,Other|Industry,Interventional,4/3/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00208091
3620,Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome,Completed,Has Results,Netherton Syndrome,Drug: Pimecrolimus 1% Cream,Children's Hospital of Philadelphia|Novartis Pharmaceuticals,Children's Hospital of Philadelphia,Novartis Pharmaceuticals,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00208026
3621,"Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole",Completed,Has Results,Schizophrenia|Type 2 Diabetes Mellitus,Other: Stayers|Other: Switchers,Washington University School of Medicine|Bristol-Myers Squibb,Washington University School of Medicine,Bristol-Myers Squibb,,,,,,Phase 4,Other|Industry,Interventional,2/5/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00205660
3622,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Docetaxel,"University of Arkansas|Genentech, Inc.",University of Arkansas,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT00203502
3623,A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity,Completed,Has Results,Migraine,Drug: dihydroergotamine mesylate,"Thomas Jefferson University|Bausch Health Americas, Inc.",Thomas Jefferson University,"Bausch Health Americas, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,12/3/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00203268
3624,An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.,Completed,Has Results,Cluster Headache,Drug: Depacon IV and Depakote ER,Thomas Jefferson University|Abbott,Thomas Jefferson University,Abbott,,,,,,Not Applicable,Other|Industry,Interventional,7/3/2019,12/6/2019,https://ClinicalTrials.gov/show/NCT00203242
3625,A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches,Completed,Has Results,Migraine,Drug: levetiracetam|Procedure: Transcranial Magnetic Stimulation,Thomas Jefferson University|UCB Pharma,Thomas Jefferson University,UCB Pharma,,,,,,Not Applicable,Other|Industry,Interventional,9/2/2019,9/5/2019,https://ClinicalTrials.gov/show/NCT00203216
3626,Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Exemestane|Drug: Fulvestrant,Ohio State University Comprehensive Cancer Center|Pfizer,Ohio State University Comprehensive Cancer Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,9/5/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00201864
3627,"Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma",Completed,Has Results,Pancreatic Neoplasms|Adenocarcinoma,Drug: Gemcitabine|Drug: Etanercept,Ohio State University Comprehensive Cancer Center|Immunex Corporation,Ohio State University Comprehensive Cancer Center,Immunex Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/1/2019,5/7/2019,https://ClinicalTrials.gov/show/NCT00201838
3628,A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients,Completed,Has Results,Lung Cancer|Non-Small-Cell Lung Carcinoma,Drug: Capecitabine|Drug: Docetaxel,Tony Bekaii-Saab|Roche Pharma AG|Ohio State University Comprehensive Cancer Center,Tony Bekaii-Saab,Roche Pharma AG,Ohio State University Comprehensive Cancer Center,,,,,Phase 2,Other|Industry,Interventional,12/4/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00201825
3629,"Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer",Completed,Has Results,Breast Cancer,Drug: Exemestane|Drug: Celecoxib|Other: Correlative studies,Ohio State University Comprehensive Cancer Center|Pfizer,Ohio State University Comprehensive Cancer Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,7/3/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00201773
3630,Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Gemcitabine|Drug: Trastuzumab|Drug: Cisplatin,Kari Kendra|Eli Lilly and Company|Ohio State University Comprehensive Cancer Center,Kari Kendra,Eli Lilly and Company,Ohio State University Comprehensive Cancer Center,,,,,Phase 2,Other|Industry,Interventional,2/25/2005,10/31/2009,https://ClinicalTrials.gov/show/NCT00201760
3631,Bone Tunnel Widening Following ACL Reconstruction,Completed,Has Results,Anterior Cruciate Ligament Injury|Knee Injuries,Procedure: Surgical reconstruction of the ACL,"Hospital for Special Surgery, New York|Inion Oy","Hospital for Special Surgery, New York",Inion Oy,,,,,,Not Applicable,Other|Industry,Interventional,6/4/2019,12/31/2015,https://ClinicalTrials.gov/show/NCT00198042
3632,"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression",Completed,Has Results,Bipolar Disorder,Drug: Divalproex Sodium ER|Drug: Placebo,University Hospitals Cleveland Medical Center|Abbott,University Hospitals Cleveland Medical Center,Abbott,,,,,,Phase 3,Other|Industry,Interventional,9/4/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00194116
3633,Study of Aripiprazole (Abilify) in Children With Symptoms of Mania,Completed,Has Results,Bipolar Disorder,Drug: Aripiprazole|Drug: Placebo,University Hospitals Cleveland Medical Center|Bristol-Myers Squibb,University Hospitals Cleveland Medical Center,Bristol-Myers Squibb,,,,,,Phase 3,Other|Industry,Interventional,8/4/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00194077
3634,Valproate in Late Life Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Valproate,University Hospitals Cleveland Medical Center|Abbott,University Hospitals Cleveland Medical Center,Abbott,,,,,,Phase 4,Other|Industry,Interventional,11/4/2019,11/6/2019,https://ClinicalTrials.gov/show/NCT00194025
3635,Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: Aripiprazole|Drug: Placebo,University Hospitals Cleveland Medical Center|Bristol-Myers Squibb,University Hospitals Cleveland Medical Center,Bristol-Myers Squibb,,,,,,Phase 3,Other|Industry,Interventional,8/4/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00194012
3636,Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Lung Cancer,Drug: Pemetrexed|Drug: Gemcitabine,"SCRI Development Innovations, LLC|Eli Lilly and Company","SCRI Development Innovations, LLC",Eli Lilly and Company,,,,,,Phase 2,Other|Industry,Interventional,5/5/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00193414
3637,Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds,Completed,Has Results,Upper Respiratory Infection,Drug: Montelukast,West Penn Allegheny Health System|Merck Sharp & Dohme Corp.,West Penn Allegheny Health System,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,10/3/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00189475
3638,"Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans",Completed,Has Results,End Stage Renal Disease|Kidney Transplantation,Drug: Sirolimus,University of Michigan|Wyeth is now a wholly owned subsidiary of Pfizer,University of Michigan,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,8/4/2019,7/1/2008,https://ClinicalTrials.gov/show/NCT00189202
3639,"Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors",Completed,Has Results,Glioblastoma Multiforme|Gliosarcoma,Drug: Tarceva|Drug: Temodar|Procedure: Radiation Therapy,"University of California, San Francisco|Genentech, Inc.","University of California, San Francisco","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/4/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00187486
3640,"Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.",Completed,Has Results,Insulin Resistance|Hypertriglyceridemia,Drug: Rosiglitazone|Drug: Fenofibrate|Behavioral: Weight Loss,Stanford University|Abbott,Stanford University,Abbott,,,,,,Not Applicable,Other|Industry,Interventional,9/3/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00186537
3641,Treatment of Nicotine Dependence and Acute Depression,Completed,Has Results,Major Depressive Disorder|Nicotine Dependence,Drug: bupropion and smoking cessation behavioral intervention,Stanford University|GlaxoSmithKline,Stanford University,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,6/4/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00186446
3642,Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women,Completed,Has Results,Breast Cancer,Drug: Anastrozole (Arimidex)|Drug: Goserelin (Zoladex),Stanford University|AstraZeneca,Stanford University,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,10/1/2000,6/13/2019,https://ClinicalTrials.gov/show/NCT00186121
3643,Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II,Completed,Has Results,Bipolar II Disorder,Drug: Quetiapine/Seroquel|Drug: Placebo,Stanford University|AstraZeneca,Stanford University,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,8/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00186043
3644,Short Term Rescue Study of Olanzapine,Completed,Has Results,Bipolar Disorder,Drug: Olanzapine/Zyprexa,Stanford University|Eli Lilly and Company,Stanford University,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,7/5/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00186017
3645,Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Drug: Vatalanib|Drug: Gemcitabine,George Albert Fisher|Novartis|Stanford University,George Albert Fisher,Novartis,Stanford University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/4/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00185588
3646,"Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas",Completed,Has Results,Non-Hodgkin's Lymphoma,"Drug: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone","University of Southern California|Ortho Biotech, Inc.",University of Southern California,"Ortho Biotech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,1/10/2003,5/7/2013,https://ClinicalTrials.gov/show/NCT00184002
3647,Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma,Completed,Has Results,Gastric Cancer|Esophageal Neoplasms,"Drug: irinotecan, docetaxel",University of Southern California|Sanofi,University of Southern California,Sanofi,,,,,,Phase 2,Other|Industry,Interventional,4/14/2005,10/20/2015,https://ClinicalTrials.gov/show/NCT00183872
3648,Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS),Completed,Has Results,ADHD NOS,Drug: Strattera (atomoxetine),Massachusetts General Hospital|Eli Lilly and Company,Massachusetts General Hospital,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,12/3/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00181766
3649,Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta,Completed,Has Results,ADHD,Drug: methylphenidate HCl (Concerta),"Massachusetts General Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC",Massachusetts General Hospital,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,Phase 4,Other|Industry,Interventional,11/3/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00181714
3650,Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT),Completed,Has Results,Asthma|Chronic Obstructive Pulmonary Disease (COPD)|Undifferentiated Asthma/COPD,Device: High Frequency Chest Wall Oscillator,University of Chicago|Hill-Rom,University of Chicago,Hill-Rom,,,,,,Not Applicable,Other|Industry,Interventional,10/3/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00181285
3651,Effectiveness of Pulmozyme in Infants With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Recombinant Human DNase (Pulmozyme)|Drug: Placebos,"Nationwide Children's Hospital|Genentech, Inc.",Nationwide Children's Hospital,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,1/5/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT00179998
3652,Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo,Completed,Has Results,Seizure Disorder|Hypogonadism|Erectile Dysfunction,Drug: Anastrozole 1mg|Drug: Placebo Oral Tablet,Beth Israel Deaconess Medical Center|AstraZeneca,Beth Israel Deaconess Medical Center,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,6/1/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00179517
3653,Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions,Completed,Has Results,"Pain, Postoperative",Device: Breg Pain Care 3000 Catheter|Drug: Bupivicaine 0.5%|Drug: Placebo,"University of Rochester|BREG, Inc",University of Rochester,"BREG, Inc",,,,,,Not Applicable,Other|Industry,Interventional,3/5/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00178178
3654,"Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer",Completed,Has Results,Cancer,Drug: Bevacizumab|Drug: Capecitabine|Drug: Oxaliplatin,"University of Pittsburgh|Genentech, Inc.",University of Pittsburgh,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,1/5/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00177307
3655,Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients,Completed,Has Results,Schizophrenia,Behavioral: Diet support group|Behavioral: Group counseling and exercise,University of Maryland|Eli Lilly and Company,University of Maryland,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,2/4/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00176436
3656,Levofloxacin Pharmacokinetics (PK) in the Severely Obese,Completed,Has Results,Obesity|Critical Illness,Drug: Levofloxacin 750 mg IV,"Joel Thompson, PhD|Ortho-McNeil Pharmaceutical|University of Kentucky","Joel Thompson, PhD",Ortho-McNeil Pharmaceutical,University of Kentucky,,,,,Phase 4,Other|Industry,Interventional,1/5/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00176306
3657,Lamotrigine Monotherapy in Pediatric Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: Lamotrigine,University of Illinois at Chicago|GlaxoSmithKline,University of Illinois at Chicago,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,2/4/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00176228
3658,Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent,Completed,Has Results,Ureteral Obstruction,Device: Memokath 051 Ureteral Stent|Device: JJ Stent,Mayo Clinic|Pnn Medical A/S,Mayo Clinic,Pnn Medical A/S,,,,,,Not Applicable,Other|Industry,Interventional,2/4/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00166361
3659,Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing,Completed,Has Results,Insomnia|Primary Insomnia|Psychophysiologic Insomnia,Drug: Zolpidem|Drug: Sugar Pill,University of Rochester|Sanofi-Synthelabo,University of Rochester,Sanofi-Synthelabo,,,,,,Phase 4,Other|Industry,Interventional,3/5/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00156533
3660,Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL),Completed,Has Results,"Lymphoma, B-Cell|Lymphoma, Non-Hodgkin",Drug: CLOFARABINE,"Oncology Specialists, S.C.|Genzyme, a Sanofi Company","Oncology Specialists, S.C.","Genzyme, a Sanofi Company",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/5/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00156013
3661,Kaletra Sex/Gender Pharmacokinetics (PK) Study,Completed,Has Results,HIV Infections,Drug: LPV/r,Emory University|Abbott,Emory University,Abbott,,,,,,Phase 4,Other|Industry,Interventional,6/5/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00148759
3662,"Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: Bortezomib|Drug: dexamethasone|Drug: liposomal doxorubicin|Drug: cyclophoshamide|Drug: filgrastim,"Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.",Weill Medical College of Cornell University,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00148317
3663,Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study),Completed,Has Results,Rheumatoid Arthritis,Drug: rituximab,"University of California, San Diego|Genentech, Inc.","University of California, San Diego","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00147966
3664,Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions,Completed,Has Results,Bone Diseases,Device: Vitoss Alone|Device: Vitoss with Bone Marrow Aspirate,State University of New York - Upstate Medical University|Orthovita d/b/a Stryker,State University of New York - Upstate Medical University,Orthovita d/b/a Stryker,,,,,,Not Applicable,Other|Industry,Interventional,12/4/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00147823
3665,AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin,Completed,Has Results,Solid Tumors|Advanced Cancer,Drug: AMG 531|Drug: Carboplatin|Drug: Adriamycin|Drug: Ifosfamide,M.D. Anderson Cancer Center|Amgen,M.D. Anderson Cancer Center,Amgen,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/5/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00147225
3666,A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment,Completed,Has Results,HIV Infections,Drug: Kaletra + Current Dual NRTI Backbone|Drug: Current Regimen,University of Chicago|Abbott,University of Chicago,Abbott,,,,,,Phase 4,Other|Industry,Interventional,4/4/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00145795
3667,Levetiracetam for the Treatment of Alcohol Dependence and Anxiety,Completed,Has Results,Alcoholism|Generalized Anxiety Disorder|Panic Disorder|Social Phobia|Anxiety Disorders,Drug: levetiracetam,New York State Psychiatric Institute|UCB Pharma,New York State Psychiatric Institute,UCB Pharma,,,,,,Phase 2,Other|Industry,Interventional,3/4/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00141115
3668,Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia,Completed,Has Results,Growth Hormone Deficiency|Septo-Optic Dysplasia|Hypopituitarism,Drug: Nutropin AQ,"Children's Hospital Los Angeles|Genentech, Inc.",Children's Hospital Los Angeles,"Genentech, Inc.",,,,,,Phase 4,Other|Industry,Interventional,12/4/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00140413
3669,Pharmacokinetics of Leptin Administration During Fasting,Completed,Has Results,Energy Deficiency Due to Short-term Fasting,Drug: r-metHuLeptin,Beth Israel Deaconess Medical Center|Amgen,Beth Israel Deaconess Medical Center,Amgen,,,,,,Phase 1,Other|Industry,Interventional,2/1/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00140205
3670,Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects,Completed,Has Results,Hepatitis C,Diagnostic Test: MR brain and neuropsychiatric tests,Beth Israel Deaconess Medical Center|Schering-Plough,Beth Israel Deaconess Medical Center,Schering-Plough,,,,,,,Other|Industry,Observational,3/4/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00136214
3671,Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis,Completed,Has Results,"Anterior Uveitis|Arthritis, Juvenile Idiopathic|Iritis|Immunosuppression",Drug: Daclizumab,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 2,NIH|Industry,Interventional,8/5/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00130637
3672,Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer,Completed,Has Results,Ovarian Neoplasms,Drug: bevacizumab|Drug: erlotinib,"University of Arizona|Genentech, Inc.",University of Arizona,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00130520
3673,Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study,Completed,Has Results,Schizophrenia,Drug: Merck L-830982|Drug: Placebo,University of Pittsburgh|Merck Sharp & Dohme Corp.,University of Pittsburgh,Merck Sharp & Dohme Corp.,,,,,,Phase 2,Other|Industry,Interventional,8/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00129441
3674,Continuous Levalbuterol for Treatment of Status Asthmaticus in Children,Completed,Has Results,Asthma,Drug: Racemic albuterol (R+S albuterol)|Drug: Levalbuterol (R albuterol),Children's Hospital of Philadelphia|Sunovion,Children's Hospital of Philadelphia,Sunovion,,,,,,Phase 4,Other|Industry,Interventional,4/4/2019,2/6/2019,https://ClinicalTrials.gov/show/NCT00124176
3675,Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: rosiglitazone|Drug: glyburide,St. Paul Heart Clinic|GlaxoSmithKline,St. Paul Heart Clinic,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,5/3/2019,12/5/2019,https://ClinicalTrials.gov/show/NCT00123643
3676,A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab,Completed,Has Results,Esophagitis,Drug: omalizumab|Drug: Placebo,University of Utah|Novartis Pharmaceuticals,University of Utah,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,11/5/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00123630
3677,Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes,Completed,Has Results,Hypertension|Type 2 Diabetes Mellitus,Drug: Carvedilol|Drug: Metoprolol,St. Paul Heart Clinic|GlaxoSmithKline,St. Paul Heart Clinic,GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,6/4/2019,6/6/2019,https://ClinicalTrials.gov/show/NCT00123604
3678,Intravenous Immunoglobulin (IVIG) in Lung Transplantation,Completed,Has Results,Hypogammaglobulinemia|Lung Transplantation,Drug: IVIG|Other: Placebo,Columbia University|Grifols Therapeutics LLC,Columbia University,Grifols Therapeutics LLC,,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00115778
3679,RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma,Completed,Has Results,Neuroendocrine Carcinoma|Islet Cell Carcinoma,Drug: RAD001|Drug: Octreotide Depot,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,M.D. Anderson Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,1/5/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00113360
3680,Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer,Completed,Has Results,Head and Neck Cancer,Drug: ABT-510,M.D. Anderson Cancer Center|Abbott,M.D. Anderson Cancer Center,Abbott,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00113334
3681,Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer,Completed,Has Results,Rectal Cancer,"Drug: Avastin (Bevacizumab, RHUMAB VEGF)|Drug: Capecitabine|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,2/5/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00113230
3682,Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma,Completed,Has Results,Renal Cell Carcinoma|Kidney Cancer,Drug: Bevacizumab,"M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,2/5/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00113217
3683,A Pilot Study of Etanercept in Dermatomyositis,Completed,Has Results,Dermatomyositis,Drug: Etanercept|Drug: Placebo,Brigham and Women's Hospital|Amgen,Brigham and Women's Hospital,Amgen,,,,,,Phase 1,Other|Industry,Interventional,3/6/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00112385
3684,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Dapsone Gel|Drug: Dapsone Gel Vehicle,"Almirall, S.A.|Allergan","Almirall, S.A.",Allergan,,,,,,Phase 3,Industry,Interventional,11/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01974323
3685,Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout,Completed,Has Results,Gout,Biological: Pegloticase,John Sundy|Savient Pharmaceuticals|Duke University,John Sundy,Savient Pharmaceuticals,Duke University,,,,,Phase 2,Other|Industry,Interventional,12/4/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00111657
3686,Trial of Growth Hormone Therapy in Pediatric Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: growth hormone|Drug: cortecosteroid,"Children's Hospital Medical Center, Cincinnati|Genentech, Inc.","Children's Hospital Medical Center, Cincinnati","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,4/5/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00109473
3687,Sildenafil for Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive|Emphysema",Drug: sildenafil citrate|Drug: Placebo,"Kawut, Steven, MD|Pfizer","Kawut, Steven, MD",Pfizer,,,,,,Phase 2,Other|Industry,Interventional,2/5/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00104637
3688,Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Completed,Has Results,Leukemia,Biological: rituximab|Drug: lenalidomide,Roswell Park Cancer Institute|Celgene,Roswell Park Cancer Institute,Celgene,,,,,,Phase 2,Other|Industry,Interventional,3/4/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00096044
3689,CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis,Completed,Has Results,Multiple Myeloma,Drug: dexamethasone|Drug: lenalidomide,Vaishali Sanchorawala|Celgene Corporation|Boston Medical Center,Vaishali Sanchorawala,Celgene Corporation,Boston Medical Center,,,,,Phase 2,Other|Industry,Interventional,1/4/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00091260
3690,Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).,Completed,Has Results,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: Clofarabine|Drug: Ara-C,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,,,,Phase 2,Other|Industry,Interventional,7/4/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00088218
3691,A Phase II Study of CC-5013 in Myelofibrosis,Completed,Has Results,Myelofibrosis,Drug: CC-5013,M.D. Anderson Cancer Center|Celgene Corporation,M.D. Anderson Cancer Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,7/4/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00087672
3692,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Completed,Has Results,Multiple Myeloma,Drug: Thalidomide|Drug: Ara-C|Drug: BCNU|Drug: Cisplatin|Drug: Cytoxan|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Etoposide|Drug: Filgrastim|Drug: Recombinant GM-CSF|Drug: Interferon-alpha-2b|Drug: Melphalan|Drug: Vincristine,University of Arkansas|Celgene Corporation,University of Arkansas,Celgene Corporation,,,,,,Phase 3,Other|Industry,Interventional,8/1/1998,8/14/2019,https://ClinicalTrials.gov/show/NCT00083551
3693,Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma,Completed,Has Results,Lymphoma,Drug: Avastin|Drug: Rituximab,"M.D. Anderson Cancer Center|Genentech, Inc.",M.D. Anderson Cancer Center,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/4/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00081861
3694,Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Campath-1H|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,M.D. Anderson Cancer Center,Bayer,,,,,,Phase 2,Other|Industry,Interventional,10/2/2019,8/7/2019,https://ClinicalTrials.gov/show/NCT00071396
3695,Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS),Completed,Has Results,Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia,Drug: Decitabine,M.D. Anderson Cancer Center|Eisai Inc.,M.D. Anderson Cancer Center,Eisai Inc.,,,,,,Phase 2,Other|Industry,Interventional,10/3/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00067808
3696,Treatment of Depression in Parkinson's Disease Trial,Completed,Has Results,Parkinson Disease|Depression,Drug: paroxetine|Drug: Nortriptyline|Other: placebo,"Rutgers, The State University of New Jersey|GlaxoSmithKline","Rutgers, The State University of New Jersey",GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,6/3/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00062738
3697,ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin,Completed,Has Results,Skin Cancer,Drug: Iressa,M.D. Anderson Cancer Center|AstraZeneca,M.D. Anderson Cancer Center,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,5/4/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00054691
3698,Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme,Completed,Has Results,Glioblastoma Multiforme,Drug: Temozolomide|Drug: R115777,M.D. Anderson Cancer Center|Johnson & Johnson,M.D. Anderson Cancer Center,Johnson & Johnson,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/2/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00050986
3699,Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Paclitaxel|Drug: Docetaxel|Drug: Capecitabine,M.D. Anderson Cancer Center|Roche Pharma AG,M.D. Anderson Cancer Center,Roche Pharma AG,,,,,,Phase 1,Other|Industry,Interventional,11/2/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00050167
3700,Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies,Completed,Has Results,Lymphoma|Leukemia,Drug: Zevalin Radioimmunotherapy|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: Allogeneic Stem Cell Transplantation,M.D. Anderson Cancer Center|Biogen,M.D. Anderson Cancer Center,Biogen,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/2/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00048737
3701,Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia,Completed,Has Results,Leukemia,Drug: Imatinib Mesylate|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Mesna|Drug: G-CSF,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,M.D. Anderson Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,3/1/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00038610
3702,Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis,Completed,Has Results,Osteoporosis,Drug: Alendronate,Medical University of South Carolina|Merck Sharp & Dohme Corp.,Medical University of South Carolina,Merck Sharp & Dohme Corp.,,,,,,Phase 2,Other|Industry,Interventional,9/1/2000,11/8/2019,https://ClinicalTrials.gov/show/NCT00010439
3703,The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tabs|Other: Basal Insulin Reduction,Jaeb Center for Health Research|Xeris Pharmaceuticals,Jaeb Center for Health Research,Xeris Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,1/16/2019,2/15/2017,https://ClinicalTrials.gov/show/NCT02660242
3704,Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound,Completed,Has Results,Breast Diseases,Device: Supine automated breast ultrasound scanner|Device: High-resolution handheld breast ultrasound,Northwestern University|Siemens Medical Solutions,Northwestern University,Siemens Medical Solutions,,,,,,Not Applicable,Other|Industry,Interventional,6/12/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02310776
3705,Hand Hygiene and Hospital Acquired Infections,Completed,Has Results,Complication of Surgical Procedure,Device: Sage Personal Hand Hygiene System,"Dartmouth-Hitchcock Medical Center|Sage Products, Inc.",Dartmouth-Hitchcock Medical Center,"Sage Products, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,9/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02252562
3706,Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma,Completed,Has Results,Lipoma,Drug: AA4500|Drug: placebo,"Gerut, Zachary, M.D.|Advance Biofactures Corporation","Gerut, Zachary, M.D.",Advance Biofactures Corporation,,,,,,Phase 2,Other|Industry,Interventional,8/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02249052
3707,Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure,Completed,Has Results,Symptomatic Uterine Fibroids and Adenomyosis,Drug: IV Ibuprofen|Drug: IV Acetaminophen|Drug: Intravenous placebo/Intravenous placebo,"University of California, Los Angeles|Sponsor Name Pending","University of California, Los Angeles",Sponsor Name Pending,,,,,,Phase 4,Other|Industry,Interventional,8/14/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02227316
3708,"Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System",Completed,Has Results,Total Knee Arthroplasty|Osteoarthritis,Device: DePuy Attune posterior stabilizing fixed bearing knee system,"The University of Tennessee, Knoxville|DePuy Orthopaedics","The University of Tennessee, Knoxville",DePuy Orthopaedics,,,,,,,Other|Industry,Observational,11/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02204748
3709,Aquaresis Utility for Hyponatremic Acute Heart Failure Study,Completed,Has Results,Heart Failure,Drug: Tolvaptan|Drug: Furosemide,University of Southern California|Otsuka America Pharmaceutical,University of Southern California,Otsuka America Pharmaceutical,,,,,,Phase 4,Other|Industry,Interventional,12/14/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT02183792
3710,Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches,Completed,Has Results,Delayed Alcohol Induced Headache,Drug: VVD-101|Drug: Placebo,"Cady, Roger, M.D.|Vivid Pharma Inc.","Cady, Roger, M.D.",Vivid Pharma Inc.,,,,,,Phase 2,Other|Industry,Interventional,7/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02176655
3711,Articulating Enseal Versus Ligasure Energy Devices,Completed,Has Results,Task Performance,Device: articulating Enseal|Device: Ligasure device,University of Louisville|Ethicon Endo-Surgery,University of Louisville,Ethicon Endo-Surgery,,,,,,Not Applicable,Other|Industry,Interventional,7/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02163538
3712,Seri Surgical Scaffold Support of the Lower Pole of the Breast,Completed,Has Results,Recurrent Ptosis of the Breast,Device: Seri Surgical Scaffold,Bengtson Center|Allergan Medical,Bengtson Center,Allergan Medical,,,,,,Not Applicable,Other|Industry,Interventional,10/13/2019,11/30/2016,https://ClinicalTrials.gov/show/NCT02016612
3713,Cardioneuroablation for Neurocardiogenic Syncope,Completed,Has Results,Neurocardiogenic Syncope|Vasovagal Syncope,Procedure: Cardioneuroablation|Device: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter,"David B. De Lurgio|Biosense Webster, Inc.|Emory University",David B. De Lurgio,"Biosense Webster, Inc.",Emory University,,,,,Not Applicable,Other|Industry,Interventional,12/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02009982
3714,Safety and Efficacy of Ranibizumab for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Ranibizumab,"Justis Ehlers|Genentech, Inc.|The Cleveland Clinic",Justis Ehlers,"Genentech, Inc.",The Cleveland Clinic,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/24/2014,5/26/2016,https://ClinicalTrials.gov/show/NCT01982435
3715,Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions,Completed,Has Results,Pancreatic Solid Lesions|Pancreatic Mass,Device: Standard technique EUS-FNA|Device: Capillary suction technique for EUS FNA,Johns Hopkins University|Boston Scientific Corporation,Johns Hopkins University,Boston Scientific Corporation,,,,,,Phase 3,Other|Industry,Interventional,1/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01936467
3716,Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion,Completed,Has Results,Acute Coronary Syndrome,Drug: Ticagrelor|Drug: Eptifibatide,University of Alabama at Birmingham|AstraZeneca,University of Alabama at Birmingham,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,2/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01919723
3717,Acthar in Treatment of Refractory Dermatomyositis and Polymyositis,Completed,Has Results,Dermatomyositis|Polymyositis,Drug: Adrenocorticotropic Hormone Gel,"Rohit Aggarwal, MD|Mallinckrodt|University of Pittsburgh","Rohit Aggarwal, MD",Mallinckrodt,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,9/13/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01906372
3718,IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus,Completed,Has Results,Cutaneous Lupus Erythematosus,Drug: IVIg,"University of California, Irvine|Grifols Therapeutics LLC","University of California, Irvine",Grifols Therapeutics LLC,,,,,,Early Phase 1,Other|Industry,Interventional,3/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01841619
3719,Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty,Completed,Has Results,Primary Total Hip and Knee Arthroplasty,Drug: Arixtra|Device: Pneumatic compression stockings|Drug: Aspirin,LifeBridge Health|Haemonetics Corporation,LifeBridge Health,Haemonetics Corporation,,,,,,Phase 4,Other|Industry,Interventional,4/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01809054
3720,Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia,Completed,Has Results,Aggressive Systemic Mastocytosis|Mast Cell Leukemia|Systemic Mastocytosis,Drug: Brentuximab vedotin,"Jason Robert Gotlib|Seattle Genetics, Inc.|Stanford University",Jason Robert Gotlib,"Seattle Genetics, Inc.",Stanford University,,,,,Phase 2,Other|Industry,Interventional,9/13/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT01807598
3721,A Home Exercise Program for Women With Infants & Young Children,Completed,Has Results,MomZing Exercise Videos Online|Standard Exercise DVD,Behavioral: MomZing Web Program|Behavioral: Standard Exercise DVD,"University of Hawaii|Klein Buendel, Inc.",University of Hawaii,"Klein Buendel, Inc.",,,,,,Phase 3,Other|Industry,Interventional,12/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01738984
3722,JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions,Completed,Has Results,Restenosis|Peripheral Vascular Disease,Device: JetStream Navitus,"Midwest Cardiovascular Research Foundation|MEDRAD, Inc.",Midwest Cardiovascular Research Foundation,"MEDRAD, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,10/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01722877
3723,The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy,Completed,Has Results,Central Serous Chorioretinopathy,Drug: Intravitreal Aflibercept Injection,Wills Eye|Regeneron Pharmaceuticals,Wills Eye,Regeneron Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,10/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01710332
3724,Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy,Completed,Has Results,Cancer|Influenza Viral Infections,Biological: Standard Trivalent Influenza Vaccine|Biological: High-Dose Influenza Vaccine,Saad Jamshed MD|Sanofi|Rochester General Hospital,Saad Jamshed MD,Sanofi,Rochester General Hospital,,,,,Phase 2,Other|Industry,Interventional,8/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01666782
3725,Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,Completed,Has Results,Metastatic Colorectal Cancer,Drug: Capecitabine and aflibercept,"John Strickler, M.D.|Sanofi|Duke University","John Strickler, M.D.",Sanofi,Duke University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/12/2019,6/12/2016,https://ClinicalTrials.gov/show/NCT01661972
3726,Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy,Completed,Has Results,Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer,Biological: bevacizumab|Other: laboratory biomarker analysis,"Barbara Ann Karmanos Cancer Institute|Genentech, Inc.",Barbara Ann Karmanos Cancer Institute,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,5/7/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01656304
3727,Safety of Intravenous Thrombolytics in Stroke on Awakening,Completed,Has Results,Stroke,Drug: tPA,"Johns Hopkins University|Genentech, Inc.",Johns Hopkins University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,1/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01643902
3728,Desvenlafaxine vs. Placebo Treatment of Chronic Depression,Completed,Has Results,Dysthymic Disorder|Dysthymia|Chronic Depressive Disorder,Drug: Desvenlafaxine|Drug: Placebo,New York State Psychiatric Institute|Pfizer,New York State Psychiatric Institute,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,2/12/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01537068
3729,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Completed,Has Results,Tonsillectomy,Drug: Dexmedetomidine|Other: Placebo,"Peter Davis|Hospira, now a wholly owned subsidiary of Pfizer|University of Pittsburgh",Peter Davis,"Hospira, now a wholly owned subsidiary of Pfizer",University of Pittsburgh,,,,,Phase 3,Other|Industry,Interventional,1/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01528891
3730,A Study to Compare the Impact of a School Based HPV Program on Vaccination Uptake and Completion Rates,Completed,Has Results,Human Papillomavirus,Other: HPV Vaccine and HPV-related Health Education|Other: Reduction of barriers,Lake Cumberland District Health Department|Merck Sharp & Dohme Corp.,Lake Cumberland District Health Department,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,8/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01526551
3731,Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital,Completed,Has Results,Herpes Zoster,Other: Choosing to receive the vaccine,NYU Langone Health|Merck Sharp & Dohme Corp.,NYU Langone Health,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,1/12/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01483378
3732,Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema,Completed,Has Results,Diabetic Retinopathy|Macular Edema,Drug: Ranibizumab,"Retina Vitreous Associates of Florida|Genentech, Inc.",Retina Vitreous Associates of Florida,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,11/11/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01476449
3733,Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS),Completed,Has Results,Complication of Transplanted Lung,Drug: Aztreonam Lysine for Inhalation (AZLI)|Procedure: Status Post Lung Transplant,Duke University|Gilead Sciences,Duke University,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,3/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01469364
3734,Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer (NSCLC)|Stage IV NSCLC|Metastatic NSCLC,Drug: Cabazitaxel-XRP6258 (3-week cycle)|Drug: Cabazitaxel-XRP6258 (5-week cycle),University of Alabama at Birmingham|Sanofi,University of Alabama at Birmingham,Sanofi,,,,,,Phase 2,Other|Industry,Interventional,9/11/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01438307
3735,Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD),Completed,Has Results,Diarrhea|Clostridium Difficile,Drug: Tigecycline,"Gary E. Stein, Pharm.D.|Pfizer|Michigan State University","Gary E. Stein, Pharm.D.",Pfizer,Michigan State University,,,,,Not Applicable,Other|Industry,Interventional,7/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01401023
3736,Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus|Hospitalization|Hyperglycemia,Drug: Sitagliptin|Drug: glargine|Drug: lispro,Emory University|Merck Sharp & Dohme Corp.,Emory University,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,8/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01378117
3737,A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies,Completed,Has Results,Thymoma|Thymus Cancer|Thymic Carcinoma,Drug: Amrubicin,Heather Wakelee|Celgene|Stanford University,Heather Wakelee,Celgene,Stanford University,,,,,Phase 2,Other|Industry,Interventional,6/11/2019,12/31/2018,https://ClinicalTrials.gov/show/NCT01364727
3738,Neoadjuvant Pazopanib in Renal Cell Carcinoma,Completed,Has Results,Renal Cell Carcinoma,Drug: Pazopanib,UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline,UNC Lineberger Comprehensive Cancer Center,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,6/11/2019,2/15/2017,https://ClinicalTrials.gov/show/NCT01361113
3739,Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU),Completed,Has Results,Pulmonary Infections,Drug: Dornase alfa|Drug: Placebo,"Georgetown University|Genentech, Inc.",Georgetown University,"Genentech, Inc.",,,,,,Phase 4,Other|Industry,Interventional,5/11/2019,4/30/2017,https://ClinicalTrials.gov/show/NCT01356147
3740,"CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet",Completed,Has Results,Menstrual Migraine,Drug: Treximet|Drug: Placebo,"Cady, Roger, M.D.|GlaxoSmithKline","Cady, Roger, M.D.",GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,5/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01329562
3741,"Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer",Completed,Has Results,Biliary Tract Cancer|Gallbladder Cancer,Drug: Panitumumab|Drug: oxaliplatin|Drug: gemcitabine,University of Rochester|Amgen,University of Rochester,Amgen,,,,,,Phase 2,Other|Industry,Interventional,12/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01308840
3742,Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine,Completed,Has Results,Migraine,Drug: Sumatriptan/Naproxen Sodium|Drug: Naproxen Sodium,"Cady, Roger, M.D.|GlaxoSmithKline","Cady, Roger, M.D.",GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,12/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01300546
3743,Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant,Completed,Has Results,Failure of Bone Marrow Graft,Drug: Plerixafor,"Mitchell Horwitz, MD|Genzyme, a Sanofi Company|Duke University","Mitchell Horwitz, MD","Genzyme, a Sanofi Company",Duke University,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01280955
3744,Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab,Completed,Has Results,Lung Cancer,Drug: Pazopanib,UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline,UNC Lineberger Comprehensive Cancer Center,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,12/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01262820
3745,Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy,Completed,Has Results,Dense Deposit Disease|Membranoproliferative Glomerulonephritis,Drug: Eculizumab,Columbia University|Alexion Pharmaceuticals,Columbia University,Alexion Pharmaceuticals,,,,,,Phase 1,Other|Industry,Interventional,7/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01221181
3746,Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block,Completed,Has Results,"Airway Reflexes, Protective|Recovery After Neuromuscular Block|Anesthetic Recovery",Drug: Sevoflurane|Drug: Desflurane|Drug: Rocuronium|Drug: Neostigmine|Drug: Glycopyrrolate,"University of California, San Francisco|Baxter Healthcare Corporation","University of California, San Francisco",Baxter Healthcare Corporation,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01199237
3747,Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL),Completed,Has Results,CLL,Drug: Ofatumumab/HDMP,"Januario Castro, M.D.|GlaxoSmithKline|University of California, San Diego","Januario Castro, M.D.",GlaxoSmithKline,"University of California, San Diego",,,,,Phase 2,Other|Industry,Interventional,8/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01191190
3748,Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.,Completed,Has Results,"Chronic Constipation, Methanogenesis",Drug: Lubiprostone|Drug: Lubiprostone Control,"Augusta University|Takeda Pharmaceuticals North America, Inc.",Augusta University,"Takeda Pharmaceuticals North America, Inc.",,,,,,Phase 1,Other|Industry,Interventional,2/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01190020
3749,Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,Completed,Has Results,"Bladder Cancer|Bladder (Urothelial, Transitional Cell) Cancer|Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)|Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)|Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable",Drug: Pazopanib (GW786034)|Drug: Paclitaxel,Sandy Srinivas|GlaxoSmithKline|Stanford University,Sandy Srinivas,GlaxoSmithKline,Stanford University,,,,,Phase 2,Other|Industry,Interventional,4/10/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01108055
3750,Irinotecan and Bevacizumab for Recurrent Ovarian Cancer,Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,Drug: Irinotecan|Drug: Bevacizumab,"NYU Langone Health|Genentech, Inc.",NYU Langone Health,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/10/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01091259
3751,Treximet in the Treatment of Chronic Migraine,Completed,Has Results,Chronic Migraine,Drug: Sumatriptan/Naproxen Sodium|Drug: Naproxen Sodium,"Cady, Roger, M.D.|GlaxoSmithKline","Cady, Roger, M.D.",GlaxoSmithKline,,,,,,Phase 4,Other|Industry,Interventional,9/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01090050
3752,Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA),Completed,Has Results,Obstructive Sleep Apnea,Drug: budesonide and montelukast|Drug: Placebo,Romaker & Associates|Merck Sharp & Dohme Corp.,Romaker & Associates,Merck Sharp & Dohme Corp.,,,,,,Phase 3,Other|Industry,Interventional,9/10/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01089647
3753,Vertos Mild - Post Market Patient Outcomes,Completed,Has Results,Lumbar Spinal Stenosis,Procedure: Minimally Invasive Lumbar Decompression,"The Center for Pain Relief, Inc.|Vertos Medical, Inc.","The Center for Pain Relief, Inc.","Vertos Medical, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,2/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01076244
3754,Calcitonin Gene-related Peptide Levels in Chronic Migraine,Completed,Has Results,Chronic Migraine,Drug: OnabotulinumtoxinA|Drug: Saline,"Cady, Roger, M.D.|Allergan","Cady, Roger, M.D.",Allergan,,,,,,Phase 4,Other|Industry,Interventional,6/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01071096
3755,Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC),Completed,Has Results,Epilepsy|Tuberous Sclerosis Complex,Drug: Everolimus,"Children's Hospital Medical Center, Cincinnati|Novartis","Children's Hospital Medical Center, Cincinnati",Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/10/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01070316
3756,"RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma",Completed,Has Results,Colorectal Cancer,Drug: RAD001|Drug: FOLFOX|Drug: Bevacizumab,University of Utah|Novartis,University of Utah,Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/10/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01047293
3757,Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population,Completed,Has Results,Atopic Dermatitis|Ichthyosis Vulgaris,Genetic: Buccal Swab,Northwestern University|ViraCor Laboratories,Northwestern University,ViraCor Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,6/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01016106
3758,Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial,Completed,Has Results,Staphylococcus Aureus,Biological: Monovalent rAT|Biological: Monovalent rLukS-PV|Biological: Bivalent rLukS-PV / rAT|Biological: Placebo with adjuvant|Biological: Placebo,Uniformed Services University of the Health Sciences|Nabi Biopharmaceuticals,Uniformed Services University of the Health Sciences,Nabi Biopharmaceuticals,,,,,,Phase 1|Phase 2,U.S. Fed|Industry,Interventional,11/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01011335
3759,"A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts",Completed,Has Results,Cholangiocarcinoma,"Drug: Gemcitabine, Capecitabine and Bevacizumab","Roswell Park Cancer Institute|Genentech, Inc.",Roswell Park Cancer Institute,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01007552
3760,Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Other: Group B SLE one blood donation|Other: Blood drawing only Group C|Drug: Group A SLE prospective study,Oklahoma Medical Research Foundation|Pfizer,Oklahoma Medical Research Foundation,Pfizer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00987831
3761,A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-small-cell Lung",Drug: Erlotinib|Radiation: Hypofractionated Radiotherapy,"Sidney Kimmel Cancer Center at Thomas Jefferson University|Genentech, Inc.|Thomas Jefferson University",Sidney Kimmel Cancer Center at Thomas Jefferson University,"Genentech, Inc.",Thomas Jefferson University,,,,,Phase 2,Other|Industry,Interventional,8/27/2009,12/12/2019,https://ClinicalTrials.gov/show/NCT00983307
3762,A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome,Completed,Has Results,Irritable Bowel Syndrome,Drug: Pregabalin|Drug: Placebo,Mayo Clinic|Pfizer,Mayo Clinic,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,3/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00977197
3763,Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome,Completed,Has Results,Constipation-predominant Irritable Bowel Syndrome,Drug: Neomycin|Drug: Placebo|Drug: Rifaximin,"Mark Pimentel, MD|Bausch Health Americas, Inc.|Cedars-Sinai Medical Center","Mark Pimentel, MD","Bausch Health Americas, Inc.",Cedars-Sinai Medical Center,,,,,Not Applicable,Other|Industry,Interventional,8/9/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00945334
3764,Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression,Completed,Has Results,Breast Cancer,Drug: nab-paclitaxel|Drug: trastuzumab|Drug: Doxorubicin|Drug: cyclophosphamide|Biological: Growth Factor Support|Procedure: Surgery,University of Kansas Medical Center|Celgene Corporation,University of Kansas Medical Center,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,7/9/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT00944047
3765,Using the SEDLine for the Titration of Sevoflurane in Elderly Patients Recovery Using the SEDLine TM for the Titration of Sevoflurane in Elderly Patients Undergoing Non-Cardiac Surgery After Beta-Adrenergic Blockade,Completed,Has Results,"Anesthesia, General",Device: Sedline,"Stanford University|Hospira, now a wholly owned subsidiary of Pfizer",Stanford University,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 4,Other|Industry,Interventional,7/6/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00938782
3766,Fluphenazine Hydrochloride for Psoriasis,Completed,Has Results,Psoriasis,Drug: Fluphenazine|Drug: Placebo,Tufts Medical Center|Immune Control,Tufts Medical Center,Immune Control,,,,,,Phase 2,Other|Industry,Interventional,11/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00929578
3767,Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients,Completed,Has Results,Prostate Cancer,Drug: torisel,"Oncology Specialists, S.C.|Wyeth is now a wholly owned subsidiary of Pfizer","Oncology Specialists, S.C.",Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 2,Other|Industry,Interventional,6/9/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00919035
3768,Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use,Completed,Has Results,Sudden Cardiac Arrest,,Duke University|Medtronic,Duke University,Medtronic,,,,,,,Other|Industry,Observational,11/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00918125
3769,Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH),Completed,Has Results,Flushing,Dietary Supplement: Quercetin|Dietary Supplement: Placebo,University of Pennsylvania|Abbott,University of Pennsylvania,Abbott,,,,,,Phase 4,Other|Industry,Interventional,2/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00913081
3770,Desensitization in Kidney Transplantation,Completed,Has Results,HLA Sensitization,Drug: plasmapheresis|Drug: Bortezomib|Drug: Rituximab|Drug: Methylprednisolone,"University of Cincinnati|Millennium Pharmaceuticals, Inc.",University of Cincinnati,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 4,Other|Industry,Interventional,5/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00908583
3771,An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica,Completed,Has Results,Neuromyelitis Optica|Devic's Disease,Drug: Eculizumab,Mayo Clinic|Alexion Pharmaceuticals,Mayo Clinic,Alexion Pharmaceuticals,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00904826
3772,The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease|Chronic Bronchitis,Drug: Tiotropium,ThomasTruncale|Boehringer Ingelheim|University of South Florida,ThomasTruncale,Boehringer Ingelheim,University of South Florida,,,,,Early Phase 1,Other|Industry,Interventional,2/8/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00870896
3773,Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes,Completed,Has Results,"Diabetes, Gestational",Device: The Seven Continuous Glucose Monitoring System,"Stanford University|DexCom, Inc.",Stanford University,"DexCom, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,2/9/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT00850135
3774,Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine,Completed,Has Results,Migraine,Drug: topiramate|Drug: frovatriptan,"Clinvest|Endo Pharmaceuticals|Cady, Roger, M.D.",Clinvest,Endo Pharmaceuticals,"Cady, Roger, M.D.",,,,,Phase 4,Other|Industry,Interventional,8/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00846495
3775,Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases,Completed,Has Results,Brain Metastases,Drug: Vorinostat|Radiation: Radiation Therapy,Sidney Kimmel Cancer Center at Thomas Jefferson University|Merck Sharp & Dohme Corp.|Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Merck Sharp & Dohme Corp.,Thomas Jefferson University,,,,,Phase 1,Other|Industry,Interventional,3/9/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00838929
3776,Long-term Varenicline Treatment for Smoking Cessation,Completed,Has Results,Smoking,Drug: varenicline|Behavioral: Individual smoking cessation counseling,"University of Wisconsin, Madison|Pfizer","University of Wisconsin, Madison",Pfizer,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00828113
3777,Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema,Completed,Has Results,Uveitic Cystoid Macular Edema,Drug: ranibizumab,"University of Miami|Genentech, Inc.",University of Miami,"Genentech, Inc.",,,,,,Phase 1,Other|Industry,Interventional,6/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00826618
3778,Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea,Completed,Has Results,Rosacea,Drug: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Drug: Placebo gel,Massachusetts General Hospital|Medicis Pharmaceutical Corporation,Massachusetts General Hospital,Medicis Pharmaceutical Corporation,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,2/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00823901
3779,Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies,Completed,Has Results,"Muscle Strength|Botulinum Toxins, Type A","Drug: Botulinum Toxin, Type A|Drug: Saline",Loma Linda University|Allergan,Loma Linda University,Allergan,,,,,,Not Applicable,Other|Industry,Interventional,1/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00822523
3780,Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK,Completed,Has Results,Myopia|Astigmatism,Device: Excimer Laser|Device: AMO/VISX CustomVue™|Device: LADARVision 4000 excimer laser,Durrie Vision|Alcon Research,Durrie Vision,Alcon Research,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00821236
3781,A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia,Completed,Has Results,Cancer Cachexia,Drug: Eicosapentaenoic Acid,H. Lee Moffitt Cancer Center and Research Institute|GlaxoSmithKline,H. Lee Moffitt Cancer Center and Research Institute,GlaxoSmithKline,,,,,,Not Applicable,Other|Industry,Interventional,7/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00815685
3782,Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females,Completed,Has Results,Vaccination,Behavioral: Girls OnGuard,Emory University|Merck Sharp & Dohme Corp.,Emory University,Merck Sharp & Dohme Corp.,,,,,,Phase 3,Other|Industry,Interventional,10/9/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00813319
3783,Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease,Completed,Has Results,Chronic Kidney Disease,Drug: Gardasil® Vaccine (FDA-approved vaccination regimen),Johns Hopkins University|Merck Sharp & Dohme Corp.,Johns Hopkins University,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,12/8/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00806676
3784,Low Dose Melphalan and Bortezomib for AML and High-Risk MDS,Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndromes,Drug: Melphalan|Drug: Bortezomib|Drug: Melphalan and bortezomib,"Dartmouth-Hitchcock Medical Center|Millennium Pharmaceuticals, Inc.",Dartmouth-Hitchcock Medical Center,"Millennium Pharmaceuticals, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,9/4/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00789256
3785,Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department,Completed,Has Results,Hypertensive Urgency,Drug: nicardipine intravenous|Drug: Labetalol,"The Cleveland Clinic|EKR Therapeutics, Inc",The Cleveland Clinic,"EKR Therapeutics, Inc",,,,,,Phase 4,Other|Industry,Interventional,10/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00765648
3786,Aminotransferase Trends During Prolonged Acetaminophen Dosing,Completed,Has Results,Drug Toxicity|Healthy,Drug: acetaminophen|Drug: placebo,"Denver Health and Hospital Authority|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Denver Health and Hospital Authority,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",,,,,,Phase 4,Other|Industry,Interventional,8/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00743093
3787,"A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",Completed,Has Results,Colorectal Neoplasms,Drug: KD018|Drug: Irinotecan|Drug: Placebo,"Edward Chu, MD|Kadmon Pharmaceuticals|University of Pittsburgh","Edward Chu, MD",Kadmon Pharmaceuticals,University of Pittsburgh,,,,,Phase 2,Other|Industry,Interventional,12/8/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT00730158
3788,Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT),Completed,Has Results,Age Related Macular Degeneration|Choroidal Neovascularization|Macular Edema,Drug: Bevacizumab|Device: verteporfin photodynamic therapy reduced fluence|Device: verteporfin photodynamic therapy standardfluence,California Retina Consultants|Novartis,California Retina Consultants,Novartis,,,,,,Phase 2,Other|Industry,Interventional,5/6/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00729846
3789,S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence,Completed,Has Results,Tobacco Dependence,Drug: S-Adenosyl-L-Methionine|Other: placebo,Mayo Clinic|Pharmavite,Mayo Clinic,Pharmavite,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,9/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00722124
3790,Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women,Completed,Has Results,Menopause|Fracture|Osteoporosis,Drug: Teriparatide (PTH 1-34),Columbia University|Eli Lilly and Company,Columbia University,Eli Lilly and Company,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,8/20/2008,1/3/2012,https://ClinicalTrials.gov/show/NCT00697463
3791,The Effect of Rituximab on the Development of Anti-Donor Antibodies,Completed,Has Results,Renal Transplant Rejection,Drug: Rituximab|Drug: No Rituximab,"University of California, San Francisco|Genentech, Inc.","University of California, San Francisco","Genentech, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,8/4/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00695097
3792,FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer,Completed,Has Results,Gastroesophageal Cancer|Gastric Cancer,Drug: FOLFOX|Drug: bevacizumab,"Yale University|Genentech, Inc.",Yale University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,5/8/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00673673
3793,Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN,Completed,Has Results,Parenteral Nutrition,"Drug: ClinOleic 20% Intravenous Emulsion|Drug: Intralipid, 20% Intravenous Emulsion",Emory University|Baxter Healthcare Corporation,Emory University,Baxter Healthcare Corporation,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,11/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00672854
3794,Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy,Completed,Has Results,Prostate Cancer|Prostatectomy,Drug: Sunitinib Malate,Duke University|Pfizer,Duke University,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,7/6/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00672594
3795,Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients,Completed,Has Results,Prostate Cancer,Drug: Revlimid,"Oncology Specialists, S.C.|Celgene Corporation","Oncology Specialists, S.C.",Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,2/8/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00654186
3796,Raltegravir Intensification in HIV-infected Patients,Completed,Has Results,HIV Infections,Drug: Raltegravir|Drug: Placebo,"University of California, San Francisco|Merck Sharp & Dohme Corp.","University of California, San Francisco",Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,2/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00631449
3797,Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab,Completed,Has Results,Lymphocytic Leukemia|Mantle Cell Lymphoma,Drug: Lenalidomide|Drug: Rituximab,H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation,H. Lee Moffitt Cancer Center and Research Institute,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00609869
3798,Effect of Valproic Acid Concentration on Photic Response,Completed,Has Results,Photosensitive Epilepsy,Drug: Valproic Acid|Drug: Placebo,Vanderbilt University Medical Center|Abbott,Vanderbilt University Medical Center,Abbott,,,,,,Phase 4,Other|Industry,Interventional,12/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00609245
3799,A Phase I/II Study of Dasatinib and Dacarbazine,Completed,Has Results,Metastatic Melanoma,Drug: Dasatinib and Dacarbazine (DTIC),H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,H. Lee Moffitt Cancer Center and Research Institute,Bristol-Myers Squibb,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/7/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00597038
3800,Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery,Completed,Has Results,Type 2 Diabetes|Inpatient Hyperglycemia,Drug: Insulin glargine|Drug: Regular insulin|Drug: Insulin glulisine,Emory University|Sanofi,Emory University,Sanofi,,,,,,Phase 4,Other|Industry,Interventional,12/7/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00596687
3801,Efficacy of Varenicline in Ambivalent Smokers,Completed,Has Results,Tobacco Use Disorder|Tobacco Use Cessation|Nicotine Dependence,Drug: Varenicline|Drug: Placebo,University of Vermont Medical Center|Pfizer,University of Vermont Medical Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,3/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00595868
3802,Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Detemir + aspart insulin before meals|Drug: NPH insulin + regular insulin,Emory University|Novo Nordisk A/S,Emory University,Novo Nordisk A/S,,,,,,Phase 4,Other|Industry,Interventional,12/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00590226
3803,Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA),Completed,Has Results,Diabetic Ketoacidosis,Drug: insulin glargine+ glulisine|Drug: NPH + Regular insulin,Emory University|Sanofi,Emory University,Sanofi,,,,,,Phase 4,Other|Industry,Interventional,12/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00590044
3804,Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors,Completed,Has Results,Leukapheresis,Device: Mononuclear cell collection.,"Terumo BCT|Blood Center of Wisconsin|Key Biologics, LLC|LeukoLab|Yale University",Terumo BCT,Blood Center of Wisconsin,"Key Biologics, LLC|LeukoLab|Yale University","Key Biologics, LLC",LeukoLab|Yale University,LeukoLab,Yale University,,Industry|Other,Observational,1/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01277549
3805,Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure,Completed,Has Results,Heart Failure,Device: SphygmoCor,"Mayo Clinic|AtCor Medical, Inc.",Mayo Clinic,"AtCor Medical, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,7/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00588692
3806,Oral Paricalcitol in Kidney Transplant Recipients,Completed,Has Results,"Transplant; Failure, Kidney|Renal Disease, End Stage|Hyperparathyroidism, Secondary",Drug: Paricalcitol|Other: Corticosteroid Avoidance Immune Suppression Protocol,Mayo Clinic|Abbott,Mayo Clinic,Abbott,,,,,,Not Applicable,Other|Industry,Interventional,1/7/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00587158
3807,Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening,Completed,Has Results,Localized Lipodystrophy,Device: 1064 nm Nd:YAG laser,"University of California, Irvine|Candela Corporation","University of California, Irvine",Candela Corporation,,,,,,Not Applicable,Other|Industry,Interventional,10/6/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00585715
3808,CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas,Completed,Has Results,Pancreatic Cancer,Drug: Pomalidomide|Drug: Gemcitabine,"SCRI Development Innovations, LLC|Celgene Corporation","SCRI Development Innovations, LLC",Celgene Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/7/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00540579
3809,Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients,Completed,Has Results,Multiple Myeloma,Drug: Bortezomib|Drug: Sorafenib,"SCRI Development Innovations, LLC|Bayer","SCRI Development Innovations, LLC",Bayer,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00536575
3810,Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck,Completed,Has Results,Head and Neck Neoplasms,Drug: Gefitinib,University of Chicago|AstraZeneca,University of Chicago,AstraZeneca,,,,,,Phase 2,Other|Industry,Interventional,3/5/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00519077
3811,Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,Completed,Has Results,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,Drug: erlotinib hydrochloride|Drug: celecoxib|Other: placebo|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: fluorescence in situ hybridization|Genetic: mutation analysis|Genetic: protein expression analysis|Genetic: gene expression analysis,City of Hope Medical Center|OSI Pharmaceuticals,City of Hope Medical Center,OSI Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,11/7/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00499655
3812,"Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL",Completed,Has Results,Leukemia,Drug: Cytarabine|Drug: Fludarabine|Drug: Oxaliplatin|Drug: Rituximab,M.D. Anderson Cancer Center|Sanofi,M.D. Anderson Cancer Center,Sanofi,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/4/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00452374
3813,"Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer",Completed,Has Results,Pancreatic Cancer,Drug: Gemcitabine|Drug: Bevacizumab|Drug: Infusional 5-Fluorouracil,"Tony Bekaii-Saab|Genentech, Inc.|Ohio State University Comprehensive Cancer Center",Tony Bekaii-Saab,"Genentech, Inc.",Ohio State University Comprehensive Cancer Center,,,,,Phase 2,Other|Industry,Interventional,12/6/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00417976
3814,A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Rapamycin|Drug: Trastuzumab,"Yale University|Genentech, Inc.",Yale University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,12/6/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00411788
3815,Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients,Completed,Has Results,"Neoplasms, Germ Cell and Embryonal",Drug: Bevacizumab and Oxaliplatin,"Indiana University|Genentech, Inc.",Indiana University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,10/6/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00393861
3816,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Completed,Has Results,Attention Deficit Hyperactivity Disorder,"Drug: Dexmethylphenidate|Drug: Mixed Amphetamine Salts, ER|Drug: placebo",Seattle Children's Hospital|Novartis,Seattle Children's Hospital,Novartis,,,,,,Phase 3,Other|Industry,Interventional,1/6/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00393042
3817,Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer,Completed,Has Results,Endometrial Cancer,Drug: Cetuximab,M.D. Anderson Cancer Center|Bristol-Myers Squibb,M.D. Anderson Cancer Center,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,10/6/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00392769
3818,Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy,Completed,Has Results,Leukemia,Drug: Azacitidine,H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation,H. Lee Moffitt Cancer Center and Research Institute,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,8/6/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00387647
3819,Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal,Completed,Has Results,End Stage Renal Disease (ESRD),Drug: Mycophenolic Acid (Myfortic),University of Cincinnati|Novartis,University of Cincinnati,Novartis,,,,,,Phase 4,Other|Industry,Interventional,4/6/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00374803
3820,Rosiglitazone Effect on Mitochondria and Lipoatrophy,Completed,Has Results,HIV Infections,Drug: Rosiglitazone|Drug: Placebo,National Institute of Allergy and Infectious Diseases (NIAID)|GlaxoSmithKline,National Institute of Allergy and Infectious Diseases (NIAID),GlaxoSmithKline,,,,,,Phase 2,NIH|Industry,Interventional,7/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00367744
3821,Perioperative Insulin Glargine Dosing Study,Completed,Has Results,Diabetes|Surgery,Drug: Lantus|Other: Insulin,Tamra Dukatz|Sanofi|William Beaumont Hospitals,Tamra Dukatz,Sanofi,William Beaumont Hospitals,,,,,Phase 4,Other|Industry,Interventional,10/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00309465
3822,Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients,Completed,Has Results,Immunosuppression,Drug: Tacrolimus|Drug: combination therapy,Newark Beth Israel Medical Center|Astellas Pharma Inc,Newark Beth Israel Medical Center,Astellas Pharma Inc,,,,,,Phase 4,Other|Industry,Interventional,4/4/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00299221
3823,Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914,Completed,Has Results,Leiomyoma,Drug: ulipristal acetate|Drug: placebo,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|HRA Pharma|National Institutes of Health Clinical Center (CC),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),HRA Pharma,National Institutes of Health Clinical Center (CC),,,,,Phase 2,NIH|Industry,Interventional,2/6/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00290251
3824,Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma,Completed,Has Results,Hepatocellular Carcinoma,Drug: Bevacizumab|Drug: Erlotinib,"University of Arkansas|Genentech, Inc.",University of Arkansas,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,2/6/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00287222
3825,Aspirin Dose and Atherosclerosis in Patients With Heart Disease,Completed,Has Results,Cardiovascular Diseases|Atherosclerosis|Myocardial Infarction,Drug: Aspirin,Florida Atlantic University|Bayer,Florida Atlantic University,Bayer,,,,,,Phase 4,Other|Industry,Interventional,10/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00272337
3826,Testosterone Replacement Therapy in Chronic Spinal Cord Injury,Completed,Has Results,Spinal Cord Injury|Hypogonadism,Drug: Testosterone Transdermal System (Androderm 5 mg patch),VA Office of Research and Development|Kessler Institute for Rehabilitation,VA Office of Research and Development,Kessler Institute for Rehabilitation,,,,,,Phase 2|Phase 3,U.S. Fed|Industry,Interventional,8/3/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00266864
3827,Management of Superficial Thrombophlebitis,Completed,Has Results,Superficial Thrombophlebitis|Upper Extremity Superficial Thrombophlebitis|Lower Extremity Superficial Thrombophlebitis,Drug: Dalteparin sodium injection,University of Oklahoma|Pfizer,University of Oklahoma,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,10/2/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00264381
3828,Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate,Completed,Has Results,Chronic Kidney Disease|Chronic Renal Disease,Other: Dialysis Flow Rate Start 600mL/min|Other: Dialysis Flow Rate Start 800mL/min,"Baxter Healthcare Corporation|University of Louisville|Vanderbilt University Medical Center|University of California, Davis|Gambro Renal Products, Inc.",Baxter Healthcare Corporation,University of Louisville,"Vanderbilt University Medical Center|University of California, Davis|Gambro Renal Products, Inc.",Vanderbilt University Medical Center,"University of California, Davis|Gambro Renal Products, Inc.","University of California, Davis","Gambro Renal Products, Inc.",Not Applicable,Industry|Other,Interventional,9/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00962000
3829,"Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer",Completed,Has Results,Endometrial Cancer,Drug: carboplatin|Drug: docetaxel|Radiation: radiation therapy,"Masonic Cancer Center, University of Minnesota|Sanofi","Masonic Cancer Center, University of Minnesota",Sanofi,,,,,,Phase 2,Other|Industry,Interventional,7/5/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00258362
3830,Treatment of Upper Extremity Deep-Vein Thrombosis,Completed,Has Results,Deep-Vein Thrombosis,Drug: Dalteparin sodium injection|Drug: Warfarin,University of Oklahoma|Pfizer,University of Oklahoma,Pfizer,,,,,,Phase 4,Other|Industry,Interventional,9/2/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00245856
3831,"Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer",Completed,Has Results,Prostate Cancer,Drug: docetaxel|Drug: leuprolide acetate|Radiation: radiation therapy,UNC Lineberger Comprehensive Cancer Center|Sanofi,UNC Lineberger Comprehensive Cancer Center,Sanofi,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/5/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00225420
3832,Geodon for the Treatment of Refractory Social Anxiety Disorder,Completed,Has Results,Social Anxiety Disorder,Drug: Ziprasidone|Drug: Sertraline,Duke University|Pfizer,Duke University,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,11/4/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00215150
3833,A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children,Completed,Has Results,Acute Otitis Media|Otitis Media|Ear Infection,Drug: Montelukast,West Penn Allegheny Health System|Merck Sharp & Dohme Corp.,West Penn Allegheny Health System,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,3/4/2019,12/5/2019,https://ClinicalTrials.gov/show/NCT00189462
3834,Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children,Completed,Has Results,Asthma,Drug: Nebulized Budesonide|Drug: Usual care (albuterol with or without oral steroid),West Penn Allegheny Health System|AstraZeneca,West Penn Allegheny Health System,AstraZeneca,,,,,,Phase 4,Other|Industry,Interventional,3/3/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00189436
3835,Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer,Completed,Has Results,Lung Cancer,Device: CyPath,"Biomoda Inc.|Alquest|Quintiles, Inc.|Radiology Associates of Albuquerque|New Mexico Technical Institute of Mining and Technology|US Department of Veterans Affairs",Biomoda Inc.,Alquest,"Quintiles, Inc.|Radiology Associates of Albuquerque|New Mexico Technical Institute of Mining and Technology|US Department of Veterans Affairs","Quintiles, Inc.",Radiology Associates of Albuquerque|New Mexico Technical Institute of Mining and Technology|US Department of Veterans Affairs,Radiology Associates of Albuquerque,New Mexico Technical Institute of Mining and Technology|US Department of Veterans Affairs,Phase 1|Phase 2,Industry|Other|U.S. Fed,Interventional,3/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00894127
3836,Rituximab in Treating Patients With Hodgkin's Lymphoma,Completed,Has Results,Lymphoma|Hodgkin Lymphoma (Category)|Nodular Lymphocyte Predominant Hodgkin Lymphoma,Drug: Rituximab,"Ranjana Advani|Genentech, Inc.|Stanford University",Ranjana Advani,"Genentech, Inc.",Stanford University,,,,,Phase 2,Other|Industry,Interventional,1/1/1999,8/8/2019,https://ClinicalTrials.gov/show/NCT00003820
3837,"Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience",Completed,Has Results,Chronic Hepatitis C,Drug: Sofosbuvir/Velpatasvir/Voxilaprevir,"University of Maryland|Unity Health Care, Inc.|Gilead Sciences",University of Maryland,"Unity Health Care, Inc.",Gilead Sciences,,,,,Phase 2,Other|Industry,Interventional,5/16/2019,10/24/2018,https://ClinicalTrials.gov/show/NCT02745535
3838,Iloperidone in Mixed States of Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: iloperidone,The University of Texas Health Science Center at San Antonio|Novartis Pharmaceuticals|Vanda Pharmaceuticals,The University of Texas Health Science Center at San Antonio,Novartis Pharmaceuticals,Vanda Pharmaceuticals,,,,,Phase 4,Other|Industry,Interventional,4/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02413918
3839,4 Pillars Toolkit for Adolescent Vaccination,Completed,Has Results,Adolescent HPV Vaccine|Adolescent Influenza Vaccine,Behavioral: 4 Pillars Toolkit,University of Pittsburgh|Pfizer|Merck Sharp & Dohme Corp.,University of Pittsburgh,Pfizer,Merck Sharp & Dohme Corp.,,,,,Not Applicable,Other|Industry,Interventional,9/13/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02165722
3840,Intravenous Exenatide in Patients With Acute Brain Injury,Completed,Has Results,Brain Injuries,Drug: Exenatide,"University of North Carolina, Chapel Hill|AstraZeneca|Medtronic","University of North Carolina, Chapel Hill",AstraZeneca,Medtronic,,,,,Phase 4,Other|Industry,Interventional,8/15/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02058940
3841,Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),Completed,Has Results,Lung Cancer|Non-small Cell Lung Cancer (NSCLC),Drug: Dasatinib - 1A|Drug: Afatinib - 1A|Drug: Dasatinib - 1B|Drug: Afatinib - 1B,H. Lee Moffitt Cancer Center and Research Institute|Boehringer Ingelheim|Bristol-Myers Squibb,H. Lee Moffitt Cancer Center and Research Institute,Boehringer Ingelheim,Bristol-Myers Squibb,,,,,Phase 1,Other|Industry,Interventional,12/31/2013,5/30/2019,https://ClinicalTrials.gov/show/NCT01999985
3842,Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients,Completed,Has Results,Recurrent Glioblastoma Multiforme|Malignant Glioma|Adult Brain Tumor,Drug: Vorinostat|Drug: Bevacizumab,"Duke University|Genentech, Inc.|Merck Sharp & Dohme Corp.",Duke University,"Genentech, Inc.",Merck Sharp & Dohme Corp.,,,,,Phase 2,Other|Industry,Interventional,1/13/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01738646
3843,Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD),Completed,Has Results,Gastrointestinal Bleeding,Drug: Octreotide LAR Depot,Virginia Commonwealth University|Thoratec Corporation|Novartis,Virginia Commonwealth University,Thoratec Corporation,Novartis,,,,,Phase 1,Other|Industry,Interventional,2/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01707225
3844,A Study Comparing CoQ10 Levels While Taking 3 Different Statins,Completed,Has Results,Hypercholesterolemia,Drug: Pitavastin 4mg|Drug: Atorvastatin 20mg|Drug: Rosuvastatin 5mg,"University of Kansas Medical Center|Kowa Pharmaceuticals America, Inc.|Eli Lilly and Company",University of Kansas Medical Center,"Kowa Pharmaceuticals America, Inc.",Eli Lilly and Company,,,,,Phase 4,Other|Industry,Interventional,12/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01660191
3845,An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder,Completed,Has Results,Posttraumatic Stress Disorder,Drug: Adjunctive asenapine,"Lori Davis, MD|Merck Sharp & Dohme Corp.|Forest Laboratories|Tuscaloosa Research & Education Advancement Corporation","Lori Davis, MD",Merck Sharp & Dohme Corp.,Forest Laboratories|Tuscaloosa Research & Education Advancement Corporation,Forest Laboratories,Tuscaloosa Research & Education Advancement Corporation,,,Phase 4,Other|Industry,Interventional,6/12/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01587118
3846,Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL),Completed,Has Results,"Leukemia, Lymphocytic, Chronic, B-Cell",Drug: Lenalidomide + Plerixafor (+ Rituximab),"David Rizzieri, MD|Celgene Corporation|Genzyme, a Sanofi Company|Duke University","David Rizzieri, MD",Celgene Corporation,"Genzyme, a Sanofi Company|Duke University","Genzyme, a Sanofi Company",Duke University,,,Phase 1,Other|Industry,Interventional,1/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01373229
3847,Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Exenatide|Drug: Placebo,"University of Colorado, Denver|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company","University of Colorado, Denver","Amylin Pharmaceuticals, LLC.",Eli Lilly and Company,,,,,Not Applicable,Other|Industry,Interventional,10/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01364584
3848,A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty,Completed,Has Results,Arthritis,Device: Vitagel,The Cleveland Clinic|Orthovita d/b/a Stryker|Stryker Instruments,The Cleveland Clinic,Orthovita d/b/a Stryker,Stryker Instruments,,,,,Not Applicable,Other|Industry,Interventional,12/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01285024
3849,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,Completed,Has Results,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Drug: Gadolinium|Drug: Adenosine,"Northwestern University|Astellas Pharma US, Inc.|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Northwestern University,"Astellas Pharma US, Inc.","Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",,,,,Phase 2|Phase 3,Other|Industry,Interventional,6/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01234870
3850,Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP),Completed,Has Results,HIV,Drug: Truvada|Drug: Raltegravir,"The University of Texas Health Science Center, Houston|Merck Sharp & Dohme Corp.|Gilead Sciences","The University of Texas Health Science Center, Houston",Merck Sharp & Dohme Corp.,Gilead Sciences,,,,,Phase 4,Other|Industry,Interventional,5/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01214759
3851,PKC412 and 5-Azacytidine,Completed,Has Results,Leukemia,Drug: 5-azacytidine|Drug: PKC412,M.D. Anderson Cancer Center|Novartis Pharmaceuticals|Celgene Corporation,M.D. Anderson Cancer Center,Novartis Pharmaceuticals,Celgene Corporation,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/11/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01202877
3852,PPI and Clopidogrel Response,Completed,Has Results,Drug Interaction,Drug: omeprazole and pantoprazole,University of Florida|Bristol-Myers Squibb|Sanofi,University of Florida,Bristol-Myers Squibb,Sanofi,,,,,Phase 1,Other|Industry,Interventional,3/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01170533
3853,Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL),Completed,Has Results,Lymphoma,Drug: azacytidine|Drug: vorinostat,Weill Medical College of Cornell University|Celgene|Merck Sharp & Dohme Corp.,Weill Medical College of Cornell University,Celgene,Merck Sharp & Dohme Corp.,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/10/2019,10/20/2016,https://ClinicalTrials.gov/show/NCT01120834
3854,Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?,Completed,Has Results,Workplace Migraine Treatment,Drug: Triptan|Drug: Treximet 85Mg-500Mg Tablet,The Cleveland Clinic|GlaxoSmithKline|Pernix Theraputics LLC,The Cleveland Clinic,GlaxoSmithKline,Pernix Theraputics LLC,,,,,Phase 4,Other|Industry,Interventional,9/9/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01086358
3855,Sleep Apnea Treatment With Expiratory Resistance(Provent™),Completed,Has Results,"Sleep Apnea, Obstructive",Device: Treatment sleep study (Provent™ device used)|Other: Baseline sleep study (No device)|Other: Physiology sleep study (Provent™ on/off),"Johns Hopkins University|ResMed|Ventus Medical, Inc.",Johns Hopkins University,ResMed,"Ventus Medical, Inc.",,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01061476
3856,Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation,Completed,Has Results,"Respiratory Distress Syndrome, Newborn",Device: Endotracheal tube insertion|Device: Laryngeal mask airway insertion,"Albany Medical College|ONY|LMA North America, Inc.",Albany Medical College,ONY,"LMA North America, Inc.",,,,,Phase 4,Other|Industry,Interventional,12/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01042600
3857,"Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,Drug: RAD001|Drug: bevacizumab,"University of Pittsburgh|Novartis Pharmaceuticals|Genentech, Inc.",University of Pittsburgh,Novartis Pharmaceuticals,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,9/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01031381
3858,Pharmacokinetics of Voriconazole in Obese Subjects,Completed,Has Results,Healthy,Drug: Voriconazole low dose|Drug: Voriconazole high dose,"Manjunath Prakash Pai|TKL Research, Inc.|Pfizer|University of Michigan",Manjunath Prakash Pai,"TKL Research, Inc.",Pfizer|University of Michigan,Pfizer,University of Michigan,,,Phase 4,Other|Industry,Interventional,11/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01030653
3859,Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244,Completed,Has Results,Thyroid Cancer,Biological: AZD6244,"Memorial Sloan Kettering Cancer Center|Genzyme, a Sanofi Company|AstraZeneca",Memorial Sloan Kettering Cancer Center,"Genzyme, a Sanofi Company",AstraZeneca,,,,,Not Applicable,Other|Industry,Interventional,9/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00970359
3860,Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma,Completed,Has Results,Head And Neck Cancer,Drug: Erlotinib|Drug: RAD001,M.D. Anderson Cancer Center|Novartis|OSI Pharmaceuticals,M.D. Anderson Cancer Center,Novartis,OSI Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,7/9/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00942734
3861,"Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas",Completed,Has Results,Brain Tumor|Glioblastoma,Drug: Vorinostst/Bevacizumab/Temozolomide,"Katy Peters|Genentech, Inc.|Merck Sharp & Dohme Corp.|Duke University",Katy Peters,"Genentech, Inc.",Merck Sharp & Dohme Corp.|Duke University,Merck Sharp & Dohme Corp.,Duke University,,,Phase 1|Phase 2,Other|Industry,Interventional,10/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00939991
3862,Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS),Completed,Has Results,Benign Prostatic Hyperplasia (BPH),Drug: Tolterodine ER 4mg|Drug: Placebo|Drug: Pre-randomization Dutasteride,"Siami, Paul F., M.D.|GlaxoSmithKline|Pfizer","Siami, Paul F., M.D.",GlaxoSmithKline,Pfizer,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00939120
3863,Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Completed,Has Results,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: perifosine,"Daphne Friedman|Keryx Biopharmaceuticals|Keryx / AOI Pharmaceuticals, Inc.|Duke University",Daphne Friedman,Keryx Biopharmaceuticals,"Keryx / AOI Pharmaceuticals, Inc.|Duke University","Keryx / AOI Pharmaceuticals, Inc.",Duke University,,,Phase 2,Other|Industry,Interventional,8/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00873457
3864,Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer,Completed,Has Results,Gastric Cancer|Stomach Cancer,Drug: Cetuximab|Drug: Irinotecan|Drug: Cisplatin|Procedure: Surgery|Drug: 5-FU|Radiation: Radiation,NYU Langone Health|Bristol-Myers Squibb|ImClone LLC,NYU Langone Health,Bristol-Myers Squibb,ImClone LLC,,,,,Phase 2,Other|Industry,Interventional,7/5/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT00857246
3865,Evaluation of Exenatide in Patients With Diabetic Neuropathy,Completed,Has Results,Type 2 Diabetes Mellitus|Diabetic Peripheral Neuropathy,Drug: Exenatide|Drug: Glargine,"University of Michigan|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company",University of Michigan,"Amylin Pharmaceuticals, LLC.",Eli Lilly and Company,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00855439
3866,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,Completed,Has Results,Hepatocellular Carcinoma|Hepatoma,Drug: sorafenib|Procedure: LC Bead-TACE,Yale University|Bayer|Biocompatibles UK Ltd,Yale University,Bayer,Biocompatibles UK Ltd,,,,,Phase 2,Other|Industry,Interventional,2/9/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00844883
3867,Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,Lung Cancer|Non-Small Cell Lung Cancer,Drug: Dasatinib|Drug: Erlotinib,M.D. Anderson Cancer Center|Bristol-Myers Squibb|OSI Pharmaceuticals,M.D. Anderson Cancer Center,Bristol-Myers Squibb,OSI Pharmaceuticals,,,,,Phase 1|Phase 2,Other|Industry,Interventional,2/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00826449
3868,Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS),Completed,Has Results,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: Clofarabine|Drug: Cytarabine|Drug: Decitabine,"M.D. Anderson Cancer Center|Eisai Inc.|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,Eisai Inc.,"Genzyme, a Sanofi Company",,,,,Phase 2,Other|Industry,Interventional,10/8/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00778375
3869,Once Weekly Subcutaneous Ports for the Administration of Anticoagulants,Completed,Has Results,Venous Thromboembolism,Device: Insuflon,"University of North Carolina, Chapel Hill|IntraPump Infusion Systems|Laboratory Corporation of America","University of North Carolina, Chapel Hill",IntraPump Infusion Systems,Laboratory Corporation of America,,,,,Not Applicable,Other|Industry,Interventional,8/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00774748
3870,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Completed,Has Results,Immune Thrombocytopenic Purpura,"Drug: Rituxan, Cyclophosphamide, Vincristine, Prednisone|Drug: Higher Dose of Rituximab","Weill Medical College of Cornell University|Biogen|Genentech, Inc.",Weill Medical College of Cornell University,Biogen,"Genentech, Inc.",,,,,Phase 2|Phase 3,Other|Industry,Interventional,11/3/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00774202
3871,"Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)",Completed,Has Results,Multiple Myeloma,Drug: Cyclophosphamide|Drug: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD),"H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc.",H. Lee Moffitt Cancer Center and Research Institute,"Millennium Pharmaceuticals, Inc.","Ortho Biotech, Inc.",,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/8/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00750815
3872,"Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy",Completed,Has Results,Inflammatory Bowel Disease,Drug: Lubiprostone|Drug: Placebo,"University of South Alabama|Takeda|Sucampo Pharmaceuticals, Inc.",University of South Alabama,Takeda,"Sucampo Pharmaceuticals, Inc.",,,,,Phase 4,Other|Industry,Interventional,4/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00746395
3873,Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: Decitabine|Drug: Temozolomide|Procedure: biopsy,Hussein Tawbi|Eisai Inc.|Schering-Plough|University of Pittsburgh,Hussein Tawbi,Eisai Inc.,Schering-Plough|University of Pittsburgh,Schering-Plough,University of Pittsburgh,,,Phase 1|Phase 2,Other|Industry,Interventional,6/8/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00715793
3874,Uro-NIRS Clinical Study,Completed,Has Results,Lower Urinary Tract Symptoms|Overactive Bladder,Device: Fully integrated Uro-NIRS:UDS,Weill Medical College of Cornell University|Urodynamix Technologies|Laborie Medical Technologies Inc.,Weill Medical College of Cornell University,Urodynamix Technologies,Laborie Medical Technologies Inc.,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00706407
3875,"Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer",Completed,Has Results,Cancer,Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetrexed|Radiation: Radiation therapy,"University of Pittsburgh|Eli Lilly and Company|Genentech, Inc.",University of Pittsburgh,Eli Lilly and Company,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,10/8/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00703976
3876,Kaletra-isentress Treatment Evaluation,Completed,Has Results,HIV Infections,Drug: Kaletra + Isentress|Drug: Pre-study antiretroviral regimen,Emory University|Abbott|Merck Sharp & Dohme Corp.,Emory University,Abbott,Merck Sharp & Dohme Corp.,,,,,Phase 4,Other|Industry,Interventional,6/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00700115
3877,Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer,Completed,Has Results,Breast Cancer,Drug: bevacizumab|Drug: carboplatin|Drug: nab-paclitaxel|Procedure: Surgery|Drug: Adjuvant chemotherapy,"Ohio State University Comprehensive Cancer Center|Celgene Corporation|Genentech, Inc.",Ohio State University Comprehensive Cancer Center,Celgene Corporation,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,7/8/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00675259
3878,Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme,Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: Erlotinib + sirolimus,"Duke University|Genentech, Inc.|OSI Pharmaceuticals",Duke University,"Genentech, Inc.",OSI Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,4/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00672243
3879,Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia,Completed,Has Results,Alveolar Bone Loss|Loss of Teeth Due to Extraction|Edentulous Alveolar Ridge,Device: OSSIX-Plus,William Giannobile|Johnson & Johnson|OraPharma|University of Michigan,William Giannobile,Johnson & Johnson,OraPharma|University of Michigan,OraPharma,University of Michigan,,,Phase 1|Phase 2,Other|Industry,Interventional,3/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00639860
3880,Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant,Completed,Has Results,Graft Versus Host Disease,Procedure: stem cell transplant|Drug: tacrolimus (standard GVHD prophylaxis)|Drug: mycophenolate (standard GVHD prophylaxis)|Drug: etanercept|Drug: methoxsalen,University of Michigan Rogel Cancer Center|Mallinckrodt|Amgen,University of Michigan Rogel Cancer Center,Mallinckrodt,Amgen,,,,,Phase 2,Other|Industry,Interventional,3/9/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT00639717
3881,"Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin",Completed,Has Results,Invasive Breast Cancer,"Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin","University of Alabama at Birmingham|Ortho Biotech, Inc.|Genentech, Inc.",University of Alabama at Birmingham,"Ortho Biotech, Inc.","Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,3/8/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00635050
3882,"CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma",Completed,Has Results,Pancreatic Neoplasms|Bile Duct Neoplasms,Drug: Oxaliplatin|Drug: Capecitabine|Drug: Sorafenib,"University of Wisconsin, Madison|Bayer|Sanofi","University of Wisconsin, Madison",Bayer,Sanofi,,,,,Phase 1|Phase 2,Other|Industry,Interventional,2/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00634751
3883,Lucentis Versus Mitomycin C During Glaucoma Surgery,Completed,Has Results,Glaucoma,Drug: Ranibizumab|Drug: Mitomycin (MMC),"Wills Eye|Genentech, Inc.|Novartis Pharmaceuticals",Wills Eye,"Genentech, Inc.",Novartis Pharmaceuticals,,,,,Phase 2|Phase 3,Other|Industry,Interventional,1/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00626782
3884,"Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome",Completed,Has Results,Myelodysplastic Syndrome,"Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid",Duke University|Cephalon|Eisai Inc.,Duke University,Cephalon,Eisai Inc.,,,,,Phase 2,Other|Industry,Interventional,11/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00621023
3885,PACT (Platelet Activity After Clopidogrel Termination),Completed,Has Results,Blood Platelets|Clopidogrel,Drug: clopidogrel + aspirin|Drug: placebo|Drug: Aspirin,"University of Massachusetts, Worcester|Sanofi|Bristol-Myers Squibb","University of Massachusetts, Worcester",Sanofi,Bristol-Myers Squibb,,,,,Not Applicable,Other|Industry,Interventional,4/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00619073
3886,"A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer",Completed,Has Results,Metastatic Breast Cancer,Drug: Paclitaxel|Drug: Gemcitabine|Drug: Avastin,"Barbara Ann Karmanos Cancer Institute|Eli Lilly and Company|Genentech, Inc.",Barbara Ann Karmanos Cancer Institute,Eli Lilly and Company,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,11/6/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00618826
3887,"Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)",Completed,Has Results,Multiple Myeloma,Drug: Lenalidomide|Drug: Pegylated Liposomal Doxorubicin (PLD)|Drug: Dexamethasone,"H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation|Ortho Biotech Clinical Affairs, L.L.C.",H. Lee Moffitt Cancer Center and Research Institute,Celgene Corporation,"Ortho Biotech Clinical Affairs, L.L.C.",,,,,Phase 2,Other|Industry,Interventional,1/8/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00617591
3888,Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas,Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: Avastin and Temozolomide,"Duke University|Genentech, Inc.|Schering-Plough",Duke University,"Genentech, Inc.",Schering-Plough,,,,,Phase 2,Other|Industry,Interventional,8/7/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00612339
3889,"Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors",Completed,Has Results,Metastatic Solid Tumor,Drug: Topotecan|Drug: Erlotinib,"Accelerated Community Oncology Research Network|GlaxoSmithKline|Genentech, Inc.",Accelerated Community Oncology Research Network,GlaxoSmithKline,"Genentech, Inc.",,,,,Phase 1,Other|Industry,Interventional,6/6/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00611468
3890,Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma,Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: Avastin|Drug: Bortezomib,"Duke University|Millennium Pharmaceuticals, Inc.|Genentech, Inc.",Duke University,"Millennium Pharmaceuticals, Inc.","Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,5/8/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00611325
3891,Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma,Completed,Has Results,Neuroendocrine Carcinoma,Drug: Avastin|Drug: RAD001,"M.D. Anderson Cancer Center|Novartis|Genentech, Inc.",M.D. Anderson Cancer Center,Novartis,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,1/8/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00607113
3892,The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot,Completed,Has Results,Age Related Macular Degeneration,Drug: Fluocinolone Acetonide/Medidur,Johns Hopkins University|Alimera Sciences|pSiVida Limited,Johns Hopkins University,Alimera Sciences,pSiVida Limited,,,,,Phase 2,Other|Industry,Interventional,1/8/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00605423
3893,Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus,Completed,Has Results,Colorectal Adenocarcinoma,Drug: Bevacizumab|Drug: Everolimus,"Herbert Hurwitz|Novartis Pharmaceuticals|Genentech, Inc.|Duke University",Herbert Hurwitz,Novartis Pharmaceuticals,"Genentech, Inc.|Duke University","Genentech, Inc.",Duke University,,,Phase 2,Other|Industry,Interventional,10/7/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00597506
3894,Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM,Completed,Has Results,Recurrent Glioblastoma Multiforme,Drug: Sorafenib and Temozolomide,Duke University|Bayer|Schering-Plough,Duke University,Bayer,Schering-Plough,,,,,Phase 2,Other|Industry,Interventional,9/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00597493
3895,"Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas",Completed,Has Results,Glioblastoma|Gliosarcoma|Brain Tumor,Drug: Avastin|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Irinotecan,"Duke University|Genentech, Inc.|Schering-Plough",Duke University,"Genentech, Inc.",Schering-Plough,,,,,Phase 2,Other|Industry,Interventional,7/7/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00597402
3896,Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility,Completed,Has Results,Breast Cancer,Drug: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P),"Memorial Sloan Kettering Cancer Center|Amgen|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,Amgen,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,12/4/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00591851
3897,Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid,Completed,Has Results,Ocular Cicatricial Pemphigoid,Drug: Rituximab,"University of Alabama at Birmingham|Genentech, Inc.|Biogen",University of Alabama at Birmingham,"Genentech, Inc.",Biogen,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/6/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00584935
3898,Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib,Completed,Has Results,Colorectal Adenoma|Colorectal Carcinoma,Drug: Celecoxib|Drug: Placebo,University of Alabama at Birmingham|Pfizer|Pharmacia,University of Alabama at Birmingham,Pfizer,Pharmacia,,,,,Phase 2,Other|Industry,Interventional,12/1/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00582660
3899,Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer,Completed,Has Results,Cancer,Drug: celecoxib|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Radiation Therapy,University of Alabama at Birmingham|Bristol-Myers Squibb|Pharmacia,University of Alabama at Birmingham,Bristol-Myers Squibb,Pharmacia,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/2/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00581971
3900,Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation,Completed,Has Results,Chronic Obstructive Pulmonary Disease|COPD,Drug: Tiotropium|Drug: Placebo,Mayo Clinic|Boehringer Ingelheim|Pfizer,Mayo Clinic,Boehringer Ingelheim,Pfizer,,,,,Phase 4,Other|Industry,Interventional,10/6/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00578968
3901,UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer,Completed,Has Results,Head and Neck Cancer,Drug: Erlotinib,"University of Alabama at Birmingham|Genentech, Inc.|OSI Pharmaceuticals",University of Alabama at Birmingham,"Genentech, Inc.",OSI Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,12/7/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00570232
3902,Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma,Completed,Has Results,Glioblastoma Multiforme,Drug: Bevacizumab|Drug: Metronomic Temozolomide,"Duke University|Genentech, Inc.|Schering-Plough",Duke University,"Genentech, Inc.",Schering-Plough,,,,,Phase 2,Other|Industry,Interventional,7/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00501891
3903,"Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",Completed,Has Results,Lymphoma,Drug: Cytoxan|Drug: Nipent|Drug: Rituxan,M.D. Anderson Cancer Center|Astex Pharmaceuticals|Pharmatech,M.D. Anderson Cancer Center,Astex Pharmaceuticals,Pharmatech,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00496873
3904,Campath in Chronic GVHD,Completed,Has Results,Chronic Graft-vs.-Host Disease,Drug: Alemtuzumab (Campath),"Dana-Farber Cancer Institute|Genzyme, a Sanofi Company|Bayer",Dana-Farber Cancer Institute,"Genzyme, a Sanofi Company",Bayer,,,,,Phase 1,Other|Industry,Interventional,7/7/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00495755
3905,Phase 2 Study of Bexxar in Relapsed/Refractory DLCL,Completed,Has Results,Lymphoma,Drug: Bexxar|Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Potassium Iodide (KI),Susan Knox|Corixa Corporation|GlaxoSmithKline|Stanford University,Susan Knox,Corixa Corporation,GlaxoSmithKline|Stanford University,GlaxoSmithKline,Stanford University,,,Phase 2,Other|Industry,Interventional,9/4/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00490009
3906,5-Alpha Reductase and Anabolic Effects of Testosterone,Completed,Has Results,Male Hypogonadism|Muscle Atrophy|Sarcopenia|Benign Prostate Hypertrophy,Drug: Testosterone Enanthate|Drug: Finasteride|Other: Placebo,VA Office of Research and Development|Endo Pharmaceuticals|Merck Sharp & Dohme Corp.,VA Office of Research and Development,Endo Pharmaceuticals,Merck Sharp & Dohme Corp.,,,,,Phase 2,U.S. Fed|Industry,Interventional,1/7/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00475501
3907,Mechanisms of Lipodystrophy in HIV-Infected Pateints,Completed,Has Results,HIV Infections,Drug: Nelfinavir|Drug: Efavirenz,University of Texas Southwestern Medical Center|Bristol-Myers Squibb|GlaxoSmithKline,University of Texas Southwestern Medical Center,Bristol-Myers Squibb,GlaxoSmithKline,,,,,Phase 4,Other|Industry,Interventional,2/2/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00457665
3908,"The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women",Completed,Has Results,Obesity|Impaired Glucose Tolerance,Drug: exenatide|Drug: Placebo,"Beth Israel Deaconess Medical Center|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company",Beth Israel Deaconess Medical Center,"Amylin Pharmaceuticals, LLC.",Eli Lilly and Company,,,,,Phase 4,Other|Industry,Interventional,4/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00456885
3909,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Completed,Has Results,Myocardial Infarction,Drug: Bivalirudin|Drug: Unfractionated heparin|Device: Bare metal stent|Device: Paclitaxel-eluting stent,"Cardiovascular Research Foundation, New York|Boston Scientific Corporation|The Medicines Company","Cardiovascular Research Foundation, New York",Boston Scientific Corporation,The Medicines Company,,,,,Phase 3,Other|Industry,Interventional,3/5/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00433966
3910,Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2|Obesity",Procedure: Gastric bypass|Procedure: Sleeve Gastrectomy,The Cleveland Clinic|Ethicon Endo-Surgery|LifeScan,The Cleveland Clinic,Ethicon Endo-Surgery,LifeScan,,,,,Not Applicable,Other|Industry,Interventional,2/7/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT00432809
3911,"Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer",Completed,Has Results,Breast Cancer|Metastatic Breast Cancer,Drug: Gemcitabine|Drug: Paclitaxel|Drug: Bevacizumab,"George Albert Fisher|Genentech, Inc.|Eli Lilly and Company|Stanford University",George Albert Fisher,"Genentech, Inc.",Eli Lilly and Company|Stanford University,Eli Lilly and Company,Stanford University,,,Phase 2,Other|Industry,Interventional,2/6/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00403130
3912,Rituximab for Prevention of Chronic GVHD,Completed,Has Results,Hematological Malignancies,Drug: Rituximab|Drug: 375 mg/m2 RRituximab,"Dana-Farber Cancer Institute|Genentech, Inc.|Biogen",Dana-Farber Cancer Institute,"Genentech, Inc.",Biogen,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/6/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00379587
3913,A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma,Completed,Has Results,Cancer,Drug: Erlotinib,"University of Alabama at Birmingham|Genentech, Inc.|OSI Pharmaceuticals",University of Alabama at Birmingham,"Genentech, Inc.",OSI Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,8/6/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00369512
3914,The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Exenatide|Drug: Glargine Insulin,"Joslin Diabetes Center|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company",Joslin Diabetes Center,"Amylin Pharmaceuticals, LLC.",Eli Lilly and Company,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00353834
3915,Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA),Completed,Has Results,Head and Neck Cancer,Drug: Erlotinib (Tarceva)|Drug: Intra-arterial Cisplatin (PLAT)|Radiation: Radiation Therapy (RAD),"Southern Illinois University|Genentech, Inc.|OSI Pharmaceuticals",Southern Illinois University,"Genentech, Inc.",OSI Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,3/6/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00304278
3916,Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab,"University of Pittsburgh|Genentech, Inc.|Biogen",University of Pittsburgh,"Genentech, Inc.",Biogen,,,,,Phase 2,Other|Industry,Interventional,6/4/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00280241
3917,"Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Bevacizumab|Drug: Gemcitabine|Drug: Carboplatin,"Ohio State University Comprehensive Cancer Center|Genentech, Inc.|Eli Lilly and Company",Ohio State University Comprehensive Cancer Center,"Genentech, Inc.",Eli Lilly and Company,,,,,Phase 2,Other|Industry,Interventional,11/5/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00267696
3918,Collagenase in the Treatment of Dupuytrens Disease,Completed,Has Results,Dupuytren's Disease,Biological: collagenase clostridium histolyticum,Stony Brook University|Biospecifics Technologies Corp.|Endo Pharmaceuticals,Stony Brook University,Biospecifics Technologies Corp.,Endo Pharmaceuticals,,,,,Phase 3,Other|Industry,Interventional,6/3/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00260429
3919,"FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Rituximab|Drug: Filgrastim,"M.D. Anderson Cancer Center|OSI Pharmaceuticals|Genentech, Inc.",M.D. Anderson Cancer Center,OSI Pharmaceuticals,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,3/14/2005,9/14/2017,https://ClinicalTrials.gov/show/NCT00254410
3920,"Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)",Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Intervention A: Irinotecan; Oxaliplatin; Neulasta|Drug: Intervention B: Etoposide; Carboplatin; Neulasta,University of Alabama at Birmingham|Sanofi-Synthelabo|Amgen,University of Alabama at Birmingham,Sanofi-Synthelabo,Amgen,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00240097
3921,Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer,Completed,Has Results,Cancer,Drug: Pemetrexed|Drug: Bevacizumab,"University of Pittsburgh|Eli Lilly and Company|Genentech, Inc.",University of Pittsburgh,Eli Lilly and Company,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,11/5/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00222729
3922,The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Vinorelbine|Drug: Docetaxel|Drug: Gemcitabine|Drug: Carboplatin,H. Lee Moffitt Cancer Center and Research Institute|Eli Lilly and Company|Aventis Pharmaceuticals,H. Lee Moffitt Cancer Center and Research Institute,Eli Lilly and Company,Aventis Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,2/4/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00215930
3923,"Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer",Completed,Has Results,Lung Cancer,Drug: Docetaxel|Drug: Gemcitabine|Drug: Carboplatin|Radiation: Radiation,"SCRI Development Innovations, LLC|Aventis Pharmaceuticals|Eli Lilly and Company","SCRI Development Innovations, LLC",Aventis Pharmaceuticals,Eli Lilly and Company,,,,,Phase 2,Other|Industry,Interventional,4/4/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00193427
3924,Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Liposomal Doxorubicin|Drug: Docetaxel,"SCRI Development Innovations, LLC|Ortho Biotech, Inc.|Aventis Pharmaceuticals","SCRI Development Innovations, LLC","Ortho Biotech, Inc.",Aventis Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,2/1/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00193037
3925,Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma,Completed,Has Results,Ovarian Carcinoma|Peritoneal Neoplasms,Drug: Docetaxel and Gemcitabine,University of Southern California|Aventis Pharmaceuticals|Eli Lilly and Company,University of Southern California,Aventis Pharmaceuticals,Eli Lilly and Company,,,,,Phase 2,Other|Industry,Interventional,11/2/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00183794
3926,"Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer",Completed,Has Results,Colorectal Cancer,Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Capecitabine,"University of Southern California|Hoffmann-La Roche|Genentech, Inc.",University of Southern California,Hoffmann-La Roche,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,2/5/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00159432
3927,Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas,Completed,Has Results,Sarcoma,Drug: Cetuximab,University of Michigan Rogel Cancer Center|Bristol-Myers Squibb|ImClone LLC,University of Michigan Rogel Cancer Center,Bristol-Myers Squibb,ImClone LLC,,,,,Phase 2,Other|Industry,Interventional,6/5/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00148109
3928,Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer,Completed,Has Results,Head and Neck Cancer|Pharynx Cancer,Radiation: Chemoradiotherapy|Drug: Cisplatin|Drug: Bevacizumab|Drug: Erlotinib,"David M. Brizel, MD|Genentech, Inc.|OSI Pharmaceuticals|Duke University","David M. Brizel, MD","Genentech, Inc.",OSI Pharmaceuticals|Duke University,OSI Pharmaceuticals,Duke University,,,Early Phase 1,Other|Industry,Interventional,8/5/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00140556
3929,Study of Tarceva and Targretin in Stage I-II Lung Cancer,Completed,Has Results,"Carcinoma, Non-small-cell Lung",Drug: erlotinib (Tarceva) and bexarotene (Targretin),"Dartmouth-Hitchcock Medical Center|Ligand Pharmaceuticals|Genentech, Inc.",Dartmouth-Hitchcock Medical Center,Ligand Pharmaceuticals,"Genentech, Inc.",,,,,Not Applicable,Other|Industry,Interventional,12/5/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00125372
3930,Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA,Completed,Has Results,Bilateral Knee Osteoarthritis,Drug: FX006 32 mg|Drug: TAcs 40 mg,"Flexion Therapeutics, Inc.","Flexion Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,12/6/2017,3/14/2018,https://ClinicalTrials.gov/show/NCT03378076
3931,Clinical Comparison of 4 Daily Disposable Soft Contact Lenses,Completed,Has Results,Refractive Error,Device: verofilcon A contact lenses|Device: senofilcon A contact lenses|Device: stenfilcon A contact lenses|Device: etafilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,1/10/2018,2/16/2018,https://ClinicalTrials.gov/show/NCT03349632
3932,Evaluation of the Baha SoundArc in Pediatric Patients,Completed,Has Results,"Hearing Loss, Conductive|Hearing Loss, Mixed|Hearing Loss, Unilateral",Device: SoundArc,Cochlear,Cochlear,,,,,,,Not Applicable,Industry,Interventional,11/2/2017,11/2/2018,https://ClinicalTrials.gov/show/NCT03333577
3933,Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects,Completed,Has Results,Safety|Healthy Subjects,Drug: MEDI9314|Drug: placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,2/18/2016,6/12/2017,https://ClinicalTrials.gov/show/NCT02669667
3934,Disposable Stress Urinary Incontinence Pessary Device Study,Completed,Has Results,Stress Urinary Incontinence,Device: SUI Device,"Rinovum Women's Health, Inc.","Rinovum Women's Health, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/16/2017,5/1/2018,https://ClinicalTrials.gov/show/NCT03323723
3935,"Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines",Completed,Has Results,Influenza|Flu,Biological: Fluzone Quadrivalent vaccine|Biological: Fluzone High-Dose vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/11/2017,11/22/2017,https://ClinicalTrials.gov/show/NCT03308825
3936,Accuracy of Noninvasive Hemoglobin Measurement (SpHb) Using Rainbow DCI Pulse Oximeter Sensor,Completed,Has Results,Healthy|Surgery,Device: Rainbow DCI pulse oximeter sensor,Masimo Corporation,Masimo Corporation,,,,,,,Not Applicable,Industry,Interventional,8/12/2008,9/9/2008,https://ClinicalTrials.gov/show/NCT03124693
3937,Clinical Performance of a Silicone Hydrogel for Daily Disposable Wear,Completed,Has Results,Refractive Error,Device: FID122819 contact lenses|Device: Stenfilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,4/19/2017,5/15/2017,https://ClinicalTrials.gov/show/NCT03095027
3938,Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses,Completed,Has Results,Myopia|Hyperopia|Astigmatism,Device: fanfilcon A|Device: enfilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02423109
3939,Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism,Completed,Has Results,Astigmatism,Device: stenfilcon A toric lens|Device: etafilcon A toric lens,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/15/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02410824
3940,A Study of Ixekizumab in Participants With Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: Drug Cocktail|Drug: Ixekizumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/22/2016,11/21/2017,https://ClinicalTrials.gov/show/NCT02993471
3941,Acceptance & Tolerance Study of Multifocal Contact Lenses by Functional Emmetropes,Completed,Has Results,Vision Correction,Device: Multifocal Test Contact lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/1/2015,9/1/2015,https://ClinicalTrials.gov/show/NCT02394925
3942,A Study of Galcanezumab in Healthy Participants.,Completed,Has Results,Healthy,Biological: Galcanezumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/16/2019,11/9/2017,https://ClinicalTrials.gov/show/NCT02836613
3943,iNod System Human Feasibility Assessment,Completed,Has Results,"Solitary Pulmonary Nodule|Biopsy, Fine-Needle",Device: iNod System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,1/18/2017,6/14/2017,https://ClinicalTrials.gov/show/NCT02832284
3944,Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism,Completed,Has Results,Hypogonadism,Combination Product: Testosterone enanthate auto-injector,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 2,Industry,Interventional,6/16/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02777242
3945,Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function,Completed,Has Results,"Infections, Bacterial",Drug: Gepotidacin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,6/29/2016,6/20/2017,https://ClinicalTrials.gov/show/NCT02729038
3946,Usability of the CP950 Sound Processor,Completed,Has Results,Hearing Loss,Device: CP950 Sound Processor|Device: Wireless programming pod,Cochlear,Cochlear,,,,,,,Not Applicable,Industry,Interventional,4/16/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02727842
3947,Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines,Completed,Has Results,Glabellar Lines|Wrinkles,Device: Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Device: Dysport reconstituted at 2.5 mL (0.08 mL/injection),"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,4/16/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02718118
3948,Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Completed,Has Results,Keratoconjunctivitis Sicca,Drug: cyclosporine|Drug: vehicle of OTX-101,Sun Pharma Global FZE,Sun Pharma Global FZE,,,,,,,Phase 3,Industry,Interventional,2/16/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02688556
3949,Florbetapir Calibration to the Centiloid Scale,Completed,Has Results,Alzheimer's Disease,Drug: Florbetapir (18F)|Drug: 11C-PiB,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 1,Industry,Interventional,4/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02120664
3950,Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease,Completed,Has Results,Peripheral Arterial Disease,Device: RA-308 Excimer Laser and DABRA Catheter,Ra Medical Systems,Ra Medical Systems,,,,,,,Not Applicable,Industry,Interventional,4/7/2016,7/14/2017,https://ClinicalTrials.gov/show/NCT02653456
3951,Acute Treatment of Migraine With e-TNS,Completed,Has Results,Migraine,Device: CEFALY Active|Device: CEFALY Placebo,Cefaly Technology,Cefaly Technology,,,,,,,Not Applicable,Industry,Interventional,2/1/2016,3/31/2017,https://ClinicalTrials.gov/show/NCT02590939
3952,Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis,Completed,Has Results,Neuropathy of Sarcoidosis,Drug: ARA 290|Other: Placebo,"Araim Pharmaceuticals, Inc.","Araim Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,1/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02039687
3953,Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: T3D-959,"T3D Therapeutics, Inc.","T3D Therapeutics, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,7/15/2019,6/30/2016,https://ClinicalTrials.gov/show/NCT02560753
3954,A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants,Completed,Has Results,Healthy,Drug: Ixekizumab|Drug: Boostrix®|Drug: Pneumovax®23,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,9/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02543918
3955,A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,11/19/2013,5/14/2014,https://ClinicalTrials.gov/show/NCT01999322
3956,Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator,Completed,Has Results,Dry Eye Syndromes|Keratoconjunctivitis Sicca,Device: Intranasal Lacrimal Neurostimulator (Oculeve),"Oculeve, Inc.","Oculeve, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/31/2015,4/30/2016,https://ClinicalTrials.gov/show/NCT02526290
3957,Auto Bilevel Adherence Following a Poor Initial Encounter With Continuous Positive Airway Pressure (CPAP),Completed,Has Results,Obstructive Sleep Apnea,Device: CPAP|Device: Auto BiLevel,Philips Respironics|Mayo Clinic|Brigham and Women's Hospital,Philips Respironics,Mayo Clinic,Brigham and Women's Hospital,,,,,Not Applicable,Industry|Other,Interventional,8/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT02522442
3958,HEMOBLAST Pilot Clinical Investigation,Completed,Has Results,Hemostasis,Device: HEMOBLAST Bellows,Biom'Up SA,Biom'Up SA,,,,,,,Phase 1,Industry,Interventional,8/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02502019
3959,Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Pramlintide acetate|Drug: Placebo|Drug: Lispro insulin U-100|Drug: Regular insulin U-100,AstraZeneca|Juvenile Diabetes Research Foundation,AstraZeneca,Juvenile Diabetes Research Foundation,,,,,,Phase 1,Industry|Other,Interventional,8/17/2015,8/5/2016,https://ClinicalTrials.gov/show/NCT02500979
3960,Study of the Consumer Use of a New Home Test to Measure Sperm Concentration,Completed,Has Results,"Fertility, Male|Sub-Fertility, Male",Device: TRAK device,Sandstone Diagnostics,Sandstone Diagnostics,,,,,,,Not Applicable,Industry,Interventional,9/2/2015,11/15/2019,https://ClinicalTrials.gov/show/NCT02475395
3961,Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Using the SPRINT System,Completed,Has Results,Total Knee Replacement|Total Knee Arthroplasty|Pain|Postoperative Pain|Orthopedic Disorders,Device: SPRINT Peripheral Nerve Stimulation (PNS) System,"SPR Therapeutics, Inc.","SPR Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/22/2015,7/17/2017,https://ClinicalTrials.gov/show/NCT02468934
3962,Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain,Completed,Has Results,Moderate-to-severe Acute Pain,Drug: sufentanil sublingual 30 mcg tablet,"AcelRx Pharmaceuticals, Inc.|U.S. Army Medical Research and Development Command","AcelRx Pharmaceuticals, Inc.",U.S. Army Medical Research and Development Command,,,,,,Phase 3,Industry|U.S. Fed,Interventional,10/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02447848
3963,CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation,Completed,Has Results,Parkinson's Disease,Device: Vercise DBS settings,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,6/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01896115
3964,A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne,Completed,Has Results,Acne Vulgaris,Drug: Next Science Acne Gel|Drug: Vehicle,Next Science TM|Jacksonville Center For Clinical Research|St. Johns Center for Clinical Research|Fleming Island Center for Clinical Research,Next Science TM,Jacksonville Center For Clinical Research,St. Johns Center for Clinical Research|Fleming Island Center for Clinical Research,St. Johns Center for Clinical Research,Fleming Island Center for Clinical Research,,,Phase 1|Phase 2,Industry|Other,Interventional,3/15/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02404285
3965,Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents,Completed,Has Results,Hypoglycemia|Diabetes Mellitus,Drug: Nasal Glucagon,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/15/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02402933
3966,Coronary Flow Reserve Following Orbital Atherectomy,Completed,Has Results,Coronary Artery Disease,Device: Coronary Orbital Atherectomy plus Stenting,Cardiovascular Systems Inc,Cardiovascular Systems Inc,,,,,,,,Industry,Observational,2/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02339545
3967,Positive Airway Pressure Program,Completed,Has Results,"Sleep Apnea, Obstructive",Behavioral: Adherence program,Fisher and Paykel Healthcare,Fisher and Paykel Healthcare,,,,,,,Not Applicable,Industry,Interventional,2/15/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02331992
3968,A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage,Completed,Has Results,Healthy Volunteer,Drug: cobimetinib,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,8/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02300025
3969,Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery,Completed,Has Results,"Pain, Post-operative",Drug: Intranasal Dexmedetomidine|Drug: Intranasal Placebo,"Recro Pharma, Inc.|Lotus Clinical Research, LLC","Recro Pharma, Inc.","Lotus Clinical Research, LLC",,,,,,Phase 2,Industry|Other,Interventional,10/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02284243
3970,Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick,Completed,Has Results,"Keratosis, Actinic",Drug: Aminolevulinic Acid (ALA)|Device: BLU-U,"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,12/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02281136
3971,Bimatoprost for the Treatment of Eyebrow Hypotrichosis,Completed,Has Results,Eyebrow Hypotrichosis,Drug: bimatoprost solution|Drug: Vehicle to bimatoprost solution,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,3/13/2013,2/11/2014,https://ClinicalTrials.gov/show/NCT01765764
3972,Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Completed,Has Results,Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Drug: TH-302|Drug: Gemcitabine|Drug: Placebo (5 percent dextrose - D5W),Threshold Pharmaceuticals,Threshold Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/12/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01746979
3973,Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis,Completed,Has Results,Cystinosis,Drug: RP103,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 3,Industry,Interventional,12/20/2012,12/13/2016,https://ClinicalTrials.gov/show/NCT01744782
3974,Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease,Completed,Has Results,Aspirin Exacerbated Respiratory Disease (AERD),"Drug: Ifetroban, Oral Capsule|Drug: Placebo, Oral Capsule",Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,8/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02216357
3975,Pancreatic Juice Diagnosis From Duodenum,Completed,Has Results,Pancreatic Adenocarcinoma,Other: Tumor markers,"Olympus Corporation|Mayo Clinic|Kyushu University|The University of Texas Health Science Center, Houston",Olympus Corporation,Mayo Clinic,"Kyushu University|The University of Texas Health Science Center, Houston",Kyushu University,"The University of Texas Health Science Center, Houston",,,Not Applicable,Industry|Other,Interventional,10/12/2019,,https://ClinicalTrials.gov/show/NCT01699698
3976,"Reverse Medical Barrel™ Device for Adjunctive Treatment for Wide-Neck, Intracranial, Bifurcating/Branching Aneurysms",Completed,Has Results,Intracranial Bifurcating Aneurysms,Device: BARREL VRD,Medtronic Neurovascular Clinical Affairs,Medtronic Neurovascular Clinical Affairs,,,,,,,Not Applicable,Industry,Interventional,10/13/2014,7/21/2017,https://ClinicalTrials.gov/show/NCT02179190
3977,A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Albuterol/salbutamol|Drug: Ipratropium,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,7/23/2012,10/22/2012,https://ClinicalTrials.gov/show/NCT01691482
3978,A Study of Evacetrapib in Participants With Abnormal Cholesterol,Completed,Has Results,Dyslipidemia,Drug: Evacetrapib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,5/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02168803
3979,Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression,Completed,Has Results,Major Depressive Disorder (MDD),Device: NeoSync EEG Synchronization Therapy|Device: Sham NeoSync EEG Synchronization Therapy,"NeoSync, Inc.","NeoSync, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT01683019
3980,A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis,Completed,Has Results,"Kidney Failure, Chronic",Drug: LY3113593|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02144285
3981,PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers,Completed,Has Results,Hepatic Impairment|Liver Diseases|Digestive System Diseases,Drug: IDN-6556,Conatus Pharmaceuticals Inc.,Conatus Pharmaceuticals Inc.,,,,,,,Phase 1,Industry,Interventional,4/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02121860
3982,A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults,Completed,Has Results,Respiratory Syncytial Virus (RSV),Biological: Placebo|Biological: RSV sF 20 mcg|Biological: MEDI7510 (20 mcg RSV sF)|Biological: RSV sF 50 mcg|Biological: MEDI7510 (50 mcg RSV sF)|Biological: RSV sF 80 mcg|Biological: MEDI7510 (80 mcg RSV sF),MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,4/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02115815
3983,Effect of Denosumab on Cellular Biomarkers in the Human Breast,Completed,Has Results,"Healthy Volunteer, Female, Breast",Drug: Denosumab|Procedure: Percutaneous core needle breast biopsy,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,4/14/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT02099461
3984,Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm,Completed,Has Results,Diabetes Mellitus,Device: Continuous Glucose Monitoring,"DexCom, Inc.","DexCom, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT02087995
3985,Robotic Arm Assisted Total Knee Arthroplasty,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Post-traumatic Arthritis,Device: Robotic Arm Assisted Total Knee Arthroplasty,MAKO Surgical Corp.,MAKO Surgical Corp.,,,,,,,Not Applicable,Industry,Interventional,2/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02058069
3986,The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study,Completed,Has Results,Hearing Impairment,Device: Sound amplification provided via EarLens System.,EarLens Corporation,EarLens Corporation,,,,,,,Not Applicable,Industry,Interventional,3/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02042404
3987,Comparison of SomnaPatch With Polysomnography in Sleep Disordered Breathing,Completed,Has Results,Obstructive Sleep Apnea|Central Sleep Apnea|Mixed Sleep Apnea|Cheyne-Stokes Respiration,Device: SomnaPatch|Device: Polysomnography,Somnarus Inc,Somnarus Inc,,,,,,,Not Applicable,Industry,Interventional,2/1/2016,11/30/2016,https://ClinicalTrials.gov/show/NCT02034175
3988,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PL2200 Aspirin Capsules|Drug: Enteric-coated aspirin caplets,PLx Pharma,PLx Pharma,,,,,,,Phase 3,Industry,Interventional,1/14/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT02008942
3989,Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: FX006 10 mg|Drug: FX006 40 mg|Drug: TCA IR 40 mg,"Flexion Therapeutics, Inc.","Flexion Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,11/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT02003365
3990,Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.,Completed,Has Results,Renal Failure,Drug: LCP-Tacro|Drug: Tacrolimus -IR,Veloxis Pharmaceuticals,Veloxis Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01962922
3991,Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus,Completed,Has Results,Tinnitus,Device: VNS Treatment|Device: VNS Control,MicroTransponder Inc.|National Institute on Deafness and Other Communication Disorders (NIDCD),MicroTransponder Inc.,National Institute on Deafness and Other Communication Disorders (NIDCD),,,,,,Not Applicable,Industry|NIH,Interventional,2/14/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01962558
3992,InterStim® Sacral Nerve Modulation Cycling Study,Completed,Has Results,Urinary Urge Incontinence,Device: InterStim® (Device Programming),MedtronicNeuro,MedtronicNeuro,,,,,,,Not Applicable,Industry,Interventional,9/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01957137
3993,Patient Registry to Observe Outcomes Following Implantation of the VariLift Interbody Fusion Device,Completed,Has Results,"Prolapsed Lumbar Disc|Prolapsed Cervical Disc|Intervertebral Disc Degeneration|Spondylolisthesis, Grade 1|Intervertebral Disc Displacement",,Wenzel Spine,Wenzel Spine,,,,,,,,Industry,Observational,6/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01944345
3994,Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas,Completed,Has Results,Advanced Solid Tumors|Lymphoma,Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,7/16/2013,1/24/2017,https://ClinicalTrials.gov/show/NCT01898078
3995,"Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine",Completed,Has Results,Meningococcal Meningitis|Meningococcal Infections,Biological: Test Vaccine|Biological: US Licensed Vaccine,JN-International Medical Corporation,JN-International Medical Corporation,,,,,,,Phase 2,Industry,Interventional,7/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01897402
3996,Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK),Completed,Has Results,Fuchs' Dystrophy|Bullous Keratopathy,Drug: Prednisolone acetate|Drug: Fluorometholone,Price Vision Group,Price Vision Group,,,,,,,Phase 2,Industry,Interventional,10/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01448213
3997,Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film,Completed,Has Results,Pain,Drug: Buprenorphine|Drug: Placebo film|Drug: Oxycodone|Drug: Morphine sulfate|Drug: Placebo capsule,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 2,Industry,Interventional,6/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01871285
3998,PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-06291874|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,5/13/2013,3/1/2014,https://ClinicalTrials.gov/show/NCT01856595
3999,Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects,Completed,Has Results,Hepatic Failure|Hepatic Impairment|Chronic Hepatitis C Infection With Hepatic Coma,Drug: 2.0mg Buprenorphine/0.5mg Naloxone|Drug: Promethazine,Indivior Inc.,Indivior Inc.,,,,,,,Phase 4,Industry,Interventional,9/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01846455
4000,Comparison Study of the ICON™ CPAP Series With and Without SensAwake™,Completed,Has Results,Obstructive Sleep Apnea,Device: SensAwake On|Device: SensAwake Off,Fisher and Paykel Healthcare,Fisher and Paykel Healthcare,,,,,,,Not Applicable,Industry,Interventional,3/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01831258
4001,"Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis",Completed,Has Results,Psoriasis,Drug: MOL4239|Drug: Placebo,"Moleculin, LLC","Moleculin, LLC",,,,,,,Phase 2,Industry,Interventional,3/13/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01826201
4002,A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants,Completed,Has Results,Cardiovascular Disease,Drug: Evacetrapib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,4/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01825889
4003,Evaluation of the Spectra Optia PMN Cell Collection Procedure,Completed,Has Results,Granulocyte/ Polymorphonuclear Cells,Device: Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|Device: Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System),Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,2/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01805180
4004,"Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes,Drug: ITCA 650 (exenatide in DUROS),Intarcia Therapeutics,Intarcia Therapeutics,,,,,,,Phase 1,Industry,Interventional,2/9/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT01798264
4005,Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs),Completed,Has Results,Severe Hemophilia A,Biological: Human-cl rhFVIII,Octapharma,Octapharma,,,,,,,Phase 3,Industry,Interventional,6/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01341912
4006,Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery,Completed,Has Results,Arteriosclerosis of Coronary Artery Bypass Graft,Procedure: Minimally invasive coronary artery bypass graft surgery,Medtronic Cardiovascular,Medtronic Cardiovascular,,,,,,,Phase 4,Industry,Interventional,12/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01334866
4007,Ciprofloxacin BioThrax Co-Administration Study,Completed,Has Results,Anthrax,Biological: BioThrax|Drug: Ciprofloxacin,Emergent BioSolutions|Department of Health and Human Services,Emergent BioSolutions,Department of Health and Human Services,,,,,,Phase 2,Industry|U.S. Fed,Interventional,12/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01753115
4008,Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss,Completed,Has Results,Alopecia|Baldness,Drug: bimatoprost Formulation A|Drug: bimatoprost Formulation B|Drug: bimatoprost Formulation C|Drug: bimatoprost vehicle solution|Drug: minoxidil 2% solution,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01325350
4009,Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia,Completed,Has Results,"Alopecia|Alopecia, Androgenetic|Baldness",Drug: bimatoprost Formulation A|Drug: bimatoprost Formulation B|Drug: bimatoprost Formulation C|Drug: bimatoprost vehicle solution|Drug: minoxidil 5% solution,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01325337
4010,Powered Bone Marrow Aspiration and Core Biopsy System Compared to Manual Devices,Completed,Has Results,Bone Marrow Biopsy Procedures,Device: OnControl Bone Marrow Biopsy and Aspiration System|Device: Manual bone marrow sampling device,Vidacare Corporation,Vidacare Corporation,,,,,,,Not Applicable,Industry,Interventional,1/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01312519
4011,"To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes",Completed,Has Results,Obesity,Drug: GSK2890457|Drug: Metformin|Drug: Placebo|Drug: Liraglutide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,2/10/2013,9/12/2013,https://ClinicalTrials.gov/show/NCT01725126
4012,Evaluation of CooperVision Avaira Toric (Enfilcon A) Soft Contact Lens When Compared to Acuvue Advance Toric Soft Contact Lens,Completed,Has Results,Ametropia,Device: enfilcon A|Device: galyfilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Phase 4,Industry,Interventional,5/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01706770
4013,Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction,Drug: Placebo|Drug: Avanafil 100 mg|Drug: Avanafil 200 mg,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 4,Industry,Interventional,9/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01698684
4014,Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression,Completed,Has Results,Plaque Psoriasis,Drug: 122-0551,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,4/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01698333
4015,Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO,Completed,Has Results,Age-Related Macular Degeneration|Geographic Atrophy|Diabetic Retinopathy|Macular Edema|Retinal Vein Occlusion|Central Serous Retinopathy|Pattern Dystrophy of Macula|Epiretinal Membrane|Macular Hole,,"Optos, PLC|Johns Hopkins University|University of Southern California","Optos, PLC",Johns Hopkins University,University of Southern California,,,,,,Industry|Other,Observational,10/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01692938
4016,Jet Injection for Influenza,Completed,Has Results,"Influenza, Human",Biological: AFLURIA vaccine (2012-2013 formulation)|Device: Needle-Syringe|Device: Stratis needle-free injection device,"PharmaJet, Inc.","PharmaJet, Inc.",,,,,,,Phase 4,Industry,Interventional,10/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01688921
4017,Study of the Cabochon System for Improvement in the Appearance of Cellulite,Completed,Has Results,Gynoid Lipodystrophy,Device: Subcutaneous tissue release with the Cabochon System,"Cabochon Aesthetics, Inc.|Merz North America, Inc.","Cabochon Aesthetics, Inc.","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,8/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01671839
4018,Clinical Evaluation of an Investigational Soft Contact Lens,Completed,Has Results,Myopia,"Device: Delefilcon A contact lens|Device: Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Device: Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Device: Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)",CIBA VISION|Alcon Research,CIBA VISION,Alcon Research,,,,,,Not Applicable,Industry,Interventional,11/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01254747
4019,Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: bimatoprost ophthalmic solution 0.01%|Drug: travoprost ophthalmic solution 0.004%|Drug: latanoprost ophthalmic solution 0.005%,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01253902
4020,A Study of LY2608204 in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2608204,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01247363
4021,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (new formulation of insulin glargine)|Drug: Lantus (insulin glargine),Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,8/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01658579
4022,A Study of IMC-TR1 in Participants With Advanced Solid Tumors,Completed,Has Results,Neoplasms|Tumor,Biological: IMC-TR1,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01646203
4023,Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy,Completed,Has Results,Vitrectomy,Drug: 400 µg Brimonidine Tartrate Implant|Drug: 200 µg Brimonidine Tartrate Implant,Allergan,Allergan,,,,,,,Phase 1,Industry,Interventional,12/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01229410
4024,Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone,Completed,Has Results,Hepatitis C,Drug: BI 201335,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,8/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01637922
4025,The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms,Completed,Has Results,"Wide-neck, Saccular Intracranial Aneurysms",Device: Stent assisted coiling with the Liberty Stent,Penumbra Inc.,Penumbra Inc.,,,,,,,Not Applicable,Industry,Interventional,9/12/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01636453
4026,Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders,Completed,Has Results,"Sleep Disordered Breathing|Sleep Apnea, Central",Device: BiPAP auto Advanced|Device: BiPAP auto SV4,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01626989
4027,POCone-UBiT-IR300 Pediatric Comparison Study,Completed,Has Results,Bacterial Infection Due to Helicobacter Pylori (H. Pylori),Other: Pranactin citric solution,Otsuka America Pharmaceutical,Otsuka America Pharmaceutical,,,,,,,Phase 4,Industry,Interventional,7/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01623154
4028,A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis,Completed,Has Results,Psoriasis|Plaque Psoriasis,Drug: Halobetasol Propionate Lotion 0.05%|Drug: Placebo,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,11/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01610596
4029,Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia (HPP),Biological: Asfotase Alfa,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,4/10/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01203826
4030,Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL,Completed,Has Results,Cataract,Drug: Dexamethasone Phosphate Ophthalmic|Drug: 100 mM Sodium Citrate Buffer,"Eyegate Pharmaceuticals, Inc.","Eyegate Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,5/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01602068
4031,Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial,Completed,Has Results,Tricuspid Valve Regurgitation|Tricuspid Valve Insufficiency,Device: Contour 3D® implant for tricuspid valve repair|Device: Tri-Ad® implant for tricuspid valve repair,Medtronic Cardiovascular,Medtronic Cardiovascular,,,,,,,,Industry,Observational,5/12/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01585779
4032,A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers,Completed,Has Results,Alzheimer Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 1,Industry,Interventional,3/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT01565330
4033,A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers,Completed,Has Results,Alzheimer Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Early Phase 1,Industry,Interventional,6/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT01565291
4034,A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers,Completed,Has Results,Healthy,Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Biological: TDV New Formulation|Drug: Placebo|Drug: New Formulation Placebo,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,2/1/2012,1/10/2014,https://ClinicalTrials.gov/show/NCT01542632
4035,Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine,Completed,Has Results,Migraine,Device: n-VNS,ElectroCore INC,ElectroCore INC,,,,,,,Not Applicable,Industry,Interventional,2/12/2019,7/25/2012,https://ClinicalTrials.gov/show/NCT01532830
4036,Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device,Completed,Has Results,Asthma,Device: AlphaCore,ElectroCore INC,ElectroCore INC,,,,,,,Not Applicable,Industry,Interventional,1/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01532817
4037,Efficacy Of PF-05089771 In Treating Postoperative Dental Pain,Completed,Has Results,Postoperative Dental Pain,Drug: PF-05089771|Other: Placebo|Drug: Ibuprofen,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/12/2011,6/25/2012,https://ClinicalTrials.gov/show/NCT01529346
4038,A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504,Completed,Has Results,Retraction of Colostomy,Drug: IV morphine sulfate or Sponsor-approved equivalent|Drug: EXPAREL,"Pacira Pharmaceuticals, Inc|Registrat-Mapi","Pacira Pharmaceuticals, Inc",Registrat-Mapi,,,,,,Phase 4,Industry|Other,Interventional,1/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01509807
4039,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,Completed,Has Results,Unresectable or Metastatic Hepatocellular Carcinoma (HCC),Drug: MEDI-573 (1 of 3 doses)|Drug: Sorafenib,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,1/17/2012,4/9/2013,https://ClinicalTrials.gov/show/NCT01498952
4040,"A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage",Completed,Has Results,Bowel Incontinence,Device: Renew Insert,Renew Medical,Renew Medical,,,,,,,Not Applicable,Industry,Interventional,12/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01475474
4041,"First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors",Completed,Has Results,Advanced Solid Tumors,Drug: AG-013736,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,11/2/2019,8/4/2019,https://ClinicalTrials.gov/show/NCT01469052
4042,Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK),Completed,Has Results,"Keratosis, Actinic",Drug: Aminolevulinic Acid PDT (ALA)|Drug: Vehicle PDT (VEH),"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,11/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01458587
4043,Mucin Balls and Corneal Inflammation Events,Completed,Has Results,Corneal Inflammation|Corneal Infiltrative Events,Device: lotrafilcon A|Device: comfilcon A|Device: balafilcon A|Other: etafilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,9/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01437319
4044,A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol,Completed,Has Results,Hyperlipidemia,Drug: LY3015014 IV|Drug: Placebo IV|Drug: LY3015014 SC|Drug: Placebo SC,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,9/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01426412
4045,Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children,Completed,Has Results,Eyelash Hypotrichosis|Alopecia Areata,Drug: bimatoprost ophthalmic solution 0.03%|Drug: Vehicle Sterile Solution,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,6/1/2010,11/30/2012,https://ClinicalTrials.gov/show/NCT01023841
4046,A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: LY2189265|Drug: Sitagliptin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,8/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01408888
4047,A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-05175157 or Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01396161
4048,Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma,Completed,Has Results,Hodgkin Lymphoma,Drug: Idelalisib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,9/11/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01393106
4049,Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures,Completed,Has Results,Heart Failure,Drug: Diuretics,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Phase 2,Industry,Interventional,6/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01370564
4050,Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation,Completed,Has Results,Mid-facial Volume Deficit Related to Aging,Device: Juvéderm® VOLUMA XC,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,8/9/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00978042
4051,Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive|Airflow Obstruction, Chronic|Chronic Obstructive Airway Disease|Chronic Obstructive Lung Disease",Device: Noninvasive Open Ventilation System,"Breathe Technologies, Inc.","Breathe Technologies, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01355978
4052,Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients,Completed,Has Results,Myelofibrosis,Drug: Ruxolitinib,Incyte Corporation,Incyte Corporation,,,,,,,Phase 2,Industry,Interventional,3/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01340651
4053,Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence,Completed,Has Results,Urinary Incontinence,Drug: UISH001|Drug: matching placebo,"Beech Tree Labs, Inc.|Norwich Clinical Research Associates Ltd.","Beech Tree Labs, Inc.",Norwich Clinical Research Associates Ltd.,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,4/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01340066
4054,Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia (HPP),Biological: asfotase alfa,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,9/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00952484
4055,Acute Pain Study Following Bunionectomy,Completed,Has Results,Pain,Drug: Hydrocodone/Acetaminophen Extended Release|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,4/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01333722
4056,Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®,Completed,Has Results,Hunter Syndrome,Behavioral: Neurobehavioral testing|Other: Visual and auditory assessments,Shire,Shire,,,,,,,,Industry,Observational,7/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00937794
4057,A Study of the Effect of LY2189265 on Two Blood Pressure Drugs,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: LY2189265|Drug: Metoprolol|Drug: Lisinopril|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,3/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01324388
4058,Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty,Completed,Has Results,"Osteoarthritis, Knee",Other: Custom Patient Instrumentation|Other: Conventional Instruments,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,5/1/2010,8/1/2013,https://ClinicalTrials.gov/show/NCT01301950
4059,A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects,Completed,Has Results,Schizophrenia,Drug: OPC-34712,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 1,Industry,Interventional,12/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01299454
4060,A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients,Completed,Has Results,Type 2 Diabetes Patients,Drug: PF-04620110|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/11/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01298518
4061,Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Completed,Has Results,Overactive Bladder,Biological: onabotulinumtoxinA|Drug: normal saline,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,9/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00910845
4062,Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin,Completed,Has Results,Hypotrichosis,Drug: Bimatoprost 0.03% solution|Drug: Vehicle solution,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,8/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00907426
4063,Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring Patients by Practicing Clinicians,Completed,Has Results,Pregnancy - Labor Monitoring,,"Reproductive Research Technologies, LP","Reproductive Research Technologies, LP",,,,,,,,Industry,Observational,8/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT01282723
4064,Comparison of SureCALL® EMG Labor Monitor® and Tocodynamometer to Intrauterine Pressure Catheter Measurement (IUPC) Measurement in Pregnant Women,Completed,Has Results,Pregnancy - Labor Monitoring,,"Reproductive Research Technologies, LP","Reproductive Research Technologies, LP",,,,,,,,Industry,Observational,8/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT01282710
4065,"Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults",Completed,Has Results,Bacillus Anthracis (Anthrax) Infection,Biological: BioThrax|Biological: AV7909 Formulation 1|Biological: AV7909 Formulation 2|Biological: AV7909 Formulation 3|Biological: AV7909 Formulation 4|Drug: Control,Emergent BioSolutions|National Institute of Allergy and Infectious Diseases (NIAID)|Department of Health and Human Services,Emergent BioSolutions,National Institute of Allergy and Infectious Diseases (NIAID),Department of Health and Human Services,,,,,Phase 1,Industry|NIH|U.S. Fed,Interventional,12/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01263691
4066,A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms,Completed,Has Results,Anti-biotic Resistance,Drug: moxifloxacin 0.5% HCI ophthalmic solution|Drug: gatifloxacin ophthalmic solution 0.3%,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,3/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00874887
4067,The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease,Completed,Has Results,Coronary Artery Disease,Drug: Prasugrel|Drug: Clopidogrel,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 4,Industry,Interventional,11/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01260584
4068,Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg,Completed,Has Results,Asthma,Drug: Formatris 24µg|Drug: Formatris 12µg|Drug: Foradil P 24µg|Drug: Foradil P 12µg,"MEDA Pharma GmbH & Co. KG|ClinResearch, GmbH|Trio Clinical Research, LLC, Raleigh, USA|NuCara Pharmacy, Waterloo, USA|Prof. Hochhaus, Gainesville, USA",MEDA Pharma GmbH & Co. KG,"ClinResearch, GmbH","Trio Clinical Research, LLC, Raleigh, USA|NuCara Pharmacy, Waterloo, USA|Prof. Hochhaus, Gainesville, USA","Trio Clinical Research, LLC, Raleigh, USA","NuCara Pharmacy, Waterloo, USA|Prof. Hochhaus, Gainesville, USA","NuCara Pharmacy, Waterloo, USA","Prof. Hochhaus, Gainesville, USA",Phase 2,Industry|Other,Interventional,12/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01256086
4069,Efficacy of an Intranasal Testosterone Product,Completed,Has Results,Hypogonadism,"Drug: 10.0 mg of Testosterone, 4.0% TID|Drug: 13.5 mg of Testosterone, 4.5% B.I.D|Drug: 11.25 mg of Testosterone, 4.5% T.I.D",Acerus Pharmaceuticals Corporation,Acerus Pharmaceuticals Corporation,,,,,,,Phase 2,Industry,Interventional,8/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01252745
4070,Study of ACUVUE® ADVANCE® PLUS Contact Lenses.,Completed,Has Results,Myopia,Device: Acuvue Advance Plus prePQ|Device: Acuvue Advance Plus postPQ,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/10/2019,,https://ClinicalTrials.gov/show/NCT01244893
4071,A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Placebo|Drug: NVA237,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,2/9/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00856193
4072,A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing,Completed,Has Results,Gingivitis,Device: Experimental Floss,Procter and Gamble,Procter and Gamble,,,,,,,Phase 4,Industry,Interventional,1/9/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00855933
4073,ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection,Completed,Has Results,Lung Cancer,Device: ENDO GIA™ Stapler with TRI-STAPLE™ Technology,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,11/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01241565
4074,A Study of LY2216684 in Participants With Impaired Hepatic Function,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01241435
4075,A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma,Completed,Has Results,Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma,Drug: panobinostat|Drug: lenalidomide,Ohio State University Comprehensive Cancer Center|Celgene|Novartis,Ohio State University Comprehensive Cancer Center,Celgene,Novartis,,,,,Phase 2,Other|Industry,Interventional,10/13/2011,11/16/2016,https://ClinicalTrials.gov/show/NCT01460940
4076,Pilot Dispensing Evaluation of a Plus Power Lens,Completed,Has Results,Hyperopia,Device: Acuvue Advance Plus|Device: Acuvue Advance,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01228591
4077,Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.,Completed,Has Results,Healthy,Drug: Cefadroxil 500 mg Capsules|Drug: DURICEF® capsules 500 mg,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/4/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00835081
4078,Famciclovir 500 mg Tablets Under Non-Fasting Conditions,Completed,Has Results,Healthy,Drug: Famciclovir 500 mg Tablets|Drug: Famvir® 500 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,8/4/2019,9/4/2019,https://ClinicalTrials.gov/show/NCT00834444
4079,Famciclovir 500 mg Tablets Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Famciclovir 500 mg Tablets|Drug: Famvir® 500 mg Tablets,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,8/4/2019,9/4/2019,https://ClinicalTrials.gov/show/NCT00834431
4080,Cefadroxil 500 mg Capsules Under Fasting Conditions,Completed,Has Results,Healthy,Drug: Cefadroxil 500 mg Capsules|Drug: DURICEF® capsules 500 mg,Teva Pharmaceuticals USA,Teva Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,9/4/2019,10/4/2019,https://ClinicalTrials.gov/show/NCT00834275
4081,Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants,Completed,Has Results,Human Immunodeficiency Virus Type 1 (HIV-1)|HIV Infections,Drug: Voriconazole|Drug: Atazanavir|Drug: Ritonavir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,9/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00833482
4082,Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing,Completed,Has Results,Inflammation|Burns|Ulcers,Device: Mepilex Border Ag,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Phase 3,Industry,Interventional,9/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01214811
4083,A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists,Completed,Has Results,Solid Cancers,Drug: Vismodegib|Drug: Rosiglitazone|Drug: Norethindrone/ethinyl estradiol,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,11/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01209143
4084,Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction,Completed,Has Results,Chalazion|Dry Eye Syndromes,Device: LipiFlow System,"TearScience, Inc.","TearScience, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,9/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01202747
4085,Bipap Automatic Servo Ventilation (autoSV) Advanced in Central Apnea Patients,Completed,Has Results,"Cheyne-Stokes Respiration|Sleep Apnea, Central",Device: BiPAP autoSV Advanced,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,9/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01199042
4086,Pilot Evaluation of a New Galyfilcon A Lens Prototype and Enfilcon A Lens,Completed,Has Results,Myopia,Device: galyfilcon A prototype lens|Device: enfilcon A lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/10/2019,,https://ClinicalTrials.gov/show/NCT01192542
4087,Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema|Vitrectomy,Drug: Dexamethasone,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,1/1/2009,12/1/2009,https://ClinicalTrials.gov/show/NCT00799227
4088,Comparison of Breathing Event Detection by a Continuous Positive Airway Pressure Device to Clinical Polysomnography,Completed,Has Results,Sleep Apnea Central|Cheyne-Stokes Respiration|Obstructive Sleep Apnea,Other: Manipulation of Positive Airway Pressure (PAP),Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,9/10/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01175031
4089,Bivalent Norovirus Vaccine Study,Completed,Has Results,Gastroenteritis,Biological: NoV GI.1/GII.4 Bivalent VLP Vaccine|Biological: Saline,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,9/3/2010,1/9/2013,https://ClinicalTrials.gov/show/NCT01168401
4090,A Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting Intraocular Lenses (IOLs),Completed,Has Results,Cataract,Device: ReSTOR +3|Device: Tecnis MF,Alcon Research,Alcon Research,,,,,,,Phase 4,Industry,Interventional,7/10/2019,,https://ClinicalTrials.gov/show/NCT01166971
4091,Pediatric Nasal Mask Usability Study,Completed,Has Results,Obstructive Sleep Apnea,Device: Pixi pediatric mask,ResMed,ResMed,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01154322
4092,Clinical Study to Examine Brushing on Dental Implants,Completed,Has Results,Gingival Diseases,"Drug: Fluoride|Drug: Triclosan, fluoride",Colgate Palmolive,Colgate Palmolive,,,,,,,Phase 3,Industry,Interventional,4/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00762619
4093,"A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function",Completed,Has Results,Pneumonia,"Drug: CP-70,429 and PF-03709270",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,11/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00759564
4094,Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population,Completed,Has Results,Psoriasis|Atopic Dermatitis,Drug: Pandel Cream 0.1%,Fougera Pharmaceuticals Inc.,Fougera Pharmaceuticals Inc.,,,,,,,Phase 4,Industry,Interventional,6/4/2019,8/5/2019,https://ClinicalTrials.gov/show/NCT01137032
4095,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Completed,Has Results,Perennial Allergic Rhinitis,Drug: Placebo Nasal Aerosol|Drug: Prednisone capsules|Drug: Placebo Prednisone Capsules|Drug: Beclomethasone dipropionate,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,6/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01133626
4096,A Study of IMC-RON8 in Advanced Solid Tumors,Completed,Has Results,Cancer,Biological: IMC-RON8,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,5/10/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01119456
4097,Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|Drug: timolol maleate 0.5%|Drug: latanoprost 0.005%,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,7/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00735449
4098,An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor,Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Device: Sensor wear,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01112696
4099,Optimization and Refinement of Technique in In-Office Sinus Dilation 2,Completed,Has Results,Sinusitis,Device: Relieva Balloon Sinuplasty System,Acclarent,Acclarent,,,,,,,,Industry,Observational,4/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01107379
4100,"A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors",Completed,Has Results,Neoplasm,Drug: PF-00337210,"Pfizer|University of Wisconsin, Madison",Pfizer,"University of Wisconsin, Madison",,,,,,Phase 1,Industry|Other,Interventional,5/6/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01105533
4101,A Clinical Study to Assess the Safety of a New Influenza Vaccine,Completed,Has Results,Healthy,Biological: Monovalent Frozen FluMist®|Other: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 4,Industry,Interventional,5/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01104493
4102,Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men,Completed,Has Results,Hypogonadism,Drug: Testerone Transdermal System,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,4/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01104246
4103,"MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer",Completed,Has Results,Breast Neoplasms,Drug: MM-111 + Herceptin,Merrimack Pharmaceuticals,Merrimack Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,4/10/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01097460
4104,The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Colesevelam HCl|Drug: Sitagliptin,KineMed,KineMed,,,,,,,Not Applicable,Industry,Interventional,3/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01092663
4105,Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Nitric Oxide generated by the GeNO nitrosyl delivery system,Geno LLC,Geno LLC,,,,,,,Phase 2,Industry,Interventional,10/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01092559
4106,"Study on ASTRA TECH Implant System, OsseoSpeed™ Implants in Patients Missing All Teeth in the Upper Jaw, Restored With Provisional Teeth Within 24 Hours",Completed,Has Results,"Jaw, Edentulous","Device: ASTRA TECH Implant System, OsseoSpeed™, all dimensions.",Dentsply Sirona Implants,Dentsply Sirona Implants,,,,,,,Not Applicable,Industry,Interventional,5/5/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00711022
4107,Evaluation of PillCam® Express Capsule Endoscopy Delivery System,Completed,Has Results,Small Bowel Disease|Inflammatory Bowel Disease,Device: PillCam® Express Capsule Endoscopy Delivery System,Given Imaging Ltd.,Given Imaging Ltd.,,,,,,,Not Applicable,Industry,Interventional,10/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01088646
4108,Oxygen Saturation Alarms in the Neonatal Intensive Care Unit,Completed,Has Results,Hypoxemia,,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,1/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01085539
4109,Oxygen Monitoring of Patients After Surgery on the Hospital General Care Floor,Completed,Has Results,Sleep Disordered Breathing,Device: Oxygen Monitoring,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,2/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01082575
4110,Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy,Completed,Has Results,"Glaucoma, Open-Angle",Drug: 400 ug Brimonidine Implant|Drug: 200 ug Brimonidine Implant|Drug: Sham (no implant),Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,9/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00693485
4111,Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence,Completed,Has Results,Eyelashes,Drug: Bimatoprost 0.03% sterile solution|Drug: vehicle sterile solution,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,4/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00693420
4112,Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults,Completed,Has Results,Influenza,Biological: GSK Biologicals' FluLaval®|Biological: Placebo (saline)|Biological: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Biological: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,2/9/2010,10/21/2011,https://ClinicalTrials.gov/show/NCT01059617
4113,"A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: PF-04937319,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/10/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01044537
4114,"Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study",Completed,Has Results,Psoriasis,Drug: Desoximetasone 0.25% spray,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,2/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01043393
4115,Vistakon Investigational Lens Worn as a Single Use Daily Wear,Completed,Has Results,Myopia,Device: narafilcon B|Device: etafilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/1/2009,12/1/2009,https://ClinicalTrials.gov/show/NCT01031004
4116,Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response,Completed,Has Results,Contact Dermatitis,Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens,Allerderm,Allerderm,,,,,,,Phase 2,Industry,Interventional,4/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00640250
4117,"Treatment of Androgenetic Alopecia in Females, 12 Beam",Completed,Has Results,Androgenetic Alopecia|Hair Loss|Female Pattern Baldness,Device: HairMax LaserComb 2009 model 12 beam|Device: Sham Device,"Lexington International, LLC","Lexington International, LLC",,,,,,,Not Applicable,Industry,Interventional,1/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01016964
4118,"Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)",Completed,Has Results,Impetigo|Secondarily Infected Traumatic Lesions,Drug: TD1414 2% cream|Drug: Bactroban® (mupirocin) 2% cream,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,2/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00626795
4119,Abiraterone Post Ketoconazole for Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Abiraterone acetate,"University of California, San Francisco|Johnson & Johnson|Cougar Biotechnology, Inc.","University of California, San Francisco",Johnson & Johnson,"Cougar Biotechnology, Inc.",,,,,Phase 2,Other|Industry,Interventional,9/10/2010,3/14/2016,https://ClinicalTrials.gov/show/NCT01199146
4120,Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age,Completed,Has Results,Influenza,Biological: VAX125,VaxInnate Corporation,VaxInnate Corporation,,,,,,,Phase 2,Industry,Interventional,9/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00966238
4121,Treatment of Androgenic Alopecia in Males,Completed,Has Results,Androgenetic Alopecia|Hair Loss|Male Pattern Baldness,Device: HairMax LaserComb|Device: Control device,"Lexington International, LLC","Lexington International, LLC",,,,,,,Not Applicable,Industry,Interventional,7/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00947219
4122,Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC),Completed,Has Results,Metastatic Non-squamous Non Small Cell Lung Cancer,Drug: CBP501 + Cisplatin + Pemetrexed|Drug: Cisplatin + Pemetrexed,CanBas Co. Ltd.,CanBas Co. Ltd.,,,,,,,Phase 2,Industry,Interventional,4/9/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00942825
4123,Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain,Completed,Has Results,Dental Pain,Drug: Oxycodone|Drug: Buprenorphine|Drug: Placebo Film|Drug: Placebo Capsule,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 2,Industry,Interventional,8/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00941304
4124,Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction,Completed,Has Results,Pain,Drug: ABT-712 Extended-release|Drug: Hydrocodone/Acetaminophen Immediate-release|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,6/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00935311
4125,Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer,Completed,Has Results,Metastatic Colorectal Cancer,Drug: OSI-906|Drug: Everolimus,"SCRI Development Innovations, LLC|Novartis Pharmaceuticals|OSI Pharmaceuticals","SCRI Development Innovations, LLC",Novartis Pharmaceuticals,OSI Pharmaceuticals,,,,,Phase 1,Other|Industry,Interventional,7/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01154335
4126,Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair,Completed,Has Results,Asthma,"Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg",Sandoz,Sandoz,,,,,,,Phase 2,Industry,Interventional,6/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00927758
4127,Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI,Completed,Has Results,Facial Wrinkles,Device: Belotero®,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00922623
4128,Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease,Completed,Has Results,Sickle Cell Disease,Drug: GMI-1070,Pfizer,Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,5/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00911495
4129,"Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246",Completed,Has Results,Orthopoxviral Disease,Drug: ST-246 400 mg|Drug: ST-246 600 mg|Drug: Placebo,SIGA Technologies|National Institutes of Health (NIH),SIGA Technologies,National Institutes of Health (NIH),,,,,,Phase 2,Industry|NIH,Interventional,6/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00907803
4130,Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Ofatumumab|Drug: Lenalidomide,Medical University of South Carolina|GlaxoSmithKline|Celgene Corporation,Medical University of South Carolina,GlaxoSmithKline,Celgene Corporation,,,,,Phase 2,Other|Industry,Interventional,5/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01123356
4131,A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars,Completed,Has Results,Scar Prevention|Scar Reduction,Drug: AZX100 Drug Product|Drug: Placebo,Capstone Therapeutics,Capstone Therapeutics,,,,,,,Phase 2,Industry,Interventional,5/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00892723
4132,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Completed,Has Results,Bacterial Conjunctivitis,Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,2/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00518089
4133,Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects,Completed,Has Results,Asthma,Drug: FP|Drug: SFC|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,8/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00517634
4134,A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine,Completed,Has Results,Healthy,Biological: Monovalent influenza virus vaccine|Biological: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 4,Industry,Interventional,5/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00873912
4135,Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH),Completed,Has Results,"Hemoglobinuria, Paroxysmal",Drug: Eculizumab,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,10/2/2009,5/12/2011,https://ClinicalTrials.gov/show/NCT00867932
4136,An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance,Completed,Has Results,Diabetes,Device: MMT-7003 subcutaneous glucose sensor,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,3/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00865345
4137,"An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement",Completed,Has Results,"Pain, Postoperative",Drug: Sufentanil NanoTab PCA System/15 mcg,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,4/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00859313
4138,Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease,Completed,Has Results,Gastroesophageal Reflux,Drug: Dexlansoprazole MR,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,5/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00847210
4139,Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Lenalidomide|Drug: ofatumumab,University of Nebraska|Celgene Corporation|GlaxoSmithKline,University of Nebraska,Celgene Corporation,GlaxoSmithKline,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/10/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT01060384
4140,Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo,"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",AstraZeneca,"Astra Zeneca, Bristol-Myers Squibb",,,,,,Phase 2,Industry|Other,Interventional,4/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00831779
4141,Staccato Loxapine in Migraine (Out Patient),Completed,Has Results,Migraine Headache,Drug: Inhaled Placebo|Drug: Inhaled Loxapine 1.25 mg|Drug: Inhaled Loxapine 2.5 mg,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,1/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00825500
4142,Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Dexamethasone|Drug: Sham injection|Procedure: Laser Photocoagulation,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,5/1/2007,2/8/2010,https://ClinicalTrials.gov/show/NCT00464685
4143,Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults,Completed,Has Results,Influenza,Biological: Influenza A Vaccine: ACAM FLU-A|Biological: Saline placebo,Sanofi,Sanofi,,,,,,,Phase 1,Industry,Interventional,7/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00819013
4144,A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis,Completed,Has Results,Bacterial Conjunctivitis,Drug: gatifloxacin|Drug: moxifloxacin 0.5% eye drops,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,6/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00464438
4145,Prometra's Utilization in Mitigating Pain (PUMP),Completed,Has Results,Intractable Pain,Device: Infusion Pump (Prometra),Flowonix Medical,Flowonix Medical,,,,,,,Not Applicable,Industry,Interventional,1/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00817596
4146,"Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.",Completed,Has Results,Congenital Venous Malformation,Drug: Ethanol 96% Gel|Drug: Ethanol 98% Solution,Orfagen|FDA Office of Orphan Products Development,Orfagen,FDA Office of Orphan Products Development,,,,,,Phase 2,Industry|U.S. Fed,Interventional,5/7/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00462462
4147,A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available,Completed,Has Results,Advanced Solid Tumors,Biological: IMC-A12,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,10/5/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00785538
4148,A Multi-Center Study to Assess the Performance of Saturation Patterns.,Completed,Has Results,Sleep-Disordered Breathing|Obstructive Sleep Apnea|Sleep Apnea|Central Sleep Apnea,,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,8/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00775346
4149,Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors,Completed,Has Results,Solid Tumors,Drug: PF-03814735,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,11/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00424632
4150,Traveler's Diarrhea (TD) Automated Process,Completed,Has Results,Prevention of Travelers' Diarrhea,Biological: heat-labile enterotoxin of E. coli (LT)|Biological: Placebo,"Intercell USA, Inc.","Intercell USA, Inc.",,,,,,,Phase 2,Industry,Interventional,9/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00751777
4151,Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients,Completed,Has Results,"Leukaemia, Lymphocytic, Chronic",Drug: Ofatumumab 500mg|Drug: Ofatumumab 1000mg|Drug: Fludarabine|Drug: Cyclophosphamide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,1/7/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00410163
4152,Study of the ENTact Septal Staple System for Tissue Approximation During Septoplasty,Completed,Has Results,Nasal Septum,,"ENTrigue Surgical, Inc.","ENTrigue Surgical, Inc.",,,,,,,,Industry,Observational,4/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00740480
4153,Study of Low Level Laser Therapy for Body Contouring,Completed,Has Results,Body Contouring,Device: Erchonia ML Scanner (MLS)|Device: Sham device,Erchonia Corporation,Erchonia Corporation,,,,,,,Not Applicable,Industry,Interventional,10/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00738426
4154,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm,Completed,Has Results,Blepharospasm,Drug: incobotulinumtoxinA (Xeomin)|Drug: Placebo,Merz Pharmaceuticals GmbH,Merz Pharmaceuticals GmbH,,,,,,,Phase 3,Industry,Interventional,10/6/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00406367
4155,Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED),Completed,Has Results,Erectile Dysfunction,Device: Inflatable Penile Prosthesis,Coloplast A/S,Coloplast A/S,,,,,,,Not Applicable,Industry,Interventional,12/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00731666
4156,Validation of TearLab Osmometer - Human Factor Usability Report,Completed,Has Results,Dry Eye Syndromes,,TearLab Corporation,TearLab Corporation,,,,,,,,Industry,Observational,7/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00731484
4157,Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.,Completed,Has Results,Toothache,Drug: Naproxen Sodium ER (BAYH6689)|Drug: Placebo,Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,6/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00720057
4158,A Preference Study Comparing Kristalose® and Liquid Lactulose,Completed,Has Results,Constipation,Drug: lactulose (Kristalose®)|Drug: liquid lactulose,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,6/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00712543
4159,"Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)",Completed,Has Results,Acute HIV Infection|HIV Infections,"Drug: efavirenz, emtricitabine, and tenofovir","University of North Carolina, Chapel Hill|Bristol-Myers Squibb|Gilead Sciences","University of North Carolina, Chapel Hill",Bristol-Myers Squibb,Gilead Sciences,,,,,Phase 4,Other|Industry,Interventional,1/5/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00924898
4160,Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System: A Pilot Study,Completed,Has Results,Low Back Pain,Biological: Biostat® Disc Augmentation System,"Spinal Restoration, Inc.","Spinal Restoration, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00693784
4161,Phase 2 Study in Adults Sensitized to Cat,Completed,Has Results,Allergy,"Biological: Standardized Allergenic Extract, Cat Hair|Biological: Placebo","Antigen Laboratories, Inc.","Antigen Laboratories, Inc.",,,,,,,Phase 2,Industry,Interventional,10/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00689299
4162,"Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults",Completed,Has Results,Typhoid,Biological: Dose of 5.0 x 10^9 CFU (Cohort 1)|Biological: Dose of 7.5 x 10^9 CFU (Cohort 2)|Biological: Dose of 1.1 x 10^10 CFU (Cohort 3)|Biological: Dose of of 1.7 x 10^10 CFU (Cohort 4)|Other: Placebo (Cohorts 1-4 pooled),Emergent BioSolutions,Emergent BioSolutions,,,,,,,Phase 2,Industry,Interventional,5/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00679172
4163,A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine,Completed,Has Results,Influenza,Biological: Trivalent influenza virus vaccine|Biological: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 4,Industry,Interventional,6/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00677820
4164,A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants,Completed,Has Results,Infantile Colic|Infantile Functional Gastrointestinal Disorders,Drug: Nepadutant,Menarini Group,Menarini Group,,,,,,,Phase 1,Industry,Interventional,3/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00655083
4165,Vitamin D3 for Aromatase Inhibitor Induced Arthralgias,Completed,Has Results,Breast Cancer,Dietary Supplement: High Dose Vitamin D|Dietary Supplement: Placebo|Dietary Supplement: Standard Dose Vitamin D3|Drug: Letrozole 2.5mg,Qamar Khan|Novartis Pharmaceuticals|BTR Group|University of Kansas Medical Center,Qamar Khan,Novartis Pharmaceuticals,BTR Group|University of Kansas Medical Center,BTR Group,University of Kansas Medical Center,,,Phase 2,Other|Industry,Interventional,3/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00867217
4166,Safety and Tolerability of Buprenorphine/Naloxone Film Strips,Completed,Has Results,Opioid-Related Disorders,Drug: Buprenorphine/naloxone Film Strip,Indivior Inc.,Indivior Inc.,,,,,,,Phase 2,Industry,Interventional,2/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00640835
4167,A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg,Incyte Corporation,Incyte Corporation,,,,,,,Phase 2,Industry,Interventional,3/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00639002
4168,Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors,Completed,Has Results,Colorectal Neoplasms|Neoplasms,Drug: sunitinib + FOLFOX,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,9/5/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00599924
4169,Mechanisms of Glucose Lowering Effect of Colesevelam HCl,Completed,Has Results,Diabetes,Drug: Colesevelam HCL|Drug: Placebo,Carine Beysen|KineMed,Carine Beysen,KineMed,,,,,,Not Applicable,Industry,Interventional,11/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00596427
4170,OASIS Wound Matrix (Oasis) Mechanism of Action,Completed,Has Results,Diabetic Foot Ulcers (DFU)|Venous Stasis Ulcers (VSU),Device: OASIS Wound Matrix,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,10/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00570141
4171,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Completed,Has Results,Allergic Conjunctivitis,Device: K-Lens (generic name not established) and Ketotifen|Device: Placebo Lens,Vistakon Pharmaceuticals,Vistakon Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00569777
4172,An Implantable Microneuromodulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects,Completed,Has Results,Shoulder Pain Chronic,Device: Battery Powered Microneuromodulator (BBPM),Bioness Inc,Bioness Inc,,,,,,,Phase 2,Industry,Interventional,6/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00567541
4173,LT Vaccine Patch Self-Administration Study,Completed,Has Results,Prevention of Travelers' Diarrhea,Biological: heat-labile enterotoxin of E. coli (LT),"Intercell USA, Inc.","Intercell USA, Inc.",,,,,,,Phase 2,Industry,Interventional,11/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00565461
4174,Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients,Completed,Has Results,Kidney Transplantation,Drug: Rabbit Antithymocyte Globulin|Drug: Velcade|Drug: Rituxan,"University of Cincinnati|Millennium Pharmaceuticals, Inc.|Genzyme, a Sanofi Company",University of Cincinnati,"Millennium Pharmaceuticals, Inc.","Genzyme, a Sanofi Company",,,,,Phase 4,Other|Industry,Interventional,9/8/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00782821
4175,Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer,Completed,Has Results,Adenocarcinoma of the Prostate,Drug: IMC-A12 (Cixutumumab),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/7/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00520481
4176,Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI),Completed,Has Results,Cystic Fibrosis|Pancreatic Insufficiency,Drug: Ultrase® MT20,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,7/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00513682
4177,The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer,Completed,Has Results,Carcinoma|Non-Small-Cell Lung Carcinoma|Head and Neck Neoplasms,Drug: AZD2171,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,12/5/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00243347
4178,Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Post-traumatic Arthritis|Juvenile Arthritis,Device: Total knee arthroplasty,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,9/6/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00487565
4179,A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches,Completed,Has Results,Migraine Disorders,Biological: Botulinum Toxin Type A|Other: Placebo (saline),Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,2/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00156910
4180,Staccato Alprazolam in Panic Attack,Completed,Has Results,Treatment of Induced Panic Attack,Drug: Inhaled placebo|Drug: Inhaled alprazolam 1 mg|Drug: Inhaled alprazolam 2 mg|Drug: IV doxapram,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,5/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00477451
4181,Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer,Completed,Has Results,Prostate Neoplasms,Drug: Abiraterone acetate|Drug: prednisone/prednisolone or dexamethasone,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 1|Phase 2,Industry,Interventional,6/6/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00473746
4182,Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma,Completed,Has Results,Pheochromocytoma|Paraganglioma,Drug: Ultratrace Iobenguane (MIBG) I 131,"Molecular Insight Pharmaceuticals, Inc.","Molecular Insight Pharmaceuticals, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,4/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00458952
4183,"Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment",Completed,Has Results,Renal Impairment,Drug: plerixafor,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 1,Industry,Interventional,1/6/2019,8/7/2019,https://ClinicalTrials.gov/show/NCT00445302
4184,Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System,Completed,Has Results,Low Back Pain,Device: DRX9000™,"NEMA Research, Inc.","NEMA Research, Inc.",,,,,,,Phase 2,Industry,Interventional,12/6/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00414596
4185,Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Biological: Talimogene Laherparepvec,BioVex Limited,BioVex Limited,,,,,,,Phase 1,Industry,Interventional,11/6/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00402025
4186,A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo|Drug: Metformin (blinded)|Drug: Metformin (open-label),AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00374907
4187,Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myeloid Leukemia,Drug: Decitabine,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,3/5/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00358644
4188,Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects,Completed,Has Results,HIV Infections,Drug: VGX-410 (Mifepristone)|Drug: Placebo for VGX-410 (Mifepristone),"VGX Pharmaceuticals, LLC","VGX Pharmaceuticals, LLC",,,,,,,Phase 2,Industry,Interventional,7/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00352911
4189,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP),Completed,Has Results,Pneumonia,Drug: Cethromycin|Drug: Clarithromycin,"Advanced Life Sciences, Inc.","Advanced Life Sciences, Inc.",,,,,,,Phase 3,Industry,Interventional,12/5/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00336505
4190,"Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study",Completed,Has Results,Metastatic Malignant Melanoma,Drug: Avastin|Drug: Abraxane,"Lynn E. Spitler, MD|Celgene Corporation|Genentech, Inc.|Northern California Melanoma Center","Lynn E. Spitler, MD",Celgene Corporation,"Genentech, Inc.|Northern California Melanoma Center","Genentech, Inc.",Northern California Melanoma Center,,,Phase 2,Other|Industry,Interventional,4/7/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00462423
4191,Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients,Completed,Has Results,Obstructive Sleep Apnea Syndrome,Drug: Xyrem (X)|Drug: Zolpidem (Z)|Drug: Modafinil (M)|Drug: Placebo (P),Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,11/3/2019,11/5/2019,https://ClinicalTrials.gov/show/NCT00086281
4192,Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Other Inflammatory Arthritis|Post-Traumatic Arthritis|Juvenile Rheumatoid Arthritis|Avascular Necrosis,Device: Total Knee Arthroplasty|Device: Total knee replacement,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,4/1/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00289107
4193,"Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine",Completed,Has Results,Pertussis,"Biological: Tetanus Toxoid, acellular pertussis, diphtheria toxoid","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,,Industry,Observational,1/6/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00258882
4194,Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer,Completed,Has Results,Breast Cancer|Metastatic Breast Cancer,Drug: Lapatinib|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Pegfilgrastim|Drug: Filgrastim|Drug: Dexamethasone|Drug: Trastuzumab,George Albert Fisher|GlaxoSmithKline|Sanofi|Stanford University,George Albert Fisher,GlaxoSmithKline,Sanofi|Stanford University,Sanofi,Stanford University,,,Phase 2,Other|Industry,Interventional,10/6/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00404066
4195,Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung","Drug: Gemcitabine, Carboplatin, Bevacizumab","Masonic Cancer Center, University of Minnesota|Eli Lilly and Company|Genentech, Inc.","Masonic Cancer Center, University of Minnesota",Eli Lilly and Company,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,3/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00400803
4196,A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease,Completed,Has Results,Coronary Artery Disease|Heart Disease,Drug: Perflutren Lipid Microsphere Injectable Suspension,Lantheus Medical Imaging,Lantheus Medical Imaging,,,,,,,Phase 4,Industry,Interventional,4/4/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00162370
4197,Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.,Completed,Has Results,Solid Malignancies,Drug: Ixabepilone,R-Pharm,R-Pharm,,,,,,,Phase 1,Industry,Interventional,9/5/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00162136
4198,Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,Completed,Has Results,Acute Lymphoblastic Leukemia,Drug: Vincristine Sulfate Liposomes Injection|Drug: Dexamethasone,"Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",,,,,,,Phase 1|Phase 2,Industry,Interventional,7/2/2019,8/6/2019,https://ClinicalTrials.gov/show/NCT00144963
4199,Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients,Completed,Has Results,Colorectal Cancer,Drug: 5-Fluorouracil|Drug: Bevacizumab|Drug: Leucovorin|Drug: Irinotecan,"M.D. Anderson Cancer Center|Genentech, Inc.|Pfizer",M.D. Anderson Cancer Center,"Genentech, Inc.",Pfizer,,,,,Phase 2,Other|Industry,Interventional,1/5/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00354978
4200,Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers,Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Topotecan|Drug: Bevacizumab,"Benaroya Research Institute|GlaxoSmithKline|Genentech, Inc.",Benaroya Research Institute,GlaxoSmithKline,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,6/6/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00343044
4201,Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma,Completed,Has Results,"Carcinoma, Renal Cell",Drug: Gefitinib + Sunitinib,Pfizer,Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/4/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00113529
4202,Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer,Completed,Has Results,Cancer|Prostate Neoplasms,Drug: goserelin with dutasteride|Drug: goserelin with bicalutamide and dutasteride|Drug: goserelin with bicalutamide and dutasteride and ketoconazole,University of Washington|GlaxoSmithKline|AstraZeneca,University of Washington,GlaxoSmithKline,AstraZeneca,,,,,Phase 2,Other|Industry,Interventional,7/6/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00298155
4203,A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI),Completed,Has Results,Cardiovascular Diseases|Heart Diseases,Drug: Prasugrel (CS-747)|Drug: Clopidogrel,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/3/2019,1/4/2019,https://ClinicalTrials.gov/show/NCT00059215
4204,"Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma",Completed,Has Results,Non-Hodgkins Lymphoma,Drug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab,"SCRI Development Innovations, LLC|Genentech, Inc.|Amgen","SCRI Development Innovations, LLC","Genentech, Inc.",Amgen,,,,,Phase 2,Other|Industry,Interventional,4/3/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00193479
4205,Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer,Completed,Has Results,"Carcinoma, Non-small-cell Lung",Drug: erlotinib and bexarotene,"Konstantin Dragnev|Ligand Pharmaceuticals|Genentech, Inc.|Dartmouth-Hitchcock Medical Center",Konstantin Dragnev,Ligand Pharmaceuticals,"Genentech, Inc.|Dartmouth-Hitchcock Medical Center","Genentech, Inc.",Dartmouth-Hitchcock Medical Center,,,Phase 2,Other|Industry,Interventional,8/5/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00125359
4206,Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors,Completed,Has Results,Cancer,Drug: E7389,Eisai Inc.,Eisai Inc.,,,,,,,Phase 1,Industry,Interventional,8/3/2019,4/5/2019,https://ClinicalTrials.gov/show/NCT00069277
4207,Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults,Completed,Has Results,Smallpox,Biological: ACAM2000 Smallpox Vaccine|Biological: Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®,Emergent BioSolutions,Emergent BioSolutions,,,,,,,Phase 2,Industry,Interventional,1/3/2019,10/3/2019,https://ClinicalTrials.gov/show/NCT00053482
4208,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Completed,Has Results,Graves' Disease,Drug: CFZ533,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,4/19/2016,4/24/2017,https://ClinicalTrials.gov/show/NCT02713256
4209,"Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis",Completed,Has Results,Hyperhidrosis,Drug: Umeclidinium|Drug: Vehicle,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/23/2015,2/25/2016,https://ClinicalTrials.gov/show/NCT02563899
4210,Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease,Completed,Has Results,Parkinson Disease,Device: Spectramax light therapy device|Device: Control light device,"PhotoPharmics, Inc.","PhotoPharmics, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/14/2019,12/23/2016,https://ClinicalTrials.gov/show/NCT02175472
4211,Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation,Completed,Has Results,Indication for PICC Placement,Device: Chest X-ray|Device: Sherlock 3CG® TCS|Procedure: Peripherally Inserted Central Catheter (PICC),"C. R. Bard|KJT Group, Inc.",C. R. Bard,"KJT Group, Inc.",,,,,,Not Applicable,Industry,Interventional,5/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02498821
4212,TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds,Completed,Has Results,"Nasolabial Folds, Wrinkles",Device: TEOSYAL® RHA Ultra Deep,Teoxane SA|ethica Clinical Research Inc.,Teoxane SA,ethica Clinical Research Inc.,,,,,,Not Applicable,Industry,Interventional,9/14/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02253147
4213,BioFiber Scaffold Post-Market Observational Study,Completed,Has Results,Full Thickness Rotator Cuff Tear,Device: BioFiber,"Tornier, Inc.","Tornier, Inc.",,,,,,,,Industry,Observational,3/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01849458
4214,Safety and Efficacy of Valiant Mona LSA Stent Graft System,Completed,Has Results,Thoracic Aortic Aneurysms,Device: Valiant Mona LSA Stent Graft System,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,4/13/2019,12/18/2019,https://ClinicalTrials.gov/show/NCT01839695
4215,A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-04991532|Drug: PF-0499132|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,12/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01469065
4216,Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Brexpiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","Otsuka Pharmaceutical Development & Commercialization, Inc.",H. Lundbeck A/S,,,,,,Phase 1,Industry,Interventional,7/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01670279
4217,A Rollover Study for Patients Who Participated in Other Romidepsin Protocols,Completed,Has Results,Lymphoma|Cancer,Drug: Romidepsin,Celgene Corporation,Celgene Corporation,,,,,,,Phase 2,Industry,Interventional,5/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01353664
4218,Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer,Completed,Has Results,Hematologic Malignancy|Malignant Lymphoma,Drug: Romidepsin|Drug: Rifampin,Celgene Corporation,Celgene Corporation,,,,,,,Phase 1,Industry,Interventional,4/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01324323
4219,Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer,Completed,Has Results,Hematologic Malignancy|Malignant Lymphoma,Drug: Romidepsin|Drug: Ketoconazole,Celgene Corporation,Celgene Corporation,,,,,,,Phase 1,Industry,Interventional,4/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01324310
4220,Study of Belimumab Administered Subcutaneously to Healthy Subjects,Completed,Has Results,Healthy,Biological: Single Dose Group: Belimumab IV 240 mg|Biological: Single Dose Group: Belimumab SC 2 x 120 mg|Biological: Single Dose Group: Belimumab SC 1 x 240 mg|Biological: Single Dose Group: Belimumab SC 1 x 200 mg|Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly,Human Genome Sciences Inc.|GlaxoSmithKline,Human Genome Sciences Inc.,GlaxoSmithKline,,,,,,Phase 1,Industry,Interventional,2/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01583530
4221,A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Biological: PRM-151|Other: Placebo,"Promedior, Inc.","Promedior, Inc.",,,,,,,Phase 1,Industry,Interventional,1/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01254409
4222,A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers,Completed,Has Results,Colorectal Cancer|Squamous Cell Head and Neck Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Other Tumors With EGFR Dependence,Drug: MM-121|Drug: Irinotecan|Drug: Cetuximab,Merrimack Pharmaceuticals|Sanofi,Merrimack Pharmaceuticals,Sanofi,,,,,,Phase 1,Industry,Interventional,10/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01451632
4223,Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia,Drug: asfotase alfa,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,6/10/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01163149
4224,A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase,Completed,Has Results,Hereditary Angioedema,Biological: CINRYZE with rHuPH20,Shire|Halozyme Therapeutics,Shire,Halozyme Therapeutics,,,,,,Phase 2,Industry,Interventional,9/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01426763
4225,Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM),Completed,Has Results,Breast Cancer,,Philips Healthcare,Philips Healthcare,,,,,,,,Industry,Observational,4/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00999596
4226,Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects,Completed,Has Results,Chronic Hepatitis C,Drug: BMS-790052|Drug: Ortho Tri-Cyclen®,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,10/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00983957
4227,Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases,Completed,Has Results,Primary Myelofibrosis (PMF)|Post-Polycythaemia Vera|Essential Thrombocythaemia Myelofibrosis,Drug: AZD1480,"AstraZeneca|University of Texas|New York City Hoffman Center|Gustave Roussy, Cancer Campus, Grand Paris",AstraZeneca,University of Texas,"New York City Hoffman Center|Gustave Roussy, Cancer Campus, Grand Paris",New York City Hoffman Center,"Gustave Roussy, Cancer Campus, Grand Paris",,,Phase 1,Industry|Other,Interventional,5/9/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00910728
4228,Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction,Completed,Has Results,Skin Resurfacing|Wrinkle Reduction,Device: Fractional RF treatment with Matrix RF applicator,Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,4/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00887913
4229,Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE),Completed,Has Results,Peripheral Artery Disease,Device: Scuba Iliac Stent System,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,3/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00880230
4230,An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence,Completed,Has Results,Stress Urinary Incontinence|Cell Therapy,Biological: autologous muscle cell injection,Cook MyoSite|Cook Group Incorporated,Cook MyoSite,Cook Group Incorporated,,,,,,Phase 2,Industry,Interventional,9/8/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00847535
4231,Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain,Completed,Has Results,Shoulder Pain,Device: The SPR System,"SPR Therapeutics, Inc.|NDI Medical, LLC","SPR Therapeutics, Inc.","NDI Medical, LLC",,,,,,Not Applicable,Industry,Interventional,4/10/2019,7/25/2017,https://ClinicalTrials.gov/show/NCT01094301
4232,Effect of Orlistat in Body Composition,Completed,Has Results,Obesity|Overweight,Drug: Orlistat|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,9/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00752726
4233,"Study on OsseoSpeed™ Implants in Patients Missing 2-5 Teeth in the Posterior Lower Jaw, Restored With Permanent Teeth Attached 6-7 Weeks Later",Completed,Has Results,"Jaw, Edentulous, Partially",Device: OsseoSpeed™,Dentsply Sirona Implants,Dentsply Sirona Implants,,,,,,,Not Applicable,Industry,Interventional,2/4/2019,,https://ClinicalTrials.gov/show/NCT00711425
4234,"Study on OsseoSpeed™ Implants Replacing 2-5 Teeth in the Posterior Upper Jaw, Restored With Provisional Teeth Attached 6-7 Weeks Later",Completed,Has Results,"Jaw, Edentulous, Partially",Device: OsseoSpeed™,Dentsply Sirona Implants,Dentsply Sirona Implants,,,,,,,Not Applicable,Industry,Interventional,12/3/2019,,https://ClinicalTrials.gov/show/NCT00711113
4235,CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation,Completed,Has Results,Alveolar Ridge Defect,Device: CopiOs Pericardium Membrane,Zimmer Biomet|Zimmer Dental,Zimmer Biomet,Zimmer Dental,,,,,,Not Applicable,Industry,Interventional,6/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00889265
4236,Study of Root Coverage With Acellular Dermal Matrix: Puros® Dermis Versus Alloderm®,Completed,Has Results,Gingival Recession,Device: Puros® Dermis versus Alloderm®,Zimmer Biomet|Zimmer Dental,Zimmer Biomet,Zimmer Dental,,,,,,Not Applicable,Industry,Interventional,8/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00881959
4237,"Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine",Completed,Has Results,Advanced Melanoma,Drug: Ipilimumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Dacarbazine,Bristol-Myers Squibb|Medarex,Bristol-Myers Squibb,Medarex,,,,,,Phase 1,Industry,Interventional,2/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00796991
4238,Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Melphalan|Drug: Panobinostat,Oncotherapeutics|Novartis,Oncotherapeutics,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,7/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00743288
4239,"Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)",Completed,Has Results,Idiopathic Solar Urticaria,Drug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|Drug: bisoctrizole 10% alone (formula RV3131A-MV1237)|Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|Drug: V0096 CR vehicle (formula RV3131A-MV1197),Orfagen,Orfagen,,,,,,,Phase 2,Industry,Interventional,9/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00483496
4240,"Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors",Completed,Has Results,"Sarcoma, Ewing's","Drug: CP-751,871",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,8/5/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00474760
4241,An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy,Completed,Has Results,Prostate Neoplasms,Drug: Abiraterone acetate|Drug: Glucocorticoid,"Cougar Biotechnology, Inc.","Cougar Biotechnology, Inc.",,,,,,,Phase 2,Industry,Interventional,11/6/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00474383
4242,Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3),Completed,Has Results,Diabetes Mellitus|Coronary Artery Disease,Drug: prasugrel|Drug: Clopidogrel,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,Phase 2,Industry,Interventional,4/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00642174
4243,Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Etanercept,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,9/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00361634
4244,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran|Drug: Quetiapine,"Duke University|Forest Laboratories|Institute for Advanced Medical Research, Alpharetta, GA",Duke University,Forest Laboratories,"Institute for Advanced Medical Research, Alpharetta, GA",,,,,Phase 3,Other|Industry,Interventional,1/23/2017,6/12/2018,https://ClinicalTrials.gov/show/NCT02720198
4245,Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,Completed,Has Results,Skin Basal Cell Carcinoma,Biological: Pembrolizumab|Drug: Vismodegib,Anne Chang|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)|Stanford University,Anne Chang,Merck Sharp & Dohme Corp.,National Cancer Institute (NCI)|Stanford University,National Cancer Institute (NCI),Stanford University,,,Phase 1|Phase 2,Other|Industry|NIH,Interventional,2/1/2016,8/29/2018,https://ClinicalTrials.gov/show/NCT02690948
4246,Intranasal Delivery of Testosterone and Its Effect on Doping Markers,Completed,Has Results,Abuse of Anabolic Steroids,Drug: Testosterone,University of Utah|Sports Medicine Research and Testing Laboratory|Partnership for Clean Competition,University of Utah,Sports Medicine Research and Testing Laboratory,Partnership for Clean Competition,,,,,Phase 4,Other|Industry,Interventional,11/18/2015,1/19/2016,https://ClinicalTrials.gov/show/NCT02611154
4247,Comparability and Standardization of Controlled Allergen Challenge Facilities,Completed,Has Results,Allergic Rhinitis,Drug: Cetirizine|Other: Placebo,"Queen's University|Biogenics Research Chamber, LLC",Queen's University,"Biogenics Research Chamber, LLC",,,,,,Phase 4,Other|Industry,Interventional,10/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02543346
4248,Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess,Completed,Has Results,Furunculosis,Biological: Antimicrobial TheraGauze,"Eastern Virginia Medical School|Soluble Systems, LLC|United States Department of Defense",Eastern Virginia Medical School,"Soluble Systems, LLC",United States Department of Defense,,,,,Phase 1|Phase 2,Other|Industry|U.S. Fed,Interventional,4/1/2016,8/30/2017,https://ClinicalTrials.gov/show/NCT02334384
4249,Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction,Completed,Has Results,Heart Failure,Drug: Sodium Nitrite Inhalation Solution|Other: Placebo,"Mayo Clinic|Aires Pharmaceuticals, Inc.|National Heart, Lung, and Blood Institute (NHLBI)",Mayo Clinic,"Aires Pharmaceuticals, Inc.","National Heart, Lung, and Blood Institute (NHLBI)",,,,,Phase 2,Other|Industry|NIH,Interventional,10/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02262078
4250,Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis,Completed,Has Results,Amyloidosis,Drug: VELCADE,"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Millennium Pharmaceuticals, Inc.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 1|Phase 2,Industry,Interventional,6/5/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00298766
4251,"Initial Efficacy Study of Supporting Play, Exploration, & Early Development Intervention",Completed,Has Results,"Infant, Premature, Diseases|Brain White Matter Disease Periventricular",Behavioral: SPEEDI Intervention,"Virginia Commonwealth University|Foundation for Physical Therapy, Inc.|Children's Hospital Foundation",Virginia Commonwealth University,"Foundation for Physical Therapy, Inc.",Children's Hospital Foundation,,,,,Not Applicable,Other|Industry,Interventional,4/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02153736
4252,Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy,Completed,Has Results,Cholecystitis,Drug: Injection of indocyanine green (ICG)|Device: Near Infrared Cholangiography Fluorescence (NIRF-C),Ohio State University|Stryker Instruments|Society of American Gastrointestinal and Endoscopic Surgeons,Ohio State University,Stryker Instruments,Society of American Gastrointestinal and Endoscopic Surgeons,,,,,Not Applicable,Other|Industry,Interventional,1/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02070640
4253,A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS),Completed,Has Results,Diabetes|Hypertension,,"University of North Carolina, Chapel Hill|Merck Sharp & Dohme Corp.|Northwestern University","University of North Carolina, Chapel Hill",Merck Sharp & Dohme Corp.,Northwestern University,,,,,,Other|Industry,Observational,11/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01998269
4254,Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents,Completed,Has Results,Contraceptive Usage,Drug: Etonogestrel contraceptive implant,Medical University of South Carolina|American College of Obstetricians and Gynecologists|Bayer,Medical University of South Carolina,American College of Obstetricians and Gynecologists,Bayer,,,,,Phase 3,Other|Industry,Interventional,1/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT03585504
4255,Assessment of an Automatic Closed-loop Insulin Delivery System,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Automatic closed-loop insulin delivery|Device: Control,Stanford University|Medtronic,Stanford University,Medtronic,,,,,,Not Applicable,Other|Industry,Interventional,6/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02366767
4256,Optimized Loading Response by JOURNEY II BCS Knee Increases Daily Physical Activity and Functions,Completed,Has Results,Knee Injuries,Device: Journey II BCS TKA,"The University of Tennessee, Knoxville|Smith & Nephew, Inc.","The University of Tennessee, Knoxville","Smith & Nephew, Inc.",,,,,,,Other|Industry,Observational,7/14/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02335710
4257,Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial,Completed,Has Results,Diabetic Macular Edema,Drug: Aflibercept|Procedure: Focal Laser,Greater Houston Retina Research|Regeneron Pharmaceuticals,Greater Houston Retina Research,Regeneron Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,11/24/2014,1/9/2017,https://ClinicalTrials.gov/show/NCT02299336
4258,Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations,Completed,Has Results,Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorder,Drug: Bevacizumab,"Johns Hopkins University|Genentech, Inc.|Guthy Jackson Charitable Foundation",Johns Hopkins University,"Genentech, Inc.",Guthy Jackson Charitable Foundation,,,,,Phase 1,Other|Industry,Interventional,6/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01777412
4259,Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment,Completed,Has Results,Port-Wine Stain,Device: Pulsed Dye Laser|Device: Combined Bipolar Radiofrequency&Pulsed Dye Laser,"University of California, Irvine|Candela Corporation|Beckman Laser Institute University of California Irvine","University of California, Irvine",Candela Corporation,Beckman Laser Institute University of California Irvine,,,,,Not Applicable,Other|Industry,Interventional,12/12/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01775722
4260,Colchicine and CRP in Atrial Fibrillation and AF Ablation,Completed,Has Results,Atrial Fibrillation,"Drug: Colchicine, 0.6 mg PO BID|Drug: Matching placebo",Mayo Clinic|Takeda|Detiger Funds,Mayo Clinic,Takeda,Detiger Funds,,,,,Phase 2,Other|Industry,Interventional,3/13/2019,12/6/2016,https://ClinicalTrials.gov/show/NCT01755949
4261,Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929),Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: GSK1265744 30mg|Drug: Placebo|Drug: GSK1265744 5mg,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 2,Industry,Interventional,6/9/2009,8/13/2009,https://ClinicalTrials.gov/show/NCT00920426
4262,SMV + SOF With/Without RBV for IFN-II Patients With CHC,Completed,Has Results,Hepatitis C,Drug: Simeprevir|Drug: Sofosbuvir|Drug: Ribavirin,"SC Liver Research Consortium, LLC|Janssen, LP","SC Liver Research Consortium, LLC","Janssen, LP",,,,,,Phase 4,Other|Industry,Interventional,10/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02214420
4263,Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,Completed,Has Results,Colorectal Neoplasms,Device: SIR-Spheres|Drug: Regorafenib,"SCRI Development Innovations, LLC|Sirtex Medical","SCRI Development Innovations, LLC",Sirtex Medical,,,,,,Phase 2,Other|Industry,Interventional,7/14/2019,6/4/2017,https://ClinicalTrials.gov/show/NCT02195011
4264,A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults,Completed,Has Results,Dengue Fever,Biological: 4 µg TDENV-PIV with Alum adjuvant|Biological: 1 µg TDENV-PIV with AS03B1 adjuvant|Other: Phosphate buffered saline|Biological: 1 µg TDENV-PIV with Alum adjuvant|Biological: 1 µg TDENV-PIV with AS01E1 adjuvant,U.S. Army Medical Research and Development Command|GlaxoSmithKline|Walter Reed Army Institute of Research (WRAIR),U.S. Army Medical Research and Development Command,GlaxoSmithKline,Walter Reed Army Institute of Research (WRAIR),,,,,Phase 1,U.S. Fed|Industry,Interventional,9/12/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT01666652
4265,Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients,Completed,Has Results,Arteriovenous Fistula,Drug: Topical Tranexamic Acid 5% with bacitracin|Other: Topical Tranexamic Acid 25% with bacitracin,"California Institute of Renal Research|Imprimis Pharmaceuticals, Inc.",California Institute of Renal Research,"Imprimis Pharmaceuticals, Inc.",,,,,,Phase 4,Other|Industry,Interventional,4/14/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT02106962
4266,Ranibizumab and Bevacizumab for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Ranibizumab|Drug: Bevacizumab,"National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)",National Eye Institute (NEI),"The Emmes Company, LLC",National Institutes of Health Clinical Center (CC),,,,,Phase 2,NIH|Industry,Interventional,5/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01610557
4267,Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography,Completed,Has Results,Aortic Stenosis,Other: Tranthoracic Echocardiogram|Device: Cardiac Ascultation Recordings with Electronic stethoscope,"United States Naval Medical Center, San Diego|3M|The Geneva Foundation","United States Naval Medical Center, San Diego",3M,The Geneva Foundation,,,,,,U.S. Fed|Industry|Other,Observational,5/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01605669
4268,Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial),Completed,Has Results,Saphenous Vein Graft Disease,Drug: Atorvastatin 80 mg daily|Drug: Atorvastatin 10 mg daily,Boca Raton Regional Hospital|Pfizer,Boca Raton Regional Hospital,Pfizer,,,,,,Phase 3,Other|Industry,Interventional,3/12/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01528709
4269,Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants,Completed,Has Results,Osteoarthritis of the Knee|Coagulopathy,Drug: Pennsaid,"Nathan Wei, MD, FACP, FACR:|Medtronic - MITG|Arthritis Treatment Center, Maryland","Nathan Wei, MD, FACP, FACR:",Medtronic - MITG,"Arthritis Treatment Center, Maryland",,,,,Phase 3,Other|Industry,Interventional,2/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01511939
4270,Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma,Completed,Has Results,Bile Duct Cancer|Intrahepatic Cholangiocarcinoma|Cholangiocarcinoma of the Extrahepatic Bile Duct,Drug: Cabozantinib,Massachusetts General Hospital|Exelixis,Massachusetts General Hospital,Exelixis,,,,,,Phase 2,Other|Industry,Interventional,9/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01954745
4271,Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia,Completed,Has Results,Benign Prostatic Hyperplasia (BPH),Device: Greenlight XPS Laser|Device: BiVAP Saline Vaporization of the prostate,Brooklyn Urology Research Group|American Medical Systems|Richard Wolf Medical Instruments Corporation (RWMIC),Brooklyn Urology Research Group,American Medical Systems,Richard Wolf Medical Instruments Corporation (RWMIC),,,,,Phase 4,Other|Industry,Interventional,12/11/2019,10/10/2016,https://ClinicalTrials.gov/show/NCT01500057
4272,Preparedness Study - HPV Vaccine,Completed,Has Results,Sexual Transmission of Infection,Biological: Gardasil Vaccine|Other: Placebo,H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.,H. Lee Moffitt Cancer Center and Research Institute,Merck Sharp & Dohme Corp.,,,,,,Not Applicable,Other|Industry,Interventional,9/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01489527
4273,A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: cannabidiol,"University of Colorado, Denver|Colorado Department of Public Health and Environment|GW Research Ltd","University of Colorado, Denver",Colorado Department of Public Health and Environment,GW Research Ltd,,,,,Phase 2,Other|Industry,Interventional,10/16/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT02818777
4274,Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.,Completed,Has Results,Gastrointestinal Hemorrhage|Clostridium Difficile Colitis,Drug: Pantoprazole 40 mg IV daily and tube feed.|Other: Placebo and tube feed,Mohamed Saad|Abbott Nutrition|University of Louisville,Mohamed Saad,Abbott Nutrition,University of Louisville,,,,,Not Applicable,Other|Industry,Interventional,9/13/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01477320
4275,Comparative Outcomes Assessment of the C-Leg With a New Knee Prosthesis,Completed,Has Results,Other and Unspecified Complications of Amputation Stump,Device: Otto Bock C-Leg|Device: Otto Bock Genium,Jason Highsmith|Otto Bock Healthcare|Florida High Tech Corridor Council|University of South Florida,Jason Highsmith,Otto Bock Healthcare,Florida High Tech Corridor Council|University of South Florida,Florida High Tech Corridor Council,University of South Florida,,,Not Applicable,Other|Industry,Interventional,1/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01473992
4276,Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2),Completed,Has Results,PCV|Polypoidal Choroidal Vasculopathy,Drug: high-dose ranibizumab|Drug: ranibizumab,"Hawaii Pacific Health|Genentech, Inc.",Hawaii Pacific Health,"Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/10/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01884597
4277,Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2,Completed,Has Results,Neurofibromatosis Type II,"Drug: Everolimus (RAD001) , Afinitor®",NYU Langone Health|Novartis Pharmaceuticals|The Children's Tumor Foundation,NYU Langone Health,Novartis Pharmaceuticals,The Children's Tumor Foundation,,,,,Phase 2,Other|Industry,Interventional,10/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01419639
4278,Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients,Completed,Has Results,Epidermolysis Bullosa|Pruritus,Drug: VPD-737|Other: Placebo,Jean Yuh Tang|Epidermolysis Bullosa Research Partnership|Menlo Therapeutics Inc.|Stanford University,Jean Yuh Tang,Epidermolysis Bullosa Research Partnership,Menlo Therapeutics Inc.|Stanford University,Menlo Therapeutics Inc.,Stanford University,,,Phase 2,Other|Industry,Interventional,8/31/2016,7/27/2018,https://ClinicalTrials.gov/show/NCT02654483
4279,Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity,Completed,Has Results,Obesity,Drug: Liraglutide|Drug: Placebo,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Novo Nordisk A/S,Mayo Clinic,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Novo Nordisk A/S,,,,,Phase 2,Other|NIH|Industry,Interventional,12/18/2015,12/30/2016,https://ClinicalTrials.gov/show/NCT02647944
4280,Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration,Completed,Has Results,Age-Related Macular Degeneration|Macular Degeneration,Drug: Intravitreal Aflibercept Injection,MidAtlantic Retina|Regeneron Pharmaceuticals|Wills Eye,MidAtlantic Retina,Regeneron Pharmaceuticals,Wills Eye,,,,,Not Applicable,Other|Industry,Interventional,2/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01773954
4281,Mechanics Analysis of Patients Having a Sigma Mobile Bearing TKA,Completed,Has Results,Knee Prosthesis|Knee Replacement Arthroplasty,Device: Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly,"The University of Tennessee, Knoxville|DePuy Orthopaedics","The University of Tennessee, Knoxville",DePuy Orthopaedics,,,,,,,Other|Industry,Observational,4/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01714492
4282,"Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion",Completed,Has Results,"Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions",Drug: 0.5mg Ranibizumab|Procedure: Targeted Pan Retinal Photocoagulation,"Charles C Wykoff, PhD, MD|Genentech, Inc.|Greater Houston Retina Research","Charles C Wykoff, PhD, MD","Genentech, Inc.",Greater Houston Retina Research,,,,,Phase 4,Other|Industry,Interventional,10/12/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01710839
4283,"BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: BIBF 1120,AA Secord|Boehringer Ingelheim|Duke University,AA Secord,Boehringer Ingelheim,Duke University,,,,,Phase 2,Other|Industry,Interventional,2/13/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT01669798
4284,Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Device: CGM Group|Device: SMBG Group,HealthPartners Institute|Roche Diagnostics|International Diabetes Center at Park Nicollet,HealthPartners Institute,Roche Diagnostics,International Diabetes Center at Park Nicollet,,,,,Not Applicable,Other|Industry,Interventional,10/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01237301
4285,Recombinant Human Leptin Therapy Effects on Insulin Action,Completed,Has Results,Type Two Diabetes Mellitus,Dietary Supplement: placebo|Drug: low-dose leptin|Drug: high-dose leptin,Washington University School of Medicine|Amgen|National Institutes of Health (NIH),Washington University School of Medicine,Amgen,National Institutes of Health (NIH),,,,,Not Applicable,Other|Industry|NIH,Interventional,8/1/1998,7/1/2000,https://ClinicalTrials.gov/show/NCT01207934
4286,"Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis",Completed,Has Results,"Arthritis, Rheumatoid",Drug: Milnacipran|Drug: Placebo,Brigham and Women's Hospital|Forest Laboratories|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Brigham and Women's Hospital,Forest Laboratories,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),,,,,Phase 4,Other|Industry|NIH,Interventional,1/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01207453
4287,Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause,Completed,Has Results,"HIV|Inflammation|Obesity|Aging, Biological",Other: High-intensity cardiovascular and resistance exercise|Other: Moderate-intensity cardiovascular and resistance exercise,"University of Colorado, Denver|National Institute on Aging (NIA)|Gilead Sciences","University of Colorado, Denver",National Institute on Aging (NIA),Gilead Sciences,,,,,Not Applicable,Other|NIH|Industry,Interventional,4/15/2019,3/1/2018,https://ClinicalTrials.gov/show/NCT02404792
4288,Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function,Completed,Has Results,"Heart Failure, Diastolic",Device: Echocardiography system Ultra DCI Model 5000|Device: Echocardiography machine GE Vivid E9|Device: Diastolic function assessment,"University of Michigan|Pixel Velocity, Inc. / Epsilon Imaging|National Heart, Lung, and Blood Institute (NHLBI)",University of Michigan,"Pixel Velocity, Inc. / Epsilon Imaging","National Heart, Lung, and Blood Institute (NHLBI)",,,,,Phase 1|Phase 2,Other|Industry|NIH,Interventional,8/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01182805
4289,Chronic Care Management/Patient Relationship Management Proof of Concept,Completed,Has Results,Diabetes Mellitus,Behavioral: Patient Relationship Management (PRM) Program,Denver Health and Hospital Authority|Microsoft Corporation|EMC Consulting,Denver Health and Hospital Authority,Microsoft Corporation,EMC Consulting,,,,,Not Applicable,Other|Industry,Interventional,5/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01182480
4290,"Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers",Completed,Has Results,"Tuberculosis|Tuberculosis, Pulmonary",Drug: Rifampin & midazolam|Drug: rifapentine & midazolam|Drug: rifapentine and midazolam,Johns Hopkins University|Sanofi|Centers for Disease Control and Prevention,Johns Hopkins University,Sanofi,Centers for Disease Control and Prevention,,,,,Phase 1,Other|Industry|U.S. Fed,Interventional,4/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01162486
4291,Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease,Completed,Has Results,Chronic Kidney Disease,Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate|Dietary Supplement: Placebo,"Indiana University|Genzyme, a Sanofi Company|Purdue University",Indiana University,"Genzyme, a Sanofi Company",Purdue University,,,,,Not Applicable,Other|Industry,Interventional,6/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01161407
4292,Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE),Completed,Has Results,Diabetic Macular Edema,Drug: 0.3 mg ranibizumab|Procedure: Targeted Pan Retinal Photocoagulation,"David M. Brown, M.D.|Genentech, Inc.|Greater Houston Retina Research","David M. Brown, M.D.","Genentech, Inc.",Greater Houston Retina Research,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/12/2019,5/18/2017,https://ClinicalTrials.gov/show/NCT01552408
4293,Nitrous Oxide for Pain Management During In-office Transcervical Sterilization,Completed,Has Results,Contraception|Inhalation of Nitrous Oxide,Procedure: In-office Transcervical Sterilization (Essure®)|Drug: Standard Oral pain medications|Drug: Intramuscular Ketorolac|Drug: Placebo pills|Other: Oxygen|Other: Nitrous Oxide,University of New Mexico|Society of Family Planning|Bayer,University of New Mexico,Society of Family Planning,Bayer,,,,,Not Applicable,Other|Industry,Interventional,2/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02312739
4294,The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome,Completed,Has Results,Obstructive Sleep Apnea,Drug: Eszopiclone|Drug: Placebo,"Brigham and Women's Hospital|Sunovion|National Heart, Lung, and Blood Institute (NHLBI)",Brigham and Women's Hospital,Sunovion,"National Heart, Lung, and Blood Institute (NHLBI)",,,,,Early Phase 1,Other|Industry|NIH,Interventional,1/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01102270
4295,"System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts",Completed,Has Results,"Influenza|Infections, Pneumococcal",Other: Arm 1: E-portal message with IVR call|Other: Arm 2: E-portal message with no IVR call|Other: Arm 3: No e-portal message with IVR call|Other: Arm 5: IVR call,"University of Massachusetts, Worcester|Reliant Medical Group|Pfizer","University of Massachusetts, Worcester",Reliant Medical Group,Pfizer,,,,,Not Applicable,Other|Industry,Interventional,11/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02266277
4296,Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma,Completed,Has Results,Advanced Adult Hepatocellular Carcinoma,Drug: Everolimus|Drug: Pasireotide,UNC Lineberger Comprehensive Cancer Center|Novartis Pharmaceuticals,UNC Lineberger Comprehensive Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,12/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01488487
4297,"Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant",Completed,Has Results,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes,Drug: azacitidine|Other: laboratory biomarker analysis,Fred Hutchinson Cancer Research Center|Celgene Corporation|National Cancer Institute (NCI),Fred Hutchinson Cancer Research Center,Celgene Corporation,National Cancer Institute (NCI),,,,,Phase 2,Other|Industry|NIH,Interventional,4/10/2019,,https://ClinicalTrials.gov/show/NCT01083706
4298,Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment,Completed,Has Results,Hepatitis C|HIV,Drug: Ribavirin|Drug: Ribavirin plus Abacavir (ABC),"Johns Hopkins University|GlaxoSmithKline|University of Colorado, Denver",Johns Hopkins University,GlaxoSmithKline,"University of Colorado, Denver",,,,,Phase 1,Other|Industry,Interventional,12/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01052701
4299,Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy,Completed,Has Results,Urothelial Carcinoma,Drug: Cabazitaxel|Drug: Neulasta|Procedure: CT Scan|Biological: Blood Draw,Sidney Kimmel Cancer Center at Thomas Jefferson University|Sanofi|Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Sanofi,Thomas Jefferson University,,,,,Phase 2,Other|Industry,Interventional,2/16/2012,3/30/2017,https://ClinicalTrials.gov/show/NCT01437488
4300,Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide,Completed,Has Results,Myeloma,Drug: Pomalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide,H. Lee Moffitt Cancer Center and Research Institute|Celgene,H. Lee Moffitt Cancer Center and Research Institute,Celgene,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/11/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01432600
4301,"""Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies""",Completed,Has Results,Dementia With Lewy Bodies,Drug: Armodafinil,Mayo Clinic|Cephalon|National Institute on Aging (NIA),Mayo Clinic,Cephalon,National Institute on Aging (NIA),,,,,Phase 4,Other|Industry|NIH,Interventional,11/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01023672
4302,Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,Completed,Has Results,Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer,Other: Laboratory Biomarker Analysis|Biological: Sipuleucel-T|Drug: Tasquinimod,Roswell Park Cancer Institute|National Cancer Institute (NCI)|Active Biotech AB,Roswell Park Cancer Institute,National Cancer Institute (NCI),Active Biotech AB,,,,,Phase 2,Other|NIH|Industry,Interventional,1/15/2019,,https://ClinicalTrials.gov/show/NCT02159950
4303,Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial,Completed,Has Results,Rheumatoid Arthritis,Drug: Teriparatide|Drug: calcium citrate|Drug: Vitamin D|Drug: TNF antagonist,Brigham and Women's Hospital|Eli Lilly and Company,Brigham and Women's Hospital,Eli Lilly and Company,,,,,,Phase 4,Other|Industry,Interventional,8/11/2019,7/28/2016,https://ClinicalTrials.gov/show/NCT01400516
4304,Functional Performance of Voluntary Opening and Closing Body Powered Prostheses,Completed,Has Results,Upper Limb Amputation,Device: Hosmer 5XA voluntary opening hook|Device: TRS Grip 3 voluntary closing hook,"University of South Florida|Florida High Tech Corridor Council|TRS, Inc.",University of South Florida,Florida High Tech Corridor Council,"TRS, Inc.",,,,,Not Applicable,Other|Industry,Interventional,9/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02136238
4305,Nicotine Vaccination and Nicotinic Receptor Occupancy,Completed,Has Results,Nicotine Dependence,Biological: NicVAX|Radiation: [123I]5-IA-85380|Drug: Nicotine bitartrate,Yale University|Nabi Biopharmaceuticals|National Institute on Drug Abuse (NIDA),Yale University,Nabi Biopharmaceuticals,National Institute on Drug Abuse (NIDA),,,,,Phase 2,Other|Industry|NIH,Interventional,9/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00996034
4306,"Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV",Completed,Has Results,HIV-HCV,Drug: Asunaprevir and Daclatasvir|Drug: Asunaprevir and Daclatasvir with BMS-791325,National Institutes of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb,National Institutes of Health Clinical Center (CC),National Institute of Allergy and Infectious Diseases (NIAID),Bristol-Myers Squibb,,,,,Phase 2,NIH|Industry,Interventional,2/14/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02124044
4307,A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia,Completed,Has Results,Chronic Myelomonocytic Leukemia,Drug: 5-Azacitidine,University of Utah|Celgene,University of Utah,Celgene,,,,,,Phase 2,Other|Industry,Interventional,4/11/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01350947
4308,Comparison of Kinematics for Subjects Implanted With a PFC Sigma Rotating Platform or Fixed Bearing TC3 Prosthesis,Completed,Has Results,Knee Prosthesis|Knee Arthroplasty,Device: DePuy fixed-bearing Total Condylar III (TC3) TKA|Device: DePuy PFC Rotating Platform TC3 TKA,"The University of Tennessee, Knoxville|DePuy Orthopaedics","The University of Tennessee, Knoxville",DePuy Orthopaedics,,,,,,,Other|Industry,Observational,2/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01290640
4309,Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide,Completed,Has Results,Malignant Glioma,Drug: Palonosetron (PALO),Duke University|Eisai Inc.|National Institute of Neurological Disorders and Stroke (NINDS),Duke University,Eisai Inc.,National Institute of Neurological Disorders and Stroke (NINDS),,,,,Phase 2,Other|Industry|NIH,Interventional,8/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00900757
4310,Effects of Daytime Eszopiclone Administration in Shift Workers,Completed,Has Results,Shift-Work Sleep Disorder,Drug: eszopiclone|Drug: matching placebo,Brigham and Women's Hospital|Sunovion|Massachusetts General Hospital,Brigham and Women's Hospital,Sunovion,Massachusetts General Hospital,,,,,Not Applicable,Other|Industry,Interventional,5/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00900159
4311,Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability,Completed,Has Results,Dizziness,Device: balance prosthesis,"Washington University School of Medicine|Barron Associates, Inc.|National Institute on Deafness and Other Communication Disorders (NIDCD)",Washington University School of Medicine,"Barron Associates, Inc.",National Institute on Deafness and Other Communication Disorders (NIDCD),,,,,Phase 1,Other|Industry|NIH,Interventional,2/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00889824
4312,Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Treprostinil,Los Angeles Biomedical Research Institute|United Therapeutics,Los Angeles Biomedical Research Institute,United Therapeutics,,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,10/5/2016,https://ClinicalTrials.gov/show/NCT01268553
4313,Interferon Gamma-1b in Friedreich Ataxia (FRDA),Completed,Has Results,Friedreich Ataxia,Drug: Interferon Gamma-1b,Children's Hospital of Philadelphia|Friedreich's Ataxia Research Alliance|Vidara Therapeutics Research Ltd,Children's Hospital of Philadelphia,Friedreich's Ataxia Research Alliance,Vidara Therapeutics Research Ltd,,,,,Phase 2,Other|Industry,Interventional,8/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01965327
4314,Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation,Completed,Has Results,Chronic Pancreatitis|Diabetes Mellitus,Device: Closed Loop Insulin,"University of Minnesota - Clinical and Translational Science Institute|University of Minnesota, MN|Medtronic Diabetes",University of Minnesota - Clinical and Translational Science Institute,"University of Minnesota, MN",Medtronic Diabetes,,,,,Not Applicable,Other|Industry,Interventional,2/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01945138
4315,Home Administration of FluMist by Parents/Caregivers,Completed,Has Results,Influenza,Biological: FluMist,"University of North Carolina, Chapel Hill|University of North Carolina|MedImmune LLC","University of North Carolina, Chapel Hill",University of North Carolina,MedImmune LLC,,,,,Not Applicable,Other|Industry,Interventional,9/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01938170
4316,Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery,Completed,Has Results,Colorectal Surgery,Drug: 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Drug: Iodine Povacrylex/74% Isopropyl Alcohol,University of Pennsylvania|3M,University of Pennsylvania,3M,,,,,,Not Applicable,Other|Industry,Interventional,12/10/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01233050
4317,Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen,Completed,Has Results,HIV Disease,"Drug: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)",Massachusetts General Hospital|Brigham and Women's Hospital|Gilead Sciences,Massachusetts General Hospital,Brigham and Women's Hospital,Gilead Sciences,,,,,Not Applicable,Other|Industry,Interventional,1/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01929759
4318,A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors,Completed,Has Results,Metastatic or Unresectable Solid Tumor Malignancy,Drug: Capecitabine|Drug: Hsp90 Inhibitor AUY 922,"SCRI Development Innovations, LLC|Novartis Pharmaceuticals","SCRI Development Innovations, LLC",Novartis Pharmaceuticals,,,,,,Phase 1,Other|Industry,Interventional,11/10/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01226732
4319,Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: eszopiclone|Drug: placebo,Massachusetts General Hospital|Sunovion|Beth Israel Deaconess Medical Center,Massachusetts General Hospital,Sunovion,Beth Israel Deaconess Medical Center,,,,,Not Applicable,Other|Industry,Interventional,9/6/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00833547
4320,Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI),Completed,Has Results,Osteoporosis|Bone Loss|Spinal Cord Injury,Drug: teriparatide|Other: weight-bearing,Thomas J. Schnitzer|Eli Lilly and Company|Shirley Ryan AbilityLab|Northwestern University,Thomas J. Schnitzer,Eli Lilly and Company,Shirley Ryan AbilityLab|Northwestern University,Shirley Ryan AbilityLab,Northwestern University,,,Phase 4,Other|Industry,Interventional,6/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00826228
4321,Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome,Completed,Has Results,Acute Coronary Syndrome|Sleep Disorder,Drug: Eszopiclone|Other: Placebo,University of Arizona|Sunovion|Southern Arizona VA Health Care System,University of Arizona,Sunovion,Southern Arizona VA Health Care System,,,,,Phase 4,Other|Industry|U.S. Fed,Interventional,10/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00822679
4322,Safety of Intravenous Thrombolysis for Wake-up Stroke,Completed,Has Results,Ischemic Stroke,Drug: Alteplase (iv t-PA),"The University of Texas Health Science Center, Houston|Genentech, Inc.","The University of Texas Health Science Center, Houston","Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,7/10/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01183533
4323,VIVITROL as a Treatment for Cocaine and Alcohol Dependence,Completed,Has Results,Cocaine Dependence|Alcohol Dependence,Drug: VIVITROL (Naltrexone extended-release injectable suspension)|Drug: Placebo,"University of Pennsylvania|Alkermes, Inc.|National Institute on Drug Abuse (NIDA)",University of Pennsylvania,"Alkermes, Inc.",National Institute on Drug Abuse (NIDA),,,,,Phase 2,Other|Industry|NIH,Interventional,7/9/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00777062
4324,"A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen",Completed,Has Results,Virus Diseases|HIV,Drug: Switch NRTIs as a Backbone to Raltegravir,"University of South Florida|Merck Sharp & Dohme Corp.|St. Joseph's Hospital, Florida",University of South Florida,Merck Sharp & Dohme Corp.,"St. Joseph's Hospital, Florida",,,,,Not Applicable,Other|Industry,Interventional,11/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00749580
4325,Emend for Multiple-day Emetogenic Chemotherapy,Completed,Has Results,Nausea|Vomiting,"Drug: aprepitant, ondansetron, dexamethasone",University of Illinois at Chicago|Merck Sharp & Dohme Corp.|Northwestern Memorial Hospital,University of Illinois at Chicago,Merck Sharp & Dohme Corp.,Northwestern Memorial Hospital,,,,,Phase 2,Other|Industry,Interventional,11/5/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00711555
4326,Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,Completed,Has Results,Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor,Drug: dovitinib|Other: laboratory biomarker analysis,"Manmeet Ahluwalia, MD|National Cancer Institute (NCI)|Novartis|Case Comprehensive Cancer Center","Manmeet Ahluwalia, MD",National Cancer Institute (NCI),Novartis|Case Comprehensive Cancer Center,Novartis,Case Comprehensive Cancer Center,,,Phase 2,Other|NIH|Industry,Interventional,12/20/2012,9/20/2017,https://ClinicalTrials.gov/show/NCT01753713
4327,Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers,Completed,Has Results,Opioid Abuse|Opioid Dependence,Drug: MN-166 (50 mg) First|Drug: Placebo First,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)|MediciNova,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),MediciNova,,,,,Phase 2,Other|NIH|Industry,Interventional,11/12/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT01740414
4328,Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?,Completed,Has Results,Epilepsy,Drug: Memantine|Other: Sugar Pill,American Academy of Neurology|Forest Laboratories,American Academy of Neurology,Forest Laboratories,,,,,,Not Applicable,Other|Industry,Interventional,1/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01054599
4329,Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation,Completed,Has Results,Severe Mood Dysregulation,Drug: lisdexamfetamine|Drug: Placebo|Drug: fluoxetine,"University of California, Los Angeles|National Institute of Mental Health (NIMH)|Shire","University of California, Los Angeles",National Institute of Mental Health (NIMH),Shire,,,,,Phase 2,Other|NIH|Industry,Interventional,1/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01714310
4330,Fracture (FX) Improvement With Teriparatide: FiX-IT Study,Completed,Has Results,Osteoporosis|Atypical Femoral Fracture,Drug: teriparatide,Susan L. Greenspan|University of Pittsburgh|Eli Lilly and Company,Susan L. Greenspan,University of Pittsburgh,Eli Lilly and Company,,,,,Phase 4,Other|Industry,Interventional,12/12/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01705587
4331,A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer,Completed,Has Results,Prostate Cancer Adenocarcinoma in Situ,Drug: degarelix acetate|Drug: Cyclophosphamide|Drug: GVAX,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|David H. Koch Charitable Foundation|BioSante Pharmaceuticals,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,David H. Koch Charitable Foundation,BioSante Pharmaceuticals,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/18/2013,12/18/2018,https://ClinicalTrials.gov/show/NCT01696877
4332,Trial of LBH589 in Metastatic Thyroid Cancer,Completed,Has Results,Thyroid Carcinoma,Drug: LBH589,"University of Wisconsin, Madison|Novartis Pharmaceuticals","University of Wisconsin, Madison",Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,1/10/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01013597
4333,Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial,Completed,Has Results,Substance Abuse,Drug: atomoxetine|Drug: placebo,Sharon Walsh|Eli Lilly and Company|National Institute on Drug Abuse (NIDA)|University of Kentucky,Sharon Walsh,Eli Lilly and Company,National Institute on Drug Abuse (NIDA)|University of Kentucky,National Institute on Drug Abuse (NIDA),University of Kentucky,,,Phase 2,Other|Industry|NIH,Interventional,7/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00617201
4334,Effects of Varenicline on Brain Activity During Nicotine Abstinence,Completed,Has Results,Nicotine Dependence,Drug: Varenicline|Drug: Placebo,University of Pennsylvania|Pfizer|National Cancer Institute (NCI),University of Pennsylvania,Pfizer,National Cancer Institute (NCI),,,,,Not Applicable,Other|Industry|NIH,Interventional,11/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00602927
4335,Fractional Resurfacing Device for Treatment of Acne Scarring,Completed,Has Results,Acne|Scar,"Device: 10,600 nm fractional carbon dioxide laser system","University of California, Irvine|Reliant Technologies, Inc. Mountain View, CA|University of Minnesota - Clinical and Translational Science Institute","University of California, Irvine","Reliant Technologies, Inc. Mountain View, CA",University of Minnesota - Clinical and Translational Science Institute,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00585286
4336,Pharmacogenomics in Autism Treatment,Completed,Has Results,Autism,Drug: Risperidone,"University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)","University of California, San Francisco","Janssen, LP",National Institute of Mental Health (NIMH),,,,,Phase 2|Phase 3,Other|Industry|NIH,Interventional,1/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00584701
4337,Study of Breast Cancer Prevention by Letrozole in High Risk Women,Completed,Has Results,Breast Cancer,Drug: Letrozole|Drug: Placebo,"Carol Fabian, MD|Novartis|National Cancer Institute (NCI)|University of Kansas Medical Center","Carol Fabian, MD",Novartis,National Cancer Institute (NCI)|University of Kansas Medical Center,National Cancer Institute (NCI),University of Kansas Medical Center,,,Phase 2,Other|Industry|NIH,Interventional,10/6/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00579826
4338,An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,Completed,Has Results,Melanoma,Drug: GSK2118436|Drug: GSK1120212,M.D. Anderson Cancer Center|Cancer Prevention Research Institute of Texas|GlaxoSmithKline,M.D. Anderson Cancer Center,Cancer Prevention Research Institute of Texas,GlaxoSmithKline,,,,,Phase 2,Other|Industry,Interventional,9/12/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01619774
4339,Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection,Completed,Has Results,HIV Infections,Drug: Etravirine (Intelence)|Drug: Truvada,"University of North Carolina, Chapel Hill|Janssen Pharmaceuticals","University of North Carolina, Chapel Hill",Janssen Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,9/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00959894
4340,Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients,Completed,Has Results,Acute Respiratory Failure|Anxiety,Drug: Dexmedetomidine,"University of Minnesota - Clinical and Translational Science Institute|National Institute of Nursing Research (NINR)|Hospira, now a wholly owned subsidiary of Pfizer",University of Minnesota - Clinical and Translational Science Institute,National Institute of Nursing Research (NINR),"Hospira, now a wholly owned subsidiary of Pfizer",,,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,3/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01606852
4341,Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers,Completed,Has Results,Breast Cancer,Drug: Exemestane|Drug: Docetaxel|Drug: Cytoxan,Emory University|Pfizer,Emory University,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,7/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00941330
4342,Sodium Nitrite in Acute Myocardial Infarction,Completed,Has Results,Acute Myocardial Infarction,Drug: Sodium Nitrite,Johns Hopkins University|Hope Pharmaceuticals,Johns Hopkins University,Hope Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,7/9/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT00924118
4343,Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency,Completed,Has Results,Type 2 Diabetes|Renal Insufficiency,Drug: 0.5 units/kg daily insulin|Drug: 0.25 units/kg daily insulin,Loyola University|Sanofi,Loyola University,Sanofi,,,,,,Phase 4,Other|Industry,Interventional,1/21/2009,6/30/2011,https://ClinicalTrials.gov/show/NCT00911625
4344,"Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",Completed,Has Results,Adenoid Cystic Carcinoma,Drug: AG-013736 (AXITINIB),Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Pfizer,Memorial Sloan Kettering Cancer Center,National Comprehensive Cancer Network,Pfizer,,,,,Phase 2,Other|Industry,Interventional,3/12/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01558661
4345,"Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",Completed,Has Results,Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,Drug: cisplatin|Biological: pegfilgrastim|Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis|Genetic: polymorphism analysis|Other: pharmacogenomic studies|Genetic: genetic linkage analysis|Drug: docetaxel,Wake Forest University Health Sciences|National Cancer Institute (NCI)|OSI Pharmaceuticals,Wake Forest University Health Sciences,National Cancer Institute (NCI),OSI Pharmaceuticals,,,,,Phase 2,Other|NIH|Industry,Interventional,7/7/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01557959
4346,Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer,Completed,Has Results,Extrahepatic Bile Duct Cancer|Nausea|Vomiting|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,Drug: aprepitant|Drug: gemcitabine hydrochloride|Drug: capecitabine|Drug: fluorouracil|Procedure: radiation therapy|Other: questionnaire administration|Procedure: quality-of-life assessment|Procedure: nausea and vomiting therapy|Procedure: management of therapy complications,Wake Forest University Health Sciences|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.,Wake Forest University Health Sciences,National Cancer Institute (NCI),Merck Sharp & Dohme Corp.,,,,,Phase 2,Other|NIH|Industry,Interventional,8/6/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01534637
4347,High-strength Glass-ionomer Dental Restorations,Completed,Has Results,Dental Caries,Device: Chemfil ROCK Glassionomer restoration|Device: Fuji IX GP Extra Glassionomer restoration,"Mathilde Peters, DMD, PhD|Mott Children's Health Center|Dentsply International|University of Michigan","Mathilde Peters, DMD, PhD",Mott Children's Health Center,Dentsply International|University of Michigan,Dentsply International,University of Michigan,,,Not Applicable,Other|Industry,Interventional,11/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01523613
4348,Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus|Dyslipidemia,Drug: Simvastatin|Drug: Ezetimibe/Simvastatin,"University of Colorado, Denver|Merck Sharp & Dohme Corp.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","University of Colorado, Denver",Merck Sharp & Dohme Corp.,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,,,,Phase 2,Other|Industry|NIH,Interventional,5/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00477204
4349,A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM),Completed,Has Results,Type 1 Diabetes Mellitus,Device: GBP CGM,"University of Virginia|Juvenile Diabetes Research Foundation|Becton, Dickinson and Company",University of Virginia,Juvenile Diabetes Research Foundation,"Becton, Dickinson and Company",,,,,Phase 2,Other|Industry,Interventional,11/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01469715
4350,Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment,Completed,Has Results,Metabolic Syndrome,Drug: simvastatin|Drug: ezetimibe/simvastatin,University of Maryland|Merck Sharp & Dohme Corp.,University of Maryland,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00819403
4351,Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding,Completed,Has Results,Herpes Simplex Type II,Drug: TDF|Drug: Placebo Vaginal Gel|Drug: Vaginal TFV Gel|Drug: Placebo Tablets,University of Washington|CONRAD|Gilead Sciences,University of Washington,CONRAD,Gilead Sciences,,,,,Phase 4,Other|Industry,Interventional,2/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01448616
4352,Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy,Completed,Has Results,HIV|AIDS|Peripheral Neuropathy|Pain|Sleep,Device: Splinting application to the lower extremities|Device: Splint liner application,Texas Woman's University|Harris County Hospital District|DJO Incorporated,Texas Woman's University,Harris County Hospital District,DJO Incorporated,,,,,Not Applicable,Other|Industry,Interventional,8/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01419314
4353,Electronic Decision Support Systems for Smokers With Severe Mental Illness,Completed,Has Results,Severe Mental Illness|Nicotine Dependence|Schizophrenia|Tobacco Use Disorder,Behavioral: EDSS with CO feedback and health checklist|Behavioral: EDSS with health checklist feedback alon,Dartmouth-Hitchcock Medical Center|U.S. Department of Education|Bristol-Myers Squibb,Dartmouth-Hitchcock Medical Center,U.S. Department of Education,Bristol-Myers Squibb,,,,,Not Applicable,Other|U.S. Fed|Industry,Interventional,5/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01412866
4354,Octreotide in Severe Polycystic Liver Disease,Completed,Has Results,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Drug: Octreotide|Drug: Placebo,Mayo Clinic|Novartis|National Center for Research Resources (NCRR),Mayo Clinic,Novartis,National Center for Research Resources (NCRR),,,,,Phase 2|Phase 3,Other|Industry|NIH,Interventional,1/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00426153
4355,Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: rosiglitazone|Drug: placebo,University of Texas Southwestern Medical Center|GlaxoSmithKline|Biosite,University of Texas Southwestern Medical Center,GlaxoSmithKline,Biosite,,,,,Phase 4,Other|Industry,Interventional,2/5/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00424762
4356,rHGH and Intestinal Permeability in Intestinal Failure,Completed,Has Results,Short Bowel Syndrome,Drug: Somatropin|Procedure: Seven Day Food Diary|Procedure: Blood Tests (standard of care)|Other: Fasting|Other: Sugar Permeability Test|Other: Urine Collection,Northwestern University|Northwestern Memorial Hospital|EMD Serono,Northwestern University,Northwestern Memorial Hospital,EMD Serono,,,,,Phase 4,Other|Industry,Interventional,10/6/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01380366
4357,"Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)",Completed,Has Results,Gastrointestinal Neoplasms|Ovarian Neoplasms,Drug: Gemcitabine,Department of Radiation Oncology|Eli Lilly and Company|University of Maryland,Department of Radiation Oncology,Eli Lilly and Company,University of Maryland,,,,,Phase 1|Phase 2,Other|Industry,Interventional,10/3/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00390182
4358,Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder,Completed,Has Results,Transitional Cell Carcinoma of the Bladder,Drug: Dasatinib|Procedure: Radical Cystectomy,Hoosier Cancer Research Network|Bristol-Myers Squibb,Hoosier Cancer Research Network,Bristol-Myers Squibb,,,,,,Not Applicable,Other|Industry,Interventional,6/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00706641
4359,Study of Sildenafil Citrate on Insulin Resistance in African American,Completed,Has Results,Metabolic Syndrome|Obesity,Drug: Sildenafil|Drug: Placebo,"Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer",Vanderbilt University Medical Center,"National Heart, Lung, and Blood Institute (NHLBI)",Pfizer,,,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,4/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01334554
4360,Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer,Completed,Has Results,Bladder Cancer,Drug: Erlotinib|Procedure: Radical Cystectomy,UNC Lineberger Comprehensive Cancer Center|OSI Pharmaceuticals|National Cancer Institute (NCI),UNC Lineberger Comprehensive Cancer Center,OSI Pharmaceuticals,National Cancer Institute (NCI),,,,,Phase 2,Other|Industry|NIH,Interventional,5/6/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00380029
4361,Beta-hCG + Erythropoietin in Acute Stroke,Completed,Has Results,Acute Stroke,Drug: Dual Growth Factor,"University of California, Irvine|Stem Cell Therapeutics Corp.|Hoag Memorial Hospital Presbyterian","University of California, Irvine",Stem Cell Therapeutics Corp.,Hoag Memorial Hospital Presbyterian,,,,,Phase 2,Other|Industry,Interventional,8/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00362414
4362,IV Glucose for Dehydration Treatment,Completed,Has Results,Dehydration,Drug: 5% Dextrose (D5) in Normal Saline (NS)|Drug: Normal Saline (NS),Children's Hospital of Philadelphia|American Academy of Pediatrics|Academic Pediatric Association,Children's Hospital of Philadelphia,American Academy of Pediatrics,Academic Pediatric Association,,,,,Phase 2,Other|Industry,Interventional,9/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01285713
4363,A Phase II Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults,Completed,Has Results,Dengue,Biological: Pre-transfection F17|Biological: Post-transfection F17|Biological: Post-transfection F19|Other: Placebo,U.S. Army Medical Research and Development Command|GlaxoSmithKline|Walter Reed Army Institute of Research (WRAIR),U.S. Army Medical Research and Development Command,GlaxoSmithKline,Walter Reed Army Institute of Research (WRAIR),,,,,Phase 2,U.S. Fed|Industry,Interventional,1/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00350337
4364,Acceptability of the NuvaRing Among Students,Completed,Has Results,Birth Control Compliance,Drug: Ortho Tri-cyclen Lo|Device: NuvaRing,University of Chicago|Organon,University of Chicago,Organon,,,,,,Phase 4,Other|Industry,Interventional,7/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00635570
4365,Reader Study of DeltaView™ Chest Radiograph Software,Completed,Has Results,Lung Neoplasm,,"Georgetown University|Riverain Medical Group, Miamisburg, OH|BioStat Solutions, Inc., Mt. Airy, MD",Georgetown University,"Riverain Medical Group, Miamisburg, OH","BioStat Solutions, Inc., Mt. Airy, MD",,,,,,Other|Industry,Observational,11/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01261507
4366,Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.,Completed,Has Results,Multiple Myeloma,Drug: melphalan|Drug: topotecan (TPT)|Procedure: Autologous Stem Cell Rescue,H. Lee Moffitt Cancer Center and Research Institute|GlaxoSmithKline|National Cancer Institute (NCI),H. Lee Moffitt Cancer Center and Research Institute,GlaxoSmithKline,National Cancer Institute (NCI),,,,,Phase 1|Phase 2,Other|Industry|NIH,Interventional,11/19/2001,1/30/2018,https://ClinicalTrials.gov/show/NCT00325416
4367,Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease,Completed,Has Results,Cardiovascular Disease,Behavioral: oral education & written tips for remembering medications|Device: pill box|Device: pocket medication card|Behavioral: sharing information with community pharmacist|Behavioral: Medication use evaluations by community pharmacist|Behavioral: informing physician if patient has stopped a medication|Behavioral: Routine discharge counseling|Other: Letter to physician/discharge summary,Duke University|Pfizer|Agency for Healthcare Research and Quality (AHRQ),Duke University,Pfizer,Agency for Healthcare Research and Quality (AHRQ),,,,,Not Applicable,Other|Industry|U.S. Fed,Interventional,6/6/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00323258
4368,Optimizing Body Composition for Function in Older Adults,Completed,Has Results,Obesity|Overweight With Indications for Weight Loss,Drug: Pioglitazone|Behavioral: Resistance exercise training to maximize muscle power|Behavioral: Hypocaloric diet|Drug: Placebo,"Wake Forest University Health Sciences|Takeda Pharmaceuticals North America, Inc.|National Institute on Aging (NIA)",Wake Forest University Health Sciences,"Takeda Pharmaceuticals North America, Inc.",National Institute on Aging (NIA),,,,,Phase 4,Other|Industry|NIH,Interventional,4/6/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00315146
4369,An Evaluation of Safety and Feasibility Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression,Completed,Has Results,Depression,Device: rTMS Treatment,Mayo Clinic|Eli Lilly and Company,Mayo Clinic,Eli Lilly and Company,,,,,,Not Applicable,Other|Industry,Interventional,5/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00587639
4370,Memantine and Cognitive Dysfunction in Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: Memantine|Drug: Placebo,Massachusetts General Hospital|Forest Laboratories,Massachusetts General Hospital,Forest Laboratories,,,,,,Phase 4,Other|Industry,Interventional,11/5/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00586066
4371,Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet,Completed,Has Results,Psoriasis,Biological: Etanercept|Other: Placebo injections,"University of California, Irvine|Amgen","University of California, Irvine",Amgen,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00585650
4372,Comparative Trial Between 3 Types of Insulin Infusion Protocols,Completed,Has Results,Hyperglycemia,Procedure: Glucommander-Guided Intravenous Insulin Infusion|Procedure: Standard Intravenous Insulin Infusion|Procedure: Simple Calculated Intravenous Insulin Infusion,University of New Mexico|Sanofi,University of New Mexico,Sanofi,,,,,,Not Applicable,Other|Industry,Interventional,8/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00582309
4373,Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks,Completed,Has Results,HIV Infections|Heart Disease,Drug: Rosuvastatin 10 mg. daily for 96 weeks|Drug: Placebo,University Hospitals Cleveland Medical Center|National Institutes of Health (NIH)|AstraZeneca,University Hospitals Cleveland Medical Center,National Institutes of Health (NIH),AstraZeneca,,,,,Phase 2,Other|NIH|Industry,Interventional,2/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01218802
4374,AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment,Completed,Has Results,"Depressive Disorder, Major",Drug: Testosterone gel|Drug: Placebo,Mclean Hospital|Solvay Pharmaceuticals,Mclean Hospital,Solvay Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,4/6/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00304746
4375,Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma,Completed,Has Results,Brain Tumors|Osteoporosis|Central Nervous System(CNS)Malignancies,Drug: IV Zometa,Duke University|Novartis|National Institute of Neurological Disorders and Stroke (NINDS),Duke University,Novartis,National Institute of Neurological Disorders and Stroke (NINDS),,,,,Phase 2,Other|Industry|NIH,Interventional,5/6/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00301873
4376,Glycine vs Placebo for the Schizophrenia Prodrome,Completed,Has Results,Schizophrenia Prodrome,Drug: Glycine|Drug: Placebo,"Yale University|Glytech, Inc|National Alliance for Research on Schizophrenia and Depression",Yale University,"Glytech, Inc",National Alliance for Research on Schizophrenia and Depression,,,,,Phase 2|Phase 3,Other|Industry,Interventional,3/6/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00291226
4377,Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women,Completed,Has Results,Healthy,Drug: Fulvestrant,Mayo Clinic|National Institutes of Health (NIH)|AstraZeneca,Mayo Clinic,National Institutes of Health (NIH),AstraZeneca,,,,,Phase 1,Other|NIH|Industry,Interventional,6/9/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01186796
4378,Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia,Completed,Has Results,Hyperglycemia,Drug: NPH insulin plus Complete Insulin Orders|Drug: Complete Insulin Orders,HealthPartners Institute|International Diabetes Center at Park Nicollet|Sanofi,HealthPartners Institute,International Diabetes Center at Park Nicollet,Sanofi,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01184014
4379,The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Exenatide SC|Drug: Exenatide IV|Drug: Placebo SC|Drug: Exendin-9|Drug: Placebo IV,"Carl T. Hayden VA Medical Center|American Diabetes Association|Amylin Pharmaceuticals, LLC.",Carl T. Hayden VA Medical Center,American Diabetes Association,"Amylin Pharmaceuticals, LLC.",,,,,Phase 4,U.S. Fed|Other|Industry,Interventional,8/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01181986
4380,Phase II Dasatinib Study in Advanced Breast Cancer,Completed,Has Results,Advanced Breast Cancer,Drug: Dasatinib,Duke University|Bristol-Myers Squibb,Duke University,Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00546104
4381,Treatment of Apathy in Alzheimer's Disease With Modafinil,Completed,Has Results,Apathy|Alzheimer's Disease,Drug: Modafinil|Drug: Placebo,Brown University|National Institute of Mental Health (NIMH)|Cephalon,Brown University,National Institute of Mental Health (NIMH),Cephalon,,,,,Phase 3,Other|NIH|Industry,Interventional,7/5/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT01172145
4382,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,Completed,Has Results,Malignant Melanoma,Drug: Peginterferon alfa-2b|Drug: Temozolomide|Drug: Recombinant interferon alfa-2b,St. Jude Children's Research Hospital|Schering-Plough,St. Jude Children's Research Hospital,Schering-Plough,,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT00539591
4383,Nilotinib in the Treatment of Systemic Sclerosis,Completed,Has Results,Systemic Sclerosis,Drug: Nilotinib (Tasigna),"Hospital for Special Surgery, New York|Rudolph Rupert Scleroderma Program|Novartis Pharmaceuticals","Hospital for Special Surgery, New York",Rudolph Rupert Scleroderma Program,Novartis Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,7/10/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01166139
4384,Ranibizumab and Reduced Fluence PDT for AMD,Completed,Has Results,Macular Degeneration,Drug: ranibizumab|Drug: verteporfin,Texas Retina Associates|Novartis,Texas Retina Associates,Novartis,,,,,,Phase 2,Other|Industry,Interventional,5/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00527475
4385,Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation,Completed,Has Results,Major Depressive Disorder|Suicidal Ideation,Drug: paliperidone|Drug: lithium|Drug: Placebo,"University of Alabama at Birmingham|American Foundation for Suicide Prevention|Ortho-McNeil Janssen Scientific Affairs, LLC",University of Alabama at Birmingham,American Foundation for Suicide Prevention,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,Phase 4,Other|Industry,Interventional,5/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01134731
4386,Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy,Completed,Has Results,Adenocarcinoma of the Esophagus|Adenocarcinomas of the Gastroesophageal Junction|Recurrent Esophageal Cancer|Squamous Cell Carcinoma of the Esophagus|Stage IV Esophageal Cancer,Drug: pralatrexate|Drug: docetaxel|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography,"Ohio State University Comprehensive Cancer Center|National Comprehensive Cancer Network|Spectrum Pharmaceuticals, Inc",Ohio State University Comprehensive Cancer Center,National Comprehensive Cancer Network,"Spectrum Pharmaceuticals, Inc",,,,,Phase 2,Other|Industry,Interventional,7/10/2019,,https://ClinicalTrials.gov/show/NCT01129206
4387,Magnetic Resonance Imaging Study of Geriatric Depression,Completed,Has Results,Major Depressive Disorder,Drug: Sertraline,Mclean Hospital|Pfizer|National Alliance for Research on Schizophrenia and Depression,Mclean Hospital,Pfizer,National Alliance for Research on Schizophrenia and Depression,,,,,Not Applicable,Other|Industry,Interventional,11/4/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00245557
4388,Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale,Completed,Has Results,Healthy,Drug: Cholestyramine|Drug: Colesevelam HCl,"Louisville Metabolic and Atherosclerosis Research Center|Provident Clinical Research|Daiichi Sankyo, Inc.",Louisville Metabolic and Atherosclerosis Research Center,Provident Clinical Research,"Daiichi Sankyo, Inc.",,,,,Phase 4,Other|Industry,Interventional,4/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01122108
4389,Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome,Completed,Has Results,Dry Eye Syndrome,Drug: Oral Omega-3-acid ethyl esters|Drug: Placebo corn oil capsule,Milton S. Hershey Medical Center|The American Society of Cataract and Refractive Surgery Foundation|GlaxoSmithKline,Milton S. Hershey Medical Center,The American Society of Cataract and Refractive Surgery Foundation,GlaxoSmithKline,,,,,Not Applicable,Other|Industry,Interventional,7/10/2019,6/15/2015,https://ClinicalTrials.gov/show/NCT01107964
4390,An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study,Completed,Has Results,Carpometacarpal Osteoarthritis,Device: Synvisc (hylan G-F20),"Hospital for Special Surgery, New York|Genzyme, a Sanofi Company|National Institutes of Health (NIH)","Hospital for Special Surgery, New York","Genzyme, a Sanofi Company",National Institutes of Health (NIH),,,,,Not Applicable,Other|Industry|NIH,Interventional,10/4/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00198029
4391,Depakote ER in Bipolar Depression,Completed,Has Results,"Depression, Bipolar",Drug: Depakote ER,Stanford University|Abbott|National Alliance for Research on Schizophrenia and Depression,Stanford University,Abbott,National Alliance for Research on Schizophrenia and Depression,,,,,Phase 4,Other|Industry,Interventional,1/4/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00186186
4392,"A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa",Completed,Has Results,Anorexia Nervosa,Drug: Risperidone|Drug: Placebo,"University of Colorado, Denver|Janssen Pharmaceuticals|National Center for Research Resources (NCRR)","University of Colorado, Denver",Janssen Pharmaceuticals,National Center for Research Resources (NCRR),,,,,Phase 4,Other|Industry|NIH,Interventional,8/4/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00140426
4393,Mesalamine to Reduce T Cell Activation in HIV Infection,Completed,Has Results,HIV Infections|Sexually Transmitted Diseases|Immune System Diseases|Lentivirus Infections|Acquired Immunodeficiency Syndrome,"Drug: Mesalamine (5-aminosalicylic acid, Apriso)|Drug: Placebo","University of California, San Francisco|California HIV/AIDS Research Program|Bausch Health Americas, Inc.","University of California, San Francisco",California HIV/AIDS Research Program,"Bausch Health Americas, Inc.",,,,,Phase 4,Other|Industry,Interventional,6/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01090102
4394,Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine,Completed,Has Results,Type 2 Diabetes,Drug: Exenatide|Drug: Insulin Glargine,HealthPartners Institute|International Diabetes Center at Park Nicollet|Sanofi,HealthPartners Institute,International Diabetes Center at Park Nicollet,Sanofi,,,,,Not Applicable,Other|Industry,Interventional,4/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01089569
4395,Understanding Mechanisms of Acquired Resistance to BIBW2992,Completed,Has Results,Non-small Cell Lung Cancer|EGFR Mutations,Drug: BIBW 2992,Massachusetts General Hospital|University of Texas|Boehringer Ingelheim,Massachusetts General Hospital,University of Texas,Boehringer Ingelheim,,,,,Not Applicable,Other|Industry,Interventional,2/11/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT01074177
4396,Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation,Completed,Has Results,Heat Stress Disorders,Drug: Daily aspirin (ASA)|Other: Active cooling|Drug: Acute aspirin (ASA)|Other: Passive cooling|Drug: Daily placebo|Drug: Acute placebo,"Dave Hostler|Federal Emergency Management Administration|Eyemarker Systems, Inc|University of Pittsburgh",Dave Hostler,Federal Emergency Management Administration,"Eyemarker Systems, Inc|University of Pittsburgh","Eyemarker Systems, Inc",University of Pittsburgh,,,Not Applicable,Other|Industry,Interventional,2/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01066923
4397,"Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training",Completed,Has Results,Alzheimer's Disease,Behavioral: Individualized management of AD including caregiver training|Drug: Memantine,NYU Langone Health|Forest Laboratories|Fisher Center for Alzheimer's Research Foundation,NYU Langone Health,Forest Laboratories,Fisher Center for Alzheimer's Research Foundation,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00120874
4398,A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study,Completed,Has Results,Healthy,Drug: Cholestyramine|Drug: Tang,"Louisville Metabolic and Atherosclerosis Research Center|Provident Clinical Research|Daiichi Sankyo, Inc.",Louisville Metabolic and Atherosclerosis Research Center,Provident Clinical Research,"Daiichi Sankyo, Inc.",,,,,Phase 4,Other|Industry,Interventional,1/10/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01062269
4399,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Completed,Has Results,Mitral Regurgitation,Drug: metoprolol succinate (Toprol XL)|Drug: Placebo,"University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca",University of Alabama at Birmingham,"National Heart, Lung, and Blood Institute (NHLBI)",AstraZeneca,,,,,Phase 2|Phase 3,Other|NIH|Industry,Interventional,8/4/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01052428
4400,Impact of Diabetes on Left Ventricular Remodeling,Completed,Has Results,Diabetes,Drug: Ramipril|Drug: Candesartan cilexetil|Drug: Allopurinol,"University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca",University of Alabama at Birmingham,"National Heart, Lung, and Blood Institute (NHLBI)",AstraZeneca,,,,,Phase 2|Phase 3,Other|NIH|Industry,Interventional,7/5/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01052272
4401,Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Azacitidine,Virginia Commonwealth University|National Cancer Institute (NCI)|Celgene Corporation,Virginia Commonwealth University,National Cancer Institute (NCI),Celgene Corporation,,,,,Not Applicable,Other|NIH|Industry,Interventional,1/10/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01050790
4402,Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia,Completed,Has Results,Cardiovascular Disease,Drug: Fenofibrate (Tricor) tablets|Drug: Placebo|Drug: Lovaza,"University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|GlaxoSmithKline",University of Pennsylvania,"National Heart, Lung, and Blood Institute (NHLBI)",GlaxoSmithKline,,,,,Not Applicable,Other|NIH|Industry,Interventional,1/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01048502
4403,Study of Self or Clinic Administration of DepoProvera,Completed,Has Results,Contraception,Drug: Medroxyprogesterone 17-Acetate,Carolyn L. Westhoff|Family Planning Fellowship|Pfizer|Columbia University,Carolyn L. Westhoff,Family Planning Fellowship,Pfizer|Columbia University,Pfizer,Columbia University,,,Not Applicable,Other|Industry,Interventional,3/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01019369
4404,The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge,Completed,Has Results,Cat Allergy,Drug: Omalizumab|Drug: Placebo,"Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|Genentech, Inc.",Johns Hopkins University,National Institute of Allergy and Infectious Diseases (NIAID),"Genentech, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,10/9/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01003301
4405,Aprepitant Effects on Oxycodone Response,Completed,Has Results,Narcotic Abuse,"Drug: Aprepitant 0mg|Drug: Aprepitant 40mg|Drug: Aprepitant 200mg|Drug: Oxycodone 0mg, p.o.|Drug: Oxycodone 20mg, p.o.|Drug: Oxycodone 40mg, p.o.|Drug: Oxycodone 0mg, IN|Drug: Oxycodone 15mg, IN|Drug: Oxycodone 30mg, IN",Sharon Walsh|National Institute on Drug Abuse (NIDA)|Merck Sharp & Dohme Corp.|University of Kentucky,Sharon Walsh,National Institute on Drug Abuse (NIDA),Merck Sharp & Dohme Corp.|University of Kentucky,Merck Sharp & Dohme Corp.,University of Kentucky,,,Not Applicable,Other|NIH|Industry,Interventional,10/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00999544
4406,Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Long-acting bedtime insulin detemir (Levemir)|Drug: Insulin detemir and pre-meal insulin aspart.,University of Florida|VA Office of Research and Development|Novo Nordisk A/S,University of Florida,VA Office of Research and Development,Novo Nordisk A/S,,,,,Phase 4,Other|U.S. Fed|Industry,Interventional,6/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00998335
4407,Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents,Completed,Has Results,Adolescent Methamphetamine Abuse,Drug: Bupropion SR 150mg tabs|Drug: Placebo tablets,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)|Behavioral Health Services, Inc.","University of California, Los Angeles",National Institute on Drug Abuse (NIDA),"Behavioral Health Services, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,10/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00994448
4408,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: colesevelam HCl|Drug: placebo,"HealthPartners Institute|International Diabetes Center at Park Nicollet|Daiichi Sankyo, Inc.",HealthPartners Institute,International Diabetes Center at Park Nicollet,"Daiichi Sankyo, Inc.",,,,,Phase 2|Phase 3,Other|Industry,Interventional,9/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00993824
4409,Effects of Gastric Bypass on Blood Levels of Duloxetine,Completed,Has Results,Bariatric Surgery,Drug: Duloxetine,"Neuropsychiatric Research Institute, Fargo, North Dakota|University of North Dakota|Eli Lilly and Company","Neuropsychiatric Research Institute, Fargo, North Dakota",University of North Dakota,Eli Lilly and Company,,,,,Phase 3,Other|Industry,Interventional,9/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00989157
4410,"A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies",Completed,Has Results,Hematologic Malignancies,Procedure: extracorporeal photopheresis|Drug: Pentostatin|Radiation: Total Body Irradiation,"Yale University|Hospira, now a wholly owned subsidiary of Pfizer",Yale University,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 2,Other|Industry,Interventional,7/6/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00402714
4411,Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia,Completed,Has Results,Waldenstrom's Macroglobulinemia,Drug: RAD001,Dana-Farber Cancer Institute|Brigham and Women's Hospital|Novartis,Dana-Farber Cancer Institute,Brigham and Women's Hospital,Novartis,,,,,Phase 2,Other|Industry,Interventional,11/9/2019,7/18/2019,https://ClinicalTrials.gov/show/NCT00976248
4412,Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor,Completed,Has Results,Multiple Sclerosis,Device: Deep Brain Stimulation,University of Florida|National Institute of Neurological Disorders and Stroke (NINDS)|Medtronic,University of Florida,National Institute of Neurological Disorders and Stroke (NINDS),Medtronic,,,,,Not Applicable,Other|NIH|Industry,Interventional,11/6/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00954421
4413,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,Completed,Has Results,Sarcoma,Drug: temsirolimus plus liposomal doxorubicin,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Comprehensive Cancer Network|Wyeth is now a wholly owned subsidiary of Pfizer,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Comprehensive Cancer Network,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/9/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00949325
4414,Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease,Completed,Has Results,Cystic Fibrosis,Drug: Lucinactant first|Drug: Placebo first,"University of North Carolina, Chapel Hill|Cystic Fibrosis Foundation|Windtree Therapeutics","University of North Carolina, Chapel Hill",Cystic Fibrosis Foundation,Windtree Therapeutics,,,,,Phase 2,Other|Industry,Interventional,10/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00934362
4415,Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO),Completed,Has Results,Alternating Hemiplegia of Childhood,Drug: Sodium Oxybate,University of Utah|Alternating Hemiplegia of Childhood Foundation|Jazz Pharmaceuticals,University of Utah,Alternating Hemiplegia of Childhood Foundation,Jazz Pharmaceuticals,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00931164
4416,Alendronate in Juvenile Osteoporosis,Completed,Has Results,Juvenile Osteoporosis|Low Bone Density|Fractures,Drug: Alendronate (Fosamax),Medical University of South Carolina|FDA Office of Orphan Products Development|Merck Sharp & Dohme Corp.,Medical University of South Carolina,FDA Office of Orphan Products Development,Merck Sharp & Dohme Corp.,,,,,,Other|U.S. Fed|Industry,Observational,7/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00920075
4417,Vatalanib in Treating Patients With Recurrent or Progressive Meningioma,Completed,Has Results,Brain and Central Nervous System Tumors|Sarcoma,Drug: vatalanib,Northwestern University|Novartis,Northwestern University,Novartis,,,,,,Phase 2,Other|Industry,Interventional,5/6/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00348790
4418,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Completed,Has Results,Pervasive Developmental Disorder,Drug: Aripiprazole oral product|Drug: Placebo oral capsule,Indiana University|National Institute of Mental Health (NIMH)|Bristol-Myers Squibb,Indiana University,National Institute of Mental Health (NIMH),Bristol-Myers Squibb,,,,,Phase 3,Other|NIH|Industry,Interventional,2/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00870727
4419,Buprenorphine/Raltegravir Pharmacokinetic Interaction Study,Completed,Has Results,HIV Infection|HIV Infections,Drug: Raltegravir,Yale University|National Institute on Drug Abuse (NIDA)|Merck Sharp & Dohme Corp.,Yale University,National Institute on Drug Abuse (NIDA),Merck Sharp & Dohme Corp.,,,,,Not Applicable,Other|NIH|Industry,Interventional,3/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00858962
4420,Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma,Completed,Has Results,Leiomyosarcoma,Drug: letrozole,Dana-Farber Cancer Institute|Brigham and Women's Hospital|Novartis,Dana-Farber Cancer Institute,Brigham and Women's Hospital,Novartis,,,,,Phase 2,Other|Industry,Interventional,2/9/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00856050
4421,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,Completed,Has Results,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Drug: Maraviroc|Drug: placebo,"University of California, San Francisco|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer","University of California, San Francisco","National Heart, Lung, and Blood Institute (NHLBI)",Pfizer,,,,,Phase 3,Other|NIH|Industry,Interventional,1/10/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00844519
4422,Effect of Raltegravir on Endothelial Function in HIV-Infected Patients,Completed,Has Results,HIV Infection|Inflammation|Cardiovascular Disease|HIV Infections,Drug: raltegravir|Drug: Placebo,"University of California, San Francisco|National Heart, Lung, and Blood Institute (NHLBI)|Merck Sharp & Dohme Corp.","University of California, San Francisco","National Heart, Lung, and Blood Institute (NHLBI)",Merck Sharp & Dohme Corp.,,,,,Phase 4,Other|NIH|Industry,Interventional,1/9/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00843713
4423,Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance,Completed,Has Results,Metabolic Syndrome|Bipolar Depression|Insulin Resistance,Drug: Pioglitazone,"University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|Takeda Pharmaceuticals North America, Inc.",University Hospitals Cleveland Medical Center,National Alliance for Research on Schizophrenia and Depression,"Takeda Pharmaceuticals North America, Inc.",,,,,Phase 4,Other|Industry,Interventional,3/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00835120
4424,"Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",Completed,Has Results,Breast Cancer,Drug: bendamustine|Drug: erlotinib|Drug: Maintenance erlotinib,"Ohio State University Comprehensive Cancer Center|National Comprehensive Cancer Network|Genentech, Inc.",Ohio State University Comprehensive Cancer Center,National Comprehensive Cancer Network,"Genentech, Inc.",,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/9/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00834678
4425,Quetiapine Augmentation for Treatment-resistant PTSD,Completed,Has Results,"Combat Disorders|Stress Disorders, Post-Traumatic",Drug: Open Label (OL) Paroxetine|Drug: Placebo|Drug: Quetiapine,US Department of Veterans Affairs|AstraZeneca|VA Office of Research and Development,US Department of Veterans Affairs,AstraZeneca,VA Office of Research and Development,,,,,Phase 4,U.S. Fed|Industry,Interventional,1/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00292370
4426,Testosterone Replacement in Older Men and Atherosclerosis Progression,Completed,Has Results,Hypogonadism|Atherosclerosis,Drug: Testosterone Gel (Androgel)|Drug: Placebo,Brigham and Women's Hospital|Solvay Pharmaceuticals,Brigham and Women's Hospital,Solvay Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,9/4/2019,5/12/2012,https://ClinicalTrials.gov/show/NCT00287586
4427,Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Small Cell|Lung Cancer",Drug: Vinflunine,"SCRI Development Innovations, LLC|Bristol-Myers Squibb","SCRI Development Innovations, LLC",Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,1/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00284154
4428,"Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality",Completed,Has Results,Chronic Pancreatitis|Insulin Resistance|Normal or Mildly Abnormal Stool Fat Levels,Drug: Pioglitazone|Drug: Placebo,"University of Michigan|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Takeda Pharmaceuticals North America, Inc.",University of Michigan,National Institute on Alcohol Abuse and Alcoholism (NIAAA),"Takeda Pharmaceuticals North America, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,11/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00782795
4429,Treatment Response of Geriatric Depression,Completed,Has Results,Depression,Drug: Escitalopram,Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)|Forest Laboratories,Weill Medical College of Cornell University,National Institute of Mental Health (NIMH),Forest Laboratories,,,,,Not Applicable,Other|NIH|Industry,Interventional,5/7/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00754936
4430,Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy,Completed,Has Results,Prostate Cancer,Drug: lapatinib ditosylate,UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline,UNC Lineberger Comprehensive Cancer Center,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,10/5/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00246753
4431,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery,Completed,Has Results,Intraocular Melanoma,Drug: nab-paclitaxel,Ohio State University Comprehensive Cancer Center|National Comprehensive Cancer Network|Celgene Corporation,Ohio State University Comprehensive Cancer Center,National Comprehensive Cancer Network,Celgene Corporation,,,,,Phase 2,Other|Industry,Interventional,8/8/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00738361
4432,Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds,Completed,Has Results,Wrinkles,Drug: onabotulinumtoxinA|Drug: JUVÉDERM,"AboutSkin Dermatology and DermSurgery, PC|Allergan","AboutSkin Dermatology and DermSurgery, PC",Allergan,,,,,,Phase 4,Industry,Interventional,1/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01269801
4433,"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",Completed,Has Results,Lung Cancer,Drug: carboplatin|Drug: paclitaxel albumin-stabilized nanoparticle formulation|Genetic: protein expression analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis,Greg Otterson|National Comprehensive Cancer Network|Celgene Corporation|Ohio State University Comprehensive Cancer Center,Greg Otterson,National Comprehensive Cancer Network,Celgene Corporation|Ohio State University Comprehensive Cancer Center,Celgene Corporation,Ohio State University Comprehensive Cancer Center,,,Phase 2,Other|Industry,Interventional,8/14/2008,12/16/2011,https://ClinicalTrials.gov/show/NCT00729612
4434,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,Completed,Has Results,"Myocardial Infarction|Death, Sudden, Cardiac",Drug: Omega-3 Fatty Acids (Fish Oil Supplements)|Drug: Placebo,"Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)|GlaxoSmithKline",Brigham and Women's Hospital,"National Heart, Lung, and Blood Institute (NHLBI)",GlaxoSmithKline,,,,,Phase 3,Other|NIH|Industry,Interventional,8/8/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00729430
4435,Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy,Completed,Has Results,Inflammatory Bowel Disease,Biological: Gardasil vaccine,Boston Children’s Hospital|Harvard School of Public Health|Merck Sharp & Dohme Corp.,Boston Children’s Hospital,Harvard School of Public Health,Merck Sharp & Dohme Corp.,,,,,Not Applicable,Other|Industry,Interventional,7/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00727636
4436,Neoadjuvant GW572016 to Treat Breast Cancer,Completed,Has Results,Breast Cancer,Drug: GW572016|Drug: lapatinib,Baylor Breast Care Center|GlaxoSmithKline,Baylor Breast Care Center,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,8/4/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00206427
4437,Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation,Completed,Has Results,Liver Disease,Drug: mycophenolate mofetil,Albert Einstein Healthcare Network|Hoffmann-La Roche,Albert Einstein Healthcare Network,Hoffmann-La Roche,,,,,,Phase 4,Other|Industry,Interventional,8/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00206076
4438,Efficacy of Losartan in Preventing Progression of COPD,Completed,Has Results,COPD|Emphysema|Chronic Bronchitis|Smoking,Drug: Losartan|Drug: Placebo,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)|Merck Sharp & Dohme Corp.",Johns Hopkins University,"National Heart, Lung, and Blood Institute (NHLBI)",Merck Sharp & Dohme Corp.,,,,,Phase 4,Other|NIH|Industry,Interventional,7/8/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT00720226
4439,A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression,Completed,Has Results,Thyroid Cancer,Drug: Bexarotene,"University of Colorado, Denver|American Cancer Society, Inc.|Eisai Inc.","University of Colorado, Denver","American Cancer Society, Inc.",Eisai Inc.,,,,,Early Phase 1,Other|Industry,Interventional,11/8/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00718770
4440,Human Laboratory Study Of Varenicline in Smokers,Completed,Has Results,Nicotine Dependence,Drug: Placebo|Drug: Varenicline,University of Minnesota - Clinical and Translational Science Institute|National Institute on Drug Abuse (NIDA)|Pfizer,University of Minnesota - Clinical and Translational Science Institute,National Institute on Drug Abuse (NIDA),Pfizer,,,,,Not Applicable,Other|NIH|Industry,Interventional,4/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00709696
4441,Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults,Completed,Has Results,Major Depressive Disorder|Back Pain|Aged,Drug: Duloxetine,University of Pittsburgh|National Institutes of Health (NIH)|Eli Lilly and Company,University of Pittsburgh,National Institutes of Health (NIH),Eli Lilly and Company,,,,,Phase 4,Other|NIH|Industry,Interventional,5/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00696293
4442,FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy,Completed,Has Results,Cirrhosis|Hepatitis B|Hepatitis C,Device: FibroScan,"Afdhal, Nezam, M.D.|Echosens|Beth Israel Deaconess Medical Center","Afdhal, Nezam, M.D.",Echosens,Beth Israel Deaconess Medical Center,,,,,Not Applicable,Other|Industry,Interventional,3/5/2019,10/1/2008,https://ClinicalTrials.gov/show/NCT00125762
4443,Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma,Completed,Has Results,T Cell Non-Hodgkin Lymphoma,Drug: Imatinib mesylate,Dana-Farber Cancer Institute|Brigham and Women's Hospital|Novartis,Dana-Farber Cancer Institute,Brigham and Women's Hospital,Novartis,,,,,Phase 2,Other|Industry,Interventional,6/8/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00684411
4444,Combination Therapy for Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Combination of pimecrolimus and fluticasone|Drug: pimecrolimus,Children's Hospital of Philadelphia|Novartis Pharmaceuticals,Children's Hospital of Philadelphia,Novartis Pharmaceuticals,,,,,,Phase 4,Other|Industry,Interventional,10/4/2019,6/5/2019,https://ClinicalTrials.gov/show/NCT00119158
4445,Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients,Completed,Has Results,HIV Infections,Drug: raltegravir,"University of California, San Francisco|National Institute of Mental Health (NIMH)|Merck Sharp & Dohme Corp.","University of California, San Francisco",National Institute of Mental Health (NIMH),Merck Sharp & Dohme Corp.,,,,,Not Applicable,Other|NIH|Industry,Interventional,4/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00672932
4446,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Completed,Has Results,Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Drug: Quetiapine XR|Drug: Placebo for quetiapine XR,University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|AstraZeneca,University Hospitals Cleveland Medical Center,National Alliance for Research on Schizophrenia and Depression,AstraZeneca,,,,,Phase 3,Other|Industry,Interventional,4/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00671853
4447,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Completed,Has Results,Chronic Pancreatitis,Drug: Triamcinolone|Drug: Bupivicaine alone,The Cleveland Clinic|American Society for Gastrointestinal Endoscopy|TAP Pharmaceutical Products Inc.,The Cleveland Clinic,American Society for Gastrointestinal Endoscopy,TAP Pharmaceutical Products Inc.,,,,,Phase 3,Other|Industry,Interventional,3/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00658736
4448,Quetiapine for the Reduction of Cocaine Use,Completed,Has Results,Cocaine Dependence|Cocaine Abuse|Cocaine Addiction|Drug Abuse|Substance Abuse,Drug: quetiapine fumarate|Drug: Matched Placebo|Behavioral: Cognitive-behavioral Therapy,Seattle Institute for Biomedical and Clinical Research|VA Puget Sound Health Care System|AstraZeneca,Seattle Institute for Biomedical and Clinical Research,VA Puget Sound Health Care System,AstraZeneca,,,,,Not Applicable,Other|U.S. Fed|Industry,Interventional,2/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00631748
4449,Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty,Completed,Has Results,Fuchs Endothelial Dystrophy|Corneal Edema,Procedure: Descemet's stripping endothelial keratoplasty,Cornea Research Foundation of America|North Carolina Lion's Eye Bank|Price Vision Group,Cornea Research Foundation of America,North Carolina Lion's Eye Bank,Price Vision Group,,,,,Not Applicable,Other|Industry,Interventional,1/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00624221
4450,"Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics",Completed,Has Results,Breast Cancer,Drug: Anastrozole|Dietary Supplement: flaxseed|Drug: Placebo,Roswell Park Cancer Institute|National Center for Complementary and Integrative Health (NCCIH)|AstraZeneca,Roswell Park Cancer Institute,National Center for Complementary and Integrative Health (NCCIH),AstraZeneca,,,,,Not Applicable,Other|NIH|Industry,Interventional,11/7/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00612560
4451,"Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine",Completed,Has Results,Fanconi Anemia,Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total body irradiation (TBI),"Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Miltenyi Biotec, Inc.",Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),"Miltenyi Biotec, Inc.",,,,,Not Applicable,Other|NIH|Industry,Interventional,6/1/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00595127
4452,Effects of Exercise in Combination With Epoetin Alfa,Completed,Has Results,Multiple Myeloma,"Drug: Epoetin Alfa|Behavioral: Exercise|Biological: Autologous Peripheral Blood Stem Cell Transplantation|Biological: Red Blood Cell Transfusion|Drug: Thalidomide|Drug: Heparin, Low-Molecular-Weight|Biological: Platelet Transfusion|Drug: Melphalan|Drug: Total Therapy II","University of Arkansas|National Institutes of Health (NIH)|Ortho Biotech Clinical Affairs, L.L.C.",University of Arkansas,National Institutes of Health (NIH),"Ortho Biotech Clinical Affairs, L.L.C.",,,,,Not Applicable,Other|NIH|Industry,Interventional,10/1/2019,6/4/2019,https://ClinicalTrials.gov/show/NCT00577096
4453,Intranasal Insulin Treatment in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Insulin or Placebo,"University of Massachusetts, Worcester|National Alliance for Research on Schizophrenia and Depression|Eli Lilly and Company","University of Massachusetts, Worcester",National Alliance for Research on Schizophrenia and Depression,Eli Lilly and Company,,,,,Phase 4,Other|Industry,Interventional,12/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00575666
4454,Sodium Thiosulfate Treatment of Vascular Calcification in ESRD,Completed,Has Results,Complication of Hemodialysis|Cardiovascular Diseases,Drug: sodium thiosulfate,"Washington University School of Medicine|Barnes-Jewish Hospital|Genzyme, a Sanofi Company",Washington University School of Medicine,Barnes-Jewish Hospital,"Genzyme, a Sanofi Company",,,,,Not Applicable,Other|Industry,Interventional,12/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00568399
4455,A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion,Completed,Has Results,Otitis Media With Effusion,Drug: lansoprazole|Drug: placebo,Washington University School of Medicine|Doris Duke Charitable Foundation|TAP Pharmaceutical Products Inc.,Washington University School of Medicine,Doris Duke Charitable Foundation,TAP Pharmaceutical Products Inc.,,,,,Not Applicable,Other|Industry,Interventional,10/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00546117
4456,"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia",Completed,Has Results,Leukemia|Lymphoma,Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Astex Pharmaceuticals,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),Astex Pharmaceuticals,,,,,Phase 2,Other|NIH|Industry,Interventional,5/5/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT00541034
4457,Hormone and Information Processing Study,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: testosterone gel|Drug: placebo gel,University of Washington|National Institute on Aging (NIA)|Solvay Pharmaceuticals,University of Washington,National Institute on Aging (NIA),Solvay Pharmaceuticals,,,,,Phase 3,Other|NIH|Industry,Interventional,7/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00539305
4458,IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia,Completed,Has Results,Von Willebrand Disease,"Drug: Oprelvekin, Interleukin 11, IL-11",Margaret Ragni|University of North Carolina|Wyeth is now a wholly owned subsidiary of Pfizer|University of Pittsburgh,Margaret Ragni,University of North Carolina,Wyeth is now a wholly owned subsidiary of Pfizer|University of Pittsburgh,Wyeth is now a wholly owned subsidiary of Pfizer,University of Pittsburgh,,,Phase 2,Other|Industry,Interventional,1/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00524342
4459,Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia,Completed,Has Results,Insomnia|Spinal Cord Injury|Tetraplegia|Sleep Disorders,Drug: Ramelteon|Drug: Placebo,US Department of Veterans Affairs|Stanford University|Takeda|VA Office of Research and Development,US Department of Veterans Affairs,Stanford University,Takeda|VA Office of Research and Development,Takeda,VA Office of Research and Development,,,Phase 4,U.S. Fed|Other|Industry,Interventional,7/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00507546
4460,Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3],Completed,Has Results,Healthy,Drug: Dihydrotestosterone (DHT) gel (0.7%)|Drug: Placebo gel,University of Washington|National Institute on Aging (NIA)|ASCEND Therapeutics,University of Washington,National Institute on Aging (NIA),ASCEND Therapeutics,,,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,6/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00490022
4461,"Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64",Completed,Has Results,Coronary Artery Disease,Procedure: CT Angiography,"Intermountain Health Care, Inc.|Deseret Foundation|Toshiba America Medical Systems, Inc.","Intermountain Health Care, Inc.",Deseret Foundation,"Toshiba America Medical Systems, Inc.",,,,,Not Applicable,Other|Industry,Interventional,6/7/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00488033
4462,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Completed,Has Results,Alzheimer Disease|Dementia,Drug: NIC5-15|Drug: Placebo,VA Office of Research and Development|National Center for Complementary and Integrative Health (NCCIH)|Humanetics Corporation,VA Office of Research and Development,National Center for Complementary and Integrative Health (NCCIH),Humanetics Corporation,,,,,Phase 2,U.S. Fed|NIH|Industry,Interventional,1/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00470418
4463,Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer,Completed,Has Results,Colorectal Cancer,Biological: bevacizumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: conventional surgery|Radiation: radiation therapy,"Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),"Genentech, Inc.",,,,,Not Applicable,Other|NIH|Industry,Interventional,3/7/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00462501
4464,Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment,Completed,Has Results,Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor,Drug: sunitinib malate,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pfizer,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),Pfizer,,,,,Phase 2,Other|NIH|Industry,Interventional,3/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00453310
4465,Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen,Completed,Has Results,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: rabbit anti-thymocyte globulin (ATG)|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: methotrexate,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Otsuka America Pharmaceutical,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),Otsuka America Pharmaceutical,,,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,10/5/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT00448357
4466,Disease Management for Smoking Cessation,Completed,Has Results,Smoking Cessation,Behavioral: High intensity disease management|Behavioral: Low intensity disease management|Behavioral: Comparison group|Drug: Bupropion,University of Kansas Medical Center|National Cancer Institute (NCI)|GlaxoSmithKline,University of Kansas Medical Center,National Cancer Institute (NCI),GlaxoSmithKline,,,,,Phase 3,Other|NIH|Industry,Interventional,6/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00440115
4467,"Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer",Completed,Has Results,Head and Neck Cancer,Biological: bevacizumab|Drug: cisplatin|Procedure: conventional surgery|Radiation: intensity-modulated radiation therapy,"Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),"Genentech, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,10/6/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT00423930
4468,BATTLE Program: Sorafenib in Patients With NSCLC,Completed,Has Results,Lung Cancer,Drug: Sorafenib,M.D. Anderson Cancer Center|United States Department of Defense|Bayer,M.D. Anderson Cancer Center,United States Department of Defense,Bayer,,,,,Phase 2,Other|U.S. Fed|Industry,Interventional,11/6/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00411671
4469,Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma,Completed,Has Results,Lymphoma,Biological: Rituximab|Biological: Sargramostim (GM-CSF),M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bayer,M.D. Anderson Cancer Center,National Cancer Institute (NCI),Bayer,,,,,Phase 2,Other|NIH|Industry,Interventional,11/6/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT00411086
4470,BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC,Completed,Has Results,Lung Cancer,Drug: ZD6474,M.D. Anderson Cancer Center|United States Department of Defense|AstraZeneca,M.D. Anderson Cancer Center,United States Department of Defense,AstraZeneca,,,,,Phase 2,Other|U.S. Fed|Industry,Interventional,11/6/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00410189
4471,The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years,Completed,Has Results,Upper Respiratory Infection|Common Cold,,West Penn Allegheny Health System|Allegheny Singer Research Institute|Merck Sharp & Dohme Corp.,West Penn Allegheny Health System,Allegheny Singer Research Institute,Merck Sharp & Dohme Corp.,,,,,,Other|Industry,Observational,10/6/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00405509
4472,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Completed,Has Results,Osteoarthritis,Drug: Synvisc (Hylan G-F20; hyaluronan injection)|Drug: Bupivicaine (local anesthesia injection)|Drug: Kenalog (triamcinolone; corticosteroid injection),"Hospital for Special Surgery, New York|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Genzyme, a Sanofi Company","Hospital for Special Surgery, New York",National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),"Genzyme, a Sanofi Company",,,,,Phase 3,Other|NIH|Industry,Interventional,8/6/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00398866
4473,"Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma",Completed,Has Results,Leukemia|Lung Cancer|Malignant Mesothelioma|Myelodysplastic Syndromes|Primary Peritoneal Cavity Cancer,Biological: WT-1 analog peptide vaccine|Biological: incomplete Freund's adjuvant|Biological: sargramostim|Genetic: polymerase chain reaction|Other: flow cytometry|Other: immunoenzyme technique,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Innovive Pharmaceuticals,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),Innovive Pharmaceuticals,,,,,Phase 1,Other|NIH|Industry,Interventional,10/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00398138
4474,Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium,Completed,Has Results,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer,Drug: sunitinib malate,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pfizer,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),Pfizer,,,,,Phase 2,Other|NIH|Industry,Interventional,9/6/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00397488
4475,Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients,Completed,Has Results,Chronic Kidney Disease|End Stage Renal Disease,Drug: MK-0677|Drug: Placebo,University of Virginia|National Institutes of Health (NIH)|Merck Sharp & Dohme Corp.,University of Virginia,National Institutes of Health (NIH),Merck Sharp & Dohme Corp.,,,,,Not Applicable,Other|NIH|Industry,Interventional,8/6/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00395291
4476,Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer,Completed,Has Results,Lung Cancer,Drug: carboplatin|Drug: irinotecan,"University of California, Davis|National Cancer Institute (NCI)|Pfizer","University of California, Davis",National Cancer Institute (NCI),Pfizer,,,,,Phase 2,Other|NIH|Industry,Interventional,10/1/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00387660
4477,Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma,Completed,Has Results,Glioblastoma|Gliosarcoma,Drug: hydroxyurea|Drug: imatinib mesylate,Duke University|National Cancer Institute (NCI)|Novartis Pharmaceuticals,Duke University,National Cancer Institute (NCI),Novartis Pharmaceuticals,,,,,Phase 2,Other|NIH|Industry,Interventional,5/5/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00354913
4478,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Completed,Has Results,Deep Venous Thrombosis,Drug: Desirudin (Iprivask™)|Drug: Heparin,"Washington University School of Medicine|Barnes-Jewish Hospital|Canyon Pharmaceuticals, Inc.",Washington University School of Medicine,Barnes-Jewish Hospital,"Canyon Pharmaceuticals, Inc.",,,,,Phase 2|Phase 3,Other|Industry,Interventional,5/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00329433
4479,Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.,Completed,Has Results,Spinal Cord Injury|Pain,Drug: botulinum toxin A|Other: placebo,Craig Hospital|The Craig H. Neilsen Foundation|Allergan,Craig Hospital,The Craig H. Neilsen Foundation,Allergan,,,,,Phase 4,Other|Industry,Interventional,4/6/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00320281
4480,Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection,Completed,Has Results,Urinary Tract Infection,Drug: Lactin-V|Drug: Placebo,"University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Osel, Inc.",University of Washington,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"Osel, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,3/6/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00305227
4481,Medtronic MiniMed Implantable Insulin Pump,Completed,Has Results,Type 1 Diabetes,Device: Aventis U-400 Insulin,Johns Hopkins University|National Institutes of Health (NIH)|Medtronic,Johns Hopkins University,National Institutes of Health (NIH),Medtronic,,,,,Not Applicable,Other|NIH|Industry,Interventional,2/3/2019,9/24/2009,https://ClinicalTrials.gov/show/NCT00298740
4482,Kybella With Triamcinolone,Completed,Has Results,Adiposity,Drug: Injectable sodium deoxycholate|Combination Product: Injectable sodium deoxycholate with Triamcinolone acetate,"Goldman, Butterwick, Fitzpatrick and Groff|Allergan|Maryland Laser Skin and Vein Institute","Goldman, Butterwick, Fitzpatrick and Groff",Allergan,Maryland Laser Skin and Vein Institute,,,,,Phase 4,Other|Industry,Interventional,3/26/2018,12/18/2018,https://ClinicalTrials.gov/show/NCT03361176
4483,Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis,Completed,Has Results,Osteoporosis,Drug: Alendronate,Medical University of South Carolina|FDA Office of Orphan Products Development|Merck Sharp & Dohme Corp.,Medical University of South Carolina,FDA Office of Orphan Products Development,Merck Sharp & Dohme Corp.,,,,,Phase 2,Other|U.S. Fed|Industry,Interventional,10/3/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00259857
4484,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Completed,Has Results,Alzheimer Disease,Drug: Memantine|Drug: Placebo pill,Stanford University|Palo Alto Veterans Institute for Research|Forest Laboratories,Stanford University,Palo Alto Veterans Institute for Research,Forest Laboratories,,,,,Phase 3,Other|Industry,Interventional,5/5/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00255086
4485,Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1),Completed,Has Results,Myotonic Dystrophy,Drug: SomatoKine/IPLEX,University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)|Imsmed Incorporated,University of Rochester,National Institute of Neurological Disorders and Stroke (NINDS),Imsmed Incorporated,,,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,11/5/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00233519
4486,Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.,Completed,Has Results,Lung Cancer,Drug: Gemcitabine|Drug: Pemetrexed|Procedure: Surgery,H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Eli Lilly and Company,H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI),Eli Lilly and Company,,,,,Phase 2,Other|NIH|Industry,Interventional,2/4/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00226577
4487,Preferred Treatment of Type 1.5 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: rosiglitazone|Drug: glyburide,University of Washington|Seattle Institute for Biomedical and Clinical Research|GlaxoSmithKline,University of Washington,Seattle Institute for Biomedical and Clinical Research,GlaxoSmithKline,,,,,Not Applicable,Other|Industry,Interventional,2/1/2000,12/8/2019,https://ClinicalTrials.gov/show/NCT00194896
4488,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Completed,Has Results,Bipolar Disorder,Drug: Lithium|Drug: Divalproex|Drug: Placebo,University Hospitals Cleveland Medical Center|National Institute of Mental Health (NIMH)|Abbott,University Hospitals Cleveland Medical Center,National Institute of Mental Health (NIMH),Abbott,,,,,Phase 3,Other|NIH|Industry,Interventional,11/1/1997,9/6/2019,https://ClinicalTrials.gov/show/NCT00194129
4489,"EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia",Completed,Has Results,Ischemic Heart Disease,Drug: Eplerenone|Drug: Placebo or sugar pill,"University of Florida|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer",University of Florida,"National Heart, Lung, and Blood Institute (NHLBI)",Pfizer,,,,,Phase 4,Other|NIH|Industry,Interventional,8/4/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00187889
4490,Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation,Completed,Has Results,COPD|Chronic Bronchitis|Emphysema,Device: pneumatic vest|Other: placebo pneumatic vest,Johns Hopkins University|Centers for Medicare and Medicaid Services|Hill-Rom,Johns Hopkins University,Centers for Medicare and Medicaid Services,Hill-Rom,,,,,Phase 4,Other|U.S. Fed|Industry,Interventional,5/4/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00181207
4491,The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Sodium hypochlorite (bleach) baths|Drug: Mupirocin ointment|Drug: Water|Drug: Petrolatum Ointment,Northwestern University|Society for Pediatric Dermatology|Johnson & Johnson,Northwestern University,Society for Pediatric Dermatology,Johnson & Johnson,,,,,Phase 4,Other|Industry,Interventional,9/5/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00179959
4492,"Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome",Completed,Has Results,HAART-induced Lipodystrophy and Metabolic Syndrome,Drug: r-metHuLeptin|Drug: Placebo,Beth Israel Deaconess Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amgen,Beth Israel Deaconess Medical Center,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Amgen,,,,,Phase 2,Other|NIH|Industry,Interventional,12/1/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00140244
4493,DHA and X-Linked Retinitis Pigmentosa,Completed,Has Results,Retinitis Pigmentosa|X-linked Genetic Diseases,Drug: docosahexaenoic acid OR corn/soy oil placebo,"Retina Foundation of the Southwest|Foundation Fighting Blindness|DSM Nutritional Products, Inc.",Retina Foundation of the Southwest,Foundation Fighting Blindness,"DSM Nutritional Products, Inc.",,,,,Phase 2,Other|Industry,Interventional,9/4/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00100230
4494,AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites,Completed,Has Results,Ovarian Neoplasms,"Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,10/6/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00396591
4495,"Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer",Completed,Has Results,Pancreatic Cancer,Biological: Recombinant Interferon Alfa|Drug: Cisplatin|Drug: Fluorouracil|Radiation: Radiation Therapy,M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Schering-Plough,M.D. Anderson Cancer Center,National Cancer Institute (NCI),Schering-Plough,,,,,Phase 2,Other|NIH|Industry,Interventional,5/2/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00068575
4496,Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma,Completed,Has Results,"Pulmonary Diseases|Neoplasms, Lung","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,1/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00284141
4497,Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine,Completed,Has Results,Schizophrenia,Drug: Placebo|Drug: Risperdal,"University of Maryland|National Institute of Mental Health (NIMH)|Ortho-McNeil Janssen Scientific Affairs, LLC",University of Maryland,National Institute of Mental Health (NIMH),"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,Phase 4,Other|NIH|Industry,Interventional,12/1/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00056498
4498,Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery,Completed,Has Results,Liver Cancer,Biological: bevacizumab,"Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.",Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),"Genentech, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,6/3/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00049322
4499,Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,Completed,Has Results,Prostate Cancer,Drug: carboplatin|Drug: paclitaxel,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),Bristol-Myers Squibb,,,,,Phase 2,Other|NIH|Industry,Interventional,10/2/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00049257
4500,Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression,Completed,Has Results,Breast Cancer,Biological: trastuzumab|Drug: erlotinib hydrochloride,"Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.",Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),"Genentech, Inc.",,,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,8/1/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00033514
4501,A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease,Completed,Has Results,Graft vs Host Disease,Drug: Alpha-1-Antitrypsin (AAT),University of Michigan Rogel Cancer Center|CSL Behring|The Leukemia and Lymphoma Society,University of Michigan Rogel Cancer Center,CSL Behring,The Leukemia and Lymphoma Society,,,,,Phase 2,Other|Industry,Interventional,7/13/2019,10/26/2018,https://ClinicalTrials.gov/show/NCT01700036
4502,Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases,Completed,Has Results,Diabetes Mellitus|Hypertension|Metabolic Disease|Obesity|Sleep Apnea Syndrome,Drug: Orlistat|Drug: Placebo,Jack Yanovski|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Roche Pharma AG|National Institutes of Health Clinical Center (CC),Jack Yanovski,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Roche Pharma AG|National Institutes of Health Clinical Center (CC),Roche Pharma AG,National Institutes of Health Clinical Center (CC),,,Phase 2,NIH|Industry,Interventional,5/1/1998,10/11/2019,https://ClinicalTrials.gov/show/NCT00001723
4503,Using mTOR Inhibitors in the Prevention of BK Nephropathy,Completed,Has Results,BK Viremia|BK Nephropathy,Drug: Tacrolimus|Drug: Mycophenolate acid|Drug: Sirolimus,Columbia University|Pfizer|Cornell University,Columbia University,Pfizer,Cornell University,,,,,Not Applicable,Other|Industry,Interventional,3/12/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01649609
4504,"Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",Completed,Has Results,Acute Myeloid Leukemia,"Drug: sorafenib, vorinostat and bortezomib","Hamid Sayar|Millennium Pharmaceuticals, Inc.|Bayer|Merck Sharp & Dohme Corp.|Indiana University",Hamid Sayar,"Millennium Pharmaceuticals, Inc.",Bayer|Merck Sharp & Dohme Corp.|Indiana University,Bayer,Merck Sharp & Dohme Corp.|Indiana University,Merck Sharp & Dohme Corp.,Indiana University,Phase 1|Phase 2,Other|Industry,Interventional,2/10/2012,2/13/2017,https://ClinicalTrials.gov/show/NCT01534260
4505,Implantable Cardioverter-Defibrillator Use in the VA System,Completed,Has Results,Cardiomyopathies,Behavioral: Clinical Reminder,Stanford University|Medtronic|VA Palo Alto Health Care System,Stanford University,Medtronic,VA Palo Alto Health Care System,,,,,Phase 3,Other|Industry|U.S. Fed,Interventional,4/10/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01217827
4506,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Completed,Has Results,Opiate Dependence,Drug: Extended-Release Naltrexone|Behavioral: Motivational Enhancement Counseling,"NYU Langone Health|Alkermes, Inc.|New York City Department of Health and Mental Hygiene",NYU Langone Health,"Alkermes, Inc.",New York City Department of Health and Mental Hygiene,,,,,Phase 3,Other|Industry,Interventional,5/10/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01180647
4507,BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,Completed,Has Results,Lung Cancer,Drug: Carboplatin|Drug: Pemetrexed|Drug: Bevacizumab|Drug: Cixutumumab,"M.D. Anderson Cancer Center|Eli Lilly and Company|Genentech, Inc.|ImClone LLC",M.D. Anderson Cancer Center,Eli Lilly and Company,"Genentech, Inc.|ImClone LLC","Genentech, Inc.",ImClone LLC,,,Phase 2,Other|Industry,Interventional,5/17/2011,8/15/2017,https://ClinicalTrials.gov/show/NCT01263782
4508,Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome,Completed,Has Results,Leukemia,Drug: Azacitidine|Drug: Sorafenib,"M.D. Anderson Cancer Center|Bayer|Onyx Therapeutics, Inc.|Celgene",M.D. Anderson Cancer Center,Bayer,"Onyx Therapeutics, Inc.|Celgene","Onyx Therapeutics, Inc.",Celgene,,,Phase 1|Phase 2,Other|Industry,Interventional,1/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01254890
4509,Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,Completed,Has Results,Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage III Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,Drug: nintedanib,Roswell Park Cancer Institute|National Cancer Institute (NCI)|Boehringer Ingelheim,Roswell Park Cancer Institute,National Cancer Institute (NCI),Boehringer Ingelheim,,,,,Phase 2,Other|NIH|Industry,Interventional,1/30/2014,8/16/2016,https://ClinicalTrials.gov/show/NCT01948141
4510,Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy,Completed,Has Results,MDS|Leukemias|Lymphomas,Drug: Busulfan|Drug: Cyclophosphamide|Radiation: Total body irradiation,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Otsuka Pharmaceutical Co., Ltd.|National Center for Research Resources (NCRR)",Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"Otsuka Pharmaceutical Co., Ltd.",National Center for Research Resources (NCRR),,,,,Phase 2,Other|Industry|NIH,Interventional,12/8/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT00796562
4511,Understanding Disparities in Quitting in African American and White Smokers,Completed,Has Results,Smoking Cessation,Drug: Varenicline,"Nikki Nollen, PhD, MA|National Institute on Drug Abuse (NIDA)|Pfizer|University of Kansas Medical Center","Nikki Nollen, PhD, MA",National Institute on Drug Abuse (NIDA),Pfizer|University of Kansas Medical Center,Pfizer,University of Kansas Medical Center,,,Phase 4,Other|NIH|Industry,Interventional,2/13/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT01836276
4512,Testosterone Antidepressant Augmentation in Women,Completed,Has Results,Depression,Drug: Testosterone|Drug: Placebo,Massachusetts General Hospital|National Institutes of Health (NIH)|Lawley Pharmaceuticals,Massachusetts General Hospital,National Institutes of Health (NIH),Lawley Pharmaceuticals,,,,,Not Applicable,Other|NIH|Industry,Interventional,8/13/2019,1/27/2017,https://ClinicalTrials.gov/show/NCT01783574
4513,Nutritional and Neurotransmitter Changes in PKU Subjects on BH4,Completed,Has Results,Phenylketonuria,Drug: KuvanTM Therapy,Emory University|BioMarin Pharmaceutical|Atlanta Clinical and Translational Science Institute,Emory University,BioMarin Pharmaceutical,Atlanta Clinical and Translational Science Institute,,,,,,Other|Industry,Observational,10/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00688844
4514,Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics,Completed,Has Results,Asthma,Drug: pioglitazone|Drug: placebo,Fernando Holguin|Takeda|University of Vermont|University of Pittsburgh,Fernando Holguin,Takeda,University of Vermont|University of Pittsburgh,University of Vermont,University of Pittsburgh,,,Phase 2,Other|Industry,Interventional,10/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00634036
4515,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Completed,Has Results,Reperfusion Injury|Liver Injury,Drug: inhaled nitric oxide|Drug: nitrogen gas,University of Alabama at Birmingham|Mallinckrodt|University of Washington,University of Alabama at Birmingham,Mallinckrodt,University of Washington,,,,,Phase 2|Phase 3,Other|Industry,Interventional,4/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00582010
4516,Rituximab in Rheumatoid Arthritis Lung Disease,Completed,Has Results,Rheumatoid Arthritis|Interstitial Pneumonia,Drug: Rituximab,"Eric Matteson|Genentech, Inc.|National Center for Research Resources (NCRR)|Mayo Clinic",Eric Matteson,"Genentech, Inc.",National Center for Research Resources (NCRR)|Mayo Clinic,National Center for Research Resources (NCRR),Mayo Clinic,,,Phase 3,Other|Industry|NIH,Interventional,5/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00578565
4517,The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women,Completed,Has Results,Contraception|Pain,Drug: Insertion of nitroglycerin ointment|Drug: Insertion of placebo ointment,Oregon Health and Science University|American College of Obstetricians and Gynecologists|Bayer,Oregon Health and Science University,American College of Obstetricians and Gynecologists,Bayer,,,,,Not Applicable,Other|Industry,Interventional,3/1/2012,11/1/2012,https://ClinicalTrials.gov/show/NCT01490073
4518,Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Everolimus|Drug: Trastuzumab,Beth Israel Deaconess Medical Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Novartis Pharmaceuticals,Dana-Farber Cancer Institute,,,,,Phase 1|Phase 2,Other|Industry,Interventional,4/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00458237
4519,A Study of Axitinib in Advanced Carcinoid Tumors,Completed,Has Results,Carcinoid Tumor,Drug: Axitinib,H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network|Pfizer,H. Lee Moffitt Cancer Center and Research Institute,National Comprehensive Cancer Network,Pfizer,,,,,Phase 2,Other|Industry,Interventional,10/25/2011,2/13/2018,https://ClinicalTrials.gov/show/NCT01435122
4520,Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer,Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Carboplatin|Drug: GM-CSF (Sargramostim)|Drug: Interferon Gamma,"M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Bristol-Myers Squibb|InterMune",M.D. Anderson Cancer Center,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Bristol-Myers Squibb|InterMune,Bristol-Myers Squibb,InterMune,,,Phase 2,Other|Industry,Interventional,1/3/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00501644
4521,Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction,Completed,Has Results,Nonmalignant Breast Conditions|Breast Cancer,Device: Sodium hypochlorite (Dakin's Solution)|Device: Chlorhexidine gluconate disk|Procedure: Control|Device: Occlusive Adhesive Dressing,"Mayo Clinic|University of California, San Francisco|Ethicon, Inc.",Mayo Clinic,"University of California, San Francisco","Ethicon, Inc.",,,,,Phase 2,Other|Industry,Interventional,5/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01286168
4522,Improving the Efficacy of Anti-Nicotine Immunotherapy,Completed,Has Results,Nicotine Dependence,Biological: NIC002 in Aluminum hydroxide (Alum)|Biological: Placebo Vaccine - Aluminum hydroxide,Alexey Mukhin|Wake Forest University Health Sciences|Novartis Pharmaceuticals|Duke University,Alexey Mukhin,Wake Forest University Health Sciences,Novartis Pharmaceuticals|Duke University,Novartis Pharmaceuticals,Duke University,,,Phase 2,Other|Industry,Interventional,12/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01280968
4523,Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface,Completed,Has Results,Myopia|Refractive Error,Drug: ReNu MultiPlus® MultiPurpose Solution|Drug: OPTI-FREE® RepleniSH®|Drug: Clear Care®,Massachusetts Eye and Ear Infirmary|University of Iowa|Alcon Research,Massachusetts Eye and Ear Infirmary,University of Iowa,Alcon Research,,,,,Phase 4,Other|Industry,Interventional,8/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01250925
4524,Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia,Completed,Has Results,Coronary Artery Disease,Drug: adenosine|Drug: regadenoson,"St. Louis University|University of Florida|Astellas Pharma US, Inc.",St. Louis University,University of Florida,"Astellas Pharma US, Inc.",,,,,Phase 1,Other|Industry,Interventional,7/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01161121
4525,External Trigeminal Nerve Stimulation for Epilepsy,Completed,Has Results,Epilepsy|Seizure Disorders,Device: Trigeminal Nerve Stimulation,Olive View-UCLA Education & Research Institute|Epilepsy Foundation|Boston Scientific Corporation,Olive View-UCLA Education & Research Institute,Epilepsy Foundation,Boston Scientific Corporation,,,,,Phase 2,Other|Industry,Interventional,1/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01159431
4526,Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: sodium chloride (7%),"University of North Carolina, Chapel Hill|Johns Hopkins University|Novartis Pharmaceuticals","University of North Carolina, Chapel Hill",Johns Hopkins University,Novartis Pharmaceuticals,,,,,Phase 1,Other|Industry,Interventional,11/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01094704
4527,The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study),Completed,Has Results,Stem Cell Transplantation,Biological: Auto-hMSCs|Biological: Allo-hMSCs,"University of Miami|National Heart, Lung, and Blood Institute (NHLBI)|The Emmes Company, LLC",University of Miami,"National Heart, Lung, and Blood Institute (NHLBI)","The Emmes Company, LLC",,,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,3/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01087996
4528,Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder,Completed,Has Results,Smoking Cessation|Bipolar Disorder,Drug: Varenicline|Drug: Placebo,K.N. Roy Chengappa|National Institute of Mental Health (NIMH)|Pfizer|University of Pittsburgh,K.N. Roy Chengappa,National Institute of Mental Health (NIMH),Pfizer|University of Pittsburgh,Pfizer,University of Pittsburgh,,,Phase 4,Other|NIH|Industry,Interventional,1/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01010204
4529,Treatment of Early Aggressive Rheumatoid Arthritis (TEAR),Completed,Has Results,Rheumatoid Arthritis,Drug: methotrexate|Drug: sulfasalazine|Drug: hydroxychloroquine|Drug: etanercept,University of Alabama at Birmingham|Amgen|Barr Laboratories|Pfizer,University of Alabama at Birmingham,Amgen,Barr Laboratories|Pfizer,Barr Laboratories,Pfizer,,,Phase 4,Other|Industry,Interventional,5/4/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00259610
4530,Lidocaine For Neuroprotection During Cardiac Surgery,Completed,Has Results,Cognitive Decline,Drug: Lidocaine|Drug: Placebo,"Duke University|National Heart, Lung, and Blood Institute (NHLBI)|CAS Medical Systems, Inc.",Duke University,"National Heart, Lung, and Blood Institute (NHLBI)","CAS Medical Systems, Inc.",,,,,Not Applicable,Other|NIH|Industry,Interventional,7/9/2019,5/23/2017,https://ClinicalTrials.gov/show/NCT00938964
4531,THA Kinematics and Sound for Subjects Implanted Using Various Surgical Approaches,Completed,Has Results,Hip Injuries,Radiation: Fluoroscopy surveillance of patients while walking,"The University of Tennessee, Knoxville|DePuy Orthopaedics","The University of Tennessee, Knoxville",DePuy Orthopaedics,,,,,,,Other|Industry,Observational,6/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01833481
4532,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,Completed,Has Results,HIV|Hyperlipidemia|Hypertriglyceridemia|HIV Infections,Drug: raltegravir,The Miriam Hospital|Tufts Medical Center|Merck Sharp & Dohme Corp.,The Miriam Hospital,Tufts Medical Center,Merck Sharp & Dohme Corp.,,,,,Phase 3,Other|Industry,Interventional,5/9/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00887653
4533,Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Drug: Erlotinib|Drug: gemcitabine,"University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc.","University of California, Davis",National Cancer Institute (NCI),"Genentech, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,4/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00810719
4534,The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy,Completed,Has Results,Milk Allergy,Drug: Milk Protein Extract Immunotherapy goal of 4mg/day|Drug: Milk Protein Extract Immunotherapy goal of 7mg/day|Drug: Milk Powder Immunotherapy goal dose 2000 mg/day|Drug: Milk Powder Immunotherapy goal dose 1000mg/day,Johns Hopkins University|Duke University|Greer Laboratories,Johns Hopkins University,Duke University,Greer Laboratories,,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/8/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00732654
4535,Cox-2 Inhibition in Radiation-induced Oral Mucositis,Completed,Has Results,Oral Mucositis,Drug: celecoxib|Drug: placebo,UConn Health|National Institute of Dental and Craniofacial Research (NIDCR)|Pfizer,UConn Health,National Institute of Dental and Craniofacial Research (NIDCR),Pfizer,,,,,Phase 2,Other|NIH|Industry,Interventional,7/3/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00698204
4536,"Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder",Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Paliperidone|Drug: Placebo,"University of South Florida|Indiana University|Ortho-McNeil Janssen Scientific Affairs, LLC",University of South Florida,Indiana University,"Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,Phase 2,Other|Industry,Interventional,10/7/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00632229
4537,RAD001 and Bicalutamide for Androgen Independent Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: RAD001|Drug: Bicalutamide,Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Novartis Pharmaceuticals,Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Novartis Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,2/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00630344
4538,Memantine Treatment Study of Pathological Gambling,Completed,Has Results,Pathological Gambling,Drug: Memantine Hydrochloride,Yale University|University of Minnesota - Clinical and Translational Science Institute|Forest Laboratories,Yale University,University of Minnesota - Clinical and Translational Science Institute,Forest Laboratories,,,,,Phase 2,Other|Industry,Interventional,12/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00585169
4539,Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome,Completed,Has Results,Fragile X-Associated Tremor/Ataxia Syndrome|Fragile X Premutation Carriers,Drug: Memantine|Drug: Placebo,"University of California, Davis|National Institute on Aging (NIA)|Forest Laboratories","University of California, Davis",National Institute on Aging (NIA),Forest Laboratories,,,,,Not Applicable,Other|NIH|Industry,Interventional,9/7/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00584948
4540,Use of Fenofibrate for Primary Biliary Cirrhosis,Completed,Has Results,Primary Biliary Cirrhosis,Drug: Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle),University of Florida|The PBCers Organization|Shionogi Inc.,University of Florida,The PBCers Organization,Shionogi Inc.,,,,,Phase 2,Other|Industry,Interventional,8/7/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00575042
4541,Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation,Completed,Has Results,Hematologic Malignancies,Drug: Bortezomib (Velcade)|Drug: Tacrolimus|Drug: Methotrexate|Procedure: blood stem cell transplantation,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc.",Dana-Farber Cancer Institute,Brigham and Women's Hospital,"Millennium Pharmaceuticals, Inc.",,,,,Phase 1|Phase 2,Other|Industry,Interventional,8/6/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00369226
4542,Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM),Completed,Has Results,HIV Infections|Depression,Drug: Bupropion|Drug: Placebo,NYU Langone Health|National Institute on Drug Abuse (NIDA)|GlaxoSmithKline,NYU Langone Health,National Institute on Drug Abuse (NIDA),GlaxoSmithKline,,,,,Phase 1,Other|NIH|Industry,Interventional,9/2/2019,9/4/2019,https://ClinicalTrials.gov/show/NCT00285584
4543,"Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia",Completed,Has Results,Waldenstrom's Macroglobulinemia,Drug: Bortezomib|Drug: Dexamethasone|Drug: Rituximab,"Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Millennium Pharmaceuticals, Inc.",Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,"Millennium Pharmaceuticals, Inc.",,,,,Phase 2,Other|Industry,Interventional,10/5/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00250926
4544,Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression,Completed,Has Results,Bipolar II Disorder|Major Depressive Episode,Drug: Ziprasidone,"The Medical Research Network|Liebowitz, Michael R., M.D.|Pfizer",The Medical Research Network,"Liebowitz, Michael R., M.D.",Pfizer,,,,,Phase 4,Other|Industry,Interventional,2/5/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00237666
4545,ET 743 (Yondelis) in Men With Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: ET 743,Massachusetts General Hospital|Dana-Farber Cancer Institute|PharmaMar,Massachusetts General Hospital,Dana-Farber Cancer Institute,PharmaMar,,,,,Phase 2,Other|Industry,Interventional,6/2/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00147212
4546,Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism,Completed,Has Results,Turner Syndrome|Hypogonadism|Premature Ovarian Failure,Drug: 17 B estradiol orally|Drug: 17 B estradiol,"Nemours Children's Clinic|Genentech, Inc.",Nemours Children's Clinic,"Genentech, Inc.",,,,,,Phase 4,Other|Industry,Interventional,1/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00837616
4547,A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: SAN021 Serum|Drug: SAN021 Placebo,"Santalis Pharmaceuticals, Inc.|ClinDatrix, Inc.|Clinical Trials of Texas, Inc.|Dermatology Research Center of San Antonio|Derm Research, PLLC|Progressive Clinical Research","Santalis Pharmaceuticals, Inc.","ClinDatrix, Inc.","Clinical Trials of Texas, Inc.|Dermatology Research Center of San Antonio|Derm Research, PLLC|Progressive Clinical Research","Clinical Trials of Texas, Inc.","Dermatology Research Center of San Antonio|Derm Research, PLLC|Progressive Clinical Research",Dermatology Research Center of San Antonio,"Derm Research, PLLC|Progressive Clinical Research",Phase 2,Industry|Other,Interventional,5/17/2017,12/14/2017,https://ClinicalTrials.gov/show/NCT03000608
4548,Angiotensin II Blockade for Chronic Allograft Nephropathy,Completed,Has Results,Kidney Disease|Proteinuria,Drug: Losartan 100mg|Drug: Placebo,University of Minnesota - Clinical and Translational Science Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Merck Sharp & Dohme Corp.,University of Minnesota - Clinical and Translational Science Institute,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Merck Sharp & Dohme Corp.,,,,,Phase 4,Other|NIH|Industry,Interventional,12/2/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00067990
4549,A Pilot Test of t:Slim X2 With Control-IQ Technology,Completed,Has Results,Type1 Diabetes Mellitus,Device: Tandem t:slim X2 with Control-IQ Technology,"University of Virginia|Tandem Diabetes Care, Inc.|DexCom, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",University of Virginia,"Tandem Diabetes Care, Inc.","DexCom, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","DexCom, Inc.",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,,Not Applicable,Other|Industry|NIH,Interventional,12/8/2017,12/11/2017,https://ClinicalTrials.gov/show/NCT03368937
4550,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Completed,Has Results,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Biological: rhIDU (recombinant human-Alpha-L-Iduronidase)|Biological: Placebo,"Genzyme, a Sanofi Company|BioMarin/Genzyme LLC|Sanofi","Genzyme, a Sanofi Company",BioMarin/Genzyme LLC,Sanofi,,,,,Phase 3,Industry,Interventional,12/1/2000,9/1/2019,https://ClinicalTrials.gov/show/NCT00912925
4551,Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid,Completed,Has Results,Alzheimer's Disease,Biological: Albutein 5%|Other: Control,"Instituto Grifols, S.A.|Grifols Biologicals, LLC","Instituto Grifols, S.A.","Grifols Biologicals, LLC",,,,,,Phase 2,Industry,Interventional,7/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00742417
4552,"Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer",Completed,Has Results,Non-small Cell Lung Cancer|Carcinoma|NSCLC,Drug: Ensartinib|Drug: Durvalumab,"Ludwig Institute for Cancer Research|MedImmune LLC|Xcovery Holding Company, LLC|Cancer Research Institute, New York City",Ludwig Institute for Cancer Research,MedImmune LLC,"Xcovery Holding Company, LLC|Cancer Research Institute, New York City","Xcovery Holding Company, LLC","Cancer Research Institute, New York City",,,Phase 1|Phase 2,Other|Industry,Interventional,5/10/2017,8/4/2017,https://ClinicalTrials.gov/show/NCT02898116
4553,Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),Completed,Has Results,Prostate Cancer,Drug: enzalutamide|Drug: Androgen Deprivation|Radiation: Radiation Therapy,"Duke University|Medivation, Inc.|Astellas Pharma Inc",Duke University,"Medivation, Inc.",Astellas Pharma Inc,,,,,Phase 2,Other|Industry,Interventional,4/14/2019,6/5/2019,https://ClinicalTrials.gov/show/NCT02057939
4554,Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Enzalutamide|Drug: Leuprolide|Drug: Dutasteride,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Pfizer,Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,Phase 2,Industry,Interventional,3/31/2012,11/30/2013,https://ClinicalTrials.gov/show/NCT01547299
4555,Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment,Completed,Has Results,Urinary Bladder Neoplasms,Drug: Tamoxifen,Seth Lerner|AstraZeneca|Cytogen Corporation|Baylor College of Medicine,Seth Lerner,AstraZeneca,Cytogen Corporation|Baylor College of Medicine,Cytogen Corporation,Baylor College of Medicine,,,Phase 2,Other|Industry,Interventional,1/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00710970
4556,Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management,Completed,Has Results,Chronic Kidney Diseases|Type 2 Diabetes,Drug: Linagliptin|Drug: Glipizide,University of Washington|American Diabetes Association|Medtronic|Abbott,University of Washington,American Diabetes Association,Medtronic|Abbott,Medtronic,Abbott,,,Not Applicable,Other|Industry,Interventional,11/15/2019,8/18/2019,https://ClinicalTrials.gov/show/NCT02608177
4557,Study of Arsenic Trioxide in Small Cell Lung Cancer,Completed,Has Results,"Lung Cancer|Cancer of Lung|Pulmonary Cancer|Pulmonary Neoplasms|Carcinoma, Small Cell",Drug: Arsenic Trioxide,Emory University|Cephalon|Teva Pharmaceuticals USA|National Cancer Institute (NCI),Emory University,Cephalon,Teva Pharmaceuticals USA|National Cancer Institute (NCI),Teva Pharmaceuticals USA,National Cancer Institute (NCI),,,Phase 2,Other|Industry|NIH,Interventional,8/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01470248
4558,Dynamic Hyperinflation and Tiotropium,Completed,Has Results,COPD,Drug: tiotropium|Drug: placebo,"Gelb, Arthur F., M.D.|Boehringer Ingelheim|Pfizer","Gelb, Arthur F., M.D.",Boehringer Ingelheim,Pfizer,,,,,Phase 4,Other|Industry,Interventional,10/6/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00569270
4559,Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Atrial Flutter,Behavioral: Decision Support|Behavioral: Educational Intervention Only,University of Cincinnati|National Center for Advancing Translational Science (NCATS)|Pfizer|Bristol-Myers Squibb,University of Cincinnati,National Center for Advancing Translational Science (NCATS),Pfizer|Bristol-Myers Squibb,Pfizer,Bristol-Myers Squibb,,,Not Applicable,Other|NIH|Industry,Interventional,12/12/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02524977
4560,Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myeloid Leukemia,Drug: 5-Azacitidine|Drug: Gemtuzumab ozogamicin,"University of California, San Diego|Celgene Corporation|Pfizer","University of California, San Diego",Celgene Corporation,Pfizer,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/5/2019,9/26/2014,https://ClinicalTrials.gov/show/NCT00766116
4561,Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Drug: Gemcitabine|Drug: Erlotinib|Drug: Sorafenib,NYU Langone Health|Bayer|OSI Pharmaceuticals,NYU Langone Health,Bayer,OSI Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,9/7/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00696696
4562,µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis,Completed,Has Results,"Osteoporosis, Osteopenia",Other: Virtual Bone Biopsy|Drug: Teriparatide|Drug: Zoledronic Acid,University of Pennsylvania|Eli Lilly and Company|Novartis Pharmaceuticals|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),University of Pennsylvania,Eli Lilly and Company,Novartis Pharmaceuticals|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Novartis Pharmaceuticals,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),,,Phase 4,Other|Industry|NIH,Interventional,7/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01153425
4563,"How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics",Completed,Has Results,Type 2 Diabetes,Drug: exenatide|Drug: placebo,"Oregon Health and Science University|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company",Oregon Health and Science University,"Amylin Pharmaceuticals, LLC.",Eli Lilly and Company,,,,,Phase 4,Other|Industry,Interventional,3/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00667732
4564,"Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma",Completed,Has Results,Esophageal Neoplasms|Stomach Neoplasms|Neoplasm Metastasis,"Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)","Duke University|Hoffmann-La Roche|Sanofi|Genentech, Inc.",Duke University,Hoffmann-La Roche,"Sanofi|Genentech, Inc.",Sanofi,"Genentech, Inc.",,,Phase 2,Other|Industry,Interventional,2/7/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00447330
4565,"Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer",Completed,Has Results,Cervical Cancer,Drug: Topotecan|Drug: Cisplatin|Drug: Bevacizumab,"Washington University School of Medicine|GlaxoSmithKline|Genentech, Inc.",Washington University School of Medicine,GlaxoSmithKline,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,2/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00548418
4566,"Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma",Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: bortezomib|Drug: bendamustine|Drug: rituximab,"University of Rochester|Millennium Pharmaceuticals, Inc.|Cephalon",University of Rochester,"Millennium Pharmaceuticals, Inc.",Cephalon,,,,,Phase 2,Other|Industry,Interventional,10/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00547534
4567,Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: CCI-779|Drug: Bortezomib,"Dana-Farber Cancer Institute|Wyeth is now a wholly owned subsidiary of Pfizer|Millennium Pharmaceuticals, Inc.",Dana-Farber Cancer Institute,Wyeth is now a wholly owned subsidiary of Pfizer,"Millennium Pharmaceuticals, Inc.",,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/7/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00483262
4568,Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion,Completed,Has Results,Branch Retinal Vein Occlusion,Drug: pegaptanib sodium (Macugen),"Palmetto Retina Center, LLC|Pfizer|Eyetech Pharmaceuticals","Palmetto Retina Center, LLC",Pfizer,Eyetech Pharmaceuticals,,,,,Phase 4,Other|Industry,Interventional,1/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00406107
4569,Viral Kinetics in HCV Clearance in Subjects With Hemophilia,Completed,Has Results,Chronic Hepatitis C|Hemophilia,Drug: PegInterferon|Drug: Ribavirin|Drug: Telaprevir,"Kenneth Sherman|National Heart, Lung, and Blood Institute (NHLBI)|Vertex Pharmaceuticals Incorporated|Genentech, Inc.|University of Cincinnati",Kenneth Sherman,"National Heart, Lung, and Blood Institute (NHLBI)","Vertex Pharmaceuticals Incorporated|Genentech, Inc.|University of Cincinnati",Vertex Pharmaceuticals Incorporated,"Genentech, Inc.|University of Cincinnati","Genentech, Inc.",University of Cincinnati,Phase 1,Other|NIH|Industry,Interventional,12/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01704521
4570,"Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer",Completed,Has Results,Lung Cancer|Non-small Cell Lung Cancer (NSCLC),Drug: Bevacizumab|Drug: Gemcitabine|Drug: Carboplatin,"Stanford University|Eli Lilly and Company|Genentech, Inc.",Stanford University,Eli Lilly and Company,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,6/6/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00323869
4571,"Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer",Completed,Has Results,Lung Cancer,Biological: bevacizumab|Drug: carboplatin|Drug: erlotinib hydrochloride|Drug: paclitaxel|Radiation: 3-dimensional conformal radiation therapy,"UNC Lineberger Comprehensive Cancer Center|Genentech, Inc.|Eli Lilly and Company",UNC Lineberger Comprehensive Cancer Center,"Genentech, Inc.",Eli Lilly and Company,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/6/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00280150
4572,Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia,Completed,Has Results,"Systemic Mastocytosis, Aggressive (ASM)|Leukemia, Mast Cell|Hematological Non-mast Cell Lineage Disease (AHNMD)",Drug: Midostaurin,Jason Robert Gotlib|Novartis|Novartis Pharmaceuticals|Stanford University,Jason Robert Gotlib,Novartis,Novartis Pharmaceuticals|Stanford University,Novartis Pharmaceuticals,Stanford University,,,Phase 2,Other|Industry,Interventional,3/5/2019,4/16/2011,https://ClinicalTrials.gov/show/NCT00233454
4573,"Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients",Completed,Has Results,"End Stage Renal Disease|Sexual Dysfunction, Physiological|Pain|Depression",Behavioral: Symptom management nurse intervention|Behavioral: Feedback intervention,"US Department of Veterans Affairs|Dialysis Clinic, Inc.|Liberty Dialysis, LLC|DaVita Dialysis|VA Office of Research and Development",US Department of Veterans Affairs,"Dialysis Clinic, Inc.","Liberty Dialysis, LLC|DaVita Dialysis|VA Office of Research and Development","Liberty Dialysis, LLC",DaVita Dialysis|VA Office of Research and Development,DaVita Dialysis,VA Office of Research and Development,Not Applicable,U.S. Fed|Industry|Other,Interventional,11/8/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00692419
4574,"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer",Completed,Has Results,Breast Cancer,Drug: Bevacizumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Capecitabine|Drug: Docetaxel,"NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche|International Drug Development Institute",NSABP Foundation Inc,"Genentech, Inc.",Hoffmann-La Roche|International Drug Development Institute,Hoffmann-La Roche,International Drug Development Institute,,,Phase 2,Other|Industry,Interventional,8/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00365417
4575,"A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma",Completed,Has Results,Pancreatic Cancer,Drug: Capecitabine|Drug: PHY906,Yale University|PhytoCeutica|National Comprehensive Cancer Network|Roche Pharma AG,Yale University,PhytoCeutica,National Comprehensive Cancer Network|Roche Pharma AG,National Comprehensive Cancer Network,Roche Pharma AG,,,Phase 1|Phase 2,Other|Industry,Interventional,12/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00411762
4576,The Purple Grape Juice Study,Completed,Has Results,Cardiovascular Disease,Dietary Supplement: Purple Grape Juice,"Intermountain Health Care, Inc.|Deseret Foundation|Welch's, Inc.|ThromboVision, Inc.","Intermountain Health Care, Inc.",Deseret Foundation,"Welch's, Inc.|ThromboVision, Inc.","Welch's, Inc.","ThromboVision, Inc.",,,Not Applicable,Other|Industry,Interventional,7/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00551746
4577,Secondary Prevention of Osteoporosis,Completed,Has Results,Osteoporosis,Drug: alendronate with cholecalciferol|Drug: calcium carbonate with cholecalciferol|Behavioral: Falls prevention measures,"Hebrew Rehabilitation Center, Boston|National Institute on Aging (NIA)|Merck Sharp & Dohme Corp.|GlaxoSmithKline","Hebrew Rehabilitation Center, Boston",National Institute on Aging (NIA),Merck Sharp & Dohme Corp.|GlaxoSmithKline,Merck Sharp & Dohme Corp.,GlaxoSmithKline,,,Phase 3,Other|NIH|Industry,Interventional,2/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00421343
4578,Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,Completed,Has Results,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: docetaxel|Drug: erlotinib hydrochloride,"University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc.|Aventis Pharmaceuticals","University of California, Davis",National Cancer Institute (NCI),"Genentech, Inc.|Aventis Pharmaceuticals","Genentech, Inc.",Aventis Pharmaceuticals,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,7/2/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00390429
4579,Improving Sleep and Psychological Functioning in People With Depression and Insomnia,Completed,Has Results,Sleep Initiation and Maintenance Disorders|Depression,Drug: Eszopiclone|Drug: Fluoxetine|Drug: Placebo,Wake Forest University Health Sciences|National Institute of Mental Health (NIMH)|Sunovion|Philips Healthcare,Wake Forest University Health Sciences,National Institute of Mental Health (NIMH),Sunovion|Philips Healthcare,Sunovion,Philips Healthcare,,,Phase 4,Other|NIH|Industry,Interventional,10/5/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00247624
4580,Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression,Completed,Has Results,Depression,"Drug: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Other: Placebo|Behavioral: Interpersonal Clinical Interaction (ICI)","University of California, Los Angeles|National Center for Complementary and Integrative Health (NCCIH)|Eli Lilly and Company|Wyeth is now a wholly owned subsidiary of Pfizer","University of California, Los Angeles",National Center for Complementary and Integrative Health (NCCIH),Eli Lilly and Company|Wyeth is now a wholly owned subsidiary of Pfizer,Eli Lilly and Company,Wyeth is now a wholly owned subsidiary of Pfizer,,,Phase 4,Other|NIH|Industry,Interventional,8/5/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00200902
4581,Two Daily Disposable Contact Lenses in Symptomatic Patients,Completed,Has Results,Myopia,Device: Delefilcon A contact lenses|Device: Senofilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,8/13/2018,9/25/2018,https://ClinicalTrials.gov/show/NCT03628599
4582,Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea,Completed,Has Results,Rosacea,Drug: Oxymetazoline HCL 1.0% Cream|Device: Energy-Based Therapy,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 4,Industry,Interventional,12/4/2017,6/15/2018,https://ClinicalTrials.gov/show/NCT03380390
4583,Assessment of an Oral Endotracheal Subglottic Tube Holder,Completed,Has Results,Intubation,Device: New oral endotracheal tube holder,Hollister Incorporated,Hollister Incorporated,,,,,,,Not Applicable,Industry,Interventional,10/23/2017,6/15/2018,https://ClinicalTrials.gov/show/NCT03328182
4584,Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle,Completed,Has Results,Diabetes,Device: BD Nano™ vs Nucleus|Device: NovoFine® vs Nucleus|Device: NovoTwist®/NovoFine® Plus vs Nucleus|Device: Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus,"Becton, Dickinson and Company","Becton, Dickinson and Company",,,,,,,Not Applicable,Industry,Interventional,9/1/2017,5/24/2018,https://ClinicalTrials.gov/show/NCT03267264
4585,"A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age",Completed,Has Results,Group B Streptococcal Infections,Biological: Multivalent group B streptococcus vaccine|Biological: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/5/2017,6/25/2018,https://ClinicalTrials.gov/show/NCT03170609
4586,Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation,Completed,Has Results,Cheek Augmentation|Midface Contour Deficiencies,Device: Restylane Lyft with Lidocaine,Q-Med AB,Q-Med AB,,,,,,,Not Applicable,Industry,Interventional,5/16/2017,10/31/2017,https://ClinicalTrials.gov/show/NCT03160716
4587,A Pilot Study of the Cala ONE Device for Essential Tremor,Completed,Has Results,Essential Tremor,Device: Cala ONE device,"Cala Health, Inc.","Cala Health, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/26/2017,3/8/2018,https://ClinicalTrials.gov/show/NCT03152136
4588,Sapphire II PRO US Clinical Study,Completed,Has Results,Coronary Artery Disease|Coronary Disease|Myocardial Ischemia|Heart Diseases|Arteriosclerosis|Cardiovascular Diseases,Device: Sapphire II PRO,OrbusNeich|Icahn School of Medicine at Mount Sinai,OrbusNeich,Icahn School of Medicine at Mount Sinai,,,,,,Not Applicable,Industry|Other,Interventional,5/5/2017,7/24/2017,https://ClinicalTrials.gov/show/NCT03052530
4589,Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease,Completed,Has Results,Atherosclerosis|Cardiovascular Disease,Drug: MEDI6012 40 mg|Drug: Placebo|Drug: MEDI6012 120 mg|Drug: MEDI6012 300 mg|Drug: Placebo IV Push|Drug: MEDI6012 IV Push,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,1/23/2017,11/2/2017,https://ClinicalTrials.gov/show/NCT03004638
4590,Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma,Completed,Has Results,Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,"Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),"Bristol-Myers Squibb|Genentech, Inc.",Bristol-Myers Squibb,"Genentech, Inc.",,,Phase 2,Other|NIH|Industry,Interventional,11/6/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00039195
4591,SlimShape Device for Abdominal Fat and Circumference Reduction,Completed,Has Results,Fat Disorder,Device: SlimShape,Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,1/13/2017,8/7/2018,https://ClinicalTrials.gov/show/NCT02999763
4592,Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery,Completed,Has Results,Postoperative Ocular Pain After PRK Surgery,Drug: SAF312|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,12/1/2016,2/21/2018,https://ClinicalTrials.gov/show/NCT02961062
4593,Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses,Completed,Has Results,Myopia,Device: fanfilcon A|Device: senofilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/27/2016,12/14/2016,https://ClinicalTrials.gov/show/NCT02956460
4594,Performance of Fanfilcon A Toric Lenses After at Least One Month Wearing Enfilcon A Toric Lenses,Completed,Has Results,Astigmatism,Device: fanfilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/1/2016,3/21/2017,https://ClinicalTrials.gov/show/NCT02921412
4595,CPAP In-home Assessment USA,Completed,Has Results,Obstructive Sleep Apnea,Device: Fisher & Paykel Healthcare CPAP Device,Fisher and Paykel Healthcare,Fisher and Paykel Healthcare,,,,,,,Not Applicable,Industry,Interventional,7/16/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02809859
4596,"Feasibility, Effectiveness and Efficacy of the PowerSleep Device",Completed,Has Results,Sleep|Sleep Disorders Not Due to A Substance or Known Physiological Condition,Device: Powersleep|Device: Sham Powersleep,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,6/16/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02797678
4597,Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia,Completed,Has Results,Friedreich's Ataxia,Drug: interferon γ-1b,"Horizon Pharma Ireland, Ltd., Dublin Ireland|Friedreich's Ataxia Research Alliance","Horizon Pharma Ireland, Ltd., Dublin Ireland",Friedreich's Ataxia Research Alliance,,,,,,Phase 3,Industry|Other,Interventional,6/28/2016,3/31/2017,https://ClinicalTrials.gov/show/NCT02797080
4598,Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females,Completed,Has Results,"Headache, Migraine",Drug: Erenumab|Drug: Ethynil Estradiol/Norgestimate Oral Contraceptive,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,2/12/2016,9/9/2016,https://ClinicalTrials.gov/show/NCT02792517
4599,A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes,Completed,Has Results,Diabetes Mellitus Type 2 in Obese,Drug: Cyclo-Z|Drug: Placebo,"NovMetaPharma Co., Ltd.","NovMetaPharma Co., Ltd.",,,,,,,Phase 2,Industry,Interventional,6/9/2016,5/17/2017,https://ClinicalTrials.gov/show/NCT02784275
4600,One Month Dispensing Study Comparing the Clinical Performance of the Comfilcon A Sphere Lenses Compared to Comfilcon A Asphere Lenses.,Completed,Has Results,Myopia,Device: comfilcon A sphere lens (control)|Device: comfilcon A asphere lens (test),"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/16/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02759471
4601,Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System,Completed,Has Results,Schizophrenia|Major Depressive Disorder|Bipolar I Disorder,Drug: Aripiprazole + IEM (Ingestible Event Marker),"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,3/16/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02722967
4602,A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents,Completed,Has Results,Pediatric Obesity|Childhood Obesity,Drug: Placebo|Drug: VI-0521 Mid Dose|Drug: VI-0521 Top Dose,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 4,Industry,Interventional,3/16/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02714062
4603,Injection Technique Assessment of Restylane Silk With Lidocaine for Lip Augmentation,Completed,Has Results,Lip Augmentation and Correction of Perioral Rhytids,Device: Restylane Silk with Lidocaine,Q-Med AB,Q-Med AB,,,,,,,Not Applicable,Industry,Interventional,3/16/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02703948
4604,A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS),Completed,Has Results,Macular Edema,Drug: Ranibizumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,3/21/2016,4/5/2016,https://ClinicalTrials.gov/show/NCT02698566
4605,Evaluation of N1539 Following Abdominoplasty Surgery,Completed,Has Results,"Pain, Post-operative",Drug: N1539|Drug: Intravenous Placebo,"Recro Pharma, Inc.","Recro Pharma, Inc.",,,,,,,Phase 3,Industry,Interventional,1/16/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02678286
4606,Evaluation of N1539 Following Bunionectomy Surgery,Completed,Has Results,"Pain, Post-operative",Drug: N1539|Drug: Intravenous Placebo,"Recro Pharma, Inc.","Recro Pharma, Inc.",,,,,,,Phase 3,Industry,Interventional,1/16/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02675907
4607,Clinical Evaluation of Approved and Investigational Contact Lenses,Completed,Has Results,Visual Disorder,Device: Investigational Contact Lenses (Test)|Device: Marketed Contact Lenses (Control),"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/16/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02669095
4608,Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial,Completed,Has Results,Nocturia,Other: Placebo|Drug: Paxerol - Dose Level 1|Drug: Paxerol - Dose Level 2|Drug: Paxerol - Dose Level 3,"Wellesley Pharmaceuticals, LLC","Wellesley Pharmaceuticals, LLC",,,,,,,Phase 2,Industry,Interventional,1/16/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT02646826
4609,Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: FX006 32 mg|Drug: TCA IR 40,"Flexion Therapeutics, Inc.","Flexion Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,11/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02637323
4610,Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain,Completed,Has Results,Pain,Drug: Buprenorphine|Drug: Placebo,INSYS Therapeutics Inc,INSYS Therapeutics Inc,,,,,,,Phase 3,Industry,Interventional,1/29/2016,6/24/2016,https://ClinicalTrials.gov/show/NCT02634788
4611,Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier,Completed,Has Results,Meningitis|Meningococcal Meningitis|Meningococcal Infections,"Biological: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,12/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02633787
4612,CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED),Completed,Has Results,Dry Eye Syndromes,Drug: Cyclosporine A|Drug: Placebo,Novaliq GmbH,Novaliq GmbH,,,,,,,Phase 2,Industry,Interventional,1/16/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02617667
4613,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study",Completed,Has Results,Friedreich's Ataxia,Drug: Interferon γ-1b,"Horizon Pharma Ireland, Ltd., Dublin Ireland|Friedreich's Ataxia Research Alliance","Horizon Pharma Ireland, Ltd., Dublin Ireland",Friedreich's Ataxia Research Alliance,,,,,,Phase 3,Industry|Other,Interventional,12/25/2015,3/21/2017,https://ClinicalTrials.gov/show/NCT02593773
4614,"Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults",Completed,Has Results,Influenza,"Biological: Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|Biological: Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|Biological: Fluzone High-Dose vaccine, 2015-2016 formulation","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02563093
4615,A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type,Completed,Has Results,Dementia of Alzheimer's Type,Drug: Donepezil|Drug: Solifenacin,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",,,,,,,Phase 2,Industry,Interventional,10/7/2015,9/28/2017,https://ClinicalTrials.gov/show/NCT02549196
4616,Pivotal Study for Validation of Philips Dx (PDx),Completed,Has Results,Pathology Processes,,Philips Digital & Computational Pathology,Philips Digital & Computational Pathology,,,,,,,,Industry,Observational,7/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02529137
4617,A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia,Completed,Has Results,Presbyopia,Drug: EV06 Ophthalmic Solution|Drug: Placebo Ophthalmic Solution,"Encore Vision, Inc.","Encore Vision, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,9/16/2015,3/10/2016,https://ClinicalTrials.gov/show/NCT02516306
4618,Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects,Completed,Has Results,Gout,Drug: RDEA3170 2.5 mg|Drug: allopurinol 300 mg,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 2,Industry,Interventional,7/28/2015,6/2/2016,https://ClinicalTrials.gov/show/NCT02498652
4619,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",Completed,Has Results,Friedreich's Ataxia,Drug: Interferon γ-1b|Drug: Placebo,"Horizon Pharma Ireland, Ltd., Dublin Ireland|Friedreich's Ataxia Research Alliance","Horizon Pharma Ireland, Ltd., Dublin Ireland",Friedreich's Ataxia Research Alliance,,,,,,Phase 3,Industry|Other,Interventional,6/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02415127
4620,A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery,Completed,Has Results,Post-Operative Pain,Drug: Sufentanil Tablet 30 mcg|Drug: Placebo Tablet,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,2/15/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02356588
4621,Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria,Completed,Has Results,Hyperoxaluria|Nephrolithiasis,Drug: ALLN-177,Allena Pharmaceuticals,Allena Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,9/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02289755
4622,Sinus Balloon Dilation in Pediatric Patients,Completed,Has Results,Sinusitis,Device: XprESS device and PathAssist confirmation tools,"Entellus Medical, Inc.","Entellus Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02278484
4623,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,Completed,Has Results,Soft Tissue Sarcoma,Drug: GPX-150 for Injection,Gem Pharmaceuticals,Gem Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/7/2015,8/18/2016,https://ClinicalTrials.gov/show/NCT02267083
4624,Study of A-101 for the Treatment of Seborrheic Keratosis,Completed,Has Results,Seborrheic Keratosis,Drug: A-101,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,10/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02260180
4625,"Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults",Completed,Has Results,Influenza,"Biological: Fluzone® Quadrivalent vaccine, 2014-2015 formulation|Biological: Fluzone I®ntradermal vaccine, 2014-2015 formulation|Biological: Fluzone High Dose vaccine, 2014-2015 formulation","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02258334
4626,A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7),Completed,Has Results,MPS 7|Sly Syndrome|Mucopolysaccharidosis|MPS VII,Drug: UX003|Other: Placebo,Ultragenyx Pharmaceutical Inc,Ultragenyx Pharmaceutical Inc,,,,,,,Phase 3,Industry,Interventional,12/14/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02230566
4627,"Mild, Moderate and Severe Renal Impairment Study",Completed,Has Results,Gout,Drug: RDEA3170,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 1,Industry,Interventional,8/1/2014,5/13/2016,https://ClinicalTrials.gov/show/NCT02219516
4628,A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.,Completed,Has Results,Burn Injury|Skin Graft,Device: Mepitel® Ag|Device: Mepilex® Transfer Ag,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,9/14/2019,6/15/2016,https://ClinicalTrials.gov/show/NCT02210208
4629,"A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK2330672|Drug: Placebo|Drug: Sitagliptin|Drug: Metformin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/27/2014,1/30/2015,https://ClinicalTrials.gov/show/NCT02202161
4630,Hummingbird TTS Ear Tube Delivery Study,Completed,Has Results,Otitis Media,Device: Ear tube placement with the Hummingbird TTS,"Preceptis Medical, Inc.","Preceptis Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/14/2019,3/1/2018,https://ClinicalTrials.gov/show/NCT02165384
4631,ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis,Completed,Has Results,Actinic Keratosis,Drug: ACT01|Drug: Comp01|Drug: Comp02|Drug: Comp03|Drug: Comp04,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 2,Industry,Interventional,4/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02126670
4632,"Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors",Completed,Has Results,Advanced Solid Tumors,Drug: MLN4924|Drug: Fluconazole|Drug: Itraconazole|Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,4/1/2014,6/5/2017,https://ClinicalTrials.gov/show/NCT02122770
4633,Safety and Efficacy of the SMART Device for Overweight and Obese Adults,Completed,Has Results,Overweight and Obesity,Device: SMART device,Scientific Intake Limited Co.,Scientific Intake Limited Co.,,,,,,,Not Applicable,Industry,Interventional,3/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02119299
4634,Market Potential of Carbon Dioxide Nasal Spray,Completed,Has Results,Nasal Congestion,Drug: Carbon Dioxide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02113449
4635,Octaplas Pediatric Plasma Replacement Trial,Completed,Has Results,Liver Surgery|Liver Dysfunction|Coagulopathy|Cardiac Surgery,Biological: octaplas,Octapharma,Octapharma,,,,,,,Phase 4,Industry,Interventional,12/14/2019,12/4/2017,https://ClinicalTrials.gov/show/NCT02050841
4636,Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist,Completed,Has Results,Myopia,Device: omafilcon A|Device: etafilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Phase 4,Industry,Interventional,1/14/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT02024698
4637,A Study of LY2928057 in Hemodialysis Participants,Completed,Has Results,"Renal Insufficiency, Chronic|Kidney Disease, Chronic",Drug: LY2928057|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,12/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01991483
4638,Using the Canary Breathing System for Panic Disorder Patients,Completed,Has Results,Panic Disorder,Device: Canary Breathing System,"Palo Alto Health Sciences, Inc.","Palo Alto Health Sciences, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/13/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01955954
4639,Senofilcon A Investigational Manufacturing Process,Completed,Has Results,Visual Acuity|Comfort|Overall Vision,Device: senofilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01951703
4640,"Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults",Completed,Has Results,Influenza,"Biological: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|Biological: Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|Biological: Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01946438
4641,Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction,Completed,Has Results,Advanced Solid Tumors|Hematologic Malignancies,Drug: IXAZOMIB,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,8/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01912222
4642,Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery,Completed,Has Results,Pain,Drug: IV ibuprofen|Drug: Ketorolac,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,7/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01901393
4643,Retrospective Multicenter Clinical Evaluation of Complications for Single or Multilevel VEO® Lateral Access and Interbody Fusion System and eXtreme Lateral Interbody Fusion (XLIF®) Subjects,Completed,Has Results,Degenerative Disc Disease,,"Baxano Surgical, Inc.","Baxano Surgical, Inc.",,,,,,,,Industry,Observational,6/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01878149
4644,A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,Completed,Has Results,GIST,Drug: Ponatinib,Ariad Pharmaceuticals|Takeda,Ariad Pharmaceuticals,Takeda,,,,,,Phase 2,Industry,Interventional,6/5/2013,7/31/2016,https://ClinicalTrials.gov/show/NCT01874665
4645,A Study of LY3025876 in Participants With Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LY3025876|Drug: Placebo|Drug: Liraglutide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01870297
4646,A Study of Multiple Doses of LY2922470 in Participants With Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: LY2922470,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,6/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01867216
4647,Powered Echelon Device in VATS Surgery,Completed,Has Results,Non-small Cell Lung Cancer (NSCLC),Device: Endocutter,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,,Industry,Observational,5/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01843192
4648,NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: NT0102|Drug: Placebo,"Neos Therapeutics, Inc","Neos Therapeutics, Inc",,,,,,,Phase 3,Industry,Interventional,7/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01835548
4649,Assessment of nanOss Bioactive 3D in the Posterolateral Spine,Completed,Has Results,Degenerative Disc Disease|Spinal Stenosis|Spondylolisthesis,Device: nanOss Bioactive 3D BVF,"Pioneer Surgical Technology, Inc.","Pioneer Surgical Technology, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/13/2019,4/18/2019,https://ClinicalTrials.gov/show/NCT01829997
4650,"Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction",Completed,Has Results,Smoking Cessation,Drug: Nadolol|Drug: Placebo,"Invion, Inc.","Invion, Inc.",,,,,,,Phase 2,Industry,Interventional,3/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01825122
4651,A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure,Completed,Has Results,Photodamaged Skin,Dietary Supplement: Imedeen|Dietary Supplement: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,1/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01787461
4652,A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels,Completed,Has Results,Anthrax,Biological: AV7909|Biological: BioThrax,Emergent BioSolutions|National Institute of Allergy and Infectious Diseases (NIAID),Emergent BioSolutions,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,Phase 2,Industry|NIH,Interventional,1/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01770743
4653,"Co-Administration Of Methotrexate And CP-690,550",Completed,Has Results,Rheumatoid Arthritis,"Drug: CP-690,550 (tofacitinib)|Drug: Methotrexate (MTX)",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/5/2019,6/6/2019,https://ClinicalTrials.gov/show/NCT01745055
4654,"Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function",Completed,Has Results,Renal Impairment,"Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,10/3/2019,3/4/2019,https://ClinicalTrials.gov/show/NCT01740362
4655,Evaluation of the Ulthera System for the Treatment of the Decolletage,Completed,Has Results,Chest Wrinkles,Device: Ulthera System Treatment,"Ulthera, Inc|Merz North America, Inc.","Ulthera, Inc","Merz North America, Inc.",,,,,,Not Applicable,Industry,Interventional,10/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01713686
4656,"An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy",Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen,Biogen,Biogen,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01703988
4657,Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|Biological: Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|Biological: Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01691339
4658,Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: CD07805/47 gel 0.5%/CD07805/47 Vehicle|Drug: azelaic acid gel 15%,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 3,Industry,Interventional,9/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01659853
4659,Tadalafil for Sarcoidosis Associated Pulmonary Hypertension,Completed,Has Results,Pulmonary Hypertension,Drug: Tadalafil,"University of North Carolina, Chapel Hill|Eli Lilly and Company|United Therapeutics|University of Cincinnati","University of North Carolina, Chapel Hill",Eli Lilly and Company,United Therapeutics|University of Cincinnati,United Therapeutics,University of Cincinnati,,,Phase 2|Phase 3,Other|Industry,Interventional,3/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01324999
4660,Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes|African American|Cholesterol|Lipoprotein|Apolipoprotein,,Mercer University|Merck Sharp & Dohme Corp.|Emory University|Celera Genomics,Mercer University,Merck Sharp & Dohme Corp.,Emory University|Celera Genomics,Emory University,Celera Genomics,,,,Other|Industry,Observational,12/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01494298
4661,CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext),Completed,Has Results,Melanoma,Biological: CVA21,Viralytics,Viralytics,,,,,,,Phase 2,Industry,Interventional,7/3/2012,4/6/2016,https://ClinicalTrials.gov/show/NCT01636882
4662,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Completed,Has Results,Other Acute Postoperative Pain,Drug: Indomethacin|Drug: Placebo,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,5/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01626118
4663,A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin,Completed,Has Results,Malignant Solid Tumor,Biological: Necitumumab|Drug: Gemcitabine|Drug: Cisplatin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/12/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01606748
4664,PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis,Completed,Has Results,Chest Pain|Cardiovascular Diseases|Angina Pectoris|Coronary Artery Disease|CAD|CVD|CHD|Coronary Heart Disease,Diagnostic Test: Corus CAD,CardioDx,CardioDx,,,,,,,,Industry,Observational,4/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01594411
4665,A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 1,Industry,Interventional,4/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT01565343
4666,A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma,Completed,Has Results,Glioblastoma|Glioblastoma Multiforme,Drug: TRC105|Drug: Bevacizumab,Tracon Pharmaceuticals Inc.|The Cleveland Clinic|Case Comprehensive Cancer Center,Tracon Pharmaceuticals Inc.,The Cleveland Clinic,Case Comprehensive Cancer Center,,,,,Phase 2,Industry|Other,Interventional,5/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01564914
4667,"Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects",Completed,Has Results,Chronic Hepatitis C Infection,Drug: ABT-267|Drug: ABT-450|Drug: ABT-333|Drug: Ritonavir|Drug: Ribavirin,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,2/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01563536
4668,Reduction of Claustrophobia and Patient Motion After Training of MRI Personnel in Comfort TalkTM,Completed,Has Results,Claustrophobia|Complication of Diagnostic Procedure,Behavioral: Comfort Talk®,"Hypnalgesics, LLC|Tufts Medical Center|Boston Medical Center|Ohio State University","Hypnalgesics, LLC",Tufts Medical Center,Boston Medical Center|Ohio State University,Boston Medical Center,Ohio State University,,,Not Applicable,Industry|Other,Interventional,8/11/2019,2/17/2016,https://ClinicalTrials.gov/show/NCT01563198
4669,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Completed,Has Results,Other Acute Postoperative Pain,Drug: Indomethacin|Drug: Celecoxib|Drug: Placebo,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,2/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01543685
4670,Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System,Completed,Has Results,Diabetes,Device: Continuous Glucose Monitoring of glucose levels (Dexcom),"DexCom, Inc.","DexCom, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01514292
4671,"Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age",Completed,Has Results,Anesthesia,Drug: Dexmedetomidine|Drug: Midazolam|Drug: Fentanyl|Drug: Morphine,"Hospira, now a wholly owned subsidiary of Pfizer","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,,Phase 2|Phase 3,Industry,Interventional,3/12/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01508455
4672,High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma|CNS Lymphoma,Procedure: Autologous stem cell transplant|Drug: High-dose chemotherapy,"Massachusetts General Hospital|Genentech, Inc.|Otsuka America Pharmaceutical|Dana-Farber Cancer Institute",Massachusetts General Hospital,"Genentech, Inc.",Otsuka America Pharmaceutical|Dana-Farber Cancer Institute,Otsuka America Pharmaceutical,Dana-Farber Cancer Institute,,,Phase 2,Other|Industry,Interventional,6/10/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01182415
4673,Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults,Completed,Has Results,Anthrax,Biological: BioThrax,Emergent BioSolutions|Department of Health and Human Services,Emergent BioSolutions,Department of Health and Human Services,,,,,,Phase 3,Industry|U.S. Fed,Interventional,11/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01491607
4674,Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium,Completed,Has Results,Vestibular Diseases|Labyrinth Diseases|Ear Diseases|Otorhinolaryngologic Diseases|Traumatic Brain Injury,Device: Usual care physical therapy plus SEMD|Other: Usual care physical therapy only,Karen L Atkins|BalanceSense LLC,Karen L Atkins,BalanceSense LLC,,,,,,Not Applicable,Industry,Interventional,11/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01483937
4675,"Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency",Completed,Has Results,Primary Immunodeficiency,Biological: GAMUNEX-C,Grifols Therapeutics LLC,Grifols Therapeutics LLC,,,,,,,Phase 4,Industry,Interventional,11/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01465958
4676,Study of Diclofenac Capsules to Treat Pain Following Bunionectomy,Completed,Has Results,Other Acute Postoperative Pain,Drug: Diclofenac Test (lower dose)|Drug: Diclofenac Test (upper dose)|Drug: Celecoxib|Drug: Placebo,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,10/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01462435
4677,30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder,Completed,Has Results,Seasonal Affective Disorder,Device: goLITE|Device: Control,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,1/6/2012,4/2/2012,https://ClinicalTrials.gov/show/NCT01462305
4678,Sleep Disordered Breathing and Chronic Pain,Completed,Has Results,Sleep Apnea Syndromes,Device: servo ventilation auto|Device: Continuous positive airway pressure|Device: servo ventilation manual,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01457014
4679,Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients,Completed,Has Results,Chronic Kidney Disease,Drug: Calcium acetate oral solution (COS)|Drug: Sevelamer carbonate,Fresenius Medical Care North America,Fresenius Medical Care North America,,,,,,,Phase 4,Industry,Interventional,9/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01427907
4680,A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode,Completed,Has Results,Epilepsy,Drug: Diazepam,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 2,Industry,Interventional,9/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01417078
4681,"Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Zicronapine open-label lead-in 10 mg daily|Drug: Zicronapine 10 mg daily|Drug: Zicronapine 20 mg once weekly|Drug: Zicronapine 30 mg once weekly|Drug: Zicronapine 45 mg once weekly,H. Lundbeck A/S,H. Lundbeck A/S,,,,,,,Phase 2,Industry,Interventional,7/11/2019,,https://ClinicalTrials.gov/show/NCT01377233
4682,"Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts",Completed,Has Results,Deep Partial Thickness Burn|Full Thickness Burns,Device: Mepitel One,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Phase 4,Industry,Interventional,2/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01365273
4683,Clinical Evaluation of Stenfilcon A Soft Contact Lens When Compared to Ocufilcon B Soft Contact Lens,Completed,Has Results,Myopia,Device: stenfilcon A contact lens|Device: ocufilcon B contact lens,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Early Phase 1,Industry,Interventional,10/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01354223
4684,"The Efficiency of the Hair2Go Device: A Prospective, Open, Label Study With Before-After Design",Completed,Has Results,Hair Removal,Device: Hair2Go (Mē),Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,3/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01348776
4685,Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated,Completed,Has Results,Adult Solid Tumor,Drug: TRC105 and Bevacizumab,Tracon Pharmaceuticals Inc.,Tracon Pharmaceuticals Inc.,,,,,,,Phase 1,Industry,Interventional,4/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01332721
4686,A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval,Completed,Has Results,Cancer,Drug: lapatinib|Drug: placebo matching lapatinib,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,12/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01328054
4687,Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection,Completed,Has Results,Oral Herpes Simplex,Drug: BTL TML HSV|Drug: Matching placebo,"Beech Tree Labs, Inc.|Norwich Clinical Research Associates Ltd.","Beech Tree Labs, Inc.",Norwich Clinical Research Associates Ltd.,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,1/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01308424
4688,Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure,Completed,Has Results,Multiple Myeloma,Device: Spectra Optia Apheresis System,Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,2/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01292486
4689,A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors,Completed,Has Results,Neoplasms,Biological: IMC-3C5,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,3/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01288989
4690,Comparison of Two Intermittent Urinary Catheters,Completed,Has Results,Urinary Retention,Device: 30 cm Intermittent Catheter|Device: 40 cm Intermittent Catheter,Hollister Incorporated,Hollister Incorporated,,,,,,,Not Applicable,Industry,Interventional,10/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01284361
4691,Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2|NIDDM",Drug: PF-04937319|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01272804
4692,Glyburide Advantage in Malignant Edema and Stroke Pilot,Completed,Has Results,Ischemic Stroke,Drug: RP-1127 (Glyburide for injection),"Remedy Pharmaceuticals, Inc.|University of Maryland|Massachusetts General Hospital","Remedy Pharmaceuticals, Inc.",University of Maryland,Massachusetts General Hospital,,,,,Phase 1|Phase 2,Industry|Other,Interventional,5/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01268683
4693,Ecopipam Treatment of Tourette Syndrome,Completed,Has Results,Tourette's Syndrome,Drug: Ecopipam,Psyadon Pharma,Psyadon Pharma,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/10/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01244633
4694,"A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)",Completed,Has Results,Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1,Drug: ABT-450|Drug: ABT-072|Drug: Ribavirin|Drug: Ritonavir,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,10/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01221298
4695,Evaluation of the Cook Biodesign® Nipple Reconstruction Cylinder (NRC),Completed,Has Results,Breast Cancer|Breast Reconstruction|Nipple Reconstruction,Device: Nipple reconstruction,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,9/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01216319
4696,Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble,Completed,Has Results,Pathological Gambling,Drug: Ecopipam,Psyadon Pharma,Psyadon Pharma,,,,,,,Phase 2,Industry,Interventional,10/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01215357
4697,A Study in Participants With Acute Leukemia,Completed,Has Results,Leukemia,Drug: LY2090314,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01214603
4698,Promiseb Topical Cream for Cradle Cap,Completed,Has Results,Cradle Cap|Infantile Seborrheic Dermatitis,Device: Promiseb Topical Cream|Other: Bland emollient,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 4,Industry,Interventional,3/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01214434
4699,Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device,Completed,Has Results,Autoimmune Diseases|Renal Disorders|Hematologic Disorders|Oncologic Disorders,Device: Therapeutic plasma exchange,"Fenwal, Inc.","Fenwal, Inc.",,,,,,,Phase 3,Industry,Interventional,9/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01210716
4700,Evaluation of the Tympanostomy Tube Delivery System,Completed,Has Results,Otitis Media With Effusion|Acute Otitis Media,Device: tympanostomy tube,Acclarent,Acclarent,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01202578
4701,Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart,Completed,Has Results,Idiopathic Dilated Cardiomyopathy,Drug: Carvedilol|Drug: Metoprolol succinate|Drug: Metoprolol succinate + doxazosin,"University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI)|GlaxoSmithKline|AstraZeneca","University of Colorado, Denver","National Heart, Lung, and Blood Institute (NHLBI)",GlaxoSmithKline|AstraZeneca,GlaxoSmithKline,AstraZeneca,,,Phase 4,Other|NIH|Industry,Interventional,9/1/2000,3/9/2019,https://ClinicalTrials.gov/show/NCT01798992
4702,Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD),Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: flibanserin 100 mg dose every evening,"Sprout Pharmaceuticals, Inc","Sprout Pharmaceuticals, Inc",,,,,,,Phase 1,Industry,Interventional,7/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01188603
4703,Dispensing Evaluation of a Galyfilcon A Prototype Lens and a Marketed Contact Lens,Completed,Has Results,Myopia,Device: galyfilcon A prototype lens|Device: comfilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/1/2010,7/1/2010,https://ClinicalTrials.gov/show/NCT01180985
4704,Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults,Completed,Has Results,Influenza,Biological: 0.5mL Intramuscular Injection,Protein Sciences Corporation,Protein Sciences Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01147068
4705,Alignment Comparison Between TruMatch™ Personalized Solutions and Conventional Total Knee Replacement Instrumentation,Completed,Has Results,"Osteoarthritis, Knee",Other: TruMatch™ Personalized Solutions|Device: Total Knee Arthroplasty with Conventional Instrumentation.,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,10/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01108237
4706,A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen,Completed,Has Results,Advanced Solid Tumors|Adenocarcinoma of the Prostate,Drug: Alisertib|Drug: Docetaxel,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,8/17/2010,1/4/2017,https://ClinicalTrials.gov/show/NCT01094288
4707,"Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer",Completed,Has Results,Ovarian Carcinoma|Fallopian Tube Cancer|Peritoneal Cancer|Breast Carcinoma,Drug: Alisertib|Drug: Paclitaxel,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,4/16/2010,7/19/2017,https://ClinicalTrials.gov/show/NCT01091428
4708,Evaluation of PillCam™ Colon 2 in Visualization of the Colon,Completed,Has Results,Colonic Diseases|Bowel Diseases,Device: PillCam™ (Capsule Endoscopy) Colon 2 capsule,Given Imaging Ltd.,Given Imaging Ltd.,,,,,,,Phase 3,Industry,Interventional,7/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01087528
4709,Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease,Completed,Has Results,Gastroesophageal Reflux,Drug: Dexlansoprazole,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,3/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01045096
4710,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: 500mcg/25mcg once daily|Drug: Placebo once daily,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,1/1/2010,4/20/2010,https://ClinicalTrials.gov/show/NCT01039675
4711,A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST),Completed,Has Results,Gastrointestinal Stromal Tumor,Drug: Ganetespib,Synta Pharmaceuticals Corp.,Synta Pharmaceuticals Corp.,,,,,,,Phase 2,Industry,Interventional,1/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01039519
4712,Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy,Completed,Has Results,Pain,Drug: Hydrocodone/Acetaminophen Extended Release|Drug: Acetaminophen|Drug: Morphine Extended Release|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,12/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01038609
4713,A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension,Completed,Has Results,Portopulmonary Hypertension|Pulmonary Arterial Hypertension|Pulmonary Hypertension,Drug: Treprostinil,"United Therapeutics|University of California, Los Angeles|Brigham and Women's Hospital|University of Texas|Emory University",United Therapeutics,"University of California, Los Angeles",Brigham and Women's Hospital|University of Texas|Emory University,Brigham and Women's Hospital,University of Texas|Emory University,University of Texas,Emory University,,Industry|Other,Observational,1/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01028651
4714,Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis|Hay Fever,Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,12/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01024608
4715,Prasugrel/Clopidogrel Maintenance Dose Washout Study,Completed,Has Results,Coronary Artery Disease,Drug: prasugrel|Drug: clopidogrel,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 4,Industry,Interventional,2/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01014624
4716,A Study of Influenza Virus Vaccines in Children and Adults,Completed,Has Results,Influenza,Biological: 2009-2010 Trivalent Influenza Virus Vaccine|Biological: 2008-2009 Trivalent Influenza Virus Vaccine|Biological: Quadrivalent Influenza Virus Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,10/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00988143
4717,Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Chronic Low Back Pain|Chronic Regional Pain Syndrome|Chronic Soft Tissue Pain,Drug: HZT-501,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 3,Industry,Interventional,9/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00984815
4718,Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura,Completed,Has Results,Migraine Without Aura,Drug: NXN-188|Drug: Placebo,NeurAxon Inc.,NeurAxon Inc.,,,,,,,Phase 2,Industry,Interventional,7/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00959751
4719,Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States,Completed,Has Results,Chronic Hepatitis B,Drug: FTC/TDF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,8/9/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT00936715
4720,Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: 4mm x 32G pen needle|Device: 8mm x 31G pen needle|Device: 5mm x 31G pen needle,"Becton, Dickinson and Company","Becton, Dickinson and Company",,,,,,,Not Applicable,Industry,Interventional,6/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00928057
4721,Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus,Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Valsartan|Drug: Placebo for Aliskiren|Drug: Placebo for Valsartan,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,5/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00927394
4722,A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Abiraterone|Drug: Leuprolide|Drug: Prednisone,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,11/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00924469
4723,"A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers",Completed,Has Results,Her2 Amplified Solid Tumors|Metastatic Breast Cancer,Drug: MM-111,Merrimack Pharmaceuticals,Merrimack Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,6/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00911898
4724,Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp,Completed,Has Results,Scalp Psoriasis,Drug: clobetasol propionate spray 0.05%|Drug: Vehicle spray,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,4/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00881868
4725,Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors,Completed,Has Results,Advanced Solid Tumors|Neoplasms|Carcinoma|Cancer|Malignancy,Biological: CVX-060,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,1/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00879684
4726,A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations,Completed,Has Results,Hypogonadism,Drug: Testosterone MD-Lotion,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,10/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00857961
4727,A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects,Completed,Has Results,Smallpox,Biological: IMVAMUNE,Bavarian Nordic,Bavarian Nordic,,,,,,,Phase 2,Industry,Interventional,6/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00857493
4728,The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes,Completed,Has Results,Impaired Glucose Tolerance,Drug: Exenatide|Drug: Metformin,"St. Paul Heart Clinic|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company|International Diabetes Center at Park Nicollet",St. Paul Heart Clinic,"Amylin Pharmaceuticals, LLC.",Eli Lilly and Company|International Diabetes Center at Park Nicollet,Eli Lilly and Company,International Diabetes Center at Park Nicollet,,,Phase 4,Other|Industry,Interventional,10/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00546728
4729,Controlled Study of the Ability of a Smokefree Tobacco Product to Increase the Quit Rate Among Cigarette Smokers,Completed,Has Results,Cigarette Smoking,"Drug: Low-nitrosamine smokefree tobacco product for oral use|Other: Non-tobacco, non-nicotine placebo product",Swedish Match AB,Swedish Match AB,,,,,,,Phase 4,Industry,Interventional,2/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00843622
4730,Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole ER|Drug: Ranitidine,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,8/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00839306
4731,Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole ER|Drug: Ranitidine,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,8/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00838526
4732,Safety and Efficacy of a Glaucoma Drug Delivery System,Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: High Dose Device|Drug: Low Dose Device|Device: Placebo Device,Vistakon Pharmaceuticals,Vistakon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00824720
4733,Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.,Completed,Has Results,Knee Injury,Other: CR Plug,RTI Surgical,RTI Surgical,,,,,,,Phase 3,Industry,Interventional,12/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00821873
4734,The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions,Completed,Has Results,Peripheral Vascular Disease,Device: Complete SE Vascular Stent System,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00814970
4735,In-Clinic and Home-Use Study of a New Blood Glucose Monitoring System,Completed,Has Results,Diabetes,Device: Investigational Blood Glucose Monitoring System,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,12/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00803777
4736,Topcon 3D OCT-1000 Optical Coherence Tomography System,Completed,Has Results,Retinal Disease|Glaucoma,,"Topcon Medical Systems, Inc.","Topcon Medical Systems, Inc.",,,,,,,,Industry,Observational,10/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00792259
4737,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: 80 mcg Ciclesonide|Drug: 160 mcg Ciclesonide|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,11/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00790023
4738,Glucose Meter Study,Completed,Has Results,Diabetes Mellitus,Device: Education + new meter|Device: Education + new meter + feature activation,Ascensia Diabetes Care,Ascensia Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00782496
4739,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease",Completed,Has Results,Alzheimer's Disease|Central Nervous System Diseases,Drug: EVP-6124 (0.1 mg/day)|Drug: EVP-6124 (0.3 mg/day)|Drug: EVP-6124 (1.0 mg/day)|Drug: Comparator: Placebo|Drug: Donepezil|Drug: Rivastigmine,FORUM Pharmaceuticals Inc|Syneos Health,FORUM Pharmaceuticals Inc,Syneos Health,,,,,,Phase 1,Industry|Other,Interventional,10/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00766363
4740,Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder,Completed,Has Results,Excessive Sleepiness,Drug: armodafinil|Drug: placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,9/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00758498
4741,Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: BD/33G|Device: OTM / 33G|Device: OTU/28G|Device: ACC/28G|Device: OTM/28G,"Becton, Dickinson and Company","Becton, Dickinson and Company",,,,,,,Not Applicable,Industry,Interventional,8/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00741390
4742,PF-04191834 Single Dose Bronchodilatory Study In Asthma.,Completed,Has Results,Asthma,Drug: PF-04191834|Drug: zileuton|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,7/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00723021
4743,Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID),Completed,Has Results,Primary Immune Deficiency,Biological: IgPro20,CSL Behring,CSL Behring,,,,,,,Phase 3,Industry,Interventional,6/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00719680
4744,A Clinical Investigation of the Discovery™ Elbow System,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Avascular Necrosis|Humeral Fractures,,"Biomet Orthopedics, LLC|Zimmer Biomet","Biomet Orthopedics, LLC",Zimmer Biomet,,,,,,,Industry,Observational,6/2/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT00698867
4745,Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma,Completed,Has Results,Asthma,Drug: MN-221|Drug: Placebo,MediciNova,MediciNova,,,,,,,Phase 2,Industry,Interventional,2/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00679263
4746,Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients,Completed,Has Results,Chronic Gout Refractory to Conventional Therapy,Drug: pegloticase 8 mg i.v.,Savient Pharmaceuticals,Savient Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00675103
4747,Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: adapalene gel, 0.3%|Drug: clindamycin/benzoyl peroxide gel","Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,12/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00671749
4748,Antibiotic Study for Dental Implants,Completed,Has Results,Periodontitis,Drug: Minocycline HCl,OraPharma,OraPharma,,,,,,,Phase 3,Industry,Interventional,4/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00662532
4749,Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods),Completed,Has Results,Dysmenorrhea,Drug: Lidocaine|Drug: Placebo,"Juniper Pharmaceuticals, Inc.","Juniper Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,8/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00651313
4750,Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate,Completed,Has Results,Acne Vulgaris,Drug: Doxycycline hyclate (Doryx)|Drug: Doxycycline hyclate,Warner Chilcott,Warner Chilcott,,,,,,,Phase 4,Industry,Interventional,3/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00635609
4751,Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age,Completed,Has Results,Infection,Drug: ceftaroline,Forest Laboratories,Forest Laboratories,,,,,,,Phase 1,Industry,Interventional,3/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00633126
4752,CryoCath Freezor CryoAblation Catheter System (CRYOFACTS),Completed,Has Results,"Tachycardia, Atrioventricular Nodal Reentry",Device: Freezor® Cardiac Cryoablation Catheter CryoConsole System,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Phase 4,Industry,Interventional,12/6/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00621621
4753,A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS),Completed,Has Results,Myelodysplastic Syndrome,Drug: decitabine,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,5/8/2019,,https://ClinicalTrials.gov/show/NCT00619099
4754,Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations,Completed,Has Results,"Dermatitis, Contact",Biological: TRUE Test allergens Fragrance Mix and Thimerosol,Allerderm,Allerderm,,,,,,,Phase 2,Industry,Interventional,1/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00612768
4755,"Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors",Completed,Has Results,Neoplasms,"Drug: Paclitaxel + Carboplatin + CP-870,893",Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,11/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00607048
4756,Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers,Completed,Has Results,Obstructive Sleep Apnea Syndrome,Device: OxiplexTS,"ISS, Inc.|National Institute of Neurological Disorders and Stroke (NINDS)|Carle Foundation Hospital|University of Illinois at Chicago|University of California, Irvine","ISS, Inc.",National Institute of Neurological Disorders and Stroke (NINDS),"Carle Foundation Hospital|University of Illinois at Chicago|University of California, Irvine",Carle Foundation Hospital,"University of Illinois at Chicago|University of California, Irvine",University of Illinois at Chicago,"University of California, Irvine",Phase 3,Industry|NIH|Other,Interventional,8/7/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00591591
4757,Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration,Completed,Has Results,Gingival Recession,Device: Gintuit|Other: Autologous palatal tissue,Organogenesis,Organogenesis,,,,,,,Phase 3,Industry,Interventional,10/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00587834
4758,A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection,Completed,Has Results,TBI (Traumatic Brain Injury),Device: Infrascanner,"InfraScan, Inc.","InfraScan, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/6/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00576147
4759,Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Arformoterol Tartrate Inhalation Solution|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 4,Industry,Interventional,11/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00571428
4760,Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel,Completed,Has Results,Ethmoid Sinusitis|Rhinosinusitis,Device: AdvaCoat sinus gel|Device: Merogel Injectable,"Carbylan Therapeutics, Inc.","Carbylan Therapeutics, Inc.",,,,,,,Phase 4,Industry,Interventional,5/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00554190
4761,"An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: Anti-KIR (1-7F9),Innate Pharma,Innate Pharma,,,,,,,Phase 1,Industry,Interventional,5/7/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00552396
4762,DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial,Completed,Has Results,Femoral Fracture (Proximal),Device: Intramedullary nailing,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Phase 4,Industry,Interventional,9/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00546429
4763,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Completed,Has Results,Healthy,Drug: DR-1021|Drug: Mircette®|Drug: Kariva®,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,10/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00544882
4764,Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus,Completed,Has Results,"Infections, Bacterial",Drug: retapamulin|Drug: Retapamulin|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00539994
4765,Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis,Completed,Has Results,Psoriasis-Type Psoriasis|Plaque-Type Psoriasis,Drug: Apremilast,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,8/1/2007,5/1/2009,https://ClinicalTrials.gov/show/NCT00521339
4766,Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy,Completed,Has Results,Colorectal Cancer,Biological: IMC-A12|Biological: cetuximab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00503685
4767,Study of INT-747 in Patients With Diabetes and Presumed NAFLD,Completed,Has Results,"Diabetes Mellitus, Type II|Fatty Liver",Drug: INT-747|Drug: Placebo,Intercept Pharmaceuticals,Intercept Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00501592
4768,Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies,Completed,Has Results,Progressive Metastatic Malignancies,Biological: ALT-801,Altor BioScience,Altor BioScience,,,,,,,Phase 1,Industry,Interventional,5/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00496860
4769,Multi-Center Pre-Bariatric Weight Loss Study,Completed,Has Results,Obesity,Device: GI Sleeve Implantable weight loss device (EndoBarrier)|Procedure: Sham Procedure,GI Dynamics,GI Dynamics,,,,,,,Phase 2,Industry,Interventional,6/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00469391
4770,Study of Cobimetinib in Participants With Solid Tumors,Completed,Has Results,Solid Tumor,Drug: cobimetinib|Drug: dextromethorphan|Drug: midazolam,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,5/7/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00467779
4771,A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung|Colorectal Cancer|Malignant Melanoma|Renal Cancer|Prostate Cancer",Biological: MDX-1106,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,8/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00441337
4772,Drug and Non-Drug Treatment Of Severe Migraine,Completed,Has Results,Migraine Headache,Drug: Propranolol or nadolol|Drug: Placebo control|Behavioral: Behavioral Migraine Management (BMM)|Drug: Optimal Acute Therapy,Ohio University|National Institute of Neurological Disorders and Stroke (NINDS)|Merck Sharp & Dohme Corp.|GlaxoSmithKline,Ohio University,National Institute of Neurological Disorders and Stroke (NINDS),Merck Sharp & Dohme Corp.|GlaxoSmithKline,Merck Sharp & Dohme Corp.,GlaxoSmithKline,,,Phase 4,Other|NIH|Industry,Interventional,7/1/2019,11/5/2019,https://ClinicalTrials.gov/show/NCT00910689
4773,Duloxetine Versus Placebo in Chronic Low Back Pain,Completed,Has Results,Back Pain Without Radiation,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/6/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00408876
4774,Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI),Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: Ultrase® MT20|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,11/6/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00408317
4775,Does Implant Design Improve Postoperative Flexion?,Completed,Has Results,Non-inflammatory Arthritis,Device: Total knee replacement using the PFC Sigma RPF knee implant.|Device: Total knee replacement using the PFC Sigma RP knee implant,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,3/6/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00380861
4776,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,Completed,Has Results,"Pain, Postoperative",Drug: diclofenac potassium (XP21L)|Drug: Placebo,Xanodyne Pharmaceuticals,Xanodyne Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/6/2019,,https://ClinicalTrials.gov/show/NCT00375934
4777,Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia,Drug: Asfotase alfa,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,6/6/2016,6/21/2017,https://ClinicalTrials.gov/show/NCT02797821
4778,Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults,Completed,Has Results,Influenza Disease; Flu,Biological: Influenza Virus Vaccine,Novartis Vaccines|Novartis Vaccines and Diagnostics (formerly Chiron Vaccines)|Novartis,Novartis Vaccines,Novartis Vaccines and Diagnostics (formerly Chiron Vaccines),Novartis,,,,,Phase 2,Industry|Other,Interventional,10/5/2019,5/6/2019,https://ClinicalTrials.gov/show/NCT00264576
4779,Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients,Completed,Has Results,Hepatitis C Virus Infection,Drug: VGX-410 (Mifepristone)|Drug: Placebo,"VGX Pharmaceuticals, LLC","VGX Pharmaceuticals, LLC",,,,,,,Phase 2,Industry,Interventional,11/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00255177
4780,Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: SNS-595 Injection,Sunesis Pharmaceuticals,Sunesis Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/27/2005,11/29/2007,https://ClinicalTrials.gov/show/NCT00252382
4781,"Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer",Completed,Has Results,Non-small Cell Lung Cancer,Drug: carboplatin|Drug: Nab-paclitaxel|Drug: Bevacizumab,"Massachusetts General Hospital|Dana-Farber Cancer Institute|Celgene Corporation|Genentech, Inc.",Massachusetts General Hospital,Dana-Farber Cancer Institute,"Celgene Corporation|Genentech, Inc.",Celgene Corporation,"Genentech, Inc.",,,Phase 2,Other|Industry,Interventional,4/8/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT00642759
4782,Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers,Completed,Has Results,Arterial Occlusive Disease|Peripheral Vascular Disease|Ischemia|Ulcers,Genetic: HGF plasmid|Genetic: Placebo,"AnGes USA, Inc.","AnGes USA, Inc.",,,,,,,Phase 2,Industry,Interventional,8/5/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00189540
4783,"Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer",Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Patupilone,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,8/3/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00171834
4784,"A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer",Completed,Has Results,"Neoplasms|Lymphoma, Non-Hodgkin",Drug: PD-0332991,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,9/4/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00141297
4785,The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS),Completed,Has Results,Lung Cancer,Device: Ablation|Procedure: Surgical Resection,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,1/15/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT02323854
4786,Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01),Completed,Has Results,HIV Infections,Drug: darunavir 800 mg|Drug: FTC 200 mg/TDF 300mg|Drug: Maraviroc|Drug: Raltegravir|Drug: Ritonavir 100 mg,Rockefeller University|Aaron Diamond AIDS Research Center|Merck Sharp & Dohme Corp.|Pfizer,Rockefeller University,Aaron Diamond AIDS Research Center,Merck Sharp & Dohme Corp.|Pfizer,Merck Sharp & Dohme Corp.,Pfizer,,,Not Applicable,Other|Industry,Interventional,10/7/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00525733
4787,"An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis",Completed,Has Results,Severe Hypertriglyceridemia,Drug: Epanova|Drug: Lovaza,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,10/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02189252
4788,Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors,Completed,Has Results,Carcinoid Tumors,Drug: Pasireotide (SOM230),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,1/4/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00088595
4789,Multicenter Dispensing Study of Biofinity Lenses in Extended Range,Completed,Has Results,Myopia|Hyperopia,Device: Biofinity XR,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02060539
4790,"A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)",Completed,Has Results,Spinal Muscular Atrophy,Drug: nusinersen,Biogen,Biogen,,,,,,,Phase 2,Industry,Interventional,5/8/2013,8/21/2017,https://ClinicalTrials.gov/show/NCT01839656
4791,An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy,Completed,Has Results,GNE Myopathy|Hereditary Inclusion Body Myopathy (HIBM),Drug: SA-ER 500 mg|Drug: SA-IR 500 mg,Ultragenyx Pharmaceutical Inc,Ultragenyx Pharmaceutical Inc,,,,,,,Phase 2,Industry,Interventional,6/4/2013,2/14/2017,https://ClinicalTrials.gov/show/NCT01830972
4792,Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound,Completed,Has Results,Treatment of Adipose Tissue in the Thighs,Device: Liposonix System (Model 2),Solta Medical|Valeant Pharmaceuticals,Solta Medical,Valeant Pharmaceuticals,,,,,,Not Applicable,Industry,Interventional,7/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01823653
4793,Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older,Completed,Has Results,Herpes Zoster,Biological: Herpes zoster vaccine GSK1437173A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/12/2013,4/8/2015,https://ClinicalTrials.gov/show/NCT01751165
4794,"Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination",Completed,Has Results,Smallpox,Biological: Vaccinia virus: ACAM2000 smallpox vaccine|Biological: vaccinia virus (calf lymph): Dryvax,Emergent BioSolutions,Emergent BioSolutions,,,,,,,Phase 2,Industry,Interventional,1/3/2019,11/3/2019,https://ClinicalTrials.gov/show/NCT00053495
4795,PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2),Completed,Has Results,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Drug: Itraconazole|Drug: PKC412,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,1/30/2002,3/27/2008,https://ClinicalTrials.gov/show/NCT00045942
4796,A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug,Completed,Has Results,Asthma,Biological: Lyophilized mepolizumab|Biological: Liquid mepolizumab|Device: Prefilled autoinjector|Device: Prefilled Safety Syringe,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/6/2017,8/11/2017,https://ClinicalTrials.gov/show/NCT03014674
4797,"Study of SCY-635, Pegasys and Copegus in Hepatitis C",Completed,Has Results,Hepatitis C Infection,Drug: Placebo|Drug: SCY-635|Drug: Pegasys|Drug: Copegus,"Scynexis, Inc.","Scynexis, Inc.",,,,,,,Phase 2,Industry,Interventional,11/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01265511
4798,Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency,Completed,Has Results,Alpha-1 Antitrypsin Deficiency,Drug: rAAV1-CB-hAAT,"Applied Genetic Technologies Corp|National Heart, Lung, and Blood Institute (NHLBI)",Applied Genetic Technologies Corp,"National Heart, Lung, and Blood Institute (NHLBI)",,,,,,Phase 2,Industry|NIH,Interventional,6/10/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01054339
4799,To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients,Completed,Has Results,Migraine,Drug: Erenumab|Drug: Placebo|Drug: PACAP-38 Challenge Agent,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,11/11/2015,11/8/2017,https://ClinicalTrials.gov/show/NCT02542605
4800,A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy,Completed,Has Results,Healthy Volunteers,Drug: Period 1 - Treatment Sequence AB|Drug: Period 1 - Treatment Sequence AC|Drug: Period 2 - Treatment Sequence AB|Drug: Period 2 - Treatment Sequence AC,Synthetic Biologics Inc.,Synthetic Biologics Inc.,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/15/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02419001
4801,PinPointe FootLaser for the Treatment of Onychomycosis,Completed,Has Results,Infected Toenails|Onychomycosis,Device: PinPointe FootLaser,"PathoLase, Inc.","PathoLase, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,6/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00935649
4802,BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis,Completed,Has Results,Osteoarthritis,Biological: onabotulinumtoxinA|Drug: Normal Saline,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,10/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02230956
4803,A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients,Completed,Has Results,"Gaucher Disease|Type 1 Gaucher Disease|Gaucher Disease, Type 1",Drug: afegostat tartrate,Amicus Therapeutics,Amicus Therapeutics,,,,,,,Phase 2,Industry,Interventional,5/11/2009,5/1/2012,https://ClinicalTrials.gov/show/NCT00813865
4804,A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin Peglispro|Drug: Insulin Glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,5/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02132637
4805,Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors,Completed,Has Results,Advanced Solid Tumors,Drug: Lipotecan,Taiwan Liposome Company,Taiwan Liposome Company,,,,,,,Phase 1,Industry,Interventional,9/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00747474
4806,Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device,Completed,Has Results,Thromboembolic Events,,"DSM Nutritional Products, Inc.","DSM Nutritional Products, Inc.",,,,,,,,Industry,Observational,4/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT02052544
4807,Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study,Completed,Has Results,Colon Cancer,Device: Tandem Colonoscopy,EndoAid,EndoAid,,,,,,,Not Applicable,Industry,Interventional,7/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01955122
4808,"A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia",Completed,Has Results,Hairy Cell Leukemia,Drug: Moxetumomab Pasudotox (CAT 8015)|Drug: CAT 8015 (Moxetumomab Pasudotox),MedImmune LLC|Cambridge Antibody Technology,MedImmune LLC,Cambridge Antibody Technology,,,,,,Phase 1,Industry|Other,Interventional,5/10/2007,5/6/2015,https://ClinicalTrials.gov/show/NCT00586924
4809,Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose,Completed,Has Results,CerebroSpinal Fluid (CSF) Leak|Chronic Otitis Media|Otospongiosis|Otosclerosis|Pulsatile Tinnitus|Cholesteatoma,Radiation: Radiation,"Carestream Health, Inc.","Carestream Health, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/21/2012,8/9/2013,https://ClinicalTrials.gov/show/NCT01855425
4810,Clinical and Laboratory Evaluation of 3 Contact Lenses With 4 Contact Lens Solutions,Completed,Has Results,Contact Lens Solutions,Other: Solution 1 (Test)|Other: Solution 2 (Test)|Other: Solution 3 (Test)|Other: Solution 4 (Control),"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/1/2013,2/1/2014,https://ClinicalTrials.gov/show/NCT01791517
4811,Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity,Completed,Has Results,Chronic Constipation,Drug: prucalopride|Drug: PEG 3350,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,1/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01707667
4812,Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment,Completed,Has Results,HIV Infections|Hepatic Impairment,Drug: efavirenz containing antiretroviral regimen,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,11/4/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00162097
4813,Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence,Completed,Has Results,"Urinary Bladder, Overactive",Drug: AGN-214868|Drug: AGN-214868 placebo,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,10/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01157377
4814,Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium,Completed,Has Results,Pterygium,Drug: cyclosporine ophthalmic emulsion 0.05%|Drug: Vehicle,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01109056
4815,A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®,Completed,Has Results,Hunter Syndrome,Other: Control|Drug: Idursulfase IT (1 mg)|Drug: Idursulfase IT (10 mg)|Drug: Idursulfase IT (30 mg),Shire,Shire,,,,,,,Phase 1|Phase 2,Industry,Interventional,11/1/2009,10/1/2012,https://ClinicalTrials.gov/show/NCT00920647
4816,Valsartan Intensified Primary Care Reduction of Blood Pressure Study,Completed,Has Results,Hypertension,Drug: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Drug: Valsartan and amlodipine|Drug: Usual care|Drug: Valsartan|Drug: Valsartan and hydrochlorothiazide (HCTZ) - combination arm,Novartis Pharmaceuticals|Baker IDI Heart and Diabetes Institute|Novartis,Novartis Pharmaceuticals,Baker IDI Heart and Diabetes Institute,Novartis,,,,,Phase 4,Industry|Other,Interventional,7/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00902304
4817,Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD),Completed,Has Results,Choroidal Neovascularization|Age-Related Maculopathy,Drug: dexamethasone|Biological: ranibizumab,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,11/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00775411
4818,Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma,Completed,Has Results,Asthma,Drug: Budesonide HFA|Drug: Budesonide CFC,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00667992
4819,Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.,Completed,Has Results,Essential Hypertension,Drug: Aliskiren|Drug: Placebo to Aliskiren,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,3/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00654875
4820,Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old,Completed,Has Results,Acute Hypoxemic Respiratory Failure,Drug: Lucinactant|Other: Sham Comparator,Windtree Therapeutics,Windtree Therapeutics,,,,,,,Phase 2,Industry,Interventional,6/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00578734
4821,A Study Of PF-03732010 In Patients With Advanced Solid Tumors,Completed,Has Results,Neoplasms,Drug: PF-03732010,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,12/7/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00557505
4822,Insulin Glulisine in Type 2 Diabetic Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Glargine|Drug: Glimepiride|Drug: Insulin Glulisine|Drug: Metformin,Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,7/6/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00360698
4823,Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma,Completed,Has Results,"Lymphoma, Non-Hodgkin",Biological: Tositumomab and Iodine I 131 Tositumomab|Biological: Rituximab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/4/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00268983
4824,Effect of Sulodexide in Early Diabetic Nephropathy,Completed,Has Results,Diabetic Nephropathy,Drug: Sulodexide|Drug: Placebo,Keryx Biopharmaceuticals|Collaborative Study Group (CSG),Keryx Biopharmaceuticals,Collaborative Study Group (CSG),,,,,,Phase 3,Industry|Other,Interventional,8/5/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00130208
4825,"Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers",Completed,Has Results,Nicotine Dependence,Drug: Nicotine Patch|Drug: Moclobemide,"Jed E. Rose|Philip Morris USA, Inc.|National Institute on Drug Abuse (NIDA)|Duke University",Jed E. Rose,"Philip Morris USA, Inc.",National Institute on Drug Abuse (NIDA)|Duke University,National Institute on Drug Abuse (NIDA),Duke University,,,Phase 2,Other|Industry|NIH,Interventional,9/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01926626
4826,Electrocardiogram Clinical Validation Study,Completed,Has Results,Atrial Fibrillation,Other: 1-Lead ECG|Device: 12-Lead ECG,Apple Inc.|Iqvia Pty Ltd,Apple Inc.,Iqvia Pty Ltd,,,,,,Not Applicable,Industry,Interventional,3/12/2018,5/14/2018,https://ClinicalTrials.gov/show/NCT03492554
4827,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Completed,Has Results,Acute Post-surgical Pain,Drug: Co-crystal E-58425 (Tramadol/Celecoxib)|Drug: Tramadol (Ultram®)|Drug: Celecoxib (Celebrex®)|Drug: Placebo,"Laboratorios del Dr. Esteve, S.A.|Premier Research Group plc","Laboratorios del Dr. Esteve, S.A.",Premier Research Group plc,,,,,,Phase 3,Industry,Interventional,3/14/2017,11/28/2017,https://ClinicalTrials.gov/show/NCT03108482
4828,Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA),Completed,Has Results,Ovarian Cancer,Drug: Doxil|Drug: Avastin,"New Mexico Cancer Care Alliance|Genentech, Inc.|NYU Langone Health",New Mexico Cancer Care Alliance,"Genentech, Inc.",NYU Langone Health,,,,,Phase 2,Other|Industry,Interventional,3/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00945139
4829,"Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6",Completed,Has Results,PT-NANBH,Drug: 8 weeks SOF/LED|Drug: 12 weeks SOF/LED,Stanford University|Gilead Sciences,Stanford University,Gilead Sciences,,,,,,Phase 4,Other|Industry,Interventional,6/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02480166
4830,Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Dexamethasone intravitreal implant (0.7 mg)|Drug: Intravitreal anti-VEGF injection,California Retina Consultants|Allergan,California Retina Consultants,Allergan,,,,,,Phase 4,Other|Industry,Interventional,6/15/2019,10/24/2018,https://ClinicalTrials.gov/show/NCT02471651
4831,"Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma",Completed,Has Results,Brain Cancer|Malignant Glioma,Other: radiotherapy (RT) in combination with temozolomide and bevacizumab,"Memorial Sloan Kettering Cancer Center|Genentech, Inc.|National Institutes of Health (NIH)",Memorial Sloan Kettering Cancer Center,"Genentech, Inc.",National Institutes of Health (NIH),,,,,Phase 2,Other|Industry|NIH,Interventional,10/28/2008,3/23/2017,https://ClinicalTrials.gov/show/NCT00782756
4832,Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),Completed,Has Results,Lymphoma|Primary Central Nervous System Lymphoma|Recurrent/Refractory Secondary Central Nervous System Lymphoma,Drug: Buparlisib (BKM120),Memorial Sloan Kettering Cancer Center|Novartis,Memorial Sloan Kettering Cancer Center,Novartis,,,,,,Phase 2,Other|Industry,Interventional,11/20/2014,10/11/2016,https://ClinicalTrials.gov/show/NCT02301364
4833,Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression,Completed,Has Results,Progressive IgA Nephropathy|Proteinuria,Drug: ACTH (Acthar) Gel,Mayo Clinic|Mallinckrodt,Mayo Clinic,Mallinckrodt,,,,,,Phase 3,Other|Industry,Interventional,3/15/2019,6/30/2018,https://ClinicalTrials.gov/show/NCT02282930
4834,Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment,Completed,Has Results,Metastatic Castration-resistant Prostate Cancer,Drug: Carfilzomib|Drug: Dexamethasone|Drug: Acyclovir,University of Alabama at Birmingham|Amgen,University of Alabama at Birmingham,Amgen,,,,,,Phase 2,Other|Industry,Interventional,4/14/2019,7/14/2017,https://ClinicalTrials.gov/show/NCT02047253
4835,Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains,Completed,Has Results,Streptococcus Agalactiae Infection,Device: Comparison between GenePOC PCR and Reference Method,GenePOC,GenePOC,,,,,,,Not Applicable,Industry,Interventional,8/10/2016,2/7/2017,https://ClinicalTrials.gov/show/NCT02718157
4836,Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy,Completed,Has Results,"Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Biological: bevacizumab|Procedure: quality-of-life assessment,"Northwestern University|Genentech, Inc.",Northwestern University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,11/27/2013,9/3/2018,https://ClinicalTrials.gov/show/NCT01898130
4837,In Vivo Kinematics Comparison of Stryker or Zimmer Total Knee Arthroplasty,Completed,Has Results,Knee Prosthesis,Device: Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|Device: Zimmer PCR TKA,"The University of Tennessee, Knoxville|Stryker Orthopaedics","The University of Tennessee, Knoxville",Stryker Orthopaedics,,,,,,,Other|Industry,Observational,6/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01864434
4838,"Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant",Completed,Has Results,Hernioplasty,Drug: 2 100mg Xaracoll implants|Drug: 3 100mg Xaracoll implants|Drug: 150mg Bupivacaine HCl injection,Innocoll|Premier Research Group plc,Innocoll,Premier Research Group plc,,,,,,Phase 2,Industry,Interventional,9/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02232178
4839,"Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis",Completed,Has Results,Pulmonary Cystic Fibrosis,Other: Placebo|Drug: QBW276,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,9/27/2017,4/24/2018,https://ClinicalTrials.gov/show/NCT02566044
4840,"TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds",Completed,Has Results,"Nasolabial Folds, Wrinkles",Device: TEOSYAL® RHA Global Action|Device: TEOSYAL® RHA Deep Lines,Teoxane SA|ethica Clinical Research Inc.,Teoxane SA,ethica Clinical Research Inc.,,,,,,Not Applicable,Industry,Interventional,6/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02195427
4841,Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab,Completed,Has Results,Macular Degeneration,Drug: 0.5 mg ranibizumab,"Charles C Wykoff, PhD, MD|Genentech, Inc.|Greater Houston Retina Research","Charles C Wykoff, PhD, MD","Genentech, Inc.",Greater Houston Retina Research,,,,,Phase 3,Other|Industry,Interventional,12/12/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT01748292
4842,Study of APD421 as PONV Treatment (no Prior Prophylaxis),Completed,Has Results,Postoperative Nausea and Vomiting,Drug: APD421|Drug: Placebo,Acacia Pharma Ltd,Acacia Pharma Ltd,,,,,,,Phase 3,Industry,Interventional,9/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02449291
4843,Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation,Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Melphalan,University of Alabama at Birmingham|Amgen,University of Alabama at Birmingham,Amgen,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/12/2019,11/1/2017,https://ClinicalTrials.gov/show/NCT01690143
4844,Endoscopic Suturing for Primary Obesity Treatment,Completed,Has Results,Obesity|Body Weight|Overweight,Device: Endoscopic gastric restrictive procedure,"Brigham and Women's Hospital|Apollo Endosurgery, Inc.",Brigham and Women's Hospital,"Apollo Endosurgery, Inc.",,,,,,Not Applicable,Other|Industry,Interventional,2/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01662024
4845,"Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)",Completed,Has Results,Mucopolysaccharidosis IIIB,Drug: SBC-103,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/22/2015,10/16/2017,https://ClinicalTrials.gov/show/NCT02324049
4846,Metronidazole Pharmacokinetics (PK) in Premature Infants,Completed,Has Results,Serious Systemic Infections|Necrotizing Enterocolitis,Drug: Metronidazole,"Michael Cohen-Wolkowiez|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC|Duke University",Michael Cohen-Wolkowiez,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"The Emmes Company, LLC|Duke University","The Emmes Company, LLC",Duke University,,,Phase 1,Other|NIH|Industry,Interventional,1/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01222585
4847,Harmonic ACE®+7 Shears in Laparoscopic Hysterectomy,Completed,Has Results,Benign Disease Where Total Hysterectomy is Indicated,Device: Harmonic ACE®+7 Shears,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Phase 4,Industry,Interventional,10/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02278640
4848,The Effects of Extraoral Photobiomodulation on the Rate of Orthodontic Alignment,Completed,Has Results,Malocclusion,Device: Extraoral OrthoPulse® PBM|Other: Fixed Orthodontic Appliance Treatment,Biolux Research Ltd.,Biolux Research Ltd.,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT02267824
4849,Harmonic ACE®+7 Shears in Laparoscopic Colectomy,Completed,Has Results,Benign or Malignant Disease Indicated for Colectomy,Device: Harmonic ACE®+7 Shears,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Phase 4,Industry,Interventional,8/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02248246
4850,"Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",Completed,Has Results,Leukemia|Myelodysplastic Syndromes,Drug: fludarabine|Drug: treosulfan|Procedure: allogeneic blood or bone marrow transplantation,OHSU Knight Cancer Institute|medac GmbH|National Cancer Institute (NCI),OHSU Knight Cancer Institute,medac GmbH,National Cancer Institute (NCI),,,,,Phase 1|Phase 2,Other|Industry|NIH,Interventional,6/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00253513
4851,"Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab",Completed,Has Results,Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion|Macular Edema,Drug: ranibizumab 0.5mg|Drug: ranibizumab 1.0mg,"Hanscom, Thomas, M.D.|Genentech, Inc.","Hanscom, Thomas, M.D.","Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01471691
4852,Meclizine as a Potential Smoking Cessation Treatment,Completed,Has Results,Smoking Cessation,Drug: Meclizine|Drug: Nicotine Patch|Drug: Placebo,"Duke University|Philip Morris USA, Inc.",Duke University,"Philip Morris USA, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01443858
4853,Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Imatinib mesylate|Drug: Paclitaxel,New Mexico Cancer Care Alliance|Fred Hutchinson Cancer Research Center|Novartis,New Mexico Cancer Care Alliance,Fred Hutchinson Cancer Research Center,Novartis,,,,,Phase 2,Other|Industry,Interventional,8/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01011075
4854,Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients,Completed,Has Results,Oculopharyngeal Muscular Dystrophy,Drug: Cabaletta,Bioblast Pharma Ltd.,Bioblast Pharma Ltd.,,,,,,,Phase 2,Industry,Interventional,2/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02015481
4855,"A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",Completed,Has Results,HER-2 Positive Breast Cancer,Drug: Everolimus|Drug: Vinorelbine|Drug: Trastuzumab,UNC Lineberger Comprehensive Cancer Center|Novartis Pharmaceuticals,UNC Lineberger Comprehensive Cancer Center,Novartis Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,9/11/2019,10/16/2017,https://ClinicalTrials.gov/show/NCT01305941
4856,In Vivo Determination of 3D Patellofemoral Mechanics,Completed,Has Results,Arthroplasty Replacement Knee|Knee Prosthesis,Device: Subjects implanted with DePuy LCS PS RP TKA|Device: Subjects implanted with DePuy Sigma PS RP TKA,"The University of Tennessee, Knoxville|DePuy Orthopaedics","The University of Tennessee, Knoxville",DePuy Orthopaedics,,,,,,,Other|Industry,Observational,2/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01290627
4857,Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis,Completed,Has Results,Chronic Kidney Disease|Anemia,Drug: Epoetin|Drug: Peginesatide,Takeda|Affymax,Takeda,Affymax,,,,,,Phase 3,Industry,Interventional,10/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01478971
4858,Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis,Completed,Has Results,Tinea Pedis|Tinea Cruris,Drug: NAFT500 (pediatric)|Drug: NAFT600 (pediatric)|Drug: NAFT500 (adult)|Drug: NAFT600 (adult),"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 4,Industry,Interventional,10/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01712360
4859,Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma,Completed,Has Results,Lymphoma,Biological: rituximab|Drug: vorinostat,City of Hope Medical Center|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.,City of Hope Medical Center,National Cancer Institute (NCI),Merck Sharp & Dohme Corp.,,,,,Phase 2,Other|NIH|Industry,Interventional,7/23/2008,6/8/2017,https://ClinicalTrials.gov/show/NCT00720876
4860,Feasibility Study of the Magnetic Anal Sphincter (FENIX System),Completed,Has Results,Fecal Incontinence,Device: Magnetic Anal Sphincter,Torax Medical Incorporated,Torax Medical Incorporated,,,,,,,Not Applicable,Industry,Interventional,12/8/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01625221
4861,Treximet Early Intervention Adolescent Migraine,Completed,Has Results,Migraine,Drug: Treximet|Drug: Placebo,Premiere Research Institute|GlaxoSmithKline,Premiere Research Institute,GlaxoSmithKline,,,,,,Phase 2|Phase 3,Other|Industry,Interventional,3/10/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01016678
4862,Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Cabazitaxel XRP6258|Drug: Abiraterone acetate|Drug: Prednisone 5 mg,Sanofi,Sanofi,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01511536
4863,A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers,Completed,Has Results,"Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,|Primary Peritoneal Cancer or Endometrial Cancer|Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer",Drug: MM-121|Drug: Paclitaxel,Merrimack Pharmaceuticals|Sanofi,Merrimack Pharmaceuticals,Sanofi,,,,,,Phase 1,Industry,Interventional,10/10/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01209195
4864,An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms,Completed,Has Results,Erectile Dysfunction|Lower Urinary Tract Symptoms,Drug: Placebo|Drug: Alfuzosin,Chesapeake Urology Research Associates|Sanofi,Chesapeake Urology Research Associates,Sanofi,,,,,,Phase 3,Other|Industry,Interventional,6/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00893113
4865,Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration,Completed,Has Results,Prostate Cancer|Prostatic Neoplasms,Drug: Panobinostat|Drug: Bicalutamide,NYU Langone Health|Novartis,NYU Langone Health,Novartis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00878436
4866,Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement,Completed,Has Results,"Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip|Thromboembolism",Drug: Rivaroxaban,"Ortho-McNeil Janssen Scientific Affairs, LLC|Bayer","Ortho-McNeil Janssen Scientific Affairs, LLC",Bayer,,,,,,Phase 3,Industry,Interventional,3/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01094886
4867,Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: BT062,Biotest Pharmaceuticals Corporation|Biotest,Biotest Pharmaceuticals Corporation,Biotest,,,,,,Phase 1|Phase 2,Industry,Interventional,8/10/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01001442
4868,Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency,Completed,Has Results,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Drug: catridecacog,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01253811
4869,Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients,Completed,Has Results,HIV Infections|AIDS|Dyslipidemia|Hypertriglyceridemia,Drug: Omega-3 fatty acid administration|Drug: Placebo,"Brown, Todd, M.D., Ph.D.|National Center for Complementary and Integrative Health (NCCIH)|GlaxoSmithKline","Brown, Todd, M.D., Ph.D.",National Center for Complementary and Integrative Health (NCCIH),GlaxoSmithKline,,,,,Phase 4,Other|NIH|Industry,Interventional,10/6/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00346697
4870,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,Completed,Has Results,Acne Vulgaris,Drug: CTGel/ BPO Wash|Drug: Soap Free Cleanser and CTGel,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,4/1/2009,6/5/2009,https://ClinicalTrials.gov/show/NCT00891982
4871,"Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4",Completed,Has Results,Influenza,Biological: Fluzone|Biological: Flumist|Other: Physiologic saline,"University of Michigan|Sanofi Pasteur, a Sanofi Company",University of Michigan,"Sanofi Pasteur, a Sanofi Company",,,,,,Phase 4,Other|Industry,Interventional,9/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00538512
4872,Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State,Completed,Has Results,Bipolar Disorder|Bipolar Depression|Depression,Drug: ziprasidone (Geodon)|Drug: placebo,Tufts Medical Center|Pfizer,Tufts Medical Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,12/6/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00490542
4873,Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia,Completed,Has Results,Ventricular Tachycardia,Device: Magnetic irrigated ablation catheter,Stereotaxis,Stereotaxis,,,,,,,Phase 4,Industry,Interventional,6/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00851279
4874,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,Completed,Has Results,Obesity,Drug: VI-0521|Drug: Placebo matched phentermine/topiramate,"VIVUS, Inc.|Medpace, Inc.","VIVUS, Inc.","Medpace, Inc.",,,,,,Phase 3,Industry,Interventional,11/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00554216
4875,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Completed,Has Results,Parkinson's Disease|Insomnia,Drug: eszopiclone|Other: placebo,"University of Medicine and Dentistry of New Jersey|Sunovion|Rutgers, The State University of New Jersey",University of Medicine and Dentistry of New Jersey,Sunovion,"Rutgers, The State University of New Jersey",,,,,Phase 3,Other|Industry,Interventional,5/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00324896
4876,Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors,Completed,Has Results,Solid Tumors,Drug: MM-121|Drug: Carboplatin|Drug: Pemetrexed|Drug: Cabazitaxel|Drug: Gemcitabine,Merrimack Pharmaceuticals|Sanofi,Merrimack Pharmaceuticals,Sanofi,,,,,,Phase 1,Industry,Interventional,10/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01447225
4877,Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: mipomersen sodium,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","Kastle Therapeutics, LLC","Ionis Pharmaceuticals, Inc.",,,,,,Phase 2,Industry,Interventional,5/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00477594
4878,"Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms",Completed,Has Results,Head and Neck Neoplasm|Prostatic Neoplasm|Pancreatic Neoplasm,Drug: PF00562271,"Verastem, Inc.","Verastem, Inc.",,,,,,,Phase 1,Industry,Interventional,12/5/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00666926
4879,Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout,Completed,Has Results,"Arthritis, Gouty",Biological: canakinumab|Drug: dexamethasone|Other: placebo matching canakinumab|Other: placebo matching dexamethasone,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,4/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00663169
4880,Risperdal Consta for Bipolar Disorder,Completed,Has Results,Bipolar I Disorder,Drug: Injectable Risperidone (Consta) or oral antipsychotic,University of Pittsburgh|Janssen Pharmaceuticals,University of Pittsburgh,Janssen Pharmaceuticals,,,,,,Phase 3,Other|Industry,Interventional,11/3/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00177164
4881,Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL,Completed,Has Results,Non-Hodgkin's Lymphoma,"Drug: Bortezomib, CHOP, Rituximab","Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.",Weill Medical College of Cornell University,"Millennium Pharmaceuticals, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,1/4/2019,4/24/2013,https://ClinicalTrials.gov/show/NCT00151320
4882,A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI,Completed,Has Results,Mucopolysaccharidosis VI|Maroteaux-Lamy Syndrome,Drug: Naglazyme,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 4,Industry,Interventional,5/6/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00299000
4883,Fat Malabsorption in Chronic Pancreatitis,Completed,Has Results,Chronic Pancreatitis,Drug: Creon36™,Children's Hospital of Philadelphia|AbbVie|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Phoenix Indian Medical Center,Children's Hospital of Philadelphia,AbbVie,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Phoenix Indian Medical Center,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phoenix Indian Medical Center,,,Phase 2,Other|Industry|NIH,Interventional,10/13/2016,11/1/2017,https://ClinicalTrials.gov/show/NCT02849704
4884,Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis,Completed,Has Results,Cirrhosis,Device: BreathID (Methacetin breath test),Virginia Commonwealth University|Exalenz Bioscience LTD.,Virginia Commonwealth University,Exalenz Bioscience LTD.,,,,,,Phase 3,Other|Industry,Interventional,3/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01157845
4885,Promoting Oral Health Among Smokers Randomized Trial,Completed,Has Results,Oral Disease|Smoking,Behavioral: Usual Care Control|Behavioral: Enhanced Intervention,Kaiser Permanente|Alere Wellbeing|University of California|National Institute of Dental and Craniofacial Research (NIDCR),Kaiser Permanente,Alere Wellbeing,University of California|National Institute of Dental and Craniofacial Research (NIDCR),University of California,National Institute of Dental and Craniofacial Research (NIDCR),,,Not Applicable,Other|Industry|NIH,Interventional,2/15/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02347124
4886,Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy,Completed,Has Results,HIV Facial Lipoatrophy,Device: Voluma,"Jared Jagdeo, MD, MS|Allergan|VA Northern California Health Care System|East Bay Institute for Research and Education","Jared Jagdeo, MD, MS",Allergan,VA Northern California Health Care System|East Bay Institute for Research and Education,VA Northern California Health Care System,East Bay Institute for Research and Education,,,Phase 1,U.S. Fed|Industry|Other,Interventional,2/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02342223
4887,Fetal and Neonatal Magnetophysiology,Completed,Has Results,Fetal Arrhythmia|Abnormality in Fetal Heart Rate or Rhythm|Long QT Syndrome,Device: magnetocardiography|Device: postnatal ECG|Device: fetal echocardiography,"University of Wisconsin, Madison|Shared Medical Technology, Inc.|Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)","University of Wisconsin, Madison","Shared Medical Technology, Inc.","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)",Medical College of Wisconsin,"National Heart, Lung, and Blood Institute (NHLBI)",,,,Other|Industry|NIH,Observational,3/14/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT01903564
4888,RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder,Completed,Has Results,Bladder Cancer,Drug: Everolimus and Intravesical Gemcitabine,Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals|New York University|University of Hawaii,Memorial Sloan Kettering Cancer Center,Novartis Pharmaceuticals,New York University|University of Hawaii,New York University,University of Hawaii,,,Phase 1|Phase 2,Other|Industry,Interventional,12/10/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT01259063
4889,Effect of Milnacipran in Chronic Neuropathic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Milnacipran|Drug: Placebo,Northwestern University|Forest Laboratories|Shirley Ryan AbilityLab|Best Practice,Northwestern University,Forest Laboratories,Shirley Ryan AbilityLab|Best Practice,Shirley Ryan AbilityLab,Best Practice,,,Phase 2,Other|Industry,Interventional,10/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01225068
4890,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Completed,Has Results,Endothelial Dysfunction,Drug: darapladib|Drug: placebo,"Mayo Clinic|GlaxoSmithKline|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)",Mayo Clinic,GlaxoSmithKline,"National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)","National Heart, Lung, and Blood Institute (NHLBI)",National Institute on Aging (NIA),,,Phase 3,Other|Industry|NIH,Interventional,2/4/2010,11/15/2019,https://ClinicalTrials.gov/show/NCT01067339
4891,Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia,Completed,Has Results,Schizophrenia|Cognition|Psychosis,Drug: Curcumin|Drug: Placebo,"VA Greater Los Angeles Healthcare System|Stanley Medical Research Institute|Theravalues, Inc.|University of California, Los Angeles",VA Greater Los Angeles Healthcare System,Stanley Medical Research Institute,"Theravalues, Inc.|University of California, Los Angeles","Theravalues, Inc.","University of California, Los Angeles",,,Phase 1|Phase 2,U.S. Fed|Other|Industry,Interventional,7/14/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02104752
4892,The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics,Completed,Has Results,Type 2 Diabetes,Drug: Colesevelam|Other: Placebo|Behavioral: Diet|Drug: Metformin,"Mayo Clinic|Daiichi Sankyo, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)",Mayo Clinic,"Daiichi Sankyo, Inc.",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Center for Research Resources (NCRR),,,Phase 4,Other|Industry|NIH,Interventional,8/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00951899
4893,Antiepileptic Drugs and Osteoporotic Prevention Trial,Completed,Has Results,Epilepsy|Bone Loss|Osteoporosis|Fractures,Drug: Risedronate|Drug: Placebo + Calcium and Vitamin D,"Boston VA Research Institute, Inc.|Procter and Gamble|Alliance for Better Bone Health|VA Boston Healthcare System","Boston VA Research Institute, Inc.",Procter and Gamble,Alliance for Better Bone Health|VA Boston Healthcare System,Alliance for Better Bone Health,VA Boston Healthcare System,,,Phase 4,Other|Industry|U.S. Fed,Interventional,6/6/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00869622
4894,The Effects of Omega-3 Fatty Acids on Aspirin Resistance,Completed,Has Results,Increased Drug Resistance,Drug: Aspirin|Drug: Lovaza|Drug: Both Aspirin and Lovaza|Other: Placebo,University of Rochester|GlaxoSmithKline|American College of Clinical Pharmacy|Cornell University,University of Rochester,GlaxoSmithKline,American College of Clinical Pharmacy|Cornell University,American College of Clinical Pharmacy,Cornell University,,,Phase 1|Phase 2,Other|Industry,Interventional,11/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00771914
4895,"YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering",Completed,Has Results,Obstructive Coronary Artery Disease|Coronary Artery Disease,Drug: rosuvastatin,Icahn School of Medicine at Mount Sinai|Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)|AstraZeneca|InfraReDx (indirect),Icahn School of Medicine at Mount Sinai,Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab),AstraZeneca|InfraReDx (indirect),AstraZeneca,InfraReDx (indirect),,,Phase 2,Other|Industry,Interventional,7/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01837823
4896,Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,Completed,Has Results,Late Effects of Surgery|Staphylococcus Aureus|Surgical Site Infection,Drug: daptomycin,Los Angeles Biomedical Research Institute|Cubist Pharmaceuticals LLC|Hartford Hospital|Western University of Health Sciences,Los Angeles Biomedical Research Institute,Cubist Pharmaceuticals LLC,Hartford Hospital|Western University of Health Sciences,Hartford Hospital,Western University of Health Sciences,,,Phase 3,Other|Industry,Interventional,7/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00701636
4897,Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Quercetin|Other: Placebo - sugar chew,University of Michigan|National Institutes of Health (NIH)|Quercegen Pharmaceuticals|National Center for Complementary and Integrative Health (NCCIH),University of Michigan,National Institutes of Health (NIH),Quercegen Pharmaceuticals|National Center for Complementary and Integrative Health (NCCIH),Quercegen Pharmaceuticals,National Center for Complementary and Integrative Health (NCCIH),,,Phase 1,Other|NIH|Industry,Interventional,2/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01708278
4898,Testing State of the Art Remote Glucose Monitoring at Diabetes Camp,Completed,Has Results,Type 1 Diabetes,Drug: Mini-glucagon|Device: Remote monitoring|Dietary Supplement: Carbohydrates,"Stanford University|University of Virginia|DexCom, Inc.|The Leona M. and Harry B. Helmsley Charitable Trust",Stanford University,University of Virginia,"DexCom, Inc.|The Leona M. and Harry B. Helmsley Charitable Trust","DexCom, Inc.",The Leona M. and Harry B. Helmsley Charitable Trust,,,Not Applicable,Other|Industry,Interventional,5/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01680653
4899,Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis,Completed,Has Results,Gastric Stasis,Device: Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1),"University of Kansas Medical Center|GI Stimulation, Inc.|National Institutes of Health (NIH)|American Diabetes Association",University of Kansas Medical Center,"GI Stimulation, Inc.",National Institutes of Health (NIH)|American Diabetes Association,National Institutes of Health (NIH),American Diabetes Association,,,Not Applicable,Other|Industry|NIH,Interventional,2/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00595621
4900,Effects of Fish Oils on Inflammation and Insulin Resistance,Completed,Has Results,Metabolic Syndrome|Insulin Resistance,Drug: omega-3 fatty acid|Drug: placebo,Philip Kern|GlaxoSmithKline|National Institutes of Health (NIH)|National Center for Research Resources (NCRR)|University of Kentucky,Philip Kern,GlaxoSmithKline,National Institutes of Health (NIH)|National Center for Research Resources (NCRR)|University of Kentucky,National Institutes of Health (NIH),National Center for Research Resources (NCRR)|University of Kentucky,National Center for Research Resources (NCRR),University of Kentucky,Not Applicable,Other|Industry|NIH,Interventional,1/7/2019,1/15/2015,https://ClinicalTrials.gov/show/NCT00579436
4901,Sleep Loss and Mechanisms of Impaired Glucose Metabolism,Completed,Has Results,Primary Insomnia,Drug: eszopiclone|Drug: placebo,Brigham and Women's Hospital|Sunovion|Mclean Hospital|National Center for Research Resources (NCRR),Brigham and Women's Hospital,Sunovion,Mclean Hospital|National Center for Research Resources (NCRR),Mclean Hospital,National Center for Research Resources (NCRR),,,Not Applicable,Other|Industry|NIH,Interventional,3/6/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00555750
4902,Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring,Completed,Has Results,Atrial Fibrillation,Drug: Non-coumadin Oral Anticoagulant,"Northwestern University|National Heart, Lung, and Blood Institute (NHLBI)|Medtronic",Northwestern University,"National Heart, Lung, and Blood Institute (NHLBI)",Medtronic,,,,,Phase 4,Other|NIH|Industry,Interventional,10/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01706146
4903,The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics,Completed,Has Results,Asthma|Obesity|Inflammation,Drug: Montelukast|Drug: Placebo,Northwell Health|Thrasher Research Fund|Merck Sharp & Dohme Corp.|New York State Department of Health,Northwell Health,Thrasher Research Fund,Merck Sharp & Dohme Corp.|New York State Department of Health,Merck Sharp & Dohme Corp.,New York State Department of Health,,,Not Applicable,Other|Industry,Interventional,4/11/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01329939
4904,The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART,Completed,Has Results,HIV-1 Infection,Drug: Vorinostat,"University of North Carolina, Chapel Hill|National Institutes of Health (NIH)|Merck Sharp & Dohme Corp.|National Institute of Allergy and Infectious Diseases (NIAID)","University of North Carolina, Chapel Hill",National Institutes of Health (NIH),Merck Sharp & Dohme Corp.|National Institute of Allergy and Infectious Diseases (NIAID),Merck Sharp & Dohme Corp.,National Institute of Allergy and Infectious Diseases (NIAID),,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,2/11/2019,3/31/2016,https://ClinicalTrials.gov/show/NCT01319383
4905,Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America,Completed,Has Results,Malaria|Plasmodium Falciparum Malaria,Biological: Falciparum Malaria Protein 11 with AS02A adjuvant,U.S. Army Medical Research and Development Command|GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)|Walter Reed Army Institute of Research (WRAIR),U.S. Army Medical Research and Development Command,GlaxoSmithKline,The PATH Malaria Vaccine Initiative (MVI)|Walter Reed Army Institute of Research (WRAIR),The PATH Malaria Vaccine Initiative (MVI),Walter Reed Army Institute of Research (WRAIR),,,Phase 1|Phase 2,U.S. Fed|Industry|Other,Interventional,4/6/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00312702
4906,Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America,Completed,Has Results,Plasmodium Falciparum Malaria,Biological: Falciparum Malaria Protein 11 with AS01B adjuvant.,U.S. Army Medical Research and Development Command|GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)|Walter Reed Army Institute of Research (WRAIR),U.S. Army Medical Research and Development Command,GlaxoSmithKline,The PATH Malaria Vaccine Initiative (MVI)|Walter Reed Army Institute of Research (WRAIR),The PATH Malaria Vaccine Initiative (MVI),Walter Reed Army Institute of Research (WRAIR),,,Phase 1|Phase 2,U.S. Fed|Industry|Other,Interventional,4/6/2019,4/7/2019,https://ClinicalTrials.gov/show/NCT00312663
4907,Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Closed Loop Control (CLC)|Device: Open Loop,"University of Virginia|Abbott Diabetes Care|Insulet Corporation|DexCom, Inc.|University of California, Santa Barbara",University of Virginia,Abbott Diabetes Care,"Insulet Corporation|DexCom, Inc.|University of California, Santa Barbara",Insulet Corporation,"DexCom, Inc.|University of California, Santa Barbara","DexCom, Inc.","University of California, Santa Barbara",Not Applicable,Other|Industry,Interventional,10/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01418703
4908,Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Open-Loop|Device: Closed-Loop,"University of Virginia|Abbott Diabetes Care|DexCom, Inc.|Insulet Corporation|University of California, Santa Barbara",University of Virginia,Abbott Diabetes Care,"DexCom, Inc.|Insulet Corporation|University of California, Santa Barbara","DexCom, Inc.","Insulet Corporation|University of California, Santa Barbara",Insulet Corporation,"University of California, Santa Barbara",Not Applicable,Other|Industry,Interventional,1/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01390259
4909,BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases,Completed,Has Results,Non Small Cell Lung Cancer With Bone Metastatses,Biological: Xofigo,Angela Taber MD|Rhode Island Hospital|The Miriam Hospital|Bayer|Brown University,Angela Taber MD,Rhode Island Hospital,The Miriam Hospital|Bayer|Brown University,The Miriam Hospital,Bayer|Brown University,Bayer,Brown University,Phase 2,Other|Industry,Interventional,9/15/2019,11/13/2018,https://ClinicalTrials.gov/show/NCT02283749
4910,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,Completed,Has Results,Melanoma,Biological: NY-ESO-1 protein; Poly-ICLC; Montanide,"Nina Bhardwaj|Ludwig Institute for Cancer Research|Oncovir, Inc.|Cancer Research Institute, New York City|Icahn School of Medicine at Mount Sinai",Nina Bhardwaj,Ludwig Institute for Cancer Research,"Oncovir, Inc.|Cancer Research Institute, New York City|Icahn School of Medicine at Mount Sinai","Oncovir, Inc.","Cancer Research Institute, New York City|Icahn School of Medicine at Mount Sinai","Cancer Research Institute, New York City",Icahn School of Medicine at Mount Sinai,Phase 1|Phase 2,Other|Industry,Interventional,9/10/2019,3/11/2013,https://ClinicalTrials.gov/show/NCT01079741
4911,Buprenorphine for Late-Life Treatment Resistant Depression,Completed,Has Results,Depression,Drug: Buprenorphine,University of Pittsburgh|National Institutes of Health (NIH)|Reckitt Benckiser LLC|National Center for Research Resources (NCRR),University of Pittsburgh,National Institutes of Health (NIH),Reckitt Benckiser LLC|National Center for Research Resources (NCRR),Reckitt Benckiser LLC,National Center for Research Resources (NCRR),,,Phase 2,Other|NIH|Industry,Interventional,5/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01071538
4912,Trial of Leptin Administration After Roux-en-Y Gastric Bypass,Completed,Has Results,Overweight,Drug: Leptin|Other: Placebo,"Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amylin Pharmaceuticals, LLC.|National Center for Research Resources (NCRR)",Columbia University,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"Amylin Pharmaceuticals, LLC.|National Center for Research Resources (NCRR)","Amylin Pharmaceuticals, LLC.",National Center for Research Resources (NCRR),,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,4/8/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00710814
4913,Ziprasidone in Pediatric Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: Ziprasidone,University of Texas Southwestern Medical Center|Stanley Medical Research Institute|Pfizer|Children's Medical Center Dallas,University of Texas Southwestern Medical Center,Stanley Medical Research Institute,Pfizer|Children's Medical Center Dallas,Pfizer,Children's Medical Center Dallas,,,Phase 4,Other|Industry,Interventional,2/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00622739
4914,Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Heart rate informed SSM+HMM,"University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|DexCom, Inc.|Insulet Corporation|Abbott Diabetes Care",University of Virginia,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"DexCom, Inc.|Insulet Corporation|Abbott Diabetes Care","DexCom, Inc.",Insulet Corporation|Abbott Diabetes Care,Insulet Corporation,Abbott Diabetes Care,Not Applicable,Other|NIH|Industry,Interventional,5/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01582139
4915,Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy,Completed,Has Results,Barrett Syndrome|Barrett's Syndrome|Barrett's Esophagus|Barrett Esophagus|Adenocarcinoma,Device: Imaging procedures (NBI)|Device: HDWLE|Device: pCLE,Mauna Kea Technologies|Cellvizio Inc.|Emissary International LLC,Mauna Kea Technologies,Cellvizio Inc.,Emissary International LLC,,,,,Not Applicable,Industry,Interventional,11/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00795184
4916,Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance,Completed,Has Results,Type 2 Diabetes|Insulin Resistance|Metabolic Syndrome,Drug: metformin|Drug: pioglitazone|Drug: Placebo,"Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America, Inc.|National Center for Research Resources (NCRR)",Mayo Clinic,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"Takeda Pharmaceuticals North America, Inc.|National Center for Research Resources (NCRR)","Takeda Pharmaceuticals North America, Inc.",National Center for Research Resources (NCRR),,,Phase 2,Other|NIH|Industry,Interventional,8/5/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00443755
4917,"Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention",Completed,Has Results,Nicotine Dependence,Drug: GSK598809|Drug: Placebo,Massachusetts General Hospital|National Institute on Drug Abuse (NIDA)|Mclean Hospital|GlaxoSmithKline,Massachusetts General Hospital,National Institute on Drug Abuse (NIDA),Mclean Hospital|GlaxoSmithKline,Mclean Hospital,GlaxoSmithKline,,,Phase 2,Other|NIH|Industry,Interventional,8/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01188967
4918,Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease,Completed,Has Results,HIV Infections|Heart Disease,Drug: Lovaza|Drug: Placebo,University Hospitals Cleveland Medical Center|The Campbell Foundation|Case Western Reserve University|GlaxoSmithKline,University Hospitals Cleveland Medical Center,The Campbell Foundation,Case Western Reserve University|GlaxoSmithKline,Case Western Reserve University,GlaxoSmithKline,,,Phase 2,Other|Industry,Interventional,4/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01001767
4919,"Lubiprostone, Colonic Motility and Sensation",Completed,Has Results,Healthy,Drug: lubiprostone|Drug: Placebo|Other: Bowel preparation,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|Takeda,Mayo Clinic,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Center for Research Resources (NCRR)|Takeda,National Center for Research Resources (NCRR),Takeda,,,Phase 4,Other|NIH|Industry,Interventional,9/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00953043
4920,"A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria",Completed,Has Results,Progeria|Hutchinson-Gilford Syndrome,Drug: Lonafarnib|Drug: Zoledronic Acid|Drug: Pravastatin,Boston Children’s Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Schering-Plough,Boston Children’s Hospital,Dana-Farber Cancer Institute,Brigham and Women's Hospital|Schering-Plough,Brigham and Women's Hospital,Schering-Plough,,,Phase 2,Other|Industry,Interventional,3/9/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00879034
4921,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer Metastatic,Drug: Carboplatin|Drug: Paclitaxel|Drug: ABP 215|Drug: Bevacizumab,Amgen|Actavis Inc.,Amgen,Actavis Inc.,,,,,,Phase 3,Industry,Interventional,11/11/2013,7/23/2015,https://ClinicalTrials.gov/show/NCT01966003
4922,Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Drug: Fish oil|Drug: Placebo,"Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)|eCardio Diagnostics|GlaxoSmithKline",Vanderbilt University,"National Heart, Lung, and Blood Institute (NHLBI)",eCardio Diagnostics|GlaxoSmithKline,eCardio Diagnostics,GlaxoSmithKline,,,Phase 4,Other|NIH|Industry,Interventional,11/7/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00552084
4923,Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma,Completed,Has Results,Brain and Central Nervous System Tumors,Drug: temozolomide|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: immunoenzyme technique,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Weill Medical College of Cornell University|Schering-Plough,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),Weill Medical College of Cornell University|Schering-Plough,Weill Medical College of Cornell University,Schering-Plough,,,Phase 2,Other|NIH|Industry,Interventional,6/7/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00498927
4924,BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM),Completed,Has Results,GBM|Glioblastoma Multiforme|Gliosarcoma,Drug: PSMA ADC,"Heinrich Elinzano, MD|Progenics Pharmaceuticals, Inc.|Rhode Island Hospital|University of Texas|Brown University","Heinrich Elinzano, MD","Progenics Pharmaceuticals, Inc.",Rhode Island Hospital|University of Texas|Brown University,Rhode Island Hospital,University of Texas|Brown University,University of Texas,Brown University,Phase 2,Other|Industry,Interventional,5/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01856933
4925,Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma,Completed,Has Results,"Leukemia|Lymphoma, Non-Hodgkin",Drug: Atorvastatin,Dean Felsher|The Leukemia and Lymphoma Society|Damon Runyon Cancer Research Foundation|Burroughs Wellcome|Stanford University,Dean Felsher,The Leukemia and Lymphoma Society,Damon Runyon Cancer Research Foundation|Burroughs Wellcome|Stanford University,Damon Runyon Cancer Research Foundation,Burroughs Wellcome|Stanford University,Burroughs Wellcome,Stanford University,Phase 2,Other|Industry,Interventional,4/5/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00185731
4926,Role of Leptin in the Neuroendocrine and Immune Response to Fasting,Completed,Has Results,Fasting,Drug: r-metHuLeptin|Other: placebo,Beth Israel Deaconess Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|Amgen,Beth Israel Deaconess Medical Center,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Center for Research Resources (NCRR)|Amgen,National Center for Research Resources (NCRR),Amgen,,,Phase 1|Phase 2,Other|NIH|Industry,Interventional,10/2/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00140231
4927,Study of Leptin for the Treatment of Hypothalamic Amenorrhea,Completed,Has Results,Amenorrhea,Drug: r-metHuLeptin|Drug: Oral Contraceptive Pills (OCPs)|Other: Placebo,Beth Israel Deaconess Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Amgen,Beth Israel Deaconess Medical Center,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),National Center for Research Resources (NCRR)|Amgen,National Center for Research Resources (NCRR),Amgen,,,Phase 2,Other|NIH|Industry,Interventional,4/10/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00130117
4928,Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma,Completed,Has Results,"Central Nervous System Tumor, Pediatric|Neuroblastoma",Drug: temozolomide|Drug: thalidomide,Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Boston Children’s Hospital|Celgene Corporation,Dana-Farber Cancer Institute,National Cancer Institute (NCI),Boston Children’s Hospital|Celgene Corporation,Boston Children’s Hospital,Celgene Corporation,,,Phase 2,Other|NIH|Industry,Interventional,9/2/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00098865
4929,Lucentis in Advanced Macular Degeneration,Completed,Has Results,Macular Degeneration,Drug: ranibizumab,"Steven R. Sanislo|Genentech, Inc.|California Pacific Medical Center|Pacific Eye Associates|Stanford University",Steven R. Sanislo,"Genentech, Inc.",California Pacific Medical Center|Pacific Eye Associates|Stanford University,California Pacific Medical Center,Pacific Eye Associates|Stanford University,Pacific Eye Associates,Stanford University,Phase 2,Other|Industry,Interventional,10/9/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00896779
4930,"Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma",Completed,Has Results,Multiple Myeloma,"Drug: carfilzomib, lenalidomide plus dexamethasone","University of Michigan Rogel Cancer Center|Onyx Therapeutics, Inc.|Celgene",University of Michigan Rogel Cancer Center,"Onyx Therapeutics, Inc.",Celgene,,,,,Phase 1|Phase 2,Other|Industry,Interventional,9/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01029054
4931,Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Everolimus|Biological: Trastuzumab,"Emory University|Genentech, Inc.|Novartis Pharmaceuticals",Emory University,"Genentech, Inc.",Novartis Pharmaceuticals,,,,,Phase 2,Other|Industry,Interventional,5/9/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT00912340
4932,Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,Completed,Has Results,Metastatic Pancreatic Cancer,"Drug: Gemcitabine, nab-Paclitaxel, GDC-0449","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Stand Up To Cancer|Genentech, Inc.|Celgene Corporation",Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Stand Up To Cancer,"Genentech, Inc.|Celgene Corporation","Genentech, Inc.",Celgene Corporation,,,Phase 2,Other|Industry,Interventional,9/17/2010,2/17/2018,https://ClinicalTrials.gov/show/NCT01088815
4933,Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus,Completed,Has Results,Mixed Mullerian Tumors of the Uterus,Drug: Gemcitabine|Drug: Oxaliplatin|Radiation: Radiation,Dana-Farber Cancer Institute|Sanofi|Brigham and Women's Hospital|Massachusetts General Hospital,Dana-Farber Cancer Institute,Sanofi,Brigham and Women's Hospital|Massachusetts General Hospital,Brigham and Women's Hospital,Massachusetts General Hospital,,,Phase 2,Other|Industry,Interventional,8/6/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00476086
4934,Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: ziprasidone,Bronx Psychiatric Center|Pfizer|Buffalo Psychiatric Center|Rochester Psychiatric Center,Bronx Psychiatric Center,Pfizer,Buffalo Psychiatric Center|Rochester Psychiatric Center,Buffalo Psychiatric Center,Rochester Psychiatric Center,,,Phase 4,Other|Industry,Interventional,5/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00458211
4935,"Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer",Completed,Has Results,Breast Cancer,Drug: Abraxane|Drug: Bevacizumab|Drug: Carboplatin,"Duke University|Genentech, Inc.|Celgene Corporation",Duke University,"Genentech, Inc.",Celgene Corporation,,,,,Phase 2,Other|Industry,Interventional,5/7/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00479674
4936,Phase 2 Trial of Bevacizumab in Combination With Pemetrexed,Completed,Has Results,Non-small Cell Lung Cancer (NSCLC)|Lung Cancer|Neoplasm Metastasis,Drug: Bevacizumab|Drug: Pemetrexed|Drug: Vitamin B12|Drug: Folate|Drug: Dexamethasone,"Heather Wakelee|Eli Lilly and Company|Genentech, Inc.|Stanford University",Heather Wakelee,Eli Lilly and Company,"Genentech, Inc.|Stanford University","Genentech, Inc.",Stanford University,,,Phase 2,Other|Industry,Interventional,3/6/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00227019
4937,The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock,Completed,Has Results,Ventricular Tachycardia|Ventricular Fibrillation|Atrial Fibrillation|Supraventricular Tachycardia,Device: Dual Chamber ICD|Device: Single Chamber ICD,Mayo Clinic|Medtronic,Mayo Clinic,Medtronic,,,,,,Phase 4,Other|Industry,Interventional,11/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00787800
4938,Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities,Completed,Has Results,Breast Cancer,Device: Stereo Navigator Accessory to PEM Flex PET Scanner,"Naviscan PET Systems|American Radiology Services, Inc|Boca Raton community Hospital, FL|Diversified Specialty Institutes, Bensalem, PA|Advanced Breast Care Imaging|Epic Imaging",Naviscan PET Systems,"American Radiology Services, Inc","Boca Raton community Hospital, FL|Diversified Specialty Institutes, Bensalem, PA|Advanced Breast Care Imaging|Epic Imaging","Boca Raton community Hospital, FL","Diversified Specialty Institutes, Bensalem, PA|Advanced Breast Care Imaging|Epic Imaging","Diversified Specialty Institutes, Bensalem, PA",Advanced Breast Care Imaging|Epic Imaging,Not Applicable,Industry|Other,Interventional,1/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00606931
4939,Bosutinib in Adult Patients With Recurrent Glioblastoma,Completed,Has Results,Glioblastoma,Drug: bosutinib,Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Pfizer,Massachusetts General Hospital,Dana-Farber Cancer Institute,Brigham and Women's Hospital|Pfizer,Brigham and Women's Hospital,Pfizer,,,Phase 2,Other|Industry,Interventional,4/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01331291
4940,Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance,Completed,Has Results,Impaired Glucose Tolerance|Prediabetic State,Drug: Aspirin|Drug: Alpha lipoic acid|Drug: Olmesartan|Drug: Placebo,"Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Daiichi Sankyo, Inc.|National Center for Research Resources (NCRR)",Emory University,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"Daiichi Sankyo, Inc.|National Center for Research Resources (NCRR)","Daiichi Sankyo, Inc.",National Center for Research Resources (NCRR),,,Not Applicable,Other|NIH|Industry,Interventional,5/5/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00122447
4941,PCI-24781 in Combination With Doxorubicin to Treat Sarcoma,Completed,Has Results,Sarcoma,Drug: PCI-24781|Drug: Doxorubicin|Drug: GCSF,Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Pharmacyclics LLC.,Massachusetts General Hospital,Dana-Farber Cancer Institute,Brigham and Women's Hospital|Pharmacyclics LLC.,Brigham and Women's Hospital,Pharmacyclics LLC.,,,Phase 1|Phase 2,Other|Industry,Interventional,2/9/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01027910
4942,Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Erlotinib,"David M. Jackman, MD|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Genentech, Inc.|Dana-Farber Cancer Institute","David M. Jackman, MD",Beth Israel Deaconess Medical Center,"Brigham and Women's Hospital|Genentech, Inc.|Dana-Farber Cancer Institute",Brigham and Women's Hospital,"Genentech, Inc.|Dana-Farber Cancer Institute","Genentech, Inc.",Dana-Farber Cancer Institute,Phase 2,Other|Industry,Interventional,2/10/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT00997334
4943,A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis|Eczema,Drug: SAN007 5% cream|Drug: Placebo|Drug: SAN007 10% cream,"Santalis Pharmaceuticals, Inc.|ClinDatrix, Inc.|Texas Dermatology and Laser Specialists|Clinical Trials of Texas, Inc.|Derm Research, PLLC|Progressive Clinical Research|U.S. Dermatology Partners Bryan","Santalis Pharmaceuticals, Inc.","ClinDatrix, Inc.","Texas Dermatology and Laser Specialists|Clinical Trials of Texas, Inc.|Derm Research, PLLC|Progressive Clinical Research|U.S. Dermatology Partners Bryan",Texas Dermatology and Laser Specialists,"Clinical Trials of Texas, Inc.|Derm Research, PLLC|Progressive Clinical Research|U.S. Dermatology Partners Bryan","Clinical Trials of Texas, Inc.","Derm Research, PLLC|Progressive Clinical Research|U.S. Dermatology Partners Bryan",Phase 2,Industry|Other,Interventional,4/21/2017,8/31/2018,https://ClinicalTrials.gov/show/NCT02871479
4944,High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas,Completed,Has Results,B-cell Lymphoma|Indolent B-cell Lymphoma,Drug: rituximab,"Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genentech, Inc.",Massachusetts General Hospital,Dana-Farber Cancer Institute,"Brigham and Women's Hospital|Genentech, Inc.",Brigham and Women's Hospital,"Genentech, Inc.",,,Phase 2,Other|Industry,Interventional,7/9/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00895661
4945,Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma,Completed,Has Results,Diffuse Large B-cell Lymphoma,Drug: Everolimus|Drug: rituximab,Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Novartis,Massachusetts General Hospital,Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute|Novartis,Dana-Farber Cancer Institute,Novartis,,,Phase 2,Other|Industry,Interventional,5/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00869999
4946,Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies,Completed,Has Results,Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer,Drug: Bevacizumab|Drug: Cyclophosphamide,"Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women's Hospital|Genentech, Inc.",Dana-Farber Cancer Institute,Massachusetts General Hospital,"Brigham and Women's Hospital|Genentech, Inc.",Brigham and Women's Hospital,"Genentech, Inc.",,,Phase 2,Other|Industry,Interventional,2/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00856180
4947,Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS),Completed,Has Results,"Stem Cell Transplantation|Ventricular Dysfunction, Left",Biological: Lower dose mesenchymal stem cell (MSC) injection|Genetic: Placebo|Biological: Higher dose MSC injection,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|Johns Hopkins University Specialized Center for Cell Based Therapy|The Emmes Company, LLC|University of Miami",Joshua M Hare,"National Heart, Lung, and Blood Institute (NHLBI)","Johns Hopkins University Specialized Center for Cell Based Therapy|The Emmes Company, LLC|University of Miami",Johns Hopkins University Specialized Center for Cell Based Therapy,"The Emmes Company, LLC|University of Miami","The Emmes Company, LLC",University of Miami,Phase 1|Phase 2,Other|NIH|Industry,Interventional,11/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00587990
4948,"Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer",Completed,Has Results,Breast Cancer,Biological: trastuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: lapatinib ditosylate|Drug: paclitaxel|Other: laboratory biomarker analysis,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Dana-Farber Cancer Institute|GlaxoSmithKline,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),Dana-Farber Cancer Institute|GlaxoSmithKline,Dana-Farber Cancer Institute,GlaxoSmithKline,,,Phase 2,Other|NIH|Industry,Interventional,3/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00482391
4949,Dasatinib in Relapsed Chronic Lymphocytic Leukemia,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Dasatinib,Massachusetts General Hospital|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Bristol-Myers Squibb,Massachusetts General Hospital,Brigham and Women's Hospital,Dana-Farber Cancer Institute|Bristol-Myers Squibb,Dana-Farber Cancer Institute,Bristol-Myers Squibb,,,Phase 2,Other|Industry,Interventional,12/6/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00438854
4950,The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2|Medication Adherence|HYPERGLYCEMIA",Other: Diabetes medication management,Medstar Health Research Institute|American Diabetes Association|Sanofi|Bayer|Washington Hospital Center,Medstar Health Research Institute,American Diabetes Association,Sanofi|Bayer|Washington Hospital Center,Sanofi,Bayer|Washington Hospital Center,Bayer,Washington Hospital Center,Not Applicable,Other|Industry,Interventional,2/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT02269098
4951,"Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking",Completed,Has Results,Nicotine Dependence,Drug: GW468816|Drug: Placebo Comparator: Placebo,Massachusetts General Hospital|National Institute on Drug Abuse (NIDA)|Mclean Hospital|GlaxoSmithKline,Massachusetts General Hospital,National Institute on Drug Abuse (NIDA),Mclean Hospital|GlaxoSmithKline,Mclean Hospital,GlaxoSmithKline,,,Phase 2,Other|NIH|Industry,Interventional,8/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00218465
4952,TRADE-Testosterone Replacement and Dutasteride Effectiveness,Completed,Has Results,Hypogonadism|Benign Prostatic Hyperplasia,Drug: Dutasteride|Drug: Testosterone gel|Drug: Placebo dutasteride,University of Washington|GlaxoSmithKline|Seattle Institute for Biomedical and Clinical Research|VA Office of Research and Development|Solvay Pharmaceuticals,University of Washington,GlaxoSmithKline,Seattle Institute for Biomedical and Clinical Research|VA Office of Research and Development|Solvay Pharmaceuticals,Seattle Institute for Biomedical and Clinical Research,VA Office of Research and Development|Solvay Pharmaceuticals,VA Office of Research and Development,Solvay Pharmaceuticals,Phase 4,Other|Industry|U.S. Fed,Interventional,3/5/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00194675
4953,Cognitive Effects of Treatment of Interictal Discharges,Completed,Has Results,Epilepsy,Drug: levetiracetam|Drug: Lamotrigine,Massachusetts General Hospital|UCB Young Investigator Research Program|National EpiFellows Foundation|UCB Pharma|GlaxoSmithKline,Massachusetts General Hospital,UCB Young Investigator Research Program,National EpiFellows Foundation|UCB Pharma|GlaxoSmithKline,National EpiFellows Foundation,UCB Pharma|GlaxoSmithKline,UCB Pharma,GlaxoSmithKline,Not Applicable,Other|Industry,Interventional,1/7/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00916149
4954,Clinical Validation of DACP Digital Design,Completed,Has Results,Refractive Errors,Device: Nelfilcon A digital contact lenses|Device: Nelfilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,6/25/2018,8/26/2018,https://ClinicalTrials.gov/show/NCT03567005
4955,Contact Lenses With New UV-blocker Manufactured With Different Techniques,Completed,Has Results,Correction of Refraction Error|Attenuation of Bright Light,Device: senofilcon A TEST Lens|Device: senofilcon A CONTROL Lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,2/19/2018,4/18/2018,https://ClinicalTrials.gov/show/NCT03475875
4956,"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma",Completed,Has Results,Asthma,Drug: AS MDI|Drug: Proventil,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/29/2017,3/26/2018,https://ClinicalTrials.gov/show/NCT03371459
4957,Evaluation of Two Marketed Multifocal Contact Lenses,Completed,Has Results,Visual Performance,Device: Multifocal Contact Lens 1|Device: Multifocal Contact Lens 2|Device: Spherical Contact Lens 2,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/11/2017,11/4/2017,https://ClinicalTrials.gov/show/NCT03322423
4958,Evaluation of Approved and Investigational Contact Lenses,Completed,Has Results,Visual Acuity,Device: CONTROL|Device: TEST,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/14/2017,9/18/2017,https://ClinicalTrials.gov/show/NCT03228212
4959,"Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women",Completed,Has Results,Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women,"Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)","AMAG Pharmaceuticals, Inc.","AMAG Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,9/16/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02940522
4960,Performance Comparison Between Comfilcon A and Senofilcon C Lenses,Completed,Has Results,Myopia,Device: comfilcon A|Device: senofilcon C,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/16/2019,11/23/2016,https://ClinicalTrials.gov/show/NCT02920957
4961,Astral VAPS AutoEPAP Clinical Trial,Completed,Has Results,Upper Airway Obstruction|Respiratory Insufficiency|Respiratory Failure,Device: Astral,ResMed,ResMed,,,,,,,Phase 3,Industry,Interventional,4/15/2016,7/6/2017,https://ClinicalTrials.gov/show/NCT02683772
4962,The Esteem® Hearing Implant Post Approval Study,Completed,Has Results,Hearing Loss,Device: The Esteem Hearing Implant,Envoy Medical Corporation,Envoy Medical Corporation,,,,,,,,Industry,Observational,8/10/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02666222
4963,A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene,Completed,Has Results,Acquired Hypogonadotropic Hypogonadism|Obesity,Drug: Placebo|Drug: Enclomiphene,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,1/11/2016,5/2/2017,https://ClinicalTrials.gov/show/NCT02651688
4964,A Study of LY3113593 in Participants With Chronic Kidney Disease,Completed,Has Results,Chronic Kidney Disease,Drug: LY3113593|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/17/2015,6/22/2016,https://ClinicalTrials.gov/show/NCT02604160
4965,A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax),Completed,Has Results,Kidney Transplantation,Biological: DT|Drug: Daclizumab|Biological: KLH,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,4/3/2019,1/6/2019,https://ClinicalTrials.gov/show/NCT02576145
4966,Phase IV O2 Consumption Study in COPD Patients.,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Drug: Matching Placebo pMDI 160/4.5 μg,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,8/25/2015,8/12/2016,https://ClinicalTrials.gov/show/NCT02533505
4967,"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",Completed,Has Results,"Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma",Drug: Cobimetinib|Drug: GDC-0994,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,6/16/2015,12/5/2016,https://ClinicalTrials.gov/show/NCT02457793
4968,Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age,Completed,Has Results,"Pain, Postoperative",Drug: Diclofenac Capsules low dose|Drug: Diclofenac Capsules high dose,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 2,Industry,Interventional,5/15/2019,4/19/2016,https://ClinicalTrials.gov/show/NCT02424578
4969,Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay,Completed,Has Results,HIV,Device: Geenius HIV1/2 Supplemental Assay,Bio-Rad Laboratories,Bio-Rad Laboratories,,,,,,,,Industry,Observational,4/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT02401555
4970,XprESS Eustachian Tube Dilation Study,Completed,Has Results,Eustachian Tube Dysfunction,Device: XprESS|Other: Control,"Entellus Medical, Inc.","Entellus Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/15/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02391584
4971,A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment,Completed,Has Results,Hepatic Insufficiency,Drug: Abemaciclib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,3/15/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02387814
4972,Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea,Completed,Has Results,Obstructive Sleep Apnea|Sleep Apnea|OSA,Device: FRESCA mask first night|Device: CPAP Mask first night,FRESCA Medical,FRESCA Medical,,,,,,,Not Applicable,Industry,Interventional,10/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02387476
4973,Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Biological: mogamulizumab|Drug: Docetaxel,"Kyowa Kirin Pharmaceutical Development, Inc.","Kyowa Kirin Pharmaceutical Development, Inc.",,,,,,,Phase 1,Industry,Interventional,1/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02358473
4974,Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes,Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: BVD-523,"BioMed Valley Discoveries, Inc","BioMed Valley Discoveries, Inc",,,,,,,Phase 1|Phase 2,Industry,Interventional,11/14/2019,6/15/2017,https://ClinicalTrials.gov/show/NCT02296242
4975,A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults,Completed,Has Results,Respiratory Syncytial Virus (RSV),Biological: MEDI7510|Biological: IIV,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,1/5/2015,2/24/2016,https://ClinicalTrials.gov/show/NCT02289820
4976,Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain,Completed,Has Results,Pain,Drug: diclofenac potassium oral solution,Depomed,Depomed,,,,,,,Phase 4,Industry,Interventional,9/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02287350
4977,Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study,Completed,Has Results,Infectious Gastroenteritis,Device: FilmArray™ Gastrointestinal (GI) Panel,"BioFire Diagnostics, LLC|National Institute of Allergy and Infectious Diseases (NIAID)","BioFire Diagnostics, LLC",National Institute of Allergy and Infectious Diseases (NIAID),,,,,,Not Applicable,Industry|NIH,Interventional,4/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02248285
4978,An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients,Completed,Has Results,Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Myelodysplastic Syndrome (MDS),Drug: CPX-351,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02238925
4979,High Flow Therapy for the Treatment of Respiratory Failure in the ED,Completed,Has Results,Acute Respiratory Failure,Device: Noninvasive positive pressure ventilation (NIPPV)|Device: Vapotherm,"Vapotherm, Inc.|University of Texas|Memorial Hermann Texas Medical Center|Piedmont Athens Regional Medical Center|University of Tennessee|Erlanger Medical Center|Memorial Hermann The Woodlands|McLeod Regional Medical Center","Vapotherm, Inc.",University of Texas,Memorial Hermann Texas Medical Center|Piedmont Athens Regional Medical Center|University of Tennessee|Erlanger Medical Center|Memorial Hermann The Woodlands|McLeod Regional Medical Center,Memorial Hermann Texas Medical Center,Piedmont Athens Regional Medical Center|University of Tennessee|Erlanger Medical Center|Memorial Hermann The Woodlands|McLeod Regional Medical Center,Piedmont Athens Regional Medical Center,University of Tennessee|Erlanger Medical Center|Memorial Hermann The Woodlands|McLeod Regional Medical Center,Not Applicable,Industry|Other,Interventional,9/14/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02236559
4980,Indego® Exoskeleton; Assessing Mobility for Persons With Spinal Cord Injury (SCI).,Completed,Has Results,Spinal Cord Injury,Device: Indego,Parker Hannifin Corporation,Parker Hannifin Corporation,,,,,,,Not Applicable,Industry,Interventional,8/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02202538
4981,Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis,Completed,Has Results,Seborrheic Keratosis,Drug: A-101 Vehicle|Drug: A-101 (40) Topical Solution|Drug: A-101 (32.5) Topical Solution,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,6/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02160626
4982,A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion,Completed,Has Results,Symptomatic Focal Vitreomacular Adhesion,Drug: 2.0mg of ALG-1001|Drug: Balanced Salt Solution,"Allegro Ophthalmics, LLC","Allegro Ophthalmics, LLC",,,,,,,Phase 2,Industry,Interventional,2/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02153476
4983,Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa,Completed,Has Results,Atrial Fibrillation|Hemorrhage,Drug: Dabigatran 75 mg|Drug: Dabigatran 150 mg,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,,Industry,Observational,6/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02149303
4984,A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers,Completed,Has Results,Neuroendocrine Tumors,Drug: fosbretabulin tromethamine,Mateon Therapeutics,Mateon Therapeutics,,,,,,,Phase 2,Industry,Interventional,9/14/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02132468
4985,Zenith® Dissection Endovascular System,Completed,Has Results,Aortic Dissection,Device: Zenith® Dissection Endovascular Graft,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,12/7/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02094300
4986,"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant",Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Sofosbuvir|Drug: Ribavirin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,3/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02032875
4987,"An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting",Completed,Has Results,Mental Health,,Pearson/Clinical Assessment,Pearson/Clinical Assessment,,,,,,,,Industry,Observational,1/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02025647
4988,"Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease",Completed,Has Results,"Inherited Mitochondrial Disease, Including Leigh Syndrome",Drug: Cysteamine Bitartrate,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 2,Industry,Interventional,5/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02023866
4989,"Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris",Completed,Has Results,Acne,Drug: Adapalene/BPO Gel|Other: Moisturizer SPF 30|Other: Foam Wash,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,10/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01951417
4990,Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia,Completed,Has Results,Friedreich's Ataxia,Drug: VP 20629|Drug: Placebo,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,8/13/2013,6/18/2015,https://ClinicalTrials.gov/show/NCT01898884
4991,Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device,Completed,Has Results,Laryngopharyngeal Reflux,Device: Reza Band UES Assist Device,"Somna Therapeutics, L.L.C.","Somna Therapeutics, L.L.C.",,,,,,,Not Applicable,Industry,Interventional,4/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01857713
4992,Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System,Completed,Has Results,Post-stroke Shoulder Pain|Hemiplegic Shoulder Pain,Device: Smartpatch Peripheral Nerve Stimulation (PNS) System,"SPR Therapeutics, Inc.","SPR Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/13/2019,11/14/2016,https://ClinicalTrials.gov/show/NCT01847885
4993,Straumann Roxolid Multi-Center Study,Completed,Has Results,"Jaw, Edentulous, Partially","Device: Straumann Bone Level Implants, 4.1 mm implant diameter|Device: Straumann Bone Level Implants, 3.3 mm implant diameter",Institut Straumann AG,Institut Straumann AG,,,,,,,Not Applicable,Industry,Interventional,3/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01842958
4994,Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis,Completed,Has Results,Osteoporosis,Drug: Romosozumab,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,4/22/2013,2/19/2014,https://ClinicalTrials.gov/show/NCT01833754
4995,A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women,Completed,Has Results,Healthy,Drug: LY2541546 - SC|Drug: LY2541546 - IV|Drug: Placebo - SC|Drug: Placebo - IV,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,9/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01742091
4996,Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients,Completed,Has Results,Sickle Cell Disease,Device: Red blood cell exchange in sickle cell,Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,11/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01736657
4997,Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET),Completed,Has Results,Recurrent Acute Rhinosinusitis,Device: balloon sinus dilation|Other: medical therapy,Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,10/1/2012,4/1/2016,https://ClinicalTrials.gov/show/NCT01714687
4998,Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: Cloderm Cream,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 4,Industry,Interventional,10/12/2019,,https://ClinicalTrials.gov/show/NCT01714544
4999,"Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis",Completed,Has Results,Plaque Psoriasis,"Drug: (CP-6890,550) Tofacitinib|Drug: Placebo|Drug: (CP-690,550) Tofacitinib",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01710046
5000,Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP),Completed,Has Results,Allergic Skin Reaction,Drug: Hyaluronidase|Drug: Histamine|Drug: Saline,"Amphastar Pharmaceuticals, Inc.","Amphastar Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,9/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01689363
5001,Pilot Study of X-82 in Patients With Wet AMD,Completed,Has Results,Exudative Macular Degeneration,Drug: X-82 oral|Drug: ranibizumab (Lucentis),Tyrogenex,Tyrogenex,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01674569
5002,Assessment of an Endotracheal Tube Securement Device,Completed,Has Results,Respiratory Insufficiency,Other: Experimental ET Tube Securement Device,Hollister Incorporated,Hollister Incorporated,,,,,,,Not Applicable,Industry,Interventional,7/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01651260
5003,Use of the VisuMax™ Femtosecond Laser,Completed,Has Results,Myopia,Device: Treatment with the VisuMax™ Femtosecond Laser,"Carl Zeiss Meditec, Inc.","Carl Zeiss Meditec, Inc.",,,,,,,Phase 1,Industry,Interventional,7/12/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01638390
5004,A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI,Completed,Has Results,Solid Tumors,Biological: Ramucirumab (IMC-1121B)|Drug: Irinotecan|Drug: Folinic acid|Drug: 5-Fluorouracil,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,10/12/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT01634555
5005,Evaluation of a HiRes™ Optima Sound Processing Strategy for the HiResolution™ Bionic Ear,Completed,Has Results,"Severe-to-profound Hearing Loss,|in Adult Users of Advanced Bionics HiResolution™ Bionic Ear System","Device: Control first, then Experimental|Device: Experimental first, then Control",Advanced Bionics,Advanced Bionics,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01616576
5006,Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults,Completed,Has Results,Influenza,Biological: PanBlok|Biological: rHA adjuvant,Protein Sciences Corporation,Protein Sciences Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,5/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01612000
5007,Norovirus Bivalent-Vaccine Efficacy Study,Completed,Has Results,Prevention From Norovirus Infection,Biological: Norovirus Bivalent Vaccine|Biological: Saline Comparator,Takeda,Takeda,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/16/2012,3/18/2014,https://ClinicalTrials.gov/show/NCT01609257
5008,CT Antigen TCR-redirected T Cells for Ovarian Cancer.,Completed,Has Results,Ovarian Cancer,Biological: NYESO-1c259 T cells,Adaptimmune,Adaptimmune,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/9/2013,6/6/2017,https://ClinicalTrials.gov/show/NCT01567891
5009,Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis,Completed,Has Results,Juvenile Idiopathic Arthritis,Drug: 800 mg ibuprofen/26.6 mg famotidine,"Horizon Pharma Ireland, Ltd., Dublin Ireland|Pediatric Rheumatology Collaborative Study Group","Horizon Pharma Ireland, Ltd., Dublin Ireland",Pediatric Rheumatology Collaborative Study Group,,,,,,Phase 4,Industry|Other,Interventional,4/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01563185
5010,Exploratory Efficacy Study of Guaifenesin in Upper Back Pain,Completed,Has Results,Upper Back Pain,Drug: Guaifenesin|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,2/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01562548
5011,"A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021",Completed,Has Results,Short Bowel Syndrome,Drug: Teduglutide,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,5/21/2012,7/23/2013,https://ClinicalTrials.gov/show/NCT01560403
5012,A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function,Completed,Has Results,Cancer,Drug: Vismodegib,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,3/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01546519
5013,Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,Completed,Has Results,"Infections, Streptococcal",Biological: Pneumococcal vaccine GSK2189242A|Biological: Placebo|Biological: Prevnar 13®|Biological: PedvaxHIB®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/21/2012,7/26/2016,https://ClinicalTrials.gov/show/NCT01545375
5014,A Pharmacodynamic Study With Ticagrelor in Hispanic Patients,Completed,Has Results,Stable Coronary Artery Disease,Drug: Ticagrelor|Drug: Clopidogrel,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,4/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01523366
5015,"Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome",Completed,Has Results,Restless Legs Syndrome,Drug: Rotigotine,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 2,Industry,Interventional,12/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01498120
5016,DFA-02 in Patients Undergoing Colorectal Surgery,Completed,Has Results,Surgical Site Infection,Drug: DFA-02|Drug: Placebo,Dr. Reddy's Laboratories Limited|Duke Clinical Research Institute,Dr. Reddy's Laboratories Limited,Duke Clinical Research Institute,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,2/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01496352
5017,Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension,Completed,Has Results,"Pain, Postoperative|Bunion",Drug: COV795|Drug: Placebo,Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,11/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01484652
5018,Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects,Completed,Has Results,Asthma,Drug: GW642444|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01453296
5019,Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women,Completed,Has Results,Pregnancy,,"Reproductive Research Technologies, LP","Reproductive Research Technologies, LP",,,,,,,,Industry,Observational,1/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01399229
5020,Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-05231023|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01396187
5021,Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome,Completed,Has Results,Cushing's Disease|Cushing's Syndrome,Drug: Mifepristone,Corcept Therapeutics,Corcept Therapeutics,,,,,,,Phase 3,Industry,Interventional,11/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01371565
5022,Safety Study of Replagal® Therapy in Children With Fabry Disease,Completed,Has Results,Fabry Disease,Biological: Replagal (agalsidase alfa),Shire,Shire,,,,,,,Phase 2,Industry,Interventional,5/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01363492
5023,Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients,Completed,Has Results,Asthma,Drug: Fluticasone furoate|Drug: Matching placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01332292
5024,Collection and Testing of Respiratory Samples,Completed,Has Results,QIAGEN ResPlex II Advanced Panel|Influenza A|Respiratory Syncytial Virus Infections|Infection Due to Human Parainfluenza Virus 1|Parainfluenza Type 2|Parainfluenza Type 3|Parainfluenza Type 4|Human Metapneumovirus A/B|Rhinovirus|Coxsackie Virus/Echovirus|Adenovirus Types B/C/E|Coronavirus Subtypes 229E|Coronavirus Subtype NL63|Coronavirus Subtype OC43|Coronavirus Subtype HKU1|Human Bocavirus|Artus Influenza A/B RT-PCR Test|Influenza B,Device: artus Influenza A/B RT-PCR Test,"QIAGEN Gaithersburg, Inc","QIAGEN Gaithersburg, Inc",,,,,,,,Industry,Observational,2/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01302418
5025,Comparison of the Hoya Surgical Optics (HSO) iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.,Completed,Has Results,Aphakia|Cataract,Device: iSert 251 intraocular lens,"Hoya Surgical Optics, Inc.","Hoya Surgical Optics, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01292629
5026,Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PF-05231023|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01285518
5027,The Jetstream G3™ Calcium Study,Completed,Has Results,Peripheral Arterial Disease,Device: Jetstream Atherectomy System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,1/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01273623
5028,A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age,Completed,Has Results,Influenza,Biological: High-Dose Trivalent Inactivated Influenza Vaccine|Biological: Trivalent Inactivated Influenza Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,11/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01258595
5029,"Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma",Completed,Has Results,Smoldering Multiple Myeloma,Drug: IPH2101,Innate Pharma,Innate Pharma,,,,,,,Phase 2,Industry,Interventional,9/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01222286
5030,Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee,Completed,Has Results,"Osteoarthritis, Knee",Biological: TissueGene-C|Drug: Normal Saline,"Kolon TissueGene, Inc.","Kolon TissueGene, Inc.",,,,,,,Phase 2,Industry,Interventional,5/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01221441
5031,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,Completed,Has Results,Solid Tumors,Drug: LY573636-sodium|Drug: Liposomal Doxorubicin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,1/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01214668
5032,Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency,Completed,Has Results,Emphysema|Alpha 1-antitrypsin Deficiency (AATD),"Biological: Prolastin-C, 60 mg/kg|Biological: Prolastin-C, 120 mg/kg",Grifols Therapeutics LLC,Grifols Therapeutics LLC,,,,,,,Phase 2,Industry,Interventional,11/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01213043
5033,A Retrospective Study With Prospective Follow-Up of Complex Ventral Hernia Repair Utilizing the AlloMax Surgical Graft,Completed,Has Results,Hernia,,C. R. Bard,C. R. Bard,,,,,,,,Industry,Observational,9/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01205399
5034,Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV),Completed,Has Results,Bacterial Vaginosis,Drug: 0.5% SPL7013 Gel|Drug: 1.0% SPL7013 Gel|Drug: 3.0% SPL7013 Gel|Other: Placebo Gel,Starpharma Pty Ltd,Starpharma Pty Ltd,,,,,,,Phase 2,Industry,Interventional,8/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01201057
5035,Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Halobetasol Proprionate Lotion 0.05%|Drug: Halobetasol Proprionate Cream 0.05%,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,7/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01166646
5036,Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Biological: 4 mg/kg|Biological: 0.5 mg/kg,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01163851
5037,Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System,Completed,Has Results,Type 1 Diabetes Mellitus,Device: The MiniMed Paradigm® X54 System,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01148862
5038,Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies,Completed,Has Results,Breast Cancer,Drug: Eribulin Mesylate,Eisai Inc.,Eisai Inc.,,,,,,,Not Applicable,Industry,Interventional,8/10/2019,,https://ClinicalTrials.gov/show/NCT01142661
5039,Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies,Completed,Has Results,Neoplasm,"Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Drug: HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Drug: HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Drug: NSCLC expansion cohort: Regorafenib 100 mg",Bayer,Bayer,,,,,,,Phase 1,Industry,Interventional,2/7/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01117623
5040,Esteem Totally Implantable Hearing System,Completed,Has Results,Mild to Severe Sensorineural Hearing Loss,Device: Esteem Totally Implantable Hearing System,Envoy Medical Corporation,Envoy Medical Corporation,,,,,,,Not Applicable,Industry,Interventional,1/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01092910
5041,Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections,Completed,Has Results,Diabetes Mellitus,Device: Finesse|Device: Pen/Syringe (Usual injection device),"Calibra Medical, Inc.|Nancy Bohannon, MD, Med. Corp.|Henry Ford Health System|Northwestern University|University of Texas Southwestern Medical Center|International Diabetes Center at Park Nicollet","Calibra Medical, Inc.","Nancy Bohannon, MD, Med. Corp.",Henry Ford Health System|Northwestern University|University of Texas Southwestern Medical Center|International Diabetes Center at Park Nicollet,Henry Ford Health System,Northwestern University|University of Texas Southwestern Medical Center|International Diabetes Center at Park Nicollet,Northwestern University,University of Texas Southwestern Medical Center|International Diabetes Center at Park Nicollet,Phase 2,Industry|Other,Interventional,1/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01073566
5042,Gender-Stratified Safety and Immunogenicity Study,Completed,Has Results,Diarrhea,Biological: Heat-Labile Enterotoxin of E. coli (LT)|Biological: Placebo,"Intercell USA, Inc.","Intercell USA, Inc.",,,,,,,Phase 2,Industry,Interventional,2/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01067781
5043,Evaluation of the Artus® CMV PCR Test,Completed,Has Results,Cytomegalovirus Infections,,"QIAGEN Gaithersburg, Inc","QIAGEN Gaithersburg, Inc",,,,,,,,Industry,Observational,12/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01034709
5044,Safety and Efficacy of a Drug Delivery System in Glaucoma,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: High Dose Drug Device|Drug: Low Dose Drug Device|Drug: Placebo Device|Drug: bimatoprost 0.03%,Vistakon Pharmaceuticals,Vistakon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/9/2019,,https://ClinicalTrials.gov/show/NCT01016691
5045,Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color,Completed,Has Results,Nasolabial Folds,Device: Radiesse® Injectable Dermal Filler,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 4,Industry,Interventional,3/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT01012388
5046,A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: Drug cocktail|Drug: RO5185426,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,11/30/2009,2/29/2012,https://ClinicalTrials.gov/show/NCT01001299
5047,A Study of LY573636-sodium in Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: LY573636-sodium,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,9/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00992225
5048,Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea,Completed,Has Results,Erythematotelangiectatic Rosacea,Drug: CD07805/47|Drug: CD07805/47 placebo,Galderma,Galderma,,,,,,,Phase 2,Industry,Interventional,9/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00989014
5049,A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age,Completed,Has Results,Head Lice,Drug: 0.5% Ivermectin Cream,Topaz Pharmaceuticals Inc,Topaz Pharmaceuticals Inc,,,,,,,Phase 1,Industry,Interventional,9/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00988533
5050,"Treatment of Androgenetic Alopecia in Females, 9 Beam",Completed,Has Results,Androgenetic Alopecia|Hair Loss|Female Pattern Baldness,Device: HairMax LaserComb|Device: Control Device,"Lexington International, LLC","Lexington International, LLC",,,,,,,Not Applicable,Industry,Interventional,10/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00981461
5051,36 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement,Completed,Has Results,Non-inflammatory Degenerative Joint Disease,Device: 36 mm ceramic head on a ceramic acetabular liner|Device: 28 mm ceramic head on a polyethylene acetabular liner,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,4/1/2003,7/1/2013,https://ClinicalTrials.gov/show/NCT00953719
5052,"A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer",Completed,Has Results,Metastatic Breast Cancer,Drug: paclitaxel|Drug: pertuzumab [Perjeta]|Drug: trastuzumab emtansine [Kadcyla],"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,8/9/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00951665
5053,A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults,Completed,Has Results,Healthy,"Biological: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|Other: Placebo",MedImmune LLC|Department of Health and Human Services,MedImmune LLC,Department of Health and Human Services,,,,,,Phase 4,Industry|U.S. Fed,Interventional,8/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00945893
5054,Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension,Completed,Has Results,Hypertension,Drug: Aliskiren/Amlodipine|Drug: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ),Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,6/9/2019,,https://ClinicalTrials.gov/show/NCT00942994
5055,"A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)",Completed,Has Results,Dry Eye,Drug: Lifitegrast|Drug: Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,6/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00926185
5056,BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Completed,Has Results,Colonoscopy,Drug: BLI800|Drug: Polyethylene glycol 3350 based bowel preparation,Braintree Laboratories,Braintree Laboratories,,,,,,,Phase 3,Industry,Interventional,2/9/2019,,https://ClinicalTrials.gov/show/NCT00856843
5057,Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).,Completed,Has Results,"Leukemia, Myeloid, Acute|Myelodysplastic Syndromes",Drug: CC-486,Celgene,Celgene,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/25/2013,5/26/2017,https://ClinicalTrials.gov/show/NCT01835587
5058,Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression,Completed,Has Results,Depression,Device: Reclaim™ DBS System,MedtronicNeuro,MedtronicNeuro,,,,,,,Phase 2,Industry,Interventional,2/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00837486
5059,Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Device: EpiCeram Skin Barrier Emulsion|Drug: Desonide Cream 0.05%,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 4,Industry,Interventional,3/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00828412
5060,"A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.",Completed,Has Results,Cancer,Drug: MEDI-575,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,3/2/2009,1/19/2012,https://ClinicalTrials.gov/show/NCT00816400
5061,A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients,Completed,Has Results,Scar Prevention|Scar Reduction,Drug: Placebo|Drug: AZX100,Capstone Therapeutics,Capstone Therapeutics,,,,,,,Phase 2,Industry,Interventional,1/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00811577
5062,Littlears Auditory Questionnaire: Validation Study in CI Children,Completed,Has Results,Hearing Loss,,Med-El Corporation,Med-El Corporation,,,,,,,,Industry,Observational,5/8/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00785707
5063,Emergency Contraception Actual Use Study,Completed,Has Results,Emergency Contraception,Drug: DR-104,Duramed Research|Teva Pharmaceutical Industries,Duramed Research,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,10/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00777556
5064,Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis,Completed,Has Results,Chronic Plaque Psoriasis,Biological: AIN457|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,9/10/2008,9/17/2009,https://ClinicalTrials.gov/show/NCT00770965
5065,Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds,Completed,Has Results,Heart Failure|Ventricular Arrythmias,Device: Testing of the autocapture features of the device,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,8/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00746356
5066,Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function,Completed,Has Results,Multiple Myeloma|Renal Insufficiency,Drug: Carfilzomib,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,11/8/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00721734
5067,Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device,Completed,Has Results,"Sleep Disordered Breathing|Sleep Apnea, Central",Device: Respironics BiPAP autoSV2|Device: Respironics BiPAP autoSV3,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,8/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00720213
5068,Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia,Completed,Has Results,Acute Myeloid Leukemia|Essential Thrombocythemia,Drug: LY573636-sodium,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,8/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00718159
5069,Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,ADHD,Drug: LDX|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,7/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00697515
5070,Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Drug: AEGR-733,"Aegerion Pharmaceuticals, Inc.","Aegerion Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,5/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00690443
5071,Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases,Completed,Has Results,Facial Wrinkles and Creases,Biological: Autologous Human Fibroblasts (azficel-T),"Fibrocell Technologies, Inc.","Fibrocell Technologies, Inc.",,,,,,,Phase 2,Industry,Interventional,3/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00654654
5072,An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS),Completed,Has Results,Squamous Cell Carcinoma,Drug: API 31510,"Berg, LLC","Berg, LLC",,,,,,,Phase 1|Phase 2,Industry,Interventional,6/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00652080
5073,Immediate Postmastectomy Breast Reconstruction (Strattice Breast),Completed,Has Results,Breast Cancer,Device: LTM - a porcine-based surgical mesh,LifeCell,LifeCell,,,,,,,,Industry,Observational,10/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00619762
5074,Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US,Completed,Has Results,Dengue Fever|Dengue Hemorrhagic Fever|Dengue Virus,"Biological: Tetravalent CYD Dengue Vaccine , 5555 formulation|Biological: Tetravalent CYD Dengue Vaccine , 5553 formulation|Biological: Tetravalent CYD Dengue Vaccine, 4444 formulation",Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,4/17/2008,2/10/2019,https://ClinicalTrials.gov/show/NCT00617344
5075,Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms,Completed,Has Results,Fecal Incontinence,Device: TOPAS,ASTORA Women's Health,ASTORA Women's Health,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00565136
5076,A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Dex-methylphenidate hydrochloride extended-release (Focalin XR)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,10/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00564954
5077,GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER),Completed,Has Results,Peripheral Vascular Diseases,Device: Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,10/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00541307
5078,"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV",Completed,Has Results,Influenza,Biological: FluBlok Influenza Vaccination|Biological: TIV (Fluzone) Influenza Vaccination,Protein Sciences Corporation,Protein Sciences Corporation,,,,,,,Phase 3,Industry,Interventional,9/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00539864
5079,Long-Term Outcomes for Lumbar Spinal Stenosis Patients Treated With X STOP®,Completed,Has Results,Lumbar Spinal Stenosis,Device: X STOP® Interspinous Process Decompression System,Medtronic Spine LLC|Medtronic Spinal and Biologics,Medtronic Spine LLC,Medtronic Spinal and Biologics,,,,,,,Industry,Observational,12/6/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00534092
5080,LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study,Completed,Has Results,"Arthroplasty, Replacement, Hip",Device: LFIT™ Femoral Heads With X3® Insert,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,4/7/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00510458
5081,Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients,Completed,Has Results,Pain|Fever,Drug: IV Acetaminophen,Mallinckrodt,Mallinckrodt,,,,,,,Phase 1,Industry,Interventional,6/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00493246
5082,Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults,Completed,Has Results,West Nile Fever,Biological: ChimeriVax-WN02 Low Dose|Biological: ChimeriVax-WN02 Medium Dose|Biological: ChimeriVax-WN02 High Dose|Biological: 0.9% Saline solution|Biological: 0.9 % NaCl solution,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,12/5/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00442169
5083,Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults,Completed,Has Results,Hypertension,Drug: HCTZ + Amlodipine|Drug: Valsartan/HCTZ,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,12/6/2019,,https://ClinicalTrials.gov/show/NCT00439738
5084,Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer,Completed,Has Results,Metastatic Prostate Cancer,Drug: Dasatinib|Drug: Docetaxel,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/7/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00439270
5085,Evaluation of the Safety and Efficacy of CosmetaLife™ for the Correction of Nasolabial Folds,Completed,Has Results,Facial Wrinkles,Device: CosmetaLife|Device: Restylane,"Cosmeta|Cosmeta Corp, A Gel-Del Technologies Company",Cosmeta,"Cosmeta Corp, A Gel-Del Technologies Company",,,,,,Phase 2,Industry|Other,Interventional,10/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00414544
5086,Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability,Completed,Has Results,Emphysema|Chronic Obstructive Pulmonary Disease (COPD)|Cystic Fibrosis|Pulmonary Fibrosis|Bronchiectasis|Sarcoidosis|Pulmonary Hypertension|Alpha-1 Antitrypsin Deficiency,Procedure: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|Device: STEEN Solution™,"University of North Carolina, Chapel Hill|Duke University|National Heart, Lung, and Blood Institute (NHLBI)|Vitrolife|XVIVO Perfusion","University of North Carolina, Chapel Hill",Duke University,"National Heart, Lung, and Blood Institute (NHLBI)|Vitrolife|XVIVO Perfusion","National Heart, Lung, and Blood Institute (NHLBI)",Vitrolife|XVIVO Perfusion,Vitrolife,XVIVO Perfusion,Not Applicable,Other|NIH|Industry,Interventional,9/13/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01615484
5087,Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer,Completed,Has Results,Metastatic Pancreatic Cancer,Drug: Gemcitabine|Drug: Albumin-bound paclitaxel,Celgene Corporation,Celgene Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,11/6/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00398086
5088,Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.,Completed,Has Results,Influenza,"Biological: Influenza Virus Vaccine, Fluzone®","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,10/6/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00390884
5089,A Phase 1b Trial in Patients With Renal Cell Cancer,Completed,Has Results,Metastatic Renal Cell Cancer,Drug: Drug: LY573636-sodium|Drug: Sunitinib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,7/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01258348
5090,A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.,Completed,Has Results,Cytomegalovirus Infections,Drug: valganciclovir [Valcyte],Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,12/4/2019,6/6/2019,https://ClinicalTrials.gov/show/NCT00377741
5091,"Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients",Completed,Has Results,"Lymphoma, Non-Hodgkin|Multiple Myeloma",Drug: G-CSF and plerixafor,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,4/4/2019,7/6/2019,https://ClinicalTrials.gov/show/NCT00322387
5092,A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection,Completed,Has Results,Graft Rejection,Biological: Placebo|Biological: C1 Esterase Inhibitor (Human),Shire,Shire,,,,,,,Phase 2,Industry,Interventional,11/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01147302
5093,A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients,Completed,Has Results,Liver Transplantation,Drug: tacrolimus modified release (MR)|Drug: tacrolimus,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 2,Industry,Interventional,1/4/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00282256
5094,Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer,Completed,Has Results,"Kidney Neoplasms|Carcinoma, Renal Cell",Drug: AG-013736 (axitinib),Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00282048
5095,"Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)",Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept or Placebo (both as IV & SC Solution)|Drug: Abatacept or Placebo (both as IV & SC solution)|Drug: Abatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/6/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00254293
5096,Efficacy of the WalkAide and AFOs for CVA,Completed,Has Results,Stroke,Device: WalkAide|Device: AFO,Innovative Neurotronics,Innovative Neurotronics,,,,,,,Not Applicable,Industry,Interventional,9/5/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00216320
5097,A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease,Completed,Has Results,Fabry Disease,Drug: migalastat HCl,Amicus Therapeutics,Amicus Therapeutics,,,,,,,Phase 2,Industry,Interventional,1/2/2006,1/29/2008,https://ClinicalTrials.gov/show/NCT00214500
5098,Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration,Completed,Has Results,Type 1 Diabetes,Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin|Device: Medtronic MiniMed Implantable Pump System|Drug: Aventis HOE21PH U400,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Phase 3,Industry,Interventional,6/2/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00211536
5099,Olmesartan Pediatric Pharmacokinetic (PK) Study,Completed,Has Results,Hypertension,Drug: Olmesartan medoxomil,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 1,Industry,Interventional,9/5/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00151814
5100,Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies,Completed,Has Results,Waldenstrom's Macroglobulinemia|Non-Hodgkin's Lymphoma|Hodgkin's Disease|Multiple Myeloma,Drug: Carfilzomib|Drug: Dexamethasone,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,9/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00150462
5101,Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver,Completed,Has Results,Colorectal Cancer|Liver Neoplasms,Drug: NV1020,MediGene,MediGene,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/4/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00149396
5102,Study Evaluating HKI-272 in Tumors,Completed,Has Results,Breast Neoplasms,Drug: neratinib,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",,,,,,,Phase 1,Industry,Interventional,11/3/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00146172
5103,Safety Study to Evaluate FluMist in Immunocompromised Children,Completed,Has Results,Cancer,Biological: FluMist|Biological: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,8/1/2005,5/1/2008,https://ClinicalTrials.gov/show/NCT00112112
5104,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,Completed,Has Results,HIV Infections,Drug: Emtricitabine (FTC)|Drug: Tenofovir Disoproxil Fumarate (TDF)|Drug: Efavirenz (EFV)|Drug: FTC/TDF|Drug: FTC/TDF/EFV|Drug: Lamivudine/zidovudine,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,7/3/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00112047
5105,Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,Completed,Has Results,Solid Tumor|Kidney Cancer,Drug: pazopanib|Drug: everolimus,Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|GlaxoSmithKline|Novartis,Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Brigham and Women's Hospital|GlaxoSmithKline|Novartis,Brigham and Women's Hospital,GlaxoSmithKline|Novartis,GlaxoSmithKline,Novartis,Phase 1,Other|Industry,Interventional,9/10/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT01184326
5106,Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors,Completed,Has Results,Neoplasms|Malignant Carcinoma,Drug: Neratinib|Drug: Temsirolimus,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",,,,,,,Phase 1,Industry,Interventional,4/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00838539
5107,"CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",Completed,Has Results,Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma,Drug: CAT-8015 (Moxetumomab Pasudotox),MedImmune LLC|National Cancer Institute (NCI),MedImmune LLC,National Cancer Institute (NCI),,,,,,Phase 1,Industry|NIH,Interventional,9/8/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00659425
5108,Control of Epidemic Influenza Through a School-based Influenza Vaccination Program,Completed,Has Results,Influenza,Biological: live attenuated and inactivated influenza vaccines,"Baylor College of Medicine|Scott and White Hospital & Clinic|Novartis|Sanofi Pasteur, a Sanofi Company|National Institute of Allergy and Infectious Diseases (NIAID)",Baylor College of Medicine,Scott and White Hospital & Clinic,"Novartis|Sanofi Pasteur, a Sanofi Company|National Institute of Allergy and Infectious Diseases (NIAID)",Novartis,"Sanofi Pasteur, a Sanofi Company|National Institute of Allergy and Infectious Diseases (NIAID)","Sanofi Pasteur, a Sanofi Company",National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,Other|Industry|NIH,Interventional,10/1/1998,6/10/2019,https://ClinicalTrials.gov/show/NCT00138294
5109,Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy,Completed,Has Results,Contact Dermatitis,Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens,Allerderm,Allerderm,,,,,,,Phase 3,Industry,Interventional,4/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00640614
5110,MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication,Completed,Has Results,Uterine Leiomyoma|Uterine Fibroids,Device: ExAblate Enhanced Sonication,InSightec,InSightec,,,,,,,Phase 3,Industry,Interventional,10/6/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00365989
5111,"Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc.",Dana-Farber Cancer Institute,Brigham and Women's Hospital,"Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc.",Massachusetts General Hospital,"Celgene Corporation|Millennium Pharmaceuticals, Inc.",Celgene Corporation,"Millennium Pharmaceuticals, Inc.",Phase 2,Other|Industry,Interventional,8/6/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT00378209
5112,A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis,Completed,Has Results,TTR-mediated Amyloidosis,Drug: Revusiran (ALN-TTRSC),Alnylam Pharmaceuticals,Alnylam Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/14/2019,2/22/2017,https://ClinicalTrials.gov/show/NCT02292186
5113,Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI),Completed,Has Results,"Infections, Clostridium Difficile",Procedure: Blood sampling|Other: Stool sample collection,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,2/2/2013,6/1/2015,https://ClinicalTrials.gov/show/NCT01716533
5114,Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study,Completed,Has Results,Atrial Fibrillation,Device: Vdrive Lasso navigation|Procedure: Manual Lasso navigation,Stereotaxis,Stereotaxis,,,,,,,Phase 3,Industry,Interventional,8/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01656772
5115,Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium,Completed,Has Results,Sinusitis,Device: SinuSys Dilation System,SinuSys Corporation,SinuSys Corporation,,,,,,,Phase 1,Industry,Interventional,4/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01623050
5116,"A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors",Completed,Has Results,Neoplasms,Drug: Ipatasertib|Drug: Cobimetinib,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,4/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01562275
5117,Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer,Completed,Has Results,Metastatic Solid Tumors,Drug: TAK-117,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,10/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01449370
5118,A Study in Benign Prostatic Hyperplasia,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,9/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01152190
5119,A Study in Subjects With Recurrent Malignant Glioma,Completed,Has Results,Glioma,Drug: Lenvatinib|Drug: Bevacizumab,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,11/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01137604
5120,"Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism",Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Placebo|Drug: Etelcalcetide,KAI Pharmaceuticals,KAI Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,9/7/2010,4/2/2011,https://ClinicalTrials.gov/show/NCT01134562
5121,Circulation Improving Resuscitation Care (CIRC),Completed,Has Results,Cardiac Arrest|Cardiopulmonary Resuscitation,Device: AutoPulse|Other: Manual,Zoll Medical Corporation|Ullevaal University Hospital,Zoll Medical Corporation,Ullevaal University Hospital,,,,,,Not Applicable,Industry|Other,Interventional,1/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00597207
5122,Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers,Completed,Has Results,Nicotine Dependence,Drug: Chantix|Drug: Zyban|Drug: Nicotine patches,"Duke University|National Institute on Drug Abuse (NIDA)|Philip Morris USA, Inc.",Duke University,National Institute on Drug Abuse (NIDA),"Philip Morris USA, Inc.",,,,,Phase 2,Other|NIH|Industry,Interventional,3/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01806779
5123,Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile,Completed,Has Results,Bacterial Infections|Obesity,Drug: Clindamycin,"Phillip Brian Smith|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC|Duke University",Phillip Brian Smith,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"The Emmes Company, LLC|Duke University","The Emmes Company, LLC",Duke University,,,Phase 1,Other|NIH|Industry,Interventional,6/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01744730
5124,Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Fosaprepitant|Drug: Dexamethasone|Drug: 5HT3,Lawrence Einhorn|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.,Lawrence Einhorn,Hoosier Cancer Research Network,Merck Sharp & Dohme Corp.,,,,,Phase 2,Other|Industry,Interventional,1/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01736917
5125,A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene,Completed,Has Results,Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST),Drug: Imatinib mesylate,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/1/2000,6/13/2019,https://ClinicalTrials.gov/show/NCT00237185
5126,Concurrent Bupropion / Varenicline for Smoking Cessation,Completed,Has Results,Nicotine Dependence,Drug: Varenicline|Drug: Bupropion|Drug: Nicotine patches|Drug: Nicotine Inhaler,"Duke University|National Institute on Drug Abuse (NIDA)|Philip Morris USA, Inc.",Duke University,National Institute on Drug Abuse (NIDA),"Philip Morris USA, Inc.",,,,,Phase 3,Other|NIH|Industry,Interventional,3/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01303861
5127,Extended Endocrine Therapy for Premenopausal Women With Breast Cancer,Completed,Has Results,Breast Cancer,Drug: leuprolide|Drug: letrozole|Drug: zoledronic acid,Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Novartis,Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Novartis,,,,,Phase 2,Other|Industry,Interventional,5/9/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00903162
5128,"To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.",Completed,Has Results,Primary Bile Acid Diarrhea,Drug: LJN452|Drug: Placebo to LJN452,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,1/16/2016,1/25/2018,https://ClinicalTrials.gov/show/NCT02713243
5129,Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC),Completed,Has Results,Prostatic Neoplasms,Radiation: Fluciclovine (18F),Blue Earth Diagnostics,Blue Earth Diagnostics,,,,,,,,Industry,Observational,1/15/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02443571
5130,Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration,Completed,Has Results,Pantothenate Kinase-Associated Neurodegeneration,Drug: Deferiprone oral solution,ApoPharma,ApoPharma,,,,,,,Phase 3,Industry,Interventional,6/14/2019,3/16/2018,https://ClinicalTrials.gov/show/NCT02174848
5131,Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR Images,Completed,Has Results,Clinical Indication for Brain MRI,Device: Neurological MRI,GE Healthcare|ICON plc,GE Healthcare,ICON plc,,,,,,Not Applicable,Industry,Interventional,11/15/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02596854
5132,Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder,Completed,Has Results,Schizophrenia|Schizoaffective Disorder|Psychotic Disorder|Substance Abuse|Alcohol Abuse,Drug: Quetiapine,Dartmouth-Hitchcock Medical Center|Augusta University|AstraZeneca,Dartmouth-Hitchcock Medical Center,Augusta University,AstraZeneca,,,,,Phase 4,Other|Industry,Interventional,3/4/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00156715
5133,Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN),Completed,Has Results,Pantothenate Kinase-Associated Neurodegeneration,Drug: Deferiprone oral solution|Drug: Placebo,ApoPharma|Food and Drug Administration (FDA),ApoPharma,Food and Drug Administration (FDA),,,,,,Phase 3,Industry|U.S. Fed,Interventional,12/13/2012,1/11/2017,https://ClinicalTrials.gov/show/NCT01741532
5134,Bimatoprost in the Treatment of Eyelash Hypotrichosis,Completed,Has Results,Idiopathic Eyelash Hypotrichosis,Drug: bimatoprost formulation A solution|Drug: bimatoprost solution 0.03 %|Drug: vehicle of bimatoprost formulation A solution|Drug: vehicle of bimatoprost solution 0.03 %,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,11/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01698554
5135,A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread,Completed,Has Results,Malignant Solid Tumor|Solid Tumor|Metastatic Tumor,Drug: LY2334737,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,9/8/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01648764
5136,"A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects",Completed,Has Results,Hyperhidrosis,Drug: Umeclidinium|Drug: Vehicle,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,3/7/2016,12/8/2016,https://ClinicalTrials.gov/show/NCT02673619
5137,Maxigesic 325 Acute Dental Pain Study,Completed,Has Results,Dental Pain,Drug: Maxigesic 325|Drug: Acetaminophen|Drug: Ibuprofen|Drug: Placebo,"AFT Pharmaceuticals, Ltd.","AFT Pharmaceuticals, Ltd.",,,,,,,Phase 3,Industry,Interventional,4/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01420653
5138,Evaluation of Radiesse® Dermal Filler for Hand Treatment,Completed,Has Results,Aging Hands,Device: Radiesse® Injectable Dermal Filler,"Merz North America, Inc.|Merz Aesthetics Inc.","Merz North America, Inc.",Merz Aesthetics Inc.,,,,,,Not Applicable,Industry,Interventional,3/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01832090
5139,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Completed,Has Results,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Drug: normal saline|Biological: onabotulinumtoxinA 44 U|Biological: onabotulinumtoxinA 24 U,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,5/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01224015
5140,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Completed,Has Results,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Biological: onabotulinumtoxinA 24 U|Biological: onabotulinumtoxinA 44 U|Drug: normal saline,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,9/1/2010,9/1/2011,https://ClinicalTrials.gov/show/NCT01189760
5141,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines,Completed,Has Results,Lateral Canthus Rhytides|Crow's Feet Lines,Biological: onabotulinumtoxinA|Drug: normal saline,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,10/1/2010,7/1/2011,https://ClinicalTrials.gov/show/NCT01189747
5142,Clinical Study of WT2725 in Patients With Advanced Malignancies,Completed,Has Results,Cancer,Biological: WT2725,"Sunovion|Sumitomo Dainippon Pharma Co., Ltd.",Sunovion,"Sumitomo Dainippon Pharma Co., Ltd.",,,,,,Phase 1,Industry,Interventional,7/31/2012,5/17/2017,https://ClinicalTrials.gov/show/NCT01621542
5143,A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia,Completed,Has Results,"Neuralgia, Postherpetic",Drug: AGN-214868|Drug: Placebo to AGN-214868,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01129531
5144,Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tablets,Jaeb Center for Health Research|Xeris Pharmaceuticals,Jaeb Center for Health Research,Xeris Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,9/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02411578
5145,Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine,Completed,Has Results,Episodic Migraine,Drug: Dextromethorphan and quinidine|Drug: Placebo,"Cady, Roger, M.D.|Avanir Pharmaceuticals","Cady, Roger, M.D.",Avanir Pharmaceuticals,,,,,,Phase 2,Other|Industry,Interventional,8/14/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02176018
5146,Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis,Completed,Has Results,Prostate Cancer,Drug: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone,"Carolina Research Professionals, LLC|Bayer","Carolina Research Professionals, LLC",Bayer,,,,,,Phase 2,Other|Industry,Interventional,3/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02097303
5147,Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older,Completed,Has Results,Influenza,Biological: GSK Biologicals' influenza vaccine GSK2186877A|Biological: GSK Biologicals' Fluarix,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/16/2008,12/4/2009,https://ClinicalTrials.gov/show/NCT00765076
5148,Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia,Completed,Has Results,MPN (Myeloproliferative Neoplasms),Drug: Ruxolitinib,Incyte Corporation,Incyte Corporation,,,,,,,Phase 2,Industry,Interventional,7/8/2019,8/20/2018,https://ClinicalTrials.gov/show/NCT00726232
5149,Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer,Completed,Has Results,Pancreatic Neoplasms,Biological: DTA-H19,Anchiano Therapeutics Israel Ltd.,Anchiano Therapeutics Israel Ltd.,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00711997
5150,"Study to Compare Survival for ASTRA TECH Implant System, OsseoSpeed™ Implants Following Immediate Loading in Extraction Sockets Versus Immediate Loading in Healed Ridges",Completed,Has Results,"Jaw, Edentulous, Partially","Device: ASTRA TECH Implant System, OsseoSpeed™",Dentsply Sirona Implants,Dentsply Sirona Implants,,,,,,,Not Applicable,Industry,Interventional,4/5/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00710944
5151,The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects,Completed,Has Results,Bladder Outlet Obstruction|Lower Urinary Tract Symptoms,Device: Disposable device|Device: Digital device|Device: Clinic flow measurement,Wellspect HealthCare,Wellspect HealthCare,,,,,,,Not Applicable,Industry,Interventional,7/8/2019,,https://ClinicalTrials.gov/show/NCT00710749
5152,An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa,Completed,Has Results,Retinitis Pigmentosa,Drug: 400 µg Brimonidine Tartrate Implant|Drug: 200 µg Brimonidine Tartrate Implant|Drug: 100 µg Brimonidine Tartrate Implant|Other: Sham (no implant),Allergan,Allergan,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00661479
5153,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",Completed,Has Results,Melanoma,Drug: LGX818,Memorial Sloan Kettering Cancer Center|Array BioPharma,Memorial Sloan Kettering Cancer Center,Array BioPharma,,,,,,Phase 2,Other|Industry,Interventional,7/13/2019,3/17/2016,https://ClinicalTrials.gov/show/NCT01894672
5154,The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis,Completed,Has Results,Transthyretin-associated Amyloidosis With Polyneuropathy,Drug: Fx-1006A,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00630864
5155,Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma,Completed,Has Results,Relapsed or Refractory Multiple Myeloma,Drug: Cabozantinib (XL184),Memorial Sloan Kettering Cancer Center|Exelixis,Memorial Sloan Kettering Cancer Center,Exelixis,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,5/28/2013,8/18/2016,https://ClinicalTrials.gov/show/NCT01866293
5156,Outcomes in Rotator Cuff Repair Using Graft Reinforcement,Completed,Has Results,Rotator Cuff Tear,Device: Conexa Reconstructive Tissue Matrix,"Tornier, Inc.|LifeCell","Tornier, Inc.",LifeCell,,,,,,Not Applicable,Industry,Interventional,10/9/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01025037
5157,Dasatinib in Combination With Revlimid (and Dexamethasone),Completed,Has Results,Multiple Myeloma,"Drug: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Drug: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Drug: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Drug: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Drug: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg",Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,5/8/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00560391
5158,A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas,Completed,Has Results,Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma,Drug: tivozanib|Other: laboratory biomarker analysis,"Northwestern University|AVEO Pharmaceuticals, Inc.",Northwestern University,"AVEO Pharmaceuticals, Inc.",,,,,,Phase 2,Other|Industry,Interventional,3/6/2013,12/28/2016,https://ClinicalTrials.gov/show/NCT01782313
5159,Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma,Completed,Has Results,Gastric Adenocarcinoma|Gastroesophageal Adenocarcinoma|Distal Esophageal Adenocarcinoma,Drug: Cabazitaxel,Weill Medical College of Cornell University|Sanofi,Weill Medical College of Cornell University,Sanofi,,,,,,Phase 2,Other|Industry,Interventional,12/12/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT01757171
5160,Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression,Completed,Has Results,Major Depressive Disorder Without Psychotic Features,Drug: Asenapine 5-20 mg daily|Drug: Placebo 1-4 tablets daily,Duke University|Merck Sharp & Dohme Corp.,Duke University,Merck Sharp & Dohme Corp.,,,,,,Phase 4,Other|Industry,Interventional,10/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01670019
5161,ABT-436 for Alcohol Dependence,Completed,Has Results,Alcohol Dependence|Alcohol Abuse|Alcohol Use Disorders|Alcoholism,Drug: ABT-436|Drug: Matched Placebo - Sugar Pill,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|AbbVie,National Institute on Alcohol Abuse and Alcoholism (NIAAA),AbbVie,,,,,,Phase 2,NIH|Industry,Interventional,2/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01613014
5162,"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.",Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Valsartan|Drug: Hydrochlorothiazide (HCTZ),Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,10/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00386607
5163,"Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE",Completed,Has Results,Hereditary Angioedema,Drug: Icatibant,"Massachusetts General Hospital|Shire Human Genetic Therapies, Inc.",Massachusetts General Hospital,"Shire Human Genetic Therapies, Inc.",,,,,,Phase 4,Other|Industry,Interventional,12/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01457430
5164,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Completed,Has Results,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Drug: CG5503 IR|Drug: Morphine|Drug: Placebo,"Grünenthal GmbH|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Grünenthal GmbH,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 3,Industry,Interventional,9/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00609466
5165,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,Completed,Has Results,Obesity|Type 2 Diabetes,Drug: VI-0521,"VIVUS, Inc.|Medpace, Inc.","VIVUS, Inc.","Medpace, Inc.",,,,,,Phase 3,Industry,Interventional,11/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00553787
5166,Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab,Completed,Has Results,Diabetic Macular Edema,Drug: Ranibizumab,"California Retina Consultants|Genentech, Inc.",California Retina Consultants,"Genentech, Inc.",,,,,,Phase 1|Phase 2,Other|Industry,Interventional,3/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01292798
5167,Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: STA-9090,Memorial Sloan Kettering Cancer Center|Synta Pharmaceuticals Corp.,Memorial Sloan Kettering Cancer Center,Synta Pharmaceuticals Corp.,,,,,,Phase 2,Other|Industry,Interventional,1/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01273896
5168,Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor,Completed,Has Results,Gastrointestinal Stromal Tumors,Drug: SU011248,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00137449
5169,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Completed,Has Results,Facial Wrinkles at the Nasolabial Folds,Device: Dermal Gel Extra (DGE)|Device: Restylane|Drug: EMLA Cream,"Genzyme, a Sanofi Company|Mentor Worldwide, LLC|Sanofi","Genzyme, a Sanofi Company","Mentor Worldwide, LLC",Sanofi,,,,,Phase 3,Industry,Interventional,5/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00444626
5170,Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity,Completed,Has Results,Malignant Pleural Mesothelioma,Drug: everolimus,Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute|University of Pennsylvania,Memorial Sloan Kettering Cancer Center,Novartis Pharmaceuticals,Dana-Farber Cancer Institute|University of Pennsylvania,Dana-Farber Cancer Institute,University of Pennsylvania,,,Phase 2,Other|Industry,Interventional,12/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01024946
5171,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Completed,Has Results,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Drug: G-Pen|Drug: Lilly Glucagon,Xeris Pharmaceuticals|SGS S.A.|Integrated Medical Development,Xeris Pharmaceuticals,SGS S.A.,Integrated Medical Development,,,,,Phase 3,Industry,Interventional,1/23/2018,5/3/2018,https://ClinicalTrials.gov/show/NCT03439072
5172,Fish Oil Study for High Triglyceride Levels in Children,Completed,Has Results,Hypertriglyceridemia,Drug: Omega-3-acid ethyl esters|Drug: Placebo,Samuel Gidding|GlaxoSmithKline|Johns Hopkins University|Thomas Jefferson University|Nemours Children's Clinic,Samuel Gidding,GlaxoSmithKline,Johns Hopkins University|Thomas Jefferson University|Nemours Children's Clinic,Johns Hopkins University,Thomas Jefferson University|Nemours Children's Clinic,Thomas Jefferson University,Nemours Children's Clinic,Phase 2|Phase 3,Other|Industry,Interventional,7/9/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00915902
5173,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Completed,Has Results,Borderline Personality Disorder,Drug: quetiapine extended-release|Drug: Placebo,University of Minnesota - Clinical and Translational Science Institute|AstraZeneca|University of Iowa|Mclean Hospital,University of Minnesota - Clinical and Translational Science Institute,AstraZeneca,University of Iowa|Mclean Hospital,University of Iowa,Mclean Hospital,,,Phase 3,Other|Industry,Interventional,6/8/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00880919
5174,Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function,Completed,Has Results,Stroke|Muscle Spasticity|Motor Neuron Disease,Biological: botulinum toxin Type A|Drug: saline,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,10/3/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00076687
5175,Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome,Completed,Has Results,Short Bowel Syndrome,"Biological: Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)",Children's Hospital of Michigan|Merck Sharp & Dohme Corp.|William Beaumont Hospitals|Boston Children’s Hospital,Children's Hospital of Michigan,Merck Sharp & Dohme Corp.,William Beaumont Hospitals|Boston Children’s Hospital,William Beaumont Hospitals,Boston Children’s Hospital,,,Phase 1,Other|Industry,Interventional,7/9/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00767364
5176,"Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",Completed,Has Results,Bladder Cancer|Urinary Bladder,Drug: Sunitinib|Drug: Gemcitabine|Drug: cisplatin,Memorial Sloan Kettering Cancer Center|Pfizer,Memorial Sloan Kettering Cancer Center,Pfizer,,,,,,Phase 2,Other|Industry,Interventional,2/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00847015
5177,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Completed,Has Results,Affective Disorders,Drug: Ziprasidone|Drug: Sertraline|Drug: Haloperidol,"Duke University|Pfizer|National Institute of Mental Health and Neuro Sciences, India",Duke University,Pfizer,"National Institute of Mental Health and Neuro Sciences, India",,,,,Phase 2|Phase 3,Other|Industry,Interventional,4/3/2019,8/5/2019,https://ClinicalTrials.gov/show/NCT00340379
5178,Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer,Completed,Has Results,Lung Cancer,Drug: Temozolomide,Memorial Sloan Kettering Cancer Center|Schering-Plough,Memorial Sloan Kettering Cancer Center,Schering-Plough,,,,,,Phase 2,Other|Industry,Interventional,8/8/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00740636
5179,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Completed,Has Results,Asthma,Drug: Budesonide|Drug: albuterol|Drug: Ipratropium bromide|Drug: Prednisone,Northwell Health|AstraZeneca|Jacobi Medical Center|Nassau University Medical Center,Northwell Health,AstraZeneca,Jacobi Medical Center|Nassau University Medical Center,Jacobi Medical Center,Nassau University Medical Center,,,Phase 3,Other|Industry,Interventional,9/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00588406
5180,"Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer",Completed,Has Results,Breast Cancer,"Drug: capecitabine, lapatinib",Memorial Sloan Kettering Cancer Center|GlaxoSmithKline,Memorial Sloan Kettering Cancer Center,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,7/8/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT00721630
5181,"Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed ""Acquired Resistance"" to Erlotinib",Completed,Has Results,Lung Adenocarcinoma,Drug: erlotinib with cetuximab,Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb,Memorial Sloan Kettering Cancer Center,Bristol-Myers Squibb,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,7/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00716456
5182,Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma,Completed,Has Results,Renal Cell Carcinoma|Neoplasm Metastases,Drug: Gemcitabine|Drug: Sunitinib,Massachusetts General Hospital|Pfizer|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute,Massachusetts General Hospital,Pfizer,Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute,,,Phase 2,Other|Industry,Interventional,12/7/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00556049
5183,"Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer",Completed,Has Results,Lung Cancer,"Drug: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)",Memorial Sloan Kettering Cancer Center|Sanofi,Memorial Sloan Kettering Cancer Center,Sanofi,,,,,,Not Applicable,Other|Industry,Interventional,5/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00675597
5184,A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma,Completed,Has Results,Osteosarcoma|Malignant Fibrous Histiocytoma (MFH) of Bone,Biological: Bevacizumab|Drug: Cisplatin|Drug: Doxorubicin|Drug: Methotrexate|Drug: Ifosfamide|Drug: etoposide|Procedure: Surgery|Radiation: Radiotherapy,"St. Jude Children's Research Hospital|Genentech, Inc.",St. Jude Children's Research Hospital,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,6/3/2008,8/17/2019,https://ClinicalTrials.gov/show/NCT00667342
5185,Lamotrigine for Symptoms of Geriatric Bipolar Depression,Completed,Has Results,"Bipolar Disorder|Depression, Bipolar",Drug: Lamotrigine regular tablet formulation|Drug: Lamotrigine novel formulation,University Hospitals Cleveland Medical Center|GlaxoSmithKline,University Hospitals Cleveland Medical Center,GlaxoSmithKline,,,,,,Phase 3,Other|Industry,Interventional,1/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00621842
5186,"Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer",Completed,Has Results,Breast Cancer,"Drug: cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim",Memorial Sloan Kettering Cancer Center|Amgen,Memorial Sloan Kettering Cancer Center,Amgen,,,,,,Not Applicable,Other|Industry,Interventional,1/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00615901
5187,Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET),Completed,Has Results,Neuroendocrine Tumors|Metastatic Neuroendocrine Tumors,Drug: MK-0646,Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.,Memorial Sloan Kettering Cancer Center,Merck Sharp & Dohme Corp.,,,,,,Phase 2,Other|Industry,Interventional,1/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00610129
5188,Targeting Right Ventricle in Pulmonary Hypertension Gilead,Completed,Has Results,Pulmonary Hypertension,Drug: Ranolazine|Drug: Placebo,University of Pennsylvania|Brigham and Women's Hospital|University of Maryland|Gilead Sciences,University of Pennsylvania,Brigham and Women's Hospital,University of Maryland|Gilead Sciences,University of Maryland,Gilead Sciences,,,Phase 4,Other|Industry,Interventional,7/16/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02829034
5189,Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit,Completed,Has Results,Nosocomial Infections,Drug: 2% Chlorhexidine gluconate cloth,"Johns Hopkins University|Sage Products, Inc.",Johns Hopkins University,"Sage Products, Inc.",,,,,,Phase 2|Phase 3,Other|Industry,Interventional,2/8/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00549393
5190,Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma,Completed,Has Results,Hodgkin Disease,Drug: Lenalidomide,Washington University School of Medicine|Celgene Corporation,Washington University School of Medicine,Celgene Corporation,,,,,,Phase 2,Other|Industry,Interventional,9/6/2007,9/1/2016,https://ClinicalTrials.gov/show/NCT00540007
5191,Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer,Completed,Has Results,"Carcinoma, Renal Cell",Drug: RAD001,University of Chicago|Novartis,University of Chicago,Novartis,,,,,,Phase 2,Other|Industry,Interventional,9/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00529802
5192,"Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients",Completed,Has Results,Breast Cancer,Drug: Trastuzumab|Drug: Bevacizumab|Drug: Docetaxel,"Bhuvaneswari Ramaswamy|Genentech, Inc.|Case Comprehensive Cancer Center|University of Pittsburgh|Ohio State University Comprehensive Cancer Center",Bhuvaneswari Ramaswamy,"Genentech, Inc.",Case Comprehensive Cancer Center|University of Pittsburgh|Ohio State University Comprehensive Cancer Center,Case Comprehensive Cancer Center,University of Pittsburgh|Ohio State University Comprehensive Cancer Center,University of Pittsburgh,Ohio State University Comprehensive Cancer Center,Phase 2,Other|Industry,Interventional,6/14/2007,2/7/2017,https://ClinicalTrials.gov/show/NCT00428922
5193,"Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer",Completed,Has Results,Pancreatic Cancer|Adenocarcinoma of the Pancreas,Drug: Bevacizumab|Drug: Erlotinib|Drug: Gemcitabine,"Massachusetts General Hospital|Genentech, Inc.|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute",Massachusetts General Hospital,"Genentech, Inc.",Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute,,,Phase 2,Other|Industry,Interventional,8/6/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00366457
5194,CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia,Completed,Has Results,Barrett Syndrome|Barrett's Syndrome|Barrett's Esophagus|Barrett Esophagus|Adenocarcinoma,Device: Standard endoscopic evaluation|Device: pCLE guided evaluation,Mauna Kea Technologies|Cellvizio Inc.,Mauna Kea Technologies,Cellvizio Inc.,,,,,,Not Applicable,Industry,Interventional,2/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01032044
5195,Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma,Completed,Has Results,Mucosal Melanoma|Acral/Lentiginous Melanoma|Chronically Sun Damaged Melanomas,Drug: Imatinib,Dana-Farber Cancer Institute|Novartis,Dana-Farber Cancer Institute,Novartis,,,,,,Phase 2,Other|Industry,Interventional,7/6/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00424515
5196,Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome,Completed,Has Results,Polycystic Ovary Syndrome,Drug: LIK066|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/24/2017,6/25/2018,https://ClinicalTrials.gov/show/NCT03152591
5197,Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma,Completed,Has Results,Glioblastoma|Gliomas,Drug: Temozolomide,Memorial Sloan Kettering Cancer Center|Schering-Plough|Columbia University|Dana-Farber Cancer Institute,Memorial Sloan Kettering Cancer Center,Schering-Plough,Columbia University|Dana-Farber Cancer Institute,Columbia University,Dana-Farber Cancer Institute,,,Phase 2,Other|Industry,Interventional,8/9/2005,5/4/2017,https://ClinicalTrials.gov/show/NCT00200161
5198,Bevacizumab in Treating Patients With Angiosarcoma,Completed,Has Results,Sarcoma,Biological: Bevacizumab,"Northwestern University|Genentech, Inc.",Northwestern University,"Genentech, Inc.",,,,,,Phase 2,Other|Industry,Interventional,10/5/2019,11/10/2016,https://ClinicalTrials.gov/show/NCT00288015
5199,PUFA Supplementation in Premature Infants,Completed,Has Results,"Premature, Extremely Low Birth Weight Infants|Polyunsaturated Fatty Acid Levels",Dietary Supplement: LCPUFA supplement|Dietary Supplement: placebo,"NorthShore University HealthSystem|Ann & Robert H Lurie Children's Hospital of Chicago|Feinberg School of Medicine, Northwestern University|Mead Johnson Nutrition",NorthShore University HealthSystem,Ann & Robert H Lurie Children's Hospital of Chicago,"Feinberg School of Medicine, Northwestern University|Mead Johnson Nutrition","Feinberg School of Medicine, Northwestern University",Mead Johnson Nutrition,,,Not Applicable,Other|Industry,Interventional,9/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01955044
5200,Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses,Completed,Has Results,Myopia,Device: comfilcon A|Device: samfilcon A,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02542072
5201,Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores,Completed,Has Results,Recurrent Herpes Labialis,Drug: Merlin|Drug: Ethanol,"Topical Remedy|Benu BioPharma, LLC|Accelovance|Optimal Research",Topical Remedy,"Benu BioPharma, LLC",Accelovance|Optimal Research,Accelovance,Optimal Research,,,Phase 2,Industry|Other,Interventional,7/5/2017,4/2/2018,https://ClinicalTrials.gov/show/NCT03192306
5202,Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer,Completed,Has Results,Prostatic Neoplasms|Prostate Cancer|Cancer of the Prostate,Device: High-resolution ultrasound guided prostate biopsy|Device: Standard ultrasound guided prostate biopsy,Exact Imaging,Exact Imaging,,,,,,,Not Applicable,Industry,Interventional,12/13/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT02079025
5203,Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma,Completed,Has Results,Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma,Drug: ofatumumab,Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|GlaxoSmithKline,Massachusetts General Hospital,Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center|GlaxoSmithKline,Beth Israel Deaconess Medical Center,GlaxoSmithKline,,,Phase 2,Other|Industry,Interventional,12/10/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01239394
5204,"Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer",Completed,Has Results,Small Cell Lung Cancer,Drug: STA-9090,"David M. Jackman, MD|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Synta Pharmaceuticals Corp.|Dana-Farber Cancer Institute","David M. Jackman, MD",Massachusetts General Hospital,Beth Israel Deaconess Medical Center|Synta Pharmaceuticals Corp.|Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Synta Pharmaceuticals Corp.|Dana-Farber Cancer Institute,Synta Pharmaceuticals Corp.,Dana-Farber Cancer Institute,Phase 2,Other|Industry,Interventional,7/28/2010,11/4/2016,https://ClinicalTrials.gov/show/NCT01173523
5205,A Study in Adolescent Females to Explore Cytomegalovirus Infection,Completed,Has Results,"Infections, Cytomegalovirus",Procedure: Blood collection|Procedure: Urine collection|Procedure: Saliva collection,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Not Applicable,Industry,Interventional,10/5/2012,4/8/2017,https://ClinicalTrials.gov/show/NCT01691820
5206,Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice),Completed,Has Results,Cardiac Disease|Coronary Artery Disease,Device: CELT ACD,Vasorum Ltd,Vasorum Ltd,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01600482
5207,Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome),Completed,Has Results,Mucopolysaccharidosis IVA|Morquio A Syndrome|MPS IVA,Drug: BMN 110,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 2,Industry,Interventional,10/11/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01515956
5208,PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK),Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Everolimus-Eluting Coronary Stent System|Drug: Aspirin|Drug: Thienopyridine,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,10/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01510327
5209,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma",Completed,Has Results,Asthma,Drug: MK-1029|Drug: Placebo for MK-1029,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 1,Industry,Interventional,6/1/2011,12/27/2011,https://ClinicalTrials.gov/show/NCT01370317
5210,Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,Completed,Has Results,Colorectal Cancer,Drug: panitumumab,Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Amgen,Massachusetts General Hospital,Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute|Amgen,Dana-Farber Cancer Institute,Amgen,,,Phase 2,Other|Industry,Interventional,5/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00842257
5211,Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY,Completed,Has Results,Lymphoma|Multiple Myeloma|Leukemia|Myelodysplastic Syndrome,"Drug: Busulfan, Fludarabine, Cytoxan","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|M.D. Anderson Cancer Center|Fred Hutchinson Cancer Research Center|Otsuka Pharmaceutical Co., Ltd.",Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,M.D. Anderson Cancer Center,"Fred Hutchinson Cancer Research Center|Otsuka Pharmaceutical Co., Ltd.",Fred Hutchinson Cancer Research Center,"Otsuka Pharmaceutical Co., Ltd.",,,Phase 1|Phase 2,Other|Industry,Interventional,5/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00809276
5212,A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women,Completed,Has Results,"Osteoporosis, Postmenopausal",Drug: LY333334|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,11/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01250145
5213,A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD,Completed,Has Results,Chronic Kidney Disease,Drug: Calcium acetate|Drug: Lanthanum Carbonate|Drug: Sevelamer Carbonate|Drug: Placebo,"Denver Nephrologists, P.C.|Shire|Fresenius Medical Care North America|Genzyme, a Sanofi Company|Novartis Pharmaceuticals|DaVita Dialysis","Denver Nephrologists, P.C.",Shire,"Fresenius Medical Care North America|Genzyme, a Sanofi Company|Novartis Pharmaceuticals|DaVita Dialysis",Fresenius Medical Care North America,"Genzyme, a Sanofi Company|Novartis Pharmaceuticals|DaVita Dialysis","Genzyme, a Sanofi Company",Novartis Pharmaceuticals|DaVita Dialysis,Not Applicable,Other|Industry,Interventional,2/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00785629
5214,"Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer",Completed,Has Results,Prostate Cancer,Drug: Docetaxel|Drug: Bevacizumab|Drug: ADT|Drug: Bicalutamide,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Genentech, Inc.",Dana-Farber Cancer Institute,Brigham and Women's Hospital,"Beth Israel Deaconess Medical Center|Genentech, Inc.",Beth Israel Deaconess Medical Center,"Genentech, Inc.",,,Phase 2,Other|Industry,Interventional,6/8/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00658697
5215,RAD001 in Advanced Hepatocellular Carcinoma,Completed,Has Results,Hepatocellular Carcinoma,Drug: RAD001,Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Novartis,Massachusetts General Hospital,Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center|Novartis,Beth Israel Deaconess Medical Center,Novartis,,,Phase 1|Phase 2,Other|Industry,Interventional,8/7/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00516165
5216,Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer,Completed,Has Results,Breast Cancer|Brain Metastases,Drug: Lapatinib|Procedure: Whole Brain Radiation|Drug: Herceptin,"Nancy Lin, MD|Brigham and Women's Hospital|Breast Cancer Research Foundation|GlaxoSmithKline|Dana-Farber Cancer Institute","Nancy Lin, MD",Brigham and Women's Hospital,Breast Cancer Research Foundation|GlaxoSmithKline|Dana-Farber Cancer Institute,Breast Cancer Research Foundation,GlaxoSmithKline|Dana-Farber Cancer Institute,GlaxoSmithKline,Dana-Farber Cancer Institute,Phase 1,Other|Industry,Interventional,4/7/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00470847
5217,RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Drug: RAD001,Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Novartis,Dana-Farber Cancer Institute,Massachusetts General Hospital,Beth Israel Deaconess Medical Center|Novartis,Beth Israel Deaconess Medical Center,Novartis,,,Phase 2,Other|Industry,Interventional,1/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00409292
5218,"Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",Completed,Has Results,Esophageal Cancer|Stomach Cancer,Drug: Bevacizumab|Drug: Docetaxel|Drug: Cisplatin|Drug: Irinotecan,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Genentech, Inc.",Dana-Farber Cancer Institute,Brigham and Women's Hospital,"Massachusetts General Hospital|Genentech, Inc.",Massachusetts General Hospital,"Genentech, Inc.",,,Phase 2,Other|Industry,Interventional,9/6/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT00394433
5219,Study to Evaluate an Implant With a Sloped Top in Patients With a Sloped Jaw Bone,Completed,Has Results,Edentulism,"Device: ASTRA TECH Implant System, OsseoSpeed™",Dentsply Sirona Implants,Dentsply Sirona Implants,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,,https://ClinicalTrials.gov/show/NCT00807456
5220,"Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer",Completed,Has Results,Rectal Cancer|Adenocarcinoma of the Rectum,Drug: 5-fluorouracil|Drug: bevacizumab|Drug: erlotinib|Procedure: External beam radiation therapy (EBRT),"Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Genentech, Inc.",Massachusetts General Hospital,Beth Israel Deaconess Medical Center,"Dana-Farber Cancer Institute|Genentech, Inc.",Dana-Farber Cancer Institute,"Genentech, Inc.",,,Phase 1|Phase 2,Other|Industry,Interventional,5/6/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00307736
5221,Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients,Completed,Has Results,Burns,Drug: Caldolor|Drug: Placebo,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00606489
5222,Belatacept Pharmacokinetic Trial in Renal Transplantation,Completed,Has Results,Renal Transplantation,Drug: Belatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,3/8/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00578448
5223,"A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers",Completed,Has Results,Axial Spondyloarthritis (AxSpA)|Non-radiographic Evidence-AxSpA|Ankylosing Spondylitis|Crohn's Disease|Psoriatic Arthritis|Rheumatoid Arthritis,Procedure: Breast milk sampling|Biological: Certolizumab Pegol,"UCB BIOSCIENCES, Inc.|PPD|Parexel|UCB Pharma","UCB BIOSCIENCES, Inc.",PPD,Parexel|UCB Pharma,Parexel,UCB Pharma,,,Phase 1,Industry,Interventional,9/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02154425
5224,OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits,Completed,Has Results,Diabetes|Diabetic Macular Edema|Diabetic Retinopathy,Device: OCT imaging,"Joslin Diabetes Center|Genentech, Inc.|Juvenile Diabetes Research Foundation|Optovue",Joslin Diabetes Center,"Genentech, Inc.",Juvenile Diabetes Research Foundation|Optovue,Juvenile Diabetes Research Foundation,Optovue,,,Not Applicable,Other|Industry,Interventional,3/17/2014,7/15/2016,https://ClinicalTrials.gov/show/NCT01875783
5225,"Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)",Completed,Has Results,"Lymphoma, T-Cell, Cutaneous",Drug: placebo for SHAPE (SHP-141)|Drug: SHAPE (SHP-141) 0.1% BID|Drug: SHAPE (SHP-141) 0.5% BID|Drug: SHAPE (SHP-141) 1.0% BID,"TetraLogic Pharmaceuticals|The Leukemia and Lymphoma Society|Therapeutics, Inc.|Veristat, Inc.|PPD",TetraLogic Pharmaceuticals,The Leukemia and Lymphoma Society,"Therapeutics, Inc.|Veristat, Inc.|PPD","Therapeutics, Inc.","Veristat, Inc.|PPD","Veristat, Inc.",PPD,Phase 1,Industry|Other,Interventional,11/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01433731
5226,Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma,Completed,Has Results,Fallopian Tube Cancer|Ovarian Cancer|Malignant Tumor of Peritoneum,Drug: Avastin|Drug: Docetaxel,"H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Genentech, Inc.|Sanofi",H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI),"Genentech, Inc.|Sanofi","Genentech, Inc.",Sanofi,,,Phase 2,Other|NIH|Industry,Interventional,3/7/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00504257
5227,"Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer",Completed,Has Results,Liver Cancer,Biological: cetuximab|Drug: capecitabine|Drug: oxaliplatin,UNC Lineberger Comprehensive Cancer Center|Sanofi|Roche Pharma AG|Bristol-Myers Squibb|National Center for Research Resources (NCRR)|National Cancer Institute (NCI),UNC Lineberger Comprehensive Cancer Center,Sanofi,Roche Pharma AG|Bristol-Myers Squibb|National Center for Research Resources (NCRR)|National Cancer Institute (NCI),Roche Pharma AG,Bristol-Myers Squibb|National Center for Research Resources (NCRR)|National Cancer Institute (NCI),Bristol-Myers Squibb,National Center for Research Resources (NCRR)|National Cancer Institute (NCI),Phase 2,Other|Industry|NIH,Interventional,10/6/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00483405
5228,Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback,Completed,Has Results,Arthropathy of Knee Joint,Other: Weight-bearing biofeedback exercise|Other: Standard of care exercise,"University of Colorado, Denver|Foundation for Physical Therapy, Inc.|National Institutes of Health (NIH)|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","University of Colorado, Denver","Foundation for Physical Therapy, Inc.",National Institutes of Health (NIH)|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),National Institutes of Health (NIH),National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),National Institute on Aging (NIA),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable,Other|Industry|NIH,Interventional,1/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01333189
5229,Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer,Completed,Has Results,Breast Cancer,Biological: trastuzumab|Drug: carboplatin|Drug: docetaxel,"Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Aventis Pharmaceuticals|Genentech, Inc.",Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),"Aventis Pharmaceuticals|Genentech, Inc.",Aventis Pharmaceuticals,"Genentech, Inc.",,,Phase 2,Other|NIH|Industry,Interventional,7/3/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00068341
5230,Enhancement by Poly-ICLC During HIV-1 Infection,Completed,Has Results,HIV-1 Infected Adults With Chronic HIV-1 Infection,Drug: Arm A: Poly-ICLC|Drug: Arm B: Normal Saline,"Nina Bhardwaj|The Campbell Foundation|Oncovir, Inc.|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Icahn School of Medicine at Mount Sinai",Nina Bhardwaj,The Campbell Foundation,"Oncovir, Inc.|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Icahn School of Medicine at Mount Sinai","Oncovir, Inc.",National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Icahn School of Medicine at Mount Sinai,National Institutes of Health (NIH),National Institute of Allergy and Infectious Diseases (NIAID)|Icahn School of Medicine at Mount Sinai,Phase 1|Phase 2,Other|Industry|NIH,Interventional,4/14/2019,7/26/2016,https://ClinicalTrials.gov/show/NCT02071095
5231,Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery,Completed,Has Results,Caloric Restriction|Exercise,Drug: Sesame Oil|Drug: testosterone enanthate,Pennington Biomedical Research Center|United States Army Research Institute of Environmental Medicine|MyoSyntax|Defence Research and Development Canada|United States Department of Defense,Pennington Biomedical Research Center,United States Army Research Institute of Environmental Medicine,MyoSyntax|Defence Research and Development Canada|United States Department of Defense,MyoSyntax,Defence Research and Development Canada|United States Department of Defense,Defence Research and Development Canada,United States Department of Defense,Phase 4,Other|U.S. Fed|Industry,Interventional,4/16/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02734238
5232,Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1,Completed,Has Results,HIV-1 Infection|HIV Infections,Drug: maraviroc|Drug: darunavir|Drug: ritonavir,"Northwestern University|Pfizer|Tibotec, Inc",Northwestern University,Pfizer,"Tibotec, Inc",,,,,Phase 2,Other|Industry,Interventional,5/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00993148
5233,Pilot Study of a Raltegravir Based NRTI Sparing Regimen,Completed,Has Results,Acquired Immune Deficiency Syndrome|AIDS|Human Immunodeficiency Virus|HIV Infections,Drug: Raltegravir|Drug: Atazanavir|Other: Standard treatment regimen,Yale University|Bristol-Myers Squibb|Merck Sharp & Dohme Corp.,Yale University,Bristol-Myers Squibb,Merck Sharp & Dohme Corp.,,,,,Not Applicable,Other|Industry,Interventional,5/9/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00814879
5234,"Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma",Completed,Has Results,Stomach Neoplasms|Esophageal Neoplasms,"Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin","Memorial Sloan Kettering Cancer Center|Sanofi|Genentech, Inc.",Memorial Sloan Kettering Cancer Center,Sanofi,"Genentech, Inc.",,,,,Phase 2,Other|Industry,Interventional,10/6/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00390416
5235,Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer,Completed,Has Results,Thyroid Cancer,Drug: Euthyroid Group,"Johns Hopkins University|Gustave Roussy, Cancer Campus, Grand Paris|M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",Johns Hopkins University,"Gustave Roussy, Cancer Campus, Grand Paris","M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",,,Phase 2,Other|Industry,Interventional,3/1/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT00181168
5236,"Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.",Completed,Has Results,Left Ventricular Diastolic Dysfunction,Drug: BNP (nesiritide)|Drug: Placebo,"Mayo Clinic|National Institutes of Health (NIH)|Scios, Inc.|National Heart, Lung, and Blood Institute (NHLBI)|National Center for Research Resources (NCRR)",Mayo Clinic,National Institutes of Health (NIH),"Scios, Inc.|National Heart, Lung, and Blood Institute (NHLBI)|National Center for Research Resources (NCRR)","Scios, Inc.","National Heart, Lung, and Blood Institute (NHLBI)|National Center for Research Resources (NCRR)","National Heart, Lung, and Blood Institute (NHLBI)",National Center for Research Resources (NCRR),Phase 1|Phase 2,Other|NIH|Industry,Interventional,3/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00405548
5237,Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir,Completed,Has Results,HIV Infection,Biological: DNA + HIV-rAd5 vaccine|Drug: ART intensification (raltegravir)|Drug: ART intensification (maraviroc),Robert L. Murphy|Objectif Recherche Vaccins SIDA|National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer|Merck Sharp & Dohme Corp.|Northwestern University,Robert L. Murphy,Objectif Recherche Vaccins SIDA,National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer|Merck Sharp & Dohme Corp.|Northwestern University,National Institute of Allergy and Infectious Diseases (NIAID),Pfizer|Merck Sharp & Dohme Corp.|Northwestern University,Pfizer,Merck Sharp & Dohme Corp.|Northwestern University,Phase 2,Other|NIH|Industry,Interventional,11/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00976404
5238,Treatment of Older Adults With Acute Lymphoblastic Leukemia,Completed,Has Results,Acute Lymphoblastic Leukemia,Drug: Prednisone|Drug: Vincristine|Drug: Doxorubicin|Drug: PEG-asparaginase|Drug: Cytarabine|Drug: Methotrexate|Drug: Imatinib|Drug: Clofarabine|Drug: 6 Mercaptopurine,"Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Enzon Pharmaceuticals, Inc.|Genzyme, a Sanofi Company",Massachusetts General Hospital,Dana-Farber Cancer Institute,"Beth Israel Deaconess Medical Center|Enzon Pharmaceuticals, Inc.|Genzyme, a Sanofi Company",Beth Israel Deaconess Medical Center,"Enzon Pharmaceuticals, Inc.|Genzyme, a Sanofi Company","Enzon Pharmaceuticals, Inc.","Genzyme, a Sanofi Company",Phase 2,Other|Industry,Interventional,8/9/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT00973752
5239,Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes,Completed,Has Results,Diabetes|Insulin,Device: insulin dose software,"HealthPartners Institute|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Hygieia, Inc|International Diabetes Center at Park Nicollet",HealthPartners Institute,National Institutes of Health (NIH),"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Hygieia, Inc|International Diabetes Center at Park Nicollet",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"Hygieia, Inc|International Diabetes Center at Park Nicollet","Hygieia, Inc",International Diabetes Center at Park Nicollet,Not Applicable,Other|NIH|Industry,Interventional,6/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01170208
5240,University Of Pennsylvania Weight Loss Study,Completed,Has Results,Weight Loss,Behavioral: Deposit contract with a 1:1 match|Behavioral: Deposit contract with a 2:1 match|Behavioral: Deposit Contract with no match,University of Pennsylvania|Carnegie Mellon University|Harvard University|incentaHEALTH|McKinsey & Company,University of Pennsylvania,Carnegie Mellon University,Harvard University|incentaHEALTH|McKinsey & Company,Harvard University,incentaHEALTH|McKinsey & Company,incentaHEALTH,McKinsey & Company,Not Applicable,Other|Industry,Interventional,5/24/2011,7/16/2019,https://ClinicalTrials.gov/show/NCT01167634
5241,Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure,Completed,Has Results,Congestive Heart Failure|Cardiomyopathy,Drug: B-type Natriuretic Peptide (BNP)|Other: Placebo,"Horng Chen|American Heart Association|Scios, Inc.|National Heart, Lung, and Blood Institute (NHLBI)|National Center for Research Resources (NCRR)|Mayo Clinic",Horng Chen,American Heart Association,"Scios, Inc.|National Heart, Lung, and Blood Institute (NHLBI)|National Center for Research Resources (NCRR)|Mayo Clinic","Scios, Inc.","National Heart, Lung, and Blood Institute (NHLBI)|National Center for Research Resources (NCRR)|Mayo Clinic","National Heart, Lung, and Blood Institute (NHLBI)",National Center for Research Resources (NCRR)|Mayo Clinic,Phase 1|Phase 2,Other|Industry|NIH,Interventional,1/1/2000,6/10/2019,https://ClinicalTrials.gov/show/NCT00252187
5242,Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis Related Diabetes|Pancreatic Insufficiency,Drug: placebo|Drug: repaglinide,"Arbelaez, Ana Maria|Washington University School of Medicine|National Institutes of Health (NIH)|Novo Nordisk A/S|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Arbelaez, Ana Maria",Washington University School of Medicine,National Institutes of Health (NIH)|Novo Nordisk A/S|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health (NIH),Novo Nordisk A/S|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Novo Nordisk A/S,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Not Applicable,Other|NIH|Industry,Interventional,11/6/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00763412
5243,Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy,Completed,Has Results,Prostate Cancer|Adenocarcinoma of the Prostate,Drug: Bevacizumab|Drug: Docetaxel,"Mary-Ellen Taplin, MD|Beth Israel Deaconess Medical Center|Duke University|Genentech, Inc.|Sanofi|Dana-Farber Cancer Institute","Mary-Ellen Taplin, MD",Beth Israel Deaconess Medical Center,"Duke University|Genentech, Inc.|Sanofi|Dana-Farber Cancer Institute",Duke University,"Genentech, Inc.|Sanofi|Dana-Farber Cancer Institute","Genentech, Inc.",Sanofi|Dana-Farber Cancer Institute,Phase 2,Other|Industry,Interventional,6/6/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00321646
5244,Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults,Completed,Has Results,Malaria|Plasmodium Vivax,Biological: VMP001|Other: P. vivax sporozoite challenge,U.S. Army Medical Research and Development Command|The PATH Malaria Vaccine Initiative (MVI)|Walter Reed Army Institute of Research (WRAIR)|United States Department of Defense|GlaxoSmithKline,U.S. Army Medical Research and Development Command,The PATH Malaria Vaccine Initiative (MVI),Walter Reed Army Institute of Research (WRAIR)|United States Department of Defense|GlaxoSmithKline,Walter Reed Army Institute of Research (WRAIR),United States Department of Defense|GlaxoSmithKline,United States Department of Defense,GlaxoSmithKline,Phase 1|Phase 2,U.S. Fed|Other|Industry,Interventional,7/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01157897
5245,HIV and Kidney Function Study,Completed,Has Results,HIV Infections|AIDS,,Tufts Medical Center|Icahn School of Medicine at Mount Sinai|University of Alabama at Birmingham|University of Minnesota - Clinical and Translational Science Institute|Gilead Sciences,Tufts Medical Center,Icahn School of Medicine at Mount Sinai,University of Alabama at Birmingham|University of Minnesota - Clinical and Translational Science Institute|Gilead Sciences,University of Alabama at Birmingham,University of Minnesota - Clinical and Translational Science Institute|Gilead Sciences,University of Minnesota - Clinical and Translational Science Institute,Gilead Sciences,,Other|Industry,Observational,1/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00905151
5246,Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage,Completed,Has Results,"Miscarriage, Recurrent|Abortion, Habitual",Biological: Gamimune N or Gamunex 10%|Other: normal saline,University of Chicago|University of British Columbia|University of Tennessee|Sunnybrook Health Sciences Centre|Grifols Therapeutics LLC,University of Chicago,University of British Columbia,University of Tennessee|Sunnybrook Health Sciences Centre|Grifols Therapeutics LLC,University of Tennessee,Sunnybrook Health Sciences Centre|Grifols Therapeutics LLC,Sunnybrook Health Sciences Centre,Grifols Therapeutics LLC,Not Applicable,Other|Industry,Interventional,11/1/1999,1/10/2019,https://ClinicalTrials.gov/show/NCT00606905
5247,Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease,Completed,Has Results,Coronary Artery Disease,Drug: prasugrel|Drug: clopidogrel,"Eli Lilly and Company|Daiichi Sankyo Co., Ltd.",Eli Lilly and Company,"Daiichi Sankyo Co., Ltd.",,,,,,Phase 1,Industry,Interventional,3/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01107925
5248,Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN),Completed,Has Results,Type 2 Diabetic Peripheral Neuropathy (DPN),Other: Metanx (a medical food)|Other: Metanx placebo,"Pamlab, Inc.|Tulane University Health Sciences Center|VA Nebraska Western Iowa Health Care System|Scott and White Hospital & Clinic|Dallas Diabetes and Endocrine Center|University of Alabama at Birmingham|dgd Research, Inc.|Baylor Health Care System","Pamlab, Inc.",Tulane University Health Sciences Center,"VA Nebraska Western Iowa Health Care System|Scott and White Hospital & Clinic|Dallas Diabetes and Endocrine Center|University of Alabama at Birmingham|dgd Research, Inc.|Baylor Health Care System",VA Nebraska Western Iowa Health Care System,"Scott and White Hospital & Clinic|Dallas Diabetes and Endocrine Center|University of Alabama at Birmingham|dgd Research, Inc.|Baylor Health Care System",Scott and White Hospital & Clinic,"Dallas Diabetes and Endocrine Center|University of Alabama at Birmingham|dgd Research, Inc.|Baylor Health Care System",Phase 4,Industry|Other|U.S. Fed,Interventional,6/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00726713
5249,Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP),Completed,Has Results,Migraine With Aura|Patent Foramen Ovale,,"Swedish Medical Center|University of Washington|Coherex Medical|The John L. Locke, Jr. Charitable Trust|National Headache Foundation",Swedish Medical Center,University of Washington,"Coherex Medical|The John L. Locke, Jr. Charitable Trust|National Headache Foundation",Coherex Medical,"The John L. Locke, Jr. Charitable Trust|National Headache Foundation","The John L. Locke, Jr. Charitable Trust",National Headache Foundation,,Other|Industry,Observational,1/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01257880
5250,"Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies",Completed,Has Results,Scabies,"Drug: Permethrin Cream, 5%|Drug: Elimite™ Cream (permethrin) 5%",Encube Ethicals Pvt. Ltd.|Novum Pharmaceutical Research Services,Encube Ethicals Pvt. Ltd.,Novum Pharmaceutical Research Services,,,,,,Phase 3,Industry,Interventional,6/1/2017,11/11/2017,https://ClinicalTrials.gov/show/NCT03178942
5251,Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age,Completed,Has Results,Influenza|Healthy,Biological: FluMist trivalent (2015-2016)|Biological: FluMist Quadrivalent (2015-2016)|Biological: FluMist Quadrivalent (2017-2018),MedImmune LLC|AstraZeneca,MedImmune LLC,AstraZeneca,,,,,,Phase 4,Industry,Interventional,5/8/2017,9/29/2017,https://ClinicalTrials.gov/show/NCT03143101
5252,Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines,Completed,Has Results,Smoking|Smoking Cessation,Drug: Nicotine patch|Drug: Nicotine gum|Behavioral: CMAC,"University of Wisconsin, Madison|Wisconsin Department of Health and Family Services|Alere Wellbeing|Department of Health and Human Services|National Cancer Institute (NCI)","University of Wisconsin, Madison",Wisconsin Department of Health and Family Services,Alere Wellbeing|Department of Health and Human Services|National Cancer Institute (NCI),Alere Wellbeing,Department of Health and Human Services|National Cancer Institute (NCI),Department of Health and Human Services,National Cancer Institute (NCI),Phase 4,Other|Industry|U.S. Fed|NIH,Interventional,4/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01087905
5253,"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis",Completed,Has Results,"Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,3/21/2017,6/5/2018,https://ClinicalTrials.gov/show/NCT03054428
5254,A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee,Completed,Has Results,Osteo Arthritis Knee,Drug: V120083|Drug: Naproxen|Drug: Placebo,Purdue Pharma LP|Shionogi,Purdue Pharma LP,Shionogi,,,,,,Phase 2,Industry,Interventional,3/14/2017,11/21/2017,https://ClinicalTrials.gov/show/NCT03028870
5255,Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glucagon,"Xeris Pharmaceuticals|The Emmes Company, LLC",Xeris Pharmaceuticals,"The Emmes Company, LLC",,,,,,Phase 3,Industry,Interventional,3/27/2017,9/27/2017,https://ClinicalTrials.gov/show/NCT03091673
5256,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Completed,Has Results,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Drug: Dupilumab SAR231893 (REGN668)|Drug: Placebo|Drug: Mometasone furoate 50 micrograms,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,12/5/2016,7/5/2018,https://ClinicalTrials.gov/show/NCT02912468
5257,Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb),Completed,Has Results,Chronic Obstructive Pulmonary Disease - COPD,Drug: Formoterol fumarate (6 μg)|Drug: Formoterol furmarate (20 μg)|Drug: Placebo for formoterol fumarate|Drug: Formoterol fumarate (12 μg)|Drug: Formoterol fumarate (40 μg),AstraZeneca|Parexel,AstraZeneca,Parexel,,,,,,Phase 2,Industry,Interventional,6/30/2016,12/7/2016,https://ClinicalTrials.gov/show/NCT02796651
5258,Adherence Study in COPD Patients,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD,Device: Arm 1: BreatheMate device with application|Device: Arm 2: BreatheMate device without application,"AstraZeneca|Quintiles, Inc.",AstraZeneca,"Quintiles, Inc.",,,,,,Phase 4,Industry,Interventional,8/12/2016,10/31/2017,https://ClinicalTrials.gov/show/NCT02864342
5259,Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Biological: Adalimumab - GP2017|Biological: Adalimumab - US licensed Humira,Sandoz|Hexal AG,Sandoz,Hexal AG,,,,,,Phase 3,Industry,Interventional,3/31/2016,9/26/2017,https://ClinicalTrials.gov/show/NCT02744755
5260,Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Drug: GSK3196165|Drug: Placebo|Drug: MTX|Drug: Folic (or folinic) acid,GlaxoSmithKline|Parexel,GlaxoSmithKline,Parexel,,,,,,Phase 2,Industry,Interventional,6/15/2016,10/30/2017,https://ClinicalTrials.gov/show/NCT02799472
5261,Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: REGN910-3|Drug: Intravitreal Aflibercept Injection (IAI),Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 2,Industry,Interventional,3/2/2016,7/10/2017,https://ClinicalTrials.gov/show/NCT02712008
5262,A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial,Completed,Has Results,Primary Open Angle Glaucoma (POAG),Device: CyPass Micro-Stent|Procedure: Cataract Surgery,"Alcon Research|Transcend Medical, Inc.",Alcon Research,"Transcend Medical, Inc.",,,,,,Not Applicable,Industry,Interventional,3/30/2016,4/18/2018,https://ClinicalTrials.gov/show/NCT02700984
5263,Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia),Completed,Has Results,Dyslipidemia,Drug: Alirocumab|Drug: Statins|Drug: Ezetimibe|Drug: Fenofibrate|Drug: Nicotinic acid|Drug: Omega-3 fatty acids|Drug: Antihyperglycemic Drug,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 4,Industry,Interventional,3/15/2016,5/15/2017,https://ClinicalTrials.gov/show/NCT02642159
5264,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Completed,Has Results,Migraine With or Without Aura,Drug: Lasmiditan 50 mg|Drug: Lasmiditan 100 mg|Drug: Lasmiditan 200 mg|Drug: Placebo,Eli Lilly and Company|CoLucid Pharmaceuticals,Eli Lilly and Company,CoLucid Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,5/16/2019,6/30/2017,https://ClinicalTrials.gov/show/NCT02605174
5265,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Completed,Has Results,Hereditary Angioedema (HAE),Drug: DX-2930 - 300mg/2wk|Drug: DX-2930 - 300mg/4wk|Drug: DX-2930 - 150mg/4wk|Drug: Placebo,Shire|Dyax Corp.,Shire,Dyax Corp.,,,,,,Phase 3,Industry,Interventional,3/3/2016,4/13/2017,https://ClinicalTrials.gov/show/NCT02586805
5266,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo|Drug: Lipid-Modifying Therapy (LMT)|Drug: Antihyperglycemic Drug,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,10/23/2015,4/3/2017,https://ClinicalTrials.gov/show/NCT02585778
5267,A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department,Completed,Has Results,Pulmonary Embolism,Drug: Rivaroxaban|Drug: Standard-of-care,"Janssen Scientific Affairs, LLC|Bayer","Janssen Scientific Affairs, LLC",Bayer,,,,,,Phase 4,Industry,Interventional,10/15/2015,3/22/2017,https://ClinicalTrials.gov/show/NCT02584660
5268,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,12/22/2015,9/20/2017,https://ClinicalTrials.gov/show/NCT02580591
5269,A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting,Completed,Has Results,Bladder Cancer,Drug: Hexaminolevulinate hydrochloride|Device: KARL STORZ D-Light C PDD Flexible Videoscope System,"Photocure|KARL STORZ Endoscopy-America, Inc.",Photocure,"KARL STORZ Endoscopy-America, Inc.",,,,,,Phase 3,Industry,Interventional,10/1/2015,4/5/2017,https://ClinicalTrials.gov/show/NCT02560584
5270,A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC),Completed,Has Results,Functional Constipation in Children Ages 6-17 Years,Drug: Placebo|Drug: LIN Dose A|Drug: LIN Dose B|Drug: LIN Dose C|Drug: LIN 145 µg,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Forest Laboratories,"Ironwood Pharmaceuticals, Inc.",,,,,,Phase 2,Industry,Interventional,11/3/2015,5/29/2018,https://ClinicalTrials.gov/show/NCT02559570
5271,Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg,Completed,Has Results,Prostatic Neoplasms,Drug: LMIS 50 mg,"Foresee Pharmaceuticals Co., Ltd.|QPS-Qualitix","Foresee Pharmaceuticals Co., Ltd.",QPS-Qualitix,,,,,,Phase 3,Industry,Interventional,2/16/2019,12/19/2017,https://ClinicalTrials.gov/show/NCT02712320
5272,Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Device: Bolus Insulin Patch (Calibra Finesse)|Device: Insulin Pen (Novo-Nordisk FlexPen®),"Calibra Medical, Inc.|Medpace, Inc.","Calibra Medical, Inc.","Medpace, Inc.",,,,,,Not Applicable,Industry,Interventional,8/1/2015,8/31/2017,https://ClinicalTrials.gov/show/NCT02542631
5273,"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®",Completed,Has Results,Rheumatoid Arthritis,Biological: GP2013 - A Proposed biosimilar rituximab|Biological: Originator rituximab - Rituxan ® or MabThera ®,Sandoz|Hexal AG,Sandoz,Hexal AG,,,,,,Phase 3,Industry,Interventional,7/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02514772
5274,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,Chronic Kidney Disease (CKD),Biological: Epoetin Hospira Arm|Other: Standard of Care Arm|Drug: IV Iron,"Pfizer|Hospira, now a wholly owned subsidiary of Pfizer",Pfizer,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 3,Industry,Interventional,7/13/2015,7/16/2016,https://ClinicalTrials.gov/show/NCT02504294
5275,Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Type 2,Drug: ORMD-0801|Drug: Placebo Comparator,"Oramed, Ltd.|Integrium","Oramed, Ltd.",Integrium,,,,,,Phase 2,Industry,Interventional,6/15/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02496000
5276,DD T2 Daily Disposable Registration Trial,Completed,Has Results,Myopia|Refractive Errors,Device: verofilcon A contact lenses|Device: delefilcon A contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,10/12/2017,2/21/2018,https://ClinicalTrials.gov/show/NCT03305770
5277,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Completed,Has Results,Asthma,Drug: Dupilumab|Drug: Placebo|Drug: Oral corticosteroid therapy (prednisone/prednisolone)|Drug: Inhaled corticosteroid (ICS) therapy|Drug: Albuterol/Salbutamol|Drug: Levalbuterol/Levosalbutamol,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,10/15/2015,11/13/2017,https://ClinicalTrials.gov/show/NCT02528214
5278,Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Biological: MEDI9929|Biological: Placebo,MedImmune LLC|Amgen,MedImmune LLC,Amgen,,,,,,Phase 2,Industry,Interventional,8/15/2015,7/15/2016,https://ClinicalTrials.gov/show/NCT02525094
5279,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Other: Placebo for dapagliflozin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,7/8/2015,4/18/2018,https://ClinicalTrials.gov/show/NCT02460978
5280,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Completed,Has Results,Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|PPD|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",PPD,Teva Pharmaceutical Industries,,,,,Phase 3,Industry,Interventional,9/28/2015,1/31/2018,https://ClinicalTrials.gov/show/NCT02452190
5281,Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: placebo|Drug: risankizumab,AbbVie|Boehringer Ingelheim,AbbVie,Boehringer Ingelheim,,,,,,Phase 2,Industry,Interventional,6/23/2015,2/2/2018,https://ClinicalTrials.gov/show/NCT02443298
5282,"Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.",Completed,Has Results,Asthma,Drug: Indacaterol maleate|Drug: Indacaterol acetate|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,9/5/2017,1/18/2018,https://ClinicalTrials.gov/show/NCT03257995
5283,"Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale",Completed,Has Results,Severe Hemophilia A,Biological: rFVIIIFc,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Bioverativ Therapeutics Inc.,Swedish Orphan Biovitrum,,,,,,Phase 3,Industry,Interventional,8/15/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02502149
5284,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,6/30/2015,10/23/2017,https://ClinicalTrials.gov/show/NCT02414958
5285,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Completed,Has Results,Asthma,Drug: Dupilumab|Drug: Placebo|Drug: Inhaled corticosteroid (ICS) therapy|Drug: Albuterol/Salbutamol|Drug: Levalbuterol/Levosalbutamol,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,4/27/2015,11/23/2017,https://ClinicalTrials.gov/show/NCT02414854
5286,A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Sarecycline,"Almirall, S.A.|Allergan","Almirall, S.A.",Allergan,,,,,,Phase 3,Industry,Interventional,3/20/2015,8/26/2016,https://ClinicalTrials.gov/show/NCT02413346
5287,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),Completed,Has Results,Central Abdominal Bulging,Drug: LIPO-202|Drug: Placebo,"Evofem Inc.|Neothetics, Inc",Evofem Inc.,"Neothetics, Inc",,,,,,Phase 3,Industry,Interventional,4/9/2015,10/29/2015,https://ClinicalTrials.gov/show/NCT02398188
5288,Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants,Completed,Has Results,"Pain, Postoperative",Drug: fentanyl,"The Medicines Company|Incline Therapeutics, Inc.",The Medicines Company,"Incline Therapeutics, Inc.",,,,,,Phase 3,Industry,Interventional,6/29/2015,9/12/2016,https://ClinicalTrials.gov/show/NCT02395653
5289,ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa,Completed,Has Results,Epidermolysis Bullosa,Drug: SD-101-6.0 cream|Drug: Placebo (SD-101-0.0) cream,"Scioderm, Inc.|Amicus Therapeutics","Scioderm, Inc.",Amicus Therapeutics,,,,,,Phase 3,Industry,Interventional,3/11/2015,7/5/2017,https://ClinicalTrials.gov/show/NCT02384460
5290,The Asahi Intecc PTCA Chronic Total Occlusion Study,Completed,Has Results,Coronary Artery Disease|Coronary Artery Chronic Total Occlusion,Device: Crossing of Coronary Artery CTO,"Asahi Intecc USA Inc|Medpace, Inc.",Asahi Intecc USA Inc,"Medpace, Inc.",,,,,,Not Applicable,Industry,Interventional,6/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02379923
5291,PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD,Completed,Has Results,ADHD,Drug: PRC-063 oral capsules|Drug: Placebo oral capsules,"Purdue Pharma, Canada","Purdue Pharma, Canada",,,,,,,Phase 3,Industry,Interventional,5/1/2017,12/19/2017,https://ClinicalTrials.gov/show/NCT03172481
5292,Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,Completed,Has Results,Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated,Drug: ZTI-01|Drug: Piperacillin-tazobactam,"Nabriva Therapeutics AG|Medpace, Inc.",Nabriva Therapeutics AG,"Medpace, Inc.",,,,,,Phase 2|Phase 3,Industry,Interventional,4/16/2019,5/30/2017,https://ClinicalTrials.gov/show/NCT02753946
5293,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Completed,Has Results,Acne Vulgaris,Drug: Sarecycline|Drug: Placebo,"Almirall, S.A.|Allergan","Almirall, S.A.",Allergan,,,,,,Phase 3,Industry,Interventional,12/3/2014,1/12/2017,https://ClinicalTrials.gov/show/NCT02322866
5294,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Completed,Has Results,Acne Vulgaris,Drug: Sarecycline|Drug: Placebo,"Almirall, S.A.|Allergan","Almirall, S.A.",Allergan,,,,,,Phase 3,Industry,Interventional,12/18/2014,2/1/2017,https://ClinicalTrials.gov/show/NCT02320149
5295,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Completed,Has Results,Bronchoscopy,Drug: Remimazolam|Drug: Placebo|Drug: Midazolam,Paion UK Ltd.|Premier Research Group plc,Paion UK Ltd.,Premier Research Group plc,,,,,,Phase 3,Industry,Interventional,4/15/2019,3/13/2017,https://ClinicalTrials.gov/show/NCT02296892
5296,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2963016|Drug: LANTUS®|Drug: Oral Antihyperglycemic Medication,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 3,Industry,Interventional,12/14/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02302716
5297,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Completed,Has Results,Chronic Idiopathic Constipation,Drug: Linaclotide|Drug: Matching Placebo,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories","Ironwood Pharmaceuticals, Inc.",Forest Laboratories,,,,,,Phase 3,Industry,Interventional,10/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02291679
5298,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Completed,Has Results,Colonoscopy,Drug: Remimazolam|Drug: Midazolam|Drug: Placebo,Paion UK Ltd.|Premier Research Group plc,Paion UK Ltd.,Premier Research Group plc,,,,,,Phase 3,Industry,Interventional,3/30/2015,4/19/2016,https://ClinicalTrials.gov/show/NCT02290873
5299,"Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",Completed,Has Results,Pancreatic Cancer,Drug: Demcizumab|Drug: Abraxane®|Drug: gemcitabine|Drug: Placebo,"OncoMed Pharmaceuticals, Inc.|Celgene Corporation","OncoMed Pharmaceuticals, Inc.",Celgene Corporation,,,,,,Phase 2,Industry,Interventional,4/20/2015,9/17/2019,https://ClinicalTrials.gov/show/NCT02289898
5300,Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo (for Dupilumab),Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,11/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02277769
5301,Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo (for Dupilumab),Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,10/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02277743
5302,MSB11022 in Moderate to Severe Chronic Plaque Psoriasis,Completed,Has Results,Psoriasis|Plaque Type Psoriasis|Moderate to Severe Plaque Psoriasis,Drug: MSB11022|Drug: Humira®,"Fresenius Kabi SwissBioSim GmbH|Merck KGaA, Darmstadt, Germany",Fresenius Kabi SwissBioSim GmbH,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 3,Industry,Interventional,2/16/2016,12/18/2017,https://ClinicalTrials.gov/show/NCT02660580
5303,"Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain",Completed,Has Results,Opioid-Induced Constipation,Drug: Linaclotide 145 micrograms|Drug: Linaclotide 290 micrograms|Drug: Placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Forest Laboratories,"Ironwood Pharmaceuticals, Inc.",,,,,,Phase 2,Industry,Interventional,10/31/2014,10/31/2015,https://ClinicalTrials.gov/show/NCT02270983
5304,"Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles",Completed,Has Results,Contraception,Drug: LF111 (drospirenone),"Laboratories Leon Farma, S.A.|Chemo France|Insud Pharma","Laboratories Leon Farma, S.A.",Chemo France,Insud Pharma,,,,,Phase 3,Industry,Interventional,10/9/2014,10/4/2017,https://ClinicalTrials.gov/show/NCT02269241
5305,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo for dapagliflozin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,11/11/2014,8/25/2017,https://ClinicalTrials.gov/show/NCT02268214
5306,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS),Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,9/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02260986
5307,"A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",Completed,Has Results,Nonsquamous Nonsmall Cell Neoplasm of Lung,Drug: Pemetrexed|Drug: Carboplatin|Drug: demcizumab,"OncoMed Pharmaceuticals, Inc.|Celgene Corporation","OncoMed Pharmaceuticals, Inc.",Celgene Corporation,,,,,,Phase 2,Industry,Interventional,2/15/2019,4/7/2017,https://ClinicalTrials.gov/show/NCT02259582
5308,Linagliptin as Add on to Basal Insulin in the Elderly,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: placebo|Drug: linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 4,Industry,Interventional,9/23/2014,4/25/2017,https://ClinicalTrials.gov/show/NCT02240680
5309,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Albiglutide|Drug: Insulin Glargine and Insulin Lispro,GlaxoSmithKline|PPD,GlaxoSmithKline,PPD,,,,,,Phase 3,Industry,Interventional,11/21/2014,7/24/2017,https://ClinicalTrials.gov/show/NCT02229227
5310,Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive,Completed,Has Results,Visual Acuity,Device: senofilcon A with new UV blocker|Device: senofilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/1/2016,2/18/2017,https://ClinicalTrials.gov/show/NCT02982018
5311,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Completed,Has Results,Clostridium Difficile-associated Diarrhea (CDAD),Drug: Fidaxomicin oral suspension|Drug: Fidaxomicin tablets|Drug: Vancomycin oral liquid|Drug: Vancomycin capsules,Astellas Pharma Europe B.V.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc,Astellas Pharma Europe B.V.,Merck Sharp & Dohme Corp.,Astellas Pharma Inc,,,,,Phase 3,Industry,Interventional,1/9/2015,3/7/2018,https://ClinicalTrials.gov/show/NCT02218372
5312,Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress,Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: Placebo + ADT|Drug: Brexpiprazole +ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","Otsuka Pharmaceutical Development & Commercialization, Inc.",H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,7/14/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02196506
5313,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Completed,Has Results,Atrophic Vaginitis,"Drug: Estradiol Vaginal Cream, 0.01%|Drug: Estrace® 0.01% cream|Drug: Placebo Vaginal Cream",Mylan Inc.|Mylan Pharmaceuticals,Mylan Inc.,Mylan Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,6/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02195986
5314,Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma,Completed,Has Results,Asthma,Drug: Placebo|Drug: Dupilumab SAR231893/REGN668|Drug: fluticasone propionate and salmeterol|Drug: budesonide and formoterol|Drug: mometasone furoate and formoterol,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,1/27/2016,1/3/2018,https://ClinicalTrials.gov/show/NCT02573233
5315,A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL),Completed,Has Results,Follicular Lymphoma,Drug: Venetoclax|Drug: Bendamustine|Drug: Rituximab,Hoffmann-La Roche|AbbVie,Hoffmann-La Roche,AbbVie,,,,,,Phase 2,Industry,Interventional,12/1/2014,3/16/2018,https://ClinicalTrials.gov/show/NCT02187861
5316,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: Empagliflozin low dose|Drug: placebo|Drug: Empagliflozin high dose,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,7/25/2014,5/18/2017,https://ClinicalTrials.gov/show/NCT02182830
5317,A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure,Completed,Has Results,Heart Failure|Decompensated Heart Failure|Acute Heart Failure,Drug: CXL-1427|Drug: Placebo,"Bristol-Myers Squibb|Cardioxyl Pharmaceuticals, Inc",Bristol-Myers Squibb,"Cardioxyl Pharmaceuticals, Inc",,,,,,Phase 2,Industry,Interventional,6/30/2014,7/31/2015,https://ClinicalTrials.gov/show/NCT02157506
5318,A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),Completed,Has Results,Advanced Solid Tumors,Drug: PF-05082566|Drug: MK-3475,Pfizer|Merck Sharp & Dohme Corp.,Pfizer,Merck Sharp & Dohme Corp.,,,,,,Phase 1,Industry,Interventional,8/14/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02179918
5319,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Completed,Has Results,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug: Benralizumab Arm A|Drug: Benralizumab Arm B|Drug: Benralizumab Arm C|Drug: Placebo,AstraZeneca|MedImmune LLC,AstraZeneca,MedImmune LLC,,,,,,Phase 3,Industry,Interventional,6/25/2014,4/9/2018,https://ClinicalTrials.gov/show/NCT02155660
5320,Phase II HDM-SPIRE Safety and Efficacy Study,Completed,Has Results,Rhinoconjunctivitis,Drug: HDM-SPIRE|Drug: Placebo,"Circassia Limited|Quintiles, Inc.",Circassia Limited,"Quintiles, Inc.",,,,,,Phase 2,Industry,Interventional,9/14/2019,4/13/2017,https://ClinicalTrials.gov/show/NCT02150343
5321,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,Completed,Has Results,ADHD,Drug: Placebo|Drug: PRC-063 25 mg|Drug: PRC-063 45 mg|Drug: PRC-063 70 mg|Drug: PRC-063 100 mg,"Rhodes Pharmaceuticals, L.P.|Purdue Pharma, Canada","Rhodes Pharmaceuticals, L.P.","Purdue Pharma, Canada",,,,,,Phase 3,Industry,Interventional,4/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02139124
5322,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Completed,Has Results,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug: Benralizumab Arm A|Drug: Benralizumab Arm B|Drug: Placebo,AstraZeneca|MedImmune LLC,AstraZeneca,MedImmune LLC,,,,,,Phase 3,Industry,Interventional,6/13/2014,4/10/2018,https://ClinicalTrials.gov/show/NCT02138916
5323,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO),Completed,Has Results,Plaque Psoriasis,Drug: Etanercept|Drug: CHS-0214,"Coherus Biosciences, Inc.|Shire","Coherus Biosciences, Inc.",Shire,,,,,,Phase 3,Industry,Interventional,6/16/2014,5/12/2016,https://ClinicalTrials.gov/show/NCT02134210
5324,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,Completed,Has Results,Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory,Drug: Ibrutinib|Drug: DA-EPOCH-R|Drug: Lenalidomide,Pharmacyclics LLC.|Celgene Corporation,Pharmacyclics LLC.,Celgene Corporation,,,,,,Phase 1|Phase 2,Industry,Interventional,5/14/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02142049
5325,To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: sarilumab SAR153191 (REGN88),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,6/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02121210
5326,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: Etanercept|Drug: CHS-0214,"Coherus Biosciences, Inc.|Daiichi Sankyo Co., Ltd.","Coherus Biosciences, Inc.","Daiichi Sankyo Co., Ltd.",,,,,,Phase 3,Industry,Interventional,5/14/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02115750
5327,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Completed,Has Results,Bronchiectasis,Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation|Drug: Placebo,Bayer|Novartis,Bayer,Novartis,,,,,,Phase 3,Industry,Interventional,4/30/2014,10/19/2016,https://ClinicalTrials.gov/show/NCT02106832
5328,"Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)",Completed,Has Results,Atrial Fibrillation,Drug: Apixaban|Drug: Parenteral heparin and/or oral Vitamin K antagonist,Pfizer|Bristol-Myers Squibb,Pfizer,Bristol-Myers Squibb,,,,,,Phase 4,Industry,Interventional,7/14/2014,2/8/2017,https://ClinicalTrials.gov/show/NCT02100228
5329,A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies,Completed,Has Results,Rheumatoid Arthritis,Drug: methotrexate|Drug: rituximab [MabThera/Rituxan],Hoffmann-La Roche|Biogen,Hoffmann-La Roche,Biogen,,,,,,Phase 3,Industry,Interventional,6/4/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT02097745
5330,Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: Rituximab|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Folic Acid,"Hoffmann-La Roche|Genentech, Inc.",Hoffmann-La Roche,"Genentech, Inc.",,,,,,Phase 2,Industry,Interventional,8/2/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT02093026
5331,"Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents",Completed,Has Results,Meningococcal Disease,Biological: MenABCWY|Other: Placebo|Biological: MenACWY,Novartis Vaccines|GlaxoSmithKline|Novartis,Novartis Vaccines,GlaxoSmithKline,Novartis,,,,,Phase 2,Industry,Interventional,5/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02140762
5332,"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: 744 Tablet|Drug: 744 LA Injection|Drug: Placebo Tablet|Drug: Placebo Injection,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,3/27/2014,2/23/2016,https://ClinicalTrials.gov/show/NCT02076178
5333,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Completed,Has Results,Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism,Drug: BAY 59-7939|Drug: ASA,"Bayer|Janssen Scientific Affairs, LLC",Bayer,"Janssen Scientific Affairs, LLC",,,,,,Phase 3,Industry,Interventional,3/5/2014,11/4/2016,https://ClinicalTrials.gov/show/NCT02064439
5334,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,Completed,Has Results,RA,Drug: Sarilumab|Device: Auto-Injector Device (AID)|Device: Pre-filled Syringe (PFS)|Drug: Methotrexate|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Hydroxychloroquine,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,3/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02057250
5335,"Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma",Completed,Has Results,Asthma,Drug: Placebo|Drug: MEDI9929 70 mg|Drug: MEDI9929 210 mg|Drug: MEDI9929 280 mg,MedImmune LLC|Amgen,MedImmune LLC,Amgen,,,,,,Phase 2,Industry,Interventional,12/13/2013,3/1/2017,https://ClinicalTrials.gov/show/NCT02054130
5336,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Completed,Has Results,Rubella|Mumps|Measles,"Biological: Priorix®|Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine",GlaxoSmithKline|Parexel,GlaxoSmithKline,Parexel,,,,,,Phase 3,Industry,Interventional,7/1/2014,9/17/2015,https://ClinicalTrials.gov/show/NCT02058563
5337,BioMonitor 2 In-Office Setting Insertion Safety and Feasibility Evaluation With Device Functionality Assessment,Completed,Has Results,Insertable Cardiac Monitor,Device: BioMonitor 2 Insertable Cardiac Monitor,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,,Industry,Observational,6/16/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT02756338
5338,CI532 - Early Experience Study,Completed,Has Results,"Sensorineural Hearing Loss, Bilateral",Device: Cochlear Nucleus CI532,Cochlear,Cochlear,,,,,,,Not Applicable,Industry,Interventional,5/16/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT02755935
5339,Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old,Completed,Has Results,Influenza,Biological: Trivalent influenza vaccine (TIVc)|Biological: Trivalent influenza vaccine-licensed,Seqirus|Novartis Vaccines,Seqirus,Novartis Vaccines,,,,,,Phase 1|Phase 2,Industry,Interventional,12/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02035696
5340,AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma,Completed,Has Results,"Glaucoma|Glaucoma, Open Angle",Device: AqueSys XEN 45 Glaucoma Implant,"AqueSys, Inc.|Allergan","AqueSys, Inc.",Allergan,,,,,,Not Applicable,Industry,Interventional,1/13/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02036541
5341,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Biological: adalimumab 40 mg|Biological: sirukumab 100 mg|Biological: sirukumab 50 mg|Drug: Placebo,"Janssen Research & Development, LLC|GlaxoSmithKline","Janssen Research & Development, LLC",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,4/4/2014,8/17/2016,https://ClinicalTrials.gov/show/NCT02019472
5342,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira,Completed,Has Results,Plaque Type Psoriasis,Drug: GP2017 Adalimumab|Drug: Humira ® Adalimumab,Sandoz|Hexal AG,Sandoz,Hexal AG,,,,,,Phase 3,Industry,Interventional,12/13/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02016105
5343,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,11/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02013622
5344,"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment",Completed,Has Results,MDD,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,11/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02013609
5345,Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms,Completed,Has Results,Major Depressive Disorder|Anxiety,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,11/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02013531
5346,Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy,Completed,Has Results,Major Depressive Disorder (MDD),Drug: ADT|Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,11/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02012218
5347,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,3/14/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02006654
5348,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,2/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02006641
5349,Open-label Study of Safety and Tolerability of Memantine in Children With Autism,Completed,Has Results,Autism|Pediatric Autism,Drug: Memantine HCl,Forest Laboratories|Merz Pharmaceuticals GmbH,Forest Laboratories,Merz Pharmaceuticals GmbH,,,,,,Phase 2,Industry,Interventional,11/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01999894
5350,Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma,Completed,Has Results,Marginal Zone Lymphoma|B-cell Lymphoma,Drug: ibrutinib,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Pharmacyclics LLC.,"Janssen Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,12/13/2019,10/2/2017,https://ClinicalTrials.gov/show/NCT01980628
5351,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for Alirocumab)|Drug: Non-statin LMT|Other: Diet Alone,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,12/16/2013,6/30/2017,https://ClinicalTrials.gov/show/NCT02023879
5352,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,10/13/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01955161
5353,Open Label Study of Long Term Safety Evaluation of Alirocumab,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,12/17/2013,6/30/2017,https://ClinicalTrials.gov/show/NCT01954394
5354,BAX 855 Continuation,Completed,Has Results,Hemophilia A,Biological: BAX855,"Baxalta now part of Shire|Baxalta Innovations GmbH, now part of Shire|Shire",Baxalta now part of Shire,"Baxalta Innovations GmbH, now part of Shire",Shire,,,,,Phase 3,Industry,Interventional,10/15/2013,3/2/2018,https://ClinicalTrials.gov/show/NCT01945593
5355,Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: Pimasertib once daily|Drug: Pimasertib placebo|Drug: SAR245409 placebo|Drug: SAR245409|Drug: Pimasertib twice daily,EMD Serono|Sanofi,EMD Serono,Sanofi,,,,,,Phase 2,Industry,Interventional,9/30/2013,11/30/2017,https://ClinicalTrials.gov/show/NCT01936363
5356,Gel-One Treatment in Knee Osteoarthritis,Completed,Has Results,Osteoarthritis Knee,Device: Gel-One|Device: PBS,Seikagaku Corporation|Zimmer Biomet,Seikagaku Corporation,Zimmer Biomet,,,,,,Not Applicable,Industry,Interventional,8/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01934218
5357,Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores,Completed,Has Results,Recurrent Herpes Labialis,Drug: ethanol/glycolic acid solution|Drug: Placebo/Ethanol,"Topical Remedy|Benu BioPharma, LLC",Topical Remedy,"Benu BioPharma, LLC",,,,,,Phase 2,Industry,Interventional,11/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01985321
5358,Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses,Completed,Has Results,Visual Disorders,Device: senofilcon C|Device: comfilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/1/2015,2/1/2016,https://ClinicalTrials.gov/show/NCT02625233
5359,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Statin,Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,9/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01926782
5360,Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Completed,Has Results,Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Drug: Icatibant|Drug: Placebo,Shire|PPD,Shire,PPD,,,,,,Phase 3,Industry,Interventional,12/2/2013,8/22/2015,https://ClinicalTrials.gov/show/NCT01919801
5361,Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women,Completed,Has Results,GBS Disease,Biological: GBS trivalent vaccine|Biological: Placebo,GlaxoSmithKline|Novartis Vaccines,GlaxoSmithKline,Novartis Vaccines,,,,,,Phase 2,Industry,Interventional,3/1/2014,3/26/2016,https://ClinicalTrials.gov/show/NCT02046148
5362,Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia,Completed,Has Results,Schizophrenia|Mental Disorder|Nervous System Diseases,"Drug: Aripiprazole, OPC-14597","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","Otsuka Pharmaceutical Development & Commercialization, Inc.",H. Lundbeck A/S,,,,,,Phase 1,Industry,Interventional,7/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01909466
5363,Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application,Completed,Has Results,Pneumonia,Device: LRT55 Testing,Curetis GmbH|Global BioClinical,Curetis GmbH,Global BioClinical,,,,,,,Industry,Observational,6/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT01922024
5364,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 4,Industry,Interventional,7/10/2013,1/18/2018,https://ClinicalTrials.gov/show/NCT01897532
5365,Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections,Completed,Has Results,Systemic Infections,Drug: CAZ-AVI,Pfizer|Forest Laboratories,Pfizer,Forest Laboratories,,,,,,Phase 1,Industry,Interventional,7/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01893346
5366,"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",Completed,Has Results,Irritable Bowel Syndrome With Constipation (IBS-C),Drug: Placebo|Drug: Linaclotide,"AstraZeneca|Ironwood Pharmaceuticals, Inc.",AstraZeneca,"Ironwood Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,7/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01880424
5367,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Completed,Has Results,Heart Failure|Coronary Artery Disease,Drug: Rivaroxaban|Drug: Placebo|Other: Standard of care for heart failure and coronary artery disease,"Janssen Research & Development, LLC|Bayer","Janssen Research & Development, LLC",Bayer,,,,,,Phase 3,Industry,Interventional,9/10/2013,4/19/2018,https://ClinicalTrials.gov/show/NCT01877915
5368,"Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear",Completed,Has Results,Myopia,Device: fanfilcon A (test)|Device: enfilcon A (control),"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02555722
5369,Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC),Completed,Has Results,Tuberous Sclerosis Complex,Drug: RAD001|Drug: Placebo,Mustafa Sahin|Tuberous Sclerosis Alliance|Autism Speaks|Novartis Pharmaceuticals|Seizure Tracker LLC|Boston Children’s Hospital,Mustafa Sahin,Tuberous Sclerosis Alliance,Autism Speaks|Novartis Pharmaceuticals|Seizure Tracker LLC|Boston Children’s Hospital,Autism Speaks,Novartis Pharmaceuticals|Seizure Tracker LLC|Boston Children’s Hospital,Novartis Pharmaceuticals,Seizure Tracker LLC|Boston Children’s Hospital,Phase 2,Other|Industry,Interventional,1/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01289912
5370,Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Dupilumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 2,Industry,Interventional,5/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01859988
5371,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,Completed,Has Results,"Arthritis, Rheumatoid",Drug: Sirukumab 100 mg|Drug: Sirukumab 50 mg|Drug: Placebo,"Janssen Research & Development, LLC|GlaxoSmithKline","Janssen Research & Development, LLC",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,8/7/2013,4/30/2018,https://ClinicalTrials.gov/show/NCT01856309
5372,An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma,Completed,Has Results,Asthma,Drug: Dupilumab|Drug: placebo|Drug: ICS/LABA therapy|Drug: Salbutamol/albuterol|Drug: Levosalbutamol/levalbuterol,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,6/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01854047
5373,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Completed,Has Results,Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Drug: Trabectedin|Drug: DOXIL|Drug: Dexamethasone,"Janssen Research & Development, LLC|PharmaMar","Janssen Research & Development, LLC",PharmaMar,,,,,,Phase 3,Industry,Interventional,10/16/2013,11/16/2018,https://ClinicalTrials.gov/show/NCT01846611
5374,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Completed,Has Results,Atrial Fibrillation|Percutaneous Coronary Intervention,Drug: rivaroxaban 2.5 mg|Drug: rivaroxaban 15 mg|Drug: rivaroxaban 10 mg|Drug: aspirin (ASA)|Drug: vitamin K antagonist (VKA)|Drug: clopidogrel|Drug: prasugrel|Drug: ticagrelor,"Janssen Scientific Affairs, LLC|Bayer","Janssen Scientific Affairs, LLC",Bayer,,,,,,Phase 3,Industry,Interventional,5/10/2013,7/28/2016,https://ClinicalTrials.gov/show/NCT01830543
5375,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Completed,Has Results,Scabies,"Drug: spinosad topical suspension, 0.9%|Other: Placebo",ParaPRO LLC|Concentrics Research,ParaPRO LLC,Concentrics Research,,,,,,Phase 3,Industry|Other,Interventional,5/2/2017,6/25/2018,https://ClinicalTrials.gov/show/NCT02485717
5376,Brexpiprazole in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Brexpiprazole,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,7/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01810783
5377,Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure,Completed,Has Results,Colorectal Cancer Screening,Device: PillCam® COLON 2 procedure-CONTROL|Drug: Senna tablets|Drug: PEG|Drug: Metoclopramide|Drug: Erythromycin|Drug: SUPREP oral sulfate solution|Drug: Bisacodyl|Drug: SUPREP oral sulfate solution with Gastrografin,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,5/15/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02481219
5378,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,Completed,Has Results,"Pneumonia, Bacterial",Drug: Amikacin Inhalation Solution (BAY41-6551)|Drug: Aerosolized Placebo,Bayer|Nektar Therapeutics,Bayer,Nektar Therapeutics,,,,,,Phase 3,Industry,Interventional,4/13/2013,4/7/2017,https://ClinicalTrials.gov/show/NCT01799993
5379,VenaSeal Sapheon Closure System Pivotal Study (VeClose),Completed,Has Results,Great Saphenous Vein (GSV) With Venous Reflux Disease,Device: VenaSeal SCS|Device: ClosureFast Radiofrequency Ablation (RFA)|Device: Roll-in (VenaSeal SCS),"Medtronic Endovascular|Sapheon, Inc.",Medtronic Endovascular,"Sapheon, Inc.",,,,,,Not Applicable,Industry,Interventional,3/13/2019,4/10/2017,https://ClinicalTrials.gov/show/NCT01807585
5380,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin 5mg,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,2/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01792518
5381,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Completed,Has Results,Major Depressive Disorder,Drug: Placebo|Drug: Brexpiprazole|Drug: ADT,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",H. Lundbeck A/S,"Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,6/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01838681
5382,Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD,Completed,Has Results,COPD,Device: GFF MDI (PT003) with Aerochamber|Device: GFF MDI (PT003) without Aerochamber,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,5/1/2015,3/25/2016,https://ClinicalTrials.gov/show/NCT02454959
5383,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: BI 10773 Placebo|Drug: BI 10773 / BI 1356|Drug: BI 10773 / BI 1356 Placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,1/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01778049
5384,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Completed,Has Results,Rheumatoid Arthritis,Drug: sarilumab SAR153191 (REGN88)|Drug: tocilizumab|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide|Drug: subcutaneous placebo|Drug: intravenous placebo,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,3/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01768572
5385,A Comparison of Two Daily Disposable Soft Contact Lenses,Completed,Has Results,Visual Acuity,Device: senofilcon A|Device: delefilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/15/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02427477
5386,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Completed,Has Results,Bronchiectasis,Drug: Ciprofloxacin DPI (BAYQ3939)|Drug: Placebo,Bayer|Novartis,Bayer,Novartis,,,,,,Phase 3,Industry,Interventional,5/2/2013,3/9/2016,https://ClinicalTrials.gov/show/NCT01764841
5387,"A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: PF-06412562 3mg BID|Drug: PF-06412562 9mg BID|Drug: PF-06412562 45mg BID|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02418819
5388,"Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder",Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: SPD489,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,4/15/2015,6/30/2016,https://ClinicalTrials.gov/show/NCT02402166
5389,A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion,Completed,Has Results,Chronic Lymphocytic Leukemia With 17p Deletion|Small Lymphocytic Lymphoma With 17p Deletion,Drug: Ibrutinib,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Pharmacyclics LLC.,"Janssen Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,1/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01744691
5390,Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs),Completed,Has Results,Venous Leg Ulcer|Chronic Venous Insufficiency|Venous Stasis Ulcer|Venous Ulcer|Venous Insufficiency,Device: Dual Action Pneumatic Compression,Tactile Medical,Tactile Medical,,,,,,,Not Applicable,Industry,Interventional,12/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02395302
5391,Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease,Completed,Has Results,Cystic Fibrosis|Advanced Lung Disease,Drug: Lumacaftor|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,3/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02390219
5392,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: ELND005|Drug: Placebo,Transition Therapeutics Ireland Limited|Elan Pharmaceuticals,Transition Therapeutics Ireland Limited,Elan Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,11/12/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01735630
5393,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin|Drug: Empagliflozin + Linagliptin|Drug: Empaglifozin placebo + Linagliptin placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,1/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01734785
5394,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries,Completed,Has Results,Soft Tissue Surgical Bleeding,Biological: Fibrin Sealant (FS) Grifols|Device: Surgicel®,"Grifols Biologicals, LLC|Instituto Grifols, S.A.","Grifols Biologicals, LLC","Instituto Grifols, S.A.",,,,,,Phase 3,Industry,Interventional,11/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01731938
5395,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,11/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01730053
5396,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Rosuvastatin|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,10/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01730040
5397,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,Completed,Has Results,Atrial Fibrillation,Drug: rivaroxaban|Drug: uninterrupted vitamin K antagonist (VKA),"Janssen Scientific Affairs, LLC|Bayer","Janssen Scientific Affairs, LLC",Bayer,,,,,,Phase 3,Industry,Interventional,2/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01729871
5398,Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL,Completed,Has Results,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Ibrutinib|Drug: Chlorambucil,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Pharmacyclics LLC.,"Janssen Research & Development, LLC",,,,,,Phase 3,Industry,Interventional,3/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01722487
5399,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2|Hyperglycemia",Drug: Metformin 500 mg bid|Drug: Metformin 1000 mg bid|Drug: Empagliflozin low dose qd|Drug: Empagliflozin high dose qd|Drug: Empagliflozin low dose bid|Drug: Empagliflozin high dose bid,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,10/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01719003
5400,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Completed,Has Results,Bipolar I,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","Otsuka Pharmaceutical Development & Commercialization, Inc.",H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,11/12/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01710709
5401,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Completed,Has Results,Rheumatoid Arthritis,Drug: Sarilumab|Drug: placebo|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,10/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01709578
5402,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Drug: Ezetimibe|Drug: Alirocumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 3,Industry,Interventional,9/12/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT01709513
5403,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting,Completed,Has Results,Hepatitis C Virus Infection,Drug: LDV/SOF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,5/22/2015,4/22/2016,https://ClinicalTrials.gov/show/NCT02350569
5404,Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir (18F),Avid Radiopharmaceuticals|Eli Lilly and Company,Avid Radiopharmaceuticals,Eli Lilly and Company,,,,,,Phase 4,Industry,Interventional,10/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01703702
5405,Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne,Completed,Has Results,Acne,Drug: ACYC|Drug: ACYC vehicle,"Bausch Health Americas, Inc.|Dow Pharmaceutical Sciences","Bausch Health Americas, Inc.",Dow Pharmaceutical Sciences,,,,,,Phase 3,Industry,Interventional,10/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01701024
5406,Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,Completed,Has Results,N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma,Drug: Pimasertib|Drug: Dacarbazine,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 2,Industry,Interventional,12/5/2012,10/24/2016,https://ClinicalTrials.gov/show/NCT01693068
5407,Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients,Completed,Has Results,Sepsis,Device: Isomark Canary™,"Isomark, LLC|University of Florida|Ohio State University|Washington University School of Medicine|University of Colorado, Denver","Isomark, LLC",University of Florida,"Ohio State University|Washington University School of Medicine|University of Colorado, Denver",Ohio State University,"Washington University School of Medicine|University of Colorado, Denver",Washington University School of Medicine,"University of Colorado, Denver",Not Applicable,Industry|Other,Interventional,4/15/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02327130
5408,Oral Rivaroxaban in Children With Venous Thrombosis,Completed,Has Results,Venous Thrombosis,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Active comparator|Drug: Rivaroxaban (BAY59-7939) suspension","Bayer|Janssen Research & Development, LLC",Bayer,"Janssen Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,2/19/2013,9/1/2016,https://ClinicalTrials.gov/show/NCT01684423
5409,A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease,Completed,Has Results,Diabetic Kidney Disease,Drug: Baricitinib|Drug: Placebo,Eli Lilly and Company|Incyte Corporation,Eli Lilly and Company,Incyte Corporation,,,,,,Phase 2,Industry,Interventional,8/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01683409
5410,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,Completed,Has Results,Atrial Fibrillation,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonist (VKA)","Bayer|Janssen Research & Development, LLC",Bayer,"Janssen Research & Development, LLC",,,,,,Phase 3,Industry,Interventional,10/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01674647
5411,Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics,Completed,Has Results,Helicobacter Pylori Infection,Device: BreathID® Hp System|Drug: BreathID® Hp Lab System|Diagnostic Test: Stool Test,Exalenz Bioscience LTD.,Exalenz Bioscience LTD.,,,,,,,Phase 3,Industry,Interventional,5/18/2017,11/5/2017,https://ClinicalTrials.gov/show/NCT02905825
5412,"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",Completed,Has Results,Acute Schizophrenia,Drug: Brexpiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Quintiles, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Quintiles, Inc.",,,,,,Phase 3,Industry,Interventional,10/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01668797
5413,Belimumab in Remission of VASculitis,Completed,Has Results,Vasculitis,Biological: Placebo|Biological: Belimumab 10 mg/kg|Drug: Azathioprine,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","Human Genome Sciences Inc., a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,3/20/2013,2/6/2017,https://ClinicalTrials.gov/show/NCT01663623
5414,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Completed,Has Results,Atherosclerotic Cardiovascular Disease,Drug: Alirocumab|Drug: Placebo|Drug: LMT,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,10/12/2019,1/23/2018,https://ClinicalTrials.gov/show/NCT01663402
5415,Inactivated Influenza Via Jet Injection,Completed,Has Results,"Influenza, Human",Biological: Influenza Vaccine,"PharmaJet, Inc.","PharmaJet, Inc.",,,,,,,Phase 4,Industry,Interventional,11/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02290691
5416,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,Completed,Has Results,Venous Leg Ulcers,Biological: HP-802-247|Biological: Vehicle,"Healthpoint|Smith & Nephew, Inc.",Healthpoint,"Smith & Nephew, Inc.",,,,,,Phase 3,Industry,Interventional,8/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01656889
5417,Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Abbott Sensor Based Glucose Monitoring System,Abbott Diabetes Care,Abbott Diabetes Care,,,,,,,Not Applicable,Industry,Interventional,11/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02283411
5418,Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH),Completed,Has Results,X-linked Hypophosphatemia,Biological: burosumab,"Ultragenyx Pharmaceutical Inc|Kyowa Kirin Co., Ltd.",Ultragenyx Pharmaceutical Inc,"Kyowa Kirin Co., Ltd.",,,,,,Phase 3,Industry,Interventional,12/23/2015,12/13/2018,https://ClinicalTrials.gov/show/NCT02537431
5419,A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency,Completed,Has Results,Alpha₁-Antitrypsin Deficiency,Biological: Liquid Alpha₁-PI|Biological: Prolastin-C,Grifols Therapeutics LLC,Grifols Therapeutics LLC,,,,,,,Phase 2|Phase 3,Industry,Interventional,10/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02282527
5420,A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: empagliflozin (low dose qd)|Drug: Empagliflozin (high dose qd)|Drug: empagliflozin (high dose bid)|Drug: empagliflozin (low dose bid),Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 2,Industry,Interventional,10/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01649297
5421,Dose Ranging of GSK2336805 in Combination Therapy,Completed,Has Results,"Hepatitis C, Chronic",Drug: GSK2336805 40 mg|Drug: GSK2336805 60 mg|Drug: Pegylated interferon alpha-2a|Drug: Ribavirin|Drug: Telaprevir,GlaxoSmithKline|PPD,GlaxoSmithKline,PPD,,,,,,Phase 2,Industry,Interventional,8/1/2012,7/16/2014,https://ClinicalTrials.gov/show/NCT01648140
5422,Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus,Completed,Has Results,Infections,Drug: Ceftaroline fosamil|Drug: Ceftriaxone plus vancomycin,Forest Laboratories|AstraZeneca,Forest Laboratories,AstraZeneca,,,,,,Phase 4,Industry,Interventional,10/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01645735
5423,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Ezetimibe|Drug: Placebo (for ezetimibe)|Drug: Lipid Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,8/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01644188
5424,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,7/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01644175
5425,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Completed,Has Results,Chronic Constipation|Constipation,Drug: Linaclotide 290 micrograms|Drug: Linaclotide 145 micrograms|Drug: Matching placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Forest Laboratories,"Ironwood Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,8/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01642914
5426,Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas,Completed,Has Results,Relapsed/Refractory Aggressive B-cell Lymphomas,Drug: MEDI-551 12 mg/kg|Drug: MEDI0680 2.5 mg/kg|Drug: MEDI0680 10 mg/kg,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1|Phase 2,Industry,Interventional,12/1/2014,5/24/2016,https://ClinicalTrials.gov/show/NCT02271945
5427,Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Biological: Placebo plus standard therapy|Biological: Belimumab 10 mg/kg plus standard therapy|Drug: Standard therapy,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","Human Genome Sciences Inc., a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,2/19/2013,1/28/2019,https://ClinicalTrials.gov/show/NCT01632241
5428,"Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris",Completed,Has Results,Acne Vulgaris,Drug: 50 mg P005672-HCl|Drug: Placebo|Drug: 100 mg P005672-HCl,"Almirall, S.A.|Allergan","Almirall, S.A.",Allergan,,,,,,Phase 2,Industry,Interventional,6/30/2012,1/31/2013,https://ClinicalTrials.gov/show/NCT01628549
5429,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: Placebo|Drug: Tiotropium low dose mcg|Drug: Tiotropium high dose,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,7/12/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01634152
5430,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Completed,Has Results,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Drug: Fingolimod|Drug: Placebo Comparator,Novartis Pharmaceuticals|Mitsubishi Tanabe Pharma Corporation|Novartis,Novartis Pharmaceuticals,Mitsubishi Tanabe Pharma Corporation,Novartis,,,,,Phase 3,Industry,Interventional,12/22/2012,9/3/2016,https://ClinicalTrials.gov/show/NCT01625182
5431,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,7/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01623115
5432,RDEA3170 and Febuxostat Combination Study in Gout Subjects,Completed,Has Results,Gout,Drug: RDEA3170 15 mg|Drug: RDEA3170 10 mg|Drug: RDEA3170 2.5|Drug: RDEA3170 5 mg|Drug: Febuxostat 40 mg|Drug: Febuxostat 80 mg,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 2,Industry,Interventional,10/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02246673
5433,Adult Accuracy Study of the Enlite 3 Glucose Sensor,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: Enlite 3|Device: Guardian Mobile App|Device: 640G Insulin Pump,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,9/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02246582
5434,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,6/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01617655
5435,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)",Completed,Has Results,"Arthritis, Rheumatoid",Drug: Placebo|Drug: Sirukumab,"Janssen Research & Development, LLC|GlaxoSmithKline","Janssen Research & Development, LLC",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,8/6/2012,1/12/2016,https://ClinicalTrials.gov/show/NCT01606761
5436,"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)",Completed,Has Results,"Arthritis, Rheumatoid",Drug: Placebo|Drug: Sirukumab,"Janssen Research & Development, LLC|GlaxoSmithKline","Janssen Research & Development, LLC",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,8/15/2012,12/6/2016,https://ClinicalTrials.gov/show/NCT01604343
5437,A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Biological: Belimumab plus Early Vaccination|Biological: Belimumab plus Late Vaccination,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","Human Genome Sciences Inc., a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,5/31/2012,9/24/2015,https://ClinicalTrials.gov/show/NCT01597492
5438,Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole,Completed,Has Results,Schizophrenia|Mental Disorder|Nervous System Diseases,Device: MIND1 System,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,8/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02219009
5439,4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease,Completed,Has Results,Anaemia,Drug: GSK1278863|Drug: rhEPO,GlaxoSmithKline|PPD,GlaxoSmithKline,PPD,,,,,,Phase 2,Industry,Interventional,5/23/2012,5/27/2013,https://ClinicalTrials.gov/show/NCT01587924
5440,4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis,Completed,Has Results,Anaemia,Drug: GSK1278863|Other: Placebo,GlaxoSmithKline|PPD,GlaxoSmithKline,PPD,,,,,,Phase 2,Industry,Interventional,5/17/2012,5/7/2013,https://ClinicalTrials.gov/show/NCT01587898
5441,A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Completed,Has Results,Relapsed or Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: ofatumumab|Drug: ibrutinib,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Pharmacyclics LLC.,"Janssen Research & Development, LLC",,,,,,Phase 3,Industry,Interventional,6/12/2019,10/25/2018,https://ClinicalTrials.gov/show/NCT01578707
5442,CPAP (Continuous Positive Airway Pressure) Study Educational Materials and Usage Feedback to Promote CPAP Adherence,Completed,Has Results,Adherence,Behavioral: Education and feedback,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,1/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02195531
5443,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,Completed,Has Results,Colorectal Cancer Metastatic,Drug: AFLIBERCEPT AVE0005|Drug: FOLFIRI,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,5/30/2012,1/31/2017,https://ClinicalTrials.gov/show/NCT01571284
5444,Cellentra Viable Cell Bone Matrix (VCBM) Anterior Cervical Discectomy and Fusion Outcomes Study (VCBM/MaxAn),Completed,Has Results,Cervical Disc Degenerative Disorder,Biological: Cellentra VCBM,Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,3/14/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02182843
5445,"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients",Completed,Has Results,Bipolar I Disorder,Drug: Intramuscular (IM) Depot Aripiprazole|Drug: Intramuscular (IM) Depot Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","Otsuka Pharmaceutical Development & Commercialization, Inc.",H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,8/12/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01567527
5446,Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old,Completed,Has Results,Herpes Labialis,Drug: acyclovir/hydrocortisone cream,"Meda Pharmaceuticals|TKL Research, Inc.",Meda Pharmaceuticals,"TKL Research, Inc.",,,,,,Phase 3,Industry,Interventional,3/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01574612
5447,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Completed,Has Results,Acute Lymphoblastic Leukemia,"Drug: inotuzumab ozogamicin|Drug: FLAG (fludarabine, cytarabine and G-CSF)|Drug: HIDAC (high dose cytarabine)|Drug: cytarabine and mitoxantrone",Pfizer|UCB Pharma,Pfizer,UCB Pharma,,,,,,Phase 3,Industry,Interventional,8/2/2012,1/4/2017,https://ClinicalTrials.gov/show/NCT01564784
5448,A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab,Completed,Has Results,Psoriasis,Drug: Brodalumab,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 1,Industry,Interventional,9/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02173392
5449,CentriMag RVAS U.S. Post-approval Study Protocol,Completed,Has Results,Right Ventricular Failure,Device: CentriMag RVAS placement,Abbott Medical Devices|Thoratec Corporation,Abbott Medical Devices,Thoratec Corporation,,,,,,Not Applicable,Industry,Interventional,9/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01568424
5450,Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction,Completed,Has Results,Atrophic Acne Scar,Drug: Normal Saline|Device: Artefill,"Suneva Medical, Inc.|ethica Clinical Research Inc.","Suneva Medical, Inc.",ethica Clinical Research Inc.,,,,,,Phase 3,Industry,Interventional,2/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01559922
5451,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Completed,Has Results,Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Biological: IgPro20 (low dose)|Biological: Placebo|Biological: IgPro10|Biological: IgPro20 (high dose),CSL Behring|ICON Clinical Research,CSL Behring,ICON Clinical Research,,,,,,Phase 3,Industry,Interventional,3/12/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01545076
5452,Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease,Completed,Has Results,Coronary Artery Disease,Drug: Prasugrel Loading Dose|Drug: Prasugrel Maintenance Dose|Drug: Ticagrelor Maintenance Dose,"Daiichi Sankyo, Inc.|Eli Lilly and Company","Daiichi Sankyo, Inc.",Eli Lilly and Company,,,,,,Phase 4,Industry,Interventional,3/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01587651
5453,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Completed,Has Results,Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Drug: Brentuximab Vedotin|Drug: Methotrexate|Drug: Bexarotene,"Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.|Takeda","Millennium Pharmaceuticals, Inc.","Seattle Genetics, Inc.",Takeda,,,,,Phase 3,Industry,Interventional,6/11/2012,7/6/2018,https://ClinicalTrials.gov/show/NCT01578499
5454,"A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments",Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Lenvatinib|Drug: Lenvatinib matched placebo|Drug: BSC,"Eisai Inc.|Quintiles, Inc.",Eisai Inc.,"Quintiles, Inc.",,,,,,Phase 2,Industry,Interventional,11/11/2019,6/27/2015,https://ClinicalTrials.gov/show/NCT01529112
5455,PK Study of Dapagliflozin in Pediatric Subjects With T2DM,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 1,Industry,Interventional,7/1/2012,9/1/2014,https://ClinicalTrials.gov/show/NCT01525238
5456,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),Completed,Has Results,Branch Retinal Vein Occlusion,Procedure: Macular Laser Photocoagulation|Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321),Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 3,Industry,Interventional,4/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01521559
5457,Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time,Completed,Has Results,Myocardial Infarction|Myocardial Ischemia,Device: Pulmonary Artery Catheter (PAC)|Device: Endotracheal Cardiac Output Monitor (ECOM)|Device: Estimated Continuous Cardiac Output (esCCO),"University of California, San Francisco|Northern California Institute of Research and Education|San Francisco Veterans Affairs Medical Center|Drexel University|Nihon Kohden","University of California, San Francisco",Northern California Institute of Research and Education,San Francisco Veterans Affairs Medical Center|Drexel University|Nihon Kohden,San Francisco Veterans Affairs Medical Center,Drexel University|Nihon Kohden,Drexel University,Nihon Kohden,Not Applicable,Other|U.S. Fed|Industry,Interventional,12/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01877941
5458,"Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: metformin|Drug: linagliptin|Drug: metformin placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 4,Industry,Interventional,1/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01512979
5459,A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study,Completed,Has Results,Major Cutaneous Abscess|Cellulitis|Erysipelas,Drug: TR701 FA,Trius Therapeutics LLC|Bayer,Trius Therapeutics LLC,Bayer,,,,,,Phase 2,Industry,Interventional,2/15/2012,8/27/2012,https://ClinicalTrials.gov/show/NCT01519778
5460,Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim,Completed,Has Results,Chemotherapy-induced Neutropenia|Breast Cancer,Drug: LA-EP2006|Drug: Neulasta®,Sandoz|Sandoz GmbH,Sandoz,Sandoz GmbH,,,,,,Phase 3,Industry,Interventional,3/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01516736
5461,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,1/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01507831
5462,Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus,Completed,Has Results,Hepatitis C Virus,Drug: Daclatasvir|Drug: Simeprevir|Drug: Ribavirin,"Bristol-Myers Squibb|Janssen Research & Development, LLC",Bristol-Myers Squibb,"Janssen Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,7/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01628692
5463,Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate,Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol (CZP)|Biological: Adalimumab (ADA)|Drug: Methotrexate (MTX),UCB Pharma SA|Parexel|UCB Pharma,UCB Pharma SA,Parexel,UCB Pharma,,,,,Phase 4,Industry,Interventional,12/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01500278
5464,Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery,Completed,Has Results,Bleeding,Drug: TachoSil®|Drug: Surgicel® Original,Takeda|Baxter Healthcare Corporation,Takeda,Baxter Healthcare Corporation,,,,,,Phase 3,Industry,Interventional,3/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01500135
5465,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Completed,Has Results,Complicated Skin and Soft Tissue Infection,Drug: Ceftaroline fosamil|Drug: Vancomycin|Drug: Aztreonam,Pfizer|Forest Laboratories,Pfizer,Forest Laboratories,,,,,,Phase 3,Industry,Interventional,5/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01499277
5466,A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis,Completed,Has Results,"Psoriasis|Skin Diseases|Skin Diseases, Papulosquamous",Drug: Placebo|Drug: Baricitinib,Eli Lilly and Company|Incyte Corporation,Eli Lilly and Company,Incyte Corporation,,,,,,Phase 2,Industry,Interventional,12/11/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01490632
5467,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Biological: Placebo|Biological: Belimumab 200 mg SC|Drug: Standard therapy,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","Human Genome Sciences Inc., a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,11/16/2011,10/1/2015,https://ClinicalTrials.gov/show/NCT01484496
5468,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids,Completed,Has Results,Asthma,Drug: Fp MDPI|Drug: Flovent Diskus|Drug: albuterol/salbutamol|Drug: Placebo MDPI,"Teva Branded Pharmaceutical Products, R&D Inc.|PPD|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",PPD,Teva Pharmaceutical Industries,,,,,Phase 2,Industry,Interventional,1/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01479621
5469,Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Biological: Elotuzumab|Drug: Bortezomib|Drug: Dexamethasone,Bristol-Myers Squibb|AbbVie,Bristol-Myers Squibb,AbbVie,,,,,,Phase 2,Industry,Interventional,11/30/2011,4/21/2017,https://ClinicalTrials.gov/show/NCT01478048
5470,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Completed,Has Results,Asthma,Drug: ADVAIR 100/50mcg|Drug: ADVAIR 250/50mcg|Drug: ADVAIR 500/50mcg|Drug: FLOVENT 100mcg|Drug: FLOVENT 250mcg|Drug: FLOVENT 500mcg,GlaxoSmithKline|Parexel,GlaxoSmithKline,Parexel,,,,,,Phase 4,Industry,Interventional,11/18/2011,6/23/2015,https://ClinicalTrials.gov/show/NCT01475721
5471,A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease,Biological: Epoetin Hospira|Biological: Epogen Amgen,"Pfizer|Hospira, now a wholly owned subsidiary of Pfizer",Pfizer,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 3,Industry,Interventional,1/17/2012,2/28/2014,https://ClinicalTrials.gov/show/NCT01473420
5472,A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Completed,Has Results,Chronic Kidney Disease|Chronic Renal Failure,Biological: Epoetin Hospira|Biological: Epogen (Amgen),"Pfizer|Hospira, now a wholly owned subsidiary of Pfizer",Pfizer,"Hospira, now a wholly owned subsidiary of Pfizer",,,,,,Phase 3,Industry,Interventional,1/31/2012,2/11/2014,https://ClinicalTrials.gov/show/NCT01473407
5473,Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Placebo|Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 2,Industry,Interventional,12/15/2011,12/12/2013,https://ClinicalTrials.gov/show/NCT01469377
5474,EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis,Completed,Has Results,Venous Thromboembolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)","Bayer|Janssen Research & Development, LLC",Bayer,"Janssen Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,1/15/2015,4/5/2017,https://ClinicalTrials.gov/show/NCT02309411
5475,A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients,Completed,Has Results,Hepatitis C,Drug: TMC435|Drug: PSI-7977 (GS7977)|Drug: Ribavirin,Janssen R&D Ireland|Gilead Sciences,Janssen R&D Ireland,Gilead Sciences,,,,,,Phase 2,Industry,Interventional,1/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01466790
5476,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Completed,Has Results,Asthma,Drug: ADVAIR 100/50mcg|Drug: ADVAIR 250/50mcg|Drug: FLOVENT 100mcg|Drug: FLOVENT 250mcg,GlaxoSmithKline|Parexel,GlaxoSmithKline,Parexel,,,,,,Phase 4,Industry,Interventional,11/17/2011,11/3/2015,https://ClinicalTrials.gov/show/NCT01462344
5477,B. Lactis HN019 for Functional Constipation,Completed,Has Results,Constipation,Dietary Supplement: B. lactis HN019|Dietary Supplement: Placebo,Fonterra Research Centre|DuPont Nutrition and Health,Fonterra Research Centre,DuPont Nutrition and Health,,,,,,Phase 3,Industry,Interventional,3/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01463293
5478,"A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair",Completed,Has Results,Ventral Hernia|Incisional Hernia,Device: Resorbable Mesh,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,2/14/2019,2/23/2017,https://ClinicalTrials.gov/show/NCT02053168
5479,A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease,Completed,Has Results,Sickle Cell Disease,Drug: Prasugrel,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,Phase 2,Industry,Interventional,11/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01476696
5480,Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders,Completed,Has Results,Smoking Cessation,Drug: Placebo|Drug: varenicline tartrate|Drug: bupropion hydrochloride|Drug: Nicotine Replacement Therapy Patch,Pfizer|GlaxoSmithKline,Pfizer,GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,11/11/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01456936
5481,"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A",Completed,Has Results,Hemophilia A,Drug: BIIB031 (rFVIIIFc)|Drug: FVIII (PK subgroup only),Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Bioverativ Therapeutics Inc.,Swedish Orphan Biovitrum,,,,,,Phase 3,Industry,Interventional,11/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01458106
5482,"Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm",Completed,Has Results,Hypercholesterolemia,Biological: Bococizumab (PF-04950615; RN316),Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02043301
5483,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: dolutegravir 50 mg OAD|Drug: darunavir 800mg OAD|Drug: ritonavir 100mg OAD,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,10/31/2011,12/26/2016,https://ClinicalTrials.gov/show/NCT01449929
5484,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Completed,Has Results,Epilepsy|Monotherapy,Drug: Lacosamide|Drug: Carbamazepine-Controlled Release (CBZ-CR),UCB BIOSCIENCES GmbH|Eden Sarl|UCB Pharma,UCB BIOSCIENCES GmbH,Eden Sarl,UCB Pharma,,,,,Phase 3,Industry,Interventional,5/12/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01465997
5485,Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine,Completed,Has Results,"Infections, Streptococcal",Biological: GBS Vaccine,GlaxoSmithKline|Novartis Vaccines,GlaxoSmithKline,Novartis Vaccines,,,,,,Phase 2,Industry,Interventional,11/1/2014,9/22/2015,https://ClinicalTrials.gov/show/NCT02270944
5486,Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma,Completed,Has Results,Smoldering Multiple Myeloma,Biological: Elotuzumab (BMS-901608; HuLuc63),Bristol-Myers Squibb|AbbVie,Bristol-Myers Squibb,AbbVie,,,,,,Phase 2,Industry,Interventional,12/28/2011,1/17/2017,https://ClinicalTrials.gov/show/NCT01441973
5487,A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers,Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: MM-121|Drug: Paclitaxel,Merrimack Pharmaceuticals|Sanofi,Merrimack Pharmaceuticals,Sanofi,,,,,,Phase 2,Industry,Interventional,10/11/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01447706
5488,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: COBI|Drug: DRV|Drug: NRTIs,"Gilead Sciences|Janssen Research & Development, LLC",Gilead Sciences,"Janssen Research & Development, LLC",,,,,,Phase 3,Industry,Interventional,9/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01440569
5489,An Open-label Extension Study of PSMA ADC 2301 in mCRPC,Completed,Has Results,Prostate Cancer,Drug: PSMA ADC,"Progenics Pharmaceuticals, Inc.","Progenics Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,10/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02020135
5490,"U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne",Completed,Has Results,Acne Vulgaris,"Other: acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%","Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Not Applicable,Industry,Interventional,6/1/2011,12/15/2011,https://ClinicalTrials.gov/show/NCT01446237
5491,The Plecanatide Chronic Idiopathic Constipation (CIC) Study,Completed,Has Results,Chronic Idiopathic Constipation,Drug: plecanatide|Other: Placebo,"Bausch Health Americas, Inc.|Parexel","Bausch Health Americas, Inc.",Parexel,,,,,,Phase 2|Phase 3,Industry,Interventional,10/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01429987
5492,"A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents",Completed,Has Results,Meningococcal Meningitis,"Biological: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|Biological: MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine",Novartis|Novartis Vaccines,Novartis,Novartis Vaccines,,,,,,Phase 4,Industry,Interventional,9/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01424644
5493,"Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects",Completed,Has Results,"Hepatitis C, Chronic",Drug: GSK2336805|Drug: Pegylated interferon alfa-2a|Drug: Ribavirin|Drug: GSK2336805 Matching Placebo,GlaxoSmithKline|PPD,GlaxoSmithKline,PPD,,,,,,Phase 2,Industry,Interventional,7/7/2011,12/5/2011,https://ClinicalTrials.gov/show/NCT01439373
5494,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: high dose FDC|Drug: BI 10773 high dose|Drug: high dose FDC placebo|Drug: low dose FDC placebo|Drug: high dose BI 10773 placebo|Drug: low dose FDC|Drug: BI 10773 low dose|Drug: linagliptin|Drug: linagliptin placebo|Drug: BI 10773 low dose placebo|Drug: low dose BI 10773 placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,8/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01422876
5495,A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer,Completed,Has Results,"ER Positive, Her2 Negative Breast Cancer Patients|Triple Negative Breast Cancer Patients",Drug: MM-121|Drug: Paclitaxel,Merrimack Pharmaceuticals|Sanofi,Merrimack Pharmaceuticals,Sanofi,,,,,,Phase 2,Industry,Interventional,8/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01421472
5496,A Study in Adults With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2963016|Drug: Lantus|Drug: OAMs,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 3,Industry,Interventional,9/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01421459
5497,A Study in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2963016|Drug: Lantus|Drug: Insulin Lispro,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 3,Industry,Interventional,8/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01421147
5498,"A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease",Completed,Has Results,Advanced Idiopathic Parkinson's Disease,Drug: Rotigotine,"UCB BIOSCIENCES GmbH|Otsuka Pharmaceutical Co., Ltd.|UCB Pharma",UCB BIOSCIENCES GmbH,"Otsuka Pharmaceutical Co., Ltd.",UCB Pharma,,,,,Phase 4,Industry,Interventional,9/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01711866
5499,A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Placebo|Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 3,Industry,Interventional,9/27/2011,9/3/2014,https://ClinicalTrials.gov/show/NCT01412060
5500,"Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression",Completed,Has Results,"Depression, Bipolar",Drug: Placebo|Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 2,Industry,Interventional,7/26/2011,1/10/2014,https://ClinicalTrials.gov/show/NCT01396447
5501,Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function,Completed,Has Results,Multiple Myeloma,Drug: Lenalidomide|Drug: Dexamethasone|Biological: Elotuzumab (BMS-901608; HuLuc63),Bristol-Myers Squibb|AbbVie,Bristol-Myers Squibb,AbbVie,,,,,,Phase 1,Industry,Interventional,1/6/2012,7/18/2016,https://ClinicalTrials.gov/show/NCT01393964
5502,A Multi-Center Study Comparing the Clinical Performance of Two Silicone Hydrogel Lenses Over 1 Month of Daily Wear,Completed,Has Results,Myopia,Device: comfilcon A|Device: lotrafilcon B,"Coopervision, Inc.","Coopervision, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01952665
5503,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Netupitant and Palonosetron|Drug: Aprepitant|Drug: Palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|Parexel,Helsinn Healthcare SA,Parexel,,,,,,Phase 3,Industry,Interventional,7/11/2019,,https://ClinicalTrials.gov/show/NCT01376297
5504,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: Placebo|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,6/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01370005
5505,Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: AAB-003 (PF-05236812),"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Pfizer,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,,,,,Phase 1,Industry,Interventional,7/11/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01369225
5506,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|Procedure: Macular Laser Photocoagulation,Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 3,Industry,Interventional,5/11/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01363440
5507,Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia,Completed,Has Results,Acute Lymphocytic Leukemia,Drug: Inotuzumab Ozogamicin,Pfizer|UCB Pharma,Pfizer,UCB Pharma,,,,,,Phase 2,Industry,Interventional,8/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01363297
5508,Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years,Completed,Has Results,H7N9 Influenza,Biological: H7N9c low dose with adjuvant|Biological: H7N9c medium dose with adjuvant|Biological: H7N9c high dose with adjuvant|Biological: H7N9c high dose without adjuvant,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 1,Industry,Interventional,8/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01928472
5509,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols|Drug: Placebo (GA-0034),"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",GW Pharmaceuticals Ltd.,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,Phase 3,Industry,Interventional,5/27/2011,11/24/2014,https://ClinicalTrials.gov/show/NCT01361607
5510,Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care,Completed,Has Results,Chronic Hepatitis C,Drug: PSI-7977|Drug: Daclatasvir|Drug: Ribavirin,Bristol-Myers Squibb|Pharmasset,Bristol-Myers Squibb,Pharmasset,,,,,,Phase 2,Industry,Interventional,6/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01359644
5511,Phase I Biomarker Study (BMS-936558),Completed,Has Results,Renal Cell Carcinoma,Drug: BMS-936558 (Anti-PD-1),Bristol-Myers Squibb|Ono Pharma USA Inc,Bristol-Myers Squibb,Ono Pharma USA Inc,,,,,,Phase 1,Industry,Interventional,8/11/2011,5/22/2019,https://ClinicalTrials.gov/show/NCT01358721
5512,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Oral palonosetron|Drug: I.V. palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|Parexel,Helsinn Healthcare SA,Parexel,,,,,,Phase 3,Industry,Interventional,7/11/2019,,https://ClinicalTrials.gov/show/NCT01363479
5513,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Completed,Has Results,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Drug: Denosumab|Drug: Zoledronic acid|Drug: Placebo to Denosumab|Drug: Placebo to zoledronic acid,"Amgen|Daiichi Sankyo, Inc.",Amgen,"Daiichi Sankyo, Inc.",,,,,,Phase 3,Industry,Interventional,5/17/2012,3/29/2019,https://ClinicalTrials.gov/show/NCT01345019
5514,A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma,Completed,Has Results,Advanced Liposarcoma or Leiomyosarcoma,Drug: Trabectedin|Drug: Dacarbazine,"Janssen Research & Development, LLC|PharmaMar","Janssen Research & Development, LLC",PharmaMar,,,,,,Phase 3,Industry,Interventional,6/11/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01343277
5515,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Completed,Has Results,Asthma,Drug: Tiotropium low dose QD|Drug: Tiotropium high dose QD|Drug: Placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,7/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01634139
5516,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Netupitant and Palonosetron|Drug: Palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|Parexel,Helsinn Healthcare SA,Parexel,,,,,,Phase 3,Industry,Interventional,4/11/2019,,https://ClinicalTrials.gov/show/NCT01339260
5517,Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols,"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",GW Pharmaceuticals Ltd.,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,Phase 3,Industry,Interventional,1/19/2011,1/27/2016,https://ClinicalTrials.gov/show/NCT01337089
5518,"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B",Completed,Has Results,Hemophilia B,Drug: rFIXFc|Drug: FIX,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Bioverativ Therapeutics Inc.,Swedish Orphan Biovitrum,,,,,,Phase 3,Industry,Interventional,6/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01440946
5519,A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer,Completed,Has Results,Advanced Metastatic (Stage IV) Colorectal Cancer,"Drug: PledOx (2 µmol/kg)|Drug: PledOx (5 µmol/kg)|Drug: PledOx (10 µmol/kg)|Drug: Placebo (0,9% NaCl)",PledPharma AB|Pharma Consulting Group AB,PledPharma AB,Pharma Consulting Group AB,,,,,,Phase 1|Phase 2,Industry,Interventional,9/12/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01619423
5520,A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B,Completed,Has Results,HIV Coinfection,Drug: Maraviroc|Drug: Placebo,ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 4,Industry,Interventional,5/18/2011,3/24/2015,https://ClinicalTrials.gov/show/NCT01327547
5521,Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: empagliflozin medium dose|Drug: empagliflozin high dose|Drug: empagliflozin low dose,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 1,Industry,Interventional,6/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02121483
5522,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo matching with Saxagliptin|Drug: Metformin IR|Drug: Metformin XR|Drug: Saxagliptin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,5/12/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01434186
5523,Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.,Completed,Has Results,"Dermatitis, Chronic",Drug: clobetasol propionate 0.05%|Drug: Vehicle / Placebo,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,11/15/2010,3/29/2011,https://ClinicalTrials.gov/show/NCT01323673
5524,"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma",Completed,Has Results,Asthma,Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Drug: Fluticasone/Salmeterol combination therapy|Drug: Fluticasone monotherapy|Drug: Albuterol|Drug: Levalbuterol,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,3/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01312961
5525,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2|Obesity",Drug: Placebo|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,2/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01306214
5526,Overnight Closed Loop Study in U.S.,Completed,Has Results,Type 1 Diabetes,Device: Hybrid Closed Loop,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,6/13/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01857973
5527,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: Placebo|Drug: Sitagliptin 100mg,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,2/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01289990
5528,A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: enzalutamide|Drug: bicalutamide,"Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,,Phase 2,Industry,Interventional,3/22/2011,11/8/2017,https://ClinicalTrials.gov/show/NCT01288911
5529,Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin|Drug: Placebo (for atorvastatin),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,1/11/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01288469
5530,Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,1/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01288443
5531,"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",Completed,Has Results,"Advanced or Recurrent Solid Tumors|Breast Neoplasms|Ovarian Cancer, Epithelial|Ewing Sarcoma|Small Cell Lung Carcinoma|Prostate Cancer|Pancreas Cancer",Drug: Talazoparib,"Pfizer|Medivation, Inc.",Pfizer,"Medivation, Inc.",,,,,,Phase 1,Industry,Interventional,1/3/2011,1/30/2017,https://ClinicalTrials.gov/show/NCT01286987
5532,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Completed,Has Results,Bacterial Infections,Drug: Tedizolid (BAY119-2631)|Drug: Placebo Tedizolid (BAY119-2631)|Drug: Linezolid|Drug: Placebo Linezolid,Bayer|Merck Sharp & Dohme Corp.,Bayer,Merck Sharp & Dohme Corp.,,,,,,Phase 3,Industry,Interventional,3/4/2014,4/18/2016,https://ClinicalTrials.gov/show/NCT02066402
5533,"Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.",Completed,Has Results,"Lupus Erythematosus, Systemic",Biological: Ala-Cpn10|Drug: Placebo,"Invion, Inc.","Invion, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,7/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01838694
5534,A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding,Completed,Has Results,Menorrhagia,Drug: Tranexamic acid,Ferring Pharmaceuticals|Xanodyne Pharmaceuticals,Ferring Pharmaceuticals,Xanodyne Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,4/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT01280981
5535,GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy,Completed,Has Results,Rheumatoid Arthritis,Biological: GP2013|Biological: MabThera|Biological: Rituxan,Sandoz|Novartis Pharmaceuticals,Sandoz,Novartis Pharmaceuticals,,,,,,Phase 1|Phase 2,Industry,Interventional,1/11/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT01274182
5536,Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: ODM-201,"Orion Corporation, Orion Pharma|Endo Pharmaceuticals","Orion Corporation, Orion Pharma",Endo Pharmaceuticals,,,,,,Phase 1|Phase 2,Industry,Interventional,3/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01317641
5537,Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Regeneron Pharmaceuticals,Sanofi,,,,,,Phase 2,Industry,Interventional,1/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01266876
5538,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols|Drug: Placebo (GA-0034),"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",GW Pharmaceuticals Ltd.,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,Phase 3,Industry,Interventional,11/25/2010,7/2/2015,https://ClinicalTrials.gov/show/NCT01262651
5539,Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors,Completed,Has Results,Hemophilia A With Inhibitors|Hemophilia B With Inhibitors,Biological: Coagulation Factor VIIa (Recombinant),rEVO Biologics|Laboratoire français de Fractionnement et de Biotechnologies,rEVO Biologics,Laboratoire français de Fractionnement et de Biotechnologies,,,,,,Phase 3,Industry,Interventional,4/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02020369
5540,Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis,Completed,Has Results,Tinea Pedis|Athlete's Foot,Drug: Econazole Nitrate Foam 1%|Other: Vehicle Foam,"AmDerma|AmDerma Pharmaceuticals, LLC",AmDerma,"AmDerma Pharmaceuticals, LLC",,,,,,Phase 3,Industry,Interventional,5/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01353976
5541,Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB),Completed,Has Results,Exercise-Induced Bronchoconstriction (EIB),Drug: Albuterol Spiromax|Drug: Placebo Spiromax,Teva Pharmaceutical Industries,Teva Pharmaceutical Industries,,,,,,,Phase 3,Industry,Interventional,3/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01791972
5542,Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial),Completed,Has Results,Polycythemia Vera,Drug: ruxolitinib tablets|Other: Best Available Therapy (BAT),Incyte Corporation|Novartis Pharmaceuticals,Incyte Corporation,Novartis Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,10/27/2010,2/9/2018,https://ClinicalTrials.gov/show/NCT01243944
5543,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Completed,Has Results,Epilepsy|Monotherapy,Drug: Lacosamide|Drug: Carbamazepine-Controlled Release,UCB BIOSCIENCES GmbH|Eden Sarl|UCB Pharma,UCB BIOSCIENCES GmbH,Eden Sarl,UCB Pharma,,,,,Phase 3,Industry,Interventional,4/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01243177
5544,Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure,Completed,Has Results,Influenza,"Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01788228
5545,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Completed,Has Results,Genotype 1 Chronic Hepatitis C|Treatment Naive,Drug: Ribavirin|Drug: Telaprevir|Drug: Pegylated interferon alfa-2a,Janssen Infectious Diseases BVBA|Vertex Pharmaceuticals Incorporated,Janssen Infectious Diseases BVBA,Vertex Pharmaceuticals Incorporated,,,,,,Phase 3,Industry,Interventional,12/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01241760
5546,A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Drug: placebo|Drug: MultiStem low dose|Drug: MultiStem high dose,"Pfizer|Athersys, Inc",Pfizer,"Athersys, Inc",,,,,,Phase 2,Industry,Interventional,2/11/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01240915
5547,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,Completed,Has Results,"Carcinoma, Hepatocellular",Drug: Mapatumumab|Drug: Placebo|Drug: Sorafenib,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","Human Genome Sciences Inc., a GSK Company",GlaxoSmithKline,,,,,,Phase 1|Phase 2,Industry,Interventional,2/8/2011,11/29/2017,https://ClinicalTrials.gov/show/NCT01258608
5548,Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma,Completed,Has Results,Asthma,Biological: Benralizumab 2 mg|Biological: Benralizumab 20 mg|Biological: Benralizumab 100 mg|Other: Placebo,MedImmune LLC|MedImmune Ltd,MedImmune LLC,MedImmune Ltd,,,,,,Phase 2,Industry,Interventional,12/10/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01238861
5549,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: tiotropium high dose|Drug: placebo|Drug: tiotropium low dose,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,1/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01277523
5550,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Completed,Has Results,Breast Cancer,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Capecitabine","Bayer|Onyx Therapeutics, Inc.",Bayer,"Onyx Therapeutics, Inc.",,,,,,Phase 3,Industry,Interventional,2/21/2011,10/20/2017,https://ClinicalTrials.gov/show/NCT01234337
5551,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Biological: ACC-001 3 μg/ QS-21 50 μg|Biological: ACC-001 10 μg/ QS-21 50 μg|Other: Placebo- Phosphate buffered saline (PBS),"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Pfizer,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,2/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01227564
5552,Clinical Trial in Females for Female Pattern Hair Loss,Completed,Has Results,Androgenetic Alopecia,Drug: 5% Minoxidil Topical Foam|Drug: Vehicle Topical Foam,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Phase 3,Industry,Interventional,9/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01226459
5553,Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL),Completed,Has Results,Mantle Cell Lymphoma,Drug: PCI-32765,Pharmacyclics LLC.|Janssen Pharmaceuticals,Pharmacyclics LLC.,Janssen Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,2/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01236391
5554,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Completed,Has Results,Asthma,Drug: tiotropium Respimat low dose|Drug: placebo Respimat|Drug: tiotropium Respimat high dose,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,12/10/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01257230
5555,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,9/10/2019,,https://ClinicalTrials.gov/show/NCT01210001
5556,A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Other: Placebo|Biological: Benralizumab 100 mg,MedImmune LLC|AstraZeneca,MedImmune LLC,AstraZeneca,,,,,,Phase 2,Industry,Interventional,11/10/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01227278
5557,Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis,Completed,Has Results,Lateral Epicondylitis,Drug: rhPDGF-BB Injection|Drug: Placebo,BioMimetic Therapeutics,BioMimetic Therapeutics,,,,,,,Phase 2,Industry,Interventional,12/12/2012,10/21/2014,https://ClinicalTrials.gov/show/NCT01746420
5558,A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients,Completed,Has Results,Human Immunodeficiency Virus (HIV),Drug: Etravirine|Drug: Ritonavir|Drug: Darunavir,"Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","Tibotec, Inc","Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 2,Industry,Interventional,5/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01199939
5559,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,10/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01195662
5560,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,9/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01194830
5561,Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: AAB-003 (PF-05236812)|Other: Placebo,"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Pfizer,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,,,,,Phase 1,Industry,Interventional,9/10/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01193608
5562,A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy,Completed,Has Results,"Arthritis, Rheumatoid",Drug: LY3009104|Drug: Placebo|Drug: Methotrexate,Eli Lilly and Company|Incyte Corporation,Eli Lilly and Company,Incyte Corporation,,,,,,Phase 2,Industry,Interventional,10/10/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01185353
5563,A Study in Second Line Metastatic Colorectal Cancer,Completed,Has Results,Colorectal Cancer,Biological: Ramucirumab|Biological: Placebo|Drug: Irinotecan|Drug: Folinic Acid|Drug: 5-Fluorouracil,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 3,Industry,Interventional,12/2/2010,6/20/2016,https://ClinicalTrials.gov/show/NCT01183780
5564,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Pioglitazone 15 mg|Drug: Pioglitazone 45 mg|Drug: Pioglitazone 30 mg|Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC|Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC|Drug: Linagliptin 5mg|Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,8/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01183013
5565,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",Completed,Has Results,Severe Hemophilia A,Drug: Factor VIII (rFVIIIFc)|Drug: Advate®,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Bioverativ Therapeutics Inc.,Swedish Orphan Biovitrum,,,,,,Phase 3,Industry,Interventional,11/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01181128
5566,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),Completed,Has Results,"Hypertension, Pulmonary",Drug: ambrisentan|Drug: tadalafil,GlaxoSmithKline|Gilead Sciences,GlaxoSmithKline,Gilead Sciences,,,,,,Phase 3,Industry,Interventional,10/1/2010,7/31/2014,https://ClinicalTrials.gov/show/NCT01178073
5567,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo identical to BI10773 high dose|Drug: BI 10773|Drug: BI 10773 open label|Drug: Placebo identical to BI10773 low dose|Drug: Placebo identical to Sitagliptin 100mg|Drug: BI10773|Drug: Sitagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,7/10/2019,,https://ClinicalTrials.gov/show/NCT01177813
5568,Safety and Efficacy Study of BondEase to Treat Traumatic Lacerations and Surgical Incisions,Completed,Has Results,Traumatic Lacerations or Surgical Incisions,Device: BondEase|Procedure: CWCD,"OptMed, Inc.","OptMed, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01716013
5569,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Completed,Has Results,Asthma,Drug: placebo|Drug: tiotropium Respimat® low dose|Drug: tiotropium Respimat® high dose|Drug: 50 mcg salmeterol HFA MDI,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,8/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01172821
5570,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Completed,Has Results,Asthma,Drug: Placebo|Drug: tiotropium Respimat® low dose|Drug: tiotropium Respimat® high dose|Drug: 50 mcg salmeterol HFA MDI,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,8/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01172808
5571,An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis,Completed,Has Results,Nasal Polyps,Drug: Placebo (for dupilumab)|Drug: Dupilumab|Drug: Mometasone furoate nasal spray,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,8/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01920893
5572,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Completed,Has Results,Non-Small Cell Lung Cancer,Biological: Ramucirumab|Drug: Placebo (for Ramucirumab)|Drug: Docetaxel,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 3,Industry,Interventional,12/10/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01168973
5573,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: Glimepiride|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,8/10/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01167881
5574,Prasugrel Versus Placebo in Adult Sickle Cell Disease,Completed,Has Results,Sickle Cell Anemia,Drug: Prasugrel|Drug: Placebo,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,Phase 2,Industry,Interventional,7/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01167023
5575,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,Completed,Has Results,"Diabetes Mellitus, Type 2|Renal Insufficiency",Drug: BI 10773|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,7/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01164501
5576,Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects,Completed,Has Results,Chronic Hepatitis C Infection,Drug: ACH-0143102|Drug: Ribavirin,Achillion Pharmaceuticals,Achillion Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,9/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01700179
5577,Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR),Completed,Has Results,Allergic Rhinitis,Drug: BDP|Drug: Placebo,Teva Pharmaceutical Industries,Teva Pharmaceutical Industries,,,,,,,Phase 3,Industry,Interventional,10/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01697956
5578,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo identical to BI 10773 high dose|Drug: Placebo identical to BI 10773 low dose|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,7/10/2019,,https://ClinicalTrials.gov/show/NCT01159600
5579,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder|Depression,Drug: TC-5214|Drug: Placebo,AstraZeneca|Targacept Inc.,AstraZeneca,Targacept Inc.,,,,,,Phase 3,Industry,Interventional,6/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01157078
5580,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder|Depression,Drug: TC-5214|Drug: Placebo,AstraZeneca|Targacept Inc.,AstraZeneca,Targacept Inc.,,,,,,Phase 3,Industry,Interventional,6/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01153347
5581,A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder|MDD|Depression,Drug: TC-5214|Drug: Placebo,AstraZeneca|Targacept Inc.,AstraZeneca,Targacept Inc.,,,,,,Phase 3,Industry,Interventional,6/10/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01152554
5582,"Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis",Completed,Has Results,Cystic Fibrosis,Biological: Alpha-1 HC 100 mg|Biological: Placebo|Biological: Alpha-1 HC 200 mg,Grifols Therapeutics LLC,Grifols Therapeutics LLC,,,,,,,Phase 2,Industry,Interventional,8/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01684410
5583,Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine,Completed,Has Results,Meningococcal Meningitis,"Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine",Novartis Vaccines|GlaxoSmithKline|Novartis,Novartis Vaccines,GlaxoSmithKline,Novartis,,,,,Phase 3,Industry,Interventional,7/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01148017
5584,The Fibrin Pad Cardiovascular Study,Completed,Has Results,Cardiovascular Disease,Biological: EVARREST™|Biological: Topical hemostat|Other: Standard of Care,"Ethicon, Inc.","Ethicon, Inc.",,,,,,,Phase 2,Industry,Interventional,8/1/2012,9/3/2013,https://ClinicalTrials.gov/show/NCT01681030
5585,Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma,Completed,Has Results,Pancreatic Adenocarcinoma,Drug: Gemzar (Gemcitabine)|Drug: TH-302,Threshold Pharmaceuticals|PRA Health Sciences,Threshold Pharmaceuticals,PRA Health Sciences,,,,,,Phase 2,Industry,Interventional,6/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01144455
5586,Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen,Completed,Has Results,HIV Infections,Drug: Subjects do not receive study medication in this study 202094,ViiV Healthcare|Janssen Pharmaceuticals|GlaxoSmithKline,ViiV Healthcare,Janssen Pharmaceuticals,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,6/12/2015,8/17/2018,https://ClinicalTrials.gov/show/NCT02478632
5587,The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis,Completed,Has Results,Psoriasis,Drug: Calcipotriene Foam|Drug: Vehicle Foam,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,5/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01139580
5588,Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies,Completed,Has Results,Atrial Flutter|Ventricular Tachycardia,Device: Amigo catheter robot,"Catheter Robotics, Inc.|Medpace, Inc.","Catheter Robotics, Inc.","Medpace, Inc.",,,,,,Not Applicable,Industry,Interventional,6/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01139814
5589,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo-matching dapagliflozin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,7/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01137474
5590,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773 low dose|Drug: Placebo BI 10773 high dose|Drug: BI 10773 high dose|Drug: Placebo BI 10773 low dose,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,7/10/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01131676
5591,Non-Invasive Neurostimulation for the Prevention of Chronic Migraine,Completed,Has Results,Chronic Migraine,Device: GammaCore Active Device|Device: GammaCore Sham Device,ElectroCore INC,ElectroCore INC,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01667250
5592,Pediatric Catheter-related Thrombosis Imaging Study,Completed,Has Results,Thrombosis,Procedure: Ultrasound|Drug: Magnetic Resonance Imaging with Contrast|Procedure: Magnetic Resonance Imaging without Contrast,Bristol-Myers Squibb|Pfizer,Bristol-Myers Squibb,Pfizer,,,,,,Not Applicable,Industry,Interventional,2/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01137578
5593,Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy,Completed,Has Results,Sedation,Drug: A. CNS 7056|Drug: B. CNS 7056|Drug: C. CNS 7056|Drug: D. Midazolam,Paion UK Ltd.|Premier Research Group plc,Paion UK Ltd.,Premier Research Group plc,,,,,,Phase 2,Industry,Interventional,5/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01145222
5594,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Completed,Has Results,Breast Cancer,Drug: docetaxel|Drug: paclitaxel|Drug: pertuzumab|Drug: pertuzumab-placebo|Drug: trastuzumab [Herceptin]|Drug: trastuzumab emtansine,"Hoffmann-La Roche|Genentech, Inc.",Hoffmann-La Roche,"Genentech, Inc.",,,,,,Phase 3,Industry,Interventional,7/31/2010,9/16/2016,https://ClinicalTrials.gov/show/NCT01120184
5595,"Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis",Completed,Has Results,"Dermatitis, Atopic","Drug: AN2728 Topical Ointment, 2%",Pfizer,Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01652885
5596,A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta,Completed,Has Results,Fabry Disease,Biological: Agalsidase beta,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,4/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01650779
5597,"Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections",Completed,Has Results,Aortic Dissection,Device: Valiant Thoracic Stent Graft with the Captivia Delivery System,Medtronic Endovascular|Medtronic,Medtronic Endovascular,Medtronic,,,,,,Not Applicable,Industry,Interventional,5/10/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT01114724
5598,"Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: DVD-R,Oncotherapeutics|Celgene Corporation,Oncotherapeutics,Celgene Corporation,,,,,,Phase 2,Industry,Interventional,9/9/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01160484
5599,An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 1,Industry,Interventional,5/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01646827
5600,Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors,Completed,Has Results,Locally Advanced Solid Tumor|Metastatic Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Melanoma|Colorectal Cancer,Drug: MSC1936369B (pimasertib)|Drug: SAR245409 (PI3K and mTOR inhibitor),EMD Serono|Sanofi,EMD Serono,Sanofi,,,,,,Phase 1,Industry,Interventional,5/11/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01390818
5601,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Saxagliptin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 4,Industry,Interventional,5/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01107886
5602,"Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis",Completed,Has Results,Psoriasis,Drug: Placebo|Drug: SRT2104,"Sirtris, a GSK Company|GlaxoSmithKline","Sirtris, a GSK Company",GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,6/7/2010,11/9/2011,https://ClinicalTrials.gov/show/NCT01154101
5603,A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns,Completed,Has Results,Burns|Wound Healing,Device: Mepitel Ag,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,8/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01636362
5604,Long-term Study of Cariprazine in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 3,Industry,Interventional,5/31/2010,1/31/2013,https://ClinicalTrials.gov/show/NCT01104792
5605,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Cariprazine|Drug: Aripiprazole|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 3,Industry,Interventional,4/23/2010,12/20/2011,https://ClinicalTrials.gov/show/NCT01104766
5606,Safety and Efficacy of Cariprazine in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Cariprazine|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 3,Industry,Interventional,4/27/2010,12/15/2011,https://ClinicalTrials.gov/show/NCT01104779
5607,A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE),Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: Reyataz + Norvir + Truvada|Drug: Reyataz + Epzicom,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,4/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01102972
5608,Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers,Completed,Has Results,Meibomian Gland Dysfunction|Dry Eye,Device: LipiFlow treatment,"TearScience, Inc.","TearScience, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02102464
5609,Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury,Completed,Has Results,Blunt Thoracic Aortic Injury,Device: Valiant Thoracic Stent Graft with the Captivia Delivery System,Medtronic Endovascular|Medtronic,Medtronic Endovascular,Medtronic,,,,,,Not Applicable,Industry,Interventional,4/10/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT01092767
5610,Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome,Completed,Has Results,Acute Coronary Syndrome,Drug: ADP receptor inhibitors,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,,Industry,Observational,3/10/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01088503
5611,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Glimepiride|Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,3/10/2019,,https://ClinicalTrials.gov/show/NCT01087502
5612,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,Completed,Has Results,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma,Drug: Ibrutinib|Drug: MEDI4736,"Pharmacyclics LLC.|AstraZeneca|Janssen Research & Development, LLC",Pharmacyclics LLC.,AstraZeneca,"Janssen Research & Development, LLC",,,,,Phase 1|Phase 2,Industry,Interventional,5/15/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT02401048
5613,Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: Placebo|Drug: Milnacipran,"Forest Laboratories|Cypress Bioscience, Inc.",Forest Laboratories,"Cypress Bioscience, Inc.",,,,,,Phase 4,Industry,Interventional,2/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01077375
5614,Ixabepilone + Carboplatin Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: Ixabepilone|Drug: Carboplatin,US Oncology Research|Bristol-Myers Squibb,US Oncology Research,Bristol-Myers Squibb,,,,,,Phase 2,Industry,Interventional,1/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01075100
5615,Treatment Interruption of Natalizumab,Completed,Has Results,Relapsing Remitting Multiple Sclerosis,Drug: natalizumab|Drug: interferon beta 1-a|Drug: methylprednisolone|Other: IV placebo|Drug: glatiramer acetate,Biogen|Elan Pharmaceuticals,Biogen,Elan Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,3/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01071083
5616,Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium|Drug: Placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 4,Industry,Interventional,2/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01072396
5617,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Biological: BIIB019 (Daclizumab High Yield Process)|Drug: Interferon beta-1a Placebo|Biological: Interferon beta-1a|Drug: Daclizumab High Yield Process Placebo,Biogen|AbbVie,Biogen,AbbVie,,,,,,Phase 3,Industry,Interventional,5/10/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01064401
5618,Remodulin® to Oral Treprostinil Transition,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: UT-15C SR,United Therapeutics,United Therapeutics,,,,,,,Phase 2,Industry,Interventional,4/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01588405
5619,Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients,Completed,Has Results,HCMV Reactivation or HCMV End-Organ Disease,Drug: 60 mg AIC246|Drug: 120 mg AIC246|Drug: 240 mg AIC246|Other: Placebo,"AiCuris Anti-infective Cures GmbH|Quintiles, Inc.",AiCuris Anti-infective Cures GmbH,"Quintiles, Inc.",,,,,,Phase 2,Industry,Interventional,3/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01063829
5620,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Completed,Has Results,Rheumatoid Arthritis,Drug: Sarilumab|Drug: Placebo (for sarilumab)|Drug: Methotrexate|Drug: Folic Acid,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2|Phase 3,Industry,Interventional,3/10/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01061736
5621,Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondylitis,Drug: Sarilumab|Drug: Placebo,Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,2/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01061723
5622,"A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)",Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Obinutuzumab|Drug: Bendamustine,"Genentech, Inc.|Roche Pharma AG","Genentech, Inc.",Roche Pharma AG,,,,,,Phase 3,Industry,Interventional,4/30/2010,11/30/2018,https://ClinicalTrials.gov/show/NCT01059630
5623,Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder,Completed,Has Results,Bipolar I Disorder,Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 3,Industry,Interventional,2/28/2010,2/29/2012,https://ClinicalTrials.gov/show/NCT01059539
5624,Safety and Efficacy of Cariprazine for Bipolar I Disorder,Completed,Has Results,Mania|Bipolar I Disorder,Drug: Cariprazine|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 3,Industry,Interventional,2/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01058668
5625,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,Completed,Has Results,"Hepatitis C, Chronic",Drug: Telaprevir|Drug: pegylated interferon (Peg-IFN) alfa-2a|Drug: ribavirin (RBV),Janssen Infectious Diseases BVBA|Vertex Pharmaceuticals Incorporated,Janssen Infectious Diseases BVBA,Vertex Pharmaceuticals Incorporated,,,,,,Phase 3,Industry,Interventional,4/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01054573
5626,Safety and Efficacy of Cariprazine for Mania,Completed,Has Results,Bipolar Disorder|Mania,Drug: Cariprazine|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 3,Industry,Interventional,2/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01058096
5627,Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: Rasagiline|Drug: Placebo,"Teva Neuroscience, Inc.|H. Lundbeck A/S|Teva Pharmaceutical Industries","Teva Neuroscience, Inc.",H. Lundbeck A/S,Teva Pharmaceutical Industries,,,,,Phase 4,Industry,Interventional,12/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01049984
5628,A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: KW-2478|Drug: Bortezomib,"Kyowa Hakko Kirin Pharma, Inc.|Kyowa Kirin Co., Ltd.|Kyowa Kirin Pharmaceutical Development, Inc.","Kyowa Hakko Kirin Pharma, Inc.","Kyowa Kirin Co., Ltd.","Kyowa Kirin Pharmaceutical Development, Inc.",,,,,Phase 1|Phase 2,Industry,Interventional,3/10/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01063907
5629,A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors,Completed,Has Results,Malignant Solid Tumor,Biological: Ramucirumab|Drug: Docetaxel,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,7/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01567163
5630,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,Completed,Has Results,Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,3/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01042977
5631,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy",Completed,Has Results,Diabetic Peripheral Neuropathy,Drug: Tapentadol extended release (ER)|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Grünenthal GmbH,,,,,,Phase 3,Industry,Interventional,12/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01041859
5632,A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks,Completed,Has Results,Phenylketonuria,Biological: BMN 165 (rAvPAL-PEG),BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 2,Industry,Interventional,5/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01560286
5633,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",Completed,Has Results,Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,2/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01031680
5634,"Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",Completed,Has Results,COPD,Drug: indacaterol|Drug: placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,1/12/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01543828
5635,Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device,Completed,Has Results,Intracranial Aneurysms,Device: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.),"Microvention-Terumo, Inc.","Microvention-Terumo, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,3/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01541254
5636,"CP-751,871 Treatment For Patients With Multiple Myeloma",Completed,Has Results,Multiple Myeloma,"Drug: CP-751,871",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,12/3/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT01536145
5637,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301",Completed,Has Results,Acne Vulgaris,Drug: Tazarotene foam|Drug: Vehicle Foam,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,10/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01017146
5638,Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine,Completed,Has Results,Migraine,Device: Sumavel DosePro|Drug: Sumatriptan,"Zogenix, Inc.|Synteract, Inc.","Zogenix, Inc.","Synteract, Inc.",,,,,,Phase 4,Industry,Interventional,11/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01016834
5639,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne",Completed,Has Results,Acne Vulgaris,Drug: Tazarotene Foam|Drug: Vehicle Foam,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,10/1/2009,11/9/2010,https://ClinicalTrials.gov/show/NCT01017120
5640,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Completed,Has Results,Tobacco Dependence,Drug: Nicotine Spray|Drug: Placebo,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|GlaxoSmithKline|McNeil AB|Johnson & Johnson Consumer and Personal Products Worldwide","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",GlaxoSmithKline,McNeil AB|Johnson & Johnson Consumer and Personal Products Worldwide,McNeil AB,Johnson & Johnson Consumer and Personal Products Worldwide,,,Phase 3,Industry,Interventional,1/31/2015,2/10/2016,https://ClinicalTrials.gov/show/NCT02355665
5641,Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: Placebo|Drug: Milnacipran,"Forest Laboratories|Cypress Bioscience, Inc.",Forest Laboratories,"Cypress Bioscience, Inc.",,,,,,Phase 4,Industry,Interventional,11/9/2019,,https://ClinicalTrials.gov/show/NCT01014585
5642,Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773 placebo|Drug: BI 10773 low dose|Drug: BI 10773 high dose,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 2,Industry,Interventional,11/9/2019,,https://ClinicalTrials.gov/show/NCT01011868
5643,Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B,Completed,Has Results,Severe Hemophilia B,Drug: Factor IX (rFIXFc)|Drug: rFIX,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Bioverativ Therapeutics Inc.,Swedish Orphan Biovitrum,,,,,,Phase 3,Industry,Interventional,12/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01027364
5644,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),Completed,Has Results,"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Drug: Golimumab 50 mg SC|Drug: Golimumab 2 mg/kg IV|Drug: Methotrexate (MTX)|Drug: Placebo SC|Drug: Placebo IV,"Janssen Biotech, Inc.|Merck Sharp & Dohme Corp.","Janssen Biotech, Inc.",Merck Sharp & Dohme Corp.,,,,,,Phase 3,Industry,Interventional,12/9/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01004432
5645,Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve,Completed,Has Results,Heart Valve Diseases,Device: Trifecta valve,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,2/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01514162
5646,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,10/9/2019,,https://ClinicalTrials.gov/show/NCT00996658
5647,"Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months",Completed,Has Results,Influenza,Biological: MF59-eH1N1_f,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 2|Phase 3,Industry,Interventional,10/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00996307
5648,Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone,Completed,Has Results,Type 2 Diabetes,Drug: KRP-104|Drug: Placebo,"ActivX Biosciences, Inc.|Kyorin Pharmaceutical Co.,Ltd","ActivX Biosciences, Inc.","Kyorin Pharmaceutical Co.,Ltd",,,,,,Phase 2,Industry,Interventional,10/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00995345
5649,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux,Drug: Rabeprazole sodium 5 mg|Drug: Rabeprazole sodium 10 mg|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Eisai Inc.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Eisai Inc.,,,,,,Phase 3,Industry,Interventional,11/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00992589
5650,NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain,Completed,Has Results,Pain|Back Pain|Low Back Pain|Back Pain With Radiation,Drug: NUCYNTA|Drug: Oxycodone IR,"Ortho-McNeil Janssen Scientific Affairs, LLC|Grünenthal GmbH","Ortho-McNeil Janssen Scientific Affairs, LLC",Grünenthal GmbH,,,,,,Phase 3,Industry,Interventional,9/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00986180
5651,Dapagliflozin DPPIV Inhibitor add-on Study,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,10/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00984867
5652,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Completed,Has Results,Thyroid Neoplasms,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo",Bayer|Amgen,Bayer,Amgen,,,,,,Phase 3,Industry,Interventional,10/15/2009,8/30/2017,https://ClinicalTrials.gov/show/NCT00984282
5653,Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV,Completed,Has Results,Hepatitis C|HIV Infections,Drug: telaprevir or matching placebo|Biological: peginterferon alfa-2a|Drug: ribavirin (fixed dose)|Drug: ribavirin (weight-based dose),Vertex Pharmaceuticals Incorporated|Tibotec Pharmaceutical Limited,Vertex Pharmaceuticals Incorporated,Tibotec Pharmaceutical Limited,,,,,,Phase 2,Industry,Interventional,10/9/2019,,https://ClinicalTrials.gov/show/NCT00983853
5654,A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Sifalimumab,MedImmune LLC|PPD,MedImmune LLC,PPD,,,,,,Phase 2,Industry,Interventional,8/10/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00979654
5655,"Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)",Completed,Has Results,Multiple System Atrophy,Drug: rasagiline mesylate|Drug: placebo,Teva Pharmaceutical Industries|H. Lundbeck A/S,Teva Pharmaceutical Industries,H. Lundbeck A/S,,,,,,Phase 2,Industry,Interventional,12/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00977665
5656,Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: ADL5859|Drug: ADL5747|Drug: Oxycodone CR|Drug: Placebo,Cubist Pharmaceuticals LLC|Pfizer,Cubist Pharmaceuticals LLC,Pfizer,,,,,,Phase 2,Industry,Interventional,10/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00979953
5657,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults,Completed,Has Results,Influenza,Biological: MF59-eH1N1_f,Novartis|Novartis Vaccines,Novartis,Novartis Vaccines,,,,,,Phase 2|Phase 3,Industry,Interventional,9/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00973349
5658,"Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens",Completed,Has Results,Refractive Ametropia,Device: etafilcon A with print and PVP for dark eyes (EAPVPDE)|Device: etafilcon A control lens (EADE),"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01484054
5659,Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: UT-15C SR|Drug: Tyvaso Inhalation Solution,United Therapeutics,United Therapeutics,,,,,,,Phase 2,Industry,Interventional,10/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01477333
5660,"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",Completed,Has Results,Neovascular Age-related Macular Degeneration,Drug: Intravitreal Aflibercept Injection 2mg,Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 3,Industry,Interventional,12/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00964795
5661,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Metformin XR,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,8/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00960076
5662,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,Completed,Has Results,"Arthritis, Rheumatoid",Drug: Golimumab|Other: Placebo|Drug: methotrexate (MTX),"Centocor, Inc.|Schering-Plough","Centocor, Inc.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,9/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00973479
5663,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,8/9/2019,,https://ClinicalTrials.gov/show/NCT00954447
5664,A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: GSK1349572 (Cohort I)|Drug: GSK1349572 (Cohort II),ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,8/9/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00950859
5665,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Completed,Has Results,Irritable Bowel Syndrome Characterized by Constipation,Drug: Linaclotide 290 micrograms|Drug: Matching placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Forest Laboratories,"Ironwood Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,7/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00948818
5666,A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study,Completed,Has Results,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.","Seattle Genetics, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Industry,Interventional,7/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00947856
5667,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),Completed,Has Results,Macular Edema Secondary to Central Retinal Vein Occlusion,Biological: VEGF Trap-Eye 2.0mg|Drug: Sham,Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 3,Industry,Interventional,7/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00943072
5668,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Completed,Has Results,Irritable Bowel Syndrome With Constipation,Drug: Linaclotide or Matching Placebo,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories","Ironwood Pharmaceuticals, Inc.",Forest Laboratories,,,,,,Phase 3,Industry,Interventional,7/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00938717
5669,ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: ELND005 (scyllo-inositol),Transition Therapeutics Ireland Limited|Transition Therapeutics,Transition Therapeutics Ireland Limited,Transition Therapeutics,,,,,,Phase 2,Industry,Interventional,6/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00934050
5670,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: alemtuzumab,"Genzyme, a Sanofi Company|Bayer|Sanofi","Genzyme, a Sanofi Company",Bayer,Sanofi,,,,,Phase 3,Industry,Interventional,8/9/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00930553
5671,Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis,Completed,Has Results,Bronchiectasis,"Drug: Ciprofloxacin (Cipro, BAYQ3939)|Drug: Placebo",Bayer|Novartis,Bayer,Novartis,,,,,,Phase 2,Industry,Interventional,6/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00930982
5672,StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns,Completed,Has Results,Skin Wound|Burns|Trauma-related Wound,Biological: StrataGraft Skin Tissue,"Stratatech, a Mallinckrodt Company","Stratatech, a Mallinckrodt Company",,,,,,,Phase 1,Industry,Interventional,9/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01437852
5673,Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke,Completed,Has Results,Cryptogenic Symptomatic Transient Ischemic Attack|Cryptogenic Ischemic Stroke,Device: Reveal® XT Insertable Cardiac Monitor,Medtronic Cardiac Rhythm and Heart Failure|Medtronic Bakken Research Center,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Bakken Research Center,,,,,,Phase 4,Industry,Interventional,6/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00924638
5674,Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|Biological: Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01430819
5675,Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing,Completed,Has Results,Fracture Healing,Biological: Romosozumab|Drug: Placebo,Amgen|UCB Pharma,Amgen,UCB Pharma,,,,,,Phase 2,Industry,Interventional,9/2/2009,5/10/2013,https://ClinicalTrials.gov/show/NCT00907296
5676,"A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases",Completed,Has Results,Primary Immunodeficiency Diseases,Biological: NewGam,Octapharma|Premier Research Group plc,Octapharma,Premier Research Group plc,,,,,,Phase 3,Industry,Interventional,1/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01012323
5677,Continued Access Protocol,Completed,Has Results,Atrial Fibrillation,Device: Arctic Front Cardiac Cryoablation System,Medtronic Cardiac Rhythm and Heart Failure|Medtronic,Medtronic Cardiac Rhythm and Heart Failure,Medtronic,,,,,,Not Applicable,Industry,Interventional,3/9/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00889681
5678,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Drug: exenatide twice daily,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,3/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00877890
5679,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: ABC/DTG/3TC FDC|Drug: Ongoing cART regimen,ViiV Healthcare|PPD|GlaxoSmithKline,ViiV Healthcare,PPD,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,4/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02105987
5680,Restorelle Direct Fix Anterior and Posterior (A&P) for Female Pelvic Organ Prolapse: A Prospective Post Market Study,Completed,Has Results,Pelvic Organ Prolapse (POP),Device: Restorelle Direct Fix A&P,Coloplast A/S,Coloplast A/S,,,,,,,,Industry,Observational,6/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01378065
5681,"Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism",Completed,Has Results,Autism,Drug: Memantine - Extended Release (ER)|Drug: Placebo,Forest Laboratories|Merz Pharmaceuticals GmbH,Forest Laboratories,Merz Pharmaceuticals GmbH,,,,,,Phase 2,Industry,Interventional,4/9/2019,,https://ClinicalTrials.gov/show/NCT00872898
5682,"Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary",Completed,Has Results,Carcinoma of Unknown Primary,"Drug: belinostat, carboplatin, paclitaxel|Drug: carboplatin, paclitaxel","Onxeo|Spectrum Pharmaceuticals, Inc",Onxeo,"Spectrum Pharmaceuticals, Inc",,,,,,Phase 2,Industry,Interventional,2/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00873119
5683,Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma,Completed,Has Results,Persistent Allergic Asthma,Drug: Omalizumab|Drug: Placebo,"Novartis Pharmaceuticals|Genentech, Inc.|Novartis",Novartis Pharmaceuticals,"Genentech, Inc.",Novartis,,,,,Phase 4,Industry,Interventional,3/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00870584
5684,"A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab",Completed,Has Results,Metastatic Breast Cancer,Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Drug: Pertuzumab 420 mg,Hoffmann-La Roche|Roche Pharma AG,Hoffmann-La Roche,Roche Pharma AG,,,,,,Phase 1|Phase 2,Industry,Interventional,5/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00875979
5685,Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma,Completed,Has Results,Lymphoma,Drug: Inotuzumab Ozogamicin (CMC-544),Pfizer|UCB Pharma,Pfizer,UCB Pharma,,,,,,Phase 2,Industry,Interventional,7/30/2009,6/27/2013,https://ClinicalTrials.gov/show/NCT00868608
5686,Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma,Completed,Has Results,"Lymphoma, B-Cell",Drug: inotuzumab ozogamicin (CMC-544)|Drug: rituximab,Pfizer|UCB Pharma,Pfizer,UCB Pharma,,,,,,Phase 2,Industry,Interventional,6/8/2009,10/31/2012,https://ClinicalTrials.gov/show/NCT00867087
5687,A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma,Completed,Has Results,"Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.","Seattle Genetics, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Industry,Interventional,3/9/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT00866047
5688,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Completed,Has Results,Ovarian Cancer,Drug: Pazopanib|Drug: Placebo,Novartis Pharmaceuticals|GlaxoSmithKline|Novartis,Novartis Pharmaceuticals,GlaxoSmithKline,Novartis,,,,,Phase 3,Industry,Interventional,5/26/2009,8/24/2017,https://ClinicalTrials.gov/show/NCT00866697
5689,Sunitinib Non Small Cell Lung Cancer Patients Over 70,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Sutent,US Oncology Research|Pfizer,US Oncology Research,Pfizer,,,,,,Phase 2,Industry,Interventional,2/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00864721
5690,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release 10mg|Drug: Desvenlafaxine Succinate Sustained-Release 50 mg|Drug: placebo,Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Pfizer,,,,,,Phase 3,Industry,Interventional,4/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00863798
5691,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Metformin XR|Drug: dapagliflozin matching Placebo|Drug: metformin HCl Modified Release matching Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,4/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00859898
5692,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Completed,Has Results,Meningococcal Meningitis,Biological: MenACWY-CRM conjugate vaccine|Biological: Licensed comparator,Novartis Vaccines|GlaxoSmithKline|Novartis,Novartis Vaccines,GlaxoSmithKline,Novartis,,,,,Phase 3,Industry,Interventional,2/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00856297
5693,Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Antidepressant + placebo|Drug: Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant + cariprazine (1-2 mg/d),Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 2,Industry,Interventional,6/30/2009,12/6/2010,https://ClinicalTrials.gov/show/NCT00854100
5694,A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2428757|Drug: TT223|Drug: Placebo for LY2428757|Drug: Placebo for TT223,Eli Lilly and Company|Transition Therapeutics,Eli Lilly and Company,Transition Therapeutics,,,,,,Phase 1,Industry,Interventional,2/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00853151
5695,Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA,Completed,Has Results,"Skin Infections, Bacterial","Drug: Retpamulin Ointment, 1%|Drug: Linezolid","Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,4/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00852540
5696,Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression,Completed,Has Results,Bipolar Depression,Drug: cariprazine|Drug: placebo,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 2,Industry,Interventional,6/30/2009,6/15/2010,https://ClinicalTrials.gov/show/NCT00852202
5697,Evaluation of Patiromer in Heart Failure Patients,Completed,Has Results,Hyperkalemia|Heart Failure,Drug: patiromer|Drug: placebo,"Relypsa, Inc.|Medpace, Inc.","Relypsa, Inc.","Medpace, Inc.",,,,,,Phase 2,Industry,Interventional,4/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00868439
5698,A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma,Completed,Has Results,"Disease, Hodgkin",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.","Seattle Genetics, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,Phase 2,Industry,Interventional,2/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00848926
5699,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo,"Pfizer|Medivation, Inc.",Pfizer,"Medivation, Inc.",,,,,,Phase 3,Industry,Interventional,2/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00838110
5700,"A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients",Completed,Has Results,Human Immunodeficiency Virus-1,Drug: maraviroc,ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 2,Industry,Interventional,3/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00827112
5701,Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass,Completed,Has Results,Cardiac Surgery|Cardiopulmonary Bypass,Biological: AT-III (Human)|Other: Placebo,Grifols Therapeutics LLC|Covance|Clinipace Worldwide,Grifols Therapeutics LLC,Covance,Clinipace Worldwide,,,,,Phase 2,Industry,Interventional,6/26/2014,1/25/2018,https://ClinicalTrials.gov/show/NCT02037555
5702,"A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)",Completed,Has Results,Breast Neoplasms|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation,Drug: talazoparib,"Pfizer|Myriad Genetic Laboratories, Inc.|Medivation, Inc.",Pfizer,"Myriad Genetic Laboratories, Inc.","Medivation, Inc.",,,,,Phase 2,Industry,Interventional,12/13/2013,10/31/2018,https://ClinicalTrials.gov/show/NCT02034916
5703,Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy,Completed,Has Results,Tonsillectomy,Drug: Intravenous ibuprofen|Other: Normal Saline,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01332253
5704,"Gemzar, Cisp, Sunitinib Urothelial Ca",Completed,Has Results,Urothelial Cancer,"Drug: Gemcitabine, Cisplatin, Sunitinib",US Oncology Research|Pfizer,US Oncology Research,Pfizer,,,,,,Phase 2,Industry,Interventional,8/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00821327
5705,CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass,Completed,Has Results,Heart Failure,Device: CentriMag Ventricular Assist System,Abbott Medical Devices|Thoratec Corporation,Abbott Medical Devices,Thoratec Corporation,,,,,,Not Applicable,Industry,Interventional,10/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00819793
5706,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Completed,Has Results,Eczema,Drug: alitretinoin|Drug: Placebo,"Stiefel, a GSK Company|Basilea Pharmaceutica|GlaxoSmithKline","Stiefel, a GSK Company",Basilea Pharmaceutica,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,1/8/2009,4/26/2012,https://ClinicalTrials.gov/show/NCT00817063
5707,Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma,Completed,Has Results,Advanced Melanoma,Biological: Ipilimumab,Bristol-Myers Squibb|Medarex,Bristol-Myers Squibb,Medarex,,,,,,Phase 1,Industry,Interventional,8/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00920907
5708,A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma,Completed,Has Results,B-cell Small Lymphocytic Lymphoma Recurrent,Drug: TRU-016|Drug: Bendamustine|Drug: Rituximab,Aptevo Therapeutics,Aptevo Therapeutics,,,,,,,Phase 1,Industry,Interventional,5/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01317901
5709,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Completed,Has Results,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Drug: Rivaroxaban 2.5 mg|Drug: Rivaroxaban 5 mg|Drug: Placebo|Drug: Standard of care,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,,,,,,Phase 3,Industry,Interventional,11/8/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00809965
5710,High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam),Completed,Has Results,Primary Immunodeficiency Disease,Biological: NewGam,Octapharma,Octapharma,,,,,,,Phase 3,Industry,Interventional,5/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01313507
5711,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Completed,Has Results,Meningitis|Meningococcal Infection,"Biological: MenACWY-CRM197|Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Biological: Hib (Haemophilus influenza b) Vaccine|Biological: IPV (Inactivated Polio Vaccine) Vaccine|Biological: Pneumococcal conjugate Vaccine|Biological: MMR (Measles, Mumps, and Rubella) Vaccine|Biological: Varicella Vaccine|Biological: Hepatitis A Virus",Novartis|Novartis Vaccines,Novartis,Novartis Vaccines,,,,,,Phase 3,Industry,Interventional,12/8/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00806195
5712,Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects,Completed,Has Results,Short Bowel Syndrome,Drug: teduglutide|Drug: placebo,Shire|Nycomed,Shire,Nycomed,,,,,,Phase 3,Industry,Interventional,11/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00798967
5713,A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure,Completed,Has Results,Hypertension,Drug: amlodipine and olmesartan medoxomil tablets|Drug: hydrochlorothiazide tablets,"Daiichi Sankyo, Inc.|Integrium","Daiichi Sankyo, Inc.",Integrium,,,,,,Phase 4,Industry,Interventional,11/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00791258
5714,Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL),Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: PCI-32765,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 1,Industry,Interventional,2/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01292135
5715,DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact,Completed,Has Results,Diabetic Macular Edema,Procedure: Laser Photocoagulation|Drug: Intravitreal Aflibercept Injection,Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 2,Industry,Interventional,12/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00789477
5716,Clinical Evaluation of Ajust™ in Stress Urinary Incontinence,Completed,Has Results,Female Stress Urinary Incontinence,Device: Ajust Adjustable Single-Incision Sling,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01290796
5717,Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: ciclesonide hydrofluoroalkane (HFA) nasal aerosol|Drug: mometasone nasal inhalation,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,2/11/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01287364
5718,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,Completed,Has Results,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Drug: Placebo|Drug: Droxidopa,Chelsea Therapeutics|Chiltern International Inc.,Chelsea Therapeutics,Chiltern International Inc.,,,,,,Phase 3,Industry,Interventional,9/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00782340
5719,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),Completed,Has Results,Asthma,Drug: tiotropium 5mcg/day|Drug: placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,10/8/2019,,https://ClinicalTrials.gov/show/NCT00776984
5720,Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease,Drug: Mipomersen|Drug: Placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","Kastle Therapeutics, LLC","Ionis Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,1/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00794664
5721,Subcutaneous Rehydration Compared to Intravenous Rehydration,Completed,Has Results,Dehydration,Drug: recombinant human hyaluronidase,Halozyme Therapeutics|Baxter Healthcare Corporation,Halozyme Therapeutics,Baxter Healthcare Corporation,,,,,,Phase 4,Industry,Interventional,10/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00773175
5722,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,Completed,Has Results,"Epilepsies, Partial",Drug: Placebo|Drug: 2400mg SPN-804|Drug: 1200mg SPN-804,"Supernus Pharmaceuticals, Inc.|Parexel","Supernus Pharmaceuticals, Inc.",Parexel,,,,,,Phase 3,Industry,Interventional,11/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00772603
5723,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),Completed,Has Results,Asthma,Drug: tiotropium 5mcg/day|Drug: placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 3,Industry,Interventional,10/8/2019,,https://ClinicalTrials.gov/show/NCT00772538
5724,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Completed,Has Results,Back Pain,Drug: oxycodone IR|Drug: placebo|Drug: tapentadol IR,"Ortho-McNeil Janssen Scientific Affairs, LLC|Grünenthal GmbH","Ortho-McNeil Janssen Scientific Affairs, LLC",Grünenthal GmbH,,,,,,Phase 3,Industry,Interventional,9/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00771758
5725,Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease,Drug: Mipomersen sodium|Drug: Placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","Kastle Therapeutics, LLC","Ionis Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,11/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00770146
5726,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,Completed,Has Results,Melanoma,Biological: Talimogene laherparepvec|Biological: GM-CSF,BioVex Limited|Amgen,BioVex Limited,Amgen,,,,,,Phase 3,Industry,Interventional,4/9/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00769704
5727,"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Completed,Has Results,Chronic Constipation|Irritable Bowel Syndrome With Constipation,Drug: Linaclotide,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Forest Laboratories,"Ironwood Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,10/31/2008,1/31/2012,https://ClinicalTrials.gov/show/NCT00765999
5728,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Completed,Has Results,Chronic Constipation,Drug: Linaclotide 290 micrograms|Drug: Linaclotide 145 micrograms|Drug: Placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Forest Laboratories,"Ironwood Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,9/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00765882
5729,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Drug: placebo|Drug: exenatide,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,10/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00765817
5730,Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy,Completed,Has Results,Procedural Sedation|Endoscopy,Drug: CNS 7056|Drug: Midazolam,Paion UK Ltd.|Premier Research Group plc,Paion UK Ltd.,Premier Research Group plc,,,,,,Phase 2,Industry,Interventional,3/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00869440
5731,Study Of Hernia Repair Utilizing The Bard Ventrio Hernia Patch,Completed,Has Results,Ventral Hernia,Device: Bard Ventrio Hernia Patch,C. R. Bard|FGK Clinical Research GmbH,C. R. Bard,FGK Clinical Research GmbH,,,,,,,Industry,Observational,3/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00866814
5732,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Completed,Has Results,Hepatitis C,Drug: telaprevir|Drug: ribavirin|Biological: peginterferon alfa-2a,Vertex Pharmaceuticals Incorporated|Tibotec Pharmaceutical Limited,Vertex Pharmaceuticals Incorporated,Tibotec Pharmaceutical Limited,,,,,,Phase 3,Industry,Interventional,10/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00758043
5733,Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment,Completed,Has Results,HIV,Drug: ritonavir|Drug: darunavir|Drug: emtricitabine [FTC]/tenofovir [TDF]|Drug: atazanavir,"Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","Tibotec, Inc","Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 4,Industry,Interventional,10/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00757783
5734,Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.,Completed,Has Results,Anemia,Drug: Peginesatide,Takeda|Affymax,Takeda,Affymax,,,,,,Phase 2,Industry,Interventional,10/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00752791
5735,Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin,Completed,Has Results,Type 2 Diabetes,Drug: exenatide,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,10/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00753896
5736,Naproxen Sodium Extended-Release Actual Use Study,Completed,Has Results,Pain,Drug: Naproxen Sodium ER (BAYH6689),"Bayer|Pegus Research, Inc.",Bayer,"Pegus Research, Inc.",,,,,,Phase 3,Industry,Interventional,7/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00751400
5737,Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.,Completed,Has Results,Anemia,Drug: Peginesatide,Takeda|Affymax,Takeda,Affymax,,,,,,Phase 2,Industry,Interventional,9/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00752609
5738,Prevention Study in Adult Patients Suffering From Migraine Headaches,Completed,Has Results,Migraine Disorders|Migraine,Drug: GSK1838262|Drug: Placebo,"XenoPort, Inc.|GlaxoSmithKline","XenoPort, Inc.",GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,8/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00742209
5739,"A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy",Completed,Has Results,Pain|Cancer|Colonic Diseases,Drug: GIC-1001,gicare Pharma Inc.|JSS Medical Research Inc.|Algorithme Pharma Inc,gicare Pharma Inc.,JSS Medical Research Inc.,Algorithme Pharma Inc,,,,,Phase 2,Industry,Interventional,7/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01926444
5740,Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination,Completed,Has Results,Meningitis|Meningococcal Meningitis|Meningococcal Infections,"Biological: Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|Biological: Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate",Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,11/10/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01239043
5741,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,9/22/2008,12/29/2009,https://ClinicalTrials.gov/show/NCT00736879
5742,An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Vortioxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Takeda,H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,6/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00734071
5743,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Covance","Otsuka Pharmaceutical Development & Commercialization, Inc.",Covance,,,,,,Phase 3,Industry,Interventional,12/8/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00731549
5744,Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Vortioxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Takeda,H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,6/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00731120
5745,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Placebo|Drug: Vortioxetine|Drug: Duloxetine,Takeda|H. Lundbeck A/S,Takeda,H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,6/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00730691
5746,Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis,Completed,Has Results,Onychomycosis,Drug: Albaconazole 100mg|Drug: Albaconazole 200mg|Drug: Albaconazole 400mg|Drug: Placebo 400 mg,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,7/16/2008,2/19/2010,https://ClinicalTrials.gov/show/NCT00730405
5747,"An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Completed,Has Results,Irritable Bowel Syndrome With Constipation|Chronic Constipation,Drug: Linaclotide,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories","Ironwood Pharmaceuticals, Inc.",Forest Laboratories,,,,,,Phase 3,Industry,Interventional,9/8/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00730171
5748,Trial of Linaclotide in Patients With Chronic Constipation,Completed,Has Results,Chronic Constipation,Drug: Matching Placebo|Drug: Linaclotide,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories","Ironwood Pharmaceuticals, Inc.",Forest Laboratories,,,,,,Phase 3,Industry,Interventional,8/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00730015
5749,A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States,Completed,Has Results,Systemic Lupus Erythematosus,Biological: Belimumab 1 mg/kg|Biological: Belimumab 10 mg/kg,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","Human Genome Sciences Inc., a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,8/8/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00724867
5750,Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma,Completed,Has Results,Hodgkin Lymphoma,Drug: PLX3397,Plexxikon,Plexxikon,,,,,,,Phase 2,Industry,Interventional,12/10/2019,,https://ClinicalTrials.gov/show/NCT01217229
5751,RESTART C0168Z05 Rheumatoid Arthritis Study,Completed,Has Results,Rheumatoid Arthritis,Biological: Infliximab,"Centocor Ortho Biotech Services, L.L.C.|Schering-Plough","Centocor Ortho Biotech Services, L.L.C.",Schering-Plough,,,,,,Phase 4,Industry,Interventional,7/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00714493
5752,Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne,Completed,Has Results,Acne Vulgaris,Drug: Benzoyl peroxide gel|Drug: Clindamycin gel|Drug: Tazarotene cream|Drug: Vehicle gel|Drug: Vehicle cream,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,6/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00713609
5753,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Completed,Has Results,Human Immunodeficiency Virus Infection,Drug: lopinavir/ritonavir (LPV/r)|Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|Drug: raltegravir (RAL),Abbott|Merck Sharp & Dohme Corp.,Abbott,Merck Sharp & Dohme Corp.,,,,,,Phase 3,Industry,Interventional,7/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00711009
5754,Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD,Completed,Has Results,Autosomal Dominant Polycystic Kidney Disease,Drug: Tolvaptan MR|Drug: Tolvaptan IR,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,10/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01210560
5755,Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vortioxetine,Takeda|H. Lundbeck A/S,Takeda,H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,6/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00707980
5756,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease,Completed,Has Results,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Drug: mipomersen sodium|Drug: placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","Kastle Therapeutics, LLC","Ionis Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,7/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00706849
5757,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Completed,Has Results,Mantle Cell Lymphoma,Drug: Rituximab 375 mg/m^2|Drug: Cyclophosphamide 750 mg/m^2|Drug: Doxorubicin 50 mg/m^2|Drug: VELCADE 1.3 mg/m^2|Drug: Prednisone 100 mg/m^2|Drug: Vincristine 1.4 mg/m^2,"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Takeda","Millennium Pharmaceuticals, Inc.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Takeda,,,,,Phase 3,Industry,Interventional,5/1/2008,6/17/2017,https://ClinicalTrials.gov/show/NCT00722137
5758,Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer,Completed,Has Results,Carcinoma|Adenocarcinoma|Renal Cell|Nephroid Carcinoma|Hypernephroid,Drug: RAD001(everolimus)|Drug: interferon alfa-2a|Drug: bevacizumab,Novartis Pharmaceuticals|Roche Pharma AG|Novartis,Novartis Pharmaceuticals,Roche Pharma AG,Novartis,,,,,Phase 2,Industry,Interventional,11/12/2008,4/15/2013,https://ClinicalTrials.gov/show/NCT00719264
5759,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment",Completed,Has Results,"Hepatitis C, Chronic",Drug: Telaprevir|Drug: Peg-IFN-alfa-2a|Drug: Ribavirin|Drug: Placebo,Tibotec BVBA|Tibotec Pharmaceutical Limited,Tibotec BVBA,Tibotec Pharmaceutical Limited,,,,,,Phase 3,Industry,Interventional,10/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00703118
5760,Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors,Completed,Has Results,Advanced Cancer,Drug: Cetuximab,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 2,Industry,Interventional,2/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00698841
5761,Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study,Completed,Has Results,Epithelial Ovarian Cancer,Biological: MUC1 Dendritic Cell Vaccine (Cvac),Prima BioMed Ltd,Prima BioMed Ltd,,,,,,,Phase 2,Industry,Interventional,12/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01617629
5762,"Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",Completed,Has Results,Metastatic Breast Cancer,Drug: Dasatinib|Drug: Letrozole,Bristol-Myers Squibb|US Oncology Research,Bristol-Myers Squibb,US Oncology Research,,,,,,Phase 2,Industry,Interventional,8/8/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00696072
5763,Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Placebo|Drug: Cariprazine|Drug: Risperidone,Forest Laboratories|Gedeon Richter Ltd.,Forest Laboratories,Gedeon Richter Ltd.,,,,,,Phase 2,Industry,Interventional,6/30/2008,8/31/2009,https://ClinicalTrials.gov/show/NCT00694707
5764,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: Mipomersen Sodium,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","Kastle Therapeutics, LLC","Ionis Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,4/8/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00694109
5765,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Completed,Has Results,Acne Vulgaris|Acne,Drug: CT Gel|Drug: Clindamycin Gel (clindamycin )|Drug: Tretinoin Gel (tretinoin)|Drug: Vehicle Gel,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,4/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00689117
5766,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies,Completed,Has Results,Psoriasis,Drug: U0267|Drug: Vehicle,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,3/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00688519
5767,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies,Completed,Has Results,Psoriasis,Drug: U0267 Foam|Drug: Vehicle foam,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,3/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00689481
5768,Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP),Completed,Has Results,Myopia,Device: etafilcon A (A)|Device: etafilcon A (B)|Device: etafilcon A (C),"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/1/2010,8/1/2010,https://ClinicalTrials.gov/show/NCT01180777
5769,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Drug: metformin|Drug: sitagliptin|Drug: pioglitazone,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,11/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00676338
5770,A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: duloxetine hydrochloride|Drug: placebo,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 4,Industry,Interventional,6/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00673452
5771,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,4/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00673231
5772,Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vortioxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Takeda,H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,4/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00672958
5773,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Takeda,H. Lundbeck A/S,,,,,,Phase 3,Industry,Interventional,4/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00672620
5774,Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness,Completed,Has Results,Opioid-Induced Constipation,Drug: Methylnaltrexone|Drug: Placebo,"Bausch Health Americas, Inc.|Progenics Pharmaceuticals, Inc.","Bausch Health Americas, Inc.","Progenics Pharmaceuticals, Inc.",,,,,,Phase 4,Industry,Interventional,6/8/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00672477
5775,Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness,Completed,Has Results,Opioid-Induced Constipation,Drug: Methylnaltrexone bromide,"Bausch Health Americas, Inc.|Progenics Pharmaceuticals, Inc.","Bausch Health Americas, Inc.","Progenics Pharmaceuticals, Inc.",,,,,,Phase 4,Industry,Interventional,7/8/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00672139
5776,A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression,Completed,Has Results,Depression,Drug: duloxetine|Drug: fluoxetine|Drug: citalopram|Drug: paroxetine|Drug: sertraline,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 4,Industry,Interventional,5/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00666757
5777,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 2|Phase 3,Industry,Interventional,6/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00663260
5778,Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS),Completed,Has Results,Short Bowel Syndrome,Drug: teduglutide,Shire|Nycomed Germany GmbH,Shire,Nycomed Germany GmbH,,,,,,Phase 3,Industry,Interventional,9/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00930644
5779,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Completed,Has Results,Advanced Parkinson's Disease,Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo Gel|Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","AbbVie (prior sponsor, Abbott)","Quintiles, Inc.",AbbVie,,,,,Phase 3,Industry,Interventional,12/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00660387
5780,The Fibrin Patch Soft Tissue Study,Completed,Has Results,Hemostasis,Drug: Fibrin Pad|Device: SURGICEL™,"Ethicon, Inc.|OMRIX Biopharmaceuticals","Ethicon, Inc.",OMRIX Biopharmaceuticals,,,,,,Phase 2,Industry,Interventional,3/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00658723
5781,Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea,Completed,Has Results,Obstructive Sleep Apnea,Device: Attune Sleep Apnea System,"ApniCure, Inc.","ApniCure, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01146782
5782,Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,"Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)|Drug: Placebo",Bayer|Novartis,Bayer,Novartis,,,,,,Phase 2,Industry,Interventional,5/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00645788
5783,Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents,Completed,Has Results,Influenza,Biological: Cell culture-derived influenza subunit vaccine (cTIV)|Biological: Egg derived influenza subunit vaccine (eTIV),Novartis|Novartis Vaccines,Novartis,Novartis Vaccines,,,,,,Phase 2|Phase 3,Industry,Interventional,10/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00645411
5784,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Completed,Has Results,Venous Thrombosis,Drug: Enoxaparin|Drug: warfarin|Drug: Placebo for apixaban|Drug: Placebo for enoxaparin|Drug: Placebo for warfarin|Drug: apixaban,Bristol-Myers Squibb|Pfizer,Bristol-Myers Squibb,Pfizer,,,,,,Phase 3,Industry,Interventional,7/8/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00643201
5785,A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcers,Drug: Santyl|Other: White Petrolatum,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,6/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01143714
5786,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Exenatide Once Weekly|Drug: Insulin Glargine,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,4/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00641056
5787,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Drug: sitagliptin|Drug: pioglitazone|Drug: placebo tablet|Drug: placebo once weekly,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,1/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00637273
5788,Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis,Completed,Has Results,Eosinophilic Esophagitis,Drug: reslizumab,Ception Therapeutics|Cephalon|Teva Pharmaceutical Industries,Ception Therapeutics,Cephalon,Teva Pharmaceutical Industries,,,,,Phase 3,Industry,Interventional,7/8/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00635089
5789,Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi,Completed,Has Results,Aspergillosis|Invasive Fungal Infections,Drug: isavuconazole,Astellas Pharma Inc|Basilea Pharmaceutica International Ltd,Astellas Pharma Inc,Basilea Pharmaceutica International Ltd,,,,,,Phase 3,Industry,Interventional,4/22/2008,5/5/2016,https://ClinicalTrials.gov/show/NCT00634049
5790,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Completed,Has Results,Venous Thrombosis,Drug: Apixaban|Drug: Placebo,Bristol-Myers Squibb|Pfizer,Bristol-Myers Squibb,Pfizer,,,,,,Phase 3,Industry,Interventional,5/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00633893
5791,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Completed,Has Results,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Drug: Placebo|Drug: Droxidopa,Chelsea Therapeutics|Chiltern International Inc.,Chelsea Therapeutics,Chiltern International Inc.,,,,,,Phase 3,Industry,Interventional,1/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00633880
5792,"PR-018: An Open-Label, Safety Extension of Study PR-011",Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: EUR-1008 (APT-1008),Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,7/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01131507
5793,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Completed,Has Results,Hepatitis C,Biological: Pegylated Interferon Alfa 2a|Drug: Telaprevir|Drug: Ribavirin|Other: Placebo,Vertex Pharmaceuticals Incorporated|Tibotec Pharmaceutical Limited,Vertex Pharmaceuticals Incorporated,Tibotec Pharmaceutical Limited,,,,,,Phase 3,Industry,Interventional,3/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00627926
5794,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),Completed,Has Results,"Lupus Erythematosus, Systemic",Drug: Atacicept 75 mg|Drug: Atacicept 150 mg|Other: Placebo Comparator,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 2|Phase 3,Industry,Interventional,1/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00624338
5795,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,Completed,Has Results,Melanoma,Drug: Ipilimumab|Drug: Corticosteroid: Betamethasone|Drug: Corticosteroid: Dexamethasone|Drug: Corticosteroid: Fludrocortisone|Drug: Corticosteroid: Hydrocortisone|Drug: Corticosteroid: Meprednisone|Drug: Corticosteroid: Methylprednisolone|Drug: Corticosteroid: Prednisolone|Drug: Corticosteroid: Prednisone|Drug: Corticosteroid: Triamcinolone,Bristol-Myers Squibb|Medarex,Bristol-Myers Squibb,Medarex,,,,,,Phase 2,Industry,Interventional,7/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00623766
5796,Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer|Locally Advanced Breast Cancer,Drug: Gemcitabine|Drug: Bevacizumab,"Eli Lilly and Company|Genentech, Inc.",Eli Lilly and Company,"Genentech, Inc.",,,,,,Phase 2,Industry,Interventional,3/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00623233
5797,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,Completed,Has Results,Fibromyalgia,Drug: Milnacipran hydrochloride|Drug: Placebo,"Forest Laboratories|Cypress Bioscience, Inc.",Forest Laboratories,"Cypress Bioscience, Inc.",,,,,,Phase 3,Industry,Interventional,10/7/2019,,https://ClinicalTrials.gov/show/NCT00618956
5798,The Vascutek AnacondaTM Stent Graft System Phase II IDE Study,Completed,Has Results,Infrarenal Abdominal Aortic Aneurysm,Device: Anaconda Stent Graft System|Device: Anaconda ONE-LOK Stent Graft System,Terumo CVS|Vascutek Ltd.,Terumo CVS,Vascutek Ltd.,,,,,,Not Applicable,Industry,Interventional,4/9/2019,7/13/2017,https://ClinicalTrials.gov/show/NCT00612924
5799,Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty,Completed,Has Results,Seroma|Hematoma,"Biological: FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Procedure: Standard of care",Baxter Healthcare Corporation,Baxter Healthcare Corporation,,,,,,,Phase 2,Industry,Interventional,5/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01112735
5800,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,1/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00614939
5801,"A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)",Completed,Has Results,Opioid Induced Constipation (OIC),Drug: placebo|Drug: NKTR-118,AstraZeneca|Nektar Therapeutics,AstraZeneca,Nektar Therapeutics,,,,,,Phase 2,Industry,Interventional,12/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00600119
5802,Phase II Sunitinib Prog Met AIPC,Completed,Has Results,Metastatic Prostate Cancer,Drug: Sunitinib,US Oncology Research|Pfizer,US Oncology Research,Pfizer,,,,,,Phase 2,Industry,Interventional,3/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00599313
5803,A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age,Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: EUR-1008 (APT-1008),Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,6/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01100606
5804,Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Darbepoetin alfa,Affymax|Takeda,Affymax,Takeda,,,,,,Phase 3,Industry,Interventional,11/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00598442
5805,Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Darbepoetin alfa,Affymax|Takeda,Affymax,Takeda,,,,,,Phase 3,Industry,Interventional,10/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00598273
5806,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Epoetin Alfa,Affymax|Takeda,Affymax,Takeda,,,,,,Phase 3,Industry,Interventional,9/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00597753
5807,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Epoetin alfa or Epoetin beta,Affymax|Takeda,Affymax,Takeda,,,,,,Phase 3,Industry,Interventional,10/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00597584
5808,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Completed,Has Results,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC","Sucampo Pharmaceuticals, Inc.",Takeda,"Sucampo Pharma Americas, LLC",,,,,Phase 3,Industry,Interventional,8/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00597428
5809,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Completed,Has Results,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC","Sucampo Pharmaceuticals, Inc.",Takeda,"Sucampo Pharma Americas, LLC",,,,,Phase 3,Industry,Interventional,8/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00595946
5810,Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: Ixabepilone,R-Pharm|US Oncology Research,R-Pharm,US Oncology Research,,,,,,Phase 2,Industry,Interventional,5/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00593827
5811,Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma,Completed,Has Results,Asthma,Biological: Reslizumab|Other: Saline,Ception Therapeutics|Cephalon|Teva Pharmaceutical Industries,Ception Therapeutics,Cephalon,Teva Pharmaceutical Industries,,,,,Phase 2,Industry,Interventional,4/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00587288
5812,A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02,Completed,Has Results,Systemic Lupus Erythematosus,Biological: Belimumab,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","Human Genome Sciences Inc., a GSK Company",GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,5/4/2005,2/23/2016,https://ClinicalTrials.gov/show/NCT00583362
5813,Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis,Completed,Has Results,Scalp Psoriasis,Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel),LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,4/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01083758
5814,Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML,Completed,Has Results,Chronic Myeloid Leukemia,Drug: Bosutinib|Drug: imatinib,Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer,Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,Phase 3,Industry,Interventional,2/5/2008,5/27/2015,https://ClinicalTrials.gov/show/NCT00574873
5815,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Completed,Has Results,Venous Thromboembolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin|Drug: Rivaroxaban placebo|Drug: Enoxaparin placebo","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 3,Industry,Interventional,12/7/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00571649
5816,TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease,Completed,Has Results,Keratoconjunctivitis Sicca,,TearLab Corporation|Alcon Research,TearLab Corporation,Alcon Research,,,,,,,Industry,Observational,2/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00848198
5817,The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility,Completed,Has Results,Mild to Severe Alzheimer's Disease,Drug: Donepezil HCl,Eisai Inc.|Pfizer,Eisai Inc.,Pfizer,,,,,,Phase 4,Industry,Interventional,1/8/2019,4/22/2009,https://ClinicalTrials.gov/show/NCT00571064
5818,ELND005 in Patients With Mild to Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer Disease,Drug: Placebo Control|Drug: ELND005,Transition Therapeutics Ireland Limited|Transition Therapeutics,Transition Therapeutics Ireland Limited,Transition Therapeutics,,,,,,Phase 2,Industry,Interventional,12/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00568776
5819,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab|Drug: Docetaxel,"Genentech, Inc.|Hoffmann-La Roche","Genentech, Inc.",Hoffmann-La Roche,,,,,,Phase 3,Industry,Interventional,2/12/2008,11/23/2018,https://ClinicalTrials.gov/show/NCT00567190
5820,Dispensing Evaluation of New Daily Disposable Toric Soft Contact Lens.,Completed,Has Results,Astigmatism,Device: Etafilcon A toric contact lens|Device: Nelfilcon A toric contact lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/10/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01055132
5821,A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease,Completed,Has Results,Crohn Disease,Biological: Cimzia,UCB BIOSCIENCES GmbH|PPD|UCB Pharma,UCB BIOSCIENCES GmbH,PPD,UCB Pharma,,,,,Phase 3,Industry,Interventional,5/8/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00552344
5822,A Study in Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small-Cell Lung Carcinoma,Drug: Pemetrexed|Drug: Cisplatin|Drug: Cixutumumab,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 2,Industry,Interventional,4/11/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01232452
5823,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,Completed,Has Results,Hyponatremia,Drug: Tolvaptan|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,8/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00550459
5824,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg|Biological: Interferon beta-1a,"Genzyme, a Sanofi Company|Bayer|Sanofi","Genzyme, a Sanofi Company",Bayer,Sanofi,,,,,Phase 3,Industry,Interventional,10/7/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00548405
5825,Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer,Completed,Has Results,Endometrial Cancer,Radiation: brachytherapy|Radiation: Xoft Axxent Electronic Brachytherapy System,"Xoft, Inc.","Xoft, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01045187
5826,A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Ortho-Novum® 1/35,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,12/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01044498
5827,Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin,Completed,Has Results,Operation Site Bleed,Device: Thrombi-Gel,"Vascular Solutions, Inc|King Pharmaceuticals is now a wholly owned subsidiary of Pfizer","Vascular Solutions, Inc",King Pharmaceuticals is now a wholly owned subsidiary of Pfizer,,,,,,Phase 4,Industry,Interventional,3/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00652314
5828,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: Ciclesonide HFA Nasal Aerosol 320 mcg|Drug: Ciclesonide HFA Nasal Aerosol 160 mcg|Drug: HFA Nasal Aerosol placebo|Drug: Ciclesonide Aqueous Nasal Spray 200 mcg|Drug: AQ Nasal Spray Placebo|Drug: Placebo plus Dexamethasone HFA|Drug: Placebo AQ plus Dexamethasone 6 mg,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,1/10/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01033825
5829,"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",H. Lundbeck A/S,Otsuka America Pharmaceutical,,,,,Phase 3,Industry,Interventional,1/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01683058
5830,"A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy",Completed,Has Results,Hepatitis C,Drug: Telaprevir|Drug: Ribavirin|Drug: Pegylated interferon alfa 2a,"Vertex Pharmaceuticals Incorporated|Tibotec, Inc",Vertex Pharmaceuticals Incorporated,"Tibotec, Inc",,,,,,Phase 2,Industry,Interventional,10/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00535847
5831,A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.,Completed,Has Results,Palliative Care|Pain|Cancer,Drug: Sativex Low Dose|Drug: Sativex Medium Dose|Drug: Sativex High Dose,"GW Pharmaceuticals Ltd.|Quintiles, Inc.",GW Pharmaceuticals Ltd.,"Quintiles, Inc.",,,,,,Phase 2,Industry,Interventional,11/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00530764
5832,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab|Biological: Interferon beta-1a,"Genzyme, a Sanofi Company|Bayer|Sanofi","Genzyme, a Sanofi Company",Bayer,Sanofi,,,,,Phase 3,Industry,Interventional,8/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00530348
5833,Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain,Completed,Has Results,Constipation,Drug: N-methylnaltrexone bromide (MOA-728)|Other: placebo,"Bausch Health Americas, Inc.|Progenics Pharmaceuticals, Inc.","Bausch Health Americas, Inc.","Progenics Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,8/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00529087
5834,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Completed,Has Results,Sarcoma,Drug: Trabectedin|Drug: Doxorubicin|Drug: Ifosfamide,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",PharmaMar,,,,,,Phase 3,Industry,Interventional,11/8/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00796120
5835,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo|Drug: Metformin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,9/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00528879
5836,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Dapagliflozin placebo|Drug: Metformin,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 3,Industry,Interventional,9/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00528372
5837,"Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD",Completed,Has Results,Macular Degeneration,Drug: VEGF Trap Eye,Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 2,Industry,Interventional,8/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00527423
5838,Tiotropium In Exercise,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive|Exercise",Drug: tiotropium 18 mcg|Drug: Placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 4,Industry,Interventional,8/7/2019,,https://ClinicalTrials.gov/show/NCT00525512
5839,Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium|Drug: Placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 4,Industry,Interventional,4/7/2019,,https://ClinicalTrials.gov/show/NCT00523991
5840,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,Completed,Has Results,Paroxysmal Atrial Fibrillation,Device: Arctic Front® Cryoablation Catheter|Drug: Flecainide or Sotalol or Propafenone,Medtronic Cardiac Rhythm and Heart Failure|Medtronic,Medtronic Cardiac Rhythm and Heart Failure,Medtronic,,,,,,Phase 3,Industry,Interventional,10/6/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00523978
5841,Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Enzalutamide|Drug: Bicalutamide,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Pfizer,Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,Phase 2,Industry,Interventional,8/12/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT01664923
5842,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",H. Lundbeck A/S,Otsuka America Pharmaceutical,,,,,Phase 3,Industry,Interventional,10/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01663532
5843,Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis,Completed,Has Results,Other Osteoporosis,Drug: Placebo tablet|Drug: Risedronate,Warner Chilcott|Sanofi,Warner Chilcott,Sanofi,,,,,,Phase 3,Industry,Interventional,6/2/2019,5/7/2019,https://ClinicalTrials.gov/show/NCT00619957
5844,The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy,Completed,Has Results,Nausea and Vomiting of Pregnancy,Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|Drug: Placebo,Duchesnay Inc.|Premier Research Group plc,Duchesnay Inc.,Premier Research Group plc,,,,,,Phase 3,Industry,Interventional,1/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00614445
5845,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Completed,Has Results,Arthralgia|Bunion|Hallux Valgus|Pain,Drug: Tapentadol (CG5503)|Drug: oxycodone|Drug: placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Grünenthal GmbH,,,,,,Phase 3,Industry,Interventional,2/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00613938
5846,Natalizumab High Titer Immunogenicity and Safety,Completed,Has Results,Multiple Sclerosis,Biological: BG00002-E (natalizumab high titer),Biogen|Elan Pharmaceuticals,Biogen,Elan Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,10/6/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00516893
5847,IGIV Study for Chronic ITP Patients Ages 3-70,Completed,Has Results,Idiopathic Thrombocytopenic Purpura,Biological: IGIV3I Grifols 10%,"Grifols Biologicals, LLC|Instituto Grifols, S.A.","Grifols Biologicals, LLC","Instituto Grifols, S.A.",,,,,,Phase 3,Industry,Interventional,5/8/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00511147
5848,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: placebo,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,1/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00603239
5849,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),Completed,Has Results,Macular Degeneration,"Biological: ranibizumab|Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)",Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 3,Industry,Interventional,8/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00509795
5850,Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy,Completed,Has Results,Face-lift|Facial Rhytidectomy,Biological: FS VH S/D 4 s-apr,Baxter Healthcare Corporation,Baxter Healthcare Corporation,,,,,,,Phase 3,Industry,Interventional,9/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00999141
5851,SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS,Completed,Has Results,"Lung Injury, Acute",Drug: SB-681323 Intravenous 3mg|Drug: SB-681323 Intravenous 7.5 mg|Drug: SB-681323 Intravenous 7.5mg|Drug: SB-681323 Intravenous 10mg|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/16/2009,2/9/2013,https://ClinicalTrials.gov/show/NCT00996840
5852,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2),Completed,Has Results,Chronic Kidney Disease,Drug: Placebo|Drug: AST-120,Mitsubishi Tanabe Pharma Corporation|Kureha Corporation,Mitsubishi Tanabe Pharma Corporation,Kureha Corporation,,,,,,Phase 3,Industry,Interventional,7/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00501046
5853,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1),Completed,Has Results,Chronic Kidney Disease,Drug: Placebo|Drug: AST-120,Mitsubishi Tanabe Pharma Corporation|Kureha Corporation,Mitsubishi Tanabe Pharma Corporation,Kureha Corporation,,,,,,Phase 3,Industry,Interventional,7/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00500682
5854,"A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients",Completed,Has Results,Obesity,Drug: exenatide|Drug: placebo,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 2,Industry,Interventional,6/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00500370
5855,Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer Disease,Biological: ACC-001 + QS-21|Biological: QS-21|Other: Diluent: Phosphate Buffered Saline|Biological: ACC-001,"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Pfizer,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,,,,,Phase 2,Industry,Interventional,11/7/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00498602
5856,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Drug: Apixaban|Drug: Acetylsalicylic acid,Bristol-Myers Squibb|Pfizer,Bristol-Myers Squibb,Pfizer,,,,,,Phase 3,Industry,Interventional,8/31/2007,5/25/2017,https://ClinicalTrials.gov/show/NCT00496769
5857,Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia,Completed,Has Results,Acute Lymphoblastic Leukemia (ALL),Drug: Marqibo® (vincristine sulfate liposomes injection),"Spectrum Pharmaceuticals, Inc|Parexel","Spectrum Pharmaceuticals, Inc",Parexel,,,,,,Phase 2,Industry,Interventional,5/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00495079
5858,Adj TC + Herceptin Early Stage Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Taxotere|Drug: Cytoxan|Drug: Herceptin,US Oncology Research|Sanofi,US Oncology Research,Sanofi,,,,,,Phase 2,Industry,Interventional,6/7/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00493649
5859,Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma,Completed,Has Results,Asthma,Drug: Mometasone furoate/formoterol fumarate (MFF)|Drug: Formoterol fumarate 12 μg pMDI (F12M)|Drug: Formoterol fumarate 12 μg DPI (F12D)|Drug: Placebo to F12D|Drug: Placebo to F12M/MFF,Novartis|Schering-Plough,Novartis,Schering-Plough,,,,,,Phase 2,Industry,Interventional,8/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00746330
5860,Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment,Completed,Has Results,Parkinson's Disease,Drug: Tigan®|Drug: Placebo,Ipsen|INC Research Limited,Ipsen,INC Research Limited,,,,,,Phase 4,Industry,Interventional,5/7/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00489255
5861,Efficacy and Tolerability of an Intra-Nasal Testosterone Product,Completed,Has Results,Hypogonadism,Drug: Nasobol®|Drug: Androderm® (Positive Control),Acerus Pharmaceuticals Corporation,Acerus Pharmaceuticals Corporation,,,,,,,Phase 2,Industry,Interventional,8/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00975650
5862,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Biological: Placebo|Biological: Golimumab 50 mg|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg,"Janssen Research & Development, LLC|Merck Sharp & Dohme Corp.","Janssen Research & Development, LLC",Merck Sharp & Dohme Corp.,,,,,,Phase 3,Industry,Interventional,9/7/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT00488631
5863,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Biological: Placebo|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg|Biological: Golimumab 400 mg|Biological: Golimumab 50 mg,"Janssen Research & Development, LLC|Merck Sharp & Dohme Corp.","Janssen Research & Development, LLC",Merck Sharp & Dohme Corp.,,,,,,Phase 2|Phase 3,Industry,Interventional,8/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00487539
5864,An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain,Completed,Has Results,Pain|Osteoarthritis|Low Back Pain,Drug: Tapentadol (CG5503) Extended Release (ER),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Grünenthal GmbH,,,,,,Phase 3,Industry,Interventional,6/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00487435
5865,Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ixazomib citrate,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,10/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00963820
5866,Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy,Completed,Has Results,Epilepsy,Drug: Keppra XR,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 2,Industry,Interventional,9/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00961441
5867,Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer,Completed,Has Results,Breast Cancer,Drug: enzalutamide|Drug: anastrozole|Drug: exemestane|Drug: fulvestrant,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Pfizer,Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,Phase 1,Industry,Interventional,4/30/2012,1/22/2018,https://ClinicalTrials.gov/show/NCT01597193
5868,ABC/Trident® Ceramic Post Approval Study,Completed,Has Results,"Arthroplasty, Replacement, Hip",Device: Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Device: Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Device: OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,3/3/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00960206
5869,"Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years",Completed,Has Results,Barrett Esophagus,Device: HALO Ablation System,"Covidien, GI Solutions|AstraZeneca|Medtronic - MITG","Covidien, GI Solutions",AstraZeneca,Medtronic - MITG,,,,,Not Applicable,Industry,Interventional,11/3/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00489268
5870,E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma,Completed,Has Results,Stage IV Melanoma,Drug: Lenvatinib|Drug: Dacarbazine,"Eisai Inc.|Quintiles, Inc.",Eisai Inc.,"Quintiles, Inc.",,,,,,Phase 1|Phase 2,Industry,Interventional,4/10/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01133977
5871,Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: VI-0521|Drug: Placebo,"VIVUS, Inc.|Synteract, Inc.","VIVUS, Inc.","Synteract, Inc.",,,,,,Phase 2,Industry,Interventional,6/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00486291
5872,eSight Eyewear Quality of Life and Efficacy Study,Completed,Has Results,"Vision, Low",Device: eSight Eyewear,"eSight Corporation|Johns Hopkins University|Université de Montréal|University Health Network, Toronto|Vitreous and Retina Consultants PA|University of Michigan|Bascom Palmer Eye Institute",eSight Corporation,Johns Hopkins University,"Université de Montréal|University Health Network, Toronto|Vitreous and Retina Consultants PA|University of Michigan|Bascom Palmer Eye Institute",Université de Montréal,"University Health Network, Toronto|Vitreous and Retina Consultants PA|University of Michigan|Bascom Palmer Eye Institute","University Health Network, Toronto",Vitreous and Retina Consultants PA|University of Michigan|Bascom Palmer Eye Institute,Not Applicable,Industry|Other,Interventional,12/16/2015,3/31/2017,https://ClinicalTrials.gov/show/NCT02616900
5873,Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma,Completed,Has Results,Asthma,Drug: Tiotropium bromide|Drug: tiotropium bromide|Drug: Placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 2,Industry,Interventional,5/10/2019,,https://ClinicalTrials.gov/show/NCT01122680
5874,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Completed,Has Results,Rheumatoid Arthritis,Drug: MabThera/Rituxan|Drug: Methotrexate|Other: Placebo,Hoffmann-La Roche|Biogen,Hoffmann-La Roche,Biogen,,,,,,Phase 3,Industry,Interventional,5/3/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00468546
5875,Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptin QD (once daily) for 7 days,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,6/9/2019,,https://ClinicalTrials.gov/show/NCT00935220
5876,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,Completed,Has Results,HIV Infections,Drug: Dolutegravir 50 mg twice daily|Drug: Dolutegravir placebo twice daily,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,4/18/2012,12/16/2013,https://ClinicalTrials.gov/show/NCT01568892
5877,Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation,Completed,Has Results,Constipation,Drug: Lubiprostone,"Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC","Sucampo Pharmaceuticals, Inc.",Takeda,"Sucampo Pharma Americas, LLC",,,,,Phase 4,Industry,Interventional,1/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00452335
5878,Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women,Completed,Has Results,Postmenopausal Osteoporosis,Drug: 150 mg|Drug: 75 mg|Drug: 100 mg,Warner Chilcott,Warner Chilcott,,,,,,,Phase 2,Industry,Interventional,5/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00918749
5879,Complex Sleep Apnea Syndrome (CompSAS) Resolution Study,Completed,Has Results,Complex Sleep Apnea Syndrome,Device: VPAP Adapt SV,ResMed|Mayo Clinic,ResMed,Mayo Clinic,,,,,,Not Applicable,Industry|Other,Interventional,5/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00915499
5880,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,Completed,Has Results,Ovarian Neoplasms,Biological: Olaratumab|Drug: liposomal doxorubicin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/9/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00913835
5881,A/H5N1/LT Dose Ranging Study,Completed,Has Results,Pandemic Influenza,Biological: A/H5N1|Biological: LT Adjuvant Patch,"Intercell USA, Inc.|Department of Health and Human Services","Intercell USA, Inc.",Department of Health and Human Services,,,,,,Phase 2,Industry|U.S. Fed,Interventional,5/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00908687
5882,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,Completed,Has Results,"Infection, Human Immunodeficiency Virus I|HIV Infection",Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV),ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,3/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00440947
5883,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,Completed,Has Results,Venous Thrombosis,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin followed by VKA","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 3,Industry,Interventional,3/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00440193
5884,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,Completed,Has Results,Pulmonary Embolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin overlapping with and followed by VKA","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 3,Industry,Interventional,3/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00439777
5885,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Completed,Has Results,Venous Thromboembolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Placebo","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 3,Industry,Interventional,2/7/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00439725
5886,"Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists",Completed,Has Results,Allergic Asthma,Drug: omalizumab at a dose of 0.016mg/kg/IU/mL|Drug: Placebo,"Novartis Pharmaceuticals|Genentech, Inc.|Novartis",Novartis Pharmaceuticals,"Genentech, Inc.",Novartis,,,,,Phase 4,Industry,Interventional,4/8/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00670930
5887,Performance Evaluation of the AMS CONTINUUM™ Device,Completed,Has Results,Prostate Cancer,Device: CONTINUUM™,American Medical Systems,American Medical Systems,,,,,,,Not Applicable,Industry,Interventional,5/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00894933
5888,Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function,Completed,Has Results,Oncology,Drug: Entospletinib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 1,Industry,Interventional,11/16/2015,10/25/2017,https://ClinicalTrials.gov/show/NCT02521376
5889,Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,10/5/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00885105
5890,Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD),Completed,Has Results,"Polycystic Kidney Disease, Autosomal Dominant",Drug: Tolvaptan|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 3,Industry,Interventional,1/7/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00428948
5891,"Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.",Completed,Has Results,Facial Wrinkles,Device: Belotero|Device: Zyplast,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 3,Industry,Interventional,12/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00876265
5892,Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years,Completed,Has Results,Meningococcal Infections|Meningococcal Meningitis,"Biological: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 1|Phase 2,Industry,Interventional,10/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00874549
5893,Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers,Completed,Has Results,Upper Gastrointestinal Mucosal Damage,Drug: acetylsalicylic acid,PLx Pharma,PLx Pharma,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00872534
5894,Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life,Completed,Has Results,Impotence,Drug: tadalafil|Drug: Placebo,Eli Lilly and Company|ICOS Corporation,Eli Lilly and Company,ICOS Corporation,,,,,,Phase 3,Industry,Interventional,11/6/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00422734
5895,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,Completed,Has Results,"Candidiasis, Invasive|Candidemia|Mycoses",Drug: Isavuconazole|Drug: Caspofungin|Drug: Voriconazole,Astellas Pharma Inc|Basilea Pharmaceutica,Astellas Pharma Inc,Basilea Pharmaceutica,,,,,,Phase 3,Industry,Interventional,3/8/2007,3/3/2015,https://ClinicalTrials.gov/show/NCT00413218
5896,Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.,Completed,Has Results,Schizoaffective Disorder|Psychotic Disorder,Drug: Placebo|Drug: Paliperidone ER,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Janssen, LP",,,,,,Phase 3,Industry,Interventional,12/6/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00412373
5897,"Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)",Completed,Has Results,"Polycystic Kidney, Autosomal Dominant",Drug: Tolvaptan,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Co., Ltd.",,,,,,Phase 2,Industry,Interventional,12/5/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00413777
5898,Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis,Completed,Has Results,Aspergillosis|Invasive Fungal Infection,Drug: Isavuconazole|Drug: Voriconazole,Astellas Pharma Inc|Basilea Pharmaceutica International Ltd,Astellas Pharma Inc,Basilea Pharmaceutica International Ltd,,,,,,Phase 3,Industry,Interventional,3/7/2007,3/28/2013,https://ClinicalTrials.gov/show/NCT00412893
5899,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Placebo|Drug: Belimumab 1 mg/kg|Drug: Belimumab 10 mg/kg,Human Genome Sciences Inc.|GlaxoSmithKline,Human Genome Sciences Inc.,GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,12/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00410384
5900,F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Completed,Has Results,Colonoscopy,Drug: PEG electrolyte lavage solution + bisacodyl - reformulation|Drug: PEG electrolyte lavage solution + bisacodyl,Braintree Laboratories,Braintree Laboratories,,,,,,,Phase 4,Industry,Interventional,2/9/2019,,https://ClinicalTrials.gov/show/NCT00857272
5901,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Completed,Has Results,Non-small Cell Lung Cancer,Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Drug: Placebo,"EMD Serono|Merck KGaA, Darmstadt, Germany",EMD Serono,"Merck KGaA, Darmstadt, Germany",,,,,,Phase 3,Industry,Interventional,1/7/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT00409188
5902,A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients,Completed,Has Results,Major Depressive Disorder,Drug: duloxetine hydrochloride|Drug: placebo,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 4,Industry,Interventional,11/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00406848
5903,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Stroke|Embolism,Drug: Rivaroxaban|Drug: Warfarin|Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)|Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,,,,,,Phase 3,Industry,Interventional,12/6/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00403767
5904,An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis,Completed,Has Results,Prostatitis,Drug: levofloxacin,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PriCara, Unit of Ortho-McNeil, Inc.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","PriCara, Unit of Ortho-McNeil, Inc.",,,,,,Phase 3,Industry,Interventional,11/6/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00402688
5905,Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy,Completed,Has Results,Diabetic Foot Ulcers,Device: V.A.C. Negative Pressure Wound Therapy System,"KCI USA, Inc.","KCI USA, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00847730
5906,A Safety and Efficacy Study in Patients With Gastric Cancer,Completed,Has Results,Gastric Cancer,Drug: S-1/Cisplatin|Drug: 5-FU/cisplatin,"Taiho Oncology, Inc.|Quintiles, Inc.","Taiho Oncology, Inc.","Quintiles, Inc.",,,,,,Phase 3,Industry,Interventional,5/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00400179
5907,The Effect Of Oral Ibandronate In Male Osteoporosis,Completed,Has Results,Male Osteoporosis,Drug: Ibandronate|Drug: placebo,Hoffmann-La Roche|GlaxoSmithKline,Hoffmann-La Roche,GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,1/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00397839
5908,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: Ketoconazole Cream 2%|Drug: Ketoconazole Cream 2% (G&W Laboratories Inc.)|Drug: Placebo,Encube Ethicals Pvt. Ltd.|Novum Pharmaceutical Research Services|ACM Global Laboratories,Encube Ethicals Pvt. Ltd.,Novum Pharmaceutical Research Services,ACM Global Laboratories,,,,,Phase 3,Industry|Other,Interventional,8/23/2018,1/24/2019,https://ClinicalTrials.gov/show/NCT03824912
5909,E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: E7389|Drug: Physician's Choice,Eisai Inc.|Eisai Limited,Eisai Inc.,Eisai Limited,,,,,,Phase 3,Industry,Interventional,10/6/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00388726
5910,"A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors",Completed,Has Results,Cancer,Drug: MEDI-573,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,3/9/2009,9/11/2012,https://ClinicalTrials.gov/show/NCT00816361
5911,"Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)",Completed,Has Results,X-linked Hypophosphatemia,Biological: burosumab,"Ultragenyx Pharmaceutical Inc|Kyowa Kirin Co., Ltd.",Ultragenyx Pharmaceutical Inc,"Kyowa Kirin Co., Ltd.",,,,,,Phase 2,Industry,Interventional,7/2/2014,10/30/2018,https://ClinicalTrials.gov/show/NCT02163577
5912,"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.",Completed,Has Results,HIV|Infectious,Drug: darunavir|Drug: ritonavir,"Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","Tibotec, Inc","Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 3,Industry,Interventional,11/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00381303
5913,A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise,Completed,Has Results,Asthma,Drug: Placebo|Drug: GSK2190915,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/1/2008,7/15/2009,https://ClinicalTrials.gov/show/NCT00812929
5914,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Completed,Has Results,Lupus Nephritis,Drug: Mycophenolate mofetil (MMF)|Drug: Cyclophosphamide|Drug: Azathioprine|Drug: Placebo to Azathioprine|Drug: Placebo to Mycophenolate mofetil|Drug: Corticosteroid,Hoffmann-La Roche|Aspreva Pharmaceuticals,Hoffmann-La Roche,Aspreva Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,7/5/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00377637
5915,Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy,Completed,Has Results,Ovarian Cancer,Drug: catumaxomab,Neovii Biotech|Fresenius Biotech North America,Neovii Biotech,Fresenius Biotech North America,,,,,,Phase 2,Industry,Interventional,9/6/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00377429
5916,Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS),Completed,Has Results,Polycystic Ovarian Syndrome|Infertility,Drug: Menotropin|Drug: Progesterone vaginal insert|Drug: Follitropin beta|Drug: Progesterone in oil|Drug: leuprolide acetate,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,1/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00805935
5917,Effect on Weight Loss of Exenatide Versus Placebo,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: placebo,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,9/6/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00375492
5918,Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma,Completed,Has Results,Soft Tissue Sarcoma,Drug: Glufosfamide,Eleison Pharmaceuticals LLC.|Threshold Pharmaceuticals,Eleison Pharmaceuticals LLC.,Threshold Pharmaceuticals,,,,,,Phase 2,Industry,Interventional,3/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00441467
5919,Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children,Completed,Has Results,Allergic Rhinitis|Upper Respiratory Infection,Drug: Doxylamine Succinate USP,Procter and Gamble|Consumer Healthcare Products Association,Procter and Gamble,Consumer Healthcare Products Association,,,,,,Phase 1,Industry|Other,Interventional,12/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00796315
5920,Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD),Completed,Has Results,Autistic Disorder|Behavioral Symptoms,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",Otsuka America Pharmaceutical,,,,,,Phase 3,Industry,Interventional,9/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00365859
5921,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Completed,Has Results,Hypertriglyceridemia|Cardiovascular Disease,"Drug: Olive oil, 4g|Drug: omega-3-carboxylic acids, 2g|Drug: omega-3-carboxylic acids, 4g","AstraZeneca|Omthera Pharmaceuticals, Inc|Medpace, Inc.",AstraZeneca,"Omthera Pharmaceuticals, Inc","Medpace, Inc.",,,,,Phase 3,Industry,Interventional,8/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01408303
5922,A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain,Completed,Has Results,"Osteoarthritis, Hip|Osteoarthritis, Knee|Lower Back Pain|Pain",Drug: Oxycodone CR|Drug: Tapentadol (CG5503) ER,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Grünenthal GmbH,,,,,,Phase 3,Industry,Interventional,11/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00361504
5923,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Completed,Has Results,Rheumatoid Arthritis,Drug: Golimumab|Drug: Methotrexate|Drug: Placebo,"Centocor, Inc.|Schering-Plough","Centocor, Inc.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,9/6/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00361335
5924,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Completed,Has Results,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","AbbVie (prior sponsor, Abbott)","Quintiles, Inc.",AbbVie,,,,,Phase 3,Industry,Interventional,6/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00360568
5925,Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company|ICOS Corporation,Eli Lilly and Company,ICOS Corporation,,,,,,Phase 2,Industry,Interventional,10/6/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00386009
5926,A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,AstraZeneca,Bristol-Myers Squibb,,,,,,Phase 2|Phase 3,Industry,Interventional,10/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00357370
5927,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Completed,Has Results,Onychomycosis,Drug: Itraconazole 100mg capsules|Drug: Itraconazole 200mg tablets|Drug: Placebo tablets,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,7/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00356915
5928,Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension,Completed,Has Results,Hypertension,Drug: Aliskiren Hydrochlorothiazide|Drug: Ramipril,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,8/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00772577
5929,Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery,Completed,Has Results,Hemophilia A,Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM),"Baxalta now part of Shire|Baxalta Innovations GmbH, now part of Shire|Shire",Baxalta now part of Shire,"Baxalta Innovations GmbH, now part of Shire",Shire,,,,,Phase 4,Industry,Interventional,6/1/2006,12/1/2015,https://ClinicalTrials.gov/show/NCT00357656
5930,"Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer",Completed,Has Results,Thrombocytopenia|Neutropenia|Lymphopenia|Anemia,Drug: TXA127|Drug: Placebo,Tarix Pharmaceuticals,Tarix Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00771810
5931,A Study of Econazole Foam 1% in Athlete's Foot,Completed,Has Results,Tinea Pedis|Athlete's Foot,Drug: Econazole Nitrate Cream 1%|Drug: Econazole Nitrate Foam 1%|Drug: Vehicle Foam,AmDerma,AmDerma,,,,,,,Phase 2,Industry,Interventional,3/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00768599
5932,Neurostimulation for the Relief of Acute Bronchoconstriction,Completed,Has Results,Asthma,Device: Resolve Stimulator and Proximity Lead,ElectroCore INC,ElectroCore INC,,,,,,,Not Applicable,Industry,Interventional,9/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00762931
5933,Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event,Completed,Has Results,Coronary Arteriosclerosis|Acute Coronary Syndrome,Drug: prasugrel 10 mg|Drug: clopidogrel|Drug: prasugrel placebo|Drug: prasugrel 60 mg|Drug: clopidogrel placebo,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,Phase 2,Industry,Interventional,7/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00356135
5934,A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC,Completed,Has Results,Non-Small Cell Lung Cancer,Biological: Cetuximab|Biological: Bevacizumab|Drug: Paclitaxel|Drug: Carboplatin,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 2,Industry,Interventional,12/6/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00343291
5935,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Completed,Has Results,Behavioral Symptoms|Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",Otsuka America Pharmaceutical,,,,,,Phase 3,Industry,Interventional,6/6/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00337571
5936,An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder|Attention Deficit Disorders With Hyperactivity|Attention Deficit Hyperactivity Disorders,"Drug: Vyvanse (lisdexamfetamine dimesylate), NRP104",New River Pharmaceuticals|Shire,New River Pharmaceuticals,Shire,,,,,,Phase 3,Industry,Interventional,7/6/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00337285
5937,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Completed,Has Results,Advanced Parkinson's Disease,Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","AbbVie (prior sponsor, Abbott)","Quintiles, Inc.",AbbVie,,,,,Phase 3,Industry,Interventional,1/8/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00335153
5938,BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.,Completed,Has Results,HIV Infections,Drug: Background ARVs|Drug: PI|Drug: enfuvirtide [Fuzeon],Hoffmann-La Roche|Trimeris,Hoffmann-La Roche,Trimeris,,,,,,Phase 4,Industry,Interventional,3/6/2019,5/7/2019,https://ClinicalTrials.gov/show/NCT00326963
5939,Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites,Completed,Has Results,Malignant Ascites,Drug: catumaxomab,Neovii Biotech|Fresenius Biotech North America,Neovii Biotech,Fresenius Biotech North America,,,,,,Phase 2,Industry,Interventional,6/6/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00326885
5940,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Completed,Has Results,Advanced Parkinson's Disease,Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo gel|Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","AbbVie (prior sponsor, Abbott)","Quintiles, Inc.",AbbVie,,,,,Phase 3,Industry,Interventional,1/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00357994
5941,Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: clobetasol propionate spray|Drug: clobetasol propionate ointment,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,8/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00733954
5942,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Completed,Has Results,Melanoma,Drug: Ipilimumab|Drug: Placebo|Drug: Dacarbazine,Bristol-Myers Squibb|Medarex,Bristol-Myers Squibb,Medarex,,,,,,Phase 3,Industry,Interventional,8/6/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00324155
5943,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Completed,Has Results,Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",Otsuka America Pharmaceutical,,,,,,Phase 3,Industry,Interventional,6/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00332241
5944,Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),Completed,Has Results,Macular Degeneration,"Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)",Regeneron Pharmaceuticals|Bayer,Regeneron Pharmaceuticals,Bayer,,,,,,Phase 2,Industry,Interventional,4/6/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00320788
5945,"A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer",Completed,Has Results,Breast Cancer,Drug: gemcitabine|Drug: paclitaxel|Drug: bevacizumab,"Eli Lilly and Company|Genentech, Inc.",Eli Lilly and Company,"Genentech, Inc.",,,,,,Phase 2,Industry,Interventional,5/6/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00320541
5946,Comparison of Two Soft Bifocal Contact Lenses,Completed,Has Results,Presbyopia,Device: balafilcon A|Device: senofilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00724945
5947,Cormet Post-PMA Study: New Enrollment,Completed,Has Results,Osteoarthritis|Avascular Necrosis|Rheumatoid Arthritis,Device: Cormet Hip Resurfacing,Corin,Corin,,,,,,,Not Applicable,Industry,Interventional,4/24/2008,5/12/2014,https://ClinicalTrials.gov/show/NCT00722007
5948,Staccato Loxapine in Agitated Patients With Bipolar Disorder,Completed,Has Results,Bipolar I Disorder,Drug: Inhaled Placebo|Drug: Inhaled loxapine 5 mg|Drug: Inhaled loxapine 10 mg,"Alexza Pharmaceuticals, Inc.","Alexza Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,7/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00721955
5949,Study of Milnacipran for the Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: Placebo|Drug: Milnacipran 100mg,"Forest Laboratories|Cypress Bioscience, Inc.",Forest Laboratories,"Cypress Bioscience, Inc.",,,,,,Phase 3,Industry,Interventional,4/6/2019,,https://ClinicalTrials.gov/show/NCT00314249
5950,Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Bortezomib + Rituximab|Drug: Rituximab,"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Millennium Pharmaceuticals, Inc.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,Phase 3,Industry,Interventional,3/6/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00312845
5951,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain,Completed,Has Results,Chronic Non-malignant Pain,Drug: Buprenorphine transdermal patch|Drug: Placebo to match BTDS,Purdue Pharma LP|Napp Pharmaceuticals Limited,Purdue Pharma LP,Napp Pharmaceuticals Limited,,,,,,Phase 3,Industry,Interventional,3/1/2019,7/1/2019,https://ClinicalTrials.gov/show/NCT00312195
5952,A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: dolutegravir,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,5/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01328041
5953,"Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures",Completed,Has Results,Facial Rhytidectomy (Face-lift),"Biological: Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)",Baxter Healthcare Corporation,Baxter Healthcare Corporation,,,,,,,Phase 2,Industry,Interventional,6/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00708071
5954,Natalizumab Re-Initiation of Dosing,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: BG00002 (natalizumab),Biogen|Elan Pharmaceuticals,Biogen,Elan Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,3/6/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00306592
5955,IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting,Completed,Has Results,"Heart Failure, Congestive|Myocardial Infarction|Ventricular Dysfunction, Left",,Medtronic Cardiac Rhythm and Heart Failure|Medtronic,Medtronic Cardiac Rhythm and Heart Failure,Medtronic,,,,,,,Industry,Observational,5/5/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00303979
5956,Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole sodium enteric-coated spheroid,Wyeth is now a wholly owned subsidiary of Pfizer|Nycomed,Wyeth is now a wholly owned subsidiary of Pfizer,Nycomed,,,,,,Phase 3,Industry,Interventional,5/6/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00300755
5957,The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy,Completed,Has Results,Cardiomyopathy,Drug: Fx-1006A,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00694161
5958,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),Completed,Has Results,"Arthritis, Rheumatoid",Drug: Placebo|Biological: Golimumab 50 mg|Biological: Golimumab 100 mg,"Centocor, Inc.|Schering-Plough","Centocor, Inc.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,2/6/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00299546
5959,Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL),Completed,Has Results,B-Cell Lymphoma,Drug: inotuzumab ozogamicin|Drug: Rituximab,Pfizer|UCB Pharma,Pfizer,UCB Pharma,,,,,,Phase 1|Phase 2,Industry,Interventional,5/4/2006,6/2/2014,https://ClinicalTrials.gov/show/NCT00299494
5960,Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects,Completed,Has Results,Metastatic Colorectal Cancer,"Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)",Bayer|Amgen,Bayer,Amgen,,,,,,Phase 2,Industry,Interventional,3/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00865709
5961,Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients,Completed,Has Results,"Lymphoma, Non-Hodgkin|Multiple Myeloma",Drug: G-CSF Plus Plerixafor,"Genzyme, a Sanofi Company|AnorMED|Sanofi","Genzyme, a Sanofi Company",AnorMED,Sanofi,,,,,Phase 2,Industry,Interventional,3/4/2019,6/6/2019,https://ClinicalTrials.gov/show/NCT00322491
5962,A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects,Completed,Has Results,Dyslipidemia,Drug: Pitavastatin|Drug: Pravastatin,"Kowa Research Institute, Inc.|Kowa Pharmaceuticals America, Inc.|Eli Lilly and Company","Kowa Research Institute, Inc.","Kowa Pharmaceuticals America, Inc.",Eli Lilly and Company,,,,,Phase 4,Industry,Interventional,12/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01301066
5963,PREFER (Pacemaker Remote Follow-Up Evaluation and Review),Completed,Has Results,Bradycardia|Arrhythmia,Other: Transtelephonic monitoring (TTM)|Other: Medtronic CareLink® Network,Medtronic Cardiac Rhythm and Heart Failure|Medtronic,Medtronic Cardiac Rhythm and Heart Failure,Medtronic,,,,,,Not Applicable,Industry,Interventional,4/4/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00294645
5964,Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis,Completed,Has Results,Non-alcoholic Steatohepatitis,Other: Placebo|Drug: Silymarin 700 mg|Drug: Silymarin 420 mg,Madaus Inc|University of Pennsylvania|University of North Carolina|Thomas Jefferson University|Beth Israel Deaconess Medical Center|Brooke Army Medical Center|University of Pittsburgh,Madaus Inc,University of Pennsylvania,University of North Carolina|Thomas Jefferson University|Beth Israel Deaconess Medical Center|Brooke Army Medical Center|University of Pittsburgh,University of North Carolina,Thomas Jefferson University|Beth Israel Deaconess Medical Center|Brooke Army Medical Center|University of Pittsburgh,Thomas Jefferson University,Beth Israel Deaconess Medical Center|Brooke Army Medical Center|University of Pittsburgh,Phase 2,Industry|Other|U.S. Fed,Interventional,4/8/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00680407
5965,A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: fosamprenavir (GW433908)|Drug: ritonavir,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 3,Industry,Interventional,11/1/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00296504
5966,Ablation of Intestinal Metaplasia Containing Dysplasia,Completed,Has Results,Barrett Esophagus,Device: Ablation System plus anti-secretory medication|Device: Sham procedure plus anti-secretory medication,Medtronic - MITG|AstraZeneca,Medtronic - MITG,AstraZeneca,,,,,,Not Applicable,Industry,Interventional,2/6/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00282672
5967,PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure,Completed,Has Results,"Heart Failure, Congestive",Device: Cardiac Resynchronization Therapy Device,Medtronic Cardiac Rhythm and Heart Failure|Medtronic,Medtronic Cardiac Rhythm and Heart Failure,Medtronic,,,,,,,Industry,Observational,6/4/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00279955
5968,A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode,Completed,Has Results,Bipolar Disorder,Drug: Lamotrigine + Aripiprazole|Drug: Lamotrigine + Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",Otsuka America Pharmaceutical,,,,,,Phase 4,Industry,Interventional,12/5/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00277212
5969,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: 0.15% Azelastine Hydrochloride,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00660829
5970,Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles,Completed,Has Results,Bilateral Nasolabial Fold Wrinkles,Biological: Autologous Human Fibroblasts (azficel-T)|Biological: Placebo,"Fibrocell Technologies, Inc.","Fibrocell Technologies, Inc.",,,,,,,Phase 3,Industry,Interventional,11/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00655356
5971,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),Completed,Has Results,"Infection, Human Immunodeficiency Virus I",Drug: Dolutegravir|Drug: Atripla|Drug: Abacavir/Lamivudine|Drug: Abacavir/Lamivudine Placebo|Drug: Dolutegravir placebo|Drug: Atripla placebo,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,2/1/2011,12/3/2015,https://ClinicalTrials.gov/show/NCT01263015
5972,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Biological: golimumab|Biological: Placebo; golimumab,"Centocor, Inc.|Schering-Plough","Centocor, Inc.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,12/5/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00265096
5973,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo injections|Drug: Placebo capsules|Drug: Methotrexate capsules|Biological: Golimumab 50 mg injections|Biological: Golimumab 100 mg injections,"Centocor, Inc.|Schering-Plough","Centocor, Inc.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,12/5/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00264537
5974,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Completed,Has Results,Rheumatoid Arthritis,Drug: Golimumab 100 mg|Drug: Golimumab 50 mg|Drug: Methotrexate|Drug: Placebo injection|Drug: Placebo capsules,"Centocor, Inc.|Schering-Plough","Centocor, Inc.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,12/5/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00264550
5975,A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis,Completed,Has Results,"Spondylitis, Ankylosing",Biological: golimumab|Biological: Golimumab (CNTO 148); placebo,"Centocor, Inc.|Schering-Plough","Centocor, Inc.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,12/5/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00265083
5976,A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania,Completed,Has Results,Bipolar Disorder,Drug: Lithium or Valproate with placebo (PBO)|Drug: Lithium or Valproate with Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",Otsuka America Pharmaceutical,,,,,,Phase 4,Industry,Interventional,9/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00261443
5977,Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD,Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole sodium enteric-coated spheroid suspension,Wyeth is now a wholly owned subsidiary of Pfizer|Nycomed,Wyeth is now a wholly owned subsidiary of Pfizer,Nycomed,,,,,,Phase 3,Industry,Interventional,11/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00259012
5978,"Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia",Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia (B-CLL),Biological: Alemtuzumab,"Genzyme, a Sanofi Company|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi","Genzyme, a Sanofi Company","Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Sanofi,,,,,Phase 2,Industry,Interventional,5/6/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00328198
5979,A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches,Completed,Has Results,Migraine,Drug: Almotriptan Malate,"Janssen-Ortho LLC|Ortho-McNeil Neurologics, Inc.",Janssen-Ortho LLC,"Ortho-McNeil Neurologics, Inc.",,,,,,Phase 3,Industry,Interventional,12/5/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00257010
5980,Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy,Completed,Has Results,Hepatocellular Carcinoma,Biological: Ramucirumab (IMC-1121B),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,2/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00627042
5981,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Pentostatin,US Oncology Research|Astex Pharmaceuticals,US Oncology Research,Astex Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,12/3/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00254163
5982,"A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine",Completed,Has Results,Breast Cancer,Drug: E7389,Eisai Inc.|Eisai Limited,Eisai Inc.,Eisai Limited,,,,,,Phase 2,Industry,Interventional,10/5/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00246090
5983,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,Completed,Has Results,"Infection, Human Immunodeficiency Virus I",Drug: GSK1349572 (dolutegravir)|Drug: raltegravir|Other: GSK1349572 Placebo|Other: ABC/3TC|Other: TDF/FTC|Other: raltegravir Placebo,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 3,Industry,Interventional,10/19/2010,12/27/2016,https://ClinicalTrials.gov/show/NCT01227824
5984,Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy,Completed,Has Results,Seizures,Drug: Retigabine|Drug: Placebo,"GlaxoSmithKline|Bausch Health Americas, Inc.",GlaxoSmithKline,"Bausch Health Americas, Inc.",,,,,,Phase 3,Industry,Interventional,9/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00232596
5985,Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness,Completed,Has Results,Insomnia|Sleeplessness|Transient Insomnia,"Device: Electric stimulation of the Vestibular Nerve - ""VirtuSom""|Device: Electric stim of the Vestibular Nerve - ""VirtuSom"" - SHAM",Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,10/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00594022
5986,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Enzalutamide|Drug: Placebo,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Pfizer,Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,Phase 3,Industry,Interventional,6/22/2010,2/8/2019,https://ClinicalTrials.gov/show/NCT01212991
5987,"An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies",Completed,Has Results,Brain Edema|Brain Tumor,Drug: hCRF [XERECEPT (corticorelin acetate injection)],Celtic Pharma Development Services|Neurobiological Technologies,Celtic Pharma Development Services,Neurobiological Technologies,,,,,,Phase 3,Industry,Interventional,7/5/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00226655
5988,Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Drug: Clobex® Spray morning and Vectical™ Ointment evening regimen,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,10/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00988637
5989,A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: CNTO148|Drug: Placebo,"Centocor, Inc.|Centocor BV","Centocor, Inc.",Centocor BV,,,,,,Phase 2,Industry,Interventional,8/4/2019,7/7/2019,https://ClinicalTrials.gov/show/NCT00207740
5990,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: lenalidomide|Drug: dexamethasone,Celgene Corporation|Prologue Research International|Celgene,Celgene Corporation,Prologue Research International,Celgene,,,,,Phase 3,Industry,Interventional,9/5/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00179647
5991,"Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",Completed,Has Results,Non-Hodgkins Lymphoma,Drug: Lenalidomide,Celgene Corporation|Prologue Research International|Celgene,Celgene Corporation,Prologue Research International,Celgene,,,,,Phase 2,Industry,Interventional,8/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00179673
5992,"Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate",Completed,Has Results,Postmenopausal Women,Drug: risedronate,Warner Chilcott,Warner Chilcott,,,,,,,Phase 2,Industry,Interventional,7/6/2019,1/7/2019,https://ClinicalTrials.gov/show/NCT00577720
5993,"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Completed,Has Results,Pneumococcal Vaccines,Biological: 13 valent Pneumococcal Conjugate Vaccine|Biological: 23-valent Pneumococcal Polysaccharide Vaccine,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 3,Industry,Interventional,11/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00574548
5994,Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies,Completed,Has Results,Chronic Hepatitis B,Drug: Telbivudine (LdT),Novartis Pharmaceuticals|Merck Sharp & Dohme Corp.|Novartis,Novartis Pharmaceuticals,Merck Sharp & Dohme Corp.,Novartis,,,,,Phase 3,Industry,Interventional,3/5/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00142298
5995,An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: exenatide|Drug: rosiglitazone,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,10/5/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00135330
5996,A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma,Completed,Has Results,Melanoma,Drug: Talimogene Laherparepvec,BioVex Limited|Symbion Research International,BioVex Limited,Symbion Research International,,,,,,Phase 2,Industry,Interventional,12/5/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00289016
5997,Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy,Completed,Has Results,"Heart Failure, Congestive|Ventricular Dysfunction|Cardiomyopathies",Device: Left Ventricular Assist System (LVAS),Abbott Medical Devices|Thoratec Corporation,Abbott Medical Devices,Thoratec Corporation,,,,,,Not Applicable,Industry,Interventional,2/5/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00121485
5998,Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation,Completed,Has Results,"Heart Failure, Congestive|Ventricular Dysfunction|Cardiomyopathies",Device: Thoratec HeartMate II Left Ventricular Assist System (LVAS),Abbott Medical Devices|Thoratec Corporation,Abbott Medical Devices,Thoratec Corporation,,,,,,Not Applicable,Industry,Interventional,3/5/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00121472
5999,Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL),Completed,Has Results,Non-Hodgkins Lymphoma,Drug: Lenalidomide,Celgene Corporation|Prologue Research International|Celgene,Celgene Corporation,Prologue Research International,Celgene,,,,,Phase 2,Industry,Interventional,8/5/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00179660
6000,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Completed,Has Results,Pediculosis,Drug: Spinosad|Drug: Permethrin 1%,ParaPRO LLC,ParaPRO LLC,,,,,,,Phase 3,Industry,Interventional,9/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00545753
6001,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Completed,Has Results,Pediculus Capitis Infestation,Drug: Spinosad|Drug: Permethrin 1%,ParaPRO LLC,ParaPRO LLC,,,,,,,Phase 3,Industry,Interventional,9/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00545168
6002,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Completed,Has Results,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Biological: Aldurazyme|Biological: placebo,"Genzyme, a Sanofi Company|BioMarin/Genzyme LLC|Sanofi","Genzyme, a Sanofi Company",BioMarin/Genzyme LLC,Sanofi,,,,,Phase 3,Industry,Interventional,5/1/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00146770
6003,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: Trabectedin|Drug: DOXIL|Drug: Dexamethasone,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",PharmaMar,,,,,,Phase 3,Industry,Interventional,4/5/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00113607
6004,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small-Cell Lung Carcinoma,Drug: Paclitaxel (Taxane)|Drug: Docetaxel (Taxane)|Drug: Carboplatin|Drug: Cetuximab,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 3,Industry,Interventional,12/4/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00112294
6005,Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants,Completed,Has Results,Diaper Rash,Drug: 0.25 % Miconazole Nitrate Ointment,"Stiefel, a GSK Company|GlaxoSmithKline","Stiefel, a GSK Company",GlaxoSmithKline,,,,,,Phase 4,Industry,Interventional,5/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00702507
6006,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Completed,Has Results,Melanoma,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Carboplatin/Paclitaxel|Drug: Placebo",Bayer|Amgen,Bayer,Amgen,,,,,,Phase 3,Industry,Interventional,5/5/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00111007
6007,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,Completed,Has Results,Cancer|Melanoma,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Dacarbazine",Bayer|Amgen,Bayer,Amgen,,,,,,Phase 2,Industry,Interventional,4/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00110994
6008,A Study of Monthly Risedronate for Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: risedronate,Warner Chilcott|Sanofi,Warner Chilcott,Sanofi,,,,,,Phase 3,Industry,Interventional,10/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00247273
6009,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Completed,Has Results,Pemphigus Vulgaris (PV),Drug: Mycophenolate Mofetil 2 g/Day|Drug: Mycophenolate Mofetil (MMF) 3 g/Day|Drug: Placebo,Hoffmann-La Roche|Aspreva Pharmaceuticals,Hoffmann-La Roche,Aspreva Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,5/4/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00683930
6010,A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency,Completed,Has Results,Factor XIII Deficiency,Biological: FXIII Concentrate (Human),CSL Behring,CSL Behring,,,,,,,Phase 2,Industry,Interventional,5/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00883090
6011,Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors,Completed,Has Results,Cancer|Refractory Solid Tumor,Drug: Cetuximab + Irinotecan,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 1,Industry,Interventional,8/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00110357
6012,A Study of Aripiprazole in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Aripiprazole+ ADT|Drug: Placebo+ ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Otsuka Pharmaceutical Development & Commercialization, Inc.",Otsuka America Pharmaceutical,,,,,,Phase 3,Industry,Interventional,3/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00105196
6013,Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL),Completed,Has Results,Cataracts,Device: Lens implantation +1.00 D postop target|Device: Lens implantation -1.00 D postop target|Device: Lens implantation 0.00 D postop target,"Calhoun Vision, Inc.","Calhoun Vision, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00845520
6014,Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: MRZ 0.5 mg/m^2,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,3/7/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00461045
6015,Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain,Completed,Has Results,Sternal Wound Infection|Sternal Non-union|Pain|Mediastinitis,Device: SternaLock Rigid Fixation Plates|Device: wire (control),Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00819286
6016,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Completed,Has Results,Parkinson's Disease,Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa,"Novartis Pharmaceuticals|Orion Corporation, Orion Pharma|Novartis",Novartis Pharmaceuticals,"Orion Corporation, Orion Pharma",Novartis,,,,,Phase 3,Industry,Interventional,9/4/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00099268
6017,"Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection",Completed,Has Results,Herpes Simplex,Drug: famciclovir,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,10/7/2019,,https://ClinicalTrials.gov/show/NCT00448227
6018,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",Completed,Has Results,HIV Infections,"Drug: Optimized Background Therapy (OBT)|Drug: maraviroc (UK-427,857)",ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 2|Phase 3,Industry,Interventional,11/4/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00098748
6019,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",Completed,Has Results,HIV Infections,"Drug: Maraviroc (UK-427,857)|Drug: optimized background therapy",ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 2|Phase 3,Industry,Interventional,12/4/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00098722
6020,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",Completed,Has Results,HIV Infections,"Drug: Maraviroc (UK-427,857)|Drug: Optimized Background Therapy|Drug: Placebo",ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 2|Phase 3,Industry,Interventional,11/4/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00098306
6021,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",Completed,Has Results,HIV-1,"Drug: Maraviroc + Zidovudine/Lamivudine|Drug: Efavirenz + Zidovudine/Lamivudine|Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine",ViiV Healthcare|Pfizer,ViiV Healthcare,Pfizer,,,,,,Phase 3,Industry,Interventional,11/4/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00098293
6022,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Thalidomide|Drug: Dexamethasone|Drug: DOXIL,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",,,,,,Phase 3,Industry,Interventional,1/5/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00097981
6023,Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia,Completed,Has Results,Myopia|Hyperopia,Device: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser,"Clinical Research Consultants, Inc.|Alcon Research|WaveLight AG","Clinical Research Consultants, Inc.",Alcon Research,WaveLight AG,,,,,Phase 3,Industry,Interventional,10/9/2019,,https://ClinicalTrials.gov/show/NCT01028378
6024,Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study,Completed,Has Results,Acute Decompensated Heart Failure|Acute Kidney Injury,,"Alere San Diego|Abbott Diagnostics Division|Alere, Inc.",Alere San Diego,Abbott Diagnostics Division,"Alere, Inc.",,,,,,Industry,Observational,12/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01291836
6025,Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine,Completed,Has Results,"Rhinitis, Allergic, Seasonal",Drug: Fluticasone furoate and fexofenadine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,12/20/2006,2/28/2007,https://ClinicalTrials.gov/show/NCT00435461
6026,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Completed,Has Results,Congestive Heart Failure,Drug: Irbesartan|Drug: Placebo,Bristol-Myers Squibb|Sanofi,Bristol-Myers Squibb,Sanofi,,,,,,Phase 3,Industry,Interventional,6/2/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00095238
6027,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed|Biological: Cetuximab|Drug: Docetaxel,Eli Lilly and Company|ImClone LLC,Eli Lilly and Company,ImClone LLC,,,,,,Phase 3,Industry,Interventional,1/5/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00095199
6028,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma,Completed,Has Results,Asthma,Drug: tiotropium-bromide|Drug: placebo,Boehringer Ingelheim|Pfizer,Boehringer Ingelheim,Pfizer,,,,,,Phase 2,Industry,Interventional,7/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01634113
6029,TAXUS Libertē Post Approval Study,Completed,Has Results,Coronary Artery Disease,Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent|Drug: prasugrel|Drug: placebo|Drug: aspirin,"Boston Scientific Corporation|Eli Lilly and Company|Daiichi Sankyo, Inc.",Boston Scientific Corporation,Eli Lilly and Company,"Daiichi Sankyo, Inc.",,,,,,Industry,Observational,12/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00997503
6030,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Completed,Has Results,Crohn Disease,Biological: infliximab infusion; AZA placebo caps|Other: infliximab (IFX) infusion; azathioprine (AZA) caps|Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps,"Centocor Ortho Biotech Services, L.L.C.|Schering-Plough","Centocor Ortho Biotech Services, L.L.C.",Schering-Plough,,,,,,Phase 3,Industry,Interventional,3/5/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00094458
6031,"An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.",Completed,Has Results,"Lymphoma, Mantle-Cell",Drug: PD-0332991,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,5/7/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00420056
6032,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Completed,Has Results,Castration-Resistant Prostate Cancer,Drug: Enzalutamide|Drug: Placebo,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Pfizer,Astellas Pharma Inc,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",,,,,Phase 3,Industry,Interventional,9/30/2009,11/2/2017,https://ClinicalTrials.gov/show/NCT00974311
6033,"48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection",Completed,Has Results,"Infection, Human Immunodeficiency Virus I",Drug: LEXIVA (GW433908)|Drug: Ritonavir,ViiV Healthcare|GlaxoSmithKline,ViiV Healthcare,GlaxoSmithKline,,,,,,Phase 2,Industry,Interventional,7/4/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00089583
6034,"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: GSK1349572|Drug: efavirenz,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 2,Industry,Interventional,7/30/2009,12/22/2016,https://ClinicalTrials.gov/show/NCT00951015
6035,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,Completed,Has Results,Brain Edema|Brain Tumor,Drug: hCRF|Drug: placebo hCRF,Celtic Pharma Development Services|Neurobiological Technologies,Celtic Pharma Development Services,Neurobiological Technologies,,,,,,Phase 3,Industry,Interventional,5/4/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00088166
6036,Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis,Completed,Has Results,Osteoporosis,Drug: Teriparatide|Drug: Denosumab|Drug: Demeclocycline|Drug: Tetracycline|Drug: Calcium Supplement|Drug: Vitamin D,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,1/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01753856
6037,A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants,Completed,Has Results,β-thalassemia Major,Genetic: LentiGlobin BB305 Drug Product,bluebird bio,bluebird bio,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/13/2019,2/21/2018,https://ClinicalTrials.gov/show/NCT01745120
6038,Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer,Completed,Has Results,Ovarian Neoplasm,Drug: KU-0059436 (AZD2281)(PARP inhibitor),AstraZeneca|KuDOS Pharmaceuticals Limited,AstraZeneca,KuDOS Pharmaceuticals Limited,,,,,,Phase 2,Industry,Interventional,6/11/2007,7/20/2017,https://ClinicalTrials.gov/show/NCT00494442
6039,A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100,Completed,Has Results,Castration-Resistant Prostate Cancer (CRPC),Drug: Enzalutamide,"Astellas Pharma Inc|Medivation, Inc.",Astellas Pharma Inc,"Medivation, Inc.",,,,,,Phase 2,Industry,Interventional,10/21/2011,4/18/2017,https://ClinicalTrials.gov/show/NCT01534052
6040,Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy,Completed,Has Results,Colorectal Neoplasms|Metastases|Neoplasm,Biological: cetuximab,ImClone LLC|Bristol-Myers Squibb,ImClone LLC,Bristol-Myers Squibb,,,,,,Phase 2,Industry,Interventional,10/4/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00083720
6041,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,Completed,Has Results,"Pain, Postoperative",Drug: diclofenac potassium (XP21L)|Drug: Placebo,Xanodyne Pharmaceuticals,Xanodyne Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/6/2019,,https://ClinicalTrials.gov/show/NCT00366444
6042,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Exenatide (AC2993)|Drug: Insulin glargine,AstraZeneca|Eli Lilly and Company,AstraZeneca,Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,6/3/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00082381
6043,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Completed,Has Results,Complicated Intra-Abdominal Infection,Drug: CAZ-AVI|Drug: Metronidazole|Drug: Meropenem,Pfizer|Forest Laboratories,Pfizer,Forest Laboratories,,,,,,Phase 3,Industry,Interventional,3/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01499290
6044,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-remitting Multiple Sclerosis,Drug: Rebif®|Drug: Copaxone®,EMD Serono|Pfizer,EMD Serono,Pfizer,,,,,,Phase 4,Industry,Interventional,2/16/2004,11/28/2006,https://ClinicalTrials.gov/show/NCT00078338
6045,Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP),Completed,Has Results,Atrial Fibrillation,Device: Ablation procedure staged catheter ablation,"AtriCure, Inc.","AtriCure, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01661205
6046,Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures,Completed,Has Results,Epilepsy,Drug: Clonazepam,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00594945
6047,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,Completed,Has Results,"Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo",Bayer|Amgen,Bayer,Amgen,,,,,,Phase 3,Industry,Interventional,11/3/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00073307
6048,Safety Study of PLX4032 in Patients With Solid Tumors,Completed,Has Results,Malignant Melanoma|Colorectal Carcinoma,Drug: PLX4032,Plexxikon|Roche Pharma AG,Plexxikon,Roche Pharma AG,,,,,,Phase 1,Industry,Interventional,11/6/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00405587
6049,A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide,Completed,Has Results,"Osteoporosis, Postmenopausal",Drug: teriparatide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,11/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00557310
6050,An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain,Completed,Has Results,"Diabetic Neuropathy, Painful",Drug: duloxetine hydrochloride|Drug: pregabalin|Drug: gabapentin,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 4,Industry,Interventional,9/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00385671
6051,Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: GSK1349572|Drug: Placebo,ViiV Healthcare|Shionogi|GlaxoSmithKline,ViiV Healthcare,Shionogi,GlaxoSmithKline,,,,,Phase 2,Industry,Interventional,6/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00708110
6052,A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition,Completed,Has Results,Detrusor Hyperreflexia,Drug: Oxybutynin transdermal system,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,12/4/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00224029
6053,Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy,Completed,Has Results,Head and Neck Cancer,Drug: Gefitinib,Massachusetts General Hospital|National Cancer Institute (NCI)|Dana-Farber Cancer Institute|Brigham and Women's Hospital|AstraZeneca,Massachusetts General Hospital,National Cancer Institute (NCI),Dana-Farber Cancer Institute|Brigham and Women's Hospital|AstraZeneca,Dana-Farber Cancer Institute,Brigham and Women's Hospital|AstraZeneca,Brigham and Women's Hospital,AstraZeneca,Phase 2,Other|NIH|Industry,Interventional,3/3/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00095836
6054,A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer,Completed,Has Results,Liposarcoma|Leiomyosarcoma,Drug: Yondelis|Drug: Dexamethasone,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",PharmaMar,,,,,,Phase 2,Industry,Interventional,5/3/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00060944
6055,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Completed,Has Results,Erectile Dysfunction,"Drug: Vardenafil ODT (STAXYN, BAY38-9456)|Drug: Placebo",Bayer|GlaxoSmithKline|Schering-Plough,Bayer,GlaxoSmithKline,Schering-Plough,,,,,Phase 3,Industry,Interventional,4/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00655629
6056,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: trastuzumab (Herceptin®)|Drug: anastrazole (Arimidex®),"Hoffmann-La Roche|Genentech, Inc.",Hoffmann-La Roche,"Genentech, Inc.",,,,,,Phase 3,Industry,Interventional,1/1/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00022672
6057,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Interferon beta-1a|Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg,"Genzyme, a Sanofi Company|Bayer|Sanofi","Genzyme, a Sanofi Company",Bayer,Sanofi,,,,,Phase 2,Industry,Interventional,12/2/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00050778
6058,A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy,Completed,Has Results,Erectile Dysfunction|Prostate Cancer,Drug: Tacrolimus|Drug: Placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 4,Industry,Interventional,2/5/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00106392
6059,A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults,Completed,Has Results,Diabetes,Drug: Phentermine/Topiramate|Drug: Placebo,"VIVUS, Inc.|Synteract, Inc.|Sentrx","VIVUS, Inc.","Synteract, Inc.",Sentrx,,,,,Phase 2,Industry,Interventional,1/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00600067
6060,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Completed,Has Results,Adenocarcinoma,Drug: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Placebo|Drug: 5-fluorouracil,"Genentech, Inc.|Hoffmann-La Roche|Chugai Pharmaceutical","Genentech, Inc.",Hoffmann-La Roche,Chugai Pharmaceutical,,,,,Phase 3,Industry,Interventional,9/7/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00548548
6061,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Completed,Has Results,Myocardial Infarction,"Drug: abciximab placebo; reteplase placebo, abciximab, abciximab|Drug: Abciximab; reteplase; abciximab placebo; abciximab|Drug: abciximab; reteplase placebo; abciximab placebo; abciximab","Centocor, Inc.|Eli Lilly and Company","Centocor, Inc.",Eli Lilly and Company,,,,,,Phase 3,Industry,Interventional,8/2/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00046228
6062,Pre-op Rectal ChemoRad +/- Cetuximab,Completed,Has Results,Rectal Cancer,Drug: Cetuximab|Drug: 5-fluorouracil|Radiation: Pelvic irradiation,US Oncology Research|Bristol-Myers Squibb|ImClone LLC,US Oncology Research,Bristol-Myers Squibb,ImClone LLC,,,,,Phase 2,Industry,Interventional,2/7/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00527111
6063,Docetaxel+Oxali+/-Cetux Met Gastric/GEJ,Completed,Has Results,Gastric Cancer Adenocarcinoma Metastatic,Drug: Docetaxel|Drug: cetuximab|Drug: oxaliplatin,US Oncology Research|ImClone LLC|Sanofi,US Oncology Research,ImClone LLC,Sanofi,,,,,Phase 2,Industry,Interventional,7/7/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00517829
6064,Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.,Completed,Has Results,Asthma,Drug: omalizumab,"Novartis|Genentech, Inc.|Tanox",Novartis,"Genentech, Inc.",Tanox,,,,,Phase 3,Industry,Interventional,7/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00500539
6065,SPECTACL: SPECTroscopic Assessment of Coronary Lipid,Completed,Has Results,"Angina Pectoris|Angina, Unstable|Myocardial Infarction",Device: Near Infrared Spectroscopy (NIRS) Imaging|Device: intravascular ultrasound (IVUS),InfraReDx,InfraReDx,,,,,,,Phase 2|Phase 3,Industry,Interventional,1/6/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00330928
6066,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Duloxetine|Drug: placebo,Eli Lilly and Company|Boehringer Ingelheim,Eli Lilly and Company,Boehringer Ingelheim,,,,,,Phase 3,Industry,Interventional,3/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00105989
6067,Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML,Completed,Has Results,Chronic Myeloid Leukemia,Drug: Omacetaxine mepesuccinate,"Teva Branded Pharmaceutical Products, R&D Inc.|Cephalon|ChemGenex Pharmaceuticals|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Cephalon,ChemGenex Pharmaceuticals|Teva Pharmaceutical Industries,ChemGenex Pharmaceuticals,Teva Pharmaceutical Industries,,,Phase 2,Industry,Interventional,3/7/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00462943
6068,Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Cetuximab|Drug: BIBW 2992,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,3/10/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01090011
6069,Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation,Completed,Has Results,Chronic Myeloid Leukemia,Drug: Omacetaxine mepesuccinate,"Teva Branded Pharmaceutical Products, R&D Inc.|Cephalon|ChemGenex Pharmaceuticals|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Cephalon,ChemGenex Pharmaceuticals|Teva Pharmaceutical Industries,ChemGenex Pharmaceuticals,Teva Pharmaceutical Industries,,,Phase 2,Industry,Interventional,9/6/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00375219
6070,A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Pertuzumab|Drug: Erlotinib,"Genentech, Inc.|Roche Pharma AG","Genentech, Inc.",Roche Pharma AG,,,,,,Phase 2,Industry,Interventional,3/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00855894
6071,T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents,Completed,Has Results,HIV Infections,Drug: Enfuvirtide,Hoffmann-La Roche|Trimeris,Hoffmann-La Roche,Trimeris,,,,,,Phase 2,Industry,Interventional,8/1/2019,,https://ClinicalTrials.gov/show/NCT00022763
6072,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Nasal Glucagon|Drug: Intramuscular Glucagon,Eli Lilly and Company|Jaeb Center for Health Research|Locemia Solutions ULC,Eli Lilly and Company,Jaeb Center for Health Research,Locemia Solutions ULC,,,,,Phase 3,Industry|Other,Interventional,11/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01994746
6073,Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: Pegylated liposomal doxorubicin|Drug: Carboplatin|Drug: trastuzumab,"US Oncology Research|Ortho Biotech, Inc.|Tibotec Pharmaceutical Limited",US Oncology Research,"Ortho Biotech, Inc.",Tibotec Pharmaceutical Limited,,,,,Phase 2,Industry,Interventional,12/5/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00303108
6074,A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram,Completed,Has Results,Solid Tumor,Drug: Trabectedin|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",PharmaMar,,,,,,Phase 2,Industry,Interventional,10/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00786838
6075,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Nasal Glucagon|Drug: Intramuscular Glucagon,Eli Lilly and Company|Jaeb Center for Health Research|Locemia Solutions ULC,Eli Lilly and Company,Jaeb Center for Health Research,Locemia Solutions ULC,,,,,Phase 2|Phase 3,Industry|Other,Interventional,11/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01997411
6076,Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor,Completed,Has Results,Alzheimer's Disease|Sleep Disorder,Drug: Circadin|Drug: Placebo,Neurim Pharmaceuticals Ltd.,Neurim Pharmaceuticals Ltd.,,,,,,,Phase 2,Industry,Interventional,9/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00940589
6077,Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer,Completed,Has Results,Thyroid Cancer,Drug: ZD6474 (vandetanib),"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,11/4/2019,4/19/2017,https://ClinicalTrials.gov/show/NCT00098345
6078,PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes,Completed,Has Results,Stroke,Drug: Aggrenox|Drug: Clopidogrel placebo|Drug: Micardis|Drug: Aggrenox placebo|Drug: Clopidogrel|Drug: Micardis placebo,Boehringer Ingelheim|GlaxoSmithKline|Bayer,Boehringer Ingelheim,GlaxoSmithKline,Bayer,,,,,Phase 4,Industry,Interventional,8/3/2019,,https://ClinicalTrials.gov/show/NCT00153062
6079,Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma,Completed,Has Results,"Liposarcoma,Myxoid",Drug: Trabectedin|Drug: Dexamethasone,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",PharmaMar,,,,,,Phase 2,Industry,Interventional,4/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00579501
6080,Phase III Cat-PAD Study,Completed,Has Results,Rhinoconjunctivitis,Drug: Cat-PAD|Drug: Placebo,Circassia Limited|inVentiv Health Clinical|Pharm-Olam International,Circassia Limited,inVentiv Health Clinical,Pharm-Olam International,,,,,Phase 3,Industry|Other,Interventional,10/12/2019,,https://ClinicalTrials.gov/show/NCT01620762
6081,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Completed,Has Results,Male Hypogonadism,Drug: Oral testosterone undecanoate|Drug: topical testosterone gel,"Clarus Therapeutics, Inc.|PharmaNet|Los Angeles Biomedical Research Institute","Clarus Therapeutics, Inc.",PharmaNet,Los Angeles Biomedical Research Institute,,,,,Phase 3,Industry|Other,Interventional,7/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01403116
6082,18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment,Completed,Has Results,Prostate Cancer,Drug: 18F-fluciclovine PET CT,Blue Earth Diagnostics|American College of Radiology|IND 2 Results LLC|Syne Qua Non Limited,Blue Earth Diagnostics,American College of Radiology,IND 2 Results LLC|Syne Qua Non Limited,IND 2 Results LLC,Syne Qua Non Limited,,,Phase 3,Industry|Other,Interventional,6/1/2016,11/1/2017,https://ClinicalTrials.gov/show/NCT02680041
6083,Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder,Completed,Has Results,Overactive Bladder,Device: (VERV™ System)|Device: Sham version of (VERV™ System),"Ethicon Endo-Surgery|Novella Clinical|Data & Inference, Inc.",Ethicon Endo-Surgery,Novella Clinical,"Data & Inference, Inc.",,,,,Not Applicable,Industry|Other,Interventional,6/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01369485
6084,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: obinutuzumab|Drug: rituximab|Drug: chlorambucil,"Hoffmann-La Roche|German CLL Study Group|Genentech, Inc.",Hoffmann-La Roche,German CLL Study Group,"Genentech, Inc.",,,,,Phase 3,Industry|Other,Interventional,12/31/2009,8/23/2017,https://ClinicalTrials.gov/show/NCT02053610
6085,Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop,Completed,Has Results,"Sensorimotor Gait Disorder|Neurologic Ambulation Disorder|Gait, Drop Foot|Poststroke Hemiparesis|Post-Cerebrovascular Accident (CVA) Hemiparesis",Device: Ness L300|Device: Ankle-foot orthosis,Bioness Inc|Medidata Solutions|University of Cincinnati,Bioness Inc,Medidata Solutions,University of Cincinnati,,,,,Not Applicable,Industry|Other,Interventional,5/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01138995
6086,VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial,Completed,Has Results,Pulmonary Embolism,Device: VenaTech Convertible Vena Cava Filter|Procedure: Vena Cava Filter Conversion,"B. Braun Interventional Systems, Inc|Bright Research Partners|NAMSA","B. Braun Interventional Systems, Inc",Bright Research Partners,NAMSA,,,,,Not Applicable,Industry|Other,Interventional,12/11/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01112917
6087,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: obinutuzumab|Drug: rituximab|Drug: chlorambucil,"Hoffmann-La Roche|German CLL Study Group|Genentech, Inc.",Hoffmann-La Roche,German CLL Study Group,"Genentech, Inc.",,,,,Phase 3,Industry|Other,Interventional,12/22/2009,8/23/2017,https://ClinicalTrials.gov/show/NCT01998880
6088,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Rituximab|Drug: Fludarabine Phosphate|Drug: Cyclophosphamide,"Hoffmann-La Roche|Biogen|Genentech, Inc.",Hoffmann-La Roche,Biogen,"Genentech, Inc.",,,,,Phase 3,Industry,Interventional,7/31/2003,5/31/2012,https://ClinicalTrials.gov/show/NCT00090051
6089,Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB),Completed,Has Results,Overactive Bladder,Device: Non-invasive neurostimulation device,"Ethicon Endo-Surgery|Novella Clinical|Data & Inference, Inc.",Ethicon Endo-Surgery,Novella Clinical,"Data & Inference, Inc.",,,,,Not Applicable,Industry|Other,Interventional,4/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01125722
6090,Assessing Choice in the Employer Setting (ACES) Study,Completed,Has Results,Healthy,Biological: Choice of TIV or FluMist with baseline advertisement|Other: Choice of TIV or FluMist with enhanced advertisement and incentives|Biological: Control - Usual care offering TIV only with baseline advertisement,MedImmune LLC|Passport Health|University of Pittsburgh,MedImmune LLC,Passport Health,University of Pittsburgh,,,,,,Industry|Other,Observational,9/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00808808
6091,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Completed,Has Results,Acute Coronary Syndrome,Drug: Clopidogrel|Drug: Prasugrel|Drug: Commercially-available Aspirin,"Eli Lilly and Company|Daiichi Sankyo Co., Ltd.|Duke Clinical Research Institute",Eli Lilly and Company,"Daiichi Sankyo Co., Ltd.",Duke Clinical Research Institute,,,,,Phase 3,Industry|Other,Interventional,6/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00699998
6092,Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers,Completed,Has Results,"Foot Ulcer, Diabetic|Diabetic Foot",Drug: NorLeu3-A(1-7) in a gel formulation,"US Biotest, Inc.|National Institutes of Health (NIH)|Integra LifeSciences Corporation","US Biotest, Inc.",National Institutes of Health (NIH),Integra LifeSciences Corporation,,,,,Phase 2,Industry|NIH,Interventional,10/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00796744
6093,Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC),Completed,Has Results,Androgen-independent Prostate Cancer,Drug: cetuximab|Drug: Mitoxantrone,US Oncology Research|ImClone LLC|Oregon Health and Science University,US Oncology Research,ImClone LLC,Oregon Health and Science University,,,,,Phase 2,Industry|Other,Interventional,5/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00661492
6094,NINDS CRC Chronic Migraine Treatment Trial,Completed,Has Results,Chronic Migraine,Drug: propranolol LA|Drug: topiramate|Drug: placebo,"Anne Lindblad|National Institute of Neurological Disorders and Stroke (NINDS)|Ortho-McNeil Janssen Scientific Affairs, LLC|The Emmes Company, LLC",Anne Lindblad,National Institute of Neurological Disorders and Stroke (NINDS),"Ortho-McNeil Janssen Scientific Affairs, LLC|The Emmes Company, LLC","Ortho-McNeil Janssen Scientific Affairs, LLC","The Emmes Company, LLC",,,Phase 3,Industry|NIH,Interventional,10/8/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00772031
6095,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,Completed,Has Results,Epilepsy,Drug: Intravenous Carbamazepine (IV CBZ),"Lundbeck LLC|Ligand Pharmaceuticals|ICON Clinical Research|Quintiles, Inc.",Lundbeck LLC,Ligand Pharmaceuticals,"ICON Clinical Research|Quintiles, Inc.",ICON Clinical Research,"Quintiles, Inc.",,,Phase 3,Industry,Interventional,6/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01128959
6096,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Completed,Has Results,Colorectal Neoplasms|Neoplasm Metastasis,"Drug: Placebo|Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)",Sanofi|Regeneron Pharmaceuticals|NSABP Foundation Inc,Sanofi,Regeneron Pharmaceuticals,NSABP Foundation Inc,,,,,Phase 3,Industry|Other,Interventional,11/7/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00561470
6097,"Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer",Completed,Has Results,Biliary Tract Cancer|Gallbladder Adenocarcinoma,Drug: Bevacizumab|Drug: Gemcitabine|Drug: Oxaliplatin,"Massachusetts General Hospital|Genentech, Inc.|Sanofi|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute",Massachusetts General Hospital,"Genentech, Inc.",Sanofi|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute,Sanofi,Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Brigham and Women's Hospital|Dana-Farber Cancer Institute,Phase 2,Other|Industry,Interventional,5/6/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00361231
6098,"Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)",Completed,Has Results,Complicated Urinary Tract Infections,Drug: Ceftazidime -avibactam|Drug: Cefepime,Pfizer|PRA Health Sciences,Pfizer,PRA Health Sciences,,,,,,Phase 2,Industry,Interventional,9/24/2015,9/15/2017,https://ClinicalTrials.gov/show/NCT02497781
6099,Benzocaine Gel Toothache Dose-Response Study,Completed,Has Results,Toothache,Drug: Placebo gel|Drug: benzocaine,"Wyeth is now a wholly owned subsidiary of Pfizer|Church & Dwight Company, Inc.|Consumer Healthcare Products Association",Wyeth is now a wholly owned subsidiary of Pfizer,"Church & Dwight Company, Inc.",Consumer Healthcare Products Association,,,,,Phase 4,Industry|Other,Interventional,5/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00474175
6100,"A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome",Completed,Has Results,Primary Sjögren's Syndrome,Biological: AMG 557/MEDI5872|Other: Placebo,MedImmune LLC|Amgen,MedImmune LLC,Amgen,,,,,,Phase 2,Industry,Interventional,6/8/2015,8/13/2018,https://ClinicalTrials.gov/show/NCT02334306
6101,Vidaza to Restore Hormone Thx Prostate,Completed,Has Results,Prostate Cancer,Drug: azacitidine for injectable suspension,US Oncology Research|Celgene Corporation|University of Southern California,US Oncology Research,Celgene Corporation,University of Southern California,,,,,Phase 2,Industry|Other,Interventional,4/6/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00384839
6102,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Completed,Has Results,Acne Vulgaris,Drug: clindamycin / benzoyl peroxide gel|Drug: clindamycin gel|Drug: BPO gel|Drug: vehicle gel,"Stiefel, a GSK Company|Rho, Inc.|Quintiles, Inc.|GlaxoSmithKline","Stiefel, a GSK Company","Rho, Inc.","Quintiles, Inc.|GlaxoSmithKline","Quintiles, Inc.",GlaxoSmithKline,,,Phase 3,Industry,Interventional,10/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00776919
6103,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Completed,Has Results,Cystic Fibrosis,Drug: Aztreonam for Inhalation Solution (AZLI)|Drug: Tobramycin Inhalation Solution (TIS),"Gilead Sciences|Chiltern International Inc.|ClinPhone, Inc.|Covance",Gilead Sciences,Chiltern International Inc.,"ClinPhone, Inc.|Covance","ClinPhone, Inc.",Covance,,,Phase 3,Industry,Interventional,8/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00757237
6104,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: obinutuzumab|Drug: rituximab|Drug: chlorambucil,"Hoffmann-La Roche|German CLL Study Group|Genentech, Inc.",Hoffmann-La Roche,German CLL Study Group,"Genentech, Inc.",,,,,Phase 3,Industry|Other,Interventional,12/21/2009,8/23/2017,https://ClinicalTrials.gov/show/NCT01010061
6105,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Completed,Has Results,Congestive Heart Failure,Drug: carvedilol controlled release|Drug: carvedilol immediate release,"CTI-1, LLC|CTI Clinical Trial and Consulting Services|GlaxoSmithKline","CTI-1, LLC",CTI Clinical Trial and Consulting Services,GlaxoSmithKline,,,,,Phase 3,Industry|Other,Interventional,3/6/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00323037
6106,"Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy",Completed,Has Results,Spinal and Bulbar Muscular Atrophy,Drug: BVS857|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,2/4/2014,4/13/2016,https://ClinicalTrials.gov/show/NCT02024932
6107,Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis,Completed,Has Results,Post Menopausal Osteoporosis,Drug: BA058 Placebo|Drug: BA058 Transdermal (50 mcg)|Drug: BA058 Transdermal (100 mcg)|Drug: BA058 Transdermal (150 mcg)|Drug: BA058 Injection (80 mcg),"Radius Health, Inc.|Nordic Bioscience A/S","Radius Health, Inc.",Nordic Bioscience A/S,,,,,,Phase 2,Industry,Interventional,8/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01674621
6108,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Ezetimibe|Drug: Placebo (for Alirocumab)|Drug: Placebo (for Ezetimibe),Sanofi|Regeneron Pharmaceuticals,Sanofi,Regeneron Pharmaceuticals,,,,,,Phase 3,Industry,Interventional,7/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01644474
6109,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Completed,Has Results,Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Doripenem|Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral),Pfizer|Forest Laboratories,Pfizer,Forest Laboratories,,,,,,Phase 3,Industry,Interventional,10/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01599806
6110,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Completed,Has Results,Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Doripenem|Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral),Pfizer|Forest Laboratories,Pfizer,Forest Laboratories,,,,,,Phase 3,Industry,Interventional,10/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01595438
6111,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2189265|Drug: Sitagliptin|Drug: Placebo solution|Drug: Placebo tablet|Drug: Metformin,Eli Lilly and Company|United BioSource Corporation|Tessella Inc.|Berry Consultants,Eli Lilly and Company,United BioSource Corporation,Tessella Inc.|Berry Consultants,Tessella Inc.,Berry Consultants,,,Phase 2|Phase 3,Industry|Other,Interventional,8/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00734474
6112,Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery,Completed,Has Results,Peripheral Vascular Diseases,Device: Zilver® PTX™ Drug Eluting Vascular Stent|Procedure: Angioplasty,"Cook Group Incorporated|William Cook Europe|MED Institute, Incorporated|Cook Japan Incorporated",Cook Group Incorporated,William Cook Europe,"MED Institute, Incorporated|Cook Japan Incorporated","MED Institute, Incorporated",Cook Japan Incorporated,,,Not Applicable,Industry,Interventional,3/5/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00120406
6113,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,Completed,Has Results,Acute Coronary Syndrome,Drug: Acetylsalicylic acid|Drug: Rivaroxaban|Drug: Clopidogrel|Drug: Ticagrelor,"Janssen Research & Development, LLC|Bayer|Duke Clinical Research Institute|Harvard Medical School","Janssen Research & Development, LLC",Bayer,Duke Clinical Research Institute|Harvard Medical School,Duke Clinical Research Institute,Harvard Medical School,,,Phase 2,Industry|Other,Interventional,4/20/2015,10/14/2016,https://ClinicalTrials.gov/show/NCT02293395
6114,The Angel® Catheter Pivotal Clinical Trial,Completed,Has Results,Pulmonary Embolism|Deep Vein Thrombosis|Venous Thromboembolism|Trauma,Device: The Angel® Catheter,"BiO2 Medical|CardioMed Device Consultants, LLC|Intrinsic Imaging, LLC|Novella Clinical",BiO2 Medical,"CardioMed Device Consultants, LLC","Intrinsic Imaging, LLC|Novella Clinical","Intrinsic Imaging, LLC",Novella Clinical,,,Not Applicable,Industry|Other,Interventional,1/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02186223
6115,Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease,Completed,Has Results,Coronary Artery Disease,Drug: prasugrel|Drug: clopidogrel,"Eli Lilly and Company|Daiichi Sankyo Co., Ltd.",Eli Lilly and Company,"Daiichi Sankyo Co., Ltd.",,,,,,Phase 1,Industry,Interventional,3/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01107912
6116,Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial,Completed,Has Results,HIV-1,Genetic: OZ1 transduced cells,Janssen-Cilag Pty Ltd,Janssen-Cilag Pty Ltd,,,,,,,Phase 2,Industry,Interventional,12/6/2004,11/30/2017,https://ClinicalTrials.gov/show/NCT01177059
6117,"SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)",Completed,Has Results,Parkinson's Disease Dementia (PDD),Drug: SYN120|Drug: Placebo,Biotie Therapies Inc.|Michael J. Fox Foundation for Parkinson's Research|Massachusetts General Hospital|Acorda Therapeutics,Biotie Therapies Inc.,Michael J. Fox Foundation for Parkinson's Research,Massachusetts General Hospital|Acorda Therapeutics,Massachusetts General Hospital,Acorda Therapeutics,,,Phase 2,Industry|Other,Interventional,12/22/2014,10/3/2017,https://ClinicalTrials.gov/show/NCT02258152
6118,IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE),Completed,Has Results,Premature Ejaculation,Drug: IX-01|Drug: Placebo,Ixchelsis Limited|New England Research Institutes|Novotech (Australia) Pty Limited|ICON plc|PHT Corporation,Ixchelsis Limited,New England Research Institutes,Novotech (Australia) Pty Limited|ICON plc|PHT Corporation,Novotech (Australia) Pty Limited,ICON plc|PHT Corporation,ICON plc,PHT Corporation,Phase 2,Industry|Other,Interventional,9/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02232425
6119,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Completed,Has Results,Metastatic Colorectal Cancer,Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Cetuximab,US Oncology Research|Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center|Prologue Research International,US Oncology Research,Bristol-Myers Squibb,Memorial Sloan Kettering Cancer Center|Prologue Research International,Memorial Sloan Kettering Cancer Center,Prologue Research International,,,Phase 3,Industry|Other,Interventional,9/5/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00252564
6120,The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma,Completed,Has Results,Glaucoma,Device: Ahmed FP7 Valve|Device: Baerveldt-350 Tube,Credit Valley EyeCare|Glaucoma Research Society of Canada,Credit Valley EyeCare,Glaucoma Research Society of Canada,,,,,,Not Applicable,Industry|Other,Interventional,7/5/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT00940823
6121,"A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta",Completed,Has Results,Axial Spondyloarthritis (AxSpA)|Non-radiographic Evidence-AxSpA|Ankylosing Spondylitis|Crohn's Disease|Psoriatic Arthritis|Rheumatoid Arthritis,Procedure: Blood sampling from mother|Procedure: Blood sampling from infant|Procedure: Blood sampling from umbilical cord|Biological: Certolizumab Pegol,"UCB BIOSCIENCES, Inc.|PPD|Parexel|UCB Pharma","UCB BIOSCIENCES, Inc.",PPD,Parexel|UCB Pharma,Parexel,UCB Pharma,,,Phase 1,Industry,Interventional,1/14/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02019602
6122,Evaluating Neuroprotection in Aneurysm Coiling Therapy,Completed,Has Results,Stroke,Drug: NA-1|Drug: Placebo,NoNO Inc.|Arbor Vita Corporation,NoNO Inc.,Arbor Vita Corporation,,,,,,Phase 2,Industry,Interventional,8/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00728182
6123,"Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)",Completed,Has Results,Lung Cancer,Drug: pemetrexed|Drug: cisplatin|Drug: Carboplatin|Drug: Gemcitabine Hydrochloride|Drug: Vinorelbine Tartrate|Drug: Docetaxel,Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|United States Department of Defense,Memorial Sloan Kettering Cancer Center,Eli Lilly and Company,United States Department of Defense,,,,,Phase 2,Other|Industry|U.S. Fed,Interventional,10/11/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01443078
6124,A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D,Completed,Has Results,Osteoporosis,Drug: SMC021 Oral calcitonin|Drug: SMC021 Placebo,Nordic Bioscience A/S|Novartis,Nordic Bioscience A/S,Novartis,,,,,,Phase 3,Industry,Interventional,3/7/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00525798
6125,Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting,Completed,Has Results,Coronary Artery Disease,Drug: Prasugrel|Drug: Clopidogrel|Drug: Placebo for Prasugrel|Drug: Placebo for Clopidogrel,"Eli Lilly and Company|Daiichi Sankyo, Inc.|The TIMI Study Group",Eli Lilly and Company,"Daiichi Sankyo, Inc.",The TIMI Study Group,,,,,Phase 2,Industry|Other,Interventional,8/6/2019,6/7/2019,https://ClinicalTrials.gov/show/NCT00357968
6126,A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery,Completed,Has Results,Peripheral Vascular Disease,Device: Misago™ Self-Expanding Stent System,Terumo Medical Corporation|ClinLogix. LLC|Massachusetts General Hospital|Beth Israel Deaconess Medical Center,Terumo Medical Corporation,ClinLogix. LLC,Massachusetts General Hospital|Beth Israel Deaconess Medical Center,Massachusetts General Hospital,Beth Israel Deaconess Medical Center,,,Not Applicable,Industry|Other,Interventional,7/10/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01118117
6127,XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort,Completed,Has Results,Chronic Total Occlusion of Coronary Artery|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis,Drug: placebo + aspirin|Drug: clopidogrel + aspirin OR prasugrel + aspirin|Device: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS),"Abbott Medical Devices|Baim Institute for Clinical Research|Bristol-Myers Squibb|Eli Lilly and Company|Daiichi Sankyo, Inc.",Abbott Medical Devices,Baim Institute for Clinical Research,"Bristol-Myers Squibb|Eli Lilly and Company|Daiichi Sankyo, Inc.",Bristol-Myers Squibb,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Eli Lilly and Company,"Daiichi Sankyo, Inc.",Phase 4,Industry|Other,Interventional,8/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01106534
6128,Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma,Completed,Has Results,Esophageal Cancer|Gastric Cancer,"Drug: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Weill Medical College of Cornell University",Memorial Sloan Kettering Cancer Center,"Genentech, Inc.",Weill Medical College of Cornell University,,,,,Phase 2,Other|Industry,Interventional,8/8/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT00737438
6129,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,Completed,Has Results,Mucosal Melanoma|Recurrent Melanoma|Recurrent Uveal Melanoma|Stage IIIA Skin Melanoma|Stage IIIA Uveal Melanoma|Stage IIIB Skin Melanoma|Stage IIIB Uveal Melanoma|Stage IIIC Skin Melanoma|Stage IIIC Uveal Melanoma|Stage IV Skin Melanoma|Stage IV Uveal Melanoma,Drug: Epacadostat|Biological: MELITAC 12.1 Peptide Vaccine,Fred Hutchinson Cancer Research Center|Incyte Corporation|National Cancer Institute (NCI)|University of Virginia,Fred Hutchinson Cancer Research Center,Incyte Corporation,National Cancer Institute (NCI)|University of Virginia,National Cancer Institute (NCI),University of Virginia,,,Phase 2,Other|Industry|NIH,Interventional,9/13/2013,5/18/2017,https://ClinicalTrials.gov/show/NCT01961115
6130,Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Completed,Has Results,Thyroid Cancer,Drug: Temsirolimus and Sorafenib,Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Pfizer,Memorial Sloan Kettering Cancer Center,National Comprehensive Cancer Network,Pfizer,,,,,Phase 2,Other|Industry,Interventional,12/1/2009,1/16/2018,https://ClinicalTrials.gov/show/NCT01025453
6131,Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC),Completed,Has Results,Squamous Cell Cancer|Head and Neck Cancer,Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin,Memorial Sloan Kettering Cancer Center|NATL COMP CA NETWORK|Pfizer,Memorial Sloan Kettering Cancer Center,NATL COMP CA NETWORK,Pfizer,,,,,Phase 1|Phase 2,Other|Industry,Interventional,11/9/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT01016769
6132,Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,Completed,Has Results,Lung Cancer,Drug: Ruxolitinib|Drug: Erlotinib,Memorial Sloan Kettering Cancer Center|Incyte Corporation,Memorial Sloan Kettering Cancer Center,Incyte Corporation,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,6/14/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02155465
6133,Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer,Completed,Has Results,Esophageal Cancer|Gastric Cancer|Neoplasm Metastasis,Drug: Cetuximab,Dana-Farber Cancer Institute|Bristol-Myers Squibb|Massachusetts General Hospital|Beth Israel Deaconess Medical Center,Dana-Farber Cancer Institute,Bristol-Myers Squibb,Massachusetts General Hospital|Beth Israel Deaconess Medical Center,Massachusetts General Hospital,Beth Israel Deaconess Medical Center,,,Phase 2,Other|Industry,Interventional,7/5/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00130689
6134,Pilot Study of Effect of Sorafenib on Portal Pressure,Completed,Has Results,Clinically Significant Portal Hypertension,Drug: Placebo|Drug: Sorafenib,"Yale University|Onyx Therapeutics, Inc.",Yale University,"Onyx Therapeutics, Inc.",,,,,,Phase 2,Other|Industry,Interventional,8/11/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01714609
6135,A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries,Completed,Has Results,Burns,Device: ReCell and Split-thickness skin graft,"Avita Medical|United States Department of Defense|Royal Perth Hospital|MedDRA Assistance Inc|BioStat International, Inc.",Avita Medical,United States Department of Defense,"Royal Perth Hospital|MedDRA Assistance Inc|BioStat International, Inc.",Royal Perth Hospital,"MedDRA Assistance Inc|BioStat International, Inc.",MedDRA Assistance Inc,"BioStat International, Inc.",Not Applicable,Industry|U.S. Fed|Other,Interventional,5/21/2010,8/26/2015,https://ClinicalTrials.gov/show/NCT01138917
6136,SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS),Completed,Has Results,Overactive Bladder Syndrome (OABS),Drug: Placebo|Drug: SMP-986,"Sunovion|Dainippon Sumitomo Pharma America|ICON Clinical Research|ClinPhone, Inc.|Covance|PPD",Sunovion,Dainippon Sumitomo Pharma America,"ICON Clinical Research|ClinPhone, Inc.|Covance|PPD",ICON Clinical Research,"ClinPhone, Inc.|Covance|PPD","ClinPhone, Inc.",Covance|PPD,Phase 2,Industry,Interventional,12/6/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00409539
6137,Amgen 386 for Recurrent Glioblastoma,Completed,Has Results,Glioblastoma Multiforme,Drug: Amgen 386|Drug: Bevacizumab,Dana-Farber Cancer Institute|Amgen,Dana-Farber Cancer Institute,Amgen,,,,,,Phase 1|Phase 2,Other|Industry,Interventional,12/10/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01290263
6138,Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder,Completed,Has Results,Depression,Other: 6(S)-5-MTHF(Deplin)|Other: Placebo,"George I. Papakostas|Pamlab, L.L.C.|Massachusetts General Hospital",George I. Papakostas,"Pamlab, L.L.C.",Massachusetts General Hospital,,,,,Phase 4,Other|Industry,Interventional,7/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00955955
6139,TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma,Completed,Has Results,Neuroblastoma|Medulloblastoma|Relapse,Drug: TPI 287,"Giselle Sholler|Cortice Biosciences, Inc.|Spectrum Health Hospitals",Giselle Sholler,"Cortice Biosciences, Inc.",Spectrum Health Hospitals,,,,,Phase 1,Other|Industry,Interventional,3/9/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00867568
6140,Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors,Completed,Has Results,Germ Cell Tumors,Drug: Aprepitant|Drug: Placebo,Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.,Hoosier Cancer Research Network,Merck Sharp & Dohme Corp.,,,,,,Phase 3,Other|Industry,Interventional,12/7/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00572572
6141,Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer,Completed,Has Results,Hormone-refractory Prostate Cancer|Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Prostate Cancer|Recurrent Prostate Cancer,Drug: Dasatinib,"University of California, Irvine|Bristol-Myers Squibb","University of California, Irvine",Bristol-Myers Squibb,,,,,,Phase 2,Other|Industry,Interventional,7/7/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00570700
6142,Lapatinib and Trastuzumab With or Without Endocrine Therapy,Completed,Has Results,Breast Cancer,Drug: Lapatinib|Drug: Trastuzumab|Drug: Endocrine,Baylor Breast Care Center|GlaxoSmithKline,Baylor Breast Care Center,GlaxoSmithKline,,,,,,Phase 2,Other|Industry,Interventional,5/8/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00548184
6143,Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma,Completed,Has Results,Bladder Cancer|Muscle-invasive Bladder Cancer,Drug: Methotrexate|Drug: Doxorubicin|Drug: vinblastine|Drug: cisplatin|Drug: Pegfilgrastim,Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Amgen,Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center,Brigham and Women's Hospital|Amgen,Brigham and Women's Hospital,Amgen,,,Phase 2,Other|Industry,Interventional,12/8/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT00808639
6144,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,Completed,Has Results,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Drug: Atorvastatin|Drug: Atorvastatin Placebo,Nemours Children's Clinic|Pfizer|Medtronic|Quest Diagnostics,Nemours Children's Clinic,Pfizer,Medtronic|Quest Diagnostics,Medtronic,Quest Diagnostics,,,Phase 3,Other|Industry,Interventional,10/10/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01236365
6145,Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System),Completed,Has Results,"Deafness|Hearing Loss|Hearing Loss, Conductive",Device: Baha Attract System,Cochlear Bone Anchored Solutions,Cochlear Bone Anchored Solutions,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT02022085
6146,"A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease",Completed,Has Results,Jansky-Bielschowsky Disease|Batten Disease|Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2|CLN2 Disease,Biological: BMN 190,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01907087
6147,Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®,Completed,Has Results,Glabellar Lines,Biological: botulinum toxin Type A,Allergan,Allergan,,,,,,,,Industry,Observational,4/1/2012,12/31/2012,https://ClinicalTrials.gov/show/NCT01608672
6148,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Completed,Has Results,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Best Available Therapy|Drug: Metronidazole,Pfizer|Forest Laboratories,Pfizer,Forest Laboratories,,,,,,Phase 3,Industry,Interventional,1/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01644643
6149,Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: placebo|Drug: BI1356 low dose|Drug: BI1356 high dose,Boehringer Ingelheim|Eli Lilly and Company,Boehringer Ingelheim,Eli Lilly and Company,,,,,,Phase 2,Industry,Interventional,4/11/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01342484
6150,"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study",Completed,Has Results,Japanese Encephalitis,Procedure: Blood draw|Biological: IC51 has given in the parent study IC51-322,Valneva Austria GmbH,Valneva Austria GmbH,,,,,,,Phase 3,Industry,Interventional,10/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01246479
6151,"A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both",Completed,Has Results,"Hepatitis B, Chronic",Drug: peginterferon alfa-2a [Pegasys]|Drug: tenofovir,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,8/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00962871
6152,Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO),Completed,Has Results,Macular Edema|Retinal Vein Occlusion,Drug: AGN208397 intravitreal injection|Drug: dexamethasone intravitreal implant,Allergan,Allergan,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01027650
6153,An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients,Completed,Has Results,Hunter Syndrome,Biological: Idursulfase,Shire,Shire,,,,,,,,Industry,Observational,10/14/2008,2/8/2013,https://ClinicalTrials.gov/show/NCT00882921
6154,A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148),Completed,Has Results,Postoperative Nausea and Vomiting,Drug: Aprepitant|Drug: Ondansetron,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 1,Industry,Interventional,1/26/2009,3/12/2013,https://ClinicalTrials.gov/show/NCT00819039
6155,A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age,Completed,Has Results,Hypertension,Drug: Aliskiren 3.125 mini-tablets,Novartis,Novartis,,,,,,,Phase 1|Phase 2,Industry,Interventional,4/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00834041
6156,Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Device: Medigus SRS endoscopic stapling system,"Aviel Roy-Shapira, M.D.|Medigus Ltd","Aviel Roy-Shapira, M.D.",Medigus Ltd,,,,,,Phase 3,Industry,Interventional,5/8/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00734747
6157,A Phase III Trial of e-TNS for the Acute Treatment of Migraine,Completed,Has Results,Migraine,Device: Verum Cefaly® Abortive Program device|Device: Sham Cefaly® Abortive Program device,Cefaly Technology,Cefaly Technology,,,,,,,Not Applicable,Industry,Interventional,4/10/2018,1/11/2019,https://ClinicalTrials.gov/show/NCT03465904
6158,An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents,Completed,Has Results,Onychomycosis|Tinea Unguium,Drug: Tavaborole 5% Topical Solution,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,10/22/2015,7/27/2017,https://ClinicalTrials.gov/show/NCT03405818
6159,The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity,Completed,Has Results,Obesity,Drug: Leu Sil 1.0mg|Drug: Leu Sil 4.0mg|Drug: Leu Met Sil 1.0mg|Drug: Leu Met Sil 4.0mg|Drug: Placebo,NuSirt Biopharma,NuSirt Biopharma,,,,,,,Phase 2,Industry,Interventional,1/8/2018,8/17/2018,https://ClinicalTrials.gov/show/NCT03364335
6160,Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.,Completed,Has Results,Smoking,"Behavioral: Counseling|Behavioral: Self-help guide|Drug: Pharmacotherapy|Behavioral: Genetic feedback, verbal|Behavioral: Genetic feedback, printed",Stanford University|SRI International|Johns Hopkins University|University of Bristol|National Institute on Drug Abuse (NIDA),Stanford University,SRI International,Johns Hopkins University|University of Bristol|National Institute on Drug Abuse (NIDA),Johns Hopkins University,University of Bristol|National Institute on Drug Abuse (NIDA),University of Bristol,National Institute on Drug Abuse (NIDA),Phase 4,Other|Industry|NIH,Interventional,7/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00991081
6161,Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma,Completed,Has Results,Asthma,Drug: AS MDI 90 μg|Drug: AS MDI 180 µg|Other: Placebo MDI|Drug: Proventil 90 μg|Drug: Proventil 180 μg,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/15/2017,3/30/2018,https://ClinicalTrials.gov/show/NCT03364608
6162,"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis",Completed,Has Results,Pruritus|Psoriasis,Drug: 5 mg Serlopitant Tablets|Drug: Matching Placebo Tablets,Menlo Therapeutics Inc.,Menlo Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,11/1/2017,11/12/2018,https://ClinicalTrials.gov/show/NCT03343639
6163,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: mipomersen|Drug: Placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","Kastle Therapeutics, LLC","Ionis Pharmaceuticals, Inc.",,,,,,Phase 3,Industry,Interventional,7/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00607373
6164,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Completed,Has Results,Rosacea,Drug: Generic Azelaic Acid Foam|Drug: Finacea® (Azelaic Acid) Foam|Drug: Vehicle Foam|Other: Cleanser|Other: Sunscreen|Other: Towel|Other: Moisturizing Lotion,Actavis Inc.,Actavis Inc.,,,,,,,Phase 3,Industry,Interventional,7/19/2016,6/22/2017,https://ClinicalTrials.gov/show/NCT03287791
6165,A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts,Completed,Has Results,Common Wart,Drug: A-101 Topical Solution|Drug: A-101 Vehicle Solution,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,7/13/2017,3/1/2018,https://ClinicalTrials.gov/show/NCT03278028
6166,"A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)",Completed,Has Results,"Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis",Drug: TAK-906 Maleate|Drug: Metaclopramide|Drug: TAK-906 Maleate Placebo,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,9/26/2017,3/9/2018,https://ClinicalTrials.gov/show/NCT03268941
6167,6-week Safety and PD Study in Adults With NAFLD,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: Placebo|Drug: PF-06835919 Low Dose|Drug: PF-06835919 High Dose,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/27/2017,4/27/2018,https://ClinicalTrials.gov/show/NCT03256526
6168,A Phase2 of A-101 Topical Solution in Subjects With Common Warts,Completed,Has Results,Common Wart,Drug: A-101 Topical Solution|Drug: A-101 Vehicle Solution,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,8/1/2017,3/16/2018,https://ClinicalTrials.gov/show/NCT03210337
6169,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease COPD,Drug: Glycopyrronium/Formoterol Fumarate|Drug: umeclidinium/vilanterol,AstraZeneca|Parexel International Ltd|Cognizant Technology Solution|Center for Information & Study on Clinical Research Participation (CISCRP)|eResearchTechnology|QuintilesIMS Limited|Corporate Translations Inc,AstraZeneca,Parexel International Ltd,Cognizant Technology Solution|Center for Information & Study on Clinical Research Participation (CISCRP)|eResearchTechnology|QuintilesIMS Limited|Corporate Translations Inc,Cognizant Technology Solution,Center for Information & Study on Clinical Research Participation (CISCRP)|eResearchTechnology|QuintilesIMS Limited|Corporate Translations Inc,Center for Information & Study on Clinical Research Participation (CISCRP),eResearchTechnology|QuintilesIMS Limited|Corporate Translations Inc,Phase 3,Industry|Other,Interventional,5/25/2017,5/4/2018,https://ClinicalTrials.gov/show/NCT03162055
6170,A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: Olumacostat Glasaretil Gel, 5.0%","Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 3,Industry,Interventional,3/21/2017,4/27/2018,https://ClinicalTrials.gov/show/NCT03127956
6171,Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL/VOX,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,4/25/2017,3/19/2018,https://ClinicalTrials.gov/show/NCT03118843
6172,Assessing Fitting Guides in Alcon Multifocal Contact Lenses,Completed,Has Results,Presbyopia|Refractive Errors,Device: Lotrafilcon B multifocal contact lenses|Device: Nelfilcon A multifocal contact lenses|Device: Delefilcon A multifocal contact lenses,Alcon Research,Alcon Research,,,,,,,Not Applicable,Industry,Interventional,5/17/2017,7/28/2017,https://ClinicalTrials.gov/show/NCT03118934
6173,"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period",Completed,Has Results,Actinic Keratosis (AK),Drug: Low dose DFD07 once daily|Drug: High dose DFD07 once daily|Drug: High dose DFD07 twice daily|Drug: Placebo twice daily,Dr. Reddy's Laboratories Limited,Dr. Reddy's Laboratories Limited,,,,,,,Phase 2|Phase 3,Industry,Interventional,2/14/2017,7/5/2018,https://ClinicalTrials.gov/show/NCT03116698
6174,"A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis",Completed,Has Results,Seborrheic Keratosis,Drug: A-101,"Aclaris Therapeutics, Inc.","Aclaris Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,5/17/2017,4/3/2018,https://ClinicalTrials.gov/show/NCT03148691
6175,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Teriflunomide|Drug: Placebo (for Teriflunomide)|Drug: Interferon-β,Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,5/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00489489
6176,Study of Mepolizumab Autoinjector in Asthmatics,Completed,Has Results,Asthma,Drug: Mepolizumab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/4/2017,11/30/2017,https://ClinicalTrials.gov/show/NCT03099096
6177,A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: ASP8062|Drug: Placebo,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","Astellas Pharma Global Development, Inc.",Astellas Pharma Inc,,,,,,Phase 2,Industry,Interventional,5/8/2017,3/6/2018,https://ClinicalTrials.gov/show/NCT03092726
6178,Evaluation of Astigmatic Contact Lenses,Completed,Has Results,Visual Acuity,Device: Investigational Contact Lens|Device: Marketed Contact Lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/1/2017,5/4/2017,https://ClinicalTrials.gov/show/NCT03086447
6179,Safety and Effectiveness of B-Laser™ in Subjects Affected With Infrainguinal PAD,Completed,Has Results,PAD,Device: B-Laser™ Atherectomy System,Eximo Medical Ltd.,Eximo Medical Ltd.,,,,,,,Not Applicable,Industry,Interventional,9/6/2017,10/11/2018,https://ClinicalTrials.gov/show/NCT03157531
6180,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: Olumacostat Glasaretil Gel, 5.0%|Other: Olumacostat Glasaretil Gel, Vehicle","Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 3,Industry,Interventional,2/6/2017,12/21/2017,https://ClinicalTrials.gov/show/NCT03073486
6181,A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment,Completed,Has Results,Hepatitis C Virus (HCV),Drug: Glecaprevir/pibrentasvir,AbbVie,AbbVie,,,,,,,Phase 3,Industry,Interventional,3/28/2017,6/5/2018,https://ClinicalTrials.gov/show/NCT03069365
6182,To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation,Completed,Has Results,Opioid Induced Constipation,Drug: Polyethylene Glycol 3350|Drug: Movantik,"AstraZeneca|QuintilesIMS, Inc.",AstraZeneca,"QuintilesIMS, Inc.",,,,,,Phase 4,Industry|Other,Interventional,3/2/2017,8/23/2017,https://ClinicalTrials.gov/show/NCT03060512
6183,An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005),Completed,Has Results,"Schizophrenia, Acute Episode",Drug: MK-8189|Drug: Risperidone|Drug: Placebo matching MK-8189|Drug: Placebo matching risperidone,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 2,Industry,Interventional,3/8/2017,1/9/2018,https://ClinicalTrials.gov/show/NCT03055338
6184,Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination,Completed,Has Results,Skin Flora Contamination,Procedure: InteguSeal* skin sealant and standard surgical preparation|Other: Standard preoperative skin preparation,Kimberly-Clark Corporation,Kimberly-Clark Corporation,,,,,,,Phase 4,Industry,Interventional,4/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00467857
6185,Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults,Completed,Has Results,"Infection, Human Immunodeficiency Virus|HIV Infections",Drug: GSK2838232|Drug: Cobicistat,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/17/2017,4/23/2018,https://ClinicalTrials.gov/show/NCT03045861
6186,"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: UMEC/VI 62.5/25 mcg via ELLIPTA|Drug: UMEC 62.5 mcg via ELLIPTA|Drug: Salmeterol 50 mcg via DISKUS|Drug: Placebo via ELLIPTA|Drug: Placebo via DISKUS,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,6/16/2017,6/18/2018,https://ClinicalTrials.gov/show/NCT03034915
6187,Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management,Completed,Has Results,Parkinson´s Disease,Device: Kinesia-ONE™|Device: Kinesia-360™|Drug: Rotigotine,UCB Biopharma S.P.R.L.|UCB Pharma,UCB Biopharma S.P.R.L.,UCB Pharma,,,,,,Phase 4,Industry,Interventional,3/16/2017,1/2/2018,https://ClinicalTrials.gov/show/NCT03103919
6188,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: Olumacostat Glasaretil Gel, 5.0%|Other: Olumacostat Glasaretil Gel, Vehicle","Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 3,Industry,Interventional,12/27/2016,11/28/2017,https://ClinicalTrials.gov/show/NCT03028363
6189,A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting,Completed,Has Results,Epilepsy,Drug: Brivaracetam|Drug: Lorazepam,UCB Biopharma S.P.R.L.|UCB Pharma,UCB Biopharma S.P.R.L.,UCB Pharma,,,,,,Phase 2,Industry,Interventional,2/6/2017,4/27/2018,https://ClinicalTrials.gov/show/NCT03021018
6190,"A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy",Completed,Has Results,Bowel Preparation,"Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder",Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/20/2017,10/12/2017,https://ClinicalTrials.gov/show/NCT03017235
6191,Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma,Completed,Has Results,Asthma,Drug: Placebo|Drug: UMEC|Drug: Fluticasone Furoate|Drug: Albuterol/salbutamol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,1/25/2017,5/30/2018,https://ClinicalTrials.gov/show/NCT03012061
6192,To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold,Completed,Has Results,Common Cold,Drug: Carbomer 980 (1146A)|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/29/2016,6/7/2017,https://ClinicalTrials.gov/show/NCT03005067
6193,A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM),Completed,Has Results,Multiple Myeloma,Drug: DARATUMUMAB|Drug: DURVALUMAB,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,3/14/2017,12/4/2017,https://ClinicalTrials.gov/show/NCT03000452
6194,"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination",Completed,Has Results,"Infections, Meningococcal","Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/8/2016,12/7/2017,https://ClinicalTrials.gov/show/NCT02986854
6195,Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis,Completed,Has Results,"Arthritis, Rheumatoid; Arthritis, Psoriatic",Drug: Commercial Formulation Etanercept|Drug: New Formulation Etanercept,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,11/29/2016,10/9/2017,https://ClinicalTrials.gov/show/NCT02986139
6196,Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma,Completed,Has Results,Renal Cell Carcinoma|Kidney Cancer,Drug: bevacizumab|Drug: temsirolimus,"Beth Israel Deaconess Medical Center|Genentech, Inc.|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Vanderbilt University Medical Center",Beth Israel Deaconess Medical Center,"Genentech, Inc.",Dana-Farber Cancer Institute|Brigham and Women's Hospital|Vanderbilt University Medical Center,Dana-Farber Cancer Institute,Brigham and Women's Hospital|Vanderbilt University Medical Center,Brigham and Women's Hospital,Vanderbilt University Medical Center,Phase 2,Other|Industry,Interventional,4/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00782275
6197,"Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis",Completed,Has Results,Pruritus|Atopic Dermatitis,Drug: Serlopitant High Dose|Drug: Placebo Oral Tablet|Drug: Serlopitant Low Dose,Menlo Therapeutics Inc.,Menlo Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,11/16/2019,2/23/2018,https://ClinicalTrials.gov/show/NCT02975206
6198,"Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age",Completed,Has Results,Herpes Zoster,Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/16/2017,5/24/2018,https://ClinicalTrials.gov/show/NCT02979639
6199,A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy,Completed,Has Results,Type 2 Diabetes,Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,12/16/2019,8/14/2017,https://ClinicalTrials.gov/show/NCT02973100
6200,Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vortioxetine,Takeda,Takeda,,,,,,,Phase 4,Industry,Interventional,12/22/2016,2/6/2018,https://ClinicalTrials.gov/show/NCT02972632
6201,A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,Completed,Has Results,Pancreatic Ductal Adenocarcinoma,Drug: Abemaciclib|Drug: LY3023414|Drug: Gemcitabine|Drug: Capecitabine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,1/12/2017,11/9/2018,https://ClinicalTrials.gov/show/NCT02981342
6202,Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC),Completed,Has Results,"Vulvovaginitis|Yeast Infection|Yeast Infection Vaginal|Candidiasis, Vulvovaginal",Drug: Oral Encochleated Amphotericin B (CAMB)|Drug: Fluconazole,"Matinas BioPharma Nanotechnologies, Inc.","Matinas BioPharma Nanotechnologies, Inc.",,,,,,,Phase 2,Industry,Interventional,11/16/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02971007
6203,Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.,Completed,Has Results,"Heart Failure, Reduced Ejection Fraction",Drug: sacubitril/valsartan (LCZ696)|Drug: enalapril|Drug: matching placebo sacubitril/valsartan (LCZ696)|Drug: matching placebo enalapril,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,12/16/2016,3/19/2018,https://ClinicalTrials.gov/show/NCT02970669
6204,A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma,Completed,Has Results,Asthma,Drug: Albuterol Sulfate,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,2/13/2017,2/2/2018,https://ClinicalTrials.gov/show/NCT02969408
6205,Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis,Completed,Has Results,Chronic Plaque Psoriasis,Drug: PF-06700841|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/16/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT02969018
6206,A Study of the Effectiveness and Efficacy of the PowerSleep Device,Completed,Has Results,Sleep Deprivation|Insufficient Sleep Syndrome|Healthy,Device: PowerSleep Stim|Device: PowerSleep Sham,Philips Respironics,Philips Respironics,,,,,,,Not Applicable,Industry,Interventional,4/25/2017,11/10/2017,https://ClinicalTrials.gov/show/NCT03162328
6207,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,3/3/2017,5/8/2018,https://ClinicalTrials.gov/show/NCT02964247
6208,A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction,Completed,Has Results,Heart Failure,Drug: Neladenoson bialanate (BAY1067197)|Drug: Placebo,Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,2/22/2017,5/16/2018,https://ClinicalTrials.gov/show/NCT02992288
6209,A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.,Completed,Has Results,Severe Sepsis,Biological: Nivolumab,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,12/7/2016,1/5/2018,https://ClinicalTrials.gov/show/NCT02960854
6210,Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use,Completed,Has Results,Irritable Bowel Syndrome With Diarrhea,Drug: Eluxadoline|Drug: Placebo,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,10/25/2016,1/22/2018,https://ClinicalTrials.gov/show/NCT02959983
6211,"Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses",Completed,Has Results,Actinic Keratosis,"Drug: GDC 695|Drug: Diclofenac Sodium Gel, 3%|Drug: Vehicle gel","Gage Development Company, LLC","Gage Development Company, LLC",,,,,,,Phase 3,Industry,Interventional,10/27/2016,9/6/2017,https://ClinicalTrials.gov/show/NCT02952898
6212,A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C),Completed,Has Results,Postpartum Depression,Drug: Placebo|Drug: SAGE-547 90 μg/kg/h,Sage Therapeutics,Sage Therapeutics,,,,,,,Phase 3,Industry,Interventional,7/16/2019,10/11/2017,https://ClinicalTrials.gov/show/NCT02942017
6213,A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B),Completed,Has Results,Postpartum Depression,Drug: Placebo|Drug: SAGE-547 60 μg/kg/h|Drug: SAGE-547 90 μg/kg/h,Sage Therapeutics,Sage Therapeutics,,,,,,,Phase 3,Industry,Interventional,8/1/2016,10/19/2017,https://ClinicalTrials.gov/show/NCT02942004
6214,A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: GLPG2222 50 mg|Drug: GLPG2222 100 mg|Drug: Placebo|Drug: GLPG2222 200 mg|Drug: GLPG2222 400 mg,Galapagos NV,Galapagos NV,,,,,,,Phase 2,Industry,Interventional,3/18/2017,10/19/2017,https://ClinicalTrials.gov/show/NCT03119649
6215,Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,"Drug: MM36 topical ointment, 1%","Medimetriks Pharmaceuticals, Inc","Medimetriks Pharmaceuticals, Inc",,,,,,,Phase 2,Industry,Interventional,10/16/2019,6/8/2017,https://ClinicalTrials.gov/show/NCT02945657
6216,"Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers",Completed,Has Results,Healthy Volunteers,Drug: Vortioxetine|Drug: Paroxetine|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 4,Industry,Interventional,11/21/2016,6/9/2017,https://ClinicalTrials.gov/show/NCT02932904
6217,Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders,Completed,Has Results,Corneal Epithelial Disorders,Drug: High Dose SJP-0035 Ophthalmic Solution|Drug: Low Dose SJP-0035 Ophthalmic Solution|Drug: Vehicle of SJP-0035 Ophthalmic solution,"Senju Pharmaceutical Co., Ltd.","Senju Pharmaceutical Co., Ltd.",,,,,,,Phase 2,Industry,Interventional,9/16/2019,5/3/2017,https://ClinicalTrials.gov/show/NCT02929823
6218,"Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home",Completed,Has Results,Asthma,Biological: Benralizumab,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,11/10/2016,8/21/2017,https://ClinicalTrials.gov/show/NCT02918071
6219,Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children,Completed,Has Results,Influenza,"Biological: Fluzone Quadrivalent vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/23/2016,3/6/2017,https://ClinicalTrials.gov/show/NCT02915302
6220,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.,Completed,Has Results,"Influenza, Human",Biological: Seqirus Quadrivalent Inactivated Influenza Vaccine|Biological: Comparator Quadrivalent Inactivated Influenza Vaccine,Seqirus,Seqirus,,,,,,,Phase 3,Industry,Interventional,9/27/2016,8/11/2017,https://ClinicalTrials.gov/show/NCT02914275
6221,MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study,Completed,Has Results,Femoral Arteriotomy Closure,Device: MANTA vascular closure device,"Essential Medical, Inc.","Essential Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/16/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02908880
6222,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec/insulin aspart|Drug: Insulin glargine|Drug: Insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/20/2016,12/24/2017,https://ClinicalTrials.gov/show/NCT02906917
6223,Open-Label Treatment Extension Study,Completed,Has Results,Opioid Use Disorder|Opioid-related Disorders,Drug: RBP-6000,Indivior Inc.,Indivior Inc.,,,,,,,Phase 3,Industry,Interventional,8/17/2016,8/23/2017,https://ClinicalTrials.gov/show/NCT02896296
6224,A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Tazarotene Cream 0.1%|Drug: Tazorac®|Drug: Placebo,Fougera Pharmaceuticals Inc.,Fougera Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,9/21/2016,5/31/2017,https://ClinicalTrials.gov/show/NCT02886715
6225,A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Tazarotene Cream 0.05%|Drug: TAZORAC® (tazarotene) Cream 0.05%|Drug: Placebo,Fougera Pharmaceuticals Inc.,Fougera Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,9/19/2016,8/2/2017,https://ClinicalTrials.gov/show/NCT02886702
6226,Treatment of Nasal Airway Obstruction Using the Aerin Medical Device,Completed,Has Results,Nasal Obstruction,Device: Vivaer Stylus,Aerin Medical,Aerin Medical,,,,,,,Not Applicable,Industry,Interventional,9/27/2016,8/18/2017,https://ClinicalTrials.gov/show/NCT02914236
6227,Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI,Completed,Has Results,Bacterial Infections|Skin Structures and Soft Tissue Infections,Drug: Omadacycline|Drug: Linezolid,Paratek Pharmaceuticals Inc,Paratek Pharmaceuticals Inc,,,,,,,Phase 3,Industry,Interventional,8/16/2019,6/6/2017,https://ClinicalTrials.gov/show/NCT02877927
6228,Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction,Completed,Has Results,Meibomian Gland Dysfunction,Device: iLux 2020 System|Device: LipiFlow Pulsation System,"Tear Film Innovations, Inc.","Tear Film Innovations, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/9/2017,7/20/2017,https://ClinicalTrials.gov/show/NCT03055832
6229,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis (SAR),Drug: GSP 301 NS|Drug: GOM-NS|Drug: GMM-2 NS|Drug: GSP 301 placebo NS,Glenmark Specialty S.A.,Glenmark Specialty S.A.,,,,,,,Phase 3,Industry,Interventional,8/16/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02870205
6230,"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",Completed,Has Results,"Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,8/26/2016,2/26/2018,https://ClinicalTrials.gov/show/NCT02867709
6231,Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women,Completed,Has Results,HIV Infection,Drug: Atazanavir + Ritonavir + Combivir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,6/6/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00326716
6232,"Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate",Completed,Has Results,Rheumatoid Arthritis,Drug: GS-9876|Drug: Filgotinib|Drug: GS-9876 placebo|Drug: Filgotinib placebo|Drug: Methotrexate,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,9/21/2016,9/20/2017,https://ClinicalTrials.gov/show/NCT02885181
6233,"Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)",Completed,Has Results,Nonalcoholic Steatohepatitis (NASH),Drug: GS-9674|Drug: Placebo to match GS-9674,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,10/26/2016,1/9/2018,https://ClinicalTrials.gov/show/NCT02854605
6234,PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB,Completed,Has Results,Overactive Bladder,Device: NURO System PTNM Therapy,MedtronicNeuro,MedtronicNeuro,,,,,,,Not Applicable,Industry,Interventional,9/16/2019,11/21/2017,https://ClinicalTrials.gov/show/NCT02857816
6235,"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,Drug: BI 695501|Drug: Humira,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,8/17/2016,1/17/2018,https://ClinicalTrials.gov/show/NCT02850965
6236,In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia,Completed,Has Results,Chronic Sinusitis,Device: PROPEL Mini Sinus Implant|Procedure: Balloon Sinus Dilation Alone,Intersect ENT,Intersect ENT,,,,,,,Not Applicable,Industry,Interventional,8/16/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02880514
6237,Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH),Completed,Has Results,Alcoholic Hepatitis (AH),Drug: Selonsertib|Drug: Prednisolone|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,9/1/2016,5/31/2018,https://ClinicalTrials.gov/show/NCT02854631
6238,"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention",Completed,Has Results,"Migraine, With or Without Aura",Drug: Atogepant|Drug: Placebo-matching Atogepant,Allergan,Allergan,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/6/2016,4/23/2018,https://ClinicalTrials.gov/show/NCT02848326
6239,"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",Completed,Has Results,Avian Influenza,Biological: aH5N1c|Biological: Placebo,Seqirus|Biomedical Advanced Research and Development Authority,Seqirus,Biomedical Advanced Research and Development Authority,,,,,,Phase 3,Industry|U.S. Fed,Interventional,7/11/2016,10/4/2017,https://ClinicalTrials.gov/show/NCT02839330
6240,"Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.",Completed,Has Results,"Colitis, Ulcerative",Drug: PF-06480605,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,10/26/2016,8/30/2018,https://ClinicalTrials.gov/show/NCT02840721
6241,Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis,Completed,Has Results,Psoriasis,Drug: Guselkumab|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,2/28/2017,2/6/2018,https://ClinicalTrials.gov/show/NCT02905331
6242,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine",Completed,Has Results,"Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,7/22/2016,12/14/2017,https://ClinicalTrials.gov/show/NCT02828020
6243,Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Secukinumab|Drug: Ustekinumab,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/22/2016,7/9/2018,https://ClinicalTrials.gov/show/NCT02826603
6244,Software Treatment for Actively Reducing Severity of ADHD - Follow Up,Completed,Has Results,Attention Deficit Disorder With Hyperactivity,Device: EVO,"Akili Interactive Labs, Inc.","Akili Interactive Labs, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/16/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT02828644
6245,Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,7/6/2016,7/21/2017,https://ClinicalTrials.gov/show/NCT02825251
6246,Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma,Completed,Has Results,Asthma,Drug: Benralizumab|Drug: Benralizumab Placebo|Drug: Seasonal influenza virus vaccine,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,7/1/2016,1/24/2017,https://ClinicalTrials.gov/show/NCT02814643
6247,Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Nintedanib|Drug: Placebo|Drug: Sildenafil,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,6/30/2016,4/13/2018,https://ClinicalTrials.gov/show/NCT02802345
6248,"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",Completed,Has Results,Cystic Fibrosis,Drug: LUM/IVA,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,5/16/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT02797132
6249,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,"Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Drug: Aclidinium bromide 400 μg (AB 400 μg)|Drug: Formoterol fumarate 12 μg (FF 12 μg)|Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Drug: Tiotropium 18 μg (TIO 18 μg)|Other: Placebo to TIO 18 μg",AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,7/5/2016,6/8/2017,https://ClinicalTrials.gov/show/NCT02796677
6250,Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use,Completed,Has Results,Asthma,Device: ELLIPTA DPI|Device: GSK MDI|Device: AZ MDI,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,8/22/2016,12/15/2016,https://ClinicalTrials.gov/show/NCT02794480
6251,Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain,Completed,Has Results,Post Surgical Ocular Inflammation and Pain,Drug: KPI-121 1% Ophthalmic Suspension dosed BID|Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID,"Kala Pharmaceuticals, Inc.","Kala Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,6/16/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02793817
6252,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),Completed,Has Results,Colorectal Cancer,"Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Drug: Cobimetinib|Drug: Regorafenib",Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,7/5/2016,12/26/2018,https://ClinicalTrials.gov/show/NCT02788279
6253,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Insulin glargine/lixisenatide fixed ratio combination|Drug: liraglutide|Drug: exenatide|Drug: exenatide extended-release|Drug: albiglutide|Drug: dulaglutide|Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)",Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,7/6/2016,11/17/2018,https://ClinicalTrials.gov/show/NCT02787551
6254,Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Placebo ELLIPTA device|Drug: Placebo capsules for use in HANDIHALER device|Other: Inhaler Preference Questionnaire Version 1|Other: Inhaler Preference Questionnaire Version 2,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,6/21/2016,10/4/2016,https://ClinicalTrials.gov/show/NCT02786927
6255,PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY,Completed,Has Results,Respiratory Depression,Device: Capnostream Monitor,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,4/7/2017,5/7/2018,https://ClinicalTrials.gov/show/NCT02811302
6256,A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males,Completed,Has Results,Alopecia,Drug: Setipiprant|Drug: Placebo|Drug: Finasteride,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,7/14/2016,5/22/2018,https://ClinicalTrials.gov/show/NCT02781311
6257,HEMOBLAST Pivotal Clinical Investigation,Completed,Has Results,Hemostasis,"Device: HEMOBLAST Bellows|Device: Absorbable gelatin sponge, USP with thrombin",Biom'Up SA,Biom'Up SA,,,,,,,Not Applicable,Industry,Interventional,7/18/2016,3/27/2017,https://ClinicalTrials.gov/show/NCT02780869
6258,Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: PF-04965842|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,4/16/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT02780167
6259,An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: UMEC/VI|Drug: TIO/OLO|Drug: Albuterol/salbutamol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,7/14/2016,4/27/2017,https://ClinicalTrials.gov/show/NCT02799784
6260,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,5/23/2016,10/23/2017,https://ClinicalTrials.gov/show/NCT02773368
6261,Biomarker Study in Participants With Migraine,Completed,Has Results,Migraine Disorders,Drug: Capsaicin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Early Phase 1,Industry,Interventional,9/28/2016,1/1/2017,https://ClinicalTrials.gov/show/NCT02766517
6262,An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Drug: LYC-30937-EC|Drug: Placebo,Lycera Corp.,Lycera Corp.,,,,,,,Phase 2,Industry,Interventional,7/16/2019,5/18/2019,https://ClinicalTrials.gov/show/NCT02762500
6263,Clinical Evaluation of Two Approved Contact Lenses,Completed,Has Results,Visual Acuity,Device: TEST Contact Lens|Device: CONTROL Contact Lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/1/2016,6/1/2016,https://ClinicalTrials.gov/show/NCT02759692
6264,"Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)",Completed,Has Results,Irritable Bowel Syndrome With Diarrhea,Drug: BEKINDA|Drug: Placebo,RedHill Biopharma Limited,RedHill Biopharma Limited,,,,,,,Phase 2,Industry,Interventional,5/19/2016,7/14/2017,https://ClinicalTrials.gov/show/NCT02757105
6265,Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients,Completed,Has Results,Hepatitis C,Drug: Alisporivir,Debiopharm International SA,Debiopharm International SA,,,,,,,Phase 3,Industry,Interventional,12/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02753699
6266,Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast,Completed,Has Results,Plaque Psoriasis,Drug: Etanercept,Amgen,Amgen,,,,,,,Phase 4,Industry,Interventional,5/18/2016,12/6/2017,https://ClinicalTrials.gov/show/NCT02749370
6267,Study of Secukinumab With 2 mL Pre-filled Syringes,Completed,Has Results,Psoriasis,Drug: Placebo|Drug: Secukinumab 2 mL form|Drug: Secukinumab 1 mL form,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,12/12/2016,6/8/2018,https://ClinicalTrials.gov/show/NCT02748863
6268,Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine,Completed,Has Results,Acute Migraine,Drug: ZP-Zolmitriptan|Drug: Placebo,Zosano Pharma Corporation,Zosano Pharma Corporation,,,,,,,Phase 2|Phase 3,Industry,Interventional,6/16/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02745392
6269,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310),Completed,Has Results,Plaque Psoriasis,Drug: 122-0551 Foam|Drug: Vehicle Foam,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,6/16/2019,6/16/2017,https://ClinicalTrials.gov/show/NCT02742441
6270,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,Completed,Has Results,Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes,Biological: Evolocumab|Drug: Placebo to Evolocumab,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,5/17/2016,8/3/2017,https://ClinicalTrials.gov/show/NCT02739984
6271,Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist,Completed,Has Results,"Diabetes Mellitus, Type 2","Drug: Insulin glargine, 300U/mL|Drug: Insulin degludec, 100 U/mL|Drug: Non-insulin anti-diabetic treatment",Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,5/19/2016,8/15/2017,https://ClinicalTrials.gov/show/NCT02738151
6272,Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study,Completed,Has Results,Cystic Fibrosis,Device: RELiZORB (immobilized lipase) cartridge|Other: Impact Peptide 1.5,"Alcresta Therapeutics, Inc.|Cystic Fibrosis Foundation","Alcresta Therapeutics, Inc.",Cystic Fibrosis Foundation,,,,,,Not Applicable,Industry|Other,Interventional,7/20/2016,3/30/2017,https://ClinicalTrials.gov/show/NCT02750501
6273,Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: Valbenazine,Neurocrine Biosciences,Neurocrine Biosciences,,,,,,,Phase 3,Industry,Interventional,6/13/2016,6/30/2017,https://ClinicalTrials.gov/show/NCT02736955
6274,SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis,Completed,Has Results,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,Drug: Liprotamase Powder for Oral Solution,Anthera Pharmaceuticals,Anthera Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,6/16/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02734810
6275,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,"Drug: Insulin glargine,300 U/mL|Drug: Insulin glargine (100 units /mL)|Drug: Background therapy",Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,4/14/2016,12/20/2018,https://ClinicalTrials.gov/show/NCT02735044
6276,Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis,Completed,Has Results,"Osteoporosis, Age-Related",,Amgen,Amgen,,,,,,,,Industry,Observational,7/6/2011,4/14/2014,https://ClinicalTrials.gov/show/NCT02732210
6277,Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke,Completed,Has Results,Acute Ischemic Stroke,Drug: natalizumab|Drug: Placebo,Biogen,Biogen,,,,,,,Phase 2,Industry,Interventional,7/18/2016,11/20/2017,https://ClinicalTrials.gov/show/NCT02730455
6278,Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB),Completed,Has Results,Asthma,Drug: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|Drug: Fluticasone propionate 250 mcg|Drug: Placebo via ELLIPTA inhaler|Drug: Placebo via DISKUS / ACCUHALER,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,5/25/2016,2/3/2017,https://ClinicalTrials.gov/show/NCT02730351
6279,EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite),Completed,Has Results,Edematous Fibrosclerotic Panniculopathy|Cellulite,Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Biological: Placebo Comparator,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,2/16/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02724644
6280,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis,Completed,Has Results,Genital Psoriasis|Psoriasis,Drug: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,4/16/2019,2/21/2018,https://ClinicalTrials.gov/show/NCT02718898
6281,Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection,Completed,Has Results,Neovascular Age-Related Macular Degeneration,Drug: REGN910-3|Drug: Intravitreal Aflibercept Injection (IAI),Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/31/2016,10/3/2017,https://ClinicalTrials.gov/show/NCT02713204
6282,Clinical Investigation of the Bacterially-Derived Healon5 Ophthalmic Viscosurgical Device (OVD),Completed,Has Results,Cataract,Device: Investigational Healon5 OVD|Device: Healon5 OVD,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Not Applicable,Industry,Interventional,6/21/2016,5/4/2017,https://ClinicalTrials.gov/show/NCT02782676
6283,Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR),Completed,Has Results,Perennial Allergic Rhinitis,Drug: GSP 301 NS|Drug: GSP 301 Placebo NS pH 3.7|Drug: GSP 301 Placebo NS pH 7.0,Glenmark Specialty S.A.,Glenmark Specialty S.A.,,,,,,,Phase 3,Industry,Interventional,4/16/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT02709538
6284,Evaluation of WIRION™ EPS in Lower Extremities Arteries,Completed,Has Results,Peripheral Arterial Disease (PAD),Device: WIRION,Gardia Medical,Gardia Medical,,,,,,,Not Applicable,Industry,Interventional,5/16/2019,9/30/2017,https://ClinicalTrials.gov/show/NCT02780349
6285,Clinical Study of Approved and Investigational Contact Lenses,Completed,Has Results,Visual Acuity,Device: Senofilcon C Contact Lens|Device: Comfilcon A Contact Lens|Device: Lotrafilcon B Contact Lens|Device: Samfilcon A Contact Lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/16/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02708524
6286,A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Drug: Baricitinib|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,3/24/2016,11/9/2017,https://ClinicalTrials.gov/show/NCT02708095
6287,"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment",Completed,Has Results,HIV-1 Infection|HCV Infection,Drug: E/C/F/TAF|Drug: F/R/TAF|Drug: LDV/SOF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,4/1/2016,9/29/2017,https://ClinicalTrials.gov/show/NCT02707601
6288,A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome,Completed,Has Results,Sjogren's Syndrome,Drug: Placebo|Drug: RO5459072,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,7/5/2016,7/10/2017,https://ClinicalTrials.gov/show/NCT02701985
6289,Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee,Completed,Has Results,"Osteoarthritis, Knee|Osteoarthritis, Hip",Other: Placebo|Biological: Tanezumab 2.5 mg|Biological: Tanezumab 2.5mg/5mg,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/21/2016,5/14/2018,https://ClinicalTrials.gov/show/NCT02697773
6290,A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA),Completed,Has Results,Iron Deficiency Anemia,Drug: Ferumoxytol|Drug: FCM,"AMAG Pharmaceuticals, Inc.","AMAG Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,2/29/2016,7/17/2017,https://ClinicalTrials.gov/show/NCT02694978
6291,Patiromer With or Without Food for the Treatment of Hyperkalemia,Completed,Has Results,Hyperkalemia,Drug: patiromer,"Relypsa, Inc.","Relypsa, Inc.",,,,,,,Phase 4,Industry,Interventional,2/16/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02694744
6292,An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis,Completed,Has Results,Psoriasis,Drug: Drug: LYC-30937-EC|Drug: Placebo,Lycera Corp.,Lycera Corp.,,,,,,,Phase 2,Industry,Interventional,12/5/2016,6/22/2017,https://ClinicalTrials.gov/show/NCT02872285
6293,Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes,Completed,Has Results,Osteoarthritis of the Knee|Type 2 Diabetes Mellitus,Drug: FX006 32 mg|Drug: TCA IR 40 mg,"Flexion Therapeutics, Inc.","Flexion Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,4/16/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02762370
6294,A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (Insulin Glargine 300 U/ml)|Drug: Lantus (Insulin Glargine 100 U/ml)|Drug: Mandated back ground therapy,Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,5/5/2016,6/19/2017,https://ClinicalTrials.gov/show/NCT02688933
6295,Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Chronic Plaque Psoriasis,Drug: Secukinumab 300 mg|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,2/10/2016,2/19/2018,https://ClinicalTrials.gov/show/NCT02690701
6296,"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent",Completed,Has Results,Anaemia,Drug: GSK1278863|Drug: GSK1278863 matching Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,2/17/2016,1/25/2017,https://ClinicalTrials.gov/show/NCT02689206
6297,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lyophilized albiglutide DCC pen injector|Drug: Lyophilized albiglutide DCC pen injector matching placebo|Drug: Albiglutide liquid auto-injector|Drug: Albiglutide liquid auto-injector matching placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/16/2016,5/15/2017,https://ClinicalTrials.gov/show/NCT02683746
6298,Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition,Completed,Has Results,Short Bowel Syndrome,Drug: Teduglutide 0.05mg/kg|Drug: Teduglutide 0.025 mg/kg|Other: Standard of Care,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,6/23/2016,8/18/2017,https://ClinicalTrials.gov/show/NCT02682381
6299,UltraShape Power for Abdominal Fat and Circumference Reduction,Completed,Has Results,Excess Abdominal Fat,Device: UltraShape Power,Syneron Medical,Syneron Medical,,,,,,,Not Applicable,Industry,Interventional,6/8/2016,4/23/2018,https://ClinicalTrials.gov/show/NCT02748928
6300,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Placebo for Dapagliflozin|Drug: Saxagliptin|Drug: Placebo for Saxagliptin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,2/26/2016,7/15/2017,https://ClinicalTrials.gov/show/NCT02681094
6301,Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma,Completed,Has Results,Asthma,Drug: NVA237 (glycopyrronium bromide)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2|Phase 3,Industry,Interventional,5/4/2017,12/29/2017,https://ClinicalTrials.gov/show/NCT03137784
6302,A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection,Completed,Has Results,Hepatitis C,Drug: DCV|Drug: SOF|Drug: RBV,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,3/15/2016,5/26/2017,https://ClinicalTrials.gov/show/NCT02673489
6303,Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL,Completed,Has Results,Opioid Use Disorder,Drug: Naltrexone|Drug: Placebo|Drug: Buprenorphine,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,4/16/2019,11/30/2017,https://ClinicalTrials.gov/show/NCT02696434
6304,"Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or ""Mini Strokes""",Completed,Has Results,Thrombosis,Drug: BMS-986141|Drug: Aspirin|Other: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,4/25/2016,3/31/2017,https://ClinicalTrials.gov/show/NCT02671461
6305,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,5/4/2016,3/3/2018,https://ClinicalTrials.gov/show/NCT02670915
6306,"Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression",Completed,Has Results,Bipolar Disorder|Depression,Drug: Cariprazine|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,3/17/2016,7/19/2017,https://ClinicalTrials.gov/show/NCT02670551
6307,Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder,Completed,Has Results,Bipolar Disorder|Depression,Drug: Cariprazine|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,3/31/2016,1/18/2018,https://ClinicalTrials.gov/show/NCT02670538
6308,Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study,Completed,Has Results,Dementia With Lewy Bodies,Drug: RVT-101 35 mg|Drug: RVT-101 70 mg|Drug: Placebo,Axovant Sciences Ltd.,Axovant Sciences Ltd.,,,,,,,Phase 2,Industry,Interventional,1/16/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02669433
6309,A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: ALKS 3831,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,1/20/2016,6/29/2018,https://ClinicalTrials.gov/show/NCT02669758
6310,Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg,Completed,Has Results,Moderate-to-severe Acute Pain,Drug: Zalviso™ 15 mcg,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,9/28/2016,5/5/2017,https://ClinicalTrials.gov/show/NCT02662764
6311,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,Completed,Has Results,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Biological: Evolocumab|Drug: Atorvastatin|Other: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,4/14/2016,12/6/2017,https://ClinicalTrials.gov/show/NCT02662569
6312,Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients,Completed,Has Results,Asthma,Drug: Mepolizumab 100mg SC|Drug: Albuterol/salbutamol MDIs|Drug: Omalizumab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,3/17/2016,5/31/2017,https://ClinicalTrials.gov/show/NCT02654145
6313,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",Completed,Has Results,HIV-1 Infection,Drug: E/C/F/TAF|Drug: E/C/F/TDF|Drug: ATV|Drug: RTV|Drug: FTC/TDF|Drug: B/F/TAF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,2/19/2016,11/26/2018,https://ClinicalTrials.gov/show/NCT02652624
6314,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: Dulaglutide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/6/2016,5/19/2017,https://ClinicalTrials.gov/show/NCT02648204
6315,12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin 100 mg|Drug: DS-8500a 25mg|Drug: Placebo Tablet|Drug: Placebo Capsule,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 2,Industry,Interventional,1/16/2019,1/31/2017,https://ClinicalTrials.gov/show/NCT02647320
6316,"The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy",Completed,Has Results,Painful Diabetic Neuropathy|Diabetic Neuropathy|Neuropathy,"Drug: Clonidine Hydrochloride Topical Gel, 0.1%|Drug: Clonidine Hydrochloride Gel Comparator",BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 2,Industry,Interventional,12/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02643251
6317,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Drug: BI 695501,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,1/22/2016,11/1/2017,https://ClinicalTrials.gov/show/NCT02640612
6318,Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL/VOX|Drug: SOF/VEL,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/23/2015,1/2/2017,https://ClinicalTrials.gov/show/NCT02639338
6319,Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL/VOX|Drug: SOF/VEL,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/23/2015,1/18/2017,https://ClinicalTrials.gov/show/NCT02639247
6320,Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: BMS-986142|Drug: Placebo|Drug: Methotrexate,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,2/16/2016,5/3/2018,https://ClinicalTrials.gov/show/NCT02638948
6321,Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: GP2015,Sandoz,Sandoz,,,,,,,Phase 3,Industry,Interventional,2/21/2015,6/12/2017,https://ClinicalTrials.gov/show/NCT02638259
6322,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: DFD06 Cream|Drug: Vehicle Cream,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 3,Industry,Interventional,12/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02635204
6323,A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study),Completed,Has Results,Schizophrenia,Drug: ALK3831|Drug: Olanzapine|Drug: Placebo,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,12/15/2019,6/7/2017,https://ClinicalTrials.gov/show/NCT02634346
6324,A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole Lauroxil,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 4,Industry,Interventional,12/15/2019,7/11/2017,https://ClinicalTrials.gov/show/NCT02634320
6325,Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL),Completed,Has Results,Nonalcoholic Steatohepatitis,Drug: Obeticholic Acid|Drug: Atorvastatin|Drug: Placebo,Intercept Pharmaceuticals,Intercept Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/4/2015,3/12/2018,https://ClinicalTrials.gov/show/NCT02633956
6326,"The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis",Completed,Has Results,AL Amyloidosis,Drug: NEOD001|Drug: Placebo,Prothena Therapeutics Ltd.,Prothena Therapeutics Ltd.,,,,,,,Phase 2,Industry,Interventional,3/16/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT02632786
6327,Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis,Drug: GSP 301 NS|Drug: Olopatadine HCl NS|Drug: Mometasone furoate NS|Drug: GSP 301 Placebo NS,Glenmark Specialty S.A.,Glenmark Specialty S.A.,,,,,,,Phase 3,Industry,Interventional,3/16/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02631551
6328,Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine,Completed,Has Results,Migraine,Drug: Fremanezumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,3/23/2016,4/10/2017,https://ClinicalTrials.gov/show/NCT02629861
6329,Dispensing Evaluation of Investigational Contact Lenses,Completed,Has Results,Myopia; Astigmatism,Device: Prototype toric lens senofilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02625220
6330,Evaluation of the Accuracy of an Implanted Glucose Sensor,Completed,Has Results,Diabetes Mellitus,Device: Continuous Glucose Monitoring System,"Senseonics, Inc.","Senseonics, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/16/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02647905
6331,A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults,Completed,Has Results,Influenza A,Drug: MHAA4549A|Drug: Placebo,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,10/12/2016,11/13/2017,https://ClinicalTrials.gov/show/NCT02623322
6332,Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine,Completed,Has Results,Migraine,Drug: Fremanezumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,3/22/2016,4/11/2017,https://ClinicalTrials.gov/show/NCT02621931
6333,Tocilizumab Real-Life Human Factors (RLHFs) Validation Study,Completed,Has Results,Rheumatoid Arthritis,Device: AI-1000 G2|Drug: Tocilizumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,3/21/2016,7/29/2016,https://ClinicalTrials.gov/show/NCT02682823
6334,"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis",Completed,Has Results,Actinic Keratosis,Drug: Generic Fluorouracil Cream|Drug: Carac® (Fluorouracil) Cream|Drug: Vehicle Cream,Actavis Inc.,Actavis Inc.,,,,,,,Phase 3,Industry,Interventional,2/27/2015,9/17/2015,https://ClinicalTrials.gov/show/NCT02616601
6335,Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study,Completed,Has Results,Migraine,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/4/2015,10/5/2018,https://ClinicalTrials.gov/show/NCT02614196
6336,Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Completed,Has Results,Migraine,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/30/2015,8/9/2018,https://ClinicalTrials.gov/show/NCT02614183
6337,Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe,Completed,Has Results,"Arthritis, Rheumatoid",Drug: BI 695501 Autoinjector|Drug: BI 695501 Prefilled syringe,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,1/6/2016,6/29/2017,https://ClinicalTrials.gov/show/NCT02636907
6338,"A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura",Completed,Has Results,Migraine,Drug: Galcanezumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/30/2015,8/14/2018,https://ClinicalTrials.gov/show/NCT02614287
6339,Accu-Chek® CONNECT at School (CATS) Pediatric Study,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Accu-Chek® CONNECT DMS|Device: DMS,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Not Applicable,Industry,Interventional,12/28/2015,1/20/2017,https://ClinicalTrials.gov/show/NCT02609633
6340,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy,Completed,Has Results,Hepatitis C,Drug: SOF/VEL/VOX|Drug: SOF/VEL,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,11/16/2015,1/11/2017,https://ClinicalTrials.gov/show/NCT02607800
6341,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy,Completed,Has Results,Hepatitis C,Drug: SOF/VEL/VOX|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,11/11/2015,6/21/2017,https://ClinicalTrials.gov/show/NCT02607735
6342,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2,Completed,Has Results,Skin Structures and Soft Tissue Infections,Drug: Iclaprim|Drug: Vancomycin,Motif Bio,Motif Bio,,,,,,,Phase 3,Industry,Interventional,11/15/2019,8/8/2017,https://ClinicalTrials.gov/show/NCT02607618
6343,Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults,Completed,Has Results,HIV-1 Infection,Drug: E/C/F/TAF|Drug: ABC/3TC|Drug: Third Antiretroviral Agent,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,11/18/2015,1/24/2018,https://ClinicalTrials.gov/show/NCT02605954
6344,Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),"Drug: SHP465 12.5mg capsules (one capsule daily)|Other: Placebo|Drug: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)",Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02604407
6345,A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza,Completed,Has Results,Influenza,Drug: Oseltamivir|Drug: MEDI8852|Drug: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1|Phase 2,Industry,Interventional,12/7/2015,12/9/2016,https://ClinicalTrials.gov/show/NCT02603952
6346,An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Drug: GED-0301,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,12/14/2015,8/8/2017,https://ClinicalTrials.gov/show/NCT02601300
6347,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1,Completed,Has Results,Skin Structures and Soft Tissue Infections,Drug: iclaprim|Drug: vancomycin,Motif Bio,Motif Bio,,,,,,,Phase 3,Industry,Interventional,11/1/2015,1/30/2017,https://ClinicalTrials.gov/show/NCT02600611
6348,A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis,Completed,Has Results,Post Menopausal Osteoporosis,Drug: Ibandronate,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,8/4/2019,5/6/2019,https://ClinicalTrials.gov/show/NCT02598934
6349,Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Nintedanib|Drug: Pirfenidone,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,1/14/2016,5/16/2017,https://ClinicalTrials.gov/show/NCT02598193
6350,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Completed,Has Results,Osteoarthritis,"Drug: Diclofenac Sodium gel, 1%|Drug: Voltaren® Gel|Drug: Placebo",Glenmark Pharmaceuticals Ltd. India,Glenmark Pharmaceuticals Ltd. India,,,,,,,Phase 3,Industry,Interventional,8/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02596451
6351,ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT),Completed,Has Results,"Diabetes Mellitus, Type 1",Device: ACCU-CHEK,Hoffmann-La Roche|Roche Diabetes Care GmbH,Hoffmann-La Roche,Roche Diabetes Care GmbH,,,,,,Not Applicable,Industry|Other,Interventional,12/30/2015,2/20/2017,https://ClinicalTrials.gov/show/NCT02600845
6352,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dulaglutide|Drug: Placebo|Drug: SGLT2 inhibitor|Drug: Metformin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/15/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02597049
6353,Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses,Completed,Has Results,Vision Disorders,Device: JJVC Marketed Contact Lens (Test)|Device: Competitor Marketed Contact Lens (Control),"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/1/2015,11/1/2015,https://ClinicalTrials.gov/show/NCT02595502
6354,Evaluation of Trima Version 7.0 Platelets in 100% Plasma,Completed,Has Results,Healthy Volunteers,Device: Trima Accel System with Version 7.0 Software,Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,4/16/2019,2/15/2017,https://ClinicalTrials.gov/show/NCT02754492
6355,Evaluation of Trima Version 7.0 Platelets in PAS,Completed,Has Results,Healthy Volunteers,Device: Trima Accel System with Version 7.0 Software,Terumo BCT,Terumo BCT,,,,,,,Not Applicable,Industry,Interventional,4/20/2016,7/28/2017,https://ClinicalTrials.gov/show/NCT02754440
6356,"Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)",Completed,Has Results,Exocrine Pancreatic Insufficiency,Device: RELiZORB|Device: Placebo,"Alcresta Therapeutics, Inc.","Alcresta Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02598128
6357,Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Placebo|Other: Questionnaire,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,10/1/2015,3/15/2016,https://ClinicalTrials.gov/show/NCT02586493
6358,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,Completed,Has Results,Alzheimer's Disease,Drug: RVT-101|Drug: Placebo,Axovant Sciences Ltd.,Axovant Sciences Ltd.,,,,,,,Phase 3,Industry,Interventional,10/15/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT02585934
6359,Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma,Completed,Has Results,Asthma,Drug: Placebo ELLIPTA inhaler|Other: Questionnaire,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,10/1/2015,2/4/2016,https://ClinicalTrials.gov/show/NCT02586506
6360,Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema,Completed,Has Results,Hereditary Angioedema (HAE),Drug: C1 esterase inhibitor [human] liquid|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/1/2015,7/24/2017,https://ClinicalTrials.gov/show/NCT02584959
6361,"POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study",Completed,Has Results,Hyperkalemia,Device: Cardiac rhythm remote monitoring system,"ZS Pharma, Inc.","ZS Pharma, Inc.",,,,,,,,Industry,Observational,9/30/2015,5/31/2016,https://ClinicalTrials.gov/show/NCT02609841
6362,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier,Completed,Has Results,Herpes Zoster,Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/15/2015,8/1/2017,https://ClinicalTrials.gov/show/NCT02581410
6363,Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis,Completed,Has Results,Chronic Plaque Psoriasis|Psoriasis,Biological: M923|Biological: Humira,"Momenta Pharmaceuticals, Inc.","Momenta Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,9/15/2019,4/4/2017,https://ClinicalTrials.gov/show/NCT02581345
6364,Use of Santyl in Diabetic Foot Ulcers,Completed,Has Results,"Diabetic Foot|Foot Ulcer, Diabetic",Biological: Santyl|Other: Product containing silver,"Smith & Nephew, Inc.","Smith & Nephew, Inc.",,,,,,,Phase 4,Industry,Interventional,10/15/2019,1/12/2017,https://ClinicalTrials.gov/show/NCT02581488
6365,"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",Completed,Has Results,Sporadic Inclusion Body Myositis,Drug: Bimagrumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,11/2/2015,2/13/2017,https://ClinicalTrials.gov/show/NCT02573467
6366,DFN-11 Injection in Episodic Migraine With or Without Aura,Completed,Has Results,Episodic Migraine,Drug: DFN-11|Other: Placebo,Dr. Reddy's Laboratories Limited,Dr. Reddy's Laboratories Limited,,,,,,,Phase 3,Industry,Interventional,9/21/2015,2/26/2018,https://ClinicalTrials.gov/show/NCT02569853
6367,Triferic Pediatric Pharmacokinetic Protocol,Completed,Has Results,End Stage Renal Disease,Drug: Triferic,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,11/1/2015,1/17/2019,https://ClinicalTrials.gov/show/NCT02595437
6368,Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face,Completed,Has Results,Actinic Keratosis,Drug: ALA|Drug: Topical Solution Vehicle|Device: IBL 10 mW|Procedure: Microneedle lesion preparation|Device: IBL 20 mW,"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/16/2019,9/12/2016,https://ClinicalTrials.gov/show/NCT02632110
6369,A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Baricitinib|Drug: Placebo|Drug: Triamcinolone (Optional),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,2/16/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02576938
6370,Usability of an AI for M923 in Subjects With Moderate to Severe RA,Completed,Has Results,Rheumatoid Arthritis,Biological: M923|Device: Autoinjector,"Momenta Pharmaceuticals, Inc.","Momenta Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,4/16/2019,2/21/2017,https://ClinicalTrials.gov/show/NCT02722044
6371,Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Batefenterol + Fluticasone Furoate|Drug: Placebo|Drug: Albuterol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02573870
6372,A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD),Completed,Has Results,"Dermatitis, Atopic",Drug: GSK2894512 1% Cream|Drug: GSK2894512 0.5% Cream|Drug: Vehicle cream,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/1/2015,1/12/2017,https://ClinicalTrials.gov/show/NCT02564055
6373,A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: GSK2894512 1% Cream|Drug: GSK2894512 0.5% Cream|Drug: Vehicle cream,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/23/2015,10/5/2016,https://ClinicalTrials.gov/show/NCT02564042
6374,PF-06372865 in Subjects With Photosensitive Epilepsy,Completed,Has Results,"Reflex Epilepsy, Photosensitive",Drug: PF-06372865|Drug: Placebo|Drug: Lorazepam,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/16/2015,2/7/2017,https://ClinicalTrials.gov/show/NCT02564029
6375,A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: PF-06291874|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,10/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02554877
6376,MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population,Completed,Has Results,Infertility,Drug: menotropin|Drug: recombinant FSH,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,8/31/2015,2/2/2017,https://ClinicalTrials.gov/show/NCT02554279
6377,Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis,Completed,Has Results,Hyperhidrosis,Drug: Glycopyrronium Topical Wipes,"Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 3,Industry,Interventional,8/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02553798
6378,Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura,Completed,Has Results,Acquired Thrombotic Thrombocytopenic Purpura,Biological: Caplacizumab|Biological: Placebo,Ablynx,Ablynx,,,,,,,Phase 3,Industry,Interventional,11/15/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02553317
6379,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Saxagliptin, Onglyza|Drug: Dapagliflozin, Farxiga|Drug: Glargine insulin|Drug: Metformin",AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,10/20/2015,11/10/2017,https://ClinicalTrials.gov/show/NCT02551874
6380,"Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors",Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|Papillary Serous Mullerian Tumor|Clear Cell Mullerian Tumor,Drug: bevacizumab|Drug: erlotinib|Drug: paclitaxel|Drug: carboplatin,"Dana-Farber Cancer Institute|Genentech, Inc.|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital",Dana-Farber Cancer Institute,"Genentech, Inc.",Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital,Beth Israel Deaconess Medical Center,Brigham and Women's Hospital|Massachusetts General Hospital,Brigham and Women's Hospital,Massachusetts General Hospital,Phase 2,Other|Industry,Interventional,8/7/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00520013
6381,Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study,Completed,Has Results,Heart Failure,Device: Quartet 1457Q LV Lead,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,10/27/2015,3/21/2017,https://ClinicalTrials.gov/show/NCT02548455
6382,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",Completed,Has Results,"Type 2 Diabetes Mellitus, CKD and Albuminuria",Drug: Dapagliflozin 10 mg|Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg|Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg,AstraZeneca,AstraZeneca,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/21/2015,5/18/2018,https://ClinicalTrials.gov/show/NCT02547935
6383,The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease,Completed,Has Results,NAFLD,Drug: Leu-Met-Sil 0.5|Drug: Leu-Met-Sil 1.0|Drug: Placebo,NuSirt Biopharma,NuSirt Biopharma,,,,,,,Phase 2,Industry,Interventional,11/19/2015,1/31/2017,https://ClinicalTrials.gov/show/NCT02546609
6384,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age,Completed,Has Results,"Influenza, Human",Biological: Seqirus QIV|Biological: Comparator QIV,Seqirus,Seqirus,,,,,,,Phase 3,Industry,Interventional,9/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02545543
6385,Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Batefenterol|Drug: Umeclidinium/ Vilanterol|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/6/2015,7/6/2016,https://ClinicalTrials.gov/show/NCT02570165
6386,A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.,Completed,Has Results,Dry Eye Syndromes,Drug: Carboxymethylcellulose Based Eye Drop|Drug: Carboxymethylcellulose Sodium 0.5%,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,1/6/2016,9/9/2016,https://ClinicalTrials.gov/show/NCT02553772
6387,Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery,Completed,Has Results,Cataract,Drug: Dexamethasone|Drug: Prednisolone,ICON Bioscience Inc,ICON Bioscience Inc,,,,,,,Phase 3,Industry,Interventional,11/6/2015,8/16/2016,https://ClinicalTrials.gov/show/NCT02547623
6388,Clinical Evaluation of Approved Contact Lenses,Completed,Has Results,Visual Acuity,Device: Test Contact Lens|Device: Control Contact Lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/1/2016,4/1/2016,https://ClinicalTrials.gov/show/NCT02699593
6389,PF-06669571 In Subjects With Idiopathic Parkinson's Disease,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: PF-06669571|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,11/16/2015,5/13/2016,https://ClinicalTrials.gov/show/NCT02565628
6390,A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia,Completed,Has Results,"Leukemia, Myeloid",Drug: Lenalidomide,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,11/19/2015,1/11/2019,https://ClinicalTrials.gov/show/NCT02538965
6391,Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC),Completed,Has Results,Spastic Hemiparesis,Drug: AbobotulinumtoxinA (Dysport®)|Other: GSC,Ipsen,Ipsen,,,,,,,Phase 4,Industry,Interventional,12/18/2016,7/18/2019,https://ClinicalTrials.gov/show/NCT02969356
6392,Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension),Completed,Has Results,Opioid Use Disorder,Drug: NTX/BUP|Drug: NTX/PBO-B|Drug: PBO-N/PBO-B,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,8/15/2019,1/9/2017,https://ClinicalTrials.gov/show/NCT02537574
6393,"To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease",Completed,Has Results,Coronary Artery Disease,Biological: MEDI6012|Biological: Placebo SC|Biological: Placebo IV,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,12/3/2015,11/3/2016,https://ClinicalTrials.gov/show/NCT02601560
6394,A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection,Completed,Has Results,Hepatitis C Virus (HCV),Drug: Glecaprevir/Pibrentasvir,AbbVie,AbbVie,,,,,,,Phase 3,Industry,Interventional,1/25/2017,8/29/2018,https://ClinicalTrials.gov/show/NCT02966795
6395,Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection,Completed,Has Results,Respiratory Syncytial Virus (RSV),Drug: Presatovir|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,12/31/2015,9/27/2017,https://ClinicalTrials.gov/show/NCT02534350
6396,Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C),Completed,Has Results,Atherosclerotic Cardiovascular Disease|Familial Hypercholesterolemia|Diabetes,Drug: ALN-PCSSC|Drug: Normal Saline,The Medicines Company,The Medicines Company,,,,,,,Phase 2,Industry,Interventional,1/16/2019,6/7/2017,https://ClinicalTrials.gov/show/NCT02597127
6397,Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients,Completed,Has Results,Cystic Fibrosis,Drug: QR-010|Drug: Placebo,ProQR Therapeutics|European Commission,ProQR Therapeutics,European Commission,,,,,,Phase 1|Phase 2,Industry|Other,Interventional,6/15/2019,9/14/2017,https://ClinicalTrials.gov/show/NCT02532764
6398,Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis,Completed,Has Results,Hyperhidrosis,Drug: glycopyrronium Topical Wipes|Other: Vehicle,"Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 3,Industry,Interventional,8/15/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02530294
6399,Study of Glycopyrronium in Axillary Hyperhydrosis,Completed,Has Results,Hyperhidrosis,Drug: glycopyrronium Topical Wipes|Other: Vehicle,"Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 3,Industry,Interventional,7/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02530281
6400,Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13),Completed,Has Results,Bacterial Pneumonia|Community-Acquired Infections,Drug: Omadacycline|Drug: Moxifloxacin,Paratek Pharmaceuticals Inc,Paratek Pharmaceuticals Inc,,,,,,,Phase 3,Industry,Interventional,11/15/2019,3/10/2017,https://ClinicalTrials.gov/show/NCT02531438
6401,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Met DR|Drug: Met IR|Drug: Placebo,"Elcelyx Therapeutics, Inc.","Elcelyx Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,9/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02526524
6402,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",Drug: dimethyl fumarate,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,8/11/2015,4/23/2018,https://ClinicalTrials.gov/show/NCT02525874
6403,Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection,Completed,Has Results,Helicobacter Pylori Infection,Device: Dual Mode BreathID Hp System,Exalenz Bioscience LTD.,Exalenz Bioscience LTD.,,,,,,,Phase 3,Industry,Interventional,10/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02528721
6404,"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Completed,Has Results,Cystic Fibrosis,Drug: VX-661 plus ivacaftor combination|Drug: Ivacaftor|Drug: Placebo (matched to VX-661 plus ivacaftor combination)|Drug: Placebo (matched to ivacaftor),Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,8/15/2019,6/7/2016,https://ClinicalTrials.gov/show/NCT02516410
6405,Treadmill Cardiovascular Safety Study of Erenumab (AMG 334),Completed,Has Results,Stable Angina,Drug: Erenumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,11/23/2015,4/13/2017,https://ClinicalTrials.gov/show/NCT02575833
6406,An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert,Completed,Has Results,Primary Open-Angle Glaucoma|Ocular Hypertension,Drug: Bimatoprost,"ForSight Vision5, Inc.","ForSight Vision5, Inc.",,,,,,,Phase 2,Industry,Interventional,8/10/2015,8/11/2016,https://ClinicalTrials.gov/show/NCT02537015
6407,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Completed,Has Results,Cystic Fibrosis,Drug: VX-809|Drug: Placebo|Drug: VX-770,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,7/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02514473
6408,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Pro-netupitant/Palonosetron|Drug: Netupitant/Palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|The Physicians' Services Incorporated Foundation,Helsinn Healthcare SA,The Physicians' Services Incorporated Foundation,,,,,,Phase 3,Industry|Other,Interventional,11/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02517021
6409,A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,8/15/2019,8/3/2017,https://ClinicalTrials.gov/show/NCT02513550
6410,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Completed,Has Results,Persistent Asthma,Drug: Beclomethasone Dipropionate 640|Drug: Placebo|Drug: Beclomethasone dipropionate via 320 mcg BAI|Drug: albuterol/salbutamol|Drug: Beclomethasone dipropionate via 320 mcg MDI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,9/30/2015,3/31/2016,https://ClinicalTrials.gov/show/NCT02513160
6411,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Completed,Has Results,Opioid Use Disorder|Opioid-related Disorders,Drug: SUBOXONE sublingual film|Drug: RBP-6000,Indivior Inc.,Indivior Inc.,,,,,,,Phase 3,Industry,Interventional,7/27/2015,1/31/2017,https://ClinicalTrials.gov/show/NCT02510014
6412,Evaluation of a Johnson & Johnson Vision Care Investigational Contact Lens Compared to a Marketed Monthly Replacement Contact Lens,Completed,Has Results,Refractive Error,Device: senofilcon C|Device: comfilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02515994
6413,The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease,Completed,Has Results,GERD Gastroesophageal Reflux Disease,Drug: Omeprazole|Device: LINX Reflux Management System,Torax Medical Incorporated,Torax Medical Incorporated,,,,,,,Phase 4,Industry,Interventional,6/15/2019,8/18/2019,https://ClinicalTrials.gov/show/NCT02505945
6414,Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism,Completed,Has Results,Hypogonadism,Combination Product: Testosterone enanthate auto-injector,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 3,Industry,Interventional,7/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02504541
6415,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Completed,Has Results,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Drug: Reslizumab|Drug: Placebo|Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication|Drug: Oral Corticosteroid (OCS),"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,9/29/2015,12/4/2017,https://ClinicalTrials.gov/show/NCT02501629
6416,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,5/4/2016,8/16/2017,https://ClinicalTrials.gov/show/NCT02500706
6417,Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®,Completed,Has Results,Multiple Sclerosis,Drug: Copaxone®,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries","Teva Pharmaceutical Industries, Ltd.",Teva Pharmaceutical Industries,,,,,,Phase 4,Industry,Interventional,8/10/2015,6/2/2017,https://ClinicalTrials.gov/show/NCT02499900
6418,OPTIONS Spinal Cord Stimulation Programming Parameters,Completed,Has Results,"Pain, Intractable",Device: Spinal Cord Stimulation (SCS),MedtronicNeuro,MedtronicNeuro,,,,,,,Not Applicable,Industry,Interventional,7/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02503787
6419,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Completed,Has Results,Treatment-resistant Depression,Drug: Esketamine (Intranasal Spray)|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral Antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,9/30/2015,10/28/2017,https://ClinicalTrials.gov/show/NCT02497287
6420,ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss,Completed,Has Results,Obesity,Device: TransPyloric Shuttle|Device: Sham procedure|Behavioral: Lifestyle Counseling,"BaroNova, Inc.","BaroNova, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/15/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT02518685
6421,Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand,Completed,Has Results,Volume Deficit in the Hand,Device: Restylane Lyft with Lidocaine,Q-Med AB,Q-Med AB,,,,,,,Not Applicable,Industry,Interventional,12/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02650921
6422,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Completed,Has Results,"Depressive Disorder, Treatment-Resistant",Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,10/1/2015,2/16/2018,https://ClinicalTrials.gov/show/NCT02493868
6423,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Completed,Has Results,Irritable Bowel Syndrome Characterized by Constipation,Drug: Plecanatide|Drug: Placebo,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,6/15/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02493452
6424,"A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C",Completed,Has Results,Irritable Bowel Syndrome With Constipation (IBS-C),Drug: SYN-010,Synthetic Biologics Inc.,Synthetic Biologics Inc.,,,,,,,Phase 2,Industry,Interventional,10/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02493036
6425,Micra Transcatheter Pacing System Continued Access Study Protocol,Completed,Has Results,Bradycardia,Device: Micra Pacemaker Implant,Medtronic,Medtronic,,,,,,,Not Applicable,Industry,Interventional,6/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02488681
6426,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: QVA149|Drug: Umeclidinium/vilanterol|Drug: Placebo (umeclidinium/vilanterol )|Drug: Placebo (QVA149),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,7/27/2015,9/6/2016,https://ClinicalTrials.gov/show/NCT02487498
6427,Efficacy and Safety Study of QVA149 in COPD Patients,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: QVA149|Drug: Umeclidinium/vilanterol|Drug: Placebo (umeclidinium/vilanterol)|Drug: Placebo (QVA149),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,7/28/2015,9/12/2016,https://ClinicalTrials.gov/show/NCT02487446
6428,Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma,Completed,Has Results,Asthma,Drug: FF|Drug: Placebo|Drug: Montelukast|Drug: Albuterol/Salbutamol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/9/2015,6/20/2016,https://ClinicalTrials.gov/show/NCT02483975
6429,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention,Completed,Has Results,Migraine,Drug: Erenumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,7/20/2015,3/20/2017,https://ClinicalTrials.gov/show/NCT02483585
6430,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Completed,Has Results,Rheumatoid Arthritis,Biological: PF-06410293|Biological: Adalimumab,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/25/2015,12/6/2017,https://ClinicalTrials.gov/show/NCT02480153
6431,Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis,Completed,Has Results,Hyperhidrosis,Biological: Vehicle|Biological: ANT-1207,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/3/2015,2/29/2016,https://ClinicalTrials.gov/show/NCT02479139
6432,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,7/1/2015,6/22/2016,https://ClinicalTrials.gov/show/NCT02480712
6433,Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Eribulin Mesylate,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,6/16/2015,9/5/2017,https://ClinicalTrials.gov/show/NCT02481050
6434,"A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus",Completed,Has Results,"Lupus Erythematosus, Systemic",Drug: IPP-201101|Drug: Placebo|Other: Standard of Care,ImmuPharma,ImmuPharma,,,,,,,Phase 3,Industry,Interventional,3/15/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02504645
6435,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Completed,Has Results,Super-Refractory Status Epilepticus,Drug: SAGE-547|Drug: Placebo,Sage Therapeutics,Sage Therapeutics,,,,,,,Phase 3,Industry,Interventional,6/15/2019,8/11/2017,https://ClinicalTrials.gov/show/NCT02477618
6436,Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU,Completed,Has Results,Chronic Spontaneous Urticaria,Biological: QGE031|Biological: Omalizumab|Other: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/15/2015,6/12/2017,https://ClinicalTrials.gov/show/NCT02477332
6437,A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia,Completed,Has Results,Schizophrenia,Drug: TAK-063 20 mg|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,7/1/2015,7/27/2016,https://ClinicalTrials.gov/show/NCT02477020
6438,A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis,Completed,Has Results,"Myasthenia Gravis, Generalized",Drug: IGIV-C|Drug: Placebo,Grifols Therapeutics LLC,Grifols Therapeutics LLC,,,,,,,Phase 2,Industry,Interventional,8/15/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02473952
6439,An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Sirukumab 50 mg|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,7/23/2015,5/22/2018,https://ClinicalTrials.gov/show/NCT02473289
6440,Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Selexipag,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,10/12/2015,12/5/2016,https://ClinicalTrials.gov/show/NCT02471183
6441,"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",Completed,Has Results,Smallpox,Drug: tecovirimat|Other: Placebo,SIGA Technologies|Biomedical Advanced Research and Development Authority,SIGA Technologies,Biomedical Advanced Research and Development Authority,,,,,,Phase 3,Industry|U.S. Fed,Interventional,6/19/2015,8/24/2016,https://ClinicalTrials.gov/show/NCT02474589
6442,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,Completed,Has Results,HIV-1 Infection,Drug: F/TAF|Drug: ABC/3TC|Drug: ABC/3TC Placebo|Drug: F/TAF Placebo|Drug: Third ARV agent,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,6/29/2015,3/13/2019,https://ClinicalTrials.gov/show/NCT02469246
6443,An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,Completed,Has Results,"Leukemia, Myeloid, Acute",Drug: Decitabine 20 mg/m^2|Drug: Talacotuzumab 9 mg/kg,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2|Phase 3,Industry,Interventional,8/4/2015,1/25/2018,https://ClinicalTrials.gov/show/NCT02472145
6444,"Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3",Completed,Has Results,Non-Alcoholic Steatohepatitis (NASH),Drug: SEL|Biological: SIM,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,6/8/2015,10/11/2016,https://ClinicalTrials.gov/show/NCT02466516
6445,Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: SHP465|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,6/18/2015,2/16/2016,https://ClinicalTrials.gov/show/NCT02466425
6446,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,Diabetes Mellitus,Biological: Albiglutide 30 mg|Biological: Albiglutide 50 mg|Biological: Albiglutide matching placebo,GlaxoSmithKline|Duke Clinical Research Institute,GlaxoSmithKline,Duke Clinical Research Institute,,,,,,Phase 4,Industry|Other,Interventional,7/1/2015,3/14/2018,https://ClinicalTrials.gov/show/NCT02465515
6447,"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.",Completed,Has Results,Acne Vulgaris,"Drug: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Drug: BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|Drug: Placebo",Glenmark Pharmaceuticals Ltd. India,Glenmark Pharmaceuticals Ltd. India,,,,,,,Phase 3,Industry,Interventional,4/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02465632
6448,"Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis",Completed,Has Results,Cystic Fibrosis,Drug: JBT-101 (lenabasum)|Other: Placebo,Corbus Pharmaceuticals Inc.,Corbus Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,9/29/2015,12/28/2016,https://ClinicalTrials.gov/show/NCT02465450
6449,Analysis of Revascularization in Ischemic Stroke With EmboTrap,Completed,Has Results,Stroke|Ischemia,Device: EmboTrap® Revascularization Device,Neuravi Inc.,Neuravi Inc.,,,,,,,Not Applicable,Industry,Interventional,11/15/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT02488915
6450,Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 2,Industry,Interventional,9/21/2015,10/13/2016,https://ClinicalTrials.gov/show/NCT02461589
6451,SEEQ™ Performance Study,Completed,Has Results,Arrhythmia Type Unknown,,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,,Industry,Observational,6/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02484898
6452,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",Completed,Has Results,Hyperlipidemia,Biological: Bococizumab 150mg|Biological: Bococizumab 75mg|Biological: Bococizumab 150mg placebo|Biological: Bococizumab 75mg placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/15/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02458287
6453,MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.,Completed,Has Results,Rosacea,Drug: Brimonidine 0.33% gel (Br)|Other: CD07805/47 (Br) placebo gel|Drug: Ivermectin 1% cream (IVM)|Other: CD5024 (IVM) placebo cream,Galderma,Galderma,,,,,,,Phase 4,Industry,Interventional,12/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02616250
6454,The EVICEL® Neurosurgery Phase III Study,Completed,Has Results,Cerebrospinal Fluid Leak,Biological: EVICEL Fibrin Sealant|Device: Hydrogel sealant,"Ethicon, Inc.","Ethicon, Inc.",,,,,,,Phase 3,Industry,Interventional,7/1/2015,10/12/2017,https://ClinicalTrials.gov/show/NCT02457546
6455,Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy,Completed,Has Results,Seizures,Drug: Retigabine|Drug: Placebo,"GlaxoSmithKline|Bausch Health Americas, Inc.",GlaxoSmithKline,"Bausch Health Americas, Inc.",,,,,,Phase 3,Industry,Interventional,12/5/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00235755
6456,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention,Completed,Has Results,Migraine,Drug: Erenumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,7/17/2015,6/19/2017,https://ClinicalTrials.gov/show/NCT02456740
6457,A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc),Completed,Has Results,Systemic Sclerosis,Drug: Placebo|Drug: Tocilizumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,11/20/2015,2/4/2019,https://ClinicalTrials.gov/show/NCT02453256
6458,Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD),Completed,Has Results,"Depression|Depressive Disorder|Depressive Disorder, Treatment-resistant|Depressive Disorder, Major",Device: LFMS,"Tal Medical, Inc.","Tal Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02452892
6459,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)",Completed,Has Results,"Diabetes Mellitus, Type 2","Drug: Insulin glargine, 300U/ml|Drug: Insulin glargine, 100U/ml|Drug: Insulin detemir|Drug: Background Therapy",Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,6/16/2015,8/9/2018,https://ClinicalTrials.gov/show/NCT02451137
6460,"A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251",Completed,Has Results,"Chronic Obstructive Pulmonary Disease, COPD",Drug: QBW251|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,4/30/2015,1/23/2017,https://ClinicalTrials.gov/show/NCT02449018
6461,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Completed,Has Results,Chronic Stable Plaque Psoriasis,Drug: DFD06-Cream|Drug: Vehicle Cream,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 3,Industry,Interventional,12/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02445807
6462,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",Completed,Has Results,Breast Cancer|Hormone Receptor Positive Tumor|Early-Stage Breast Carcinoma,Drug: Abemaciclib|Drug: Loperamide|Drug: Anastrozole,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/15/2019,2/12/2018,https://ClinicalTrials.gov/show/NCT02441946
6463,AirXpanders AeroForm Tissue Expander System for Breast Reconstruction,Completed,Has Results,Breast Cancer,Device: AeroForm Tissue Expander,"AirXpanders, Inc.","AirXpanders, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/12/2015,9/26/2017,https://ClinicalTrials.gov/show/NCT02504424
6464,Condition of Submental Fullness and Treatment Outcomes Registry,Completed,Has Results,Submental Fullness,Drug: Deoxycholic acid|Procedure: Surgical Procedures|Procedure: Laser Liposuction|Device: Energy Devices|Other: Other Treatments,Kythera Biopharmaceuticals,Kythera Biopharmaceuticals,,,,,,,,Industry,Observational,5/11/2015,11/10/2016,https://ClinicalTrials.gov/show/NCT02438813
6465,A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus,Completed,Has Results,"Lupus Erythematosus, Systemic",Biological: ALX-0061|Biological: Placebo,Ablynx,Ablynx,,,,,,,Phase 2,Industry,Interventional,7/15/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02437890
6466,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),Completed,Has Results,Clostridium Difficile,Drug: SER-109|Drug: Placebo,"Seres Therapeutics, Inc.|Syneos Health","Seres Therapeutics, Inc.",Syneos Health,,,,,,Phase 2,Industry|Other,Interventional,5/15/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02437487
6467,Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older,Completed,Has Results,Influenza,Biological: Panblok|Biological: rHA adjuvant,Protein Sciences Corporation,Protein Sciences Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02464163
6468,"Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease",Completed,Has Results,Dry Eye Syndromes,Drug: AGN-223575 ophthalmic solution|Drug: AGN-223575 vehicle ophthalmic solution,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,6/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02435914
6469,Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Device: Insulin Pump,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,6/15/2019,10/18/2019,https://ClinicalTrials.gov/show/NCT02463097
6470,Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma,Completed,Has Results,Asthma,Drug: Glycopyrronium MDI|Drug: Serevent Diskus 50 μg|Drug: Placebo,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,5/27/2015,3/26/2016,https://ClinicalTrials.gov/show/NCT02433834
6471,A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Bryostatin 1|Other: Placebo,"Neurotrope Bioscience, Inc.","Neurotrope Bioscience, Inc.",,,,,,,Phase 2,Industry,Interventional,11/15/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02431468
6472,A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Olumacostat Glasaretil|Other: Vehicle,"Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 2,Industry,Interventional,4/15/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02431052
6473,Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin,Completed,Has Results,Type II Diabetes,Drug: Farxiga|Drug: Placebo|Drug: Metformin|Drug: Insulin,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,5/15/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02429258
6474,A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.,Completed,Has Results,Parapsoriasis,Drug: Apremilast|Drug: Placebo|Drug: Placebo-Apremilast,Celgene,Celgene,,,,,,,Phase 4,Industry,Interventional,4/20/2015,11/22/2016,https://ClinicalTrials.gov/show/NCT02425826
6475,Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: Vedolizumab,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,3/30/2015,2/21/2018,https://ClinicalTrials.gov/show/NCT02425111
6476,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression",Completed,Has Results,"Depressive Disorder, Treatment-Resistant",Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral Antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (New Antidepressant),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,8/20/2015,8/10/2017,https://ClinicalTrials.gov/show/NCT02422186
6477,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,7/26/2015,10/5/2016,https://ClinicalTrials.gov/show/NCT02420262
6478,Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study,Completed,Has Results,Coronary Artery Disease,Device: Resolute Onyx Stent - 2.25 mm - 4.0 mm,Medtronic Vascular,Medtronic Vascular,,,,,,,Not Applicable,Industry,Interventional,7/7/2015,12/3/2018,https://ClinicalTrials.gov/show/NCT02419521
6479,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Completed,Has Results,Treatment-resistant Depression,Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,8/10/2015,2/20/2018,https://ClinicalTrials.gov/show/NCT02417064
6480,"Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home",Completed,Has Results,Asthma,Biological: Benralizumab,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/27/2015,3/14/2016,https://ClinicalTrials.gov/show/NCT02417961
6481,Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache,Completed,Has Results,Tension-Type Headache,Drug: TNX-201|Drug: Placebo,"Tonix Pharmaceuticals, Inc.","Tonix Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,6/15/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02423408
6482,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin 10 mg|Drug: Matching Placebo for Dapagliflozin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,6/15/2015,11/7/2017,https://ClinicalTrials.gov/show/NCT02413398
6483,Medtronic Resolute Onyx 2.0 mm Clinical Study,Completed,Has Results,Coronary Artery Disease,Device: Resolute Onyx Stent - 2.0 mm,Medtronic Vascular,Medtronic Vascular,,,,,,,Not Applicable,Industry,Interventional,4/6/2015,2/21/2019,https://ClinicalTrials.gov/show/NCT02412501
6484,An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Low Metformin|Drug: Mid Metformin|Drug: High Metformin|Drug: Metformin,NuSirt Biopharma,NuSirt Biopharma,,,,,,,Phase 2,Industry,Interventional,10/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02435277
6485,"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Tezacaftor/Ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,6/15/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT02412111
6486,A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome,Completed,Has Results,"Cystitis, Interstitial|Painful Bladder Syndrome",Combination Product: LiRIS®|Combination Product: LiRIS Placebo,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,5/21/2015,1/9/2017,https://ClinicalTrials.gov/show/NCT02411110
6487,Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Dexamethasone,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,9/9/2015,1/7/2019,https://ClinicalTrials.gov/show/NCT02412878
6488,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,Completed,Has Results,Multiple Sclerosis,Drug: dimethyl fumarate|Drug: montelukast|Drug: Placebo,Biogen,Biogen,,,,,,,Phase 4,Industry,Interventional,6/29/2015,4/27/2017,https://ClinicalTrials.gov/show/NCT02410278
6489,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Completed,Has Results,Treatment-resistant Depression,Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,8/7/2015,11/6/2017,https://ClinicalTrials.gov/show/NCT02418585
6490,The EarLens Contact Hearing Device (CHD) Spectrum Study,Completed,Has Results,"Hearing Loss, Sensorineural",Device: Sound amplification provided via the EarLens CHD,EarLens Corporation,EarLens Corporation,,,,,,,Not Applicable,Industry,Interventional,6/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02470494
6491,Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: NBI-98854,Neurocrine Biosciences,Neurocrine Biosciences,,,,,,,Phase 3,Industry,Interventional,3/15/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT02405091
6492,"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients",Completed,Has Results,"Arthritis, Rheumatoid",Drug: FKB327|Drug: Humira®,"Fujifilm Kyowa Kirin Biologics Co., Ltd.","Fujifilm Kyowa Kirin Biologics Co., Ltd.",,,,,,,Phase 3,Industry,Interventional,6/10/2015,1/18/2018,https://ClinicalTrials.gov/show/NCT02405780
6493,"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",Completed,Has Results,Psoriatic Arthritis,Biological: Secukinumab,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,8/31/2015,1/24/2019,https://ClinicalTrials.gov/show/NCT02404350
6494,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,Completed,Has Results,Non-Small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer,Drug: Ibrutinib|Drug: Durvalumab,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/15/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT02403271
6495,Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment,Completed,Has Results,Major Depression Disorder,Drug: Adjunct brexpiprazole|Drug: ADT,H. Lundbeck A/S,H. Lundbeck A/S,,,,,,,Phase 3,Industry,Interventional,3/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02400346
6496,"Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV-1 Infection,Drug: BIC|Drug: F/TAF|Drug: DTG|Drug: BIC Placebo|Drug: DTG Placebo|Drug: B/F/TAF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,3/23/2015,2/20/2019,https://ClinicalTrials.gov/show/NCT02397694
6497,A Study Of Galcanezumab In Participants With Episodic Cluster Headache,Completed,Has Results,Episodic Cluster Headache,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,5/22/2015,6/4/2018,https://ClinicalTrials.gov/show/NCT02397473
6498,"Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients",Completed,Has Results,Hidradenitis Suppurativa (Acne Inversa),Biological: CJM112|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,4/13/2015,11/23/2016,https://ClinicalTrials.gov/show/NCT02421172
6499,Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States,Completed,Has Results,Arrhythmia,Other: office setting|Other: hosptial setting,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,3/30/2015,5/31/2016,https://ClinicalTrials.gov/show/NCT02395536
6500,A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions,Completed,Has Results,"Cystitis, Interstitial|Ulcer",Drug: LiRIS®|Drug: LiRIS Placebo,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,4/15/2015,11/20/2017,https://ClinicalTrials.gov/show/NCT02395042
6501,A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria,Completed,Has Results,Urticaria,Drug: Omalizumab|Drug: Placebo,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 4,Industry,Interventional,5/18/2015,3/9/2017,https://ClinicalTrials.gov/show/NCT02392624
6502,Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris),Completed,Has Results,Warts,Biological: CANDIN|Other: Placebo,"Nielsen BioSciences, Inc.","Nielsen BioSciences, Inc.",,,,,,,Phase 2,Industry,Interventional,3/15/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT02393417
6503,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",Completed,Has Results,Cystic Fibrosis,Drug: VX-661/Ivacaftor|Drug: Ivacaftor|Drug: Placebo matched to VX-661/ ivacaftor|Drug: Placebo matched to Ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,3/15/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02392234
6504,ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate,Completed,Has Results,Rheumatoid Arthritis,Drug: acalabrutinib|Drug: Placebo,Acerta Pharma BV,Acerta Pharma BV,,,,,,,Phase 2,Industry,Interventional,4/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02387762
6505,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Completed,Has Results,Irritable Bowel Syndrome Characterized by Constipation,Drug: Plecanatide|Drug: Placebo,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,12/14/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02387359
6506,Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation,Completed,Has Results,Epilepsy|Seizures,Device: Vagus Nerve Stimulation Therapy,"Cyberonics, Inc.|LivaNova","Cyberonics, Inc.",LivaNova,,,,,,,Industry,Observational,4/28/2015,10/10/2016,https://ClinicalTrials.gov/show/NCT02385526
6507,Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infections|Complicated Appendicitis,Drug: Eravacycline|Drug: Meropenem|Drug: Placebo,"Tetraphase Pharmaceuticals, Inc.","Tetraphase Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,10/13/2016,5/19/2017,https://ClinicalTrials.gov/show/NCT02784704
6508,PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial,Completed,Has Results,Portopulmonary Hypertension,Drug: Macitentan|Other: Placebo,Actelion,Actelion,,,,,,,Phase 4,Industry,Interventional,6/23/2015,10/31/2018,https://ClinicalTrials.gov/show/NCT02382016
6509,Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: VOX|Drug: SOF/VEL,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,2/16/2015,1/26/2016,https://ClinicalTrials.gov/show/NCT02378961
6510,Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: VOX|Drug: SOF/VEL|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,2/17/2015,4/12/2016,https://ClinicalTrials.gov/show/NCT02378935
6511,Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23),Completed,Has Results,Bacterial Infections|Skin Structures and Soft Tissue Infections,Drug: Omadacycline|Drug: Linezolid,Paratek Pharmaceuticals Inc,Paratek Pharmaceuticals Inc,,,,,,,Phase 3,Industry,Interventional,6/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02378480
6512,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Etanercept|Drug: Methotrexate|Drug: Placebo to Etanercept|Drug: Placebo to Methotrexate,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,3/3/2015,7/6/2018,https://ClinicalTrials.gov/show/NCT02376790
6513,RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity,Completed,Has Results,Retinopathy of Prematurity,Drug: Ranibizumab|Procedure: Laser therapy,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,12/30/2015,12/14/2017,https://ClinicalTrials.gov/show/NCT02375971
6514,A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN),Completed,Has Results,Postherpetic Neuralgia,Drug: TV-45070|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,2/26/2015,5/9/2017,https://ClinicalTrials.gov/show/NCT02365636
6515,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Bevacizumab-Pfizer|Drug: Bevacizumab-EU|Drug: Paclitaxel|Drug: Carboplatin,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,4/15/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02364999
6516,An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD),Completed,Has Results,Duchenne Muscular Dystrophy,Drug: Vamorolone 0.25 mg/day/day|Drug: Vamorolone 0.75 mg/day/day|Drug: Vamorolone 2.0 mg/day/day|Drug: Vamorolone 6.0 mg/day/day,"ReveraGen BioPharma, Inc.|University of Pittsburgh|National Institute of Neurological Disorders and Stroke (NINDS)|Cooperative International Neuromuscular Research Group|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","ReveraGen BioPharma, Inc.",University of Pittsburgh,National Institute of Neurological Disorders and Stroke (NINDS)|Cooperative International Neuromuscular Research Group|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),National Institute of Neurological Disorders and Stroke (NINDS),Cooperative International Neuromuscular Research Group|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Cooperative International Neuromuscular Research Group,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2,Industry|Other|NIH,Interventional,7/28/2016,4/26/2018,https://ClinicalTrials.gov/show/NCT02760277
6517,A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD),Completed,Has Results,Duchenne Muscular Dystrophy,Drug: Vamorolone 0.25 mg/kg/day|Drug: Vamorolone 0.75 mg/kg/day|Drug: Vamorolone 2.0 mg/kg/day|Drug: Vamorolone 6.0 mg/kg/day,"ReveraGen BioPharma, Inc.|University of Pittsburgh|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institute of Neurological Disorders and Stroke (NINDS)|Cooperative International Neuromuscular Research Group","ReveraGen BioPharma, Inc.",University of Pittsburgh,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institute of Neurological Disorders and Stroke (NINDS)|Cooperative International Neuromuscular Research Group,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),National Institute of Neurological Disorders and Stroke (NINDS)|Cooperative International Neuromuscular Research Group,National Institute of Neurological Disorders and Stroke (NINDS),Cooperative International Neuromuscular Research Group,Phase 2,Industry|Other|NIH,Interventional,6/16/2019,5/1/2018,https://ClinicalTrials.gov/show/NCT02760264
6518,A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,Completed,Has Results,T-cell Acute Lymphoblastic Leukemia|T-cell Lymphoblastic Lymphoma,Drug: LY3039478|Drug: Dexamethasone|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/1/2015,1/15/2018,https://ClinicalTrials.gov/show/NCT02518113
6519,SMART-SF Radiofrequency Ablation Safety Study,Completed,Has Results,Atrial Fibrillation,Device: THERMOCOOL® SMARTTOUCH® (RF ablation treatment),"Biosense Webster, Inc.","Biosense Webster, Inc.",,,,,,,Phase 3,Industry,Interventional,3/1/2015,11/8/2016,https://ClinicalTrials.gov/show/NCT02359890
6520,Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine,Completed,Has Results,Opioid Dependence|Opioid Related Disorders,Drug: SUBOXONE|Drug: RBP-6000|Drug: Placebo,Indivior Inc.,Indivior Inc.,,,,,,,Phase 3,Industry,Interventional,1/28/2015,4/29/2016,https://ClinicalTrials.gov/show/NCT02357901
6521,Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: FX006|Drug: Placebo|Drug: TCA IR 40,"Flexion Therapeutics, Inc.","Flexion Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,1/15/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02357459
6522,Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Completed,Has Results,Diabetes Mellitus|Diabetes Mellitus Complications|Gastroparesis,Drug: Relamorelin|Drug: Placebo,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,1/29/2015,6/9/2016,https://ClinicalTrials.gov/show/NCT02357420
6523,Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients,Completed,Has Results,"Patients, Resistant Hypertension",Drug: LHW090|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,11/4/2015,8/17/2017,https://ClinicalTrials.gov/show/NCT02515331
6524,A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,Completed,Has Results,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,Drug: Ramucirumab|Drug: Paclitaxel,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,10/12/2015,12/28/2018,https://ClinicalTrials.gov/show/NCT02514551
6525,"A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy",Completed,Has Results,Painful Diabetic Neuropathy|Diabetes,"Drug: clonidine hydrochloride topical gel, 0.1%",BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 2,Industry,Interventional,6/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02355158
6526,Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery,Completed,Has Results,Lumbar Surgery,Device: Provant,"Regenesis Biomedical, Inc.","Regenesis Biomedical, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/15/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02416973
6527,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: CVT-301|Other: Observational cohort,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,3/15/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02352363
6528,Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Luminate 1.0mg|Drug: Luminate 2.0mg|Drug: Luminate 3.0mg|Drug: Avastin|Drug: Luminate 0.5mg,"Allegro Ophthalmics, LLC|Trial Runners, LLC|Duke University","Allegro Ophthalmics, LLC","Trial Runners, LLC",Duke University,,,,,Phase 2,Industry|Other,Interventional,10/13/2014,6/13/2017,https://ClinicalTrials.gov/show/NCT02348918
6529,Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT),Completed,Has Results,Atrial Fibrillation,Drug: Warfarin|Drug: Dabigatran Etexilate 150mg,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,4/28/2015,11/14/2016,https://ClinicalTrials.gov/show/NCT02348723
6530,"""A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA""",Completed,Has Results,Narcolepsy|Obstructive Sleep Apnea,Drug: JZP-110,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/15/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT02348632
6531,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA""",Completed,Has Results,Obstructive Sleep Apnea,Drug: JZP-110|Drug: Placebo oral tablet,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02348606
6532,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy""",Completed,Has Results,Narcolepsy,Drug: JZP-110|Drug: Placebo oral tablet,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/15/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02348593
6533,"A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Completed,Has Results,Cystic Fibrosis,Drug: Tezacaftor/Ivacaftor|Drug: Ivacaftor|Drug: Tezacaftor/Ivacaftor matching placebo|Drug: Ivacaftor matching placebo,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 2,Industry,Interventional,2/16/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02508207
6534,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4),Completed,Has Results,COPD|Chronic Obstructive Pulmonary Disease,Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer|Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer|Drug: Placebo eFlow (CS) nebulizer,Sunovion Respiratory Development Inc.,Sunovion Respiratory Development Inc.,,,,,,,Phase 3,Industry,Interventional,2/15/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02347774
6535,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD,Completed,Has Results,COPD,Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer|Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer|Drug: Placebo BID eFlow Closed System (CS) nebulizer,Sunovion Respiratory Development Inc.,Sunovion Respiratory Development Inc.,,,,,,,Phase 3,Industry,Interventional,2/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02347761
6536,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Completed,Has Results,Cystic Fibrosis,Drug: VX-661 Plus Ivacaftor Combination|Drug: Ivacaftor|Drug: VX-661 Plus Ivacaftor Combination Placebo|Drug: Ivacaftor placebo,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,1/15/2019,1/20/2017,https://ClinicalTrials.gov/show/NCT02347657
6537,Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Other: Placebo|Biological: Tralokinumab Dose 1|Biological: Tralokinumab Dose 2|Biological: Tralokinumab Dose 3,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,1/23/2015,2/5/2016,https://ClinicalTrials.gov/show/NCT02347176
6538,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,2/23/2015,6/15/2016,https://ClinicalTrials.gov/show/NCT02346721
6539,"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus",Completed,Has Results,"Lupus Erythematosus, Systemic",Drug: Ustekinumab IV|Drug: Placebo Infusion|Drug: Placebo SC|Drug: Ustekinumab SC|Other: Concomitant Medication,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,10/15/2015,3/13/2019,https://ClinicalTrials.gov/show/NCT02349061
6540,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Completed,Has Results,Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Biological: Etanercept|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,UCB Biopharma S.P.R.L.,UCB Pharma,,,,,,Phase 3,Industry,Interventional,2/11/2015,12/17/2018,https://ClinicalTrials.gov/show/NCT02346240
6541,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TAF|Drug: FTC/RPV/TDF Placebo|Drug: FTC/RPV/TDF|Drug: FTC/RPV/TAF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,1/26/2015,1/9/2019,https://ClinicalTrials.gov/show/NCT02345252
6542,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TAF|Drug: EFV/FTC/TDF Placebo|Drug: EFV/FTC/TDF|Drug: FTC/RPV/TAF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,1/26/2015,1/2/2019,https://ClinicalTrials.gov/show/NCT02345226
6543,Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss,Completed,Has Results,Age-Related Hearing Loss,Drug: AUT00063|Drug: Placebo,Autifony Therapeutics Limited,Autifony Therapeutics Limited,,,,,,,Phase 2,Industry,Interventional,1/15/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02345031
6544,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: GFF MDI (PT003)|Drug: FF MDI (PT005)|Drug: GP MDI (PT001)|Drug: Placebo MDI,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,3/30/2015,8/31/2017,https://ClinicalTrials.gov/show/NCT02343458
6545,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: 122-0551 Foam|Drug: Vehicle Foam,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,1/15/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02367911
6546,Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis,Completed,Has Results,"Secondary Hyperparathyroidism, Chronic Kidney Disease",Drug: Cinacalcet,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,6/10/2015,3/15/2017,https://ClinicalTrials.gov/show/NCT02341417
6547,Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain,Completed,Has Results,Osteoarthritis of the Knee,Device: Cooled Radiofrequency|Drug: Corticosteroid injection,Halyard Health,Halyard Health,,,,,,,Not Applicable,Industry,Interventional,1/15/2019,3/16/2017,https://ClinicalTrials.gov/show/NCT02343003
6548,A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension,Completed,Has Results,Catecholamine-resistant Hypotension (CRH)|Distributive Shock|High Output Shock|Sepsis,Drug: LJPC-501|Drug: Placebo,La Jolla Pharmaceutical Company,La Jolla Pharmaceutical Company,,,,,,,Phase 3,Industry,Interventional,3/15/2019,2/18/2017,https://ClinicalTrials.gov/show/NCT02338843
6549,The Advocate Study,Completed,Has Results,Ostomy,Device: Test Ostomy Barrier|Device: Control Ostomy Barrier,Hollister Incorporated,Hollister Incorporated,,,,,,,Not Applicable,Industry,Interventional,3/16/2015,2/3/2017,https://ClinicalTrials.gov/show/NCT02401412
6550,Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus,Completed,Has Results,Humerus Fracture Metastatic Bone Disease,Device: Photodynamic Bone Stabilization System,"IlluminOss Medical, Inc.","IlluminOss Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/15/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT02338492
6551,Phase IIIb Study of APD421 in Combination as PONV Prophylaxis,Completed,Has Results,PONV,Drug: APD421|Drug: Placebo,Acacia Pharma Ltd,Acacia Pharma Ltd,,,,,,,Phase 3,Industry,Interventional,2/15/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02337062
6552,Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL),Completed,Has Results,Epilepsy,Other: blood draw,Sunovion,Sunovion,,,,,,,,Industry,Observational,9/15/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02491073
6553,BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,Completed,Has Results,Alzheimer Disease,Drug: Placebo|Drug: BI 409306|Drug: Donepezil,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,1/21/2015,10/10/2017,https://ClinicalTrials.gov/show/NCT02337907
6554,"AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients",Completed,Has Results,"Multiple System Atrophy, MSA",Drug: AZD3241|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,4/27/2015,9/19/2016,https://ClinicalTrials.gov/show/NCT02388295
6555,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Completed,Has Results,Scabies,"Drug: spinosad topical suspension, 0.9%|Other: Placebo",ParaPRO LLC|Concentrics Research,ParaPRO LLC,Concentrics Research,,,,,,Phase 3,Industry|Other,Interventional,5/10/2017,8/3/2018,https://ClinicalTrials.gov/show/NCT02485704
6556,Investigating the Effect of Vortioxetine in Adult ADHD Patients,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: vortioxetine 10 mg tablet|Drug: vortioxetine 20 mg tablet|Other: Placebo tablet,H. Lundbeck A/S,H. Lundbeck A/S,,,,,,,Phase 2,Industry,Interventional,12/14/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02327013
6557,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Completed,Has Results,Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,UCB Biopharma S.P.R.L.,UCB Pharma,,,,,,Phase 3,Industry,Interventional,12/15/2014,9/12/2018,https://ClinicalTrials.gov/show/NCT02326272
6558,Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants,Completed,Has Results,Respiratory Syncytial Virus Infections,Drug: Suptavumab 30 mg/kg|Drug: Placebo Matched to Suptavumab|Drug: Suptavumab 30 mg/kg- 1 Dose|Drug: Suptavumab 30 mg/kg - 2 Doses,Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/21/2015,9/26/2017,https://ClinicalTrials.gov/show/NCT02325791
6559,Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer,Completed,Has Results,Head and Neck Neoplasms|Mucositis,Drug: Brilacidin|Other: Placebo,"Innovation Pharmaceuticals, Inc.","Innovation Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,8/14/2014,11/22/2017,https://ClinicalTrials.gov/show/NCT02324335
6560,Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,2/2/2015,10/7/2015,https://ClinicalTrials.gov/show/NCT02322775
6561,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin Glargine (HOE901 - U300)|Drug: Insulin Glargine (HOE901 - U100)|Drug: Background therapy,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,1/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02320721
6562,A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL),Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Bendamustine|Drug: Obinutuzumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,3/31/2015,1/29/2019,https://ClinicalTrials.gov/show/NCT02320487
6563,ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC),Completed,Has Results,"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related|Familial Transthyretin Cardiac Amyloidosis",Drug: Revusiran (ALN-TTRSC)|Drug: Sterile Normal Saline (0.9% NaCl),Alnylam Pharmaceuticals,Alnylam Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/14/2019,3/30/2017,https://ClinicalTrials.gov/show/NCT02319005
6564,Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders,Completed,Has Results,Seizures,Drug: Cannabidiol Oral Solution,INSYS Therapeutics Inc,INSYS Therapeutics Inc,,,,,,,Phase 1|Phase 2,Industry,Interventional,4/13/2015,5/9/2016,https://ClinicalTrials.gov/show/NCT02324673
6565,Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder,Completed,Has Results,Seizures,Drug: Cannabidiol Oral Solution,INSYS Therapeutics Inc,INSYS Therapeutics Inc,,,,,,,Phase 3,Industry,Interventional,1/8/2016,6/22/2017,https://ClinicalTrials.gov/show/NCT02318602
6566,A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema,Completed,Has Results,Hereditary Angioedema Types I and II,Biological: C1-esterase inhibitor,CSL Behring,CSL Behring,,,,,,,Phase 3,Industry,Interventional,12/31/2014,9/21/2017,https://ClinicalTrials.gov/show/NCT02316353
6567,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306),Completed,Has Results,Plaque Psoriasis,Drug: 122-0551 Foam|Drug: Vehicle Foam,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,1/15/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT02368210
6568,A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency,Completed,Has Results,Growth Hormone Deficiency,Drug: Somatropin,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 4,Industry,Interventional,3/31/2015,11/8/2017,https://ClinicalTrials.gov/show/NCT02311894
6569,A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis,Completed,Has Results,Pain,Drug: Paracetamol 1000 mg SR tablets|Drug: Paracetamol 665 mg SR tablets|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/15/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02311881
6570,To Study GSP 301 in Patients With Seasonal Allergic Rhinitis,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: GSP 301-1 NS (QD)|Drug: GSP 301-2 NS (BID)|Drug: GSP 301 Placebo NS|Drug: Olopatadine HCl-1 NS (QD)|Drug: Olopatadine HCl-2 NS (BID)|Drug: Mometasone Furoate-1 NS (QD)|Drug: Mometasone Furoate-2 NS (BID),Glenmark Pharmaceuticals Ltd. India,Glenmark Pharmaceuticals Ltd. India,,,,,,,Phase 2,Industry,Interventional,12/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02318303
6571,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,12/1/2014,11/21/2015,https://ClinicalTrials.gov/show/NCT02305381
6572,Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,11/24/2014,3/9/2018,https://ClinicalTrials.gov/show/NCT02304484
6573,A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo,"Genentech, Inc.|SOLTI Breast Cancer Research Group","Genentech, Inc.",SOLTI Breast Cancer Research Group,,,,,,Phase 2,Industry|Other,Interventional,2/17/2015,8/2/2017,https://ClinicalTrials.gov/show/NCT02301988
6574,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",Completed,Has Results,Asthma,Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|Drug: Placebo inhalation powders via ELLIPTA inhaler|Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2015,11/25/2016,https://ClinicalTrials.gov/show/NCT02301975
6575,"A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids",Completed,Has Results,Uterine Fibroids,Drug: Telapristone Acetate|Drug: Placebo,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,3/16/2015,6/2/2017,https://ClinicalTrials.gov/show/NCT02301897
6576,Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC),Completed,Has Results,Pancreatic Neoplasms,Drug: nab-Paclitaxel|Drug: Gemcitabine|Drug: Chemoradiation|Drug: Capecitabine|Procedure: Surgery,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,4/21/2015,4/26/2018,https://ClinicalTrials.gov/show/NCT02301143
6577,Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,12/1/2014,9/15/2016,https://ClinicalTrials.gov/show/NCT02300103
6578,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,Completed,Has Results,Enterocolitis Clostridium Difficile Recurrent,Biological: RBX2660 (microbiota suspension)|Other: Placebo,Rebiotix Inc.,Rebiotix Inc.,,,,,,,Phase 2,Industry,Interventional,12/14/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT02299570
6579,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,11/21/2014,12/23/2015,https://ClinicalTrials.gov/show/NCT02298192
6580,Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: olodaterol|Drug: tiotropium,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,1/13/2015,3/29/2017,https://ClinicalTrials.gov/show/NCT02296138
6581,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: SAR342434|Drug: Humalog|Drug: insulin glargine HOE901,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,1/15/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02294474
6582,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis",Completed,Has Results,"Arthritis, Psoriatic",Biological: Secukinumab|Other: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,5/29/2015,12/19/2017,https://ClinicalTrials.gov/show/NCT02294227
6583,Actual Use Trial of Ibuprofen 400 mg,Completed,Has Results,Patient Compliance,Drug: Ibuprofen 400 mg caplet,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02294019
6584,"A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae",Completed,Has Results,Gonorrhea,Drug: GSK2140944,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/15/2015,7/27/2016,https://ClinicalTrials.gov/show/NCT02294682
6585,Addressing Involuntary Movements in Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: SD-809|Drug: Placebo,"Auspex Pharmaceuticals, Inc.|Teva Pharmaceutical Industries","Auspex Pharmaceuticals, Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,10/31/2014,8/19/2016,https://ClinicalTrials.gov/show/NCT02291861
6586,S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps,Completed,Has Results,Chronic Sinusitis|Nasal Polyposis,Drug: S8 Sinus Implant|Drug: Mometasone furoate nasal spray|Procedure: Sham,Intersect ENT,Intersect ENT,,,,,,,Phase 3,Industry,Interventional,12/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02291549
6587,A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy,Completed,Has Results,Geographic Atrophy,Other: Sham|Drug: Lampalizumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,3/30/2015,6/2/2017,https://ClinicalTrials.gov/show/NCT02288559
6588,"A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder",Completed,Has Results,"Depressive Disorder, Major",Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,11/18/2014,9/16/2016,https://ClinicalTrials.gov/show/NCT02288325
6589,Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.,Completed,Has Results,Type 2 Diabetes,Drug: Bydureon|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,12/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02288273
6590,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,11/24/2014,2/20/2017,https://ClinicalTrials.gov/show/NCT02292537
6591,Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age,Completed,Has Results,Influenza,Biological: Flublok Quadrivalent Influenza Vaccine|Biological: Inactivated Influenza Vaccine,Protein Sciences Corporation,Protein Sciences Corporation,,,,,,,Phase 3,Industry,Interventional,10/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02285998
6592,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Sitagliptin|Drug: Placebo matching with Saxagliptin|Drug: Placebo matching with Dapagliflozin|Drug: Placebo matching with Sitagliptin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/9/2014,9/20/2016,https://ClinicalTrials.gov/show/NCT02284893
6593,A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3),Completed,Has Results,Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/6/2014,10/5/2015,https://ClinicalTrials.gov/show/NCT02284516
6594,"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo",Completed,Has Results,Primary Progressive Multiple Sclerosis,Drug: Placebo|Drug: Laquinimod,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,1/12/2015,10/1/2017,https://ClinicalTrials.gov/show/NCT02284568
6595,"A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.",Completed,Has Results,Schizophrenia,Drug: BI 409306 100 mg QD|Drug: BI 498306 50 mg QD|Drug: Placebo|Drug: BI 498306 25 mg QD|Drug: BI 409306 10 mg QD,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,11/10/2014,6/13/2016,https://ClinicalTrials.gov/show/NCT02281773
6596,Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery,Completed,Has Results,Von Willebrand Disease,Biological: Recombinant von Willebrand Factor (rVWF),Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 3,Industry,Interventional,4/1/2015,7/6/2016,https://ClinicalTrials.gov/show/NCT02283268
6597,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries,Completed,Has Results,Acute Blunt Soft Tissue Injuries/Contusions,Drug: placebo|Drug: Placebos,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,12/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02290821
6598,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Completed,Has Results,Influenza,Biological: Flublok Quadrivalent|Biological: Inactivated Influenza Vaccine (IIV4),Protein Sciences Corporation|Syneos Health|Department of Health and Human Services,Protein Sciences Corporation,Syneos Health,Department of Health and Human Services,,,,,Phase 3,Industry|Other|U.S. Fed,Interventional,10/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02290509
6599,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control,Completed,Has Results,Asthma,Biological: Mepolizumab|Drug: Placebo|Drug: SOC,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/11/2014,6/10/2016,https://ClinicalTrials.gov/show/NCT02281318
6600,Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma,Completed,Has Results,Asthma,Biological: Tralokinumab|Other: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,2/19/2015,9/7/2017,https://ClinicalTrials.gov/show/NCT02281357
6601,SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis,Completed,Has Results,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,Drug: Liprotamase|Drug: porcine (pig) PERT,Anthera Pharmaceuticals,Anthera Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,6/15/2019,1/20/2017,https://ClinicalTrials.gov/show/NCT02279498
6602,DFN-02 Open Label Safety Study in Patients With Acute Migraine,Completed,Has Results,Acute Migraine,Drug: DFN-02,Dr. Reddy's Laboratories Limited,Dr. Reddy's Laboratories Limited,,,,,,,Phase 3,Industry,Interventional,9/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02279082
6603,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer|Drug: Spiriva® 18 mcg QD Handihaler,Sunovion Respiratory Development Inc.,Sunovion Respiratory Development Inc.,,,,,,,Phase 3,Industry,Interventional,10/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02276222
6604,ESSENTIAL Trial™ Sham Cross-over,Completed,Has Results,Obesity,Device: g-Cath EZ™ Suture Anchor Delivery Catheter,USGI Medical,USGI Medical,,,,,,,Not Applicable,Industry,Interventional,1/5/2015,9/30/2016,https://ClinicalTrials.gov/show/NCT02279420
6605,Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis,Completed,Has Results,"Scleroderma, Systemic","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,1/15/2015,3/28/2019,https://ClinicalTrials.gov/show/NCT02283762
6606,Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Etanercept,Amgen,Amgen,,,,,,,Phase 4,Industry,Interventional,1/15/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02274792
6607,Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia,Completed,Has Results,Dyskinesia|Levodopa-Induced Dyskinesia (LID)|Parkinson's Disease (PD),Drug: ADS-5102|Other: Placebo,"Adamas Pharmaceuticals, Inc.","Adamas Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,10/14/2019,3/10/2016,https://ClinicalTrials.gov/show/NCT02274766
6608,A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: NBI-98854|Drug: Placebo,Neurocrine Biosciences,Neurocrine Biosciences,,,,,,,Phase 3,Industry,Interventional,10/14/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02274558
6609,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: SAR342434|Drug: Humalog|Drug: Insulin glargine HOE901,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,10/14/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02273180
6610,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,Completed,Has Results,Post-Ischemic Stroke,Drug: Placebo|Drug: dalfampridine-ER 7.5mg|Drug: dalfampridine-ER 10mg,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,12/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02271217
6611,A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease,Completed,Has Results,Dry Eye Syndromes,Drug: Refresh Optive® Gel Drops|Drug: REFRESH LIQUIGEL®,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,11/13/2014,3/16/2015,https://ClinicalTrials.gov/show/NCT02280473
6612,KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD,Completed,Has Results,Anemia of Chronic Kidney Disease,Drug: ferric citrate|Drug: Placebo,Keryx Biopharmaceuticals,Keryx Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02268994
6613,Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: G-Pen (glucagon injection)|Drug: Lilly Glucagon (glucagon injection [rDNA origin]),Xeris Pharmaceuticals,Xeris Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/15/2017,9/25/2017,https://ClinicalTrials.gov/show/NCT02656069
6614,Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis,Completed,Has Results,Chronic Scalp Psoriasis,Biological: Secukinumab 300 mg|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/29/2014,12/7/2015,https://ClinicalTrials.gov/show/NCT02267135
6615,An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Completed,Has Results,Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,UCB Biopharma S.P.R.L.,UCB Pharma,,,,,,Phase 3,Industry,Interventional,12/16/2014,10/24/2018,https://ClinicalTrials.gov/show/NCT02326298
6616,Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus,Completed,Has Results,Lupus,Drug: BMS-931699|Drug: Placebo matching BMS-931699,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,11/13/2014,11/30/2017,https://ClinicalTrials.gov/show/NCT02265744
6617,A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: UMEC/VI DPI|Drug: Placebo DPI|Drug: Albuterol/salbutamol MDI,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,1/23/2015,6/2/2016,https://ClinicalTrials.gov/show/NCT02275052
6618,PF-06372865 In Subjects With Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Drug: PF-06372865|Drug: Placebo|Drug: Naproxen,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,10/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02262754
6619,Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy,Completed,Has Results,"Muscular Dystrophy, Duchenne",Drug: Eteplirsen,"Sarepta Therapeutics, Inc.","Sarepta Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,11/14/2019,3/23/2018,https://ClinicalTrials.gov/show/NCT02286947
6620,Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids,Completed,Has Results,Uterine Fibroids,Drug: Placebo|Drug: Telapristone Acetate,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,2/12/2015,4/6/2017,https://ClinicalTrials.gov/show/NCT02323646
6621,Cleancision IntRaoperative Contamination prEvention Study,Completed,Has Results,Wound Contamination|Colorectal Surgery,Device: CleanCision,Prescient Surgical,Prescient Surgical,,,,,,,Not Applicable,Industry,Interventional,3/15/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02413879
6622,A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients,Completed,Has Results,"Arthritis, Rheumatoid",Drug: FKB327|Drug: Humira®,"Fujifilm Kyowa Kirin Biologics Co., Ltd.","Fujifilm Kyowa Kirin Biologics Co., Ltd.",,,,,,,Phase 3,Industry,Interventional,12/14/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT02260791
6623,Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma,Completed,Has Results,Asthma,Drug: OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Drug: Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Drug: Placebo,Oriel Therapeutics,Oriel Therapeutics,,,,,,,Phase 1,Industry,Interventional,9/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02260492
6624,Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD,Completed,Has Results,COPD,Drug: Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,11/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02268396
6625,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Completed,Has Results,Asthma,Biological: Benralizumab,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,11/19/2014,7/2/2018,https://ClinicalTrials.gov/show/NCT02258542
6626,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Completed,Has Results,Chronic Sinusitis,Device: PROPEL Mini Sinus Implant.|Procedure: Sinus Surgery alone|Device: Propel Nova Sinus Implant,Intersect ENT|Advance Research Associates,Intersect ENT,Advance Research Associates,,,,,,Phase 3,Industry|Other,Interventional,9/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02266810
6627,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Completed,Has Results,Prophylaxis: Influenza,Biological: TIVc_LOT A|Biological: TIVc_LOT B|Biological: TIVc_LOT C|Biological: TIVf,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,9/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02256488
6628,Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract,Completed,Has Results,Respiratory Syncytial Virus,Drug: Presatovir|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,1/23/2015,7/14/2017,https://ClinicalTrials.gov/show/NCT02254408
6629,Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis,Completed,Has Results,"Renal Insufficiency, Chronic|Anemia|Renal Dialysis|Erythrocyte Transfusion",Drug: Epoetin alfa,Amgen,Amgen,,,,,,,Phase 4,Industry,Interventional,4/1/2015,5/25/2016,https://ClinicalTrials.gov/show/NCT02253654
6630,Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women,Completed,Has Results,Vulvovaginal Atrophy|Menopause|Dyspareunia|Painful Intercourse,Drug: Estradiol|Drug: Placebo,TherapeuticsMD,TherapeuticsMD,,,,,,,Phase 3,Industry,Interventional,9/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02253173
6631,"Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults",Completed,Has Results,Colon Cancer|Colorectal Carcinoma|Colon Cleansing,Drug: NER1006|Drug: Trisulfate solution,Norgine,Norgine,,,,,,,Phase 3,Industry,Interventional,9/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02254486
6632,A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides,Completed,Has Results,Facial Rhytides|Glabellar Rhytides,Biological: OnabotulinumtoxinA|Drug: Normal Saline,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,10/27/2014,4/20/2016,https://ClinicalTrials.gov/show/NCT02261493
6633,"Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years",Completed,Has Results,PAH,Drug: oral treprostinil,United Therapeutics,United Therapeutics,,,,,,,Phase 2,Industry,Interventional,12/18/2014,7/20/2017,https://ClinicalTrials.gov/show/NCT02276872
6634,BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH,Completed,Has Results,Non-Alcoholic Steatohepatitis,Device: Suspected NASH BreathID test with 13C-Octanoate|Device: Suspected NASH Breath test with 13C Methacetin,Exalenz Bioscience LTD.,Exalenz Bioscience LTD.,,,,,,,Phase 2,Industry,Interventional,3/15/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02314026
6635,Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation,Completed,Has Results,Diffuse Large B Cell Lymphoma,Drug: IMO-8400,"Idera Pharmaceuticals, Inc.","Idera Pharmaceuticals, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,6/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02252146
6636,Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract,Completed,Has Results,Respiratory Syncytial Virus Infection,Drug: Presatovir|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,1/31/2015,4/17/2017,https://ClinicalTrials.gov/show/NCT02254421
6637,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,11/5/2014,8/24/2018,https://ClinicalTrials.gov/show/NCT02249182
6638,Handling Comparison Between Two Contact Lens Types,Completed,Has Results,Presbyopia,Device: etafilcon A (multi-focal)|Device: etafilcon A (sphere),"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/1/2014,12/1/2014,https://ClinicalTrials.gov/show/NCT02310126
6639,Mirvaso in Use Study,Completed,Has Results,Rosacea,Drug: Brimonidine,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,9/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02249065
6640,BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis,Completed,Has Results,Gastroenteritis|Gastritis,Drug: RHB-102|Drug: Placebo Oral Tablet,RedHill Biopharma Limited,RedHill Biopharma Limited,,,,,,,Phase 3,Industry,Interventional,12/8/2014,2/16/2017,https://ClinicalTrials.gov/show/NCT02246439
6641,"A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders",Completed,Has Results,Urea Cycle Disorder,Drug: RAVICTI,"Horizon Therapeutics, LLC|Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Therapeutics, LLC","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,Phase 4,Industry,Interventional,12/31/2014,7/17/2017,https://ClinicalTrials.gov/show/NCT02246218
6642,Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants,Completed,Has Results,Obesity,Drug: Canagliflozin|Drug: Phentermine|Drug: Matching Placebo to Canagliflozin|Drug: Matching Placebo to Phentermine,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,9/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02243202
6643,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age,Completed,Has Results,Influenza,Biological: FluLaval™ Quadrivalent|Biological: Fluzone® Quadrivalent,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/1/2014,6/23/2015,https://ClinicalTrials.gov/show/NCT02242643
6644,PLATINUM Diversity,Completed,Has Results,Atherosclerosis|Coronary Artery Disease,Device: Percutaneous coronary intervention (Promus PREMIER),Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,,Industry,Observational,10/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02240810
6645,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: CVT-301 Low Dose|Drug: CVT-301 High Dose|Other: Placebo,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,11/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02240030
6646,Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry,Completed,Has Results,Ischemic Stroke,,Medtronic Neurovascular Clinical Affairs,Medtronic Neurovascular Clinical Affairs,,,,,,,,Industry,Observational,8/21/2014,10/7/2016,https://ClinicalTrials.gov/show/NCT02239640
6647,A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy,Completed,Has Results,Chronic Obstructive Pulmonary Disease COPD,Drug: AZD7624 1.0 mg|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,10/28/2014,4/4/2016,https://ClinicalTrials.gov/show/NCT02238483
6648,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Completed,Has Results,Bacterial Vaginosis,Drug: Metronidazole oral tablets 500mg|Drug: 1% SPL7013 Gel|Drug: Placebo gel,Starpharma Pty Ltd,Starpharma Pty Ltd,,,,,,,Phase 3,Industry,Interventional,10/13/2014,2/22/2017,https://ClinicalTrials.gov/show/NCT02237950
6649,A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides,Completed,Has Results,Forehead Rhytides|Glabellar Rhytides,Biological: OnabotulinumtoxinA|Drug: Normal Saline,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,10/21/2014,4/26/2016,https://ClinicalTrials.gov/show/NCT02261467
6650,Obalon Balloon System Pivotal IDE (SMART) Trial,Completed,Has Results,Obesity,Device: Obalon Intragastric Balloons|Device: Sham Device|Behavioral: Nutrition and Lifestyle Program,"Obalon Therapeutics, Inc.","Obalon Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02235870
6651,Selonsertib in Adults With Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Placebo|Drug: Selonsertib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,11/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02234141
6652,Quadripolar CRT-D On Currently Approved Lead SystemS,Completed,Has Results,Heart Failure,,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,,Industry,Observational,10/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02232984
6653,A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension,Completed,Has Results,Liver Cirrhosis|Hepatic Cirrhosis|Portal Hypertension,Drug: IDN-6556,Conatus Pharmaceuticals Inc.,Conatus Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,8/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02230683
6654,A Study of IDN-6556 in Subjects With Liver Cirrhosis,Completed,Has Results,Liver Cirrhosis|Hepatic Cirrhosis,Drug: IDN-6556|Drug: Placebo,Conatus Pharmaceuticals Inc.,Conatus Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,8/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02230670
6655,Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: nab-Paclitaxel|Drug: Carboplatin,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,4/28/2015,2/22/2017,https://ClinicalTrials.gov/show/NCT02289456
6656,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,Completed,Has Results,Diabetes Mellitus,Drug: Exantide with Dapagliflozin|Drug: Exentide|Drug: Dapagliflozin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/4/2014,12/28/2017,https://ClinicalTrials.gov/show/NCT02229396
6657,Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Exenatide|Drug: Exenatide matching placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/6/2014,8/29/2016,https://ClinicalTrials.gov/show/NCT02229383
6658,"Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents",Completed,Has Results,Meningococcal Disease,Biological: Meningococcal ABCWY|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/1/2014,6/11/2015,https://ClinicalTrials.gov/show/NCT02285777
6659,Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction,Completed,Has Results,Chronic Heart Failure With Reduced Ejection Fraction,Drug: LCZ696,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/16/2014,12/28/2017,https://ClinicalTrials.gov/show/NCT02226120
6660,Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK,Completed,Has Results,Neurotrophic Keratitis,Drug: rhNGF 20µg/ml|Other: Placebo,Dompé Farmaceutici S.p.A,Dompé Farmaceutici S.p.A,,,,,,,Phase 2,Industry,Interventional,2/15/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02227147
6661,A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Completed,Has Results,Epilepsy|Lennox-Gastaut Syndrome,Drug: GWP42003-P 20 mg/kg/day Dose|Drug: Placebo,GW Research Ltd,GW Research Ltd,,,,,,,Phase 3,Industry,Interventional,4/28/2015,3/18/2016,https://ClinicalTrials.gov/show/NCT02224690
6662,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease",Completed,Has Results,Parkinson`s Disease,Drug: PF-06649751,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,10/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02224664
6663,Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Completed,Has Results,Epilepsy|Lennox Gastaut Syndrome,Drug: GWP42003-P|Drug: Placebo control,GW Research Ltd,GW Research Ltd,,,,,,,Phase 3,Industry,Interventional,6/8/2015,5/19/2016,https://ClinicalTrials.gov/show/NCT02224560
6664,Evaluation of an Investigational Multifocal Lens,Completed,Has Results,Presbyopia,Device: lotrafilcon B|Device: etafilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02223754
6665,A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).,Completed,Has Results,Rheumatoid Arthritis,Biological: PF-06438179|Biological: Infliximab,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,8/26/2014,6/1/2017,https://ClinicalTrials.gov/show/NCT02222493
6666,A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy,Completed,Has Results,Narcolepsy With Cataplexy,Drug: Xyrem,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/1/2014,1/25/2019,https://ClinicalTrials.gov/show/NCT02221869
6667,Safety Evaluation of 3K3A-APC in Ischemic Stroke,Completed,Has Results,Ischemic Stroke,Biological: 3K3A-APC|Drug: Placebo,"ZZ Biotech, LLC|National Institute of Neurological Disorders and Stroke (NINDS)|Cedars-Sinai Medical Center|Massachusetts General Hospital|University of Iowa","ZZ Biotech, LLC",National Institute of Neurological Disorders and Stroke (NINDS),Cedars-Sinai Medical Center|Massachusetts General Hospital|University of Iowa,Cedars-Sinai Medical Center,Massachusetts General Hospital|University of Iowa,Massachusetts General Hospital,University of Iowa,Phase 2,Industry|NIH|Other,Interventional,10/14/2019,6/29/2017,https://ClinicalTrials.gov/show/NCT02222714
6668,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,9/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02220998
6669,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: fampridine|Drug: Placebo,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,9/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02219932
6670,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study,Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461|Drug: Placebo,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,7/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02218008
6671,Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis,Completed,Has Results,Nonalcoholic Steatohepatitis,Drug: Cenicriviroc|Drug: Placebo,"Tobira Therapeutics, Inc.","Tobira Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,9/18/2014,6/22/2017,https://ClinicalTrials.gov/show/NCT02217475
6672,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Completed,Has Results,Overactive Bladder (OAB),Drug: Mirabegron|Drug: Placebo,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","Astellas Pharma Global Development, Inc.",Astellas Pharma Inc,,,,,,Phase 4,Industry,Interventional,10/7/2014,1/2/2018,https://ClinicalTrials.gov/show/NCT02216214
6673,A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod,Completed,Has Results,Huntington's Disease,Drug: Laquinimod|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,10/28/2014,6/19/2018,https://ClinicalTrials.gov/show/NCT02215616
6674,A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN),Completed,Has Results,"Diabetic Neuropathy, Painful",Drug: PF-05089771 150 mg|Drug: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Drug: Pregabalin 300 mg|Drug: PF-05089771 150 mg + Pregabalin 300 mg,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/10/2014,9/28/2015,https://ClinicalTrials.gov/show/NCT02215252
6675,A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),Completed,Has Results,Breast Cancer,Drug: Letrozole|Other: Placebo|Drug: Taselisib,"Genentech, Inc.|SOLTI Breast Cancer Research Group|Breast International Group|Austrian Breast and Colorectal Cancer Group","Genentech, Inc.",SOLTI Breast Cancer Research Group,Breast International Group|Austrian Breast and Colorectal Cancer Group,Breast International Group,Austrian Breast and Colorectal Cancer Group,,,Phase 2,Industry|Other,Interventional,11/12/2014,3/13/2017,https://ClinicalTrials.gov/show/NCT02273973
6676,A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.,Completed,Has Results,"Influenza, Human",Biological: Quadrivalent Influenza Vaccine (QIV)|Biological: Trivalent Influenza Vaccine (TIV-1)|Biological: Trivalent Influenza Vaccine (TIV-2),Seqirus,Seqirus,,,,,,,Phase 3,Industry,Interventional,8/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02214225
6677,Cerebral Protection in Transcatheter Aortic Valve Replacement,Completed,Has Results,Severe Symptomatic Calcified Native Aortic Valve Stenosis,Device: Cerebral Protection System-The SENTINEL System with TAVR|Device: TAVR,Claret Medical,Claret Medical,,,,,,,Not Applicable,Industry,Interventional,9/14/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT02214277
6678,"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",Completed,Has Results,Follicular Lymphoma,Biological: PF-05280586|Biological: MabThera®,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/30/2014,4/19/2018,https://ClinicalTrials.gov/show/NCT02213263
6679,"Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women",Completed,Has Results,Respiratory Syncytial Virus Infections,Biological: RSV vaccine GSK3003895A (formulation 1)|Biological: RSV vaccine GSK3003898A (formulation 2)|Biological: RSV vaccine GSK3003899A (formulation 3)|Biological: Boostrix,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/20/2015,6/21/2016,https://ClinicalTrials.gov/show/NCT02360475
6680,Cardiac Resynchronization Therapy Efficacy Enhancements,Completed,Has Results,Atrial Fibrillation,Device: Conducted AF Response (CAFR)|Device: Conducted AF Response Plus (CAFRPlus),Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,10/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02222818
6681,Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents,Completed,Has Results,"Infections, Meningococcal",Biological: Bexsero|Other: Saline Placebo|Biological: Havrix|Biological: MenABCWY,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/21/2014,3/3/2016,https://ClinicalTrials.gov/show/NCT02212457
6682,Pilot Study of PEMF Therapy in Treatment of Post-operative Pain Following Total Knee Arthroplasty,Completed,Has Results,Post-Operative Pain Following Total Knee Arthroplasty,Device: Pulsed Electromagnetic Field Device (Provant)|Device: Sham Pulsed Electromagnetic Field Device,"Regenesis Biomedical, Inc.","Regenesis Biomedical, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02211534
6683,A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis,Completed,Has Results,Gastroparesis,Drug: Placebo|Drug: Camicinal,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/27/2014,8/24/2015,https://ClinicalTrials.gov/show/NCT02210000
6684,A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years,Completed,Has Results,"Influenza, Human",Biological: bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Biological: Comparator Quadrivalent Influenza Virus Vaccine,Seqirus,Seqirus,,,,,,,Phase 4,Industry,Interventional,9/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02212106
6685,BAX 855 Pediatric Study,Completed,Has Results,Hemophilia A,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Biological: PEGylated Recombinant Factor VIII,Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 3,Industry,Interventional,10/31/2014,10/23/2015,https://ClinicalTrials.gov/show/NCT02210091
6686,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,Completed,Has Results,Dyslipidemia,Biological: Evolocumab|Drug: Placebo|Drug: Background Statin Therapy,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,9/10/2014,11/11/2016,https://ClinicalTrials.gov/show/NCT02207634
6687,Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: RBP-7000,Indivior Inc.,Indivior Inc.,,,,,,,Phase 3,Industry,Interventional,6/14/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02203838
6688,Clinical Investigation of a New Intraocular Lens,Completed,Has Results,Cataract,"Device: TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Device: TECNIS Monofocal IOL, Model ZCB00",Abbott Medical Optics,Abbott Medical Optics,,,,,,,Not Applicable,Industry,Interventional,9/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02203721
6689,"Bay98-7196, Dose Finding / POC Study",Completed,Has Results,Endometriosis,Drug: Placebo|Drug: Levonorgestrel|Drug: Anastrozole|Drug: Lupron / Leuprolide acetate,Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,10/16/2014,10/24/2016,https://ClinicalTrials.gov/show/NCT02203331
6690,A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab,Completed,Has Results,Psoriasis,Drug: Ustekinumab|Drug: Guselkumab|Drug: Placebo for ustekinumab|Drug: Placebo for guselkumab,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,10/7/2014,5/24/2016,https://ClinicalTrials.gov/show/NCT02203032
6691,"Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection",Completed,Has Results,Hepatitis C Virus,Drug: Simeprevir 150 mg|Drug: Daclatasvir 60 mg|Drug: Sofosbuvir 400 mg,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,1/15/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT02349048
6692,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,7/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02201953
6693,Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,7/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02201940
6694,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,7/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02201901
6695,"A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects",Completed,Has Results,Rheumatoid Arthritis|Musculoskeletal and Connective Tissue Diseases,Biological: Adalimumab|Other: Placebo,AbbVie,AbbVie,,,,,,,Phase 4,Industry,Interventional,1/5/2015,8/8/2018,https://ClinicalTrials.gov/show/NCT02198651
6696,"Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF",Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Nintedanib|Drug: Pirfenidone,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,10/16/2015,1/31/2017,https://ClinicalTrials.gov/show/NCT02579603
6697,"Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease",Completed,Has Results,Huntington's Disease,Drug: PF-02545920|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02197130
6698,"Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: BFF MDI 320/9.6 μg|Drug: BFF MDI 160/9.6 μg|Drug: BFF MDI 80/9.6 μg|Drug: BD MDI 320 μg|Drug: FF MDI 9.6 μg,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,8/1/2014,3/1/2015,https://ClinicalTrials.gov/show/NCT02196077
6699,Aim to Reduce Movements in Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: SD-809|Drug: Placebo,"Auspex Pharmaceuticals, Inc.|Teva Pharmaceutical Industries","Auspex Pharmaceuticals, Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2|Phase 3,Industry,Interventional,6/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02195700
6700,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Completed,Has Results,Uncontrolled Asthma,Biological: Experimental: Tralokinumab|Other: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,10/30/2014,9/21/2017,https://ClinicalTrials.gov/show/NCT02194699
6701,Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults,Completed,Has Results,Migraine Disorders,Biological: onabotulinumtoxinA|Drug: Topiramate,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,8/5/2014,9/1/2017,https://ClinicalTrials.gov/show/NCT02191579
6702,Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION),Completed,Has Results,"Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)",Bayer,Bayer,,,,,,,Phase 4,Industry,Interventional,9/23/2014,7/16/2016,https://ClinicalTrials.gov/show/NCT02191137
6703,LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),Completed,Has Results,Tumors With CDK4/6 Pathway Activation,Drug: LEE011,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/25/2014,1/17/2018,https://ClinicalTrials.gov/show/NCT02187783
6704,An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate,Completed,Has Results,Rhematoid Arthritis,Drug: Tofacitinib with methotrexate|Drug: Tofacitinib without methotrexate|Biological: Adalimumab with methotrexate,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,8/14/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02187055
6705,Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device,Completed,Has Results,Intracranial Aneurysm,Device: Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device,Medtronic Neurovascular Clinical Affairs,Medtronic Neurovascular Clinical Affairs,,,,,,,Not Applicable,Industry,Interventional,7/24/2014,12/13/2018,https://ClinicalTrials.gov/show/NCT02186561
6706,Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease,Completed,Has Results,Graft Versus Host Disease,Drug: Ibrutinib,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/14/2014,9/15/2017,https://ClinicalTrials.gov/show/NCT02195869
6707,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Completed,Has Results,Measles; Mumps; Rubella,Biological: Priorix|Biological: M-M-R II|Biological: Varivax|Biological: Havrix|Biological: Prevnar 13,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,8/25/2014,12/22/2015,https://ClinicalTrials.gov/show/NCT02184572
6708,The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B,Completed,Has Results,Severe|Symptomatic|Calcific Aortic Stenosis,Device: TAVR Implantation with SAPIEN XT|Device: TAVR Implantation with SAPIEN,Edwards Lifesciences|American College of Cardiology,Edwards Lifesciences,American College of Cardiology,,,,,,Not Applicable,Industry|Other,Interventional,3/9/2011,5/30/2017,https://ClinicalTrials.gov/show/NCT02184442
6709,Plaque Psoriasis Study in Pediatric Subjects,Completed,Has Results,Plaque Psoriasis,Drug: calcitriol ointment|Drug: placebo comparator,Galderma,Galderma,,,,,,,Phase 4,Industry,Interventional,7/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02186665
6710,A Study of Golimumab in Participants With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondylitis,Drug: Placebo|Drug: Golimumab,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,9/3/2014,10/11/2016,https://ClinicalTrials.gov/show/NCT02186873
6711,Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy,Completed,Has Results,Actinic Keratosis,Drug: Aminolevulinic Acid|Drug: Topical Solution Vehicle|Device: BLU-U|Procedure: Cryotherapy,"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,9/14/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02239679
6712,A Study of Golimumab in Participants With Active Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Drug: Placebo|Drug: Golimumab,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,9/8/2014,3/22/2017,https://ClinicalTrials.gov/show/NCT02181673
6713,A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI,Completed,Has Results,Clostridium Difficile|Clostridium Infections,Drug: SYN-004|Drug: Placebo,Synthetic Biologics Inc.,Synthetic Biologics Inc.,,,,,,,Phase 2,Industry,Interventional,10/15/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02563106
6714,Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee,Completed,Has Results,Knee Osteoarthritis,Drug: Fasitibant- low dose|Drug: Fasitibant- intermediate dose|Drug: Fasitibant- high dose|Drug: Placebo comparator,Menarini Group,Menarini Group,,,,,,,Phase 2,Industry,Interventional,4/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02205814
6715,"Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease",Completed,Has Results,Diabetic Kidney Disease,Drug: Selonsertib|Drug: Placebo to match selonsertib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,6/14/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT02177786
6716,"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",Completed,Has Results,Prostatic Neoplasms,Drug: Leuprolide Mesylate,"Foresee Pharmaceuticals Co., Ltd.","Foresee Pharmaceuticals Co., Ltd.",,,,,,,Phase 3,Industry,Interventional,8/14/2019,1/5/2017,https://ClinicalTrials.gov/show/NCT02234115
6717,Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients,Completed,Has Results,Cystic Fibrosis,Drug: Placebo|Device: Tobi Podhaler,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,8/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02178540
6718,Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC),Completed,Has Results,Primary Sclerosing Cholangitis (PSC),Drug: OCA|Drug: Placebo,Intercept Pharmaceuticals,Intercept Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,2/9/2015,3/22/2018,https://ClinicalTrials.gov/show/NCT02177136
6719,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Completed,Has Results,Persistent Asthma,Drug: Fp MDPI|Drug: FS MDPI|Drug: FLOVENT HFA|Drug: ADVAIR DISKUS|Drug: albuterol/salbutamol HFA,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,7/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02175771
6720,Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,7/7/2014,9/13/2018,https://ClinicalTrials.gov/show/NCT02175758
6721,"Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus",Completed,Has Results,"Diabetes Mellitus, Type II",Drug: Placebo|Drug: PF-06291874,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02175121
6722,A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.,Completed,Has Results,Treatment for Prevention of Chronic Migraine,Drug: Erenumab,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,6/30/2014,5/26/2017,https://ClinicalTrials.gov/show/NCT02174861
6723,"This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas",Completed,Has Results,Pediatrics|Solid Tumors,Drug: Eribulin Mesylate,Eisai Inc.|Children's Oncology Group,Eisai Inc.,Children's Oncology Group,,,,,,Phase 1,Industry|Other,Interventional,7/31/2014,1/28/2016,https://ClinicalTrials.gov/show/NCT02171260
6724,Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment,Completed,Has Results,Chronic Hepatitis B,Drug: Tenofovir disoproxil fumarate|Biological: GS-4774,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,7/24/2014,5/30/2018,https://ClinicalTrials.gov/show/NCT02174276
6725,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Completed,Has Results,Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Drug: Vabomere|Drug: Best Available Therapy,"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)|Department of Health and Human Services|Melinta Therapeutics, Inc.","Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",Department of Health and Human Services,"Melinta Therapeutics, Inc.",,,,,Phase 3,Industry|U.S. Fed,Interventional,7/14/2019,7/21/2017,https://ClinicalTrials.gov/show/NCT02168946
6726,Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules,Completed,Has Results,Dupuytren's Disease,Biological: Collagenase clostridium histolyticum|Biological: Placebo,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02193828
6727,"Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study",Completed,Has Results,Clostridium Difficile,Biological: VLA84|Biological: Placebo,Valneva Austria GmbH,Valneva Austria GmbH,,,,,,,Phase 2,Industry,Interventional,12/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02316470
6728,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Completed,Has Results,Atrial Fibrillation|Percutaneous Coronary Intervention,Drug: Dabigatran Etexilate 110mg|Drug: Warfarin 3mg|Drug: Aspirin|Drug: Dabigatran Etexilate 150mg|Drug: Clopidogrel or Ticagrelor|Drug: Warfarin 5mg|Drug: Warfarin 1mg,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,7/22/2014,6/5/2017,https://ClinicalTrials.gov/show/NCT02164864
6729,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: fluticasone furoate (FF)|Drug: vilanterol (VI)|Drug: umeclidinium bromide (UMEC),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/30/2014,7/17/2017,https://ClinicalTrials.gov/show/NCT02164513
6730,A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache,Completed,Has Results,Migraine Headache,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,7/7/2014,2/12/2018,https://ClinicalTrials.gov/show/NCT02163993
6731,Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF|Drug: UMEC|Drug: VI,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/1/2014,7/18/2015,https://ClinicalTrials.gov/show/NCT02164539
6732,Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months,Completed,Has Results,Hyperkalemia,Drug: Sodium Zirconium Cyclosilicate,"ZS Pharma, Inc.","ZS Pharma, Inc.",,,,,,,Phase 3,Industry,Interventional,6/30/2014,11/30/2016,https://ClinicalTrials.gov/show/NCT02163499
6733,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Completed,Has Results,Uncontrolled Asthma,Biological: Tralokinumab|Other: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,6/13/2014,7/18/2017,https://ClinicalTrials.gov/show/NCT02161757
6734,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Completed,Has Results,Chronic Kidney Disease|Autosomal Dominant Polycystic Kidney Disease,Drug: Tolvaptan (OPC-41061)|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,4/18/2017,https://ClinicalTrials.gov/show/NCT02160145
6735,Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism,Completed,Has Results,Hypogonadism,Combination Product: Testosterone enanthate auto-injector,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 3,Industry,Interventional,7/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02159469
6736,Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,Completed,Has Results,Multiple Myeloma,Drug: Elotuzumab|Drug: Lenalidomide|Drug: Dexamethasone,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,3/8/2014,7/11/2018,https://ClinicalTrials.gov/show/NCT02159365
6737,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study,Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461|Drug: Placebo,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02158546
6738,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study,Completed,Has Results,Major Depressive Disorder,Drug: High Dose ALKS 5461|Drug: Low Dose ALKS 5461|Drug: Placebo,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02158533
6739,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,Completed,Has Results,COPD Patients,Drug: Symbicort|Drug: Formoterol turbohaler|Other: Placebo for Symbicort pMDI|Other: Placebo for Formoterol Turbohaler,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,6/27/2014,2/8/2016,https://ClinicalTrials.gov/show/NCT02157935
6740,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis",Completed,Has Results,"Spondylitis, Ankylosing",Biological: Secukinumab|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,5/18/2015,1/2/2018,https://ClinicalTrials.gov/show/NCT02159053
6741,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dulaglutide|Drug: Placebo|Drug: Insulin Glargine|Drug: Metformin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,5/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02152371
6742,Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly,Completed,Has Results,"Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Large Cell|Lung Neoplasm",Drug: nab-paclitaxel|Drug: Carboplatin,Celgene,Celgene,,,,,,,Phase 4,Industry,Interventional,6/9/2014,7/14/2017,https://ClinicalTrials.gov/show/NCT02151149
6743,A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males,Completed,Has Results,Adult Male Hypogonadism,Drug: Testosterone gel (FE 999303),Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02149264
6744,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),Completed,Has Results,Colorectal Neoplasms,Drug: Nintedanib (BIBF 1120)|Drug: Placebo|Drug: BSC,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,9/25/2014,8/25/2016,https://ClinicalTrials.gov/show/NCT02149108
6745,A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis,Completed,Has Results,Bacterial Vaginosis,Drug: SYM-1219|Drug: Placebo,Symbiomix Therapeutics,Symbiomix Therapeutics,,,,,,,Phase 2,Industry,Interventional,5/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02147899
6746,A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate,Completed,Has Results,Rheumatoid Arthritis,Drug: Tofacitinib|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02147587
6747,A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: UMEC/VI|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/1/2014,3/5/2015,https://ClinicalTrials.gov/show/NCT02152605
6748,A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Denosumab (CP2)|Drug: Denosumab (CP4),Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,5/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02157948
6749,A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas,Completed,Has Results,Leiomyoma|Uterine Hemorrhage,Drug: Ulipristal acetate (UPA)|Drug: Placebo,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,3/31/2014,3/29/2016,https://ClinicalTrials.gov/show/NCT02147197
6750,A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas,Completed,Has Results,Leiomyoma|Uterine Hemorrhage,Drug: Ulipristal acetate (UPA)|Drug: Placebo,Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,1/29/2014,11/24/2016,https://ClinicalTrials.gov/show/NCT02147158
6751,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Completed,Has Results,Acute Coronary Syndrome,Drug: Losmapimod 7.5 mg twice daily|Drug: Placebo twice daily|Drug: Standard therapy,GlaxoSmithKline|The TIMI Study Group,GlaxoSmithKline,The TIMI Study Group,,,,,,Phase 3,Industry|Other,Interventional,6/3/2014,12/14/2015,https://ClinicalTrials.gov/show/NCT02145468
6752,Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study),Completed,Has Results,Delayed Graft Function,Drug: Eculizumab|Drug: Placebo,Alexion Pharmaceuticals|CTI Clinical Trial and Consulting Services,Alexion Pharmaceuticals,CTI Clinical Trial and Consulting Services,,,,,,Phase 2|Phase 3,Industry|Other,Interventional,8/21/2014,11/22/2016,https://ClinicalTrials.gov/show/NCT02145182
6753,Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo,Completed,Has Results,Ischemic Stroke,Device: Trevo Thrombectomy Procedure|Other: Medical Management,Stryker Neurovascular,Stryker Neurovascular,,,,,,,Not Applicable,Industry,Interventional,7/14/2019,5/15/2017,https://ClinicalTrials.gov/show/NCT02142283
6754,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Completed,Has Results,Asthma,Drug: FS MDPI|Drug: Fp MDPI|Drug: Placebo MDPI|Drug: Albuterol/salmeterol HFA MDI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,6/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02141854
6755,"A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants",Completed,Has Results,Respiratory Syncytial Virus,Drug: Placebo|Drug: MEDI8897 10 mg|Drug: MEDI8897 25 mg|Drug: MEDI8897 50 mg,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,1/13/2015,9/28/2016,https://ClinicalTrials.gov/show/NCT02290340
6756,A Long-Term Safety Study of ALKS 5461,Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,11/20/2017,https://ClinicalTrials.gov/show/NCT02141399
6757,A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,5/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02139943
6758,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Completed,Has Results,Asthma,Drug: FS MDPI|Drug: Fp MDPI|Drug: Placebo MDPI|Drug: albuterol/salbutamol|Drug: Beclomethasone dipropionate,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,6/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02139644
6759,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Completed,Has Results,Gout,Drug: Febuxostat IR|Drug: Febuxostat XR|Drug: Febuxostat placebo|Drug: Colchicine|Drug: Naproxen|Drug: Lansoprazole,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,4/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02139046
6760,A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB),Completed,Has Results,Overactive Bladder (OAB),Drug: Mirabegron|Drug: Tolterodine ER,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","Astellas Pharma Global Development, Inc.",Astellas Pharma Inc,,,,,,Phase 4,Industry,Interventional,7/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02138747
6761,Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities,Completed,Has Results,Actinic Keratosis,Drug: Aminolevulinic Acid (ALA)|Drug: Topical Solution Vehicle|Device: Blue Light Photodynamic Therapy Illuminator (BLU-U),"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02137785
6762,BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Drug: BI 695501|Drug: US-licensed Humira®,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,1/26/2015,10/18/2016,https://ClinicalTrials.gov/show/NCT02137226
6763,ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study),Completed,Has Results,Dyskinesia|Levodopa Induced Dyskinesia (LID)|Parkinson's Disease,Drug: ADS-5102|Other: Placebo,"Adamas Pharmaceuticals, Inc.","Adamas Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02136914
6764,National Prevalence and Impact of Noninvasive Prenatal Testing,Completed,Has Results,Aneuploidy,Other: non-invasive prenatal testing,"Obstetrix Medical Group|Mednax Center for Research, Education, Quality and Safety",Obstetrix Medical Group,"Mednax Center for Research, Education, Quality and Safety",,,,,,,Industry,Observational,1/14/2019,12/1/2016,https://ClinicalTrials.gov/show/NCT02284399
6765,"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects",Completed,Has Results,Asthma,Biological: Mepolizumab|Drug: SOC,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/29/2014,10/5/2017,https://ClinicalTrials.gov/show/NCT02135692
6766,Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: TAK-385|Drug: Degarelix,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,6/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02135445
6767,An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product,Completed,Has Results,Primary Open-Angle Glaucoma|Ocular Hypertension,Drug: Bimatoprost,"ForSight Vision5, Inc.","ForSight Vision5, Inc.",,,,,,,Phase 2,Industry,Interventional,6/5/2014,1/31/2016,https://ClinicalTrials.gov/show/NCT02143843
6768,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615;RN316)|Drug: Atorvastatin|Other: Placebo for Bococizumab (PF-04950615;RN316)|Other: Placebo for atorvastatin,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02135029
6769,The Closer Trial: A Safety and Efficacy Study of the Rex Medical Vascular Sealing System,Completed,Has Results,Surgical Wound,Device: Closer VSS,Rex Medical,Rex Medical,,,,,,,Not Applicable,Industry,Interventional,5/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02136004
6770,3 Month PHI PAD PoM Study,Completed,Has Results,"Vascular Disease, Peripheral",Drug: GSK1278863|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/15/2010,11/1/2011,https://ClinicalTrials.gov/show/NCT02135848
6771,Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults,Completed,Has Results,Norovirus Prevention,Biological: Norovirus Bivalent VLP Vaccine|Drug: Placebo (Saline),Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,5/15/2014,1/6/2016,https://ClinicalTrials.gov/show/NCT02142504
6772,"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide",Completed,Has Results,Major Depressive Disorder,Drug: Esketamine|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,5/23/2014,2/1/2016,https://ClinicalTrials.gov/show/NCT02133001
6773,"Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap",Completed,Has Results,Leiomyoma,Drug: BAY1002670|Drug: Placebo,Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,5/15/2014,5/4/2016,https://ClinicalTrials.gov/show/NCT02131662
6774,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Carboplatin|Drug: Docetaxel|Drug: Pertuzumab|Drug: Trastuzumab|Drug: Trastuzumab Emtansine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,6/25/2014,5/29/2018,https://ClinicalTrials.gov/show/NCT02131064
6775,"DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis",Completed,Has Results,Psoriasis,Drug: DFD06 Cream|Drug: Clobetasol Propionate Cream 0.05%,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 2,Industry,Interventional,5/8/2014,8/11/2016,https://ClinicalTrials.gov/show/NCT02131324
6776,Coronary Orbital Atherectomy System Study,Completed,Has Results,CAD,Device: Diamondback 360® Coronary OAS Micro Crown,Cardiovascular Systems Inc,Cardiovascular Systems Inc,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02132611
6777,Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis,Completed,Has Results,Hyperhidrosis,"Drug: Dose 1 of glycopyrrolate, 2.0% QD|Drug: Dose 2 of glycopyrrolate, 3.0% QD|Drug: Dose 1 of glycopyrronium, 2.5% QD|Drug: Dose 2 of glycopyrronium, 3.75% QD|Other: Vehicle","Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 2,Industry,Interventional,4/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02129660
6778,Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Low Metformin|Drug: Metformin|Drug: Mid Metformin|Drug: High Metformin,NuSirt Biopharma,NuSirt Biopharma,,,,,,,Phase 2,Industry,Interventional,7/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02151461
6779,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/4/2014,9/3/2015,https://ClinicalTrials.gov/show/NCT02128932
6780,Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: Sofosbuvir|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,6/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02128542
6781,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment,Completed,Has Results,Gout|Moderate Renal Impairment,Drug: Febuxostat IR|Drug: Febuxostat XR|Drug: Febuxostat placebo|Drug: Colchicine|Drug: Naproxen|Drug: Lansoprazole,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,5/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02128490
6782,Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Drug: Dalbavancin|Drug: Dalbavancin-matching Placebo,"Durata Therapeutics Inc., an affiliate of Allergan plc","Durata Therapeutics Inc., an affiliate of Allergan plc",,,,,,,Phase 3,Industry,Interventional,4/18/2014,3/11/2015,https://ClinicalTrials.gov/show/NCT02127970
6783,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Completed,Has Results,Asthma,Drug: Albuterol MDPI|Drug: Placebo|Drug: ProAir HFA inhaler,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,5/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02126839
6784,"A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector",Completed,Has Results,Systemic Lupus Erythematosus,Device: Belimumab autoinjector,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/20/2014,4/13/2015,https://ClinicalTrials.gov/show/NCT02124798
6785,Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.,Completed,Has Results,PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE,Biological: 13-valent pneumococcal conjugate vaccine|Biological: Seasonal Inactivated Influenza Vaccine|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,9/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02124161
6786,Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries,Completed,Has Results,Athletic Injuries,Drug: Diclofenac hydroxyethylpyrrolidine,IBSA Institut Biochimique SA,IBSA Institut Biochimique SA,,,,,,,Phase 4,Industry,Interventional,5/14/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02132247
6787,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Completed,Has Results,Chronic Idiopathic Constipation,Drug: Plecanatide|Drug: Placebo,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,4/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02122471
6788,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,Completed,Has Results,HIV-1 Infection,Drug: FTC/TDF|Drug: F/TAF|Drug: Allowed third antiretroviral agent|Drug: FTC/TDF Placebo|Drug: F/TAF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,5/6/2014,3/1/2019,https://ClinicalTrials.gov/show/NCT02121795
6789,Threshold Suspend in Pediatrics at Home,Completed,Has Results,Type 1 Diabetes,Device: 530G Insulin pump,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,6/14/2019,6/16/2017,https://ClinicalTrials.gov/show/NCT02120794
6790,Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204|Drug: Placebo,LEO Pharma,LEO Pharma,,,,,,,Phase 1|Phase 2,Industry,Interventional,5/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02120456
6791,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders,Completed,Has Results,Chronic HCV Infection,Drug: LDV/SOF|Drug: SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,4/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02120300
6792,"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine",Completed,Has Results,Healthy,Biological: HEPLISAV|Biological: Engerix-B,Dynavax Technologies Corporation,Dynavax Technologies Corporation,,,,,,,Phase 3,Industry,Interventional,4/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02117934
6793,Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access,Completed,Has Results,Implantable Defibrillator,Device: MRI scan sequences of the head and chest regions|Other: Waiting Period Visit,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,4/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02117414
6794,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF|Drug: VI|Drug: UMEC|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT02119286
6795,Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: FX006 32 mg|Drug: Placebo|Drug: FX006 16 mg,"Flexion Therapeutics, Inc.","Flexion Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,4/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02116972
6796,"A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",Completed,Has Results,Clostridium Difficile Associated Disease,Biological: Clostridium difficile vaccine|Biological: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,7/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02117570
6797,OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females,Completed,Has Results,"Depressive Disorder, Major",Biological: onabotulinumtoxinA|Drug: Normal Saline,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,4/22/2014,12/22/2016,https://ClinicalTrials.gov/show/NCT02116361
6798,Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Biological: ABP 501,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,4/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02114931
6799,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: Simeprevir|Drug: Sofosbuvir,Janssen Infectious Diseases BVBA,Janssen Infectious Diseases BVBA,,,,,,,Phase 3,Industry,Interventional,4/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02114177
6800,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: Simeprevir|Drug: Sofosbuvir,Janssen Infectious Diseases BVBA,Janssen Infectious Diseases BVBA,,,,,,,Phase 3,Industry,Interventional,4/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02114151
6801,"Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease",Completed,Has Results,Phase 1 Sickle Cell,Drug: PDE9i|Drug: placebo for PDE9i,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,12/14/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT02114203
6802,"Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection",Completed,Has Results,Respiratory Syncytial Virus Infection,Drug: Presatovir|Drug: Presatovir placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,6/9/2014,4/12/2017,https://ClinicalTrials.gov/show/NCT02135614
6803,A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1),Completed,Has Results,Chronic Kidney Disease,Drug: PRT-201|Drug: Placebo,Proteon Therapeutics,Proteon Therapeutics,,,,,,,Phase 3,Industry,Interventional,7/14/2019,12/18/2019,https://ClinicalTrials.gov/show/NCT02110901
6804,"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients",Completed,Has Results,Schizophrenia,Drug: RBP-7000|Drug: Placebo|Drug: Risperidone,Indivior Inc.,Indivior Inc.,,,,,,,Phase 3,Industry,Interventional,4/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02109562
6805,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Completed,Has Results,Urinary Tract Infection Complicated|Acute Pyelonephritis,Drug: Meropenem-Vaborbactam|Drug: Piperacillin-Tazobactam|Drug: Levofloxacin|Drug: Saline,"Melinta Therapeutics, Inc.|Department of Health and Human Services","Melinta Therapeutics, Inc.",Department of Health and Human Services,,,,,,Phase 3,Industry|U.S. Fed,Interventional,11/20/2014,4/28/2016,https://ClinicalTrials.gov/show/NCT02166476
6806,12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D),Completed,Has Results,Irritable Bowel Syndrome With Diarrhea,Drug: Ibodutant 10 mg|Drug: Placebo,Menarini Group,Menarini Group,,,,,,,Phase 3,Industry,Interventional,3/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02107196
6807,Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.,Completed,Has Results,Hyperkalemia,Drug: Sodium Zirconium Cyclosilicate,"ZS Pharma, Inc.","ZS Pharma, Inc.",,,,,,,Phase 3,Industry,Interventional,5/31/2014,8/31/2015,https://ClinicalTrials.gov/show/NCT02107092
6808,Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate/Vilanterol|Drug: Vilanterol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/7/2014,7/8/2015,https://ClinicalTrials.gov/show/NCT02105974
6809,Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Mepolizumab|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/24/2014,1/16/2017,https://ClinicalTrials.gov/show/NCT02105961
6810,Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Mepolizumab|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/15/2014,1/17/2017,https://ClinicalTrials.gov/show/NCT02105948
6811,Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma,Completed,Has Results,Asthma,Drug: BD MDI 320 µg|Drug: BD MDI 160 µg|Drug: BD MDI 80 µg|Drug: BD MDI 40 µg|Drug: Placebo MDI,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,4/1/2014,9/4/2015,https://ClinicalTrials.gov/show/NCT02105012
6812,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Completed,Has Results,Hemorrhage,Drug: idarucizumab,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,5/6/2014,10/20/2016,https://ClinicalTrials.gov/show/NCT02104947
6813,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Completed,Has Results,Ventricular Arrhythmia,Drug: Eleclazine|Drug: Placebo to match eleclazine,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,9/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02104583
6814,A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread,Completed,Has Results,Metastatic Breast Cancer,Drug: Abemaciclib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/10/2014,10/22/2018,https://ClinicalTrials.gov/show/NCT02102490
6815,Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,3/25/2014,6/26/2017,https://ClinicalTrials.gov/show/NCT02102204
6816,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615; RN316)|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/28/2014,7/10/2017,https://ClinicalTrials.gov/show/NCT02100514
6817,The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,5/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02098395
6818,Evaluation of Automatic Threshold Algorithms,Completed,Has Results,Heart Failure,Device: CRT-D,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,4/14/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02097290
6819,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,Completed,Has Results,Relapsing Forms of Multiple Sclerosis,Drug: dimethyl fumarate|Biological: tetanus diphtheria toxoids vaccine|Biological: 23-valent pneumococcal polysaccharide vaccine|Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Drug: non-pegylated interferon,Biogen,Biogen,,,,,,,Phase 2,Industry,Interventional,2/28/2015,5/2/2016,https://ClinicalTrials.gov/show/NCT02097849
6820,ProMRI Study of the Iforia ICD System (Phase C),Completed,Has Results,Implantable Cardioverter-Defibrillator With Magnetic Resonance Imaging,Device: Patients with a ProMRI ICD System|Other: Magnetic Resonance Imaging (MRI) scan,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,,Industry,Observational,6/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02096692
6821,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Completed,Has Results,Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Biological: Infanrix hexa|Biological: Pediarix|Biological: ActHIB|Biological: Pentacel|Biological: Engerix-B|Biological: Infanrix|Biological: Hiberix|Biological: Prevnar13|Biological: Rotarix,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/16/2014,11/13/2015,https://ClinicalTrials.gov/show/NCT02096263
6822,Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo,Completed,Has Results,Alzheimer Disease,Drug: BI 409306|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,1/15/2015,10/9/2017,https://ClinicalTrials.gov/show/NCT02240693
6823,Atrasentan Spermatogenesis and Testicular Function,Completed,Has Results,Nephropathy|Diabetes,Drug: Atrasentan,AbbVie,AbbVie,,,,,,,Phase 2,Industry,Interventional,4/6/2015,7/16/2018,https://ClinicalTrials.gov/show/NCT02118714
6824,"Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects",Completed,Has Results,Hereditary Angioedema,Drug: DX-2930|Drug: Placebo,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,4/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02093923
6825,The MiDAS ENCORE Study,Completed,Has Results,"Spinal Stenosis, Lumbar Region, With Neurogenic Claudication",Procedure: MILD Procedure|Drug: Epidural Steroid Injection,"Vertos Medical, Inc.","Vertos Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/14/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT02093520
6826,"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg",Completed,Has Results,Asthma,Drug: Symbicort pMDI|Other: Budesonide pMDI,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02091986
6827,A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LY2409021|Drug: Placebo|Drug: Metformin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,3/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02091362
6828,Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1),Completed,Has Results,Epilepsy|Dravet Syndrome,Drug: GWP42003-P 20 mg/kg/day Dose|Drug: Placebo control,GW Research Ltd,GW Research Ltd,,,,,,,Phase 3,Industry,Interventional,3/30/2015,11/26/2015,https://ClinicalTrials.gov/show/NCT02091375
6829,Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option,Completed,Has Results,Hepatitis C|Liver Disease,Drug: Alisporivir|Drug: Ribavirin,Debiopharm International SA,Debiopharm International SA,,,,,,,Phase 2,Industry,Interventional,3/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02094443
6830,A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes,Completed,Has Results,Diabetes Mellitus Type 2,Biological: BMS-986036|Biological: Placebo (Matching with BMS-986036),Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,4/15/2014,5/17/2016,https://ClinicalTrials.gov/show/NCT02097277
6831,Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.,Completed,Has Results,Hyperkalemia,Drug: Sodium zirconium cyclosilicate|Drug: Placebo,"ZS Pharma, Inc.","ZS Pharma, Inc.",,,,,,,Phase 3,Industry,Interventional,3/31/2014,1/31/2015,https://ClinicalTrials.gov/show/NCT02088073
6832,Study of Safety and Efficacy for the Eustachian Tube Balloon Catheter,Completed,Has Results,Eustachian Tube Dysfunction,Device: Acclarent Eustachian Tube Balloon Catheter (ETBC),Acclarent,Acclarent,,,,,,,Not Applicable,Industry,Interventional,2/1/2014,1/12/2017,https://ClinicalTrials.gov/show/NCT02087150
6833,Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic Dermatitis",Drug: Apremilast|Drug: Placebo,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,6/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02087943
6834,AXIOS Stent With Electrocautery Enhanced Delivery System,Completed,Has Results,Pancreatic Pseudocyst(s),Device: AXIOS Stent with Electrocautery Enhanced Delivery System,"Xlumena, Inc.","Xlumena, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02146352
6835,The Treatment of Glabellar Frown Lines,Completed,Has Results,Glabellar Frown Lines,Drug: IncobotulinumtoxinA|Drug: OnabotulinumtoxinA,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 4,Industry,Interventional,2/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02096081
6836,"A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer",Completed,Has Results,Prostate Cancer,Drug: Relugolix|Drug: Leuprorelin,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,3/26/2014,2/23/2017,https://ClinicalTrials.gov/show/NCT02083185
6837,"Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)",Completed,Has Results,Hypophosphatasia (HPP),,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,,Industry,Observational,3/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02104219
6838,A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.,Completed,Has Results,Peripheral Arterial Disease,Device: Stenting of the Common and/or External Iliac Arteries,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,7/14/2019,10/18/2019,https://ClinicalTrials.gov/show/NCT02080871
6839,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),Completed,Has Results,Alzheimer's Disease,Drug: T-817MA-H|Drug: T-817MA-L|Drug: Placebo,"FUJIFILM Toyama Chemical Co., Ltd.|Alzheimer's Disease Cooperative Study (ADCS)","FUJIFILM Toyama Chemical Co., Ltd.",Alzheimer's Disease Cooperative Study (ADCS),,,,,,Phase 2,Industry|Other,Interventional,3/14/2019,5/5/2017,https://ClinicalTrials.gov/show/NCT02079909
6840,Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Idalopirdine 60 mg,H. Lundbeck A/S,H. Lundbeck A/S,,,,,,,Phase 3,Industry,Interventional,4/7/2014,7/6/2017,https://ClinicalTrials.gov/show/NCT02079246
6841,Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/28/2014,8/8/2016,https://ClinicalTrials.gov/show/NCT02075255
6842,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Completed,Has Results,Chronic Plaque Type Psoriasis,Drug: AIN457 300 mg|Drug: ustekinumab 45/90 mg|Drug: placebo secukinumab,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,2/26/2014,6/29/2016,https://ClinicalTrials.gov/show/NCT02074982
6843,A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Completed,Has Results,Immune Thrombocytopenic Purpura,Drug: Fostamatinib disodium|Drug: Placebo,Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/14/2014,4/21/2016,https://ClinicalTrials.gov/show/NCT02076399
6844,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection,Completed,Has Results,Hepatitis C Virus|HIV,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,2/14/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT02073656
6845,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF),Completed,Has Results,Atrial Fibrillation,Drug: Edoxaban|Drug: Warfarin|Drug: Enoxaparin,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,3/25/2014,2/3/2016,https://ClinicalTrials.gov/show/NCT02072434
6846,Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults,Completed,Has Results,HIV|HBV,Drug: E/C/F/TAF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,2/25/2014,10/26/2016,https://ClinicalTrials.gov/show/NCT02071082
6847,"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion",Completed,Has Results,Cystic Fibrosis,Drug: VX-661|Drug: Ivacaftor|Drug: Placebo matched to VX-661|Drug: Placebo matched to Ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 2,Industry,Interventional,3/14/2019,5/27/2016,https://ClinicalTrials.gov/show/NCT02070744
6848,Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates,Completed,Has Results,Respiratory Distress Syndrome,Drug: Lucinactant for Inhalation|Device: nCPAP alone,"Windtree Therapeutics|National Heart, Lung, and Blood Institute (NHLBI)",Windtree Therapeutics,"National Heart, Lung, and Blood Institute (NHLBI)",,,,,,Phase 2,Industry|NIH,Interventional,2/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02074059
6849,DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: DFD01 Spray|Drug: Comp01 Lotion,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 2,Industry,Interventional,1/14/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT02070965
6850,In Clinic Evaluation of the PLGM Feature,Completed,Has Results,Type 1 Diabetes,Device: Predictive Low Glucose Management Feature in Insulin pump,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,10/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02130284
6851,"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer",Completed,Has Results,Advanced Breast Cancer,Drug: Dexamethasone based mouthwash|Drug: Everolimus|Drug: Exemestane,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/14/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02069093
6852,A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: TV-45070|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,4/14/2014,5/4/2015,https://ClinicalTrials.gov/show/NCT02068599
6853,"Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy",Completed,Has Results,Painful Diabetic Neuropathy|Diabetic Neuropathy|Neuropathy,Drug: Clonidine Gel 0.1%|Drug: Placebo,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 2,Industry,Interventional,3/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02068027
6854,A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis,Completed,Has Results,Osteoarthritis of the Knee,Drug: X0002|Drug: Placebo,Lina Xu|Techfields Pharma Co. Ltd,Lina Xu,Techfields Pharma Co. Ltd,,,,,,Phase 2,Industry,Interventional,2/14/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT02067611
6855,A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention,Completed,Has Results,Treatment for Prevention of Chronic Migraine,Biological: Erenumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,3/5/2014,4/28/2016,https://ClinicalTrials.gov/show/NCT02066415
6856,Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,Completed,Has Results,Advanced Solid Tumors|Relapsed/Refractory Lymphoma,Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,8/21/2014,7/18/2016,https://ClinicalTrials.gov/show/NCT02214147
6857,Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis,Completed,Has Results,Femoral Artery Stenosis|Femoral Artery Occlusion|Restenosis,Device: Lutonix DCB|Device: Standard Uncoated Balloon Angioplasty Catheter,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,3/14/2019,3/19/2019,https://ClinicalTrials.gov/show/NCT02063672
6858,Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly,Completed,Has Results,Cushing's Disease|Acromegaly,Drug: Pasireotide s.c.|Drug: Sitagliptin|Drug: Liraglutide|Drug: Insulin|Drug: Pasireotide LAR|Drug: Metformin,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,5/23/2014,3/26/2018,https://ClinicalTrials.gov/show/NCT02060383
6859,"A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,Type 2 Diabetes Mellitus,Biological: PF-06293620|Biological: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,9/15/2014,1/27/2017,https://ClinicalTrials.gov/show/NCT02211261
6860,Hospital Wearable Defibrillator Inpatient Study,Completed,Has Results,In-Hospital Cardiac Arrest,Device: HWD1000,Zoll Medical Corporation,Zoll Medical Corporation,,,,,,,Not Applicable,Industry,Interventional,4/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02122549
6861,A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ),Completed,Has Results,"ADHD|Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type",Drug: MG01CI (1400 mg)|Drug: placebo,Alcobra Ltd.,Alcobra Ltd.,,,,,,,Phase 2|Phase 3,Industry,Interventional,3/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02059642
6862,"Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia",Completed,Has Results,Preeclampsia,Biological: Recombinant human antithrombin (ATryn)|Other: Normal Saline 0.9%,rEVO Biologics,rEVO Biologics,,,,,,,Phase 3,Industry,Interventional,7/11/2014,11/16/2019,https://ClinicalTrials.gov/show/NCT02059135
6863,Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,Completed,Has Results,Metastatic Colorectal Cancer,Drug: Sym004 (12 mg/kg)|Drug: Sym004 (9/6 mg/kg)|Other: Best Supportive Care (BSC)|Drug: Fluorouracil (5-FU)|Drug: Capecitabine,Symphogen A/S,Symphogen A/S,,,,,,,Phase 2,Industry,Interventional,3/6/2014,4/26/2017,https://ClinicalTrials.gov/show/NCT02083653
6864,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)|Drug: Insulin glargine (HOE901)|Drug: Metformin (Background Drug),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,1/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02058160
6865,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Completed,Has Results,Type 2 Diabetes,Drug: Insulin glargine/lixisenatide Fixed Ratio Combination|Drug: Insulin glargine (HOE901)|Drug: Lixisenatide (AVE0010)|Drug: Metformin,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,2/14/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02058147
6866,Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure,Completed,Has Results,Open Angle Glaucoma|Ocular Hypertension,Drug: PG324 Ophthalmic Solution 0.01%|Drug: PG324 Ophthalmic Solution 0.02%|Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Drug: Latanoprost Ophthalmic Solution 0.005%,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/14/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT02057575
6867,Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome,Completed,Has Results,Alagille Syndrome,Drug: LUM001|Drug: Placebo,"Mirum Pharmaceuticals, Inc.|Childhood Liver Disease Research and Education Network","Mirum Pharmaceuticals, Inc.",Childhood Liver Disease Research and Education Network,,,,,,Phase 2,Industry|Other,Interventional,11/24/2014,11/16/2016,https://ClinicalTrials.gov/show/NCT02057692
6868,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,2/3/2014,5/8/2015,https://ClinicalTrials.gov/show/NCT02054897
6869,"BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab",Completed,Has Results,Psoriasis,Drug: BI 655066|Drug: Ustekinumab,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,2/14/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT02054481
6870,"Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster vaccine GSK 1437173A|Biological: Boostrix,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/7/2014,4/21/2016,https://ClinicalTrials.gov/show/NCT02052596
6871,Lurasidone Pediatric Bipolar Study,Completed,Has Results,Bipolar I Depression,Drug: Lurasidone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,3/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT02046369
6872,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Completed,Has Results,Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Drug: Solifenacin succinate|Drug: Mirabegron|Drug: Placebo to match solifenacin|Drug: Placebo to match mirabegron,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Astellas Pharma Europe B.V.,Astellas Pharma Inc,,,,,,Phase 3,Industry,Interventional,3/17/2014,9/8/2016,https://ClinicalTrials.gov/show/NCT02045862
6873,Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,"Infections, Bacterial",Drug: GSK2140944 Lyophile|Drug: GSK2140944 Capsules,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/24/2014,6/29/2015,https://ClinicalTrials.gov/show/NCT02045797
6874,A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation,Completed,Has Results,Smoking Cessation,Drug: APD356-lorcaserin hydrochloride|Drug: Placebo,Arena Pharmaceuticals,Arena Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/14/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02044874
6875,Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV),Completed,Has Results,Dengue Fever,Drug: TDV Liquid Formulation 1|Drug: TDV Liquid Formulation 2|Drug: TDV IDT Lyophilized|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,8/6/2014,5/19/2015,https://ClinicalTrials.gov/show/NCT02193087
6876,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Completed,Has Results,Persistent Asthma,Drug: Beclomethasone dipropionate breath-actuated inhaler|Drug: Placebo breath-actuated inhaler|Drug: albuterol/salbutamol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,12/26/2013,12/24/2014,https://ClinicalTrials.gov/show/NCT02040779
6877,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Completed,Has Results,Asthma,Drug: Beclomethasone dipropionate BAI|Drug: Placebo BAI|Drug: albuterol/salbutamol 90 mcg|Drug: Beclomethasone dipropionate MDI|Drug: Placebo MDI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,12/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT02040766
6878,A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Placebo|Biological: PF-06342674 Dose A|Biological: PF-06342674 Dose B|Biological: PF-06342674 Dose C|Biological: PF-06342674 Dose D,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,6/4/2014,9/13/2016,https://ClinicalTrials.gov/show/NCT02038764
6879,"A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement",Completed,Has Results,Neutropenia,Drug: tbo-filgrastim,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries","Teva Pharmaceutical Industries, Ltd.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,5/12/2015,4/4/2017,https://ClinicalTrials.gov/show/NCT02190721
6880,Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),Completed,Has Results,Small Cell Lung Cancer,Drug: Alisertib|Drug: Placebo|Drug: Paclitaxel,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,5/12/2014,7/10/2017,https://ClinicalTrials.gov/show/NCT02038647
6881,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,Completed,Has Results,Melanoma and Brain Metastases,Drug: Dabrafenib|Drug: Trametinib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,2/21/2014,2/14/2018,https://ClinicalTrials.gov/show/NCT02039947
6882,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),Completed,Has Results,Prostatic Neoplasms,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Abiraterone acetate|Drug: Prednisone|Drug: Enzalutamide",Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,3/7/2014,6/26/2018,https://ClinicalTrials.gov/show/NCT02034552
6883,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/5/2014,1/11/2016,https://ClinicalTrials.gov/show/NCT02034513
6884,Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors,Completed,Has Results,Primary Brain Tumor,Drug: Dotarem®|Drug: Gadovist®/Gadavist®,Guerbet,Guerbet,,,,,,,Phase 4,Industry,Interventional,6/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02034708
6885,Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV,Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Sofosbuvir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,1/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02032901
6886,A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.,Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Sofosbuvir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,2/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02032888
6887,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Completed,Has Results,Asthma,Drug: Beclomethasone dipropionate|Drug: Placebo|Drug: Albuterol/salbutamol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,12/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02031640
6888,A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Atezolizumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,1/22/2014,1/11/2019,https://ClinicalTrials.gov/show/NCT02031458
6889,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/6/2014,12/4/2015,https://ClinicalTrials.gov/show/NCT02030600
6890,A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1),Completed,Has Results,Epilepsy|Dravet Syndrome,Drug: GWP42003-P 5 mg/kg/day Dose|Drug: Placebo control|Drug: GWP42003-P 10 mg/kg/day Dose|Drug: GWP42003-P 20 mg/kg/day Dose,GW Research Ltd,GW Research Ltd,,,,,,,Phase 2,Industry,Interventional,10/22/2014,3/9/2015,https://ClinicalTrials.gov/show/NCT02091206
6891,Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139),Completed,Has Results,Lymphoma. Non-Hodgkin,Drug: Nivolumab,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,2/10/2014,5/2/2019,https://ClinicalTrials.gov/show/NCT02038933
6892,A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD,Completed,Has Results,COPD,Drug: Placebo|Drug: SUN101 3 mcg|Drug: SUN-101 6.25 mcg|Drug: SUN-101 12.5 mcg|Drug: SUN-101 50 mcg|Drug: Aclidinium,Sunovion Respiratory Development Inc.,Sunovion Respiratory Development Inc.,,,,,,,Phase 2,Industry,Interventional,1/14/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT02038829
6893,Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media,Completed,Has Results,Acute Otitis Media,Drug: Antipyrine and Benzocaine otic solution|Drug: Antipyrine Otic Solution|Drug: Benzocaine Otic Solution|Drug: Placebo Otic solution,Pernix Theraputics LLC,Pernix Theraputics LLC,,,,,,,Phase 2,Industry,Interventional,11/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02037893
6894,"SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",Completed,Has Results,Mild-Moderate Alzheimer's Disease|Healthy Elderly,Biological: MEDI1814 for IV injection|Biological: MEDI1814 for Subcutaneous Injection|Biological: IV Placebo|Biological: Placebo for Subcutaneous Injection,AstraZeneca,AstraZeneca,,,,,,,Phase 1,Industry,Interventional,2/4/2014,9/15/2016,https://ClinicalTrials.gov/show/NCT02036645
6895,Study of SPARC1103 in Subjects With Spasticity,Completed,Has Results,Spasticity,Drug: SPARC1103 low dose|Drug: SPARC1103 high dose|Drug: SPARC Placebo,Sun Pharma Advanced Research Company Limited,Sun Pharma Advanced Research Company Limited,,,,,,,Phase 2,Industry,Interventional,4/21/2014,4/28/2017,https://ClinicalTrials.gov/show/NCT02027025
6896,A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin,Completed,Has Results,"Diabetes Mellitus, Type 2","Drug: Canagliflozin, 100 mg|Drug: Canagliflozin, 300 mg|Drug: Placebo","Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 4,Industry,Interventional,2/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT02025907
6897,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,Completed,Has Results,Coronary Artery Bypass Grafting|Mitral Valve Surgery|Low Cardiac Output Syndrome,Drug: Levosimendan|Drug: Placebo,"Tenax Therapeutics, Inc.","Tenax Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,7/14/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT02025621
6898,"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)",Completed,Has Results,Hepatitis C,Drug: DCV/ASV/BMS-791325|Drug: Ribavirin|Drug: Sofosbuvir|Drug: Peginterferon α-2a,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,7/28/2014,12/17/2015,https://ClinicalTrials.gov/show/NCT02175966
6899,A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,2/14/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02085135
6900,Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa,Completed,Has Results,Atrial Fibrillation,,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,,Industry,Observational,1/14/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT02022020
6901,Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone,Completed,Has Results,Prostatic Neoplasms,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,3/10/2014,8/9/2018,https://ClinicalTrials.gov/show/NCT02023697
6902,Rebif® Rebidose® Versus Rebiject II® Ease-of-Use,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Device: Rebif Rebidose|Device: Rebiject II,EMD Serono,EMD Serono,,,,,,,Phase 4,Industry,Interventional,3/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT02019550
6903,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Completed,Has Results,Cardiovascular Disease|High Cardiovascular Risk|Obesity|Overweight|Type 2 Diabetes,Drug: Lorcaserin hydrochloride|Drug: Placebo,Eisai Inc.|Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization,Eisai Inc.,Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization,,,,,,Phase 4,Industry|Other,Interventional,1/24/2014,5/14/2018,https://ClinicalTrials.gov/show/NCT02019264
6904,A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis,Completed,Has Results,Hyperhidrosis,"Drug: glycopyrrolate, 1.0%|Drug: glycopyrrolate, 2.0%|Drug: glycopyrrolate, 3.0%|Drug: glycopyrrolate, 4.0%|Other: Vehicle","Dermira, Inc.","Dermira, Inc.",,,,,,,Phase 2,Industry,Interventional,11/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT02016885
6905,The Fibrin Pad CV Phase III Study,Completed,Has Results,Cardiovascular Disease,Biological: EVARREST™ Fibrin Sealant Patch|Biological: Topical hemostat,"Ethicon, Inc.","Ethicon, Inc.",,,,,,,Phase 3,Industry,Interventional,1/1/2014,9/1/2015,https://ClinicalTrials.gov/show/NCT02040428
6906,12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients,Completed,Has Results,Primary Fibromyalgia,Drug: TNX-102 SL,"Tonix Pharmaceuticals, Inc.","Tonix Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,12/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02015234
6907,Clinical Assessment of a HYDRAGLYDE® Regimen,Completed,Has Results,Refractive Errors|Myopia|Hypermetropia,Device: Lotrafilcon B contact lenses with added wetting agent|Device: Samfilcon A contact lenses|Device: POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Device: Hydrogen peroxide-based contact lens solution with added wetting agent|Device: Senofilcon C contact lenses|Device: Senofilcon A contact lenses|Device: Comfilcon A contact lenses|Device: Habitual Multi-Purpose Solution (HMPS),"Alcon, a Novartis Company|Alcon Research","Alcon, a Novartis Company",Alcon Research,,,,,,Not Applicable,Industry,Interventional,2/13/2017,8/18/2017,https://ClinicalTrials.gov/show/NCT03026257
6908,"Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia",Completed,Has Results,Acute Myeloid Leukemia,Drug: Gilteritinib|Drug: Voriconazole|Drug: Midazolam|Drug: Cephalexin,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","Astellas Pharma Global Development, Inc.",Astellas Pharma Inc,,,,,,Phase 1|Phase 2,Industry,Interventional,10/9/2013,3/7/2018,https://ClinicalTrials.gov/show/NCT02014558
6909,Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery,Completed,Has Results,Hemostasis,Biological: Human thrombin|Biological: Bovine thrombin,"Instituto Grifols, S.A.|Grifols Biologicals, LLC","Instituto Grifols, S.A.","Grifols Biologicals, LLC",,,,,,Phase 2,Industry,Interventional,12/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT02014402
6910,Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis,Completed,Has Results,Psoriasis Vulgaris,Drug: LEO 90100,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,3/16/2019,3/28/2018,https://ClinicalTrials.gov/show/NCT02387853
6911,Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause,Completed,Has Results,Vaginal Atrophy,Drug: Placebo|Drug: Prasterone (DHEA),EndoCeutics Inc.,EndoCeutics Inc.,,,,,,,Phase 3,Industry,Interventional,2/14/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT02013544
6912,Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort,Completed,Has Results,Chronic Venous Insufficiency,Device: Dual Action Pneumatic Compression Device|Device: Standard Compression Garments,Tactile Medical,Tactile Medical,,,,,,,Not Applicable,Industry,Interventional,11/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT02015221
6913,SUNBURST (Success Using Neuromodulation With BURST) Study,Completed,Has Results,Chronic Pain,Device: Tonic Stimulation|Device: Burst Stimulation,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,12/13/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02011893
6914,Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec,Completed,Has Results,Melanoma,Drug: Talimogene laherparepvec,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,4/7/2014,4/19/2018,https://ClinicalTrials.gov/show/NCT02014441
6915,ProMRI Study of the Entovis Pacemaker System (Phase B),Completed,Has Results,Magnetic Resonance Imaging (MRI); Cardiac Pacing,Device: Patients with a ProMRI Pacemaker System|Other: Magnetic Resonance Imaging (MRI) scan,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,,Industry,Observational,12/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT02009696
6916,EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX,Completed,Has Results,Malignant Esophageal Strictures,Device: EndoMAXX Endoluminal Valve Technology (EVT)|Device: EndoMAXX,"Merit Medical Systems, Inc.|Geisinger Clinic|Medical College of Wisconsin|Indiana University|University of Colorado, Denver|Mayo Clinic|Weill Medical College of Cornell University|University of Florida","Merit Medical Systems, Inc.",Geisinger Clinic,"Medical College of Wisconsin|Indiana University|University of Colorado, Denver|Mayo Clinic|Weill Medical College of Cornell University|University of Florida",Medical College of Wisconsin,"Indiana University|University of Colorado, Denver|Mayo Clinic|Weill Medical College of Cornell University|University of Florida",Indiana University,"University of Colorado, Denver|Mayo Clinic|Weill Medical College of Cornell University|University of Florida",Not Applicable,Industry|Other,Interventional,1/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT02159898
6917,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),Completed,Has Results,Hypertriglyceridemia,Drug: Epanova|Drug: Olive Oil,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,12/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02009865
6918,Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Drug: Lisdexamfetamine dimesylate|Other: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,1/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02009163
6919,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Atezolizumab|Drug: Docetaxel,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,3/11/2014,1/9/2019,https://ClinicalTrials.gov/show/NCT02008227
6920,"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients",Completed,Has Results,"Spondylitis, Ankylosing",Drug: Secukinumab|Drug: Placebo secukinumab,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,1/14/2014,12/11/2017,https://ClinicalTrials.gov/show/NCT02008916
6921,Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: olodaterol|Drug: tiotropium|Drug: placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT02006732
6922,Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder,Completed,Has Results,Adhesive Capsulitis|Frozen Shoulder,Biological: Collagenase Clostridium Histolyticum|Other: Placebo,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT02006719
6923,Micra Transcatheter Pacing Study,Completed,Has Results,Class I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National Guidelines,Device: Micra Pacemaker Implant,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,11/13/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT02004873
6924,Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,Completed,Has Results,"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer",Biological: GVAX Pancreas Vaccine|Biological: CRS-207|Drug: Chemotherapy|Drug: cyclophosphamide,"Aduro Biotech, Inc.|Johns Hopkins University","Aduro Biotech, Inc.",Johns Hopkins University,,,,,,Phase 2,Industry|Other,Interventional,2/5/2014,8/23/2016,https://ClinicalTrials.gov/show/NCT02004262
6925,Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data,Completed,Has Results,Diabetes,Device: Medtronic MiniMed 530G Insulin Pump,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,11/26/2013,2/20/2018,https://ClinicalTrials.gov/show/NCT02003898
6926,Telotristat Etiprate for Carcinoid Syndrome Therapy,Completed,Has Results,Carcinoid Syndrome,Drug: Telotristat etiprate|Drug: Placebo,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/11/2014,3/29/2016,https://ClinicalTrials.gov/show/NCT02063659
6927,Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU,Completed,Has Results,Epilepsy,Drug: USL261|Drug: Placebo,"Proximagen, LLC","Proximagen, LLC",,,,,,,Phase 3,Industry,Interventional,11/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01999777
6928,A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression,Completed,Has Results,Treatment Resistant Depressive Disorder,Drug: Esketamine 14 mg|Drug: Esketamine 28 mg|Drug: Esketamine 56 mg|Drug: Esketamine 84 mg|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,1/27/2014,9/25/2015,https://ClinicalTrials.gov/show/NCT01998958
6929,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Completed,Has Results,Metastatic gpNMB Over-expressing Triple Negative Breast Cancer,Drug: CDX-011|Drug: Capecitabine,Celldex Therapeutics,Celldex Therapeutics,,,,,,,Phase 2,Industry,Interventional,11/13/2019,8/7/2018,https://ClinicalTrials.gov/show/NCT01997333
6930,Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study),Completed,Has Results,Refractory Generalized Myasthenia Gravis,Biological: Eculizumab|Drug: Placebo,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01997229
6931,Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy,Completed,Has Results,Transthyretin (TTR) Amyloid Cardiomyopathy,Drug: Tafamidis|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/9/2013,2/7/2018,https://ClinicalTrials.gov/show/NCT01994889
6932,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],Completed,Has Results,Acute Ischaemic Stroke|Transient Ischaemic Attack,Drug: ticagrelor|Drug: Acetylsalicylic acid (ASA),AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,1/7/2014,3/2/2016,https://ClinicalTrials.gov/show/NCT01994720
6933,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Shionogi|Shionogi Inc.,Shionogi,Shionogi Inc.,,,,,,Phase 3,Industry,Interventional,11/4/2013,6/9/2015,https://ClinicalTrials.gov/show/NCT01993940
6934,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Completed,Has Results,Influenza,Biological: QIVc|Biological: TIV1c|Biological: TIV2c,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,11/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01992107
6935,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Completed,Has Results,Influenza,Biological: QIVc|Biological: TIV1c|Biological: TIV2c,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,11/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01992094
6936,A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2|Albuminuria","Drug: Placebo|Drug: Canagliflozin, 100 mg|Drug: Canagliflozin, 300 mg","Janssen Research & Development, LLC|The George Institute for Global Health, Australia","Janssen Research & Development, LLC","The George Institute for Global Health, Australia",,,,,,Phase 4,Industry|Other,Interventional,1/16/2014,2/23/2017,https://ClinicalTrials.gov/show/NCT01989754
6937,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,Completed,Has Results,Clostridium Difficile Infection,Drug: Cadazolid|Drug: Vancomycin|Drug: Cadazolid-matching placebo|Drug: Vancomycin-matching placebo,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,3/27/2014,3/24/2017,https://ClinicalTrials.gov/show/NCT01987895
6938,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Biological: Secukinumab|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/10/2014,3/28/2018,https://ClinicalTrials.gov/show/NCT01989468
6939,Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study,Completed,Has Results,HCV Infection,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,7/14/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01987453
6940,CEP249 Pediatric Accuracy Study,Completed,Has Results,Insulin Requiring Diabetes,Device: Enlite sensors,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,3/15/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01991470
6941,Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections,Drug: delafloxacin|Drug: vancomycin|Drug: aztreonam,"Melinta Therapeutics, Inc.","Melinta Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,5/14/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01984684
6942,An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD,Completed,Has Results,Multiple Myeloma,Drug: Daratumumab 16 mg/kg (Part 1)|Drug: Daratumumab 8 mg/kg (Part 1)|Drug: Methylprednisolone|Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Daratumumab (Part 2),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,9/27/2013,5/30/2017,https://ClinicalTrials.gov/show/NCT01985126
6943,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Completed,Has Results,Hyperlipidemia,Drug: Atorvastatin|Drug: Placebo to Atorvastatin|Other: Placebo to Ezetimibe|Drug: Ezetimibe|Other: Placebo to Evolocumab|Drug: Evolocumab,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,12/10/2013,11/21/2017,https://ClinicalTrials.gov/show/NCT01984424
6944,A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma,Completed,Has Results,Renal Cell Carcinoma,"Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Drug: Bevacizumab|Drug: Sunitinib",Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,1/31/2014,1/9/2019,https://ClinicalTrials.gov/show/NCT01984242
6945,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,Completed,Has Results,Clostridium Difficile Infection,Drug: Cadazolid|Drug: Vancomycin|Drug: Cadazolid-matching placebo|Drug: Vancomycin-matching placebo,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,12/12/2013,5/2/2017,https://ClinicalTrials.gov/show/NCT01983683
6946,"Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer",Completed,Has Results,Extensive-Stage Small-Cell Lung Cancer,Drug: Carfilzomib|Drug: Carboplatin|Drug: Etoposide,Amgen,Amgen,,,,,,,Phase 1|Phase 2,Industry,Interventional,11/5/2013,5/4/2017,https://ClinicalTrials.gov/show/NCT01987232
6947,CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients,Completed,Has Results,Non-left Bundle Branch Block|Ischemic or Non-ischemic Cardiomyopathy,Device: QLV based implant strategy|Device: Standard of care implant strategy,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,11/13/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT01983293
6948,12-Week Study of Plecanatide for CIC (The CIC3 Study),Completed,Has Results,Chronic Idiopathic Constipation,Drug: Plecanatide|Drug: Placebo|Drug: Bisacodyl,Synergy Pharmaceuticals Inc.,Synergy Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,11/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01982240
6949,The EVARREST® Fibrin Sealant Patch Liver Study,Completed,Has Results,Hemorrhage,Biological: EVARREST® Fibrin Sealant Patch|Other: Standard of Care (SoC),"Ethicon, Inc.","Ethicon, Inc.",,,,,,,Phase 3,Industry,Interventional,10/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01993888
6950,"Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab",Completed,Has Results,Rheumatoid Arthritis,Other: no intervention,Pfizer,Pfizer,,,,,,,,Industry,Observational,1/14/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01981473
6951,A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer,Completed,Has Results,Metastatic Prostate Cancer,Biological: sipuleucel-T|Drug: enzalutamide,Dendreon,Dendreon,,,,,,,Phase 2,Industry,Interventional,9/13/2019,6/30/2017,https://ClinicalTrials.gov/show/NCT01981122
6952,Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-fit Into Senofilcon A Contact Lenses,Completed,Has Results,Lapsed Contact Lens Wear,Device: senofilcon A|Device: senofilcon A for Astigmatism,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01990664
6953,Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma,Completed,Has Results,Follicular Lymphoma|B-cell Lymphoma|Non-Hodgkin's Lymphoma,Drug: Ibrutinib|Drug: rituximab,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 2,Industry,Interventional,12/13/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT01980654
6954,"A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy",Completed,Has Results,Edematous Fibrosclerotic Panniculopathy (EFP),Biological: Collagenase Clostridium Histolyticum|Biological: Placebo,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01987986
6955,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Completed,Has Results,Neisseria Meningitidis|Haemophilus Influenzae Type b,Biological: Hib-MenCY-TT (MenHibrix®)|Biological: Pediarix®|Biological: Rotarix®|Biological: Prevnar 13®|Biological: PedvaxHIB®|Biological: Havrix®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/1/2014,3/18/2016,https://ClinicalTrials.gov/show/NCT01978093
6956,ERADICATE Hp - Treating Helicobacter Pylori With RHB-105,Completed,Has Results,Dyspepsia|Helicobacter Pylori Infection,Drug: RHB-105|Drug: Placebo,RedHill Biopharma Limited,RedHill Biopharma Limited,,,,,,,Phase 3,Industry,Interventional,11/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01980095
6957,A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD),Completed,Has Results,Anaemia,Drug: GSK1278863|Drug: rhEPO,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/31/2013,6/15/2015,https://ClinicalTrials.gov/show/NCT01977573
6958,"Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia",Completed,Has Results,Anaemia,Drug: GSK1278863|Drug: Placebo|Drug: rhEPO,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/1/2013,2/6/2015,https://ClinicalTrials.gov/show/NCT01977482
6959,AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN,Completed,Has Results,Contrast Induced Nephropathy (CIN),Device: AVERT,"Osprey Medical, Inc","Osprey Medical, Inc",,,,,,,Not Applicable,Industry,Interventional,12/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01976299
6960,Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure,Completed,Has Results,Thrombocytopenia Associated With Liver Disease,Drug: avatrombopag (lower baseline platelet count)|Drug: placebo (lower baseline platelet count)|Drug: avatrombopag (higher baseline platelet count)|Drug: placebo (higher baseline platelet count),Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,11/13/2019,2/21/2017,https://ClinicalTrials.gov/show/NCT01976104
6961,Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Matching Placebo|Drug: Nintedanib,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/26/2013,10/27/2016,https://ClinicalTrials.gov/show/NCT01979952
6962,"An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects",Completed,Has Results,Psoriasis Vulgaris,Drug: LEO 80185 gel,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,1/14/2019,2/13/2018,https://ClinicalTrials.gov/show/NCT02038569
6963,The SENTRY Clinical Study,Completed,Has Results,Pulmonary Embolism|Deep Vein Thrombosis,Device: SENTRY IVC Filter,Novate Medical,Novate Medical,,,,,,,Not Applicable,Industry,Interventional,9/14/2019,12/18/2019,https://ClinicalTrials.gov/show/NCT01975090
6964,Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age,Completed,Has Results,Influenza,Biological: FluLaval® Quadrivalent|Biological: Fluzone®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/23/2013,7/3/2014,https://ClinicalTrials.gov/show/NCT01974895
6965,Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine,Completed,Has Results,Acute Migraine,Drug: Acetaminophen 250 mg and Aspirin 250 mg|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,10/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01973205
6966,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Completed,Has Results,Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Drug: Solifenacin succinate|Drug: Mirabegron|Drug: Placebo to match solifenacin succinate|Drug: Placebo to match mirabegron,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Astellas Pharma Europe B.V.,Astellas Pharma Inc,,,,,,Phase 3,Industry,Interventional,11/5/2013,10/22/2015,https://ClinicalTrials.gov/show/NCT01972841
6967,Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus,Completed,Has Results,"Lupus Erythematosus, Systemic",Drug: Atacicept 75 milligram (mg)|Drug: Atacicept 150 mg|Drug: Placebo,EMD Serono,EMD Serono,,,,,,,Phase 2,Industry,Interventional,12/13/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01972568
6968,Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure,Completed,Has Results,Thrombocytopenia Associated With Liver Disease,Drug: avatrombopag (lower baseline platelet count)|Drug: placebo (lower baseline platelet count)|Drug: avatrombopag (higher baseline platelet count)|Drug: placebo (higher baseline platelet count),Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,2/14/2019,2/27/2017,https://ClinicalTrials.gov/show/NCT01972529
6969,"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: GFF MDI (PT 003)|Drug: GP MDI (PT001)|Drug: FF MDI (PT005)|Drug: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®),"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,11/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01970878
6970,Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia,Completed,Has Results,"Pneumonia, Bacterial",Drug: Amikacin fosfomycin inhalation solution|Drug: Aerosolized placebo,Cardeas Pharma,Cardeas Pharma,,,,,,,Phase 2,Industry,Interventional,12/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01969799
6971,A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia,Completed,Has Results,Heterozygous Familial Hypercholesterolemia,Drug: Bococizumab (PF-04950615;RN316)|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/23/2013,4/15/2016,https://ClinicalTrials.gov/show/NCT01968980
6972,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615; RN316)|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/29/2013,7/10/2017,https://ClinicalTrials.gov/show/NCT01968967
6973,Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615;RN316)|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01968954
6974,Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults,Completed,Has Results,HIV-1|HIV Infections|Acquired Immunodeficiency Syndrome,Drug: E/C/F/TAF|Drug: DRV|Drug: Baseline DRV- containing ARV regimen,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,9/3/2013,7/9/2016,https://ClinicalTrials.gov/show/NCT01968551
6975,A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis,Completed,Has Results,Psoriasis,Drug: DFD01 Spray|Drug: Vehicle Spray,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 3,Industry,Interventional,11/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01967069
6976,Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains,Completed,Has Results,Clostridium Difficile Infection,Device: Comparison between GenePOC PCR and Reference Method,GenePOC,GenePOC,,,,,,,Not Applicable,Industry,Interventional,2/6/2017,8/10/2017,https://ClinicalTrials.gov/show/NCT02968758
6977,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,Completed,Has Results,COPD|Chronic Obstructive Pulmonary Disease|Moderate to Very Severe COPD,Drug: Aclidinium Bromide|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,10/16/2013,9/21/2017,https://ClinicalTrials.gov/show/NCT01966107
6978,Long Term Safety of Naldemedine,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Shionogi|Shionogi Inc.,Shionogi,Shionogi Inc.,,,,,,Phase 3,Industry,Interventional,9/24/2013,1/12/2016,https://ClinicalTrials.gov/show/NCT01965652
6979,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Shionogi|Shionogi Inc.,Shionogi,Shionogi Inc.,,,,,,Phase 3,Industry,Interventional,8/29/2013,1/22/2015,https://ClinicalTrials.gov/show/NCT01965158
6980,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium|Drug: placebo|Drug: olodaterol,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01964352
6981,Actual Use Trial of Atorvastatin Calcium 10 mg,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin calcium 10 mg,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01964326
6982,Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure,Completed,Has Results,Chronic Heart Failure,Drug: RLX030 (serelaxin)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/14/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01982292
6983,A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis,Completed,Has Results,Churg-Strauss Syndrome,Biological: Mepolizumab|Drug: Placebo,GlaxoSmithKline|National Institute of Allergy and Infectious Diseases (NIAID),GlaxoSmithKline,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,Phase 3,Industry|NIH,Interventional,2/5/2014,9/5/2016,https://ClinicalTrials.gov/show/NCT02020889
6984,SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection,Completed,Has Results,Hepatitis C,Drug: SOF|Drug: RBV|Drug: Peg-IFN,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,9/24/2013,7/7/2016,https://ClinicalTrials.gov/show/NCT01962441
6985,"A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects",Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,8/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01980589
6986,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,10/29/2013,10/16/2016,https://ClinicalTrials.gov/show/NCT01959529
6987,Progel Vascular Sealant,Completed,Has Results,Aortic Valve Stenosis|Aneurysm of Ascending Aorta|Aortic Valve Disorder|Bicuspid Valve Disorder,Device: Progel Vascular Sealant|Device: Gelfoam Plus,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,11/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01959503
6988,"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",Completed,Has Results,"TTR-mediated Amyloidosis|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Familial Amyloid Polyneuropathies|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related",Drug: patisiran (ALN-TTR02)|Drug: Sterile Normal Saline (0.9% NaCl),Alnylam Pharmaceuticals,Alnylam Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/13/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT01960348
6989,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: APF530|Drug: Ondansetron|Drug: Ondansetron placebo|Drug: APF530 placebo|Drug: Fosaprepitant|Drug: Dexamethasone,Heron Therapeutics,Heron Therapeutics,,,,,,,Phase 3,Industry,Interventional,3/14/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT02106494
6990,"Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma",Completed,Has Results,Asthma,Drug: Indacaterol 27.5 mcg|Drug: Indacaterol 37.5|Drug: Indacaterol 55 mcg|Drug: Indacaterol 75 mcg|Drug: Indacaterol 150 mcg|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,11/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01959412
6991,Optimal Management of Vasa Previa Study - A Retrospective Study,Completed,Has Results,Vasa Previa,,"Obstetrix Medical Group|Mednax Center for Research, Education, Quality and Safety",Obstetrix Medical Group,"Mednax Center for Research, Education, Quality and Safety",,,,,,,Industry,Observational,1/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01977040
6992,Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate/Vilanterol|Drug: Vilanterol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,1/28/2014,3/26/2018,https://ClinicalTrials.gov/show/NCT01957150
6993,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF|Drug: VI|Drug: UMEC|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/1/2013,4/1/2014,https://ClinicalTrials.gov/show/NCT01957163
6994,Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke,Completed,Has Results,Acute Ischemic Stroke,Drug: natalizumab|Drug: Placebo,Biogen,Biogen,,,,,,,Phase 2,Industry,Interventional,1/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01955707
6995,Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating,Completed,Has Results,Degenerative Disc Disease,Device: ROIC interbody cage with VerteBRIDGE plating,LDR Spine USA,LDR Spine USA,,,,,,,,Industry,Observational,9/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT02104167
6996,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/20/2013,11/4/2014,https://ClinicalTrials.gov/show/NCT01952145
6997,"A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome",Completed,Has Results,Short Bowel Syndrome,Drug: teduglutide,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/14/2013,1/9/2015,https://ClinicalTrials.gov/show/NCT01952080
6998,"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,4/14/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT02100475
6999,Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Denosumab|Drug: Zoledronic acid|Drug: Placebo to Denosumab|Drug: Standard Chemotherapy|Drug: Placebo to Zoledronic Acid,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,12/31/2013,11/28/2017,https://ClinicalTrials.gov/show/NCT01951586
7000,Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM),Completed,Has Results,End Stage Renal Disease (ESRD)|Chronic Kidney Disease (CKD)|Hemodialysis|Renal Replacement Therapy|Renal Transplantation,Biological: Induction therapy|Drug: Corticosteroids|Drug: EVR+rCNI|Drug: MPA+sCNI,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,12/3/2013,1/17/2018,https://ClinicalTrials.gov/show/NCT01950819
7001,"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis",Completed,Has Results,Psoriasis,Drug: DFD01 Spray|Drug: Comp01 Lotion|Drug: Vehicle Lotion|Drug: Vehicle Spray,"Promius Pharma, LLC","Promius Pharma, LLC",,,,,,,Phase 3,Industry,Interventional,11/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01947491
7002,"A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)",Completed,Has Results,"Glomerulosclerosis, Focal Segmental",Drug: Losmapimod,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/1/2014,5/11/2016,https://ClinicalTrials.gov/show/NCT02000440
7003,Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia,Completed,Has Results,Relapsed/Refractory Philadelphia Positive B-precursor ALL,Drug: Blinatumomab,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,1/3/2014,1/6/2017,https://ClinicalTrials.gov/show/NCT02000427
7004,OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder,Completed,Has Results,Overactive Bladder,Biological: onabotulinumtoxinA|Drug: Normal saline,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,10/28/2013,1/5/2017,https://ClinicalTrials.gov/show/NCT01945489
7005,5% Topical Ibuprofen (IBU) for Ankle Sprain,Completed,Has Results,Ankle Injuries,Drug: Topical IBU twice daily|Drug: Placebo twice daily|Drug: Topical IBU three times daily|Drug: Placebo three times daily,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01945034
7006,Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens,Completed,Has Results,Uterine Cervical Neoplasms,Device: BD Onclarity™ HPV assay on BD Viper™ LT|Procedure: Colposcopy,"Becton, Dickinson and Company","Becton, Dickinson and Company",,,,,,,Not Applicable,Industry,Interventional,8/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01944722
7007,Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,12/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01946412
7008,A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms,Completed,Has Results,Menopause,Drug: Estradiol|Drug: Progesterone|Drug: Placebo,TherapeuticsMD,TherapeuticsMD,,,,,,,Phase 3,Industry,Interventional,8/5/2013,10/28/2016,https://ClinicalTrials.gov/show/NCT01942668
7009,Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy,Completed,Has Results,Major Depressive Disorder|Irritability,Drug: Brexpiprazole,H. Lundbeck A/S,H. Lundbeck A/S,,,,,,,Phase 3,Industry,Interventional,10/13/2019,,https://ClinicalTrials.gov/show/NCT01942785
7010,Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects,Completed,Has Results,Known Crohn Disease Subjects,Device: Capsule endoscopy and Ileocolonoscopy tests,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,8/13/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01942720
7011,"Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents",Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: Canagliflozin|Drug: Placebo,"Janssen Scientific Affairs, LLC","Janssen Scientific Affairs, LLC",,,,,,,Phase 4,Industry,Interventional,10/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01939496
7012,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),Completed,Has Results,Relapsing Multiple Sclerosis,Drug: BIIB017|Drug: naproxen,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,11/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01939002
7013,Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant,Completed,Has Results,Chronic HCV Infection,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,9/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01938430
7014,"Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)",Completed,Has Results,Meningococcal Disease,Biological: MenABCWY+OMV|Biological: MenABCWY+¼OMV|Biological: Placebo,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 2,Industry,Interventional,12/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01992536
7015,Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS),Completed,Has Results,Systemic Sclerosis,Drug: Pirfenidone,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,10/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01933334
7016,A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211],Completed,Has Results,Bladder Cancer,"Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Drug: Docetaxel|Drug: Paclitaxel|Drug: Vinflunine",Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,1/13/2015,11/8/2018,https://ClinicalTrials.gov/show/NCT02302807
7017,Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,8/12/2013,2/14/2017,https://ClinicalTrials.gov/show/NCT01932970
7018,Real World Expanded Multicenter Study of the MitraClip® System (REALISM),Completed,Has Results,Mitral Valve Insufficiency|Mitral Valve Regurgitation|Mitral Valve Incompetence|Mitral Regurgitation|Mitral Insufficiency,Device: MitraClip® implant,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,1/22/2009,6/18/2019,https://ClinicalTrials.gov/show/NCT01931956
7019,A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases,Completed,Has Results,Nonalcoholic Steatohepatitis|Non-alcoholic Fatty Liver Disease,Drug: IDN-6556|Other: Placebo,Conatus Pharmaceuticals Inc.,Conatus Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,3/14/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT02077374
7020,Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta,Completed,Has Results,Osteogenesis Imperfecta,Drug: Teriparatide (FORTEO)|Drug: Placebos,Oregon Health and Science University|Eli Lilly and Company|Osteogenesis Imperfecta Foundation|National Institutes of Health (NIH)|National Center for Research Resources (NCRR),Oregon Health and Science University,Eli Lilly and Company,Osteogenesis Imperfecta Foundation|National Institutes of Health (NIH)|National Center for Research Resources (NCRR),Osteogenesis Imperfecta Foundation,National Institutes of Health (NIH)|National Center for Research Resources (NCRR),National Institutes of Health (NIH),National Center for Research Resources (NCRR),Phase 4,Other|Industry|NIH,Interventional,6/5/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00131469
7021,A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis,Completed,Has Results,"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,10/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01931839
7022,Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE),Completed,Has Results,Coronary Artery Disease,Device: Percutaneous Coronary Intervention,Cardiovascular Systems Inc,Cardiovascular Systems Inc,,,,,,,,Industry,Observational,9/26/2013,6/1/2017,https://ClinicalTrials.gov/show/NCT01930214
7023,Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/19/2013,4/5/2016,https://ClinicalTrials.gov/show/NCT01928771
7024,"Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis",Completed,Has Results,Vulvovaginal Candidiasis,Biological: NDV-3A|Biological: NDV-3|Biological: Placebo,"NovaDigm Therapeutics, Inc.","NovaDigm Therapeutics, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,7/13/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01926028
7025,Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 30 mg|Drug: Placebo,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,9/4/2013,11/17/2016,https://ClinicalTrials.gov/show/NCT01925768
7026,Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea,Completed,Has Results,Recurrent Clostridium Difficile Infection,Biological: RBX2660 (microbiota suspension),Rebiotix Inc.,Rebiotix Inc.,,,,,,,Phase 2,Industry,Interventional,8/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01925417
7027,"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",Completed,Has Results,Sporadic Inclusion Body Myositis,Drug: BYM338/bimagrumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2|Phase 3,Industry,Interventional,9/26/2013,1/6/2016,https://ClinicalTrials.gov/show/NCT01925209
7028,"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",Completed,Has Results,Breast Cancer,Drug: alpelisib|Drug: buparlisib|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,3/11/2014,7/8/2017,https://ClinicalTrials.gov/show/NCT01923168
7029,"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",Completed,Has Results,Low Back Pain,Drug: Hydrocodone ER|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,7/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01922739
7030,Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients,Completed,Has Results,Heart Failure With Reduced Ejection Fraction,Drug: LCZ696,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,11/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01922089
7031,A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair),Completed,Has Results,Asthma,Drug: Omalizumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,6/19/2013,3/31/2016,https://ClinicalTrials.gov/show/NCT01922037
7032,Evaluation of Etafilcon A Daily Disposable Lenses,Completed,Has Results,Myopia,Device: etafilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/14/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT02061592
7033,"A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis",Completed,Has Results,Actinic Keratosis,Drug: LEO 43204 Formulation 1|Drug: LEO 43204 Formulation 2|Drug: LEO 43204 Formulation 1 Dose X|Drug: LEO 43204 Formulation 1 Dose Y|Drug: LEO 43204 Formulation 2 Dose XX|Drug: LEO 43204 Formulation 2 Dose YY|Drug: Placebo Formulation 1|Drug: Placebo Formulation 2,LEO Pharma,LEO Pharma,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01922050
7034,Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures,Completed,Has Results,Epilepsy,Drug: Lacosamide|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,8/29/2013,1/24/2017,https://ClinicalTrials.gov/show/NCT01921205
7035,Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair,Completed,Has Results,Surgical Procedures,Drug: GSK1278863|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/31/2013,10/8/2014,https://ClinicalTrials.gov/show/NCT01920594
7036,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Completed,Has Results,Chronic Idiopathic Constipation,Drug: Plecanatide,"Bausch Health Americas, Inc.|Syneos Health","Bausch Health Americas, Inc.",Syneos Health,,,,,,Phase 3,Industry|Other,Interventional,8/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01919697
7037,A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis,Completed,Has Results,"Rhinitis, Allergic, Perennial and Seasonal",Drug: FPNS|Drug: FPNS Placebo|Drug: Cetirizine|Drug: Cetirizine Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,8/1/2013,10/17/2013,https://ClinicalTrials.gov/show/NCT01916226
7038,Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis,Drug: azelastine hydrochloride and fluticasone propionate|Drug: Dymista vehicle,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/13/2019,,https://ClinicalTrials.gov/show/NCT01915823
7039,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,8/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01914757
7040,Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS),Completed,Has Results,Congenital Sucrase-isomaltase Deficiency (CSID),,"QOL Medical, LLC|Arnold Palmer Hospital for Children|Texas Children's Hospital|Nationwide Children's Hospital|Ann & Robert H Lurie Children's Hospital of Chicago|University of Mississippi Medical Center|Children's Hospital and Research Center at Oakland|Columbia University|Children's Hospital Los Angeles|Children's Hospital and Health System Foundation, Wisconsin|Children's Center for Digestive Healthcare, LLC|Massachusetts General Hospital|Duke University|Johns Hopkins University|Children's Hospital of Philadelphia|Children's Mercy Hospital Kansas City|Children's Hospital Colorado|Riley Children's Hospital|Primary Children's Hospital|State University of New York - Downstate Medical Center","QOL Medical, LLC",Arnold Palmer Hospital for Children,"Texas Children's Hospital|Nationwide Children's Hospital|Ann & Robert H Lurie Children's Hospital of Chicago|University of Mississippi Medical Center|Children's Hospital and Research Center at Oakland|Columbia University|Children's Hospital Los Angeles|Children's Hospital and Health System Foundation, Wisconsin|Children's Center for Digestive Healthcare, LLC|Massachusetts General Hospital|Duke University|Johns Hopkins University|Children's Hospital of Philadelphia|Children's Mercy Hospital Kansas City|Children's Hospital Colorado|Riley Children's Hospital|Primary Children's Hospital|State University of New York - Downstate Medical Center",Texas Children's Hospital,"Nationwide Children's Hospital|Ann & Robert H Lurie Children's Hospital of Chicago|University of Mississippi Medical Center|Children's Hospital and Research Center at Oakland|Columbia University|Children's Hospital Los Angeles|Children's Hospital and Health System Foundation, Wisconsin|Children's Center for Digestive Healthcare, LLC|Massachusetts General Hospital|Duke University|Johns Hopkins University|Children's Hospital of Philadelphia|Children's Mercy Hospital Kansas City|Children's Hospital Colorado|Riley Children's Hospital|Primary Children's Hospital|State University of New York - Downstate Medical Center",Nationwide Children's Hospital,"Ann & Robert H Lurie Children's Hospital of Chicago|University of Mississippi Medical Center|Children's Hospital and Research Center at Oakland|Columbia University|Children's Hospital Los Angeles|Children's Hospital and Health System Foundation, Wisconsin|Children's Center for Digestive Healthcare, LLC|Massachusetts General Hospital|Duke University|Johns Hopkins University|Children's Hospital of Philadelphia|Children's Mercy Hospital Kansas City|Children's Hospital Colorado|Riley Children's Hospital|Primary Children's Hospital|State University of New York - Downstate Medical Center",,Industry|Other,Observational,5/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01914003
7041,Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate),Completed,Has Results,Benign Prostatic Hyperplasia|Lower Urinary Tract Symptom,Device: Rezum System|Procedure: Rigid Cystoscopy,NxThera Inc,NxThera Inc,,,,,,,Not Applicable,Industry,Interventional,7/13/2019,10/17/2016,https://ClinicalTrials.gov/show/NCT01912339
7042,Study to Evaluate Safety and Efficacy in Adult Subjects With ITP,Completed,Has Results,Immune Thrombocytopenic Purpura,Drug: BMS-986004 75 mg IV|Drug: BMS-986004 225 mg IV|Drug: BMS-986004 675 mg IV|Drug: BMS-986004 1500 mg IV,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1|Phase 2,Industry,Interventional,11/17/2014,1/22/2018,https://ClinicalTrials.gov/show/NCT02273960
7043,Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy,Completed,Has Results,Need for Bowel Preparation,Drug: Prepopik® ½ Sachet x 2 (9-12 years)|Drug: Prepopik® 1 Sachet x 2 (9-12 years)|Drug: Oral polyethylene glycol (PEG) based preparation (9-12 years)|Drug: Prepopik® 1 Sachet x 2 (13-16 years)|Drug: Oral polyethylene glycol (PEG) based preparation (13-16 years),Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/3/2014,3/16/2017,https://ClinicalTrials.gov/show/NCT01928862
7044,Lurasidone Pediatric Autism Study,Completed,Has Results,Autism,Drug: Lurasidone 20 mg daily|Drug: Lurasidone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,8/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01911442
7045,Pediatric Schizophrenia Efficacy and Safety Study,Completed,Has Results,Schizophrenia,Drug: Lurasidone 40 mg|Drug: Lurasidone 80 mg|Drug: Placebo 40 or 80 mg,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,8/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01911429
7046,Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection,Completed,Has Results,Hepatitis C,Drug: SOF|Drug: VEL|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,6/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01909804
7047,"Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability",Completed,Has Results,"Diabetic Neuropathy, Painful; Diabetic Neuropathies",Drug: AZD5213 + pregabalin|Drug: Placebo|Drug: pregabalin capsules,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,11/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01928381
7048,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,Completed,Has Results,"Opioid Dependence, on Agonist Therapy",Drug: BNX sublingual tablets|Drug: BNX sublingual film|Drug: Buprenorphine,Orexo AB|Worldwide Clinical Trials,Orexo AB,Worldwide Clinical Trials,,,,,,Phase 3,Industry|Other,Interventional,8/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01908842
7049,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Completed,Has Results,Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Drug: mirabegron 25 mg|Drug: mirabegron 50 mg|Drug: solifenacin 5 mg|Drug: solifenacin 10 mg|Drug: mirabegron 25 mg matching placebo|Drug: mirabegron 50 mg matching placebo|Drug: solifenacin 5 mg matching placebo|Drug: solifenacin 10 mg matching placebo,Astellas Pharma Europe Ltd.|Astellas Pharma Inc,Astellas Pharma Europe Ltd.,Astellas Pharma Inc,,,,,,Phase 3,Industry,Interventional,7/10/2013,11/25/2014,https://ClinicalTrials.gov/show/NCT01908829
7050,Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: sitagliptin|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 4,Industry,Interventional,12/2/2013,6/15/2015,https://ClinicalTrials.gov/show/NCT01907854
7051,Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Primary Open-Angle Glaucoma|Ocular Hypertension,Drug: Bimatoprost|Drug: Timolol 0.5%|Drug: Placebo Eye Drops|Device: Placebo Ocular Insert,"ForSight Vision5, Inc.","ForSight Vision5, Inc.",,,,,,,Phase 2,Industry,Interventional,10/23/2013,11/14/2014,https://ClinicalTrials.gov/show/NCT01915940
7052,Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities,Completed,Has Results,Sleep Disorders,Drug: Circadin 2/5/10 mg|Drug: Placebo,Neurim Pharmaceuticals Ltd.,Neurim Pharmaceuticals Ltd.,,,,,,,Phase 3,Industry,Interventional,10/13/2019,3/27/2018,https://ClinicalTrials.gov/show/NCT01906866
7053,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Mallinckrodt,Mallinckrodt,,,,,,,Phase 2,Industry,Interventional,7/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01906658
7054,Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis,Completed,Has Results,PBC|Primary Biliary Cirrhosis,Drug: LUM001|Drug: Placebo|Drug: Ursodeoxycholic Acid,"Mirum Pharmaceuticals, Inc.","Mirum Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,8/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01904058
7055,"A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - ""POPLAR""",Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Docetaxel|Drug: Atezolizumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,8/6/2013,8/31/2018,https://ClinicalTrials.gov/show/NCT01903993
7056,BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT),Completed,Has Results,Primary Fibromyalgia,Drug: TNX-102 SL 2.8mg|Drug: Placebo,"Tonix Pharmaceuticals, Inc.","Tonix Pharmaceuticals, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,9/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01903265
7057,"Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence",Completed,Has Results,"Opioid Dependence, on Agonist Therapy",Drug: Higher bioavailability BNX sublingual tablets,Orexo AB|Worldwide Clinical Trials,Orexo AB,Worldwide Clinical Trials,,,,,,Phase 4,Industry|Other,Interventional,7/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01903005
7058,Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept,Completed,Has Results,Rheumatoid Arthritis|Psoriatic Arthritis,Drug: Etanercept / Autoinjector A,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,6/11/2013,12/30/2013,https://ClinicalTrials.gov/show/NCT01901185
7059,A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Emibetuzumab|Drug: Erlotinib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01900652
7060,To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca,Completed,Has Results,Keratoconjunctivitis Sicca,"Drug: R348 Ophthalmic Solution, 0.2%|Drug: R348 Ophthalmic Solution, 0.5%|Drug: Placebo",Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01900249
7061,Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients,Completed,Has Results,Asthma,Drug: Albuterol Spiromax|Drug: ProAir HFA|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,7/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01899144
7062,Alternatives for Reducing Chorea in Huntington Disease,Completed,Has Results,Chorea Associated With Huntington Disease,Drug: SD-809,"Auspex Pharmaceuticals, Inc.|Teva Pharmaceutical Industries","Auspex Pharmaceuticals, Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,11/12/2013,8/21/2017,https://ClinicalTrials.gov/show/NCT01897896
7063,"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Completed,Has Results,Cystic Fibrosis,Drug: Lumacaftor|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,7/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01897233
7064,Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function,Completed,Has Results,Atrial Fibrillation,"Drug: Pradaxa, dabigatran etexilate",Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,7/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01896297
7065,Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Completed,Has Results,Secondary Hyperparathyroidism|Chronic Kidney Disease,Drug: Etelcalcetide|Drug: Cinacalcet|Drug: Oral Placebo|Drug: Intravenous Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,8/13/2013,1/8/2015,https://ClinicalTrials.gov/show/NCT01896232
7066,A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA),Completed,Has Results,Juvenile Idiopathic Arthritis,Drug: Tocilizumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,7/13/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01904279
7067,Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation,Completed,Has Results,Chronic Idiopathic Constipation,Drug: Elobixibat 10 mg,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01895543
7068,An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Completed,Has Results,Schizophrenia,"Drug: ALKS 9072, Low Dose|Drug: ALKS 9072, High Dose","Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,7/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01895452
7069,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,Completed,Has Results,Multiple Sclerosis,Drug: Teriflunomide,Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,6/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01895335
7070,A Continuation Study To Monitor The Long Term Safety Of Patients Completing Protocols ACU-P08-020/020A,Completed,Has Results,Presbyopia,Device: AcuFocus Corneal Inlay ACI 7000 PDT,"AcuFocus, Inc.","AcuFocus, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01895088
7071,The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel,Completed,Has Results,Hypogonadism,Drug: Topical Testosterone Solution,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,7/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01893281
7072,Complete Lesion Assessment With ffR and IVUS TechnologY,Completed,Has Results,Peripheral Artery Disease|Critical Limb Ischemia,Device: Orbital Atherectomy System|Device: Balloon Angioplasty,Cardiovascular Systems Inc,Cardiovascular Systems Inc,,,,,,,Not Applicable,Industry,Interventional,3/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01941030
7073,Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Secukinumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/30/2013,1/11/2018,https://ClinicalTrials.gov/show/NCT01892436
7074,A Study of LY3015014 in Participants With High Cholesterol,Completed,Has Results,Hypercholesterolemia,Drug: LY3015014|Drug: Placebo|Drug: Statin|Drug: Ezetimibe,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01890967
7075,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,Completed,Has Results,"Leukaemia, Acute",Drug: Daunorubicin|Drug: Cytarabine|Drug: Eltrombopag|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,9/5/2013,1/25/2017,https://ClinicalTrials.gov/show/NCT01890746
7076,Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU,Completed,Has Results,Phenylketonuria (PKU),Drug: BMN165 20mg/day|Drug: BMN165 40mg/day|Drug: Placebo,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 3,Industry,Interventional,7/29/2013,2/5/2019,https://ClinicalTrials.gov/show/NCT01889862
7077,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),Completed,Has Results,Coronary Artery Disease,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,8/26/2013,11/10/2016,https://ClinicalTrials.gov/show/NCT01890434
7078,Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1,Industry,Interventional,7/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01890473
7079,"Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery",Completed,Has Results,Surgical Site Infections,Drug: DFA-02 Antibiotic Gel|Drug: DFA-02 Placebo Gel,Dr. Reddy's Laboratories Limited|Duke Clinical Research Institute,Dr. Reddy's Laboratories Limited,Duke Clinical Research Institute,,,,,,Phase 2,Industry|Other,Interventional,10/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01888367
7080,Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee,Completed,Has Results,"Osteoarthritis, Knee",Drug: Traumeel® / Zeel® Injectable Solution|Drug: Placebo,Biologische Heilmittel Heel GmbH,Biologische Heilmittel Heel GmbH,,,,,,,Phase 3,Industry,Interventional,6/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01887678
7081,Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: PF-04937319 once-daily|Drug: PF-04937319 split-dose|Drug: Sitagliptin once-daily,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,10/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01933672
7082,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: exenatide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,12/2/2013,7/13/2015,https://ClinicalTrials.gov/show/NCT01885208
7083,Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors,Completed,Has Results,Psoriatic Arthritis,Drug: Tofacitinib|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,8/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01882439
7084,China Adherence Through Technology Study,Completed,Has Results,Medication Adherence,Behavioral: adherence feedback|Behavioral: standard of care,Boston University|FHI 360|Guangxi Center for Disease Control and Prevention|Dimagi Inc.|Massachusetts General Hospital,Boston University,FHI 360,Guangxi Center for Disease Control and Prevention|Dimagi Inc.|Massachusetts General Hospital,Guangxi Center for Disease Control and Prevention,Dimagi Inc.|Massachusetts General Hospital,Dimagi Inc.,Massachusetts General Hospital,Not Applicable,Other|Industry,Interventional,11/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01722552
7085,Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer),Completed,Has Results,Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer,Drug: nab-Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine,Celgene,Celgene,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/26/2013,10/28/2016,https://ClinicalTrials.gov/show/NCT01881230
7086,Efficacy and Safety of AQX-1125 in IC/BPS,Completed,Has Results,Interstitial Cystitis|Bladder Pain Syndrome,Drug: AQX-1125|Drug: Placebo,Aquinox Pharmaceuticals (Canada) Inc.,Aquinox Pharmaceuticals (Canada) Inc.,,,,,,,Phase 2,Industry,Interventional,6/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01882543
7087,Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR,Completed,Has Results,Allergic Rhinitis,Drug: 205.5 mcg of azelastine hydrochloride|Drug: 137 mcg of azelastine hydrochloride,Meda Pharmaceuticals|Novella Clinical,Meda Pharmaceuticals,Novella Clinical,,,,,,Phase 4,Industry|Other,Interventional,6/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01880840
7088,"Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris",Completed,Has Results,Acne Vulgaris,Drug: CD0271 0.3% / CD1579 2.5%|Drug: CD0271 0.1% / CD1579 2.5%|Drug: Topical Gel Vehicle,Galderma R&D,Galderma R&D,,,,,,,Phase 3,Industry,Interventional,7/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01880320
7089,Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Biological: Evolocumab AMD|Biological: Evolocumab AI/pen,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,7/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01879319
7090,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|Drug: Placebo DISKUS|Drug: Placebo NDPI,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/13/2013,1/9/2014,https://ClinicalTrials.gov/show/NCT01879410
7091,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305),Completed,Has Results,Plaque Psoriasis,Drug: 000-0551 Lotion|Drug: Vehicle Lotion,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,6/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01882647
7092,Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study,Completed,Has Results,Psoriatic Arthritis,Drug: Tofacitinib 5 mg BID|Drug: Tofacitinib 10 mg BID|Drug: Adalimumab|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/20/2014,12/18/2015,https://ClinicalTrials.gov/show/NCT01877668
7093,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Completed,Has Results,Hypertension,Drug: LCZ696|Drug: Olmesartan|Drug: Placebo of LCZ696|Drug: Placebo of Olmesartan,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01876368
7094,Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept,Completed,Has Results,Rheumatoid Arthritis|Plaque Psoriasis,Drug: Etanercept via Autoinjector A|Drug: Etanercept via Autoinjector B,Amgen,Amgen,,,,,,,Phase 4,Industry,Interventional,6/5/2013,3/4/2014,https://ClinicalTrials.gov/show/NCT01875991
7095,Safety and Tolerability of Glatiramer Acetate,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: GA 20 mg/mL|Drug: GA 40 mg/mL,Teva Pharmaceutical Industries,Teva Pharmaceutical Industries,,,,,,,Phase 3,Industry,Interventional,6/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01874145
7096,Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States,Completed,Has Results,Relapsing Forms of Multiple Sclerosis,Drug: BG00012 (DMF),Biogen,Biogen,,,,,,,Phase 4,Industry,Interventional,5/13/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01873417
7097,Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma,Completed,Has Results,Hodgkin Disease,Drug: brentuximab vedotin|Drug: bendamustine,"Seattle Genetics, Inc.","Seattle Genetics, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,6/13/2019,2/20/2018,https://ClinicalTrials.gov/show/NCT01874054
7098,A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Lebrikizumab|Drug: Pirfenidone|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,10/13/2013,11/6/2017,https://ClinicalTrials.gov/show/NCT01872689
7099,A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Alectinib,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/30/2013,8/31/2017,https://ClinicalTrials.gov/show/NCT01871805
7100,Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs,Completed,Has Results,Compression Fracture of Vertebral Body|Osteoporosis|Cancer,Device: Balloon kyphoplasty,Medtronic Spinal and Biologics,Medtronic Spinal and Biologics,,,,,,,Not Applicable,Industry,Interventional,5/13/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01871519
7101,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Completed,Has Results,Acute Heart Failure,Drug: RLX030|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/2/2013,2/1/2017,https://ClinicalTrials.gov/show/NCT01870778
7102,"An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Obinutuzumab|Drug: Chlorambucil,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,8/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01868893
7103,DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: ELLIPTA|Device: DISKUS,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01868009
7104,"Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",Completed,Has Results,Neoplasms,Drug: GSK3052230|Drug: paclitaxel|Drug: carboplatin|Drug: docetaxel|Drug: pemetrexed|Drug: cisplatin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,10/9/2013,10/24/2017,https://ClinicalTrials.gov/show/NCT01868022
7105,Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic Surgery,Completed,Has Results,Pulmonary Disease,Device: Progel® Pleural Air Leak Sealant,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,6/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01867658
7106,Stroke Feasibility Study,Completed,Has Results,Atrial Fibrillation|AFib,Device: AtriClip LAA Exclusion Device,"AtriCure, Inc.","AtriCure, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,1/14/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01997905
7107,Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Completed,Has Results,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,Drug: teprotumumab|Drug: normal saline,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 2,Industry,Interventional,7/13/2019,2/22/2017,https://ClinicalTrials.gov/show/NCT01868997
7108,Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants,Completed,Has Results,Liver Transplantation,Drug: Everolimus + reduced tacrolimus|Drug: Standard tacrolimus,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/25/2013,4/21/2018,https://ClinicalTrials.gov/show/NCT01888432
7109,Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Metformin XR|Drug: Metformin IR|Drug: Placebo matching with Metformin XR|Drug: Placebo matching with Metformin IR,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 4,Industry,Interventional,6/20/2013,6/1/2016,https://ClinicalTrials.gov/show/NCT01864174
7110,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304),Completed,Has Results,Plaque Psoriasis,Drug: 000-0551 Lotion|Drug: Vehicle Lotion,"Therapeutics, Inc.","Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,5/13/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01871402
7111,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",Completed,Has Results,Multiple Sclerosis,Drug: BIIB033|Other: Placebo|Drug: Avonex,Biogen,Biogen,,,,,,,Phase 2,Industry,Interventional,8/13/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01864148
7112,CCFZ533X2201 - PoC Study in de Novo Renal Transplantation,Completed,Has Results,Kidney Transplantation,Biological: CFZ533|Drug: Tacrolimus (Tac)|Drug: Mycophenolate mofetil (MMF)|Drug: Corticosteroids (CS)|Biological: anti-IL2 Induction,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,2/5/2015,11/29/2017,https://ClinicalTrials.gov/show/NCT02217410
7113,Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures,Completed,Has Results,Hemophilia A,Biological: PEGylated Recombinant factor VIII (rFVIII),Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 3,Industry,Interventional,12/20/2013,9/23/2016,https://ClinicalTrials.gov/show/NCT01913405
7114,Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting,Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: AR11|Drug: Placebo,"Arbor Pharmaceuticals, Inc.","Arbor Pharmaceuticals, Inc.",,,,,,,Phase 4,Industry,Interventional,12/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01986062
7115,Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection,Completed,Has Results,Hepatitis C,Drug: SOF|Drug: VEL|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,4/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01858766
7116,A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease,Completed,Has Results,Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease,Drug: Ticagrelor Dose 1a + Dose 2a|Drug: Ticagrelor Dose 1b + Dose 2b,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,9/11/2014,2/27/2017,https://ClinicalTrials.gov/show/NCT02214121
7117,Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI),Completed,Has Results,Asthma|Chronic Obstructive Pulmonary Disease (COPD),Drug: Albuterol Spiromax®,Teva Pharmaceutical Industries,Teva Pharmaceutical Industries,,,,,,,Phase 3,Industry,Interventional,5/13/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01857323
7118,Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age,Completed,Has Results,Influenza|Fever,Biological: Mammalian cell based flu vaccine|Biological: Egg based flu vaccine,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,5/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01857206
7119,A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Dacomitinib,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,7/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01858389
7120,A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab (TCZ)|Drug: Methotrexate (MTX)|Drug: Placebo (PBO),Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,11/7/2013,10/14/2016,https://ClinicalTrials.gov/show/NCT01855789
7121,Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia,Completed,Has Results,Hyperlipidemia and Mixed Dyslipidemia,Biological: Evolocumab|Drug: Standard of Care,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,4/23/2013,5/31/2018,https://ClinicalTrials.gov/show/NCT01854918
7122,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: GFF MDI (PT003)|Drug: GP MDI (PT001)|Drug: FF MDI (PT005)|Drug: Placebo,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,7/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01854658
7123,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: GFF MDI|Drug: GP MDI|Drug: FF MDI|Drug: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Drug: Placebo MDI,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,5/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01854645
7124,A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials,Completed,Has Results,"Hepatitis C, Chronic",Drug: Peginterferon alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,9/3/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01853254
7125,"Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.",Completed,Has Results,Prophylaxis of A/H3N2v Influenza,Biological: Swine Influenza,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 1,Industry,Interventional,5/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01855945
7126,A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds,Completed,Has Results,Moderate to Severe Nasolabial Folds,Device: JUVEDERM VOLIFT® XC|Device: Control,Allergan,Allergan,,,,,,,Not Applicable,Industry,Interventional,10/29/2013,10/26/2015,https://ClinicalTrials.gov/show/NCT01976663
7127,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3),Completed,Has Results,Chronic Hepatitis C Virus,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,5/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01851330
7128,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Faster-acting insulin aspart|Drug: basal insulin,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/23/2013,11/17/2014,https://ClinicalTrials.gov/show/NCT01850615
7129,Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),Completed,Has Results,Metastatic|Uveal Melanoma,Drug: 75mg selumetinib|Drug: placebo|Drug: Dacarbazine,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/14/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01974752
7130,Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Biological: Evolocumab Pre-filled Syringe|Biological: Evolocumab AI/pen,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,4/18/2013,,https://ClinicalTrials.gov/show/NCT01849497
7131,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin Degludec|Drug: Insulin Glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/2/2013,5/15/2014,https://ClinicalTrials.gov/show/NCT01849289
7132,CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM),Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Commercial Hylenex® recombinant (hyaluronidase human injection)|Drug: Precommercial Hylenex recombinant (hyaluronidase human injection)|Drug: Insulin lispro|Drug: Insulin aspart|Drug: Insulin glulisine,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 4,Industry,Interventional,3/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01848990
7133,Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Cancer,Drug: Rovalpituzumab tesirine (SC16LD6.5),Stemcentrx,Stemcentrx,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/13/2019,11/28/2016,https://ClinicalTrials.gov/show/NCT01901653
7134,Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence,Completed,Has Results,Opioid-Related Disorders|Opiate Dependence,Drug: Buprenorphine/naloxone sublingual tablets|Drug: Buprenorphine,Orexo AB|Worldwide Clinical Trials,Orexo AB,Worldwide Clinical Trials,,,,,,Phase 3,Industry|Other,Interventional,6/13/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01848054
7135,A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR],Completed,Has Results,Non-Small Cell Lung Cancer,"Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody","Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,5/30/2013,12/18/2017,https://ClinicalTrials.gov/show/NCT01846416
7136,VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37),Completed,Has Results,Epilepsy,Device: M106 VNS Therapy System,"Cyberonics, Inc.","Cyberonics, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01846741
7137,Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infections,Drug: Eravacycline|Drug: Ertapenem|Drug: Placebo,"Tetraphase Pharmaceuticals, Inc.","Tetraphase Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,8/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01844856
7138,Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Completed,Has Results,Differentiated Thyroid Cancer,Drug: Selumetinib|Drug: Placebo|Drug: Radioactive Iodine Therapy,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,8/27/2013,3/6/2019,https://ClinicalTrials.gov/show/NCT01843062
7139,A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects,Completed,Has Results,Asthma,Biological: Mepolizumab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/27/2013,3/13/2015,https://ClinicalTrials.gov/show/NCT01842607
7140,Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Macitentan,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,4/1/2013,11/1/2015,https://ClinicalTrials.gov/show/NCT01841762
7141,A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection),Completed,Has Results,"Candidiasis, Vulvovaginal",Drug: VT-1161|Drug: Fluconazole,Viamet,Viamet,,,,,,,Phase 2,Industry,Interventional,8/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01891331
7142,The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,11/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01836523
7143,A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients,Completed,Has Results,Asthma,Drug: QAW039|Drug: Placebo QAW039|Drug: Fluticasone 250 mcg|Drug: Fluticasone 100 mcg,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/13/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01836471
7144,Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort,Completed,Has Results,Primary Open Angle Glaucoma,,Glaukos Corporation,Glaukos Corporation,,,,,,,,Industry,Observational,7/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01836042
7145,A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: insulin aspart|Drug: insulin detemir,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,10/17/2013,11/7/2014,https://ClinicalTrials.gov/show/NCT01835431
7146,Study of Oasis Ultra in Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcer,Device: Oasis|Other: Standard,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,5/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01835379
7147,BKM120 for Patients With PI3K-activated Tumors,Completed,Has Results,PI3K Pathway Activated Tumors,Drug: BKM120,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,3/29/2013,9/26/2016,https://ClinicalTrials.gov/show/NCT01833169
7148,Post- Approval Study on Patients Who Received a HeartWare HVAD® During IDE Trials,Completed,Has Results,Heart Failure,Device: HeartWare® VAS,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,,Industry,Observational,1/13/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT01832610
7149,Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin detemir|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/26/2013,6/11/2015,https://ClinicalTrials.gov/show/NCT01831765
7150,Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,Completed,Has Results,Tumor Pathway Activations Inhibited by Dovitinib,Drug: Dovitinib (TKI258),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01831726
7151,Tofacitinib Ointment For Chronic Plaque Psoriasis,Completed,Has Results,Psoriasis Vulgaris|Psoriasis,Drug: tofacitinib ointment 20 mg/g|Drug: tofacitinib ointment 10 mg/g|Drug: placebo ointment (vehicle),Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,5/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01831466
7152,"Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency",Completed,Has Results,HCV Infection,Drug: SOF|Drug: RBV|Drug: LDV/SOF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,10/7/2013,10/19/2017,https://ClinicalTrials.gov/show/NCT01958281
7153,A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI),Completed,Has Results,Acute Kidney Injury,Drug: THR-184|Drug: Placebo,"Thrasos Innovation, Inc.","Thrasos Innovation, Inc.",,,,,,,Phase 2,Industry,Interventional,5/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01830920
7154,"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years",Completed,Has Results,Meningococcal Vaccine,Biological: rLP2086|Biological: Havrix (HAV)|Biological: Saline,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,4/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01830855
7155,Cardiogenesis Transmyocardial Revascularization Registry,Completed,Has Results,Class IV Angina,,"Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.","Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.",,,,,,,,Industry,Observational,5/13/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01827319
7156,Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer,Completed,Has Results,HER2-mutant Non-Small Cell Lung Cancer,Drug: neratinib|Drug: temsirolimus,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",,,,,,,Phase 2,Industry,Interventional,7/1/2013,10/6/2017,https://ClinicalTrials.gov/show/NCT01827267
7157,"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age",Completed,Has Results,Influenza,Biological: Flublok|Biological: Afluria,Protein Sciences Corporation,Protein Sciences Corporation,,,,,,,Phase 3,Industry,Interventional,3/13/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01825200
7158,Sidus Stem-Free Shoulder IDE Study,Completed,Has Results,Osteoarthritis|Posttraumatic Arthrosis|Rheumatoid Arthritis,Device: Sidus Stem-Free Total Shoulder Arthroplasty System,Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,7/13/2019,1/19/2019,https://ClinicalTrials.gov/show/NCT01878253
7159,"Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose",Completed,Has Results,Meningococcal Disease,"Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine",Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 4,Industry,Interventional,5/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01823536
7160,Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment,Completed,Has Results,Multiple Myeloma|Advanced Solid Tumors,Drug: Ixazomib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,9/16/2013,11/18/2016,https://ClinicalTrials.gov/show/NCT01830816
7161,Lurasidone Low-Dose - High-Dose Study Study,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,5/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01821378
7162,"Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy",Completed,Has Results,HIV-associated Enteropathy,Other: Serum-derived bovine immunoglobulin protein isolate (SBI)|Other: Placebo,"Entera Health, Inc","Entera Health, Inc",,,,,,,Not Applicable,Industry,Interventional,4/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01828593
7163,An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165,Completed,Has Results,Phenylketonuria,Drug: BMN 165,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 3,Industry,Interventional,5/13/2019,11/25/2015,https://ClinicalTrials.gov/show/NCT01819727
7164,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Faster-acting insulin aspart|Drug: Insulin aspart|Drug: Insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/9/2013,1/22/2015,https://ClinicalTrials.gov/show/NCT01819129
7165,Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment,Completed,Has Results,HIV|HIV Infections,Drug: E/C/F/TAF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,3/27/2013,7/18/2018,https://ClinicalTrials.gov/show/NCT01818596
7166,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Bortezomib|Drug: Melphalan|Drug: Prednisone,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,7/8/2013,11/4/2016,https://ClinicalTrials.gov/show/NCT01818752
7167,Evaluation of Skin Testing Reagents for Penicillin Allergy,Completed,Has Results,History of IgE Dependent Reaction to a Penicillin Product,Drug: Penicillin skin test kit,AllerQuest LLC,AllerQuest LLC,,,,,,,Phase 3,Industry,Interventional,12/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01818336
7168,"Respicardia, Inc. Pivotal Trial of the remedē System",Completed,Has Results,"Sleep Apnea, Central|Sleep Disordered Breathing|Heart Failure",Device: Treatment Group (transvenous stimulation of the phrenic nerve)|Device: Control Group (Optimal Medical Therapy),"Respicardia, Inc.","Respicardia, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/13/2019,11/7/2017,https://ClinicalTrials.gov/show/NCT01816776
7169,"A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy",Completed,Has Results,Hypogonadism,Drug: Testosterone Solution|Drug: Placebo Solution,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,5/13/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01816295
7170,A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas,Completed,Has Results,Basal Cell Carcinoma,Drug: Vismodegib|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,4/30/2013,8/31/2016,https://ClinicalTrials.gov/show/NCT01815840
7171,A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin degludec|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,3/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01814137
7172,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,4/18/2013,7/29/2016,https://ClinicalTrials.gov/show/NCT01813422
7173,ADAM-Afatinib Diarrhea Assessment and Management,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: afatinib|Drug: loperamide,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,4/13/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01814553
7174,Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections,Drug: Delafloxacin|Drug: Vancomycin|Drug: Aztreonam|Drug: Placebo,"Melinta Therapeutics, Inc.","Melinta Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,4/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01811732
7175,Neonatal Outcome by Reason for Delivery,Completed,Has Results,Preterm Delivery,,"Obstetrix Medical Group|Mednax Center for Research, Education, Quality and Safety",Obstetrix Medical Group,"Mednax Center for Research, Education, Quality and Safety",,,,,,,Industry,Observational,7/13/2019,7/25/2016,https://ClinicalTrials.gov/show/NCT01818518
7176,Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia,Completed,Has Results,"Leukemia, Hairy Cell",Drug: Moxetumomab pasudotox|Drug: IV Bag Protectant for Moxetumomab pasudotox,MedImmune LLC,MedImmune LLC,,,,,,,Phase 3,Industry,Interventional,4/29/2013,4/29/2019,https://ClinicalTrials.gov/show/NCT01829711
7177,"A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)",Completed,Has Results,Chronic Kidney Disease (CKD)|Hyperkalemia (HK),Drug: Patiromer|Drug: Placebo,"Relypsa, Inc.","Relypsa, Inc.",,,,,,,Phase 3,Industry,Interventional,2/13/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01810939
7178,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Metformin XR,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,6/4/2013,12/2/2014,https://ClinicalTrials.gov/show/NCT01809327
7179,Lesinurad and Febuxostat Combination Extension Study in Gout,Completed,Has Results,Gout,Drug: lesinurad|Drug: febuxostat,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 3,Industry,Interventional,3/1/2013,10/6/2016,https://ClinicalTrials.gov/show/NCT01808144
7180,"Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients",Completed,Has Results,Non-alcoholic Fatty Liver Disease (NAFLD),Drug: LCQ908|Drug: placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01811472
7181,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,Completed,Has Results,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Drug: Placebo|Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,4/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01807949
7182,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,Completed,Has Results,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 3,Industry,Interventional,5/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01807923
7183,An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access,Completed,Has Results,Arteriovenous Fistula,Biological: SRM003|Other: Participating Site's standard practice,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,3/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01806545
7184,A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib),Completed,Has Results,"Multiple Myeloma, Neoplasms",,"Genentech, Inc.","Genentech, Inc.",,,,,,,,Industry,Observational,12/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01804140
7185,Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)),Completed,Has Results,"Subjects With Hyperlipidemia, Dyslipidemia",Drug: Evolocumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,4/14/2016,4/5/2018,https://ClinicalTrials.gov/show/NCT02729025
7186,Edoxaban in Peripheral Arterial Disease,Completed,Has Results,Peripheral Arterial Disease,Drug: edoxaban|Drug: Clopidogrel|Drug: Aspirin,"Daiichi Sankyo, Inc.|UMC Utrecht","Daiichi Sankyo, Inc.",UMC Utrecht,,,,,,Phase 2,Industry|Other,Interventional,2/6/2013,12/3/2014,https://ClinicalTrials.gov/show/NCT01802775
7187,Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip,Completed,Has Results,Osteoarthritis,Drug: Meloxicam Test Capsules,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,3/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01801735
7188,A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment,Completed,Has Results,Non-Small-Cell Lung Carcinoma,Drug: Erlotinib|Drug: Alectinib,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/20/2013,10/27/2017,https://ClinicalTrials.gov/show/NCT01801111
7189,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium/vilanterol|Drug: Fluticasone propionate/salmeterol|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2013,10/25/2013,https://ClinicalTrials.gov/show/NCT01817764
7190,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Antidiabetic background therapy,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,6/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01798706
7191,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: E/C/F/TAF|Drug: E/C/F/TDF|Drug: E/C/F/TDF Placebo|Drug: E/C/F/TAF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,3/12/2013,10/3/2018,https://ClinicalTrials.gov/show/NCT01797445
7192,Safety Study of SPARC1104,Completed,Has Results,Spasticity,Drug: SPARC1104 modified dose regimen I|Drug: SPARC1104 modified dose regimen II|Drug: SPARC1104 modified dose regimen III,Sun Pharma Advanced Research Company Limited,Sun Pharma Advanced Research Company Limited,,,,,,,Phase 3,Industry,Interventional,4/9/2013,10/17/2019,https://ClinicalTrials.gov/show/NCT01797185
7193,First Time Use of SD-809 in Huntington Disease,Completed,Has Results,Chorea,Drug: SD-809|Drug: Placebo,Teva Pharmaceutical Industries,Teva Pharmaceutical Industries,,,,,,,Phase 3,Industry,Interventional,8/5/2013,12/5/2014,https://ClinicalTrials.gov/show/NCT01795859
7194,"Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)",Completed,Has Results,Primary Immune Deficiency Disorder,Biological: RI-002,"ADMA Biologics, Inc.","ADMA Biologics, Inc.",,,,,,,Phase 3,Industry,Interventional,2/14/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01814800
7195,3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis,Completed,Has Results,Allergic Rhinitis,Drug: Dymista Nasal Spray|Drug: Fluticasone propionate nasal spray,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/13/2019,,https://ClinicalTrials.gov/show/NCT01794741
7196,Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza,Completed,Has Results,Influenza,Drug: 40 mg Laninamivir Octanoate|Drug: 80 mg Laninamivir Octanoate|Drug: Placebo,Biota Scientific Management Pty Ltd|Department of Health and Human Services|Vaxart,Biota Scientific Management Pty Ltd,Department of Health and Human Services,Vaxart,,,,,Phase 2,Industry|U.S. Fed,Interventional,5/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01793883
7197,Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache,Completed,Has Results,Cluster Headache,Device: GammaCore|Device: Sham GammaCore device,ElectroCore INC,ElectroCore INC,,,,,,,Not Applicable,Industry,Interventional,2/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01792817
7198,A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: LY2605541|Drug: Insulin Lispro,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,2/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01792284
7199,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Completed,Has Results,Giant Cell Arteritis,Drug: Tocilizumab|Drug: Prednisone|Drug: Tocilizumab Placebo|Drug: Prednisone Placebo|Drug: Corticosteroids|Drug: Methotrexate,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,7/22/2013,6/4/2018,https://ClinicalTrials.gov/show/NCT01791153
7200,A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2605541|Drug: Human Insulin NPH|Drug: Oral Antihyperglycemic Medications (OAM),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01790438
7201,Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Hydrocodone ER|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,3/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01789970
7202,Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet,Completed,Has Results,Analgesia,Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/24/2012,6/3/2013,https://ClinicalTrials.gov/show/NCT01789606
7203,Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension,Completed,Has Results,Hypertension,Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106),Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,2/14/2013,5/1/2014,https://ClinicalTrials.gov/show/NCT01788358
7204,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,3/12/2013,5/9/2014,https://ClinicalTrials.gov/show/NCT01788046
7205,Study of Meloxicam Capsules to Treat Osteoarthritis Pain,Completed,Has Results,Osteoarthritis,Drug: Meloxicam Test Capsules|Drug: Placebo Capsules,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,2/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01787188
7206,MultiPoint Pacing IDE Study,Completed,Has Results,Heart Failure,Device: MultiPoint Pacing|Device: Traditional Biventricular Pacing,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 3,Industry,Interventional,4/13/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01786993
7207,Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondylitis,Drug: Tofacitinib 2 mg|Drug: Tofacitinib 5 mg|Drug: Tofacitinib 10 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,4/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01786668
7208,"Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Danirixin|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,2/13/2014,8/29/2016,https://ClinicalTrials.gov/show/NCT02130193
7209,Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,7/31/2013,7/1/2015,https://ClinicalTrials.gov/show/NCT01785875
7210,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,3/12/2013,6/12/2014,https://ClinicalTrials.gov/show/NCT01785849
7211,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis",Completed,Has Results,Moderate to Severe Nail Psoriasis,Biological: Secukinumab|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/20/2013,1/3/2017,https://ClinicalTrials.gov/show/NCT01807520
7212,Post Market Study Of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence,Completed,Has Results,Stress Urinary Incontinence,Device: Solyx Single Incision Sling System|Device: Obtryx II Sling System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,6/13/2019,1/17/2018,https://ClinicalTrials.gov/show/NCT01784588
7213,Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR),Completed,Has Results,Allergic Rhinitis,Drug: BDP Nasal Aerosol|Drug: Placebo,Teva Pharmaceutical Industries,Teva Pharmaceutical Industries,,,,,,,Phase 3,Industry,Interventional,1/13/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01783548
7214,An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery,Completed,Has Results,Coronary Artery Disease|Angina Pectoris|Cardiac Valve Disease,Device: SternaLock Blue closure system|Device: Suture Wire,Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,1/13/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01783483
7215,Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: Rotigotine|Other: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,UCB BIOSCIENCES GmbH,UCB Pharma,,,,,,Phase 4,Industry,Interventional,2/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01782222
7216,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: E/C/F/TAF|Drug: E/C/F/TDF|Drug: E/C/F/TDF Placebo|Drug: E/C/F/TAF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/26/2012,9/6/2017,https://ClinicalTrials.gov/show/NCT01780506
7217,BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Completed,Has Results,Colonoscopy|Bowel Preparation|Endoscopy,Drug: SUPREP Bowel Prep Kit|Drug: FDA approved bowel preparation containing electrolytes,Braintree Laboratories,Braintree Laboratories,,,,,,,Phase 4,Industry,Interventional,12/12/2019,,https://ClinicalTrials.gov/show/NCT01786629
7218,The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium/Vilanterol 62.5/25 mcg|Drug: Tiotropium 18 mcg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/23/2013,9/24/2013,https://ClinicalTrials.gov/show/NCT01777334
7219,Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Ixekizumab Auto-Injector|Drug: Ixekizumab Prefilled Syringe,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/13/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01777191
7220,"Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder",Completed,Has Results,Tourette Syndrome,Drug: AZD5213 and placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,8/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01904773
7221,Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Human Regular U-500 Insulin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,2/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01774968
7222,Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium bromide 62.5mcg|Drug: Umeclidinium bromide 125mcg|Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/13/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01772147
7223,Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium bromide 62.5mcg|Drug: Umeclidinium bromide 125mcg|Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/1/2013,7/22/2013,https://ClinicalTrials.gov/show/NCT01772134
7224,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: 75mg SHP647 (PF-00547659)|Drug: 225mg SHP647 (PF-00547659),Shire,Shire,,,,,,,Phase 2,Industry,Interventional,3/18/2013,12/13/2017,https://ClinicalTrials.gov/show/NCT01771809
7225,A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,Completed,Has Results,Squamous Non Small Cell Lung Cancer,Drug: Necitumumab|Drug: Paclitaxel|Drug: Carboplatin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,1/13/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT01769391
7226,Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT),Completed,Has Results,Parkinson's Disease|Motor Symptoms|Akinesia|Hypomobility|Delayed Levodopa Onset,Drug: APOKYN|Drug: L-dopa|Drug: Trimethobenzamide,US WorldMeds LLC,US WorldMeds LLC,,,,,,,Phase 4,Industry,Interventional,12/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01770145
7227,Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children,Completed,Has Results,Pandemic H5N1 Influenza,Biological: Adjuvanted H5N1 pandemic influenza vaccine,Novartis Vaccines|Department of Health and Human Services|Novartis,Novartis Vaccines,Department of Health and Human Services,Novartis,,,,,Phase 2,Industry|U.S. Fed,Interventional,1/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01776554
7228,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes,Drug: Lixisenatide (AVE0010)|Drug: Insulin glulisine QD|Drug: Insulin glulisine TID|Drug: Insulin Glargine (Mandatory background drug)|Drug: Metformin (Background drug),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,1/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01768559
7229,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection,Completed,Has Results,Chronic Hepatitis C Virus,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,1/13/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01768286
7230,Study Evaluating the Effects of Avanafil on Semen Parameters,Completed,Has Results,Erectile Dysfunction,Drug: avanafil|Drug: Placebo,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 4,Industry,Interventional,12/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01768676
7231,Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer,Completed,Has Results,Endometrial Cancer,Drug: AEZS-108 / zoptarelin doxorubicin|Drug: doxorubicin,AEterna Zentaris,AEterna Zentaris,,,,,,,Phase 3,Industry,Interventional,4/13/2019,1/30/2017,https://ClinicalTrials.gov/show/NCT01767155
7232,Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: BMS-986020|Drug: Placebo matching with BMS-986020,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,1/31/2013,2/29/2016,https://ClinicalTrials.gov/show/NCT01766817
7233,Safety and Efficacy Trial of Testosterone Undecanoate,Completed,Has Results,Male Hypogonadism,Drug: Oral testosterone undecanoate,"Clarus Therapeutics, Inc.|inVentiv Health Clinical","Clarus Therapeutics, Inc.",inVentiv Health Clinical,,,,,,Phase 3,Industry|Other,Interventional,1/13/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01765179
7234,Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects,Completed,Has Results,Pandemic H5N1 Influenza,Biological: Adjuvanted H5N1 pandemic influenza vaccine,Novartis Vaccines|Department of Health and Human Services|Novartis,Novartis Vaccines,Department of Health and Human Services,Novartis,,,,,Phase 2,Industry|U.S. Fed,Interventional,1/13/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01766921
7235,Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects,Completed,Has Results,Asthma,Drug: Fp MDPI|Drug: FS MDPI|Drug: Advair Diskus|Drug: Albuterol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,1/13/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01772368
7236,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Completed,Has Results,Dyslipidemia,Biological: Evolocumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,2/8/2013,11/11/2016,https://ClinicalTrials.gov/show/NCT01764633
7237,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Placebo to Evolocumab|Drug: Ezetimibe|Drug: Placebo to Ezetimibe,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,1/24/2013,11/19/2013,https://ClinicalTrials.gov/show/NCT01763905
7238,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Drug: Placebo to Evolocumab|Drug: Placebo to Ezetimibe|Drug: Atorvastatin|Drug: Rosuvastatin|Drug: Simvastatin,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,1/15/2013,12/4/2013,https://ClinicalTrials.gov/show/NCT01763866
7239,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Biological: Placebo to Evolocumab|Other: Placebo to Ezetimibe,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,1/21/2013,10/29/2013,https://ClinicalTrials.gov/show/NCT01763827
7240,Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects,Completed,Has Results,Obesity|Overweight,Drug: NB|Behavioral: CLI|Behavioral: Usual Care,"Orexigen Therapeutics, Inc","Orexigen Therapeutics, Inc",,,,,,,Phase 3,Industry,Interventional,2/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01764386
7241,Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population,Completed,Has Results,Presbyopia,Device: etafilcon A|Device: lotrafilcon B,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01763047
7242,A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: VT-1161|Drug: placebo,Viamet,Viamet,,,,,,,Phase 2,Industry,Interventional,8/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01891305
7243,ProMRI Study of the Entovis Pacemaker System,Completed,Has Results,Safety of the ProMRI Pacemaker System Under Specific MRI Conditions,Device: Patients with a ProMRI Pacemaker System|Other: Magnetic Resonance Imaging (MRI) scan,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,,Industry,Observational,2/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01761162
7244,Study of Erenumab (AMG 334) in Women With Hot Flashes,Completed,Has Results,Vasomotor Symptoms; Hot Flashes,Biological: Erenumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,5/13/2013,3/11/2014,https://ClinicalTrials.gov/show/NCT01890109
7245,Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks,Completed,Has Results,Hereditary Angioedema (HAE),Biological: CINRYZE with rHuPH20,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,2/4/2013,9/13/2013,https://ClinicalTrials.gov/show/NCT01756157
7246,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Completed,Has Results,Moderate to Severe Palmoplantar Psoriasis,Biological: secukinumab 150 mg|Biological: secukinumab 300 mg|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/19/2013,11/2/2016,https://ClinicalTrials.gov/show/NCT01806597
7247,Long-term Open-Label Safety Study to Evaluate EN3409,Completed,Has Results,Low Back Pain|Osteoarthritis|Neuropathic Pain,Drug: EN3409,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 3,Industry,Interventional,12/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01755546
7248,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries,Completed,Has Results,Parenchymous Tissue Surgical Bleeding,Biological: Fibrin Sealant Grifols|Device: Surgicel®,"Instituto Grifols, S.A.|Grifols Biologicals, LLC","Instituto Grifols, S.A.","Grifols Biologicals, LLC",,,,,,Phase 3,Industry,Interventional,3/13/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01754480
7249,Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia,Completed,Has Results,Cervical Dystonia,Drug: Dysport®,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,3/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01753336
7250,Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.,Completed,Has Results,Cervical Dystonia,Drug: Dysport®|Drug: Placebo,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,1/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01753310
7251,Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim,Completed,Has Results,Breast Cancer,Other: General Education DVD|Other: Bone Pain Education DVD,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,1/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01752907
7252,ABSORB III Randomized Controlled Trial (RCT),Completed,Has Results,Coronary Artery Disease|Coronary Artery Stenosis|Coronary Disease|Coronary Stenosis,Device: Absorb BVS|Device: XIENCE,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,4/19/2019,https://ClinicalTrials.gov/show/NCT01751906
7253,UroLift System TOlerability and ReCovery When Administering Local Anesthesia,Completed,Has Results,Benign Prostatic Hyperplasia,Device: UroLift® System,"NeoTract, Inc.","NeoTract, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/13/2019,9/4/2018,https://ClinicalTrials.gov/show/NCT01876706
7254,Attain Performa(TM) Quadripolar Lead Study,Completed,Has Results,Heart Failure,Device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system),Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01751022
7255,Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors,Completed,Has Results,Malignant Solid Tumor - Malignant Nervous System Neoplasm,Drug: Cabazitaxel (XRP6258),Sanofi,Sanofi,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/13/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01751308
7256,Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics,Completed,Has Results,Asthma,Drug: Placebo MDPI|Drug: Albuterol MDPI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,12/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01747629
7257,Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation,Completed,Has Results,Cystic Fibrosis,Drug: N6022|Drug: Normal saline,"Nivalis Therapeutics, Inc.","Nivalis Therapeutics, Inc.",,,,,,,Phase 1,Industry,Interventional,2/14/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01746784
7258,"A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot",Completed,Has Results,Schizophrenia,Drug: aripiprazole IM depot|Drug: aripiprazole tablets,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 1,Industry,Interventional,11/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT01870999
7259,An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic",Drug: VTP-38543|Other: Vehicle with Transcutol®P|Other: Vehicle without Transcutol®P,"Vitae Pharmaceuticals, Inc.","Vitae Pharmaceuticals, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,12/15/2015,9/9/2016,https://ClinicalTrials.gov/show/NCT02655679
7260,A Study of LY2405319 in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2405319|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,4/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT01869959
7261,A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye,Completed,Has Results,Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,12/7/2012,10/1/2013,https://ClinicalTrials.gov/show/NCT01743729
7262,A Pilot RCT of Veraflo With Prontosan vs VAC in Wounds Requiring Operative Debridement,Completed,Has Results,Wounds and Injuries,Device: V.A.C.Ulta with Prontosan instillation|Device: V.A.C.Ulta without instillation,"KCI USA, Inc.","KCI USA, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01867580
7263,"Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients",Completed,Has Results,Kidney Transplant,Drug: Belatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,5/9/2013,12/6/2016,https://ClinicalTrials.gov/show/NCT01791491
7264,PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis,Completed,Has Results,Primary Sclerosing Cholangitis,Drug: Cenicriviroc 150 mg,"Tobira Therapeutics, Inc.","Tobira Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,3/14/2016,8/31/2017,https://ClinicalTrials.gov/show/NCT02653625
7265,Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis,Completed,Has Results,Primary Biliary Cirrhosis,Drug: obeticholic acid (OCA),Intercept Pharmaceuticals,Intercept Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/13/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01865812
7266,Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism,Completed,Has Results,Secondary Hypogonadism,Drug: enclomiphene citrate|Drug: Placebo,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 3,Industry,Interventional,11/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01739595
7267,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults,Completed,Has Results,Tetanus|Acellular Pertussis|Diphtheria,Biological: Boostrix,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/31/2013,4/2/2014,https://ClinicalTrials.gov/show/NCT01738477
7268,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2,Completed,Has Results,Venous Leg Ulcers,Biological: HP802-247|Biological: Vehicle,Healthpoint,Healthpoint,,,,,,,Phase 3,Industry,Interventional,11/12/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01737762
7269,Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction,Completed,Has Results,Pulmonary Hypertension,Drug: Macitentan|Drug: Placebo,Actelion,Actelion,,,,,,,Phase 2,Industry,Interventional,7/1/2014,11/1/2015,https://ClinicalTrials.gov/show/NCT02070991
7270,Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia,Completed,Has Results,Hyperkalemia,Drug: Zirconium silicate (acute phase)|Drug: Zirconium silicate (subacute phase)|Drug: Placebo (acute phase)|Drug: Placebo ( subacute phase),"ZS Pharma, Inc.","ZS Pharma, Inc.",,,,,,,Phase 3,Industry,Interventional,11/30/2012,11/30/2013,https://ClinicalTrials.gov/show/NCT01737697
7271,Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study),Completed,Has Results,Hemophilia A,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Biological: PEGylated Recombinant Factor VIII,Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 2|Phase 3,Industry,Interventional,1/31/2013,7/17/2014,https://ClinicalTrials.gov/show/NCT01736475
7272,Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis,Completed,Has Results,Iron Deficiency|Iron Deficiency Anemia,Drug: Ferric Citrate|Drug: Placebo,Keryx Biopharmaceuticals,Keryx Biopharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01736397
7273,Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML),Completed,Has Results,Anemia|Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Low to Intermediate-1 MDS|Myelodysplastic Syndromes (MDS)|Chronic Myelomonocytic Leukemia (CMML),Drug: Sotatercept,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,11/28/2012,4/30/2018,https://ClinicalTrials.gov/show/NCT01736683
7274,Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain,Completed,Has Results,Advanced Idiopathic Parkinson's Disease,Drug: Rotigotine|Drug: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,UCB BIOSCIENCES GmbH,UCB Pharma,,,,,,Phase 4,Industry,Interventional,11/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01744496
7275,NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: NBI-98854|Drug: Placebo,Neurocrine Biosciences,Neurocrine Biosciences,,,,,,,Phase 2,Industry,Interventional,12/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01733121
7276,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Completed,Has Results,Peripheral Artery Disease,Drug: Ticagrelor|Drug: Clopidogrel,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,12/4/2012,9/26/2016,https://ClinicalTrials.gov/show/NCT01732822
7277,IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1,Completed,Has Results,"Hepatitis C, Chronic",Drug: Ribavirin (RBV)|Drug: BI 201335 (Faldaprevir)|Drug: BI 207127|Drug: Faldaprevir (BI 201335),Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,12/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01732796
7278,Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps,Completed,Has Results,Chronic Sinusitis|Nasal Polyps,Drug: S8 Sinus Implant|Procedure: Sham procedure|Drug: Mometasone furoate nasal spray,Intersect ENT,Intersect ENT,,,,,,,Phase 2|Phase 3,Industry,Interventional,1/13/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01732536
7279,Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure,Completed,Has Results,Ocular Hypertension|Open Angle Glaucoma,Drug: AR-13324 Ophthalmic Solution 0.01%|Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: Latanoprost ophthalmic solution 0.005%,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01731002
7280,Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery,Completed,Has Results,Reduction of Hypertrophic Skin Scarring,Drug: PF-06473871,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01730339
7281,Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women,Completed,Has Results,Overactive Bladder,Drug: Tolterodine tartrate extended release capsules|Drug: Desmopressin orally disintegrating tablets|Drug: Placebo orally disintegrating tablets,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01729819
7282,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2",Completed,Has Results,"Hepatitis C, Chronic",Drug: BI 207127-placebo: 8-week treatment|Drug: Ribavirin: 24-week treatment|Drug: BI 207127: 24-week treatment|Drug: Faldaprevir: 24-week treatment|Drug: Ribavirin-placebo: 8-week treatment|Drug: Faldaprevir-placebo: 8-week treatment|Drug: Faldaprevir: 16-week treatment|Drug: Ribavirin: 16-week treatment|Drug: RBV: 24-week treatment|Drug: BI 207127: 16-week treatment,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01728324
7283,"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial",Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: Brexpiprazole|Drug: Seroquel XR|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,12/12/2019,11/10/2016,https://ClinicalTrials.gov/show/NCT01727726
7284,Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder,Completed,Has Results,Tourette's Disorder|Tic Disorder,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,1/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01727713
7285,Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder,Completed,Has Results,Tourette's Disorder|Tic Disorder,Drug: Aripiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,11/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01727700
7286,REVEAL AF: Incidence of AF in High Risk Patients,Completed,Has Results,Atrial Fibrillation,Device: REVEAL Implantable Cardiac Monitor,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,11/13/2012,1/30/2017,https://ClinicalTrials.gov/show/NCT01727297
7287,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: QVA149|Drug: QAB149|Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,11/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01727141
7288,"Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects",Completed,Has Results,"Hepatitis C, Chronic",Drug: Sovaprevir|Drug: ACH-3102|Drug: RBV|Drug: Placebo,Achillion Pharmaceuticals,Achillion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,4/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01849562
7289,Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: Rasagiline|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 4,Industry,Interventional,11/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01723228
7290,"Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis",Completed,Has Results,Endometriosis,Drug: Placebo|Drug: Telapristone acetate,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,5/2/2013,3/15/2017,https://ClinicalTrials.gov/show/NCT01728454
7291,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Completed,Has Results,Irritable Bowel Syndrome Characterized by Constipation,Drug: Plecanatide|Drug: Placebo,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 2,Industry,Interventional,11/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01722318
7292,Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection),Completed,Has Results,Age - Related Macular Degeneration (AMD),Drug: Intravitreal Aflibercept Injection (IAI),Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,11/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01722045
7293,A Study in Moderate to Severe Rheumatoid Arthritis Participants,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo|Drug: Baricitinib|Drug: cDMARD,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01721057
7294,A Moderate to Severe Rheumatoid Arthritis Study,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo|Drug: Baricitinib|Drug: cDMARD,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/13/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01721044
7295,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,2/21/2013,3/15/2016,https://ClinicalTrials.gov/show/NCT01720446
7296,"Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",Completed,Has Results,Solid Tumors|Lymphoma,Drug: Alisertib|Drug: Esomeprazole|Drug: Rifampin,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,6/25/2013,9/6/2016,https://ClinicalTrials.gov/show/NCT01844583
7297,Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers,Completed,Has Results,Herpes Zoster,Biological: Herpes zoster vaccine (GSK 1437173A)|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2013,1/6/2017,https://ClinicalTrials.gov/show/NCT01767467
7298,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01718509
7299,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01718483
7300,Study to Evaluate the Prospective Payment System,Completed,Has Results,Chronic Kidney Disease,,Amgen,Amgen,,,,,,,,Industry,Observational,6/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01717989
7301,PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Calcitriol 3 mcg/g ointment,Galderma,Galderma,,,,,,,Phase 4,Industry,Interventional,3/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01766440
7302,Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy,Completed,Has Results,FAP|Familial Amyloid Polyneuropathy|TTR|Transthyretin|Amyloidosis,Drug: Inotersen|Drug: Placebo,"Ionis Pharmaceuticals, Inc.","Ionis Pharmaceuticals, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,3/15/2013,11/7/2017,https://ClinicalTrials.gov/show/NCT01737398
7303,"Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Completed,Has Results,Prostate Cancer Metastatic,Drug: DOCETAXEL (XRP6976)|Drug: CABAZITAXEL (XRP6258)|Drug: Prednisone,Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,3/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01718353
7304,Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Cyclophosphamide|Drug: Ixazomib|Drug: Dexamethasone,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,3/5/2014,6/29/2018,https://ClinicalTrials.gov/show/NCT02046070
7305,Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma,Completed,Has Results,Asthma,Drug: QGE031|Drug: Omalizumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,12/12/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01716754
7306,CARTO® 3 System and Real Time Intracardiac Ultrasound,Completed,Has Results,Atrial Fibrillation|Paroxysmal AF,Device: Catheter Ablation,"Biosense Webster, Inc.","Biosense Webster, Inc.",,,,,,,,Industry,Observational,10/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01716663
7307,NVA237 BID Versus Placebo Twelve-week Efficacy Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,11/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01715298
7308,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Completed,Has Results,Lupus Nephritis,Biological: BMS-188667|Drug: Mycophenolate mofetil|Drug: Prednisone|Biological: Placebo matching with BMS-188667,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,1/22/2013,5/30/2018,https://ClinicalTrials.gov/show/NCT01714817
7309,Clinical Investigation of Expanded Designs of a Multifocal IOL,Completed,Has Results,Cataract,Device: Tecnis Multifocal Intraocular Lens|Device: Monofocal Intraocular Lens,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Phase 1,Industry,Interventional,11/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01714635
7310,"Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.",Completed,Has Results,Crohn's Disease,Drug: MEDI2070|Drug: placebo,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,2/1/2013,12/14/2016,https://ClinicalTrials.gov/show/NCT01714726
7311,Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis,Completed,Has Results,Post Menopausal Osteoporosis,Biological: Denosumab|Drug: Zoledronic Acid|Drug: Placebo to Denosumab|Drug: Placebo to Zoledronic Acid,Amgen,Amgen,,,,,,,Phase 4,Industry,Interventional,11/7/2012,1/7/2015,https://ClinicalTrials.gov/show/NCT01732770
7312,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Completed,Has Results,Tuberous Sclerosis Complex-associated Refractory Seizures,Drug: RAD001|Drug: Placebo|Drug: Antiepileptic drug (1 to 3 only)|Drug: open label RAD001 (only used for post-extension phase),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/29/2013,10/25/2017,https://ClinicalTrials.gov/show/NCT01713946
7313,A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin degludec|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,2/21/2013,1/9/2014,https://ClinicalTrials.gov/show/NCT01713530
7314,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Completed,Has Results,Influenza,"Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,10/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01712984
7315,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: QVA149|Drug: QAB149|Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,12/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01712516
7316,A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: dornase alfa [Pulmozyme®],"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 4,Industry,Interventional,12/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01712334
7317,A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy,Completed,Has Results,Diabetic Nephropathy,Drug: PF-04634817|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01712061
7318,NOLAN: Naproxen or Loratadine and Neulasta,Completed,Has Results,Bone Pain in Stage I - III Breast Cancer,Drug: Naproxen|Drug: Loratadine|Biological: Pegfilgrastim|Drug: Chemotherapy,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,11/1/2012,3/18/2015,https://ClinicalTrials.gov/show/NCT01712009
7319,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Baricitinib|Drug: Methotrexate|Drug: Baricitinib Placebo|Drug: MTX Placebo|Drug: Folic Acid,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/12/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01711359
7320,A Non-dispensing Fit Evaluation of Investigational Limbal Ring Soft Contact Lenses With Polyvinylpyrrolidone (PVP) in Asian Eyes,Completed,Has Results,Vision Correction,Device: etafilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/14/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT02036320
7321,A Study in Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Adalimumab|Drug: Baricitinib|Drug: Methotrexate|Drug: Adalimumab Placebo|Drug: Baricitinib Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,10/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01710358
7322,NVA237 Versus Placebo 12-week Efficacy Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,11/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01709864
7323,VERtebral Fracture Treatment Comparisons in Osteoporotic Women,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Teriparatide|Drug: Risedronate|Drug: Placebo|Drug: Calcium|Drug: Vitamin D,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,10/12/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01709110
7324,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",Completed,Has Results,Multiple Sclerosis,Drug: Laquinimod|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,2/20/2013,7/4/2017,https://ClinicalTrials.gov/show/NCT01707992
7325,Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,2/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01707290
7326,A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,COPD,Drug: Placebo|Drug: EP-101 12.5 mcg|Drug: EP-101 25 mcg|Drug: EP-101 50 mcg|Drug: EP-101 100 mcg,Sunovion Respiratory Development Inc.,Sunovion Respiratory Development Inc.,,,,,,,Phase 2,Industry,Interventional,10/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01706536
7327,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/VI 100/25 Inhalation Powder NDPI|Drug: Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Drug: Placebo Inhalation Powder NDPI|Drug: Placebo Inhalation Powder ACCUHALER/DISKUS|Drug: Salbutamol as needed,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/15/2012,6/17/2013,https://ClinicalTrials.gov/show/NCT01706328
7328,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: E/C/F/TDF|Drug: RTV|Drug: ATV|Drug: FTC/TDF|Drug: E/C/F/TDF Placebo|Drug: RTV Placebo|Drug: ATV Placebo|Drug: FTC/TDF Placebo|Drug: E/C/F/TAF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,10/24/2012,9/6/2018,https://ClinicalTrials.gov/show/NCT01705574
7329,Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,1/13/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01705145
7330,A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel,Completed,Has Results,Adult Male Hypogonadism,Drug: Testosterone Gel (FE 999093),Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01703741
7331,"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",Completed,Has Results,Rubella|Measles|Mumps,Biological: Priorix|Biological: M-M-R II|Biological: Varivax|Biological: Havrix|Biological: Prevnar 13,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,11/9/2012,4/16/2015,https://ClinicalTrials.gov/show/NCT01702428
7332,"A Study Of CP-690,550 In Stable Kidney Transplant Patients",Completed,Has Results,Kidney Transplant,"Drug: Placebo|Drug: CP-690,550 5 mg BID|Drug: CP-690,550 15 mg BID|Drug: CP-690,550 30 mg BID",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,9/3/2019,4/5/2019,https://ClinicalTrials.gov/show/NCT01710033
7333,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV,Completed,Has Results,Chronic Hepatitis C Virus,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,9/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01701401
7334,Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain,Completed,Has Results,Neuropathic Pain,Drug: pregabalin|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/12/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01701362
7335,"Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men",Completed,Has Results,Male Hypogonadism,Drug: Oral testosterone undecanoate|Drug: Transdermal testosterone gel (AndroGel),"Clarus Therapeutics, Inc.","Clarus Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,8/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01699178
7336,Safety Study of Albuterol Spiromax® in Subjects With Asthma,Completed,Has Results,Asthma,Drug: Placebo MDPI|Drug: Albuterol MDPI,Teva Pharmaceutical Industries,Teva Pharmaceutical Industries,,,,,,,Phase 3,Industry,Interventional,10/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01698320
7337,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: NVA237|Drug: Long-acting beta 2-agonist (LABA)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01697696
7338,"Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy",Completed,Has Results,Cerebral Amyloid Angiopathy,Biological: Ponezumab|Other: placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01821118
7339,Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: Abrilumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,12/4/2012,4/10/2018,https://ClinicalTrials.gov/show/NCT01696396
7340,Spinal Cord Stimulation for Predominant Low Back Pain,Completed,Has Results,"Failed Back Surgery Syndrome|Back Pain|Pain in Leg, Unspecified",Device: Spinal Cord Stimulation (SCS)|Drug: Optimal Medical Management (OMM),MedtronicNeuro,MedtronicNeuro,,,,,,,Phase 4,Industry,Interventional,1/8/2013,6/20/2017,https://ClinicalTrials.gov/show/NCT01697358
7341,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium|Drug: Placebo matching Olodaterol|Drug: Olodaterol,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,9/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01696058
7342,A Study of Ixekizumab in Participants With Active Psoriatic Arthritis,Completed,Has Results,"Psoriasis, Arthritic",Drug: Ixekizumab|Drug: Placebo|Drug: Adalimumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/12/2019,9/17/2019,https://ClinicalTrials.gov/show/NCT01695239
7343,A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC),Completed,Has Results,Prostate Cancer,Drug: PSMA ADC,"Progenics Pharmaceuticals, Inc.","Progenics Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,9/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01695044
7344,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium|Drug: Placebo matching Olodaterol|Drug: Olodaterol,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,9/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01694771
7345,Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Biological: Abrilumab|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,11/16/2012,4/10/2018,https://ClinicalTrials.gov/show/NCT01694485
7346,Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa,Completed,Has Results,Anemia|Chronic Kidney Disease (CKD),Drug: HX575 epoetin alfa|Drug: US-licensed epoetin alfa,Sandoz,Sandoz,,,,,,,Phase 3,Industry,Interventional,9/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01693029
7347,Adult Attention Deficit Hyperactivity Disorder,Completed,Has Results,Adult Attention Deficit Hyperactivity Disorder,Drug: SEP-225289|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 2,Industry,Interventional,12/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01692782
7348,A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL),Completed,Has Results,Follicular Lymphoma|Diffuse Large B-Cell Lymphoma,Drug: Obinutuzumab|Drug: Pinatuzumab Vedotin|Drug: Polatuzumab Vedotin|Drug: Rituximab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,9/27/2012,2/7/2019,https://ClinicalTrials.gov/show/NCT01691898
7349,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,Completed,Has Results,Asthma,Drug: Mepolizumab IV|Drug: Mepolizumab SC|Drug: IV Placebo|Drug: SC Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/8/2012,1/18/2014,https://ClinicalTrials.gov/show/NCT01691521
7350,MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects,Completed,Has Results,Asthma,Drug: Mepolizumab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/28/2012,5/31/2017,https://ClinicalTrials.gov/show/NCT01691859
7351,Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis,Completed,Has Results,Psoriasis|Psoriatic Arthritis,Drug: Apremilast|Drug: Etanercept|Drug: Placebo tablet|Drug: Placebo injection,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,10/1/2012,4/4/2016,https://ClinicalTrials.gov/show/NCT01690299
7352,Safety and Performance Study of the INGEVITY Lead,Completed,Has Results,Bradycardia|Sinus Node Dysfunction,Device: INGEVITY lead,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,2/19/2019,https://ClinicalTrials.gov/show/NCT01688843
7353,Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension,Completed,Has Results,Hypertension,Drug: LCZ696|Drug: Olmesartan|Drug: LCZ696 matching placebo|Drug: Olmesartan matching placebo|Drug: amlodipine|Drug: hydrochlorothiazide,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,12/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01692301
7354,NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study),Completed,Has Results,Tardive Dyskinesia,Drug: NBI-98854|Drug: Placebo,Neurocrine Biosciences,Neurocrine Biosciences,,,,,,,Phase 2,Industry,Interventional,9/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01688037
7355,Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF,Completed,Has Results,Infertility,Drug: AFOLIA|Drug: Gonal-f® RFF,Fertility Biotech AG,Fertility Biotech AG,,,,,,,Phase 3,Industry,Interventional,11/25/2013,11/14/2016,https://ClinicalTrials.gov/show/NCT01687712
7356,Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation,Completed,Has Results,Paroxysmal Atrial Fibrillation (PAF),Device: Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|Device: FDA Approved Open-Irrigated Ablation Catheter,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,10/12/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01687166
7357,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",Completed,Has Results,Asthma,Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg|Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg|Drug: Fluticasone Furoate 100 mcg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/20/2012,10/15/2013,https://ClinicalTrials.gov/show/NCT01686633
7358,Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP),Completed,Has Results,Chronic Low Back Pain,Drug: Oxycodone DETERx|Drug: Placebo,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",,,,,,,Phase 3,Industry,Interventional,8/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01685684
7359,Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure,Completed,Has Results,Carotid Artery Disease,Device: MICHI NPS+f,Silk Road Medical,Silk Road Medical,,,,,,,Phase 3,Industry,Interventional,11/12/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01685567
7360,Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis,Completed,Has Results,Sinusitis,Device: Balloon sinus dilation|Drug: Medical Management,Acclarent,Acclarent,,,,,,,,Industry,Observational,9/1/2012,8/1/2015,https://ClinicalTrials.gov/show/NCT01685229
7361,LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: LDK378,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,11/26/2012,3/29/2016,https://ClinicalTrials.gov/show/NCT01685060
7362,Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury,Completed,Has Results,Spinal Cord Injury|Muscle Spasticity,Drug: Fampridine-SR|Drug: Placebo,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,6/2/2019,2/4/2019,https://ClinicalTrials.gov/show/NCT01683838
7363,Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery,Completed,Has Results,Blepharitis|Dry Eye Syndrome,Device: LipiFlow Pre-Treatment|Device: LipiFlow Post-treatment,"TearScience, Inc.","TearScience, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/13/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01808560
7364,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (Insulin glargine new formulation)|Drug: Lantus (Insulin glargine),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,9/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01683266
7365,"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.",Completed,Has Results,"Meningococcal Disease|Infections, Meningococcal",Biological: MenACWY-CRM,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/7/2012,5/30/2014,https://ClinicalTrials.gov/show/NCT01682876
7366,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: QVA149|Drug: QAB149|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01682863
7367,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life,Completed,Has Results,Measles|Mumps|Rubella,Biological: Priorix|Biological: M-M-R II|Biological: Varivax|Biological: Havrix|Biological: Prevnar 13,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/10/2012,8/18/2015,https://ClinicalTrials.gov/show/NCT01681992
7368,A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy,Completed,Has Results,Narcolepsy,Drug: ADX-N05|Drug: Placebo,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,9/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01681121
7369,Investigation of Sacroiliac Fusion Treatment (INSITE),Completed,Has Results,Degenerative Sacroiliitis|Sacroiliac Joint Disruption,Device: iFuse Implant System|Other: Non-surgical management,"SI-BONE, Inc.","SI-BONE, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/12/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT01681004
7370,Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/31/2012,8/22/2013,https://ClinicalTrials.gov/show/NCT01680341
7371,TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome),Completed,Has Results,Carcinoid Syndrome,Drug: Telotristat etiprate|Drug: Placebo-matching telotristat etiprate,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,1/8/2013,3/21/2016,https://ClinicalTrials.gov/show/NCT01677910
7372,A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Dexamethasone,Amgen,Amgen,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/4/2012,10/31/2018,https://ClinicalTrials.gov/show/NCT01677858
7373,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: HOE901-U300 (new formulation of insulin glargine)|Drug: Lantus (insulin glargine),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,8/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01676220
7374,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: liraglutide|Drug: exenatide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/29/2012,3/11/2014,https://ClinicalTrials.gov/show/NCT01676116
7375,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects,Completed,Has Results,Low Back Pain,Drug: Buprenorphine|Drug: Placebo,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 3,Industry,Interventional,9/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01675167
7376,Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures,Completed,Has Results,Dupuytren's Contracture,Biological: XIAFLEX / XIAPEX,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01674634
7377,Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma,Completed,Has Results,Melanoma,Drug: Ipilimumab|Biological: Vemurafenib,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,9/13/2012,5/12/2015,https://ClinicalTrials.gov/show/NCT01673854
7378,Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Melliuts, Type 2",Other: Placebo|Drug: 25 mg PF-05231023|Drug: 50 mg PF-05231023|Drug: 100 mg PF-05231023|Drug: 150 mg PF-05231023,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,10/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01673178
7379,Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study,Completed,Has Results,Restless Legs Syndrome,Drug: GSK1838262 600 mg|Drug: GSK1838262 450 mg|Drug: GSK1838262 300 mg|Drug: GSK1838262 Placebo match,"XenoPort, Inc.","XenoPort, Inc.",,,,,,,Phase 4,Industry,Interventional,6/12/2019,,https://ClinicalTrials.gov/show/NCT01668667
7380,Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency,Completed,Has Results,Growth Hormone Deficiency With Pituitary Anomalies,Drug: Macimorelin|Drug: Insulin,AEterna Zentaris,AEterna Zentaris,,,,,,,Phase 3,Industry,Interventional,12/3/2015,11/29/2016,https://ClinicalTrials.gov/show/NCT02558829
7381,"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults",Completed,Has Results,Hepatitis C|Human Immunodeficiency Virus,Drug: SOF|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,7/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01667731
7382,A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma,Completed,Has Results,Melanoma,Drug: Vemurafenib|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,9/24/2012,7/13/2018,https://ClinicalTrials.gov/show/NCT01667419
7383,Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections,Completed,Has Results,cUTI,Drug: Eravacycline|Drug: Levofloxacin,"Tetraphase Pharmaceuticals, Inc.","Tetraphase Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,10/6/2014,8/21/2015,https://ClinicalTrials.gov/show/NCT01978938
7384,Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura,Completed,Has Results,Migraine|Headaches,Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet,Avanir Pharmaceuticals,Avanir Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01667679
7385,"Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant",Completed,Has Results,Renal Failure,Drug: LCP-Tacro tablets|Drug: Prograf,Veloxis Pharmaceuticals,Veloxis Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01666951
7386,A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel,Completed,Has Results,Adult Male Hypogonadism,Drug: Testosterone gel (FE 999303),Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01665599
7387,The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s),Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Plus|Device: SYNERGY,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,11/12/2019,12/22/2018,https://ClinicalTrials.gov/show/NCT01665053
7388,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: placebo|Drug: liraglutide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,10/1/2012,12/31/2013,https://ClinicalTrials.gov/show/NCT01664247
7389,Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium bromide|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,8/1/2012,5/1/2014,https://ClinicalTrials.gov/show/NCT01663987
7390,A Study LY2228820 for Recurrent Ovarian Cancer,Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: LY2228820|Drug: Carboplatin|Drug: Placebo|Drug: Gemcitabine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/12/2019,5/11/2018,https://ClinicalTrials.gov/show/NCT01663857
7391,A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls,Completed,Has Results,Cytomegalovirus Infections,Drug: Valganciclovir,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,1/30/2012,12/30/2016,https://ClinicalTrials.gov/show/NCT01663740
7392,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",Completed,Has Results,Metastatic Breast Cancer,Drug: Bevacizumab [Avastin]|Drug: Paclitaxel|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,8/27/2012,11/21/2017,https://ClinicalTrials.gov/show/NCT01663727
7393,Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium bromide|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,8/1/2012,4/1/2014,https://ClinicalTrials.gov/show/NCT01662986
7394,"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis",Completed,Has Results,Deep Vein Thrombosis|Venous Thrombosis,Drug: edoxaban tosylate|Drug: enoxaparin/unfractionated heparin|Drug: warfarin,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 2,Industry,Interventional,8/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01662908
7395,Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery,Completed,Has Results,Vascular Surgical Bleeding,Biological: Fibrin Sealant Grifols|Procedure: Manual Compression,"Instituto Grifols, S.A.|Grifols Biologicals, LLC","Instituto Grifols, S.A.","Grifols Biologicals, LLC",,,,,,Phase 3,Industry,Interventional,8/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01662856
7396,A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine,Completed,Has Results,Migraine Disorders,Biological: Botulinum toxin type A Dose 1|Biological: Botulinum toxin type A Dose 2|Drug: Placebo (Normal Saline),Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,10/12/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01662492
7397,A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,8/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01662063
7398,Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear,Completed,Has Results,Myopia,Device: delefilcon A|Device: etafilcon A,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01669629
7399,Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age,Completed,Has Results,Meningitis|Meningococcal Infection|Diphtheria|Tetanus|Pertussis|Haemophilus Influenzae Serotype b (Hib),"Biological: Meningococcal polysaccharide diphtheria toxoid conjugate|Biological: Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,7/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01659996
7400,A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology,Completed,Has Results,Prostate Cancer,Drug: Drug: 99mTc-MIP-1404,"Molecular Insight Pharmaceuticals, Inc.","Molecular Insight Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,8/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01667536
7401,Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Idelalisib|Drug: Ofatumumab,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/4/2012,8/15/2018,https://ClinicalTrials.gov/show/NCT01659021
7402,A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB),Completed,Has Results,Medulloblastoma,Drug: LDE225|Drug: TMZ,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/6/2013,10/5/2016,https://ClinicalTrials.gov/show/NCT01708174
7403,An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects,Completed,Has Results,Opioid Dependence,Drug: BEMA Buprenorphine NX films,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 2,Industry,Interventional,8/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01666119
7404,Open Label Extension in Adults With Binge Eating Disorder (BED),Completed,Has Results,Binge Eating Disorder,Drug: Lisdexamfetamine dimesylate,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,8/21/2012,10/21/2014,https://ClinicalTrials.gov/show/NCT01657019
7405,Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors,Completed,Has Results,Hyperopia,Device: LASIK correction of hyperopic refractive errors,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Not Applicable,Industry,Interventional,12/12/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01675479
7406,A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.,Completed,Has Results,Epilepsy,Drug: Lacosamide,UCB Pharma,UCB Pharma,,,,,,,Phase 2,Industry,Interventional,2/13/2014,4/10/2018,https://ClinicalTrials.gov/show/NCT01969851
7407,Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors,Other: No treatment given,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 2,Industry,Interventional,4/3/2015,4/15/2016,https://ClinicalTrials.gov/show/NCT02541942
7408,A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR),Completed,Has Results,Perennial Allergic Rhinitis,Drug: ciclesonide nasal aerosol|Drug: ciclesonide nasal spray,Sunovion,Sunovion,,,,,,,Phase 4,Industry,Interventional,9/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01654536
7409,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Completed,Has Results,Anemia in Chronic Kidney Disease Patients Not on Dialysis,Biological: Darbepoetin alfa|Other: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,7/30/2012,10/19/2017,https://ClinicalTrials.gov/show/NCT01652872
7410,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,Diabetes Type 2,Drug: Exenatide once weekly suspension|Drug: Sitagliptin|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,2/13/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01652729
7411,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Exenatide once weekly suspension|Drug: Exenatide twice daily,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,1/13/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01652716
7412,Open-Label Lesinurad Monotherapy Extension Study in Gout,Completed,Has Results,Gout,Drug: lesinurad,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 3,Industry,Interventional,8/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01650246
7413,"Multicenter, Open-label, Safety and Tolerability Study",Completed,Has Results,Schizophrenia,Drug: OPC-34712,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,8/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01649557
7414,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Saxagliptin|Drug: Metformin immediate release (IR),AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01646320
7415,Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04),Completed,Has Results,Rheumatoid Arthritis,Biological: Rituximab-Pfizer (PF-05280586) x 3 courses|Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses,Pfizer,Pfizer,,,,,,,Not Applicable,Industry,Interventional,8/16/2012,3/14/2016,https://ClinicalTrials.gov/show/NCT01643928
7416,Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents,Completed,Has Results,Gastroesophageal Reflux Disease|Erosive Esophagitis,Drug: Dexlansoprazole|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,7/12/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01642615
7417,Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents,Completed,Has Results,Gastroesophageal Reflux Disease,Drug: Dexlansoprazole,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,7/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01642602
7418,"OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension",Completed,Has Results,Eosinophilic Esophagitis,Drug: Oral Budesonide Suspension (MB-9)|Drug: Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,7/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01642212
7419,Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF,Completed,Has Results,Cystic Fibrosis,Drug: AZLI|Drug: Placebo to match AZLI|Drug: Tobramycin inhalation solution,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01641822
7420,"Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",Completed,Has Results,Chronic Hepatitis C,Drug: Sofosbuvir|Drug: RBV|Drug: PEG,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,6/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01641640
7421,Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma,Completed,Has Results,Asthma,Drug: Mepolizumab|Drug: Placebo|Drug: OCS (prednisone/prednisolone),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01691508
7422,Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma,Completed,Has Results,Asthma,"Drug: Formoterol Fumarate in the Pressair DPI, Low Dose|Drug: Formoterol Fumarate in the Pressair DPI, High Dose|Drug: Foradil Aerolizer, Low Dose|Drug: Foradil Aerolizer, High Dose|Drug: Placebo",AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,6/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01641081
7423,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Completed,Has Results,Moderate to Severe Chronic Plaque-Type Psoriasis,Drug: AIN457 150 mg|Drug: AIN457 300 mg|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/16/2012,5/4/2017,https://ClinicalTrials.gov/show/NCT01640951
7424,A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma,Completed,Has Results,Asthma,Drug: GSK573719 Active treatment or Placebo|Procedure: GSK573719 (Sub-group cohort)|Drug: Salbutamol/Albuterol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01641692
7425,Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects,Completed,Has Results,"Infections, Meningococcal",Biological: Meningococcal vaccine GSK134612,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/10/2012,3/3/2015,https://ClinicalTrials.gov/show/NCT01641042
7426,Sacroiliac Joint Fusion With iFuse Implant System (SIFI),Completed,Has Results,Degenerative Sacroiliitis|Sacroiliac Joint Disruption,,"SI-BONE, Inc.","SI-BONE, Inc.",,,,,,,,Industry,Observational,7/12/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01640353
7427,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS,Completed,Has Results,Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation,Device: THERMOCOOL® SMARTTOUCH™ Catheter,"Biosense Webster, Inc.","Biosense Webster, Inc.",,,,,,,Phase 3,Industry,Interventional,7/1/2012,10/1/2014,https://ClinicalTrials.gov/show/NCT01639495
7428,Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant,Completed,Has Results,Recurrent Chronic Hepatitis C Virus|Post Liver Transplant,Drug: Sofosbuvir|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,11/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01687270
7429,Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects,Completed,Has Results,Gastroduodenal Ulceration,Drug: PL2200|Drug: Aspirin tablets,PLx Pharma,PLx Pharma,,,,,,,Phase 2,Industry,Interventional,9/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01646814
7430,Safety Study of Lifitegrast to Treat Dry Eye,Completed,Has Results,Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,10/16/2012,3/3/2014,https://ClinicalTrials.gov/show/NCT01636206
7431,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Completed,Has Results,Plaque-type Psoriasis,Drug: Placebo|Drug: Secukinumab 150mg|Drug: Secukinumab 300mg,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/17/2012,10/27/2016,https://ClinicalTrials.gov/show/NCT01636687
7432,Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease,Completed,Has Results,Relapsed Multiple Myeloma|End-stage Renal Disease,Drug: Carfilzomib,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,1/14/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01949532
7433,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects,Completed,Has Results,Low Back Pain,Drug: Buprenorphine|Drug: Placebo,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 3,Industry,Interventional,8/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01633944
7434,A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction,Completed,Has Results,Meibomian Gland Dysfunction,Drug: AGN-195263 0.1%|Drug: AGN-195263 0.03%|Drug: AGN-195263 0.01%|Drug: AGN-195263 Vehicle,Allergan,Allergan,,,,,,,Phase 2,Industry,Interventional,8/22/2012,2/5/2015,https://ClinicalTrials.gov/show/NCT01633788
7435,Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study,Completed,Has Results,Polycythemia Vera,Drug: Ruxolitinib|Drug: Hydroxyurea (HU)|Drug: HU-placebo|Drug: Ruxolitinib-placebo,Incyte Corporation,Incyte Corporation,,,,,,,Phase 3,Industry,Interventional,6/12/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01632904
7436,NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: NWP09|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,7/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01654250
7437,Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis,Completed,Has Results,Postmenopausal Women With Osteoporosis,Biological: Romosozumab|Drug: Alendronate|Drug: Placebo to Romosozumab|Drug: Placebo to Alendronate,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,5/4/2012,6/29/2017,https://ClinicalTrials.gov/show/NCT01631214
7438,"A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin",Completed,Has Results,Chronic Renal Failure Requiring Hemodialysis,Biological: Epoetin Hospira,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,5/31/2012,2/13/2015,https://ClinicalTrials.gov/show/NCT01628120
7439,"A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin",Completed,Has Results,Chronic Renal Failure Requiring Hemodialysis,Biological: Epoetin Hospira,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,7/16/2012,1/2/2015,https://ClinicalTrials.gov/show/NCT01628107
7440,A Study of Ketamine in Patients With Treatment-resistant Depression,Completed,Has Results,Major Depressive Disorder,Drug: Placebo|Drug: Ketamine,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,8/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01627782
7441,A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Completed,Has Results,Schizophrenia,"Drug: ALKS 9072, Low|Drug: ALKS 9072, High","Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,6/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01626456
7442,Safety and Effectiveness of Wavefront-guided LASIK for the Correction of Mixed Astigmatism,Completed,Has Results,Astigmatism,Device: LASIK,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Not Applicable,Industry,Interventional,12/6/2012,11/22/2016,https://ClinicalTrials.gov/show/NCT01675492
7443,Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies,Completed,Has Results,Chronic Hepatitis C,Drug: SOF|Drug: RBV|Drug: Peg-IFN,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,6/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01625338
7444,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: LY2189265|Drug: Liraglutide|Drug: Metformin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,6/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01624259
7445,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,Completed,Has Results,Relapsing Remitting Multiple Sclerosis,Drug: Fingolimod|Drug: Disease Modifying therapy,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,6/8/2012,7/13/2015,https://ClinicalTrials.gov/show/NCT01623596
7446,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: fluticasone furoate/vilanterol 100/25mcg|Drug: tiotropium bromide 18mcg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/1/2012,12/21/2012,https://ClinicalTrials.gov/show/NCT01627327
7447,"A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects",Completed,Has Results,Obesity,Device: ReShape Duo balloon|Other: Diet counseling|Other: Exercise counseling,ReShape Lifesciences,ReShape Lifesciences,,,,,,,Not Applicable,Industry,Interventional,8/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01673698
7448,Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps,Completed,Has Results,Chronic Sinusitis With or Without Nasal Polyps,Drug: Fluticasone Propionate,Optinose US Inc.,Optinose US Inc.,,,,,,,Phase 3,Industry,Interventional,9/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01623323
7449,12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device,Completed,Has Results,Nasal Polyps,Drug: Fluticasone Propionate,Optinose US Inc.,Optinose US Inc.,,,,,,,Phase 3,Industry,Interventional,9/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01623310
7450,"Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety",Completed,Has Results,Bilateral Nasal Polyposis,Drug: Fluticasone Propionate,Optinose US Inc.,Optinose US Inc.,,,,,,,Phase 3,Industry,Interventional,11/19/2013,10/1/2015,https://ClinicalTrials.gov/show/NCT01622569
7451,Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Actively Extending Plaque Psoriasis|Moderate to Severe Plaque Psoriasis,Drug: IMO-3100 at 0.16 mg/kg|Drug: Saline for Injection|Drug: IMO-3100 at 0.32 mg/kg,"Idera Pharmaceuticals, Inc.","Idera Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,5/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01622348
7452,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age,Completed,Has Results,Rubella|Mumps|Measles,Biological: Priorix|Biological: M-M-R II|Biological: Kinrix|Biological: ProQuad,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/21/2012,11/9/2015,https://ClinicalTrials.gov/show/NCT01621802
7453,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Completed,Has Results,Type 2 Diabetes|Chronic Kidney Disease,Drug: Dulaglutide|Drug: Insulin glargine|Drug: Insulin lispro,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,7/12/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01621178
7454,Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/14/2012,8/20/2013,https://ClinicalTrials.gov/show/NCT01620489
7455,A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: Placebo|Drug: PF-00547659 SC Injection,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,11/12/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01620255
7456,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Metformin IR|Drug: Placebo matching with Saxagliptin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,6/12/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01619059
7457,Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Macitentan 10 mg|Drug: Placebo,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,5/21/2013,12/1/2016,https://ClinicalTrials.gov/show/NCT01743001
7458,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus,Completed,Has Results,Hepatitis B,Biological: Engerix™-B vaccine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,7/24/2012,12/18/2013,https://ClinicalTrials.gov/show/NCT01627340
7459,KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL),Completed,Has Results,Adult T-cell Leukemia-Lymphoma,Biological: KW-0761|Drug: Pralatrexate|Drug: gemcitabine plus oxaliplatin|Drug: DHAP,"Kyowa Kirin Pharmaceutical Development, Inc.","Kyowa Kirin Pharmaceutical Development, Inc.",,,,,,,Phase 2,Industry,Interventional,6/12/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT01626664
7460,A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip,Completed,Has Results,"Osteoarthritis, Hip",Device: Synvisc-One (hylan G-F 20)|Device: Placebo,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Not Applicable,Industry,Interventional,9/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01618708
7461,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),Completed,Has Results,Coronary Artery Disease (CAD),Drug: Regadenoson|Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI),"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","Astellas Pharma Global Development, Inc.",Astellas Pharma Inc,,,,,,Phase 3,Industry,Interventional,6/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01618669
7462,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/29/2012,10/23/2013,https://ClinicalTrials.gov/show/NCT01618162
7463,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01617434
7464,Belotero Post Approval Study,Completed,Has Results,Nasolabial Folds,Device: Belotero®,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 4,Industry,Interventional,6/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01635855
7465,"A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer",Completed,Has Results,Breast Cancer,Drug: LCL161|Drug: paclitaxel,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01617668
7466,"Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device",Completed,Has Results,Bilateral Nasal Polyposis,Drug: Fluticasone propionate,Optinose US Inc.,Optinose US Inc.,,,,,,,Phase 3,Industry,Interventional,10/30/2013,7/3/2015,https://ClinicalTrials.gov/show/NCT01624662
7467,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT),Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,7/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01614457
7468,An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis,Completed,Has Results,Granulomatosis With Polyangiitis|Microscopic Polyangiitis,Drug: Rituximab,"Genentech, Inc.","Genentech, Inc.",,,,,,,,Industry,Observational,6/20/2012,4/28/2017,https://ClinicalTrials.gov/show/NCT01613599
7469,BIOHELIX-I Bare Metal Stent Study,Completed,Has Results,Coronary Arteries Disease,Device: PRO-Kinetic Energy Stent,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,11/12/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT01612767
7470,Lurasidone Pediatric Pharmacokinetics Study,Completed,Has Results,Schizophrenia|Autism,Drug: Lurasidone,Sunovion,Sunovion,,,,,,,Phase 1,Industry,Interventional,6/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01620060
7471,Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients,Completed,Has Results,Cytomegalovirus (CMV),Drug: Maribavir,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,7/17/2012,12/5/2014,https://ClinicalTrials.gov/show/NCT01611974
7472,"Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,7/13/2012,2/1/2017,https://ClinicalTrials.gov/show/NCT01610414
7473,Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System,Completed,Has Results,Chlamydia Trachomatis|Neisseria Gonorrhoeae Infection,Device: APTIMA COMBO 2 Assay (AC2 Assay),"Gen-Probe, Incorporated","Gen-Probe, Incorporated",,,,,,,,Industry,Observational,11/10/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01733069
7474,Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies,Completed,Has Results,Colorectal Cancer,Drug: TAS-102|Drug: Placebo,"Taiho Oncology, Inc.","Taiho Oncology, Inc.",,,,,,,Phase 3,Industry,Interventional,6/17/2012,5/23/2016,https://ClinicalTrials.gov/show/NCT01607957
7475,Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder,Completed,Has Results,Female Orgasmic Disorder,Drug: Placebo|Drug: Low dose TBS-2|Drug: Medium dose TBS-2|Drug: High dose TBS-2,Acerus Pharmaceuticals Corporation,Acerus Pharmaceuticals Corporation,,,,,,,Phase 2,Industry,Interventional,5/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01607658
7476,Evaluation of a New Cardiac Biomarker Assay,Completed,Has Results,Acute Coronary Syndrome|Acute Myocardial Infarction,Device: ARCHITECT STAT High Sensitive Troponin I Assay,Abbott Diagnostics Division,Abbott Diagnostics Division,,,,,,,Phase 3,Industry,Interventional,6/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01608100
7477,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Metformin XR|Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Placebo matching with Saxagliptin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,7/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01606007
7478,A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke,Completed,Has Results,Ischemic Stroke,Drug: placebo/dalfampridine-ER|Drug: dalfampridine-ER/placebo,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 2,Industry,Interventional,5/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01605825
7479,Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100,Completed,Has Results,Prostate Cancer|Castration Resistant Prostate Cancer|Pain|Prostatic Neoplasms,Drug: cabozantinib|Drug: prednisone,Exelixis,Exelixis,,,,,,,Phase 3,Industry,Interventional,7/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01605227
7480,Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION),Completed,Has Results,Chronic Hepatitis C,Drug: SOF|Drug: RBV|Drug: Placebo to match SOF|Drug: Placebo to match RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,6/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01604850
7481,BOTOX® Treatment in Pediatric Lower Limb Spasticity,Completed,Has Results,Pediatrics|Muscle Spasticity|Cerebral Palsy,Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo),Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,9/11/2012,6/28/2017,https://ClinicalTrials.gov/show/NCT01603628
7482,BOTOX® Treatment in Pediatric Upper Limb Spasticity,Completed,Has Results,Pediatrics|Muscle Spasticity|Cerebral Palsy|Stroke,Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo),Allergan,Allergan,,,,,,,Phase 3,Industry,Interventional,7/12/2012,7/6/2017,https://ClinicalTrials.gov/show/NCT01603602
7483,Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids,Completed,Has Results,Moderate-to-Severe Asthma,Biological: Anti-GM-CSF Monoclonal Antibody 400mg|Other: Placebo,"Humanigen, Inc.","Humanigen, Inc.",,,,,,,Phase 2,Industry,Interventional,7/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01603277
7484,Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients,Completed,Has Results,Acute Coronary Syndrome,Drug: Ticagrelor|Drug: Clopidogrel,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,7/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01603082
7485,A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM),Completed,Has Results,Multiple Myeloma,Drug: Placebo|Drug: Dexamethasone|Drug: Bortezomib|Biological: Tabalumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,7/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01602224
7486,Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic","Drug: AN2728 Topical Ointment, 2% QD|Drug: AN2728 Topical Ointment, 0.5% QD|Drug: AN2728 Topical Ointment, 2% BID|Drug: AN2728 Topical Ointment, 0.5% BID",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01602341
7487,A Study to Explore the Utility of Fractional Exhaled Nitric Oxide (FeNO) Compared With Methacholine Challenge (MCC) Testing in the Assessment of Patients With Suspected But Undiagnosed Asthma,Completed,Has Results,Asthma,Device: NIOX MINO® Instrument (09-1100),Aerocrine AB,Aerocrine AB,,,,,,,,Industry,Observational,6/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01648920
7488,Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir,Completed,Has Results,Hepatitis C Virus,Biological: Peginterferon Lambda-1a|Biological: Peginterferon Alfa-2a|Drug: Ribavirin|Drug: Telaprevir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,6/14/2012,5/15/2015,https://ClinicalTrials.gov/show/NCT01598090
7489,"Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: EVG/COBI/FTC/TDF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2|Phase 3,Industry,Interventional,12/6/2012,1/29/2018,https://ClinicalTrials.gov/show/NCT01721109
7490,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Completed,Has Results,Melanoma,Drug: Dabrafenib|Drug: Vemurafenib|Drug: Trametinib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/4/2012,4/25/2019,https://ClinicalTrials.gov/show/NCT01597908
7491,"The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury",Completed,Has Results,"Lung Injury, Acute",Drug: Dose 1 GSK2586881|Drug: Dose 2 GSK2586881|Drug: Dose 3 GSK2586881|Drug: Dose 4 GSK2586881|Drug: Placebo (saline),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/1/2012,10/6/2014,https://ClinicalTrials.gov/show/NCT01597635
7492,Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions,Completed,Has Results,"Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic",Drug: R932333|Drug: Placebo,Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,8/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01597050
7493,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Infection,Drug: Topical pexiganan cream 0.8%|Drug: Topical placebo cream|Other: Standard wound care,"Dipexium Pharmaceuticals, Inc.","Dipexium Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,6/14/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01594762
7494,"Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza",Completed,Has Results,Virus Diseases,Drug: GSK1325756 (Danirixin)|Drug: Placebo To Match GSK1325756|Drug: Oseltamivir Phosphate|Drug: Placebo To Match Oseltamivir Phosphate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/1/2015,4/25/2016,https://ClinicalTrials.gov/show/NCT02469298
7495,Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients,Completed,Has Results,Diabetic Nephropathy,Drug: Repository Corticotropin Injection|Drug: Placebo,Mallinckrodt,Mallinckrodt,,,,,,,Phase 2,Industry,Interventional,5/12/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01601236
7496,"An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",Completed,Has Results,Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS),Drug: Memantine Hydrochloride (HCl),Forest Laboratories,Forest Laboratories,,,,,,,Phase 2,Industry,Interventional,6/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01592786
7497,"Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine",Completed,Has Results,Autistic Disorder|Autism|Asperger's Disorder|Asperger Syndrome|Autism Spectrum Disorders|Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS),Drug: Memantine Hydrochloride (HCl)|Drug: Placebo capsules,Forest Laboratories,Forest Laboratories,,,,,,,Phase 2,Industry,Interventional,9/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01592747
7498,Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin,Completed,Has Results,Hypercholesterolemia,Drug: PBO|Drug: 200mg PF-04950615 (RN316)|Drug: 300mg PF-04950615 (RN316)|Drug: PF-04950615,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,7/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01592240
7499,Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy,Completed,Has Results,Chronic Pain,Device: StimRouter - active stimulation|Device: StimRouter - Control,Bioness Inc,Bioness Inc,,,,,,,Not Applicable,Industry,Interventional,4/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01592344
7500,ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma,Completed,Has Results,Neuroblastoma,Biological: ch14.18 -NCI|Biological: ch14.18-UTC|Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Biological: Aldesleukin (IL-2)|Drug: Isotretinoin,United Therapeutics,United Therapeutics,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01592045
7501,A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma,Completed,Has Results,Asthma,Drug: Placebo|Drug: R940343 1mg|Drug: R940343 2mg,Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01591044
7502,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Infection,Drug: Topical pexiganan cream 0.8%|Drug: Topical placebo cream|Other: Standard wound care,"Dipexium Pharmaceuticals, Inc.","Dipexium Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,6/14/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01590758
7503,Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease,Completed,Has Results,Huntington Disease,Drug: PBT2|Drug: Placebo,Prana Biotechnology Limited,Prana Biotechnology Limited,,,,,,,Phase 2,Industry,Interventional,4/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01590888
7504,PROMUS Element Plus US Post-Approval Study,Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Plus Coronary Stent System|Drug: Aspirin|Drug: P2Y12 antagonist,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,5/12/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT01589978
7505,Effect of KYG0395 on Primary Dysmenorrhea,Completed,Has Results,Primary Dysmenorrhea,Drug: high dose KYG0395|Drug: lower dose KYG0395|Drug: Placebo,"Jiangsu Kanion Pharmaceutical Co., Ltd","Jiangsu Kanion Pharmaceutical Co., Ltd",,,,,,,Phase 2,Industry,Interventional,5/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01588236
7506,Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: PT003|Drug: PT001|Drug: PT005|Drug: Tiotropium inhalation powder,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,4/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01587079
7507,Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,Completed,Has Results,Neoplasm Malignant,Drug: SAR245408|Drug: SAR245409,Sanofi,Sanofi,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/20/2012,5/23/2018,https://ClinicalTrials.gov/show/NCT01587040
7508,NAVISTAR® THERMOCOOL® SF Catheter: Observational Study,Completed,Has Results,Atrial Fibrillation|Paroxysmal Arrhythmia,Device: Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter),"Biosense Webster, Inc.","Biosense Webster, Inc.",,,,,,,,Industry,Observational,4/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01585961
7509,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Completed,Has Results,Melanoma,Drug: dabrafenib|Drug: dabrafenib plus trametinib placebo|Drug: Trametinib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,5/4/2012,2/28/2019,https://ClinicalTrials.gov/show/NCT01584648
7510,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,5/2/2012,10/25/2018,https://ClinicalTrials.gov/show/NCT01583374
7511,Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study),Completed,Has Results,Venous Thromboembolism (VTE),Drug: Betrixaban|Drug: Enoxaparin,Portola Pharmaceuticals,Portola Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/12/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01583218
7512,A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2605541|Drug: Insulin glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,5/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01582451
7513,"An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.",Completed,Has Results,Cushing's Disease,Drug: Pasireotide sub-cutaneous,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,8/16/2011,1/26/2017,https://ClinicalTrials.gov/show/NCT01582061
7514,Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors,Completed,Has Results,Solid Tumors,Drug: lurbinectedin (PM01183),PharmaMar,PharmaMar,,,,,,,Phase 2,Industry,Interventional,8/12/2015,8/19/2016,https://ClinicalTrials.gov/show/NCT02451007
7515,Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents,Completed,Has Results,Tetanus|Diphtheria|Pertussis|Whooping Cough,"Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,6/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01629589
7516,"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.",Completed,Has Results,Renal Function|Liver Transplant,"Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.",Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/12/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01598987
7517,"Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification",Completed,Has Results,Intraocular Lens Replacement,Drug: OMS302|Drug: Placebo,Omeros Corporation,Omeros Corporation,,,,,,,Phase 3,Industry,Interventional,4/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01579565
7518,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications,Completed,Has Results,Asthma,Drug: Fp MDPI|Other: Placebo MDPI|Drug: Flovent Diskus|Drug: albuterol/salbutamol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,4/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01576718
7519,Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo,Completed,Has Results,Crohn's Disease,Biological: Trichuris suis ova (TSO)|Biological: Placebo,"Coronado Biosciences, Inc.","Coronado Biosciences, Inc.",,,,,,,Phase 2,Industry,Interventional,7/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01576471
7520,Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,Completed,Has Results,Advanced Cancer,Drug: crizotinib,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,7/12/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01576406
7521,Evaluation of the GORE TIGRIS Vascular Stent,Completed,Has Results,Peripheral Arterial Disease,Device: TIGRIS Vascular Stent|Device: BARD LifeStent,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,4/12/2019,8/17/2019,https://ClinicalTrials.gov/show/NCT01576055
7522,Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids,Completed,Has Results,"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor",Drug: Denosumab|Drug: Placebo for risendronate|Drug: Risendronate|Drug: Placebo for denosumab,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,3/28/2012,6/29/2017,https://ClinicalTrials.gov/show/NCT01575873
7523,Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Romosozumab|Drug: Placebo|Drug: Denosumab,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,3/15/2012,12/28/2016,https://ClinicalTrials.gov/show/NCT01575834
7524,A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors,Completed,Has Results,Solid Tumors,Biological: Necitumumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01624467
7525,"This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296",Completed,Has Results,Bipolar I Disorder,Drug: Lurasidone,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,6/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01575561
7526,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors",Completed,Has Results,Solid Tumors,Biological: MEDI0639,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,4/12/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01577745
7527,Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.,Completed,Has Results,Smoking Cessation,Drug: placebo|Drug: varenicline tartrate|Drug: bupropion hydrochloride|Drug: Nicotine Replacement Therapy Patch,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,5/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01574703
7528,An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease,Completed,Has Results,Hyperphosphatemia|Chronic Kidney Disease,Drug: Placebo|Drug: Sevelamer carbonate,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,5/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01574326
7529,Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children,Completed,Has Results,Asthma,Drug: Fluticasone propionate 100mcg|Drug: Placebo|Drug: Vilanterol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01573767
7530,The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy,Completed,Has Results,Colorectal Cancer,Drug: Methylene Blue MMX®|Drug: Placebo,Cosmo Technologies Ltd,Cosmo Technologies Ltd,,,,,,,Phase 3,Industry,Interventional,9/13/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT01694966
7531,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Drug: Aclidinium bromide|Drug: Formoterol Fumarate|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01572792
7532,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Completed,Has Results,Breast Cancer,Drug: Paclitaxel|Drug: BKM120 matching placebo|Drug: BKM120,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2|Phase 3,Industry,Interventional,8/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01572727
7533,A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Chronic Pain|Low Back Pain|Analgesia,Drug: ALO-02|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01571362
7534,"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,4/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01570751
7535,"8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension",Completed,Has Results,Hypertension,Drug: Aliskiren,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,4/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01570686
7536,Transition From Alendronate to Romosozumab (AMG 785),Completed,Has Results,Osteoporosis,Drug: Romosozumab,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,3/30/2012,11/21/2012,https://ClinicalTrials.gov/show/NCT01588509
7537,Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS),Completed,Has Results,Restless Legs Syndrome,Drug: Rotigotine|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,3/12/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01569464
7538,The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome,Completed,Has Results,Bladder Pain Syndrome,Drug: Gefapixant|Drug: Sugar Pill,"Afferent Pharmaceuticals, Inc.","Afferent Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,4/13/2012,5/14/2014,https://ClinicalTrials.gov/show/NCT01569438
7539,"A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Placebo to match idelalisib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,6/26/2012,6/10/2019,https://ClinicalTrials.gov/show/NCT01569295
7540,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Bortezomib|Drug: Dexamethasone,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,6/20/2012,2/5/2018,https://ClinicalTrials.gov/show/NCT01568866
7541,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,7/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01614470
7542,"Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis",Completed,Has Results,"Multiple Sclerosis, Relapsing Forms",Drug: MEDI-551 30 MG-IV|Drug: MEDI-551 60 MG-SC|Drug: PLACEBO-IV-SC|Drug: MEDI-551 100 MG-IV|Drug: MEDI-551 300 MG-SC|Drug: MEDI-551 600 MG-IV,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,4/24/2012,6/20/2016,https://ClinicalTrials.gov/show/NCT01585766
7543,"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Lurasidone,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,4/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01566162
7544,"D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: D/C/F/TAF|Drug: DRV|Drug: COBI|Drug: FTC/TDF|Drug: D/C/F/TAF Placebo|Drug: DRV Placebo|Drug: COBI Placebo|Drug: FTC/TDF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,4/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01565850
7545,A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Pertuzumab|Drug: Trastuzumab|Drug: Vinorelbine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,4/12/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01565083
7546,Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: vortioxetine (Lu AA21004)|Drug: Duloxetine|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,4/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01564862
7547,Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: fostamatinib|Drug: placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,4/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01563978
7548,A Dose-ranging Study of Fluticasone Furoate (FF),Completed,Has Results,Asthma,Drug: Fluticasone Furoate|Drug: Fluticasone Propionate|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/28/2012,9/24/2014,https://ClinicalTrials.gov/show/NCT01563029
7549,Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant,Completed,Has Results,Hepatitis C|Hepatocellular Carcinoma,Drug: Sofosbuvir|Drug: Ribavirin,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,3/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01559844
7550,PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: PT001 MDI|Drug: Tiotropium Bromide|Drug: PT001 Placebo MDI,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,3/12/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01566773
7551,Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity|Obstructive Sleep Apnoea,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/7/2012,6/17/2013,https://ClinicalTrials.gov/show/NCT01557166
7552,Perindopril Amlodipine for the Treatment of Hypertension,Completed,Has Results,Essential Hypertension,Drug: XOMA 985|Drug: Amlodipine Besylate|Drug: Perindopril Erbumine,Symplmed Pharmaceuticals LLC,Symplmed Pharmaceuticals LLC,,,,,,,Phase 3,Industry,Interventional,2/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01556997
7553,Perfusion Assessment in Laparoscopic Left Anterior Resection,Completed,Has Results,Rectal Cancer|Colon Cancer|Crohn's Disease|Polyp|Procidentia|Diverticulitis,Device: PINPOINT Endoscopic Fluorescence Imaging System,"Novadaq Technologies ULC, now a part of Stryker","Novadaq Technologies ULC, now a part of Stryker",,,,,,,Phase 1,Industry,Interventional,5/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01560377
7554,"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",Completed,Has Results,Papulopustular Rosacea,"Drug: Azelaic acid foam, 15% (BAY39-6251)|Drug: Vehicle foam",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,9/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01555463
7555,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Placebo to match ranolazine|Drug: Metformin|Drug: Placebo to match metformin|Behavioral: Diet|Behavioral: Exercise,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,6/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01555164
7556,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: secukinumab 150 mg|Drug: secukinumab 300 mg|Drug: placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,5/8/2012,10/24/2016,https://ClinicalTrials.gov/show/NCT01555125
7557,A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis,Completed,Has Results,End Stage Renal Disease|Kidney Failure|Renal Failure|Hyperphosphatemia|ESRD,Drug: ferric citrate,Keryx Biopharmaceuticals,Keryx Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01554982
7558,A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: Gefapixant|Drug: Sugar Pill,"Afferent Pharmaceuticals, Inc.","Afferent Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/29/2012,11/21/2013,https://ClinicalTrials.gov/show/NCT01554579
7559,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Completed,Has Results,Irritable Bowel Syndrome,Drug: Eluxadoline|Drug: Placebo,"Furiex Pharmaceuticals, Inc","Furiex Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,5/29/2012,1/9/2014,https://ClinicalTrials.gov/show/NCT01553747
7560,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Completed,Has Results,Irritable Bowel Syndrome,Drug: Eluxadoline|Drug: Placebo,"Furiex Pharmaceuticals, Inc","Furiex Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,5/29/2012,7/29/2014,https://ClinicalTrials.gov/show/NCT01553591
7561,Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder,Completed,Has Results,Attention-deficit/Hyperactivity Disorder,Drug: Lisdexamfetamine dimesylate|Drug: Methylphenidate Hydrochloride|Drug: Placebo,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,4/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01552915
7562,Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder,Completed,Has Results,Attention-deficit/Hyperactivity Disorder,Drug: Lisdexamfetamine dimesylate|Drug: Methylphenidate Hydrochloride|Drug: Placebo,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,4/12/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01552902
7563,"A Study of Ustekinumab to Evaluate a ""Subject-tailored"" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis",Completed,Has Results,Psoriasis,Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg|Drug: Placebo,"Janssen Biotech, Inc.","Janssen Biotech, Inc.",,,,,,,Phase 3,Industry,Interventional,3/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01550744
7564,Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole,Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 1,Industry,Interventional,1/12/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01552772
7565,A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment,Completed,Has Results,Mild Cognitive Impairment|Mild Alzheimer's Disease,Drug: AZD5213|Other: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,4/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01548287
7566,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic acid injection|Drug: Placebo,Kythera Biopharmaceuticals,Kythera Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01546142
7567,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Completed,Has Results,Acute Myeloid Leukemia,Drug: PF-04449913|Drug: Low dose ARA-C (LDAC)|Drug: Decitabine|Drug: Daunorubicin|Drug: Cytarabine,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/27/2012,3/4/2019,https://ClinicalTrials.gov/show/NCT01546038
7568,Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: Secukinumab (AIN457)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/19/2012,6/26/2017,https://ClinicalTrials.gov/show/NCT01544595
7569,A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA),Completed,Has Results,Juvenile Idiopathic Arthritis (JIA),Drug: VIMOVO 250/20|Drug: VIMOVO 375/20|Drug: VIMOVO 500/20,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 4,Industry,Interventional,4/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01544114
7570,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Completed,Has Results,Irritable Bowel Syndrome With Diarrhea,Drug: open-label rifaximin|Drug: double-blind placebo|Drug: double-blind rifaximin,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,2/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01543178
7571,"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",Completed,Has Results,Chronic Hepatitis C,Drug: SOF|Drug: RBV|Drug: Placebo to match SOF|Drug: Placebo to match RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,3/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01542788
7572,Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary,Completed,Has Results,Nocturia,Drug: Desmopressin|Drug: Placebo,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01552343
7573,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic acid injection|Drug: Placebo,Kythera Biopharmaceuticals,Kythera Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01542034
7574,A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp,Completed,Has Results,Actinic Keratosis,Procedure: Cryotherapy|Drug: Vehicle|Drug: Ingenol metabute,LEO Pharma,LEO Pharma,,,,,,,Phase 3,Industry,Interventional,3/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01541553
7575,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo|Drug: metformin,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,11/13/2012,5/23/2018,https://ClinicalTrials.gov/show/NCT01541215
7576,"A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain",Completed,Has Results,Post-Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: morphine IV PCA,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,4/12/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01539538
7577,"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Idelalisib|Drug: Rituximab|Drug: Placebo to match idelalisib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,4/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01539512
7578,The EVICEL® Gastrointestinal Study,Completed,Has Results,Gastrointestinal Diseases,Biological: EVICEL Fibrin Sealant,"Ethicon, Inc.","Ethicon, Inc.",,,,,,,Phase 2,Industry,Interventional,6/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01589822
7579,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery",Completed,Has Results,Post-Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: Placebo Sufentanil NanoTab PCA System,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,2/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01539642
7580,"Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy",Completed,Has Results,Duchenne Muscular Dystrophy (DMD),Drug: AVI-4658 (Eteplirsen),"Sarepta Therapeutics, Inc.","Sarepta Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,2/27/2012,8/16/2017,https://ClinicalTrials.gov/show/NCT01540409
7581,Chronic Total Occlusion Crossing With the Ocelot System - CONNECT II,Completed,Has Results,Total Atherosclerotic Occlusion of Femoral Artery,Device: CTO crossing in femoropopliteal arteries CONNECT II,"Avinger, Inc.","Avinger, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/12/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01537302
7582,Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections,Completed,Has Results,Acute Upper Respiratory Tract Infection,Drug: Mucinex|Drug: Immediate-release Guaifenesin|Drug: Placebo,Reckitt Benckiser LLC,Reckitt Benckiser LLC,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01537081
7583,LEO 90100 in the Treatment of Psoriasis Vulgaris,Completed,Has Results,Psoriasis Vulgaris,Drug: LEO 90100|Drug: Calcipotriol|Drug: Betamethasone,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,5/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01536938
7584,"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris",Completed,Has Results,Psoriasis Vulgaris,Drug: LEO 90100|Drug: Betamethasone plus calcipotriol|Drug: Ointment vehicle|Drug: LEO 90100 vehicle,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,5/12/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01536886
7585,Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients,Completed,Has Results,"Psoriasis, Plaque-type Psoriasis",Drug: secukinumab|Drug: placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,1/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01537432
7586,Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism,Completed,Has Results,Secondary Hypogonadism,Drug: Androxal,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 3,Industry,Interventional,5/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01534208
7587,"A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke",Completed,Has Results,Acute Ischemic Stroke From Large Vessel Occlusion,Device: Penumbra System with Separator 3D|Device: Penumbra System alone,Penumbra Inc.,Penumbra Inc.,,,,,,,Not Applicable,Industry,Interventional,4/12/2019,12/17/2019,https://ClinicalTrials.gov/show/NCT01584609
7588,A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN),Completed,Has Results,Diabetic Peripheral Neuropathy|Pain,Drug: Capsaicin 8%|Drug: Placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 3,Industry,Interventional,2/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01533428
7589,A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis,Completed,Has Results,"Sclerosis, Systemic",Drug: Placebo|Drug: tocilizumab [RoActemra/Actemra],Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,3/12/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01532869
7590,Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism,Completed,Has Results,Secondary Hypogonadism,Drug: Androxal|Drug: Placebo,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 3,Industry,Interventional,8/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01532414
7591,Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation,Completed,Has Results,Cystic Fibrosis,Drug: VX-661|Drug: Ivacaftor|Drug: Placebo matched to VX-661|Drug: Placebo matched to ivacaftor,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 2,Industry,Interventional,2/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01531673
7592,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Placebo|Drug: Tiotropium + Olodaterol|Drug: tiotropium + Olodaterol|Drug: Tiotropium|Drug: Olodaterol|Device: Respimat,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,2/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01533935
7593,A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: PP3M 175 mg eq.|Drug: PP3M 263 mg eq.|Drug: PP3M 350 mg eq.|Drug: PP3M 525 mg eq.|Drug: Placebo (20% Intralipid emulsion),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,5/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01529515
7594,Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD),Completed,Has Results,Geographic Atrophy|Age-related Macular Degeneration,Drug: LFG316|Drug: Sham|Drug: LFG316 Lower dose,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,1/25/2012,6/24/2015,https://ClinicalTrials.gov/show/NCT01527500
7595,"Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs",Completed,Has Results,Central Nervous System,Drug: perampanel,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,1/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01527006
7596,Study of AR-13324 in Patients With Elevated Intraocular Pressure,Completed,Has Results,Ocular Hypertension|Open Angle Glaucoma,Drug: AR-13324 Ophthalmic Solution 0.01%|Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: AR-13324 Ophthalmic Solution 0.04%|Other: AR-13324 Ophthalmic Solution Vehicle,Aerie Pharmaceuticals,Aerie Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/12/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01528787
7597,A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: Respimat inhaler|Drug: tiotropium+olodaterol (low dose)|Drug: tiotropium + olodaterol (high dose)|Drug: placebo to tiotropium+olodaterol,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,2/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01525615
7598,Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children,Completed,Has Results,Asthma,Drug: Mepolizumab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/25/2015,1/31/2018,https://ClinicalTrials.gov/show/NCT02377427
7599,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: afatinib|Drug: erlotinib,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,3/5/2012,12/27/2017,https://ClinicalTrials.gov/show/NCT01523587
7600,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol + Methotrexate (MTX)|Biological: Placebo + Methotrexate (MTX),UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,1/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01521923
7601,A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers,Completed,Has Results,"Multiple Myeloma, Neoplasms",Drug: cetuximab|Drug: vemurafenib,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,4/12/2012,10/28/2016,https://ClinicalTrials.gov/show/NCT01524978
7602,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol|Other: Placebo|Biological: Methotrexate,UCB Pharma SA|UCB Pharma,UCB Pharma SA,UCB Pharma,,,,,,Phase 3,Industry,Interventional,1/12/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01519791
7603,Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis,Completed,Has Results,Pulmonary Infections|Pseudomonas Aeruginosa in Cystic Fibrosis,Drug: TBM100,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,1/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01519661
7604,BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3,Completed,Has Results,"Hepatitis C, Chronic",Drug: Ribavirin|Drug: BI 207127 high dose|Drug: Faldaprevir|Drug: BI 207127 low dose,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,4/13/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01830127
7605,Clinical Evaluation of Florbetapir F 18 (18F-AV-45),Completed,Has Results,Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,Drug: Florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/9/2019,5/3/2017,https://ClinicalTrials.gov/show/NCT01518374
7606,Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension,Completed,Has Results,Orthostatic Hypotension,Drug: Midodrine HCl|Drug: Placebo,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,5/14/2012,6/22/2013,https://ClinicalTrials.gov/show/NCT01518946
7607,Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms,Completed,Has Results,Asthma,Device: NIOX MINO®,Aerocrine AB,Aerocrine AB,,,,,,,,Industry,Observational,11/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01518322
7608,Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lixisenatide (AVE0010)|Device: Self-injector pen device (OptiClik®)|Drug: Metformin,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,2/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01517412
7609,Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: PF-04937319 10 mg|Drug: PF-04937319 50 mg|Drug: PF-04937319 100 mg|Drug: Glimepiride,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,2/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01517373
7610,"A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine",Completed,Has Results,Migraine Disorders,Biological: onabotulinumtoxinA,Allergan,Allergan,,,,,,,Phase 4,Industry,Interventional,12/11/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01516892
7611,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Biological: Placebo|Drug: Atorvastatin|Drug: Ezetimibe|Other: Diet Only,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,1/5/2012,10/14/2013,https://ClinicalTrials.gov/show/NCT01516879
7612,Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation,Completed,Has Results,Menorrhagia,Device: Aurora Endometrial Ablation|Device: Rollerball Ablation/Resection,"Minerva Surgical, Inc.","Minerva Surgical, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/12/2019,3/2/2018,https://ClinicalTrials.gov/show/NCT01569763
7613,Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension,Completed,Has Results,Symptomatic Orthostatic Hypotension,Drug: Midodrine HCl|Drug: Placebo,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,5/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01515865
7614,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: PP3M 175 mg eq.|Drug: PP3M 263 mg eq.|Drug: PP3M 350 mg eq.|Drug: PP3M 525 mg eq.|Drug: Placebo (20% Intralipid)|Drug: PP1M 50 mg eq.|Drug: PP1M 75 mg eq.|Drug: PP1M 100 mg eq.|Drug: PP1M 150 mg eq.,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,5/12/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01515423
7615,Wound Fluid Protease Levels During Use of Novel Wound Dressing,Completed,Has Results,Venous Stasis Ulcers,Device: Novel Dressing,Hollister Incorporated,Hollister Incorporated,,,,,,,Phase 4,Industry,Interventional,2/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01567150
7616,Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy,Completed,Has Results,Pulmonary Embolism|Acute Pulmonary Embolism|Sub-massive Pulmonary Embolism|Massive Pulmonary Embolism|Pulmonary Thromboembolism,Drug: recombinant tissue plasminogen activator|Device: EKOS EkoSonic Endovascular System,EKOS Corporation,EKOS Corporation,,,,,,,Phase 3,Industry,Interventional,6/7/2012,2/17/2013,https://ClinicalTrials.gov/show/NCT01513759
7617,A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin detemir|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/16/2012,7/30/2013,https://ClinicalTrials.gov/show/NCT01513473
7618,Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab,Completed,Has Results,Melanoma,Biological: Ipilimumab,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,2/17/2012,8/17/2017,https://ClinicalTrials.gov/show/NCT01515189
7619,"Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: Stribild,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,1/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01533259
7620,Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain,Completed,Has Results,Osteoarthritis,Drug: Diclofenac,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,1/12/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01510912
7621,Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat,Completed,Has Results,Tophaceous Gout,Drug: Lesinurad|Drug: Placebo|Drug: Febuxostat,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 3,Industry,Interventional,1/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01510769
7622,Combining Lesinurad With Allopurinol in Inadequate Responders,Completed,Has Results,Gout,Drug: Lesinurad|Drug: Placebo|Drug: Allopurinol,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 3,Industry,Interventional,1/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01510158
7623,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,2/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01508936
7624,Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina,Completed,Has Results,Chronic Myocardial Ischemia|Refractory Angina Pectoris|Advanced Coronary Heart Disease,Biological: Auto-CD34+ cells|Biological: Placebo: Diluent used to suspend Auto-CD34+ cells|Other: Standard of care,"Caladrius Biosciences, Inc.","Caladrius Biosciences, Inc.",,,,,,,Phase 3,Industry,Interventional,4/12/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01508910
7625,Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors,Completed,Has Results,Gout,Drug: lesinurad|Drug: Placebo,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 3,Industry,Interventional,1/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01508702
7626,An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1,Completed,Has Results,"Hepatitis C, Chronic",,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,,Industry,Observational,1/31/2012,3/31/2014,https://ClinicalTrials.gov/show/NCT01508130
7627,Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis,Completed,Has Results,End Stage Renal Disease|Chronic Kidney Disease,Drug: SFP|Other: Placebo,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 3,Industry,Interventional,11/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01503021
7628,Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye,Completed,Has Results,Meibomian Gland Dysfunction|Dry Eye,Device: LipiFlow System|Device: Warm Compress Therapy + Lid Scrub,"TearScience, Inc.","TearScience, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01521507
7629,Melody PB1016 Surveillance Study,Completed,Has Results,Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects,Device: Melody Transcatheter Pulmonary Valve PB1016,Medtronic Heart Valves|Medtronic Cardiovascular,Medtronic Heart Valves,Medtronic Cardiovascular,,,,,,Not Applicable,Industry,Interventional,11/14/2019,5/8/2018,https://ClinicalTrials.gov/show/NCT02347189
7630,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL),Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Coronary Stent System|Drug: Aspirin|Drug: Thienopyridine,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,2/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01500434
7631,A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461|Drug: Placebo,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 2,Industry,Interventional,12/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01500200
7632,"Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation",Completed,Has Results,Ultrasound|CT Scans|MRIs,Drug: Dexmedetomidine|Drug: Midazolam|Drug: Fentanyl,"Hospira, now a wholly owned subsidiary of Pfizer","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,,Phase 4,Industry,Interventional,10/12/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01519167
7633,"Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer",Completed,Has Results,Diffuse Large B-Cell Lymphoma,Drug: Fostamatinib,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01499303
7634,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lantus (Insulin glargine)|Drug: HOE901-U300 (new formulation of insulin glargine),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,12/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01499095
7635,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: HOE901-U300 (new formulation of insulin glargine)|Drug: Lantus (insulin glargine),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,12/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01499082
7636,Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature,Completed,Has Results,Type 1 Diabetes,Device: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Device: Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Phase 3,Industry,Interventional,12/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01497938
7637,"Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: E/C/F/TDF|Drug: E/C/F/TAF Placebo|Drug: E/C/F/TAF|Drug: E/C/F/TDF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,12/28/2011,8/22/2016,https://ClinicalTrials.gov/show/NCT01497899
7638,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels,Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Coronary Stent System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,2/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01498692
7639,Phase 3 Study of Sofosbuvir and Ribavirin,Completed,Has Results,Hepatitis C,Drug: Sofosbuvir|Drug: PEG|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01497366
7640,"BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes",Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin,"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",AstraZeneca,"Astra Zeneca, Bristol-Myers Squibb",,,,,,Phase 2,Industry|Other,Interventional,2/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01498185
7641,Effect of Febuxostat on Blood Pressure,Completed,Has Results,Hypertension,Drug: Febuxostat|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,2/12/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01496469
7642,Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism,Completed,Has Results,Cataract,Device: LAL (Light Adjustable Lens) and Light Deliver Device (LDD)|Device: Monofocal control IOL,"Calhoun Vision, Inc.","Calhoun Vision, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/11/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01496066
7643,"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: NNRTI|Drug: FTC/TDF|Drug: Stribild,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01495702
7644,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Placebo|Drug: Glimepiride|Behavioral: Diet|Behavioral: Exercise,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,1/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01494987
7645,"Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer",Completed,Has Results,Metastatic Pancreatic Cancer,Drug: MM-398|Drug: 5 Fluorouracil|Drug: Leucovorin,Merrimack Pharmaceuticals,Merrimack Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01494506
7646,Phase 3 Papulopustular Rosacea Study,Completed,Has Results,Papulopustular Rosacea,Drug: CD5024|Drug: Azelaic acid 15% Gel,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,12/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01494467
7647,Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome,Completed,Has Results,Restless Legs Syndrome,Drug: Rotigotine,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 2,Industry,Interventional,12/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01495793
7648,Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/17/2012,12/5/2018,https://ClinicalTrials.gov/show/NCT01493778
7649,Phase 3 Papulopustular Rosacea Study,Completed,Has Results,Papulopustular Rosacea (PPR),Drug: CD5024|Drug: Azelaic acid 15% Gel,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,12/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01493687
7650,"A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation",Completed,Has Results,Atrial Fibrillation,"Drug: pantoprazole|Drug: Pradaxa (dabigatran etexilate)|Drug: Pradaxa, within 30 minutes after a meal",Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,12/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01493557
7651,Combining Lesinurad With Allopurinol in Inadequate Responders,Completed,Has Results,Gout,Drug: Lesinurad|Drug: Placebo|Drug: Allopurinol,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 3,Industry,Interventional,12/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01493531
7652,Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection,Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Telaprevir|Drug: Peginterferon alfa-2a|Drug: Ribavirin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,1/12/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01492426
7653,Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer Metastatic|Hormone Refractory Prostate Cancer|Castration-resistant Prostate Cancer,Biological: sipuleucel-T|Drug: abiraterone acetate,Dendreon,Dendreon,,,,,,,Phase 2,Industry,Interventional,12/11/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT01487863
7654,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Placebo|Drug: Tiotropium|Drug: Olodaterol|Drug: tiotropium + olodaterol|Drug: Tiotropium + Olodaterol|Device: Respimat,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,3/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01533922
7655,"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy",Completed,Has Results,Hepatitis C,Drug: TMC435|Drug: TVR,Janssen R&D Ireland,Janssen R&D Ireland,,,,,,,Phase 3,Industry,Interventional,2/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01485991
7656,eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam,Completed,Has Results,Epilepsy,Drug: Lacosamide,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,12/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01484977
7657,Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens,Completed,Has Results,Refractive Ametropia,Device: etafilcon A control lens (1DM)|Device: etafilcon A with print and PVP for light eyes (EALE)|Device: etafilcon A with print and PVP for dark eyes (EADE),"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01484028
7658,AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder,Completed,Has Results,Adhesive Capsulitis|Frozen Shoulder,Biological: AA4500 0.29 mg/1 mL|Biological: AA4500 0.58 mg/2 mL|Biological: AA4500 0.58 mg/1 mL|Biological: AA4500 0.58 mg/0.5 mL|Other: Shoulder exercises,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01483963
7659,Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,11/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01483625
7660,A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis,Completed,Has Results,Psoriasis,Drug: CNTO 1959 (5 mg)|Drug: CNTO 1959 (15 mg)|Drug: CNTO 1959 (50 mg)|Drug: CNTO 1959 (100 mg)|Drug: CNTO 1959 (200 mg)|Drug: Adalimumab|Drug: Placebo,Janssen Inc.,Janssen Inc.,,,,,,,Phase 2,Industry,Interventional,11/10/2011,8/5/2013,https://ClinicalTrials.gov/show/NCT01483599
7661,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Completed,Has Results,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Drug: Alisertib|Drug: Pralatrexate|Drug: Gemcitabine|Drug: Romidepsin,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 3,Industry,Interventional,6/11/2012,12/18/2017,https://ClinicalTrials.gov/show/NCT01482962
7662,Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure,Completed,Has Results,Atrial Fibrillation|Heart Failure,Device: Reveal XT® Insertable Cardiac Monitor|Other: Heart Failure Risk Status Diagnostic,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,11/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01486316
7663,A Study in Older Participants Who Have Fallen and Have Muscle Weakness,Completed,Has Results,Muscle Weakness,Biological: LY2495655|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,5/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01604408
7664,A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: AZD6765 iv|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/16/2011,8/26/2013,https://ClinicalTrials.gov/show/NCT01482221
7665,"A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease",Completed,Has Results,Parkinson Disease,Drug: ropinirole monotherapy|Drug: placebo monotherapy,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,1/31/2012,4/30/2014,https://ClinicalTrials.gov/show/NCT01485172
7666,The Evaluation of Belimumab in Myasthenia Gravis (MG),Completed,Has Results,Myasthaenia Gravis,Biological: Belimumab|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/13/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01480596
7667,A Study in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01481779
7668,Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease,Completed,Has Results,Intestinal Disease|Inflammatory Bowel Disease|Crohn Disease|Ulcer|Celiac Disease,Device: PillCam SB2 capsule|Device: CapsoCam SV-1,"Capso Vision, Inc.","Capso Vision, Inc.",,,,,,,Not Applicable,Industry,Interventional,5/12/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01787825
7669,A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma,Completed,Has Results,Asthma,Drug: QBX258|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,2/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01479595
7670,"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Biological: Immune Globulin Infusion (Human), 10%|Biological: Recombinant human hyaluronidase",Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 2|Phase 3,Industry,Interventional,12/29/2011,1/1/2013,https://ClinicalTrials.gov/show/NCT01485796
7671,A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy,Completed,Has Results,Colorectal Cancer,Drug: Tivozanib|Drug: Bevacizumab|Drug: mFOLFOX6,"AVEO Pharmaceuticals, Inc.","AVEO Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,12/11/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01478594
7672,Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin glargine /lixisenatide Fixed Ratio Combination|Drug: Insulin glargine|Drug: Metformin (Background drug),Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,11/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01476475
7673,Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK),Completed,Has Results,Actinic Keratosis,Drug: Broad Area ALA 1-hour incubation|Drug: Broad Area ALA 2 hour incubation|Drug: broad area ALA 3-hour incubation|Drug: Spot ALA 2 hour incubation|Drug: Vehicle PDT|Device: Blue Light Treatment,"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,12/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01475955
7674,"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: PI|Drug: RTV|Drug: FTC/TDF|Drug: Stribild,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,11/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01475838
7675,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,Completed,Has Results,Hypercholesterolemia|Heterozygous Familial,Drug: mipomersen sodium 200 mg|Drug: Placebo|Drug: mipomersen sodium 70 mg,"Kastle Therapeutics, LLC","Kastle Therapeutics, LLC",,,,,,,Phase 3,Industry,Interventional,12/11/2019,12/29/2015,https://ClinicalTrials.gov/show/NCT01475825
7676,Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: PF-04937319 - 3mg|Drug: PF-04937319 - 20mg|Drug: PF-04937319 - 50mg|Drug: PF-04937319 - 100mg|Drug: Sitagliptin - 100mg,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01475461
7677,A Pharmacodynamic Study With Ticagrelor in African American Patients,Completed,Has Results,Stable Coronary Artery Disease,Drug: Ticagrelor|Drug: Clopidogrel,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,3/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01523392
7678,A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease,Completed,Has Results,Parkinson Disease,Drug: ropinirole/L-dopa|Drug: placebo/L-dopa,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,4/2/2012,11/18/2014,https://ClinicalTrials.gov/show/NCT01494532
7679,Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN),Completed,Has Results,Diabetic Peripheral Neuropathy,Drug: Pregabalin|Other: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01474772
7680,A Phase 3 Study in Participants With Moderate to Severe Psoriasis,Completed,Has Results,Psoriasis,"Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Drug: Placebo",Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/16/2011,9/20/2018,https://ClinicalTrials.gov/show/NCT01474512
7681,Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: PCI-32765|Drug: Dexamethasone,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 2,Industry,Interventional,3/12/2019,8/18/2019,https://ClinicalTrials.gov/show/NCT01478581
7682,Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients,Completed,Has Results,Systemic Sclerosis|Ulcers,Drug: macitentan 3mg|Drug: macitentan 10mg|Drug: placebo,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,12/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01474109
7683,Second Study of the Effect of Teriparatide on Hip Fracture Healing,Completed,Has Results,Femur Neck Fracture,Drug: Teriparatide|Drug: Placebo|Dietary Supplement: Calcium supplementation|Dietary Supplement: Vitamin D supplementation,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01473602
7684,Effect of Teriparatide on Hip Fracture Healing,Completed,Has Results,Femur Neck Fracture,Drug: Teriparatide|Drug: Placebo|Dietary Supplement: Calcium supplementation|Dietary Supplement: Vitamin D supplementation,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,2/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01473589
7685,Safety and Efficacy of Vilazodone in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vilazodone|Drug: Placebo to citalopram|Drug: Placebo to vilazodone|Drug: Citalopram,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,12/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01473381
7686,Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease,Drug: SSP-002358 (0.1 mg) + PPI|Drug: SSP-002358 (0.5 mg) + PPI|Drug: SSP-002358 (2.0 mg) + PPI|Drug: Placebo + PPI,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,2/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01472939
7687,Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis,Completed,Has Results,Primary Biliary Cirrhosis,Drug: Obeticholic Acid (OCA)|Drug: Placebo,Intercept Pharmaceuticals,Intercept Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,1/12/2019,12/17/2018,https://ClinicalTrials.gov/show/NCT01473524
7688,Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin Lispro|Drug: Insulin Aspart,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01474538
7689,Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia,Completed,Has Results,Hyperkalemia|Chronic Kidney Disease|Kidney Dysfunction,Drug: Zirconium silicate (ZS)|Drug: Placebo,"ZS Pharma, Inc.","ZS Pharma, Inc.",,,,,,,Phase 2,Industry,Interventional,11/30/2011,6/30/2012,https://ClinicalTrials.gov/show/NCT01493024
7690,"Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder",Completed,Has Results,Major Depressive Disorder,Drug: Dose-matched placebo|Drug: Vilazodone,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,12/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01473394
7691,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Placebo|Behavioral: Diet|Behavioral: Exercise,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,11/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01472185
7692,"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1",Completed,Has Results,Hepatitis C Virus Genotype-1,Drug: TMC435|Drug: Pegylated interferon alpha-2a|Drug: Ribavirin,Janssen R&D Ireland,Janssen R&D Ireland,,,,,,,Phase 3,Industry,Interventional,10/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01479868
7693,Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus,Completed,Has Results,"Hepatitis C, Genotype 1",Drug: Daclatasvir|Drug: Ribavirin|Drug: PEG-Interferon alfa 2a,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,12/11/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01471574
7694,Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure,Completed,Has Results,Acute Alcoholic Hepatitis,Biological: ELAD treatment|Other: Standard of care (Control),"Vital Therapies, Inc.","Vital Therapies, Inc.",,,,,,,Phase 3,Industry,Interventional,2/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01471028
7695,"A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease",Completed,Has Results,Crohn's Disease,"Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,4/12/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01470599
7696,"SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)",Completed,Has Results,"Generalized Anxiety Disorder (GAD)|Anxiety, Separation|Phobia, Social",Drug: SPD503 (extended-release Guanfacine hydrochloride)|Drug: Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,1/12/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01470469
7697,Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients,Completed,Has Results,Primary Insomnia,Drug: Neu-P11,Neurim Pharmaceuticals Ltd.,Neurim Pharmaceuticals Ltd.,,,,,,,Phase 2,Industry,Interventional,12/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01489969
7698,"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: ALKS 9072|Drug: Placebo,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,12/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01469039
7699,A Study in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2605541|Drug: Insulin Glargine|Drug: Insulin Lispro,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01468987
7700,Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia,Completed,Has Results,Acute Lymphoblastic Leukemia,Biological: Blinatumomab,Amgen Research (Munich) GmbH,Amgen Research (Munich) GmbH,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/12/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01471782
7701,Study of LY3016859 in Participants With Diabetic Nephropathy,Completed,Has Results,Diabetic Nephropathy,Drug: Placebo|Drug: LY3016859,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/13/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01774981
7702,Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY,Completed,Has Results,Myopia|Hyperopia,Device: narafilcon B daily disposable soft contact lenses|Device: etafilcon A daily disposable soft contact lenses,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,,Industry,Observational,10/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01467557
7703,"An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A",Completed,Has Results,Hemophilia A,Biological: rVIII-SingleChain|Biological: Octocog alfa,CSL Behring,CSL Behring,,,,,,,Phase 2|Phase 3,Industry,Interventional,2/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01486927
7704,Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout,Completed,Has Results,Refractory Chronic Gout,Biological: Pegloticase,Horizon Pharma Rheumatology LLC,Horizon Pharma Rheumatology LLC,,,,,,,,Industry,Observational,11/15/2011,6/30/2017,https://ClinicalTrials.gov/show/NCT01466166
7705,Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,Completed,Has Results,Non Small Cell Lung Cancer (NSCLC),Drug: Dacomitinib|Drug: Doxycycline|Drug: Probiotic|Drug: Alclometasone cream,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/26/2011,5/18/2015,https://ClinicalTrials.gov/show/NCT01465802
7706,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,Drug: tofacitinib|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,4/12/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01465763
7707,"A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",Completed,Has Results,Chronic Lymphocytic Leukemia (CLL),Drug: Rituximab|Drug: Bendamustine|Drug: MEDI-551,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,2/7/2012,1/8/2016,https://ClinicalTrials.gov/show/NCT01466153
7708,Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma,Completed,Has Results,Glioblastoma|GBM|Glioma,Drug: Trans Sodium Crocetinate (TSC),Diffusion Pharmaceuticals Inc,Diffusion Pharmaceuticals Inc,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/12/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01465347
7709,ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients,Completed,Has Results,Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1,Drug: ABT-450|Drug: ABT-333|Drug: ABT-267|Drug: Ribavirin|Drug: Ritonavir,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,10/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01464827
7710,Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy,Completed,Has Results,Cerebral Palsy (CP),Drug: dalfampridine-ER 10mg|Other: Placebo,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 1,Industry,Interventional,12/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01468350
7711,"Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty",Completed,Has Results,Central Precocious Puberty,Drug: Triptorelin,Debiopharm International SA,Debiopharm International SA,,,,,,,Phase 3,Industry,Interventional,4/12/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01467882
7712,Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL),Completed,Has Results,Acute Lymphoblastic Leukemia,Biological: Blinatumomab,Amgen Research (Munich) GmbH,Amgen Research (Munich) GmbH,,,,,,,Phase 2,Industry,Interventional,12/11/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT01466179
7713,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke,Completed,Has Results,Post-stroke Spasticity of the Lower Limb,Drug: IncobotulinumtoxinA (400 Units)|Drug: Placebo Comparator,Merz Pharmaceuticals GmbH,Merz Pharmaceuticals GmbH,,,,,,,Phase 3,Industry,Interventional,12/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01464307
7714,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: Dulaglutide|Drug: Glimepiride,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01769378
7715,Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine,Completed,Has Results,Migraine Headache,Drug: Sumatriptan|Drug: Placebo,Optinose US Inc.,Optinose US Inc.,,,,,,,Phase 3,Industry,Interventional,1/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01462812
7716,A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD),Completed,Has Results,Muscular Dystrophies,Drug: GSK2402968 3mg/kg/week|Drug: GSK2402968 6 mg/kg/week|Drug: Placebo to match GSK2402968 3 mg/kg/week|Drug: Placebo to match GSK2402968 6 mg/kg/week,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/26/2011,11/4/2013,https://ClinicalTrials.gov/show/NCT01462292
7717,"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17",Completed,Has Results,Vaccines|Meningococcal Vaccines,Biological: rLP2086 and Gardasil|Biological: rLP2086|Biological: Gardasil,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/28/2011,7/6/2013,https://ClinicalTrials.gov/show/NCT01461993
7718,"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age",Completed,Has Results,Vaccines|Meningococcal Vaccines,Biological: rLP2086 + MCV4 + Tdap|Biological: MCV4 + Tdap + saline|Biological: rLP2086 + saline,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/28/2011,5/8/2014,https://ClinicalTrials.gov/show/NCT01461980
7719,Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies,Completed,Has Results,"Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Anemia, Refractory, With Excess of Blasts|Solid Tumors",Drug: brentuximab vedotin,"Seattle Genetics, Inc.","Seattle Genetics, Inc.",,,,,,,Phase 2,Industry,Interventional,10/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01461538
7720,Study of Diclofenac Capsules to Treat Osteoarthritis Pain,Completed,Has Results,Osteoarthritis,Drug: Diclofenac|Drug: Placebo,"Iroko Pharmaceuticals, LLC","Iroko Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,10/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01461369
7721,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,Drug: tofacitinib|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01458951
7722,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,"Drug: Placebo|Drug: CP690,550|Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,7/20/2012,5/27/2016,https://ClinicalTrials.gov/show/NCT01458574
7723,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Ciclesonide nasal aerosol 37 mcg|Drug: ciclesonide nasal aerosol 74 mcg|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,11/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01458275
7724,Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Ofatumumab 3mg|Drug: Ofatumumab 30mg|Drug: Ofatumumab 60mg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/1/2011,6/10/2015,https://ClinicalTrials.gov/show/NCT01457924
7725,Efficacy and Safety of SPARC0921 in Subjects With Spasticity,Completed,Has Results,Spasticity,Drug: SPARC0921|Drug: Placebo0921,Sun Pharma Advanced Research Company Limited,Sun Pharma Advanced Research Company Limited,,,,,,,Phase 3,Industry,Interventional,11/14/2012,8/25/2017,https://ClinicalTrials.gov/show/NCT01457352
7726,Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS),Completed,Has Results,Paroxysmal Atrial Fibrillation (PAF),Device: Medtronic Arctic Front® Cardiac CryoAblation System,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,6/26/2012,11/30/2017,https://ClinicalTrials.gov/show/NCT01456949
7727,Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Fasiglifam,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,11/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01456195
7728,HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF),Completed,Has Results,Paroxysmal Atrial Fibrillation,Device: EAS-AC (HeartLight)|Procedure: Control Arm Ablation,CardioFocus,CardioFocus,,,,,,,Phase 3,Industry,Interventional,1/12/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01456000
7729,Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain,Completed,Has Results,Painful Diabetic Peripheral Neuropathy,Drug: pregabalin|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01455415
7730,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,Completed,Has Results,Hemophilia A,Drug: rFVIIIFc,Bioverativ Therapeutics Inc.,Bioverativ Therapeutics Inc.,,,,,,,Phase 3,Industry,Interventional,12/11/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT01454739
7731,"A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Trastuzumab Emtansine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,12/15/2014,8/20/2018,https://ClinicalTrials.gov/show/NCT02289833
7732,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer",Completed,Has Results,Non-Small Cell Lung Cancer (NSCLC),"Drug: Eribulin|Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed",Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,12/9/2011,5/2/2016,https://ClinicalTrials.gov/show/NCT01454934
7733,A Study in Participants With Type I Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01454284
7734,Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification,Completed,Has Results,Intraocular Lens Replacement,Drug: OMS302|Drug: Placebo,Omeros Corporation,Omeros Corporation,,,,,,,Phase 3,Industry,Interventional,9/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01454063
7735,"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",Completed,Has Results,Diffuse Large B-Cell Lymphoma,Drug: MEDI-551 2 mg/kg|Drug: Rituximab|Drug: ICE|Drug: DHAP|Procedure: Autologous Stem Cell Transplant (ASCT)|Drug: MEDI-551 4 mg/kg,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,2/27/2012,7/11/2016,https://ClinicalTrials.gov/show/NCT01453205
7736,Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Drug: Hydrocodone bitartrate q24h film-coated tablets|Drug: Placebo to match hydrocodone bitartrate q24h tablets,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,10/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01452529
7737,"A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,Drug: Telotristat Etiprate|Drug: Placebo,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/30/2012,9/3/2013,https://ClinicalTrials.gov/show/NCT01456052
7738,REducing 30-day ADMIssions in posT-discharge Subjects (READMIT),Completed,Has Results,Acute Decompensated Heart Failure,Device: AVIVO™ PiiX Patch Monitor System,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,,Industry,Observational,4/12/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01574144
7739,8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD),Completed,Has Results,Autosomal Dominant Polycystic Kidney Disease,Drug: Tolvaptan MR|Drug: Tolvaptan IR|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,10/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01451827
7740,Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol,Completed,Has Results,Intercritical Gout,Drug: Colchicine (Colcrys®)|Drug: placebo|Drug: allopurinol,Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,10/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01451645
7741,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).,Completed,Has Results,Perennial Allergic Rhinitis|PAR,Drug: Ciclesonide nasal aerosol 37 mcg|Drug: ciclesonide nasal aerosol 74 mcg|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,10/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01451541
7742,Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Drug: Technosphere® Insulin|Drug: Technosphere Powder,Mannkind Corporation,Mannkind Corporation,,,,,,,Phase 3,Industry,Interventional,11/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01451398
7743,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,Completed,Has Results,Small Cell Lung Carcinoma,Biological: Ipilimumab|Biological: Placebo matching Ipilimumab|Drug: Etoposide|Drug: Cisplatin|Drug: Carboplatin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,12/13/2011,5/17/2017,https://ClinicalTrials.gov/show/NCT01450761
7744,Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01447719
7745,Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: ADT|Drug: OPC-34712,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,9/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01447576
7746,A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease,"Biological: MEDI8968 600 mg IV, 300 mg SC|Other: Placebo",MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,11/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01448850
7747,SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain,Completed,Has Results,Low Back Pain,Device: Intracept Treatment|Device: Sham Treatment,"Relievant Medsystems, Inc.","Relievant Medsystems, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/11/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01446419
7748,Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab,Completed,Has Results,Rheumatoid Arthritis,Biological: New formulation adalimumab,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,12/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01752855
7749,Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism,Completed,Has Results,Male Hypogonadism,Drug: Testosterone,Acerus Pharmaceuticals Corporation,Acerus Pharmaceuticals Corporation,,,,,,,Phase 3,Industry,Interventional,9/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01446042
7750,Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Technosphere® Insulin with MedTone C Inhaler|Drug: Technosphere ®Insulin with Gen2 Inhaler|Drug: Insulin Aspart in combination with a basal insulin,Mannkind Corporation,Mannkind Corporation,,,,,,,Phase 3,Industry,Interventional,9/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01445951
7751,Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis,Completed,Has Results,Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis,Drug: Ruxolitinib,Incyte Corporation,Incyte Corporation,,,,,,,Phase 2,Industry,Interventional,9/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01445769
7752,A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis,Completed,Has Results,Granulomatosis With Polyangiitis,Drug: Rituximab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,5/23/2013,5/10/2018,https://ClinicalTrials.gov/show/NCT01750697
7753,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,Completed,Has Results,Asthma,Drug: Symbicort pMDI|Drug: budesonide pMDI,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,12/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01444430
7754,Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients,Completed,Has Results,Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura|Immune Thrombocytopenia,Drug: Romiplostim|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,1/12/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01444417
7755,Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS),Completed,Has Results,COPD|COPD Exacerbation|Lung Diseases|Respiratory Disorders|Pulmonary Disease|Chronic Obstructive Lung Diseases|Chronic Obstructive Airway Disease,Drug: Roflumilast|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,9/30/2011,1/31/2016,https://ClinicalTrials.gov/show/NCT01443845
7756,A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy,Completed,Has Results,Opioid-induced Constipation,Drug: Placebo|Drug: Naldemedine,Shionogi|Shionogi Inc.,Shionogi,Shionogi Inc.,,,,,,Phase 2,Industry,Interventional,8/17/2011,8/22/2012,https://ClinicalTrials.gov/show/NCT01443403
7757,Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI),Completed,Has Results,Coronary Artery Disease|Angina Pectoris,Drug: Ranolazine|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,10/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01442038
7758,Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine,Completed,Has Results,Meningitis|Meningococcal Infection,"Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,9/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01442675
7759,Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Palonosetron|Drug: Ondansetron|Drug: Placebo to Ondansetron|Drug: Placebo to Palonosetron,Helsinn Healthcare SA,Helsinn Healthcare SA,,,,,,,Phase 3,Industry,Interventional,9/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01442376
7760,Safety Study of Entocort for Children With Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: Entocort,Perrigo Company,Perrigo Company,,,,,,,Phase 3,Industry,Interventional,11/11/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01444092
7761,A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia,Completed,Has Results,Thrombocytopaenia,Drug: eltrombopag|Drug: placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,9/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01440374
7762,Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma,Completed,Has Results,Nasopharyngeal Neoplasms,Drug: CC-486,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,2/13/2015,4/20/2017,https://ClinicalTrials.gov/show/NCT02269943
7763,Open Label Study of Long Term Evaluation Against LDL-C Trial,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Other: Standard of care,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,10/7/2011,6/20/2018,https://ClinicalTrials.gov/show/NCT01439880
7764,Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer,Completed,Has Results,Estrogen Receptor Positive Tumor|Breast Cancer,Drug: eribulin mesylate|Drug: capecitabine,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,8/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01439282
7765,Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose,Completed,Has Results,Tetanus|Diphtheria|Pertussis|Whooping Cough,"Biological: Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|Biological: Tetanus and Diphtheria Toxoids Adsorbed For Adult Use","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,11/11/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT01439165
7766,A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma,Completed,Has Results,Extensive Stage Small Cell Lung Carcinoma,Drug: LY2510924|Drug: Carboplatin|Drug: Etoposide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,9/11/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01439568
7767,Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients,Completed,Has Results,HCMV,Biological: CSJ148|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/2/2015,12/7/2016,https://ClinicalTrials.gov/show/NCT02268526
7768,A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,Biological: Anifrolumab 300 mg|Biological: Anifrolumab 1000 mg|Other: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,1/12/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01438489
7769,Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium Bromide/Formoterol Fumarate|Drug: Formoterol Fumarate,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/19/2011,4/30/2013,https://ClinicalTrials.gov/show/NCT01437540
7770,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium Bromide/Formoterol Fumarate|Drug: Aclidinium Bromide|Drug: Formoterol Fumarate|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01437397
7771,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Drug: Antidepressant + Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,10/19/2011,12/10/2013,https://ClinicalTrials.gov/show/NCT01436162
7772,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate )|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,10/27/2011,12/23/2013,https://ClinicalTrials.gov/show/NCT01436149
7773,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone furoate 50mcg|Drug: Fluticasone propionate 100mcg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01436110
7774,PEARL Schizophrenia Maintenance,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Matching Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,9/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01435928
7775,SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Drug: Antidepressant + Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,5/31/2011,1/17/2014,https://ClinicalTrials.gov/show/NCT01435759
7776,A Study in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Glargine|Drug: LY2605541,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01435616
7777,Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients,Completed,Has Results,Hepatorenal Syndrome,Drug: Ifetroban Injection|Drug: Placebo,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/11/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01436500
7778,The Jetstream (JET) Post-market Registry,Completed,Has Results,Peripheral Arterial Diseases,Device: Jetstream Atherectomy System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,9/11/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01436435
7779,Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder,Drug: desvenlafaxine succinate sustained-release 50 mg/day|Drug: desvenlafaxine succinate sustained-release 100 mg/day|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,10/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01432457
7780,Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole,Completed,Has Results,Schizophrenia,Drug: Aripiprazole (Abilify®) IM Depot Injection,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,9/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01432444
7781,Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO),Completed,Has Results,Renal Failure|Tremors,Drug: Prograf|Drug: LCP-Tacro,Veloxis Pharmaceuticals,Veloxis Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/11/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01438710
7782,A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression,Completed,Has Results,Fibromyalgia,Drug: Pregabalin|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01432236
7783,Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents,Completed,Has Results,Asthma,Drug: fluticasone furoate|Drug: albuterol/salbutamol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01431950
7784,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Drug: IV Dalbavancin|Drug: Vancomycin/Linezolid,"Durata Therapeutics Inc., an affiliate of Allergan plc","Durata Therapeutics Inc., an affiliate of Allergan plc",,,,,,,Phase 3,Industry,Interventional,7/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01431339
7785,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium + olodaterol|Drug: tiotropium|Drug: olodaterol|Device: Respimat,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,9/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01431287
7786,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium + olodaterol|Drug: tiotropium|Drug: olodaterol|Device: Respimat,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,9/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01431274
7787,Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer,Completed,Has Results,Prostatic Neoplasm|Prostate Cancer|Prostatic Adenocarcinoma,Biological: sipuleucel-T|Drug: leuprolide acetate,Dendreon,Dendreon,,,,,,,Phase 2,Industry,Interventional,9/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01431391
7788,Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder,Completed,Has Results,Non-24-Hour Sleep-Wake Disorder,Drug: tasimelteon|Drug: Placebo,Vanda Pharmaceuticals,Vanda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01430754
7789,"A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL",Completed,Has Results,Allergic Asthma|Atopic Dermatitis|Allergic Rhinitis|Healthy Volunteers,Other: Placebo|Biological: Omalizumab|Biological: MEDI4212 5 mg Subcutaneous|Biological: MEDI4212 15 mg Subcutaneous|Biological: MEDI4212 60 mg Subcutaneous|Biological: MEDI4212 150 mg Subcutaneous|Biological: MEDI4212 300 mg Subcutaneous|Biological: MEDI4212 300 mg Intravenous,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,1/12/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01544348
7790,Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive),Completed,Has Results,Magnetic Resonance Imaging,"Drug: Gadobutrol (Gadavist, BAY86-4875)",Bayer,Bayer,,,,,,,Phase 1,Industry,Interventional,5/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01544166
7791,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone furoate 50mcg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01436071
7792,Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole,Completed,Has Results,Vitreomacular Adhesion Including Macular Hole,Drug: Ocriplasmin|Other: Sham injection,ThromboGenics,ThromboGenics,,,,,,,Phase 3,Industry,Interventional,10/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01429441
7793,Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: tasimelteon|Drug: placebo,Vanda Pharmaceuticals,Vanda Pharmaceuticals,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01428661
7794,Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain,Completed,Has Results,Chronic Noncancer Pain,Drug: oxycodone HCl and naltrexone HCl extended-release capsules,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01428583
7795,"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy",Completed,Has Results,Epilepsy,Drug: Brivaracetam,UCB Pharma SA|UCB Pharma,UCB Pharma SA,UCB Pharma,,,,,,Phase 3,Industry,Interventional,10/12/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01728077
7796,"Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials",Completed,Has Results,Hepatitis C Virus Infection,Drug: Daclatasvir|Drug: Asunaprevir|Drug: Pegylated interferon alfa-2a|Drug: Ribavirin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,9/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01428063
7797,A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer,Completed,Has Results,Breast Cancer,Biological: Ramucirumab (IMC-1121B)|Drug: Eribulin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01427933
7798,Actual Use Trial of Naproxen Sodium,Completed,Has Results,Pain,Drug: Naproxen Sodium ER (BAYH6689),Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,9/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01427803
7799,A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults,Completed,Has Results,Influenza,Biological: High Dose Trivalent Inactivated Influenza Vaccine|Biological: Trivalent Inactivated Influenza Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,9/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01427309
7800,Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing,Completed,Has Results,Colon Cleansing,Drug: Polyethylene glycol|Drug: Oral sodium phosphate solution,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 4,Industry,Interventional,9/16/2011,12/9/2014,https://ClinicalTrials.gov/show/NCT01427296
7801,A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo|Drug: Secukinumab,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01426789
7802,Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia,Completed,Has Results,AtrioVentricular Nodal Reentrant Tachycardia|Supraventricular Tachycardia|Heart Disease,Device: Freezor Xtra Cryoablation Catheter,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Phase 3,Industry,Interventional,5/12/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01426425
7803,Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic acid injection,Kythera Biopharmaceuticals,Kythera Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01426373
7804,"Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia",Completed,Has Results,Post Herpetic Neuralgia,,Depomed,Depomed,,,,,,,,Industry,Observational,9/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01426230
7805,Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina,Completed,Has Results,Angina Pectoris|Coronary Artery Disease|Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Ranolazine placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,9/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01425359
7806,Patient Controlled Tissue Expansion for Breast Reconstruction,Completed,Has Results,Breast Cancer,Device: AeroForm Tissue Expansion|Procedure: Saline Tissue Expansion,"AirXpanders, Inc.","AirXpanders, Inc.",,,,,,,Not Applicable,Industry,Interventional,10/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01425268
7807,A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma,Completed,Has Results,Asthma,Drug: Placebo MDPI|Drug: Albuterol MDPI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,12/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01424813
7808,Study of Ruxolitinib in Pancreatic Cancer Patients,Completed,Has Results,Pancreatic Cancer,Drug: Capecitabine|Drug: Ruxolitinib|Drug: Placebo,Incyte Corporation,Incyte Corporation,,,,,,,Phase 2,Industry,Interventional,7/11/2019,11/16/2019,https://ClinicalTrials.gov/show/NCT01423604
7809,"Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo",Completed,Has Results,Rosacea,Drug: Doxycycline|Drug: Metronidazole|Drug: Placebo,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,9/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01426269
7810,"Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia",Completed,Has Results,Hemophilia A,Biological: PF-05280602,Catalyst Biosciences,Catalyst Biosciences,,,,,,,Phase 1,Industry,Interventional,12/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01439971
7811,Major Depressive Disorder With Mixed Features - Extension,Completed,Has Results,Major Depressive Disorder,Drug: Lurasidone,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,9/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01423253
7812,ION US Post-Approval Study,Completed,Has Results,Atherosclerosis|Coronary Artery Disease,Device: ION™ Coronary Stent System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,,Industry,Observational,9/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01422889
7813,A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma,Completed,Has Results,"Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell",Drug: brentuximab vedotin|Drug: rituximab,"Seattle Genetics, Inc.","Seattle Genetics, Inc.",,,,,,,Phase 2,Industry,Interventional,8/11/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01421667
7814,TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections,Drug: TR-701 FA|Drug: Linezolid,Trius Therapeutics LLC,Trius Therapeutics LLC,,,,,,,Phase 3,Industry,Interventional,9/15/2011,1/10/2013,https://ClinicalTrials.gov/show/NCT01421511
7815,Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose,Completed,Has Results,Major Depressive Disorder With Mixed Features,Drug: Lurasidone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,9/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01421134
7816,Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1),Completed,Has Results,Keratoconjunctivitis Sicca|Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,8/29/2011,4/28/2012,https://ClinicalTrials.gov/show/NCT01421498
7817,"Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: EP-101 via nebulizer (eFlow®) 25 ug|Drug: EP-101 via nebulizer (eFlow®) 50 ug|Drug: EP-101 via nebulizer (eFlow®) 100 ug|Drug: Placebo EP-101|Drug: Tiotropium bromide via (Spiriva® Handihaler®)|Drug: Ipratropium bromide Inhalation Solution via Handihaler® DPI|Drug: EP-101 via nebulizer (eFlow®) 200 ug,Sunovion Respiratory Development Inc.,Sunovion Respiratory Development Inc.,,,,,,,Phase 2,Industry,Interventional,8/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01426009
7818,Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B,Completed,Has Results,Severe Hemophilia B,Biological: rFIXFc,Bioverativ Therapeutics Inc.,Bioverativ Therapeutics Inc.,,,,,,,Phase 3,Industry,Interventional,12/8/2011,10/17/2019,https://ClinicalTrials.gov/show/NCT01425723
7819,A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy,Completed,Has Results,Breast Cancer,Drug: Trastuzumab emtansine|Drug: Treatment of physician's choice,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,9/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01419197
7820,Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA,Completed,Has Results,Staphylococcal Skin Infections,Drug: Daptomycin|Drug: Vancomycin,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 4,Industry,Interventional,9/9/2011,10/5/2012,https://ClinicalTrials.gov/show/NCT01419184
7821,The OMEGA Clinical Trial,Completed,Has Results,Atherosclerosis|Coronary Artery Disease,Device: OMEGA™ Monorail Coronary Stent System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,10/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01419171
7822,52-104 Week Off-therapy Second Extension to Study CSPP100A2365,Completed,Has Results,Hypertension,Drug: SPP100,Noden Pharma,Noden Pharma,,,,,,,,Industry,Observational,8/19/2011,8/3/2017,https://ClinicalTrials.gov/show/NCT01420068
7823,Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck,Completed,Has Results,Squamous Cell Carcinoma of the Head and Neck,Biological: Dalantercept,"Acceleron Pharma, Inc.","Acceleron Pharma, Inc.",,,,,,,Phase 2,Industry,Interventional,10/11/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01458392
7824,Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer,Completed,Has Results,Prostate Cancer,"Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA",GP-Pharm,GP-Pharm,,,,,,,Phase 3,Industry,Interventional,9/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01415960
7825,Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years),Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,8/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01415531
7826,A Study of LY2523355 in Participants With Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: LY2523355|Drug: ixabepilone|Drug: pegfilgrastim|Drug: filgrastim,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01416389
7827,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),Completed,Has Results,"Lymphoma, B-Cell",Drug: obinutuzumab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: prednisone|Drug: vincristine,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,8/31/2011,12/23/2016,https://ClinicalTrials.gov/show/NCT01414855
7828,A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: Obinutuzumab|Drug: Corticosteroids,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,10/31/2011,3/31/2016,https://ClinicalTrials.gov/show/NCT01414205
7829,Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD,Completed,Has Results,Exudative Age-related Macular Degeneration,Drug: 4.0 mg iSONEP|Drug: 0.5 mg iSONEP|Drug: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|Drug: sham injection,"Lpath, Inc.","Lpath, Inc.",,,,,,,Phase 2,Industry,Interventional,8/12/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01414153
7830,"A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety",Completed,Has Results,Rheumatoid Arthritis,"Biological: Adalimumab, current formulation|Biological: Adalimumab, new formulation","AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,6/12/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01712178
7831,Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer,Completed,Has Results,Stage IV Pancreatic Cancer,Drug: Gemcitabine|Drug: PEGPH20|Drug: Placebo,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01453153
7832,A Dose-Escalation Study in Participants With Advanced Cancer,Completed,Has Results,Advanced Cancer,Drug: LY2495655,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,1/8/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01524224
7833,Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination,Completed,Has Results,Tachycardia,Device: PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770,MicroPort CRM,MicroPort CRM,,,,,,,Not Applicable,Industry,Interventional,10/11/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01410552
7834,Menopur Mixed Protocol,Completed,Has Results,Infertility,Drug: Bravelle|Drug: Menopur,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,7/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01417195
7835,Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer,Completed,Has Results,Metastatic Pancreatic Cancer,Biological: GVAX Pancreas|Biological: CRS-207|Drug: Cyclophosphamide,"Aduro Biotech, Inc.|Johns Hopkins University","Aduro Biotech, Inc.",Johns Hopkins University,,,,,,Phase 2,Industry|Other,Interventional,9/21/2011,2/10/2017,https://ClinicalTrials.gov/show/NCT01417000
7836,Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty,Completed,Has Results,Knee Replacement Surgery|Osteoarthritis,Procedure: Standard of Care|Drug: FLOSEAL Hemostatic Matrix + Standard of care,Baxter Healthcare Corporation,Baxter Healthcare Corporation,,,,,,,Phase 4,Industry,Interventional,9/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01410240
7837,Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Epratuzumab,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,7/11/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01408576
7838,Therapy™ Cool Flex™ Irrigated Ablation System for Typical Atrial Flutter,Completed,Has Results,Typical Atrial Flutter,Device: Therapy™ Cool Flex™ Irrigated Ablation System,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,11/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01408485
7839,Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),Completed,Has Results,Mucopolysaccharidosis IV A|Morquio A Syndrome|MPS IVA,Drug: BMN 110 - Weekly|Drug: BMN 110 - Every Other Week,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 3,Industry,Interventional,7/11/2019,6/16/2016,https://ClinicalTrials.gov/show/NCT01415427
7840,Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: AIN457 150mg|Drug: AIN457 300mg,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,8/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01406938
7841,Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus,Completed,Has Results,"Lupus Erythematosus, Systemic",Biological: PF-04236921,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01405196
7842,Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations,Completed,Has Results,Parkinson's Disease|Motor Fluctuations,Drug: DM-1992|Drug: Sinemet IR,Depomed,Depomed,,,,,,,Phase 2,Industry,Interventional,1/12/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01515410
7843,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Completed,Has Results,Von Willebrand Disease,Biological: Recombinant von Willebrand factor (rVWF)|Drug: Placebo|Biological: Recombinant factor VIIII (rFVIII),Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 3,Industry,Interventional,11/1/2011,2/1/2014,https://ClinicalTrials.gov/show/NCT01410227
7844,"Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome",Completed,Has Results,Lambert-Eaton Myasthenic Syndrome|Eaton-Lambert Myasthenic Syndrome,"Drug: Continuous 3,4-DAP|Drug: Taper 3,4-DAP to Placebo",Jacobus Pharmaceutical,Jacobus Pharmaceutical,,,,,,,Phase 2,Industry,Interventional,1/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01511978
7845,Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System,Completed,Has Results,Typical Atrial Flutter,Device: Treatment Arm,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 3,Industry,Interventional,10/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01401361
7846,"Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray",Completed,Has Results,Perennial Allergic Rhinitis,Drug: ciclesonide|Drug: mometasone,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,7/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01401465
7847,Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline,Completed,Has Results,Progressive Cognitive Decline,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01400425
7848,Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.,Completed,Has Results,Chronic Nonmalignant and Nonneuropathic Pain,Drug: Hydrocodone bitartrate q24h film-coated tablets,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,7/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01400139
7849,Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4),Completed,Has Results,"Hepatitis C, Chronic",Drug: PegIFN/RBV|Drug: BI201335|Drug: BI201335 24W|Drug: Bi 201335,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,9/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01399619
7850,A Safety and Efficacy Study of Tralokinumab in Adults With Asthma,Completed,Has Results,Asthma,"Other: Placebo Q2W|Biological: Tralokinumab 300 mg, Q2W|Other: Placebo, Q2/4W|Biological: Tralokinumab 300 mg, Q2/4W",MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,8/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01402986
7851,Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients,Completed,Has Results,Gout,Drug: Arhalofenate|Drug: Allopurinol|Drug: Colchicine|Drug: Placebo,"CymaBay Therapeutics, Inc.","CymaBay Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,6/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01399008
7852,A Study of a Novel Silicone Dressing to Minimize Scar Formation,Completed,Has Results,Hypertrophic,Device: embrace device,"Neodyne Biosciences, Inc.|U.S. Army Medical Research and Development Command","Neodyne Biosciences, Inc.",U.S. Army Medical Research and Development Command,,,,,,Not Applicable,Industry|U.S. Fed,Interventional,6/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01399099
7853,Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: OPC-34712,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,9/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01397786
7854,Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer,Completed,Has Results,Colorectal Neoplasms|Digestive System Diseases|Colonic Diseases|Colorectal Cancer,,Exact Sciences Corporation,Exact Sciences Corporation,,,,,,,,Industry,Observational,6/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01397747
7855,MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine,Completed,Has Results,Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma,Drug: Alisertib (MLN8237)|Drug: Rituximab|Drug: Vincristine,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1|Phase 2,Industry,Interventional,8/9/2011,10/5/2016,https://ClinicalTrials.gov/show/NCT01397825
7856,Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study),Completed,Has Results,Dyskinesia|Levodopa Induced Dyskinesia|Parkinson's Disease,Drug: ADS-5102 (extended release amantadine HCl),"Adamas Pharmaceuticals, Inc.","Adamas Pharmaceuticals, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,7/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01397422
7857,Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways,Completed,Has Results,Cystic Fibrosis|Pseudomonas Aeruginosa,Drug: AZLI,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,12/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01404234
7858,Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia,Completed,Has Results,Acute Schizophrenia,Drug: OPC-34712 [Brexpiprazole] High Dose|Drug: Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Drug: Experimental: OPC-34712 [Brexpiprazole] Low Dose|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,7/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01396421
7859,Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3),Completed,Has Results,Cachexia|Non-Small Cell Lung Cancer,Drug: Anamorelin HCl|Drug: Placebo,"Helsinn Therapeutics (U.S.), Inc","Helsinn Therapeutics (U.S.), Inc",,,,,,,Phase 3,Industry,Interventional,7/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01395914
7860,Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia B,Drug: nonacog beta pegol,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,4/15/2012,3/30/2014,https://ClinicalTrials.gov/show/NCT01395810
7861,Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Completed,Has Results,Metastatic Non-Small Cell Lung Cancer,"Drug: ARQ 197 plus erlotinib|Drug: Pemetrexed, docetaxel or gemcitabine",ArQule,ArQule,,,,,,,Phase 2,Industry,Interventional,7/11/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01395758
7862,A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping,Completed,Has Results,Endometrial Cancer|Uterine Cancer|Cervical Cancer,Device: PINPOINT,"Novadaq Technologies ULC, now a part of Stryker","Novadaq Technologies ULC, now a part of Stryker",,,,,,,Not Applicable,Industry,Interventional,12/15/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT02209532
7863,A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,7/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01395524
7864,NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study,Completed,Has Results,Lung Cancer|Lung Tumor,Other: Control|Device: ProGEL Pleural Air Leak Sealant,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,6/11/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01394978
7865,Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients,Completed,Has Results,Postoperative Nausea and Vomiting,Drug: Palonosetron|Drug: Ondansetron|Drug: Placebo to Ondansetron|Drug: Placebo to Palonosetron,Helsinn Healthcare SA,Helsinn Healthcare SA,,,,,,,Phase 3,Industry,Interventional,6/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01395901
7866,Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients,Completed,Has Results,End Stage Renal Disease,Dietary Supplement: ergocalciferol supplementation|Other: placebo,"Dialysis Clinic, Inc.","Dialysis Clinic, Inc.",,,,,,,Phase 4,Industry,Interventional,6/11/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01395823
7867,"Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC",Completed,Has Results,Peripheral Arterial Disease,Drug: sodium nitrite,TheraVasc Inc.,TheraVasc Inc.,,,,,,,Phase 2,Industry,Interventional,7/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01401517
7868,"The Safety And Efficacy Of Maintenance Therapy With CP-690,550",Completed,Has Results,Crohn's Disease,"Drug: Placebo|Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/12/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01393899
7869,"A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease",Completed,Has Results,Crohn's Disease,"Drug: Placebo|Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,10/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01393626
7870,Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia,Completed,Has Results,Acute Schizophrenia,Drug: OPC-34712|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,7/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01393613
7871,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin degludec,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,11/28/2011,10/4/2012,https://ClinicalTrials.gov/show/NCT01392573
7872,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Completed,Has Results,Psoriatic Arthritis,Drug: Secukinumab (75 mg)|Drug: Secukinumab (150 mg)|Drug: Placebo Comparator,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01392326
7873,Allopurinol Outcome Study,Completed,Has Results,Gout,Drug: Allopurinol,"Ardea Biosciences, Inc.","Ardea Biosciences, Inc.",,,,,,,Phase 4,Industry,Interventional,7/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01391325
7874,Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Drug: dasatinib|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,6/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01395017
7875,Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors,Drug: vatreptacog alfa (activated)|Drug: eptacog alfa (activated),Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,7/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01392547
7876,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke,Completed,Has Results,Post-stroke Spasticity of the Upper Limb,Drug: IncobotulinumtoxinA (400 Units)|Drug: Placebo Comparator,Merz Pharmaceuticals GmbH,Merz Pharmaceuticals GmbH,,,,,,,Phase 3,Industry,Interventional,9/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01392300
7877,A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years,Completed,Has Results,"Epilepsy, Partial Seizures",Drug: Pregabalin add-on therapy,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/27/2011,8/10/2016,https://ClinicalTrials.gov/show/NCT01389596
7878,"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C",Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Peg-Interferon Alfa-2a|Drug: Ribavirin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,9/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01389323
7879,NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder,Completed,Has Results,Tardive Dyskinesia,Drug: NBI-98854|Drug: Placebo,Neurocrine Biosciences,Neurocrine Biosciences,,,,,,,Phase 2,Industry,Interventional,8/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01393600
7880,Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty,Completed,Has Results,"Primary Generalized (Osteo)Arthritis|Post-traumatic Arthrosis of Other Joints, Upper Arm",Device: Simpliciti™ Shoulder System,"Tornier, Inc.","Tornier, Inc.",,,,,,,Phase 3,Industry,Interventional,7/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01390038
7881,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Completed,Has Results,Hot Flashes,"Drug: Estradiol transdermal one 90 μL spray|Drug: Estradiol transdermal spray, two 90 μL sprays|Drug: Estradiol transdermal three 90 μL sprays|Drug: Placebo transdermal two 90 μL sprays|Drug: Placebo transdermal three 90 μL sprays|Drug: Placebo transdermal one 90 μL spray","Lumara Health, Inc.","Lumara Health, Inc.",,,,,,,Phase 3,Industry,Interventional,12/4/2019,11/6/2019,https://ClinicalTrials.gov/show/NCT01389102
7882,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin aspart|Drug: liraglutide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01388361
7883,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2),Completed,Has Results,Cachexia|Non-Small Cell Lung Cancer,Drug: Anamorelin HCl|Drug: Placebo,"Helsinn Therapeutics (U.S.), Inc","Helsinn Therapeutics (U.S.), Inc",,,,,,,Phase 3,Industry,Interventional,7/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01387282
7884,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1),Completed,Has Results,Cachexia|Non-Small Cell Lung Cancer,Drug: Anamorelin HCl|Drug: Placebo,"Helsinn Therapeutics (U.S.), Inc","Helsinn Therapeutics (U.S.), Inc",,,,,,,Phase 3,Industry,Interventional,7/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01387269
7885,Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients,Completed,Has Results,Proteinuria|Idiopathic Membranous Nephropathy,Drug: Repository Corticotropin Injection|Drug: Placebo,Mallinckrodt,Mallinckrodt,,,,,,,Phase 4,Industry,Interventional,8/11/2019,5/5/2017,https://ClinicalTrials.gov/show/NCT01386554
7886,Retreatment of Recurrent Dupuytren's Contractures,Completed,Has Results,Dupuytren's Disease,Biological: Collagenase clostridium histolyticum,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,3/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01498640
7887,Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis,Completed,Has Results,Oral Mucositis,Drug: Clonidine Lauriad® 50µg|Drug: Clonidine Lauriad® 100µg|Drug: Placebo Lauriad®,Onxeo,Onxeo,,,,,,,Phase 2,Industry,Interventional,4/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01385748
7888,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,Completed,Has Results,Heart Diseases|Arrhythmia|Atrial Fibrillation,Device: THERMOCOOL® SMARTTOUCH™ Catheter,"Biosense Webster, Inc.","Biosense Webster, Inc.",,,,,,,Phase 3,Industry,Interventional,6/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01385202
7889,"A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema",Completed,Has Results,Hereditary Angioedema (HAE),Drug: icatibant,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,1/27/2012,3/12/2018,https://ClinicalTrials.gov/show/NCT01386658
7890,HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: BMS-663068 400 mg|Drug: BMS-663068 800 mg|Drug: BMS-663068 600 mg|Drug: BMS-663068 1200 mg|Drug: Raltegravir 400 mg|Drug: Tenofovir 300 mg|Drug: Ritonavir 100 mg|Drug: Atazanavir 300 mg,ViiV Healthcare,ViiV Healthcare,,,,,,,Phase 2,Industry,Interventional,7/26/2011,5/12/2017,https://ClinicalTrials.gov/show/NCT01384734
7891,Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1|Phase 2,Industry,Interventional,10/31/2011,11/27/2017,https://ClinicalTrials.gov/show/NCT01383928
7892,A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: rituximab|Drug: methotrexate|Drug: methylprednisolone|Drug: acetaminophen|Drug: antihistamine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,7/26/2011,1/6/2013,https://ClinicalTrials.gov/show/NCT01382940
7893,Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder,Completed,Has Results,Female Sexual Arousal Disorder|Hypoactive Sexual Desire Disorder,Drug: bremelanotide,Palatin Technologies,Palatin Technologies,,,,,,,Phase 2,Industry,Interventional,6/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01382719
7894,A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy,Completed,Has Results,Metastatic ER+ Her2- Breast Cancer|Postmenopausal,Drug: Exemestane|Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Drug: Abiraterone acetate + Prednisone or Prednisolone,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,8/24/2011,8/8/2018,https://ClinicalTrials.gov/show/NCT01381874
7895,LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Other: Placebo to Evolocumab,Amgen|TIMI Study Group,Amgen,TIMI Study Group,,,,,,Phase 2,Industry|Other,Interventional,7/1/2011,4/5/2012,https://ClinicalTrials.gov/show/NCT01380730
7896,A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer,Completed,Has Results,Solid Tumors and Advanced Endometrial Cancer|Endometrial Cancer|Second-line Treatment|VEGF,Drug: TKI258,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,11/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01379534
7897,Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,6/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01377194
7898,Drug-drug Interaction Study,Completed,Has Results,Pompe Disease,Drug: duvoglustat|Drug: rhGAA,Amicus Therapeutics,Amicus Therapeutics,,,,,,,Phase 2,Industry,Interventional,10/31/2011,1/4/2013,https://ClinicalTrials.gov/show/NCT01380743
7899,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",Completed,Has Results,Rheumatoid Arthritis,Biological: Secukinumab (AIN457)|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,8/30/2011,9/9/2015,https://ClinicalTrials.gov/show/NCT01377012
7900,Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: 75 mg LX4211|Drug: 200 mg LX4211|Drug: 400 mg LX4211|Drug: Placebo,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,6/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01376557
7901,A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases,Completed,Has Results,Malignant Melanoma,Drug: Vemurafenib,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,7/11/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01378975
7902,Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Other: Placebo to Evolocumab,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,7/6/2011,3/2/2012,https://ClinicalTrials.gov/show/NCT01375777
7903,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Other: Placebo to Evolocumab,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,7/28/2011,5/8/2012,https://ClinicalTrials.gov/show/NCT01375764
7904,"Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients",Completed,Has Results,Kidney Transplantation,Drug: Tofacitinib,Pfizer,Pfizer,,,,,,,,Industry,Observational,8/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01375127
7905,Aztreonam Lysine for Pseudomonas Infection Eradication Study,Completed,Has Results,Cystic Fibrosis,Drug: Aztreonam for Inhalation Solution (AZLI),Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,8/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01375049
7906,Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: OPC-34712 (4mg)|Drug: Moxifloxacin|Drug: OPC-34712 (12mg)|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 1,Industry,Interventional,7/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01423916
7907,Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC),Completed,Has Results,Colorectal Cancer,Drug: 5-Fluorouracil|Drug: Bevacizumab|Drug: Irinotecan|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Capecitabine,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,8/11/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01374425
7908,Efficacy and Safety of GTR in Comparison to Copaxone®,Completed,Has Results,Multiple Sclerosis,Drug: Glatiramer Acetate (GTR)|Drug: Glatiramer Acetate (Copaxone®)|Drug: Placebo,Synthon BV,Synthon BV,,,,,,,Phase 3,Industry,Interventional,10/11/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01489254
7909,Self Selection Trial of Naproxen Sodium,Completed,Has Results,Pain,Drug: Naproxen sodium ER (BAYH6689)|Drug: Advil,Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,7/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01383486
7910,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Completed,Has Results,Cushing's Disease,Drug: pasireotide LAR|Drug: SOM230 LAR 30 mg|Drug: SOM230 LAR 10 mg,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,11/4/2011,12/21/2016,https://ClinicalTrials.gov/show/NCT01374906
7911,Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine,Completed,Has Results,Dengue|Dengue Fever|Dengue Hemorrhagic Fever|Yellow Fever,"Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|Biological: Yellow Fever","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,12/6/2011,9/27/2013,https://ClinicalTrials.gov/show/NCT01488890
7912,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Completed,Has Results,Major Depressive Disorder,Drug: desvenlafaxine succinate sustained release|Drug: fluoxetine|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/17/2011,3/20/2015,https://ClinicalTrials.gov/show/NCT01372150
7913,A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy,Completed,Has Results,Urinary Incontinence,Drug: solifenacin succinate|Drug: Placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 4,Industry,Interventional,8/2/2011,10/21/2013,https://ClinicalTrials.gov/show/NCT01371994
7914,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,8/11/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01371734
7915,"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD",Completed,Has Results,Major Depressive Disorder,Drug: DVS SR,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/12/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01371721
7916,"A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD",Completed,Has Results,Major Depressive Disorder,Drug: DVS SR,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/2/2012,4/22/2016,https://ClinicalTrials.gov/show/NCT01371708
7917,"A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719|Drug: Tiotropium|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/1/2011,10/27/2011,https://ClinicalTrials.gov/show/NCT01372410
7918,Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Device: NEST-1 (NeoSync EEG Synchronized TMS)|Device: SHAM,"NeoSync, Inc.","NeoSync, Inc.",,,,,,,Phase 3,Industry,Interventional,5/12/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01370733
7919,A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near Vision in Presbyopic Patients,Completed,Has Results,Presbyopia,Device: The Raindrop Near Vision Inlay,"ReVision Optics, Inc.","ReVision Optics, Inc.",,,,,,,Not Applicable,Industry,Interventional,4/10/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01373580
7920,A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement,Completed,Has Results,Muscular Atrophy,Drug: LY2495655|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,7/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01369511
7921,Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon,Completed,Has Results,CRC Screening,Device: PillCam® COLON 2 procedure|Procedure: Colonoscopy,Given Imaging Ltd.,Given Imaging Ltd.,,,,,,,Not Applicable,Industry,Interventional,6/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01372878
7922,A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction,Completed,Has Results,Smoking Cessation,Drug: Varenicline Tartrate|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,7/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01370356
7923,Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001,Completed,Has Results,Pain,Drug: Oxycodone hydrochloride controlled-release tablets,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,10/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01369615
7924,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2),Completed,Has Results,Crohn's Disease|Inflammatory Bowel Disease|IBD|Colitis,Drug: Group 1: Placebo|Drug: Group 2 ustekinumab 130 mg|Drug: Group 3: ustekinumab approximately 6 mg/kg,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,7/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01369342
7925,A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1),Completed,Has Results,Crohn's Disease|IBD|Colitis|Inflammatory Bowel Disease,Drug: Group 2 ustekinumab 130 mg|Drug: Group 3: ustekinumab approximately 6 mg/kg|Drug: Group 1: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,7/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01369329
7926,Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01365507
7927,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: secukinumab 150 mg|Drug: placebo to secukinumab 150 mg,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01365455
7928,Safety Trial of Naproxen Sodium/ Diphenhydramine,Completed,Has Results,Pain,Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|Drug: Placebo,Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,5/11/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01365052
7929,Phase 2 Chronic Low Back Pain Study,Completed,Has Results,Chronic Low Back Pain,Drug: hydrocodone/acetaminophen extended release|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,6/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01364922
7930,Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction,Completed,Has Results,Treatment Outcome,Drug: Vortioxetine|Drug: Escitalopram|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,6/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01364649
7931,Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01364428
7932,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: E/C/F/TDF|Drug: COBI|Drug: ATV|Drug: DRV|Drug: NRTI,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,5/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01363011
7933,Efficacy of Esomeprazole in Patients With Frequent Heartburn,Completed,Has Results,Heartburn,Drug: Esomeprazole,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,8/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01370538
7934,Efficacy of Esomeprazole in Patients With Frequent Heartburn,Completed,Has Results,Heartburn,Drug: Esomeprazole,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,8/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01370525
7935,An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer,Completed,Has Results,"Lung Cancer, Non-Small Cell",Drug: GSK1120212|Drug: docetaxel,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01362296
7936,Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery,Completed,Has Results,Postoperative Pain,Drug: CR845|Drug: Placebo,"Cara Therapeutics, Inc.","Cara Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,7/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01361568
7937,Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study,Completed,Has Results,Parkinson's Disease,Drug: IPX066,"Impax Laboratories, LLC|Michael J. Fox Foundation for Parkinson's Research","Impax Laboratories, LLC",Michael J. Fox Foundation for Parkinson's Research,,,,,,Phase 3,Industry|Other,Interventional,8/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01411137
7938,Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS),Completed,Has Results,Postmenopausal Symptoms,Drug: Brisdelle (paroxetine mesylate)|Drug: Placebo capsules,Noven Therapeutics,Noven Therapeutics,,,,,,,Phase 3,Industry,Interventional,5/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01361308
7939,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: OPC-34712|Drug: Escitalopram|Drug: Fluoxetine|Drug: Paroxetine CR|Drug: Sertraline|Drug: Duloxetine|Drug: Venlafaxine XR,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,10/11/2019,5/18/2017,https://ClinicalTrials.gov/show/NCT01360866
7940,Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial),Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: OPC-34712 + ADT|Drug: Placebo + ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,7/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01360645
7941,Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial),Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: OPC-34712 + ADT|Drug: Placebo + ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,6/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01360632
7942,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Dacomitinib (PF-00299804)|Drug: Active Comparator (erlotinib)|Drug: Placebo erlotinib|Drug: Placebo PF00299804,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/16/2011,9/14/2015,https://ClinicalTrials.gov/show/NCT01360554
7943,New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day,Completed,Has Results,Asthma,Drug: Symbicort|Drug: Budesonide,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,11/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01360021
7944,EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer,Completed,Has Results,Prostate Cancer Metastatic,Drug: EMD 525797|Other: Placebo|Other: Standard of Care (SoC),EMD Serono,EMD Serono,,,,,,,Phase 2,Industry,Interventional,4/11/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01360840
7945,"A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo",Completed,Has Results,Rheumatoid Arthritis,"Drug: CP-690,550|Drug: placebo",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01359150
7946,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3),Completed,Has Results,"Hepatitis C, Chronic",Drug: BI 201335|Drug: Pegylated Interferon-alpha (IFN)|Drug: Ribavirin (RBV)|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,6/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01358864
7947,Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy,Completed,Has Results,Vaginal Atrophy,Drug: Placebo|Drug: DHEA,EndoCeutics Inc.,EndoCeutics Inc.,,,,,,,Phase 3,Industry,Interventional,6/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01358760
7948,A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia,Completed,Has Results,Acute Myeloid Leukemia|Acute Myelogenous Leukemia,Drug: Azacitidine|Drug: Lenalidomide|Other: Best Supportive Care (BSC),Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,4/27/2012,5/15/2018,https://ClinicalTrials.gov/show/NCT01358734
7949,Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Oxycodone/Naloxone Controlled-release|Drug: Placebo,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,5/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01358526
7950,Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex,Completed,Has Results,Bipolar I Disorder,Drug: Lurasidone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,6/11/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01358357
7951,Study Assessing Double-masked Uveitis Treatment,Completed,Has Results,"Uveitis; Posterior, Disorder",Drug: DE-109 44 ug|Drug: DE-109 440 ug|Drug: DE-109 880 ug,Santen Inc.,Santen Inc.,,,,,,,Phase 3,Industry,Interventional,5/11/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01358266
7952,Pharmacokinetics/Pharmacodynamics of Albiglutide,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide (GSK716155),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01357889
7953,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Completed,Has Results,Chronic Plaque Psoriasis,Drug: Placebo|Drug: secukinumab (AIN457)|Drug: etanercept,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01358578
7954,"A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure",Completed,Has Results,"Heart Failure, Congestive",Drug: GSK716155|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/15/2010,9/18/2012,https://ClinicalTrials.gov/show/NCT01357850
7955,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Completed,Has Results,Acute Gouty Arthritis,Drug: Canakinumab pre-filled syringe|Drug: Canakinumab lyophilized powder|Drug: Triamcinolone Acetonide|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,5/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01356602
7956,Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout,Completed,Has Results,Gout,Biological: pegloticase,Savient Pharmaceuticals,Savient Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/6/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT01356498
7957,Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy,Completed,Has Results,Epilepsy,Drug: Brivaracetam tablets|Drug: Brivaracetam bolus|Drug: Brivaracetam infusion|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,8/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01405508
7958,Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,Muscle Wasting|Non Small Cell Lung Cancer,Drug: GTx-024|Drug: placebo,GTx,GTx,,,,,,,Phase 3,Industry,Interventional,7/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01355484
7959,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Completed,Has Results,Rosacea,Drug: CD07805/47 Gel|Drug: Placebo,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,5/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01355471
7960,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Completed,Has Results,Rosacea,Drug: CD07805/47 gel|Drug: Placebo,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,5/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01355458
7961,Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV),Completed,Has Results,Epilepsy,Drug: Brivaracetam,UCB Pharma SA|UCB Pharma,UCB Pharma SA,UCB Pharma,,,,,,Phase 3,Industry,Interventional,7/12/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01653262
7962,Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis,Completed,Has Results,Renal Impairment,Drug: Denosumab,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,11/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01464931
7963,"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.",Completed,Has Results,Healthy,Biological: rLP2086|Other: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,5/13/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01352845
7964,A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years,Completed,Has Results,"Meningitis, Meningococcal",Biological: rLP2086 vaccine|Biological: control,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01352793
7965,A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use,Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Device: Enlite Sensor,Medtronic Diabetes,Medtronic Diabetes,,,,,,,Not Applicable,Industry,Interventional,11/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01464346
7966,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondylitis,Drug: Secukinumab (75 mg)|Drug: Secukinumab (150 mg)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01358175
7967,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Bevacizumab|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,6/25/2011,6/25/2016,https://ClinicalTrials.gov/show/NCT01351415
7968,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Completed,Has Results,Rheumatoid Arthritis,Biological: AIN457|Biological: Placebo|Biological: Abatacept,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01350804
7969,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,Completed,Has Results,Melanoma,Biological: Talimogene Laherparepvec|Drug: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF),BioVex Limited,BioVex Limited,,,,,,,Phase 3,Industry,Interventional,10/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01368276
7970,A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Other: Placebo|Drug: PF-04950615 (RN316),Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01350141
7971,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: Midazolam|Other: Caffeine|Drug: S-warfarin|Other: Vitamin K|Drug: Omeprazole|Drug: Dextromethorphan|Biological: BIIB019 (Daclizumab),Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,11/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01462318
7972,PT003 MDI Dose Confirmation Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: PT003|Drug: PT001|Drug: PT005,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,6/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01349816
7973,3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection,Completed,Has Results,Hepatitis C,Drug: No treatment,Janssen R&D Ireland,Janssen R&D Ireland,,,,,,,Phase 3,Industry,Interventional,7/4/2011,1/5/2016,https://ClinicalTrials.gov/show/NCT01349465
7974,A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.,Completed,Has Results,Coronary Artery Disease,Drug: Flurpiridaz F18|Drug: 99mTechnicium (sestamibi or tetrofosmin),Lantheus Medical Imaging,Lantheus Medical Imaging,,,,,,,Phase 3,Industry,Interventional,6/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01347710
7975,"A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris",Completed,Has Results,Acne Vulgaris,Drug: Visonac PDT|Drug: Vehicle cream with PDT,Photocure,Photocure,,,,,,,Phase 2,Industry,Interventional,5/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01347879
7976,Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age,Completed,Has Results,Tetanus|Diphtheria|Pertussis|Measles|Polio,"Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,4/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01346293
7977,B0151005 Open-Label Extension Study,Completed,Has Results,Crohn's Disease,Biological: PF-04236921,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/11/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT01345318
7978,Gadobutrol Enhanced MRA of the Renal Arteries,Completed,Has Results,Renal Artery Obstruction,"Drug: Gadobutrol (Gadovist, BAY86-4875)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,5/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01344460
7979,Gadobutrol Enhanced MRA of the Supra-aortic Vessels,Completed,Has Results,Carotid Stenosis,"Drug: Gadobutrol (Gadovist, BAY86-4875)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,5/12/2011,5/28/2014,https://ClinicalTrials.gov/show/NCT01344447
7980,GORE Flow Reversal System and GORE Embolic Filter Extension Study,Completed,Has Results,"Carotid Stenosis|Constriction, Pathologic|Carotid Artery Diseases|Cerebrovascular Disorders|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Arterial Occlusive Diseases|Vascular Diseases|Cardiovascular Diseases|Pathological Conditions, Anatomical",Device: Gore Flow Reversal System|Device: Gore Embolic Filter,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,4/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01343667
7981,"Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome",Completed,Has Results,Dumping Syndrome,Drug: SOM230,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,1/8/2013,8/7/2015,https://ClinicalTrials.gov/show/NCT01637272
7982,PT003 MDI Cardiovascular Safety Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: PT005 MDI|Drug: PT001 MDI|Drug: PT003 MDI|Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®),"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,5/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01349803
7983,Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration,Completed,Has Results,"Atrophy, Geographic",Drug: GSK933776|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/1/2011,4/1/2016,https://ClinicalTrials.gov/show/NCT01342926
7984,A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Biological: Placebo|Drug: Statin|Biological: PF-04950615 (RN316)|Drug: Satin,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,7/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01342211
7985,Safety and Maintenance Study of Entocort for Children With Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: Entocort,Perrigo Company,Perrigo Company,,,,,,,Phase 3,Industry,Interventional,12/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01453946
7986,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin 50 mg|Drug: Placebo|Drug: Canagliflozin 150 mg|Drug: Metformin,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,7/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01340664
7987,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Drug: Dalbavancin|Drug: Vancomycin / Linezolid,"Durata Therapeutics Inc., an affiliate of Allergan plc","Durata Therapeutics Inc., an affiliate of Allergan plc",,,,,,,Phase 3,Industry,Interventional,3/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01339091
7988,Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: 25 mg PF-04991532|Drug: 75 mg PF-04991532|Drug: 150 mg PF-04991532|Drug: 300 mg PF-04991532|Drug: Sitagliptin 100 mg,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01338870
7989,Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder,Completed,Has Results,Attention Deficit/Hyperactivity Disorder,Drug: Ritalin LA (methylphenidate hydrochloride extended release),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01338818
7990,Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes, Type 2",Drug: Placebo|Drug: 150 mg PF-04991532|Drug: 450 mg PF-04991532|Drug: 750 mg PF-04991532|Drug: Sitagliptin 100 mg,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01336738
7991,A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate/Vilanterol|Drug: Vilanterol|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/4/2011,11/4/2014,https://ClinicalTrials.gov/show/NCT01336608
7992,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Usual care,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01336205
7993,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin degludec|Drug: liraglutide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,5/23/2011,11/22/2012,https://ClinicalTrials.gov/show/NCT01336023
7994,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II,Completed,Has Results,Pulmonary Fibrosis,Drug: placebo|Drug: BIBF 1120,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,5/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01335477
7995,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients,Completed,Has Results,Pulmonary Fibrosis,Drug: placebo|Drug: BIBF 1120,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,4/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01335464
7996,Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen,Completed,Has Results,Pain,Drug: Intravenous ibuprofen,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,6/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01334957
7997,Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen,Completed,Has Results,Pain|Fever,Drug: Intravenous ibuprofen,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,6/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01334944
7998,A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors,Completed,Has Results,Rheumatoid Arthritis,Drug: Etanercept|Drug: Tocilizumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,8/2/2011,3/25/2016,https://ClinicalTrials.gov/show/NCT01331837
7999,A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT),Completed,Has Results,Coronary Artery Disease (CAD),Drug: regadenoson|Radiation: technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Radiation: Contrast|Procedure: Single Photon Emission Computed Tomography|Procedure: Multidetector Computed Tomography,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 2,Industry,Interventional,4/26/2011,7/2/2012,https://ClinicalTrials.gov/show/NCT01334918
8000,Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia B,Drug: nonacog beta pegol,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,4/27/2011,3/31/2013,https://ClinicalTrials.gov/show/NCT01333111
8001,Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders,Completed,Has Results,Severe Familial Hypercholesterolemia,Biological: Evolocumab,Amgen,Amgen,,,,,,,Phase 2|Phase 3,Industry,Interventional,6/1/2012,5/11/2018,https://ClinicalTrials.gov/show/NCT01624142
8002,Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis,Completed,Has Results,Peripheral Arterial Disease,Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|Procedure: Balloon angioplasty,Spectranetics Corporation,Spectranetics Corporation,,,,,,,Phase 2|Phase 3,Industry,Interventional,6/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01330628
8003,Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet),Completed,Has Results,Chronic Iron Overload Due to Transfusion-dependant Anemias,Drug: Deferasirox dispersible tablet|Drug: Defearisox film-coated tablet,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/8/2014,2/24/2016,https://ClinicalTrials.gov/show/NCT02125877
8004,A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients,Completed,Has Results,Hepatitis C,Drug: BI 201335|Drug: PegIFN/RBV,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,7/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01330316
8005,"Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6",Completed,Has Results,"Hepatitis C, Chronic",Drug: Sofosbuvir|Drug: RBV|Drug: PEG,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,3/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01329978
8006,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Dalfampridine-ER 5mg|Drug: Dalfampridine-ER 10mg|Other: Placebo,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,3/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01328379
8007,Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma,Completed,Has Results,Soft Tissue Sarcoma,"Drug: Eribulin mesylate 1.4 mg/m^2 intravenous|Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV",Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,3/11/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01327885
8008,A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,Completed,Has Results,Basal Cell Carcinoma,Drug: LDE225,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/29/2011,6/29/2018,https://ClinicalTrials.gov/show/NCT01327053
8009,A Study of a New Drug Treatment for Acne,Completed,Has Results,Acne Vulgaris,Drug: 1.2% JNJ 10229570-AAA|Drug: 2.4% JNJ 10229570-AAA|Drug: 3.6% JNJ 10229570-AAA|Other: Vehicle control,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 2,Industry,Interventional,3/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01326780
8010,Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,3/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01326026
8011,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK 573719 +GW642444 125/25|Drug: GSK573719 + GW642444 62.5/25|Drug: GSK 573719 125|Drug: GSK 573719 62.5|Drug: GW642444 25|Drug: Plb,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2011,6/14/2012,https://ClinicalTrials.gov/show/NCT01328444
8012,Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma,Completed,Has Results,Diffuse Large Cell B-lymphoma,Drug: ibrutinib,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 2,Industry,Interventional,5/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01325701
8013,"Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children",Completed,Has Results,Pain,Drug: Buprenorphine transdermal system,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,7/11/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01324570
8014,A Phase 1 Study of LY2787106 in Cancer and Anemia,Completed,Has Results,Anemia,Drug: LY2787106|Dietary Supplement: Iron Supplementation,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1,Industry,Interventional,1/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01340976
8015,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,3/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01323790
8016,A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia|Dyslipidemias|Hyperlipidemias|Lipid Metabolism Disorders|Metabolic Diseases,Biological: PF-04950615 (RN316),Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,10/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01435382
8017,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GSK573719 125|Drug: GSK573719 62.5|Drug: GW642444 25|Device: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/16/2011,7/16/2012,https://ClinicalTrials.gov/show/NCT01323660
8018,Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease,Completed,Has Results,Crohn's Disease,Biological: Trichuris suis ova|Other: Placebo,"Coronado Biosciences, Inc.","Coronado Biosciences, Inc.",,,,,,,Phase 1,Industry,Interventional,11/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01434693
8019,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|Drug: Fluticasone Propionate 250mcg / salmeterol 50mcg|Drug: Double-dummy placebo|Drug: Salbutamol as needed,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/18/2011,1/24/2012,https://ClinicalTrials.gov/show/NCT01323621
8020,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2),Completed,Has Results,Renal Failure Chronic Requiring Hemodialysis,Drug: Soluble Ferric Pyrophosphate (SFP)|Device: Standard dialysate,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 3,Industry,Interventional,4/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01322347
8021,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/18/2011,12/14/2011,https://ClinicalTrials.gov/show/NCT01323634
8022,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",Completed,Has Results,Thyroid Cancer,Drug: Lenvatinib|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,3/17/2011,3/19/2019,https://ClinicalTrials.gov/show/NCT01321554
8023,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients,Completed,Has Results,Renal Failure Chronic Requiring Hemodialysis,Drug: Soluble Ferric Pyrophosphate (SFP)|Device: Standard dialysate,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 3,Industry,Interventional,3/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01320202
8024,Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents,Completed,Has Results,Peripheral Artery Disease|Peripheral Vascular Disease,Device: Astron Stents|Device: Pulsar Stents,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,Phase 2,Industry,Interventional,7/11/2019,9/7/2017,https://ClinicalTrials.gov/show/NCT01319812
8025,Safety and Pharmacokinetic Study of Oral Morphine Sulfate in Pediatric Subjects,Completed,Has Results,Pain,Drug: Morphine Sulfate,Roxane Laboratories|West-Ward Pharmaceutical,Roxane Laboratories,West-Ward Pharmaceutical,,,,,,Phase 4,Industry,Interventional,4/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01322360
8026,"Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate",Completed,Has Results,Rheumatoid Arthritis,Biological: secukinumab (AIN457)|Drug: placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,10/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01359943
8027,Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Completed,Has Results,Rosacea,Drug: CD07805/47 gel 0.5%,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,3/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01318733
8028,Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants,Completed,Has Results,Hepatitis C,Drug: Alisporivir|Drug: Peginterferon alfa-2a|Drug: Ribavirin|Drug: ALV Placebo,Debiopharm International SA,Debiopharm International SA,,,,,,,Phase 3,Industry,Interventional,3/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01318694
8029,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GSK573719|Drug: tiotropium bromide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01316913
8030,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GW642444|Drug: tiotropium bromide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2011,4/24/2012,https://ClinicalTrials.gov/show/NCT01316900
8031,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: 125/25 mcg once-daily GSK573719/GW642444|Drug: 125mcg once-daily GSK573719|Drug: Placebo once-daily,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/1/2011,7/21/2012,https://ClinicalTrials.gov/show/NCT01316887
8032,MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study,Completed,Has Results,Lumbar Spinal Stenosis,Procedure: Percutaneous Lumbar Decompression|Drug: Epidural Steroid Injection,"Vertos Medical, Inc.","Vertos Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01315145
8033,Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome,Completed,Has Results,Fragile X Syndrome,Drug: AFQ056|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01357239
8034,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Completed,Has Results,Bronchiectasis,Drug: AZLI|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,4/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01314716
8035,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: fluticasone furoate/vilanterol|Drug: fluticasone furoate|Drug: vilanterol|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/25/2011,7/15/2015,https://ClinicalTrials.gov/show/NCT01313676
8036,A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: 62.5/25mcg|Drug: 62.5mcg|Drug: 25mcg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2011,4/5/2012,https://ClinicalTrials.gov/show/NCT01313650
8037,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25mcg|Drug: GSK573719 125mcg|Drug: GW642444 25mcg|Drug: Placebo only,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/1/2011,4/19/2012,https://ClinicalTrials.gov/show/NCT01313637
8038,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Completed,Has Results,Bronchiectasis,Drug: AZLI|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,4/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01313624
8039,Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel),Completed,Has Results,Rheumatoid Arthritis,Drug: etanercept|Drug: Placebo|Drug: DMARD Therapy,Amgen,Amgen,,,,,,,Phase 4,Industry,Interventional,3/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01313208
8040,Smoking Cessation Study In Healthy Adolescent Smokers,Completed,Has Results,Smoking Cessation,Drug: Varenicline 1mg BID|Drug: Varenicline 0.5mg BID|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,4/11/2019,1/18/2019,https://ClinicalTrials.gov/show/NCT01312909
8041,Dysport® Adult Upper Limb Spasticity,Completed,Has Results,Nervous System Disorders,Drug: Botulinum type A toxin (Dysport®)|Drug: Placebo,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,8/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01313299
8042,Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm,Completed,Has Results,Spasticity of the Upper and Lower Limb Due to Cerebral Causes,Drug: IncobotulinumtoxinA,Merz Pharmaceuticals GmbH,Merz Pharmaceuticals GmbH,,,,,,,Phase 3,Industry,Interventional,5/12/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01603459
8043,Dysport® Adult Upper Limb Spasticity Extension Study,Completed,Has Results,Nervous System Disorders,Drug: Dysport®,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,11/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01313312
8044,Study of Adacel® Vaccine Administered to Persons 10 Years of Age,Completed,Has Results,Tetanus|Diphtheria|Pertussis,"Biological: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed",Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,3/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01311557
8045,A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Placebo|Drug: Erlotinib|Drug: Second-Line Chemotherapy,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,9/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01328951
8046,A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma,Completed,Has Results,Asthma,Drug: Placebo twice daily|Drug: Olodaterol low daily dose twice daily|Drug: Olodaterol medium daily dose twice daily|Drug: Olodaterol high daily dose once daily and placebo|Drug: Olodaterol medium daily dose once daily and placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,3/11/2019,,https://ClinicalTrials.gov/show/NCT01311661
8047,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,3/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01309841
8048,"A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,"Drug: CP-690,550|Drug: Placebo/CP-690,550",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01309737
8049,"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TDF|Drug: EFV/FTC/TDF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,2/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01309243
8050,Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Cabazitaxel (XRP6258)|Drug: Prednisone (or Prednisolone),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,4/11/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01308580
8051,Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Cabazitaxel (XRP6258)|Drug: Docetaxel (XRP6976)|Drug: Prednisone,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,5/5/2011,5/18/2019,https://ClinicalTrials.gov/show/NCT01308567
8052,Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age,Completed,Has Results,Influenza,Biological: Influenza A (H5N1) Virus monovalent vaccine|Biological: Saline placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/7/2011,1/26/2014,https://ClinicalTrials.gov/show/NCT01310413
8053,Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects,Completed,Has Results,Chronic Hepatitis C|Hepatitis C Virus (HCV) Infection,Drug: ABT-267|Drug: Pegylated interferon (pegIFN)|Drug: Ribavirin (RBV)|Other: Placebo for ABT-267,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,3/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01314261
8054,PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: PT001 MDI|Drug: Ipratropium Bromide HFA Inhalation Aerosol|Other: Placebo MDI,"Pearl Therapeutics, Inc.","Pearl Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,5/1/2011,10/1/2011,https://ClinicalTrials.gov/show/NCT01350128
8055,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA),Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,12/9/2010,8/16/2017,https://ClinicalTrials.gov/show/NCT01307423
8056,Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis|SAR,Drug: BDP HFA|Drug: Placebo nasal aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,3/11/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01307319
8057,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Completed,Has Results,Advanced Prostate Cancer|Prostatic Neoplasms,Biological: sipuleucel-T,Dendreon,Dendreon,,,,,,,,Industry,Observational,1/27/2011,1/17/2017,https://ClinicalTrials.gov/show/NCT01306890
8058,"A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System",Completed,Has Results,Pulmonary Embolism,Device: Denali inferior vena cava filter,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,6/11/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01305564
8059,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Completed,Has Results,Depression,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,3/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01305408
8060,Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions,Completed,Has Results,Degenerative Joint Disease|Congenital Deformity|Arthritis|Osteoarthritis|Rheumatoid Arthritis,Device: Augment® Injectable Bone Graft|Procedure: Autologous bone graft,BioMimetic Therapeutics,BioMimetic Therapeutics,,,,,,,Not Applicable,Industry,Interventional,3/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01305356
8061,"Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)",Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 3,Industry,Interventional,7/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01347073
8062,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",Completed,Has Results,Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus,Drug: ABT-450|Drug: ABT-333|Drug: ribavirin|Drug: ritonavir,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,2/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01306617
8063,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,Completed,Has Results,"Head and Neck Neoplasms|Carcinoma, Squamous Cell",Drug: Afatinib|Drug: Methotrexate,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,1/5/2012,12/6/2016,https://ClinicalTrials.gov/show/NCT01345682
8064,Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Completed,Has Results,Onychomycosis of Toenails,"Drug: AN2690 Topical Solution, 5%|Drug: Solution Vehicle",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/11/2019,2/20/2013,https://ClinicalTrials.gov/show/NCT01302119
8065,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Completed,Has Results,Overactive Bladder,Drug: Fesoterodine 8mg|Drug: Fesoterodine 4mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,5/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01302067
8066,"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.",Completed,Has Results,"Urinary Bladder, Overactive",Drug: Fesoterodine 8 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,5/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01302054
8067,Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo,Completed,Has Results,Rosacea,Drug: Doxycycline|Other: Placebo,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 4,Industry,Interventional,4/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01308619
8068,A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: Fludarabine|Drug: Obinutuzumab|Drug: Bendamustine|Drug: Cyclophosphamide,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,5/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01300247
8069,A Study in Prevention of Re-emergence of Depression Symptoms,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,5/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01299272
8070,Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain,Completed,Has Results,Pain|Low Back Pain|Osteoarthritis|Neuropathic Pain,Drug: BEMA Buprenorphine,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 3,Industry,Interventional,3/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01298765
8071,A Study To Monitor Long-Term Treatment With PF-00547659,Completed,Has Results,Crohn's Disease,Drug: PF-00547659,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,7/1/2011,7/27/2016,https://ClinicalTrials.gov/show/NCT01298492
8072,Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer,Drug: BKM120,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01297491
8073,RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT),Completed,Has Results,Surgical Wound,Other: Manual compression|Device: Cardiva VASCADE™ Vascular Closure System,"Cardiva Medical, Inc.","Cardiva Medical, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01297322
8074,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2),Completed,Has Results,Hepatitis C,Drug: BI201335|Drug: PegIFN/RBV|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,4/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01297270
8075,Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD),Completed,Has Results,GVHD|Adult Acute Myeloid Leukemia|Adult Acute Lymphoid Leukemia|Myelodysplastic Syndrome,Biological: US-ATG-F|Biological: Placebo,Neovii Biotech,Neovii Biotech,,,,,,,Phase 3,Industry,Interventional,10/10/2011,10/15/2015,https://ClinicalTrials.gov/show/NCT01295710
8076,Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL),Completed,Has Results,"Lymphoma, Non-Hodgkin",Biological: Ofatumumab|Drug: Bendamustine,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/17/2011,12/20/2016,https://ClinicalTrials.gov/show/NCT01294579
8077,The Safety and Effectiveness of UroLift: LIFT Pivotal Study,Completed,Has Results,Benign Prostatic Hyperplasia,Device: UroLift System|Other: Cystoscopy|Device: Crossover,"NeoTract, Inc.","NeoTract, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/11/2019,7/5/2017,https://ClinicalTrials.gov/show/NCT01294150
8078,SuperNOVA Clinical Stenting Trial,Completed,Has Results,"Atherosclerosis of Native Arteries of the Extremities, Unspecified",Device: Stent implantation,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,4/11/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01292928
8079,Using Santyl on Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcers|Diabetic Foot Wounds,Biological: Santyl|Procedure: Control,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,8/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01408277
8080,AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis,Completed,Has Results,Psoriasis,"Drug: AN2728 ointment, 2%|Drug: Ointment Vehicle",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,1/26/2011,6/6/2011,https://ClinicalTrials.gov/show/NCT01300052
8081,"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",Completed,Has Results,Chronic Idiopathic Urticaria,Drug: Placebo|Drug: Omalizumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,3/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01292473
8082,"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.",Completed,Has Results,Partial Onset Seizures,Drug: Pregabalin Dose Level 1|Drug: Pregabalin Dose Level 2|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/16/2014,3/13/2018,https://ClinicalTrials.gov/show/NCT02072824
8083,Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Drug: lisdexamfetamine dimesylate (SPD489)|Drug: Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,5/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01291173
8084,Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcers,Device: Epiflo|Other: Moist Wound Therapy,"Neogenix, LLC dba Ogenix","Neogenix, LLC dba Ogenix",,,,,,,Phase 2|Phase 3,Industry,Interventional,10/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01291160
8085,Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: NAFT-600 (naftin 2 % gel)|Drug: Placebo,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 3,Industry,Interventional,2/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01290341
8086,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients",Completed,Has Results,Hepatitis C,Drug: Placebo|Drug: TMC435|Drug: Peginterferon alpha-2a (PegIFN alpha-2a)|Drug: Ribavirin (RBV),Janssen R&D Ireland,Janssen R&D Ireland,,,,,,,Phase 3,Industry,Interventional,2/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01289782
8087,Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: NAFT-600 ( naftin 2 % gel )|Drug: Placebo,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 3,Industry,Interventional,2/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01289015
8088,A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy,Completed,Has Results,Crohn's Disease,Drug: PF-04236921 SC injection,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,2/11/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01287897
8089,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants",Completed,Has Results,Hepatitis C,Drug: Placebo|Drug: TMC435|Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|Drug: Ribavirin (RBV),Janssen R&D Ireland,Janssen R&D Ireland,,,,,,,Phase 3,Industry,Interventional,3/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01290679
8090,"Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients",Completed,Has Results,"HIV, Combination Therapy",Drug: Atazanavir|Drug: Ritonavir (heat-stable)|Drug: Raltegravir|Drug: Tenofovir/Emtricitabine,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 4,Industry,Interventional,10/11/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01332227
8091,A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment,Completed,Has Results,Chronic Idiopathic Urticaria,Drug: Omalizumab|Drug: Placebo,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,2/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01287117
8092,A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,4/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01287039
8093,Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR,Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TDF,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,1/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01286740
8094,A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts,Completed,Has Results,Common Warts,Drug: 10% EISO|Drug: Placebo|Drug: 20% EISO|Drug: 30% EISO,ViroXis Corporation,ViroXis Corporation,,,,,,,Phase 2,Industry,Interventional,11/12/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01286441
8095,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients,Completed,Has Results,End Stage Renal Disease,Drug: Soluble Ferric Pyrophosphate in liquid bicarbonate|Drug: Placebo: Conventional liquid bicarbonate|Drug: Erythrocyte Stimulating Agent (ESA)|Drug: Intravenous (IV) Iron,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 2,Industry,Interventional,1/11/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01286012
8096,A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease,Completed,Has Results,Multicentric Castleman's Disease,Drug: Siltuximab,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,4/1/2011,3/1/2017,https://ClinicalTrials.gov/show/NCT01400503
8097,A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis,Completed,Has Results,Osteopenia,Drug: Oral calcitonin at dinnertime|Drug: Oral placebo at dinnertime|Drug: Oral calcitonin at bedtime|Drug: Oral placebo at bedtime,"Tarsa Therapeutics, Inc.","Tarsa Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,1/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01292187
8098,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,Completed,Has Results,Lung Cancer - Non Small Cell Squamous,Drug: Ipilimumab|Drug: Placebo|Drug: Paclitaxel|Drug: Carboplatin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,1/16/2011,8/22/2017,https://ClinicalTrials.gov/show/NCT01285609
8099,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,3/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01285323
8100,Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression,Completed,Has Results,Bipolar Depression,Drug: Lurasidone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,11/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01284517
8101,Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis,Completed,Has Results,Primary Sclerosing Cholangitis (PSC),Drug: LUM001,"Mirum Pharmaceuticals, Inc.","Mirum Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/14/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT02061540
8102,Guanfacine in Children With Tic Disorders,Completed,Has Results,Tourette Disorder|Tourette Syndrome,Drug: placebo|Drug: extended-release guanfacine (Intuniv),Yale University|Icahn School of Medicine at Mount Sinai|University of South Florida|Shire|New York University,Yale University,Icahn School of Medicine at Mount Sinai,University of South Florida|Shire|New York University,University of South Florida,Shire|New York University,Shire,New York University,Phase 4,Other|Industry,Interventional,4/12/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT01547000
8103,Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients,Completed,Has Results,"Colitis, Ulcerative",Biological: Anrukinzumab|Other: placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01284062
8104,A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections,Drug: Delafloxacin|Drug: Linezolid|Drug: Vancomycin,"Melinta Therapeutics, Inc.","Melinta Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,1/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01283581
8105,A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,"Biological: Sifalimumab 200 mg|Biological: Sifalimumab 600 mg|Biological: Sifalimumab 1,200 mg|Other: Placebo",MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,3/31/2011,4/17/2014,https://ClinicalTrials.gov/show/NCT01283139
8106,"Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma",Completed,Has Results,Carcinoma of Urinary Tract|Urethral Carcinoma|Carcinoma of Ureter|Carcinoma of Renal Pelvis,Drug: Docetaxel|Biological: Ramucirumab DP|Biological: Icrucumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01282463
8107,Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas,Completed,Has Results,Follicular Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Marginal Zone Lymphoma,Drug: Idelalisib,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,3/18/2011,5/16/2018,https://ClinicalTrials.gov/show/NCT01282424
8108,An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension,Completed,Has Results,Systolic Hypertension,Drug: LCZ696|Drug: Valsartan|Drug: AHU377|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,1/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01281306
8109,"A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: MSDC-0602 100 mg|Drug: MSDC-0602 250 mg|Drug: Pioglitazone,Metabolic Solutions Development Company,Metabolic Solutions Development Company,,,,,,,Phase 2,Industry,Interventional,2/11/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01280695
8110,Vigabatrin for the Treatment of Cocaine Dependency,Completed,Has Results,Cocaine Addiction|Cocaine Dependence,Drug: Vigabatrin|Drug: Matching Placebo,"Catalyst Pharmaceuticals, Inc.|National Institute on Drug Abuse (NIDA)|VA Office of Research and Development","Catalyst Pharmaceuticals, Inc.",National Institute on Drug Abuse (NIDA),VA Office of Research and Development,,,,,Phase 2|Phase 3,Industry|NIH|U.S. Fed,Interventional,1/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01281202
8111,Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement,Completed,Has Results,Ventral Incisional Hernia,Device: GORE® BIO-A® Tissue Reinforcement,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,,Industry,Observational,2/11/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01325792
8112,A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM),Completed,Has Results,Glioblastoma Multiforme,Biological: ICT-107|Biological: Placebo DC,Precision Life Sciences Group,Precision Life Sciences Group,,,,,,,Phase 2,Industry,Interventional,1/11/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01280552
8113,"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy",Completed,Has Results,Hepatitis C,Drug: TMC435|Drug: Placebo|Drug: Peginterferon alpha-2a (PegIFN alpha-2a)|Drug: Ribavirin (RBV),Janssen R&D Ireland,Janssen R&D Ireland,,,,,,,Phase 3,Industry,Interventional,2/11/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01281839
8114,A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®),Completed,Has Results,Adult Refractory Complex Partial Seizures,Drug: Sabril,Lundbeck LLC,Lundbeck LLC,,,,,,,Phase 4,Industry,Interventional,12/10/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01278173
8115,A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: GSK1605786A|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/20/2010,7/11/2013,https://ClinicalTrials.gov/show/NCT01277666
8116,Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B,Completed,Has Results,Chronic Hepatitis B,Drug: TDF|Drug: Peg-IFN,Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,4/11/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01277601
8117,A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion,Completed,Has Results,Macular Edema,Drug: Ranibizumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 4,Industry,Interventional,2/11/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01277302
8118,"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,"Drug: CP-690,550|Drug: Placebo/CP-690,550",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01276639
8119,Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: PF-00547659 SC injection,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,4/6/2011,10/9/2015,https://ClinicalTrials.gov/show/NCT01276509
8120,Study of AC-201 in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: AC-201, 25mg|Drug: AC-201, 50mg|Drug: AC-201, 75mg|Drug: Placebo","TWi Biotechnology, Inc.","TWi Biotechnology, Inc.",,,,,,,Phase 2,Industry,Interventional,1/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01276106
8121,Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia B,Drug: nonacog beta pegol,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/7/2012,12/1/2013,https://ClinicalTrials.gov/show/NCT01386528
8122,The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study,Completed,Has Results,Stress Urinary Incontinence,Device: Altis® Single Incision Sling System (SIS),Coloplast A/S,Coloplast A/S,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01272284
8123,Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/1/2011,1/25/2013,https://ClinicalTrials.gov/show/NCT01272232
8124,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/1/2011,3/2/2015,https://ClinicalTrials.gov/show/NCT01272219
8125,Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients,Completed,Has Results,Fibromyalgia,Drug: pregabalin|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01271933
8126,Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Completed,Has Results,Onychomycosis of Toenails,"Drug: AN2690 Topical Solution, 5%|Drug: Solution Vehicle",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/1/2010,1/8/2013,https://ClinicalTrials.gov/show/NCT01270971
8127,BKM120 as Second-line Therapy for Advanced Endometrial Cancer,Completed,Has Results,Advanced Endometrial Cancer,Drug: BKM120,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,2/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01289041
8128,Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism,Completed,Has Results,Secondary Hypogonadism,Drug: Placebo|Drug: topical testosterone|Drug: Androxal,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,1/11/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01270841
8129,Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia,Completed,Has Results,Post Herpetic Neuralgia,Drug: Pregabalin|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/11/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01270828
8130,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,2/11/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01270464
8131,Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa,Completed,Has Results,Pompe Disease (Late-Onset)|Glycogen Storage Disease Type II (GSD II)|Glycogenesis 2 Acid Maltase Deficiency,Biological: Alglucosidase Alfa,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,6/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01288027
8132,Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Eribulin Mesylate,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,12/10/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01269346
8133,Assessmet of Patients With PAH Right Ventricular Volume,Completed,Has Results,Pulmonary Arterial Hypertension,Device: Ventripoint Medical System,VentriPoint Diagnostics Ltd.,VentriPoint Diagnostics Ltd.,,,,,,,Not Applicable,Industry,Interventional,4/12/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01557582
8134,"Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",Completed,Has Results,Recurrent Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma,Biological: Carotuximab (TRC105),Tracon Pharmaceuticals Inc.,Tracon Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,7/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01381861
8135,A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation,Completed,Has Results,Neoplasms,Drug: Vemurafenib,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,6/11/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01286753
8136,Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis|PAR,Drug: ciclesonide nasal aerosol|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,7/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01378429
8137,A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme,Completed,Has Results,Glioblastoma Multiforme,Drug: MEDI-575,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,1/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01268566
8138,A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer,Completed,Has Results,Locally Recurrent|Metastatic Breast Cancer ( HER2 Negative),Drug: Eribulin mesylate,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,2/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01268150
8139,Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY),Completed,Has Results,Hypoparathyroidism,Drug: NPSP558,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,1/11/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01268098
8140,Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: inhaled prostacyclin|Drug: prostacyclin|Drug: subcutaneous and intravenous prostacyclin|Drug: oral ERA|Drug: oral PDE5 inhibitors,United Therapeutics,United Therapeutics,,,,,,,,Industry,Observational,12/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01266265
8141,"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",Completed,Has Results,Chronic Idiopathic Urticaria,"Drug: Omalizumab|Drug: Placebo|Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Drug: Diphenhydramine","Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,2/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01264939
8142,Once-A-Day Pregabalin For Partial Seizures,Completed,Has Results,"Partial Seizures|Epilepsies, Partial",Drug: pregabalin|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/17/2011,8/1/2012,https://ClinicalTrials.gov/show/NCT01262677
8143,Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients,Completed,Has Results,Nocturia,Drug: Desmopressin|Drug: Placebo,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01262456
8144,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Epratuzumab|Drug: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,12/10/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01262365
8145,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Drug: Placebo|Drug: Epratuzumab,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,12/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01261793
8146,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,Completed,Has Results,Epilepsy,Drug: Placebo|Drug: Brivaracetam|Drug: Antiepileptic drugs with market authorization available per country,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,12/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01261325
8147,Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),Completed,Has Results,"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",Biological: IgPro20,CSL Behring,CSL Behring,,,,,,,Phase 3,Industry,Interventional,7/30/2014,7/10/2017,https://ClinicalTrials.gov/show/NCT02027701
8148,Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection,Completed,Has Results,Clostridium Difficile Infection,Biological: VP20621|Other: Placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,5/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01259726
8149,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit/Hyperactivity Disorder,Drug: Placebo|Drug: Ritalin LA 20 mg|Drug: Ritalin LA 30 mg,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,11/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01259492
8150,Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis,Completed,Has Results,Gastroparesis,Drug: GSK962040 (5 mg tablet)|Drug: GSK962040 (25 mg tablet)|Drug: GSK962040 (125 mg tablet)|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/3/2011,2/26/2013,https://ClinicalTrials.gov/show/NCT01262898
8151,To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs),Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100,"Horizon Therapeutics, LLC|Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Therapeutics, LLC","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,Phase 4,Industry,Interventional,10/4/2010,2/16/2017,https://ClinicalTrials.gov/show/NCT01257737
8152,A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: RO5185426,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,1/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01264380
8153,FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis,Completed,Has Results,Restenosis,Device: Fluency Plus Endovascular Stent Graft|Device: Percutaneous Transluminal Angioplasty only,C. R. Bard,C. R. Bard,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01257438
8154,A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: Cobimetinib|Drug: vemurafenib,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,2/17/2011,12/12/2017,https://ClinicalTrials.gov/show/NCT01271803
8155,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),Completed,Has Results,Gastrointestinal Stromal Tumors,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Drug: Best supportive care",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,1/4/2011,4/15/2019,https://ClinicalTrials.gov/show/NCT01271712
8156,DHEA Against Vaginal Atrophy - 3-Month Efficacy Study,Completed,Has Results,Vaginal Atrophy,Drug: Placebo|Drug: DHEA,EndoCeutics Inc.,EndoCeutics Inc.,,,,,,,Phase 3,Industry,Interventional,12/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01256684
8157,DHEA Against Vaginal Atrophy - Safety Study of 12 Months,Completed,Has Results,Vaginal Atrophy,Drug: DHEA,EndoCeutics Inc.,EndoCeutics Inc.,,,,,,,Phase 3,Industry,Interventional,12/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01256671
8158,Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia,Completed,Has Results,Primary Dyslipidemia|Mixed Dyslipidemia,Drug: pitavastatin|Drug: pravastatin,"Kowa Research Institute, Inc.","Kowa Research Institute, Inc.",,,,,,,Phase 4,Industry,Interventional,10/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01256476
8159,Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain,Completed,Has Results,Pain|Low Back Pain,Drug: Buprenorphine|Drug: Placebo,BioDelivery Sciences International,BioDelivery Sciences International,,,,,,,Phase 3,Industry,Interventional,11/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01256450
8160,A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects,Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol (CZP),UCB Pharma,UCB Pharma,,,,,,,Phase 4,Industry,Interventional,11/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01255761
8161,A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis,Completed,Has Results,Restless Legs Syndrome|End-Stage Renal Disease,Drug: Rotigotine|Drug: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,UCB BIOSCIENCES GmbH,UCB Pharma,,,,,,Phase 3,Industry,Interventional,4/12/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01537042
8162,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,"Drug: Levomilnacipran ER|Drug: Paroxetine, Sertraline, Citalopram or Fluoxetine.|Drug: Placebo",Forest Laboratories,Forest Laboratories,,,,,,,Phase 2,Industry,Interventional,4/11/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01254305
8163,LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study,Completed,Has Results,Contraception,"Drug: Levonorgestrel IUD (LCS, BAY86-5028)|Drug: Yasmin (EE30/DRSP, BAY86-5131)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,1/6/2011,5/28/2014,https://ClinicalTrials.gov/show/NCT01254292
8164,"Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism",Completed,Has Results,Secondary Hyperparathyroidism,Drug: Etelcalcetide|Drug: Placebo,KAI Pharmaceuticals,KAI Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,2/20/2011,8/24/2011,https://ClinicalTrials.gov/show/NCT01254565
8165,Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter,Completed,Has Results,Atrial Flutter,Device: Blazer® Open-Irrigated Ablation Catheter|Device: Control Catheter,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01253200
8166,Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF,Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TDF|Drug: PI|Drug: RTV|Drug: NRTIs,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,11/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01252940
8167,A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women,Completed,Has Results,Hemostasis|Oral Contraceptive,Drug: 91-day Levonorgestrel Oral Contraceptive|Drug: 28-day Levonorgestrel Oral Contraceptive|Drug: 28-day Desogestrel Oral Contraceptive,Teva Women's Health|Teva Pharmaceutical Industries,Teva Women's Health,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,11/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01252186
8168,Dysport® Adult Lower Limb Spasticity Follow-on Study,Completed,Has Results,Post-stroke Spasticity|Spasticity Post-Traumatic Brain Injury,Drug: Dysport®,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,6/11/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01251367
8169,A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis,Completed,Has Results,Chronic Sinusitis,Device: Sinus Stent with drug coating|Device: Non Coated Sinus Stent,Intersect ENT,Intersect ENT,,,,,,,Phase 3,Industry,Interventional,12/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01253577
8170,Dysport® Adult Lower Limb Spasticity Study,Completed,Has Results,Leg Spasticity,Drug: Botulinum type A toxin (Dysport®)|Drug: Placebo,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,3/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01249404
8171,A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain,Completed,Has Results,Melanoma and Brain Metastases,Drug: GSK2118436,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,2/11/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01266967
8172,A Study of RO5185426 in Patients With Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: RO5185426,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,12/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01248936
8173,"Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine",Completed,Has Results,"Pain, Migraine","Drug: Aspirin, acetaminophen and caffeine|Drug: Sumatriptan|Drug: Placebo",Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,11/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01248468
8174,Evaluation Of New Onset Postoperative Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation New Onset,Device: CorMatrix ECM for Pericardial Closure,"Aziyo Biologics, Inc.","Aziyo Biologics, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01247974
8175,"A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer",Completed,Has Results,Stomach Cancer|Esophageal Cancer,Biological: Ramucirumab|Drug: Placebo|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-Fluorouracil,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01246960
8176,Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control,Completed,Has Results,Ovulation Suppression,Drug: levonorgestrel and ethinyl estradiol,Agile Therapeutics,Agile Therapeutics,,,,,,,Phase 2,Industry,Interventional,9/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT01250210
8177,Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain,Completed,Has Results,Back Pain,Device: TransDiscal System|Other: Medical Management,Halyard Health,Halyard Health,,,,,,,Not Applicable,Industry,Interventional,12/10/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01263054
8178,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,Completed,Has Results,Melanoma,Drug: GSK1120212|Drug: Chemotherapy,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,11/22/2010,12/16/2016,https://ClinicalTrials.gov/show/NCT01245062
8179,Multi-Center 2-Week Clinical Evaluation of Three Silicone Hydrogel Contact Lenses,Completed,Has Results,Myopia,"Device: galyfilcon A, BC 8.30|Device: lotrafilcon B, BC 8.60|Device: comfilcon A, BC 8.60","Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/1/2010,11/1/2010,https://ClinicalTrials.gov/show/NCT01244516
8180,"Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,",Completed,Has Results,Non-infectious Intermediate Uveitis|Non-infectious Posterior Uveitis|Non-infectious Panuveitis,Drug: LFG316|Drug: Conventional Therapy,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,12/20/2012,8/24/2017,https://ClinicalTrials.gov/show/NCT01526889
8181,"Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,"Drug: CP-690,550 (tasocitinib)",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,5/11/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01262118
8182,A Study of AA4500 in Men With Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01243411
8183,ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids,Completed,Has Results,Uterine Fibroids,Device: ExAblate Treatment UF V2,InSightec,InSightec,,,,,,,Not Applicable,Industry,Interventional,5/12/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01285960
8184,Epanova® for Lowering Very High Triglycerides,Completed,Has Results,Severe Hypertriglyceridemia,Drug: placebo|Drug: omefas,AstraZeneca,AstraZeneca,,,,,,,Phase 2|Phase 3,Industry,Interventional,1/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01242527
8185,A Study of LY2409021 in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2409021|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,1/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01241448
8186,Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Extended-release Guanfacine Hydrochloride|Drug: Atomoxetine Hydrochloride|Drug: Placebo Comparator,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,1/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01244490
8187,A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,Completed,Has Results,Advanced Solid Tumors|Advanced Recurrent Ovarian Tumors,Drug: MEDI3617|Drug: Bevacizumab|Drug: Paclitaxel|Drug: Carboplatin,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,10/10/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01248949
8188,Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time,Completed,Has Results,Chronic Pain,Drug: Hydrocodone ER|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,11/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01240863
8189,Study of Quadrivalent Influenza Vaccine Among Children,Completed,Has Results,Influenza,"Biological: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|Biological: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|Biological: Quadrivalent Influenza Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,11/10/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01240746
8190,Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL),Completed,Has Results,"Chronic Lymphocytic Leukemia (CLL)|Leukaemia, Lymphocytic, Chronic",Biological: Ofatumumab|Drug: Bendamustine,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,3/12/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01520922
8191,A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome,Completed,Has Results,Fibromyalgia,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/11/2019,11/28/2017,https://ClinicalTrials.gov/show/NCT01237587
8192,"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm",Completed,Has Results,Contraception,Drug: AG200-15|Drug: Levora,Agile Therapeutics,Agile Therapeutics,,,,,,,Phase 3,Industry,Interventional,10/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01236768
8193,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain,Completed,Has Results,Ankle Sprain,Drug: Diclofenac sodium topical gel 1%|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,11/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01255423
8194,Bosutinib For Autosomal Dominant Polycystic Kidney Disease,Completed,Has Results,"Polycystic Kidney, Autosomal Dominant",Drug: Bosutinib|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/10/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01233869
8195,A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab 162 mg|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,3/11/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01232569
8196,Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin detemir|Dietary Supplement: Dietary regimen,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 4,Industry,Interventional,10/29/2010,11/14/2011,https://ClinicalTrials.gov/show/NCT01232491
8197,Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.,Completed,Has Results,Plaque Psoriasis,Drug: Apremilast|Drug: Placebo|Other: Topical or Phototherapy Therapy,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,11/22/2010,11/30/2016,https://ClinicalTrials.gov/show/NCT01232283
8198,Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI),Completed,Has Results,Coronary Artery Disease|Coronary Disease|Myocardial Ischemia|Heart Diseases|Cardiovascular Diseases|Arteriosclerosis|Arterial Occlusive Diseases|Vascular Diseases,Device: CorPath robotic-assisted PCI,Corindus Inc.,Corindus Inc.,,,,,,,Phase 2,Industry,Interventional,1/11/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01275092
8199,A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza,Completed,Has Results,"Influenza, Human",Drug: Zanamivir|Drug: Placebo to match zanamivir|Drug: Oseltamivir|Drug: Placebo to match oseltamivir,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/15/2011,3/18/2015,https://ClinicalTrials.gov/show/NCT01231620
8200,Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults,Completed,Has Results,Invasive Meningococcal Disease,"Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.",Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 2,Industry,Interventional,8/11/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01272180
8201,A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access System,Completed,Has Results,Diagnostic Catheterization Access Through a 5F or 6F Femoral Artery Introducer,Device: Diagnostic catheterization procedure,"Arstasis, Inc.","Arstasis, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01271946
8202,Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder,Completed,Has Results,Irritability Associated With Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 4,Industry,Interventional,3/11/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01227668
8203,A Phase IV Trial of Repeated Doses of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,The Treatment of Iron Deficiency Anemia in Patients With Chronic Kidney Disease,Drug: Ferumoxytol|Drug: Iron Sucrose,"AMAG Pharmaceuticals, Inc.","AMAG Pharmaceuticals, Inc.",,,,,,,Phase 4,Industry,Interventional,8/13/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT01227616
8204,CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib,Completed,Has Results,Chronic Myelogenous Leukemia in Chronic Phase,Drug: Nilotinib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,11/10/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01227577
8205,"PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin",Completed,Has Results,Atrial Fibrillation,Drug: dabigatran with ASA|Drug: warfarin|Drug: dabigatran without ASA,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,9/3/2019,,https://ClinicalTrials.gov/show/NCT01227629
8206,A Study in Pediatric Participants With Generalized Anxiety Disorder,Completed,Has Results,"Anxiety Neuroses|Anxiety States, Neurotic|Neuroses, Anxiety",Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,6/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01226511
8207,Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: 4 mm x 32G Pen Needle|Device: 8mm x 31G Pen Needle|Device: 12.7mm x 29G Pen Needle,"Becton, Dickinson and Company","Becton, Dickinson and Company",,,,,,,Not Applicable,Industry,Interventional,10/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01231984
8208,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",Completed,Has Results,Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke,Drug: Ticagrelor 90 mg|Drug: Ticagrelor 60 mg|Drug: Ticagrelor Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,10/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01225562
8209,Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Biological: PF-04950615 (RN316),Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,2/11/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01243151
8210,Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Lumacaftor|Drug: Ivacaftor|Drug: Lumacaftor Placebo|Drug: Ivacaftor Placebo,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 2,Industry,Interventional,10/10/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01225211
8211,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,Completed,Has Results,Cancer,Drug: GSK2118436|Drug: Dacarbazine (DTIC),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/23/2010,9/16/2016,https://ClinicalTrials.gov/show/NCT01227889
8212,Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: vedolizumab|Other: Placebo,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,11/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01224171
8213,Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients,Completed,Has Results,Nocturia,Drug: Desmopressin|Drug: Placebo,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01223937
8214,Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time,Completed,Has Results,Chronic Pain,Drug: Hydrocodone ER,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,10/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01223365
8215,Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma,Completed,Has Results,Metastatic Renal Cell Carcinoma,Drug: Dovitinib|Drug: Sorafenib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01223027
8216,Study of AA4500 in the Treatment of Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500|Biological: Placebo,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01221623
8217,Study of AA4500 in the Treatment of Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500|Biological: Placebo,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01221597
8218,Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging,Completed,Has Results,Myocardial Perfusion Imaging|Myocardial Ischemia,Drug: Ranolazine|Drug: Placebo to match ranolazine|Procedure: SPECT MPI|Behavioral: Exercise,Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,9/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01221272
8219,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: peginterferon beta-1a,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,4/11/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01332019
8220,A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ),Completed,Has Results,Malignant Melanoma,Biological: Coxsackievirus A21 (CVA21),Viralytics,Viralytics,,,,,,,Phase 2,Industry,Interventional,12/29/2011,4/6/2016,https://ClinicalTrials.gov/show/NCT01227551
8221,"Phase 2/3 Study of IGSC, 20% in PIDD",Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Biological: Immune Globulin Intravenous (Human), 10% Solution|Drug: Immune Globulin Subcutaneous (Human), 20% Solution",Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 2|Phase 3,Industry,Interventional,1/13/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01218438
8222,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin",Completed,Has Results,Dyslipidaemias|Dyslipidemias,Drug: 10mg atorvastatin|Drug: 80mg atorvastatin|Drug: GSK1292263 Placebo|Drug: 100mg GSK1292263|Drug: 300mg GSK1292263|Drug: 800mg GSK1292263|Drug: 10mg ezetimibe|Other: Washout,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/14/2010,6/29/2011,https://ClinicalTrials.gov/show/NCT01218204
8223,Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons,Completed,Has Results,AIDS,Biological: GSK Biologicals HIV Vaccine 732462|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/8/2010,11/5/2012,https://ClinicalTrials.gov/show/NCT01218113
8224,Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension,Completed,Has Results,Stage 2 Diastolic Hypertension,Drug: nebivolol and lisinopril (free combination)|Drug: nebivolol monotherapy|Drug: lisinopril monotherapy|Drug: placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,10/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01218100
8225,A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1|Phase 2,Industry,Interventional,11/22/2010,2/2/2018,https://ClinicalTrials.gov/show/NCT01217957
8226,Study of Quadrivalent Influenza Vaccine Among Adults,Completed,Has Results,Influenza,"Biological: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|Biological: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|Biological: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,10/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01218646
8227,Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Biological: ABP 501|Biological: Adalimumab,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,10/13/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01970475
8228,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",Completed,Has Results,Relapsing Forms of Multiple Sclerosis,Drug: Fingolimod|Drug: Standard MS DMTs,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,8/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01216072
8229,Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin lispro|Drug: Glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,12/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01215955
8230,Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants,Completed,Has Results,Hepatitis C|Chronic Pain,Drug: Alisporivir|Drug: Peginterferon alfa-2a|Drug: Ribavirin,Debiopharm International SA,Debiopharm International SA,,,,,,,Phase 2,Industry,Interventional,10/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01215643
8231,Angio-Seal Interventional Radiology (IR) Registry,Completed,Has Results,Diagnostic and/or Interventional Radiology Procedures,,Abbott Medical Devices,Abbott Medical Devices,,,,,,,,Industry,Observational,10/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01222104
8232,Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life,Completed,Has Results,Meningococcal Disease|Meningococcal Meningitis,Biological: MenACWY-CRM|Biological: Routine Vaccines,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,10/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01214837
8233,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",Completed,Has Results,HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Drug: TAF|Drug: Placebo|Drug: E/C/F/TAF|Drug: Current failing ARV regimen|Drug: ATV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,10/25/2013,7/31/2017,https://ClinicalTrials.gov/show/NCT01967940
8234,Post-Myocardial Infarction Remodeling Prevention Therapy,Completed,Has Results,Acute Myocardial Infarction|Pacing Therapy|Cardiac Remodeling|Heart Failure,Device: Single Site Pacing|Device: Dual Site Pacing,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Phase 2,Industry,Interventional,12/10/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01213251
8235,PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,9/30/2010,2/9/2017,https://ClinicalTrials.gov/show/NCT01212770
8236,PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,9/27/2010,1/25/2017,https://ClinicalTrials.gov/show/NCT01212757
8237,Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions,Completed,Has Results,Diagnostic Self Evaluation|Central Nervous System Diseases,Drug: Dotarem (gadoterate meglumine)|Drug: Magnevist (gadopentetate dimeglumine),Guerbet,Guerbet,,,,,,,Phase 3,Industry,Interventional,9/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01211873
8238,Zomig - Treatment of Acute Migraine Headache in Adolescents,Completed,Has Results,Migraine Headache,Drug: Placebo|Drug: Zolmitriptan,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,9/10/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01211145
8239,Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma,Completed,Has Results,Hepatocellular Carcinoma,Drug: Axitinib (AG-013736)|Other: Best Supportive Care|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/6/2010,12/20/2016,https://ClinicalTrials.gov/show/NCT01210495
8240,PRESERVE-Zenith® Iliac Branch System Clinical Study,Completed,Has Results,Aorto-iliac Aneurysms|Iliac Aneurysms,Device: Endovascular repair for aortoiliac or iliac aneurysms.,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,1/11/2019,10/10/2017,https://ClinicalTrials.gov/show/NCT01208415
8241,Switching to Iloperidone From Other Antipsychotics in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: iloperidone,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,8/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01207414
8242,Dysport® Pediatric Lower Limb Spasticity Follow-on Study,Completed,Has Results,Cerebral Palsy|Muscle Spasticity|Children,Drug: Botulinum type A toxin (Dysport®),Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,10/11/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT01251380
8243,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Drug: LY2127399|Drug: Placebo every 2 weeks|Drug: Placebo every 4 weeks,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/11/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01205438
8244,Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Apo805K1,ApoPharma,ApoPharma,,,,,,,Phase 2,Industry,Interventional,11/11/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01483924
8245,Dysport® Pediatric Lower Limb Spasticity Study,Completed,Has Results,Cerebral Palsy|Muscle Spasticity|Children,Drug: Botulinum type A toxin (Dysport®)|Drug: Placebo,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,7/11/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01249417
8246,A Rheumatoid Arthritis Study in Participants,Completed,Has Results,Rheumatoid Arthritis,Drug: LY2127399|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/11/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT01202760
8247,Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI,Completed,Has Results,Acute Upper Respiratory Track Infection,Drug: Guaifenesin|Device: Placebo,Reckitt Benckiser LLC,Reckitt Benckiser LLC,,,,,,,Phase 4,Industry,Interventional,10/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01202279
8248,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: indacaterol and glycopyrronium (QVA149)|Drug: glycopyrronium (NVA237)|Drug: indacaterol (QAB149)|Drug: tiotropium|Drug: placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01202188
8249,A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma,Completed,Has Results,Basal Cell Carcinoma,Drug: Vismodegib,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,10/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01201915
8250,A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy,Completed,Has Results,Neuropathic Pain,Drug: AZD2423|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,9/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01201317
8251,"A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy",Completed,Has Results,Diabetic Nephropathies,Drug: PF-00489791|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/10/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01200394
8252,A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider,Completed,Has Results,Smoking Cessation,Drug: Varenicline|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,12/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01244061
8253,Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Escitalopram,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,9/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01198795
8254,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children,Completed,Has Results,Influenza,Biological: Quadrivalent seasonal influenza vaccine GSK2282512A|Biological: Fluarix™ VB|Biological: Fluarix™ YB,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/1/2010,7/1/2011,https://ClinicalTrials.gov/show/NCT01198756
8255,Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment,Completed,Has Results,Solid Tumors|Hematologic Malignancies|Hepatic Impairment,Drug: Carfilzomib,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,10/13/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01949545
8256,Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older,Completed,Has Results,Influenza,Biological: Investigational H7N1 vaccine GSK2789869A|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/25/2013,10/23/2014,https://ClinicalTrials.gov/show/NCT01949090
8257,"Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients",Completed,Has Results,Asthma Patients,Drug: AZD1981|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,10/10/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01197794
8258,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist,Completed,Has Results,Rheumatoid Arthritis,Drug: fostamatinib|Drug: placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01197755
8259,Registry Study of Genesys HTA for Treatment of Menorrhagia,Completed,Has Results,Menorrhagia,Device: Genesys HTA,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,11/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01197547
8260,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.,Completed,Has Results,Rheumatoid Arthritis,"Drug: fostamatinib|Drug: placebo, fostamatinib",AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01197534
8261,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.,Completed,Has Results,Rheumatoid Arthritis,"Drug: fostamatinib|Drug: placebo, fostamatinib",AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,9/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01197521
8262,Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children,Completed,Has Results,Influenza,Biological: Influenza vaccine GSK2321138A|Biological: FluarixTM|Biological: Influenza vaccine GSK2604409A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/4/2010,6/15/2011,https://ClinicalTrials.gov/show/NCT01196988
8263,Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),Completed,Has Results,Diffuse Large B-cell Lymphoma,Drug: Lenalidomide|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Rituximab|Drug: Etoposide,Celgene,Celgene,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/2/2010,4/5/2018,https://ClinicalTrials.gov/show/NCT01197560
8264,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Drug: LY2127399|Drug: Placebo every 2 weeks|Drug: Placebo every 4 weeks|Drug: Standard of Care,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01196091
8265,"A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer",Completed,Has Results,Breast Cancer,Drug: Trastuzumab emtansine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,10/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01196052
8266,Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A),Completed,Has Results,Influenza,Biological: Influenza vaccine GSK2321138A|Biological: FluarixTM|Biological: Influenza vaccine GSK2604409A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/4/2010,6/6/2011,https://ClinicalTrials.gov/show/NCT01204671
8267,"A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)",Completed,Has Results,Postherpetic Neuralgia,Drug: XPF-002|Drug: Placebo,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,8/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01195636
8268,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: tocilizumab SC|Drug: tocilizumab IV|Drug: placebo to tocilizumab SC|Drug: placebo to tocilizumab IV|Drug: Disease-modifying antirheumatic drugs (DMARDs),Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,9/10/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01194414
8269,"Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)",Completed,Has Results,Phenylketonuria,Drug: rAvPAL-PEG,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 2,Industry,Interventional,3/11/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01212744
8270,Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type II",Drug: Insulin lispro|Drug: Insulin aspart|Drug: Recombinant human hyaluronidase PH20|Drug: Insulin glulisine|Drug: Insulin glargine,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 2,Industry,Interventional,8/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01194258
8271,Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin lispro|Drug: recombinant human hyaluronidase PH20|Drug: Insulin aspart|Drug: Insulin glulisine|Drug: Insulin glargine,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 2,Industry,Interventional,8/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01194245
8272,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Completed,Has Results,Prostate Cancer,Drug: Orteronel|Drug: Prednisone|Drug: Orteronel Placebo,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 3,Industry,Interventional,11/15/2010,2/29/2016,https://ClinicalTrials.gov/show/NCT01193257
8273,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Orteronel|Drug: Placebo|Drug: Prednisone,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 3,Industry,Interventional,10/1/2010,4/7/2016,https://ClinicalTrials.gov/show/NCT01193244
8274,A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder,Completed,Has Results,Schizoaffective Disorder,Drug: Placebo|Drug: paliperidone palmitate,"Janssen Scientific Affairs, LLC","Janssen Scientific Affairs, LLC",,,,,,,Phase 3,Industry,Interventional,9/10/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01193153
8275,Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR),Completed,Has Results,Cataract,Drug: OMS302 Solution|Drug: OMS302 Mydriatic Solution|Drug: OMS302 Anti-inflammatory Solution|Drug: Balanced Salt Solution (BSS) Solution,Omeros Corporation,Omeros Corporation,,,,,,,Phase 2,Industry,Interventional,7/10/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT01193127
8276,Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids,Completed,Has Results,Pain,Drug: Oxycodone HCl controlled-release tablets,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,11/10/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT01192295
8277,Fall Epidemic Viral Pediatric Study,Completed,Has Results,Asthma,Drug: FLOVENT™ DISKUS™ 100 mcg BID|Drug: ADVAIR™ DISKUS™ 100/50 mcg BID,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,8/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01192178
8278,TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery,Completed,Has Results,Hemorrhage,Biological: TachoSil®|Device: Surgicel® Original,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,8/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01192022
8279,Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML,Completed,Has Results,Acute Myeloid Leukemia,Drug: vosaroxin + cytarabine|Drug: placebo + cytarabine,Sunesis Pharmaceuticals,Sunesis Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/17/2010,3/1/2017,https://ClinicalTrials.gov/show/NCT01191801
8280,Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus|Secondary Hypogonadism,Drug: Placebo|Drug: Androxal,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,10/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01191320
8281,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Glargine|Drug: LY2189265|Drug: Insulin Lispro,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01191268
8282,A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis,Completed,Has Results,Hyperphosphatemia|Kidney Failure,"Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo",Keryx Biopharmaceuticals,Keryx Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01191255
8283,Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: USL255,Upsher-Smith Laboratories,Upsher-Smith Laboratories,,,,,,,Phase 3,Industry,Interventional,10/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01191086
8284,Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study,Completed,Has Results,"Infections, Papillomavirus",Biological: GSK580299 (Cervarix),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,4/1/2011,11/23/2017,https://ClinicalTrials.gov/show/NCT01190189
8285,Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females,Completed,Has Results,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders|Metabolic Diseases|Endocrine System Diseases",Biological: Placebo|Biological: PF-04856883,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,3/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01301456
8286,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),Completed,Has Results,Psoriasis Vulgaris,"Drug: Calcipotriol plus betamethasone|Drug: Betamethasone-17,21-dipropionate|Drug: Calcipotriene|Drug: Topical suspension vehicle",LEO Pharma,LEO Pharma,,,,,,,Phase 3,Industry,Interventional,9/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01188928
8287,Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects,Completed,Has Results,Psoriasis,Drug: Brodalumab,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 1,Industry,Interventional,9/13/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01937260
8288,Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients,Completed,Has Results,Hepatitis C Virus,Drug: Sofosbuvir|Drug: Placebo to match sofosbuvir|Drug: PEG|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,8/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01188772
8289,"Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",Completed,Has Results,Hereditary Angioedema,Drug: rhC1INH|Drug: Placebo (Saline),Pharming Technologies B.V.,Pharming Technologies B.V.,,,,,,,Phase 3,Industry,Interventional,1/11/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01188564
8290,"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx",Completed,Has Results,Renal Failure,Drug: Prograf (tacrolimus)|Drug: LCP-Tacro,Veloxis Pharmaceuticals,Veloxis Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/10/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01187953
8291,A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment,Completed,Has Results,Major Depressive Disorder (MDD),Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/11/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01187407
8292,"A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,"Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01186744
8293,A Study of Olaratumab in Soft Tissue Sarcoma,Completed,Has Results,"Sarcoma, Soft Tissue",Biological: Olaratumab|Drug: doxorubicin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/10/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01185964
8294,"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo (Saxagliptin)|Drug: Metformin IR|Drug: Placebo (Metformin)|Drug: Metformin (Active Rescue),AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,6/11/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01204775
8295,A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01185340
8296,Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA),Completed,Has Results,Early Rheumatoid Arthritis,Biological: adalimumab|Drug: methotrexate,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 3,Industry,Interventional,10/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01185301
8297,A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA),Completed,Has Results,Rheumatoid Arthritis,Biological: Adalimumab|Drug: Methotrexate,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 4,Industry,Interventional,9/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01185288
8298,Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH),Completed,Has Results,"Hypertension, Pulmonary",Drug: current marketed FLOLAN (epoprostenol sodium)|Drug: new thermo stable formulation of epoprostenol sodium,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,11/1/2011,11/8/2012,https://ClinicalTrials.gov/show/NCT01462565
8299,Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment,Completed,Has Results,Hepatitis C,Drug: Alisporivir|Drug: Peginterferon alfa-2a|Drug: Ribavirin|Drug: Placebo,Debiopharm International SA,Debiopharm International SA,,,,,,,Phase 2,Industry,Interventional,8/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01183169
8300,"Time to Eugonadal Range, Time to Steady State and Drying Time",Completed,Has Results,Male Hypogonadism,Drug: testosterone gel 2%,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01228071
8301,Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,Completed,Has Results,Atrial Fibrillation|Stroke,Device: WATCHMAN Device|Drug: Warfarin,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,11/10/2019,11/17/2019,https://ClinicalTrials.gov/show/NCT01182441
8302,Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System,Completed,Has Results,Contraception,Drug: AG200-15 (cycles 1-13)|Drug: Lessina crossover to AG200-15,Agile Therapeutics,Agile Therapeutics,,,,,,,Phase 3,Industry,Interventional,8/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01181479
8303,"Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects",Completed,Has Results,Hepatitis C,Drug: ACH-0141625 (Sovaprevir)|Drug: Placebo|Drug: Pegylated Interferon alpha-2a|Drug: Ribavirin,Achillion Pharmaceuticals,Achillion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,9/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01180790
8304,Melody® Transcatheter Pulmonary Valve Post-Approval Study,Completed,Has Results,Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduit,Device: Melody® Transcatheter Pulmonary Valve,Medtronic Cardiovascular,Medtronic Cardiovascular,,,,,,,Not Applicable,Industry,Interventional,7/10/2019,10/17/2019,https://ClinicalTrials.gov/show/NCT01186692
8305,Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Vortioxetine|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,8/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01179516
8306,A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia,Completed,Has Results,Sickle Cell Anemia|Sickle ß0-Thalassemia,Drug: L-glutamine|Drug: Placebo,"Emmaus Medical, Inc.","Emmaus Medical, Inc.",,,,,,,Phase 3,Industry,Interventional,5/10/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01179217
8307,Tiotropium Bromide in Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: tiotropium Respimat® inhaler|Drug: Placebo Respimat® inhaler,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,9/10/2019,,https://ClinicalTrials.gov/show/NCT01179347
8308,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/31/2010,12/17/2015,https://ClinicalTrials.gov/show/NCT01179048
8309,Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence,Completed,Has Results,Primary Myelofibrosis|MPN-associated Myelofibrosis,Drug: Pomalidomide 0.5 mg|Drug: Placebo|Drug: Pomalidomide,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,9/8/2010,5/15/2018,https://ClinicalTrials.gov/show/NCT01178281
8310,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,Completed,Has Results,Asthma,Drug: Vilanterol|Drug: Salmeterol Inhalation Powder|Drug: Placebo Inhalation Powder NDPI|Drug: Placebo Inhalation Powder Diskus,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/1/2010,8/26/2011,https://ClinicalTrials.gov/show/NCT01181895
8311,A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy,Completed,Has Results,Contraception|Female Contraception,Drug: DR-102,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,8/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01178125
8312,Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea,Completed,Has Results,Irritable Bowel Syndrome With Diarrhea,Drug: Placebo|Drug: Mesalamine Granules 750 mg|Drug: Mesalamine Granules 1500 mg,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 2,Industry,Interventional,7/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01177410
8313,A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease,Completed,Has Results,Orthostatic Hypotension|Parkinson's Disease,Drug: Droxidopa|Other: Placebo,Chelsea Therapeutics,Chelsea Therapeutics,,,,,,,Phase 3,Industry,Interventional,6/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01176240
8314,A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection,Completed,Has Results,Rhinovirus,Drug: BTA798|Drug: Placebo,Biota Scientific Management Pty Ltd|Vaxart,Biota Scientific Management Pty Ltd,Vaxart,,,,,,Phase 2,Industry,Interventional,8/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01175226
8315,"An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia",Completed,Has Results,Schizophrenia,Drug: PF-02545920|Drug: Placebo|Drug: Risperidone,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,10/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01175135
8316,Chronic Total Occlusion Crossing With the Wildcat Catheter,Completed,Has Results,Peripheral Arterial Disease,Device: Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer,"Avinger, Inc.","Avinger, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01174784
8317,Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease,Completed,Has Results,Fabry Disease,Drug: migalastat hydrochloride|Biological: agalsidase,Amicus Therapeutics,Amicus Therapeutics,,,,,,,Phase 3,Industry,Interventional,9/8/2011,5/28/2015,https://ClinicalTrials.gov/show/NCT01218659
8318,"Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: losmapimod|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/4/2010,12/21/2011,https://ClinicalTrials.gov/show/NCT01218126
8319,Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Completed,Has Results,Rosacea,Drug: CD07805/47 Gel|Drug: Vehicle Gel,Galderma,Galderma,,,,,,,Phase 2,Industry,Interventional,8/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01174030
8320,A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: pimavanserin tartrate|Drug: placebo,ACADIA Pharmaceuticals Inc.,ACADIA Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,7/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01174004
8321,A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/10/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01173601
8322,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,6/2/2010,10/27/2016,https://ClinicalTrials.gov/show/NCT01172938
8323,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Biological: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|Biological: SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|Biological: IV treatment with IGSC, 10%",Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 3,Industry,Interventional,7/28/2010,8/6/2013,https://ClinicalTrials.gov/show/NCT01175213
8324,Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia,Completed,Has Results,Chronic Lymphocytic Leukemia (CLL),Drug: TRU-016 and bendamustine|Drug: Bendamustine|Drug: 15 mg/kg TRU-016 and bendamustine|Drug: 20 mg/kg TRU-016 and bendamustine,Aptevo Therapeutics,Aptevo Therapeutics,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01188681
8325,Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment,Completed,Has Results,Hepatitis C Virus,Drug: BMS-790052|Drug: Placebo|Drug: peginterferon alfa-2a|Drug: ribavirin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,8/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01170962
8326,TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections,Drug: TR-701 FA|Drug: Linezolid,Trius Therapeutics LLC,Trius Therapeutics LLC,,,,,,,Phase 3,Industry,Interventional,8/15/2010,9/30/2011,https://ClinicalTrials.gov/show/NCT01170221
8327,A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma,Completed,Has Results,Gastric Cancer,Biological: Ramucirumab (IMC-1211B) DP|Drug: Placebo|Drug: Paclitaxel,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/10/2019,2/17/2019,https://ClinicalTrials.gov/show/NCT01170663
8328,"Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects",Completed,Has Results,Post Operative Pain,Drug: oxymorphone HCl,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/13/2010,10/6/2017,https://ClinicalTrials.gov/show/NCT01210352
8329,The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial,Completed,Has Results,Chronic Heart Failure,Device: HeartWare® VAS|Device: Control LVAD,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,8/10/2019,5/17/2019,https://ClinicalTrials.gov/show/NCT01166347
8330,Trial of the PresVIEW Implant for the Improvement of Near Vision in Patients With Presbyopia,Completed,Has Results,Presbyopia,Device: PresVIEW Scleral Implants,"Refocus Group, Inc.","Refocus Group, Inc.",,,,,,,Not Applicable,Industry,Interventional,12/3/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01166568
8331,"Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin aspart|Drug: insulin detemir,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 4,Industry,Interventional,10/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01165684
8332,Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB,Completed,Has Results,Bladder Cancer,,Photocure,Photocure,,,,,,,,Industry,Observational,6/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01166230
8333,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults,Completed,Has Results,"Infections, Meningococcal",Biological: Meningococcal vaccine GSK 134612|Biological: Menactra®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/19/2010,7/29/2011,https://ClinicalTrials.gov/show/NCT01165242
8334,"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster Vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,8/2/2010,7/24/2015,https://ClinicalTrials.gov/show/NCT01165229
8335,"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster Vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,8/1/2010,7/27/2015,https://ClinicalTrials.gov/show/NCT01165177
8336,Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Completed,Has Results,Asthma,Drug: Fluticasone furoate/Vilanterol Inhalation Powder|Drug: Fluticasone Furoate Inhalation Powder|Drug: Placebo Inhaltion Powder,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,8/20/2010,10/19/2011,https://ClinicalTrials.gov/show/NCT01165138
8337,A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA),Completed,Has Results,Rheumatoid Arthritis,Biological: tocilizumab|Drug: methotrexate|Biological: 23-Valent Pneumococcal Polysaccharide Vaccine|Biological: Tetanus Toxoid Adsorbed Vaccine,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 4,Industry,Interventional,9/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01163747
8338,Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases,Completed,Has Results,Breast Neoplasms|Neoplasm Metastasis,Drug: Vinorelbine|Drug: Investigator's choice of treatment|Drug: afatinib,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,10/11/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01441596
8339,Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Vortioxetine|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,7/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01163266
8340,Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder,Completed,Has Results,Non-24-Hour Sleep-Wake Disorder,Drug: tasimelteon|Drug: Placebo,Vanda Pharmaceuticals,Vanda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01163032
8341,Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects,Completed,Has Results,Influenza,Biological: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|Biological: Non-adjuvanted trivalent subunit influenza vaccine (TIV),Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,8/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01162122
8342,Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration,Completed,Has Results,Prostate Cancer,Drug: Triptorelin pamoate|Drug: Leuprolide acetate,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,7/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01161563
8343,Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com),Completed,Has Results,Obstructive Sleep Apnea,Device: Inspire Upper Airway Stimulation System,"Inspire Medical Systems, Inc.","Inspire Medical Systems, Inc.",,,,,,,Phase 3,Industry,Interventional,7/10/2019,4/17/2019,https://ClinicalTrials.gov/show/NCT01161420
8344,A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Biological: IMC-1121B (ramucirumab)|Drug: Pemetrexed|Drug: Carboplatin (AUC 6)|Drug: Cisplatin|Drug: Gemcitabine|Drug: Carboplatin (AUC 5),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,9/10/2019,4/18/2019,https://ClinicalTrials.gov/show/NCT01160744
8345,A Study of LY900010 in Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction,Drug: LY2452473|Drug: tadalafil|Drug: placebo (tadalafil)|Drug: placebo (LY2452473),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,10/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01160289
8346,Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents,Completed,Has Results,Asthma,Drug: Fluticasone propionate|Drug: Fluticasone furoate|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/30/2010,1/16/2012,https://ClinicalTrials.gov/show/NCT01159912
8347,Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients,Completed,Has Results,Opioid Analgesia,Drug: Oxycodone hydrochloride controlled-release (ORF) tablets,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 1,Industry,Interventional,7/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01160614
8348,"Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age",Completed,Has Results,Sedation,Drug: Midazolam|Drug: Fentanyl/Morphine|Drug: Dexmedetomidine,"Hospira, now a wholly owned subsidiary of Pfizer","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,,Phase 2|Phase 3,Industry,Interventional,7/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01159262
8349,Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures,Completed,Has Results,Elective Cranial Procedures With Dural Incision,Device: Adherus Dural Sealant,"HyperBranch Medical Technology, Inc","HyperBranch Medical Technology, Inc",,,,,,,Phase 3,Industry,Interventional,6/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01158378
8350,"A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents",Completed,Has Results,Epilepsy,Drug: Perampanel|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,9/10/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01161524
8351,15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated,Completed,Has Results,Schizophrenia,Drug: paliperidone|Drug: risperidone|Drug: haloperidole|Drug: perphenazine|Drug: aripiprazole|Drug: quetiapine|Drug: paliperidone palmitate|Drug: olanzapine,"Janssen Scientific Affairs, LLC","Janssen Scientific Affairs, LLC",,,,,,,Phase 4,Industry,Interventional,5/10/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01157351
8352,The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients,Completed,Has Results,Rheumatoid Arthritis,Device: Adalimumab delivered in current syringe|Device: Adalimumab delivered in Physiolis syringe|Device: Adalimumab delivered in current autoinjector|Device: Adalimumab delivered in Physiolis autoinjector,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,5/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01163617
8353,"Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol",Completed,Has Results,Persistent Asthma,Drug: Indacaterol|Drug: Placebo to Indacaterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,3/10/2019,,https://ClinicalTrials.gov/show/NCT01156844
8354,Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age,Completed,Has Results,Asthma,Drug: FP 100|Drug: GSK2190915 100|Drug: GSK2190915 300|Drug: montelukast|Drug: placebo|Drug: FP/SAL 100/50,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01156792
8355,BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,Drug: dimethyl fumarate,Biogen,Biogen,,,,,,,Phase 2,Industry,Interventional,6/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01156311
8356,A Safety Study in Participants With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684 (edivoxetine)|Drug: SSRI,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,10/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01155661
8357,Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis,Completed,Has Results,Uveitis,Drug: Sarilumab|Drug: Prednisone|Drug: Methotrexate|Drug: Folic/folinic acid|Other: Placebo (for Sarilumab),Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,10/13/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01900431
8358,"Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)",Completed,Has Results,Steatohepatitis,Drug: Placebo capsule|Drug: EPA-E 300 mg capsule,"Mochida Pharmaceutical Company, Ltd.","Mochida Pharmaceutical Company, Ltd.",,,,,,,Phase 2,Industry,Interventional,6/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01154985
8359,Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas,Completed,Has Results,Cachexia,Drug: BYM338 active drug|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/11/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01433263
8360,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,Completed,Has Results,Non Squamous Lung Cancer,Drug: treatment,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/13/2011,11/30/2016,https://ClinicalTrials.gov/show/NCT01154140
8361,Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,6/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01153009
8362,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Enalapril,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,8/10/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01151410
8363,Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens,Completed,Has Results,Myopia,Device: narafilcon B contact lens|Device: nelfilcon A contact lens|Device: lotrafilcon B contact lens,"Johnson & Johnson Vision Care, Inc.|Visioncare Research Ltd.","Johnson & Johnson Vision Care, Inc.",Visioncare Research Ltd.,,,,,,Not Applicable,Industry|Other,Interventional,2/1/2010,4/1/2010,https://ClinicalTrials.gov/show/NCT01151371
8364,Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP),Completed,Has Results,Acquired Thrombotic Thrombocytopenic Purpura,Biological: Caplacizumab|Biological: Placebo,Ablynx,Ablynx,,,,,,,Phase 2,Industry,Interventional,1/11/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01151423
8365,Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study,Completed,Has Results,Chronic Nonmalignant Pain,Drug: Buprenorphine transdermal patch,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,4/1/2019,2/2/2019,https://ClinicalTrials.gov/show/NCT01151098
8366,Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer,Completed,Has Results,Her2 Negative Breast Cancer Patients,Drug: MM-121|Drug: Placebo|Drug: Exemestane,Merrimack Pharmaceuticals,Merrimack Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,6/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01151046
8367,TX2® Low Profile TAA Endovascular Graft,Completed,Has Results,Aortic Aneurysm|Penetrating Ulcer|Vascular Disease,Device: Zenith® TX2® Low Profile TAA Endovascular Graft,Cook Research Incorporated|Cook Group Incorporated,Cook Research Incorporated,Cook Group Incorporated,,,,,,Not Applicable,Industry,Interventional,3/10/2019,5/11/2018,https://ClinicalTrials.gov/show/NCT01151020
8368,Reveal In-Office Implants,Completed,Has Results,"Arrhythmias, Cardiac",Device: Reveal® DX or Reveal® XT Insertable Cardiac Monitor,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,,Industry,Observational,8/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01168427
8369,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Completed,Has Results,Hypertension,Drug: Aliskiren (6.25/12.5/25 mg)|Drug: Aliskiren (37.5/75/150 mg)|Drug: Aliskiren (150/300/600 mg),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/10/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01150357
8370,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Completed,Has Results,Liver Transplant Recipient,Drug: Tacrolimus (reduced tacrolimus)|Drug: Everolimus (reduced tacrolimus)|Drug: Tacrolimus (tacrolimus elimination)|Drug: Everolimus (tacrolimus elimination)|Drug: Tacrolimus (tacrolimus control)|Drug: Corticosteroids,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/31/2010,5/3/2013,https://ClinicalTrials.gov/show/NCT01150097
8371,A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2189265|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01149421
8372,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,Completed,Has Results,Asthma,Drug: Fluticasone furoate/Vilanterol Inhalation Powder|Drug: Fluticasone propionate/salmeterol Inhalation Powder|Drug: Placebo (1)|Drug: Placebo (2),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01147848
8373,Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag,Completed,Has Results,Thrombocytopaenia,Drug: Eltrombopag olamine|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/10/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01147809
8374,Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily,Completed,Has Results,Asthma,Drug: Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Drug: GSK2190915 100mg|Drug: GSK2190915 10mg|Drug: GSK2190915 300mg|Drug: GSK2190915 30mg|Drug: Montelukast 10mg|Drug: Placebo GSK2190915 one tablet|Drug: Placebo montelukast|Drug: Placebo fluticasone propionate via ACCUHALER/DISKUS|Drug: Placebo GSK2190915 two tablets,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/28/2010,10/6/2011,https://ClinicalTrials.gov/show/NCT01147744
8375,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Completed,Has Results,Acute Coronary Syndrome,Drug: Lixisenatide (AVE0010)|Drug: Placebo,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,6/10/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01147250
8376,Study of Silodosin to Facilitate Passage of Urinary Stones,Completed,Has Results,Ureteral Calculi|Kidney Stones|Urolithiasis,Drug: silodosin|Drug: placebo,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,6/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01144949
8377,Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Ranolazine|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,6/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01163721
8378,"A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects",Completed,Has Results,Smallpox,Biological: IMVAMUNE®|Other: Placebo,Bavarian Nordic,Bavarian Nordic,,,,,,,Phase 3,Industry,Interventional,2/13/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01144637
8379,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Exenatide Once Weekly|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,6/18/2010,4/24/2017,https://ClinicalTrials.gov/show/NCT01144338
8380,Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infection,Drug: CXA-101/ tazobactam and metronidazole|Drug: meropenem plus saline placebo,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 2,Industry,Interventional,6/25/2010,3/25/2011,https://ClinicalTrials.gov/show/NCT01147640
8381,A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: Lurasidone HCl,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,8/10/2019,,https://ClinicalTrials.gov/show/NCT01143090
8382,A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: Lurasidone HCl,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,6/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01143077
8383,Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: USL255|Drug: Placebo,Upsher-Smith Laboratories,Upsher-Smith Laboratories,,,,,,,Phase 3,Industry,Interventional,5/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01142193
8384,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Methotrexate|Drug: Abatacept placebo|Drug: Methotrexate placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,12/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01142726
8385,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Completed,Has Results,Relapsing Remitting Multiple Sclerosis,Drug: BAF312,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/30/2010,10/10/2016,https://ClinicalTrials.gov/show/NCT01185821
8386,Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase,Completed,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,4/3/2019,7/4/2019,https://ClinicalTrials.gov/show/NCT01141283
8387,Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free,Completed,Has Results,Sarcoma,Biological: Trivalent ganglioside vaccine|Biological: OPT-821,"MabVax Therapeutics, Inc.","MabVax Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,6/10/2019,3/10/2017,https://ClinicalTrials.gov/show/NCT01141491
8388,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,Completed,Has Results,Hepatocellular Carcinoma,Biological: Placebo|Biological: Ramucirumab DP (IMC-1121B)|Other: BSC,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,10/10/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT01140347
8389,Epiduo Pediatric Acne Study,Completed,Has Results,Acne,Drug: adapalene/benzoyl peroxide|Drug: Topical Gel Vehicle,Galderma,Galderma,,,,,,,Phase 4,Industry,Interventional,6/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01138735
8390,Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01138501
8391,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Sitagliptin 100 mg|Drug: Canagliflozin 300 mg|Drug: Metformin|Drug: Sulphonylurea,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,7/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01137812
8392,"An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",Completed,Has Results,Unresectable Stage III|Stage IV Melanoma,Drug: Lenvatinib,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,8/10/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01136967
8393,AXIOS Stent & Delivery System Study,Completed,Has Results,Pancreatic Pseudocyst(s),Device: AXIOS Stent & Delivery System,"Xlumena, Inc.","Xlumena, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01419769
8394,A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels,Completed,Has Results,Ejaculatory Dysfunction|Hypogonadism,Drug: Testosterone Solution 2%|Drug: Placebo Solution,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01419236
8395,A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy,Completed,Has Results,Asthma,Drug: 80/2.25 μg Symbicort pMDI|Drug: 80/4.5 μg Symbicort pMDI|Drug: Foradil Aerolizer 12 μg|Drug: 40 μg budesonide HFA pMDI|Drug: placebo HFA pMDI,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,9/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01136655
8396,A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo,Completed,Has Results,Asthma,Drug: budesonide|Drug: placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,7/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01136382
8397,Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™),Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01135992
8398,"A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment",Completed,Has Results,Metastatic Renal Cell Carcinoma,Drug: Lenvatinib|Drug: Everolimus,Eisai Inc.,Eisai Inc.,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/5/2010,2/8/2018,https://ClinicalTrials.gov/show/NCT01136733
8399,Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis),Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Drug: Placebo Nasal Aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,5/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01134705
8400,Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration,Completed,Has Results,Macular Degeneration,Drug: pazopanib eye drops|Drug: placebo|Biological: ranibizumab intravitreal injection,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/1/2010,10/1/2012,https://ClinicalTrials.gov/show/NCT01134055
8401,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Completed,Has Results,Asthma,Drug: Fluticasone Furoate/Vilanterol Inhalation Powder|Drug: Fluticasone Furoate Inhalation Powder|Drug: Fluticasone Propionate Inhalation Powder|Other: Placebo Inhalation Powder 1|Other: Placebo Inhalation Powder 2,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01134042
8402,Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A,Completed,Has Results,Acquired Hemophilia A,Biological: OBI-1,Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 2|Phase 3,Industry,Interventional,11/10/2010,10/9/2013,https://ClinicalTrials.gov/show/NCT01178294
8403,AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis,Completed,Has Results,Plaque-type Psoriasis,Drug: AIN457|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,5/11/2010,10/18/2016,https://ClinicalTrials.gov/show/NCT01132612
8404,HOME Study: Hysteroscopic Office Myomectomy Evaluation,Completed,Has Results,Uterine Fibroids|Polyps,Device: Myomectomy,"Hologic, Inc.","Hologic, Inc.",,,,,,,Not Applicable,Industry,Interventional,6/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01152112
8405,A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms,Completed,Has Results,Benign Prostatic Hyperplasia|Enlarged Prostate,Drug: Tadalafil|Drug: Placebo|Drug: Finasteride,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,9/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01139762
8406,"Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection",Completed,Has Results,"Hepatitis C, Chronic",Drug: BI 207127|Drug: BI 201335|Drug: Ribavirin|Drug: BI 207217,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,5/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01132313
8407,A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors,Completed,Has Results,Nonarteritic Anterior Ischemic Optic Neuropathy,Drug: PDE5 Inhibitors,Eli Lilly and Company,Eli Lilly and Company,,,,,,,,Industry,Observational,5/10/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT01131104
8408,A Study in Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,8/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01130532
8409,A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066,Completed,Has Results,Parkinson's Disease,Drug: IPX066|Drug: CLE,"Impax Laboratories, LLC","Impax Laboratories, LLC",,,,,,,Phase 3,Industry,Interventional,5/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01130493
8410,Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis,Completed,Has Results,Plaque-type Psoriasis,Drug: secukinumab 150mg|Drug: secukinumab 10mg/kg i.v. regimen,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,12/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01412944
8411,Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients,Completed,Has Results,First or Second Line HER2-negative Breast Cancer|Metastatic Disease Without Bone Metastasis,Drug: Zoledronic acid|Drug: Standard Therapy,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,6/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01129336
8412,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: liraglutide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01128894
8413,Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery,Completed,Has Results,Reducing Time to Vaginal Delivery|Cervical Ripening|Induction of Labor,Drug: MVI 200|Drug: Dinoprostone Vaginal Insert (DVI),Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01127581
8414,Safety Study of Cosmetic Tissue Augmentation in People of Color,Completed,Has Results,Wrinkles,Device: Elevess,"Anika Therapeutics, Inc.","Anika Therapeutics, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01147172
8415,A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations,Completed,Has Results,Sedation,Drug: fospropofol disodium Subgroup 1 Lower Dose|Drug: fospropofol disodium Subgroup 1 Approved Dose|Drug: fospropofol disodium Subgroup 2 Lower Dose|Drug: fospropofol disodium Subgroup 2 Approved Dose|Drug: fospropofol disodium Subgroup 3 Lower Dose|Drug: fospropofol disodium Subgroup 3 Approved Dose,Eisai Inc.,Eisai Inc.,,,,,,,Phase 4,Industry,Interventional,4/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01127438
8416,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Metformin|Drug: LY2189265|Drug: Placebo (oral)|Drug: Placebo (subcutaneous),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,5/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01126580
8417,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium 18 mcg|Drug: tiotropium 1.25 mcg (2 actuations/day)|Drug: tiotropium 2.5 mcg (2 actuations/day),Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,5/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01126437
8418,A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy,Completed,Has Results,Allergic Asthma,Drug: Omalizumab|Drug: Placebo|Drug: Asthma therapies,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 4,Industry,Interventional,5/10/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01125748
8419,Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients,Completed,Has Results,Hepatitis C Virus,Drug: Daclatasvir|Drug: Placebo|Drug: peg-interferon alfa-2a|Drug: ribavirin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,7/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01125189
8420,LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment,Completed,Has Results,Breast Neoplasms,Drug: BIBW 2992|Drug: trastuzumab|Drug: vinorelbine,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,6/22/2010,7/6/2018,https://ClinicalTrials.gov/show/NCT01125566
8421,A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP),Completed,Has Results,Metastatic Pancreatic Adenocarcinoma,Drug: CO-1.01|Drug: Gemcitabine,"Clovis Oncology, Inc.","Clovis Oncology, Inc.",,,,,,,Phase 2,Industry,Interventional,5/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01124786
8422,Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Drug: tiotropium bromide inhalation powder HandiHaler,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,7/19/2010,5/2/2011,https://ClinicalTrials.gov/show/NCT01124422
8423,Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: MMX mesalamine/ mesalazine,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,6/29/2010,12/7/2012,https://ClinicalTrials.gov/show/NCT01124149
8424,The Kiva® System as a Vertebral Augmentation Treatment,Completed,Has Results,"Spinal Fractures|Fractures, Compression|Back Injuries",Device: Vertebral augmentation,"Benvenue Medical, Inc.","Benvenue Medical, Inc.",,,,,,,Phase 3,Industry,Interventional,7/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01123512
8425,Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364),Completed,Has Results,Major Depressive Disorder,Drug: desvenlafaxine succinate sustained-release|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,6/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01121484
8426,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: QVA149|Drug: NVA237|Drug: tiotropium|Drug: Salbutamol/albuterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01120691
8427,A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Adalimumab|Drug: Placebo to tocilizumab|Drug: Placebo to adalimumab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,5/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01119859
8428,"Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)",Completed,Has Results,Preterm Delivery,"Drug: 17-alpha-hydroxy-progesterone caproate, Makena®|Drug: Castor Oil (Placebo)","Obstetrix Medical Group|Mednax Center for Research, Education, Quality and Safety",Obstetrix Medical Group,"Mednax Center for Research, Education, Quality and Safety",,,,,,Phase 2|Phase 3,Industry,Interventional,10/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01119963
8429,Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy,Completed,Has Results,Epilepsy,Drug: Lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 2,Industry,Interventional,8/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT01118962
8430,Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy,Completed,Has Results,Epilepsy,Drug: Lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 2,Industry,Interventional,5/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01118949
8431,"Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)",Completed,Has Results,Rheumatoid Arthritis,Drug: Tasocitinib plus Methotrexate|Drug: Tofacitinib plus placebo methotrexate|Drug: Placebo tofacitinib plus Methotrexate,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,10/10/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01164579
8432,Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin glargine|Drug: Liraglutide|Drug: Metformin,Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,7/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01117350
8433,Rollover Study of VX-770 in Cystic Fibrosis Subjects,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,7/10/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01117012
8434,"A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration",Completed,Has Results,Degenerative Disc Disease,Drug: Intradiscal rhGDF-5|Other: Water for injection,DePuy Spine,DePuy Spine,,,,,,,Phase 2,Industry,Interventional,1/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01124006
8435,Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain,Completed,Has Results,Chronic Pain,Drug: Hydrocodone Bitartrate,"Zogenix, Inc.","Zogenix, Inc.",,,,,,,Phase 3,Industry,Interventional,5/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01115569
8436,Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients,Completed,Has Results,Phenylketonuria,Drug: Sapropterin dihydrochloride|Drug: Placebo,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 3,Industry,Interventional,8/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01114737
8437,A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia,Completed,Has Results,Iron Deficiency Anemia,Drug: Ferumoxytol,"AMAG Pharmaceuticals, Inc.","AMAG Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,7/27/2010,4/23/2013,https://ClinicalTrials.gov/show/NCT01114217
8438,A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia,Completed,Has Results,Iron Deficiency Anemia,Drug: Ferumoxytol|Other: Placebo,"AMAG Pharmaceuticals, Inc.","AMAG Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,6/19/2010,10/22/2012,https://ClinicalTrials.gov/show/NCT01114139
8439,Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin,Completed,Has Results,Urogential Chlamydia Trachomatis Infection,Drug: Doxycyline Hyclate tablet|Drug: Vibramycin (doxycyline hyclate) capsule,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,4/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01113931
8440,"To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee",Completed,Has Results,Osteoarthritis,Biological: Canakinumab|Drug: Placebo to canakinumab|Drug: Naproxen|Drug: Placebo to Naproxen,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,4/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01160822
8441,Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment,Completed,Has Results,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)",Bayer,Bayer,,,,,,,Phase 1,Industry,Interventional,6/13/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT01853046
8442,A Study of Duloxetine in Elderly Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,10/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01118780
8443,Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression,Completed,Has Results,Endometrial Cancer,Drug: Lenvatinib,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,3/10/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01111461
8444,Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: ADVAIR DISKUS 250/50 mg BID|Drug: SEREVENT 50 mcg BID,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,4/30/2010,5/8/2012,https://ClinicalTrials.gov/show/NCT01110200
8445,Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer,Completed,Has Results,Lung Neoplasms|Carcinoma|Cancer of the Lung|Non-Small-Cell Lung Carcinoma,Drug: Cetuximab|Drug: Cisplatin|Drug: Vinorelbine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,7/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01109524
8446,A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid,Completed,Has Results,Primary Biliary Cirrhosis,Drug: ustekinumab 90 mg|Drug: ustekinumab 45 mg|Drug: ustekinumab 180 mg|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,9/11/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01389973
8447,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: COBI|Drug: RTV|Drug: ATV|Drug: FTC/TDF|Drug: COBI placebo|Drug: RTV placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,4/10/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01108510
8448,Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL),Completed,Has Results,Non-Hodgkin's Lymphoma (NHL),Drug: Bendamustine hydrochloride|Drug: Ofatumumab,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,5/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01108341
8449,Advisa MRI Clinical Study,Completed,Has Results,"Magnetic Resonance Imaging|Cardiac Pacemaker, Artificial",Device: Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Device: Medtronic CapSureFix MRI™ active fixation MRI lead,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01110915
8450,A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch,Completed,Has Results,Hernia,Device: PARIETEX™ Composite Ventral Patch,Medtronic - MITG,Medtronic - MITG,,,,,,,,Industry,Observational,5/13/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01848184
8451,A Study in Participants With Moderate to Severe Psoriasis,Completed,Has Results,Psoriasis,Biological: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/10/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01107457
8452,Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis,Completed,Has Results,"Rhinitis, Allergic, Perennial and/or Seasonal",Drug: Placebo nasal spray|Drug: Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|Drug: Claritin® Syrup,Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,6/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01154153
8453,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin|Drug: Pioglitazone,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,6/10/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01106690
8454,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin immediate release,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,5/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01106677
8455,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Antihyperglycemic agent(s)|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,6/10/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01106651
8456,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin|Drug: Placebo|Drug: Metformin|Drug: Sulphonylruea,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,5/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01106625
8457,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: Stribild|Drug: ATV|Drug: Ritonavir|Drug: FTC/TDF|Drug: Stribild Placebo|Drug: ATV Placebo|Drug: RTV Placebo|Drug: FTC/TDF Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,4/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01106586
8458,Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin lispro 2 day reservoir in-use|Drug: Insulin lispro 6 day reservoir in-use|Drug: Insulin aspart 6 day reservoir in-use,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,4/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01109316
8459,Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate,Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Drug: Lisdexamfetamine Dimesylate|Drug: Atomoxetine Hydrochloride,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,6/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01106430
8460,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Selexipag|Drug: Placebo,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,12/1/2009,10/1/2014,https://ClinicalTrials.gov/show/NCT01106014
8461,A Study of LY2484595 in Patients With High LDL-C or Low HDL-C,Completed,Has Results,Dyslipidemia,Drug: LY2484595|Drug: Atorvastatin|Drug: Simvastatin|Drug: Rosuvastatin|Drug: Placebo for LY2484595|Drug: Placebo for Statins,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01105975
8462,A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: RO5185426,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,5/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01107418
8463,"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer",Completed,Has Results,Non-small Cell Lung Cancer,Drug: eribulin mesylate + erlotinib,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,2/24/2010,1/18/2017,https://ClinicalTrials.gov/show/NCT01104155
8464,A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer,Completed,Has Results,Non Small Cell Lung Cancer,Drug: PF-02341066|Drug: PF-00299804,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,8/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01121575
8465,HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device,Completed,Has Results,Age Related Macular Degeneration,Diagnostic Test: ForeseeHome AMD Monitoring Device,Notal Vision Ltd,Notal Vision Ltd,,,,,,,Not Applicable,Industry,Interventional,5/10/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01103505
8466,"Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients",Completed,Has Results,Type 2 Diabetes,Drug: Mitoglitazone|Drug: Pioglitazone|Drug: Placebo,Metabolic Solutions Development Company,Metabolic Solutions Development Company,,,,,,,Phase 2,Industry,Interventional,9/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01103414
8467,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,Completed,Has Results,Metastatic Colorectal Cancer,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Other: Best Supportive Care (BSC)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,4/10/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT01103323
8468,Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: DiaPep277|Drug: Placebo,Andromeda Biotech Ltd.,Andromeda Biotech Ltd.,,,,,,,Phase 3,Industry,Interventional,4/10/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01103284
8469,Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,7/11/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01149655
8470,24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms,Completed,Has Results,Hot Flashes,Drug: Brisdelle (paroxetine mesylate)|Drug: Placebo capsules,Noven Therapeutics,Noven Therapeutics,,,,,,,Phase 3,Industry,Interventional,3/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01101841
8471,Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES),Completed,Has Results,Cardiovascular Disease,Drug: Febuxostat|Drug: Allopurinol,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,4/23/2010,7/18/2017,https://ClinicalTrials.gov/show/NCT01101035
8472,Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,ADHD Specifically With Executive Function Impairment,Drug: SPD489|Other: Placebo,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,5/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01101022
8473,A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS),Completed,Has Results,Lambert Eaton Myasthenic Syndrome,Drug: Amifampridine Phosphate|Drug: Placebo,"Catalyst Pharmaceuticals, Inc.","Catalyst Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,6/11/2019,7/16/2019,https://ClinicalTrials.gov/show/NCT01377922
8474,Clinical Trial in Females With Female Pattern Hair Loss,Completed,Has Results,Alopecia,Drug: 5% Minoxidil|Drug: 2% Minoxidil,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,Phase 3,Industry,Interventional,6/10/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT01145625
8475,RestoreSensor Study,Completed,Has Results,Chronic Pain,Device: RestoreSensor Neurostimulation System,MedtronicNeuro,MedtronicNeuro,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01106404
8476,Safety of PCI-32765 in Chronic Lymphocytic Leukemia,Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: PCI-32765,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 1|Phase 2,Industry,Interventional,5/10/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01105247
8477,Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim,Completed,Has Results,Idiopathic Thrombocytopenic Purpura,Biological: Romiplostim,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,11/30/2010,12/26/2013,https://ClinicalTrials.gov/show/NCT01143038
8478,"Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003",Completed,Has Results,Myelodysplastic Syndrome,,Celgene Corporation,Celgene Corporation,,,,,,,,Industry,Observational,3/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01099267
8479,Safety Study of ExAblate for the Treatment of Uterine Fibroids,Completed,Has Results,Uterine Fibroids,Device: ExAblate,InSightec,InSightec,,,,,,,Not Applicable,Industry,Interventional,5/10/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01142791
8480,GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection,Completed,Has Results,"Skin Infections, Bacterial",Drug: GSK1322322|Drug: Linezolid|Drug: GSK1322322 placebo|Drug: Linezolid placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/17/2010,1/18/2011,https://ClinicalTrials.gov/show/NCT01209078
8481,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: sitagliptin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01098539
8482,An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: IPX066 95 mg|Drug: IPX066 145 mg|Drug: IPX066 195 mg|Drug: IPX066 245 mg,"Impax Laboratories, LLC","Impax Laboratories, LLC",,,,,,,Phase 3,Industry,Interventional,3/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01096186
8483,"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: Stribild|Drug: Atripla|Drug: Stribild Placebo|Drug: Atripla Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,3/10/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT01095796
8484,Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions,Completed,Has Results,Coronary Artery Disease,Device: Diamondback 360 Orbital Atherectomy System,Cardiovascular Systems Inc,Cardiovascular Systems Inc,,,,,,,Not Applicable,Industry,Interventional,5/10/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01092416
8485,Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Docetaxel|Drug: LY2181308,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,5/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01107444
8486,Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic,Completed,Has Results,Epilepsy,Drug: Eslicarbazepine acetate 1600 mg|Drug: Eslicarbazepine acetate 1200 mg,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,6/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01091662
8487,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,Completed,Has Results,Healthy or Stable Chronic Illness,Biological: Q/LAIV (MEDI3250)|Biological: FluMist/B/Yamagata|Biological: FluMist/B/Victoria,MedImmune LLC,MedImmune LLC,,,,,,,Phase 3,Industry,Interventional,3/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01091246
8488,PF-00489791 For The Treatment Of Raynaud's,Completed,Has Results,Raynaud's Disease|Peripheral Vascular Disease,Drug: PF-00489791,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/4/2010,5/31/2011,https://ClinicalTrials.gov/show/NCT01090492
8489,A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension,Completed,Has Results,Pulmonary Hypertension,Drug: UT-15C,United Therapeutics,United Therapeutics,,,,,,,Phase 2,Industry,Interventional,4/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01104870
8490,Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence,Completed,Has Results,Fecal Incontinence,Device: TOPAS Treatment for Fecal Incontinence,ASTORA Women's Health,ASTORA Women's Health,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,4/16/2019,https://ClinicalTrials.gov/show/NCT01090739
8491,Effect of Prevnar 13 on Ear Infections in Children,Completed,Has Results,Otitis Media,Procedure: Tympanocentesis|Procedure: Nose/throat swab|Biological: Observational,Pfizer,Pfizer,,,,,,,,Industry,Observational,9/10/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01199016
8492,"Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).",Completed,Has Results,Sickle Cell Disease,Drug: ICL670,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/4/2019,,https://ClinicalTrials.gov/show/NCT01090323
8493,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI),Completed,Has Results,Breast Cancer,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,5/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01104584
8494,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol|Drug: Salmeterol 50 μg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01089127
8495,Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia,Completed,Has Results,Leukemia,Drug: Bendamustine,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 1|Phase 2,Industry,Interventional,8/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01088984
8496,A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer,Completed,Has Results,Head and Neck Neoplasms,Drug: Pemetrexed|Drug: Cetuximab|Drug: Carboplatin|Drug: Cisplatin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/10/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01087970
8497,WalkAide Compared to Ankle-Foot Orthosis (AFO) in Stroke Patients,Completed,Has Results,Stroke,Device: WalkAide|Other: Ankle-Foot Orthosis (AFO),Innovative Neurotronics,Innovative Neurotronics,,,,,,,Not Applicable,Industry,Interventional,3/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01087957
8498,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Biological: CZP 200 mg Q2W|Biological: CZP 400 mg Q4W|Other: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,UCB BIOSCIENCES GmbH,UCB Pharma,,,,,,Phase 3,Industry,Interventional,3/10/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01087788
8499,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Completed,Has Results,Spondyloarthropathies,Biological: CZP 200 mg Q2W|Biological: CZP 400 mg Q4W|Other: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,UCB BIOSCIENCES GmbH,UCB Pharma,,,,,,Phase 3,Industry,Interventional,3/10/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT01087762
8500,Asthma Exacerbation Study,Completed,Has Results,Asthma,Drug: Fluticasone Furoate/GW642444|Drug: Fluticasone furoate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/22/2010,9/15/2011,https://ClinicalTrials.gov/show/NCT01086384
8501,Registry of AngioJet Use in the Peripheral Vascular System,Completed,Has Results,Peripheral Vascular Disease|Embolism and Thrombosis|Venous Thrombosis,,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,,Industry,Observational,1/10/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01086215
8502,A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C,Completed,Has Results,"Hepatitis C, Chronic",Device: Autoinjector|Device: Pre-filled syringe,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,3/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01087944
8503,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",Completed,Has Results,Clostridium Difficile Infection|Diarrhea,"Drug: CB-183,315|Drug: Placebo|Drug: Vancomycin",Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 2,Industry,Interventional,4/1/2010,5/13/2011,https://ClinicalTrials.gov/show/NCT01085591
8504,Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma,Completed,Has Results,Relapsed and Bortezomib Refractory Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse,Drug: panobinostat|Drug: bortezomib|Drug: dexamethasone,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01083602
8505,Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol,Completed,Has Results,Crohn's Disease,Drug: certolizumab pegol,UCB Pharma,UCB Pharma,,,,,,,Phase 2,Industry,Interventional,8/10/2019,11/27/2017,https://ClinicalTrials.gov/show/NCT01190410
8506,Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment,Completed,Has Results,Renal Impairment,Drug: Febuxostat|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,4/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01082640
8507,Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain,Completed,Has Results,Back Pain Lower Back Chronic,Drug: Placebo|Drug: Hydrocodone bitartrate,"Zogenix, Inc.","Zogenix, Inc.",,,,,,,Phase 3,Industry,Interventional,3/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01081912
8508,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin|Drug: Placebo|Drug: Sitagliptin,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,3/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01081834
8509,Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention-deficit/Hyperactivity Disorder,Drug: Extended-release Guanfacine Hydrochloride|Other: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,5/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01081145
8510,Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl,Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Drug: Extended-release Guanfacine Hydrochloride|Other: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,9/11/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01081132
8511,A Study in Head and Neck Cancer,Completed,Has Results,Head and Neck Cancer,Drug: Cetuximab|Drug: Cisplatin|Drug: Carboplatin|Drug: 5-Fluorouracil,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/10/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT01081041
8512,"Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors",Completed,Has Results,Cancer,Drug: Birinapant,TetraLogic Pharmaceuticals,TetraLogic Pharmaceuticals,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/10/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT01188499
8513,Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder,Completed,Has Results,Excessive Sleepiness,Drug: Armodafinil|Drug: Matching Placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 4,Industry,Interventional,3/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01080807
8514,"Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",Completed,Has Results,Relapsed Multiple Myeloma,Drug: Dexamethasone|Drug: Lenalidomide|Drug: Carfilzomib,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,7/14/2010,12/5/2017,https://ClinicalTrials.gov/show/NCT01080391
8515,Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women,Completed,Has Results,Hot Flashes,Drug: Gabapentin Extended Release|Drug: Placebo,Depomed,Depomed,,,,,,,Phase 3,Industry,Interventional,8/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01080300
8516,Study To Assess FRacTure Healing With SclerosTin Antibody - Hip,Completed,Has Results,Fracture Healing,Drug: Placebo|Drug: Romosozumab,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,6/20/2010,5/10/2013,https://ClinicalTrials.gov/show/NCT01081678
8517,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Completed,Has Results,Acute Gout,Drug: Canakinumab 150 mg|Drug: Triamcinolone acetonide 40 mg|Drug: Placebo to canakinumab|Drug: Placebo to triamcinolone acetonide,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01080131
8518,Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,3/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01079234
8519,A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection,Completed,Has Results,"Chronic Hepatitis B Virus, Pediatric",Drug: Entecavir|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,6/30/2010,3/31/2018,https://ClinicalTrials.gov/show/NCT01079806
8520,Efficacy and Safety of Different Doses of Indacaterol,Completed,Has Results,Asthma,Drug: Indacaterol|Drug: Salmeterol|Drug: Placebo to Indacaterol|Drug: Placebo to Salmeterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,2/10/2019,,https://ClinicalTrials.gov/show/NCT01079130
8521,Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout,Completed,Has Results,Joint Damage,Drug: Febuxostat|Drug: Placebo for Febuxostat,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,3/10/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT01078389
8522,Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression,Completed,Has Results,Smoking Cessation|Depression,Drug: varenicline|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,3/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01078298
8523,Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens,Completed,Has Results,Myopia,Device: galyfilcon A prototype lens|Device: marketed galyfilcon A lens,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/1/2010,4/1/2010,https://ClinicalTrials.gov/show/NCT01094730
8524,A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas,Completed,Has Results,Brainstem Glioma,Drug: Capecitabine|Radiation: Radiation therapy,Hoffmann-La Roche|Pediatric Brain Tumor Consortium,Hoffmann-La Roche,Pediatric Brain Tumor Consortium,,,,,,Phase 2,Industry|Other,Interventional,5/7/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT01118377
8525,Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome,Completed,Has Results,Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome,Biological: Serostim,EMD Serono,EMD Serono,,,,,,,Phase 3,Industry,Interventional,2/5/2019,1/6/2019,https://ClinicalTrials.gov/show/NCT01077960
8526,A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents,Completed,Has Results,"Arthritis, Psoriatic",Drug: placebo|Drug: ustekinumab 45 mg|Drug: ustekinumab 90 mg,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,3/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01077362
8527,Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones,Completed,Has Results,Hyperuricosuria|Kidney Stones,Drug: Febuxostat|Drug: Allopurinol|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,2/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01077284
8528,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,3/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01076647
8529,Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study,Completed,Has Results,Arrhythmia|Heart Failure,,Medtronic,Medtronic,,,,,,,,Industry,Observational,9/1/1999,9/10/2019,https://ClinicalTrials.gov/show/NCT01076361
8530,Model 4965 Post-Approval Study,Completed,Has Results,Heart Failure|Pacing|Bradycardia|Arrhythmia,,Medtronic,Medtronic,,,,,,,,Industry,Observational,9/1/1996,4/11/2019,https://ClinicalTrials.gov/show/NCT01076348
8531,REASSURE AV Registry,Completed,Has Results,Sudden Cardiac Death|Bradycardia,Device: AV Therapy Assessment-B301 investigational device,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,4/6/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01074034
8532,"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072",Completed,Has Results,Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1,Drug: ABT-450|Drug: ABT-072|Drug: ABT-333|Drug: Ritonavir|Drug: Peginterferon alpha-2a|Drug: Ribavirin|Other: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,3/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01074008
8533,A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease,Completed,Has Results,Hyperphosphatemia|End-Stage Renal Disease,Drug: ferric citrate,Keryx Biopharmaceuticals|Collaborative Study Group (CSG),Keryx Biopharmaceuticals,Collaborative Study Group (CSG),,,,,,Phase 3,Industry|Other,Interventional,5/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01074125
8534,Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL),Completed,Has Results,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Drug: Bendamustine|Drug: Rituximab,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,2/10/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01073163
8535,A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Completed,Has Results,Depression,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,1/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01072929
8536,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Completed,Has Results,Depression,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,3/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01072630
8537,12-week Efficacy of Indacaterol,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 75 μg|Drug: Placebo to indacaterol,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,1/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01072448
8538,A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura,Completed,Has Results,Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP,Biological: Romiplostim,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,12/30/2009,1/12/2017,https://ClinicalTrials.gov/show/NCT01071954
8539,"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212",Completed,Has Results,Cancer,Drug: GSK2118436|Drug: GSK1120212,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,3/26/2010,2/27/2018,https://ClinicalTrials.gov/show/NCT01072175
8540,Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.,Completed,Has Results,Hormone Replacement Therapy,Drug: Estradiol acetate|Drug: Estradiol|Drug: Conjugated equine estrogens,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,2/3/2019,9/3/2019,https://ClinicalTrials.gov/show/NCT01070979
8541,A Study in Depression and Associated Painful Physical Symptoms,Completed,Has Results,Major Depressive Disorder,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,3/10/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT01070329
8542,"Remission in Subjects With Crohn's Disease, Open Label Extension",Completed,Has Results,Crohn's Disease,Biological: Adalimumab 40 mg eow or ew,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,8/2/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT01070303
8543,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep,Completed,Has Results,Bowel Preparation,Drug: PicoPrep|Drug: HalfLytely|Drug: bisacodyl,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01073943
8544,Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza,Completed,Has Results,Influenza,Drug: Favipiravir|Drug: Placebo comparator,"MDVI, LLC","MDVI, LLC",,,,,,,Phase 2,Industry,Interventional,2/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01068912
8545,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,2/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01068678
8546,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,3/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01068665
8547,Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol|Drug: Placebo to indacaterol,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,1/10/2019,,https://ClinicalTrials.gov/show/NCT01068600
8548,Ovarian Cancer Vaccine for Patients in Remission,Completed,Has Results,Epithelial Ovarian Cancer,Biological: Cvac,Prima BioMed Ltd,Prima BioMed Ltd,,,,,,,Phase 2,Industry,Interventional,7/10/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01068509
8549,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE),Completed,Has Results,Gaucher Disease,Drug: Eliglustat tartrate,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,6/10/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01074944
8550,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",Completed,Has Results,Relapsing Remitting Multiple Sclerosis,Drug: Glatiramer acetate (GA)|Drug: Placebo,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries","Teva Pharmaceutical Industries, Ltd.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,6/22/2010,5/12/2017,https://ClinicalTrials.gov/show/NCT01067521
8551,A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Completed,Has Results,Perennial Allergic Rhinitis,Drug: ciclesonide HFA 160 μg,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,2/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01067105
8552,PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b,Completed,Has Results,"Hepatitis C, Chronic",Drug: Peginterferon alfa-2a [Pegasys]|Drug: Peginterferon alfa-2b [PegIntron®],Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,,Industry,Observational,1/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01066819
8553,To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies,Completed,Has Results,Type 2 Diabetes Mellitus|Impaired Glucose Tolerance,Drug: Canakinumab 150 mg|Drug: Placebo to Canakinumab,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,2/10/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01068860
8554,An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Romozosumab|Drug: Teriparatide,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,1/31/2013,5/14/2015,https://ClinicalTrials.gov/show/NCT01796301
8555,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,Completed,Has Results,Breast Cancer|Melanoma,Drug: Lymphoseek,Navidea Biopharmaceuticals,Navidea Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,6/10/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01106040
8556,"A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure",Completed,Has Results,Raised Intraocular Pressure,Drug: AZD4017|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/10/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT01173471
8557,A Study in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2189265|Drug: Exenatide|Drug: Placebo|Drug: Metformin|Drug: Pioglitazone,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,2/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01064687
8558,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",Completed,Has Results,"Diabetes Mellitus, Type 2|Renal Insufficiency",Drug: Canagliflozin|Drug: Placebo,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,6/10/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01064414
8559,S-ICD® System IDE Clinical Study,Completed,Has Results,"Tachycardia, Ventricular",Device: S-ICD System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Not Applicable,Industry,Interventional,1/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01064076
8560,Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction|Sexual Dysfunction,Drug: Placebo|Drug: Dapoxetine|Drug: PDE5I (phosphodiesterase-5 inhibitor),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 3,Industry,Interventional,4/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01063855
8561,"A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors",Completed,Has Results,Head and Neck Cancer|Liver Cancer|Breast Cancer|Gastric Cancer|Non-Small Cell Lung Cancer,Drug: CUDC-101,"Curis, Inc.","Curis, Inc.",,,,,,,Phase 1,Industry,Interventional,7/10/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT01171924
8562,A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers,Completed,Has Results,Neuropathic Diabetic Ulcer - Foot,Device: Integra® Dermal Regeneration Template|Other: Conventional Wound Therapy,Integra LifeSciences Corporation,Integra LifeSciences Corporation,,,,,,,Not Applicable,Industry,Interventional,4/10/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT01060670
8563,"A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck",Completed,Has Results,Ovarian Cancer|Non Small Cell Lung Cancer|Prostate Cancer|Colorectal Cancer|Gastric Cancer|Esophageal Cancer|Cancer of Head and Neck,Drug: LY2523355|Drug: pegfilgrastim,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/11/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01059643
8564,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection,Completed,Has Results,Cystic Fibrosis|Burkholderia Infections,Drug: AZLI|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,2/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01059565
8565,Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema,Completed,Has Results,Hereditary Angioedema (HAE),Drug: ecallantide,Shire,Shire,,,,,,,,Industry,Observational,2/1/2010,6/1/2014,https://ClinicalTrials.gov/show/NCT01059526
8566,A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma,Completed,Has Results,Asthma,Drug: Albuterol Spiromax®|Drug: ProAir® HFA|Other: Placebo Inhaler,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,2/10/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT01058863
8567,Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Ipilimumab|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,7/10/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01057810
8568,Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy,Completed,Has Results,"Diabetic Neuropathy, Painful",Drug: pregabalin (Lyrica)|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/31/2010,1/30/2012,https://ClinicalTrials.gov/show/NCT01057693
8569,Nebivolol in Patients With Systolic Stage 2 Hypertension,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,3/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01057251
8570,Irrigated Ablation System Evaluation for Atrial Fibrillation (AF),Completed,Has Results,Paroxysmal Atrial Fibrillation,Device: SJM Irrigated Cardiac Ablation System|Device: FDA approved Open Irrigated RF Ablation System,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,2/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01056328
8571,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep,Completed,Has Results,Bowel Preparation,Drug: PicoPrep|Drug: HalfLytely|Drug: bisacodyl,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01073930
8572,Investigational Multi-purpose Contact Lens Care Solution.,Completed,Has Results,Contact Lens Wear,Device: Vistakon Investigational Multi-Purpose Solution I|Device: ReNu MultiPlus Multi-Purpose Solution,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/9/2019,,https://ClinicalTrials.gov/show/NCT01055613
8573,Vistakon Investigational Multi-purpose Contact Lens Care Solution.,Completed,Has Results,Contact Lens Wear,Device: Vistakon Investigational Multi-Purpose Solution II|Device: ReNu MultiPlus Multi-Purpose Solution,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/1/2009,5/1/2010,https://ClinicalTrials.gov/show/NCT01055457
8574,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF Inhalation Powder|Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/19/2009,2/8/2011,https://ClinicalTrials.gov/show/NCT01054885
8575,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/GW642444 Inhalation Powder|Drug: FF Inhalation Powder|Drug: GW642444 Inhalation Powder|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/5/2009,4/14/2011,https://ClinicalTrials.gov/show/NCT01053988
8576,IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity,Completed,Has Results,Retinopathy of Prematurity (ROP),Drug: rhIGF-I/rhIGFBP-3,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,6/1/2010,3/1/2016,https://ClinicalTrials.gov/show/NCT01096784
8577,"Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550",Completed,Has Results,Rheumatoid Arthritis,"Drug: CP-690,550|Drug: Atorvastatin|Drug: Atorvastatin Placebo",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,2/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01059864
8578,CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12,Completed,Has Results,Hereditary Angioedema (HAE),Biological: CINRYZE,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,6/2/2010,4/17/2012,https://ClinicalTrials.gov/show/NCT01095510
8579,Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: OPC-34712|Drug: Placebo|Drug: ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,3/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01052077
8580,A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease,Completed,Has Results,Iron Deficiency|Anemia|Kidney Disease,Drug: Ferumoxytol|Drug: Iron Sucrose,"AMAG Pharmaceuticals, Inc.","AMAG Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/1/2010,4/19/2012,https://ClinicalTrials.gov/show/NCT01052779
8581,Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders,Completed,Has Results,Hepatitis C,Drug: CTS-1027|Drug: Pegylated interferon|Drug: Ribavirin,Conatus Pharmaceuticals Inc.,Conatus Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,1/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01051921
8582,A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza,Completed,Has Results,Influenza,Drug: Oseltamivir IV|Drug: Oseltamivir Oral,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,1/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT01050257
8583,A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children,Completed,Has Results,Schizophrenia|Bipolar Disorder|Autistic Disorder|Conduct and Other Disruptive Behavior Disorders,Drug: Risperidone|Drug: Other atypical antipsychotic drugs,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 4,Industry,Interventional,10/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01050582
8584,CryoValve SG Pulmonary Human Heart Valve Post Clearance Study,Completed,Has Results,Pulmonary Valve Stenosis|Pulmonary Valve Insufficiency|Aortic Valve Stenosis|Aortic Valve Insufficiency,Procedure: Echocardiogram,"CryoLife, Inc.","CryoLife, Inc.",,,,,,,,Industry,Observational,1/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01092442
8585,"Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium 400 μg / Formoterol 12 μg|Drug: Aclidinium 400 μg / Formoterol 6 μg|Drug: Aclidinium 400 μg|Drug: Formoterol 12 μg|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01049360
8586,Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy,Completed,Has Results,Infantile Hemangioma,Drug: Propranolol|Drug: Placebo,Pierre Fabre Dermatology,Pierre Fabre Dermatology,,,,,,,Phase 2|Phase 3,Industry,Interventional,1/10/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT01056341
8587,ClearVoice Sound-processing Strategy for AB HiRes 120 Cochlear Implant Users,Completed,Has Results,Implant,Device: ClearVoice,Advanced Bionics,Advanced Bionics,,,,,,,Not Applicable,Industry,Interventional,3/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT01066780
8588,Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock,Completed,Has Results,Septic Shock|Endotoxemia,Device: TORAYMYXIN PMX-20R (PMX cartridge)|Other: Standard medical care for septic shock,Spectral Diagnostics (US) Inc.,Spectral Diagnostics (US) Inc.,,,,,,,Not Applicable,Industry,Interventional,6/10/2019,6/17/2019,https://ClinicalTrials.gov/show/NCT01046669
8589,Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: sitagliptin,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01046110
8590,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01045707
8591,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,1/10/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01045447
8592,A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE),Completed,Has Results,Coronary Heart Disease,Drug: dalcetrapib|Drug: placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,3/11/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01323153
8593,"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,3/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01045161
8594,"Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium Bromide 200 µg|Drug: Aclidinium Bromide 400 µg,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,11/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01044459
8595,TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD,Completed,Has Results,Cardiac Implantable Electronic Device Infection,,"TYRX, Inc.","TYRX, Inc.",,,,,,,,Industry,Observational,1/10/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01043705
8596,A Study for Patients With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2605541|Drug: Insulin glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,1/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01049412
8597,"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Disease-modifying antirheumatic drug",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01039688
8598,Santyl vs. Sharp Debridement of Diabetic Foot Wounds,Completed,Has Results,Diabetic Foot Ulcers|Foot Wounds,Drug: Santyl|Procedure: Control,Healthpoint,Healthpoint,,,,,,,Phase 4,Industry,Interventional,2/10/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01056198
8599,MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study,Completed,Has Results,Lumbar Spinal Stenosis,Procedure: lumbar decompression,"Vertos Medical, Inc.","Vertos Medical, Inc.",,,,,,,Phase 4,Industry,Interventional,2/10/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01082159
8600,Treatment of Erectile Dysfunction I,Completed,Has Results,Erectile Dysfunction,Drug: Udenafil|Drug: Placebo,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,9/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT01037244
8601,Treatment of Erectile Dysfunction II,Completed,Has Results,Erectile Dysfunction,Drug: Udenafil|Drug: Placebo,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,9/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01037218
8602,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Completed,Has Results,Carcinoma,Drug: Everolimus|Drug: Everolimus Placebo|Other: Best Supportive Care (BSC),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/10/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT01035229
8603,A Study of Semagacestat for Alzheimer's Patients,Completed,Has Results,Alzheimer's Disease,Drug: semagacestat,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01035138
8604,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,12/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01034462
8605,"A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)",Completed,Has Results,Hodgkin's Lymphoma,Drug: Panobinostat|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/10/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01034163
8606,A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza,Completed,Has Results,Influenza,Drug: oseltamivir [Tamiflu],Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,12/10/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT01033734
8607,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.,Completed,Has Results,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Olmesartan medoxomil and hydrochlorothiazide,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,1/10/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01033071
8608,CANVAS - CANagliflozin cardioVascular Assessment Study,Completed,Has Results,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Drug: Placebo|Drug: Canagliflozin (JNJ-28431754) 100 mg|Drug: Canagliflozin (JNJ-28431754) 300 mg,"Janssen Research & Development, LLC|The George Institute for Global Health, Australia","Janssen Research & Development, LLC","The George Institute for Global Health, Australia",,,,,,Phase 3,Industry|Other,Interventional,12/9/2009,2/22/2017,https://ClinicalTrials.gov/show/NCT01032629
8609,"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Device: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/1/2010,7/1/2010,https://ClinicalTrials.gov/show/NCT01072149
8610,A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,Completed,Has Results,Melanoma,Drug: Nilotinib|Drug: DTIC,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01028222
8611,Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic acid injection|Drug: Placebo,Kythera Biopharmaceuticals,Kythera Biopharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01032889
8612,Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients,Completed,Has Results,Kidney Transplant,Drug: Everolimus and tacrolimus|Drug: mycophenolate mofetil and tacrolimus,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,1/10/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01025817
8613,"Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea",Completed,Has Results,Papulopustular Rosacea,Drug: Azelaic acid foam 15%|Drug: Vehicle foam,Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,12/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT01025635
8614,Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated,Completed,Has Results,Healthy,Other: Blood draw,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01025336
8615,Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result,Completed,Has Results,Prostatic Neoplasms,Other: PCA3 Assay,"Gen-Probe, Incorporated","Gen-Probe, Incorporated",,,,,,,Not Applicable,Industry,Interventional,8/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01024959
8616,Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer,Completed,Has Results,Neoplasms,"Drug: BI 6727, IV infusion",Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,11/19/2009,9/19/2011,https://ClinicalTrials.gov/show/NCT01023958
8617,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Alogliptin|Drug: Metformin|Drug: Alogliptin Placebo|Drug: Metformin Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,11/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT01023581
8618,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Panobinostat|Drug: Bortezomib|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,12/9/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01023308
8619,A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation,Completed,Has Results,Head Lice,Drug: Ivermectin Cream|Drug: vehicle control,Topaz Pharmaceuticals Inc,Topaz Pharmaceuticals Inc,,,,,,,Phase 3,Industry,Interventional,3/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01066585
8620,Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.,Completed,Has Results,Hodgkin Lymphoma,Drug: Everolimus (RAD001),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,12/9/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01022996
8621,AZD7268 Safety and Tolerability Study,Completed,Has Results,Major Depressive Disorder,Drug: AZD7268|Drug: Escitalopram|Drug: Placebo capsules|Drug: Placebo tablets,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,11/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT01020799
8622,A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease,Completed,Has Results,Multicentric Castleman's Disease,Drug: Siltuximab|Drug: Placebo|Drug: Best Supportive Care (BSC),"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 2,Industry,Interventional,3/18/2010,2/24/2017,https://ClinicalTrials.gov/show/NCT01024036
8623,Pregabalin In Adolescent Patients With Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: pregabalin,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,9/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01020526
8624,Adolescent Fibromyalgia Study,Completed,Has Results,Fibromyalgia,Drug: placebo|Drug: pregabalin (Lyrica),Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,5/10/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01020474
8625,Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine,Completed,Has Results,Pancreatic Cancer|Ductal Adrenocarcinoma|Exocrine Pancreatic Cancer,Drug: PCI-27483|Drug: Gemcitabine,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 2,Industry,Interventional,11/9/2019,,https://ClinicalTrials.gov/show/NCT01020006
8626,Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Combivent CFC-MDI|Drug: Combivent Respimat 20/100 mcg|Drug: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/9/2019,,https://ClinicalTrials.gov/show/NCT01019694
8627,A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: Azelastine hydrochloride nasal spray 0.15%|Drug: Azelastine hydrochloride nasal spray 0.10%|Drug: Placebo,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01018862
8628,A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis,Completed,Has Results,Osteoarthritis Knee Pain,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT01018680
8629,Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia,Completed,Has Results,Hepatitis C Virus,Biological: Pegylated-Interferon-lambda|Drug: Ribavirin|Drug: Daclatasvir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,3/31/2013,1/31/2015,https://ClinicalTrials.gov/show/NCT01741545
8630,Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study,Completed,Has Results,Asthma,Drug: Fluticasone Furoate/GW642444|Drug: Fluticasone propionate,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/19/2009,5/12/2011,https://ClinicalTrials.gov/show/NCT01018186
8631,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/25/2009,10/17/2011,https://ClinicalTrials.gov/show/NCT01017952
8632,LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer,Completed,Has Results,Ovarian Neoplasms|Peritoneal Neoplasms,Drug: Placebo|Drug: Paclitaxel|Drug: BIBF 1120|Drug: Carboplatin,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/17/2009,9/15/2016,https://ClinicalTrials.gov/show/NCT01015118
8633,Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital,Completed,Has Results,"Influenza, Human",Drug: zanamivir aqueous solution,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/9/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT01014988
8634,SISTERS: Spasticity In Stroke Study - Randomized Study,Completed,Has Results,Severe Spasticity,Drug: intrathecal baclofen,MedtronicNeuro,MedtronicNeuro,,,,,,,Phase 4,Industry,Interventional,11/9/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT01032239
8635,"Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis",Completed,Has Results,Cystinosis,Drug: RP103|Drug: Cystagon®,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 3,Industry,Interventional,1/31/2013,7/10/2017,https://ClinicalTrials.gov/show/NCT01733316
8636,"A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK1292263|Drug: GSK1292263 matching placebo|Drug: Sitagliptin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/5/2009,3/19/2010,https://ClinicalTrials.gov/show/NCT01119846
8637,Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma,Completed,Has Results,"Lymphoma, Large-Cell, Diffuse",Drug: OFATUMUMAB + DHAP|Drug: RITUXIMAB + DHAP,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/10/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT01014208
8638,Open Abdomen Study Comparing ABThera™ Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique,Completed,Has Results,Open Abdomen,Device: NPWT|Device: BVPT,"KCI USA, Inc.","KCI USA, Inc.",,,,,,,,Industry,Observational,12/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT01016353
8639,Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine USP Trivalent Types A and B,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,9/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01011049
8640,Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus Type 2,Drug: EGT0001442|Drug: Placebo capsules to match EGT0001442,Theracos,Theracos,,,,,,,Phase 2,Industry,Interventional,12/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01029704
8641,Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD),Completed,Has Results,"Muscular Dystrophy, Duchenne|Ambulatory Care",Drug: Placebo|Drug: Idebenone,Santhera Pharmaceuticals,Santhera Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/9/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01027884
8642,Post Market Study Using the Xoft Axxent System,Completed,Has Results,Breast Cancer,Radiation: Electronic brachytherapy (Axxent System),"Xoft, Inc.","Xoft, Inc.",,,,,,,Phase 4,Industry,Interventional,3/7/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT01017549
8643,A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase,Completed,Has Results,Tumors Characterized by Genetic Abnormalities of ALK,Drug: LDK378,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1,Industry,Interventional,1/24/2011,5/3/2016,https://ClinicalTrials.gov/show/NCT01283516
8644,A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/25/2009,10/31/2011,https://ClinicalTrials.gov/show/NCT01009463
8645,A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Drug: Placebo|Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,12/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT01009086
8646,Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: GSK239512|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/1/2009,8/10/2011,https://ClinicalTrials.gov/show/NCT01009060
8647,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,Completed,Has Results,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Drug: everolimus|Drug: Placebo|Drug: vinorelbine|Drug: trastuzumab,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,10/9/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01007942
8648,A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Placebo to tocilizumab|Drug: Methotrexate|Drug: Placebo to methotrexate,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,10/31/2009,1/28/2014,https://ClinicalTrials.gov/show/NCT01007435
8649,IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients,Completed,Has Results,Multiple Myeloma,Drug: IV busulfan|Drug: bortezomib|Procedure: Autologous Hematopoietic Stem Cell Transplant (HSCT),"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,5/10/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT01009840
8650,Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation,Completed,Has Results,Constipation|Chronic Constipation,Drug: A3309,Albireo,Albireo,,,,,,,Phase 2,Industry,Interventional,11/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01007123
8651,A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3),Completed,Has Results,Malignant Melanoma,Drug: Vemurafenib|Drug: Dacarbazine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,1/10/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT01006980
8652,A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy,Completed,Has Results,Excessive Daytime Sleepiness|Narcolepsy,Drug: Placebo|Drug: PF-03654746,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT01006122
8653,"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Glycopyrronium bromide|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,10/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01005901
8654,C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf)|Drug: Placebo (saline),Shire,Shire,,,,,,,Phase 3,Industry,Interventional,9/5/2019,8/7/2019,https://ClinicalTrials.gov/show/NCT01005888
8655,"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine",Completed,Has Results,Healthy,Biological: HEPLISAV and/or Placebo|Biological: Engerix-B,Dynavax Technologies Corporation,Dynavax Technologies Corporation,,,,,,,Phase 3,Industry,Interventional,2/10/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT01005407
8656,Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access,Completed,Has Results,HIV,Drug: Atazanavir|Drug: Atazanavir/Ritonavir|Drug: Tenofovir/Emtricitabine|Drug: Lopinavir/ritonavir,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,10/2/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT01003990
8657,"Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients",Completed,Has Results,Fever,Drug: ibuprofen|Drug: acetaminophen,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,7/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01002573
8658,A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),Completed,Has Results,MPS IV A,Drug: BMN 110 Weekly|Drug: Placebo|Drug: BMN 110 Every Other Week,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 3,Industry,Interventional,2/11/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT01275066
8659,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Completed,Has Results,Haemophilus Influenzae Type b,Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Biological: ActHIB™|Biological: Pentacel™|Biological: Pediarix™|Biological: Prevnar 13™|Biological: Rotarix™|Biological: Engerix™-B|Biological: Infanrix™,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/18/2010,7/17/2013,https://ClinicalTrials.gov/show/NCT01000974
8660,A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms,Completed,Has Results,Major Depressive Disorder,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,11/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT01000805
8661,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Completed,Has Results,Acute Coronary Syndrome,Drug: Darapladib 160 mg|Drug: Placebo|Other: Standard Therapy,GlaxoSmithKline|The TIMI Study Group,GlaxoSmithKline,The TIMI Study Group,,,,,,Phase 3,Industry|Other,Interventional,12/1/2009,4/24/2014,https://ClinicalTrials.gov/show/NCT01000727
8662,Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma,Completed,Has Results,Asthma,Biological: Mepolizumab 750|Biological: Mepolizumab 250|Biological: Mepolizumab 75|Drug: Placebo saline,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/1/2009,3/23/2012,https://ClinicalTrials.gov/show/NCT01000506
8663,Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder,Completed,Has Results,Post-Traumatic Stress Disorder,Drug: orvepitant|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/2/2009,6/28/2010,https://ClinicalTrials.gov/show/NCT01000493
8664,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Completed,Has Results,Meningococcal Disease,Biological: MenACWY-CRM|Biological: DTaP-IPV/Hib|Biological: HBV|Biological: PCV|Biological: MMR,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,11/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT01000311
8665,Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: ACT-385781A (Actelion Epoprostenol)|Drug: Flolan®,Actelion,Actelion,,,,,,,Phase 4,Industry,Interventional,5/10/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT01105117
8666,Epoprostenol for Injection in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: ACT-385781A (Actelion Epoprostenol)|Drug: Flolan®,Actelion,Actelion,,,,,,,Phase 4,Industry,Interventional,3/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01105091
8667,A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy,Completed,Has Results,Cirrhosis|Hepatic Encephalopathy,Drug: HPN-100|Drug: Placebo,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 2,Industry,Interventional,12/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00999167
8668,Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study),Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Drug: extended-release guanfacine hydrochloride (SPD503)|Drug: placebo|Drug: extended-release guanfacine hydrochloride,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00997984
8669,A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy,Completed,Has Results,Pregnancy Prevention,Drug: DR-103,Teva Women's Health|Teva Pharmaceutical Industries,Teva Women's Health,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,10/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00996580
8670,This is a Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence,Completed,Has Results,Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency,Device: Coaptite®,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Not Applicable,Industry,Interventional,1/8/2008,11/2/2015,https://ClinicalTrials.gov/show/NCT00996489
8671,Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women,Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: flibanserin|Drug: placebo,"Sprout Pharmaceuticals, Inc","Sprout Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,10/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00996372
8672,Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: Flibanserin|Drug: Placebo,"Sprout Pharmaceuticals, Inc","Sprout Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,10/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00996164
8673,A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: MM-121|Drug: Erlotinib,Merrimack Pharmaceuticals,Merrimack Pharmaceuticals,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00994123
8674,Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines,Completed,Has Results,Rheumatoid Arthritis,Other: Placebo|Biological: Certolizumab pegol,UCB Pharma,UCB Pharma,,,,,,,Phase 4,Industry,Interventional,9/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00993668
8675,Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects,Completed,Has Results,Head Lice,Drug: Ivermectin cream|Drug: vehicle control,Topaz Pharmaceuticals Inc,Topaz Pharmaceuticals Inc,,,,,,,Phase 2,Industry,Interventional,10/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00994422
8676,Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders,Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100|Drug: Buphenyl (NaPBA),"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 3,Industry,Interventional,10/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00992459
8677,Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance,Completed,Has Results,Restless Legs Syndrome,Drug: pregabalin|Drug: placebo|Drug: pramipexole,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00991276
8678,Attain Success Clinical Trial,Completed,Has Results,Heart Failure,Device: Attain Success Lead,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,,Industry,Observational,11/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00990964
8679,Promote Q Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Quartet Left Ventricular Heart Lead Study,Completed,Has Results,Heart Failure,Device: CRT-D and LV lead (Quartet™ lead and Promote Q® device system),Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00990665
8680,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration",Completed,Has Results,Hereditary Angioedema,Biological: CINRYZE,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,5/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01095497
8681,Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,10/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00988247
8682,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Lenalidomide|Drug: Docetaxel|Drug: Prednisone|Drug: Placebo,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,11/11/2009,11/28/2016,https://ClinicalTrials.gov/show/NCT00988208
8683,Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Device: 1.2% Sodium Hyaluronate|Device: Buffered Saline,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,9/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00988091
8684,Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects,Completed,Has Results,Hepatitis|Hepatitis C,Drug: Filibuvir|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00987337
8685,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,Completed,Has Results,Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Thromboembolism|Venous Thrombosis,Drug: edoxaban tosylate(DU-176b)|Drug: low molecular weight heparin/unfractionated heparin|Drug: warfarin,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,10/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00986154
8686,SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Matching placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,10/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00985725
8687,COMPRES - COMpression Anastomosis Ring (CAR™ 27/ColonRing™) Post maRketing Evaluation Study,Completed,Has Results,Colorectal Surgery,Device: ColonRing (Colorectal anastomosis),"novoGI|Atlanta Colon & Rectal Surgery, Atlanta, GA|FPMG Center for Colon & Rectal Surgery|Lester E. Cox Medical Centers|UCI Medical Center Irvine CA|NorthShore University HealthSystem|St.Louis University hospital MO|University of Southern California|Bnai Zion Medical Center|Barmherzig Brueder|Catharina Ziekenhuis Eindhoven|Ziekenhuis Oost-Limburg|University Hospital, Gasthuisberg|Klinikum Neuperlach",novoGI,"Atlanta Colon & Rectal Surgery, Atlanta, GA","FPMG Center for Colon & Rectal Surgery|Lester E. Cox Medical Centers|UCI Medical Center Irvine CA|NorthShore University HealthSystem|St.Louis University hospital MO|University of Southern California|Bnai Zion Medical Center|Barmherzig Brueder|Catharina Ziekenhuis Eindhoven|Ziekenhuis Oost-Limburg|University Hospital, Gasthuisberg|Klinikum Neuperlach",FPMG Center for Colon & Rectal Surgery,"Lester E. Cox Medical Centers|UCI Medical Center Irvine CA|NorthShore University HealthSystem|St.Louis University hospital MO|University of Southern California|Bnai Zion Medical Center|Barmherzig Brueder|Catharina Ziekenhuis Eindhoven|Ziekenhuis Oost-Limburg|University Hospital, Gasthuisberg|Klinikum Neuperlach",Lester E. Cox Medical Centers,"UCI Medical Center Irvine CA|NorthShore University HealthSystem|St.Louis University hospital MO|University of Southern California|Bnai Zion Medical Center|Barmherzig Brueder|Catharina Ziekenhuis Eindhoven|Ziekenhuis Oost-Limburg|University Hospital, Gasthuisberg|Klinikum Neuperlach",Phase 4,Industry|Other,Interventional,3/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01091155
8688,Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone propionate/salmeterol combination product|Drug: Salmeterol|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,10/29/2009,7/1/2010,https://ClinicalTrials.gov/show/NCT00984659
8689,Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL),Completed,Has Results,Typical Atrial Flutter,Device: Therapy Cool Path Duo,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 3,Industry,Interventional,10/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00984204
8690,"Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015",Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,10/26/2009,6/29/2016,https://ClinicalTrials.gov/show/NCT00984126
8691,A Study for Participants With Small-Cell Lung Cancer,Completed,Has Results,Small Cell Lung Cancer,Drug: LY2523355|Drug: Granulocyte colony-stimulating factor (G-CSF),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,12/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT01025284
8692,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00982644
8693,Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,Completed,Has Results,Leukemia,Drug: Dasatinib|Drug: Imatinib,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,10/7/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00982488
8694,Safety and Clinical Performance of the Protecta ICD and CRT-D,Completed,Has Results,Tachyarrhythmias|Heart Failure|Ventricular Dysfunction,Device: Protecta VR-ICD|Device: Protecta DR-ICD or CRT-D,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00982397
8695,Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/1/2009,11/8/2010,https://ClinicalTrials.gov/show/NCT00982228
8696,A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis,Completed,Has Results,Juvenile Idiopathic Arthritis,Drug: Tocilizumab|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,11/30/2009,1/28/2013,https://ClinicalTrials.gov/show/NCT00988221
8697,Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency,Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: EUR-1008 (APT-1008),Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,5/6/2019,9/6/2019,https://ClinicalTrials.gov/show/NCT00981214
8698,"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment",Completed,Has Results,Hepatitis C,Drug: TMC435|Drug: Placebo|Drug: Peg-IFN-alfa-2a (P)|Drug: Ribavirin (R),"Tibotec Pharmaceuticals, Ireland","Tibotec Pharmaceuticals, Ireland",,,,,,,Phase 2,Industry,Interventional,10/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00980330
8699,Adaptive Cardiac Resynchronization Therapy Study,Completed,Has Results,Heart Failure,Device: Adaptive CRT (aCRT)|Device: Echo,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,10/1/2009,3/8/2012,https://ClinicalTrials.gov/show/NCT00980057
8700,Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children,Completed,Has Results,Influenza,Biological: GSK investigational vaccine GSK1557482A|Biological: Fluzone®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/13/2009,6/17/2010,https://ClinicalTrials.gov/show/NCT00980005
8701,"Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older",Completed,Has Results,Influenza,Biological: GSK2340274A|Biological: GSK2340273A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,11/9/2009,2/1/2011,https://ClinicalTrials.gov/show/NCT00979602
8702,Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology,Completed,Has Results,Alzheimer Disease,Drug: Florbetaben (BAY94-9172),Life Molecular Imaging SA,Life Molecular Imaging SA,,,,,,,Phase 3,Industry,Interventional,11/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT01020838
8703,Safety and Efficacy of BKM120 in Relapsed and Refractory NHL,Completed,Has Results,"Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma",Drug: Buparlisib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,2/28/2013,7/21/2017,https://ClinicalTrials.gov/show/NCT01693614
8704,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: insulin detemir|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00978627
8705,Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older,Completed,Has Results,Influenza,Biological: GSK2340274A|Biological: GSK2340273A|Biological: Saline placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/11/2009,12/16/2010,https://ClinicalTrials.gov/show/NCT00985088
8706,Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D,Completed,Has Results,Chronic Kidney Disease|Secondary Hyperparathyroidism|Hemodialysis,Drug: Paricalcitol|Drug: Cinacalcet,Abbott,Abbott,,,,,,,Phase 4,Industry,Interventional,11/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00977080
8707,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lixisenatide (AVE0010)|Drug: Lixisenatide Placebo|Device: Pen auto-injector|Drug: Sitagliptin|Drug: Sitagliptin Placebo|Drug: Metformin,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,8/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00976937
8708,Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725,Completed,Has Results,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Drug: catridecacog,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/21/2009,10/20/2015,https://ClinicalTrials.gov/show/NCT00978380
8709,Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age,Completed,Has Results,Influenza,Biological: GSK2340274A|Biological: GSK2340273A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/20/2009,3/21/2011,https://ClinicalTrials.gov/show/NCT00976820
8710,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide + insulin glargine|Drug: insulin glargine + preprandial lispro insulin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00976391
8711,"A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,"Drug: CP-690,550 + methotrexate|Drug: Placebo + Methotrexate",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00976599
8712,Clinical Performance Comparison of Two Contact Lenses,Completed,Has Results,Myopia,Device: senofilcon A|Device: lotrafilcon B,"Johnson & Johnson Vision Care, Inc.|Visioncare Research Ltd.","Johnson & Johnson Vision Care, Inc.",Visioncare Research Ltd.,,,,,,Not Applicable,Industry|Other,Interventional,8/1/2009,10/1/2009,https://ClinicalTrials.gov/show/NCT00975585
8713,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Insulin glargine|Device: Pen auto-injector|Drug: Metformin|Drug: Thiazolidinedione (TZD),Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,10/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00975286
8714,Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,Completed,Has Results,"Hyperparathyroidism, Primary|Hypercalcemia",Drug: Cinacalcet|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,3/10/2010,12/21/2012,https://ClinicalTrials.gov/show/NCT00975221
8715,Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne,Completed,Has Results,Severe Nodular Acne,Drug: CIP-Isotretinoin|Drug: Isotretinoin,Cipher Pharmaceuticals Inc.,Cipher Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,9/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00975143
8716,A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).,Completed,Has Results,Parkinson's Disease,Drug: IPX066|Drug: IR CD-LD,"Impax Laboratories, LLC","Impax Laboratories, LLC",,,,,,,Phase 3,Industry,Interventional,9/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00974974
8717,Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,Completed,Has Results,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,Drug: Cinacalcet|Drug: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,12/3/2009,4/16/2013,https://ClinicalTrials.gov/show/NCT00975000
8718,Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients,Completed,Has Results,Presbyopia,Device: etafilcon A multifocal contact lens|Device: etafilcon A Contact Lens,"Johnson & Johnson Vision Care, Inc.|Visioncare Research Ltd.","Johnson & Johnson Vision Care, Inc.",Visioncare Research Ltd.,,,,,,Not Applicable,Industry|Other,Interventional,10/1/2009,12/1/2009,https://ClinicalTrials.gov/show/NCT01016652
8719,Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System,Completed,Has Results,Human Papillomavirus Infection,Device: APTIMA HPV Assay|Device: FDA-Approved HPV DNA Test,"Gen-Probe, Incorporated","Gen-Probe, Incorporated",,,,,,,Phase 3,Industry,Interventional,3/8/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00973362
8720,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years),Completed,Has Results,Influenza,Biological: MF59-eH1N1,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 2|Phase 3,Industry,Interventional,9/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00972816
8721,Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: i.v. selexipag|Drug: oral selexipag (Uptravi),Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,12/4/2017,5/29/2018,https://ClinicalTrials.gov/show/NCT03187678
8722,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/1/2009,10/28/2010,https://ClinicalTrials.gov/show/NCT00972283
8723,A Study of Advanced or Metastatic Non-small Cell Lung Cancer,Completed,Has Results,Non Small Cell Lung Cancer,Drug: LY2603618|Drug: Pemetrexed,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/9/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00988858
8724,"Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,8/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00970268
8725,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,9/9/2019,,https://ClinicalTrials.gov/show/NCT00969709
8726,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,9/9/2019,,https://ClinicalTrials.gov/show/NCT00969150
8727,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Glimepiride|Drug: Canagliflozin (JNJ-28431754)|Drug: Metformin,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,9/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00968812
8728,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,Completed,Has Results,"Diabetes Mellitus, Type 2|Acute Coronary Syndrome",Drug: Alogliptin|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,9/9/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00968708
8729,A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults,Completed,Has Results,Asthma,Biological: MEDI528 30 mg|Biological: MEDI528 100 mg|Biological: MEDI528 300 mg|Other: Placebo,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,12/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00968669
8730,Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds,Completed,Has Results,Diabetic Foot Ulcers|Pressure Ulcers,Device: HP828-101|Device: Hydrogel/Hydrocolloid,Healthpoint,Healthpoint,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00971048
8731,A Study in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Biological: LY2439821|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00966875
8732,"Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer",Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Erlotinib|Drug: PF-02341066,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,1/10/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00965731
8733,Genotropin Study Assessing Use of Injection Pen,Completed,Has Results,Growth Hormone Deficiency|Idiopathic Short Stature,Device: New Genotropin Pen,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00965484
8734,Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation,Completed,Has Results,Paroxysmal Atrial Fibrillation,Device: CardioFocus HeartLight Endoscopic Ablation System,CardioFocus,CardioFocus,,,,,,,Phase 2,Industry,Interventional,9/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00971204
8735,NAVISTAR® THERMOCOOL® Catheter Post Approval Registry,Completed,Has Results,Paroxysmal Atrial Fibrillation,Procedure: Atrial fibrillation ablation,"Biosense Webster, Inc.","Biosense Webster, Inc.",,,,,,,Phase 4,Industry,Interventional,9/1/2009,1/5/2018,https://ClinicalTrials.gov/show/NCT00964392
8736,Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients,Completed,Has Results,"Vaccines, Pneumococcal Conjugate Vaccine",Biological: 13vPnC|Biological: 23vPS,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/18/2010,5/16/2013,https://ClinicalTrials.gov/show/NCT00980655
8737,Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Completed,Has Results,Relapsed or Refractory Chronic Lymphocytic Leukemia,Drug: lenalidomide,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,10/19/2009,9/5/2017,https://ClinicalTrials.gov/show/NCT00963105
8738,Efficacy and Safety Study in Subjects With Asthma,Completed,Has Results,Asthma,Drug: Dose 4 QD|Drug: Dose 3 QD|Drug: placebo|Drug: Dose 2 QD|Drug: Dose 1 BD,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00980200
8739,Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS,Completed,Has Results,HIV Infections|Pneumococcal Infections,Biological: 13-valent pneumococcal conjugate vaccine|Procedure: Blood draw,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00963235
8740,A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects,Completed,Has Results,Head Lice,Drug: 0.5% Ivermectin Cream|Drug: Placebo control,Topaz Pharmaceuticals Inc,Topaz Pharmaceuticals Inc,,,,,,,Phase 3,Industry,Interventional,3/10/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT01068158
8741,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI,Completed,Has Results,Breast Cancer|Diagnostic Imaging,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,2/10/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT01067976
8742,Restoration® Modular Revision Hip System Post Market Study,Completed,Has Results,"Arthroplasty, Replacement, Hip",Device: Restoration® Modular Revision Hip System,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,1/4/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00962013
8743,"Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00960440
8744,Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo|Drug: Hydrochlorothiazide,"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",AstraZeneca,"Astra Zeneca, Bristol-Myers Squibb",,,,,,Phase 2,Industry|Other,Interventional,10/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00976495
8745,A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population,Completed,Has Results,Influenza,Biological: CSL's Influenza Virus Vaccine (Afluria)|Biological: Influenza Virus Vaccine (Fluzone),Seqirus,Seqirus,,,,,,,Phase 3,Industry,Interventional,9/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00959049
8746,A Study in Relapse Prevention of Treatment-Resistant Depression,Completed,Has Results,Treatment Resistant Depression,Drug: Olanzapine and Fluoxetine combination (OFC)|Drug: Fluoxetine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,8/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00958568
8747,Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza,Completed,Has Results,Seasonal Influenza|Cough|Sore Throat|Nasal Congestion|Myalgia|Headache|Fatigue,Drug: Peramivir,BioCryst Pharmaceuticals|Department of Health and Human Services,BioCryst Pharmaceuticals,Department of Health and Human Services,,,,,,Phase 3,Industry|U.S. Fed,Interventional,10/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00957996
8748,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA,Completed,Has Results,Influenza,Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: Placebo,Seqirus,Seqirus,,,,,,,Phase 2,Industry,Interventional,8/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00958243
8749,BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD) With Cachexia,Drug: Placebo|Drug: BYM338,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,9/12/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT01669174
8750,MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study,Completed,Has Results,Lumbar Spinal Stenosis,Procedure: Interlaminar Decompression,"Vertos Medical, Inc.","Vertos Medical, Inc.",,,,,,,Phase 4,Industry,Interventional,7/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00956631
8751,Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis,Completed,Has Results,Allergic Rhinitis Due to Grass Pollens,Drug: 300 IR|Drug: Placebo,Stallergenes Greer,Stallergenes Greer,,,,,,,Phase 3,Industry,Interventional,10/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00955825
8752,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Completed,Has Results,Type 2 Diabetes,Drug: Tagatose|Drug: Sugar Substitute Splenda,Robert Lodder|University of Kentucky|Spherix Incorporated,Robert Lodder,University of Kentucky,Spherix Incorporated,,,,,Phase 3,Industry|Other,Interventional,4/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00955747
8753,Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures,Completed,Has Results,Partial Epilepsies,Drug: Lacosamide,UCB Pharma,UCB Pharma,,,,,,,Phase 4,Industry,Interventional,8/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00955357
8754,A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis,Completed,Has Results,Sarcoidosis,Drug: Placebo|Drug: Golimumab|Drug: Ustekinumab,"Centocor, Inc.","Centocor, Inc.",,,,,,,Phase 2,Industry,Interventional,11/9/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00955279
8755,Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003,Completed,Has Results,Uterine Fibroids,Drug: Proellex®,Repros Therapeutics Inc.,Repros Therapeutics Inc.,,,,,,,Phase 2,Industry,Interventional,9/7/2006,10/15/2008,https://ClinicalTrials.gov/show/NCT00958334
8756,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA,Completed,Has Results,Influenza,Biological: CSL425|Biological: Placebo,Seqirus,Seqirus,,,,,,,Phase 2,Industry,Interventional,8/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00958126
8757,Triathlon® Cruciate Retaining (CR) Total Knee System Outcomes Study,Completed,Has Results,"Arthroplasty, Replacement, Knee",Device: Triathlon® CR Total Knee System,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,2/5/2019,9/26/2017,https://ClinicalTrials.gov/show/NCT00957723
8758,Accolade® TMZF® Hip Stem Outcomes Study,Completed,Has Results,"Arthroplasty, Replacement, Hip",Device: Accolade® TMZF® Hip Stem,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,3/6/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00957658
8759,Triathlon® Posteriorly Stabilized (PS) Total Knee System - Outcomes Study,Completed,Has Results,"Arthroplasty, Replacement, Knee",Device: Triathlon® PS Total Knee System,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,12/5/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00957021
8760,A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Completed,Has Results,Allergic Rhinitis|Perennial Allergic Rhinitis,Drug: Ciclesonide HFA 80 mcg|Drug: Ciclesonide HFA 160 mcg|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,8/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00953147
8761,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age,Completed,Has Results,Healthy or Stable Underlying Chronic Medical Condition,Biological: Q/LAIV-BFS (MEDI8662)|Biological: FluMist/B/Yamagata|Biological: FluMist/B/Victoria,MedImmune LLC,MedImmune LLC,,,,,,,Phase 3,Industry,Interventional,8/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00952705
8762,A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years,Completed,Has Results,Influenza|Swine-origin A/H1N1 Influenza,Biological: Monovalent Subvirion A/H1N1 Influenza vaccine|Biological: Normal saline solution (placebo),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,8/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00952419
8763,Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients,Completed,Has Results,Venous Thromboembolism,Drug: dalteparin,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/9/2019,3/18/2019,https://ClinicalTrials.gov/show/NCT00952380
8764,COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial,Completed,Has Results,MPN (Myeloproliferative Neoplasms),Drug: Ruxolitinib|Drug: Placebo,Incyte Corporation,Incyte Corporation,,,,,,,Phase 3,Industry,Interventional,8/9/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT00952289
8765,A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly,Completed,Has Results,Influenza|Swine-origin A/H1N1 Influenza,Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|Biological: Normal saline solution (placebo),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,8/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00953524
8766,A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly,Completed,Has Results,Influenza|Swine-origin A/H1N1 Influenza,Biological: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|Biological: Monovalent Subvirion A/H1N1 influenza vaccine|Biological: Normal saline solution,Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,10/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00952276
8767,Impact of Experience on Results With the Third Eye Retroscope,Completed,Has Results,Colorectal Neoplasms,Device: Third Eye Retroscope,Avantis Medical Systems,Avantis Medical Systems,,,,,,,Not Applicable,Industry,Interventional,1/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00969124
8768,A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study,Completed,Has Results,Ovarian Cancer|Basal Cell Carcinoma|Metastatic Colorectal Cancer,Drug: Vismodegib|Drug: FOLFOX|Drug: FOLFIRI|Drug: Bevacizumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,9/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00959647
8769,6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin glargine (HOE901)|Drug: Neutral Protamine Hagedorn (NPH) insulin|Drug: Insulin lispro,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,10/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00993473
8770,Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection,Completed,Has Results,Hemophilia A,"Biological: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)",Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 1,Industry,Interventional,9/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00952822
8771,"Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",Completed,Has Results,Chronic Phase Chronic Myeloid Leukemia,Drug: Dasatinib,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 4,Industry,Interventional,12/12/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01660906
8772,Olmesartan Comparison to Losartan in Hypertensive Subjects,Completed,Has Results,Hypertension,Drug: olmesartan medoxomil|Drug: Placebo|Drug: losartan potassium,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 4,Industry,Interventional,8/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00949884
8773,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44",Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine 4.6 mg/24 h (5 cm^2)|Drug: Rivastigmine 9.5 mg/24 h (10 cm^2)|Drug: Rivastigmine 13.3 mg/24 h (15 cm^2)|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,7/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00948766
8774,PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients,Completed,Has Results,Lymphoma,"Drug: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)","Otsuka Pharmaceutical Development & Commercialization, Inc.|Center for International Blood and Marrow Transplant Research","Otsuka Pharmaceutical Development & Commercialization, Inc.",Center for International Blood and Marrow Transplant Research,,,,,,Phase 2,Industry|Other,Interventional,1/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00948090
8775,A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: vemurafenib,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,9/30/2009,6/3/2014,https://ClinicalTrials.gov/show/NCT00949702
8776,Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD),Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 3,Industry,Interventional,11/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00947297
8777,A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH),Completed,Has Results,Lower Urinary Tract Symptoms (LUTS),Drug: Placebo|Drug: Degarelix 10 mg|Drug: Degarelix 20 mg|Drug: Degarelix 30 mg,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,8/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00947882
8778,A Trial of Degarelix in Patients With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix|Drug: Goserelin acetate,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,6/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00946920
8779,A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age,Completed,Has Results,Influenza,"Biological: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|Biological: Placebo",MedImmune LLC|Department of Health and Human Services,MedImmune LLC,Department of Health and Human Services,,,,,,Phase 4,Industry|U.S. Fed,Interventional,8/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00946101
8780,An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency,Completed,Has Results,Factor XIII Deficiency,Biological: FXIII Concentrate (Human) (FXIII),CSL Behring,CSL Behring,,,,,,,Phase 3,Industry,Interventional,9/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00945906
8781,GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium|Drug: Placebo|Drug: GSK573179,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/1/2009,3/15/2010,https://ClinicalTrials.gov/show/NCT00950807
8782,Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Other: ITCA 650|Drug: Exenatide Injection|Other: Ex Inj/ITCA 650,Intarcia Therapeutics,Intarcia Therapeutics,,,,,,,Phase 2,Industry,Interventional,8/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00943917
8783,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE),Completed,Has Results,"Gaucher Disease, Type 1",Drug: Eliglustat tartrate|Drug: Imiglucerase,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,9/9/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00943111
8784,"Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate",Completed,Has Results,Degeneration of Lumbar Intervertebral Disc,Device: chronOS Strip,"Synthes USA HQ, Inc.","Synthes USA HQ, Inc.",,,,,,,Not Applicable,Industry,Interventional,7/9/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00943384
8785,Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer,Completed,Has Results,Cancer,Drug: dalteparin,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,6/9/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00942968
8786,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Completed,Has Results,Actinic Keratoses,Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel,Peplin,Peplin,,,,,,,Phase 3,Industry,Interventional,7/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00942604
8787,Evaluation of an Investigational Multi-Purpose Solution (MPS),Completed,Has Results,Study Focus is Healthy Contact Lens Wearers,Device: Investigational MPS|Device: Opti-Free,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Phase 3,Industry,Interventional,2/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00961051
8788,Optimize RV Follow-up Selective Site Pacing Clinical Trial,Completed,Has Results,Cardiac Pacing|Right Ventricular Pacing|Left Ventricular Ejection Fraction,Device: Medtronic or Vitatron Dual-Chamber Pacemaker|Device: Medtronic SelectSecure 3830 Lead,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00949715
8789,A Study of LY2189102 in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: LY2189102|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00942188
8790,A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma,Completed,Has Results,Melanoma,Biological: Immunotherapeutic GSK2132231A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/14/2009,4/1/2015,https://ClinicalTrials.gov/show/NCT00942162
8791,Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma,Completed,Has Results,Asthma,Drug: QMF149 Twisthaler®|Drug: Mometasone Twisthaler®,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00941798
8792,A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women,Completed,Has Results,"Osteoporosis, Postmenopausal",Drug: Oral Calcitonin Tablets|Drug: Intranasal Calcitonin|Drug: Placebo tablets and placebo intranasal spray,"Tarsa Therapeutics, Inc.","Tarsa Therapeutics, Inc.",,,,,,,Phase 3,Industry,Interventional,6/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00959764
8793,AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis,Completed,Has Results,Chronic Plaque-type Psoriasis,Drug: AIN457|Drug: AIN457A|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00941031
8794,Trident® X3 Polyethylene Insert Study,Completed,Has Results,"Arthroplasty, Replacement, Hip",Device: Trident® X3 Polyethylene Insert,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,5/5/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00958191
8795,A Study of Duloxetine in Patients With Osteoarthritis Knee Pain,Completed,Has Results,Osteoarthritis Knee Pain,Drug: Duloxetine (DLX)|Drug: Placebo (PLA),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,7/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00945945
8796,Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects,Completed,Has Results,"Infections, Papillomavirus",Procedure: Gynaecological follow-up,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,8/5/2009,1/20/2014,https://ClinicalTrials.gov/show/NCT00937950
8797,"A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures",Completed,Has Results,Epilepsy,Drug: Lacosamide,UCB Pharma,UCB Pharma,,,,,,,Phase 2,Industry,Interventional,11/9/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00938431
8798,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),Completed,Has Results,Multiple Sclerosis,Drug: Rebif®,EMD Serono,EMD Serono,,,,,,,,Industry,Observational,7/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01207648
8799,An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome,Completed,Has Results,Cushing's Syndrome,Drug: mifepristone,Corcept Therapeutics,Corcept Therapeutics,,,,,,,Phase 3,Industry,Interventional,7/9/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00936741
8800,A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment,Completed,Has Results,Mild Cognitive Impairment,Drug: Aricept (donepezil hydrochloride)|Drug: placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 4,Industry,Interventional,2/6/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00934375
8801,Safety/Efficacy Study of Restylane® in Lip Augmentation,Completed,Has Results,Lip Augmentation,Device: Restylane®|Device: Non-Treatment,Medicis Global Service Corporation,Medicis Global Service Corporation,,,,,,,Not Applicable,Industry,Interventional,7/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00935272
8802,A Study of DER 45-EV Gel to Treat Rosacea,Completed,Has Results,Rosacea,Drug: DER 45 EV|Drug: Vehicle,"Sol-Gel Technologies, Ltd.","Sol-Gel Technologies, Ltd.",,,,,,,Phase 2,Industry,Interventional,1/12/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00940992
8803,Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery,Completed,Has Results,Peripheral Vascular Disease,Device: SUPERA® Nitinol Stent System,Abbott Medical Devices|Baim Institute for Clinical Research,Abbott Medical Devices,Baim Institute for Clinical Research,,,,,,Not Applicable,Industry|Other,Interventional,7/9/2019,7/14/2019,https://ClinicalTrials.gov/show/NCT00933270
8804,Evaluation of Diagnostic HIV Ag/Ab Combo Assay,Completed,Has Results,Human Immunodeficiency Viruses,Device: ARCHITECT HIV Ag/Ab Combo,Abbott Diagnostics Division,Abbott Diagnostics Division,,,,,,,Phase 3,Industry,Interventional,6/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00933933
8805,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: PF-02341066|Drug: Pemetrexed|Drug: Docetaxel,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/9/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT00932893
8806,"An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: PF-02341066,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,1/10/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00932451
8807,Study of Safety and Efficacy of an Oral Contraceptive,Completed,Has Results,Prevention of Pregnancy,Drug: Norethindrone Acetate/Ethinyl Estradiol 24 Days|Drug: Norethindrone Acetate /Ethinyl Estradiol 21 Days,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,1/4/2019,11/4/2019,https://ClinicalTrials.gov/show/NCT00932321
8808,A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: AZD9668|Drug: AZD9668 Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,7/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00949975
8809,Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: BI 1744 (Olodaterol) Low Dose|Drug: BI 1744 (Olodaterol) Medium Dose|Drug: Placebo|Drug: Foradil,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,6/9/2019,,https://ClinicalTrials.gov/show/NCT00932646
8810,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,Completed,Has Results,Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL),Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 2,Industry,Interventional,10/9/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00931918
8811,Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants,Completed,Has Results,Bronchopulmonary Dysplasia,Drug: Inhaled Nitric Oxide|Drug: Placebo,Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,11/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00931632
8812,Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty,Completed,Has Results,Degenerative Disc Disease,Device: NuBac|Device: Prodisc-L,"Pioneer Surgical Technology, Inc.","Pioneer Surgical Technology, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00931515
8813,Abatacept Versus Adalimumab Head-to-Head,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Adalimumab,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,10/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00929864
8814,A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction,Completed,Has Results,Heart Failure,Drug: Neladenoson bialanate (BAY1067197)|Drug: Placebo,Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,5/10/2017,6/20/2018,https://ClinicalTrials.gov/show/NCT03098979
8815,"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Glycopyrronium bromide|Drug: Placebo to glycopyrronium bromide|Drug: Tiotropium,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,6/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00929110
8816,A Study of Degarelix in Patients With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix|Drug: Leuprolide,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/9/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00928434
8817,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: BI 1744|Drug: bi1744|Drug: Placebo|Drug: Foradil,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,6/9/2019,,https://ClinicalTrials.gov/show/NCT00931385
8818,"Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)",Completed,Has Results,Rheumatoid Arthritis,Drug: Secukinmab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00928512
8819,Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor,Completed,Has Results,Cancer,Drug: GSK1120212,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT01037127
8820,A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder,Completed,Has Results,Overactive Bladder,Drug: Fesoterodine|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,9/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00928070
8821,A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer,Completed,Has Results,Solid Cancers,Drug: carboplatin|Drug: docetaxel|Drug: trastuzumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 1,Industry,Interventional,7/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00927589
8822,Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms,Completed,Has Results,"Urinary Bladder, Overactive",Device: Urgent PC,"Uroplasty, Inc","Uroplasty, Inc",,,,,,,Phase 4,Industry,Interventional,1/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00928395
8823,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults,Completed,Has Results,Influenza,Biological: Quadrivalent seasonal influenza vaccine GSK2282512A|Biological: FluLavalTM-VB|Biological: FluLavalTM-YB,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/1/2010,6/24/2011,https://ClinicalTrials.gov/show/NCT01196975
8824,Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension,Completed,Has Results,Hypertension,Drug: Telmisartan|Drug: Hydrochlorothiazide,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,6/9/2019,,https://ClinicalTrials.gov/show/NCT00926289
8825,CTS-1027 in Interferon-Naive Hepatitis C Patients,Completed,Has Results,Hepatitis C,Drug: ribavirin|Drug: CTS-1027|Drug: Placebo for ribavirin,Conatus Pharmaceuticals Inc.,Conatus Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,6/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00925990
8826,A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma,Completed,Has Results,Glioblastoma,Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation therapy|Drug: Placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,6/29/2009,9/9/2015,https://ClinicalTrials.gov/show/NCT00943826
8827,Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss,Completed,Has Results,Cancer|Cataract|Low Bone Mineral Density|Osteopenia|Osteoporosis|Prostate Cancer,Biological: Denosumab|Biological: Placebo,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,11/30/2009,5/12/2016,https://ClinicalTrials.gov/show/NCT00925600
8828,Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease,Completed,Has Results,Fabry Disease,Drug: migalastat hydrochloride|Drug: Placebo,Amicus Therapeutics,Amicus Therapeutics,,,,,,,Phase 3,Industry,Interventional,10/23/2009,1/29/2014,https://ClinicalTrials.gov/show/NCT00925301
8829,A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females,Completed,Has Results,Bone Mineral Density,Drug: 91-day Levonorgestrel Oral Contraceptive|Drug: 28-day Levonorgestrel Oral Contraceptive,Duramed Research|Teva Pharmaceutical Industries,Duramed Research,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,6/9/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00924560
8830,Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL),Completed,Has Results,Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia,Drug: CAT-8015 20 mcg/kg|Drug: CAT-8015 30 mcg/kg|Drug: CAT-8015 40 mcg/kg|Drug: CAT-8015 50 mcg/kg|Drug: CAT-8015 60 mcg/kg,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/15/2010,3/4/2013,https://ClinicalTrials.gov/show/NCT01030536
8831,A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: LY2216684|Drug: Methylphenidate|Drug: Placebo (tablet)|Drug: Placebo (capsule),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2|Phase 3,Industry,Interventional,6/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00922636
8832,"Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms",Completed,Has Results,Schizophrenia and Predominant Negative Symptoms,Drug: SPD489 (lisdexamfetamine dimesylate)|Drug: Placebo matching SPD489 (lisdexamfetamine dimesylate),Shire,Shire,,,,,,,Phase 2,Industry,Interventional,9/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00922272
8833,"Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU",Completed,Has Results,Phenylketonuria,Drug: rAvPAL-PEG 0.001 mg/kg|Drug: rAvPAL-PEG 0.003 mg/kg|Drug: rAvPAL-PEG 0.01 mg/kg|Drug: rAvPAL-PEG 0.03 mg/kg|Drug: rAvPAL-PEG 0.1 mg/kg,BioMarin Pharmaceutical,BioMarin Pharmaceutical,,,,,,,Phase 2,Industry,Interventional,9/9/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00925054
8834,Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A,Completed,Has Results,Blood Coagulation Disorders|Hemophilia A,"Biological: Recombinant Factor VIII (BAY81-8973)|Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,12/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT01029340
8835,A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q,Completed,Has Results,Anemia,Drug: Lenalidomide|Other: Placebo,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,1/26/2010,5/9/2018,https://ClinicalTrials.gov/show/NCT01029262
8836,Study of NXN 188 for the Treatment of Migraine With Aura,Completed,Has Results,Migraine With Aura,Drug: NXN-188|Drug: placebo|Drug: sumatriptan succinate,NeurAxon Inc.,NeurAxon Inc.,,,,,,,Phase 2,Industry,Interventional,6/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00920686
8837,Study of Adalimumab in Patients With Axial Spondyloarthritis,Completed,Has Results,Axial Spondyloarthritis,Biological: Adalimumab|Biological: Placebo|Biological: Open-label Adalimumab,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 3,Industry,Interventional,7/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00939003
8838,Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C,Completed,Has Results,Hepatitis C|Liver Transplantation,Drug: cyclosporin (Neoral)|Drug: tacrolimus (Prograf),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,9/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00938860
8839,"Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias",Completed,Has Results,Cancer,Drug: GSK1120212,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/11/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00920140
8840,Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: bendamustine|Drug: bortezomib,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 1|Phase 2,Industry,Interventional,6/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00920855
8841,Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome,Completed,Has Results,Interstitial Cystitis|Painful Bladder Syndrome,Drug: 2% sodium chondroitin sulfate|Drug: Placebo,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00919113
8842,Contrast-enhanced MRI in Children 2 Months to <2 Years,Completed,Has Results,Magnetic Resonance Imaging,"Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,1/10/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00937391
8843,Efficacy and Safety Study of CD2027 Ointment 3 Mcg/g Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: CD 2027|Drug: CD 2027 Vehicle,Galderma,Galderma,,,,,,,Phase 2,Industry,Interventional,5/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00919763
8844,Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa,Completed,Has Results,Hidradenitis Suppurativa,Biological: adalimumab|Drug: Placebo,Abbott,Abbott,,,,,,,Phase 2,Industry,Interventional,4/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00918255
8845,A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,Non-Small Cell Lung Cancer,Biological: Olaratumab|Drug: Paclitaxel|Drug: Carboplatin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,1/10/2019,11/17/2017,https://ClinicalTrials.gov/show/NCT00918203
8846,Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection,Completed,Has Results,Thoracic Injuries,Device: Gore Conformable TAG Thoracic Endoprosthesis,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,11/9/2019,2/28/2017,https://ClinicalTrials.gov/show/NCT00917852
8847,Detect Fluid Early From Intra-thoracic Impedance Monitoring,Completed,Has Results,Heart Failure,Device: Impedance Monitoring Feature,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,5/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00916929
8848,Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A,Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster Vaccine 1437173A|Biological: Placebo vaccine (saline),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/14/2009,3/21/2012,https://ClinicalTrials.gov/show/NCT00920218
8849,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Metformin XR|Drug: Placebo matching Metformin XR|Drug: Placebo matching Saxagliptin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,8/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00918138
8850,Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma,Completed,Has Results,Gastric Cancer|Adenocarcinoma,Biological: ramucirumab|Drug: Placebo|Other: Best Supportive Care (BSC),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,8/9/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00917384
8851,SPIRIT PRIME Clinical Trial,Completed,Has Results,Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis,Device: Core size Xience Prime|Device: Xience Prime Long Lesion (LL),Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 3,Industry,Interventional,6/9/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00916370
8852,"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Completed,Has Results,Actinic Keratosis,Drug: PEP005 Gel|Drug: Vehicle gel,Peplin,Peplin,,,,,,,Phase 3,Industry,Interventional,6/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00916006
8853,"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Completed,Has Results,Actinic Keratosis,"Drug: PEP005 (Ingenol Mebutate) gel, 0.015%|Drug: Vehicle Gel",Peplin,Peplin,,,,,,,Phase 3,Industry,Interventional,6/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00915551
8854,Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Neratinib|Drug: Trastuzumab|Drug: Paclitaxel,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",,,,,,,Phase 2,Industry,Interventional,8/21/2009,6/28/2018,https://ClinicalTrials.gov/show/NCT00915018
8855,"Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis",Completed,Has Results,Thrombosis,Drug: Desirudin,"Canyon Pharmaceuticals, Inc.","Canyon Pharmaceuticals, Inc.",,,,,,,Phase 4,Industry,Interventional,3/10/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00913133
8856,Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC),Completed,Has Results,Atopic Dermatitis,Drug: TS022|Drug: Vehicle,Taisho Pharmaceutical R&D Inc.,Taisho Pharmaceutical R&D Inc.,,,,,,,Phase 2,Industry,Interventional,6/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00914186
8857,A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Mirabegron|Drug: Placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 3,Industry,Interventional,4/28/2009,4/27/2010,https://ClinicalTrials.gov/show/NCT00912964
8858,A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3),Completed,Has Results,Hereditary Angioedema,Drug: Icatibant|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,6/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00912093
8859,A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency,Completed,Has Results,Overactive Bladder,Drug: Fesoterodine|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,8/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00911937
8860,Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion,Completed,Has Results,Exudative Age-Related Macular Degeneration|Focal Vitreomacular Adhesion,Drug: Ocriplasmin|Drug: Sham injection,ThromboGenics,ThromboGenics,,,,,,,Phase 2,Industry,Interventional,1/10/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00913744
8861,"Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)",Completed,Has Results,Symptomatic Gastroesophageal Reflux Disease (sGERD),Drug: rabeprazole sodium|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,1/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00911534
8862,A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE,Completed,Has Results,Hereditary Angioedema,Biological: C1 inhibitor (human) [C1 INH],Shire,Shire,,,,,,,Phase 4,Industry,Interventional,7/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00914966
8863,PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study,Completed,Has Results,Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer,Drug: Pegfilgrastim|Drug: Placebo|Biological: Bevacizumab|Drug: Standard Chemotherapy,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,11/3/2009,1/2/2015,https://ClinicalTrials.gov/show/NCT00911170
8864,"A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation",Completed,Has Results,Acute Coronary Syndrome,Drug: GW856553|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/8/2009,3/6/2012,https://ClinicalTrials.gov/show/NCT00910962
8865,Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial),Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia,Drug: Lenalidomide|Drug: Chlorambucil,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,10/13/2009,5/9/2018,https://ClinicalTrials.gov/show/NCT00910910
8866,"Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study",Completed,Has Results,Psoriasis,Drug: Desoximetasone 0.05% once daily|Drug: Desoximetasone 0.05% twice daily|Drug: Desoximetasone 0.25% once daily|Drug: Vehicle once daily|Drug: Vehicle twice daily,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 2,Industry,Interventional,11/9/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT01018134
8867,Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes,Completed,Has Results,Cancer|Solid Tumor,Biological: IMC-1121B|Drug: Moxifloxacin|Drug: Diphenhydramine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01017731
8868,Eslicarbazepine Acetate Monotherapy Long Term Study,Completed,Has Results,Epilepsy,Drug: Eslicarbazepine acetate,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,8/9/2019,4/15/2017,https://ClinicalTrials.gov/show/NCT00910247
8869,Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers,Completed,Has Results,Venous Leg Ulcer,Device: Dermagraft(R)|Device: Profore,Organogenesis,Organogenesis,,,,,,,Phase 3,Industry,Interventional,6/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00909870
8870,Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Arformoterol|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,6/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00909779
8871,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,8/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00909727
8872,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 3,Industry|Other,Interventional,6/9/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00909532
8873,Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin detemir|Drug: insulin glargine,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 4,Industry,Interventional,5/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00909480
8874,Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women,Completed,Has Results,"Osteoporosis, Post-menopausal",Drug: Teriparatide|Drug: Zoledronic Acid,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,7/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00927186
8875,"Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients",Completed,Has Results,Acute Myeloid Leukemia,Drug: AZD1152|Drug: LDAC,AstraZeneca,AstraZeneca,,,,,,,Phase 2|Phase 3,Industry,Interventional,7/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00952588
8876,Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: temsirolimus,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,3/11/2019,6/18/2019,https://ClinicalTrials.gov/show/NCT01180049
8877,Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence,Completed,Has Results,Urge Urinary Incontinence|Urinary Frequency,Drug: Oxybutynin|Drug: Placebo,Antares Pharma Inc.,Antares Pharma Inc.,,,,,,,Phase 3,Industry,Interventional,3/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00909181
8878,Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection,Completed,Has Results,Type B Aortic Dissection,Device: GORE TAG® Thoracic Endoprosthesis,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,10/9/2019,2/28/2017,https://ClinicalTrials.gov/show/NCT00908388
8879,Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy,Completed,Has Results,Partial Epilepsy,Drug: Oxcarbazepine XR,"Supernus Pharmaceuticals, Inc.","Supernus Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,6/9/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00908349
8880,Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP),Completed,Has Results,"Purpura, Thrombocytopaenic, Idiopathic",Drug: eltrombopag|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/30/2009,2/1/2014,https://ClinicalTrials.gov/show/NCT00908037
8881,Primovist / Eovist in Renally Impaired Patients,Completed,Has Results,Contrast Media,"Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)",Bayer,Bayer,,,,,,,Phase 4,Industry,Interventional,5/9/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00908596
8882,A Study of Acne Treatment in Children Ages 9 to 11,Completed,Has Results,Acne Vulgaris,Drug: Retin-A Micro 0.04% facial acne treatment|Drug: Vehicle control,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 2,Industry,Interventional,2/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00907335
8883,A Study of Different Use Regimens Using Two Acne Treatments,Completed,Has Results,Acne Vulgaris,Drug: benzoyl peroxide wash|Drug: Tretinoin gel,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 4,Industry,Interventional,2/9/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00907257
8884,"Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia",Completed,Has Results,Schizophrenia,Drug: OPC-34712|Drug: Placebo|Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,7/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00905307
8885,Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant,Completed,Has Results,Major Depressive Disorder,Drug: Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Drug: Antidepressant + placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,7/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00905424
8886,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: BIIB017 (peginterferon beta-1a)|Drug: Placebo,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,6/9/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00906399
8887,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Ciclesonide HFA 160 μg|Drug: Ciclesonide HFA 80 μg|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,12/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT01010971
8888,Effect on Primary Dysmenorrhea,Completed,Has Results,Primary Dysmenorrhea,"Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Ethinyl estradiol, Levonorgestrel (Miranova)|Drug: Placebo Match to SH T00658ID|Drug: Placebo Match to SH D593B",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,4/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00909857
8889,"Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",Completed,Has Results,Hypertriglyceridemia,Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,11/15/2005,6/27/2008,https://ClinicalTrials.gov/show/NCT00903409
8890,28 Day Repeat Dose in Cystic Fibrosis Patients,Completed,Has Results,Cystic Fibrosis,Drug: SB656933|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/28/2009,12/29/2010,https://ClinicalTrials.gov/show/NCT00903201
8891,Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma,Completed,Has Results,Renal Cell Carcinoma,Drug: everolimus|Drug: sunitinib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,10/9/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00903175
8892,Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: ACT-064992 (macitentan)|Drug: Placebo,Actelion,Actelion,,,,,,,Phase 2,Industry,Interventional,5/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00903331
8893,Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate,Completed,Has Results,Rheumatoid Arthritis,Drug: LX3305 low dose|Drug: LX3305 mid dose|Drug: LX3305 high dose|Drug: Placebo,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/9/2019,,https://ClinicalTrials.gov/show/NCT00903383
8894,INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs,Completed,Has Results,Rheumatoid Arthritis,Drug: INCB028050|Drug: Placebo,Incyte Corporation,Incyte Corporation,,,,,,,Phase 2,Industry,Interventional,5/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00902486
8895,Imatinib (QTI571) in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: imatinib mesylate|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00902174
8896,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,Completed,Has Results,"Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Erlotinib (Tarceva)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,5/21/2009,5/23/2018,https://ClinicalTrials.gov/show/NCT00901901
8897,Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer,Completed,Has Results,Prostate Cancer,Biological: sipuleucel-T,Dendreon,Dendreon,,,,,,,Phase 2,Industry,Interventional,10/9/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00901342
8898,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol|Drug: Placebo to tiotropium,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00900731
8899,Study to Test GSK256073 in Patients With Dyslipidemia,Completed,Has Results,Dyslipidaemias,Drug: GSK256073|Drug: Placebo|Drug: Niaspan,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/15/2009,2/16/2010,https://ClinicalTrials.gov/show/NCT00903617
8900,Safety Follow-Up to HP 802-247-09-015,Completed,Has Results,Venous Leg Ulcer|Venous Stasis Ulcer,Biological: No HP802 Treatment|Other: No HP802 Vehicle Treatment,Healthpoint,Healthpoint,,,,,,,,Industry,Observational,6/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00900029
8901,EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries,Completed,Has Results,Iliac Artery Stenosis,Device: Epic™ Nitinol Stent System|Drug: Anti-platelet therapy|Drug: Anti-coagulation therapy,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,5/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00896337
8902,A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence,Completed,Has Results,"Urinary Incontinence, Stress",Device: The AMS Male Transobturator Sling System|Device: AdVance Male Sling,American Medical Systems,American Medical Systems,,,,,,,Not Applicable,Industry,Interventional,9/5/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00904969
8903,Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients,Completed,Has Results,Graft Rejection|Kidney Transplant|Renal Allograft Recipients|Renal Transplant,Drug: Tacrolimus|Drug: Sirolimus,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,6/9/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00895583
8904,Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium,Completed,Has Results,Breast Cancer|Hypercalcemia of Malignancy|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer,Drug: denosumab,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,11/16/2009,8/21/2013,https://ClinicalTrials.gov/show/NCT00896454
8905,Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy,Completed,Has Results,Erectile Dysfunction,Drug: Placebo|Drug: Avanafil,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 3,Industry,Interventional,4/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00895011
8906,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",Completed,Has Results,Acute Decompensated Heart Failure|Congestive Heart Failure,Drug: Aliskiren|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,5/9/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00894387
8907,Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery,Completed,Has Results,Actinic Keratosis,Drug: imiquimod cream|Drug: placebo cream,"Graceway Pharmaceuticals, LLC","Graceway Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,5/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00894647
8908,FS VH S/D 500 S-apr in Vascular Surgery,Completed,Has Results,Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses,"Biological: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Other: Surgical gauze pads",Baxter Healthcare Corporation,Baxter Healthcare Corporation,,,,,,,Phase 3,Industry,Interventional,7/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00892957
8909,"Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV-1 Infection,Drug: COBI|Drug: RTV|Drug: ATV|Drug: FTC/TDF|Drug: COBI placebo|Drug: RTV placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,5/9/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00892437
8910,A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR),Completed,Has Results,Age-related Macular Degeneration,Drug: Ranibizumab,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 3,Industry,Interventional,7/9/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00891735
8911,Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00891462
8912,"A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™",Completed,Has Results,Hypertriglyceridemia,Drug: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,3/6/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00891293
8913,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Completed,Has Results,Rheumatoid Arthritis,Drug: tocilizumab [RoActemra/Actemra]|Drug: Nonbiologic DMARDs of investigator's choice,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,5/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00891020
8914,A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C,Completed,Has Results,Morbid Obesity,,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,,Industry,Observational,11/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00999661
8915,"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients",Completed,Has Results,HIV Infections|Acquired Immunodeficiency Syndrome,Drug: Atazanavir (ATV) 300 mg|Drug: Atazanavir (ATV) 400 mg|Drug: Ritonavir (rtv) 100 mg|Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|Drug: Etravirine (ETR) 200 mg|Drug: Tenofovir disoproxil fumarate (TDF) 300 mg,Janssen R&D Ireland,Janssen R&D Ireland,,,,,,,Phase 2,Industry,Interventional,8/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00896051
8916,Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma,Completed,Has Results,Mantle Cell Lymphoma,Drug: Bendamustine|Drug: Rituximab,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,6/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00891839
8917,Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI,Completed,Has Results,Non Therapeutic Body Modification,Device: EVOLENCE®,Johnson & Johnson Consumer and Personal Products Worldwide,Johnson & Johnson Consumer and Personal Products Worldwide,,,,,,,Not Applicable,Industry,Interventional,12/31/2008,11/30/2009,https://ClinicalTrials.gov/show/NCT00891774
8918,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Completed,Has Results,Systemic Juvenile Idiopathic Arthritis With Active Flare,Drug: canakinumab|Drug: placebo,Novartis Pharmaceuticals|Pediatric Rheumatology International Trials Organization|Novartis,Novartis Pharmaceuticals,Pediatric Rheumatology International Trials Organization,Novartis,,,,,Phase 3,Industry|Other,Interventional,7/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00889863
8919,Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT),Completed,Has Results,Acne Vulgaris,Drug: Visonac PDT (MAL PDT)|Drug: Vehicle cream (placebo)|Procedure: PDT,Photocure,Photocure,,,,,,,Phase 2,Industry,Interventional,8/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00933543
8920,Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Hypertension,Drug: UT-15C SR|Drug: Placebo,United Therapeutics,United Therapeutics,,,,,,,Phase 3,Industry,Interventional,6/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00887978
8921,Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine succinate sustained release 50 mg|Drug: Desvenlafaxine succinate sustained release 25 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00887224
8922,Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Abiraterone acetate|Drug: Placebo|Drug: Prednisone,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,4/28/2009,5/25/2017,https://ClinicalTrials.gov/show/NCT00887198
8923,Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs),Completed,Has Results,Coronary Artery Chronic Total Occlusion,Device: Recanalization of a coronary chronic total occlusion,BridgePoint Medical,BridgePoint Medical,,,,,,,Phase 2,Industry,Interventional,3/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00886899
8924,A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency,Completed,Has Results,Factor XIII Deficiency,Biological: FXIII Concentrate (Human),CSL Behring,CSL Behring,,,,,,,Phase 3,Industry,Interventional,8/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00885742
8925,Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Saxagliptin plus metformin IR|Drug: Placebo plus metformin IR,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,5/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00885378
8926,LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction,Completed,Has Results,Chronic Heart Failure,Drug: LCZ696|Drug: Valsartan|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,11/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00887588
8927,A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols,Completed,Has Results,Multiple Myeloma|Solid Tumors,Drug: Carfilzomib,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,4/9/2009,5/17/2017,https://ClinicalTrials.gov/show/NCT00884312
8928,Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia,Completed,Has Results,Fibromyalgia|Sleep Disorders,Drug: Pregabalin|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00883740
8929,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: azelastineHcl|Drug: fluticasone propionate|Drug: azelastine Hcl/fluticasone propionate,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00883168
8930,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: LY2127399|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00882999
8931,A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment,Completed,Has Results,Hepatitis C,Drug: TMC435|Drug: Ribavirin (R)|Drug: PegIFNα-2a (P)|Drug: Placebo,"Tibotec Pharmaceuticals, Ireland","Tibotec Pharmaceuticals, Ireland",,,,,,,Phase 2,Industry,Interventional,6/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00882908
8932,Study of Mepolizumab Safety Syringe in Asthmatics,Completed,Has Results,Asthma,Drug: Mepolizumab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/1/2017,8/8/2017,https://ClinicalTrials.gov/show/NCT03021304
8933,A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma,Completed,Has Results,Melanoma,Drug: GSK2118436,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/9/2010,6/1/2016,https://ClinicalTrials.gov/show/NCT01153763
8934,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: Placebo|Drug: IPX066 95 mg LD|Drug: IPX066 145 mg LD|Drug: IPX066 195 mg LD|Drug: IPX066 245 mg LD,"Impax Laboratories, LLC","Impax Laboratories, LLC",,,,,,,Phase 3,Industry,Interventional,4/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00880620
8935,"Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: Metformin|Drug: Sitagliptin,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,3/9/2019,,https://ClinicalTrials.gov/show/NCT00881530
8936,Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF),Completed,Has Results,Cystic Fibrosis|Pancreatic Insufficiency,Drug: Ultrase® MT12,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,4/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00880100
8937,PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction,Completed,Has Results,Macromastia,Device: PEAK PlasmaBlade|Procedure: Traditional Electrosurgery with scalpel,Medtronic Surgical Technologies,Medtronic Surgical Technologies,,,,,,,Not Applicable,Industry,Interventional,1/10/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00986453
8938,A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis,Completed,Has Results,Conjunctivitis,Device: RPS Adeno Detector IV,Rapid Pathogen Screening,Rapid Pathogen Screening,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00921895
8939,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Hypertension,Drug: Telmisartan 80|Drug: Amlodipine 10,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,2/9/2019,,https://ClinicalTrials.gov/show/NCT00877929
8940,Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice,Completed,Has Results,Psoriasis|Psoriatic Arthritis,Procedure: lab draws and imaging,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,8/10/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT01147874
8941,Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder,Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,4/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00877487
8942,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00877383
8943,"Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration",Completed,Has Results,Age-Related Maculopathy|Age-Related Maculopathies|Eye Diseases|Retinal Degeneration|Macular Degeneration,Biological: RN6G|Biological: Placebo,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00877032
8944,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Completed,Has Results,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Drug: bendamustine|Drug: rituximab|Drug: vincristine|Drug: prednisone|Drug: cyclophosphamide|Drug: doxorubicin,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,4/30/2009,3/31/2012,https://ClinicalTrials.gov/show/NCT00877006
8945,Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery,Completed,Has Results,Acute Pain,Drug: CR845|Drug: Placebo,"Cara Therapeutics, Inc.","Cara Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,3/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00877799
8946,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Everolimus|Drug: Placebo|Drug: Trastuzumab|Drug: Paclitaxel,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/10/2009,10/23/2017,https://ClinicalTrials.gov/show/NCT00876395
8947,A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure,Completed,Has Results,Pulmonary Heart Disease,Drug: Definity,Lantheus Medical Imaging,Lantheus Medical Imaging,,,,,,,Phase 4,Industry,Interventional,7/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00918866
8948,Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects,Completed,Has Results,Sedation,Drug: Dexmedetomidine|Drug: Midazolam|Drug: Fentanyl|Drug: Morphine,"Hospira, now a wholly owned subsidiary of Pfizer","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,,Phase 3,Industry,Interventional,1/10/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00875550
8949,Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study,Completed,Has Results,Abdominal Aortic Aneurysms|Aorto-iliac Aneurysms|Juxtarenal Aneurysms,Device: Zenith(R) Fenestrated AAA Endovascular Graft,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,1/5/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT00875563
8950,Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin),Completed,Has Results,Hepatitis C Infection,Drug: Daclatasvir|Drug: Placebo|Drug: Peginterferon alpha-2a|Drug: ribavirin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,6/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00874770
8951,A Study for Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2409021|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,3/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00871572
8952,"Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status",Completed,Has Results,Colorectal Cancer,Drug: olaparib,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,5/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00912743
8953,"Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: Stribild|Drug: Atripla,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,4/9/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00869557
8954,A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Gemcitabine|Drug: Cisplatin|Biological: IMC-A12 (cixutumumab)|Biological: Cetuximab|Drug: Carboplatin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,3/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00870870
8955,Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression,Completed,Has Results,Bipolar Depression,Drug: lurasidone,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,4/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00868959
8956,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy),Completed,Has Results,Bipolar Depression,Drug: lurasidone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,4/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00868699
8957,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on),Completed,Has Results,Bipolar Depression,Drug: lurasidone + (lithium or divalproex)|Drug: Placebo + (lithium or divalproex),Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,4/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00868452
8958,Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years,Completed,Has Results,Tetanus|Acellular Pertussis|Diphtheria,Biological: GSK Biologicals'Kinrix®|Biological: Merck and Company's MMRII|Biological: Merck and Company's Varivax,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/31/2009,6/15/2010,https://ClinicalTrials.gov/show/NCT00871117
8959,Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 3,Industry,Interventional,3/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00868296
8960,The INFUSE - Anterior Myocardial Infarction (AMI) Study,Completed,Has Results,Acute Anterior Myocardial Infarction,Drug: Abciximab local infusion|Other: No local infusion|Procedure: Thrombus aspiration,Atrium Medical Corporation,Atrium Medical Corporation,,,,,,,Not Applicable,Industry,Interventional,9/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00976521
8961,Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST),Completed,Has Results,Gastrointestinal Stromal Tumor (GIST),Drug: imatinib mesylate,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/22/2009,12/20/2016,https://ClinicalTrials.gov/show/NCT00867113
8962,Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs,Completed,Has Results,Epilepsy With Simple or Complex Partial Onset Seizures,Drug: Eslicarbazepine acetate,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,4/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00866775
8963,Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation,Completed,Has Results,Cystic Fibrosis,Drug: VX-809|Drug: Placebo,Vertex Pharmaceuticals Incorporated,Vertex Pharmaceuticals Incorporated,,,,,,,Phase 2,Industry,Interventional,3/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00865904
8964,FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT,Completed,Has Results,Coronary Artery Disease,Other: Stenting plus OMT|Other: OMT|Other: Standard of care,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Phase 4,Industry,Interventional,5/10/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT01132495
8965,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,Completed,Has Results,Malignant Melanoma,Drug: ABI-007|Drug: Dacarbazine,Celgene|University of Arizona,Celgene,University of Arizona,,,,,,Phase 3,Industry|Other,Interventional,4/9/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00864253
8966,A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment,Completed,Has Results,Kidney Diseases|Coronary Artery Disease,Drug: Regadenoson|Drug: Placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 4,Industry,Interventional,4/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00863707
8967,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Completed,Has Results,Breast Cancer,Drug: Everolimus|Drug: Exemestane|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/3/2009,12/4/2014,https://ClinicalTrials.gov/show/NCT00863655
8968,A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Asthma|Coronary Artery Disease|Pulmonary Disease, Chronic Obstructive",Drug: Regadenoson|Drug: Placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 4,Industry,Interventional,4/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00862641
8969,Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI),Completed,Has Results,Brain Diseases|Spinal Cord Diseases,"Drug: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Drug: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Drug: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Drug: OptiMARK~0.1 mmol/kg BW",Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,8/5/2019,3/7/2019,https://ClinicalTrials.gov/show/NCT00862459
8970,Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: MMX Mesalamine,Shire,Shire,,,,,,,Phase 1,Industry,Interventional,10/10/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT01130844
8971,Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine,Completed,Has Results,Meningococcal Infections|Meningitis,Biological: Menactra®|Biological: Menomune®,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,,Industry,Observational,12/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00862277
8972,"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age",Completed,Has Results,Rubella|Mumps|Measles,Biological: GSK Biological's investigational vaccine 209762|Biological: M-M-R® II (Merck and Co)|Biological: Varivax®|Biological: Havrix®|Biological: Prevnar®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/3/2009,6/18/2012,https://ClinicalTrials.gov/show/NCT00861744
8973,Study of Immunotherapy to Treat Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Ipilimumab|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,5/9/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00861614
8974,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,Completed,Has Results,Hypertension,Drug: amlodipine|Drug: telmisartan|Drug: telmisartan and amlodipine,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,3/9/2019,,https://ClinicalTrials.gov/show/NCT00860262
8975,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age,Completed,Has Results,Healthy or Stable Underlying Chronic Medical Condition,Biological: Q/LAIV (MEDI3250)|Biological: FluMist/B/Yamagata|Biological: FluMist/B/Victoria,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2|Phase 3,Industry,Interventional,3/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00860067
8976,A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: ADVAIR DISKUS™ 250/50mcg|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,3/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00857766
8977,Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy,Completed,Has Results,Pain|Diabetic Neuropathy,Drug: AZD2066|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00857623
8978,Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00857415
8979,Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia,Completed,Has Results,Insomnia|Attention Deficit Hyperactivity Disorder,Drug: eszopiclone,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,5/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00857220
8980,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: insulin detemir|Drug: metformin,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,3/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00856986
8981,Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia,Completed,Has Results,Insomnia|Attention Deficit Hyperactivity Disorder,Drug: eszopiclone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,5/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00856973
8982,Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids,Completed,Has Results,Uterine Fibroids|Uterine Myomas,Device: Halt Procedure,"Acessa Health, Inc.","Acessa Health, Inc.",,,,,,,Not Applicable,Industry,Interventional,3/9/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00874029
8983,"A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,5/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00856544
8984,Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming,Completed,Has Results,Cardiovascular Disease,Behavioral: Therapy Programming Report (TPR),Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,,Industry,Observational,4/9/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00856349
8985,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Alogliptin|Drug: Metformin|Drug: Glipizide,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,3/9/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00856284
8986,Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE),Completed,Has Results,Gout,Biological: Rilonacept|Other: Placebo,Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00856206
8987,Study Utilizing Rilonacept in Gout Exacerbations,Completed,Has Results,Acute Gout Flare,Drug: Rilonacept|Drug: Indomethacin|Other: Placebo (for Indomethacin)|Other: Placebo (for Rilonacept),Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/9/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00855920
8988,Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea,Completed,Has Results,Papulopustular Rosacea,"Drug: Azelaic acid (Finacea, BAY39-6251)|Drug: Metronidazole (Metrogel)|Drug: Doxycycline (Oracea)",Bayer,Bayer,,,,,,,Phase 4,Industry,Interventional,2/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00855595
8989,A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia,Completed,Has Results,Erectile Dysfunction|Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00855582
8990,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,Completed,Has Results,Pulmonary Hypertension,"Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,2/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00855465
8991,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",Completed,Has Results,HIV|HIV Infections|Pregnancy,Drug: Darunavir|Drug: Ritonavir|Drug: Etravirine|Drug: Rilpivirine|Drug: Darunavir/Cobicistat (FDC),"Janssen Scientific Affairs, LLC","Janssen Scientific Affairs, LLC",,,,,,,Phase 3,Industry,Interventional,4/9/2009,8/11/2016,https://ClinicalTrials.gov/show/NCT00855335
8992,"A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).",Completed,Has Results,"Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,3/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00855218
8993,Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR,Completed,Has Results,Seasonal Allergic Rhinitis|Hayfever,Drug: Beclomethasone dipropionate HFA Nasal Aerosol|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,3/9/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00854360
8994,A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations,Completed,Has Results,Hypogonadism,Drug: Testosterone MD-Lotion,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,10/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00857454
8995,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Completed,Has Results,Pediculosis,Drug: Malathion gel 0.5%|Drug: Permethrin 1% rinse (Nix Crème),Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 3,Industry,Interventional,8/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00963508
8996,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Completed,Has Results,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Drug: Placebo|Drug: Aliskiren,Novartis Pharmaceuticals|The Cleveland Clinic|Novartis,Novartis Pharmaceuticals,The Cleveland Clinic,Novartis,,,,,Phase 3,Industry|Other,Interventional,3/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00853827
8997,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,Completed,Has Results,Chronic Heart Failure,Drug: Enalapril|Drug: Aliskiren,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/9/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT00853658
8998,Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction,Drug: avanafil,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 3,Industry,Interventional,3/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00853606
8999,Model 4396 Left Ventricular (LV) Lead Study,Completed,Has Results,Heart Failure,Device: Pacing Lead,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,3/9/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00853593
9000,"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,"Drug: CP 690,550|Drug: CP-690,550|Other: Placebo|Biological: Biologic TNFi",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,5/9/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00853385
9001,"Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis",Completed,Has Results,"Kidney Failure, Chronic",Drug: Placebo|Drug: Genz-644470|Drug: Sevelamer carbonate,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00853242
9002,Dose Finding Study of HP802-247 in Venous Leg Ulcers,Completed,Has Results,Venous Leg Ulcer|Venous Stasis Ulcers,Biological: HP802-247|Biological: Placebo (Vehicle),Healthpoint,Healthpoint,,,,,,,Phase 2,Industry,Interventional,2/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00852995
9003,Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: NVA237 12.5 µg once daily|Drug: NVA237 25.0 µg once daily|Drug: NVA237 12.5 µg twice daily|Drug: NVA237 50.0 µg once daily|Drug: NVA237 25.0 µg twice daily|Drug: NVA237 100.0 µg once daily|Drug: NVA237 50.0 µg twice daily|Drug: Placebo to NVA237 once daily,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,4/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01119950
9004,Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo|Drug: PF-06651600,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/20/2016,12/12/2017,https://ClinicalTrials.gov/show/NCT02969044
9005,Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Other: Placebo for Nasulin|Drug: Nasulin,CPEX Pharmaceuticals Inc.,CPEX Pharmaceuticals Inc.,,,,,,,Phase 2,Industry,Interventional,1/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00850096
9006,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: duloxetine|Drug: Placebo|Drug: fluoxetine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/9/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00849901
9007,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Placebo|Drug: fluoxetine|Drug: duloxetine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00849693
9008,Treatment With Pazopanib for Neoadjuvant Breast Cancer,Completed,Has Results,"Neoplasms, Breast",Drug: doxorubicin + cyclophosphamide|Drug: paclitaxel + pazopanib|Procedure: surgery|Drug: pazopanib monotherapy,GlaxoSmithKline|NSABP Foundation Inc,GlaxoSmithKline,NSABP Foundation Inc,,,,,,Phase 2,Industry|Other,Interventional,7/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00849472
9009,Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442),Completed,Has Results,Metastatic Androgen Independent Prostate Cancer,Biological: APC8015F,Dendreon,Dendreon,,,,,,,Phase 2,Industry,Interventional,4/4/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00849290
9010,Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158,Completed,Has Results,Ischemia,Drug: BMS747158,Lantheus Medical Imaging,Lantheus Medical Imaging,,,,,,,Phase 2,Industry,Interventional,1/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00849108
9011,Safety and Efficacy of Albiglutide in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00849056
9012,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Biological: albiglutide uptitration|Biological: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00849017
9013,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00848081
9014,"Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Alogliptin,Takeda,Takeda,,,,,,,Phase 1,Industry,Interventional,9/9/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00957268
9015,Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy,Completed,Has Results,Gastroesophageal Reflux,Drug: Dexlansoprazole MR QD,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,2/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00847808
9016,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Chlorthalidone|Drug: Azilsartan medoxomil,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,1/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00847626
9017,"A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00847613
9018,OptiVol® Care Pathway,Completed,Has Results,Heart Failure,Other: Monthly Review Arm|Other: Quarterly Review Arm,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Phase 4,Industry,Interventional,3/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00847288
9019,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00846586
9020,Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension,Completed,Has Results,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Olmesartan medoxomil-hydrochlorothiazide,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,3/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00846365
9021,Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis,Completed,Has Results,Gastroparesis|Diabetic Gastroparesis|Diabetes|Diabetes Mellitus|Delayed Gastric Emptying,Drug: metoclopramide|Drug: Placebo,Evoke Pharma,Evoke Pharma,,,,,,,Phase 2,Industry,Interventional,4/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00845858
9022,"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects",Completed,Has Results,Influenza|Orthomyxoviruses|Myxovirus Infection,Biological: Influenza virus vaccine - cell based (2007-2008 Formulation)|Biological: Influenza virus vaccine - cell-based (2007-2008 Formulation)|Biological: Influenza virus vaccine (2007-2008 Formulation),Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,10/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00845429
9023,Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas,Completed,Has Results,Metastatic Pancreatic Cancer,Drug: Albumin-bound paclitaxel (ABI-007)|Drug: Gemcitabine,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,3/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00844649
9024,Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure,Completed,Has Results,Heart Failure,Device: Medtronic PrimeADVANCED Neurostimulator,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Phase 2,Industry,Interventional,4/10/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT01112579
9025,Treatment for Aggression and Agitation in Patients With Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: LY451395|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,2/9/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00843518
9026,Migraine Study in Adolescent Patients,Completed,Has Results,Migraine Disorders,Drug: Sumatriptan and Naproxen Sodium|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00843024
9027,Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,4/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00840086
9028,A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,2/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00840034
9029,Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro|Drug: regular human insulin|Drug: recombinant human hyaluronidase PH20|Drug: Insulin glargine,Halozyme Therapeutics,Halozyme Therapeutics,,,,,,,Phase 2,Industry,Interventional,5/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00883558
9030,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: placebo to match albiglutide|Biological: albiglutide|Drug: metformin|Drug: glimepiride|Drug: pioglitazone|Drug: placebo to match pioglitazone,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00839527
9031,A Study for Participants With Pancreatic Cancer,Completed,Has Results,Pancreatic Neoplasms,Drug: LY2603618|Drug: Gemcitabine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1|Phase 2,Industry,Interventional,2/9/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00839332
9032,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: insulin glargine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/9/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00838916
9033,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: sitagliptin|Drug: glimepiride|Drug: metformin|Biological: placebo albiglutide|Drug: placebo sitagliptin|Drug: placebo glimepiride,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/9/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00838903
9034,Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years,Completed,Has Results,Overactive Bladder|Neurogenic Detrusor Overactivity,Drug: Fesoterodine,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00857896
9035,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",Drug: Pemetrexed|Drug: BIBW 2992|Drug: Cisplatin,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,8/14/2009,3/16/2017,https://ClinicalTrials.gov/show/NCT00949650
9036,Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer,Completed,Has Results,Cancer|Carcinoma|Castrate-Resistant Prostate Cancer|Prostate Cancer|Tumors,Drug: Denosumab,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,2/1/2009,5/3/2012,https://ClinicalTrials.gov/show/NCT00838201
9037,An Open Label Extension Study in Participants With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Biological: LY2127399,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,2/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00837811
9038,Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders,Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100|Drug: NaPBA,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 2,Industry,Interventional,3/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00947544
9039,A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC),Completed,Has Results,Bone Metastases|Castration-Resistant Prostate Cancer,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Docetaxel",Bayer,Bayer,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/10/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT01106352
9040,Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY),Completed,Has Results,Patients Indicated for an ICD,Device: ICD Therapy - ICD Lead Registry,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,,Industry,Observational,12/8/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00836589
9041,Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer,Completed,Has Results,"Carcinoma, Renal Cell",Drug: axitinib,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/9/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00835978
9042,Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: Butenafine cream 1% manufactured by Taro|Drug: Lotrimin Ultra (butenafine) 1%|Drug: Butenafine Vehicle manufactured by Taro,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00835510
9043,Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.,Completed,Has Results,Tetanus|Acellular Pertussis|Diphtheria,Biological: Boostrix®|Biological: Decavac™,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/17/2009,10/15/2009,https://ClinicalTrials.gov/show/NCT00835237
9044,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Completed,Has Results,Advanced Gastric Cancer,Drug: Everolimus|Drug: Everolimus placebo|Drug: Best Supportive Care (BSC),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,7/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00879333
9045,Zenith(R) Low Profile AAA Endovascular Graft Clinical Study,Completed,Has Results,Abdominal Aortic Aneurysms|Iliac Aneurysms|Aorto-iliac Aneurysms,Device: Zenith(R) Low Profile AAA Endovascular Graft,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,5/8/2019,6/16/2019,https://ClinicalTrials.gov/show/NCT00833924
9046,"A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma",Completed,Has Results,Basal Cell Carcinoma,Drug: Vismodegib 150 mg,"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,2/9/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT00833417
9047,Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix|Drug: Goserelin|Drug: Bicalutamide,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00833248
9048,Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension,Completed,Has Results,Hypertension,Drug: Aliskiren/Amlodipine|Drug: Amlodipine,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00853957
9049,"MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: Pomalidomide|Drug: Dexamethasone|Drug: Aspirin,Celgene Corporation,Celgene Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/8/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT00833833
9050,Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy,Completed,Has Results,Carcinoid Syndrome,Drug: Telotristat etiprate|Drug: Octreotide LAR Depot|Drug: Placebo,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/9/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00853047
9051,"A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain",Completed,Has Results,Cancer|Pain,Drug: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™,"AcelRx Pharmaceuticals, Inc.","AcelRx Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,4/9/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00833040
9052,ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals,Completed,Has Results,Opiate Dependence,Drug: Medisorb naltrexone 380 mg,"Alkermes, Inc.","Alkermes, Inc.",,,,,,,Phase 3,Industry,Interventional,3/9/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00834080
9053,PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1,Completed,Has Results,Intercritical Gout,Other: Placebo|Drug: Rilonacept 80 mg|Drug: Rilonacept 160 mg,Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00829829
9054,A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Trastuzumab emtansine|Drug: Lapatinib|Drug: Capecitabine,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,2/9/2019,9/15/2019,https://ClinicalTrials.gov/show/NCT00829166
9055,Bioequivalence Study of Two Imiquimod Cream 5%,Completed,Has Results,Actinic Keratosis,Drug: Imiquimod 5% manufactured by Taro|Drug: Aldara - Imiquimod 5%|Drug: Imiquimod Vehicle manufactured by Taro,Taro Pharmaceuticals USA,Taro Pharmaceuticals USA,,,,,,,Phase 1,Industry,Interventional,6/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00828568
9056,Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye,Completed,Has Results,Chalazion|Dry Eye Syndromes,Device: Manual Mini System|Device: iHeat Portable Warm Compress Therapy,"TearScience, Inc.","TearScience, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/9/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00832130
9057,Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors,Completed,Has Results,Neoplasms,Drug: PF-05212384 (also known as PKI-587),Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,1/10/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00940498
9058,Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients,Completed,Has Results,"Hepatitis C, Chronic",Drug: midazolam|Drug: BI 201335|Drug: tenofovir|Drug: caffeine|Drug: tolbutamide|Drug: pegylated interferon|Drug: BI 207127|Drug: ribavirin,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,4/12/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01525628
9059,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,Completed,Has Results,Multiple Sclerosis,Device: single-use autoinjector with a prefilled liquid Avonex syringe|Device: Avonex prefilled syringe via manual IM injection|Drug: BG9418 (interferon beta-1a),Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,1/9/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00828204
9060,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),Completed,Has Results,Coronary Artery Disease (CAD),Drug: regadenoson|Drug: overencapsulated caffeine|Radiation: technetium|Drug: placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 3,Industry,Interventional,3/24/2009,7/15/2010,https://ClinicalTrials.gov/show/NCT00826280
9061,"Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor",Completed,Has Results,Cervical Ripening|Induction of Labor,Drug: MVI 100|Drug: MVI 150|Drug: MVI 200,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,4/9/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00828711
9062,Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Placebo|Drug: tadalafil,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00827242
9063,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,Completed,Has Results,Coronary Artery Disease,Device: PROMUS Coronary Stent System|Device: PROMUS Element Coronary Stent System|Drug: Aspirin|Drug: Thienopyridine,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,1/9/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00823212
9064,Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myeloid Leukemia,Drug: CPX-351|Drug: Intensive Salvage Therapy,Jazz Pharmaceuticals|The Leukemia and Lymphoma Society,Jazz Pharmaceuticals,The Leukemia and Lymphoma Society,,,,,,Phase 2,Industry|Other,Interventional,2/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00822094
9065,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Indacaterol 150 µg|Drug: Salmeterol 50 µg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,1/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00821093
9066,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,Completed,Has Results,"Metastases, Brain",Drug: capecitabine|Drug: lapatinib|Drug: trastuzumab,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/14/2009,3/22/2018,https://ClinicalTrials.gov/show/NCT00820222
9067,Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis,Completed,Has Results,"Primary Focal Hyperhidrosis, Axilla",Device: DTS-G2 System|Device: DTS System (Sham treatment),Miramar Labs,Miramar Labs,,,,,,,Not Applicable,Industry,Interventional,6/9/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00931359
9068,PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors,Completed,Has Results,Colon Cancer|Colorectal Cancer|Rectal Cancer|Metastatic Colorectal Cancer,Drug: Panitumumab|Drug: Bevacizumab|Drug: mFOLFOX6,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,4/24/2009,7/7/2016,https://ClinicalTrials.gov/show/NCT00819780
9069,A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study),Completed,Has Results,Gout,Drug: Canakinumab|Drug: Colchicine|Drug: Allopurinol|Drug: Placebo Matching Canakinumab|Drug: Placebo Matching Colchicine,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,12/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00819585
9070,"Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin",Completed,Has Results,Obesity,Drug: Placebo|Drug: Pramlintide and Metreleptin,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,11/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00819234
9071,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,Completed,Has Results,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and hydrochlorothiazide,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,2/9/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00818883
9072,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Completed,Has Results,Alzheimer´s Disease,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg|Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg",Baxalta now part of Shire|Alzheimer's Disease Cooperative Study (ADCS)|Shire,Baxalta now part of Shire,Alzheimer's Disease Cooperative Study (ADCS),Shire,,,,,Phase 3,Industry|Other,Interventional,12/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00818662
9073,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 1356|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,12/8/2019,,https://ClinicalTrials.gov/show/NCT00819091
9074,4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma,Completed,Has Results,Asthma,Drug: Combivent CFC MDI|Drug: Albuterol HFA MDI|Drug: Respimat Combivent,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,12/8/2019,,https://ClinicalTrials.gov/show/NCT00818454
9075,Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung,Completed,Has Results,"Carcinoma, Non-small Cell",Drug: Dacomitinib (PF-00299804),Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/11/2009,4/30/2015,https://ClinicalTrials.gov/show/NCT00818441
9076,Actuation Indicator Trial in Patients With COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: Ipratropium bromide,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,6/9/2019,,https://ClinicalTrials.gov/show/NCT00928746
9077,A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients,Completed,Has Results,Cancer,Drug: PF-04691502,Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,12/9/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00927823
9078,Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients,Completed,Has Results,HIV Infections,Drug: Nevirapine XR|Drug: Nevirapine IR,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,12/8/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00819052
9079,Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms,Completed,Has Results,"Aortic Aneurysm, Abdominal",Device: Talent Abdominal Stent Graft,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,12/8/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00816062
9080,A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume,Completed,Has Results,"Bloodloss|Surgical Procedures, Operative",Drug: ecallantide|Drug: placebo,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 2,Industry,Interventional,3/9/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00816023
9081,Study of SyntheCelTM Dura Replacement to Other Dura Replacements,Completed,Has Results,Cranial Dura Repair,Device: SyntheCel|Device: Other FDA cleared dura replacements,"Synthes USA HQ, Inc.","Synthes USA HQ, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/6/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00859508
9082,Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age,Completed,Has Results,Influenza,Biological: Influenza virus vaccine (2004-2005 Formulation),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 1|Phase 2,Industry,Interventional,4/5/2019,12/6/2019,https://ClinicalTrials.gov/show/NCT00858468
9083,A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Drug: LY2495655|Drug: Placebo|Drug: Standard of Care Chemotherapy,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,12/11/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT01505530
9084,Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45),Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00857506
9085,Virtue® Male Incontinence Sling Study,Completed,Has Results,Stress Urinary Incontinence,Device: Virtue® Male Incontinence Sling,Coloplast A/S,Coloplast A/S,,,,,,,Not Applicable,Industry,Interventional,1/9/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00856778
9086,"A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/9/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00814307
9087,Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections,Completed,Has Results,Complicated Urinary Tract Infection,Drug: CXA-101|Drug: Ceftazidime,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 2,Industry,Interventional,6/30/2009,3/11/2010,https://ClinicalTrials.gov/show/NCT00921024
9088,Gammagard Liquid and rHuPH20 in PID,Completed,Has Results,Primary Immunodeficiency Diseases (PID),Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV),Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 3,Industry,Interventional,12/18/2008,11/11/2010,https://ClinicalTrials.gov/show/NCT00814320
9089,Clinical Evaluation of the Long‑Term Effects of Contact Lens Care Systems,Completed,Has Results,Myopia,Device: O2Optix contact lens|Device: Proclear contact lens|Device: ReNu MultiPlus Multi-Purpose Solution|Device: Clear Care Cleaning and Disinfecting Solution,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,9/1/2008,8/1/2009,https://ClinicalTrials.gov/show/NCT00813761
9090,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablet|Drug: Immediate release oxycodone,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,12/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00813488
9091,Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome,Completed,Has Results,Irritable Bowel Syndrome,Drug: LX1031 High Dose|Drug: LX1031 Low Dose|Drug: Placebo,Lexicon Pharmaceuticals,Lexicon Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00813098
9092,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides",Completed,Has Results,"Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",Drug: ABT-143|Drug: simvastatin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,11/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00812955
9093,Pediatric Bipolar Depression,Completed,Has Results,Bipolar Depression,Drug: Quetiapine XR|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,1/9/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00811473
9094,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),Completed,Has Results,Pulmonary Hypertension,"Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,12/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00810693
9095,Study of Phosphate Levels in Patients With Chronic Kidney Disease,Completed,Has Results,Chronic Kidney Disease,"Drug: 1.25 g PA21 (250 mg iron)|Drug: 5.0 g PA21 (1,000 mg iron)|Drug: 7.5 g PA21 (1,500 mg iron)|Drug: 10.0 g PA21 (2,000 mg iron)|Drug: 12.5 g PA21 (2,500 mg iron)|Drug: Sevelamer hydrochloride",Vifor Inc.,Vifor Inc.,,,,,,,Phase 2,Industry,Interventional,12/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00824460
9096,A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment,Completed,Has Results,Rheumatoid Arthritis,Drug: tocilizumab [RoActemra/Actemra]|Drug: methotrexate|Drug: placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,3/9/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00810199
9097,"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma",Completed,Has Results,Asthma,Drug: Levalbuterol|Drug: Levalbuterol UDV TID|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,12/8/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00809757
9098,Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D),Completed,Has Results,Erectile Dysfunction,Drug: placebo|Drug: avanafil,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 3,Industry,Interventional,12/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00809471
9099,Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer,Completed,Has Results,Small Cell Lung Cancer,Drug: Cabazitaxel|Drug: Topotecan,Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,3/12/2019,4/14/2019,https://ClinicalTrials.gov/show/NCT01500720
9100,"Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System",Completed,Has Results,Irritation/Irritant,Drug: 350 mg Donepezil Transdermal Patch|Drug: Placebo Patch,"Teikoku Pharma USA, Inc.","Teikoku Pharma USA, Inc.",,,,,,,Phase 2,Industry,Interventional,5/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00916383
9101,AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD),Completed,Has Results,Anxiety Disorders,Drug: AZD7325|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00808249
9102,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Completed,Has Results,Menopause|Osteoporosis,Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|Drug: bazedoxifene 20 mg|Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00808132
9103,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,Completed,Has Results,Atrial Fibrillation,Drug: dabigatran dose 1|Drug: dabigatran dose 2,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00808067
9104,Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325,Completed,Has Results,Anxiety Disorders,Drug: AZD7325|Drug: Lorazepam|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,12/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00807937
9105,Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery,Completed,Has Results,Acquired Bleeding Disorder|Cardiac Surgery Requiring Cardiopulmonary Bypass,Drug: catridecacog|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 2,Industry,Interventional,7/9/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00914589
9106,A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects,Completed,Has Results,"Arthritis, Juvenile Rheumatoid",Drug: Celecoxib|Drug: Naproxen,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,9/9/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00807846
9107,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Nintedanib (BIBF1120)|Drug: Pemetrexed|Drug: pemetrexed|Drug: B12|Drug: dexamethasone (or corticosteroid equivalent)|Drug: placebo|Drug: Folic Acid,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,12/8/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00806819
9108,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months,Completed,Has Results,Migraine Disorders,Drug: NP101,NuPathe Inc.|Teva Pharmaceutical Industries,NuPathe Inc.,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,2/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00806546
9109,Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients,Completed,Has Results,Idiopathic Restless Legs Syndrome,Drug: placebo and pregabalin|Drug: pramipexol|Drug: Pregabalin,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00806026
9110,A Study in the Treatment of Alcohol Dependence.,Completed,Has Results,Alcohol Dependence,Drug: LY686017|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,12/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00805441
9111,Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis,Completed,Has Results,Bronchiectasis,Drug: AZLI,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,12/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00805025
9112,A Study for the Treatment of Alcohol Dependence,Completed,Has Results,Alcohol Dependence,Drug: LY2196044|Drug: placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00804570
9113,A Study for Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2428757|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,12/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00804986
9114,Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders,Completed,Has Results,Autism Spectrum Disorders,Drug: Arbaclofen,"Seaside Therapeutics, Inc.","Seaside Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,2/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00846547
9115,"Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis",Completed,Has Results,Ankylosing Spondylitis,Biological: AIN457|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,3/9/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00809159
9116,"An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure",Completed,Has Results,Reversal of Coagulopathy,Biological: Beriplex® P/N (Kcentra)|Biological: Fresh frozen plasma,CSL Behring,CSL Behring,,,,,,,Phase 3,Industry,Interventional,2/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00803101
9117,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: Sodium Oxybate|Drug: Sodium Oxybate & 6 Tablets|Drug: Sodium Oxybate & 8 Tablets|Drug: Sodium Oxybate Oral Solution (6 grams),Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/10/2019,,https://ClinicalTrials.gov/show/NCT00803023
9118,Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™,Completed,Has Results,Diphtheria|Tetanus|Pertussis|Polio|Haemophilus Infection,Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,2/4/2019,9/5/2019,https://ClinicalTrials.gov/show/NCT00802867
9119,"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 1356|Drug: placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,12/8/2019,,https://ClinicalTrials.gov/show/NCT00800683
9120,The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial,Completed,Has Results,Atherosclerosis,Drug: Darapladib|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,12/1/2008,10/17/2013,https://ClinicalTrials.gov/show/NCT00799903
9121,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US,Completed,Has Results,"Infections, Papillomavirus",Biological: GSK Biological's HPV vaccine GSK580299 (Cervarix™),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/1/2009,8/2/2012,https://ClinicalTrials.gov/show/NCT00799825
9122,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,Completed,Has Results,Hepatocellular Carcinoma,Biological: IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|Biological: IMC-A12 (cixutumumab) - 20 mg/kg|Drug: Sorafenib,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,5/9/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00906373
9123,Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.,Completed,Has Results,Postoperative Pain,Drug: Oxymorphone IR,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,2/17/2009,4/18/2011,https://ClinicalTrials.gov/show/NCT00801398
9124,"Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency",Completed,Has Results,Cholesterol Ester Storage Disease (CESD)|Lysosomal Acid Lipase Deficiency|LAL-Deficiency,Drug: sebelipase alfa,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,12/12/2011,6/21/2017,https://ClinicalTrials.gov/show/NCT01488097
9125,Rollover Protocol for Prior SU011248 Protocols,Completed,Has Results,Solid Tumors,Drug: Sunitinib,Pfizer,Pfizer,,,,,,,Not Applicable,Industry,Interventional,3/4/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00798889
9126,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00798707
9127,Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients,Completed,Has Results,Acute Gout,Drug: Canakinumab|Drug: Triamcinolone acetonide,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,11/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00798369
9128,Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.,Completed,Has Results,Vitreomacular Adhesion,Drug: Ocriplasmin 125µg|Drug: Placebo,ThromboGenics,ThromboGenics,,,,,,,Phase 3,Industry,Interventional,12/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00798317
9129,A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols,Completed,Has Results,"Hepatitis C, Chronic",Drug: Pegylated-interferon alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,4/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00800735
9130,Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: OPC-34712|Drug: Placebo|Drug: ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 2,Industry,Interventional,5/9/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00797966
9131,Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: No Treatment Added|Drug: Milnacipran Added,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,11/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00797797
9132,A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization,Completed,Has Results,"Pneumonia, Bacterial",Drug: sulopenem and PF-03709270|Drug: Sulopenem and PF-03709270|Drug: Ceftriaxone and amoxicillin/clavulanate,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,1/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00797108
9133,A Study in Adult Patients With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2|Phase 3,Industry,Interventional,12/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00795821
9134,"A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550 or Placebo|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,4/12/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT01484561
9135,A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Tadalafil- Tablet or Oral suspension,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/17/2012,4/4/2019,https://ClinicalTrials.gov/show/NCT01484431
9136,A Study in Advanced Solid Tumors,Completed,Has Results,Solid Tumor,Drug: Cetuximab|Drug: Carboplatin|Drug: 5 - FU,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/10/2019,10/15/2019,https://ClinicalTrials.gov/show/NCT01063075
9137,SILS™ Port Laparoscopic Cholecystectomy Post Market Study,Completed,Has Results,Gallbladder Disease,Procedure: SILS™ port laparoscopic cholecystectomy|Procedure: Four Port Laparoscopic Cholecystectomy,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,4/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00832767
9138,A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia,Completed,Has Results,Nocturia|Prostatic Hyperplasia,Drug: silodosin,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,1/9/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00793819
9139,"A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period",Completed,Has Results,Migraine Disorders,Drug: sumatriptan and naproxen sodium combination tablet|Drug: sumatriptan tablet|Drug: naproxen sodium tablet,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,11/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00792636
9140,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months,Completed,Has Results,Migraine Disorders,Drug: NP101,NuPathe Inc.|Teva Pharmaceutical Industries,NuPathe Inc.,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,1/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00792103
9141,Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: No intervention,GlaxoSmithKline,GlaxoSmithKline,,,,,,,,Industry,Observational,12/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00791518
9142,An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease,Completed,Has Results,Ulcerative Colitis|Crohn's Disease,Drug: Vedolizumab,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,5/22/2009,10/31/2017,https://ClinicalTrials.gov/show/NCT00790933
9143,Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED,Completed,Has Results,Erectile Dysfunction,Drug: placebo|Drug: avanafil,"VIVUS, Inc.","VIVUS, Inc.",,,,,,,Phase 3,Industry,Interventional,11/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00790751
9144,Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Quetiapine XR|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,10/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00790192
9145,Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy,Completed,Has Results,Diffuse Large B-cell Lymphoma,Drug: Everolimus|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,7/24/2009,6/15/2016,https://ClinicalTrials.gov/show/NCT00790036
9146,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Colesevelam|Drug: Placebo|Drug: Pioglitazone,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,4/9/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00789750
9147,Welchol as Monotherapy for Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Welchol|Drug: Placebo,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,1/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00789737
9148,Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia,Completed,Has Results,Chronic Schizophrenia,Drug: Lurasidone HC1|Drug: Quetiapine XR,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,12/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00789698
9149,Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2189265 and Lifestyle Measures|Drug: Placebo solution and Lifestyle Measures,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,12/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00791479
9150,Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF),Completed,Has Results,In Vitro Fertilization,Drug: Progesterone,IBSA Institut Biochimique SA,IBSA Institut Biochimique SA,,,,,,,Phase 3,Industry,Interventional,12/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00828191
9151,Atorvastatin Three Year Pediatric Study,Completed,Has Results,Familial Hypercholesterolemia,Drug: atorvastatin,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,3/9/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00827606
9152,Trial of CPX-351 in Newly Diagnosed Elderly AML Patients,Completed,Has Results,Acute Myeloid Leukemia,Drug: CPX-351|Drug: Cytarabine|Drug: Daunorubicin,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00788892
9153,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),Completed,Has Results,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Drug: Everolimus|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,8/9/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00789828
9154,Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012,Completed,Has Results,"Carcinoma, Renal Cell",Drug: axitinib: observational study,Pfizer,Pfizer,,,,,,,,Industry,Observational,4/10/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT01056263
9155,"Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome",Completed,Has Results,Fragile X Syndrome,Drug: STX209|Drug: Placebo,"Seaside Therapeutics, Inc.","Seaside Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,11/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00788073
9156,Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO),Completed,Has Results,Hypertension|Heart Failure,Drug: Clevidipine|Drug: Standard of Care IV antihypertensive,The Medicines Company,The Medicines Company,,,,,,,Phase 3,Industry,Interventional,12/8/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00803634
9157,Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients,Completed,Has Results,Hepatitis C,Drug: Sofosbuvir|Drug: Placebo|Drug: PEG|Drug: RBV,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,1/10/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT01054729
9158,A Study of Nilotinib Versus Imatinib in GIST Patients,Completed,Has Results,Gastrointestinal Stromal Tumor (GIST),Drug: Nilotinib (AMN107)|Drug: imatinib (STI571),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/9/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00785785
9159,A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,11/8/2019,,https://ClinicalTrials.gov/show/NCT00785512
9160,An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia,Completed,Has Results,Primary Insomnia|Secondary Insomnia,Drug: LY2624803|Drug: Placebo|Drug: zolpidem,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,10/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00784875
9161,"A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.",Completed,Has Results,Dry Eye Syndromes,"Drug: CP-690,550|Drug: Cyclosporine|Drug: CP-690,550 Vehicle",Pfizer,Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,11/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00784719
9162,A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium Bromide|Drug: Fluticasone Propionate/Salmeterol,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,12/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00784550
9163,Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1,Completed,Has Results,HIV,Drug: Ibalizumab,TaiMed Biologics Inc.,TaiMed Biologics Inc.,,,,,,,Phase 2,Industry,Interventional,8/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00784147
9164,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: vedolizumab|Other: Placebo,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,1/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00783718
9165,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: vedolizumab|Other: Placebo,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,12/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00783692
9166,12 / 48 wk Pivotal PFT vs PBO in COPD II,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Olodaterol (BI 1744)|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,2/9/2019,,https://ClinicalTrials.gov/show/NCT00782509
9167,12 / 48 Week Pivotal PFT vs PBO in COPD I,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Olodaterol (BI1744)|Drug: placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/8/2019,,https://ClinicalTrials.gov/show/NCT00782210
9168,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin detemir|Drug: sitagliptin|Drug: metformin|Drug: sulphonylurea,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,11/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00789191
9169,Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,10/30/2008,9/1/2010,https://ClinicalTrials.gov/show/NCT00781937
9170,Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.,Completed,Has Results,Vitreomacular Adhesion,Drug: 125 µg Ocriplasmin|Drug: Placebo,ThromboGenics,ThromboGenics,,,,,,,Phase 3,Industry,Interventional,12/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00781859
9171,A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches,Completed,Has Results,Migraine,Drug: 91-day Levonorgestrel Oral Contraceptive|Drug: Placebo,Duramed Research|Teva Pharmaceutical Industries,Duramed Research,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,1/9/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00781456
9172,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Completed,Has Results,Stroke|Atrial Fibrillation|Embolism,Drug: warfarin tablets|Drug: Edoxaban tablets (high dose regimen-60mg)|Drug: Edoxaban tablets (low dose regimen-30mg)|Drug: placebo warfarin|Drug: placebo edoxaban,"Daiichi Sankyo, Inc.|The TIMI Study Group","Daiichi Sankyo, Inc.",The TIMI Study Group,,,,,,Phase 3,Industry|Other,Interventional,11/8/2019,5/13/2019,https://ClinicalTrials.gov/show/NCT00781391
9173,Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause,Completed,Has Results,Hot Flashes,Drug: Brisdelle (paroxetine mesylate)|Drug: Sugar pill,Noven Therapeutics,Noven Therapeutics,,,,,,,Phase 2,Industry,Interventional,11/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00786188
9174,PROvenge Treatment and Early Cancer Treatment,Completed,Has Results,Prostate Cancer,Other: Control|Biological: Sipuleucel-T,Dendreon,Dendreon,,,,,,,Phase 3,Industry,Interventional,10/1/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00779402
9175,Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris,Completed,Has Results,Psoriasis Vulgaris,Drug: Calcipotriene plus betamethasone dipropionate ointment,LEO Pharma,LEO Pharma,,,,,,,Phase 2,Industry,Interventional,7/9/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00817219
9176,Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine,Completed,Has Results,Meningitis|Meningococcemia|Pertussis|Tetanus|Diphtheria,Biological: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Biological: Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,4/5/2019,9/7/2019,https://ClinicalTrials.gov/show/NCT00777257
9177,Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma,Completed,Has Results,Recurrent Glioblastoma,Drug: Cediranib|Drug: Lomustine Chemotherapy|Drug: Placebo Cediranib,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,10/8/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT00777153
9178,Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer,Completed,Has Results,Advanced Breast Cancer|Breast Cancer,Drug: Neratinib|Drug: Lapatinib|Drug: Capecitabine,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",,,,,,,Phase 2,Industry,Interventional,2/4/2009,6/3/2018,https://ClinicalTrials.gov/show/NCT00777101
9179,Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.,Completed,Has Results,Hot Flashes,Drug: Gabapentin Extended-Release (G-ER) 1200 mg|Drug: Gabapentin Extended-Release (G-ER) 1800 mg|Drug: Placebo,Depomed,Depomed,,,,,,,Phase 3,Industry,Interventional,10/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00777023
9180,LINX Reflux Management System Clinical Study Protocol,Completed,Has Results,Gastroesophageal Reflux,Device: Magnetic Sphincter Augmentation,Torax Medical Incorporated,Torax Medical Incorporated,,,,,,,Not Applicable,Industry,Interventional,11/8/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00776997
9181,Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine,Completed,Has Results,Systemic Sclerosis|Scleroderma,Drug: treprostinil diethanolamine|Drug: placebo,United Therapeutics,United Therapeutics,,,,,,,Phase 2,Industry,Interventional,5/9/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00775463
9182,Influenza Vaccine Revaccination in Ambulatory Elderly Subjects,Completed,Has Results,Influenza|Orthomyxovirus Infection|Myxovirus Infection,Biological: Influenza Virus Vaccine USP Trivalent Types A and B,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,10/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00775450
9183,"A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.",Completed,Has Results,Major Depressive Disorder,Drug: Trazodone Hydrochloride (HCl) Extended-Release Tablets|Drug: Placebo,Labopharm Inc.,Labopharm Inc.,,,,,,,Phase 3,Industry,Interventional,6/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00775203
9184,A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer,Completed,Has Results,Carcinoma|Neuroendocrine Tumors,Biological: Cixutumumab|Drug: depot octreotide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,2/9/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT00781911
9185,An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome,Completed,Has Results,Carcinoid Syndrome,Drug: Lanreotide|Drug: Placebo,Ipsen,Ipsen,,,,,,,Phase 3,Industry,Interventional,5/9/2019,12/15/2019,https://ClinicalTrials.gov/show/NCT00774930
9186,Study Evaluating Changes In Mammographic Breast Density,Completed,Has Results,Osteoporosis,Drug: BZA 20 mg/CE 0.45 mg|Drug: BZA 20 mg/CE 0.625 mg|Drug: Raloxifene 60 mg|Drug: Placebo,Pfizer,Pfizer,,,,,,,,Industry,Observational,1/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00774267
9187,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Drug: Pancrelipase Delayed Release,Solvay Pharmaceuticals,Solvay Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/9/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00775528
9188,Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML),Completed,Has Results,Refractory Leukemia|Acute Myelogenous Leukemia,Drug: Panobinostat/LBH589,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00880269
9189,Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study),Completed,Has Results,Psoriasis|Plaque-type Psoriasis,Drug: Apremilast 10mg|Drug: Apremilast 20mg|Drug: Apremilast 30 mg|Drug: Placebo|Drug: Apremilast 30mg,Celgene Corporation,Celgene Corporation,,,,,,,Phase 2,Industry,Interventional,9/8/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00773734
9190,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Device: FlexTouch®|Device: FlexPen®,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,9/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00773279
9191,Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™,Completed,Has Results,Diphtheria|Tetanus|Haemophilus Infection|Pertussis|Polio,Biological: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,10/3/2019,11/6/2019,https://ClinicalTrials.gov/show/NCT00772928
9192,Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia,Completed,Has Results,Chronic Kidney Disease|Dialysis|Hyperphosphatemia,Drug: MCI-196,Mitsubishi Tanabe Pharma Corporation,Mitsubishi Tanabe Pharma Corporation,,,,,,,Phase 3,Industry,Interventional,12/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00772382
9193,Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults,Completed,Has Results,Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Biological: Influenza Virus Vaccine USP Trivalent Types A and B,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,10/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00772109
9194,Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: armodafinil|Drug: placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,9/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00772005
9195,A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy,Completed,Has Results,Crohn's Disease,Drug: Placebo (IP)|Drug: Ustekinumab 1mg/kg (IP)|Drug: Ustekinumab 3 mg/kg (IP)|Drug: Ustekinumab 6 mg/kg (IP)|Drug: Placebo IV - Responder - Placebo SC (MP)|Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Drug: Ustekinumab IV - Responder - Placebo SC (MP)|Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP)|Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP),"Centocor, Inc.","Centocor, Inc.",,,,,,,Phase 2,Industry,Interventional,12/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00771667
9196,Parastomal Reinforcement With Strattice,Completed,Has Results,Parastomal Hernia,Device: Strattice Reconstructive Matrix|Other: Standard ostomy creation,LifeCell,LifeCell,,,,,,,Phase 4,Industry,Interventional,12/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00771407
9197,"A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)",Completed,Has Results,Chronic Pancreatitis|Exocrine Pancreatic Insufficiency,Drug: Placebo|Drug: EUR-1008 (APT-1008) High Dose|Drug: EUR-1008 (APT-1008) Low Dose,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,1/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00788593
9198,Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms,Completed,Has Results,Overactive Bladder,Device: Urgent PC Neuromodulation System,"Uroplasty, Inc","Uroplasty, Inc",,,,,,,Phase 4,Industry,Interventional,9/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00771264
9199,Intradiscal rhGDF-5 Phase I/II Clinical Trial,Completed,Has Results,Degenerative Disc Disease,Drug: Intradiscal rhGDF-5,DePuy Spine,DePuy Spine,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/8/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00813813
9200,A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,9/8/2019,,https://ClinicalTrials.gov/show/NCT00770861
9201,A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Erlotinib|Drug: PF-00299804,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/8/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00769067
9202,Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer,Completed,Has Results,"Carcinoma, Non-Small Cell Lung",Drug: axitinib|Drug: chemotherapy,Pfizer,Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/9/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00768755
9203,"Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)",Completed,Has Results,"Hepatitis C, Chronic",Drug: BI 201335 NA 240 mg QD / LI|Drug: PegIFN/RBV|Drug: BI 201335 NA 120mg QD / LI|Drug: BI 201335 NA 240 mg QD|Drug: BI 201335 NA 240 mg BID|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,10/8/2019,,https://ClinicalTrials.gov/show/NCT00774397
9204,Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma,Completed,Has Results,Asthma,Drug: GW685698X,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00766090
9205,Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study,Completed,Has Results,ADHD,Drug: Lisdexamfetamine Dimesylate (LDX),Shire,Shire,,,,,,,Phase 3,Industry,Interventional,10/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00764868
9206,Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children,Completed,Has Results,Influenza,Biological: Fluarix|Biological: Fluzone,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/1/2008,6/1/2009,https://ClinicalTrials.gov/show/NCT00764790
9207,Reverse Shoulder Prosthesis Study,Completed,Has Results,Rotator Cuff Arthropathy|Failed Total Shoulder|Failed Hemi-arthroplasty,Device: Reverse Shoulder Prosthesis,"Encore Medical, L.P.","Encore Medical, L.P.",,,,,,,Phase 3,Industry,Interventional,10/2/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00764504
9208,Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis,Completed,Has Results,Scleroderma,Drug: dasatinib,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/9/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00764309
9209,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",Completed,Has Results,Diabetes Mellitus Type 2,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Pioglitazone|Drug: Metformin,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,9/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00763815
9210,Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia,Completed,Has Results,Leukemia,Drug: Midostaurin (PKC412),Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,10/13/2008,8/24/2017,https://ClinicalTrials.gov/show/NCT00782067
9211,Safety and Efficacy Study of the QuickFlex Micro Model 1258T Left Heart Pacing Lead,Completed,Has Results,Heart Failure,Device: QuickFlex Micro Model 1258T Left Heart Lead,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,10/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00763698
9212,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Completed,Has Results,Chronic Low Back Pain,Drug: ABT-712|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 3,Industry,Interventional,9/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00763321
9213,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,9/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00762411
9214,Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis,Completed,Has Results,Eosinophilic Esophagitis (EoE),Drug: budesonide|Drug: placebo,Shire,Shire,,,,,,,Phase 2,Industry,Interventional,11/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00762073
9215,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",Completed,Has Results,Non-small Cell Lung Cancer,Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Biological: Bevacizumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,12/8/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00762034
9216,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam",Completed,Has Results,Epilepsy,Drug: Brivaracetam,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,11/8/2019,3/17/2019,https://ClinicalTrials.gov/show/NCT00761774
9217,A Study to Compare the NexGen LPS and LPS-Flex Knee Implants,Completed,Has Results,Total Knee Arthroplasty|Osteoarthritis,Device: NexGen LPS-Flex Fixed Bearing Knee|Device: NexGen Legacy Posterior Stabilized Knee,Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,6/1/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00763386
9218,Phase 3 Clinical Study for the Treatment of Cold Sore,Completed,Has Results,Herpes Labialis,Drug: Acyclovir Lauriad|Drug: Placebo,Onxeo,Onxeo,,,,,,,Phase 3,Industry,Interventional,5/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00769314
9219,Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome,Completed,Has Results,Hunter Syndrome,Other: No treatment,Shire,Shire,,,,,,,,Industry,Observational,3/11/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT01449240
9220,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years,Completed,Has Results,Healthy Subjects,Biological: 13 valent pneumococcal conjugate vaccine,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00761631
9221,BAY 0 9867 Cipro Pediatric Use Study (QUIP),Completed,Has Results,Infectious Diseases,Drug: Ciprofloxacin|Drug: Non-quinolone antibiotic,Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,10/1/1999,1/8/2019,https://ClinicalTrials.gov/show/NCT00761462
9222,"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis",Completed,Has Results,Candidemia,Drug: Anidulafungin|Drug: Fluconazole,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/9/2019,2/18/2019,https://ClinicalTrials.gov/show/NCT00761267
9223,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Completed,Has Results,Chronic Low Back Pain,Drug: ABT-712|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 3,Industry,Interventional,9/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00761150
9224,"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B",Completed,Has Results,Hemophilia B,Biological: IB1001|Biological: nonacog alfa,Aptevo BioTherapeutics|Aptevo Therapeutics,Aptevo BioTherapeutics,Aptevo Therapeutics,,,,,,Phase 2|Phase 3,Industry,Interventional,1/9/2019,12/16/2019,https://ClinicalTrials.gov/show/NCT00768287
9225,Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections,Completed,Has Results,"Skin Diseases, Infectious|Skin Diseases, Bacterial",Drug: TR-701 200 mg|Drug: TR-701 300 mg|Drug: TR-701 400 mg,Trius Therapeutics LLC,Trius Therapeutics LLC,,,,,,,Phase 2,Industry,Interventional,9/17/2008,2/24/2009,https://ClinicalTrials.gov/show/NCT00761215
9226,A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION,Completed,Has Results,"Optic Neuropathy, Ischemic",Drug: No intervention,Pfizer,Pfizer,,,,,,,,Industry,Observational,11/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00759174
9227,Performance of the Hedrocel(R) Cervical Fusion Device,Completed,Has Results,Symptomatic Cervical Disc Disease,Device: Anterior Cervical Discectomy and Fusion,Zimmer Biomet,Zimmer Biomet,,,,,,,Phase 3,Industry,Interventional,12/1/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00758758
9228,Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer,Completed,Has Results,Tumor|Breast Cancer,Drug: NKTR-102,Nektar Therapeutics,Nektar Therapeutics,,,,,,,Phase 2,Industry,Interventional,10/8/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00802945
9229,Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin,Completed,Has Results,Type 2 Diabetes,"Drug: Saxagliptin, 5 mg + insulin|Drug: Placebo + insulin",AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,11/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00757588
9230,Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents,Completed,Has Results,Meningitis|Meningococcemia,Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,2/4/2019,4/5/2019,https://ClinicalTrials.gov/show/NCT00777790
9231,A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.,Completed,Has Results,Human Volunteer,Drug: minocycline extended release|Drug: Placebo,Medicis Pharmaceutical Corporation,Medicis Pharmaceutical Corporation,,,,,,,Phase 4,Industry,Interventional,11/6/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00765336
9232,Duloxetine for Multiple Sclerosis Pain,Completed,Has Results,Multiple Sclerosis,Drug: Duloxetine Hydrochloride (HCI)|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,10/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00755807
9233,Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women,Completed,Has Results,Hot Flashes,Drug: Gabapentin Extended-Release (G-ER) 1200 mg|Drug: Gabapentin Extended-Release (G-ER) 1800 mg|Drug: Placebo,Depomed,Depomed,,,,,,,Phase 3,Industry,Interventional,9/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00755417
9234,BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Completed,Has Results,Colon Cancer,Drug: BLI850|Drug: polyethylene glycol 3350 based bowel preparation,Braintree Laboratories,Braintree Laboratories,,,,,,,Phase 3,Industry,Interventional,8/8/2019,,https://ClinicalTrials.gov/show/NCT00756977
9235,BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Completed,Has Results,Colon Cancer,Drug: BLI850|Drug: polyethylene glycol 3350 based bowel preparation,Braintree Laboratories,Braintree Laboratories,,,,,,,Phase 3,Industry,Interventional,8/8/2019,,https://ClinicalTrials.gov/show/NCT00756548
9236,"An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler,Mannkind Corporation,Mannkind Corporation,,,,,,,Phase 2,Industry,Interventional,5/4/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00754624
9237,Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor,Completed,Has Results,Advanced Breast Cancer,Drug: Dasatinib|Drug: Fulvestrant,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,9/8/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00754325
9238,To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada),Completed,Has Results,Contraception,"Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Ortho Tri Cyclen Lo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,9/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00754065
9239,The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500|Biological: Placebo,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,8/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00755222
9240,Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: Certolizumab pegol,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,9/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00753454
9241,Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older,Completed,Has Results,Influenza,Biological: GSK Bio's influenza vaccine GSK2186877A|Biological: Fluarix TM,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/15/2008,1/5/2011,https://ClinicalTrials.gov/show/NCT00753272
9242,Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly,Completed,Has Results,Influenza,Biological: Influenza vaccine GSK2186877A|Biological: GSK Biologicals' Fluarix™,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/9/2008,12/15/2009,https://ClinicalTrials.gov/show/NCT00772889
9243,Flurbiprofen Tape for Treatment of Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Drug: Placebo Tape (Arm 1)|Drug: Flurbiprofen Tape (Arm 2)|Drug: Placebo Tape (Arm 3)|Drug: Flurbiprofen Tape (Arm 4),"Teikoku Pharma USA, Inc.","Teikoku Pharma USA, Inc.",,,,,,,Phase 2,Industry,Interventional,10/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00759330
9244,Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma,Completed,Has Results,T Cell Lymphoma,Drug: Fostamatinib Disodium,Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/9/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00798096
9245,Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure,Completed,Has Results,Chronic Heart Failure,Device: HeartWare® VAS,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Not Applicable,Industry,Interventional,8/8/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00751972
9246,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Placebo|Drug: Teriflunomide,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,8/8/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00751881
9247,"A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation",Completed,Has Results,Premature Ejaculation,Drug: GSK557296|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/23/2009,5/5/2011,https://ClinicalTrials.gov/show/NCT01021553
9248,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis,Completed,Has Results,Tinea Pedis|Athlete's Foot,Drug: NAFT-500|Drug: Placebo 2-weeks|Drug: Naftin 1%|Drug: Placebo 4-weeks,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 3,Industry,Interventional,8/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00750139
9249,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris,Completed,Has Results,Tinea Cruris|Jock Itch,Drug: NAFT-500|Drug: Placebo,"Merz North America, Inc.","Merz North America, Inc.",,,,,,,Phase 3,Industry,Interventional,9/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00750152
9250,"MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery",Completed,Has Results,Breast Cancer,Device: MarginProbe|Procedure: Lumpectomy,Dune Medical Devices,Dune Medical Devices,,,,,,,Not Applicable,Industry,Interventional,10/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00749931
9251,BI 10773 add-on to Metformin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: placebo|Drug: sitagliptin,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,8/8/2019,,https://ClinicalTrials.gov/show/NCT00749190
9252,Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance,Completed,Has Results,Restless Legs Syndrome|Restless Legs Syndrome (RLS),Drug: GSK1838262 Extended Release Tablets|Drug: Placebo,"XenoPort, Inc.","XenoPort, Inc.",,,,,,,Phase 3,Industry,Interventional,10/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00748098
9253,Safety and Effectiveness of the MED-EL Electric-Acoustic System,Completed,Has Results,Hearing Loss,Device: Electric Acoustic System,Med-El Corporation,Med-El Corporation,,,,,,,Not Applicable,Industry,Interventional,2/7/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00747435
9254,Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy,Completed,Has Results,"Sarcoma, Soft Tissue",Drug: PAZOPANIB|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00753688
9255,Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults,Completed,Has Results,West Nile Fever,Biological: ChimeriVax-WN02 vaccine|Biological: Placebo,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,10/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00746798
9256,A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty,Completed,Has Results,Postoperative Pain,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,8/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00745290
9257,Safety and Efficacy of the Vibrant Soundbridge (VSB) for Mixed and Conductive Hearing Losses,Completed,Has Results,Hearing Loss,Device: Vibrant Soundbridge,Med-El Corporation,Med-El Corporation,,,,,,,Not Applicable,Industry,Interventional,12/7/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00748540
9258,Spy II Clinical Registry,Completed,Has Results,Biliary Tract Diseases,Device: SpyGlass,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,11/6/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00751998
9259,Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist,Completed,Has Results,Fibrosis|Kidney Failure|Renal Insufficiency,"Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)",Bayer,Bayer,,,,,,,,Industry,Observational,11/8/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00744939
9260,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,Completed,Has Results,Hemorrhoids,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc","Pacira Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,8/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00744848
9261,Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Placebo|Drug: Dasatinib|Drug: Docetaxel|Drug: Prednisone,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,10/8/2019,7/15/2019,https://ClinicalTrials.gov/show/NCT00744497
9262,Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL),Completed,Has Results,Cataract,Device: modified light transmission intraocular lens|Device: monofocal acrylic intraocular lens,Abbott Medical Optics,Abbott Medical Optics,,,,,,,Phase 3,Industry,Interventional,12/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00747227
9263,Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients,Completed,Has Results,Hypertension|Type 2 Diabetes Mellitus,Drug: Nebivolol|Drug: Metoprolol ER|Drug: HCTZ,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,8/8/2019,,https://ClinicalTrials.gov/show/NCT00744237
9264,Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.,Completed,Has Results,Pneumococcal Disease|13-valent Pneumococcal Vaccine,Biological: 13-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/9/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00743652
9265,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",Completed,Has Results,Chronic Hepatitis C Virus Infection,Drug: ABT-333|Other: Placebo for ABT-333|Drug: Pegylated interferon|Drug: Ribavirin,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,3/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00851890
9266,"Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin",Completed,Has Results,Atrial Fibrillation,Drug: betrixaban|Drug: Warfarin,Portola Pharmaceuticals,Portola Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00742859
9267,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Completed,Has Results,Actinic Keratoses,Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel,Peplin,Peplin,,,,,,,Phase 3,Industry,Interventional,9/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00742391
9268,A Carotid Stenting Boston Scientific Surveillance Program,Completed,Has Results,Carotid Artery Disease,Device: Carotid WALLSTENT Monorail Endoprosthesis|Device: FilterWire EZ™ System™,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 4,Industry,Interventional,12/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00741091
9269,Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Inhaled treprostinil,United Therapeutics,United Therapeutics,,,,,,,Phase 4,Industry,Interventional,9/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00741819
9270,A Study for Treatment of Pain in Patients With Diabetic Neuropathy.,Completed,Has Results,"Diabetic Neuropathy, Painful",Drug: Placebo|Drug: Pregabalin|Drug: LY545694 21 mg|Drug: LY545694 49 mg|Drug: LY545694 105 mg,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00785577
9271,A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: azelastine HCl/fluticasone propionate|Drug: azelastine Hcl|Drug: fluticasone propionate|Drug: placebo,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00740792
9272,Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.,Completed,Has Results,Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome,Drug: Silodosin 8 mg|Drug: Placebo|Drug: Silodosin 4 mg,Watson Pharmaceuticals,Watson Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,9/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00740779
9273,Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Neratinib|Drug: Capecitabine,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,12/9/2008,6/18/2019,https://ClinicalTrials.gov/show/NCT00741260
9274,A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: MP-376|Drug: Placebo,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 2,Industry,Interventional,10/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00739648
9275,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin|Drug: Linagliptin Placebo|Drug: Glimepiride,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,8/8/2019,,https://ClinicalTrials.gov/show/NCT00740051
9276,An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Paliperidone extended release (ER)|Drug: Aripiprazole,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,12/9/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT01009047
9277,Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection,Completed,Has Results,Candidiasis|Candidemia,Drug: voriconazole (Vfend),Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00739934
9278,A Study of CX157 (TriRima) for the Treatment of Depression,Completed,Has Results,Major Depressive Disorder,Drug: CX157 (TriRima)|Drug: Placebo,CeNeRx BioPharma Inc.,CeNeRx BioPharma Inc.,,,,,,,Phase 2,Industry,Interventional,9/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00739908
9279,Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Completed,Has Results,Neurogenic Orthostatic Hypotension|Non-Diabetic Autonomic Neuropathy|Multiple System Atrophy|Dopamine Beta Hydroxylase Deficiency,Drug: Droxidopa|Drug: Placebo,Chelsea Therapeutics,Chelsea Therapeutics,,,,,,,Phase 3,Industry,Interventional,1/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00738062
9280,GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis,Completed,Has Results,Renal Failure|Hemodialysis,Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Procedure: Percutaneous Transluminal Angioplasty,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Phase 3,Industry,Interventional,9/8/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00737672
9281,"A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The ""EMERGE"" Trial",Completed,Has Results,Mantle Cell Lymphoma,Drug: lenalidomide,Celgene,Celgene,,,,,,,Phase 2,Industry,Interventional,12/22/2008,11/8/2017,https://ClinicalTrials.gov/show/NCT00737529
9282,Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Placebo Respimat|Drug: Tiotropium bromide 5 mcg|Drug: tiotropium bromide-low dose-2.5mcg,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,9/8/2019,,https://ClinicalTrials.gov/show/NCT00737100
9283,Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infections,Drug: ceftazidime/NXL104 + metronidazole|Drug: meropenem,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/31/2009,12/31/2009,https://ClinicalTrials.gov/show/NCT00752219
9284,"Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®",Completed,Has Results,Second Degree Burn,Device: Mepilex|Device: Silvadene,Molnlycke Health Care AB,Molnlycke Health Care AB,,,,,,,Not Applicable,Industry,Interventional,8/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00742183
9285,A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection,Completed,Has Results,Chronic Hepatitis B,Drug: Tenofovir disoproxil fumarate,Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,8/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00736190
9286,Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts,Completed,Has Results,Genital Warts,Drug: 2.5% imiquimod cream|Drug: 3.75% imiquimod cream|Drug: Placebo cream,"Graceway Pharmaceuticals, LLC","Graceway Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,8/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00735462
9287,Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptine 5 mg|Drug: linagliptine 5 mg and pioglitazone 30 mg,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,8/8/2019,,https://ClinicalTrials.gov/show/NCT00736099
9288,A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine,Completed,Has Results,Influenza,Biological: CSL Limited Influenza Virus Vaccine (Afluria®)|Biological: US Licensed Influenza Virus Vaccine (Fluzone®),Seqirus,Seqirus,,,,,,,Phase 4,Industry,Interventional,10/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00735475
9289,Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Completed,Has Results,Epilepsy,Drug: perampanel,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,10/8/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00735397
9290,Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: LDX 30 mg|Drug: LDX 50 mg|Drug: LDX 70 mg|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,10/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00735371
9291,Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients,Completed,Has Results,Hypertension,Drug: nebivolol|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,8/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00734630
9292,Follow-Up Study for Exubera,Completed,Has Results,Diabetes Mellitus,Drug: Exubera|Other: Randomized diabetes therapy,Pfizer,Pfizer,,,,,,,,Industry,Observational,8/8/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00734591
9293,Efficacy and Safety of SPD503 in Combination With Psychostimulants,Completed,Has Results,ADHD,Drug: SPD503-AM|Drug: SPD503-PM|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,9/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00734578
9294,A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: GSK561679|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/2/2008,6/18/2010,https://ClinicalTrials.gov/show/NCT00733980
9295,Pipeline for Uncoilable or Failed Aneurysms,Completed,Has Results,Intracranial Aneurysm,Device: Pipeline Embolization Device (PED),Medtronic Neurovascular Clinical Affairs,Medtronic Neurovascular Clinical Affairs,,,,,,,Not Applicable,Industry,Interventional,10/8/2019,9/22/2014,https://ClinicalTrials.gov/show/NCT00777088
9296,Use of NPSP558 in the Treatment of Hypoparathyroidism,Completed,Has Results,Hypoparathyroidism,Drug: Placebo|Drug: NPSP558,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,12/8/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00732615
9297,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Completed,Has Results,Non-Constipation Irritable Bowel Syndrome,Drug: Rifaximin|Drug: Placebo,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,7/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00731679
9298,Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.,Completed,Has Results,Attention-Deficit/Hyperactivity Disorder (ADHD),Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,10/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00776009
9299,Effects of the V1a Agonist FE 202158 in Patients With Septic Shock,Completed,Has Results,Septic Shock,Drug: FE 202158 1.25|Drug: FE 202158 2.5|Drug: FE 202158 3.75|Other: Placebo,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/9/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT01000649
9300,Study of New Implantable Loop Recorder,Completed,Has Results,Tachyarrhythmias|Syncope,Device: SJM Confirm,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,9/8/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00746564
9301,A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia (HPP),,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,,Industry,Observational,8/12/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01419028
9302,Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine,Completed,Has Results,Meningitis|Meningococcemia|Neisseria Meningitidis,"Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,3/3/2019,5/4/2019,https://ClinicalTrials.gov/show/NCT00772070
9303,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,Completed,Has Results,Diabetes Mellitus,Drug: Pioglitazone and metformin|Drug: Pioglitazone|Drug: Metformin,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,6/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00727857
9304,BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma,Completed,Has Results,Glioma,Drug: BIBW 2992|Drug: TMZ|Drug: BIBW 2992 plus TMZ,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,7/14/2008,5/25/2016,https://ClinicalTrials.gov/show/NCT00727506
9305,Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma,Completed,Has Results,Soft Tissue Sarcoma,Drug: TH-302,Threshold Pharmaceuticals,Threshold Pharmaceuticals,,,,,,,Phase 1|Phase 2,Industry,Interventional,8/8/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00742963
9306,Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390,Completed,Has Results,Hepatitis C,Drug: Eltrombopag|Drug: Antiviral therapy,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,9/9/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00996216
9307,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines,Completed,Has Results,Moderate to Severe Glabellar Frown Lines,Drug: IncobotulinumtoxinA (Xeomin) (20 Units)|Drug: Placebo,Merz Pharmaceuticals GmbH,Merz Pharmaceuticals GmbH,,,,,,,Phase 3,Industry,Interventional,10/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00770211
9308,Oral Cladribine in Early Multiple Sclerosis (MS),Completed,Has Results,Multiple Sclerosis,Drug: Cladribine|Drug: Placebo|Drug: Rebif® new formulation (RNF),EMD Serono,EMD Serono,,,,,,,Phase 3,Industry,Interventional,12/31/2008,4/30/2012,https://ClinicalTrials.gov/show/NCT00725985
9309,Study of GSK1363089 in Metastatic Gastric Cancer,Completed,Has Results,"Neoplasms, Gastrointestinal Tract",Drug: GSK1363089 (formerly XL880),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/31/2007,11/30/2009,https://ClinicalTrials.gov/show/NCT00725712
9310,Fibromyalgia Health Outcome Study on Cost of Treatments,Completed,Has Results,Fibromyalgia,Drug: Treatment for Fibromyalgia,Eli Lilly and Company,Eli Lilly and Company,,,,,,,,Industry,Observational,6/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00725101
9311,The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine,Completed,Has Results,Migraine Disorders,Drug: NP101 - Sumatriptan iontophoretic transdermal patch|Drug: Placebo,NuPathe Inc.|Teva Pharmaceutical Industries,NuPathe Inc.,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,1/9/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00724815
9312,A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC),Completed,Has Results,"Carcinoma, Renal Cell",Drug: foretinib (formerly GSK1363089 or XL880),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/30/2006,8/18/2010,https://ClinicalTrials.gov/show/NCT00726323
9313,Safety and Efficacy Study of Switching From Epzicom to Truvada,Completed,Has Results,HIV Infection,Drug: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|Drug: abacavir (ABC)/lamivudine (3TC),Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,7/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00724711
9314,FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer,Completed,Has Results,Colorectal Cancer|Colorectal Carcinoma|Liver Metastases,Device: SIR-Spheres yttrium-90 microspheres|Drug: Systemic chemotherapy (FOLFOX),Sirtex Medical,Sirtex Medical,,,,,,,Not Applicable,Industry,Interventional,8/6/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00724503
9315,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Completed,Has Results,Non-Constipation Irritable Bowel Syndrome,Drug: Rifaximin|Drug: Placebo,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,7/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00724126
9316,Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients,Completed,Has Results,Bipolar Disorder,Drug: lamictal,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,7/8/2019,8/13/2019,https://ClinicalTrials.gov/show/NCT00723450
9317,"Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)",Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: CLONICEL (Clonidine HCl sustained release),Shionogi|Shionogi Inc.,Shionogi,Shionogi Inc.,,,,,,Phase 3,Industry,Interventional,1/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00723190
9318,Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck,Completed,Has Results,"Neoplasms, Head and Neck",Drug: GSK1363089 (foretinib),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/27/2007,5/2/2009,https://ClinicalTrials.gov/show/NCT00725764
9319,Mobile - Bearing Knee Study,Completed,Has Results,Inflammatory Tissue Disorder|Osteoarthritis|Avascular Necrosis|Post-traumatic Arthritis|Secondary Arthritis,Device: Encore Mobile-Bearing Knee,"Encore Medical, L.P.","Encore Medical, L.P.",,,,,,,Phase 3,Industry,Interventional,1/1/2000,8/8/2019,https://ClinicalTrials.gov/show/NCT00765362
9320,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,Completed,Has Results,Breast Cancer,Drug: PD 0332991|Drug: letrozole,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/15/2008,12/20/2017,https://ClinicalTrials.gov/show/NCT00721409
9321,An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Disease-modifying anti-rheumatic drugs|Drug: Non-steroidal anti-inflammatory drugs|Drug: Oral corticosteroids,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,9/5/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00720798
9322,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: 0.15% azelastine hydrochloride,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00824473
9323,A Study to Compare the NexGen CR and CR-Flex Knee Implants,Completed,Has Results,Total Knee Arthroplasty|Osteoarthritis,Device: NexGen CR-Flex Fixed Bearing Knee|Device: NexGen CR Knee,Zimmer Biomet,Zimmer Biomet,,,,,,,Not Applicable,Industry,Interventional,9/4/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00761956
9324,A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: 0.15% azelastine hydrochloride|Drug: Mometasone furoate,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00720382
9325,A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: 0.15% azelastine hydrochloride 1644 mcg daily|Drug: 0.1% azelastine hydrochloride 1096 mcg daily|Drug: Placebo,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00720278
9326,A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo nasal spray|Drug: 0.15% azelastine hydrochloride Nasal Spray,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00719862
9327,Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections,Completed,Has Results,Skin Structure Infections|Bacterial Skin Diseases|Staphylococcal Skin Infections,Drug: delafloxacin|Drug: tigecycline,"Melinta Therapeutics, Inc.","Melinta Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,6/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00719810
9328,"Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A",Completed,Has Results,Hemophilia A,Biological: Human-cl rhFVIII|Biological: Kogenate FS,Octapharma,Octapharma,,,,,,,Phase 2,Industry,Interventional,5/10/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00989196
9329,The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers,Completed,Has Results,"Infections, Meningococcal",Biological: Meningococcal vaccine GSK134612,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/20/2008,3/28/2014,https://ClinicalTrials.gov/show/NCT00718666
9330,A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: Pioglitazone|Drug: MSDC-0160 90 mg|Drug: MSDC-0160 220 mg,Metabolic Solutions Development Company,Metabolic Solutions Development Company,,,,,,,Phase 2,Industry,Interventional,9/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00760578
9331,Study of Ramucirumab in Ovarian Cancer,Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,Biological: Ramucirumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/8/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00721162
9332,Vistakon Investigational Contact Lenses Worn for Daily Wear,Completed,Has Results,Myopia,Device: galyifilcon A control lens|Device: galyfilcon A with a silver additive,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,8/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00717249
9333,Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Certolizumab pegol (CZP)|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,7/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00717236
9334,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,Completed,Has Results,Relapsed Follicular Lymphoma,Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: VELCADE|Drug: prednisone,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,9/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00715208
9335,"Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)",Completed,Has Results,Hepatitis C,Drug: BI 201335|Drug: Pegylated Interferon-alpha (IFN)|Drug: Ribavirin (RBV),Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,9/9/2019,,https://ClinicalTrials.gov/show/NCT00984620
9336,To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen,Completed,Has Results,Prostate Cancer,Biological: sipuleucel-T,Dendreon,Dendreon,,,,,,,Phase 2,Industry,Interventional,10/8/2019,5/15/2019,https://ClinicalTrials.gov/show/NCT00715078
9337,AMPLATZER Duct Occluder II Clinical Study,Completed,Has Results,Patent Ductus Arteriosus,Device: AMPLATZER Duct Occluder II,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,8/8/2019,10/5/2016,https://ClinicalTrials.gov/show/NCT00713700
9338,Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: Asacol 400 mg,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,12/8/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00713310
9339,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies,Completed,Has Results,Perennial Allergic Rhinitis,Drug: 0.15% azelastine hydrochloride|Drug: 0.1% azelastine hydrochloride|Drug: Placebo,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,1/7/2019,,https://ClinicalTrials.gov/show/NCT00712920
9340,A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Biological: IMC-A12 (cixutumumab)|Drug: tamoxifen|Drug: Anastrozole|Drug: Letrozole|Drug: Exemestane|Drug: Fulvestrant,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/8/2019,2/15/2019,https://ClinicalTrials.gov/show/NCT00728949
9341,Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years,Completed,Has Results,Influenza,"Biological: A/turkey H5N1 vaccine|Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Biological: Placebo",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/11/2008,2/18/2011,https://ClinicalTrials.gov/show/NCT00719043
9342,3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs,Completed,Has Results,Post-menopausal Osteoporosis,Drug: Placebo|Drug: Zoledronic acid,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,5/8/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00718861
9343,"Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa",Completed,Has Results,Cystic Fibrosis|Lung Infection|Pseudomonas Aeruginosa,Drug: AZLI 75 mg three times daily (TID)|Drug: Placebo three times daily (TID),Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,5/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00712166
9344,Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections,Completed,Has Results,"Skin Diseases, Infectious",Drug: Daptomycin|Drug: Standard of Care (SOC),Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 4,Industry,Interventional,7/23/2008,10/11/2013,https://ClinicalTrials.gov/show/NCT00711802
9345,Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency,Completed,Has Results,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Drug: catridecacog,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00713648
9346,"A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease",Completed,Has Results,Alzheimer's Disease,Drug: SB-742457 15mg|Drug: SB-742457 35mg|Drug: Placebo|Drug: donepezil 5-10mg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/1/2008,11/16/2010,https://ClinicalTrials.gov/show/NCT00710684
9347,Iloprost Power 15 in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: iloprost (5 µg)|Drug: placebo,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,7/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00709956
9348,Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease,Completed,Has Results,Human Papilloma Virus (HPV),Device: cobas® 4800 HPV Test,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Not Applicable,Industry,Interventional,5/8/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00709891
9349,Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging,Completed,Has Results,Diagnostic Imaging|Central Nervous System Diseases,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Drug: Gadoteridol (ProHance)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,6/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00709852
9350,APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer|Metastatic Pancreatic Cancer,Drug: gemcitabine|Drug: placebo|Drug: Erlotinib|Drug: apricoxib,"Tragara Pharmaceuticals, Inc.","Tragara Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,8/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00709826
9351,Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: iloprost,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,9/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00709098
9352,Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib/nab-Paclitaxel,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,7/2/2008,1/3/2018,https://ClinicalTrials.gov/show/NCT00709761
9353,The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults,Completed,Has Results,"Infections, Meningococcal",Biological: Nimenrix|Procedure: Blood sampling,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/8/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00715910
9354,Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML),Completed,Has Results,"Leukaemia, Myelocytic, Acute",Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 1,Industry,Interventional,10/1/2008,6/22/2016,https://ClinicalTrials.gov/show/NCT00725283
9355,Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy,Completed,Has Results,Blood Coagulation Disorders|Acute Major Bleeding,Biological: Beriplex® P/N (Kcentra)|Biological: Fresh frozen plasma,CSL Behring,CSL Behring,,,,,,,Phase 3,Industry,Interventional,6/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00708435
9356,A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy,Completed,Has Results,Postoperative Ileus,Drug: Alvimopan|Drug: Placebo,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 4,Industry,Interventional,3/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00708201
9357,Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.,Completed,Has Results,Bone Metabolism,Drug: Pioglitazone|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 4,Industry,Interventional,5/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00708175
9358,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",Completed,Has Results,HIV Infection,Drug: Elvitegravir|Drug: Raltegravir|Drug: EVG placebo|Drug: RAL placebo|Drug: Background regimen,Gilead Sciences,Gilead Sciences,,,,,,,Phase 3,Industry,Interventional,7/8/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT00708162
9359,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Glipizide,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,6/8/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00707993
9360,Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing,Completed,Has Results,Allergic Asthma,Drug: Xolair,"Genentech, Inc.","Genentech, Inc.",,,,,,,,Industry,Observational,3/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00813748
9361,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole depot 300 or 400 mg|Drug: Aripiprazole 10-30 mg orally|Drug: Aripiprazole depot 25 or 50 mg|Drug: Placebo depot|Drug: Placebo tablets,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,9/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00706654
9362,Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne,Completed,Has Results,Acne Vulgaris,Drug: aminolevulinic acid HCL (ALA)|Other: Vehicle (VEH),"DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,3/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00706433
9363,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole depot|Drug: Placebo depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,Phase 3,Industry,Interventional,7/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00705783
9364,Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System,Completed,Has Results,Abdominal Aortic Aneurysms,Device: Endurant Stent Graft System,Medtronic Endovascular,Medtronic Endovascular,,,,,,,Not Applicable,Industry,Interventional,6/8/2019,9/26/2016,https://ClinicalTrials.gov/show/NCT00705718
9365,"A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza",Completed,Has Results,"Acute, Uncomplicated Human Influenza",Drug: Peramivir|Drug: Placebo,BioCryst Pharmaceuticals,BioCryst Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00705406
9366,A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia,Completed,Has Results,Waldenstrom Macroglobulinaemia,Biological: Ofatumumab,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/1/2009,2/1/2014,https://ClinicalTrials.gov/show/NCT00811733
9367,Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma,Completed,Has Results,Cancer,Drug: CGC-11047 and gemcitabine|Drug: CGC-11047 and docetaxel|Drug: CGC-11047 and bevacizumab|Drug: CGC-11047 and erlotinib|Drug: CGC-11047 and cisplatin|Drug: CGC-11047 and 5-flurouracil / leucovorin|Drug: CGC-11047 and sunitinib,Progen Pharmaceuticals,Progen Pharmaceuticals,,,,,,,Phase 1,Industry,Interventional,5/6/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00705874
9368,A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection,Completed,Has Results,Hepatitis C,Drug: PF-00868554|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00720434
9369,Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms,Completed,Has Results,GERD|Acid Reflux Disease|Heartburn|Regurgitation,Drug: AZD3355|Drug: Placebo|Drug: Gelusil®,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,5/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00703534
9370,Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans,Completed,Has Results,Asthma,Drug: Budesonide / formoterol fumarate (SYMBICORT)|Drug: Budesonide,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,6/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00702325
9371,"A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Avid Radiopharmaceuticals,,,,,,,Phase 2,Industry,Interventional,6/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00702143
9372,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: sitagliptin|Drug: metformin,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,6/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00700817
9373,Dose Comparison Study of Menactra® in US Children,Completed,Has Results,Meningitis|Meningococcal Infection|Neisseria Meningitidis,Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,6/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00700635
9374,A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations,Completed,Has Results,Hypogonadism,Drug: Testosterone MD-Lotion,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,6/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00702650
9375,Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26,Completed,Has Results,Meningitis|Meningococcemia,Biological: Meningococcal polysaccharide diphtheria toxoid conjugate,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,6/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00700713
9376,A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp),Completed,Has Results,Actinic Keratosis,Drug: PEP005 Topical Gel|Drug: Vehicle gel,Peplin,Peplin,,,,,,,Phase 2,Industry,Interventional,6/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00700063
9377,Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Completed,Has Results,Refractory Partial Seizures,Drug: E2007 (perampanel)|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,6/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00699972
9378,To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Completed,Has Results,Refractory Partial Seizures,Drug: E2007 (perampanel)|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,5/8/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00699582
9379,Oocyte Cryopreservation Registry (HOPE Registry),Completed,Has Results,Oocyte Cryopreservation,,EMD Serono,EMD Serono,,,,,,,,Industry,Observational,6/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00699400
9380,Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.,Completed,Has Results,Hypertension,Drug: Valsartan + HCTZ|Drug: Valsartan|Drug: HCTZ,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,4/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00698646
9381,Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer,Completed,Has Results,"Recurrent Small-cell Lung Cancer (SCLC)|Lung Cancer, Small Cell",Drug: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00698516
9382,Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density,Completed,Has Results,Osteoporosis,Drug: Placebo|Drug: DP001,Deltanoid Pharmaceuticals,Deltanoid Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00715676
9383,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil|Drug: Valsartan|Drug: Olmesartan|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,4/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00696436
9384,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Completed,Has Results,Hypertension,"Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Drug: Placebo",Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,6/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00696384
9385,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil and olmesartan|Drug: Olmesartan|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,6/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00696241
9386,Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: BI 1744 CL/tiotropium bromide fixed dose combination|Drug: tiotropium bromide|Device: Respimat® Inhaler,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,6/8/2019,,https://ClinicalTrials.gov/show/NCT00696020
9387,One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil with or without add-on chlorthalidone|Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,6/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00695955
9388,Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy,Completed,Has Results,Painful Diabetic Neuropathy,Drug: Placebo Gel|Drug: Clonidine Topical Gel (ARC-4558),Arcion Therapeutics Inc,Arcion Therapeutics Inc,,,,,,,Phase 2,Industry,Interventional,5/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00695565
9389,Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years,Completed,Has Results,Herpes Zoster,Biological: Herpes zoster vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,1/12/2009,7/2/2010,https://ClinicalTrials.gov/show/NCT00802464
9390,Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance,Completed,Has Results,Excessive Sleepiness,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 4,Industry,Interventional,9/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00711516
9391,MENOPUR® Versus FOLLISTIM®,Completed,Has Results,Infertility,Drug: Menotropin|Drug: Progestrone vaginal insert|Drug: follitropin beta|Drug: Progesterone in oil|Drug: Ganirelix,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,12/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00802360
9392,BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis,Completed,Has Results,Chronic Liver Disease,Device: c13 methacetin solution with breath analyzer,Exalenz Bioscience LTD.,Exalenz Bioscience LTD.,,,,,,,Phase 3,Industry,Interventional,8/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00736840
9393,Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet,Completed,Has Results,Psoriasis,Biological: Placebo|Biological: Adalimumab,Abbott,Abbott,,,,,,,Phase 4,Industry,Interventional,8/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00735787
9394,Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM),Completed,Has Results,"Carcinoma, Hepatocellular","Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,8/15/2008,11/28/2014,https://ClinicalTrials.gov/show/NCT00692770
9395,An Extension to Study MD7108240,Completed,Has Results,Macular Degeneration,Drug: Pazopanib,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,6/25/2008,9/9/2009,https://ClinicalTrials.gov/show/NCT00733304
9396,Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections,Completed,Has Results,Complicated Urinary Tract Infection,Drug: NXL104/ceftazidime|Drug: Imipenem/Cilastatin,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00690378
9397,"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",Completed,Has Results,Multiple Myeloma,"Drug: Lenalidomide and low-dose dexamethasone|Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|Drug: Melphalan, Prednisone and Thalidomide",Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,8/21/2008,7/14/2016,https://ClinicalTrials.gov/show/NCT00689936
9398,A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy,Completed,Has Results,"Arthritis, Rheumatoid",Biological: LY2127399|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,6/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00689728
9399,Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date,Completed,Has Results,Smoking Cessation,Drug: placebo|Drug: varenicline,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,9/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00691483
9400,Study of MLN8237 in Participants With Advanced Hematological Malignancies,Completed,Has Results,B-cell Follicular Lymphoma|B-cell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma|B-Cell Chronic Lymphocytic Leukemia|Multiple Myeloma|Waldenstrom's Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma|NK Lymphoma,Drug: Alisertib,"Millennium Pharmaceuticals, Inc.|Takeda","Millennium Pharmaceuticals, Inc.",Takeda,,,,,,Phase 1,Industry,Interventional,7/11/2008,10/19/2016,https://ClinicalTrials.gov/show/NCT00697346
9401,Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Mirabegron|Drug: Tolterodine|Drug: Placebo to Mirabegron|Drug: Placebo to Tolterodine,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 3,Industry,Interventional,4/25/2008,5/6/2010,https://ClinicalTrials.gov/show/NCT00688688
9402,Evaluation of Dermal Closure With an Absorbable Barbed Suture as Compared to a Conventional Absorbable Suture,Completed,Has Results,Breast Ptosis|Obesity,Device: V-Loc 180/90 Wound Closure Device|Device: 3-0 Monocryl Absorbable Sutures,Medtronic - MITG,Medtronic - MITG,,,,,,,Not Applicable,Industry,Interventional,8/9/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00959374
9403,Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris,Completed,Has Results,Severe Acne Vulgaris,Drug: Adapalene BPO Gel associated with Doxycyline Hyclate|Drug: Vehicle Gel associated with Doxycycline Hyclate,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,8/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00688064
9404,Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance,Completed,Has Results,Acne,Drug: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Drug: Vehicle Gel,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,11/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00687908
9405,Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder,Completed,Has Results,"Bladder, Neurogenic",Drug: tamsulosin hydrochloride|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2|Phase 3,Industry,Interventional,1/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00796614
9406,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Cisplatin|Drug: Etoposide|Drug: Vinorelbine|Drug: Paclitaxel|Drug: Carboplatin|Radiation: Thoracic Radiation Therapy (TRT),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,9/8/2019,11/14/2019,https://ClinicalTrials.gov/show/NCT00686959
9407,"A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants",Completed,Has Results,Healthy,"Biological: MEDI-534, Cohort 1|Other: Placebo, Cohort 1|Biological: MEDI-534, Cohort 2|Other: Placebo, Cohort 2|Biological: MEDI-534, Cohort 3|Other: Placebo, Cohort 3|Biological: MEDI-534, Cohort 4|Other: Placebo, Cohort 4|Biological: MEDI-534, Cohort 5|Other: Placebo, Cohort 5",MedImmune LLC,MedImmune LLC,,,,,,,Phase 1|Phase 2,Industry,Interventional,6/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00686075
9408,Safety and Efficacy of AIN457 in Noninfectious Uveitis,Completed,Has Results,Non-infectious Uveitis,Drug: AIN457|Drug: AIN 457,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,6/8/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00685399
9409,Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL),Completed,Has Results,"Skin Infections, Bacterial","Drug: Retapamulin Ointment, 1%|Drug: Placebo ointment",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00684177
9410,Add-on to Thiazolidinedione (TZD) Failures,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin|Drug: Thiazolidinedione (Pioglitazone),"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",AstraZeneca,"Astra Zeneca, Bristol-Myers Squibb",,,,,,Phase 3,Industry|Other,Interventional,7/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00683878
9411,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF),Completed,Has Results,Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Drug: Pancrelipase Delayed Release|Drug: Placebo Comparator,Solvay Pharmaceuticals,Solvay Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,6/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00690820
9412,Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women,Completed,Has Results,Vasomotor Symptoms,Drug: desvenlafaxine succinate (DVS) SR|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00683800
9413,A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer,Completed,Has Results,Prostate Cancer,Biological: IMC-A12|Drug: Mitoxantrone|Drug: Prednisone|Biological: IMC-1121B (ramucirumab),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/8/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00683475
9414,Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,7/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00683657
9415,Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease,Completed,Has Results,Symptomatic Refractory Resistant Carcinoid Disease,Drug: Pasireotide|Drug: Octreotide,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00690430
9416,A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: fluticasone furoate nasal spray|Drug: vehicle placebo nasal spray,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,6/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00682643
9417,Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma,Completed,Has Results,"Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin",Drug: PCI-24781,Pharmacyclics LLC.,Pharmacyclics LLC.,,,,,,,Phase 1|Phase 2,Industry,Interventional,7/8/2019,,https://ClinicalTrials.gov/show/NCT00724984
9418,Fibrin Sealant for the Sealing of Dura Sutures,Completed,Has Results,Pathological Processes in the Posterior Fossa|Dura Defects,"Biological: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Procedure: Standard of care",Baxter Healthcare Corporation,Baxter Healthcare Corporation,,,,,,,Phase 2,Industry,Interventional,5/8/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00681824
9419,30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease,Completed,Has Results,Dyslipidemia|Kidney Disease,Drug: ABT-335 plus rosuvastatin|Drug: Rosuvastatin,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,6/8/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00680017
9420,Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Rosiglitazone|Drug: Metformin,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,4/21/2008,9/16/2010,https://ClinicalTrials.gov/show/NCT00679939
9421,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,"Procedure: Blood sampling, endoscopy|Drug: budesonide-MMX® 6 mg|Drug: budesonide-MMX® 9 mg|Drug: Placebo|Drug: Asacol® 400 mg","Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,6/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00679432
9422,Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: otelixizumab infusion plus physician determined standard of care|Biological: placebo infusion plus physician determined standard of care,GlaxoSmithKline|Juvenile Diabetes Research Foundation,GlaxoSmithKline,Juvenile Diabetes Research Foundation,,,,,,Phase 3,Industry|Other,Interventional,7/29/2008,1/31/2012,https://ClinicalTrials.gov/show/NCT00678886
9423,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Completed,Has Results,Kidney Neoplasms,Drug: Axitinib (AG-013736)|Drug: Sorafenib,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/3/2008,2/25/2016,https://ClinicalTrials.gov/show/NCT00678392
9424,"Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,"Drug: CP-690,550|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,7/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00678210
9425,"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,COPD,Drug: Indacaterol|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,5/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00677807
9426,Study of Denosumab in Subjects With Giant Cell Tumor of Bone,Completed,Has Results,Cancer|Giant Cell Tumors|Giant Cell Tumor of Bone|Benign Giant Cell Tumors,Drug: Denosumab,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,9/9/2008,5/17/2018,https://ClinicalTrials.gov/show/NCT00680992
9427,"Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients",Completed,Has Results,Cystic Fibrosis (CF),Drug: MP-376|Drug: Placebo,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 2,Industry,Interventional,6/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00677365
9428,Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients,Completed,Has Results,Restless Legs Syndrome,Drug: placebo|Drug: Pregabalin,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,4/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00676403
9429,A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Completed,Has Results,"Arthritis, Rheumatoid",Drug: CNTO 136 100 mg|Drug: CNTO 136 50 mg|Drug: CNTO 136 25 mg|Drug: Placebo|Drug: Methotrexate,"Centocor, Inc.","Centocor, Inc.",,,,,,,Phase 2,Industry,Interventional,8/11/2008,3/3/2011,https://ClinicalTrials.gov/show/NCT00718718
9430,Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK233705 12.5mcg|Drug: GSK233705 25mcg|Drug: GSK233705 50mcg|Drug: GSK233705 100mcg|Drug: GSK233705 200mcg|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,5/16/2008,12/22/2008,https://ClinicalTrials.gov/show/NCT00676052
9431,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),Completed,Has Results,Thromboembolism,Drug: Warfarin|Drug: Dabigatran etexilate,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,4/8/2019,,https://ClinicalTrials.gov/show/NCT00680186
9432,"A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes",Completed,Has Results,"Diabetes Mellitus, Type 2",Device: Accu-Chek 360° View Blood Glucose Analysis Tool|Device: Accu-Chek Aviva Glucose Meter,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Not Applicable,Industry,Interventional,3/8/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00674986
9433,Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts,Completed,Has Results,Genital Warts,Drug: Imiquimod|Drug: 3.75% imiquimod cream|Drug: placebo cream,"Graceway Pharmaceuticals, LLC","Graceway Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,5/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00674739
9434,"Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects",Completed,Has Results,Overweight|Obesity,Drug: pramlintide acetate|Drug: metreleptin|Drug: placebo-P|Drug: placebo-M,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,4/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00673387
9435,The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease,Completed,Has Results,Hypertension|Coronary Artery Disease,Drug: Nebivolol|Drug: Carvedilol,Forest Laboratories,Forest Laboratories,,,,,,,Phase 4,Industry,Interventional,5/8/2019,,https://ClinicalTrials.gov/show/NCT00673075
9436,Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Completed,Has Results,Lower Back Pain,Drug: Carisoprodol SR 700 mg|Drug: Carisoprodol SR 500 mg|Drug: Placebo,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00671879
9437,A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Completed,Has Results,Lower Back Pain,Drug: Carisoprodol SR|Drug: Placebo,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00671502
9438,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,Completed,Has Results,Breast Cancer|Melanoma,Drug: Lymphoseek,Navidea Biopharmaceuticals,Navidea Biopharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00671918
9439,AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery,Completed,Has Results,Left Atrial Appendage Exclusion,Device: AtriCure LAA Exclusion System,"AtriCure, Inc.","AtriCure, Inc.",,,,,,,Phase 2,Industry,Interventional,9/8/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00779857
9440,Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH),Completed,Has Results,Benign Prostatic Hypertrophy,Drug: Cetrorelix Pamoate,AEterna Zentaris,AEterna Zentaris,,,,,,,Phase 3,Industry,Interventional,3/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00670306
9441,Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis,Completed,Has Results,Bronchiectasis,Drug: Inhaled mannitol|Drug: Matched control,Pharmaxis,Pharmaxis,,,,,,,Phase 3,Industry,Interventional,11/9/2019,1/14/2019,https://ClinicalTrials.gov/show/NCT00669331
9442,"Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients",Completed,Has Results,Rheumatoid Arthritis,Biological: AIN457|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 1|Phase 2,Industry,Interventional,12/5/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00669942
9443,Escitalopram in Adult Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Escitalopram|Drug: Placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,4/8/2019,,https://ClinicalTrials.gov/show/NCT00668525
9444,Corneal Collagen Cross-Linking for Ectasia (CXL),Completed,Has Results,Ectasia,Drug: riboflavin ophthalmic solution|Device: UVA Irradiation,"Avedro, Inc.","Avedro, Inc.",,,,,,,Phase 3,Industry,Interventional,12/7/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00674661
9445,Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD,Completed,Has Results,Cervical Degenerative Disc Disease,Device: PRESTIGE® LP Cervical Disc|Device: ATLANTIS Anterior Cervical Plate,Medtronic Spinal and Biologics,Medtronic Spinal and Biologics,,,,,,,Phase 3,Industry,Interventional,1/5/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00667459
9446,Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty,Completed,Has Results,Precocious|Leuprolide Acetate|Luteinizing Hormone (LH)|Gonadotrophin-releasing Hormone Agonist (GnRHa)|Tanner Staging|Depot Formulation|Suppression of LH|Central Precocious Puberty (CPP)|Gonadotrophin-releasing Hormone (GnRH)|Lupron|GnRH Analog|Pediatrics Central Precocious Puberty,Drug: Leuprolide Acetate 3 Month Depot,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 3,Industry,Interventional,12/8/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00667446
9447,"Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)",Completed,Has Results,Major Depressive Disorder,Drug: vilazodone|Drug: placebo,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,3/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00683592
9448,Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Fostamatinib disodium (R935788)|Drug: Placebo,Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00665925
9449,Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3),Completed,Has Results,Rheumatoid Arthritis,Drug: Fostamatinib disodium (R935788)|Drug: Placebo,Rigel Pharmaceuticals,Rigel Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00665626
9450,Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE),Completed,Has Results,Hypertension|Hemorrhage,Drug: clevidipine,The Medicines Company,The Medicines Company,,,,,,,Phase 3,Industry,Interventional,6/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00666328
9451,"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents",Completed,Has Results,HIV-1,Drug: Etravirine (TMC125)|Drug: Optimized background regimen (OBR),"Tibotec Pharmaceuticals, Ireland","Tibotec Pharmaceuticals, Ireland",,,,,,,Phase 2,Industry,Interventional,11/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00665847
9452,Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy,Completed,Has Results,Multifocal Motor Neuropathy,"Biological: Immune Globulin Intravenous (human), 10%|Biological: 0.25% human albumin solution (Placebo)",Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 3,Industry,Interventional,8/8/2019,9/11/2019,https://ClinicalTrials.gov/show/NCT00666263
9453,Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years,Completed,Has Results,Influenza,Biological: GSK A/turkey H5N1 Influenza vaccine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,10/16/2008,12/4/2009,https://ClinicalTrials.gov/show/NCT00771615
9454,Phase IIIB Switching From Intravenous to Subcutaneous Study,Completed,Has Results,"Arthritis, Rheumatoid",Drug: Abatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,5/8/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00663702
9455,"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",Completed,Has Results,Complicated Urinary Tract Infection|Pyelonephritis,Drug: CXA-201|Drug: Levofloxacin,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 3,Industry,Interventional,6/20/2011,9/4/2013,https://ClinicalTrials.gov/show/NCT01345929
9456,Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer,Completed,Has Results,Breast Cancer|Advanced Malignant Solid Tumors,Drug: neratinib|Drug: vinorelbine,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,4/29/2008,6/7/2018,https://ClinicalTrials.gov/show/NCT00706030
9457,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,Completed,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00663026
9458,A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Mirabegron|Drug: Placebo,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 3,Industry,Interventional,3/28/2008,4/22/2009,https://ClinicalTrials.gov/show/NCT00662909
9459,A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: celecoxib|Drug: tramadol HCL,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00662558
9460,A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer,Completed,Has Results,Bladder Cancer|Transitional Cell Bladder Cancer|Urethra Cancer|Ureter Cancer|Renal Pelvis Cancer,Drug: AZD4877,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,5/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00661609
9461,Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women,Completed,Has Results,Osteoporosis|Postmenopausal Osteoporosis,Drug: Placebo|Drug: BA058 80 mcg|Drug: teriparatide,"Radius Health, Inc.","Radius Health, Inc.",,,,,,,Phase 3,Industry,Interventional,4/11/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT01343004
9462,"Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US",Completed,Has Results,Gastroesophageal Reflux Disease,Drug: Esomeprazole|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,4/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00660660
9463,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: macitentan (ACT-064992)|Drug: placebo,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,5/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00660179
9464,A Study for Patient With Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,9/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00767806
9465,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole sodium|Drug: Esomeprazole,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,2/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00658632
9466,A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate (ACP-103),ACADIA Pharmaceuticals Inc.,ACADIA Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,3/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00658567
9467,Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients,Completed,Has Results,Kidney Transplantation,"Drug: Cyclosporine|Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/8/2019,6/15/2019,https://ClinicalTrials.gov/show/NCT00658359
9468,Black Widow Spider Antivenin for Patients With Systemic Latrodectism,Completed,Has Results,Latrodectism,Drug: Analatro|Drug: Saline,Instituto Bioclon S.A. de C.V.|Rare Disease Therapeutics Inc.,Instituto Bioclon S.A. de C.V.,Rare Disease Therapeutics Inc.,,,,,,Phase 3,Industry|Other,Interventional,10/9/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00657540
9469,"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis",Completed,Has Results,Psoriasis,Drug: clobetasol propionate spray 0.05%|Drug: calcitriol ointment,"Galderma Laboratories, L.P.","Galderma Laboratories, L.P.",,,,,,,Phase 3,Industry,Interventional,3/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00658788
9470,Panitumumab in Children With Solid Tumors,Completed,Has Results,Solid Tumors,Biological: Panitumumab,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,3/8/2019,3/15/2019,https://ClinicalTrials.gov/show/NCT00658658
9471,Study of APD421 as PONV Treatment (Prior Prophylaxis),Completed,Has Results,Postoperative Nausea and Vomiting,Drug: APD421|Drug: Placebo,Acacia Pharma Ltd,Acacia Pharma Ltd,,,,,,,Phase 3,Industry,Interventional,3/16/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT02646566
9472,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: placebo|Drug: BIBW 2992,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,4/8/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00656136
9473,A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency,Completed,Has Results,Exocrine Pancreatic Insufficiency|Steatorrhea|Malabsorption Syndromes|Cystic Fibrosis,"Drug: Pancrease MT 10.5, or MT 21|Drug: Placebo for Pancrease MT 10.5 or MT 21","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 3,Industry,Interventional,8/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00662675
9474,FUTURE 3 Study Extension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Bosentan,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,3/8/2011,8/13/2014,https://ClinicalTrials.gov/show/NCT01338415
9475,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR b.i.d. (Twice Daily),Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,11/3/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00654927
9476,"18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics",Completed,Has Results,Type 2 Diabetes|Hypertension,Drug: Amlodipine|Drug: amlodipine / olmesartan medoxomil combination|Drug: Hydrochlorothiazide,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 4,Industry,Interventional,5/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00654745
9477,"A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer",Completed,Has Results,Tumors,Drug: Fosbretabulin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Bevacizumab,Mateon Therapeutics,Mateon Therapeutics,,,,,,,Phase 2,Industry,Interventional,3/8/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00653939
9478,A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: levocetirizine dihydrochloride|Drug: placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 4,Industry,Interventional,4/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00653224
9479,Multicenter Continuous Peripheral Nerve Block Surveillance Study,Completed,Has Results,Postoperative Pain,Device: Ultrasound imaging|Device: Peripheral nerve stimulator,Halyard Health,Halyard Health,,,,,,,Not Applicable,Industry,Interventional,5/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00653133
9480,APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer,Completed,Has Results,Recurrent Non Small Cell Lung Cancer,Drug: apricoxib/erlotinib|Drug: erlotinib/placebo,"Tragara Pharmaceuticals, Inc.","Tragara Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,4/8/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00652340
9481,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,Completed,Has Results,Venous Thromboembolism,Drug: Enoxaparin|Drug: Dabigatran etexilate,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,3/8/2019,,https://ClinicalTrials.gov/show/NCT00657150
9482,Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major Depressive Disorder",Drug: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR),Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 2,Industry,Interventional,5/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00669110
9483,Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®,Completed,Has Results,Paget's Disease of the Bone|Hypocalcemia,"Drug: Reclast (ZOL446, zoledronic acid)|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D",Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 4,Industry,Interventional,5/8/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00668200
9484,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: azelastine Hcl|Drug: azelastineHcl / fluticasone propionate|Drug: fluticasone propionate,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00651118
9485,Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study,Completed,Has Results,Atrial Septal Defect,Device: AMPLATZER Septal Occluder,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,8/7/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00650936
9486,A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes,Completed,Has Results,Obesity,Drug: Canagliflozin (JNJ-28431754)|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 2,Industry,Interventional,5/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00650806
9487,Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: MR prednisone|Drug: Placebo,"Horizon Pharma Ireland, Ltd., Dublin Ireland","Horizon Pharma Ireland, Ltd., Dublin Ireland",,,,,,,Phase 3,Industry,Interventional,3/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00650078
9488,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,8/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00649792
9489,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Completed,Has Results,Hypertension,Drug: Olmesartan medoxomil|Drug: Amlodipine|Drug: Hydrochlorothiazide,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,5/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00649389
9490,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial",Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,6/6/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00648908
9491,Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function,Completed,Has Results,MDS|AML|Solid Tumors|Multiple Myeloma|Non-Hodgkin's Lymphoma|Hodgkin's Disease,Drug: azacitidine,Celgene Corporation,Celgene Corporation,,,,,,,Phase 1,Industry,Interventional,11/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00652626
9492,"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing",Completed,Has Results,Rheumatoid Arthritis,Drug: adalimumab|Drug: Placebo,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,12/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00647270
9493,Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections,Completed,Has Results,Infectious Skin Diseases|Bacterial Skin Diseases|Staphylococcal Skin Infections|Streptococcal Infections|Abscess,Drug: Radezolid|Drug: Linezolid,"Melinta Therapeutics, Inc.","Melinta Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,12/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00646958
9494,Balloon REmodeling Antrostomy THErapy Study,Completed,Has Results,Sinusitis,Device: RS-Series Rhinosinusitis Treatment System|Device: FinESS Balloon,"Entellus Medical, Inc.","Entellus Medical, Inc.",,,,,,,Phase 2,Industry,Interventional,9/7/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00645762
9495,A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder,Drug: vilazodone,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,12/31/2007,5/31/2009,https://ClinicalTrials.gov/show/NCT00644358
9496,"An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)",Completed,Has Results,Chronic Angina,Drug: Ranolazine,Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,11/7/2019,1/11/2019,https://ClinicalTrials.gov/show/NCT00644332
9497,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Metformin XR,"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",AstraZeneca,"Astra Zeneca, Bristol-Myers Squibb",,,,,,Phase 3,Industry|Other,Interventional,6/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00643851
9498,A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN),Completed,Has Results,"Neuropathy, Diabetic",Drug: Placebo|Drug: GEn 1200mg/day|Drug: GEn 2400mg/day|Drug: GEn 3600mg/day|Drug: Pregabalin,"XenoPort, Inc.","XenoPort, Inc.",,,,,,,Phase 2,Industry,Interventional,3/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00643760
9499,Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age,Completed,Has Results,Meningitis|Meningococcal Infection,"Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)","Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,12/4/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00643916
9500,"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes",Completed,Has Results,"Diabetes Mellitus, Type II|Diabetes Mellitus, Non Insulin Dependent",Drug: Canagliflozin (JNJ-28431754)|Drug: Sitagliptin|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 2,Industry,Interventional,4/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00642278
9501,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA),Completed,Has Results,Juvenile Idiopathic Arthritis,Drug: tocilizumab [RoActemra/Actemra]|Drug: Placebo|Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)|Drug: methotrexate|Drug: corticosteroids,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,5/8/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00642460
9502,Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: Lurasidone HCl|Drug: Risperidone,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,3/8/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00641745
9503,CLARITY Extension Study,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: Cladribine|Drug: Placebo,EMD Serono,EMD Serono,,,,,,,Phase 3,Industry,Interventional,2/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00641537
9504,Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers,Completed,Has Results,Alzheimer Disease|Amyloid Beta-Protein,Drug: Florbetaben (BAY94-9172),Life Molecular Imaging SA,Life Molecular Imaging SA,,,,,,,Phase 2,Industry,Interventional,8/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00750282
9505,Study of Lupron Depot In The Treatment of Central Precocious Puberty,Completed,Has Results,"Puberty, Precocious",Drug: Lupron (leuprolide acetate),Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,1/1/1991,4/9/2019,https://ClinicalTrials.gov/show/NCT00660010
9506,Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164,Completed,Has Results,Parkinson Disease,Drug: Ropinirole XL (formerly CR),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,5/2/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00650104
9507,Corneal Collagen Cross-linking for Progressive Keratoconus,Completed,Has Results,Progressive Keratoconus,Drug: riboflavin ophthalmic solution|Device: UVA Irradiation,"Avedro, Inc.","Avedro, Inc.",,,,,,,Phase 3,Industry,Interventional,12/7/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00647699
9508,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Completed,Has Results,Pain,Drug: morphine sulfate extended release capsules,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,3/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00640042
9509,A Study to Describe Pediatric Influenza Vaccine Coverage,Completed,Has Results,Healthy,Biological: Influenza vaccination,MedImmune LLC,MedImmune LLC,,,,,,,,Industry,Observational,8/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00639418
9510,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,Completed,Has Results,Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia,Drug: ABT-335|Drug: placebo|Drug: atorvastatin|Drug: ezetimibe,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,2/8/2019,,https://ClinicalTrials.gov/show/NCT00639158
9511,Performance of Two Silicone Hydrogel Toric Contact Lenses,Completed,Has Results,Vision Correction,Device: senofilcon A toric|Device: balafilcon A toric,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/8/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00638846
9512,Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy,Completed,Has Results,Prostatic Neoplasms,Drug: Placebo|Drug: Abiraterone acetate|Drug: Prednisone/prednisolone,"Cougar Biotechnology, Inc.","Cougar Biotechnology, Inc.",,,,,,,Phase 3,Industry,Interventional,5/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00638690
9513,Pelvic Floor Repair Systems for Prolapse Repair,Completed,Has Results,Pelvic Organ Prolapse,"Device: AMS Apogee™ with IntePro|Device: AMS Apogee™ with Intexen LP|Device: AMS Perigee™ with IntePro|Device: AMS Perigee™ with IntePro Lite|Device: AMS Apogee™ with IntePro Lite|Device: AMS Elevate™ Apical & Posteiror with IntePro Lite|Device: AMS Elevate™ Apical & Posteiror with IntXen LP|Device: AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Device: AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)",ASTORA Women's Health,ASTORA Women's Health,,,,,,,,Industry,Observational,5/6/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00638235
9514,A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer,Completed,Has Results,Pancreatic Neoplasms,Drug: imexon in combination with gemcitabine|Drug: imexon placebo + gemcitabine,AmpliMed Corporation,AmpliMed Corporation,,,,,,,Phase 2,Industry,Interventional,4/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00637247
9515,Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels,Completed,Has Results,Cervical Degenerative Disc Disease|Radiculopathy|Myelopathy,Device: PRESTIGE LP device at two adjacent levels|Device: Bi-level fusion with ATLANTIS Cervical Plate System,Medtronic Spinal and Biologics,Medtronic Spinal and Biologics,,,,,,,Not Applicable,Industry,Interventional,6/6/2019,2/1/2018,https://ClinicalTrials.gov/show/NCT00637156
9516,Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra,Completed,Has Results,Aortic Valve Insufficiency|Aortic Valve Regurgitation|Aortic Valve Stenosis|Aortic Valve Incompetence|Mitral Valve Insufficiency|Mitral Valve Regurgitation|Mitral Valve Stenosis|Mitral Valve Incompetence,Device: Biocor and Biocor Supra valves,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,4/7/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT00636987
9517,Strattice in Repair of Inguinal Hernias,Completed,Has Results,"Hernia, Inguinal",Device: Inguinal hernia repair with Ultrapro|Device: Inguinal hernia repair with Strattice,LifeCell,LifeCell,,,,,,,Phase 4,Industry,Interventional,4/8/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00681291
9518,Safety and Efficacy of Gabapentin in Postherpetic Neuralgia,Completed,Has Results,"Neuralgia,Postherpetic",Drug: Gabapentin Extended Release tablets|Drug: Placebo,Depomed,Depomed,,,,,,,Phase 3,Industry,Interventional,3/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00636636
9519,A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty,Completed,Has Results,"Puberty, Precocious",Drug: Leuprolide acetate 11.25 mg|Drug: Leuprolide acetate 30 mg,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,6/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00635817
9520,Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa,Completed,Has Results,Cystic Fibrosis,Biological: KB001|Other: Placebo,"Humanigen, Inc.","Humanigen, Inc.",,,,,,,Phase 1|Phase 2,Industry,Interventional,3/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00638365
9521,A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension,Completed,Has Results,Hypertension,Drug: irbesartan|Drug: placebo|Drug: PS433540,Ligand Pharmaceuticals,Ligand Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00635232
9522,Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin detemir,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 4,Industry,Interventional,2/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00634842
9523,Advair HFA For Chronic Obstructive Pulmonary Disease(COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|Drug: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,3/8/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00633217
9524,An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease,Completed,Has Results,Parkinson Disease|Parkinson's Disease,Drug: Ropinirole XL (formerly CR),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/4/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00632736
9525,Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections,Completed,Has Results,Bacterial Infection,Drug: ceftaroline|Drug: linezolid|Drug: Aztreonam,Forest Laboratories,Forest Laboratories,,,,,,,Phase 2,Industry,Interventional,2/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00633152
9526,RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness,Completed,Has Results,Upper Respiratory Tract Infection|Lower Respiratory Tract Infection,Biological: RI-001,"ADMA Biologics, Inc.","ADMA Biologics, Inc.",,,,,,,Phase 2,Industry,Interventional,2/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00632463
9527,Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo,Completed,Has Results,Healthy,Drug: Pregabalin|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,2/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00631696
9528,Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Bosentan,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,4/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00631475
9529,Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects,Completed,Has Results,Renal Cell Carcinoma,Drug: Bevacizumab|Drug: Temsirolimus|Drug: Interferon-Alfa 9MU,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,4/8/2019,4/15/2019,https://ClinicalTrials.gov/show/NCT00631371
9530,"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: INT131 besylate|Drug: Pioglitazone HCl|Drug: Placebo,"InteKrin Therapeutics, Inc.","InteKrin Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,2/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00631007
9531,Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve,Completed,Has Results,Heart Valve Diseases,Device: Mitroflow Aortic Heart Valve,"Sorin Group USA, Inc.","Sorin Group USA, Inc.",,,,,,,Not Applicable,Industry,Interventional,11/3/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00630916
9532,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,Completed,Has Results,Dyslipidemia,Drug: Niacin extended-release (NER)|Drug: Niacin extended-release (NER) placebo|Drug: Aspirin (ASA)|Drug: Aspirin (ASA) placebo,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,2/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00630877
9533,A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus Type 2,Drug: LY2189265|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00630825
9534,Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase,Completed,Has Results,Hunter Syndrome|Mucopolysaccharidosis II (MPS II),Biological: Idursulfase,Shire,Shire,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/4/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00630747
9535,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Completed,Has Results,Influenza,Biological: Cell culture-derived influenza vaccine|Biological: Egg-derived influenza virus vaccine|Biological: Placebo,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,10/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00630331
9536,"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients",Completed,Has Results,Chronic Hepatitis C,Drug: Nitazoxanide|Drug: Placebo|Biological: Peginterferon alfa-2a|Drug: Ribavirin,Romark Laboratories L.C.,Romark Laboratories L.C.,,,,,,,Phase 2,Industry,Interventional,3/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00637923
9537,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Completed,Has Results,Hepatic Veno-Occlusive Disease,Drug: Defibrotide,Jazz Pharmaceuticals,Jazz Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/7/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT00628498
9538,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months,Completed,Has Results,Allergic Rhinitis|Chronic Urticaria,Drug: Levocetirizine 1.25 mg|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,3/8/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00628108
9539,An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease,Completed,Has Results,"Gaucher Disease, Type 1",Biological: VPRIV®,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,5/8/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00635427
9540,Multicenter Infection Surveillance Study Following Open Heart Surgery,Completed,Has Results,Surgery|Pneumonia|Surgical Site Infection,Device: Continuous Sternal Block|Drug: Opioid based analgesia,Halyard Health,Halyard Health,,,,,,,Phase 4,Industry,Interventional,4/8/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00673712
9541,Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder,Completed,Has Results,Smoking Cessation,"Drug: placebo|Drug: varenicline (CP-526,555)",Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,5/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00644969
9542,A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn,Completed,Has Results,Gastroesophageal Reflux,Drug: Dexlansoprazole|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,3/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00627016
9543,A Study of Leuprolide to Treat Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Leuprolide acetate - Formulation A|Drug: Leuprolide acetate - Formulation B,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,2/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00626431
9544,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,Completed,Has Results,Dyslipidemia,Drug: niacin extended-release (NER)|Drug: aspirin (ASA)|Drug: aspirin placebo (ASA Pbo),Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,2/8/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00626392
9545,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Completed,Has Results,Meningococcal Infections,Biological: MenACWY-CRM + MMRV|Biological: MMRV|Biological: MenACWY-CRM,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,2/8/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00626327
9546,"A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice",Completed,Has Results,Cardiovascular Disease,Drug: DEFINITY®,Lantheus Medical Imaging,Lantheus Medical Imaging,,,,,,,Phase 4,Industry,Interventional,2/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00625365
9547,A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer,Completed,Has Results,Non Small Cell Lung Cancer,Biological: Ramucirumab|Drug: Paclitaxel|Drug: Carboplatin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,1/9/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00735696
9548,Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 150 μg|Drug: Placebo to indacaterol,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,2/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00624286
9549,"Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003",Completed,Has Results,Idiopathic Thrombocytopenic Purpura,Drug: Blinded (placebo)|Drug: Open Label (Avatrombopag tablets)|Drug: Blinded (Avatrombopoag tablets),Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,5/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00625443
9550,A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.,Completed,Has Results,Erectile Dysfunction,Drug: tadalafil once a day [T(OaD)]|Drug: sildenafil citrate as needed [S(PRN)]|Drug: tadalafil as needed [T(PRN)],Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,8/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00734604
9551,A Study of IXAZOMIB in Adult Patients With Lymphoma,Completed,Has Results,Lymphoma,Drug: IXAZOMIB,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,8/9/2019,10/14/2019,https://ClinicalTrials.gov/show/NCT00893464
9552,Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure,Completed,Has Results,Hypertension,Drug: carvedilol controlled release/lisinopril|Drug: lisinopril + placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00624065
9553,Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment,Completed,Has Results,Hemophilia A,"Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,3/8/2019,11/13/2019,https://ClinicalTrials.gov/show/NCT00623480
9554,Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging,Completed,Has Results,Central Nervous System Diseases,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,12/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00623467
9555,A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response,Completed,Has Results,"Hepatitis C, Chronic",Drug: peginterferon alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,6/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00623428
9556,Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD),Completed,Has Results,Parkinson's Disease Dementia,Drug: Rivastigmine capsule|Drug: Rivastigmine transdermal patch,Novartis,Novartis,,,,,,,Phase 3,Industry,Interventional,1/8/2019,,https://ClinicalTrials.gov/show/NCT00623103
9557,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Completed,Has Results,Liver Transplantation,Drug: Tacrolimus (reduced tacrolimus)|Drug: Tacrolimus (tacrolimus elimination)|Drug: Tacrolimus (tacrolimus control)|Drug: Everolimus (reduced tacrolimus)|Drug: Everolimus (tacrolimus elimination)|Drug: Corticosteroids,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,1/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00622869
9558,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Teriflunomide|Drug: Placebo,Sanofi,Sanofi,,,,,,,Phase 3,Industry,Interventional,2/8/2019,2/16/2019,https://ClinicalTrials.gov/show/NCT00622700
9559,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo identical to BI 1356 5mg|Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Drug: BI 1356|Drug: Glimepiride,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,2/8/2019,,https://ClinicalTrials.gov/show/NCT00622284
9560,A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: levocetirizine dihydrochloride|Drug: placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 4,Industry,Interventional,3/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00621959
9561,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE),Completed,Has Results,"Gaucher Disease, Type 1",Drug: Eliglustat tartrate|Drug: Placebo,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,11/9/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT00891202
9562,CRESTOR Athero Imaging Head to Head IVUS Study,Completed,Has Results,Coronary Atherosclerosis,Drug: Rosuvastatin|Drug: Atorvastatin,AstraZeneca|The Cleveland Clinic,AstraZeneca,The Cleveland Clinic,,,,,,Phase 3,Industry|Other,Interventional,1/8/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00620542
9563,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin,Completed,Has Results,Allergic Rhinitis|Chronic Urticaria,Drug: Levocetirizine|Drug: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,3/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00619801
9564,A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN),Completed,Has Results,"Neuralgia, Postherpetic",Drug: GEn 1200mg/day|Drug: GEn 2400mg/day|Drug: GEn 3600mg/day|Drug: Placebo,"XenoPort, Inc.","XenoPort, Inc.",,,,,,,Phase 2,Industry,Interventional,2/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00619476
9565,Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia,Completed,Has Results,Bacterial Pneumonia,Drug: Ceftaroline fosamil for Injection|Drug: IV Ceftriaxone|Drug: Placebo|Drug: Clarithromycin,Forest Laboratories,Forest Laboratories,,,,,,,Phase 3,Industry,Interventional,1/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00621504
9566,An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.,Completed,Has Results,Systemic Juvenile Idiopathic Arthritis,Drug: Canakinumab,Novartis Pharmaceuticals|Pediatric Rheumatology International Trials Organization|Novartis,Novartis Pharmaceuticals,Pediatric Rheumatology International Trials Organization,Novartis,,,,,Phase 3,Industry|Other,Interventional,9/9/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00891046
9567,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,Completed,Has Results,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x|Drug: Placebo,CERESPIR,CERESPIR,,,,,,,Phase 2,Industry,Interventional,3/11/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT01303744
9568,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Docetaxel|Drug: ZD4054|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,1/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00617669
9569,A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment,Completed,Has Results,"Neuralgia, Postherpetic",Drug: GEn 1200mg/day|Drug: GEn 3600mg/day,"XenoPort, Inc.","XenoPort, Inc.",,,,,,,Phase 2,Industry,Interventional,3/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00617461
9570,Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1),Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Ambrisentan|Drug: Placebo|Drug: Sildenafil|Drug: Tadalafil,Gilead Sciences,Gilead Sciences,,,,,,,Phase 4,Industry,Interventional,4/8/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00617305
9571,Repair of Infected or Contaminated Hernias,Completed,Has Results,Hernia,Device: LTM (Strattice Reconstructive Tissue Matrix),LifeCell,LifeCell,,,,,,,Not Applicable,Industry,Interventional,9/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00617357
9572,"Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck",Completed,Has Results,Head and Neck Cancer,Biological: IMC-A12 (cixutumumab)|Biological: cetuximab (Erbitux ®),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,3/8/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00617734
9573,Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years,Completed,Has Results,Influenza,"Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Biological: Placebo",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/23/2008,3/19/2009,https://ClinicalTrials.gov/show/NCT00616928
9574,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Completed,Has Results,Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Drug: ABT-335|Drug: Placebo|Other: Atorvastatin,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 3,Industry,Interventional,2/8/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00616772
9575,Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects,Completed,Has Results,Generalized Anxiety Disorder,Drug: eszopiclone|Drug: Placebo,Sunovion,Sunovion,,,,,,,Phase 2,Industry,Interventional,1/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00616655
9576,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,Completed,Has Results,Meningococcal Infections,Biological: MenACWY-CRM|Biological: Licensed meningococcal ACWY vaccine,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,3/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00616421
9577,A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture,Completed,Has Results,Osteoporosis,Drug: Teriparatide|Drug: Risedronate|Drug: Placebo|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,4/9/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00887354
9578,"An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (""Melt"") Formulation of Desmopressin for the Treatment of Nocturia in Adults",Completed,Has Results,Nocturia,Drug: Desmopressin Melt,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00615836
9579,PREGNANT Short Cervix Trial,Completed,Has Results,Preterm Delivery|Short Cervix|Short Uterine Cervical Length,Drug: progesterone|Drug: placebo,"Juniper Pharmaceuticals, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Juniper Pharmaceuticals, Inc.",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),,,,,,Phase 3,Industry|NIH,Interventional,3/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00615550
9580,Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Olanzapine|Drug: Placebo comparator|Drug: Lurasidone 40 mg tablets,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,1/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00615433
9581,"A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease",Completed,Has Results,Crohn's Disease,"Drug: CP-690,550|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,1/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00615199
9582,A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen,Completed,Has Results,Colorectal Neoplasms,"Drug: Bevacizumab (avastin)|Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Drug: AG-013736 (axitinib)|Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,3/8/2019,4/12/2019,https://ClinicalTrials.gov/show/NCT00615056
9583,AZD9773 Dose Escalation Study,Completed,Has Results,Severe Sepsis,Drug: AZD9773 (CytoFab)|Other: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,1/8/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00615017
9584,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014",Completed,Has Results,"Infections, Meningococcal",Biological: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Biological: Infanrix®|Biological: ActHIB®|Biological: Pediarix®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/13/2008,9/17/2009,https://ClinicalTrials.gov/show/NCT00614614
9585,N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma,Completed,Has Results,Neuroblastoma,Drug: UltratraceTM Iobenguane I 131 Imaging|Drug: UltratraceTM Iobenguane I 131 Therapy,"Molecular Insight Pharmaceuticals, Inc.","Molecular Insight Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,6/8/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00659984
9586,Treatment of Moderate to Severe Facial Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Doxycycline 0.6 mg/kg/day|Drug: Doxycycline 1.2 mg/kg/day|Drug: Doxycycline 2.4 mg/kg/day|Drug: Placebo,Warner Chilcott,Warner Chilcott,,,,,,,Phase 2,Industry,Interventional,2/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00612573
9587,"To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD",Completed,Has Results,Macular Degeneration,Drug: Pazopanib,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/5/2008,6/17/2009,https://ClinicalTrials.gov/show/NCT00612456
9588,Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN),Completed,Has Results,Postherpetic Neuralgia,Drug: Retigabine|Drug: Placebo,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 2,Industry,Interventional,10/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00612105
9589,"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin glargine|Drug: insulin degludec|Drug: metformin,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 2,Industry,Interventional,1/8/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00611884
9590,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.,Completed,Has Results,Overactive Bladder,Drug: Tolterodine ER|Drug: Placebo|Drug: Fesoterodine,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00611026
9591,Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares,Completed,Has Results,Gout,Biological: Rilonacept|Other: Placebo (for Rilonacept),Regeneron Pharmaceuticals,Regeneron Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00610363
9592,TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy,Completed,Has Results,Lipodystrophy|HIV Infections,Drug: Tesamorelin|Drug: Placebo for Tesamorelin,Theratechnologies,Theratechnologies,,,,,,,Phase 3,Industry,Interventional,8/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00608023
9593,Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia,Completed,Has Results,Leukemia|Acute Disease|Acute Myeloid Leukemia|Nonlymphocytic Leukemia|Myelodysplastic Syndromes,Drug: vosaroxin,Sunesis Pharmaceuticals,Sunesis Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/15/2008,11/23/2009,https://ClinicalTrials.gov/show/NCT00607997
9594,Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia,Completed,Has Results,Attention Deficit Hyperactivity Disorder|Dyslexia,Drug: Atomoxetine|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,3/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00607919
9595,A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: Fluticasone furoate nasal spray|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,1/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00609674
9596,Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis,Amgen,Amgen,,,,,,,Phase 3,Industry,Interventional,12/21/2015,1/20/2017,https://ClinicalTrials.gov/show/NCT02585895
9597,ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain,Completed,Has Results,Bone Metastases|Multiple Myeloma,Device: ExAblate MRfFUS|Device: Sham,InSightec,InSightec,,,,,,,Not Applicable,Industry,Interventional,3/8/2019,9/12/2019,https://ClinicalTrials.gov/show/NCT00656305
9598,Vigabatrin for Treatment of Cocaine Dependence,Completed,Has Results,Cocaine Dependence,Drug: vigabatrin|Drug: placebo,"Catalyst Pharmaceuticals, Inc.","Catalyst Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,1/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00611130
9599,A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GW642444 6.25|Drug: GW642444 3mcg|Drug: GW642444 12.5mcg|Drug: GW642444 25mcg|Drug: GW642444 50mcg|Other: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,2/8/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00606684
9600,Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia,Completed,Has Results,Chronic Primary Insomnia,Drug: ACT-078573 oral capsules at 25 and 100 mg and matching placebo|Drug: ACT-078573 and matching placebo,"Midnight Pharma, LLC","Midnight Pharma, LLC",,,,,,,Phase 2,Industry,Interventional,12/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00606593
9601,Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Pralatrexate|Drug: Erlotinib|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid,"Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",,,,,,,Phase 2,Industry,Interventional,1/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00606502
9602,Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody,Completed,Has Results,Renal Cell Carcinoma|Kidney Cancer,Drug: 124-Iodine-cG250 (124I-cG250)|Procedure: CT,Wilex,Wilex,,,,,,,Phase 3,Industry,Interventional,3/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00606632
9603,Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection,Completed,Has Results,Genotype 1 Chronic Hepatitis C,Drug: GI-5005|Drug: Pegylated Interferon and Ribavirin,GlobeImmune,GlobeImmune,,,,,,,Phase 2,Industry,Interventional,12/7/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00606086
9604,"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.",Completed,Has Results,Macular Edema Associated With Diabetes Mellitus,Drug: Standard of Care|Drug: Macugen,Pfizer,Pfizer,,,,,,,Phase 2|Phase 3,Industry,Interventional,9/5/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00605280
9605,Evaluation of Chagas Blood Screening and Confirmatory Assays,Completed,Has Results,Healthy,Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay,Abbott Diagnostics Division,Abbott Diagnostics Division,,,,,,,Not Applicable,Industry,Interventional,6/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00718042
9606,Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs),Completed,Has Results,Actinic Keratoses,Drug: imiquimod cream|Drug: Placebo,"Graceway Pharmaceuticals, LLC","Graceway Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,1/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00605176
9607,Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study),Completed,Has Results,Menopausal and Female Climacteric States,Drug: Other: Placebo|Drug: GSK232802|Drug: PREMARIN,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/17/2007,7/23/2008,https://ClinicalTrials.gov/show/NCT00604825
9608,Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock,Completed,Has Results,Sepsis,Drug: Drotrecogin alfa (activated)|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00604214
9609,Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs),Completed,Has Results,Actinic Keratosis,Drug: Imiquimod cream|Drug: Placebo cream,"Graceway Pharmaceuticals, LLC","Graceway Pharmaceuticals, LLC",,,,,,,Phase 3,Industry,Interventional,1/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00603798
9610,A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.,Completed,Has Results,Asthma,Drug: GW685698X,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/1/2007,9/20/2008,https://ClinicalTrials.gov/show/NCT00603746
9611,A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.,Completed,Has Results,Asthma,Drug: GW685698X|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/1/2007,10/2/2008,https://ClinicalTrials.gov/show/NCT00603382
9612,A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.,Completed,Has Results,Asthma,Drug: GW685698X|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00603278
9613,Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy,Completed,Has Results,Peripheral Neuropathy|Neuropathic Pain,Drug: ADL5859|Drug: Duloxetine|Drug: Placebo,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 2,Industry,Interventional,11/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00603265
9614,"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.",Completed,Has Results,Glaucoma,Drug: Timolol|Drug: latanoprost,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,7/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00716859
9615,Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects,Completed,Has Results,Intubated and Mechanically Ventilated Pediatric Subjects,"Drug: Dexmedetomidine, midazolam; fentanyl","Hospira, now a wholly owned subsidiary of Pfizer","Hospira, now a wholly owned subsidiary of Pfizer",,,,,,,Phase 2,Industry,Interventional,11/8/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00652028
9616,Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptin,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,1/8/2019,,https://ClinicalTrials.gov/show/NCT00601250
9617,Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age,Completed,Has Results,Alzheimer's Disease,Drug: CNP520|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,8/10/2015,3/11/2016,https://ClinicalTrials.gov/show/NCT02576639
9618,Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer,Completed,Has Results,Prostate Cancer,Biological: Sipuleucel-T with Booster|Biological: Sipuleucel-T without Booster,"Dendreon|University of California, San Francisco",Dendreon,"University of California, San Francisco",,,,,,Phase 2,Industry|Other,Interventional,7/8/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00715104
9619,Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder,Completed,Has Results,Depression|Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR),Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 2,Industry,Interventional,2/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00619619
9620,A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.,Completed,Has Results,"Nausea and Vomiting, Chemotherapy-Induced",Drug: Casopitant|Drug: Dexamethasone|Drug: Placebo|Drug: Ondansetron,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,3/10/2008,4/13/2009,https://ClinicalTrials.gov/show/NCT00601172
9621,A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis,Completed,Has Results,Moderate to Severe Chronic Plaque Psoriasis,Drug: Doxercalciferol|Drug: Placebo,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 2,Industry,Interventional,4/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00601107
9622,A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.,Completed,Has Results,Non-Small-Cell Lung Carcinoma|Adenocarcinoma,Drug: Bevacizumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: AG-013736 (axitinib),Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,4/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00600821
9623,Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma,Completed,Has Results,Superficial Basal Cell Carcinoma,Drug: API 31510 3% Topical Cream|Drug: API 31510 1.5% Topical Cream|Other: Placebo,"Berg, LLC","Berg, LLC",,,,,,,Phase 1|Phase 2,Industry,Interventional,3/8/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00604890
9624,Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly,Completed,Has Results,Acromegaly,Drug: Pasireotide|Drug: Octreotide,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,2/11/2008,3/11/2016,https://ClinicalTrials.gov/show/NCT00600886
9625,Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.,Completed,Has Results,Asthma,Drug: GW642444M|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00600171
9626,Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies,Completed,Has Results,Allergic Rhinitis,Biological: Standardized Ragweed Allergenic Extract|Biological: Placebo,Greer Laboratories,Greer Laboratories,,,,,,,Phase 3,Industry,Interventional,3/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00599872
9627,Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma,Completed,Has Results,Relapsed Multiple Myeloma,Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,5/8/2019,1/16/2019,https://ClinicalTrials.gov/show/NCT00603447
9628,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Completed,Has Results,Acne Vulgaris,Drug: Adapalene lotion 0.1%|Drug: Adapalene Lotion Vehicle,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,11/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00599521
9629,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Completed,Has Results,Acne Vulgaris,Drug: Adapalene lotion 0.1%|Drug: Adapalene Lotion Vehicle,Galderma,Galderma,,,,,,,Phase 3,Industry,Interventional,11/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00598832
9630,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612),Completed,Has Results,Bladder Cancer,Drug: Apaziquone|Drug: Placebo|Procedure: TURBT,"Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,8/7/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00598806
9631,Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC),Completed,Has Results,Hepatocellular Carcinoma,Drug: ThermoDox|Drug: 5% Dextrose Solution,Celsion,Celsion,,,,,,,Phase 3,Industry,Interventional,5/8/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT00617981
9632,Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients,Completed,Has Results,Pain|Fever,Drug: IV Acetaminophen,Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,1/8/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00598702
9633,Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients,Completed,Has Results,Acute Pain|Fever,Drug: IV Acetaminophen,Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,1/8/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00598559
9634,Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures,Completed,Has Results,Epilepsy,Drug: pregabalin,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,4/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00596466
9635,Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).,Completed,Has Results,Parkinson Disease,Drug: Placebo|Drug: Pramipexole,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,1/8/2019,,https://ClinicalTrials.gov/show/NCT00601523
9636,Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia,Completed,Has Results,Community-Acquired Pneumonia (CAP),Drug: Radezolid,"Melinta Therapeutics, Inc.","Melinta Therapeutics, Inc.",,,,,,,Phase 2,Industry,Interventional,10/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00640926
9637,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,3/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00594568
9638,An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: Rotigotine,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,8/2/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00594386
9639,An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.,Completed,Has Results,Early-Stage Parkinson's Disease,Drug: Rotigotine,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,6/2/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00594165
9640,Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome,Completed,Has Results,"Sleep Disorders, Circadian Rhythm",Drug: Ramelteon|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 2,Industry,Interventional,10/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00593736
9641,Atrium iCAST Iliac Stent Pivotal Study,Completed,Has Results,Peripheral Vascular Disease,Device: iCAST covered stent,Atrium Medical Corporation,Atrium Medical Corporation,,,,,,,Not Applicable,Industry,Interventional,10/7/2019,5/14/2019,https://ClinicalTrials.gov/show/NCT00593385
9642,"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 2,Industry,Interventional,1/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00612040
9643,Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne,Completed,Has Results,Acne Vulgaris,Drug: Methyl aminolevulinate (MAL) PDT,Photocure,Photocure,,,,,,,Phase 2,Industry,Interventional,2/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00594425
9644,"Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women",Completed,Has Results,Nocturnal Vasomotor Symptoms,Drug: SCE-B|Drug: Placebo,Duramed Research|Teva Pharmaceutical Industries,Duramed Research,Teva Pharmaceutical Industries,,,,,,Phase 4,Industry,Interventional,12/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00592839
9645,Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN),Completed,Has Results,Neuralgia,Drug: E2007 (perampanel)|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 2,Industry,Interventional,1/8/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00592774
9646,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Chlorthalidone,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,9/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00591773
9647,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan Medoxomil|Drug: Valsartan,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,12/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00591578
9648,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension",Completed,Has Results,Hypertension,Drug: Azilsartan Medoxomil and amlodipine|Drug: Amlodipine,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,10/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00591266
9649,Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil|Drug: Placebo,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,10/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00591253
9650,Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms,Completed,Has Results,"Aortic Aneurysm, Thoracic",Device: GORE TAG® Thoracic Endoprosthesis,W.L.Gore & Associates,W.L.Gore & Associates,,,,,,,Not Applicable,Industry,Interventional,8/5/2019,4/13/2019,https://ClinicalTrials.gov/show/NCT00590759
9651,Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort,Completed,Has Results,Vulvodynia,Drug: Lidocaine/Diphenhydramine|Drug: lidocaine|Drug: placebo,"Lumara Health, Inc.","Lumara Health, Inc.",,,,,,,Phase 2,Industry,Interventional,10/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00590590
9652,"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Paliperidone palmitate 25 mg eq.|Drug: Paliperidone palmitate 150 mg eq.|Drug: Placebo|Drug: Paliperidone palmitate 100 mg eq.,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 3,Industry,Interventional,3/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00590577
9653,Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: Lidoderm (Lidocaine 5% Patch)|Drug: Placebo Patch,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,3/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00589979
9654,Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease,Completed,Has Results,Degenerative Disc Disease,Device: Activ-L Artificial Disc|Device: ProDisc-L Total Disc Replacement or Charité Artificial Disc,Aesculap Implant Systems,Aesculap Implant Systems,,,,,,,Not Applicable,Industry,Interventional,1/7/2019,1/17/2019,https://ClinicalTrials.gov/show/NCT00589797
9655,Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: RISPERDAL CONSTA|Drug: Paliperidone palmitate,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 3,Industry,Interventional,3/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00589914
9656,MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ,Completed,Has Results,DCIS,Device: MammoSite Radiation Therapy System,"Hologic, Inc.|University of Southern California","Hologic, Inc.",University of Southern California,,,,,,Phase 2,Industry|Other,Interventional,8/3/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00586326
9657,A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases,Completed,Has Results,Hormone Refractory Prostate Cancer|Bone Metastases,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo|Drug: Best standard of care (BSoC)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,6/8/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00699751
9658,A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects,Completed,Has Results,Asthma,Drug: arformoterol|Drug: levalbuterol,Sunovion,Sunovion,,,,,,,Phase 2,Industry,Interventional,1/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00583947
9659,Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder,Completed,Has Results,Patent Ductus Arteriosus (PDA),Device: Device closure with AMPLATZER Duct Occluder|Other: Objective Performance Criteria,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,10/1/1999,2/9/2019,https://ClinicalTrials.gov/show/NCT00583596
9660,Augment® Bone Graft (Formerly GEM OS™1 Bone Graft) Compared to Autologous Bone Graft in Foot and Ankle Fusions,Completed,Has Results,Foot Fusion,Device: Augment® Bone Graft|Procedure: Standard of Care,BioMimetic Therapeutics,BioMimetic Therapeutics,,,,,,,Not Applicable,Industry,Interventional,4/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00583375
9661,Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device,Completed,Has Results,Heart Failure|Cardiomyopathies,Device: EXCOR Pediatric,"Berlin Heart, Inc","Berlin Heart, Inc",,,,,,,Not Applicable,Industry,Interventional,5/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00583661
9662,Dosing Flexibility Study in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Certolizumab pegol|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 4,Industry,Interventional,12/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00580840
9663,Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder,Completed,Has Results,"Heart Septal Defects, Ventricular",Device: Device closure with the AMPLATZER Muscular VSD Occluder,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,7/1/2000,11/9/2019,https://ClinicalTrials.gov/show/NCT00583791
9664,An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder,Completed,Has Results,Mood Disorders,Drug: Lamotrigine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,1/8/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00579982
9665,Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Canakinumab|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00581945
9666,Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: ADL5859|Drug: Naproxen|Drug: Placebo,Cubist Pharmaceuticals LLC,Cubist Pharmaceuticals LLC,,,,,,,Phase 2,Industry,Interventional,10/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00626275
9667,Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing,Completed,Has Results,Idiopathic Pulmonary Arterial Hypertension|Congenital Heart Disease With Pulmonary Hypertension|Cardiomyopathy,Drug: Nitric Oxide for inhalation|Drug: Oxygen|Drug: Nitric Oxide plus Oxygen,Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,9/4/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00626028
9668,Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Plerixafor|Drug: bortezomib|Drug: Dexamethasone,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genzyme, a Sanofi Company|Millennium Pharmaceuticals, Inc.",Dana-Farber Cancer Institute,Brigham and Women's Hospital,"Genzyme, a Sanofi Company|Millennium Pharmaceuticals, Inc.","Genzyme, a Sanofi Company","Millennium Pharmaceuticals, Inc.",,,Phase 1|Phase 2,Other|Industry,Interventional,5/9/2019,10/16/2019,https://ClinicalTrials.gov/show/NCT00903968
9669,PCM Cervical Disc System,Completed,Has Results,Radiculopathy|Myelopathy,Device: Anterior Cervical Discectomy and Fusion (ACDF)|Device: PCM Cervical Disc,NuVasive,NuVasive,,,,,,,Phase 3,Industry,Interventional,1/5/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT00578812
9670,Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age,Completed,Has Results,Varicella|Rubella|Mumps|Measles,Biological: Priorix-Tetra™ (MMRV vaccine 208136)|Biological: ProQuad®|Biological: Havrix®|Biological: Prevnar®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,11/20/2007,3/17/2009,https://ClinicalTrials.gov/show/NCT00578175
9671,Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy,Completed,Has Results,Osteoporosis,Drug: teriparatide,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,1/8/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00577863
9672,Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I),Completed,Has Results,Ulcerative Colitis,Drug: mesalamine,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,2/1/2019,2/3/2019,https://ClinicalTrials.gov/show/NCT00577473
9673,Albuterol HFA MDI in Pediatric Participants With Asthma,Completed,Has Results,Asthma,Drug: Albuterol|Drug: Placebo|Drug: Proventil® HFA,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Teva Branded Pharmaceutical Products, R&D Inc.",Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,8/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00577655
9674,A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder,Completed,Has Results,Autistic Disorder|Autism,Drug: Placebo|Drug: Risperidone high dose|Drug: Risperidone low dose,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 4,Industry,Interventional,12/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00576732
9675,Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infection,Drug: TP-434|Drug: Ertapenem|Drug: Placebo,"Tetraphase Pharmaceuticals, Inc.","Tetraphase Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,1/11/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT01265784
9676,GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: obinutuzumab (RO5072759)|Drug: rituximab,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 2,Industry,Interventional,1/8/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00576758
9677,Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery,Completed,Has Results,Bacterial Infections|Eye Infections|Cataract Extraction,Drug: AzaSite Eye Drops|Drug: Vigamox Eye Drops,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,,,,,,,Phase 4,Industry,Interventional,12/7/2019,,https://ClinicalTrials.gov/show/NCT00575380
9678,Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Placebo|Drug: Solifenacin Succinate,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 4,Industry,Interventional,8/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00573508
9679,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,Avanir Pharmaceuticals|Syneos Health,Avanir Pharmaceuticals,Syneos Health,,,,,,Phase 3,Industry|Other,Interventional,12/7/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00573443
9680,TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults,Completed,Has Results,"Migraine Disorders|Migraine, Acute",Drug: TREXIMET®|Drug: Butalbital-containing Combination Medications (BCM)|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,2/8/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00573170
9681,Fibrin Sealant Vascular Surgery Study,Completed,Has Results,Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts),"Biological: FS VH S/D 500 s-apr, 60-seconds polymerization time|Biological: FS VH S/D 500 s-apr, 120-seconds polymerization time|Procedure: Manual compression with surgical gauze pads",Baxter Healthcare Corporation,Baxter Healthcare Corporation,,,,,,,Phase 2,Industry,Interventional,12/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00576420
9682,RNS® System LTT Study,Completed,Has Results,Epilepsy,Device: RNS® System,NeuroPace,NeuroPace,,,,,,,Phase 4,Industry,Interventional,4/6/2019,5/18/2019,https://ClinicalTrials.gov/show/NCT00572195
9683,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",Completed,Has Results,Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Drug: Metformin HCl and Colesevelam Placebo|Drug: Metformin HCl tablets and Colesevelam tablets|Drug: Colesevelam placebo|Drug: Colesevelam,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,11/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00570739
9684,An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer,Completed,Has Results,Pancreatic Cancer,Drug: MORAb-009|Drug: Placebo|Drug: Gemcitabine,Morphotek,Morphotek,,,,,,,Phase 2,Industry,Interventional,12/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00570713
9685,Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: Fluticasone furoate nasal spray|Drug: Placebo nasal spray,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,11/26/2007,3/17/2011,https://ClinicalTrials.gov/show/NCT00570492
9686,Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay,Completed,Has Results,Healthy Donors|HIV Positive,Device: collection of follow-up sample based on PRISM HIV O Plus result,Abbott Diagnostics Division,Abbott Diagnostics Division,,,,,,,Phase 3,Industry,Interventional,8/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00686205
9687,A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome,Completed,Has Results,Cushing's Syndrome,Drug: mifepristone,Corcept Therapeutics,Corcept Therapeutics,,,,,,,Phase 3,Industry,Interventional,12/7/2019,,https://ClinicalTrials.gov/show/NCT00569582
9688,Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS,Completed,Has Results,Atypical Hemolytic Uremic Syndrome,Drug: Eculizumab,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/9/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00844844
9689,Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS,Completed,Has Results,Atypical Hemolytic Uremic Syndrome,Drug: Eculizumab,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/9/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00844545
9690,Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma,Completed,Has Results,Asthma,Drug: INTRAVENOUS GSK679586|Drug: INTRAVENOUS PLACEBO|Drug: FLUTICASONE PROPIONATE,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/9/2008,7/25/2010,https://ClinicalTrials.gov/show/NCT00843193
9691,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects,Completed,Has Results,Obesity|Overweight,Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day|Drug: Placebo|Behavioral: Ancillary therapy,"Orexigen Therapeutics, Inc","Orexigen Therapeutics, Inc",,,,,,,Phase 3,Industry,Interventional,12/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00567255
9692,Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ,Completed,Has Results,"Contraception|Ovulation Inhibition|Contraceptives, Oral","Drug: EE20/DRSP (BAY86-5300)|Drug: EE20/DRSP (YAZ, BAY86-5300)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,10/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00567164
9693,Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy,Completed,Has Results,Psoriasis,Biological: adalimumab,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,1/8/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00566722
9694,"A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee",Completed,Has Results,Osteoarthritis,Drug: SD-6010|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,11/7/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00565812
9695,Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain,Completed,Has Results,Pain,Drug: IV Placebo|Drug: IV Acetaminophen,Mallinckrodt,Mallinckrodt,,,,,,,Phase 3,Industry,Interventional,11/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00564486
9696,Study Evaluating Vabicaserin in Subjects With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: vabicaserin|Drug: risperidone|Other: placebo,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00563706
9697,Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure,Completed,Has Results,Pneumothorax,Device: Bio-Seal Plug,Angiotech Pharmaceuticals,Angiotech Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/5/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00562302
9698,VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients,Completed,Has Results,HIV Infections,Drug: nevirapine IR|Drug: nevirapine XR,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/7/2019,,https://ClinicalTrials.gov/show/NCT00561925
9699,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,11/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00560417
9700,Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS,Completed,Has Results,Hyperlipidemia,Drug: AEGR-733|Drug: placebo|Drug: AEGR-733 and atorvastatin|Drug: AEGR-733 and fenofibrate|Drug: AEGR-733 and ezetimibe,"Aegerion Pharmaceuticals, Inc.","Aegerion Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,10/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00559962
9701,Methotrexate-Inadequate Response Study,Completed,Has Results,Rheumatoid Arthritis (RA),Drug: Subcutaneous (SC) Abatacept|Drug: Intravenous (IV) Abatacept,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,1/8/2019,9/14/2019,https://ClinicalTrials.gov/show/NCT00559585
9702,Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa,Completed,Has Results,Cystic Fibrosis,Drug: Arikayce™ 560 mg|Drug: Placebo for 560 mg|Drug: Arikayce™ 70 mg|Drug: Arikayce™ 140 mg|Drug: Placebo for 70 mg / 140 mg,Insmed Incorporated,Insmed Incorporated,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00558844
9703,Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria,Completed,Has Results,Tourette Syndrome,Drug: pramipexole immediate release (IR)|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,1/8/2019,,https://ClinicalTrials.gov/show/NCT00558467
9704,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,Completed,Has Results,Venous Thromboembolism,Drug: dabigatran etexilate 150 mg twice daily (BID)|Drug: matching placebo twice daily (BID),Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,11/7/2019,,https://ClinicalTrials.gov/show/NCT00558259
9705,Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer,Completed,Has Results,"Neoplasms, Breast",Drug: lapatinib|Drug: Pazopanib,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,12/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00558103
9706,"An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.",Completed,Has Results,Multiple Myeloma,Drug: Bortezomib|Drug: Dexamethasone|Drug: PD 0332991,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,1/8/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00555906
9707,"A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",Completed,Has Results,Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET)|Rhabdomyosarcoma|Leiomyosarcoma|Adipocytic Sarcoma|Synovial Sarcoma,Biological: IMC-A12 (cixutumumab),Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,7/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00668148
9708,Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia,Completed,Has Results,"Leukaemia, Lymphocytic, Chronic",Drug: OFC Infusion|Drug: FC infusion,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/12/2009,10/25/2017,https://ClinicalTrials.gov/show/NCT00824265
9709,"Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors",Completed,Has Results,Ewing's Sarcoma Family of Tumors,"Drug: CP-751,871",Pfizer,Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/8/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00560235
9710,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases,Completed,Has Results,Prostate Cancer,Drug: ZD4054|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,11/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00554229
9711,Asacol Acute Diverticulitis(DIVA)Study,Completed,Has Results,Diverticulitis,Drug: Mesalamine|Drug: Probiotic|Drug: Placebo|Other: Dietary Advice|Drug: Antibiotic for Diverticulitis,Warner Chilcott,Warner Chilcott,,,,,,,Phase 2,Industry,Interventional,11/7/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00554099
9712,Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension,Completed,Has Results,"Hypotension, Orthostatic",Drug: Midodrine hydrochloride|Drug: Placebo,Shire,Shire,,,,,,,Phase 4,Industry,Interventional,9/4/2019,3/5/2019,https://ClinicalTrials.gov/show/NCT00555880
9713,To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures,Completed,Has Results,Partial Epilepsies,Drug: lacosamide,UCB Pharma,UCB Pharma,,,,,,,Phase 2,Industry,Interventional,8/1/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00552305
9714,Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT),Completed,Has Results,HIV Infections,Drug: tenofovir DF 300 mg QD|Drug: emtricitabine 200 mg QD|Drug: Nevirapine 200 mg BID|Drug: Atazanavir 300 mg|Drug: Ritonavir 100 mg,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 4,Industry,Interventional,9/7/2019,,https://ClinicalTrials.gov/show/NCT00552240
9715,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,Completed,Has Results,Crohn Disease,"Biological: certolizumab pegol (CDP870, CZP)|Other: Placebo",UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,3/8/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00552058
9716,A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects,Completed,Has Results,Chronic Hepatitis C,Drug: Daclatasvir|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,5/8/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00663208
9717,Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: CRx-102 (2.7/180)|Drug: prednisolone|Drug: dipyridamole|Drug: placebo|Drug: CRx-102 (2.7/360),Zalicus,Zalicus,,,,,,,Phase 2,Industry,Interventional,10/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00551707
9718,Surgical Pain After Inguinal Hernia Repair (SPAIHR),Completed,Has Results,"Pain, Postoperative|Hernia, Inguinal",Drug: Pregabalin|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,1/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00551135
9719,"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects",Completed,Has Results,Influenza|Myxovirus Infection,"Biological: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|Biological: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|Biological: Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|Biological: Split, Inactivated, Trivalent Influenza Vaccine (High-dose)",Sanofi,Sanofi,,,,,,,Phase 2,Industry,Interventional,10/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00551031
9720,Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC),Completed,Has Results,"Liver Cirrhosis, Biliary",Drug: INT-747|Drug: Ursodeoxycholic Acid (URSO)|Drug: Placebo,Intercept Pharmaceuticals,Intercept Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,10/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00550862
9721,A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid","Drug: Adalimumab|Drug: CP-690-550|Drug: CP-690,550|Drug: Placebo",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,9/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00550446
9722,A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate (ACP-103),ACADIA Pharmaceuticals Inc.,ACADIA Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,7/7/2019,5/30/2018,https://ClinicalTrials.gov/show/NCT00550238
9723,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: MP29-02|Drug: azelastine Hcl|Drug: fluticasone propionate|Drug: placebo,Meda Pharmaceuticals,Meda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00660517
9724,Efficacy and Safety of LCZ696A in Patients With Essential Hypertension,Completed,Has Results,Hypertension,Drug: LCZ696|Drug: Valsartan|Drug: AHU377|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 2,Industry,Interventional,9/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00549770
9725,Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Lurasidone HCl,Sunovion,Sunovion,,,,,,,Phase 3,Industry,Interventional,10/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00549718
9726,Celebrex In Acute Gouty Arthritis Study,Completed,Has Results,"Arthritis, Gouty",Drug: Indomethacin|Drug: Celecoxib,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,2/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00549549
9727,"A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,Drug: INCB018424|Drug: Placebo,Incyte Corporation,Incyte Corporation,,,,,,,Phase 2,Industry,Interventional,10/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00550043
9728,AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Device: AtriCure Bipolar System,"AtriCure, Inc.","AtriCure, Inc.",,,,,,,Phase 3,Industry,Interventional,11/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00560885
9729,VEC-162 Study in Adult Patients With Primary Insomnia,Completed,Has Results,Primary Insomnia,Drug: VEC-162 20 mg|Drug: Placebo|Drug: VEC-162 50 mg,Vanda Pharmaceuticals,Vanda Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00548340
9730,Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis,Completed,Has Results,Chronic Kidney Disease,Device: Standard Bicarbonate Solution|Drug: Soluble Ferric Pyrophosphate,"Rockwell Medical Technologies, Inc.","Rockwell Medical Technologies, Inc.",,,,,,,Phase 2,Industry,Interventional,8/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00548249
9731,"PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib",Completed,Has Results,"Carcinoma, Non Small Cell Lung",Drug: PF-00299804,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,4/29/2008,6/11/2012,https://ClinicalTrials.gov/show/NCT00548093
9732,Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures,Completed,Has Results,Partial Epilepsies|Partial Onset Seizures,Drug: lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 3,Industry,Interventional,4/8/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00655551
9733,Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures,Completed,Has Results,Partial Epilepsies|Partial Onset Seizures,Drug: lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 3,Industry,Interventional,4/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00655486
9734,Phase IIIB Subcutaneous Abatacept Monotherapy Study,Completed,Has Results,Rheumatoid Arthritis (RA),Drug: abatacept|Drug: Methotrexate (MTX),Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,12/7/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00547521
9735,"Fesoterodine ""add-on"" Male Overactive Bladder Study",Completed,Has Results,Overactive Bladder Syndrome,Drug: Fesoterodine|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,11/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00546637
9736,"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Completed,Has Results,Pneumococcal Infections,Biological: 13 valent Pneumococcal Conjugate Vaccine|Biological: 23vPS,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 3,Industry,Interventional,11/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00546572
9737,Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America,Completed,Has Results,"Infections, Papillomavirus",Biological: Cervarix™,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,1/14/2008,12/1/2009,https://ClinicalTrials.gov/show/NCT00546078
9738,Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease,Completed,Has Results,Breast Cancer|Prostate Cancer|Bone Neoplasms,Drug: AZD0530|Drug: Zoledronic Acid,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,2/8/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00558272
9739,Prevention of Recurrence of Diverticulitis,Completed,Has Results,Diverticulitis,Drug: SPD476 (1.2g)|Drug: SPD476 (2.4 g)|Drug: SPD476 (4.8 g)|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,11/7/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00545740
9740,A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.,Completed,Has Results,"Influenza, Human",Drug: oseltamivir|Other: placebo,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,2/4/2008,5/2/2017,https://ClinicalTrials.gov/show/NCT00545532
9741,A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.,Completed,Has Results,"Hepatitis C, Chronic",Drug: peginterferon alfa-2a [Pegasys]|Drug: ribavirin [Copegus]|Drug: Pioglitazone,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,1/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00545233
9742,Prevention of Recurrence of Diverticulitis,Completed,Has Results,Diverticulitis,"Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet|Drug: Placebo",Shire,Shire,,,,,,,Phase 3,Industry,Interventional,12/7/2019,11/11/2019,https://ClinicalTrials.gov/show/NCT00545103
9743,A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents,Completed,Has Results,Pharmacokinetics,Drug: Voriconazole,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,6/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00556998
9744,Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: bosentan,Actelion,Actelion,,,,,,,Phase 3,Industry,Interventional,3/8/2011,8/19/2013,https://ClinicalTrials.gov/show/NCT01223352
9745,TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors,Completed,Has Results,HIV Infections|HIV-1,Drug: TMC278|Drug: efavirenz,"Tibotec Pharmaceuticals, Ireland","Tibotec Pharmaceuticals, Ireland",,,,,,,Phase 3,Industry,Interventional,6/8/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00543725
9746,A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients,Completed,Has Results,Kidney Transplantation,Drug: Alefacept|Drug: tacrolimus|Drug: basiliximab|Drug: mycophenolate mofetil|Drug: Corticosteroids,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 2,Industry,Interventional,2/8/2019,2/11/2019,https://ClinicalTrials.gov/show/NCT00543569
9747,Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE),Completed,Has Results,Coronary Artery Disease (CAD),Drug: M118|Drug: Unfractionated Heparin,"Momenta Pharmaceuticals, Inc.","Momenta Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,9/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00543400
9748,Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles,Completed,Has Results,Bilateral Nasolabial Fold Wrinkles,Biological: Autologous Human Fibroblast (azficel-T)|Biological: Placebo,"Fibrocell Technologies, Inc.","Fibrocell Technologies, Inc.",,,,,,,Phase 3,Industry,Interventional,10/6/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00649428
9749,A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: risedronate,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,10/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00541658
9750,Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Carcinoma,Drug: Albumin-bound paclitaxel|Drug: Paclitaxel|Drug: Carboplatin,Celgene,Celgene,,,,,,,Phase 3,Industry,Interventional,11/7/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00540514
9751,TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.,Completed,Has Results,HIV Infections|HIV-1|Human Immunodeficiency Virus Type 1,Drug: TMC278|Drug: Efavirenz,"Tibotec Pharmaceuticals, Ireland","Tibotec Pharmaceuticals, Ireland",,,,,,,Phase 3,Industry,Interventional,5/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00540449
9752,A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms,Completed,Has Results,Abdominal Aortic Aneurysm,Device: TriVascular Stent-Graft System,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 1,Industry,Interventional,2/3/2019,3/10/2019,https://ClinicalTrials.gov/show/NCT00646048
9753,Cutivate Lotion HPA Axis Pediatric Study,Completed,Has Results,Atopic Dermatitis,Drug: Fluticasone propionate 0.05% lotion,Fougera Pharmaceuticals Inc.,Fougera Pharmaceuticals Inc.,,,,,,,Phase 4,Industry,Interventional,7/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00546000
9754,Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: FPNS|Drug: FFNS|Drug: placebo FPNS|Drug: placebo FFNS,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,8/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00539006
9755,"Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)",Completed,Has Results,Primary Immune Deficiency Disorders (PIDD),Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%],Biotest Pharmaceuticals Corporation,Biotest Pharmaceuticals Corporation,,,,,,,Phase 3,Industry,Interventional,9/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00538915
9756,Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain,Completed,Has Results,Cancer|Pain,Drug: Fentanyl sublingual spray,INSYS Therapeutics Inc,INSYS Therapeutics Inc,,,,,,,Phase 3,Industry,Interventional,12/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00538863
9757,A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease,Completed,Has Results,Congenital Heart Disease,Biological: Motavizumab|Biological: Palivizumab,MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,10/5/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00538785
9758,Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring,Completed,Has Results,Acne Scarring of the Face,Biological: Autologous Human Fibroblasts (azficel-T)|Biological: Placebo,"Fibrocell Technologies, Inc.","Fibrocell Technologies, Inc.",,,,,,,Phase 2|Phase 3,Industry,Interventional,11/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00642642
9759,"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).",Completed,Has Results,Complicated Intra-abdominal Infections,Drug: Ceftazidime -avibactam|Drug: Meropenem|Drug: Metronidazole,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/1/2015,6/1/2017,https://ClinicalTrials.gov/show/NCT02475733
9760,Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years,Completed,Has Results,Eosinophilic Esophagitis,Biological: Reslizumab|Other: Saline,Ception Therapeutics|Teva Pharmaceutical Industries,Ception Therapeutics,Teva Pharmaceutical Industries,,,,,,Phase 2|Phase 3,Industry,Interventional,3/8/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00538434
9761,Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin detemir|Drug: insulin aspart,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 4,Industry,Interventional,10/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00537303
9762,Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcers,Device: acoustical pulse energy (extracorporeal shockwave)|Other: Sham,"SANUWAVE, Inc.","SANUWAVE, Inc.",,,,,,,Phase 3,Industry,Interventional,10/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00536744
9763,Comparison of Two Toric Contact Lenses on Current Toric Wearers,Completed,Has Results,Ametropia,Device: senofilcon A toric|Device: alphafilcon A toric,"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson Vision Care, Inc.",,,,,,,Not Applicable,Industry,Interventional,2/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00639379
9764,Fesoterodine Flexible Dose Study,Completed,Has Results,Overactive Bladder,Drug: Fesoterodine|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,8/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00536484
9765,A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients,Completed,Has Results,Major Depressive Disorder,Drug: Duloxetine hydrochloride|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,9/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00536471
9766,A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Placebo|Drug: Methotrexate,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,10/31/2007,1/31/2011,https://ClinicalTrials.gov/show/NCT00535782
9767,Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease,Completed,Has Results,Schizophrenia|Schizoaffective Disorder|Psychotic Disorders,"Drug: Treatment as usual (TAU), Paliperidone ER","Ortho-McNeil Janssen Scientific Affairs, LLC","Ortho-McNeil Janssen Scientific Affairs, LLC",,,,,,,Phase 4,Industry,Interventional,10/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00535145
9768,Generalized Anxiety Disorder Adjunct Study,Completed,Has Results,Anxiety|Anxiety Disorders|Anxiety Neuroses|Anxiety States,Drug: Placebo|Drug: quetiapine fumarate XR,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,8/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00534599
9769,Trident® Tritanium™ Acetabular Shell Revision Study,Completed,Has Results,"Arthroplasty, Replacement, Hip",Device: Trident® Tritanium™ Acetabular Shell,Stryker Orthopaedics,Stryker Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,11/6/2019,9/16/2019,https://ClinicalTrials.gov/show/NCT00535626
9770,Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone,Completed,Has Results,Schizophrenia,Drug: Oral Risperidone|Drug: Paliperidone ER,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 4,Industry,Interventional,10/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00535132
9771,Phase IIIB Subcutaneous Missed Dose Study,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,11/7/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT00533897
9772,Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure,Completed,Has Results,Lacerations,Device: cyanoacrylate with pressure sensitive mesh|Device: cyanoacrylate,"Ethicon, Inc.","Ethicon, Inc.",,,,,,,Phase 2,Industry,Interventional,8/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00547638
9773,A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma,Completed,Has Results,Metastatic Malignant Melanoma,Biological: IMC-1121B (ramucirumab)|Drug: Dacarbazine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00533702
9774,Evaluation of the 2005 AMS (American Medical System) IPP (Inflatable Penile Prosthesis),Completed,Has Results,Erectile Dysfunction,Device: AMS 700 IPP with MS Pump,American Medical Systems,American Medical Systems,,,,,,,Phase 2,Industry,Interventional,8/5/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00636506
9775,"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects",Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Drug: Immune Globulin Intravenous (Human), 10%",Baxalta now part of Shire|Shire,Baxalta now part of Shire,Shire,,,,,,Phase 2|Phase 3,Industry,Interventional,10/3/2007,9/1/2009,https://ClinicalTrials.gov/show/NCT00546871
9776,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,Completed,Has Results,Obesity|Overweight,Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day|Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day|Drug: Placebo|Behavioral: Ancillary therapy,"Orexigen Therapeutics, Inc","Orexigen Therapeutics, Inc",,,,,,,Phase 3,Industry,Interventional,10/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00532779
9777,CT-011 MAb in DLBCL Patients Following ASCT,Completed,Has Results,"Lymphoma, Large Cell, Diffuse|Lymphoma, Mixed Cell, Diffuse|Primary Mediastinal Large B-Cell Lymphoma",Drug: CT-011,CureTech Ltd,CureTech Ltd,,,,,,,Phase 2,Industry,Interventional,10/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00532259
9778,Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects,Completed,Has Results,Primary Immune Deficiency Disease,Biological: Flebogamma 5% DIF,"Instituto Grifols, S.A.|Grifols Biologicals, LLC","Instituto Grifols, S.A.","Grifols Biologicals, LLC",,,,,,Phase 4,Industry,Interventional,5/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00634569
9779,Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression,Completed,Has Results,Major Depressive Disorder,Drug: Selegiline Transdermal System|Drug: Placebo,Somerset Pharmaceuticals,Somerset Pharmaceuticals,,,,,,,Phase 4,Industry,Interventional,7/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00531947
9780,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Placebo|Drug: Permitted DMARDs,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,10/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00531817
9781,Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis,Completed,Has Results,Aspergillosis,Drug: voriconazole|Drug: anidulafungin,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,7/8/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00531479
9782,Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee,Completed,Has Results,Chronic Pain|Osteoarthritis of the Knee,Drug: Buprenorphine|Drug: Placebo,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,9/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00531427
9783,THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial,Completed,Has Results,Critical Aortic Stenosis,Device: Edwards SAPIEN Transcatheter Heart Valve|Device: Surgical Valve Replacement|Other: medical management and/or balloon aortic valvuloplasty,Edwards Lifesciences,Edwards Lifesciences,,,,,,,Not Applicable,Industry,Interventional,4/7/2019,7/17/2019,https://ClinicalTrials.gov/show/NCT00530894
9784,Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: Lacosamide,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,2/8/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00530855
9785,Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: carfilzomib,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,9/7/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00530816
9786,The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Biological: BG00002 (natalizumab)|Biological: keyhole limpet hemocyanin (KLH)|Biological: tetanus diphtheria toxoid vaccine (Td),Biogen,Biogen,,,,,,,Phase 4,Industry,Interventional,1/8/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00536120
9787,Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: duloxetine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00529789
9788,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease,Completed,Has Results,"Hepatitis C, Chronic",Drug: eltrombopag|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00529568
9789,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: Indacaterol 300 μg|Drug: Salmeterol 50 μg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,9/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00529529
9790,REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent,Completed,Has Results,Renal Artery Stenosis,Device: Formula Balloon-Expandable Stent,Cook Group Incorporated,Cook Group Incorporated,,,,,,,Not Applicable,Industry,Interventional,2/8/2019,5/12/2019,https://ClinicalTrials.gov/show/NCT00631540
9791,Effect of Panitumumab on the Pharmacokinetics of Irinotecan,Completed,Has Results,Metastatic Colorectal Cancer,Drug: Panitumumab|Drug: Irinotecan,Amgen,Amgen,,,,,,,Phase 1,Industry,Interventional,3/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00563316
9792,Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia,Biological: asfotase alfa,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,4/9/2019,8/16/2019,https://ClinicalTrials.gov/show/NCT01205152
9793,BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Bevacizumab|Drug: Standard adjuvant chemotherapy,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 3,Industry,Interventional,12/7/2019,6/14/2019,https://ClinicalTrials.gov/show/NCT00528567
9794,Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study,Completed,Has Results,Contraception,Drug: LCS12|Drug: LCS16,Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,8/7/2019,6/13/2019,https://ClinicalTrials.gov/show/NCT00528112
9795,"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture",Completed,Has Results,Dupuytren's Contracture,Biological: collagenase clostridium histolyticum|Biological: Placebo,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,8/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00528606
9796,"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",Completed,Has Results,Advanced Dupuytren's Disease,Biological: AA4500,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,12/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00528424
9797,"Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",Completed,Has Results,Advanced Dupuytren's Disease,Biological: collagenase clostridium histolyticum,Endo Pharmaceuticals,Endo Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,10/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00528840
9798,Zalutumumab in Non-curable Patients With SCCHN,Completed,Has Results,Head and Neck Cancer|Squamous Cell Cancer,Drug: Zalutumumab,Genmab,Genmab,,,,,,,Phase 2,Industry,Interventional,1/8/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00542308
9799,Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC),Completed,Has Results,"Lung Cancer|Small Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung",Drug: Ipilimumab|Drug: Placebo|Drug: Paclitaxel|Drug: Carboplatin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,2/8/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00527735
9800,Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension,Completed,Has Results,Hypertension,Drug: Amlodipine|Drug: Olmesartan medoxomil plus amlodipine,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,9/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00527514
9801,Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System,Completed,Has Results,Non-inflammatory Degenerative Joint Disease,Device: ASR™-XL Modular Acetabular Cup System|Device: Pinnacle™ acetabular shell,DePuy Orthopaedics,DePuy Orthopaedics,,,,,,,Not Applicable,Industry,Interventional,11/1/2006,1/1/2012,https://ClinicalTrials.gov/show/NCT00561600
9802,Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans,Completed,Has Results,Acute Myeloid Leukemia,Drug: Voreloxin injection and cytarabine,Sunesis Pharmaceuticals,Sunesis Pharmaceuticals,,,,,,,Phase 1|Phase 2,Industry,Interventional,10/6/2007,2/15/2012,https://ClinicalTrials.gov/show/NCT00541866
9803,"Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced",Completed,Has Results,"Hepatitis C, Chronic",Drug: BI201335|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 1,Industry,Interventional,9/7/2019,1/25/2011,https://ClinicalTrials.gov/show/NCT00793793
9804,Treatment of Patients With Blepharitis and Facial Rosacea,Completed,Has Results,Blepharitis|Meibomianitis|Dry Eye,"Drug: COL-101 (doxycycline, USP) capsules|Drug: placebo",Galderma,Galderma,,,,,,,Phase 2,Industry,Interventional,11/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00560703
9805,Dialysis Catheter Comparative Clinical Trial,Completed,Has Results,End Stage Renal Disease,Device: Symmetric Tip Catheter|Device: Conventional Split-tip Catheter,Tyco Healthcare Group,Tyco Healthcare Group,,,,,,,Not Applicable,Industry,Interventional,9/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00526123
9806,"LUX Lung 2 Phase II Single Arm BIBW 2992 ""Afatinib"" in NSCLC With EGFR Activating Mutations",Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: BIBW 2992,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,8/7/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00525148
9807,A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN),Completed,Has Results,Human Immunodeficiency Virus - Type 1,Drug: Darunavir (DRV)|Drug: Ritonavir (rtv),"Tibotec Pharmaceuticals, Ireland","Tibotec Pharmaceuticals, Ireland",,,,,,,Phase 3,Industry,Interventional,10/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00524368
9808,Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.,Completed,Has Results,"Neoplasms, Breast",Drug: Trastuzumab|Drug: Paclitaxel|Drug: FEC75|Drug: Lapatinib,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/7/2019,8/15/2019,https://ClinicalTrials.gov/show/NCT00524303
9809,An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Paliperidone ER|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 4,Industry,Interventional,9/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00524043
9810,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),Completed,Has Results,Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),Drug: Everolimus (RAD001)|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,4/9/2019,11/15/2019,https://ClinicalTrials.gov/show/NCT00790400
9811,Long-term Effect of Lanthanum Carbonate on Bone,Completed,Has Results,Hyperphosphatemia,Drug: Lanthanum carbonate,Shire,Shire,,,,,,,,Industry,Observational,8/5/2019,8/10/2019,https://ClinicalTrials.gov/show/NCT00557323
9812,Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis,Completed,Has Results,Adult Periodontitis,Drug: minocycline HCl 2.1%|Procedure: Scaling and root planing,Sunstar Americas,Sunstar Americas,,,,,,,Phase 3,Industry,Interventional,1/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00529555
9813,Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103),Completed,Has Results,Cystinosis,Drug: Cysteamine Bitartrate Delayed-release Capsules,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.",,,,,,,Phase 3,Industry,Interventional,8/27/2010,6/26/2017,https://ClinicalTrials.gov/show/NCT01197378
9814,Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease,Completed,Has Results,Fabry Disease,Drug: Migalastat HCl|Biological: Agalsidase Beta|Biological: Agalsidase Alfa,Amicus Therapeutics,Amicus Therapeutics,,,,,,,Phase 2,Industry,Interventional,2/2/2011,10/9/2012,https://ClinicalTrials.gov/show/NCT01196871
9815,Endometrial Safety Study,Completed,Has Results,Postmenopause,Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: 0.5mg NETA / 1.0mg E2 (Activella),"Bayer|Laboratorium für Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco",Bayer,Laboratorium für Klinische Forschung,"Diagnostic Cytology Laboratory|University of California, San Francisco",Diagnostic Cytology Laboratory,"University of California, San Francisco",,,Phase 3,Industry|Other,Interventional,8/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00522873
9816,A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension,Completed,Has Results,Hypertension,Drug: PS433540|Drug: placebo,Ligand Pharmaceuticals,Ligand Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,8/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00522925
9817,Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch,Completed,Has Results,Parkinson's Disease,Drug: Rotigotine|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,7/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00522379
9818,Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures,Completed,Has Results,Partial Epilepsies,Drug: lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 3,Industry,Interventional,10/4/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00522275
9819,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 300 μg|Drug: Placebo to indacaterol|Drug: Salmeterol 50 μg,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,1/8/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00622635
9820,Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine,Completed,Has Results,Influenza,Biological: 13 valent pneumococcal conjugate vaccine,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/7/2019,12/13/2019,https://ClinicalTrials.gov/show/NCT00521586
9821,"An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome",Completed,Has Results,Atypical Hemolytic-Uremic Syndrome,Drug: Eculizumab,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/10/2019,2/14/2019,https://ClinicalTrials.gov/show/NCT01194973
9822,Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: Lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma","UCB BIOSCIENCES, Inc.",UCB Pharma,,,,,,Phase 3,Industry,Interventional,8/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00520741
9823,EMPOWER Clinical Trial: Vagal Blocking for Obesity Control,Completed,Has Results,Obesity,Device: Therapy ON|Device: Therapy OFF,ReShape Lifesciences,ReShape Lifesciences,,,,,,,Not Applicable,Industry,Interventional,8/7/2019,5/18/2019,https://ClinicalTrials.gov/show/NCT00521079
9824,Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy,Completed,Has Results,Epilepsy,Drug: Levetiracetam,UCB Pharma,UCB Pharma,,,,,,,Phase 2,Industry,Interventional,9/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00535392
9825,A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy,Completed,Has Results,Rheumatoid Arthritis,Biological: LY2127399|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,10/8/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00785928
9826,A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: ASC-J9 cream|Drug: placebo,AndroScience Corp,AndroScience Corp,,,,,,,Phase 2,Industry,Interventional,8/7/2019,7/8/2019,https://ClinicalTrials.gov/show/NCT00525499
9827,A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas,Completed,Has Results,Glioma,Drug: capecitabine [Xeloda],Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 1,Industry,Interventional,5/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00532948
9828,Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: FPNS|Drug: FFNS|Drug: placebo FFNS|Drug: placebo FPNS,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,8/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00519636
9829,Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea,Completed,Has Results,Papulopustular Rosacea,Drug: Azelaic acid|Drug: Vehicle foam,Bayer,Bayer,,,,,,,Phase 2,Industry,Interventional,1/8/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00617903
9830,Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression,Completed,Has Results,Sleep Disorders|Obstructive Sleep Apnea|Major Depressive Disorder|Dysthymic Disorder,Drug: armodafinil|Drug: placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 4,Industry,Interventional,10/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00518986
9831,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: exenatide,Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 3,Industry,Interventional,8/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00518882
9832,Clobazam in Patients With Lennox-Gastaut Syndrome,Completed,Has Results,"Epilepsy|Epilepsy, Generalized|Seizures",Drug: Clobazam Low Dose|Drug: Clobazam Medium Dose|Drug: Clobazam High Dose|Drug: Placebo,Lundbeck LLC,Lundbeck LLC,,,,,,,Phase 3,Industry,Interventional,8/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00518713
9833,Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Albiglutide (GSK716155) or exenatide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00518115
9834,Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults,Completed,Has Results,Influenza,Biological: Fluarix|Biological: GSK Biologicals Influenza Vaccine GSK576389A,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/15/2007,6/4/2008,https://ClinicalTrials.gov/show/NCT00529516
9835,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease,Completed,Has Results,"Hepatitis C, Chronic",Drug: eltrombopag|Drug: placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,10/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00516321
9836,Lamotrigine Extended-Release In Elderly Patients With Epilepsy,Completed,Has Results,Epilepsy,Drug: Lamotrigine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,8/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00516139
9837,A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients,Completed,Has Results,Drooling,Biological: Botulinum Toxin Type B (Myobloc)|Biological: Matched placebo to Myobloc,Solstice Neurosciences|US WorldMeds LLC,Solstice Neurosciences,US WorldMeds LLC,,,,,,Phase 2,Industry,Interventional,7/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00515437
9838,BIBW 2992 (Afatinib) in Head & Neck Cancer,Completed,Has Results,"Head and Neck Neoplasms|Carcinoma, Squamous Cell",Drug: BIBW 2992|Drug: Cetuximab,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,8/7/2019,7/13/2019,https://ClinicalTrials.gov/show/NCT00514943
9839,Tailored Treatment of Permanent Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Procedure: Medtronic Cardiac Ablation System|Drug: Class I or III Antiarrhythmic Medications,Medtronic Cardiac Rhythm and Heart Failure,Medtronic Cardiac Rhythm and Heart Failure,,,,,,,Phase 3,Industry,Interventional,5/7/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00514735
9840,Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome,Completed,Has Results,Acute Coronary Syndrome,Drug: Iodofiltic acid I 123,"Molecular Insight Pharmaceuticals, Inc.","Molecular Insight Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,5/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00514501
9841,Phase 2 Study for the Treatment of Superficial Lipomas,Completed,Has Results,Lipoma,Drug: Deoxycholic Acid Injection|Drug: Placebo,Kythera Biopharmaceuticals,Kythera Biopharmaceuticals,,,,,,,Phase 2,Industry,Interventional,11/7/2019,1/10/2019,https://ClinicalTrials.gov/show/NCT00608842
9842,A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma,Completed,Has Results,Metastatic Renal Cell Carcinoma,Biological: Ramucirumab,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,11/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00515697
9843,"A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients",Completed,Has Results,Schizophrenia,Drug: Paliperidone ER|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 3,Industry,Interventional,8/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00518323
9844,Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: carfilzomib,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,8/7/2019,10/12/2019,https://ClinicalTrials.gov/show/NCT00511238
9845,Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: NVA237 100 µg|Drug: Placebo|Drug: NVA237 200 µg,Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,8/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00510510
9846,Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Pancrelipase Delayed Release|Drug: Placebo Comparator,Solvay Pharmaceuticals,Solvay Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,11/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00510484
9847,Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Atomoxetine hydrochloride|Drug: Placebo,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 4,Industry,Interventional,8/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00510276
9848,Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors,Completed,Has Results,Advanced Neuroendocrine Tumors of Pancreatic Origin,Drug: Everolimus|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,7/7/2019,3/14/2019,https://ClinicalTrials.gov/show/NCT00510068
9849,Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band,Completed,Has Results,Morbid Obesity,Device: REALIZE™ Swedish Adjustable Gastric Band,Ethicon Endo-Surgery,Ethicon Endo-Surgery,,,,,,,Phase 4,Industry,Interventional,8/6/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00543140
9850,A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: Trastuzumab emtansine [Kadcyla],"Genentech, Inc.","Genentech, Inc.",,,,,,,Phase 2,Industry,Interventional,7/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00509769
9851,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Glargine,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,8/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00510952
9852,Interventricular Delay of Lumax HF-T for Heart Failure,Completed,Has Results,Congestive Heart Failure,Device: Optimized interventricular delay biventricular pacing,"Biotronik, Inc.","Biotronik, Inc.",,,,,,,Phase 2,Industry,Interventional,7/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00508391
9853,Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction,Completed,Has Results,Lower Urinary Tract Symptoms|Bladder Outlet Obstruction,Drug: solifenacin succinate|Drug: tamsulosin hydrochloride|Drug: Placebo to solifenacin|Drug: Placebo to tamsulosin,Astellas Pharma Inc,Astellas Pharma Inc,,,,,,,Phase 2,Industry,Interventional,6/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00507455
9854,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Completed,Has Results,Multiple Myeloma,Drug: Bortezomib|Drug: Dexamethasone|Drug: Melphalan|Drug: Prednisone|Drug: Thalidomide,"Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",,,,,,,Phase 3,Industry,Interventional,6/7/2019,3/13/2019,https://ClinicalTrials.gov/show/NCT00507416
9855,GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes,Completed,Has Results,Diabetes Mellitus Type 2,Device: Positive Airway Pressure therapy|Behavioral: Lifestyle counseling,ResMed|Royal North Shore Hospital|Baker IDI Heart and Diabetes Institute|International Diabetes Center at Park Nicollet,ResMed,Royal North Shore Hospital,Baker IDI Heart and Diabetes Institute|International Diabetes Center at Park Nicollet,Baker IDI Heart and Diabetes Institute,International Diabetes Center at Park Nicollet,,,Not Applicable,Industry|Other,Interventional,7/7/2019,2/12/2019,https://ClinicalTrials.gov/show/NCT00509223
9856,MPC-004 for the Treatment of an Acute Gout Flare,Completed,Has Results,Gout,Drug: High Dose Colchicine (4.8 mg total dose)|Drug: Low Dose Colchicine (1.8mg total dose)|Other: Placebo Control,Takeda,Takeda,,,,,,,Phase 3,Industry,Interventional,4/7/2019,10/7/2019,https://ClinicalTrials.gov/show/NCT00506883
9857,"A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia",Completed,Has Results,Chronic Kidney Disease|Dialysis|Hyperphosphatemia,Drug: MCI-196|Drug: Placebo,Mitsubishi Tanabe Pharma Corporation,Mitsubishi Tanabe Pharma Corporation,,,,,,,Phase 3,Industry,Interventional,9/7/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00506441
9858,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Completed,Has Results,Alzheimer Disease,Drug: Rivastigmine 5 cm^2|Drug: Rivastigmine 10 cm^2|Drug: Rivastigmine 15 cm^2|Drug: Placebo to 15 cm^2 patch|Drug: Placebo to 10 cm^2 patch,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,6/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00506415
9859,Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent,Completed,Has Results,Atrial Fibrillation,Device: Cardioblate Surgical Ablation System|Procedure: Surgical RF Ablation,Medtronic Cardiovascular,Medtronic Cardiovascular,,,,,,,Phase 3,Industry,Interventional,9/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00506493
9860,A Comparison of Once a Day Dose Compared to 2 Doses/Day,Completed,Has Results,Ulcerative Colitis,Drug: Mesalamine Once-Daily|Drug: Mesalamine Twice-Daily,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,7/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00505778
9861,A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Thromboembolism,Drug: Edoxaban (DU-176b)|Drug: warfarin,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 2,Industry,Interventional,6/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00504556
9862,"An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia",Completed,Has Results,"Pneumonia|Bacterial Pneumonia|Ventilator-Associated Pneumonia|Infections, Nosocomial",Drug: doripenem,"PriCara, Unit of Ortho-McNeil, Inc.","PriCara, Unit of Ortho-McNeil, Inc.",,,,,,,Phase 2,Industry,Interventional,8/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00502801
9863,Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine,Completed,Has Results,"Rhinitis, Allergic, Seasonal","Drug: fluticasone furoate, fexofenadine",GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,8/7/2019,11/7/2019,https://ClinicalTrials.gov/show/NCT00502775
9864,A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.,Completed,Has Results,Post-Menopausal Osteoporosis,Drug: ibandronate [Bonviva/Boniva]|Drug: Alendronate,Hoffmann-La Roche,Hoffmann-La Roche,,,,,,,Phase 4,Industry,Interventional,7/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00503113
9865,Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus,Completed,Has Results,Kidney Transplant,Drug: ramipril,Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,12/7/2019,9/13/2019,https://ClinicalTrials.gov/show/NCT00502242
9866,Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,Completed,Has Results,ADHD,Drug: Methylphenidate Transdermal System,Noven Therapeutics,Noven Therapeutics,,,,,,,Phase 3,Industry,Interventional,8/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00501293
9867,A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT),Completed,Has Results,Chronic Hepatitis B,Drug: Tenofovir DF|Drug: FTC|Drug: Placebo,Gilead Sciences,Gilead Sciences,,,,,,,Phase 2,Industry,Interventional,9/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00507507
9868,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,Completed,Has Results,Moderate Risk of CVD,"Drug: Aspirin (Acetylsalicylic acid, BAYE4465)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,7/5/2007,11/15/2016,https://ClinicalTrials.gov/show/NCT00501059
9869,A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Aclidinium Bromide|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,7/7/2019,9/10/2019,https://ClinicalTrials.gov/show/NCT00500318
9870,"Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD",Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Vyvanse (lisdexamfetamine dimesylate),Shire,Shire,,,,,,,Phase 4,Industry,Interventional,7/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00500071
9871,Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,Completed,Has Results,ADHD,Drug: methylphenidate transdermal system|Drug: Placebo,Noven Therapeutics,Noven Therapeutics,,,,,,,Phase 3,Industry,Interventional,7/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00499863
9872,Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK189075|Drug: pioglitazone|Other: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,1/23/2007,2/14/2008,https://ClinicalTrials.gov/show/NCT00500331
9873,Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects,Completed,Has Results,Pneumococcal Infections,Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC),Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,5/8/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00500266
9874,Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects,Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster Vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,9/30/2010,5/14/2013,https://ClinicalTrials.gov/show/NCT01165203
9875,Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients,Completed,Has Results,Cytomegalovirus Infections,Drug: maribavir|Drug: ganciclovir,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,7/7/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00497796
9876,An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed,Completed,Has Results,Lung Neoplasms,Drug: Pemetrexed,Eli Lilly and Company,Eli Lilly and Company,,,,,,,,Industry,Observational,2/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00497770
9877,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Completed,Has Results,Chronic Kidney Disease|Left Ventricular Hypertrophy,Drug: paricalcitol|Drug: placebo,"AbbVie (prior sponsor, Abbott)|Massachusetts General Hospital|AbbVie","AbbVie (prior sponsor, Abbott)",Massachusetts General Hospital,AbbVie,,,,,Phase 3,Industry|Other,Interventional,2/8/2019,3/12/2019,https://ClinicalTrials.gov/show/NCT00497146
9878,Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis,Completed,Has Results,Candidiasis,Drug: Eraxis (anidulafungin)|Drug: Diflucan (fluconazole)|Drug: Vfend (voriconazole),Pfizer,Pfizer,,,,,,,Phase 4,Industry,Interventional,7/7/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00496197
9879,Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK189075|Drug: Placebo,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,8/17/2007,6/5/2008,https://ClinicalTrials.gov/show/NCT00495469
9880,"A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin",Completed,Has Results,Coronary Artery Disease,Drug: Ticagrelor Tablets|Drug: Clopidogrel (over encapsulated) capsule|Drug: Aspirin Tablets,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,10/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00528411
9881,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),Completed,Has Results,Diabetes Mellitus Type 2,Drug: Insulin Lispro Protamine Suspension|Drug: Detemir,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 3,Industry,Interventional,8/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00494013
9882,Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib,Completed,Has Results,"Neoplasms, Gastrointestinal Tract",Drug: Lapatinib and Capecitabine,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,3/8/2019,1/15/2019,https://ClinicalTrials.gov/show/NCT00526669
9883,Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age,Completed,Has Results,"Respiratory Viral Infections|Respiratory Syncytial Virus Infections|Parainfluenza Virus 3, Human",Biological: MEDI-534,MedImmune LLC,MedImmune LLC,,,,,,,Phase 1,Industry,Interventional,7/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00493285
9884,Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL),Completed,Has Results,Choroidal Neovascularization|Macular Degeneration,Drug: verteporfin|Drug: ranibizumab|Drug: dexamethasone,QLT Inc.,QLT Inc.,,,,,,,Phase 2,Industry,Interventional,7/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00492284
9885,Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia,Completed,Has Results,Chronic Insomnia,Drug: Ramelteon and zolpidem|Drug: Placebo and zolpidem,Takeda,Takeda,,,,,,,Phase 4,Industry,Interventional,4/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00492232
9886,BAY12-8039: 5 Days for Sinusitis vs Placebo,Completed,Has Results,Sinusitis,"Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Placebo",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,1/5/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00492024
9887,An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: Rotigotine,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,2/5/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00505687
9888,A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder,Completed,Has Results,Bipolar Disorder,Drug: Olanzapine|Drug: Paliperidone ER|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,Phase 3,Industry,Interventional,5/6/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00490971
9889,Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Buprenorphine transdermal system|Drug: Placebo,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 3,Industry,Interventional,6/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00490919
9890,"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9",Completed,Has Results,Acellular Pertussis|Tetanus|Diphtheria,Procedure: Taking of blood samples|Biological: Boostrix|Biological: Adacel,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,6/7/2019,3/16/2019,https://ClinicalTrials.gov/show/NCT00489970
9891,"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C",Completed,Has Results,Chronic Hepatitis C,Drug: Nitazoxanide|Drug: Placebo|Biological: Peginterferon alfa-2a|Drug: Ribavirin,Romark Laboratories L.C.,Romark Laboratories L.C.,,,,,,,Phase 2,Industry,Interventional,7/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00495391
9892,TAXUS PERSEUS Small Vessel,Completed,Has Results,Coronary Artery Disease,Device: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,7/7/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00489541
9893,Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia (HPP),Biological: asfotase alfa,Alexion Pharmaceuticals,Alexion Pharmaceuticals,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00744042
9894,Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents,Completed,Has Results,Migraine Disorders,Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium),GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 3,Industry,Interventional,7/13/2007,8/20/2009,https://ClinicalTrials.gov/show/NCT00488514
9895,"Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age",Completed,Has Results,"Bacterial Infections|Intra-Abdominal Infection|Pneumonia, Bacterial|Skin Diseases, Bacterial|Skin Diseases, Infectious",Drug: Tygacil,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,Phase 2,Industry,Interventional,12/7/2019,9/9/2019,https://ClinicalTrials.gov/show/NCT00488345
9896,Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.,Completed,Has Results,Schizophrenia|Schizophrenic Disorders|Psychotic Disorders|Dementia Praecox,Drug: Paliperidone ER,"Janssen Research & Development, LLC","Janssen Research & Development, LLC",,,,,,,Phase 3,Industry,Interventional,6/7/2019,7/12/2019,https://ClinicalTrials.gov/show/NCT00488319
9897,Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Canakinumab (investigational)|Drug: Placebo|Drug: Methotrexate (MTX),Novartis,Novartis,,,,,,,Phase 2,Industry,Interventional,3/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00487825
9898,Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits,Completed,Has Results,Schizophrenia,Drug: armodafinil|Drug: placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,7/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00487942
9899,"A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)",Completed,Has Results,Rheumatoid Arthritis,Drug: AZD9056|Drug: Etanercept|Drug: Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 2,Industry,Interventional,8/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00520572
9900,"Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)",Completed,Has Results,"Hereditary Inclusion Body Myopathy|Distal Myopathy With Rimmed Vacuoles|Distal Myopathy, Nonaka Type|GNE Myopathy",Drug: aceneuramic acid extended-release (Ace-ER)|Drug: Placebo,Ultragenyx Pharmaceutical Inc,Ultragenyx Pharmaceutical Inc,,,,,,,Phase 3,Industry,Interventional,5/20/2015,6/9/2017,https://ClinicalTrials.gov/show/NCT02377921
9901,A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,ADHD,Drug: Vyvanse (lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,6/7/2019,12/7/2019,https://ClinicalTrials.gov/show/NCT00500149
9902,"Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study",Completed,Has Results,Inflammatory Bowel Disease|Ulcerative Colitis,Drug: Balsalazide Disodium,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",,,,,,,Phase 3,Industry,Interventional,10/6/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00486031
9903,Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A|Haemophilia B,Drug: eptacog alfa (activated)|Drug: vatreptacog alfa (activated),Novo Nordisk A/S,Novo Nordisk A/S,,,,,,,Phase 2,Industry,Interventional,6/7/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00486278
9904,A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma,Completed,Has Results,"Sarcoma, Soft Tissue",Drug: LY573636-sodium,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,8/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00490451
9905,INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial,Completed,Has Results,Degenerative Disc Disease,Device: INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate,Medtronic Spinal and Biologics,Medtronic Spinal and Biologics,,,,,,,Not Applicable,Industry,Interventional,6/7/2019,6/12/2019,https://ClinicalTrials.gov/show/NCT00485173
9906,An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy,Completed,Has Results,Prostatic Neoplasms|Prostate Cancer,Drug: Abiraterone acetate|Drug: Prednisone,"Cougar Biotechnology, Inc.","Cougar Biotechnology, Inc.",,,,,,,Phase 2,Industry,Interventional,6/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00485303
9907,RexMedical- Option* Vena Cava Filter IDE Study,Completed,Has Results,Pulmonary Embolism,Device: Intravascular Filter Device,Rex Medical,Rex Medical,,,,,,,Not Applicable,Industry,Interventional,10/6/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00488865
9908,"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",Completed,Has Results,Type 2 Diabetes|Hyperlipidemia,Drug: Colesevelam HCl|Drug: rosiglitazone maleate|Drug: sitagliptin phosphate,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.",,,,,,,Phase 3,Industry,Interventional,5/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00484419
9909,TAXUS PERSEUS Workhorse,Completed,Has Results,Coronary Artery Disease,Device: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|Device: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement,Boston Scientific Corporation,Boston Scientific Corporation,,,,,,,Phase 3,Industry,Interventional,7/7/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00484315
9910,Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients,Completed,Has Results,Kidney Transplantation,"Drug: Cyclosporine|Drug: CP-690,550",Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00483756
9911,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR|Drug: Placebo,Acorda Therapeutics,Acorda Therapeutics,,,,,,,Phase 3,Industry,Interventional,5/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00483652
9912,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Completed,Has Results,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|Biological: Measles-mumps-rubella-varicella vaccine|Biological: Routine paediatric vaccine - Pneumococcal conjugate (PCV)|Biological: Routine paediatric vaccine - Hepatitis A,"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,5/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00483574
9913,Adjunctive Ziprasidone in the Treatment of Bipolar I Depression,Completed,Has Results,"Bipolar Disorder|Depression, Bipolar",Drug: Ziprasidone|Drug: Placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,10/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00483548
9914,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myeloid Leukemia,Biological: GTI-2040,Aptose Biosciences Inc.|Ohio State University,Aptose Biosciences Inc.,Ohio State University,,,,,,Phase 2,Industry|Other,Interventional,8/7/2019,2/10/2019,https://ClinicalTrials.gov/show/NCT00565058
9915,Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies,Completed,Has Results,Relapsed or Refractory Lymphoproliferative Malignancies|Hodgkin's Lymphoma|Peripheral T-cell Lymphoma|B-cell Lymphoma|Waldenstrom's Macroglobulinemia,Drug: Pralatrexate Injection|Drug: Gemcitabine Hydrochloride|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid,"Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",,,,,,,Phase 1|Phase 2,Industry,Interventional,5/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00481871
9916,Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Completed,Has Results,Bipolar I Depression,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 2,Industry,Interventional,6/7/2019,12/8/2019,https://ClinicalTrials.gov/show/NCT00481195
9917,Titan® One Touch Release Inflatable Penile Prosthesis,Completed,Has Results,Erectile Dysfunction,Device: Inflatable Penile Prosthesis,Coloplast A/S,Coloplast A/S,,,,,,,Not Applicable,Industry,Interventional,11/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00731939
9918,"Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients",Completed,Has Results,Early Parkinson Disease (Early PD),Drug: Pramipexol Extended Release|Drug: Pramipexol Immediate Release|Drug: Placebo,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 3,Industry,Interventional,5/7/2019,,https://ClinicalTrials.gov/show/NCT00479401
9919,"Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients",Completed,Has Results,Hepatitis C,Drug: IMO-2125|Drug: Saline placebo,"Idera Pharmaceuticals, Inc.","Idera Pharmaceuticals, Inc.",,,,,,,Phase 1,Industry,Interventional,9/7/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00728936
9920,Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia,Completed,Has Results,Hyponatremia,Drug: Conivaptan|Drug: Placebo,Cumberland Pharmaceuticals,Cumberland Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,4/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00478192
9921,A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate (ACP-103)|Drug: Placebo,ACADIA Pharmaceuticals Inc.,ACADIA Pharmaceuticals Inc.,,,,,,,Phase 3,Industry,Interventional,6/7/2019,7/9/2019,https://ClinicalTrials.gov/show/NCT00477672
9922,Study of Safety and Efficacy of an Oral Contraceptive,Completed,Has Results,Contraception,Drug: Norethindrone/ethinyl estradiol,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,6/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00477633
9923,Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia,Completed,Has Results,Nocturia,Drug: desmopressin acetate|Drug: Placebo,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,5/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00477490
9924,Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients,Completed,Has Results,Genital Herpes,Drug: Famciclovir|Drug: Placebo,Novartis,Novartis,,,,,,,Phase 4,Industry,Interventional,6/7/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00477334
9925,A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies,Completed,Has Results,HCV Infection,Procedure: Blood sample collection only|Drug: ABT-333,"AbbVie (prior sponsor, Abbott)|AbbVie","AbbVie (prior sponsor, Abbott)",AbbVie,,,,,,Phase 2,Industry,Interventional,8/8/2019,5/10/2019,https://ClinicalTrials.gov/show/NCT00726882
9926,Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase,Completed,Has Results,Gaucher Disease,Biological: GA-GCB (velaglucerase alfa),Shire,Shire,,,,,,,Phase 2|Phase 3,Industry,Interventional,7/25/2007,6/26/2009,https://ClinicalTrials.gov/show/NCT00478647
9927,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,Completed,Has Results,Heart Decompensation,Drug: Nesiritide|Drug: Placebo,"Scios, Inc.","Scios, Inc.",,,,,,,Phase 3,Industry,Interventional,5/7/2019,3/11/2019,https://ClinicalTrials.gov/show/NCT00475852
9928,Aortic Valve Replacement With Trifecta(TM),Completed,Has Results,"Aortic Valve Insufficiency|Regurgitation, Aortic Valve|Aortic Valve Incompetence|Aortic Valve Stenosis",Device: Trifecta Aortic Heart Valve,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,6/7/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00475709
9929,A Study of Enzastaurin in Participants With Follicular Lymphoma,Completed,Has Results,"Lymphoma, Follicular",Drug: Enzastaurin,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,5/7/2019,12/14/2019,https://ClinicalTrials.gov/show/NCT00475644
9930,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,Completed,Has Results,Renal Cell Carcinoma,Drug: Sorafenib|Drug: temsirolimus (Torisel),Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,9/7/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00474786
9931,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes,Completed,Has Results,"Obesity|Overweight|Diabetes Mellitus, Type 2",Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day|Drug: Placebo|Behavioral: Ancillary therapy,"Orexigen Therapeutics, Inc","Orexigen Therapeutics, Inc",,,,,,,Phase 3,Industry,Interventional,5/7/2019,6/9/2019,https://ClinicalTrials.gov/show/NCT00474630
9932,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,Completed,Has Results,"Meningitis, Meningococcal",Biological: Meningococcal ACWY Conjugate Vaccine|Biological: DTaP-IPV-HBV|Biological: Hib|Biological: Rotavirus|Biological: Pneumococcal 7-valent Conjugate Vaccine|Biological: HAV|Biological: MMR-V|Biological: DTaP,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,3/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00474526
9933,AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin 20 mg|Drug: AEGR-733 5 mg|Drug: AEGR-733 10 mg|Drug: Placebo|Drug: AEGR-733 5 mg + atorvastatin 20 mg|Drug: AEGR-733 10 mg + atorvastatin 20 mg,"Aegerion Pharmaceuticals, Inc.","Aegerion Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,4/7/2019,10/8/2019,https://ClinicalTrials.gov/show/NCT00474240
9934,High Dose or High Dose Frequency Study of Alglucosidase Alfa,Completed,Has Results,Pompe Disease|Glycogen Storage Disease Type II (GSD-II)|Glycogenesis 2 Acid Maltase Deficiency,Biological: alglucosidase alfa,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,5/7/2019,7/10/2019,https://ClinicalTrials.gov/show/NCT00483379
9935,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: sunitinib,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,8/7/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00471276
9936,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,Completed,Has Results,"Carcinoma, Pancreatic Ductal",Drug: AG-013736|Drug: Gemcitabine|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,7/7/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00471146
9937,Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.,Completed,Has Results,"Infections, Meningococcal",Biological: Meningococcal vaccine GSK134612,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,7/5/2007,11/26/2008,https://ClinicalTrials.gov/show/NCT00471081
9938,Chronic Evaluation of Respicardia Therapy,Completed,Has Results,Sleep Disordered Breathing|Cheyne Stokes Respiration|Periodic Breathing|Sleep Apnea|Central Sleep Apnea,Device: remedē (TM) system,"Respicardia, Inc.","Respicardia, Inc.",,,,,,,Phase 2,Industry,Interventional,5/10/2019,8/14/2019,https://ClinicalTrials.gov/show/NCT01124370
9939,Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy,Completed,Has Results,"Neoplasms, Prostate",Drug: dutasteride|Drug: placebo|Drug: bicalutamide,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,5/7/2019,2/13/2019,https://ClinicalTrials.gov/show/NCT00470834
9940,"A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer",Completed,Has Results,Non-Small-Cell Lung Cancer,Drug: pemetrexed|Drug: cisplatin|Drug: carboplatin|Radiation: radiation therapy,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 1|Phase 2,Industry,Interventional,5/7/2019,10/11/2019,https://ClinicalTrials.gov/show/NCT00482014
9941,Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib,Completed,Has Results,Gastrointestinal Stromal Tumors,Drug: Nilotinib|Other: Best Supportive Care (BSC) +/- imatinib or sunitinib,Novartis Pharmaceuticals|Novartis,Novartis Pharmaceuticals,Novartis,,,,,,Phase 3,Industry,Interventional,3/7/2019,6/11/2019,https://ClinicalTrials.gov/show/NCT00471328
9942,Ultrasound Elastography of Breast Lesions,Completed,Has Results,Breast Neoplasms,,SuperSonic Imagine,SuperSonic Imagine,,,,,,,,Industry,Observational,7/8/2019,6/10/2019,https://ClinicalTrials.gov/show/NCT00716482
9943,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),Completed,Has Results,Clostridium Infections|Diarrhea,Drug: PAR-101/OPT-80|Drug: Vancomycin,Optimer Pharmaceuticals LLC,Optimer Pharmaceuticals LLC,,,,,,,Phase 3,Industry,Interventional,10/4/2006,12/11/2009,https://ClinicalTrials.gov/show/NCT00468728
9944,Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy,Completed,Has Results,"Pain, Postoperative",Drug: pregabalin (Lyrica)|Drug: matched placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,6/7/2019,10/10/2019,https://ClinicalTrials.gov/show/NCT00468845
9945,Phase 3/Safety & Efficacy of Esomeprazole in Infants,Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Open Label Run In Esomeprazole|Drug: Double Blind Esomeprazole|Drug: Double Blind Placebo,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/7/2019,6/8/2019,https://ClinicalTrials.gov/show/NCT00468559
9946,Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.,Completed,Has Results,Cachexia,Drug: GTx-024|Drug: Placebo,GTx,GTx,,,,,,,Phase 2,Industry,Interventional,5/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00467844
9947,A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: pramlintide acetate (Symlin)|Drug: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|Drug: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])",AstraZeneca,AstraZeneca,,,,,,,Phase 4,Industry,Interventional,5/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00467649
9948,Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age,Completed,Has Results,Tetanus|Diphtheria|Pertussis,Biological: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|Biological: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed),"Sanofi Pasteur, a Sanofi Company|Sanofi","Sanofi Pasteur, a Sanofi Company",Sanofi,,,,,,Phase 3,Industry,Interventional,4/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00467519
9949,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,Completed,Has Results,Hypoactive Sexual Desire Disorder,Drug: Testosterone Transdermal System|Drug: Placebo patch,Warner Chilcott,Warner Chilcott,,,,,,,Phase 3,Industry,Interventional,4/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00467259
9950,Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy,Completed,Has Results,Prostate Cancer,Drug: Degarelix,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,5/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00468286
9951,An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain,Completed,Has Results,Postoperative Pain,Drug: Hydromorphone,Purdue Pharma LP,Purdue Pharma LP,,,,,,,Phase 4,Industry,Interventional,4/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00465647
9952,Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial,Completed,Has Results,Cryptogenic Stroke,Device: AMPLATZER PFO Occluder|Other: Standard of Care - Medical Management,Abbott Medical Devices,Abbott Medical Devices,,,,,,,Not Applicable,Industry,Interventional,8/3/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT00465270
9953,An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME),Completed,Has Results,Hyperlipidemia|Mixed Dyslipidemia,Drug: Niacin ER/Simvastatin Tablets|Drug: atorvastatin,Abbott,Abbott,,,,,,,Phase 3,Industry,Interventional,4/7/2019,,https://ClinicalTrials.gov/show/NCT00465088
9954,The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.,Completed,Has Results,Fibromyalgia Syndrome,Drug: Rotigotine|Other: Placebo,UCB Pharma,UCB Pharma,,,,,,,Phase 2,Industry,Interventional,3/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00464737
9955,A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects,Completed,Has Results,Chronic Hepatitis C,Drug: Daclatasvir|Drug: Placebo,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 1|Phase 2,Industry,Interventional,11/7/2019,5/8/2019,https://ClinicalTrials.gov/show/NCT00546715
9956,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Completed,Has Results,Epilepsy,Other: Placebo|Drug: Brivaracetam 2.5 mg|Drug: Brivaracetam 10 mg|Drug: Brivaracetam 25 mg,UCB Pharma,UCB Pharma,,,,,,,Phase 3,Industry,Interventional,9/7/2019,1/9/2019,https://ClinicalTrials.gov/show/NCT00464269
9957,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335|Drug: rosuvastatin calcium,AstraZeneca,AstraZeneca,,,,,,,Phase 3,Industry,Interventional,4/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00463606
9958,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive|COPD|Lung Diseases, Obstructive",Drug: Indacaterol|Drug: Formoterol (12 µg b.i.d.)|Drug: Tiotropium (18 µg o.d.)|Drug: Placebo to Indacaterol|Drug: Placebo to Formoterol,Novartis,Novartis,,,,,,,Phase 2|Phase 3,Industry,Interventional,4/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00463567
9959,Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone,Cephalon|Teva Pharmaceutical Industries,Cephalon,Teva Pharmaceutical Industries,,,,,,Phase 3,Industry,Interventional,7/7/2019,2/9/2019,https://ClinicalTrials.gov/show/NCT00463047
9960,Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf),Shire,Shire,,,,,,,Phase 3,Industry,Interventional,6/6/2019,3/9/2019,https://ClinicalTrials.gov/show/NCT00462709
9961,Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma,Completed,Has Results,Asthma,Drug: BI 1744 CL,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,5/7/2019,,https://ClinicalTrials.gov/show/NCT00467740
9962,A Phase 2 Study to Evaluate Immune Responses of FluMist®,Completed,Has Results,Influenza Vaccine,"Biological: TIV, Trivalent Inactivated Influenza Virus Vaccine|Biological: FluMist, Influenza Virus Vaccine Live",MedImmune LLC,MedImmune LLC,,,,,,,Phase 2,Industry,Interventional,5/7/2019,2/8/2019,https://ClinicalTrials.gov/show/NCT00461981
9963,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611),Completed,Has Results,Bladder Cancer,Drug: Apaziquone|Drug: Placebo|Procedure: TURBT,"Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",,,,,,,Phase 3,Industry,Interventional,4/7/2019,1/12/2019,https://ClinicalTrials.gov/show/NCT00461591
9964,"Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII",Completed,Has Results,Hemophilia A,Biological: Moroctocog alfa (AF-CC),Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,12/7/2019,4/18/2019,https://ClinicalTrials.gov/show/NCT00543439
9965,"Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",Completed,Has Results,Irritable Bowel Syndrome With Constipation,Drug: Linaclotide Acetate|Drug: Matching placebo,"Ironwood Pharmaceuticals, Inc.","Ironwood Pharmaceuticals, Inc.",,,,,,,Phase 2,Industry,Interventional,4/7/2019,4/8/2019,https://ClinicalTrials.gov/show/NCT00460811
9966,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,Completed,Has Results,Colorectal Neoplasms,Drug: bevacizumab|Drug: AG-013726|Drug: AG-013736 (axitinib),Pfizer,Pfizer,,,,,,,Phase 1|Phase 2,Industry,Interventional,1/6/2019,11/12/2019,https://ClinicalTrials.gov/show/NCT00460603
9967,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,5/7/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00459667
9968,Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease,Completed,Has Results,Crohn's Disease,Device: Capsule Endoscopy,Given Imaging Ltd.,Given Imaging Ltd.,,,,,,,Not Applicable,Industry,Interventional,9/7/2019,11/10/2019,https://ClinicalTrials.gov/show/NCT00487396
9969,Safety Study of Ivacaftor in Subjects With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor 25 mg/75 mg|Drug: Ivacaftor 75 mg/150 mg|Drug: Ivacaftor 150 mg or 250 mg|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Vertex Pharmaceuticals Incorporated,Cystic Fibrosis Foundation,,,,,,Phase 2,Industry|Other,Interventional,5/7/2019,8/8/2019,https://ClinicalTrials.gov/show/NCT00457821
9970,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,Completed,Has Results,"Carcinoma, Non-Small Cell Lung",Drug: erlotinib|Drug: sunitinib|Drug: placebo,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,7/7/2019,12/12/2019,https://ClinicalTrials.gov/show/NCT00457392
9971,A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older,Completed,Has Results,Pertussis|Tetanus|Diphtheria,"Biological: ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|Biological: DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed",Sanofi,Sanofi,,,,,,,Phase 4,Industry,Interventional,3/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00457249
9972,Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE),Completed,Has Results,Hereditary Angioedema (HAE),"Drug: ecallantide|Drug: Phosphate Buffer Saline (PBS), pH 7.0",Shire,Shire,,,,,,,Phase 3,Industry,Interventional,4/1/2007,6/1/2008,https://ClinicalTrials.gov/show/NCT00457015
9973,Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness,Completed,Has Results,Venous Thrombosis|Pulmonary Embolism,Drug: Apixaban|Drug: Enoxaparin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 3,Industry,Interventional,6/7/2019,5/11/2019,https://ClinicalTrials.gov/show/NCT00457002
9974,Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE),Completed,Has Results,Hereditary Angioedema (HAE),Drug: ecallantide,Shire,Shire,,,,,,,Phase 3,Industry,Interventional,4/1/2007,9/1/2010,https://ClinicalTrials.gov/show/NCT00456508
9975,A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment,Completed,Has Results,Chronic Hepatitis C,Drug: Debio 025|Drug: Peg-IFNα2a|Drug: Ribavirin,Debiopharm International SA,Debiopharm International SA,,,,,,,Phase 2,Industry,Interventional,9/7/2019,4/10/2019,https://ClinicalTrials.gov/show/NCT00537407
9976,An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Docetaxel|Drug: Prednisone|Biological: Intetumumab|Drug: Placebo,"Centocor, Inc.","Centocor, Inc.",,,,,,,Phase 2,Industry,Interventional,5/7/2019,11/9/2019,https://ClinicalTrials.gov/show/NCT00537381
9977,Efficacy and Safety Study for an Oral Contraceptive Containing Folate,Completed,Has Results,Neural Tube Defects|Contraception|Oral Contraceptives (OC),Drug: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|Drug: Drospirenone/Ethinylestradiol (Yaz),Bayer,Bayer,,,,,,,Phase 3,Industry,Interventional,4/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00468481
9978,Late-Onset Treatment Study Extension Protocol,Completed,Has Results,Pompe Disease (Late-Onset)|Glycogen Storage Disease Type II (GSD-II)|Glycogenesis Type II|Acid Maltase Deficiency (AMD),Biological: alglucosidase alfa,"Genzyme, a Sanofi Company|Sanofi","Genzyme, a Sanofi Company",Sanofi,,,,,,Phase 4,Industry,Interventional,3/7/2019,11/8/2019,https://ClinicalTrials.gov/show/NCT00455195
9979,Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure,Completed,Has Results,"Heart Failure, Congestive|Dilated Cardiomyopathy","Genetic: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|Procedure: Placebo Infusion|Genetic: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)",Celladon Corporation,Celladon Corporation,,,,,,,Phase 1|Phase 2,Industry,Interventional,3/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00454818
9980,PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response,Completed,Has Results,Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck,Drug: Cisplatin|Drug: Panitumumab|Drug: Docetaxel,Amgen,Amgen,,,,,,,Phase 2,Industry,Interventional,1/1/2007,1/1/2014,https://ClinicalTrials.gov/show/NCT00454779
9981,Study in Advanced Solid Tumors,Completed,Has Results,Solid Tumor,Drug: Cetuximab|Drug: Cisplatin|Drug: 5 - Fluorouracil,Eli Lilly and Company,Eli Lilly and Company,,,,,,,Phase 2,Industry,Interventional,4/10/2019,5/16/2019,https://ClinicalTrials.gov/show/NCT01099358
9982,Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza,Completed,Has Results,Influenza,Drug: Peramivir 200 mg|Drug: Peramivir 400 mg|Drug: Oseltamivir,BioCryst Pharmaceuticals,BioCryst Pharmaceuticals,,,,,,,Phase 2,Industry,Interventional,7/7/2019,8/9/2019,https://ClinicalTrials.gov/show/NCT00453999
9983,Treatment of Oral Warts in HIV+ Patients,Completed,Has Results,Papillomatosis|HIV Infections,Drug: Interferon-alpha|Other: placebo,"Amarillo Biosciences, Inc.","Amarillo Biosciences, Inc.",,,,,,,Phase 2,Industry,Interventional,2/7/2019,10/9/2019,https://ClinicalTrials.gov/show/NCT00454181
9984,A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization,Completed,Has Results,Benign Prostatic Hyperplasia,Device: GreenLight HPS,American Medical Systems,American Medical Systems,,,,,,,Phase 4,Industry,Interventional,5/7/2019,1/13/2019,https://ClinicalTrials.gov/show/NCT00465101
9985,A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation,Completed,Has Results,Disorder Related to Renal Transplantation,Drug: Thymoglobulin|Drug: Belatacept|Drug: Sirolimus|Drug: Tacrolimus|Drug: Mycophenolate Mofetil (MMF),Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,7/7/2019,8/12/2019,https://ClinicalTrials.gov/show/NCT00455013
9986,A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Drug: Fluticasone propionate 250 mcg BID,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,5/7/2019,5/9/2019,https://ClinicalTrials.gov/show/NCT00452699
9987,Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive|Asthma",Drug: BI 1744CL,Boehringer Ingelheim,Boehringer Ingelheim,,,,,,,Phase 2,Industry,Interventional,3/7/2019,,https://ClinicalTrials.gov/show/NCT00452400
9988,A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Drug: Fluticasone propionate 250 mcg BID,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 4,Industry,Interventional,5/7/2019,4/9/2019,https://ClinicalTrials.gov/show/NCT00452348
9989,A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: PF-03654746|Drug: Placebo capsules,Pfizer,Pfizer,,,,,,,Phase 2,Industry,Interventional,12/7/2019,9/8/2019,https://ClinicalTrials.gov/show/NCT00531752
9990,A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy,Completed,Has Results,Prostate Cancer,Drug: Degarelix 80 mg / Degarelix 80 mg|Drug: Degarelix 160 mg / Degarelix 160 mg|Drug: Leuprolide 7.5 mg / Degarelix 80 mg|Drug: Leuprolide 7.5 mg / Degarelix 160 mg,Ferring Pharmaceuticals,Ferring Pharmaceuticals,,,,,,,Phase 3,Industry,Interventional,3/7/2019,12/11/2019,https://ClinicalTrials.gov/show/NCT00451958
9991,"Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma",Completed,Has Results,Ovarian Cancer|Renal Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Solid Tumors|Multiple Myeloma|Lymphoma,Drug: Carfilzomib|Drug: Dexamethasone,Amgen,Amgen,,,,,,,Phase 1|Phase 2,Industry,Interventional,9/7/2019,5/22/2017,https://ClinicalTrials.gov/show/NCT00531284
9992,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: BG00012|Drug: Placebo|Drug: Glatiramer Acetate,Biogen,Biogen,,,,,,,Phase 3,Industry,Interventional,6/7/2019,8/11/2019,https://ClinicalTrials.gov/show/NCT00451451
9993,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Ixabepilone|Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Doxorubicin,Bristol-Myers Squibb,Bristol-Myers Squibb,,,,,,,Phase 2,Industry,Interventional,10/7/2019,12/9/2019,https://ClinicalTrials.gov/show/NCT00455533
9994,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults,Completed,Has Results,Meningococcal Infections|Meningococcal Meningitis,Biological: MenACWY CRM|Biological: Meningococcal ACWY Conjugate vaccine,Novartis Vaccines|Novartis,Novartis Vaccines,Novartis,,,,,,Phase 3,Industry,Interventional,3/7/2019,1/8/2019,https://ClinicalTrials.gov/show/NCT00450437
9995,Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.,Completed,Has Results,"Infections, Meningococcal",Biological: Meningococcal vaccine 134612|Biological: Menactra®,GlaxoSmithKline,GlaxoSmithKline,,,,,,,Phase 2,Industry,Interventional,4/23/2007,4/11/2008,https://ClinicalTrials.gov/show/NCT00454909
9996,Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor,Completed,Has Results,Neoplasms,Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Drug: Axitinib + Paclitaxel (Cohort 4)|Drug: Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Drug: Axitinib + Docetaxel (Cohort 5)|Drug: Axitinib + Capecitabine (Cohort 6)|Drug: Axitinib + Capecitabine (Cohort 7)|Drug: Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Drug: Axitinib + Pemetrexed + Cisplatin (Cohort 9),Pfizer,Pfizer,,,,,,,Phase 1,Industry,Interventional,12/5/2019,4/11/2019,https://ClinicalTrials.gov/show/NCT00454649
9997,Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura,Completed,Has Results,Migraine With Aura,Device: Active Transcranial Magnetic Stimulation (TMS) Device|Device: Sham TMS Device,Neuralieve,Neuralieve,,,,,,,Phase 3,Industry,Interventional,8/6/2019,3/8/2019,https://ClinicalTrials.gov/show/NCT00449540
9998,Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures,Completed,Has Results,"Epilepsies, Partial",Drug: Pregabalin,Pfizer,Pfizer,,,,,,,Phase 3,Industry,Interventional,5/7/2019,10/13/2019,https://ClinicalTrials.gov/show/NCT00448916
9999,Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,Completed,Has Results,Refractory Partial Onset Seizures,Drug: Rufinamide|Drug: Placebo,Eisai Inc.,Eisai Inc.,,,,,,,Phase 3,Industry,Interventional,3/7/2019,12/10/2019,https://ClinicalTrials.gov/show/NCT00448539
10000,"Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.",Completed,Has Results,Diagnosis of Adult Growth Hormone Deficiency (AGDH),Drug: AEZS-130 (formerly ARD-07)|Drug: L-ARG+GHRH,AEterna Zentaris,AEterna Zentaris,,,,,,,Phase 3,Industry,Interventional,6/7/2019,7/11/2019,https://ClinicalTrials.gov/show/NCT00448747
